FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Newbold, SC
   Finnoff, D
   Thunstrom, L
   Ashworth, M
   Shogren, JF
AF Newbold, Stephen C.
   Finnoff, David
   Thunstrom, Linda
   Ashworth, Madison
   Shogren, Jason F.
TI Effects of Physical Distancing to Control COVID-19 on Public Health, the
   Economy, and the Environment
SO ENVIRONMENTAL & RESOURCE ECONOMICS
LA English
DT Article
DE COVID-19; Air pollution; Co-benefits; Physical distancing; Social
   distancing; Optimal control
ID IMPACT; RISK; GLOBALIZATION
AB Physical distancing measures are important tools to control disease spread, especially in the absence of treatments and vaccines. While distancing measures can safeguard public health, they also can profoundly impact the economy and may have important indirect effects on the environment. The extent to which physical distancing measures should be applied therefore depends on the trade-offs between their health benefits and their economic costs. We develop an epidemiological-economic model to examine the optimal duration and intensity of physical distancing measures aimed to control the spread of COVID-19. In an application to the United States, our model considers the trade-off between the lives saved by physical distancing-both directly from stemming the spread of the virus and indirectly from reductions in air pollution during the period of physical distancing-and the short- and long-run economic costs that ensue from such measures. We examine the effect of air pollution co-benefits on the optimal physical distancing policy and conduct sensitivity analyses to gauge the influence of several key parameters and uncertain model assumptions. Using recent estimates of the association between airborne particulate matter and the virulence of COVID-19, we find that accounting for air pollution co-benefits can significantly increase the intensity and duration of the optimal physical distancing policy. To conclude, we broaden our discussion to consider the possibility of durable changes in peoples' behavior that could alter local markets, the global economy, and our relationship to nature for years to come.
C1 [Newbold, Stephen C.; Finnoff, David; Thunstrom, Linda; Ashworth, Madison; Shogren, Jason F.] Univ Wyoming, Dept Econ, Laramie, WY 82071 USA.
RP Newbold, SC (corresponding author), Univ Wyoming, Dept Econ, Laramie, WY 82071 USA.
EM snewbold@uwyo.edu
OI Newbold, Stephen/0000-0002-7723-445X
CR Abel T, 2020, INT J PUBLIC HEALTH, V65, P231, DOI 10.1007/s00038-020-01366-7
   Abrams J, 2010, GREAT PLAINS QUART, V30, P271
   Acemoglu D, 2020, TECHNICAL REPORT
   Aguero JM, 2017, J HEALTH ECON, V54, P40, DOI 10.1016/j.jhealeco.2017.03.008
   Allen D, 2020, ROADMAP PANDEMIC RES, P20
   American Hospital Association, 2020, FAST FACTS US HOSP
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Annez P. C., 2009, URBANIZATION GROWTH
   Aronson JK, 2020, INTRO VIRAL REPROD N
   Barbier EB, 2020, ENVIRON RESOUR ECON, V76, P685, DOI 10.1007/s10640-020-00437-w
   BAUR JE, 1959, MISS VALLEY HIST REV, V46, P91, DOI 10.2307/1892389
   Berry K, 2018, ENVIRON RESOUR ECON, V70, P631, DOI 10.1007/s10640-017-0142-7
   Bertsekas DP, 2015, IEEE T NEUR NET LEAR, V28, P500
   Bolzoni L, 2019, MATH BIOSCI, V315, DOI 10.1016/j.mbs.2019.108232
   Bowe B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15834
   Boyce JK, 2004, OXFORD REV ECON POL, V20, P105, DOI 10.1093/oxrep/grh007
   Bratman GN, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax0903
   Burnett R, 2018, P NATL ACAD SCI USA, V115, P9592, DOI 10.1073/pnas.1803222115
   Cameron TA, 2010, REV ENV ECON POLICY, V4, P161, DOI 10.1093/reep/req010
   CDC, 2020, COR DIS 2019 COVID 1
   Cicala S, 2020, 27135 NBER
   COX DR, 1972, J R STAT SOC B, V34, P187
   Cropper M, 2011, ANNU REV RESOUR ECON, V3, P313, DOI 10.1146/annurev.resource.012809.103949
   di Toppi LS, 2020, CHALLENGES, V11, P1
   Dorigatti I, 2020, 4 NCOV, DOI [10.25561/77154, DOI 10.25561/77154]
   Eikenberry SE, 2020, INFECT DIS MODEL, V5, P293, DOI 10.1016/j.idm.2020.04.001
   Evans MF, 2006, RESOUR ENERGY ECON, V28, P242, DOI 10.1016/j.reseneeco.2006.02.004
   Farboodi Maryam, 2020, 27059 NBER
   Fenichel EP, 2013, J HEALTH ECON, V32, P440, DOI 10.1016/j.jhealeco.2013.01.002
   Fenichel EP, 2011, P NATL ACAD SCI USA, V108, P6306, DOI 10.1073/pnas.1011250108
   Ferguson N, 2020, 9 NPIS
   Fernando EAlvarez, 2020, 26981 NBER
   Foss KA, 2020, EPIDEMICS SHAPED MOD
   Freedman DH, 2020, WIRED
   Frick SA, 2018, GROWTH CHANGE, V49, P4, DOI 10.1111/grow.12232
   Gallagher KP, 2009, ANNU REV ENV RESOUR, V34, P279, DOI 10.1146/annurev.environ.33.021407.092325
   Gersovitz M, 2004, ECON J, V114, P1, DOI 10.1046/j.0013-0133.2003.0174.x
   Gersovitz M, 2011, ANNU REV RESOUR ECON, V3, P277, DOI 10.1146/annurev-resource-083110-120052
   Gonzalez-Eiras M, 2020, CESIFO WORKING PAPER
   Goodkind AL, 2019, P NATL ACAD SCI USA, V116, P8775, DOI 10.1073/pnas.1816102116
   Gossling S, 2020, J SUSTAIN TOUR, V29, P1, DOI 10.1080/09669582.2020.1758708
   Greenstone M., 2020, 202026 BECK FRIEDM I
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Hall RE, 2020, TECHNICAL REPORT
   Hammitt JK, 2007, REV ENV ECON POLICY, V1, P228, DOI 10.1093/reep/rem015
   Hansen E, 2011, J MATH BIOL, V62, P423, DOI 10.1007/s00285-010-0341-0
   Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7
   Helm D, 2020, ENVIRON RESOUR ECON, V76, P21, DOI 10.1007/s10640-020-00426-z
   Hethcote W.W., 1989, Biomathematics (Berlin), V18, P119
   Howard J, 2020, FACE MASKS COVID 19, DOI [DOI 10.20944/PREPRINTS202004.0203.V1, 10.20944/preprints202004.0203.v1]
   IEA, 2020, GLOB EN REV 2020
   IGES, 2020, IMPL COVID 19 ENV SU
   Keeling M. J., 2011, MODELING INFECT DIS
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Kniesner T. J., 2006, BE J ECON ANAL POLI, V5, P4
   Kniesner T. J, 2019, VALUE STAT LIFE, DOI 10.1093/acrefore/9780190625979.013.138
   Kruse J, 2020, FRONT FOR GLOB CHANG, V3, DOI 10.3389/ffgc.2020.00005
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5
   Lee J, 2020, LANCET, DOI [10.1016/S2352-4642(20)30128-0, DOI 10.1016/S2352-4642(20)30128-0]
   Lee S, 2010, J THEOR BIOL, V265, P136, DOI 10.1016/j.jtbi.2010.04.003
   Lippi G, 2020, EUR J PREV CARDIOL, V27, P906, DOI 10.1177/2047487320916823
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Majumder MS, 2020, LANCET GLOB HEALTH, V8, pE627, DOI 10.1016/S2214-109X(20)30113-3
   Martelletti Luigi, 2020, SN Compr Clin Med, P1, DOI 10.1007/s42399-020-00274-4
   Martin SEichenbaum, 2020, 26882 NBER
   Mattioli AV, 2020, EUR J CLIN NUTR, V74, P852, DOI 10.1038/s41430-020-0646-z
   Mohler G, 2020, J CRIM JUST, V68, DOI 10.1016/j.jcrimjus.2020.101692
   Nair HC, 2020, SUST WAT RESOUR MAN, V6, DOI 10.1007/s40899-020-00363-1
   National Research Council, 2008, EST MORT RISK RED EC
   Newell RG, 2003, J REGUL ECON, V23, P43, DOI 10.1023/A:1021879330491
   Newman P, 2006, ENVIRON URBAN, V18, P275, DOI 10.1177/0956247806069599
   Nisa CF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12457-2
   Ogen Y, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138605
   Ou ZY, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-0257-2
   Parkinson M, 2015, EUR PLAN STUD, V23, P1054, DOI 10.1080/09654313.2014.904998
   Perrings C, 2014, ECOHEALTH, V11, P464, DOI 10.1007/s10393-014-0963-6
   Persico CL, 2020, IZA I LABOR EC DISCU, P13231
   Philipson T., 2016, EC EPIDEMIOLOGY, P1
   Piguillem F, 2020, TECHNICAL REPORT
   Pindyck R.S, 2020, 27121 NBER
   Poll Harris, 2020, COVID 19 PANDEMIC UR
   Rice W.L, 2020, COVID 19 PANDEMIC IS, DOI [10.31235/osf.io/prnz9, DOI 10.31235/OSF.IO/PRNZ9]
   Riou J., 2020, ADJUSTED AGE SPECIFI
   Rowthorn RE, 2009, J R SOC INTERFACE, V6, P1135, DOI 10.1098/rsif.2008.0402
   .S. Department of Transportation, 2016, GUID TREATM EC VAL S
   Sachs G, 2020, BEAR ESSENTIALS GUID
   Samuelsson K, 2020, URBAN NATURE SOURCE
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Setti L, 2020, POTENTIAL ROLE PARTI
   SHEPARD DS, 1984, MANAGE SCI, V30, P423, DOI 10.1287/mnsc.30.4.423
   Simon NB, 2019, REV ENV ECON POLICY, V13, P155, DOI 10.1093/reep/rey022
   Stier A, 2020, COVID 19 ATTACK RATE
   Stock JH, 2020, COVID EC, V1-3, P1
   Taipale J., 2020, POPULATION SCALE TES
   Tang SY, 2018, ENVIRON POLLUT, V232, P477, DOI 10.1016/j.envpol.2017.09.071
   Thunstrom L, 2020, J BENEFIT-COST ANAL, V11, P179, DOI 10.1017/bca.2020.12
   Toxvaerd Flavio, 2020, CAMBRIDGE INET WORKI, V2020
   Tukker A, 2011, ECOL ECON, V70, P1776, DOI 10.1016/j.ecolecon.2011.05.001
   U.S. Department of Labor, 2020, EMPL INS WEEKL CLAIM
   U.S. Environmental Protection Agency, 2014, GUID PREP EC AN
   Unwin H, 2020, REPORT 23 STATE LEVE, DOI [10.25561/79231, DOI 10.25561/79231]
   US Office of Management and Budget, 2003, A4 US OFF MAN BUDG
   van Gelder N, 2020, EClinicalMedicine, V21, P100348, DOI 10.1016/j.eclinm.2020.100348
   Venter Z., 2020, ENV RES LETT, DOI [10.31235/osf.io/kbdum, 10.1088/1748-9326/abb396/pdf, DOI 10.1088/1748-9326/ABB396/PDF]
   Viscusi W. K, 2018, PRICING LIVES GUIDEP
   White MP, 2019, SCI REP, V9, P1
   WHO, 2020, AIR POLLUTION
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   Wu X, 2020, EXPOSURE AIR POLLUTI, DOI 10.1101/2020.04.05.20054502
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu J, 2018, MORTALITY US
NR 112
TC 0
Z9 0
U1 13
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-6460
EI 1573-1502
J9 ENVIRON RESOUR ECON
JI Environ. Resour. Econ.
PD AUG
PY 2020
VL 76
IS 4
SI SI
BP 705
EP 729
DI 10.1007/s10640-020-00440-1
EA AUG 2020
PG 25
WC Economics; Environmental Studies
SC Business & Economics; Environmental Sciences & Ecology
GA NI2YK
UT WOS:000555732200014
PM 32836854
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU McCallum, M
   Walls, AC
   Bowen, JE
   Corti, D
   Veesler, D
AF McCallum, Matthew
   Walls, Alexandra C.
   Bowen, John E.
   Corti, Davide
   Veesler, David
TI Structure-guided covalent stabilization of coronavirus spike
   glycoprotein trimers in the closed conformation
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article; Early Access
ID CRYO-EM STRUCTURE; RESPIRATORY SYNDROME CORONAVIRUS; STOMATITIS-VIRUS
   GLYCOPROTEIN; MERS-COV; INFLUENZA HEMAGGLUTININ; FUNCTIONAL RECEPTOR;
   CRYSTAL-STRUCTURE; PROTEIN; MICROSCOPY; BINDING
AB The conformational dynamics of SARS-CoV-2 spike are constrained by engineering a disulfide bond that locks the protein in a closed conformation, a strategy that was also applied to SARS-CoV and MERS-CoV.
   SARS-CoV-2 is the causative agent of the COVID-19 pandemic, with 10 million infections and more than 500,000 fatalities by June 2020. To initiate infection, the SARS-CoV-2 spike (S) glycoprotein promotes attachment to the host cell surface and fusion of the viral and host membranes. Prefusion SARS-CoV-2 S is the main target of neutralizing antibodies and the focus of vaccine design. However, its limited stability and conformational dynamics are limiting factors for developing countermeasures against this virus. We report here the design of a construct corresponding to the prefusion SARS-CoV-2 S ectodomain trimer, covalently stabilized by a disulfide bond in the closed conformation. Structural and antigenicity analyses show we successfully shut S in the closed state without otherwise altering its architecture. We demonstrate that this strategy is applicable to other beta-coronaviruses, such as SARS-CoV and MERS-CoV, and might become an important tool for structural biology, serology, vaccine design and immunology studies.
C1 [McCallum, Matthew; Walls, Alexandra C.; Bowen, John E.; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Corti, Davide] Humabs Biomed SA, Bellinzona, Switzerland.
RP Veesler, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM dveesler@uw.edu
OI Bowen, John/0000-0003-3590-9727
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM120553];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700059C]; Pew Biomedical Scholars Award; Investigators in the
   Pathogenesis of Infectious Disease Award from the Burroughs Wellcome
   Fund; Bill & Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1156262]; Fast Grants; University of Washington Arnold and Mabel
   Beckman Cryo-EM Center
FX This study was supported by the National Institute of General Medical
   Sciences (grant no. R01GM120553 to D.V.), the National Institute of
   Allergy and Infectious Diseases (grant no. HHSN272201700059C to D.V.), a
   Pew Biomedical Scholars Award (D.V.), an Investigators in the
   Pathogenesis of Infectious Disease Award from the Burroughs Wellcome
   Fund (D.V.), the Bill & Melinda Gates Foundation (grant no. OPP1156262
   to D.V.), Fast Grants (to D.V.) and the University of Washington Arnold
   and Mabel Beckman Cryo-EM Center. We thank J. Bloom, A. Dingens and H.
   Chu for providing the COVID-19 convalescent serum sample and the study
   participant who contributed this serum.
CR Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   CAI YH, 2020, ISCIENCE, V23, DOI DOI 10.1126/SCIENCE.ABD4251
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Dang HV, 2019, NAT STRUCT MOL BIOL, V26, P980, DOI 10.1038/s41594-019-0308-9
   DiMaio F, 2015, NAT METHODS, V12, P361, DOI [10.1038/NMETH.3286, 10.1038/nmeth.3286]
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ferlin A, 2014, J VIROL, V88, P13396, DOI 10.1128/JVI.01962-14
   Frenz B, 2019, STRUCTURE, V27, P134, DOI 10.1016/j.str.2018.09.006
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Joyce M Gordon, 2020, bioRxiv, DOI 10.1101/2020.03.15.992883
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Ke Z., 2020, BIORXIV, DOI [10.1101/2020.06.27.174979, DOI 10.1101/2020.06.27.174979]
   Kirchdoerfer RN, 2018, SCI REP, V8
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Liu C, 2020, VIRAL ARCHITECTURE S, DOI [10.1101/2020.03.02.972927, DOI 10.1101/2020.03.02.972927]
   Liu Q, 2015, J VIROL, V89, P1838, DOI 10.1128/JVI.02277-14
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Roche S, 2007, SCIENCE, V315, P843, DOI 10.1126/science.1135710
   Roche S, 2006, SCIENCE, V313, P187, DOI 10.1126/science.1127683
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stewart-Jones GBE, 2018, P NATL ACAD SCI USA, V115, P12265, DOI 10.1073/pnas.1811980115
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Turoova B., 2020, BIORXIV, DOI [10.1101/2020.06.26.173476, DOI 10.1101/2020.06.26.173476]
   Walls A, 2017, PROTEIN SCI, V26, P113, DOI 10.1002/pro.3048
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang RY, 2016, ROSETTA ELIFE, V5
   Wong JJW, 2016, P NATL ACAD SCI USA, V113, P1056, DOI 10.1073/pnas.1523303113
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong XL, 2018, J VIROL, V92
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan YC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14657
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 83
TC 5
Z9 5
U1 7
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
DI 10.1038/s41594-020-0483-8
EA AUG 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA MU5IT
UT WOS:000555707700001
PM 32753755
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Simmering, JE
   Polgreen, LA
   Polgreen, PM
   Teske, RE
   Comellas, AP
   Carter, BL
AF Simmering, Jacob E.
   Polgreen, Linnea A.
   Polgreen, Philip M.
   Teske, Rebecca E.
   Comellas, Alejandro P.
   Carter, Barry L.
TI The Cardiovascular Effects of Treatment with Hydroxychloroquine and
   Azithromycin
SO PHARMACOTHERAPY
LA English
DT Article
DE hydroxychloroquine; azithromycin; coronavirus infections
ID CHLOROQUINE; DISEASE; RISK
AB Hydroxychloroquine combined with azithromycin has been investigated for activity against coronavirus disease 2019 (COVID-19), but concerns about adverse cardiovascular (CV) effects have been raised. This study evaluated claims data to determine if risks for CV events were increased with hydroxychloroquine alone or combined with azithromycin. We identified data from 43,752 enrollees that qualified for analysis. The number of CV events increased by 25 (95% confidence interval [CI]: 8, 42, p=0.005) per 1000 people per year of treatment with hydroxychloroquine alone compared with pretreatment levels and by 201 (95% CI: 145, 256, p<0.001) events per 1000 people per year when individuals took hydroxychloroquine and azithromycin. These rates translate to an additional 0.34 (95% CI: 0.11, 0.58) CV events per 1000 patients placed on a 5-day treatment with hydroxychloroquine monotherapy and 2.75 (95% CI: 1.99, 3.51) per 1000 patients on a 5-day treatment with both hydroxychloroquine and azithromycin. The rate of adverse events increased with age following exposure to hydroxychloroquine alone and combined with azithromycin. For females aged 60 to 79 years prescribed hydroxychloroquine, the rate of adverse CV events was 0.92 per 1000 patients on 5 days of therapy, but it increased to 4.78 per 1000 patients when azithromycin was added. The rate of adverse CV events did not differ significantly from zero for patients 60 years of age or younger. These data suggest that hydroxychloroquine with or without azithromycin is likely safe in individuals under 60 years of age if they do not have additional CV risks. However, the combination of hydroxychloroquine and azithromycin should be used with extreme caution in older patients.
C1 [Simmering, Jacob E.] Univ Iowa, Hlth Ventures Signal Ctr Healthcare Innovat, Iowa City, IA 52242 USA.
   [Polgreen, Linnea A.; Carter, Barry L.] Univ Iowa, Coll Pharm, Dept Pharm Practice & Sci, Iowa City, IA 52242 USA.
   [Polgreen, Philip M.; Teske, Rebecca E.; Comellas, Alejandro P.] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.
   [Polgreen, Philip M.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA 52242 USA.
   [Carter, Barry L.] Univ Iowa, Dept Family Med, Coll Med, Iowa City, IA 52242 USA.
RP Carter, BL (corresponding author), Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA.
EM barry-carter@uiowa.edu
OI Carter, Barry/0000-0002-0466-343X
FU University of Iowa; National Center for Advancing Translational Sciences
   of the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002537]
FX The authors have no conflicts of interest regarding the data or writing
   of this manuscript. The MarketScan data used for this project were
   obtained using departmental institutional funding from the University of
   Iowa. This project was supported in part by the National Center for
   Advancing Translational Sciences of the National Institutes of Health
   under Award Number UL1TR002537 (to Dr. Philip M. Polgreen). Drs.
   Simmering, Philip Polgreen and Linnea Polgreen have access to all the
   primary study databases and this access is ongoing. The authors had full
   access to all of the data in this study and take complete responsibility
   for the integrity of the data and the accuracy of the data analysis.
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Bansal M, 2020, DIABETES METAB SYND, V14, P247, DOI 10.1016/j.dsx.2020.03.013
   Bauman JL, 2020, PHARMACOTHERAPY, V40, P387, DOI 10.1002/phar.2387
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Cramer CL, 2017, POSTGRAD MED, V129, P493, DOI 10.1080/00325481.2017.1285677
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Medicare Learning Network Centers for Medicare & Medicaid Services, 2009, GEN EQ MAPP ICD 9 CM
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Mortensen EM, 2014, JAMA-J AM MED ASSOC, V311, P2199, DOI 10.1001/jama.2014.4304
   NEU HC, 1992, ANN INTERN MED, V116, P517, DOI 10.7326/0003-4819-116-6-517
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Polgreen LA, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008074
   Rao GA, 2014, ANN FAM MED, V12, P121, DOI 10.1370/afm.1601
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Zuckerman JM, 2004, INFECT DIS CLIN N AM, V18, P621, DOI 10.1016/j.idc.2004.04.010
NR 22
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD SEP
PY 2020
VL 40
IS 9
BP 978
EP 983
DI 10.1002/phar.2445
EA AUG 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NN7PJ
UT WOS:000555418100001
PM 32677113
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xiong, R
   Zhang, LK
   Li, SL
   Sun, Y
   Ding, MY
   Wang, Y
   Zhao, YL
   Wu, Y
   Shang, WJ
   Jiang, XM
   Shan, JW
   Shen, ZH
   Tong, Y
   Xu, LX
   Chen, Y
   Liu, YL
   Zou, G
   Lavillete, D
   Zhao, ZJ
   Wang, R
   Zhu, LL
   Xiao, GF
   Lan, K
   Li, HL
   Xu, K
AF Xiong, Rui
   Zhang, Leike
   Li, Shiliang
   Sun, Yuan
   Ding, Minyi
   Wang, Yong
   Zhao, Yongliang
   Wu, Yan
   Shang, Weijuan
   Jiang, Xiaming
   Shan, Jiwei
   Shen, Zihao
   Tong, Yi
   Xu, Liuxin
   Chen, Yu
   Liu, Yingle
   Zou, Gang
   Lavillete, Dimitri
   Zhao, Zhenjiang
   Wang, Rui
   Zhu, Lili
   Xiao, Gengfu
   Lan, Ke
   Li, Honglin
   Xu, Ke
TI Novel and potent inhibitors targeting DHODH are broad-spectrum
   antivirals against RNA viruses including newly-emerged coronavirus
   SARS-CoV-2
SO PROTEIN & CELL
LA English
DT Article
DE de novopyrimidine biosynthesis; DHODH inhibitors; SARS-CoV-2; influenza
   viruses; virus replication; immuno-regulation
ID PYRIMIDINE BIOSYNTHESIS; SEXUAL TRANSMISSION; DENGUE VIRUS; ZIKA;
   PNEUMONIA; INVOLVEMENT; BREQUINAR; DISCOVERY; INFECTION; CYTOKINES
AB Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we identified two potent inhibitors of human DHODH, S312 and S416, with favorable drug-likeness and pharmacokinetic profiles, which all showed broad-spectrum antiviral effects against various RNA viruses, including influenza A virus, Zika virus, Ebola virus, and particularly against SARS-CoV-2. Notably, S416 is reported to be the most potent inhibitor so far with an EC(50)of 17 nmol/L and an SI value of 10,505.88 in infected cells. Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacyin vivoand low virus replication in DHODH knock-out cells. This work demonstrates that both S312/S416 and old drugs (Leflunomide/Teriflunomide) with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide, no matter such viruses are mutated or not.
C1 [Wang, Yong; Zhao, Yongliang; Chen, Yu; Liu, Yingle; Lan, Ke; Xu, Ke] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Xiong, Rui; Li, Shiliang; Ding, Minyi; Shan, Jiwei; Shen, Zihao; Tong, Yi; Xu, Liuxin; Zhao, Zhenjiang; Wang, Rui; Zhu, Lili; Li, Honglin] East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
   [Zhang, Leike; Sun, Yuan; Wu, Yan; Shang, Weijuan; Jiang, Xiaming; Xiao, Gengfu] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Zou, Gang; Lavillete, Dimitri; Xu, Ke] Univ Chinese Acad Sci, Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China.
RP Xu, K (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.; Li, HL (corresponding author), East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.; Xu, K (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China.
EM hlli@ecust.edu.cn; xuke03@whu.edu.cn
RI ; Li, Shiliang/K-9864-2018
OI Chen, Yu/0000-0003-1300-4652; Li, Shiliang/0000-0003-4414-237X; ,
   Yuan/0000-0001-8244-7436
FU National Key Research and Development Program Grants [2018FYA0900801,
   2018ZX10101004003001, 2016YFA0502304]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [31922004, 81772202, 81825020]; National Science & Technology Major
   Project "Key New Drug Creation and Manufacturing Program" of China
   [2018ZX09711002]; Application & Frontier Research Program of Wuhan
   Government [2019020701011463]; National Program for Special Supports of
   Eminent Professionals; National Program for Support of Top-Notch Young
   Professionals
FX This work was supported in part by the National Key Research and
   Development Program Grants (2018FYA0900801 and 2018ZX10101004003001 to
   K.X., 2016YFA0502304 to H.L.), the National Natural Science Foundation
   of China (Grants 31922004 and 81772202 to K.X., 81825020 to H.L.), the
   National Science & Technology Major Project "Key New Drug Creation and
   Manufacturing Program" of China (Grant 2018ZX09711002 to H.L.),
   Application & Frontier Research Program of Wuhan Government
   (2019020701011463 to K.X.). Honglin Li is also sponsored by the National
   Program for Special Supports of Eminent Professionals and National
   Program for Support of Top-Notch Young Professionals. We thank Dr.
   Zhengli Shi for reviewing and Dr. Andy T. Y. Lau for English
   proofreading of this manuscript. We also thank our group members of the
   SARS-CoV-2 working group in State Key Laboratory of Virology, Wuhan
   University, who work tightly together during this new virus outbreak
   inside and outside of Wuhan city for their research spirits and courage,
   especially to Fang Liu, Qi Zhang, Ming Guo, Yuan Liu, Yan Zhang, and
   Ying Zhu for their efforts. We are grateful to Taikang Insurance Group
   Co., Ltd, Beijing Taikang Yicai Foundation, and Special Fund for
   COVID-19 Research of Wuhan University for their great supports to this
   work.
CR Adalja A, 2019, EXPERT REV ANTI-INFE, V17, P467, DOI 10.1080/14787210.2019.1635009
   Adcock RS, 2017, ANTIVIR RES, V138, P47, DOI 10.1016/j.antiviral.2016.11.018
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Carroll T, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006537
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   CHEN SF, 1992, CANCER RES, V52, P3521
   Chen SR, 2019, ANTIVIR RES, V167, P35, DOI 10.1016/j.antiviral.2019.04.005
   Cheung NN, 2017, J GEN VIROL, V98, P946, DOI 10.1099/jgv.0.000758
   Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x
   Chung DH, 2016, ANTIMICROB AGENTS CH, V60, P4552, DOI 10.1128/AAC.00282-16
   Coelho FC, 2016, INT J INFECT DIS, V51, P128, DOI 10.1016/j.ijid.2016.08.023
   Das P, 2013, ACS MED CHEM LETT, V4, P517, DOI 10.1021/ml300464h
   DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122
   Debing Y, 2015, CURR OPIN INFECT DIS, V28, P596, DOI 10.1097/QCO.0000000000000212
   Deng CL, 2016, VIROL SIN, V31, P176, DOI 10.1007/s12250-016-3778-5
   Diao YY, 2012, J MED CHEM, V55, P8341, DOI 10.1021/jm300630p
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Fox RI, 1999, CLIN IMMUNOL, V93, P198, DOI 10.1006/clim.1999.4777
   Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025
   Gao HN, 2013, NEW ENGL J MED, V368, P2277, DOI 10.1056/NEJMoa1305584
   Gong MJ, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109305
   Grandin C, 2016, ANTIVIR RES, V125, P58, DOI 10.1016/j.antiviral.2015.11.006
   Han QL, 2014, J VIROL, V88, P9379, DOI 10.1128/JVI.00509-14
   Harvey R, 2009, ANTIVIR RES, V82, P1, DOI 10.1016/j.antiviral.2008.12.015
   Hoffmann HH, 2011, P NATL ACAD SCI USA, V108, P5777, DOI 10.1073/pnas.1101143108
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Ianevski A, 2019, DRUG DISCOV TODAY, V24, P1224, DOI 10.1016/j.drudis.2019.04.006
   Jasenosky LD, 2010, ANTIMICROB AGENTS CH, V54, P3007, DOI 10.1128/AAC.00138-10
   JI SF, 2009, EUR J PHARM SCI, V3, P215
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Jordheim LP, 2013, NAT REV DRUG DISCOV, V12, P447, DOI 10.1038/nrd4010
   Kottkamp AC, 2019, J VIROL, V93, DOI [10.1128/JVI.00389-19, 10.1128/jvi.00389-19]
   Li SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep14836
   Lucas-Hourani M, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00383-17, 10.1128/aac.00383-17]
   Lucas-Hourani M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003678
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Luthra P, 2018, ANTIVIR RES, V158, P288, DOI 10.1016/j.antiviral.2018.08.012
   Marschall M, 2013, ANTIVIR RES, V100, P640, DOI 10.1016/j.antiviral.2013.10.003
   Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63
   Matsuoka Y, 2009, CURR PROTOC MICROBIO, V13, p15G
   McNicholl IR, 2001, ANN PHARMACOTHER, V35, P57, DOI 10.1345/aph.10118
   Min JY, 2010, NAT BIOTECHNOL, V28, P239, DOI 10.1038/nbt0310-239
   Munier-Lehmann H, 2013, J MED CHEM, V56, P3148, DOI 10.1021/jm301848w
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Qing M, 2010, ANTIMICROB AGENTS CH, V54, P3686, DOI 10.1128/AAC.00561-10
   Raveh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082318
   Rozman B, 2002, CLIN PHARMACOKINET, V41, P421, DOI 10.2165/00003088-200241060-00003
   Song WL, 2016, MEDCHEMCOMM, V7, P1441, DOI 10.1039/c6md00179c
   Tang WW, 2016, CELL REP, V17, P3091, DOI 10.1016/j.celrep.2016.11.070
   Van Hoecke L, 2017, JOVE-J VIS EXP, DOI 10.3791/55398
   Wan S., 2020, CHARACTERISTICS LYMP
   Wang CH, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-42
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QY, 2011, J VIROL, V85, P6548, DOI 10.1128/JVI.02510-10
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang YQ, 2019, J MED CHEM, V62, P4056, DOI 10.1021/acs.jmedchem.9b00091
   Yokota Shumpei, 2003, Nihon Rinsho, V61, P1953
   Yuen K. Y., 2005, Hong Kong Medical Journal, V11, P189
   Zeng HS, 2005, TRANSPLANTATION, V79, P17, DOI 10.1097/01.TP.0000137334.46155.94
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu JD, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00517
   Zhu JS, 2015, J MED CHEM, V58, P1123, DOI 10.1021/jm501127s
NR 66
TC 4
Z9 4
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-800X
EI 1674-8018
J9 PROTEIN CELL
JI Protein Cell
PD OCT
PY 2020
VL 11
IS 10
SI SI
BP 723
EP 739
DI 10.1007/s13238-020-00768-w
EA AUG 2020
PG 17
WC Cell Biology
SC Cell Biology
GA NS2SM
UT WOS:000555738000001
PM 32754890
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arbyn, M
   Gultekin, M
   Morice, P
   Nieminen, P
   Cruickshank, M
   Poortmans, P
   Kelly, D
   Poljak, M
   Bergeron, C
   Ritchie, D
   Schmidt, D
   Kyrgiou, M
   Van den Bruel, A
   Bruni, L
   Basu, P
   Bray, F
   Weiderpass, E
AF Arbyn, Marc
   Gultekin, Murat
   Morice, Philippe
   Nieminen, Pekka
   Cruickshank, Maggie
   Poortmans, Philip
   Kelly, Daniel
   Poljak, Mario
   Bergeron, Christine
   Ritchie, David
   Schmidt, Dietmar
   Kyrgiou, Maria
   Van den Bruel, Ann
   Bruni, Laia
   Basu, Partha
   Bray, Freddie
   Weiderpass, Elisabete
TI The European response to theWHOcall to eliminate cervical cancer as a
   public health problem
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE cervical cancer screening; COVID-19; elimination of cervical cancer;
   Europe; HPV vaccination; WHO
ID QUALITY-ASSURANCE; NORDIC COUNTRIES; HPV INFECTION; VACCINE; PREVENTION;
   GUIDELINES; MORTALITY; EFFICACY; DISEASE
AB The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost-effective; they should introduce organised population-based HPV-based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling.
C1 [Arbyn, Marc] Sciensano, Belgian Canc Ctr, Unit Canc Epidemiol, J Wytsmanst 14, B-1050 Brussels, Belgium.
   [Gultekin, Murat] Hacettepe Univ, Fac Med, Dept Obstet & Gynecol, Div Gynaecol Oncol, Ankara, Turkey.
   [Morice, Philippe] Gustave Roussy Inst, Dept Gynecol Surg, Villejuif, France.
   [Nieminen, Pekka] Univ Helsinki, Dept Obstet & Gynaecol, Helsinki, Finland.
   [Nieminen, Pekka] Univ Hosp Helsinki, Helsinki, Finland.
   [Cruickshank, Maggie] Univ Aberdeen, Aberdeen Ctr Womens Hlth Res, Aberdeen, Scotland.
   [Poortmans, Philip] European Canc Org, Brussels, Belgium.
   [Kelly, Daniel] Cardiff Univ, Sch Healthcare Sci, Cardiff, S Glam, Wales.
   [Poljak, Mario] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
   [Bergeron, Christine] Lab Cerba, Cergy Pontoise, France.
   [Ritchie, David] Assoc European Canc Leagues, Brussels, Belgium.
   [Schmidt, Dietmar] MVZ Pathol Cytol & Mol Diagnost, Trier, Germany.
   [Schmidt, Dietmar] Univ Kiel, Kiel, Germany.
   [Kyrgiou, Maria] Imperial Coll London, Fac Med, Dept Gut Metab & Reprod, London, England.
   [Kyrgiou, Maria] Imperial Coll London, Fac Med, Dept Surg & Canc, London, England.
   [Kyrgiou, Maria] Imperial Coll Healthcare NHS Trust, West London Gynaecol Canc Ctr, London, England.
   [Van den Bruel, Ann] Univ Leuven, Acad Ctr Gen Practice, Leuven, Belgium.
   [Bruni, Laia] Catalan Inst Oncol IDIBELL, Canc Epidemiol Res Program, Barcelona, Spain.
   [Basu, Partha; Bray, Freddie; Weiderpass, Elisabete] Int Agcy Res Canc, Lyon, France.
RP Arbyn, M (corresponding author), Sciensano, Belgian Canc Ctr, Unit Canc Epidemiol, J Wytsmanst 14, B-1050 Brussels, Belgium.
EM marc.arbyn@sciensano.be
OI Kelly, Daniel/0000-0002-1847-0655; Poljak, Mario/0000-0002-3216-7564;
   Arbyn, Marc/0000-0001-7807-5908
FU European Society of Gynaecologic Oncology [2019]; Horizon 2020 Framework
   Programme [847845]; Stichting Tegen Kanker; International Agency for
   Research on Cancer (IARC)World Health Organization
FX European Society of Gynaecologic Oncology, Grant/Award Number: 2019;
   Horizon 2020 Framework Programme, Grant/Award Number: 847845; Stichting
   Tegen Kanker, Grant/Award Number: IHUVAC; International Agency for
   Research on Cancer (IARC)
CR Arbyn M, 2020, BJOG-INT J OBSTET GY, V127, P388, DOI 10.1111/1471-0528.16023
   Arbyn M, 2010, ANN ONCOL, V21, P448, DOI 10.1093/annonc/mdp471
   Arbyn M, 2018, COCHRANE DB SYST REV, V5, P1
   Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6
   Arbyn M, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4823
   Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9
   Arbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095
   Arbyn M, 2009, EUR J CANCER, V45, P2640, DOI 10.1016/j.ejca.2009.07.018
   Beachler DC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv302
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Castanon A, 2018, PREV MED, V107, P21, DOI 10.1016/j.ypmed.2017.12.002
   Ciavattini A, 2020, INT J GYNECOL OBSTET, V149, P269, DOI 10.1002/ijgo.13158
   Datta S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4108-y
   Dillner J, 2018, LAKARTIDNINGEN, V115
   European Commission, 2008, EUR GUID QUAL ASS CE, P291
   European Commission, 2020, GUID HPV VACC EU COU, P1
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Goff SL, 2011, VACCINE, V29, P7343, DOI 10.1016/j.vaccine.2011.07.082
   LAARA E, 1987, LANCET, V1, P1247
   McDonald SA, 2017, CANCER CAUSE CONTROL, V28, P203, DOI 10.1007/s10552-017-0870-6
   O'Connor M, 2018, PREV MED, V115, P90, DOI 10.1016/j.ypmed.2018.08.017
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
   Simms KT, 2019, LANCET ONCOL, V20, P394, DOI 10.1016/S1470-2045(18)30836-2
   Vaccarella S, 2014, BRIT J CANCER, V111, P965, DOI 10.1038/bjc.2014.362
   von Karsa L, 2015, PAPILLOMAVIRUS RES, V1, P22, DOI 10.1016/j.pvr.2015.06.006
   WHO, 2018, WHO DIR GEN CALLS AL
   World Health Organization, 2019, GLOB STRAT EL CERV C
   Xu L, 2019, EXPERT REV VACCINES, DOI 10.1080/14760584.2019.1692658
NR 30
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 15
PY 2021
VL 148
IS 2
BP 277
EP 284
DI 10.1002/ijc.33189
EA AUG 2020
PG 8
WC Oncology
SC Oncology
GA OV2ME
UT WOS:000555269800001
PM 32638362
OA Other Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Gul, S
   Ozcan, O
   Asar, S
   Okyar, A
   Baris, I
   Kavakli, IH
AF Gul, Seref
   Ozcan, Onur
   Asar, Sinan
   Okyar, Alper
   Baris, Ibrahim
   Kavakli, Ibrahim Halil
TI In silico identification of widely used and well-tolerated drugs as
   potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA
   polymerase inhibitors for direct use in clinical trials
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; 3 chymotrypsin like protease; RNA dependent RNA polymerase;
   drug repurposing; tetracycline
ID VASOPRESSIN-RECEPTOR ANTAGONIST; ANTIVIRAL ACTIVITY; ORAL CONIVAPTAN;
   PROSTATE-CANCER; SOFTWARE NEWS; CORONAVIRUS; EFFICACY; SAFETY; VIRUS;
   HIV
AB Despite strict measures taken by many countries, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an issue of global concern. Currently, there are no clinically proven pharmacotherapies for coronavirus disease 2019, despite promising initial results obtained from drugs such as azithromycin and hydroxychloroquine. Therefore, the repurposing of clinically approved drugs for use against SARS-CoV-2 has become a viable strategy. Here, we searched for drugs that target SARS-CoV-2 3C-like protease (3CL(pro)) and viral RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs were selected for molecular dynamics (MD) simulations to evaluate drug-protein interactions and their persistence under physiological conditions. Tetracycline, dihydroergotamine, ergotamine, dutasteride, nelfinavir, and paliperidone formed stable interactions with 3CL(pro)based on MD simulation results. Similar analysis with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies. Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity. As these drugs are well tolerated, cost-effective, and widely used, our study suggests that they could potentially to be used in clinical trials for the treatment of SARS-CoV-2-infected patients. Communicated by Ramaswamy H. Sarma
C1 [Gul, Seref; Kavakli, Ibrahim Halil] Koc Univ, Dept Chem & Biol Engn, Istanbul, Turkey.
   [Ozcan, Onur; Baris, Ibrahim; Kavakli, Ibrahim Halil] Koc Univ, Dept Mol Biol & Genet, Istanbul, Turkey.
   [Asar, Sinan] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey.
   [Okyar, Alper] Istanbul Univ, Dept Pharmacol, Fac Pharm, Istanbul, Turkey.
RP Kavakli, IH (corresponding author), Koc Univ, Chem & Biol Engn, Rumelifener Yolu, Istanbul, Turkey.
EM hkavakli@ku.edu.tr
RI GUL, SEREF/AAR-3289-2020
OI GUL, SEREF/0000-0002-5613-1339
CR Agwuh KN, 2006, J ANTIMICROB CHEMOTH, V58, P256, DOI 10.1093/jac/dkl224
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andriole GL, 2003, EUR UROL, V44, P82, DOI 10.1016/S0302-2838(03)00198-2
   Annane D, 2009, AM J MED SCI, V337, P28, DOI 10.1097/MAJ.0b013e31817b8148
   Armutlu P, 2009, LETT DRUG DES DISCOV, V6, P337, DOI 10.2174/1570180810906050337
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Cakir B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031787
   Case D. A., 2018, AMBER, V208
   Chan JFW, 2017, ANTIVIR RES, V141, P29, DOI 10.1016/j.antiviral.2017.02.002
   Christie S, 2003, EUR NEUROL, V49, P20, DOI 10.1159/000067018
   Clark RV, 2004, J CLIN ENDOCR METAB, V89, P2179, DOI 10.1210/jc.2003-030330
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Davidson M., 2006, SCHIZOPHRENIA RES, V81
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   DeLano WL, 2009, ABSTR PAP AM CHEM S, V238
   Deng YL, 2011, DRUG METAB DISPOS, V39, P1734, DOI 10.1124/dmd.111.040170
   Diener HC, 2002, EUR NEUROL, V47, P99, DOI 10.1159/000047960
   Doruk YU, 2020, J BIOL CHEM, V295, P3518, DOI 10.1074/jbc.RA119.011332
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Erickson-Miller CL, 2009, STEM CELLS, V27, P424, DOI 10.1634/stemcells.2008-0366
   Firth AE, 2012, J GEN VIROL, V93, P1385, DOI 10.1099/vir.0.042499-0
   Gantt S, 2013, CURR OPIN ONCOL, V25, P495, DOI 10.1097/CCO.0b013e328363dfee
   Ghali JK, 2006, J CLIN ENDOCR METAB, V91, P2145, DOI 10.1210/jc.2005-2287
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Graham RL, 2008, VIRUS RES, V133, P88, DOI 10.1016/j.virusres.2007.02.017
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   He YF, 2020, WORLD J CLIN CASES, V8, DOI 10.12998/wjcc.v8.i11.2325
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Janicak P. G., 2007, NEUROPSYCH DIS TREAT, V3, DOI [10.2147/NDT.S1365, DOI 10.2147/NDT.S1365, 10.2147/ndt.s1365]
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Kato F, 2016, ANTIVIR RES, V131, P141, DOI 10.1016/j.antiviral.2016.04.014
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kim S, 2017, J COMPUT CHEM, V38, P1879, DOI 10.1002/jcc.24829
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kvernmo T, 2006, CLIN THER, V28, P1065, DOI 10.1016/j.clinthera.2006.08.004
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li YM, 2017, 2017 IEEE INTERNATIONAL SYMPOSIUM ON ELECTROMAGNETIC COMPATIBILITY & SIGNAL/POWER INTEGRITY (EMCSI), P364, DOI 10.1109/ISEMC.2017.8077896
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lo HS, 2020, BIORXIV, DOI [10.1101/2020.05.26.116020, DOI 10.1101/2020.05.26.116020]
   Lucas J, 2008, J PATHOL, V215, P118, DOI 10.1002/path.2330
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Maksimovic-Ivanic D, 2017, INT J CANCER, V140, P1713, DOI 10.1002/ijc.30529
   Marberger M, 2006, NAT CLIN PRACT UROL, V3, P495, DOI 10.1038/ncpuro0577
   Marder SR, 2007, BIOL PSYCHIAT, V62, P1363, DOI 10.1016/j.biopsych.2007.01.017
   Montes-Grajales D, 2020, ANTIVIR RES, V173, DOI 10.1016/j.antiviral.2019.104668
   Mortier E, 2001, AM J MED, V110, P594, DOI 10.1016/S0002-9343(01)00655-6
   Mostaghel EA, 2014, J CLIN ONCOL, V32, P229, DOI 10.1200/JCO.2012.48.6431
   Musarrat F, 2020, J MED VIROL, V92, P2087, DOI 10.1002/jmv.25985
   Owen C. D., 2020, COVID 19 MAIN PROTEA, DOI 10.2210/pdb6Y84
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Roehrborn CG, 2002, UROLOGY, V60, P434, DOI 10.1016/S0090-4295(02)01905-2
   Rosenthal E., 1999, JAMA-J AM MED ASSOC, V281, DOI [10.1001/jama.281.11.987, DOI 10.1001/JAMA.281.11.987]
   Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7
   Sarma P., 2020, J BIOMOLECULAR STRUC
   Scandella E., 2006, ADV EXPT MED BIOL, V581, DOI [10.1007/978-0-387-33012-9_111, DOI 10.1007/978-0-387-33012-9_111]
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Smilack JD, 1999, MAYO CLIN PROC, V74, P727, DOI 10.4065/74.7.727
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tardu M, 2016, RAIRO-OPER RES, V50, P387, DOI 10.1051/ro/2015042
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thomson A, 2005, CORE EVID, V1, P65
   Tomar S, 2015, J BIOL CHEM, V290, P19403, DOI 10.1074/jbc.M115.651463
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Via MA, 2010, DIABETES METAB SYNDR, V3, P43, DOI 10.2147/DMSO.S9575
   WHO, 2020, WHO DIR GEN REM MED
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
   Wu ZC, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnv195
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Young WB, 1997, HEADACHE, V37, P15, DOI 10.1046/j.1526-4610.1997.3701015.x
   Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095
   Yuan SF, 2017, ANTIVIR RES, V145, P33, DOI 10.1016/j.antiviral.2017.07.007
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 86
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1802346
EA AUG 2020
PG 20
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MU4KJ
UT WOS:000555638600001
PM 32752938
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Joshi, T
   Joshi, T
   Pundir, H
   Sharma, P
   Mathpal, S
   Chandra, S
AF Joshi, Tanuja
   Joshi, Tushar
   Pundir, Hemlata
   Sharma, Priyanka
   Mathpal, Shalini
   Chandra, Subhash
TI Predictive modeling by deep learning, virtual screening and molecular
   dynamics study of natural compounds against SARS-CoV-2 main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; deep learning; molecular docking; main protease (MPro);
   natural compounds
ID HIGH-THROUGHPUT; DRUG DISCOVERY; DOCKING
AB The whole world is facing a great challenging time due to Coronavirus disease (COVID-19) caused by SARS-CoV-2. Globally, more than 14.6 M people have been diagnosed and more than 595 K deaths are reported. Currently, no effective vaccine or drugs are available to combat COVID-19. Therefore, the whole world is looking for new drug candidates that can treat the COVID-19. In this study, we conducted a virtual screening of natural compounds using a deep-learning method. A deep-learning algorithm was used for the predictive modeling of a CHEMBL3927 dataset of inhibitors of Main protease (Mpro). Several predictive models were developed and evaluated based on R-2, MAE MSE, RMSE, and Loss. The best model with R-2=0.83, MAE = 1.06, MSE = 1.5, RMSE = 1.2, and loss = 1.5 was deployed on the Selleck database containing 1611 natural compounds for virtual screening. The model predicted 500 hits showing the value score between 6.9 and 3.8. The screened compounds were further enriched by molecular docking resulting in 39 compounds based on comparison with the reference (X77). Out of them, only four compounds were found to be drug-like and three were non-toxic. The complexes of compounds and Mpro were finally subjected to Molecular dynamic (MD) simulation for 100 ns. The MMPBSA result showed that two compounds Palmatine and Sauchinone formed very stable complex with Mpro and had free energy of -71.47 kJ mol(-1)and -71.68 kJ mol(-1)respectively as compared to X77 (-69.58 kJ mol(-1)). From this study, we can suggest that the identified natural compounds may be considered for therapeutic development against the SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Joshi, Tanuja; Chandra, Subhash] Kumaun Univ, Dept Bot, Computat Biol & Biotechnol Lab, SSJ Campus, Almora 263601, Uttarakhand, India.
   [Joshi, Tushar; Mathpal, Shalini] Kumaun Univ Uttarakhand, Dept Biotechnol, Bhimtal Campus, Bhimtal, India.
   [Pundir, Hemlata; Sharma, Priyanka] Kumaun Univ, Dept Bot, DSB Campus, Naini Tal, India.
RP Chandra, S (corresponding author), Kumaun Univ, Dept Bot, Computat Biol & Biotechnol Lab, SSJ Campus, Almora 263601, Uttarakhand, India.
EM scjnu@yahoo.co.in
RI Joshi, Tushar/AAJ-9626-2020
OI Chandra, Subhash/0000-0002-8978-5427
CR Biovia D.S., 2015, DISCOVERY STUDIO MOD
   Elmezayen A. D., 2020, J BIOMOLECULAR STRUC
   Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   He JX, 2019, NAT MED, V25, P30, DOI 10.1038/s41591-018-0307-0
   He ZK, 2018, BIOMED PHARMACOTHER, V101, P355, DOI 10.1016/j.biopha.2018.02.121
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   Joshi T, 2020, MOL DIVERS, DOI 10.1007/s11030-020-10118-x
   Kumar A., 2020, J BIOMOLECULAR STRUC
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu ZH, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz104
   Long JY, 2019, BIOCHIMIE, V162, P176, DOI 10.1016/j.biochi.2019.04.008
   Mahady GB, 2001, J NUTR, V131, p1120S, DOI 10.1093/jn/131.3.1120S
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Nisha CM, 2016, J MOL GRAPH MODEL, V65, P100, DOI 10.1016/j.jmgm.2016.03.001
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Robitzski D., 2020, SCI CORONAVIRUS ALRE
   Rusk N, 2016, NAT METHODS, V13, P35, DOI 10.1038/nmeth.3707
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanommeslaeghe K., 2009, J COMPUTATIONAL CHEM, V31
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   Yang LQ, 2014, J BIOMOL STRUCT DYN, V32, P372, DOI 10.1080/07391102.2013.770372
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Yuan S., 2017, WILEY INTERDISCIPLIN, V7
NR 30
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1802341
EA AUG 2020
PG 19
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MU4RU
UT WOS:000555657900001
PM 32752947
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Khelfaoui, H
   Harkati, D
   Saleh, BA
AF Khelfaoui, Hadjer
   Harkati, Dalal
   Saleh, Basil A.
TI Molecular docking, molecular dynamics simulations and reactivity,
   studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding
   with ACE2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Angiotensin-converting enzyme 2 (ACE2); SARS-CoV-2; molecular docking;
   molecular dynamincs simulation; global reactivity
ID OPTIMIZATION; RECEPTOR; HEALTH; ZINC
AB The recent new contagion coronavirus 2019 (COVID-19) disease is a new generation of severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 which infected millions confirmed cases and hundreds of thousands death cases around the world so far. Molecular docking combined with molecular dynamics is one of the most important tools of drug discovery and drug design, which it used to examine the type of binding between the ligand and its protein enzyme. Global reactivity has important properties, which enable chemists to understand the chemical reactivity and kinetic stability of compounds. In this study, molecular docking and reactivity were applied for eighteen drugs, which are similar in structure to chloroquine and hydroxychloroquine, the potential inhibitors to angiotensin-converting enzyme (ACE2). Those drugs were selected from DrugBank. The reactivity, molecular docking and molecular dynamics were performed for two receptors ACE2 and [SARS-CoV-2/ACE2] complex receptor in two active sites to find a ligand, which may inhibit COVID-19. The results obtained from this study showed thatRamipril,DelaprilandLisinoprilcould bind with ACE2 receptor and [SARS-CoV-2/ACE2] complex better than chloroquine and hydroxychloroquine. This new understanding should help to improve predictions of the impact of such alternatives on COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Khelfaoui, Hadjer; Harkati, Dalal] Univ Biskra, Dept Matter Sci, Fac Exact & Nat Sci, Grp Computat Pharmaceut Chem,LMCE Lab, Biskra 07000, Algeria.
   [Saleh, Basil A.] Univ Basrah, Coll Sci, Dept Chem, Basrah, Iraq.
RP Harkati, D (corresponding author), Univ Biskra, Dept Matter Sci, Fac Exact & Nat Sci, Grp Computat Pharmaceut Chem,LMCE Lab, Biskra 07000, Algeria.; Saleh, BA (corresponding author), Univ Basrah, Coll Sci, Dept Chem, Basrah, Iraq.
EM d.harkati@univ-biskra.dz; basil.saleh@uobasrah.edu.iq
CR Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Alirezaei M, 1999, J BIOL CHEM, V274, P32433, DOI 10.1074/jbc.274.45.32433
   Amin M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775703
   [Anonymous], 2019, MARVINSKETCH 19 25 0
   Azarhazin E, 2019, CAN J CHEM, V97, P120, DOI 10.1139/cjc-2018-0126
   Basit A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768150
   Becke AD, 1997, J CHEM PHYS, V107, P8554, DOI 10.1063/1.475007
   Berman H. M., 2020, PROTEIN DATA BANK
   Bohm H. J., 2005, PROTEIN LIGAND INTER, DOI [10.1002/3527601813, DOI 10.1002/3527601813]
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   Cavalli A, 2006, CHEM REV, V106, P3497, DOI 10.1021/cr050579p
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   De Vivo M, 2016, J MED CHEM, V59, P4035, DOI 10.1021/acs.jmedchem.5b01684
   Defranceschi M., 2000, MATH MOD METH APPL S, V136, DOI [10.1016/0166-1280(86)87076-2, DOI 10.1016/0166-1280(86)87076-2]
   Dennington R.K., 2016, GAUSSVIEW VERSION 6
   Didierjean C., 2016, ACTA CRYSTALLOGR D, V72, P1308, DOI [10.1107/S2059798316018283, DOI 10.1107/S2059798316018283]
   Domingo LR, 2016, MOLECULES, V21, DOI 10.3390/molecules21060748
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671
   Gurley SB, 2008, EXP PHYSIOL, V93, P538, DOI 10.1113/expphysiol.2007.040014
   Harkati D., 2017, QUANTUM MATTER, V6, P1, DOI [10.1166/qm.2017.1441, DOI 10.1166/QM.2017.1441]
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HyperChem (8.08), 2009, MOL MODELLING SYSTEM
   Jaramillo P, 2008, J MOL STRUC-THEOCHEM, V865, P68, DOI 10.1016/j.theochem.2008.06.022
   Kellenberger E, 2004, PROTEINS, V57, P225, DOI 10.1002/prot.20149
   Kerrigan John E, 2013, Methods Mol Biol, V993, P95, DOI 10.1007/978-1-62703-342-8_7
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lazarczyk M, 2008, J VIROL, V82, P11486, DOI 10.1128/JVI.01314-08
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Marechal Y., 2007, HYDROGEN BOND WATER, DOI [10.1016/B978-0-444-51957-3.X5000-8., DOI 10.1016/B978-0-444-51957-3.X5000-8]
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   Ramalho TC, 2009, J BIOMOL STRUCT DYN, V27, P195, DOI 10.1080/07391102.2009.10507309
   Shahab S, 2016, DYES PIGMENTS, V129, P9, DOI 10.1016/j.dyepig.2016.02.003
   SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v3, DOI 10.26434/CHEMRXIV.11871402.V3]
   Srivastava R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1725642
   Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x
   Sturgeon JB, 2000, J CHEM PHYS, V112, P3474, DOI 10.1063/1.480502
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Veeramachaneni GK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1773318
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Venugopal C, 2008, CNS NEUROL DISORD-DR, V7, P278, DOI 10.2174/187152708784936626
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zekri A, 2020, J MOL STRUCT, V1217, DOI 10.1016/j.molstruc.2020.128442
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 56
TC 1
Z9 1
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1803967
EA AUG 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MU4PT
UT WOS:000555652600001
PM 32752951
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Elsaie, ML
   Jafferany, M
   Jorgaqi, E
AF Elsaie, Mohamed L.
   Jafferany, Mohammad
   Jorgaqi, Etleva
TI Nonsteroidal anti-inflammatory drugs (NSAIDs) consideration by
   dermatologists during the COVID19 pandemic
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article; Early Access
DE NSAID; COVID19; SARS-CoV-2
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) have been an important therapy in the treatment of a large number of cutaneous pathologies for more than three decades. Concerns have been raised that NSAIDs may be associated with an increased risk of adverse effects when used in patients with acute viral respiratory infections. Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is of extreme importance Although accumulating evidence support the existence of a harmful effect of NSAIDs in some infectious settings, no clinical studies demonstrating that such risk applies in case of COVID-19. Pending further research, a pragmatic and cautionary approach would be to avoid regular NSAID use or as first line option in suspicion of COVID19 symptoms.
C1 [Elsaie, Mohamed L.] Natl Res Ctr, Dept Dermatol, Cairo, Egypt.
   [Jafferany, Mohammad] Cent Michigan Univ, Coll Med, Saginaw, MI USA.
   [Jorgaqi, Etleva] Mother Theresa Hosp, Tirana, Albania.
RP Elsaie, ML (corresponding author), Natl Res Ctr, Dept Dermatol, Cairo, Egypt.
EM egydoc77@yahoo.com
RI Elsaie, Mohamed/E-6175-2010
OI Elsaie, Mohamed/0000-0001-7541-5241
CR Dorris SL, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/926968
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   GOV.UK, 2020, COMM HUM MED ADV IB
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   LICHTENSTEIN J, 1987, INT J DERMATOL, V26, P80, DOI 10.1111/j.1365-4362.1987.tb00525.x
   Micallef J, 2020, THERAPIE, V75, P355, DOI 10.1016/j.therap.2020.05.003
   Pirmohamed M, 2004, BMJ, V329
   Reardon B, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-2470
   Tan SHS, 2020, INT ORTHOP, V44, P1599, DOI 10.1007/s00264-020-04643-5
   Voiriot G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060786
   WHO TEAM scientific brief, US NONST ANT DRUGS N
NR 11
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1800580
EA AUG 2020
PG 2
WC Dermatology
SC Dermatology
GA MU4JW
UT WOS:000555637300001
PM 32723104
DA 2021-01-01
ER

PT J
AU Upadhyay, S
   Tripathi, PK
   Singh, M
   Raghavendhar, S
   Bhardwaj, M
   Patel, AK
AF Upadhyay, Saurabh
   Tripathi, Praveen K.
   Singh, Manju
   Raghavendhar, Siva
   Bhardwaj, Mohit
   Patel, Ashok K.
TI Evaluation of medicinal herbs as a potential therapeutic option
   againstSARS-CoV-2 targeting its main protease
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE 3CL(pro); Haritaki; medicinal plants; SARS-CoV-2; tea
ID GREEN TEA; CAMELLIA-SINENSIS; SARS; BENEFITS
AB The COVID-19 disease caused by the SARS-CoV-2 has emerged as a worldwide pandemic and caused huge damage to the lives and economy of more than hundred countries. As on May 10, 2020, more than 4,153,300 people stand infected from the virus due to an unprecedented rate of transmission and 282,700 have lost their lives because of the disease. In this context, medicinal plants may provide a way to treat the disease by targeting specific essential proteins of the virus. We screened about 51 medicinal plants and found that Tea (Camellia sinensis)and Haritaki (Terminalia chebula) has potential against SARS-COV-2 3CL(pro), with an IC(50)for Green Tea as 8.9 +/- 0.5 mu g/ml and Haritaki 8.8 +/- 0.5 mu g/ml. The in-silico studies suggested that Tea component Thearubigins binds to the cysteine 145 of protease active site and could be a pharmacoactive molecule. We predict that the inhibition in protease activity may be able to halt the SARS-CoV-2 replication cycle and therefore, we propose Green Tea, Black Tea, and Haritaki plant extracts as potential therapeutic candidates for SARS-CoV-2 infection. Further investigation on role of bioactive constituents of extracts is needed to establish the molecular basis of inhibition and towards expedited drug discovery.
C1 [Upadhyay, Saurabh; Tripathi, Praveen K.; Raghavendhar, Siva; Bhardwaj, Mohit; Patel, Ashok K.] Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi 110016, India.
   [Singh, Manju] Morarji Desai Natl Inst Yoga, New Delhi, India.
RP Patel, AK (corresponding author), Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi 110016, India.
EM ashokpatel@bioschool.iitd.ac.in
OI PATEL, ASHOK/0000-0001-6134-7794
FU Indian Institute of Technology Delhi [MI02217G]
FX Indian Institute of Technology Delhi, Grant/Award Number: MI02217G
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Banik Swarnali, 2018, F1000Res, V7, P1151, DOI 10.12688/f1000research.15642.1
   Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518
   Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009
   Carneiro BM, 2016, VIROLOGY, V496, P215, DOI 10.1016/j.virol.2016.06.012
   Chan EWC, 2007, FOOD CHEM, V102, P1214, DOI 10.1016/j.foodchem.2006.07.009
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Cheng Hua-Yew, 2002, Antivir Chem Chemother, V13, P223
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P639, DOI 10.1089/acm.2005.11.639
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P521, DOI 10.1089/acm.2005.11.521
   Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306
   Cupp-Enyard C., 2008, JOVE-J VIS EXP, V17, pe899, DOI [DOI 10.3791/899, 10.3791/899., 10.3791/899]
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Karamese Murat, 2015, Asian Pac J Cancer Prev, V16, P4199
   Kesharwani A, 2017, BMC COMPLEM ALTERN M, V17, P1, DOI 10.1186/s12906-017-1620-8
   Lee D, 2011, J KOREAN SOC APPL BI, V54, P295, DOI 10.3839/jksabc.2011.046
   Lee YH, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-017-0092-1
   Li P, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00182
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Mahmood MS, 2016, AFR J TRADIT COMPLEM, V13, P176, DOI 10.4314/ajtcam.v13i2.21
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   Raghavendhar S, 2019, VIROLOGY, V533, P45, DOI 10.1016/j.virol.2019.04.007
   Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
NR 27
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD DEC
PY 2020
VL 34
IS 12
BP 3411
EP 3419
DI 10.1002/ptr.6802
EA AUG 2020
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PC4GH
UT WOS:000555282800001
PM 32748969
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hou, ZY
   Du, FX
   Zhou, XY
   Jiang, H
   Martin, S
   Larson, HD
   Lin, L
AF Hou, Zhiyuan
   Du, Fanxing
   Zhou, Xinyu
   Jiang, Hao
   Martin, Sam
   Larson, Heidi
   Lin, Leesa
TI Cross-Country Comparison of Public Awareness, Rumors, and Behavioral
   Responses to the COVID-19 Epidemic: Infodemiology Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE COVID-19; internet; surveillance; infodemic; infodemiology;
   infoveillance; Google Trends; public response; behavior; rumor; trend
ID COMMUNICATION; OUTBREAK; SYSTEMS; RISK
AB Background: Understanding public behavioral responses to the coronavims disease (COVID-19) epidemic and the accompanying infodemic is crucial to controlling the epidemic.
   Objective: The aim of this study was to assess real-time public awareness and behavioral responses to the COVID-19 epidemic across 12 selected countries.
   Methods: Internet surveillance was used to collect real-time data from the general public to assess public awareness and rumors (China . Baidu; worldwide: Google Trends) and behavior responses (China . Ali Index; worldwide: Google Shopping). These indices measured the daily number of searches or purchases and were compared with the numbers of daily COVID-19 cases. The trend comparisons across selected countries were observed from December 1, 2019 (prepandemic baseline) to April 11, 2020 (at least one month after the governments of selected countries took actions for the pandemic).
   Results: We identified missed windows of opportunity for early epidemic control in 12 countries, when public awareness was very low despite the emerging epidemic. China's epidemic and the declaration of a public health emergency of international concern did not prompt a worldwide public reaction to adopt health-protective measures; instead, most countries and regions only responded to the epidemic after their own case counts increased. Rumors and misinformation led to a surge of sales in herbal remedies in China and antimalarial drugs worldwide, and timely clarification of rumors mitigated the rush to purchase unproven remedies.
   Conclusions: Our comparative study highlights the urgent need for international coordination to promote mutual learning about epidemic characteristics and effective control measures as well as to trigger early and timely responses in individual countries. Early release of official guidelines and timely clarification of rumors led by governments are necessary to guide the public to take rational action.
C1 [Hou, Zhiyuan; Du, Fanxing; Zhou, Xinyu; Jiang, Hao] Fudan Univ, Sch Publ Hlth, Mailbox 250,138 Yixueyuan Rd, Shanghai, Peoples R China.
   [Hou, Zhiyuan] Fudan Univ, Global Hlth Inst, NHC Key Lab Hlth Technol Assessment, Shanghai, Peoples R China.
   [Martin, Sam] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Larson, Heidi; Lin, Leesa] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Larson, Heidi] Univ Washington, Dept Hlth Metr Sci, Seattle, WA USA.
RP Hou, ZY (corresponding author), Fudan Univ, Sch Publ Hlth, Mailbox 250,138 Yixueyuan Rd, Shanghai, Peoples R China.
EM zyhou@fudan.edu.cn
RI Martin, Sam/ABC-4849-2020; Lin, Leesa/ABH-7167-2020
OI Martin, Sam/0000-0002-4466-8374; Lin, Leesa/0000-0003-4123-4762; Zhou,
   Xinyu/0000-0003-0968-4229
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [71874034]
FX ZH acknowledges financial support from the National Natural Science
   Foundation of China (No. 71874034). The funders had no role in the study
   design, data collection, data analysis, data interpretation, or writing
   of the report.
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Anna PA, 2020, VARIATION GOVT RESPO
   [Anonymous], 2020, LANCET, V395, P537
   [Anonymous], 2020, ACT PLAN GUID COVID
   Arora VS, 2019, HEALTH POLICY, V123, P338, DOI 10.1016/j.healthpol.2019.01.001
   Betsch C, 2020, LANCET, V395, P1255, DOI 10.1016/S0140-6736(20)30729-7
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Kar Keung, 2020, Lancet, DOI 10.1016/S0140-6736(20)30918-1
   Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   Hsu YC, 2017, HEALTH SECUR, V15, P165, DOI 10.1089/hs.2016.0111
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Husnayain A, 2020, INT J INFECT DIS, V95, P221, DOI 10.1016/j.ijid.2020.03.021
   Jaffe S, 2020, LANCET, V395, P1179, DOI 10.1016/S0140-6736(20)30817-5
   Larson HJ, 2020, NATURE, V580, P306, DOI 10.1038/d41586-020-00920-w
   Legido-Quigley H, 2020, LANCET, V395, P848, DOI 10.1016/S0140-6736(20)30551-1
   Li CL, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.10.2000199
   Lin LS, 2014, PUBLIC HEALTH REP, V129, P49, DOI 10.1177/00333549141296S408
   Lin L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-484
   Lin YH, 2020, BRAIN BEHAV IMMUN, V87, P30, DOI 10.1016/j.bbi.2020.04.020
   Majumder Maimuna S, 2016, JMIR Public Health Surveill, V2, pe30, DOI 10.2196/publichealth.5814
   Milinovich GJ, 2014, LANCET INFECT DIS, V14, P160, DOI 10.1016/S1473-3099(13)70244-5
   National Health Commission of the People's Republic of China, WEBP CHIN
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Robertson A., 2020, VERGE           0409
   Sullivan B., 2020, FORBES
   World Health Organization, COR DIS 2019 COVID 1
NR 29
TC 2
Z9 2
U1 11
U2 11
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 3
PY 2020
VL 22
IS 8
AR e21143
DI 10.2196/21143
PG 12
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NW5LK
UT WOS:000575053200001
PM 32701460
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pirone, L
   Del Gatto, A
   Di Gaetano, S
   Saviano, M
   Capasso, D
   Zaccaro, L
   Pedone, E
AF Pirone, Luciano
   Del Gatto, Annarita
   Di Gaetano, Sonia
   Saviano, Michele
   Capasso, Domenica
   Zaccaro, Laura
   Pedone, Emilia
TI A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE spike protein; galectin; integrin; ACE2; ganglioside
ID SPIKE; BINDING; PROTEIN; RECEPTOR; FUSION
AB The public health has declared an international state of emergency due to the spread of a new coronavirus (SARS-CoV-2) representing a real pandemic threat so that to find potential therapeutic agents is a dire need. To this aim, the SARS-CoV-2 spike (S) glycoprotein represents a crucial target for vaccines, therapeutic antibodies, and diagnostics. Since virus binding to ACE-2 alone could not be sufficient to justify such severe infection, in order to facilitate medical countermeasure development and to search for new targets, two further regions of S protein have been taken into consideration here. One is represented by the recently identified ganglioside binding site, exactly localized in our study in the galectin-like domain, and the other one by the putative integrin binding sites contained in the RBD. We propose that a cooperating therapy using inhibitors against multiple targets altogether i.e., ACE2, integrins and sugars could be definitely more effective.
C1 [Pirone, Luciano; Del Gatto, Annarita; Di Gaetano, Sonia; Zaccaro, Laura; Pedone, Emilia] CNR, Inst Biostruct & Bioimaging, Naples, Italy.
   [Del Gatto, Annarita; Di Gaetano, Sonia; Saviano, Michele; Capasso, Domenica; Zaccaro, Laura; Pedone, Emilia] Univ Naples Federico II, CIRPEB, Naples, Italy.
   [Saviano, Michele] CNR, Inst Crystallog, Bari, Italy.
   [Capasso, Domenica] Univ Naples Federico II, CESTEV, Naples, Italy.
RP Zaccaro, L (corresponding author), CNR, Inst Biostruct & Bioimaging, Naples, Italy.; Capasso, D; Zaccaro, L (corresponding author), Univ Naples Federico II, CIRPEB, Naples, Italy.; Capasso, D (corresponding author), Univ Naples Federico II, CESTEV, Naples, Italy.
EM domenica.capasso@unina.it; lzaccaro@unina.it
RI Saviano, Michele/R-1693-2016; Pirone, Luciano/ABG-2892-2020
OI Saviano, Michele/0000-0001-5086-2459; 
CR Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chang A, 2012, J VIROL, V86, P3230, DOI 10.1128/JVI.06706-11
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Comegna D, 2017, J MED CHEM, V60, P9874, DOI 10.1021/acs.jmedchem.7b01590
   Del Gatto A, 2006, J MED CHEM, V49, P3416, DOI 10.1021/jm060233m
   Di Gaetano S, 2019, CARBOHYD RES, V482, DOI 10.1016/j.carres.2019.107740
   Di Gaetano S, 2018, PEPTIDE SCI, V110, DOI 10.1002/pep2.24054
   Fang L, 2020, LANCET RESP MED, V8, pE32, DOI 10.1016/S2213-2600(20)30159-4
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Farina B, 2016, CHEM-EUR J, V22, P681, DOI 10.1002/chem.201503126
   Gao Shan-dian, 2008, Virologica Sinica, V23, P1, DOI 10.1007/s12250-008-2886-2
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Kanduc D, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108426
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Matrosovich M, 2015, TOP CURR CHEM, V367, P1, DOI 10.1007/128_2013_466
   Peng GQ, 2012, J BIOL CHEM, V287, P41931, DOI 10.1074/jbc.M112.418210
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Teoh CM, 2015, CURR MOL MED, V15, P714, DOI 10.2174/1566524015666150921105339
   Tresoldi I, 2020, J MED VIROL, V92, P1741, DOI 10.1002/jmv.25831
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wei YW, 2014, J VIROL, V88, P4338, DOI 10.1128/JVI.03491-13
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan S., 2020, PREPRINT, DOI [10.20944/preprints202002.0447.v1, DOI 10.20944/PREPRINTS202002.0447.V1]
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
NR 25
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD AUG 3
PY 2020
VL 7
AR 186
DI 10.3389/fmolb.2020.00186
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NF5GP
UT WOS:000563324900001
PM 32850973
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sung, HK
   Kim, JY
   Heo, J
   Seo, H
   Jang, YS
   Kim, H
   Koh, BR
   Jo, N
   Oh, HS
   Baek, YM
   Park, KH
   Shon, JA
   Kim, MC
   Kim, JH
   Chang, HH
   Park, Y
   Kang, YM
   Lee, DH
   Oh, DH
   Park, HJ
   Song, KH
   Lee, EK
   Jeong, H
   Lee, JY
   Ko, JY
   Choi, J
   Ryu, EH
   Chung, KH
   Oh, MD
AF Sung, Ho Kyung
   Kim, Jin Yong
   Heo, Jeonghun
   Seo, Haesook
   Jang, Young soo
   Kim, Hyewon
   Koh, Bo Ram
   Jo, Neungsun
   Oh, Hong Sang
   Baek, Young Mi
   Park, Kyung-Hwa
   Shon, Jeung A.
   Kim, Min-Chul
   Kim, Joon Ho
   Chang, Hyun-Ha
   Park, Yukyung
   Kang, Yu Min
   Lee, Dong Hyun
   Oh, Dong Hyun
   Park, Hyun Jung
   Song, Kyoung-Ho
   Lee, Eun Kyoung
   Jeong, Hyeongseok
   Lee, Ji Yeon
   Ko, Ja-Young
   Choi, Jihee
   Ryu, Eun Hwa
   Chung, Ki-hyun
   Oh, Myoung-don
CA Korea Natl Comm Clinical Managemen
TI Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease
   2019 in Korea, January-May 2020
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Prognosis; Cohort Study; Korea
AB Background: The fatality rate of patients with coronavirus disease 2019 (COVID-19) varies among countries owing to demographics, patient comorbidities, surge capacity of healthcare systems, and the quality of medical care. We assessed the clinical outcomes of patients with COVID-19 during the first wave of the epidemic in Korea.
   Methods: Using a modified World Health Organization clinical record form, we obtained clinical data for 3,060 patients with COVID-19 treated at 55 hospitals in Korea. Disease severity scores were defined as: 1) no limitation of daily activities; 2) limitation of daily activities but no need for supplemental oxygen; 3) supplemental oxygen via nasal cannula; 4) supplemental oxygen via facial mask; 5) non-invasive mechanical ventilation; 6) invasive mechanical ventilation; 7) multi-organ failure or extracorporeal membrane oxygenation therapy; and 8) death. Recovery was defined as a severity score of 1 or 2, or discharge and release from isolation.
   Results: The median age of the patients was 43 years of age; 43.6% were male. The median time from illness onset to admission was 5 days. Of the patients with a disease severity score of 3-4 on admission, 65 (71.5%) of the 91 patients recovered, and 7 (7.7%) died due to illness by day 28. Of the patients with disease severity scores of 5-7, 7 (19.5%) of the 36 patients recovered, and 8 (22.2%) died due to illness by day 28. None of the 1,324 patients who were < 50 years of age died; in contrast, the fatality rate due to illness by day 28 was 0.5% (2/375), 0.9% (2/215), 5.8% (6/104), and 14.0% (7/50) for the patients aged 50-59, 60-69, 70-79, and >= 80 years of age, respectively.
   Conclusion: In Korea, almost all patients of < 50 years of age with COVID-19 recovered without supplemental oxygen. In patients of >= 50 years of age, the fatality rate increased with age, reaching 14% in patients of >= 80 years of age.
C1 [Sung, Ho Kyung] Natl Med Ctr, Natl Emergency Med Ctr, Seoul, South Korea.
   [Kim, Jin Yong] Incheon Med Ctr, Dept Internal Med, Div Infect Dis, Incheon, South Korea.
   [Heo, Jeonghun] Busan Med Ctr, Dept Pulmonol, Busan, South Korea.
   [Seo, Haesook] Seoul Metropolitan Seobuk Hosp, Dept TB, Seoul, South Korea.
   [Jang, Young soo] Seoul Metropolitan Seonam Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Kim, Hyewon] Chungju Med Ctr, Dept Lab Med, Chungju, South Korea.
   [Koh, Bo Ram] Gyeonggi Prov Med Ctr, Dept Internal Med, Ansung Hosp, Anseong, South Korea.
   [Jo, Neungsun] Chungcheongnam Do Gongju Med Ctr, Dept Infect Control, Gongju, South Korea.
   [Oh, Hong Sang] Armed Forces Capital Hosp, Dept Internal Med, Div Infect Dis, Seongnam, South Korea.
   [Baek, Young Mi] Chungcheongnam Seosan Med Ctr, Dept Infect Control, Seosan, South Korea.
   [Park, Kyung-Hwa] Chonnam Natl Univ, Dept Infect Dis, Med Sch, Gwangju, South Korea.
   [Shon, Jeung A.] Yeongju Red Cross Hosp, Dept Nursing, Yeongju, South Korea.
   [Kim, Min-Chul] Chung Ang Univ Hosp, Dept Internal Med, Div Infect Dis, Seoul, South Korea.
   [Kim, Joon Ho] Gyeonggi Prov Med Ctr, Dept Surg, Uijeongbu Hosp, Uijongbu, South Korea.
   [Chang, Hyun-Ha] Kyungpook Natl Univ Hosp, Dept Internal Med, Div Infect Dis, Daegu, South Korea.
   [Park, Yukyung] Korea Workers Compensat & Welf Serv, Dept Internal Med, Daegu Hosp, Daegu, South Korea.
   [Kang, Yu Min] Myongji Hosp, Dept Internal Med, Div Infect Dis, Goyang, South Korea.
   [Lee, Dong Hyun] Chungcheongnam Do Cheonan Med Ctr, Dept Internal Med, Cheonan, South Korea.
   [Oh, Dong Hyun] Seoul Med Ctr, Dept Internal Med, Div Infect Dis, Seoul, South Korea.
   [Park, Hyun Jung] Jeonllanam Do Suncheon Med Ctr, Dept Internal Med, Sunchon, South Korea.
   [Song, Kyoung-Ho] Seoul Natl Univ, Dept Internal Med, Div Infect Dis, Bundang Hosp, Seongnam, South Korea.
   [Lee, Eun Kyoung] Cheongju Med Ctr, Infect Control Team, Cheongju, South Korea.
   [Jeong, Hyeongseok] Chungnam Natl Univ, Dept Internal Med, Div Infect Dis, Sch Med, Daejeon, South Korea.
   [Lee, Ji Yeon] Keimyung Univ, Dept Internal Med, Div Infect Dis, Dongsan Hosp, Daegu, South Korea.
   [Ko, Ja-Young] Gyeonggi Prov Med Ctr, Paju Hosp, Intens Care Team, Paju, South Korea.
   [Choi, Jihee] Gyeonggi Prov Med Ctr, Icheon Hosp, Infect Control Team, Icheon, South Korea.
   [Ryu, Eun Hwa] Korea Workers Compensat & Welf Serv, Changwon Hosp, Infect Control Team, Chang Won, South Korea.
   [Chung, Ki-hyun] Natl Med Ctr, Seoul, South Korea.
   [Oh, Myoung-don] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea.
RP Oh, MD (corresponding author), Seoul Natl Univ, Dept Internal Med, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea.
EM mdohmd@snu.ac.kr
OI Sung, Ho Kyung/0000-0002-1207-0298; Jeong,
   Hyeongseok/0000-0002-4539-079X; Kim, Jin Yong/0000-0002-4306-1597
FU Korea Centers for Disease Control and Prevention [4838-330-320-01]
FX This work was supported by the Korea Centers for Disease Control and
   Prevention (grant No. 4838-330-320-01).
CR Beigel J. H., 2020, N ENGL J MED
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Kang E, EMERGING EMERG INFEC
   Kim ES, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e142
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Kim NJ, 2020, KOREAN J INTERN MED, V35, P758, DOI 10.3904/kjim.2020.122
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Lee YH, 2020, EMERG INFECT DIS
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   WHO, 2020, REP WHO CHIN JOINT M
   WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection, 2020, LANCET INFECT DIS
   World Health Organization, 2020, GLOB COVID 19 CLIN P
   World Health Organization, 143 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 18
TC 7
Z9 7
U1 1
U2 1
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD AUG 3
PY 2020
VL 35
IS 30
AR e280
DI 10.3346/jkms.2020.35.e280
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX2ND
UT WOS:000557561800008
PM 32743995
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tan, EJ
   Meyer, D
   Neill, E
   Phillipou, A
   Toh, WL
   Van Rheenen, TE
   Rossell, SL
AF Tan, Eric J.
   Meyer, Denny
   Neill, Erica
   Phillipou, Andrea
   Toh, Wei Lin
   Van Rheenen, Tamsyn E.
   Rossell, Susan L.
TI Considerations for assessing the impact of the COVID-19 pandemic on
   mental health in Australia
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Coronavirus; COVID-19; mental health
ID LIFE EVENTS; INCREASES
AB During this unprecedented novel coronavirus (COVID-19) pandemic, there is an urgent need for empirical data to characterise its impact on the mental health and well-being of Australians. In this viewpoint, we outline a number of considerations for research on this topic, highlighting areas necessitating special attention, consideration of particular vulnerable groups and the need for longitudinal studies to track mental health fluctuations in the general population. We conclude by introducing the COLLATE (COvid-19 and you: mentaL heaLth in AusTralia now survEy) project, outlining its aims, addressing some considerations raised herein and detailing avenues for future research. Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 (WHO, 2020), the COVID-19 pandemic has caused major upheaval both in Australia and globally. While the search for a vaccine continues, current efforts towards tackling the virus and limiting contagion in several nations have focused on social distancing and the shutdown of non-essential services. In Australia, the first case was reported on 13 January 2020 (COVID-19 National Incident Room Surveillance Team, 2020), the first death occurred on 24 February and a spate of progressive restrictions were enforced throughout the 2 weeks leading up to 31 March 2020 (COVID-19 National Incident Room Surveillance Team, 2020a).
C1 [Tan, Eric J.; Meyer, Denny; Neill, Erica; Phillipou, Andrea; Toh, Wei Lin; Van Rheenen, Tamsyn E.; Rossell, Susan L.] Swinburne Univ Technol, Fac Hlth Arts & Design, Ctr Mental Hlth, Melbourne, Vic, Australia.
   [Tan, Eric J.; Neill, Erica; Phillipou, Andrea; Rossell, Susan L.] St Vincents Hosp Melbourne, Dept Mental Hlth, Melbourne, Vic, Australia.
   [Neill, Erica; Phillipou, Andrea] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia.
   [Phillipou, Andrea] Austin Hosp, Dept Mental Hlth, Melbourne, Vic, Australia.
   [Van Rheenen, Tamsyn E.] Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia.
   [Van Rheenen, Tamsyn E.] Melbourne Hlth, Melbourne, Vic, Australia.
RP Rossell, SL (corresponding author), Swinburne Univ Technol, Fac Hlth Arts & Design, Ctr Mental Hlth, John St, Hawthorn, Vic 3122, Australia.
EM srossell@swin.edu.au
OI Neill, Erica/0000-0002-6920-2159; Rossell, Susan/0000-0002-7415-8252
FU National Health & Medical Research Council of Australia (NHMRC)National
   Health and Medical Research Council of Australia [GNT1142424, GNT10
   88785, GNT1154651]; NHMRCNational Health and Medical Research Council of
   Australia [CIA-GNT1159953, CIA-GNT1161609]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: E.J.T. and
   T.E.V.R. are in receipt of Early Career (GNT1142424 and GNT10 88785) and
   S.L.R. in receipt of Senior Research (GNT1154651) fellowships from the
   National Health & Medical Research Council of Australia (NHMRC). A.P.
   and W.L.T. are supported by NHMRC Project Grants (CIA-GNT1159953 and
   CIA-GNT1161609, respectively).
CR Australian Bureau of Statistics (ABS), 2016, ABS 2016 CENS TABL B
   Cordova-Villalobos Jose A, 2009, Health Res Policy Syst, V7, P21, DOI 10.1186/1478-4505-7-21
   Costarelli V, 2012, EAT WEIGHT DISORD-ST, V17, pE164, DOI 10.1007/BF03325343
   COVID-19 National Incident Room Surveillance Team, 2020, COMMUNICABLE DIS INT, V44, DOI [10.33321/cdi.2020.44.30., DOI 10.33321/CDI.2020.44.30.]
   COVID-19 National Incident Room Surveillance Team, 2020, COMMUNICABLE DIS INT, V44, DOI [10.33321/cdi.2020.44.13., DOI 10.33321/CDI.2020.44.13]
   Docherty NM, 2009, SCHIZOPHRENIA BULL, V35, P638, DOI 10.1093/schbul/sbn002
   Druss BG, 2020, JAMA PSYCHIAT, DOI [10.1001/jamapsychiatry.2020.0894., DOI 10.1001/JAMAPSYCHIATRY.2020.0894.]
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191
   Lau JTF, 2006, J INFECTION, V53, P114, DOI 10.1016/j.jinf.2005.10.019
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Losada-Baltar A, 2020, J GERONTOL B-PSYCHOL, DOI [10.1093/geronb/gbaa048., DOI 10.1093/GERONB/GBAA048.]
   Peng EYC, 2010, J FORMOS MED ASSOC, V109, P524, DOI 10.1016/S0929-6646(10)60087-3
   Tan EJ, 2020, AUST NZ J PSYCHIAT, V54, P210, DOI 10.1177/0004867419877958
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   World Health Organisation, 2020, STAT 2 M INT HLTH RE
   Zhang K, 2020, BRIT J PSYCHIAT, V217, P351, DOI 10.1192/bjp.2020.84
   Zhang WR, 2020, PSYCHOTHER PSYCHOSOM, V89, P242, DOI 10.1159/000507639
NR 19
TC 1
Z9 1
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD NOV
PY 2020
VL 54
IS 11
BP 1067
EP 1071
AR 0004867420947815
DI 10.1177/0004867420947815
EA AUG 2020
PG 5
WC Psychiatry
SC Psychiatry
GA ON6NK
UT WOS:000556335100001
PM 32746614
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Coccheri, S
AF Coccheri, Sergio
TI COVID-19: The crucial role of blood coagulation and fibrinolysis
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE COVID-19; Coagulation; Fibrinolysis; Micro-thrombosis;
   Immuno-thrombosis; CID
ID THROMBOSIS
AB The overflow of studies in the recent literature on COVID-19 often gives provisional or contradictory results and therefore deserves pauses of reflection and reconsideration. In fact, knowledges of pathophysiology of this new disease are still in development and hence originate discussions and interpretations. Regarding the role of blood coagulation and fibrinolysis, these mechanisms should be considered as crucial especially in severe cases. It is proposed to consider two distinct phenotypes of thrombotic manifestations: the current "thromboembolic type" also occurring in other kinds of sepsis, and the diffuse micro-thrombotic type, prevailing in the lungs but sometimes extending to other organs. Both types can induce severe disease and are potentially lethal. The micro-thrombotic pattern, more specific for COVID-19, results from a massive activation of coagulation strictly coupled with a hyper-intense inflammatory and immune reaction. This results in widespread occlusive thrombotic micro-angiopathy with destruction of alveoli and obstructive neoangiogenesis. The involvement of fibrinolysis, often neglected, confers a double faceted process of activation/inhibition, finally conducive to a fibrinolytic shutdown that reinforces persistence of micro-thrombi. Considering these peculiar mechanisms, it seems evident that both prophylactic and therapeutic effects of current anti-thrombotic drugs cannot be taken for granted and need therefore new specific and rigorous controlled trials.
C1 [Coccheri, Sergio] Univ Bologna, Bologna, Italy.
RP Coccheri, S (corresponding author), Univ Bologna, Bologna, Italy.
EM coccheris.angio@libero.it
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   ALBRECHTSEN OK, 1957, BRIT J HAEMATOL, V3, P284, DOI 10.1111/j.1365-2141.1957.tb05798.x
   Bazzan M, 2020, INTERN EMERG MED, V18, P1
   Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656
   Cavezzi A, 2020, CLINICS PRACT, V10, P24, DOI 10.4081/cp.2020.1271
   Harenberg J, 2020, CLIN CHEM LAB MED, V58, P1029, DOI 10.1515/cclm-2020-0502
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Klok FA, 2020, THROMB RES, DOI [10.1016/thromres2020.04.0137146714, DOI 10.1016/THROMRES2020.04.0137146714]
   Kwaan HC, 2020, SEMIN THROMB HEMOST, V46, P841, DOI 10.1055/s-0040-1709996
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Marongiu F, 2019, SEMIN THROMB HEMOST, V45, P778, DOI 10.1055/s-0039-1696942
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Neri Serneri GG, 1981, MALATTIE EMORRAGICHE
   Paranjpe I, 2020, J AM COLL CARDIOL, DOI [10.1016/j.jacc.2020.05.0017279721, DOI 10.1016/J.JACC.2020.05.0017279721]
   Pilli VS, 2018, BLOOD, V132, P452, DOI 10.1182/blood-2018-04-841585
   Radmanesh A, 2020, RADIOLOGY, V21, DOI 10.1148/radiol.20202040
   Sadler JE, 2008, BLOOD, V112, P11, DOI 10.1182/blood-2008-02-078170
   Schulman S, 2020, SEMIN THROMB HEMOST, DOI [10.1055/s0040-1710337, DOI 10.1055/S0040-1710337]
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Thachil J, 2020, SEMIN THROMB HEMOST, V46, P777, DOI 10.1055/s-0040-1712155
   White D, 2020, J THROMB THROMBOLYS, V22, P1
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
   Wygrecka M, 2008, THROMB HAEMOSTASIS, V99, P494, DOI 10.1160/TH07-11-0666
NR 24
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD NOV
PY 2020
VL 15
IS 8
SI SI
BP 1369
EP 1373
DI 10.1007/s11739-020-02443-8
EA AUG 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OM3BZ
UT WOS:000555384600003
PM 32748128
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Saha, S
   Chakrabarti, S
   Singh, PK
   Poddar, J
   Satapathi, S
   Saini, S
   Kakar, SS
   Roy, P
AF Saha, Sarama
   Chakrabarti, Sasanka
   Singh, Praveen Kumar
   Poddar, Jit
   Satapathi, Soumitra
   Saini, Surendra
   Kakar, Sham S.
   Roy, Partha
TI Physiological Relevance of Angiotensin Converting Enzyme 2 As a
   Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells
   in COVID-19 and Hypertension
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE Angiotensin converting enzyme 2; Renin-angiotensin-aldosterone-system;
   Severe acute respiratory syndrome; Coronavirus-2; Spike protein;
   COVID-19; Transmembrane protease serine-2; Mesenchymal Stem Cell
ID RESPIRATORY SYNDROME; ACE2; TRANSPLANTATION; INHIBITION; MECHANISMS;
   EXPRESSION; CHEMOKINES; RECEPTOR; COV
AB Severe acute respiratory syndrome corona virus - 2 (SARS-CoV-2) is a single stranded RNA virus and responsible for infecting human being. In many cases the individual may remain asymptomatic. Some recently reported studies revealed that individuals of elderly age group and with pre-existing medical conditions such as hypertension, diabetes mellitus had severe consequences, even may lead to death. However, it is not clearly delineated whether hypertension itself or associated comorbidities or antihypertensive therapy contributes to the grave prognosis of COVID-19 infections. This review is aimed to decipher the exact mechanisms involved at molecular level from existing evidence and as reported. It has been reported that SARS-CoV-2 enters into the host cell through interaction between conserved residues of viral spike protein and angiotensin converting enzyme 2 (ACE2) receptor which is highly expressed in host's cardiac and pulmonary cells and finally transmembrane protease, serine-2 (TMPRSS2), helps in priming of the surface protein. Subsequently, symptom related to multi organ involvement is primarily contributed by cytokine storm. Although various clinical trials are being conducted on renin- angiotensin- system inhibitor, till to date there is no standard treatment protocol approved for critically ill COVID-19 positive cases with pre-existing hypertension. Recently, several studies are carried out to document the safety and efficacy outcome of mesenchymal stem cell transplantation based on its immunomodulatory and regenerative properties. Therefore, identification of future novel therapeutics in the form of mesenchymal stem cell either alone or in combination with pharmacological approach could be recommended for combating SARS-CoV-2 which might be dreadful to debilitating elderly people.
C1 [Saha, Sarama; Singh, Praveen Kumar] All India Inst Med Sci, Dept Biochem, Rishikesh, India.
   [Chakrabarti, Sasanka; Poddar, Jit] Maharishi Markandeshwar Deemed Be Univ, Dept Biochem & Cent Res Cell, Mullana, Haryana, India.
   [Satapathi, Soumitra] Indian Inst Technol Roorkee, Dept Phys, Roorkee 247667, Uttarakhand, India.
   [Saini, Surendra; Roy, Partha] Indian Inst Technol Roorkee, Dept Biotechnol, Roorkee 247667, Uttarakhand, India.
   [Kakar, Sham S.] Univ Louisville, Dept Physiol, Louisville, KY 40292 USA.
   [Kakar, Sham S.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
RP Roy, P (corresponding author), Indian Inst Technol Roorkee, Dept Biotechnol, Roorkee 247667, Uttarakhand, India.
EM patha.roy@bt.iitr.ac.in
OI CHAKRABARTI, SASANKA/0000-0002-9429-4892
CR Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Bernstein KE, 2018, NAT REV NEPHROL, V14, P325, DOI 10.1038/nrneph.2018.15
   Bessout R, 2014, MUCOSAL IMMUNOL, V7, P656, DOI 10.1038/mi.2013.85
   Bhandari Sudhir, 2020, J Assoc Physicians India, V68, P13
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Bukowska A, 2017, EXP BIOL MED, V242, P1412, DOI 10.1177/1535370217718808
   Carrion F, 2010, LUPUS, V19, P317, DOI 10.1177/0961203309348983
   Chakrabarti SS, 2020, AGING DIS, V11, P480, DOI 10.14336/AD.2020.0402
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chrzanowski W, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00554
   Co COC, 2020, J CLIN NEUROSCI, V77, P234, DOI 10.1016/j.jocn.2020.05.006
   Comoli P, 2008, NEPHROL DIAL TRANSPL, V23, P1196, DOI 10.1093/ndt/gfm740
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fedson DS, 2015, MBIO, V6, DOI 10.1128/mBio.00716-15
   Ferrario CM, 2005, AM J PHYSIOL-HEART C, V289, pH2281, DOI 10.1152/ajpheart.00618.2005
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1016/S0928-8244(99)00142-X
   Ghannam S, 2010, J IMMUNOL, V185, P302, DOI 10.4049/jimmunol.0902007
   Golchin A., 2019, ADV EXPT MED BIOL, V1247, P89
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Golchin A, 2019, CURR STEM CELL RES T, V14, P22, DOI 10.2174/1574888X13666180913123424
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han KH, 2011, TRANSPL IMMUNOL, V25, P7, DOI 10.1016/j.trim.2011.05.004
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iyer SN, 2000, J CARDIOVASC PHARM, V36, P109, DOI 10.1097/00005344-200007000-00015
   Jia DM, 2005, METABOLISM, V54, P619, DOI 10.1016/j.metabol.2004.12.005
   Jiang T, 2013, CURR NEUROPHARMACOL, V11, P209, DOI 10.2174/1570159X11311020007
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li P, 1997, HYPERTENSION, V29, P394, DOI 10.1161/01.HYP.29.1.394
   Liang B, 2020, CHINAXIV, V2, pv10
   Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Liu W., 2020, COVID 19 ATTACKS 1 B
   Lu DB, 2011, DIABETES RES CLIN PR, V92, P26, DOI 10.1016/j.diabres.2010.12.010
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Metcalfe Su M, 2020, Med Drug Discov, V5, P100019, DOI 10.1016/j.medidd.2020.100019
   Novello S, 2020, J PERIODONTAL RES, V55, P1, DOI 10.1111/jre.12684
   Ratajczak MZ, 2020, LEUKEMIA, V34, P1726, DOI 10.1038/s41375-020-0887-9
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sobenin IA, 2008, J ATHEROSCLER THROMB, V15, P334, DOI 10.5551/jat.E550
   Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004-0359
   te Riet L, 2015, CIRC RES, V116, P960, DOI 10.1161/CIRCRESAHA.116.303587
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9
   Tunc A, 2020, J CLIN NEUROSCI, V77, P227, DOI 10.1016/j.jocn.2020.05.018
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weyand CM, 2016, ANN AM THORAC SOC, V13, pS422, DOI 10.1513/AnnalsATS.201602-095AW
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xiao JH, 2012, TRANSFUSION, V52, P2551, DOI 10.1111/j.1537-2995.2012.03642.x
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang P., 2014, SCI REPORTS, V4, P1
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 73
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10012-x
EA AUG 2020
PG 12
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA MU0ZW
UT WOS:000555400200002
PM 32748331
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abah, RC
AF Abah, Roland C.
TI Achieving HIV targets by 2030: the possibility of using debt relief
   funds for sustainable HIV treatment in sub-Saharan Africa
SO JOURNAL OF PUBLIC HEALTH POLICY
LA English
DT Article
DE Sub-Saharan Africa; HIV treatment; Antiretroviral; Debt relief; Agenda
   2030; COVID-19
AB This paper assesses the possibility of using debt relief funds to sustain HIV treatment in sub-Saharan Africa, suppress transmission, and reach global goals to quell the epidemic by 2030. The cost of providing antiretroviral treatment is a huge burden on African countries. Concerns for Africa's capacity to keep pace with global advances are well founded. By analysing levels of 'debt distress', health expenditure per capita, and HIV antiretroviral therapy requirements in sub-Saharan African countries, the need for innovative finance with international cooperation emerges clearly. In addition to the HIV epidemic, African countries may become more vulnerable to disasters and other public health diseases such as malaria, tuberculosis, Ebola and COVID-19, especially without alternatives to current means of financing. Relief from debt service payments could release funds for sub-Saharan African countries to support universal HIV antiretroviral treatment with sustainable results.
C1 [Abah, Roland C.] Natl Agcy Control AIDS, Cent Area, Abuja, Nigeria.
RP Abah, RC (corresponding author), Natl Agcy Control AIDS, Cent Area, Abuja, Nigeria.
EM Rolann04@yahoo.com
CR AfDB, 2019, AFR EC OUTL 2019
   African Development Bank (AfDB), 2018, AFR EC OUTL 2018
   CDC-Centres for Disease Control and Prevention, 2017, HIV COST EFF
   Cook N, 2017, SUB SAHARAN AFRICA K
   DMO-Debt Management Office, 2018, NIG ACT EXT DEBT SER
   DMO-Debt Management Office, 2017, REP ANN NAT DEBT SUS
   Dwyer-Lindgren L, 2019, NATURE, V570, P189, DOI 10.1038/s41586-019-1200-9
   GBC Health mission Aliko Dangote Foundation UNECA, 2018, HEALTHC EC GROWTH AF
   GOGA A, 2019, BMJ-BRIT MED J, V364, DOI DOI 10.1136/BMJ.L660
   Granich Reuben, 2016, J Int Assoc Provid AIDS Care, V15, P91, DOI 10.1177/2325957415623261
   Hankins C, 2017, BMJ GLOB HEALTH, V2, pA1, DOI [10.1136/bmjgh-2016-000260.4, DOI 10.1136/BMJGH-2016-000260.4]
   Kharsany Ayesha B M, 2016, Open AIDS J, V10, P34, DOI 10.2174/1874613601610010034
   Manga LJO, 2018, J PUBLIC HEALTH AFR, V9, DOI 10.4081/jphia.2018.760
   Micah AE, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001159
   Mustapha S., 2018, AFRICAS RISING DEBT
   NACA-National Agency for the Control of AIDS, 2018, HIV AIDS POL ADV NEW
   Omotola JS, 2009, S AFR J INT AFF, V16, P87, DOI 10.1080/10220460902986180
   Onyekwena C., 2019, AFRICA FOCUS IS DEBT
   Paul E, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000664
   Ridde V, 2018, INT J HEALTH SERV, V48, P549, DOI 10.1177/0020731418779508
   Sambira J., 2015, BORROWING RESPONSIBL
   Sandefur J, 2018, CHART WEEK NEW AFRIC
   Sandford JE, 1996, CSIS AFRICA NOTES
   The World Bank, 2018, PREV HIV TOT POP AG
   Treskova M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003961
   UNAIDS-Joint United Nations Programme on HIV/AIDS, 2018, HIV DAT 2018
   UNDP, 2015, WORLD AIDS DAY REC D
   WHO-World Health Organisation, 2014, AFR REG EXP ATL
   World Bank, 2019, INT DEBTS STAT
   World Bank, 2013, M CHALL WORLD BANK H
   World Bank, 2017, PERF BAS FIN IMPR QU
NR 31
TC 0
Z9 0
U1 0
U2 0
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 0197-5897
EI 1745-655X
J9 J PUBLIC HEALTH POL
JI J. Public Health Policy
PD DEC
PY 2020
VL 41
IS 4
BP 421
EP 435
DI 10.1057/s41271-020-00238-x
EA AUG 2020
PG 15
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA OU3DB
UT WOS:000555387300003
PM 32747703
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Batteux, B
   Bodeau, S
   Gras-Champel, V
   Liabeuf, S
   Lanoix, JP
   Schmit, JL
   Andrejak, C
   Zerbib, Y
   Haye, G
   Masmoudi, K
   Lemaire-Hurtel, AS
   Bennis, Y
AF Batteux, Benjamin
   Bodeau, Sandra
   Gras-Champel, Valerie
   Liabeuf, Sophie
   Lanoix, Jean-Philippe
   Schmit, Jean-Luc
   Andrejak, Claire
   Zerbib, Yoann
   Haye, Guillaume
   Masmoudi, Kamel
   Lemaire-Hurtel, Anne-Sophie
   Bennis, Youssef
TI Abnormal laboratory findings and plasma concentration monitoring of
   lopinavir and ritonavir in COVID-19
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE adverse drug reactions; antiretroviral drug; hepatotoxicity;
   pharmacovigilance; therapeutic drug monitoring
ID LOPINAVIR/RITONAVIR; HIV; PHARMACOKINETICS; ASSOCIATION; VIRUS; RISK
AB It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade >= 2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19.
C1 [Batteux, Benjamin; Bodeau, Sandra; Gras-Champel, Valerie; Liabeuf, Sophie; Masmoudi, Kamel; Lemaire-Hurtel, Anne-Sophie; Bennis, Youssef] Amiens Univ Hosp, Dept Clin Pharmacol, Amiens, France.
   [Batteux, Benjamin; Bodeau, Sandra; Gras-Champel, Valerie; Liabeuf, Sophie; Bennis, Youssef] Jules Verne Univ Picardie, Lab MP3CV, EA 7517, Amiens, France.
   [Liabeuf, Sophie] Amiens Univ Hosp, Dept Clin Res, Amiens, France.
   [Lanoix, Jean-Philippe; Schmit, Jean-Luc] Amiens Univ Hosp, Dept Infect Dis, Amiens, France.
   [Lanoix, Jean-Philippe; Schmit, Jean-Luc; Andrejak, Claire] Jules Verne Univ Picardie, AGIR, EA 4294, Amiens, France.
   [Andrejak, Claire] Amiens Univ Hosp, Dept Pulmonol, Amiens, France.
   [Zerbib, Yoann] Amiens Univ Hosp, Dept Intens Care, Amiens, France.
   [Zerbib, Yoann] Amiens Univ Hosp, BoReal Study Grp, Amiens, France.
   [Haye, Guillaume] Amiens Univ Hosp, Dept Anaesthesiol & Crit Care Med, Amiens, France.
RP Bennis, Y (corresponding author), UPJV, EA7517, Lab Pharmacol & Toxicol, CHU Amiens Picardie, F-80054 Amiens, France.
EM bennis.youssef@chu-amiens.fr
RI Bennis, Youssef/ABC-8816-2020
OI Bennis, Youssef/0000-0002-0186-4797; liabeuf, sophie/0000-0001-5384-9006
FU Amiens University Hospital
FX Amiens University Hospital
CR Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI 10.1111/bph.13877
   Bierman WFW, 2011, ANTIVIR THER, V16, P647, DOI 10.3851/IMP1824
   Boffito M, 2003, AIDS, V17, P1107, DOI 10.1097/00002030-200305020-00029
   Canta F, 2005, J ANTIMICROB CHEMOTH, V55, P280, DOI 10.1093/jac/dkh516
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Crommentuyn KML, 2004, ANTIVIR THER, V9, P779
   De Requena DG, 2003, AIDS PATIENT CARE ST, V17, P443, DOI 10.1089/108729103322395465
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dicenzo R, 2006, J ANTIMICROB CHEMOTH, V58, P393, DOI 10.1093/jac/dkl238
   Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gutierrez F, 2003, JAIDS-J ACQ IMM DEF, V33, P594, DOI 10.1097/00126334-200308150-00007
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hicks C, 2004, AIDS, V18, P775, DOI 10.1097/00002030-200403260-00008
   Aspiroz EL, 2011, THER DRUG MONIT, V33, P573, DOI 10.1097/FTD.0b013e31822d578b
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Molto J, 2008, CLIN PHARMACOKINET, V47, P681, DOI 10.2165/00003088-200847100-00005
   Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302
   National Institutes of Health, CTCAE COMM TERM CRIT
   Rhew DC, 2003, CLIN INFECT DIS, V37, P959, DOI 10.1086/378064
   Seminari E, 2005, J ANTIMICROB CHEMOTH, V56, P790, DOI 10.1093/jac/dki314
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Solas C, 2004, BRIT J CLIN PHARMACO, V57, P436, DOI 10.1046/j.1365-2125.2003.02020.x
   Stohr W, 2010, J ANTIMICROB CHEMOTH, V65, P129, DOI 10.1093/jac/dkp408
   Vogel Martin, 2005, Expert Opin Drug Saf, V4, P403, DOI 10.1517/14740338.4.3.403
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
NR 28
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14489
EA AUG 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MT9TD
UT WOS:000555310900001
PM 32692462
OA Bronze
DA 2021-01-01
ER

PT J
AU Watson, MF
   Bacigalupe, G
   Daneshpour, M
   Han, WJ
   Parra-Cardona, R
AF Watson, Marlene F.
   Bacigalupe, Gonzalo
   Daneshpour, Manijeh
   Han, Wen-Jui
   Parra-Cardona, Ruben
TI COVID-19 Interconnectedness: Health Inequity, the Climate Crisis, and
   Collective TraumaPalabras clave(sic)(sic)(sic)
SO FAMILY PROCESS
LA English
DT Article
DE COVID-19; Health Inequity; Social Determinants of Health; Ethics of
   Care; Collective Trauma; Climate Crisis
ID ENVIRONMENTAL HAZARDS; INEQUALITIES; FAMILIES; RACE
AB The COVID-19 pandemic brings to the forefront the complex interconnected dilemmas of globalization, health equity, economic security, environmental justice, and collective trauma, severely impacting the marginalized and people of color in the United States. This lack of access to and the quality of healthcare, affordable housing, and lack of financial resources also continue to have a more significant impact on documented and undocumented immigrants. This paper aims at examining these critical issues and developing a framework for family therapists to address these challenges by focusing on four interrelated dimensions: cultural values, social determinants of health, collective trauma, and the ethical and moral responsibility of family therapists. Given the fact that family therapists may unwittingly function as the best ally of an economic and political system that perpetuates institutionalized racism and class discrimination, we need to utilize a set of principles, values, and practices that are not just palliative or after the fact but bring forth into the psychotherapeutic and policy work a politics of care. Therefore, a strong call to promote and advocate for the broader continuum of health and critical thinking preparing professionals to meet the challenges of health equity, as well as economic and environmental justice, is needed. The issues discussed in this paper are specific to the United States despite their relevance to family therapy as a field. We are mindful not to generalize the United States' reality to the rest of the world, recognizing that issues discussed in this paper could potentially contribute to international discourse.
C1 [Watson, Marlene F.] Drexel Univ, Dept Counseling & Family Therapy, Philadelphia, PA 19104 USA.
   [Bacigalupe, Gonzalo] Univ Massachusetts, Sch Educ & Human Dev, Boston, MA 02125 USA.
   [Daneshpour, Manijeh] Alliant Int Univ, Irvine, CA USA.
   [Han, Wen-Jui] NYU, New York, NY USA.
   [Parra-Cardona, Ruben] Steve Hicks Sch Social Work, Austin, TX USA.
RP Bacigalupe, G (corresponding author), Univ Massachusetts, Sch Educ & Human Dev, Counseling Psychol, 100 Morrissey Bvld, Boston, MA 02125 USA.
EM gonzalo.baci-galupe@umb.edu
FU Fondo de Fomento al Desarrollo Cientifico y Tecnologico [CIGIDEN
   ANID/FONDAP/15110017] Funding Source: Medline
CR Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   Alexander M., 2010, NEW JIM CROW MASS IN
   Anderson RE, 2019, FAM PROCESS, V58, P53, DOI 10.1111/famp.12412
   Atallah D., 2019, J HUMANIST PSYCHOL, V59, P1, DOI [10.1177/0022167818825305, DOI 10.1177/0022167818825305]
   Babayemi JO, 2016, ENV QUALITY MANAGEME, V26, P51, DOI DOI 10.1002/TQEM.21480
   Bacigalupe G, 2011, FAM PROCESS, V50, P12, DOI 10.1111/j.1545-5300.2010.01343.x
   Baier A, 1985, POSTURES MIND ESSAYS
   Beaumont P., 2020, GUARDIAN
   Benevolenza MA, 2019, J HUM BEHAV SOC ENVI, V29, P266, DOI 10.1080/10911359.2018.1527739
   Berger ZD, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1141
   Bolam B, 2004, SOC SCI MED, V59, P1355, DOI 10.1016/j.socscimed.2004.01.018
   Brender JD, 2011, AM J PUBLIC HEALTH, V101, pS37, DOI 10.2105/AJPH.2011.300183
   Bullard R. D., 1997, RACE GENDER CLASS, V5, P63
   Bullard R.D., 1999, LOCAL ENVIRON, V4, P5, DOI DOI 10.1080/13549839908725577
   Cabral J, 2020, J RACIAL ETHN HEALTH, V7, P874, DOI 10.1007/s40615-020-00710-0
   Castaneda H, 2010, SOC SCI MED, V71, P2028, DOI 10.1016/j.socscimed.2010.09.024
   Chen J, 2013, SOC SCI MED, V80, P85, DOI 10.1016/j.socscimed.2012.12.002
   Coibion O., 2020, 27017 NBER
   Dalmiya Vrinda, 2016, CARING KNOW COMP CAR
   DeGruy J., 2005, POST TRAUMATIC SLAVE
   Downey L, 1998, SOC SCI QUART, V79, P766
   Dyson ME, 2005, COME HELL HIGH WATER
   Falicov C. J., 2019, REVISIONING FAMILY T, P108
   Fraenkel P, 2006, FAM PROCESS, V45, P237, DOI 10.1111/j.1545-5300.2006.00093.x
   Gilbert E, 2014, ANTIPODE, V46, P404, DOI 10.1111/anti.12063
   Gonzalez D., 2020, HISPANIC ADULTS FAMI
   Haque I, 2020, HABITAT INT, V99, DOI 10.1016/j.habitatint.2020.102157
   Hardy K. V., 2019, REVISIONING FAMILY T, P57
   Haynes N, 2020, CIRCULATION, V142, P105, DOI 10.1161/CIRCULATIONAHA.120.048126
   Held V., 2006, ETHICS CARE PERSONAL
   Hirschberger G, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01441
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Kalleberg AL, 2013, CONTEMP SOCIOL, V42, P700, DOI 10.1177/0094306113499536
   Kaul G., 2019, MINNPOST        0222
   Kawachi I, 2005, HEALTH AFFAIR, V24, P343, DOI 10.1377/hlthaff.24.2.343
   Kendi Ibram X, 2016, STAMPED BEGINNING DE
   Kjellstrom T, 2007, J URBAN HEALTH, V84, pI86, DOI 10.1007/s11524-007-9171-9
   Knowles SG, 2014, TECHNOL CULT, V55, P773, DOI 10.1353/tech.2014.0110
   Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0
   Lebow JL, 2020, FAM PROCESS, V59, P3, DOI 10.1111/famp.12529
   Levy B. S., 2011, OCCUPATIONAL ENV HLT
   Maani N., MILBANK Q
   Mayes R., 2004, HLTH CARE LAW POLICY, V7, P242
   McGowan AK, 2016, ANNU REV PUBL HEALTH, V37, P185, DOI 10.1146/annurev-publhealth-032315-021926
   Nightingale M., 2019, J BLACK RELATIONSHIP, V6, P37, DOI [10.1353/bsr.2019.0020, DOI 10.1353/BSR.2019.0020]
   Noddings N., 2007, WORKING VIRTUE VIRTU, P41
   Nunez Ana, 2020, Health Equity, V4, P117, DOI 10.1089/heq.2020.29000.rtl
   Page KR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005953
   Peterson K. J., 2020, LOUISIANAS RESPONSE, P185
   Pilkington E, 2020, GUARDIAN
   Poteat T, 2020, ANN EPIDEMIOL, V47, P1, DOI 10.1016/j.annepidem.2020.05.004
   Priest JB, 2019, FAM PROCESS, V58, P79, DOI 10.1111/famp.12357
   Qiu J., 2020, GEN PSYCHIAT, V33, P1
   Rosenbaum S, 2005, MIGRANT SEASONAL FAR
   Saul J., 2013, COLLECTIVE TRAUMA CO, V48
   Scambler G, 1999, SOCIOLOGY, V33, P275
   Smedley BD, 2003, UNEQUAL TREATMENT CO
   Steckler A B, 1993, Health Educ Q, VSuppl 1, pS3
   Stevenson B., 2015, JUST MERCY STORY JUS
   TRONTO J., 2013, CARING DEMOCRACY MAR
   Tronto J. C., 1993, MORAL BOUNDARIES POL
   Utrzan DS, 2020, FAM PROCESS, V59, P209, DOI 10.1111/famp.12408
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Waite R, 2020, PUBLIC HEALTH NURS, V37, P147, DOI 10.1111/phn.12717
   Walsh F., 2019, REVISIONING FAMILY T, P37
   Walz K., 2017, WHAT NATURAL DISASTE
   Watson M. F., 2013, FACING BLACK SHADOW
   Watson M. F., 2019, REVISIONING FAMILY T, P200
   Watson MF, 2019, FAM PROCESS, V58, P23, DOI 10.1111/famp.12427
   World Health Organization, 2018, CLIM CHANG HLTH
   Yearby R., 2020, J LAW BIOSCI, P30
   Zepeda-Millan C., 2017, LATINO MASS MOBILIZA, DOI [10.1017/9781139924719, DOI 10.1017/9781139924719]
NR 72
TC 4
Z9 4
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 832
EP 846
DI 10.1111/famp.12572
EA AUG 2020
PG 15
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000554561200001
PM 32589267
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Roman, MTA
   Coll, NB
   Barcenilla, SG
   Gonzalez, LP
   Collazo, ID
   Rodriguez, HD
   Garrido, JAR
   Salces, MM
   Pollmar, MIR
   Cebanu, T
   Gonzalez-Zorrilla, E
   Acuna, P
   Manzano, EM
   Merchan, ECR
   Martinez, RT
   Banares, MJB
   Alvarino, MG
   Yuste, VJ
AF Alvarez Roman, Maria Teresa
   Coll, Nora Butta
   Barcenilla, Sara Garcia
   Perez Gonzalez, Lourdes
   de la Plaza Collazo, Ivan
   De la Corte Rodriguez, Hortensia
   Romero Garrido, Jose A.
   Martin Salces, Monica
   Rivas Pollmar, Maria Isabel
   Cebanu, Tamara
   Gonzalez-Zorrilla, Elena
   Acuna, Paula
   Monzon Manzano, Elena
   Rodriguez Merchan, Emerito Carlos
   Trelles Martinez, Roberto
   Blanco Banares, Maria J.
   Gutierrez Alvarino, Mar
   Jimenez Yuste, Victor
TI Registry of patients with congenital bleeding disorders and COVID-19 in
   Madrid
SO HAEMOPHILIA
LA English
DT Article
DE COVID-19; haemophilia A; rare bleeding disorders; telemedicine; von
   Willebrand disease
AB Introduction We present the first registry of patients with congenital bleeding disorders and COVID-19. The study has been carried out in the Community of Madrid, which has the highest number of cases in Spain. The objective is to understand the incidence of COVID-19, the course of the disease if it occurs and the psychosocial and occupational impact on this population. Methods We included 345 patients (246 of haemophilia, 69 of von Willebrand Disease, two rare bleeding disorders and 28 carriers of haemophilia). A telephone survey was used to collect the data. Results Forty-two patients presented symptoms suggestive of infection by COVID-19, and in six cases, the disease was confirmed by RT-PCR. The cumulative incidence of our series was 1.73%. It is worth noting the complexity of the management of COVID-19 in two patients on prophylaxis with non-factor replacement therapy. Adherence to the prescribed treatment was maintained by 95.5% of patients. Although 94% were independent for daily living activities, 42.4% had a recognized disability and 58% required assistance, provided by the Madrid Haemophilia Association (Ashemadrid) in 75% of cases. Only 4.4% of consultations were held in person. Conclusions Patients with congenital bleeding disorders infected with SARS-CoV-2 presented a mild course of the disease that did not require admission. Their identification and treatment by a specialist team from a Haemophilia Treatment Center are essential to make a correct assessment of the risk of haemorrhage/thrombosis. COVID-19 had a major impact on the psychosocial aspects of these patients which must be remedied with recovery plans.
C1 [Alvarez Roman, Maria Teresa; Coll, Nora Butta; Barcenilla, Sara Garcia; Martin Salces, Monica; Rivas Pollmar, Maria Isabel; Cebanu, Tamara; Gonzalez-Zorrilla, Elena; Acuna, Paula; Monzon Manzano, Elena; Trelles Martinez, Roberto; Blanco Banares, Maria J.; Gutierrez Alvarino, Mar; Jimenez Yuste, Victor] La Paz Univ Hosp IdiPaz, Dept Hematol, Madrid, Spain.
   [Perez Gonzalez, Lourdes; de la Plaza Collazo, Ivan] Madrid Haemophilia Assoc, Madrid, Spain.
   [De la Corte Rodriguez, Hortensia] La Paz Univ Hosp IdiPaz, Dept Phys Med & Rehabil, Madrid, Spain.
   [Romero Garrido, Jose A.] La Paz Univ Hosp, Dept Pharm, Madrid, Spain.
   [Rodriguez Merchan, Emerito Carlos] Univ Autonoma Madrid, Dept Orthopaed Surg Unit, Madrid, Spain.
   [Jimenez Yuste, Victor] Univ Autonoma Madrid, Med Fac, Madrid, Spain.
RP Roman, MTA (corresponding author), Paseo Castellana 261, Madrid 28046, Spain.
EM talvarezroman@gmail.com
OI BUTTA, Nora/0000-0003-4601-7150; Garcia-Barcenilla,
   Sara/0000-0002-8706-0668; Monzon Manzano, Maria
   Elena/0000-0002-7967-6358
FU FIS-Fondos FEDEREuropean Union (EU) [PI19/00631, PI19/00772]
FX FIS-Fondos FEDER, Grant/Award Number: PI19/00631 and PI19/00772
CR Borobia AM, 2020, COHORT PATIENTS COVI, DOI [10.1101/2020.04.29.20080853., DOI 10.1101/2020.04.29.20080853, 10.1101/2020.04.29.20080853]
   Bridwell Rachel, 2020, Am J Emerg Med, V38, DOI 10.1016/j.ajem.2020.05.024
   Cui DY, 2020, HAEMOPHILIA, V26, pE214, DOI 10.1111/hae.14000
   Favalli EG, 2020, ANN RHEUM DIS, V22
   Hermans C, 2020, HAEMOPHILIA, V26, P371, DOI 10.1111/hae.14001
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Kulkarni R, 2018, HAEMOPHILIA, V24, P33, DOI 10.1111/hae.13364
   Ministerio de Sanidad, INF CIENT TECN ENF C
   Ministerio de Sanidad. Gobierno de Espana, PROC ACT FRENT CAS I
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Valentino LA, 2020, HAEMOPHILIA, V26, pE230, DOI 10.1111/hae.14044
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   World Federation of Haemophilia, COVID 19 COR DIS 201
NR 13
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
EI 1365-2516
J9 HAEMOPHILIA
JI Haemophilia
PD SEP
PY 2020
VL 26
IS 5
BP 773
EP 778
DI 10.1111/hae.14089
EA AUG 2020
PG 6
WC Hematology
SC Hematology
GA NU0EM
UT WOS:000554865400001
PM 32524712
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zaheer, T
   Waseem, M
   Waqar, W
   Dar, HA
   Shehroz, M
   Naz, K
   Ishaq, Z
   Ahmad, T
   Ullah, N
   Bakhtiar, SM
   Muhammad, SA
   Ali, A
AF Zaheer, Tahreem
   Waseem, Maaz
   Waqar, Walifa
   Dar, Hamza Arshad
   Shehroz, Muhammad
   Naz, Kanwal
   Ishaq, Zaara
   Ahmad, Tahir
   Ullah, Nimat
   Bakhtiar, Syeda Marriam
   Muhammad, Syed Aun
   Ali, Amjad
TI Anti-COVID-19 multi-epitope vaccine designs employing global viral
   genome sequences
SO PEERJ
LA English
DT Article
DE SARS-CoV-2; COVID-19; Global pandemic; Immunoinformatics; Immunity
ID T-CELL EPITOPES; RESPIRATORY SYNDROME; PROTEIN-STRUCTURE;
   IMMUNE-RESPONSES; PEPTIDE VACCINE; NEURAL-NETWORKS; FUSION PROTEIN;
   B-CELL; PREDICTION; IMMUNOINFORMATICS
AB Background: The coronavirus SARS-CoV-2 is a member of the Coronaviridae family that has caused a global public health emergency. Currently, there is no approved treatment or vaccine available against it. The current study aimed to cover the diversity of SARS-CoV-2 strains reported from all over the world and to design a broad-spectrum multi-epitope vaccine using an immunoinformatics approach.
   Methods: For this purpose, all available complete genomes were retrieved from GISAID and NGDC followed by genome multiple alignments to develop a global consensus sequence to compare with the reference genome. Fortunately, comparative genomics and phylogeny revealed a significantly high level of conservation between the viral strains. All the Open Reading Frames (ORFs) of the reference sequence NC_045512.2 were subjected to epitope mapping using CTLpred and HLApred, respectively. The predicted CTL epitopes were then screened for antigenicity, immunogenicity and strong binding affinity with HLA superfamily alleles. HTL predicted epitopes were screened for antigenicity, interferon induction potential, overlapping B cell epitopes and strong HLA DR binding potential. The shortlisted epitopes were arranged into two multi-epitope sequences, Cov-I-Vac and Cov-II-Vac, and molecular docking was performed with Toll-Like Receptor 8 (TLR8).
   Results: The designed multi-epitopes were found to be antigenic and non-allergenic. Both multi-epitopes were stable and predicted to be soluble in an Escherichia coli expression system. The molecular docking with TLR8 also demonstrated that they have a strong binding affinity and immunogenic potential. These in silico analyses suggest that the proposed multi-epitope vaccine can effectively evoke an immune response.
C1 [Zaheer, Tahreem; Waseem, Maaz; Waqar, Walifa; Dar, Hamza Arshad; Naz, Kanwal; Ishaq, Zaara; Ahmad, Tahir; Ullah, Nimat; Ali, Amjad] Natl Univ Sci & Technol NUST, Atta Ur Rahman Sch Appl Biosci ASAB, Islamabad, Pakistan.
   [Shehroz, Muhammad] Virtual Univ Pakistan, Dept Biotechnol, Peshawar, Pakistan.
   [Bakhtiar, Syeda Marriam] Capital Univ Sci & Technol, Dept Bioinformat & Biosci, Islamabad, Pakistan.
   [Muhammad, Syed Aun] Bahauddin Zakariya Univ, Inst Mol Biol & Biotechnol, Multan, Pakistan.
RP Ali, A (corresponding author), Natl Univ Sci & Technol NUST, Atta Ur Rahman Sch Appl Biosci ASAB, Islamabad, Pakistan.
EM amjaduni@gmail.com
RI Muhammad, Syed Aun/ABF-5369-2020; Ali, Amjad/F-6436-2015
OI Ali, Amjad/0000-0002-0486-4661; Ullah, Nimat/0000-0002-7138-1272; Dar,
   Hamza Arshad/0000-0002-0667-5653
CR Abdelmageed MI, 2020, DESIGN MULTIEPITOPE, DOI [10.1101/2020.02.04.934232, DOI 10.1101/2020.02.04.934232]
   Allaker RP, 2008, T ROY SOC TROP MED H, V102, P3, DOI 10.1016/j.trstmh.2007.07.005
   Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016
   Amet N, 2009, PHARM RES-DORDR, V26, P523, DOI 10.1007/s11095-008-9767-0
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Bai Y, 2006, PHARM RES-DORDR, V23, P2116, DOI 10.1007/s11095-006-9059-5
   Barrett S, 1999, J HEPATOL, V30, P979, DOI 10.1016/S0168-8278(99)80249-9
   Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Ceraolo C, 2020, PHYLOGENOMIC ANAL 20, DOI [10.1101/2020.02.02.931162., DOI 10.1101/2020.02.02.931162]
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chen HY, 2017, J MOL MICROB BIOTECH, V27, P64, DOI 10.1159/000454813
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   Dar H, 2016, ASIAN PAC J TROP MED, V9, P822, DOI 10.1016/j.apjtm.2016.07.004
   Dar HA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030088
   de Vries SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017695
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5
   Jamroz M, 2014, BIOINFORMATICS, V30, P2150, DOI 10.1093/bioinformatics/btu184
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Keicho N, 2009, HUM IMMUNOL, V70, P527, DOI 10.1016/j.humimm.2009.05.006
   Kim J, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1035-2
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   Kuriata A, 2018, NUCLEIC ACIDS RES, V46, pW338, DOI 10.1093/nar/gky356
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Lehrer RI, 2012, IMMUNOL REV, V245, P84, DOI 10.1111/j.1600-065X.2011.01082.x
   LEHTINEN M, 1995, BIOCHEM BIOPH RES CO, V209, P541, DOI 10.1006/bbrc.1995.1535
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Lin XY, 2016, CELL MOL IMMUNOL, V13, P492, DOI 10.1038/cmi.2015.29
   Lorente E, 2016, MOL CELL PROTEOMICS, V15, P2141, DOI 10.1074/mcp.M115.057356
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Newman MJ, 2002, FRONT BIOSCI, V7, pD1503, DOI 10.2741/newman
   Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091
   Pandey RK, 2018, VACCINE, V36, P4555, DOI 10.1016/j.vaccine.2018.05.082
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5
   Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Sahin A., 2020, EURASIAN J MED ONCOL, V4, P1, DOI DOI 10.14744/ejmo.2020.12220
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108
   Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706
   Srivastava S, 2018, INFECT DRUG RESIST, V11, P2377, DOI 10.2147/IDR.S175114
   Tani K, 2000, INT IMMUNOL, V12, P691, DOI 10.1093/intimm/12.5.691
   Tomar N, 2010, IMMUNOLOGY, V131, P153, DOI 10.1111/j.1365-2567.2010.03330.x
   Trimaille T, 2015, VACCINES, V3, P803, DOI 10.3390/vaccines3040803
   ulQamar MT, 2020, RES SQ, DOI [10.21203/rs.2.23973/v1., DOI 10.21203/RS.2.23973/V1]
   Van Regenmortal Marc H. V., 1996, Methods (Orlando), V9, P465, DOI 10.1006/meth.1996.0054
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   WHO, 2020, COR DIS COVID 19 PAN
   Wilkins MR, 1999, METH MOL B, V112, P531
   Worldometer, 2020, COR CAS
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 77
TC 0
Z9 0
U1 4
U2 4
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD AUG 3
PY 2020
VL 8
AR e9541
DI 10.7717/peerj.9541
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MT2UU
UT WOS:000554824100002
PM 32832263
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kelly, M
   O'Connor, R
   Townsend, L
   Coghlan, M
   Relihan, E
   Moriarty, M
   Carr, B
   Melanophy, G
   Doyle, C
   Bannan, C
   O'Riordan, R
   Merry, C
   Clarke, S
   Bergin, C
AF Kelly, Mary
   O'Connor, Roisin
   Townsend, Liam
   Coghlan, Miriam
   Relihan, Eileen
   Moriarty, Miriam
   Carr, Bernard
   Melanophy, Gail
   Doyle, Caitriona
   Bannan, Ciaran
   O'Riordan, Ruth
   Merry, Concepta
   Clarke, Susie
   Bergin, Colm
TI Clinical outcomes and adverse events in patients hospitalised with
   COVID-19, treated with off-label hydroxychloroquine and azithromycin
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE adverse drug events; azithromycin; clinical pharmacy; COVID-19;
   hydroxychloroquine; medication safety
AB Aims To assess clinical outcomes and adverse drug events in patients hospitalised with COVID-19 treated with off-label hydroxychloroquine (HCQ) and azithromycin (Az). Methods We performed a retrospective analysis of hospitalised patients who had a positive polymerase chain reaction test for SARS-CoV-2 and received HCQ plus Az or no targeted therapy. The primary end point was clinical improvement on day 7 defined as either hospital discharge or an improvement of 2 points on a 6-category ordinal scale. Secondary outcomes included mortality at day 28, intensive care admission, requirement for mechanical ventilation and incidence of adverse events. Results Data from a total of 134 patients were evaluated; 82 patients received HCQ/Az and 52 patients received no targeted therapy. Clinical improvement was seen in 26.8% of patients who received HCQ/Az but this was not significant. The rates of intensive care transfer and mechanical ventilation were higher in the treatment group, but these differences were not significant. Mortality at day 28 was significantly higher in the treatment group (P =.03). Hypoglycaemia elevated liver function tests and QT prolongation were monitored in both groups. The risk of QT prolongation was significantly higher in the treatment group. Treatment was stopped early in 6 (7.3%) patients due to adverse events. Conclusion Although patients who received HCQ/Az were more severely ill the administration of these repurposed drugs did not result in clinical improvement and was associated with a significant increase in toxicity. This descriptive study highlights the importance of monitoring all repurposed agents for adverse events.
C1 [Kelly, Mary; O'Connor, Roisin; Coghlan, Miriam; Relihan, Eileen; Moriarty, Miriam; Carr, Bernard; Melanophy, Gail] St James Hosp, Pharm Dept, Dublin 8, Ireland.
   [O'Connor, Roisin; Townsend, Liam; Doyle, Caitriona; Bannan, Ciaran; O'Riordan, Ruth; Merry, Concepta; Clarke, Susie; Bergin, Colm] Hosp 5 St Jamess Hosp, Dept Genitourinary Med & Infect Dis GUIDe, Dublin, Ireland.
   [Townsend, Liam; Bannan, Ciaran; Bergin, Colm] Trinity Coll Dublin, Dublin, Ireland.
RP Kelly, M (corresponding author), St James Hosp, Pharm Dept, Dublin 8, Ireland.
EM marykellympharm@gmail.com
RI Townsend, Liam/ABH-3502-2020
OI Townsend, Liam/0000-0002-7089-0665; Kelly, Mary/0000-0003-1755-5769
CR Atkinson T, 2016, SUPPORT CARE CANCER, V24, P3669, DOI 10.1007/s00520-016-3297-9
   Cansu DU, 2008, RHEUMATOLOGY, V47, P378, DOI 10.1093/rheumatology/kem378
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   El-Solia Ahmed, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-223639
   Fossa AA, 2007, AM J TROP MED HYG, V77, P929, DOI 10.4269/ajtmh.2007.77.929
   Jaffe S, 2020, LANCET, V395, P1179, DOI 10.1016/S0140-6736(20)30817-5
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO, V2020
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   World Health Organization (WHO), 2020, CLIN MAN SEV AC REP
NR 11
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14482
EA AUG 2020
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MS6VO
UT WOS:000554414900001
PM 32687645
OA Bronze
DA 2021-01-01
ER

PT J
AU Turkoglu, S
   Ucar, HN
   Cetin, FH
   Guler, HA
   Tezcan, ME
AF Turkoglu, Serhat
   Ucar, Halit Necmi
   cetin, Fatih Hilmi
   Guler, Hasan Ali
   Tezcan, Muatafa Esat
TI The relationship between chronotype, sleep, and autism symptom severity
   in children with ASD in COVID-19 home confinement period
SO CHRONOBIOLOGY INTERNATIONAL
LA English
DT Article
DE COVID-19 confinement; chronotype; autism spectrum disorder; sleep
   problems; children
ID SPECTRUM DISORDER; MORNINGNESS-EVENINGNESS; QUESTIONNAIRE; BEHAVIOR;
   QUALITY; INDIVIDUALS
AB This study aimed to investigate the relationship between chronotype preference/sleep problems and symptom severity of children with Autism spectrum disorder (ASD) during the confinement and social isolation of the COVID-19 outbreak. This study included 46 drug-naive children aged 4-17 y diagnosed with ASD. The Autism Behavior Checklist (AuBC), Children's Sleep Habits Questionnaire (CSHQ), and Children's chronotype questionnaire (CCQ) were filled out before and at the end of the COVID-19 mandated home confinement by the children's parents. Children with ASD during the home confinement reported higher chronotype scores, i.e., eveningness chronotype, sleep problems, and autism symptom scores compared to the normal non-hone confinement state. The chronotype score and sleep problems of children with ASD during the home confinement period varied according to the AuBC score. The sleep problems of the children with ASD during the home confinement period mediated the relationship between chronotype score and severity of autism symptoms. It is essential to validate the role of the mediator effect of sleep problems and chronotype in larger samples of children with ASD with restricted to home confinement during the pandemic period. If sleep problems can be controlled with parental education, pharmacotherapy, and psychotherapeutic interventions, the impact on children with ASD of home confinement can be reduced.
C1 [Turkoglu, Serhat; Ucar, Halit Necmi; cetin, Fatih Hilmi; Tezcan, Muatafa Esat] Selcuk Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-42075 Konya, Turkey.
   [Guler, Hasan Ali] Afyon State Hosp, Dept Child & Adolescent Psychiat, Afyon, Turkey.
RP Turkoglu, S (corresponding author), Selcuk Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-42075 Konya, Turkey.
EM drserhat@gmail.com
CR Bellicoso D, 2017, CHRONOBIOL INT, V34, P808, DOI 10.1080/07420528.2017.1314301
   Carmassi C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00366
   Cavallera GM, 2014, MED SCI MONITOR, V20, DOI 10.12659/MSM.889030
   Czeisler CA, 1999, SCIENCE, V284, P2177, DOI 10.1126/science.284.5423.2177
   Dagys N, 2012, J CHILD PSYCHOL PSYC, V53, P660, DOI 10.1111/j.1469-7610.2011.02502.x
   Doo S, 2006, DEV MED CHILD NEUROL, V48, P650, DOI 10.1017/S001216220600137X
   Dursun OB, 2015, EURASIAN J MED, V47, P56, DOI 10.5152/eajm.2014.0061
   Erren TC, 2020, CHRONOBIOL INT, V37, P1115, DOI 10.1080/07420528.2020.1779993
   Fis NP, 2010, ANADOLU PSIKIYATR DE, V11, P151
   Henderson JA, 2011, RES AUTISM SPECT DIS, V5, P758, DOI 10.1016/j.rasd.2010.09.003
   Hoefman R, 2014, J AUTISM DEV DISORD, V44, P1933, DOI 10.1007/s10803-014-2066-1
   Hong ER, 2015, J AUTISM DEV DISORD, V45, P2792, DOI 10.1007/s10803-015-2444-3
   Irmak TY, 2007, TURK J CHILD ADOLESC, V14, P13
   Johnson CR, 1996, CHILD ADOL PSYCH CL, V5, P673, DOI 10.1016/S1056-4993(18)30355-9
   Johnson CR, 2018, SLEEP MED, V44, P61, DOI 10.1016/j.sleep.2018.01.008
   KRUG DA, 1980, J CHILD PSYCHOL PSYC, V21, P221, DOI 10.1111/j.1469-7610.1980.tb01797.x
   Loke YJ, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00107
   Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y
   Monk TH, 2004, CHRONOBIOL INT, V21, P435, DOI 10.1081/CBI-120038614
   Owens JA, 2000, SLEEP, V23, P1043
   Peterson JL, 2019, J CHILD ADOLES TRAUM, V12, P529, DOI 10.1007/s40653-019-00253-5
   Portaluppi F, 2010, CHRONOBIOL INT, V27, P1911, DOI 10.3109/07420528.2010.516381
   Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879
   Richdale AL, 2009, SLEEP MED REV, V13, P403, DOI 10.1016/j.smrv.2009.02.003
   Singh K, 2015, SEMIN PEDIATR NEUROL, V22, P113, DOI 10.1016/j.spen.2015.03.006
   Sivertsen B, 2012, AUTISM, V16, P139, DOI 10.1177/1362361311404255
   Trkoglu S, 2019, CHRONOBIOL INT, V36, P1138, DOI 10.1080/07420528.2019.1622131
   Wiggs L, 1996, J INTELL DISABIL RES, V40, P518, DOI 10.1046/j.1365-2788.1996.799799.x
   Wimpory D, 2002, J INTELL DISABIL RES, V46, P352, DOI 10.1046/j.1365-2788.2002.00423.x
   Yoshii T, 2012, PROG BRAIN RES, V199, P59, DOI 10.1016/B978-0-444-59427-3.00027-7
   Zavada A, 2005, CHRONOBIOL INT, V22, P267, DOI 10.1081/CBI-200053536
NR 31
TC 1
Z9 1
U1 14
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0742-0528
EI 1525-6073
J9 CHRONOBIOL INT
JI Chronobiol. Int.
PD AUG 2
PY 2020
VL 37
IS 8
BP 1207
EP 1213
DI 10.1080/07420528.2020.1792485
EA AUG 2020
PG 7
WC Biology; Physiology
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA NV0TG
UT WOS:000555249800001
PM 32746638
DA 2021-01-01
ER

PT J
AU Zhang, CT
   Lin, LC
   Tang, DG
   Liu, FJ
   Li, M
   Li, QY
   Deng, ZX
   Chu, GH
   Gu, DY
   Dai, Y
AF Zhang, Cantong
   Lin, Liancheng
   Tang, Donge
   Liu, Fuju
   Li, Meng
   Li, Qiongying
   Deng, Zhaoxiang
   Chu, Guohai
   Gu, Dayong
   Dai, Yong
TI Antibody responses to SARS-CoV-2 in healthy individuals returning to
   Shenzhen
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; IgA; IgG; IgM; SARS-CoV-2
AB To verify reliability of antibody detection and investigate population immunity to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in the local Chinese population. A cross-sectional study was conducted in Shenzhen to detect anti-coronavirus antibodies including, immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA). In the COVID-19 group, nine patients were enrolled after diagnosis. In the control group, 1589 individuals without clinical symptoms (cough, fever, and fatigue) and returning from outside Shenzhen were enrolled. The first study enrollment occurred at the end of February 2020; the final study visit was 18 March 2020. In the COVID-19 group, the seven of nine patients were positive for IgM, IgG, and IgA. Meanwhile, six of the 1589 healthy individuals were found to be weakly positive for IgG. According to SARS-CoV-2 nucleic acid tests, the six individuals were all negative. Strong supplemental support for clinical information can be provided by antibody detection, especially for IgA. According to comparison with overseas reports, the infection rate of the Chinese population outside Shenzhen, China, is significantly low, so most of the population in China is still susceptible. Hence, social distancing measures are still inevitable until a vaccine is developed successfully.
C1 [Zhang, Cantong; Tang, Donge; Dai, Yong] Southern Univ Sci & Technol, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Clin Med Res Ctr,Affiliated Hosp 1,Jinan Uni, Shenzhen, Guangdong, Peoples R China.
   [Lin, Liancheng; Liu, Fuju; Li, Meng; Li, Qiongying] Shenzhen Sciarray Biotech Co Ltd, Res & Dev Dept R&D, Shenzhen, Guangdong, Peoples R China.
   [Deng, Zhaoxiang] Shenzhen Exit Entry Inspect Gen Hosp, Dept Clin Med Res Ctr, Shenzhen, Guangdong, Peoples R China.
   [Chu, Guohai] Shenzhen Dongyi Lab, Clin Lab Ctr, Shenzhen, Guangdong, Peoples R China.
   [Gu, Dayong] Shenzhen Univ, Shenzhen Peoples Hosp 2, Dept Clin Lab, Affiliated Hosp 1,Hlth Sci Ctr, Shenzhen 518035, Guangdong, Peoples R China.
RP Gu, DY (corresponding author), Shenzhen Univ, Shenzhen Peoples Hosp 2, Dept Clin Lab, Affiliated Hosp 1,Hlth Sci Ctr, Shenzhen 518035, Guangdong, Peoples R China.; Dai, Y (corresponding author), Southern Univ Sci & Technol, Dept Clin Med Res Ctr, Clin Med Coll 2,Jinan Dept,Clin Med Res Ctr, Affiliated Hosp 1,Jinan Univ,Shenzhen Peoples Hos, Shenzhen 518035, Guangdong, Peoples R China.
EM wanhood@163.com; daiyong22@aliyun.com
OI Dai, Yong/0000-0002-6840-9158; Zhang, Cantong/0000-0001-6315-3811
CR Choe JY, 2020, J MED VIROL, V92, P2567, DOI 10.1002/jmv.26060
   FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hendrik S, 2020, VORLAUFIGES ERGEBNIS, P4
   [里进 Li Jin], 2020, [中华检验医学杂志, Chinese Journal of Laboratory Medicine], V43, P221
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   National Health Commission of the People's Republic of China, 2020, NATL HLTH COMMISSION
   Sakamoto S, 2018, J NAT MED-TOKYO, V72, P32, DOI 10.1007/s11418-017-1144-z
   The Boston Globe, BOSTON GLOBE
   World Health Organization, 2020, COR DIS COVID 2019 S
   Xiang F, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa461
   Xiang J., 2020, EVALUATION ENZYME LI
   Xu XL, 2020, MYCOKEYS, P1, DOI 10.3897/mycokeys.70.54231
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
NR 15
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26355
EA AUG 2020
PG 4
WC Virology
SC Virology
GA MS6TC
UT WOS:000554405600001
PM 32710647
OA Bronze
DA 2021-01-01
ER

PT J
AU Koker, O
   Demirkan, FG
   Kayaalp, G
   Cakmak, F
   Tanatar, A
   Karadag, SG
   Sonmez, HE
   Omeroglu, R
   Ayaz, NA
AF Koker, Oya
   Demirkan, Fatma Gul
   Kayaalp, Gulsah
   Cakmak, Figen
   Tanatar, Ayse
   Karadag, Serife Gul
   Sonmez, Hafize Emine
   Omeroglu, Rukiye
   Ayaz, Nuray Aktay
TI Does immunosuppressive treatment entail an additional risk for children
   with rheumatic diseases? A survey-based study in the era of COVID-19
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Biological therapies; COVID-19; Dmards; Immunosuppressants; Paediatric
   rheumatology
ID CHALLENGE; INFECTION
AB The aim of the research was to further extend current knowledge of whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19) entails a risk for children with various rheumatic diseases under immunosuppressive treatment. Telephone survey was administered by conducting interviews with the parents from May 1, 2020 to May 20, 2020. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments. Patients who were followed-up under immunosuppressive treatment (n = 439) were attempted to be contacted. The diagnostic distribution of patients (n = 414) eligible for the study was as follows: juvenile idiopathic arthritis (JIA) (n = 243, 58.7%), autoinflammatory diseases (n = 109, 26.3%), connective tissue diseases (n = 51, 12.3%), and vasculitis (n = 11, 2.7%). In the entire cohort, the mean age was 12 +/- 4.7 years, and 54.1% (n = 224) were female. Nine patients have attended the hospital for COVID-19 evaluation, 6 of whom were in close contact with confirmed cases. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic was identified to be diagnosed with COVID-19. None, including the confirmed case, had any severe symptoms. More than half of the patients with household exposure did not require hospitalization as they were asymptomatic. Although circumstances such as compliance in social distancing policy, transmission patterns, attitude following contact may have influenced the results, immunosuppressive treatment does not seem to pose an additional risk in terms of COVID-19.
C1 [Koker, Oya; Demirkan, Fatma Gul; Kayaalp, Gulsah; Cakmak, Figen; Tanatar, Ayse; Omeroglu, Rukiye; Ayaz, Nuray Aktay] Istanbul Univ, Istanbul Fac, Dept Paediat Rheumatol, Med Sch, Istanbul, Turkey.
   [Karadag, Serife Gul; Sonmez, Hafize Emine] Kanuni Sultan Suleyman Res & Training Hosp, Dept Paediat Rheumatol, Istanbul, Turkey.
RP Ayaz, NA (corresponding author), Istanbul Univ, Istanbul Fac, Dept Paediat Rheumatol, Med Sch, Istanbul, Turkey.
EM nurayaktay@gmail.com
RI Tanatar, Ayse/AAD-4491-2020
OI Tanatar, Ayse/0000-0002-1386-4575; Sonmez, Hafize
   Emine/0000-0002-9186-3068; Karadag, Serife Gul/0000-0002-3232-0055;
   Aktay Ayaz, Nuray/0000-0003-3594-7387; Kavrul Kayaalp,
   Gulsah/0000-0001-7490-7076
FU Scientific Research Projects Coordination Unit of Istanbul
   UniversityIstanbul University [36852]
FX This study was funded by Scientific Research Projects Coordination Unit
   of Istanbul University. Project Number: 36852. No other specific funding
   was received from any bodies in the public, commercial or not-for-profit
   sectors to carry out the work described in this article.
CR Aygun D, 2019, CLIN RHEUMATOL, V38, P1025, DOI 10.1007/s10067-018-4367-9
   Batu ED, 2020, RHEUMATOL INT, V40, P1193, DOI 10.1007/s00296-020-04612-6
   Cao Q, 2020, J FORMOS MED ASSOC, V119, P670, DOI 10.1016/j.jfma.2020.02.009
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Chen F, 2020, Zhonghua Er Ke Za Zhi, V58, P179, DOI [10.3760/cma.j.issn.0578-1310.2020.0005, 10.3760/cma.j.issn.0578-1310.2020.03.003]
   Choi Soo-Han, 2020, Clin Exp Pediatr, V63, P125, DOI 10.3345/cep.2020.00535
   Conticini Edoardo, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217681, 10.1136/annrheumdis-2020-218761]
   Costi S, 2020, PEDIATR DRUGS, V22, P263, DOI 10.1007/s40272-020-00395-2
   Cron Randy Q, 2020, J Rheumatol, DOI 10.3899/jrheum.200492
   Cron RQ, 2020, J RHEUMATOL, V47, P1723, DOI [10.3899/jrheum.200744, 10.3899/jrheum.200334]
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   European League Against Rheumatism (EULAR).org, GUID PAT COVID 19 OU
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Favalli Ennio Giulio, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217615, 10.1136/annrheumdis-2020-217787]
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P373
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Filocamo Giovanni, 2020, J Rheumatol, DOI 10.3899/jrheum.200483
   Georgiev T, 2020, RHEUMATOL INT, V40, P825, DOI 10.1007/s00296-020-04570-z
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Haslak F, 2020, RHEUMATOL INT, V40, P1423, DOI 10.1007/s00296-020-04645-x
   Haslak F, 2020, BALK MED J, V37, P184, DOI 10.4274/balkanmedj.galenos.2020.2020.4.43
   Hedrich CM, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108420
   Li YZ, 2020, PEDIATR PULM, V55, pE1, DOI 10.1002/ppul.24734
   Licciardi F, 2020, PEDIATR RHEUMATOL, V18, DOI 10.1186/s12969-020-00422-z
   Lucchino B, 2020, RHEUMATOLOGY, V59, P1200, DOI 10.1093/rheumatology/keaa194
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Mukusheva Z, 2020, RHEUMATOL INT, V40, P1351, DOI 10.1007/s00296-020-04613-5
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Paediatric Rheumatology INternational Trials Organisation (PRINTO).org, 2020, PRES REC COR ER COVI
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sarzi-Puttini P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102574
   Scuccimarri R, 2020, J RHEUMATOL, V47, P783, DOI 10.3899/jrheum.200369
   Shen QX, 2020, PEDIATR PULM, V55, P1424, DOI 10.1002/ppul.24762
   Silva JT, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13176
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zheng F, 2020, CURR MED SCI, V40, P275, DOI 10.1007/s11596-020-2172-6
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 49
TC 3
Z9 3
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD OCT
PY 2020
VL 40
IS 10
BP 1613
EP 1623
DI 10.1007/s00296-020-04663-9
EA AUG 2020
PG 11
WC Rheumatology
SC Rheumatology
GA NF2MU
UT WOS:000554852400001
PM 32743705
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bossini, N
   Alberici, F
   Delbarba, E
   Valerio, F
   Manenti, C
   Possenti, S
   Econimo, L
   Maffei, C
   Pola, A
   Terlizzi, V
   Salviani, C
   Moscato, M
   Pasquali, S
   Zambetti, N
   Tonoli, M
   Affatato, S
   Pecchini, P
   Viola, FB
   Malberti, F
   Depetri, G
   Gaggiotti, M
   Scolari, F
AF Bossini, Nicola
   Alberici, Federico
   Delbarba, Elisa
   Valerio, Francesca
   Manenti, Chiara
   Possenti, Stefano
   Econimo, Laura
   Maffei, Camilla
   Pola, Alessandra
   Terlizzi, Vincenzo
   Salviani, Chiara
   Moscato, Marianna
   Pasquali, Stefano
   Zambetti, Nicole
   Tonoli, Michela
   Affatato, Stefania
   Pecchini, Paola
   Viola, Fabio B.
   Malberti, Fabio
   Depetri, Giorgio
   Gaggiotti, Mario
   Scolari, Francesco
CA Brescia Renal COVID Task Force
TI Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal
   COVID task force experience
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; infection and infectious agents - viral;
   infectious disease; kidney disease; infectious
ID REPLICATION
AB The outcome of kidney transplant patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still unclear. Here we describe the clinical characteristics, disease outcome, and risk factors for acute respiratory distress syndrome (ARDS) and death of a cohort of 53 kidney transplant patients with coronavirus disease 2019 (COVID-19). Eight of 53 have been handled as outpatients because of mild disease, on average with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin; no patients required admission, developed ARDS, or died. Because of severe symptoms, 45/53 required admission: this cohort has been managed with immunosuppression withdrawal, methylprednisolone 16 mg/d, hydroxychloroquine, and antiviral drugs. Dexamethasone and tocilizumab were considered in case of ARDS. About 33% of the patients developed acute kidney injury, 60% ARDS, and 33% died. In this group, thrombocytopenia was associated to ARDS whereas lymphopenia at the baseline, higher D-dimer, and lack of C-reactive protein reduction were associated with risk of death. In the overall population, dyspnea was associated with the risk of ARDS and age older than 60 years and dyspnea were associated with the risk of death with only a trend toward an increased risk of death for patients on tacrolimus. In conclusion, SARS-CoV-2 infection may have a variable outcome in renal transplant patients, with higher risk of ARDS and death in the ones requiring admission.
C1 [Bossini, Nicola; Alberici, Federico; Delbarba, Elisa; Valerio, Francesca; Manenti, Chiara; Possenti, Stefano; Econimo, Laura; Maffei, Camilla; Pola, Alessandra; Terlizzi, Vincenzo; Salviani, Chiara; Moscato, Marianna; Pasquali, Stefano; Zambetti, Nicole; Tonoli, Michela; Affatato, Stefania; Viola, Fabio B.; Gaggiotti, Mario; Scolari, Francesco] ASST Spedali Civili Brescia, Spedali Civili Hosp, Nephrol Unit, Brescia, Italy.
   [Alberici, Federico; Scolari, Francesco] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
   [Pecchini, Paola; Malberti, Fabio] ASST Cremona, Nephrol Unit, Cremona, Italy.
   [Depetri, Giorgio] ASST Crema, Nephrol Unit, Crema, Italy.
RP Alberici, F (corresponding author), ASST Spedali Civili Brescia, Spedali Civili Hosp, Nephrol Unit, Brescia, Italy.; Alberici, F (corresponding author), Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
EM federico.alberici@unibs.it
OI Alberici, Federico/0000-0002-1686-5709
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Becchetti C, 2020, GUT, V69, P1832, DOI 10.1136/gutjnl-2020-321923
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Husain SA, 2020, CLIN J AM SOC NEPHRO, V15, P1174, DOI 10.2215/CJN.05170420
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Maggiore U, 2020, NEPHROL DIAL TRANSPL, V35, P899, DOI 10.1093/ndt/gfaa130
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rodriguez-Cubillo B, 2020, AM J TRANSPLANT, V20, P3173, DOI 10.1111/ajt.16141
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   WINKLER M, 1995, DRUG SAFETY, V12, P348, DOI 10.2165/00002018-199512050-00006
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 3019
EP 3029
DI 10.1111/ajt.16176
EA AUG 2020
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000554395500001
PM 32627319
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Monfared, A
   Dashti-Khavidaki, S
   Jafari, R
   Jafari, A
   Ramezanzade, E
   Lebadi, MK
   Haghdar-Saheli, Y
   Aghajanzadeh, P
   Khosravi, M
   Movassaghi, A
   Taghvaye-Masoumi, H
   Foumani, AA
AF Monfared, Ali
   Dashti-Khavidaki, Simin
   Jafari, Ramezan
   Jafari, Atefeh
   Ramezanzade, Elham
   Lebadi, Mohamad-Kazem
   Haghdar-Saheli, Yalda
   Aghajanzadeh, Pegah
   Khosravi, Masoud
   Movassaghi, Ali
   Taghvaye-Masoumi, Hamidreza
   Foumani, Ali Alavi
TI Clinical characteristics and outcome of COVID-19 pneumonia in kidney
   transplant recipients in Razi hospital, Rasht, Iran
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE coronavirus; COVID-19; immunosuppression; kidney transplantation
AB Background In late December 2019, a novel coronavirus SARS-CoV-2 started to spread around the world in different populations. Its clinical and laboratory characteristics and outcome in kidney transplant recipients are little known. Therefore, we describe 22 kidney transplant recipients with SARS-CoV-2-induced pneumonia. Methods All kidney transplant recipients who referred to the Razi Hospital of Rasht with a diagnosis of SARS-CoV-2 infection from February 20 to 19th of April 2020 have been included in this observational study. Results We present 22 cases of COVID-19 in kidney transplant recipients (median age 52 years [interquartile range 40.75-62.75 years]) and baseline eGFR 60 (mL/min/1.73 m(2)) (44.75-86.75). Patients complained of cough (72.7%), dyspnea (63.6%), fever (68.2%), and chill (72.7%) with greater prevalence. We decreased the dose of immunosuppression and started stress dose of intravenous hydrocortisone or equivalent oral prednisolone. Each patient received antiviral therapy based on the latest updated version of local protocol at the time of admission. CT scan findings in 90.9% of patients showed bilateral multifocal lesions. Acute kidney injury (AKI) was observed in 12 patients during hospitalization. Six patients died after a median of 12 days from admission (IQR, 1-21). Conclusions In this small observational study, we observed high AKI occurrence and mortality rate in kidney transplant recipients with COVID-19.
C1 [Monfared, Ali; Jafari, Atefeh; Foumani, Ali Alavi] Guilan Univ Med Sci, Razi Hosp, Inflammatory Lung Dis Res Ctr, Sch Med, Rasht, Iran.
   [Monfared, Ali; Ramezanzade, Elham; Lebadi, Mohamad-Kazem; Haghdar-Saheli, Yalda; Aghajanzadeh, Pegah; Khosravi, Masoud; Movassaghi, Ali] Guilan Univ Med Sci, Razi Clin Res Dev Ctr, Rasht, Iran.
   [Dashti-Khavidaki, Simin] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran.
   [Jafari, Ramezan] Baqiyatallah Univ Med Sci, Dept Radiol, Tehran, Iran.
   [Jafari, Atefeh; Taghvaye-Masoumi, Hamidreza] Guilan Univ Med Sci, Sch Pharm, Dept Clin Pharm, Rasht, Iran.
RP Jafari, A (corresponding author), Guilan Univ Med Sci, Sch Pharm, POB 41635-1655, Rasht, Iran.
EM atf.jafari@gmail.com
RI Khosravi, Masoud/D-1724-2019; Jafari, Atefeh/H-2058-2011
OI Khosravi, Masoud/0000-0002-7495-4937; Jafari, Atefeh/0000-0001-5782-3559
CR Ahmadpoor P, 2020, TRANSPL INT, V33, P824, DOI 10.1111/tri.13611
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ison MG, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00042-19
   Ju Chun-Rong, 2020, Chronic Dis Transl Med, V6, P87, DOI 10.1016/j.cdtm.2020.02.003
   Liu Y, 2020, ONTOLOGICAL BIOINFOR
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Pan F, 2019, RADIOLOGY, V2020
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13420
DI 10.1111/tid.13420
EA AUG 2020
PG 8
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA MS6IN
UT WOS:000554377200001
PM 32681756
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bourassa, KJ
   Sbarra, DA
   Caspi, A
   Moffitt, TE
AF Bourassa, Kyle J.
   Sbarra, David A.
   Caspi, Avshalom
   Moffitt, Terrie E.
TI Social Distancing as a Health Behavior: County-Level Movement in the
   United States During the COVID-19 Pandemic Is Associated with
   Conventional Health Behaviors
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Article
DE COVID-19; Social distancing; Health behaviors; Smoking; Physical
   activity; Counties
ID INFLUENZA VACCINATION RATES; SOCIOECONOMIC DISPARITIES; INTERVENTIONS;
   PATTERNS; MODELS; ADULTS
AB Background Social distancing-when people limit close contact with others outside their household-is a primary intervention available to combat the COVID-19 pandemic. The importance of social distancing is unlikely to change until effective treatments or vaccines become widely available. However, relatively little is known about how best to promote social distancing. Applying knowledge from social and behavioral research on conventional health behaviors (e.g., smoking, physical activity) to support public health efforts and research on social distancing is promising, but empirical evidence supporting this approach is needed.
   Purpose We examined whether one type of social distancing behavior-reduced movement outside the home-was associated with conventional health behaviors.
   Method We examined the association between GPS-derived movement behavior in 2,858 counties in USA from March 1 to April 7, 2020 and the prevalence of county-level indicators influenced by residents' conventional health behaviors.
   Results Changes in movement were associated with conventional health behaviors, and the magnitude of these associations were similar to the associations among the conventional health behaviors. Counties with healthier behaviors-particularly less obesity and greater physical activity-evidenced greater reduction in movement outside the home during the initial phases of the pandemic in the USA.
   Conclusions Social distancing, in the form of reduced movement outside the home, is associated with conventional health behaviors. Existing scientific literature on health behavior and health behavior change can be more confidently used to promote social distancing behaviors during the COVID-19 pandemic.
C1 [Bourassa, Kyle J.; Caspi, Avshalom; Moffitt, Terrie E.] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA.
   [Bourassa, Kyle J.; Caspi, Avshalom; Moffitt, Terrie E.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA.
   [Sbarra, David A.] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA.
   [Caspi, Avshalom; Moffitt, Terrie E.] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
RP Bourassa, KJ (corresponding author), Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA.; Bourassa, KJ (corresponding author), Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA.
RI Moffitt, Terrie/D-5295-2011
OI Moffitt, Terrie/0000-0002-8589-6760
FU National Institute on Aging training grant [T32-AG000029]
FX The first author received support from National Institute on Aging
   training grant [grant T32-AG000029]. Aggregated mobility data were
   provided by three companies: Citymapper (via Citymapper. com), Cuebiq,
   and Streetlight. Cuebiq is a location intelligence and measurement
   platform. Through its Data for Good program, Cuebiq provides access to
   aggregated mobility data for academic research and humanitarian
   initiatives. These first-party data are collected from anonymized users
   who have opted-in to provide access to their location data anonymously,
   through a GDPR-compliant framework. It is then aggregated to the county
   level to provide insights on changes in human mobility over time.
   Streetlight made data available for the purpose of nonprofit, public
   benefit research in response to the COVID-19 pandemic. State-and
   county-level demographic, socioeconomic, and health behavior data were
   made available from the County Health Rankings & Roadmaps
   (https://www.countyhealthrankings.org/).The program is a collaboration
   between the Robert Wood Johnson Foundation and the University of
   Wisconsin Population Health Institute.
CR Aubry MC, 2000, CLIN CHEST MED, V21, P11, DOI 10.1016/S0272-5231(05)70005-8
   Bavel Jay J Van, 2020, Nat Hum Behav, V4, P460, DOI 10.1038/s41562-020-0884-z
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Berrigan D, 2003, PREV MED, V36, P615, DOI 10.1016/S0091-7435(02)00067-1
   Betsch C, 2015, POLICY INSIGHTS BEHA, V2, P61, DOI DOI 10.1177/2372732215600716
   Blavatnik School of Government at the University of Oxford, COR GOV RESP TRACK
   Braveman PA, 2010, AM J PUBLIC HEALTH, V100, pS186, DOI 10.2105/AJPH.2009.166082
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Centre for Longitudinal Studies, UCLS LONG STUD SURV
   Corace KM, 2016, VACCINE, V34, P3235, DOI 10.1016/j.vaccine.2016.04.071
   Curran PJ, 2011, ANNU REV PSYCHOL, V62, P583, DOI 10.1146/annurev.psych.093008.100356
   de Vries H, 2008, PREV MED, V46, P203, DOI 10.1016/j.ypmed.2007.08.005
   Glanz K, 2008, HLTH BEHAV HLTH ED
   Glanz K, 2010, ANNU REV PUBL HEALTH, V31, P399, DOI 10.1146/annurev.publhealth.012809.103604
   Glass RJ, 2006, EMERG INFECT DIS, V12, P1671, DOI 10.3201/eid1211.060255
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lau D, 2012, ANN FAM MED, V10, P538, DOI 10.1370/afm.1405
   Lee VJ, 2020, J TRAVEL MED, V27, P1
   Muthen L.K., 1998, MPLUS USERS GUIDE
   Nimptsch K, 2019, METABOLISM, V92, P61, DOI 10.1016/j.metabol.2018.12.006
   Pampel FC, 2010, ANNU REV SOCIOL, V36, P349, DOI 10.1146/annurev.soc.012809.102529
   Pueyo T., MEDIUM
   Reid AE, 2010, HDB BEHAV MED
   Richard L, 2011, ANNU REV PUBL HEALTH, V32, P307, DOI 10.1146/annurev-publhealth-031210-101141
   Robinson WS, 2009, INT J EPIDEMIOL, V38, P337, DOI 10.1093/ije/dyn357
   Roser M, OUR WORLD DATA CORON
   Sallis J. F., 2015, HLTH BEHAV THEORY RE, P43
   Shrestha SS, 2011, CLIN INFECT DIS, V52, pS75, DOI 10.1093/cid/ciq012
   Soucy JR, 2020, ESTIMATING EFFECTS P, DOI [10.1101/2020.04.05.20054288, DOI 10.1101/2020.04.05.20054288]
   Thomas RE, 2010, VACCINE, V28, P1684, DOI 10.1016/j.vaccine.2009.11.067
   West R, 2020, NAT HUM BEHAV, DOI 10.1038/s41562-020-0887-9
   Wilmot EG, 2012, DIABETOLOGIA, V55, P2895, DOI 10.1007/s00125-012-2677-z
   World Health Organization, NAM COR DIS COVID 19
   World Health Organization, COR PAND
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 38
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD AUG
PY 2020
VL 54
IS 8
BP 548
EP 556
DI 10.1093/abm/kaaa049
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA OW2RL
UT WOS:000592740600003
PM 32608474
OA Green Published
DA 2021-01-01
ER

PT J
AU Gatfaoui, S
   Sagaama, A
   Issaoui, N
   Roisnel, T
   Marouani, H
AF Gatfaoui, Sofian
   Sagaama, Abir
   Issaoui, Noureddine
   Roisnel, Thierry
   Marouani, Houda
TI Synthesis, experimental, theoretical study and molecular docking of
   1-ethylpiperazine-1,4-diium bis(nitrate)
SO SOLID STATE SCIENCES
LA English
DT Article
DE X-ray diffraction; COVID-19; Molecular docking; NBO; HOMO-LUMO;
   Hirshfeld surface
ID DENSITY-FUNCTIONAL THEORY; HYBRID MATERIAL; PROTON-TRANSFER;
   NANOPARTICLES; CHEMISTRY; GEOMETRY; MODES; DRUG
AB The present work undertakes the study of a new hybrid material C6H16N2(NO3)(2) symbolized as follows 1EPBN (1-Ethylpiperazine-1,4-diium Bis(Nitrate)), a synergy between the two experimental and theoretical approach allows us to characterize and evaluate our crystal. 1EPBN has been successfully synthesized at room temperature by slow evaporation and crystallized to the orthorhombic system with space group Pnma with a following lattice parameters are 12.158 (2) angstrom, 6.5939 (9) angstrom, 13.058 (2) angstrom, V = 1046.8 (3) angstrom 3 and Z = 4. The diprotonated 1-ethyl-piperazine molecules are linked to the nitrate anions by multiple bifurcated and non-bifurcated N-H center dot center dot center dot (O,O) and weak C-HO hydrogen bonds forming R-1(4) (4), R-2(1) (5), R-2(1) (6) and R-4(2) (10) motifs. The hydrogen bonding network is confirmed by the great contribution of O center dot center dot center dot H/H center dot center dot center dot O contacts (63.2%) on the Hirshfeld surface. Topological analysis such as atom in molecule (AIM), reduced density gradient (RDG) natural bond orbital (NBO), molecular electrostatic potential (MEP) and Mulliken charges have been used to evaluate in detail the intermolecular interactions, especially the hydrogen bonds. The HOMO and LUMO energies and other calculated quantum parameters reveal the hardness and the great stability of the material. Molecular docking analysis reveals that 1EPBN might display the inhibitory activity against coronavirus proteins (COVID-19 and SARSCoV2).
C1 [Gatfaoui, Sofian; Marouani, Houda] Univ Carthage, Fac Sci Bizerte, LR13ES08 Lab Chim Mat, Bizerte 7021, Tunisia.
   [Sagaama, Abir; Issaoui, Noureddine] Univ Monastir, Fac Sci, Lab Quantum & Stat Phys LR18ES18, Monastir 5079, Tunisia.
   [Roisnel, Thierry] Univ Rennes, ISCR Inst Sci Chim Rennes, CNRS, UMR 6226, F-35000 Rennes, France.
RP Marouani, H (corresponding author), Univ Carthage, Fac Sci Bizerte, LR13ES08 Lab Chim Mat, Bizerte 7021, Tunisia.
EM houdamarouani2015@gmail.com
FU Tunisian Ministry of Higher Education Scientific Research
FX We are grateful to the Tunisian Ministry of Higher Education Scientific
   Research for the provided financial support.
CR Abagyan R, 2001, CURR OPIN CHEM BIOL, V5, P375, DOI 10.1016/S1367-5931(00)00217-9
   Altomare A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717
   [Anonymous], 2006, SAINT SADABS
   Bader R.F.W., 1990, ATOMS MOL QUANTUM TH
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Ben M'leh C, 2018, J MOL STRUCT, V1171, P771, DOI 10.1016/j.molstruc.2018.06.041
   BLESSING RH, 1986, ACTA CRYSTALLOGR B, V42, P613, DOI 10.1107/S0108768186097641
   BOGAERT MG, 1994, CARDIOVASC DRUG THER, V8, P693, DOI 10.1007/BF00877116
   Brandan S.A., 2012, NITRATE OCCURRENCE C
   Brandan S.A., 2012, STRUCTURAL VIBRATION, V1, P3311
   Brandan S.A., 2015, DESCRIPTORS STRUCTUR
   Brandenburg K., 1998, DIAMOND VERSION 2 0
   Braun PV, 1999, J AM CHEM SOC, V121, P7302, DOI 10.1021/ja9833725
   BROWN ID, 1976, ACTA CRYSTALLOGR A, V32, P24, DOI 10.1107/S0567739476000041
   Carlson HA, 2000, MOL PHARMACOL, V57, P213
   Castillo MV, 2011, J MOL STRUCT, V994, P202, DOI 10.1016/j.molstruc.2011.03.018
   Coupez B, 2006, CURR MED CHEM, V13, P2995, DOI 10.2174/092986706778521797
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Englebienne P, 2005, J COLLOID INTERF SCI, V292, P445, DOI 10.1016/j.jcis.2005.06.001
   Espinosa E, 2001, CHEM PHYS LETT, V336, P457, DOI 10.1016/S0009-2614(01)00178-6
   Espinosa E., J CHEM PHYS LETT, P336
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Gatfaoui S, 2018, J MOL STRUCT, V1151, P152, DOI 10.1016/j.molstruc.2017.09.027
   Gatfaoui S, 2019, J MOL STRUCT, V1191, P183, DOI 10.1016/j.molstruc.2019.04.093
   Gatfaoui S, 2017, J MOL STRUCT, V1150, P242, DOI 10.1016/j.molstruc.2017.08.092
   Gatfaoui S, 2017, J MOL STRUCT, V1139, P52, DOI 10.1016/j.molstruc.2017.03.028
   Gatfaoui S, 2014, ACTA CRYSTALLOGR E, V70, P0198, DOI 10.1107/S1600536814001469
   Gatfaoui S, 2014, ACTA CRYSTALLOGR E, V70, pO725, DOI 10.1107/S1600536814012100
   Gatfaoui S, 2014, ACTA CRYSTALLOGR E, V70, pO571, DOI 10.1107/S1600536814008265
   Gatfaoui S, 2014, ACTA CRYSTALLOGR E, V70, pO398, DOI 10.1107/S1600536814004620
   Gatfaoui S, 2013, ACTA CRYSTALLOGR E, V69, pO1453, DOI 10.1107/S1600536813022836
   Glendening E.D., 1996, NBO 3 1, P1990
   GRIBBLE GW, 1984, J ORG CHEM, V49, P4518, DOI 10.1021/jo00197a039
   Gunasekaran S, 2008, J CHEM SCI, V120, P315, DOI 10.1007/s12039-008-0054-8
   Halperin I, 2002, PROTEINS, V47, P409, DOI 10.1002/prot.10115
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Johnson ER, 2010, J AM CHEM SOC, V132, P6498, DOI 10.1021/ja100936w
   KOCH U, 1995, J PHYS CHEM-US, V99, P9747, DOI 10.1021/j100024a016
   Kosar B, 2011, SPECTROCHIM ACTA A, V78, P160, DOI 10.1016/j.saa.2010.09.016
   Kose E., 2018, J MOL STRUCT, V10, P2
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li YZ, 2013, APPL SURF SCI, V273, P135, DOI 10.1016/j.apsusc.2013.01.213
   Majerz I, 2004, ACTA CRYSTALLOGR B, V60, P406, DOI 10.1107/S0108768104010365
   MULLER A, 1995, ANGEW CHEM INT EDIT, V34, P2328, DOI 10.1002/anie.199523281
   Muller A, 1998, CHEM REV, V98, P239, DOI 10.1021/cr9603946
   Mulliken RS, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749394
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588
   Noureddine O, 2020, J MOL STRUCT, V1202, DOI 10.1016/j.molstruc.2019.127351
   Novena LM, 2016, J MOL STRUCT, V1116, P45, DOI 10.1016/j.molstruc.2016.03.014
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   Pearson R.G., 1997, CHEM HARDNESS
   POPELIER PLA, 1994, J PHYS CHEM-US, V98, P4473, DOI 10.1021/j100067a040
   REED AE, 1985, J CHEM PHYS, V83, P1736, DOI 10.1063/1.449360
   Rozas I, 2000, J AM CHEM SOC, V122, P11154, DOI 10.1021/ja0017864
   RUNGE E, 1984, PHYS REV LETT, V52, P997, DOI 10.1103/PhysRevLett.52.997
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Sotriffer CA, 2000, METHODS, V20, P280, DOI 10.1006/meth.1999.0922
   TORFGARD KE, 1994, CARDIOVASC DRUG THER, V8, P701, DOI 10.1007/BF00877117
   Visualizer D.S., 2005, DISC STUD VIS, V2
   Weinhold F., 2005, VALENCY BONDING NATU
   Wolff S.K., 2013, CRYSTAL EXPLORER 3 1
   Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035
NR 63
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1293-2558
EI 1873-3085
J9 SOLID STATE SCI
JI Solid State Sci.
PD AUG
PY 2020
VL 106
AR 106326
DI 10.1016/j.solidstatesciences.2020.106326
PG 13
WC Chemistry, Inorganic & Nuclear; Chemistry, Physical; Physics, Condensed
   Matter
SC Chemistry; Physics
GA OU0YF
UT WOS:000591261700006
DA 2021-01-01
ER

PT J
AU Heman-Ackah, SM
   Su, YRS
   Spadola, M
   Petrov, D
   Chen, HI
   Schuster, J
   Lucas, T
AF Heman-Ackah, Sabrina M.
   Su, YouRong Sophie
   Spadola, Michael
   Petrov, Dmitriy
   Chen, H. Isaac
   Schuster, James
   Lucas, Timothy
TI Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19
   Patients on Extracorporeal Membrane Oxygenation: A Case Series
SO NEUROSURGERY
LA English
DT Article
DE COVID-19; Extracorporeal membrane oxygenation; Intracranial hemorrhage;
   Intraparenchymal hemorrhage; Patient selection; Resource allocation;
   SARS-CoV-2
ID CORONAVIRUS DISEASE 2019; COMPLICATIONS; INFLUENZA
AB BACKGROUND AND IMPORTANCE: Extracorporeal membrane oxygenation (ECMO) represents a life-saving therapy in cases of refractory hypoxia and has been utilized in patients suffering from the most severe forms of coronavirus disease 2019 (COVID-19). A strikingly high mortality rate of 94% was described in early reports of patients with COVID-19 transitioned to ECMO. Later case reports and series demonstrating successful recovery from COVID-19 after ECMO have revived interest in this therapeutic modality, including the recent approval of ECMO for COVID-19 patients by the Food and Drug Administration (FDA). Here, we present the first reports of devastating intracranial hemorrhage as a complication of veno-venous (VV) ECMO in two COVID-19 patients.
   CLINICAL PRESENTATION: We performed a retrospective analysis of 2 cases of devastating intracranial hemorrhage in patients on VV-ECMO for the treatment of COVID-19. Collected data included clinical history, laboratory results, treatment, and review of all available imaging. Both patients demonstrated activated partial thromboplastin times (aPTT) within an appropriate therapeutic range. No risk factors that clearly predicted likelihood of this complication were identified.
   CONCLUSION: Understanding the complications of ECMO in this cohort and developing therapeutic algorithms to aid in optimal patient selection will be critical in the limited resource setting experienced as a result of global pandemic. We propose the use of head computed tomography (CT) to identify devastating neurological complications as early as possible, aiding in the resource allocation of ECMO machines to the most appropriately selected patients.
C1 [Heman-Ackah, Sabrina M.; Su, YouRong Sophie; Spadola, Michael; Petrov, Dmitriy; Chen, H. Isaac; Schuster, James; Lucas, Timothy] Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Lucas, Timothy] Univ Penn, Ctr Neuroengn & Therapeut, Philadelphia, PA 19104 USA.
RP Heman-Ackah, SM (corresponding author), Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM sabrina.heman-ackah@pennmedicine.upenn.edu
CR Cavayas YA, 2018, PERFUSION-UK, V33, P42, DOI 10.1177/0267659118766435
   Chaves Renato Carneiro de Freitas, 2019, Rev. bras. ter. intensiva, V31, P410, DOI [10.5935/0103-507x.20190063, 10.5935/0103-507X.20190063]
   Chow FC, 2011, NEUROCRIT CARE, V15, P156, DOI 10.1007/s12028-011-9534-7
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Fletcher-Sandersjoo A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190365
   Hampton CR, 2002, ARTIF ORGANS, V26, P902, DOI 10.1046/j.1525-1594.2002.07122.x
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Lidegran MK, 2007, ACAD RADIOL, V14, P62, DOI 10.1016/j.acra.2006.10.004
   Luo W, CLIN PATHOLOGY CRITI
   Matthay MA, 2020, LANCET RESP MED, P30127
   Patel B, 2019, J THORAC DIS, V11, pS1688, DOI 10.21037/jtd.2019.05.73
   Shinn JR, 2020, CRIT CARE MED, V48, pE339, DOI 10.1097/CCM.0000000000004214
   Thomas J, 2018, SEMIN THROMB HEMOST, V44, P20, DOI 10.1055/s-0037-1606179
   Zhan WQ, 2020, EUR REV MED PHARMACO, V24, P3385, DOI 10.26355/eurrev_202003_20705
NR 15
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0148-396X
EI 1524-4040
J9 NEUROSURGERY
JI Neurosurgery
PD AUG
PY 2020
VL 87
IS 2
BP E147
EP E151
DI 10.1093/neuros/nyaa198
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA OW8HL
UT WOS:000593120500021
PM 32424429
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gagnon, K
   Young, B
   Bachman, T
   Longbottom, T
   Severin, R
   Walker, MJ
AF Gagnon, Kendra
   Young, Brian
   Bachman, Teresa
   Longbottom, Thomas
   Severin, Richard
   Walker, Michael J.
TI Doctor of Physical Therapy Education in a Hybrid Learning Environment:
   Reimagining the Possibilities and Navigating a "New Normal"
SO PHYSICAL THERAPY
LA English
DT Article
ID PROGRAM; STRATEGIES; STUDENTS
AB Professional physical therapist education has experienced a transformation over the last few decades, moving to a doctoring profession with more autonomy and a broader scope of practice. These changes have occurred in parallel with systemic and structural changes in health care and higher education, both of which have experienced challenges with improving access and controlling costs, and have become a centerpiece of legislative and political discourse. At the same time, advances in technology have introduced new possibilities in education, with the emergence of online, blended, and "flipped" learning models that supplement or replace face-to-face instruction with distance learning. Hybrid education is a type of blended learning, utilizing both face-to-face and online instructional strategies. In a hybrid learning environment, online content may be delivered synchronously or asynchronously, replacing traditional face-to-face instructional time and reducing "seat time" for students. Recent attention has been brought to online and hybrid/blended learning in physical therapist education in the wake of the COVID-19 pandemic, as programs have been required to abruptly move from face-to-face to remote instruction. Hybrid and other forms of blended learning strategies have been described at the physical therapist education course level. However, there is no literature describing hybrid learning implementation at the physical therapist education program "levels," and there has been limited discussion on best practices for delivering hybrid, blended, and online instruction in physical therapist education. This perspective provides an overview of hybrid education, describes theoretical frameworks that guide implementation of a hybrid education curriculum, and discusses future directions for hybrid physical therapist education and educational research.
C1 [Gagnon, Kendra; Young, Brian; Bachman, Teresa; Longbottom, Thomas; Severin, Richard; Walker, Michael J.] Baylor Univ, Phys Therapy Program, One Bear Pl 97264, Waco, TX 76798 USA.
RP Gagnon, K (corresponding author), Baylor Univ, Phys Therapy Program, One Bear Pl 97264, Waco, TX 76798 USA.
EM kendra_gagnon@baylor.edu
OI Severin, Richard/0000-0003-3432-6634
CR Adams C., 2013, J PHYS THER ED, V27, P20, DOI DOI 10.1097/00001416-201310000-00005
   Allen I. E., 2016, ONLINE REPORT CARD T
   Anderson LC, 2017, ADV PHYSIOL EDUC, V41, P383, DOI 10.1152/advan.00099.2016
   Anderson T., 2001, J ASYNCHRONOUS LEARN, V5, P1, DOI DOI 10.24059/OLJ.V5I2.1875
   [Anonymous], 2020, COVID 19 ENT SOL
   [Anonymous], 2006, TRANSFORMATION TECHN
   [Anonymous], 2020, 6350 DPT BAYL U
   [Anonymous], CLIN ED COVID 19 REP
   Bada Steven Olusegun, 2015, IOSR J RES METHOD ED, V5, P66, DOI DOI 10.9790/7388-05616670
   Bata-Jones B, 2004, J NURS EDUC, V43, P185
   Bayliss AJ, 2011, J PHYS THER ED, V25, P14
   Bersin J., 2004, BLENDED LEARNING BOO
   Blondy LC, 2007, J INTERACT ONLINE LE, V6, P116
   Bonk CJ, 2012, HDB BLENDED LEARNING
   Boucher Brenda, 2013, J PHYS THERAPY ED, V27, P72, DOI DOI 10.1097/00001416-201307000-00010
   Buxton T, 2016, NURS EDUC, V41, P1, DOI 10.1097/NNE.0000000000000183
   Cook DA, 2008, JAMA-J AM MED ASSOC, V300, P1181, DOI 10.1001/jama.300.10.1181
   Dal Bello-Haas V, 2013, J PHYS THERAPY ED, V27, P10, DOI DOI 10.1097/00001416-201310000-00004
   Davidson SC, 2011, J CONTIN EDUC NURS, V42, P223, DOI 10.3928/00220124-20110103-02
   Deprey SM, 2018, J PHYS THER ED, V32, P289
   Dziuban C, 2018, INT J EDUC TECHNOL H, V15, DOI 10.1186/s41239-017-0087-5
   Gardner P, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0593-5
   Garrison D. R., 1999, Internet and Higher Education, V2, P87, DOI 10.1016/S1096-7516(00)00016-6
   Garrison D. R., 2009, ENCY DISTANCE LEARNI, V2, P352, DOI DOI 10.4018/978-1-60566-198-8.CH052
   Garrison D. R., 2001, AM J DISTANCE ED, V15, P7, DOI DOI 10.1080/08923640109527071
   Ge Weiqing, 2018, J Allied Health, V47, P103
   George PP, 2014, J GLOB HEALTH, V4, DOI 10.7189/jogh.04.010406
   Goldberg MW, 1996, COMPUT NETWORKS ISDN, V28, P1219, DOI 10.1016/0169-7552(96)00021-9
   Hyland MR, 2010, COMP ANAL COMPUTER A, V1, P7
   Ilic D, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0321-6
   Johnson L, 2016, NMC HORIZON REPORT
   Kearns SP, 2006, TEACH LEARN NURS, V1, P10, DOI 10.1016/j.teln.2006.02.002
   Kenny N, 2017, INT SOC SCHOL TEACH
   Knowles M.S., 1980, MODERN PRACTICE ADUL
   Krathwohl DR, 2002, THEOR PRACT, V41, P212, DOI 10.1207/s15430421tip4104_2
   Kumrow DE, 2007, J NURS EDUC, V46, P140, DOI 10.3928/01484834-20070301-10
   Liu Q, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4807
   Maureen Tam, 2000, ED TECHNOLOGY SOC, V3, P50
   Mu Keli, 2014, Am J Occup Ther, V68 Suppl 2, pS51, DOI 10.5014/ajot.2014.685S02
   Munro V, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1328-6
   MURRAY L, 2014, J PHYS THER ED, V28, P35, DOI DOI 10.1097/00001416-201407000-00006
   Parsad B, 2008, DISTANCE ED DEGREE G
   Picciano AG, 2017, ONLINE LEARN, V21, P166, DOI 10.24059/olj.v21i3.1225
   Robinia KJ, 2012, NURS EDUC PERSPECT, V33, P374, DOI 10.5480/1536-5026-33.6.374
   Seaman J, 2019, GRADE INCREASE TRACK
   Shead Dorothy Agnes, 2020, JBI Evid Synth, V18, P893, DOI 10.11124/JBISRIR-2017-003903
   Swisher D, 2019, IMPLEMENTING DISTANC
   Veneri Diana A, 2014, J Allied Health, V43, pe75
NR 48
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD AUG
PY 2020
VL 100
IS 8
BP 1268
EP 1277
DI 10.1093/ptj/pzaa096
PG 10
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8TY
UT WOS:000593153400006
PM 32424417
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Earnshaw, VA
   Eaton, LA
   Kalichman, SC
   Brousseau, NM
   Hill, EC
   Fox, AB
AF Earnshaw, Valerie A.
   Eaton, Lisa A.
   Kalichman, Seth C.
   Brousseau, Natalie M.
   Hill, E. Carly
   Fox, Annie B.
TI COVID-19 conspiracy beliefs, health behaviors, and policy support
SO TRANSLATIONAL BEHAVIORAL MEDICINE
LA English
DT Article
DE Conspiracy beliefs; COVID-19; Pandemic; Vaccination; USA
AB Conspiracy theories have been proliferating during the COVID-19 pandemic. Evidence suggests that belief in conspiracy theories undermines engagement in pro-health behaviors and support for public health policies. Moreover, previous work suggests that inoculating messages from opinion leaders that expose conspiracy theories as false before people are exposed to them can help to prevent belief in new conspiracies. Goals of this study were to: (a) explore associations between COVID-19 conspiracy beliefs with SARS-CoV-2 vaccine intentions, cooperation with public health recommendations, and support for public health policies among U.S. adults and (b) investigate trusted sources of COVID-19 information to inform strategies to address conspiracy beliefs. A cross-sectional, online survey was conducted with 845 U.S. adults in April 2020. Data were analyzed using analyses of variance and multivariable regressions. One-third (33%) of participants believed one or more conspiracies about COVID-19. Participants who believed conspiracies reported that their intentions to vaccinate were 3.9 times lower and indicated less support for COVID-19 public health policies than participants who disbelieved conspiracies. There were no differences in cooperation with public health recommendations by conspiracy belief endorsement in the multivariable regression analysis. Although there were some key differences in trusted sources of COVID-19 information, doctor(s) were the most trusted source of information about COVID-19 overall with 90% of participants trusting doctor(s). Doctor(s) may play a role in addressing COVID-19 conspiracy theories before people are exposed to them to promote COVID-19 prevention efforts.
C1 [Earnshaw, Valerie A.; Brousseau, Natalie M.; Hill, E. Carly] Univ Delaware, Dept Human Dev & Family Sci, 111 Alison Hall West, Newark, DE 19716 USA.
   [Kalichman, Seth C.] Univ Connecticut, Dept Psychol Sci, Storrs, CT USA.
   [Eaton, Lisa A.] Univ Connecticut, Dept Human Dev & Family Sci, Storrs, CT USA.
   [Fox, Annie B.] MGM Inst Hlth Profess, Ctr Interprofess Studies & Innovat, Boston, MA USA.
RP Earnshaw, VA (corresponding author), Univ Delaware, Dept Human Dev & Family Sci, 111 Alison Hall West, Newark, DE 19716 USA.
EM earnshaw@udel.edu
OI Reis, AlessanRSS/0000-0001-8486-7469
FU University of Delaware
FX This study was funded by the University of Delaware.
CR Allington D., 2020, RELATIONSHIP CONSPIR
   Allyn B., RES NEARLY HALF ACCO
   Bogart LM, 2010, JAIDS-J ACQ IMM DEF, V53, P648, DOI 10.1097/QAI.0b013e3181c57dbc
   Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980
   Centers for Disease Control and Prevention, COR DIS COVID 19 PAN
   Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261
   Earnshaw VA, ED AMPLIFY FOCUS ADD
   Earnshaw VA, 2019, J HEALTH PSYCHOL, V24, P219, DOI 10.1177/1359105316650507
   Imhoff R, 2020, SOC PSYCHOL PERS SCI, V11, P1110, DOI 10.1177/1948550620934692
   [Internet] National Cancer Institute, HLTH INF NAT TRENDS
   Jin F, 2014, COMPUTER, V47, P90, DOI 10.1109/MC.2014.361
   Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Jolley D, 2014, BRIT J PSYCHOL, V105, P35, DOI 10.1111/bjop.12018
   Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061
   Klofstad CA, 2019, PALGR COMMUN, V5, DOI 10.1057/s41599-019-0243-8
   LaVeist TA, 2009, HEALTH SERV RES, V44, P2093, DOI 10.1111/j.1475-6773.2009.01017.x
   Le TT, COVID 19 VACCINE DEV
   Montanaro D., POLL AM DONT TRUST W
   Muller RT, 2020, BIOL LETTERS, V16, DOI 10.1098/rsbl.2020.0417
   National Governors Association, COR WHAT YOU NEED KN
   Oliver JE, 2014, JAMA INTERN MED, V174, P817, DOI 10.1001/jamainternmed.2014.190
   RTI International, RTI COVID 19 US SURV
   SteelFisher GK, 2015, NEW ENGL J MED, V373, P789, DOI 10.1056/NEJMp1506290
   Thomas K, TOP SCI HLTH OFFICIA
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
   Wood MJ, 2012, SOC PSYCHOL PERS SCI, V3, P767, DOI 10.1177/1948550611434786
NR 27
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1869-6716
EI 1613-9860
J9 TRANSL BEHAV MED
JI Transl. Behav. Med.
PD AUG
PY 2020
VL 10
IS 4
BP 850
EP 856
DI 10.1093/tbm/ibaa090
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OX0GS
UT WOS:000593255200006
PM 32910819
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Scemama, P
   Farah, F
   Mann, G
   Margulis, R
   Gritsenko, K
   Shaparin, N
AF Scemama, Pascal
   Farah, Fadi
   Mann, Glen
   Margulis, Roman
   Gritsenko, Karina
   Shaparin, Naum
TI Considerations for Epidural Blood Patch and Other Postdural Puncture
   Headache Treatments in Patients with COVID-19
SO PAIN PHYSICIAN
LA English
DT Article
DE COVID-19; PDPH; Epidural Blood Patch; Post-dural Puncture Headache
ID NEURAXIAL ANESTHESIA; REGIONAL ANESTHESIA; PARTURIENTS; BLOCK
AB Background: A primary concern in the use of EBP in these patients is the possibility of seeding the virus in the CNS. Another important concern is related to the known hypercoagulable state in COVID-19 positive patients and associated organ dysfunction that may alter the metabolism of anticoagulants. The safety of the providers performing the EBP, the position of the patient and choices for image guidance (blind, fluoroscopic) are also key considerations to review. It is also important to explore the current state of knowledge about using allogenic instead of autologous blood as well as emerging techniques to eliminate the coronavirus from the blood.
   Objectives: In this article we pose the questions of how to manage PDPH in the COVID-19 positive patient and more specifically, the use of epidural blood patch (EBP).
   Methods: Literature review.
   Results: EBP is usually considered after the failure of conservative and pharmacological treatments. Because of the additional risks of EBP in COVID-19 patients it is important to also consider less traditional pharmacological treatments such as theophylinnes and cosyntropin that may offer some additional benefit for COVID-19 patient. Finally, other interventions other than EBP should also be considered including occipital nerve blocks, sphenopalatine ganglion blocks (infratemporal or transnasal).
   Limitations: A narrative review with paucity of literature.
   Conclusion: Going forward, an effective treatment for COVID-19 or a safe vaccine and a deeper understanding of the pathophysiology of the virus will certainly change the risk calculus involved in performing an EBP in a COVID-19 patient.
C1 [Scemama, Pascal] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA.
   [Farah, Fadi; Mann, Glen; Margulis, Roman; Gritsenko, Karina; Shaparin, Naum] Albert Einstein Coll Med, Bronx, NY USA.
   [Mann, Glen] Childrens Hosp Montefiore, Bronx, NY USA.
   [Shaparin, Naum] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.
RP Scemama, P (corresponding author), Univ Massachusetts, Dept Anesthesiol & Perioperat Med, Sch Med, UMass Mem Med Ctr, 55 Lake Ave North, Worcester, MA 01655 USA.
EM pascal.scemamadegjalluly@umassmed.edu
CR [Anonymous], 2020, EXTHERAMEDICAL  0326
   BADER AM, 1992, REGION ANESTH, V17, P84
   BADER AM, 1990, REGION ANESTH, V15, P261
   Bernstein J, 2016, ANESTH ANALG, V123, P165, DOI 10.1213/ANE.0000000000001312
   Bhandari A, 2001, PAIN CLINIC, V13, P77, DOI 10.1163/15685690152385781
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cesur M, 2005, INT J OBSTET ANESTH, V14, P261, DOI 10.1016/j.ijoa.2004.11.006
   CROSBY ET, 1989, CAN J ANAESTH, V36, P701, DOI 10.1007/BF03005425
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Goodman EJ, 1996, REGION ANESTH, V21, P436
   Gritsenko K, 2012, BRIT J ANAESTH, V108, P485, DOI 10.1093/bja/aer416
   HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743
   Horlocker TT, 2006, REGION ANESTH PAIN M, V31, P334, DOI 10.1016/j.rapm.2006.04.002
   Jilani TN, 2019, STATPEARLS
   Katz D, 2017, ANESTH ANALG, V124, P1219, DOI 10.1213/ANE.0000000000001840
   Kuenstner JT, 2019, COGENT MED, V6
   Lazzeri M, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1285
   Lie SA, 2020, CAN J ANESTH, V67, P885, DOI 10.1007/s12630-020-01637-0
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Nader A, 2013, PAIN PHYSICIAN, V16, pE537
   Pal R, 2020, ENDOCRINE, V68, P251, DOI 10.1007/s12020-020-02325-1
   Plewa MC, 2019, STATPEARLS
   Rasouli MR, 2015, CLIN ORTHOP RELAT R, V473, P1472, DOI 10.1007/s11999-015-4175-3
   Russell R, 2019, INT J OBSTET ANESTH, V38, P93, DOI 10.1016/j.ijoa.2018.12.006
   Safa-Tisseront V, 2001, ANESTHESIOLOGY, V95, P334, DOI 10.1097/00000542-200108000-00012
   Shaparin N, 2014, PAIN PHYSICIAN, V17, P119
   SUPINSKI GS, 1986, J APPL PHYSIOL, V60, P2040
   TOM DJ, 1992, ANESTHESIOLOGY, V76, P943, DOI 10.1097/00000542-199206000-00012
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Uppal V, 2020, ANAESTHESIA, V75, P1350, DOI 10.1111/anae.15105
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
NR 31
TC 0
Z9 0
U1 0
U2 0
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD AUG
PY 2020
VL 23
IS 4
SU S
SI SI
BP S305
EP S310
PG 6
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA OS6HP
UT WOS:000590262800009
PM 32942790
DA 2021-01-01
ER

PT J
AU Shah, S
   Diwan, S
   Kohan, L
   Rosenblum, D
   Gharibo, C
   Soin, A
   Sulindro, A
   Nguyen, Q
   Provenzano, DA
AF Shah, Shalini
   Diwan, Sudhir
   Kohan, Lynn
   Rosenblum, David
   Gharibo, Christopher
   Soin, Amol
   Sulindro, Adrian
   Quinn Nguyen
   Provenzano, David A.
TI The Technological Impact of COVID-19 on the Future of Education and
   Health Care Delivery
SO PAIN PHYSICIAN
LA English
DT Article
DE Continuing medical education; COVID-19; fellowship program; medical
   education; medical meetings; residency program; telehealth; telemedicine
ID CHRONIC PAIN; TELEMEDICINE; TELEHEALTH; MANAGEMENT; BENZODIAZEPINES;
   SATISFACTION; SIMULATION; TRIAL
AB Background: The unexpected COVID-19 crisis has disrupted medical education and patient care in unprecedented ways. Despite the challenges, the health-care system and patients have been both creative and resilient in finding robust "temporary" solutions to these challenges. It is not clear if some of these COVID-era transitional steps will be preserved in the future of medical education and telemedicine.
   Objectives: The goal of this commentary is to address the sometimes substantial changes in medical education, continuing medical education (CME) activities, residency and fellowship programs, specialty society meetings, and telemedicine, and to consider the value of some of these profound shifts to "business as usual" in the health-care sector.
   Methods: This is a commentary is based on the limited available literature, online information, and the front-line experiences of the authors.
   Results: COVID-19 has clearly changed residency and fellowship programs by limiting the amount of hands-on time physicians could spend with patients. Accreditation Council for Graduate Medicine Education has endorsed certain policy changes to promote greater flexibility in programs but still rigorously upholds specific standards. Technological interventions such as telemedicine visits with patients, virtual meetings with colleagues, and online interviews have been introduced, and many trainees are "technoomnivores" who are comfortable using a variety of technology platforms and techniques. Webinars and e-learning are gaining traction now, and their use, practicality, and cost-effectiveness may make them important in the post-COVID era. CME activities have migrated increasingly to virtual events and online programs, a trend that may also continue due to its practicality and cost-effectiveness. While many medical meetings of specialty societies have been postponed or cancelled altogether, technology allows for virtual meetings that may offer versatility and time-saving opportunities for busy clinicians. It may be that future medical meetings embrace a hybrid approach of blending digital with face-toface experience. Telemedicine was already in place prior to the COVID-19 crisis but barriers are rapidly coming down to its widespread use and patients seem to embrace this, even as health-care systems navigate the complicated issues of cybersecurity and patient privacy. Regulatory guidance may be needed to develop safe, secure, and patient-friendly telehealth applications. Telemedicine has affected the prescribing of controlled substances in which online counseling, informed consent, and follow-up must be done in a virtual setting. For example, pill counts can be done in a video call and patients can still get questions answered about their pain therapy, although it is likely that after the crisis, prescribing controlled substances may revert to face-to-face visits.
   Limitations: The health-care system finds itself in a very fluid situation at the time this was written and changes are still occurring and being assessed.
   Conclusions: Many of the technological changes imposed so abruptly on the health-care system by the COVID-19 pandemic may be positive and it may be beneficial that some of these transitions be preserved or modified as we move forward. Clinicians must be objective in assessing these changes and retaining those changes that clearly improve health-care education and patient care as we enter the COVID era.
C1 [Shah, Shalini; Sulindro, Adrian] Univ Calif Irvine, Dept Anesthesiol & Perioperat Care, Orange, CA USA.
   [Diwan, Sudhir] Albert Einstein Coll Med, Adv Spine Pk Ave, New York, NY USA.
   [Kohan, Lynn] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA.
   [Rosenblum, David] Maimonides Hosp, Dept Anesthesiol, Brooklyn, NY USA.
   [Gharibo, Christopher] NYU Langone Hlth, Dept Anesthesiol, Perioperat Care & Pain Med, New York, NY USA.
   [Soin, Amol] Wright State Univ, Dayton, OH 45435 USA.
   [Quinn Nguyen] NYU Langone Hlth, NYC Hlth Hosp Bellevue, Dept Anesthesiol, Perioperat Care & Pain Med, New York, NY USA.
   [Provenzano, David A.] Pain Diagnost & Intervent, Sewickley, PA USA.
RP Shah, S (corresponding author), Univ Calif Irvine, Dept Anesthesiol, 101 City Dr South,Bldg 53, Orange, CA 92868 USA.
EM shahshalini@gmail.com
FU Avanos; MedtronicMedtronic; Nevro; Stimgenics; AbbottAbbott Laboratories
FX Dr. Provenzano has consulted for Avanos, Boston Scientific, Medtronic,
   Nevro, and Esteve. He has received research support from Avanos,
   Medtronic, Nevro, Stimgenics, and Abbott. Dr. Shah is a consultant for
   Masimo Corporation and a speaking consultant for Allergan, Inc. David
   Rosenblum, MD has consulted for Pfizer, Clarius, SPR Therapeutics and
   Nalu Medical. He has used his PainExam platform to market for the
   Injured Worker's Pharmacy, Scilex and Clarius.
CR Accreditation Council for Graduate Medical Education, 2020, ACGME RESP COR COVID
   Accreditation Council for Graduate Medical Education, 2020, STAG 3 PAND EM STAT
   Accreditation Council for Graduate Medical Education, 2020, ACGME GUID STAT
   Accreditation Council for Graduate Medical Education, 2020, ACGME REAFF ITS 4 ON
   AlJamal YN, 2014, SURGERY, V156, P723, DOI 10.1016/j.surg.2014.04.049
   Almarzooq ZI, 2020, J AM COLL CARDIOL, V75, P2635, DOI 10.1016/j.jacc.2020.04.015
   Alraies MC, 2018, CIRCULATION, V138, P1287, DOI 10.1161/CIRCULATIONAHA.118.032999
   American Academy of Family Physicians, US TEL CAR PAT COVID
   American College of Cardiology, 2020, ACC 20 WCC COR COVID
   Andrade C, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.19f13000
   [Anonymous], 2020, STAT WEB REP KNOW IT
   Ballester JMS, 2018, SURGERY, V163, P672, DOI 10.1016/j.surg.2017.08.015
   Bambakidis NC, 2020, J NEUROSURG, V133, P10, DOI 10.3171/2020.3.JNS20965
   Brandt J, 2017, DRUGS R&D, V17, P493, DOI 10.1007/s40268-017-0207-7
   Cook DA, 2005, ACAD MED, V80, P541, DOI 10.1097/00001888-200506000-00005
   du Toit M, 2019, J TELEMED TELECARE, V25, P3, DOI 10.1177/1357633X17734239
   Edwards L, 2014, J MED INTERNET RES, V16, P154, DOI 10.2196/jmir.3257
   Ehlers U-D, 2006, HDB QUALITY STANDARD
   Gottlieb M, 2020, MED EDUC, V54, P116, DOI 10.1111/medu.13956
   Guina J, 2017, AUSTRALAS PSYCHIATRY, V25, P415, DOI 10.1177/1039856217711061
   Hanna GM, 2016, PAIN MED, V17, P1658, DOI 10.1093/pm/pnw069
   Healthcare Convention and Exhibitors Association, 2020, STAT IND REP
   Hirschtick RE, 2020, JAMA-J AM MED ASSOC, V323, P1702, DOI 10.1001/jama.2020.2978
   Khalil MK, 2018, CLIN ANAT, V31, P323, DOI 10.1002/ca.23052
   Liddy C, 2016, PAIN MED, V17, P1049, DOI 10.1093/pm/pnw038
   Liu Q, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4807
   Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314
   Muller KI, 2017, CEPHALALGIA, V37, P855, DOI 10.1177/0333102416654885
   Muller KI, 2017, NEUROLOGY, V89, P153, DOI 10.1212/WNL.0000000000004085
   Nobles CJ, 2017, J CLIN PSYCHIAT, V78, pE559, DOI 10.4088/JCP.16m10904
   O'Neil PM, 2012, OBESITY, V20, P1426, DOI 10.1038/oby.2012.66
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Pape-Koehler C, 2013, SURG ENDOSC, V27, P1737, DOI 10.1007/s00464-012-2672-y
   Polinski JM, 2016, J GEN INTERN MED, V31, P269, DOI 10.1007/s11606-015-3489-x
   Porpiglia F, 2020, EUR UROL, pS0302
   Powell RE, 2017, ANN FAM MED, V15, P225, DOI 10.1370/afm.2095
   Price M, 2020, COVID 19 FORCES C ON
   Pronovost A, 2009, CAN J ANAESTH, V56, P590, DOI 10.1007/s12630-009-9123-9
   Provenzano D, 2020, ANN HEAD MED, V2, P3
   Provenzano DA, 2014, CURR MED RES OPIN, V30, P2051, DOI 10.1185/03007995.2014.921610
   Rowse PG, 2015, J SURG EDUC, V72, P1057, DOI 10.1016/j.jsurg.2015.04.009
   Schafer AGM, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9465
   Schulz-Quach C, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1186-2
   Shanthanna H, 2020, ANAESTHESIA, V75, P935, DOI 10.1111/anae.15076
   Sherbino J, 2004, ANN EMERG MED, V44, P229, DOI 10.1016/j.annemergmed.2004.05.021
   Singh P, 2015, ANN SURG, V261, P862, DOI 10.1097/SLA.0000000000000857
   Smeekens AEFN, 2011, ARCH DIS CHILD, V96, P330, DOI 10.1136/adc.2010.190801
   Solomon DH, 2017, AM J MED, V130, P1415, DOI 10.1016/j.amjmed.2017.06.028
   Spithoff S, 2014, CAN FAM PHYSICIAN, V60, P694
   Theodore BR, 2015, PAIN MED, V16, P1045, DOI 10.1111/pme.12688
   Verghese A, 2015, AM J MED, V128, P1322, DOI 10.1016/j.amjmed.2015.06.004
   Vodovar D, 2020, REV MED INTERNE, V41, P368, DOI 10.1016/j.revmed.2019.12.021
   Weinstein RS, 2018, MED CLIN N AM, V102, P533, DOI 10.1016/j.mcna.2018.01.002
   Whelan A PJ, 2020, GUIDANCE MED STUDENT
   Yarns BC, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0697-y
NR 55
TC 4
Z9 4
U1 2
U2 2
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD AUG
PY 2020
VL 23
IS 4
SU S
SI SI
BP S367
EP S380
PG 14
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA OS6HP
UT WOS:000590262800013
PM 32942794
DA 2021-01-01
ER

PT J
AU Cheng, BJ
   Li, TJ
AF Cheng, Bijun
   Li, Tianjiao
TI Discovery of alliin as a putative inhibitor of the main protease of
   SARS-CoV-2 by molecular docking
SO BIOTECHNIQUES
LA English
DT Article
DE alliin; molecular docking; remdesivir; ritonavir; SARS-CoV-2 Mpro
AB The outbreak of viral pneumonia caused by the novel coronavirus SARS-CoV-2 that began in December 2019 caused high mortality. It has been suggested that the main protease (Mpro) of SARS-CoV-2 may be an important target to discover pharmaceutical compounds for the therapy of this life-threatening disease. Remdesivir, ritonavir and chloroquine have all been reported to play a role in suppressing SARS-CoV-2. Here, we applied a molecular docking method to study the binding stability of these drugs with SARS-CoV-2 Mpro. It appeared that the ligand-protein binding stability of the alliin and SARS-CoV-2 Mpro complex was better than others. The results suggested that alliin may serve as a good candidate as an inhibitor of SARS-CoV-2 Mpro. Therefore, the present research may provide some meaningful guidance for the prevention and treatment of SARS-CoV-2.
   METHOD SUMMARY Molecular docking was used to assess the binding stability of various drugs with SARS-CoV-2 main protease (Mpro). PyMOL software was used to align the protein structures of SARS-CoV Mpro (ID: 5C5N) and SARS-CoV-2 Mpro (ID: 6LU7).
C1 [Cheng, Bijun; Li, Tianjiao] Jilin Agr Sci & Technol Univ, Coll Food Engn, Jilin 132101, Jilin, Peoples R China.
RP Li, TJ (corresponding author), Jilin Agr Sci & Technol Univ, Coll Food Engn, Jilin 132101, Jilin, Peoples R China.
EM 280395882@qq.com
FU Fund project of Jilin Agricultural Science and Technology University
   [20190277, [2019]XZ003]
FX This study was supported in part by Fund project of Jilin Agricultural
   Science and Technology University (no. 20190277) and in part by Fund
   project of Jilin Agricultural Science and Technology University (no.
   [2019]XZ003). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest.
CR Ankri S, 1999, MICROBES INFECT, V1, P125, DOI 10.1016/S1286-4579(99)80003-3
   Banerjee SK, 2002, NUTR J, V1, DOI 10.1186/1475-2891-1-4
   Banerjee SK, 2003, PHYTOTHER RES, V17, P97, DOI 10.1002/ptr.1281
   Bazgier V, 2016, J COMPUT CHEM, V37, P2485, DOI 10.1002/jcc.24473
   Fu Y, 2018, J THEOR BIOL, V457, P180, DOI 10.1016/j.jtbi.2018.08.034
   Georgia S., 2014, ANTI-CANCER AGENT ME, V14, P233, DOI [10.2174/18715206113136660370, DOI 10.2174/18715206113136660370]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Li Y, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070728
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Morozova EA, 2014, ACTA CRYSTALLOGR D, V70, P3034, DOI 10.1107/S1399004714020938
   Navneet B, 2020, GOPALAKRISHNAN B NOV
   Puccinelli MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081645
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang L, 2017, EUR J MED CHEM, V137, P450, DOI 10.1016/j.ejmech.2017.05.045
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
NR 18
TC 1
Z9 1
U1 3
U2 3
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 0736-6205
EI 1940-9818
J9 BIOTECHNIQUES
JI Biotechniques
PD AUG
PY 2020
VL 69
IS 2
BP 109
EP +
DI 10.2144/btn-2020-0038
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OQ2XH
UT WOS:000588651700006
PM 32459144
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ayoub, BM
   Ramadan, E
   Ashoush, N
   Tadros, MM
   Hendy, MS
   Elmazar, MM
   Mousa, SA
AF Ayoub, B. M.
   Ramadan, E.
   Ashoush, N.
   Tadros, M. M.
   Hendy, M. S.
   Elmazar, M. M.
   Mousa, S. A.
TI Avoiding COVID-19 complications with diabetic patients could be achieved
   by multi-dose Bacillus Calmette-Guerin vaccine: a case study of beta
   cells regeneration
SO PHARMAZIE
LA English
DT Article
ID IMMUNE-RESPONSES; BCG; GENE; EMPAGLIFLOZIN; REVERSAL; MUTATION
AB Diabetes mellitus (DM) is one of the major risk factors for COVID-19 complications as it is one of the chronic immune-compromising conditions especially if patients have uncontrolled diabetes, poor HbA(1c) and/or irregular blood glucose levels. Diabetic patients' mortality rates with COVID-19 are higher than those of cardiovascular or cancer patients. Recently, Bacillus Calmette-Guerin (BCG) vaccine has shown successful results in reversing diabetes in both rats and clinical trials based on different mechanisms from aerobic glycolysis to beta cells regeneration. BCG is a multi-face vaccine that has been used extensively in protection from tuberculosis (TB) and leprosy and has been repositioned for treatment of bladder cancer, diabetes and multiple sclerosis. Recently, COVID-19 epidemiological studies confirmed that universal BCG vaccination reduced morbidity and mortality in certain geographical areas. Countries without universal policies of BCG vaccination (Italy, Nederland, USA) have been more severely affected compared to countries with universal and long-standing BCG policies that have shown low numbers of reported COVID-19 cases. Some countries have started clinical trials that included a single dose BCG vaccine as prophylaxis from COVID-19 or an attempt to minimize its side effects.This proposed research aims to use BCG vaccine as a double-edged weapon countering both COVID-19 and diabetes, not only as protection but also as therapeutic vaccination. The work includes a case study of regenerated pancreatic beta cells based on improved C-peptide and PCPRI laboratory findings after BCG vaccination for a 9 year old patient. The patient was re-vaccinated based on a negative tuberculin test and no scar at the site of injection of the 1st BCG vaccination at birth. The authors suggest and invite the scientific community to take into consideration the concept of direct BCG re-vaccination (after 4 weeks) because of the reported gene expressions and exaggerated innate immunity consequently. As the diabetic MODY-5 patient (mutation of HNF1B, Val2Leu) was on low dose Riomet (R) while eliminating insulin gradually, a simple analytical method for metformin assay was recommended to ensure its concentration before use as it is not approved yet by the Egyptian QC labs.
C1 [Ayoub, B. M.; Ramadan, E.; Ashoush, N.; Hendy, M. S.; Elmazar, M. M.] British Univ Egypt, Fac Pharm, Ctr Drug Res & Dev CDRD, Cairo, Egypt.
   [Ayoub, B. M.; Hendy, M. S.] British Univ Egypt, Fac Pharm, Pharmaceut Chem Dept, Cairo, Egypt.
   [Ramadan, E.; Elmazar, M. M.] British Univ Egypt, Fac Pharm, Pharmacol & Biochem Dept, Cairo, Egypt.
   [Ashoush, N.] British Univ Egypt, Fac Pharm, Clin Pharm & Pharm Practice Dept, Cairo, Egypt.
   [Tadros, M. M.] Ain Shams Univ, Fac Pharm, Analyt Chem Dept, Cairo, Egypt.
   [Mousa, S. A.] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA.
RP Mousa, SA (corresponding author), Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA.; Ayoub, BM (corresponding author), British Univ Egypt, Fac Pharm, Ctr Drug Res & Dev CDRD, Pharmaceut Chem Dept, Suez Rd, El Sherouk City, Cairo Governora, Egypt.
EM bassam.ayoub@bue.edu.eg; shaker.mousa@acphs.edu
CR [Anonymous], 2005, INT C HARMONIZATION
   Ayoub BM, 2020, PHARMAZIE, V75, P159, DOI 10.1691/ph.2020.0444
   Ayoub BM, 2017, J CHROMATOGR SCI, V55, P742, DOI 10.1093/chromsci/bmx030
   Ayoub BM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02895-7
   Ayoub BM, 2015, RSC ADV, V5, P95703, DOI 10.1039/c5ra17231d
   Ban LQ, 2008, P NATL ACAD SCI USA, V105, P13644, DOI 10.1073/pnas.0803429105
   Chou R, 2017, J UROLOGY, V197, P1189, DOI 10.1016/j.juro.2016.12.090
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   De Vas MG, 2015, DEVELOPMENT, V142, P871, DOI 10.1242/dev.110759
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Dow CT, 2020, MICROORGANISMS, V8, P212
   El-Khairi R, 2016, DIABETES OBES METAB, V18, P23, DOI 10.1111/dom.12715
   Fajans SS, 2011, DIABETES CARE, V34, P1878, DOI 10.2337/dc11-0035
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Faustman DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041756
   Fu YN, 1998, ANN NY ACAD SCI, V842, P138, DOI 10.1111/j.1749-6632.1998.tb09642.x
   Fukunaga S, 2011, J CLIN PHARMACOL, V51, P1237, DOI 10.1177/0091270010381500
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Hayashi T, 1999, MOL CELL BIOL, V19, P8646
   Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384
   Kato T, 2018, INTERNAL MED, V57, P2035, DOI 10.2169/internalmedicine.9692-17
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Kodama S, 2003, SCIENCE, V302, P1223, DOI 10.1126/science.1088949
   Kowalewicz-Kulbat M, 2017, EXPERT REV VACCINES, V16, P699, DOI 10.1080/14760584.2017.1333906
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Kuhtreiber WM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0062-8
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Leighton E, 2017, DIABETES THER, V8, P475, DOI 10.1007/s13300-017-0265-4
   Limdi NA, 2015, BLOOD, V126, P539, DOI 10.1182/blood-2015-02-627042
   MADKOUR M, 1977, J TROP MED HYG, V80, P144
   Matsumiya M, 2015, J INFECT DIS, V211, P1499, DOI 10.1093/infdis/jiu615
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   Mourits VP, 2018, CURR OPIN PHARMACOL, V41, P52, DOI 10.1016/j.coph.2018.04.007
   Okubo Y, 2013, SCI REP, V3, P1
   Ristori G, 2018, CURR OPIN IMMUNOL, V55, P89, DOI 10.1016/j.coi.2018.09.016
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666
   Ryu S, 2001, J CLIN INVEST, V108, P63, DOI 10.1172/JCI200112335
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Thada S, 2020, GENES IMMUN, V21, P13, DOI 10.1038/s41435-019-0080-1
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang LM, 2012, DIABETES CARE, V35, P465, DOI 10.2337/dc11-1236
   Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 45
TC 0
Z9 0
U1 1
U2 1
PU AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH
PI ESCHBORN
PA CARL-MANNICH-STR 26, ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD AUG
PY 2020
VL 75
IS 8
BP 375
EP 380
DI 10.1691/ph.2020.0494
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA OP8NM
UT WOS:000588347100003
PM 32758336
DA 2021-01-01
ER

PT J
AU Yu, X
   Li, N
   Li, YY
AF Yu, Xiang
   Li, Na
   Li, Yayi
TI Were it business opportunities or hidden risks: Observations on clinical
   trials and marketing authorizations of Gilead Science's remdesivir in
   China
SO PHARMAZIE
LA English
DT Article
ID CORONAVIRUS; GS-5734
AB New drugs against the in COVID-19 pandemic are urgently needed. Gilead Science's remdesivir has been introduced to China through special approval procedures, and was directly conducting the Phase III clinical trial. As expected, the marketing authorization process was completed soon. The drug brought hope to patients as well as business opportunities to companies. However, we must pay attention to the patent competition, generic drug competition and other unfair competition that remdesivir may face in China. China also needs to strengthen the innovation ability and international cooperation ability of local pharmaceutical companies by taking advantages of the opportunity to introduce remdesivir.
C1 [Yu, Xiang] Fujian Jiangxia Univ, Sch Publ Affairs, Beijing, Peoples R China.
   [Li, Na] Ningbo Univ, Sch Law, Ningbo 315211, Zhejiang, Peoples R China.
   [Li, Na] Ningbo Univ, Res Acad Belt & Rd, Ningbo 315211, Zhejiang, Peoples R China.
   [Li, Yayi] Beijing Univ Chinese Med, Sch Management, Beijing, Peoples R China.
RP Li, N (corresponding author), Ningbo Univ, Sch Law, Ningbo 315211, Zhejiang, Peoples R China.; Li, N (corresponding author), Ningbo Univ, Res Acad Belt & Rd, Ningbo 315211, Zhejiang, Peoples R China.
EM nali321@126.com
FU KC Wong Magna Fund in Ningbo University
FX This work was supported by KC Wong Magna Fund in Ningbo University.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bornstein SR, 2020, NAT REV ENDOCRINOL, V16, P297, DOI 10.1038/s41574-020-0353-9
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dunne S, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-1
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hemphill T, 2019, BUS SOC REV, V124, P467
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jordan R., 2017, OPEN FORUM INFECT DI, V4, pS737
   Jorgensen SCJ, 2020, PHARMACOTHERAPY, V40, P659, DOI 10.1002/phar.2429
   LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5
   Li N, 2016, DRUG DES DEV THER, V10, P2015, DOI 10.2147/DDDT.S104642
   Omrani AS, 2015, PATHOG GLOB HEALTH, V109, P354, DOI 10.1080/20477724.2015.1122852
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   World Health Organization, SOL CLIN TRIAL COVID
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 0
Z9 0
U1 2
U2 2
PU AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH
PI ESCHBORN
PA CARL-MANNICH-STR 26, ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD AUG
PY 2020
VL 75
IS 8
BP 407
EP 410
DI 10.1691/ph.2020.0549
PG 4
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA OP8NM
UT WOS:000588347100009
PM 32758342
DA 2021-01-01
ER

PT J
AU Yao, XT
   Ye, F
   Zhang, M
   Cui, C
   Huang, BY
   Niu, PH
   Liu, X
   Zhao, L
   Dong, ED
   Song, CL
   Zhan, SY
   Lu, RJ
   Li, HY
   Tan, WJ
   Liu, DY
AF Yao, Xueting
   Ye, Fei
   Zhang, Miao
   Cui, Cheng
   Huang, Baoying
   Niu, Peihua
   Liu, Xu
   Zhao, Li
   Dong, Erdan
   Song, Chunli
   Zhan, Siyan
   Lu, Roujian
   Li, Haiyan
   Tan, Wenjie
   Liu, Dongyang
TI In Vitro Antiviral Activity and Projection of Optimized Dosing Design of
   Hydroxychloroquine for the Treatment of Severe Acute Respiratory
   Syndrome Coronavirus 2 (SARS-CoV-2)
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE chloroquine; hydroxychloroquine; SARS-CoV-2
ID CHLOROQUINE; PHARMACOKINETICS; DRUG; DISPOSITION; ABSORPTION; TABLETS
AB Background. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.
   Methods. The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2-infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile.
   Results. Hydroxychloroquine (EC50 = 0.72 mu M) was found to be more potent than chloroquine (EC50 = 5.47 mu M) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.
   Conclusions. Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.
C1 [Yao, Xueting; Zhang, Miao; Cui, Cheng; Liu, Xu; Li, Haiyan; Liu, Dongyang] Peking Univ, Drug Clin Trial Ctr, Hosp 3, 49 Huayuan North Rd, Beijing 100089, Peoples R China.
   [Ye, Fei; Huang, Baoying; Niu, Peihua; Zhao, Li; Lu, Roujian; Tan, Wenjie] Chinese Ctr Dis Control & Prevent, NHC Key Lab Biosafety, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.
   [Dong, Erdan; Li, Haiyan] Peking Univ, Dept Cardiol, Hosp 3, Beijing, Peoples R China.
   [Dong, Erdan; Li, Haiyan] Peking Univ, Inst Vasc Med, Hosp 3, Beijing, Peoples R China.
   [Song, Chunli] Peking Univ, Dept Orthoped, Hosp 3, Beijing, Peoples R China.
   [Zhan, Siyan] Peking Univ, Res Ctr Clin Epidemiol, Hosp 3, Beijing, Peoples R China.
RP Liu, DY (corresponding author), Peking Univ, Drug Clin Trial Ctr, Hosp 3, 49 Huayuan North Rd, Beijing 100089, Peoples R China.
EM liudongyang@sina.vip.com
FU "13th FiveYear" National Major New Drug Projects of China, Ministry of
   Science and Technology of the People's Republic of China
   [2017ZX09101001-002-001]; Bill & Melinda Gates FoundationBill & Melinda
   Gates FoundationCGIAR [OPP1204780]
FX This work was supported by the "13th FiveYear" National Major New Drug
   Projects of China, Ministry of Science and Technology of the People's
   Republic of China (grant number 2017ZX09101001-002-001) and the Bill &
   Melinda Gates Foundation (grant number OPP1204780).
CR Abdel-Aziz AK, 2014, CHEM-BIOL INTERACT, V217, P28, DOI 10.1016/j.cbi.2014.04.007
   ADELUSI SA, 1982, GEN PHARMACOL, V13, P433, DOI 10.1016/0306-3623(82)90110-0
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   Fan HW, 2015, RHEUMATOL THER, V2, P183, DOI 10.1007/s40744-015-0012-0
   FDA  CDER, 2018, PHYS BAS PHARM AN FO
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x
   Hsueh CH, 2018, CLIN PHARMACOKINET, V57, P1337, DOI 10.1007/s40262-018-0635-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JB, 2020, LOGOS PNEUMA-CHIN J, P13
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li Y, MINISTRY SCI TECHNOL
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   NEUVONEN PJ, 1992, HUM EXP TOXICOL, V11, P117, DOI 10.1177/096032719201100210
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   QUINTART J, 1979, J CELL BIOL, V82, P644, DOI 10.1083/jcb.82.3.644
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Strand V, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0880-2
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   WALKER O, 1987, BRIT J CLIN PHARMACO, V23, P467, DOI 10.1111/j.1365-2125.1987.tb03077.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Ying C, 2000, J VIRAL HEPATITIS, V7, P79
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 621
Z9 628
U1 14
U2 40
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2020
VL 71
IS 15
BP 732
EP 739
DI 10.1093/cid/ciaa237
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OF1UF
UT WOS:000581001200006
PM 32150618
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cao, JL
   Tu, WJ
   Cheng, WL
   Yu, L
   Liu, YK
   Hu, XY
   Liu, Q
AF Cao, Jianlei
   Tu, Wen-Jun
   Cheng, Wenlin
   Yu, Lei
   Liu, Ya-Kun
   Hu, Xiaoyong
   Liu, Qiang
TI Clinical Features and Short-term Outcomes of 102 Patients with
   Coronavirus Disease 2019 in Wuhan, China
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; human-to-human transmission; nosocomial infections; outcome
   SARS-CoV-2
ID 2019-NCOV; PNEUMONIA; SARS
AB Background. In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China. In this study, we investigate the clinical and laboratory features and short-term outcomes of patients with coronavirus disease 2019 (COVID-19).
   Methods. All patients with COVID-19 admitted to Wuhan University Zhongnan Hospital in Wuhan, China, between 3 January and 1 February 2020 were included. All those patients were with laboratory-confirmed infections. Epidemiological, clinical, and radiological characteristics; underlying diseases; laboratory tests; treatments; complications; and outcomes data were collected. Outcomes were followed up at discharge until 15 February 2020.
   Results. The study cohort included 102 adult patients. The median age was 54 years (interquartile ranger, 37-67 years), and 48.0% were female. A total of 34 patients (33.3%) were exposed to a source of transmission in the hospital setting (as health-care workers, patients, or visitors) and 10 patients (9.8%) had a familial cluster. There were 18 patients ( 17.6%) who were admitted to the intensive care unit (ICU), and 17 patients died (mortality, 16.7%; 95% confidence interval, 9.4-23.9%). Those patients who survived were younger, were more likely to be health-care workers, and were less likely to suffer from comorbidities. They were also less likely to suffer from complications. There was no difference in drug treatment rates between the survival and nonsurvival groups. Those patients who survived were less likely to require admission to the ICU (14.1% vs 35.3% of those admitted). Chest imaging examinations showed that patients who died were more likely to have ground-glass opacity (41.2% vs 12.9% in survivors).
   Conclusions. The mortality rate was high among the COVID-19 patients described in our cohort who met our criteria for inclusion in this analysis. The patient characteristics seen more frequently in those who died were the development of systemic complications following onset of the illness and a severity of disease requiring admission to the ICU. Our data support those described by others indicating that COVID-19 infection results from human-to-human transmission, including familial clustering of cases, and from nosocomial transmission. There were no differences in mortality among those who did or did not receive antimicrobial or glucocorticoid drug treatments.
C1 [Cao, Jianlei; Cheng, Wenlin; Hu, Xiaoyong] Wuhan Univ, Zhongnan Hosp, Dept Cardiol, Wuhan, Peoples R China.
   [Tu, Wen-Jun; Liu, Qiang] China Acad Med Sci, Inst Radiat Med, Tianjin, Peoples R China.
   [Tu, Wen-Jun; Liu, Qiang] Peking Union Med Coll, Tianjin, Peoples R China.
   [Yu, Lei] Harbin Med Univ, Dept Infect Dis, Affiliated Hosp 4, Harbin, Peoples R China.
   [Liu, Ya-Kun] Shandong Univ, Qilu Hosp, Jinan, Peoples R China.
RP Tu, WJ (corresponding author), 238 Baiti Rd, Tianjin 300192, Peoples R China.
EM tuwenjun@irrn-carns.ac.cn
OI YU, LEI/0000-0002-8837-2022
FU Chinese Academy of Medical Science Innovation Fund for Medical Science
   [2017-I2M-1-016, 2019-I2M-2-006]; Natural Science Foundation of
   TianjinNatural Science Foundation of Tianjin [19JCYBJC26600]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2019M660921]
FX This work was supported by the Chinese Academy of Medical Science
   Innovation Fund for Medical Science (grant number 2017-I2M-1-016 to Q.
   L.; grant number 2019-I2M-2-006 to W.-J. T.), the Natural Science
   Foundation of Tianjin (grant number 19JCYBJC26600 to W.-J. T.), and the
   China Postdoctoral Science Foundation (grant number 2019M660921 to W.-J.
   T.).
CR Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Cao JL, 2020, INTENS CARE MED, V46, P851, DOI 10.1007/s00134-020-05987-7
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Daszak Peter, 2020, Biosaf Health, V2, P6, DOI 10.1016/j.bsheal.2020.01.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang PK, 2020, RADIOLOGY, V295, P22, DOI 10.1148/radiol.2020200330
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Liu T., 2020, TRANSMISSION DYNAMIC
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wu P, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.3.2000044
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang M., 2020, MORE PNEUMONIA POTEN, DOI [10.2139/ssrn.3532272, DOI 10.2139/SSRN.3532272]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 72
Z9 72
U1 2
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2020
VL 71
IS 15
BP 748
EP 755
DI 10.1093/cid/ciaa243
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OF1UF
UT WOS:000581001200008
PM 32239127
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, ZL
   Yang, BH
   Li, QW
   Wen, L
   Zhang, RG
AF Wang, Zhongliang
   Yang, Bohan
   Li, Qianwen
   Wen, Lu
   Zhang, Ruiguang
TI Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan,
   China
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE coronavirus; pneumonia; Wuhan
ID ACUTE RESPIRATORY SYNDROME; INFLAMMATORY CYTOKINES; TRANSMISSION;
   PATHOGENESIS; THERAPY; ARBIDOL; SARS
AB Background. From December 2019 to February 2020, 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China. Related clinical features are needed.
   Methods. We reviewed 69 patients who were hospitalized in Union hospital in Wuhan between 16 January and 29 January 2020. All patients were confirmed to be infected with SARS-CoV-2, and the final date of follow-up was 4 February 2020.
   Results. The median age of 69 enrolled patients was 42.0 years (interquartile range 35.0-62.0), and 32 patients (46%) were men. The most common symptoms were fever (60 [87%]), cough (38 [55%]), and fatigue (29 [42%]). Most patients received antiviral therapy (66 [98.5%] of 67 patients) and antibiotic therapy (66 [98.5%] of 67 patients). As of 4 February 2020, 18 (26.9%) of 67 patients had been discharged, and 5 patients had died, with a mortality rate of 7.5%. According to the lowest SpO(2) during admission, cases were divided into the SpO(2) = 90% group (n = 55) and the SpO(2) < 90% group (n = 14). All 5 deaths occurred in the SpO(2) < 90% group. Compared with SpO(2) = 90% group, patients of the SpO(2) < 90% group were older and showed more comorbidities and higher plasma levels of interleukin (IL) 6, IL10, lactate dehydrogenase, and C reactive protein. Arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate.
   Conclusions. COVID-19 appears to show frequent fever, dry cough, and increase of inflammatory cytokines, and induced a mortality rate of 7.5%. Older patients or those with underlying comorbidities are at higher risk of death.
C1 [Wang, Zhongliang; Li, Qianwen; Wen, Lu; Zhang, Ruiguang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 130022, Peoples R China.
   [Yang, Bohan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
RP Zhang, RG (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 130022, Peoples R China.
EM zrg27@163.com
CR Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Kiselev OI, 2015, TERAPEVT ARKH, V87, P88, DOI 10.17116/terarkh201587188-96
   Lan L, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.783, DOI 10.1001/JAMA.2020.783]
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   National Health Commission of China, GUID MAN COVID 19 VE
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Seys LJM, 2018, CLIN INFECT DIS, V66, P45, DOI 10.1093/cid/cix741
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 252
Z9 253
U1 3
U2 20
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2020
VL 71
IS 15
BP 769
EP 777
DI 10.1093/cid/ciaa272
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OF1UF
UT WOS:000581001200011
PM 32176772
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU LaCourse, SM
   John-Stewart, G
   Waldorf, KMA
AF LaCourse, Sylvia M.
   John-Stewart, Grace
   Waldorf, Kristina M. Adams
TI Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19
   Therapeutic Trials
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE pregnancy; COVID-19; treatment; trial
AB Investigators are employing unprecedented innovation in the design of clinical trials to rapidly and rigorously assess potentially promising therapies for coronavirus disease 2019 (COVID-19); this is in stark contrast to the continued near-universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials that allow their inclusion focus on postexposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies. These restrictions were put in place despite experience with these drugs in pregnant women. In this Viewpoint, we call attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order to develop data-driven recommendations regarding the risks and benefits of therapies in this unique but not uncommon population.
C1 [LaCourse, Sylvia M.; John-Stewart, Grace] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA.
   [LaCourse, Sylvia M.; John-Stewart, Grace; Waldorf, Kristina M. Adams] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [LaCourse, Sylvia M.; John-Stewart, Grace] Univ Washington, Global Ctr Integrated Hlth Women Adolescents & Ch, Seattle, WA USA.
   [John-Stewart, Grace] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [John-Stewart, Grace] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Waldorf, Kristina M. Adams] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
   [Waldorf, Kristina M. Adams] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden.
RP LaCourse, SM (corresponding author), 325 9th Ave,Box 359931, Seattle, WA 98104 USA.
EM sylvia12@uw.edu
RI Adams Waldorf, Kristina/F-2608-2013
OI Adams Waldorf, Kristina/0000-0002-6939-7224
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Institutes of Health/NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K23AI120793]
FX S. M. L. is supported by the National Institute of Allergy and
   Infectious Diseases (NIAID) (grant number National Institutes of
   Health/NIAID K23AI120793).
CR Breslin Noelle, 2020, Am J Obstet Gynecol MFM, V2, P100111, DOI 10.1016/j.ajogmf.2020.100111
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Eunice Kennedy Shriver National Institute of Child Health and Human Development, TASK FORC RES SPEC P
   Fan H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212212
   Kaplan YC, 2016, BRIT J CLIN PHARMACO, V81, P835, DOI 10.1111/bcp.12872
   Liu Yangli, 2020, J Infect, DOI 10.1016/j.jinf.2020.02.028
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   US Food and Drug Administration, REQ EM US AUTH US CH
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zeng H, 2020, JAMA-J AM MED ASSOC, V323, P1848, DOI 10.1001/jama.2020.4861
   Zeng LK, 2020, JAMA PEDIATR, V174, P722, DOI 10.1001/jamapediatrics.2020.0878
NR 11
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2020
VL 71
IS 15
BP 879
EP 881
DI 10.1093/cid/ciaa444
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OF1UF
UT WOS:000581001200032
PM 32296817
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pagliano, P
   Piazza, O
   De Caro, F
   Ascione, T
   Filippelli, A
AF Pagliano, Pasquale
   Piazza, Ornella
   De Caro, Francesco
   Ascione, Tiziana
   Filippelli, Amelia
TI Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit
   the Transmission to Healthcare Workers Exposed to Coronavirus Disease
   2019?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Pagliano, Pasquale; Piazza, Ornella; De Caro, Francesco; Filippelli, Amelia] Univ Salerno, Dept Med & Surg, Baronissi, Italy.
   [Ascione, Tiziana] Cardarelli Hosp, Infect Dis Serv, Naples, Italy.
RP Pagliano, P (corresponding author), Univ Salerno, Dept Infect Dis, I-84081 Baronissi, Italy.
EM ppagliano@unisa.it
OI DE CARO, Francesco/0000-0001-9659-9940
CR Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schwartz J, 2020, CLIN INFECT DIS, V71, P858, DOI [10.1093/cid/ciaa255, 10.1080/10409238.2020.1841726]
   Shiryaev SA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15467-6
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
NR 6
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2020
VL 71
IS 15
BP 887
EP 888
DI 10.1093/cid/ciaa320
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OF1UF
UT WOS:000581001200036
PM 32211764
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Khan, YH
   Mallhi, TH
   Alotaibi, NH
   Alzarea, AI
   Alanazi, AS
   Tanveer, N
   Hashmi, FK
AF Khan, Yusra Habib
   Mallhi, Tauqeer Hussain
   Alotaibi, Nasser Hadal
   Alzarea, Abdulaziz Ibrahim
   Alanazi, Abdullah Salah
   Tanveer, Nida
   Hashmi, Furqan Khurshid
TI Threat of COVID-19 Vaccine Hesitancy in Pakistan: The Need for Measures
   to Neutralize Misleading Narratives
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB Immediately after declaring COVID-19 as a pandemic, numerous wild conspiracy theories sprouted through social media. Pakistan is quite vulnerable to such conspiracy narratives and has experienced failures of polio vaccination programs because of such claims. Recently, two well-known political figures raised conspiracy theories against COVID-19 vaccines in Pakistan, stating that COVID-19 is a grand illusion and a conspiracy against Muslim countries. This theory is much discussed in the local community, supporting COVID-19 vaccine hesitancy. We urge healthcare authorities in Pakistan to take necessary measures against such claims before they penetrate to the general community. Anti-vaccine movements could undermine efforts to end the COVID-19 pandemic. We believe that ethical and responsible behavior of mass media, a careful advisory from the Pakistan Electronic Media Regulatory Authority, stern measures from healthcare authorities, effective maneuvers to increase public awareness on COVID-19, vigorous analysis of information by data or communications scientists, and publication of counter opinions from health professionals against such theories will go a long way in neutralizing such misleading claims. Because Pakistan is experiencing a large burden of disease, with a sharp rise in confirmed cases, immediate action is of paramount importance to eradicate any potential barriers to a future COVID-19 vaccination program.
C1 [Khan, Yusra Habib; Mallhi, Tauqeer Hussain; Alotaibi, Nasser Hadal; Alzarea, Abdulaziz Ibrahim; Alanazi, Abdullah Salah] Jouf Univ, Coll Pharm, Dept Clin Pharm, Sakaka 72341, Al Jouf, Saudi Arabia.
   [Tanveer, Nida] Tehsil Head Quarter Hosp Jaranwala, Primary & Secondary Healthcare Dept, Faisalabad, Punjab, Pakistan.
   [Hashmi, Furqan Khurshid] Univ Punjab, Univ Coll Pharm, Lahore, Pakistan.
RP Mallhi, TH (corresponding author), Jouf Univ, Coll Pharm, Dept Clin Pharm, Sakaka 72341, Al Jouf, Saudi Arabia.
EM yusrahabib@ymail.com; tauqeer.hussain.mallhi@hotmail.com;
   nhotaibi.1@ju.edu.sa; aizarea.1@ju.edu.sa; asdalanazai@ju.edu.sa;
   nidatanveer131@gmail.com; furgan.pharmacy@pu.edu.pk
RI Hashmi, Furqan/ABG-5594-2020
OI Hashmi, Furqan/0000-0003-4921-3739; Khan, Yusra/0000-0002-9479-6147
CR Ali M, 2019, LANCET, V394, P915, DOI 10.1016/S0140-6736(19)32101-4
   [Anonymous], 2018, WELLC GLOB MON REP
   Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z
   Bugvi AS, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-232
   El-Showk S, 2019, NATURE, V575, pS57, DOI 10.1038/d41586-019-03641-x
   Khan TM, 2015, LANCET, V386, P1733, DOI 10.1016/S0140-6736(15)00689-3
   OpIndia Staff, 2020, COR IS NOT NAT INV L
   OpIndia Staff, 2020, BILL GAT COR VACC WI
NR 8
TC 1
Z9 1
U1 4
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 2020
VL 103
IS 2
BP 603
EP 604
DI 10.4269/ajtmh.20-0654
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE8OI
UT WOS:000580782700022
PM 32588810
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lopes, RD
   Macedo, AVS
   Silva, PGMDE
   Moll-Bernardes, RJ
   Feldman, A
   Arruda, GDS
   de Souza, AS
   de Albuquerque, DC
   Mazza, L
   Santos, MF
   Salvador, NZ
   Gibson, CM
   Granger, CB
   Alexander, JH
   de Souza, OF
AF Lopes, Renato D.
   Scarlatelli Macedo, Ariane Vieira
   Melo de Barros e Silva, Pedro Gabriel
   Moll-Bernardes, Renata Junqueira
   Feldman, Andre
   Saba Arruda, Guilherme D'Andrea
   de Souza, Andrea Silvestre
   de Albuquerque, Denilson Campos
   Mazza, Lilian
   Santos, Mayara Fraga
   Salvador, Natalia Zerbinatti
   Gibson, C. Michael
   Granger, Christopher B.
   Alexander, John H.
   de Souza, Olga Ferreira
CA BRACE CORONA Investigators
TI Continuing versus suspending angiotensin-converting enzyme inhibitors
   and angiotensin receptor blockers: Impact on adverse outcomes in
   hospitalized patients with severe acute respiratory syndrome coronavirus
   2 (SARS-CoV-2)-The BRACE CORONA Trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID CLINICAL-TRIALS; HEART-FAILURE
AB Background Angiotensin-converting enzyme-2 (ACE2) expression may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain.
   Design BRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 34 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from cardiovascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, and troponin, B-type natriuretic peptide (BNP), N-terminal-proBNP, and D-dimer levels.
   Summary BRACE CORONA will evaluate whether the strategy of continued ACEI/ARB therapy compared with temporary discontinuation of these drugs impacts clinical outcomes among patients with COVID-19.
C1 [Lopes, Renato D.; Scarlatelli Macedo, Ariane Vieira; Moll-Bernardes, Renata Junqueira; Feldman, Andre; Saba Arruda, Guilherme D'Andrea; de Souza, Andrea Silvestre; de Albuquerque, Denilson Campos; Santos, Mayara Fraga; Salvador, Natalia Zerbinatti; de Souza, Olga Ferreira] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Lopes, Renato D.; Granger, Christopher B.; Alexander, John H.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
   [Lopes, Renato D.; Melo de Barros e Silva, Pedro Gabriel; Mazza, Lilian] Brazilian Clin Res Inst, Sao Paulo, Brazil.
   [Lopes, Renato D.; Scarlatelli Macedo, Ariane Vieira; Feldman, Andre; Saba Arruda, Guilherme D'Andrea; de Souza, Olga Ferreira] Rede DOr Sao Luiz RDSL, Sao Paulo, Brazil.
   [Scarlatelli Macedo, Ariane Vieira] Santa Casa Sao Paulo, Sao Paulo, Brazil.
   [de Souza, Andrea Silvestre] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [de Souza, Andrea Silvestre] Fed Univ Rio de Janeiro UFRJ, Rio De Janeiro, Brazil.
   [de Albuquerque, Denilson Campos] Univ Estado Rio de Janeiro UERJ, Rio De Janeiro, Brazil.
   [Gibson, C. Michael] Harvard Med Sch, Boston, MA 02115 USA.
RP Lopes, RD (corresponding author), Duke Clin Res Inst, 200 Morris St, Durham, NC 27701 USA.
EM renato.lopes@dm.duke.edu
OI Macedo, Ariane/0000-0002-3453-8488
CR [Anonymous], 2005, TREATMENT ACE INHIBI, DOI [10.1101/2020.04.07.20056788. 04.07.20056788, DOI 10.1101/2020.04.07.20056788.04.07.20056788]
   Blenkinsop A, 2019, CLIN TRIALS, V16, P132, DOI 10.1177/1740774518823551
   Bothwell LE, 2016, NEW ENGL J MED, V375, P501, DOI 10.1056/NEJMp1604635
   Brown NJ, 2002, HYPERTENSION, V40, P859, DOI 10.1161/01.HYP.0000040264.15961.48
   Cheng J, 2014, JAMA INTERN MED, V174, P773, DOI 10.1001/jamainternmed.2014.348
   Danser AHJ, 2020, HYPERTENSION, DOI [10.1161/HYPERTENSIO-NAHA.120.15082, DOI 10.1161/HYPERTENSIO-NAHA.120.15082]
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   Dimou C, 2019, J HUM HYPERTENS, V33, P188, DOI 10.1038/s41371-018-0138-y
   Ellenberg SS, 2018, CLIN INFECT DIS, V66, P1467, DOI 10.1093/cid/cix1032
   Fanaroff AC, 2020, J AM COLL CARDIOL, V75, P556, DOI 10.1016/j.jacc.2019.11.043
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Frobert O, 2013, NEW ENGL J MED, V369, P1587, DOI 10.1056/NEJMoa1308789
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793
   James S, 2015, NAT REV CARDIOL, V12, P312, DOI 10.1038/nrcardio.2015.33
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425
   Lauer MS, 2013, NEW ENGL J MED, V369, P1579, DOI 10.1056/NEJMp1310102
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Richardson S, JAMA-J AM MED ASSOC, DOI DOI 10.1001/JAMA.2020.677
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sanchis-Gomar F, 2020, MAYO CLIN PROC, V95, P1222, DOI 10.1016/j.mayocp.2020.03.026
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Sundh J, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0809-7
   Teerlink JR, 2015, CURR CARDIOL REV, V11, P53, DOI 10.2174/1573403X09666131117174414
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vincent JL, 2020, LANCET RESP MED, V8, P430, DOI 10.1016/S2213-2600(20)30165-X
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Whelton PK, 2018, J AM COLL CARDIOL, V71, P2275, DOI 10.1016/j.jacc.2018.03.016
   World Health Organization, 51 WHO
   Yancy CW, 2017, CIRCULATION, V136, pE137, DOI 10.1161/CIR.0000000000000509
   Yang X, 2020, LANCET RESP MED, DOI [10.1016/S22132600(20)30079-, DOI 10.1016/S22132600(20)30079-]
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 36
TC 13
Z9 14
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD AUG
PY 2020
VL 226
BP 49
EP 59
DI 10.1016/j.ahj.2020.05.002
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH6NW
UT WOS:000582710900008
PM 32502882
OA Green Published
DA 2021-01-01
ER

PT J
AU Gommans, DHF
   Nas, J
   Pinto-Sietsma, SJ
   Koop, Y
   Konst, RE
   Mensink, F
   Aarts, GWA
   Konijnenberg, LSF
   Cortenbach, K
   Verhaert, DVM
   Thannhauser, J
   Mol, JQ
   Rooijakkers, MJP
   Vos, JL
   van Rumund, A
   Vart, P
   Hassing, RJ
   Cornel, JH
   de Jager, CPC
   van den Heuvel, MM
   van der Hoeven, HG
   Verbon, A
   Pinto, YM
   van Royen, N
   van Kimmenade, RRJ
   de Leeuw, PW
   van Agtmael, MA
   Bresser, P
   van Gilst, WH
   Vonk-Noordergraaf, A
   Tijssen, JGP
AF Gommans, D. H. Frank
   Nas, Joris
   Pinto-Sietsma, Sara-Joan
   Koop, Yvonne
   Konst, Regina E.
   Mensink, Frans
   Aarts, Goaris W. A.
   Konijnenberg, Lara S. F.
   Cortenbach, Kimberley
   Verhaert, Dominique V. M.
   Thannhauser, Jos
   Mol, Jan-Quinten
   Rooijakkers, Maxim J. P.
   Vos, Jacqueline L.
   van Rumund, Anouke
   Vart, Priya
   Hassing, Robert-Jan
   Cornel, Jan-Hein
   de Jager, C. Peter C.
   van den Heuvel, Michel M.
   van der Hoeven, Hans G.
   Verbon, Annelies
   Pinto, Yigal M.
   van Royen, Niels
   van Kimmenade, Roland R. J.
   de Leeuw, Peter W.
   van Agtmael, Michiel A.
   Bresser, Paul
   van Gilst, Wiek H.
   Vonk-Noordergraaf, Anton
   Tijssen, Jan G. P.
CA Event Comm
   Data Safety Monitoring Board
   Steering Comm
TI Rationale and design of the PRAETORIAN-COVID trial: A double-blind,
   placebo-controlled randomized clinical trial with valsartan for
   PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized
   patieNts with SARS-COV-2 Infection Disease
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME-2; RECEPTOR; ACE2; SARS; CORONAVIRUS
AB Background There is much debate on the use of angiotensin receptor blockers (ARBs) in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)-infected patients. Although it has been suggested that ARBs might lead to a higher susceptibility and severity of SARS-CoV-2 infection, experimental data suggest that ARBs may reduce acute lung injury via blocking angiotensin-II-mediated pulmonary permeability, inflammation, and fibrosis. However, despite these hypotheses, specific studies on ARBs in SARS-CoV-2 patients are lacking.
   Methods The PRAETORIAN-COVID trial is a multicenter, double-blind, placebo-controlled 1:1 randomized clinical trial in adult hospitalized SARS-CoV-2-infected patients (n = 651). The primary aim is to investigate the effect of the ARB valsartan compared to placebo on the composite end point of admission to an intensive care unit, mechanical ventilation, or death within 14 days of randomization. The active-treatment arm will receive valsartan in a dosage titrated to blood pressure up to a maximum of 160 mg bid, and the placebo arm will receive matching placebo. Treatment duration will be 14 days, or until the occurrence of the primary end point or until hospital discharge, if either of these occurs within 14 days. The trial is registered at clinicaltrials.gov (NCT04335786, 2020).
   Summary The PRAETORIAN-COVID trial is a double-blind, placebo-controlled 1:1 randomized trial to assess the effect of valsartan compared to placebo on the occurrence of ICU admission, mechanical ventilation, and death in hospitalized SARS-CoV-2-infected patients. The results of this study might impact the treatment of SARS-CoV-2 patients globally.
C1 [Gommans, D. H. Frank; Nas, Joris; Koop, Yvonne; Konst, Regina E.; Mensink, Frans; Aarts, Goaris W. A.; Konijnenberg, Lara S. F.; Cortenbach, Kimberley; Verhaert, Dominique V. M.; Thannhauser, Jos; Mol, Jan-Quinten; Rooijakkers, Maxim J. P.; Vos, Jacqueline L.; Cornel, Jan-Hein; van Royen, Niels; van Kimmenade, Roland R. J.] Radboudumc, Dept Cardiol, Nijmegen, Netherlands.
   [Pinto-Sietsma, Sara-Joan] Amsterdam UMC, Dept Vasc Med, Amsterdam, Netherlands.
   [Verhaert, Dominique V. M.] Maastricht Univ, Med Ctr MUMC, Dept Cardiol, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands.
   [van Rumund, Anouke] Radboudumc, Dept Neurol, Nijmegen, Netherlands.
   [Vart, Priya] Radboudumc, Dept Biostat, Nijmegen, Netherlands.
   [Hassing, Robert-Jan] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands.
   [Cornel, Jan-Hein] Noordwest Ziekenhuis Grp, Dept Cardiol, Alkmaar, Netherlands.
   [de Jager, C. Peter C.] Jeroen Bosch Hosp, Dept Intens Care, Shertogenbosch, Netherlands.
   [van den Heuvel, Michel M.] Radboudumc, Dept Pulm Dis, Nijmegen, Netherlands.
   [van der Hoeven, Hans G.] Radboudumc, Dept Intens Care, Nijmegen, Netherlands.
   [Verbon, Annelies] ErasmusMC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands.
   [Pinto, Yigal M.; Tijssen, Jan G. P.] Amsterdam UMC, Dept Cardiol, Amsterdam, Netherlands.
   [de Leeuw, Peter W.] Maastricht UMC, Dept Internal Med, Maastricht, Netherlands.
   [van Agtmael, Michiel A.] Amsterdam UMC, Dept Internal Med, Amsterdam, Netherlands.
   [Bresser, Paul] Onze Lieve Vrouw Hosp, Dept Pulm Dis, Amsterdam, Netherlands.
   [van Gilst, Wiek H.] Univ Med Ctr Groningen, Dept Expt Cardiol, Groningen, Netherlands.
   [Vonk-Noordergraaf, Anton] Amsterdam UMC, Dept Pulm Dis, Amsterdam, Netherlands.
RP Gommans, DHF (corresponding author), Rodboud Univ, Med Ctr, Dept Cardiol, 616,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM frank.gommans@radboudumc.nl
RI ; cornel, jan/Y-7065-2019
OI Rooijakkers, Maxim/0000-0002-6815-7667; Koop,
   Yvonne/0000-0001-6150-0859; , yigal/0000-0002-2836-571X; Verhaert,
   Dominique/0000-0003-3477-2589; cornel, jan/0000-0002-1006-2112
FU Netherlands Heart Institute; Dutch Heart FoundationNetherlands Heart
   Foundation; Dutch CardioVascular Alliance; Novartis Pharma BV
FX This work is supported by the Netherlands Heart Institute, the Dutch
   Heart Foundation, the Dutch CardioVascular Alliance, and Novartis Pharma
   BV.
CR Abraham HMA, 2015, DRUG SAFETY, V38, P33, DOI 10.1007/s40264-014-0239-7
   Battistoni A, 2020, EUR HEART J CARDIOVA
   Bavishi C, 2020, JAMA CARDIOL
   Campbell DJ, 2004, J HYPERTENS, V22, P1971, DOI 10.1097/00004872-200410000-00020
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Ciwit BV, 2016, CASTOR ELECT DATA CA
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deshotels MR, 2014, HYPERTENSION, V64, P1368, DOI 10.1161/HYPERTENSIONAHA.114.03743
   Fang L., 2020, LANCET RESP MED
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, P1
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Patel AB, 2020, JAMA
   Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Van de Veerdonk FL, KININS CYTOKINES COV
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang P, 2020, CIRCULATION RES
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 37
TC 2
Z9 2
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD AUG
PY 2020
VL 226
BP 60
EP 68
DI 10.1016/j.ahj.2020.05.010
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH6NW
UT WOS:000582710900009
PM 32512291
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kala, S
   Dunk, C
   Acosta, S
   Serghides, L
AF Kala, Smriti
   Dunk, Caroline
   Acosta, Sebastian
   Serghides, Lena
TI Periconceptional exposure to lopinavir, but not darunavir, impairs
   decidualization: a potential mechanism leading to poor birth outcomes in
   HIV-positive pregnancies
SO HUMAN REPRODUCTION
LA English
DT Article
DE HIV protease inhibitors; lopinavir; darunavir; decidualization; spiral
   artery remodeling; trophoblasts; uterine natural killer cells; birth
   outcomes; drug safety; COVID-19
ID NATURAL-KILLER-CELLS; ANTIRETROVIRAL THERAPY; INFECTED WOMEN; PREMATURE
   DELIVERY; NK CELLS; ANGIOGENESIS
AB STUDY QUESTION Does HIV protease inhibitor (PI)-based combination antiretroviral therapy (cART) initiated at periconception affect key events in early pregnancy, i.e. decidualization and spiral artery remodeling?
   SUMMARY ANSWER Two PIs, lopinavir and darunavir, currently offered as cART options in HIV-positive pregnancies were evaluated, and we found that lopinavir-based cART, but not darunavir-based cART, impaired uterine decidualization and spiral artery remodeling in both human ex vivo and mouse in vivo experimental models.
   WHAT IS KNOWN ALREADY Early initiation of cART is recommended for pregnant women living with HIV. However, poor birth outcomes are frequently observed in HIV-positive pregnancies exposed to PI-based cART, especially when it is initiated prior to conception. The correlation between early initiation of PI-cART and adverse birth outcomes is poorly understood, due to lack of data on the specific effects of PI-cART on the early stages of pregnancy involving uterine decidualization and spiral artery remodeling.
   STUDY DESIGN, SIZE, DURATION Lopinavir and darunavir were evaluated in clinically relevant combinations using an ex vivo human first-trimester placenta-decidua explant model, an in vitro human primary decidual cell culture system, and an in vivo mouse pregnancy model. The first-trimester (gestational age, 6-8 weeks) human placenta-decidua tissue was obtained from 11 to 15 healthy women undergoing elective termination of pregnancy. C57Bl/6 female mice (four/treatment group) were administered either lopinavir-cART, darunavir-cART or water by oral gavage once daily starting on the day of plug detection until sacrifice.
   PARTICIPANTS/MATERIALS, SETTING, METHODS Human: Spiral artery remodeling was assessed by immunohistochemical analysis of first-trimester placenta-decidua explant co-culture system. Trophoblast migration was measured using a placental explant culture. A primary decidual cell culture was used to evaluate the viability of immune cell populations by flow cytometry. Soluble factors, including biomarkers of decidualization and angiogenesis, were quantified by ELISA and Luminex assay using decidua-conditioned media. Mouse: In the mouse pregnancy model, gestational day 6.5 or 9.5 implantation sites were used to assess decidualization, spiral artery remodeling and uterine natural killer (uNK) cell numbers by immunohistochemistry. Transcription factor STAT3 was assayed by immunohistochemistry in both human decidua and mouse implantation sites.
   MAIN RESULTS AND THE ROLE OF CHANCE Lopinavir-cART, but not darunavir-cART, impaired uterine decidualization and spiral artery remodeling in both experimental models. Lopinavir-cART treatment was also associated with selective depletion of uNK cells, reduced trophoblast migration and defective placentation. The lopinavir-associated decidualization defects were attributed to a decrease in expression of transcription factor STAT3, known to regulate decidualization. Our results suggest that periconceptional initiation of lopinavir-cART, but not darunavir-cART, causes defective maturation of the uterine endometrium, leading to impairments in spiral artery remodeling and placentation, thus contributing to the poor birth outcomes.
   LARGE SCALE DATA N/A
   LIMITATIONS, REASONS FOR CAUTION The human first-trimester placenta/decidua samples could only be obtained from healthy females undergoing elective termination of pregnancy. As biopsy is the only way to obtain first-trimester decidua from pregnant women living with HIV on PI-cART, ethics approval and participant consent are difficult to obtain. Furthermore, our animal model is limited to the study of cART and does not include HIV. HIV infection is also associated with immune dysregulation, inflammation, alterations in angiogenic factors and complement activation, all of which could influence decidual and placental vascular remodeling and modify any cART effects.
   WIDER IMPLICATIONS OF THE FINDINGS Our findings provide mechanistic insight with direct clinical implications, rationalizing why the highest adverse birth outcomes are reported in HIV-positive pregnancies exposed to lopinavir-cART from conception. We demonstrate that dysregulation of decidualization is the mechanism through which lopinavir-cART, but not darunavir-cART, use in early pregnancy leads to poor birth outcomes. Although lopinavir is no longer a first-line regimen in pregnancy, it remains an alternate regimen and is often the only PI available in low resource settings. Our results highlight the need for reconsidering current guidelines recommending lopinavir use in pregnancy and indicate that lopinavir should be avoided especially in the first trimester, whereas darunavir is safe to use and should be the preferred PI in pregnancy. Further, in current times of the COVID-19 pandemic, lopinavir is among the top drug candidates which are being repurposed for inclusion in clinical trials world-over, to assess their therapeutic potential against the dangerous respiratory disease. Current trials are also testing the efficacy of lopinavir given prophylactically to protect health care workers and people with potential exposures. Given the current extraordinary numbers, these might include women with early pregnancies, who may or may not be cognizant of their gestational status. This is a matter of concern as it could mean that women with early pregnancies might be exposed to this drug, which can cause decidualization defects. Our findings provide evidence of safety concerns surrounding lopinavir use in pregnancy, that women of reproductive age considering participation in such trials should be made aware of, so they can make a fully informed decision.
C1 [Kala, Smriti; Acosta, Sebastian; Serghides, Lena] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Princess Margaret Canc Res Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.
   [Dunk, Caroline] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
   [Serghides, Lena] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   [Serghides, Lena] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
RP Serghides, L (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Res Inst, Princess Margaret Canc Res Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.
EM lena.serghides@utoronto.ca
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [PJT-148684, MOP-130398]; CIHR FoundationCanadian
   Institutes of Health Research (CIHR) [FDN143262]; Toronto General
   Hospital Research Institute (TGHRI) postdoctoral fellowship
FX This work was supported by funding from the Canadian Institutes of
   Health Research (CIHR) (PJT-148684 and MOP-130398 to L.S.). C.D.
   received support from CIHR Foundation (FDN143262 to Stephen Lye). S.K.
   received a Toronto General Hospital Research Institute (TGHRI)
   postdoctoral fellowship. The funders were not involved in the study
   design, collection, analysis or interpretation of data, in the writing
   of the report or in the decision to submit the paper for publication.
CR Balogun KA, 2018, CLIN INFECT DIS, V66, P420, DOI 10.1093/cid/cix761
   Bhurke AS, 2016, AM J REPROD IMMUNOL, V75, P237, DOI 10.1111/aji.12473
   Burton GJ, 2009, PLACENTA, V30, P473, DOI 10.1016/j.placenta.2009.02.009
   Cahill LS, 2019, AM J PHYSIOL-HEART C, V316, pH664, DOI 10.1152/ajpheart.00733.2018
   Carlino C, 2008, BLOOD, V111, P3108, DOI 10.1182/blood-2007-08-105965
   Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553
   Croy BA, 2002, J REPROD IMMUNOL, V57, P151, DOI 10.1016/S0165-0378(02)00005-0
   Dunk C, 2003, LAB INVEST, V83, P1821, DOI 10.1097/01.LAB.0000101730.69754.5A
   Dunk C, 2008, IMMUNOL INVEST, V37, P583, DOI 10.1080/08820130802191466
   Fowler MG, 2016, NEW ENGL J MED, V375, P1726, DOI 10.1056/NEJMoa1511691
   Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014-1045
   GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235
   Hazan AD, 2010, AM J PATHOL, V177, P1017, DOI 10.2353/ajpath.2010.091105
   Jiang YL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13735
   Kala S, 2018, ANTIVIR RES, V159, P45, DOI 10.1016/j.antiviral.2018.09.008
   Kalk E, 2017, TROP MED INT HEALTH, V22, P604, DOI 10.1111/tmi.12858
   Kaufmann P, 2003, BIOL REPROD, V69, P1, DOI 10.1095/biolreprod.102.014977
   Kelleher AM, 2017, P NATL ACAD SCI USA, V114, pE1018, DOI 10.1073/pnas.1618433114
   Keskin DB, 2007, P NATL ACAD SCI USA, V104, P3378, DOI 10.1073/pnas.0611098104
   Kieckbusch J, 2015, JOVE-J VIS EXP, V106
   Kourtis AP, 2007, AIDS, V21, P607, DOI 10.1097/QAD.0b013e32802ef2f6
   Li N, 2016, J INFECT DIS, V213, P1057, DOI 10.1093/infdis/jiv389
   Lima PDA, 2014, CELL MOL IMMUNOL, V11, P522, DOI 10.1038/cmi.2014.63
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mofenson LM, 2016, J INFECT DIS, V213, P1051, DOI 10.1093/infdis/jiv390
   Mohammadi H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24680-w
   Money D, 2014, J OBSTET GYNAECOL CA, V36, P721, DOI 10.1016/S1701-2163(15)30515-6
   Obimbo MM, 2019, JAIDS-J ACQ IMM DEF, V80, P94, DOI 10.1097/QAI.0000000000001871
   Papp E, 2015, J INFECT DIS, V211, P10, DOI 10.1093/infdis/jiu393
   Robson A, 2012, FASEB J, V26, P4876, DOI 10.1096/fj.12-210310
   Saleska JL, 2018, JAIDS-J ACQ IMM DEF, V79, P1, DOI [10.1097/QAI.0000000000001770, 10.1097/qai.0000000000001770]
   Sibiude J, 2012, CLIN INFECT DIS, V54, P1348, DOI 10.1093/cid/cis198
   Smith SD, 2009, AM J PATHOL, V174, P1959, DOI 10.2353/ajpath.2009.080995
   Snijdewind IJM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191389
   Tanaka M, 2016, FRONT IMMUNOL, V7, P199
   Vinketova K, 2016, J PREGNANCY, V2016, DOI 10.1155/2016/8689436
   Wang LM, 2018, INT J GYNECOL OBSTET, V142, P300, DOI 10.1002/ijgo.12532
   Whitley GSJ, 2010, PLACENTA, V31, P465, DOI 10.1016/j.placenta.2010.03.002
   WHO, 2015, GUID START ANT THER
   Wright JK, 2006, PLACENTA, V27, pS114, DOI 10.1016/j.placenta.2006.01.013
   Wright JK, 2010, BIOL REPROD, V83, P1036, DOI 10.1095/biolreprod.109.083246
   Zash R, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2017.2222
   Zhang Z, 2015, J MOL HISTOL, V46, P205, DOI 10.1007/s10735-015-9613-8
NR 43
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2020
VL 35
IS 8
BP 1781
EP 1796
DI 10.1093/humrep/deaa151
PG 16
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA OH6JP
UT WOS:000582696700006
PM 32712670
OA Green Published
DA 2021-01-01
ER

PT J
AU Sia, CH
   Ngiam, JN
   Chew, N
   Beh, DLL
   Poh, KK
AF Sia, Ching-Hui
   Ngiam, Jinghao Nicholas
   Chew, Nicholas
   Beh, Darius Lian Lian
   Poh, Kian Keong
TI Educational case series of electrocardiographs during the COVID-19
   pandemic and the implications for therapy
SO SINGAPORE MEDICAL JOURNAL
LA English
DT Article
ID CORONAVIRUS; INFECTION
C1 [Sia, Ching-Hui; Poh, Kian Keong] Natl Univ Heart Ctr Singapore, Dept Cardiol, 1E Kent Ridge Rd,NUHS Tower Block Level 9, Singapore 119228, Singapore.
   [Sia, Ching-Hui; Poh, Kian Keong] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Ngiam, Jinghao Nicholas; Chew, Nicholas] Natl Univ Hlth Syst, Univ Med Cluster, Singapore, Singapore.
   [Beh, Darius Lian Lian] Natl Univ Hlth Syst, Univ Med Cluster, Div Infect Dis, Singapore, Singapore.
RP Sia, CH (corresponding author), Natl Univ Heart Ctr Singapore, Dept Cardiol, 1E Kent Ridge Rd,NUHS Tower Block Level 9, Singapore 119228, Singapore.
EM ching_hui_sia@nuhs.edu.sg
OI Poh, Kian-Keong/0000-0003-3515-7924; Ngiam, Nicholas/0000-0002-3339-7281
CR Ambhore A, 2014, SINGAP MED J, V55, P607, DOI 10.11622/smedj.2014172
   Amin A S, 2010, Neth Heart J, V18, P165, DOI 10.1007/BF03091755
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chang David, 2020, HeartRhythm Case Rep, V6, P237, DOI 10.1016/j.hrcr.2020.03.012
   Cherian R, 2020, SINGAP MED J, V61, P373, DOI 10.11622/smedj.2020042
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Lakkireddy DR, 2020, GUIDANCE CARDIAC ELE, DOI 10.1016/j.hrthm.2020.03.028
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roden DM, 2020, J AM COLL CARDIOL, V75, P2623, DOI 10.1016/j.jacc.2020.04.016
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   SIZUN J, 1993, ACTA PAEDIATR, V82, P238, DOI 10.1111/j.1651-2227.1993.tb12650.x
   SIZUN J, 1995, ACTA PAEDIATR, V84, P617, DOI 10.1111/j.1651-2227.1995.tb13710.x
   Soliman EZ, 2011, AIDS, V25, P367, DOI 10.1097/QAD.0b013e328341dcc0
   Vandael E, 2017, INT J CLIN PHARM-NET, V39, P16, DOI 10.1007/s11096-016-0414-2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CI, 2020, HEART RHYTHM
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 22
TC 1
Z9 1
U1 0
U2 0
PU SINGAPORE MEDICAL ASSOC
PI SINGAPORE
PA 2985 JALAN BUKIT MERAH, #02-2C, SMF BUILDING, SINGAPORE, SINGAPORE
SN 0037-5675
J9 SINGAP MED J
JI Singap. Med. J.
PD AUG
PY 2020
VL 61
IS 8
BP 406
EP 412
DI 10.11622/smedj.2020087
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OF0SN
UT WOS:000580929200004
PM 32480434
OA Bronze
DA 2021-01-01
ER

PT J
AU ul Qamar, MT
   Alqahtani, SM
   Alamri, MA
   Chen, LL
AF ul Qamar, Muhammad Tahir
   Alqahtani, Safar M.
   Alamri, Mubarak A.
   Chen, Ling-Ling
TI Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery
   from medicinal plants
SO JOURNAL OF PHARMACEUTICAL ANALYSIS
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Natural products; Protein homology
   modelling; Molecular docking; Molecular dynamics simulation
ID SARS-COV; PROTEASE; CORONAVIRUS; DATABASE; DESIGN
AB The recent pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has raised global health concerns. The viral 3-chymotrypsin-like cysteine protease (3CL(pro)) enzyme controls coronavirus replication and is essential for its life cycle. 3CL(pro) is a proven drug discovery target in the case of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Recent studies revealed that the genome sequence of SARS-CoV-2 is very similar to that of SARS-CoV. Therefore, herein, we analysed the 3CL(pro) sequence, constructed its 3D homology model, and screened it against a medicinal plant library containing 32,297 potential anti-viral phytochemicals/traditional Chinese medicinal compounds. Our analyses revealed that the top nine hits might serve as potential anti- SARS-CoV-2 lead molecules for further optimisation and drug development process to combat COVID-19. (C) 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.
C1 [ul Qamar, Muhammad Tahir; Chen, Ling-Ling] Guangxi Univ, Coll Life Sci & Technol, Nanning 530004, Peoples R China.
   [ul Qamar, Muhammad Tahir; Chen, Ling-Ling] Huazhong Agr Univ, Coll Informat, Hubei Key Lab Agr Bioinformat, Wuhan 430070, Peoples R China.
   [Alqahtani, Safar M.; Alamri, Mubarak A.] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Alkarj 11323, Saudi Arabia.
RP Chen, LL (corresponding author), Huazhong Agr Univ, Coll Informat, Hubei Key Lab Agr Bioinformat, Wuhan 430070, Peoples R China.
EM llchen@mail.hzau.edu.cn
RI Qamar, Muhammad Tahir ul/E-5803-2015
OI Qamar, Muhammad Tahir ul/0000-0003-4832-4250
FU National Key Research and Development Program of China [2020YFC0845600];
   Hubei Provincial Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [2019CFA014]; Starting Research Grant
   for High-level Talents from Guangxi University, Nanning, China;
   Postdoctoral Research Platform Grant of Guangxi University, Nanning,
   China
FX This work was supported by the National Key Research and Development
   Program of China (2020YFC0845600), the Hubei Provincial Natural Science
   Foundation of China (2019CFA014), the Starting Research Grant for
   High-level Talents from Guangxi University, Nanning, China and
   Postdoctoral Research Platform Grant of Guangxi University, Nanning,
   China. We also acknowledge all the authors and laboratories mentioned in
   Table S1 for their sampling, analysis, and genome sequencing efforts. In
   addition, we acknowledge GISAID (https://www.gisaid.org/) for
   facilitating open data sharing.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ashfaq UA, 2013, BIOINFORMATION, V9, P993, DOI 10.6026/97320630009993
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Castrignano T, 2006, NUCLEIC ACIDS RES, V34, pD306, DOI 10.1093/nar/gkj105
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305
   Jacobs J., 2010, PROBE REPORTS NIH MO
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Kumar V, 2016, BIOORGAN MED CHEM, V24, P3035, DOI 10.1016/j.bmc.2016.05.013
   Li SX, 2011, 2011 INTERNATIONAL CONFERENCE ON COMPUTATIONAL SCIENCE AND APPLICATIONS, P1, DOI 10.1109/GSIS.2011.6044018
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Mumtaz A, 2020, NAT PROD RES, V34, P1051, DOI 10.1080/14786419.2020.1735129
   Mumtaz A, 2017, NAT PROD RES, V31, P1228, DOI 10.1080/14786419.2016.1233409
   Muneer I, 2019, ANTI-CANCER DRUG, V30, P363, DOI 10.1097/CAD.0000000000000727
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Salem MM, 2006, J NAT PROD, V69, P43, DOI 10.1021/np0502600
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   ul Qamar MT, 2019, SCI REP, V9, P1
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Ye J, 2006, NUCLEIC ACIDS RES, V34, pW6, DOI 10.1093/nar/gkl164
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 114
Z9 117
U1 12
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-1779
EI 2214-0883
J9 J PHARM ANAL
JI J. Pharm. Anal.
PD AUG
PY 2020
VL 10
IS 4
BP 313
EP 319
DI 10.1016/j.jpha.2020.03.009
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF1RF
UT WOS:000580993400003
PM 32296570
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mirza, MU
   Froeyen, M
AF Mirza, Muhammad Usman
   Froeyen, Matheus
TI Structural elucidation of SARS-CoV-2 vital proteins: Computational
   methods reveal potential drug candidates against main protease, Nsp12
   polymerase and Nsp13 helicase
SO JOURNAL OF PHARMACEUTICAL ANALYSIS
LA English
DT Article
DE SARS-CoV-2; COVID-19 outbreak; CoV-Mpro; CoV-Nsp12 polymerase; CoV-Nsp13
   helicase
ID MUTATIONAL ANALYSIS; CONSERVED MOTIFS; GENOME SEQUENCE; CORONAVIRUS;
   INHIBITORS; IDENTIFICATION; ACCURACY
AB Recently emerged SARS-CoV-2 caused a major outbreak of coronavirus disease 2019 (COVID-19) and instigated a widespread fear, threatening global health safety. To date, no licensed antiviral drugs or vaccines are available against COVID-19 although several clinical trials are under way to test possible therapies. During this urgent situation, computational drug discovery methods provide an alternative to tiresome high-throughput screening, particularly in the hit-to-lead-optimization stage. Identification of small molecules that specifically target viral replication apparatus has indicated the highest potential towards antiviral drug discovery. In this work, we present potential compounds that specifically target SARS-CoV-2 vital proteins, including the main protease, Nsp12 RNA polymerase and Nsp13 helicase. An integrative virtual screening and molecular dynamics simulations approach has facilitated the identification of potential binding modes and favourable molecular interaction profile of corresponding compounds. Moreover, the identification of structurally important binding site residues in conserved motifs located inside the active site highlights relative importance of ligand binding based on residual energy decomposition analysis. Although the current study lacks experimental validation, the structural information obtained from this computational study has paved way for the design of targeted inhibitors to combat COVID-19 outbreak. (C) 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.
C1 [Mirza, Muhammad Usman; Froeyen, Matheus] Univ Leuven, Rega Inst Med Res, Dept Pharmaceut & Pharmacol Sci, Med Chem, B-3000 Leuven, Belgium.
RP Froeyen, M (corresponding author), Univ Leuven, Rega Inst Med Res, Dept Pharmaceut & Pharmacol Sci, Med Chem, B-3000 Leuven, Belgium.
EM mathy.froeyen@kuleuven.be
FU IRO scholarship
FX We would like to thank the computational facilities provided by KU
   Leuven. This study was supported by IRO scholarship Ph.D. Grant.
CR Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Bajorath J., 2011, CHEMOINFORMATICS COM
   Benvenuto D., 2020, BIORXIV
   BISWAS SK, 1994, J VIROL, V68, P1819, DOI 10.1128/JVI.68.3.1819-1826.1994
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chang HP, 2007, BIOPHYS J, V92, P1374, DOI 10.1529/biophysj.106.091736
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Colson P., 2020, INT J ANTIMICROB AGE, V55
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Ikram N, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040124
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jones P, 2017, J MED CHEM, V60, P767, DOI 10.1021/acs.jmedchem.6b01634
   Kiss R., 2012, J CHEMINFORMATICS, V4, pP17, DOI [10.1186/1758-2946-4-S1-P17, DOI 10.1186/1758-2946-4-S1-P17]
   Kruger A., 2019, ADME PROFILING DRUG
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mirza M.U., 2020, SCI REP, V9, p1e18
   Mirza MU, 2019, J MED VIROL, V91, P2029, DOI 10.1002/jmv.25357
   Mirza MU, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111748
   Mirza MU, 2015, DRUG DES DEV THER, V9, P1825, DOI 10.2147/DDDT.S75886
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Peersen OB, 2017, VIRUS RES, V234, P4, DOI 10.1016/j.virusres.2017.01.026
   Pires D. E., 2018, COMPUTATIONAL DRUG D, P271
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sampath A, 2009, ANTIVIR RES, V81, P6, DOI 10.1016/j.antiviral.2008.08.004
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Srivastava HK, 2012, J CHEM INF MODEL, V52, P3088, DOI 10.1021/ci300385h
   Surana P, 2014, NUCLEIC ACIDS RES, V42, P2758, DOI 10.1093/nar/gkt1106
   Tan JJ, 2006, J MOL STRUC-THEOCHEM, V766, P77, DOI 10.1016/j.theochem.2006.02.022
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Williams HD, 2013, PHARMACOL REV, V65, P315, DOI 10.1124/pr.112.005660
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yamamoto N., 2020, BIORXIV
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007
   Zhou Y, 2011, SCI CHINA LIFE SCI, V54, P870, DOI 10.1007/s11427-011-4216-4
   Zhu R-F, 2020, SYSTEMATIC REV REGIS
NR 53
TC 24
Z9 25
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-1779
EI 2214-0883
J9 J PHARM ANAL
JI J. Pharm. Anal.
PD AUG
PY 2020
VL 10
IS 4
BP 320
EP 328
DI 10.1016/j.jpha.2020.04.008
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF1RF
UT WOS:000580993400004
PM 32346490
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cattrini, C
   Bersanelli, M
   Latocca, MM
   Conte, B
   Vallome, G
   Boccardo, F
AF Cattrini, Carlo
   Bersanelli, Melissa
   Latocca, Maria Maddalena
   Conte, Benedetta
   Vallome, Giacomo
   Boccardo, Francesco
TI Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications
   for Patients with Cancer
SO CANCERS
LA English
DT Article
DE COVID-19; SARS-CoV-2; estrogens; androgens; progesterone; testosterone;
   TMPRSS2; ACE2; camostat; androgen-deprivation therapy; tamoxifen
ID RESPIRATORY SYNDROME CORONAVIRUS; CONVERTING ENZYME 2; PROSTATE-CANCER;
   KAPPA-B; TESTOSTERONE; EXPRESSION; RESPONSES; RECEPTOR; ACE2; MEN
AB The novel coronavirus disease 2019 (COVID-19) shows a wide spectrum of clinical presentations, severity, and fatality rates. The reason older patients and males show increased risk of severe disease and death remains uncertain. Sex hormones, such as estradiol, progesterone, and testosterone, might be implicated in the age-dependent and sex-specific severity of COVID-19. High testosterone levels could upregulate transmembrane serine protease 2 (TMPRSS2), facilitating the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into host cells via angiotensin-converting enzyme 2 (ACE2). Data from patients with prostate cancer treated with androgen-deprivation therapy seem to confirm this hypothesis. Clinical studies on TMPRSS2 inhibitors, such as camostat, nafamostat, and bromhexine, are ongoing. Antiandrogens, such as bicalutamide and enzalutamide, are also under investigation. Conversely, other studies suggest that the immune modulating properties of androgens could protect from the unfavorable cytokine storm, and that low testosterone levels might be associated with a worse prognosis in patients with COVID-19. Some evidence also supports the notion that estrogens and progesterone might exert a protective effect on females, through direct antiviral activity or immune-mediated mechanisms, thus explaining the higher COVID-19 severity in post-menopausal women. In this perspective, we discuss the available evidence on sex hormones and hormone therapy in patients infected with SARS-CoV-2, and we highlight the possible implications for cancer patients, who can receive hormonal therapies during their treatment plans.
C1 [Cattrini, Carlo; Latocca, Maria Maddalena; Conte, Benedetta; Vallome, Giacomo; Boccardo, Francesco] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DIMI, I-16132 Genoa, Italy.
   [Cattrini, Carlo] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid 28029, Spain.
   [Bersanelli, Melissa] Univ Hosp Parma, Med Oncol Unit, I-43126 Parma, Italy.
   [Latocca, Maria Maddalena; Conte, Benedetta; Vallome, Giacomo; Boccardo, Francesco] IRCCS Osped Policlin San Martino, Acad Unit Med Oncol, I-16132 Genoa, Italy.
RP Boccardo, F (corresponding author), Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DIMI, I-16132 Genoa, Italy.; Boccardo, F (corresponding author), IRCCS Osped Policlin San Martino, Acad Unit Med Oncol, I-16132 Genoa, Italy.
EM carlo.cattrini@gmail.com; bersamel@libero.it;
   mariamaddalena.latocca@gmail.com; bntconte@gmail.com;
   giacomo.vallome@gmail.com; fboccardo@unige.it
OI Cattrini, Carlo/0000-0003-4785-9480
FU ESMO Clinical Research Fellowship
FX C.C. is supported by an ESMO Clinical Research Fellowship (2019-2020).
CR Al-Lami RA, 2020, MAYO CLIN PROC, V95, P1710, DOI 10.1016/j.mayocp.2020.05.013
   Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Asselta R, 2020, AGING-US, V12, P10087, DOI 10.18632/aging.103415
   Banu N, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117905
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Benetti E, 2020, EUR J HUM GENET, V28, P1602, DOI 10.1038/s41431-020-0691-z
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   Caffo O, 2020, ANN ONCOL, V31, P1415, DOI 10.1016/j.annonc.2020.06.005
   Cai G., 2020, BULK SINGLE CELL TRA, DOI [10.1101/2020.02.05.20020107, DOI 10.1101/2020.02.05.20020107]
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen JW, 2020, AGING CELL, V19, DOI 10.1111/acel.13168
   Costeira R., 2020, ESTROGEN COVID 19 SY, DOI [10.1101/2020.07.30.20164921, DOI 10.1101/2020.07.30.20164921]
   D'Agostino P, 1999, ANN NY ACAD SCI, V876, P426, DOI 10.1111/j.1749-6632.1999.tb07667.x
   Ding T., 2020, CHINA CLIN INFECT DI, DOI [10.1093/cid/ciaa1022, DOI 10.1093/CID/CIAA1022]
   Dutta S, 2020, REPROD SCI, DOI 10.1007/s43032-020-00261-z
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Felsenstein S, 2020, LANCET RHEUMATOL, V2, pE514, DOI 10.1016/S2665-9913(20)30212-5
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   Ghazizadeh Zaniar, 2020, bioRxiv, DOI 10.1101/2020.05.12.091082
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Golan R, 2015, AGING MALE, V18, P201, DOI 10.3109/13685538.2015.1052392
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jansen A, 2015, WEST PAC SURVEILL RE, V6, P68, DOI [10.5365/wpsar.2015.6.3.002, 10.5365/WPSAR.2015.6.3.002]
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Lin BY, 1999, CANCER RES, V59, P4180
   Liu S, 2020, CLIN REV ALLERG IMMU, V59, P78, DOI 10.1007/s12016-020-08797-3
   Liva SM, 2001, J IMMUNOL, V167, P2060, DOI 10.4049/jimmunol.167.4.2060
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Ma L, 2020, EFFECT SARS COV 2 IN, DOI [10.1101/2020.03.21.20037267., DOI 10.1101/2020.03.21.20037267, 10.1101/2020.03.21.20037267]
   McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Musabak U, 2003, CLIN EXP IMMUNOL, V132, P265, DOI 10.1046/j.1365-2249.2003.02141.x
   Ni Lochlainn M., 2020, KEY PREDICTORS ATTEN, DOI [10.1101/2020.04.25.20079251, DOI 10.1101/2020.04.25.20079251]
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Oudit GY, 2020, EUR HEART J, V41, P1818, DOI 10.1093/eurheartj/ehaa414
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   PICCINNI MP, 1995, J IMMUNOL, V155, P128
   Pinato DJ, 2020, CANCER DISCOV, V10, P1465, DOI 10.1158/2159-8290.CD-20-0773
   Pozzilli P, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154252
   RASTRELLI G, 2020, ANDROLOGY US 0603, DOI DOI 10.1111/ANDR.12821
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robinson DP, 2014, J VIROL, V88, P4711, DOI 10.1128/JVI.02081-13
   Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149
   Salonia A, 2020, ANDROLOGY-US, DOI 10.1111/andr.12811
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Schroeder M., 2020, MAJORITY MALE PATIEN, DOI [10.1101/2020.05.07.20073817, DOI 10.1101/2020.05.07.20073817]
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   Stall NM, 2020, J AM GERIATR SOC, V68, P2188, DOI 10.1111/jgs.16761
   Stelzig KE, 2020, AM J PHYSIOL-LUNG C, V318, pL1280, DOI 10.1152/ajplung.00153.2020
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Taneja V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01931
   Trigunaite A, 2015, CELL IMMUNOL, V294, P87, DOI 10.1016/j.cellimm.2015.02.004
   Villa A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15224
   von Langen J, 2005, CHEMBIOCHEM, V6, P1110, DOI 10.1002/cbic.200400361
   Wadman M, 2020, SCIENCE, V368, P1038, DOI 10.1126/science.368.6495.1038
   Walker RF, 2020, JAMA INTERN MED, V180, P190, DOI 10.1001/jamainternmed.2019.5135
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P680, DOI 10.1016/j.jaad.2020.05.079
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   Wang XL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113843
   Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 85
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG
PY 2020
VL 12
IS 8
AR 2325
DI 10.3390/cancers12082325
PG 13
WC Oncology
SC Oncology
GA OD1VC
UT WOS:000579642100001
PM 32824674
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saverino, D
AF Saverino, Daniele
TI Hyper-immune/convalescent plasma: an old option and a valid strategy for
   treatment of COVID-19?
SO MINERVA MEDICA
LA English
DT Article
DE COVID-19 serotherapy; COVID-19; Therapeutics
ID CONVALESCENT PLASMA
AB Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper-immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials.
C1 [Saverino, Daniele] Univ Genoa, Dept Expt Med, Via Toni 14, I-16132 Genoa, Italy.
   [Saverino, Daniele] San Martino Hosp, Genoa, Italy.
RP Saverino, D (corresponding author), Univ Genoa, Dept Expt Med, Via Toni 14, I-16132 Genoa, Italy.
EM daniele.saverino@unige.it
CR Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Bloch EM, 2020, J CLIN INVEST, V1
   Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X
   Dhar D R, 1918, Ind Med Gaz, V53, P436
   Drury F J, 1895, Ind Med Gaz, V30, P78
   Duan K, 2020, FEASIBILITY CONVALES
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Jakhar D, 2020, NAT MED
   Luczkowiak J, 2018, J INFECT DIS, V218, pS574, DOI 10.1093/infdis/jiy302
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Shen C, 2020, JAMA
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Zhang B, 2020, CHEST
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
NR 19
TC 0
Z9 0
U1 2
U2 2
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4806
EI 1827-1669
J9 MINERVA MED
JI Minerva Med.
PD AUG
PY 2020
VL 111
IS 4
BP 362
EP 364
DI 10.23736/S0026-4806.20.06616-1
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OE6SO
UT WOS:000580658500012
PM 32407051
DA 2021-01-01
ER

PT J
AU Adam, R
   Zsuzsanna, G
   Orsolya, C
   Laszlo, W
   Katalin, F
   Adrienn, M
   Attila, P
   Szilard, T
   Anita, HS
   Marina, V
   Attila, D
   Aniko, S
   Janos, F
   Laszlo, K
AF Adam, Remport
   Zsuzsanna, Gerlei
   Orsolya, Cseprekal
   Laszlo, Wagner
   Katalin, Foldes
   Adrienn, Marton
   Attila, Patonai
   Szilard, Torok
   Anita, Haboub-Sandil
   Marina, Varga
   Attila, Doros
   Aniko, Smudla
   Janos, Fazakas
   Laszlo, Kobori
TI Guidance on the special care of liver or kidney transplant recipients
   diagnosed with COVID-19
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE COVID-19; liver transplantation; renal transplantation;
   immunosuppression
ID HYPERINFLAMMATION; MANAGEMENT; INJURY
AB Due to the COVID-19 pandemic caused by infection with the novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), transplant medicine also had to face a new, hitherto unknown challenge. To be prepared for any possibility, we consider it important to summarize the current knowledge regarding COVID-19 of liver and kidney transplant patients. Very early reports from Spanish and French registry recorded fatality rates of 18.6% and 13%, respectively, in renal patients which suggests a moderately worse outcome compared to the general population. In patients with positive PCR test but not showing clinical signs, the reduction of immunosuppression is not advised. In the case of gastrointestinal or respiratory signs with fever, the discontinuation of mycophenolate or mTOR in-hibitors is recommended with decrease of the trough levels of calcineurin inhibitors to the lowest effective limit. Stop (kidney transplanted patients) or decrease (liver transplanted patients) immunosuppression and maintain corticosteroids when pulmonal injury develops and consider anti-IL1 and anti-IL6 monoclonal antibody use when hyperinflammatory syndrome is evolving. No proven effective treatment for SARS-CoV-2 exists currently. The use of lopinavir/ritonavir should be avoided because of the severe drug interaction with calcineurin inhibitors. The efficacy and tolerability of hidroxychloroquin remains to be also questionable; enroll patients into clinical trial with remdesivir or favipiravir if available. COVID-19 is characterized by virus-induced endothelial dysfunction, procoagulant state and renin-angiotensin-aldosteron system imbalance. Early thromboprofilaxis combination with low-molecular-weight heparin and low-dose aspirin is strongly recommended with the maintenance of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-II-receptor blocker (ARB) therapy when they were prescribed earlier.
C1 [Adam, Remport; Zsuzsanna, Gerlei; Orsolya, Cseprekal; Laszlo, Wagner; Katalin, Foldes; Adrienn, Marton; Attila, Patonai; Szilard, Torok; Anita, Haboub-Sandil; Attila, Doros; Aniko, Smudla; Janos, Fazakas; Laszlo, Kobori] Semmelweis Egyet, Altalanos Orvostud Kar, Transzplantacios Sebeszeti Klin, Budapest, Hungary.
   [Marina, Varga] Semmelweis Egyet, Altalanos Orvostud Kar, Lab Med Int, Budapest, Hungary.
RP Adam, R (corresponding author), Baross U 23-25, H-1083 Budapest, Hungary.
EM remportadam@hotmail.com
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Akos F, 2020, ORVOSI HETILAP, V161, P685, DOI 10.1556/650.2020.31812
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   American Association for the Study of Liver Disease, CLIN BEST PRACT ADV
   Andras L, 2020, ORVOSI HETILAP, V161, P672, DOI 10.1556/650.2020.31814
   Anita K, 2020, ORVOSI HETILAP, V161, P667, DOI 10.1556/650.2020.31815
   [Anonymous], 2020, HDB PREV MAN NEW COR
   [Anonymous], 2020, MASSACHUSETTS GEN HO
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   BC Transplant, 2019, CLIN GUID TRANSPL ME
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   British Transplant Society, GUID MAN TRANSPL REC
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   Cho HJ, 2020, J INFECT PUBLIC HEAL, V13, P1678, DOI 10.1016/j.jiph.2020.05.001
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henry BM, 2020, CLIN CHIM ACTA, V507, P167, DOI 10.1016/j.cca.2020.04.027
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5
   Kekes E, 2020, HYPERTON NEPHROL, V24, P5
   Lopez V, 2020, NEFROLOGIA, V40, P265, DOI 10.1016/j.nefro.2020.03.002
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   National Institutes of Health, NIH CLIN TRIAL SHOWS
   Pirola CJ, 2020, LIVER INT, V40, P2038, DOI 10.1111/liv.14500
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Trujillo H, 2020, KIDNEY INT REP, V5, P905, DOI 10.1016/j.ekir.2020.04.024
   US Food and Drug Administration, COR COVID 19 UPD FDA
   Wang JP, 2020, EUR UROL, V77, P769, DOI 10.1016/j.eururo.2020.03.036
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang X, 2020, LANCET RESP MED, V8, pE26
   Zatroch I, 2020, ORVOSI HETILAP, V161, P899, DOI 10.1556/650.2020.31870
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 48
TC 0
Z9 0
U1 0
U2 0
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD AUG
PY 2020
VL 161
IS 32
BP 1310
EP 1321
DI 10.1556/650.2020.31923
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD3LT
UT WOS:000579753700001
PM 32750019
OA Other Gold
DA 2021-01-01
ER

PT J
AU Hafner, SJ
AF Hafner, Sophia Julia
TI Pandemic number five - Latest insights into the COVID-19 crisis
SO BIOMEDICAL JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; Pseudovirus system; Repurposing drugs; Contact
   tracing
ID NATURAL-PRODUCTS; SARS; VIRUS
AB About nine months after the emergence of SARS-CoV-2, this special issue of the Biomedical Journal takes stock of its evolution into a pandemic. We acquire an elaborate overview of the history and virology of SARS-CoV-2, the epidemiology of COVID-19, and the development of therapies and vaccines, based on useful tools such as a pseudovirus system, artificial intelligence, and repurposing of existing drugs. Moreover, we learn about a potential link between COVID-19 and oral health, and some of the strategies that allowed Taiwan to handle the outbreak exceptionally well, including a COVID-19 biobank establishment, online tools for contact tracing, and the efficient management of emergency departments.
C1 [Hafner, Sophia Julia] Univ Copenhagen, BRIC Biotech Res & Innovat Ctr, Anders Lund Grp, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.
RP Hafner, SJ (corresponding author), Univ Copenhagen, BRIC Biotech Res & Innovat Ctr, Anders Lund Grp, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.
EM sophia.hafner@bric.ku.dk
CR Alam MN, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4154185
   Botros N, 2020, BIOMED J, V43, P325, DOI 10.1016/j.bj.2020.05.016
   Bui FQ, 2019, BIOMED J, V42, P27, DOI 10.1016/j.bj.2018.12.001
   Chauhan S, 2020, BIOMED J, V43, P334, DOI 10.1016/j.bj.2020.05.023
   Chen WJ, 2020, BIOMED J, V43, P318, DOI 10.1016/j.bj.2020.06.007
   Cheng HY, 2020, J FORMOS MED ASSOC, V119, P771, DOI 10.1016/j.jfma.2020.03.007
   Cross AR, 2019, MICROBES INFECT, V21, P10, DOI 10.1016/j.micinf.2018.06.001
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dubey K, 2020, BIOMED J, V43, P363, DOI 10.1016/j.bj.2020.05.002
   Guasch-Ferre M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6723931
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Hoffmann M, 2020, BIORXIV, V12, P233
   Huang SF, 2020, BIOMED J, V43, P314, DOI 10.1016/j.bj.2020.05.018
   Huang SW, BIOMED J
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Ke YY, 2020, BIOMED J, V43, P355, DOI 10.1016/j.bj.2020.05.001
   Ledford H, 2020, NATURE, V584, P333, DOI 10.1038/d41586-020-02360-y
   Li QQ, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1963
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu YC, 2020, BIOMED J, V43, P328, DOI 10.1016/j.bj.2020.04.007
   Maleki SJ, 2019, FOOD CHEM, V299, DOI 10.1016/j.foodchem.2019.125124
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Ni J, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00920
   Peeples L., P NATL ACAD SCI
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Rossiter SE, 2017, CHEM REV, V117, P12415, DOI 10.1021/acs.chemrev.7b00283
   Seak CJ, BIOMED J
   Shih HI, 2020, BIOMED J, V43, P341, DOI 10.1016/j.bj.2020.05.021
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Welch SR, 2016, ANTIVIR RES, V136, P9, DOI 10.1016/j.antiviral.2016.10.007
   Woolhouse MEJ, 2008, NATURE, V451, P898, DOI 10.1038/451898a
   Wu YM, 2007, J CLIN MICROBIOL, V45, P3665, DOI 10.1128/JCM.00374-07
   Yamamoto Naoki, 2020, Med Hypotheses, V144, P110160, DOI 10.1016/j.mehy.2020.110160
   Yang CW, 2020, BIOMED J, V43, P368, DOI 10.1016/j.bj.2020.05.003
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD AUG
PY 2020
VL 43
IS 4
BP 305
EP 310
DI 10.1016/j.bj.2020.08.008
PG 6
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA OC8ZS
UT WOS:000579445300001
PM 32967801
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ke, YY
   Peng, TT
   Yeh, TK
   Huang, WZ
   Chang, SE
   Wu, SH
   Hung, HC
   Hsu, TA
   Lee, SJ
   Song, JS
   Lin, WH
   Chiang, TJ
   Lin, JH
   Sytwu, HK
   Chen, CT
AF Ke, Yi-Yu
   Peng, Tzu-Ting
   Yeh, Teng-Kuang
   Huang, Wen-Zheng
   Chang, Shao-En
   Wu, Szu-Huei
   Hung, Hui-Chen
   Hsu, Tsu-An
   Lee, Shiow-Ju
   Song, Jeng-Shin
   Lin, Wen-Hsing
   Chiang, Tung-Jung
   Lin, Jiunn-Horng
   Sytwu, Huey-Kang
   Chen, Chiung-Tong
TI Artificial intelligence approach fighting COVID-19 with repurposing
   drugs
SO BIOMEDICAL JOURNAL
LA English
DT Article
DE AI; DNN; COVID-19; SARS-CoV-2; Feline coronavirus; Drug repurposing
ID 3CL PROTEASE INHIBITORS; RESPIRATORY SYNDROME SARS; SMALL-MOLECULE
   INHIBITORS; BIOLOGICAL EVALUATION; CORONAVIRUS; DESIGN; DISCOVERY;
   PHARMACOKINETICS; ANALOGS; IDENTIFICATION
AB Background: The ongoing COVID-19 pandemic has caused more than 193,825 deaths during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic medicine that has prior use experiences in patients in order to resolve the current pandemic situation before it could become worsening. Artificial intelligence (AI) technology is hereby applied to identify the marketed drugs with potential for treating COVID-19.
   Methods: An AI platform was established to identify potential old drugs with anti-coronavirus activities by using two different learning databases; one consisted of the compounds reported or proven active against SARS-CoV, SARS-CoV-2, human immunodeficiency virus, influenza virus, and the other one containing the known 3C-like protease inhibitors. All AI predicted drugs were then tested for activities against a feline coronavirus in in vitro cell-based assay. These assay results were feedbacks to the AI system for relearning and thus to generate a modified AI model to search for old drugs again.
   Results: After a few runs of AI learning and prediction processes, the AI system identified 80 marketed drugs with potential. Among them, 8 drugs (bedaquiline, brequinar, celecoxib, clofazimine, conivaptan, gemcitabine, tolcapone, and vismodegib) showed in vitro activities against the proliferation of a feline infectious peritonitis (FIP) virus in Fcwf-4 cells. In addition, 5 other drugs (boceprevir, chloroquine, homoharringtonine, tilorone, and salinomycin) were also found active during the exercises of AI approaches.
   Conclusion: Having taken advantages of AI, we identified old drugs with activities against FIP coronavirus. Further studies are underway to demonstrate their activities against SARS-CoV-2 in vitro and in vivo at clinically achievable concentrations and doses. With prior use experiences in patients, these old drugs if proven active against SARS-CoV-2 can readily be applied for fighting COVID-19 pandemic.
C1 [Ke, Yi-Yu; Yeh, Teng-Kuang; Chang, Shao-En; Wu, Szu-Huei; Hung, Hui-Chen; Hsu, Tsu-An; Lee, Shiow-Ju; Song, Jeng-Shin; Lin, Wen-Hsing; Chen, Chiung-Tong] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan, Taiwan.
   [Peng, Tzu-Ting; Huang, Wen-Zheng; Lin, Jiunn-Horng] Agr Technol Res Inst, Anim Technol Labs, Hsinchu, Taiwan.
   [Chiang, Tung-Jung] Natl Hlth Res Inst, Off Environm Safety & Hlth, Miaoli, Taiwan.
   [Sytwu, Huey-Kang] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Taiwan.
RP Ke, YY; Chen, CT (corresponding author), Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, 35 Keyan Rd, Miaoli 35053, Taiwan.
EM yiyuke@nhri.edu.tw; ctchen@nhri.edu.tw
FU Ministry of Health and Welfare, Taiwan
FX A special government fund to tackle the COVID-19 pandemic from the
   Ministry of Health and Welfare, Taiwan.
CR ARTEAGA CL, 1989, CANCER RES, V49, P4648
   Barik S, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-104
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Caffo O, 2010, CANCER CHEMOTH PHARM, V65, P1197, DOI 10.1007/s00280-010-1255-7
   Chang YW, 2006, J FOOD DRUG ANAL, V14, P329
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Chen LL, 2006, J BIOMOL SCREEN, V11, P915, DOI 10.1177/1087057106293295
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Chow WA, 2009, LANCET ONCOL, V10, P61, DOI 10.1016/S1470-2045(08)70334-6
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Ekins S, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-02799-8
   GHOSE AK, 1987, J CHEM INF COMP SCI, V27, P21, DOI 10.1021/ci00053a005
   Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P5684, DOI 10.1016/j.bmcl.2008.08.082
   Ghosh AK, 2007, BIOORG MED CHEM LETT, V17, P5876, DOI 10.1016/j.bmcl.2007.08.031
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jadhav M V, 2004, Indian J Pathol Microbiol, V47, P281
   Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873
   Kaeppler U, 2005, J MED CHEM, V48, P6832, DOI 10.1021/jm0501782
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   Kuo CJ, 2009, FEBS LETT, V583, P549, DOI 10.1016/j.febslet.2008.12.059
   Liang RY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120721
   Lin CN, 2013, VIRUS GENES, V46, P316, DOI 10.1007/s11262-012-0864-0
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Ma JS, 2015, J CHEM INF MODEL, V55, P263, DOI 10.1021/ci500747n
   Marbury T, 2017, DRUG DES DEV THER, V11, DOI 10.2147/DDDT.S125459
   Mukherjee P, 2008, BIOORGAN MED CHEM, V16, P4138, DOI 10.1016/j.bmc.2008.01.011
   Paltrinieri S, 2004, J FELINE MED SURG, V6, P131, DOI 10.1016/j.jfms.2003.11.001
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   SHEN HSL, 1988, CANCER CHEMOTH PHARM, V22, P183, DOI 10.1007/BF00273407
   Siddall E, 2017, KIDNEY INT, V92, P37, DOI 10.1016/j.kint.2016.11.029
   Swanson RV, 2015, ANTIMICROB AGENTS CH, V59, P3042, DOI 10.1128/AAC.00260-15
   Sykes DB, 2018, EXPERT OPIN THER TAR, V22, P893, DOI 10.1080/14728222.2018.1536748
   Thanigaimalai P, 2013, EUR J MED CHEM, V68, P372, DOI 10.1016/j.ejmech.2013.07.037
   Thanigaimalai P, 2013, EUR J MED CHEM, V65, P436, DOI 10.1016/j.ejmech.2013.05.005
   Tsai KC, 2006, J MED CHEM, V49, P3485, DOI 10.1021/jm050852f
   Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Yang QG, 2008, CHEM PHARM BULL, V56, P1400, DOI 10.1248/cpb.56.1400
   Zhang JM, 2007, J MED CHEM, V50, P1850, DOI 10.1021/jm061425k
   Zhang JM, 2008, BIOORG CHEM, V36, P229, DOI 10.1016/j.bioorg.2008.01.001
NR 50
TC 15
Z9 15
U1 8
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD AUG
PY 2020
VL 43
IS 4
BP 355
EP 362
DI 10.1016/j.bj.2020.05.001
PG 8
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA OC8ZS
UT WOS:000579445300009
PM 32426387
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yang, CW
   Peng, TT
   Hsu, HY
   Lee, YZ
   Wu, SH
   Lin, WH
   Ke, YY
   Hsu, TA
   Yeh, TK
   Huang, WZ
   Lin, JH
   Sytwu, HK
   Chen, CT
   Lee, SJ
AF Yang, Cheng-Wei
   Peng, Tzu-Ting
   Hsu, Hsing-Yu
   Lee, Yue-Zhi
   Wu, Szu-Huei
   Lin, Wen-Hsing
   Ke, Yi-Yu
   Hsu, Tsu-An
   Yeh, Teng-Kuang
   Huang, Wen-Zheng
   Lin, Jiunn-Horng
   Sytwu, Huey-Kang
   Chen, Chiung-Tong
   Lee, Shiow-Ju
TI Repurposing old drugs as antiviral agents for coronaviruses
SO BIOMEDICAL JOURNAL
LA English
DT Article
DE Coronavirus; COVID-19; Cytopathic effect; HCoV-OC43; SARS-CoV-2; Drug
   repurpose
ID FELINE INFECTIOUS PERITONITIS; SARS; IDENTIFICATION; REPLICATION;
   INHIBITION; VIRUS
AB Background: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2.
   Methods: FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC50) of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined. The viabilities of Fcwf-4 and HCT-8 cells were measured by crystal violet staining and MTS/PMS assay, respectively.
   Results: Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC50 values ranging from 11 nM to 75 mu M. They are all old drugs as follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine, homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomycin, and vismodegib.
   Conclusion: All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effectonSARS-CoV-2, should be consideredforimmediateuses in COVID-19 patients.
C1 [Yang, Cheng-Wei; Hsu, Hsing-Yu; Lee, Yue-Zhi; Wu, Szu-Huei; Lin, Wen-Hsing; Ke, Yi-Yu; Hsu, Tsu-An; Yeh, Teng-Kuang; Chen, Chiung-Tong; Lee, Shiow-Ju] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, 35 Keyan Rd, Miaoli 350, Taiwan.
   [Peng, Tzu-Ting; Huang, Wen-Zheng; Lin, Jiunn-Horng] Agr Technol Res Inst, Anim Technol Labs, Hsinchu, Taiwan.
   [Sytwu, Huey-Kang] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Taiwan.
RP Chen, CT; Lee, SJ (corresponding author), Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, 35 Keyan Rd, Miaoli 350, Taiwan.
EM ctchen@nhri.edu.tw; slee@nhri.org.tw
FU National Health Research Institutes, Taiwan, R.O.C.National Health
   Research Institutes - Taiwan; Ministry of Science and Technology,
   Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [MOST
   106-2320-B-400-009-MY3, MOST 108-2811-B-400-511]; Ministry of Health and
   Welfare, Taiwan, R.O.C.
FX The authors gratefully acknowledge Dr. Kung-Yee Liang, National Health
   Research Institutes, for his full support and supervision on this work.
   This work was funded by the National Health Research Institutes, Taiwan,
   R.O.C. and the Ministry of Science and Technology, Taiwan, R.O.C.
   (grants of MOST 106-2320-B-400-009-MY3 and MOST 108-2811-B-400-511) as
   well as an emergent grant from the Ministry of Health and Welfare,
   Taiwan, R.O.C.
CR Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Ball MD, 2001, ANTIMICROB AGENTS CH, V45, P1473, DOI 10.1128/AAC.45.5.1473-1479.2001
   Barnard DL, 2011, FUTURE VIROL, V6, P615, DOI 10.2217/fvl.11.33
   Bleasel MD, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13030051
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Gao JJ, 2020, BIOSCI TRENDS, V14, P156, DOI 10.5582/bst.2020.03072
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   HOHDATSU T, 1992, J VET MED SCI, V54, P557, DOI 10.1292/jvms.54.557
   Kantarjian HM, 2013, CL LYMPH MYELOM LEUK, V13, P530, DOI 10.1016/j.clml.2013.03.017
   Kautz TF, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110600
   Lau SKP, 2011, J VIROL, V85, P11325, DOI 10.1128/JVI.05512-11
   Lee YZ, 2012, J MED CHEM, V55, P10363, DOI 10.1021/jm300705j
   Liang RY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120721
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   Lin Chao-Nan, 2009, Taiwan Veterinary Journal, V35, P145
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Murphy BG, 2018, VET MICROBIOL, V219, P226, DOI 10.1016/j.vetmic.2018.04.026
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Paltrinieri S, 2004, J FELINE MED SURG, V6, P131, DOI 10.1016/j.jfms.2003.11.001
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   Rajamuthiah R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124595
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Udelson JE, 2001, CIRCULATION, V104, P2417, DOI 10.1161/hc4501.099313
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang CW, 2018, TOXICOL APPL PHARM, V356, P90, DOI 10.1016/j.taap.2018.07.028
   Yang CW, 2017, TOXICOL APPL PHARM, V332, P129, DOI 10.1016/j.taap.2017.04.017
   Yang CW, 2010, ANTIVIR RES, V88, P160, DOI 10.1016/j.antiviral.2010.08.009
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
NR 39
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD AUG
PY 2020
VL 43
IS 4
BP 368
EP 374
DI 10.1016/j.bj.2020.05.003
PG 7
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA OC8ZS
UT WOS:000579445300011
PM 32563698
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, SW
   Tai, CH
   Hsu, YM
   Cheng, DN
   Hung, SJ
   Chai, KM
   Wang, YF
   Wang, JR
AF Huang, Sheng-Wen
   Tai, Ching-Hui
   Hsu, Yin-Mei
   Cheng, Dayna
   Hung, Su-Jhen
   Chai, Kit Man
   Wang, Ya-Fang
   Wang, Jen-Ren
TI Assessing the application of a pseudovirus system for emerging
   SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine
   development
SO BIOMEDICAL JOURNAL
LA English
DT Article
DE Pseudovirus; Pseudovirus system; SARS-CoV-2; Avian influenza virus;
   Antigen; Antibody
ID NEUTRALIZATION ASSAY; SARS CORONAVIRUS; HEMAGGLUTININ CLEAVAGE; ENABLES
   EVALUATION; ACTIVATION; ESTABLISHMENT; DETERMINANTS; EVOLUTION;
   DYNAMICS; TROPISM
AB Background: Highly pathogenic emerging and re-emerging viruses continuously threaten lives worldwide. In order to provide prophylactic prevention from the emerging and re-emerging viruses, vaccine is suggested as the most efficient way to prevent individuals from the threat of viral infection. Nonetheless, the highly pathogenic viruses need to be handled in a high level of biosafety containment, which hinders vaccine development. To shorten the timeframe of vaccine development, the pseudovirus system has been widely applied to examine vaccine efficacy or immunogenicity in the emerging and re-emerging viruses.
   Methods: We developed pseudovirus systems for emerging SARS coronavirus 2 (SARS-CoV-2) and re-emerging avian influenza virus H5 subtypes which can be handled in the biosafety level 2 facility. Through the generated pseudovirus of SARS-CoV-2 and avian influenza virus H5 subtypes, we successfully established a neutralization assay to quantify the neutralizing activity of antisera against the viruses.
   Results: The result of re-emerging avian influenza virus H5Nx pseudoviruses provided valuable information for antigenic evolution and immunogenicity analysis in vaccine candidate selection. Together, our study assessed the potency of pseudovirus systems in vaccine efficacy, antigenic analysis, and immunogenicity in the vaccine development of emerging and re-emerging viruses.
   Conclusion: Instead of handling live highly pathogenic viruses in a high biosafety level facility, using pseudovirus systems would speed up the process of vaccine development to provide community protection against emerging and re-emerging viral diseases with high pathogenicity.
C1 [Huang, Sheng-Wen; Hung, Su-Jhen] Natl Hlth Res Inst, Natl Mosquitoborne Dis Control Res Ctr, Tainan, Taiwan.
   [Tai, Ching-Hui; Cheng, Dayna; Chai, Kit Man; Wang, Ya-Fang; Wang, Jen-Ren] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Tainan, Taiwan.
   [Hsu, Yin-Mei; Wang, Jen-Ren] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan.
   [Wang, Jen-Ren] Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan, Taiwan.
   [Wang, Jen-Ren] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan.
RP Wang, JR (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, 1 Univ Rd, Tainan 701, Taiwan.
EM jrwang@mail.ncku.edu.tw
FU National Health Research InstitutesNational Health Research Institutes,
   Japan [IV-109-GP-09, COVID-19]
FX This work was financially supported by the National Health Research
   Institutes [grant number: IV-109-GP-09 and grant for COVID-19].
CR Barlan A, 2014, J VIROL, V88, P4953, DOI 10.1128/JVI.00161-14
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   BOYCOTT R, 1994, VIROLOGY, V203, P313, DOI 10.1006/viro.1994.1489
   Chen QQ, 2018, HUM VACC IMMUNOTHER, V14, P199, DOI 10.1080/21645515.2017.1373922
   Cheresiz SV, 2010, DOKL BIOCHEM BIOPHYS, V435, P295, DOI 10.1134/S1607672910060049
   Du LY, 2010, BIOCHEM BIOPH RES CO, V397, P580, DOI 10.1016/j.bbrc.2010.05.161
   Fan CF, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090448
   Follis KE, 2006, VIROLOGY, V350, P358, DOI 10.1016/j.virol.2006.02.003
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Gao J, 2019, MBIO, V10, DOI 10.1128/mBio.00307-19
   Goyvaerts C, 2013, GENE THERAPY TOOLS P
   Haydon DT, 2001, GENETICS, V157, P7
   Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5
   Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300
   Hu DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110893
   Huang SW, 2015, J VIROL, V89, P11500, DOI 10.1128/JVI.02035-15
   Huang SW, 2009, J CLIN MICROBIOL, V47, P3653, DOI 10.1128/JCM.00630-09
   Jaijyan DK, 2018, ANN MICROBIOLOGY RES, V2, P31, DOI [10.36959/958/567, DOI 10.36959/958/567]
   Johnson BA, 2019, J VIROL, V93, DOI 10.1128/JVI.01282-19
   Katzelnick LC, 2015, SCIENCE, V349, P1338, DOI 10.1126/science.aac5017
   KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6
   Koel BF, 2013, SCIENCE, V342, P976, DOI 10.1126/science.1244730
   Li MJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4031
   Li QQ, 2017, VACCINE, V35, P5172, DOI 10.1016/j.vaccine.2017.07.101
   Lukashev AN, 2014, J GEN VIROL, V95, P868, DOI 10.1099/vir.0.060004-0
   Mather ST, 2014, J VIROL METHODS, V210, P51, DOI 10.1016/j.jviromet.2014.09.021
   Matsuyama S, 2005, P NATL ACAD SCI USA, V102, P12543, DOI 10.1073/pnas.0503203102
   McKay T, 2006, GENE THER, V13, P715, DOI 10.1038/sj.gt.3302715
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nie JH, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2019.1702479
   Nie JH, 2019, EMERG MICROBES INFEC, V8, P272, DOI 10.1080/22221751.2019.1571871
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Stein DR, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0104-x
   Steinhauer DA, 1999, VIROLOGY, V258, P1, DOI 10.1006/viro.1999.9716
   Sun XJ, 2010, J VIROL, V84, P8683, DOI 10.1128/JVI.00797-10
   Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764
   Tani H, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2011.00272
   Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang W, 2008, J VIROL METHODS, V153, P111, DOI 10.1016/j.jviromet.2008.07.015
   Wu XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064800
   Zhang L, 2017, HUM VACC IMMUNOTHER, V13, P1811, DOI 10.1080/21645515.2017.1325050
   Zhao GY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-266
NR 46
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD AUG
PY 2020
VL 43
IS 4
BP 375
EP 387
DI 10.1016/j.bj.2020.06.003
PG 13
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA OC8ZS
UT WOS:000579445300012
PM 32611537
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Karakas, M
   Jarczak, D
   Becker, M
   Roedl, K
   Addo, MM
   Hein, F
   Bergmann, A
   Zimmermann, J
   Simon, TP
   Marx, G
   Lutgehetmann, M
   Nierhaus, A
   Kluge, S
AF Karakas, Mahir
   Jarczak, Dominik
   Becker, Martin
   Roedl, Kevin
   Addo, Marylyn M.
   Hein, Frauke
   Bergmann, Andreas
   Zimmermann, Jens
   Simon, Tim-Philipp
   Marx, Gernot
   Luetgehetmann, Marc
   Nierhaus, Axel
   Kluge, Stefan
TI Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill
   Patients with COVID-19 Using the Anti-Adrenomedullin Antibody
   Adrecizumab (HAM8101)
SO BIOMOLECULES
LA English
DT Article
DE COVID-19; Adrecizumab; HAM 8101; adrenomedullin; endothelial function
ID HEART-FAILURE
AB Recently, the stabilization of the endothelium has been explicitly identified as a therapeutic goal in coronavirus disease 2019 (COVID-19). Adrecizumab (HAM8101) is a first-in-class humanized monoclonal anti-Adrenomedullin (anti-ADM) antibody, targeting the sepsis- and inflammation-based vascular and capillary leakage. Within a "treatment on a named-patient basis" approach, Adrecizumab was administered to eight extreme-critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). The patients received a single dose of Adrecizumab, which was administered between 1 and 3 days after the initiation of mechanical ventilation. The SOFA (median 12.5) and SAPS-II (median 39) scores clearly documented the population at highest risk. Moreover, six of the patients suffered from acute renal failure, of whom five needed renal replacement therapy. The length of follow-up ranged between 13 and 27 days. Following the Adrecizumab administration, one patient in the low-dose group died at day 4 due to fulminant pulmonary embolism, while four were in stable condition, and three were discharged from the intensive care unit (ICU). Within 12 days, the SOFA score, as well as the disease severity score (range 0-16, mirroring critical resources in the ICU, with higher scores indicating more severe illness), decreased in five out of the seven surviving patients (in all high-dose patients). The PaO2/FiO2 increased within 12 days, while the inflammatory parameters C-reactive protein, procalcitonin, and interleukin-6 decreased. Importantly, the mortality was lower than expected and calculated by the SOFA score. In conclusion, in this preliminary uncontrolled case series of eight shock patients with life-threatening COVID-19 and ARDS, the administration of Adrecizumab was followed by a favorable outcome. Although the non-controlled design and the small sample size preclude any definitive statement about the potential efficacy of Adrecizumab in critically ill COVID-19 patients, the results of this case series are encouraging.
C1 [Karakas, Mahir] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, D-20251 Hamburg, Germany.
   [Karakas, Mahir; Becker, Martin] Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, D-20251 Hamburg, Germany.
   [Jarczak, Dominik; Roedl, Kevin; Nierhaus, Axel; Kluge, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care Med, D-20251 Hamburg, Germany.
   [Addo, Marylyn M.] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Div Infect Dis, D-20251 Hamburg, Germany.
   [Addo, Marylyn M.] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, D-20359 Hamburg, Germany.
   [Addo, Marylyn M.] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, D-20359 Hamburg, Germany.
   [Hein, Frauke; Bergmann, Andreas; Zimmermann, Jens] Adrenomed AG, D-16761 Hennigsdorf, Germany.
   [Bergmann, Andreas] SphingoTec GmbH, D-16761 Hennigsdorf, Germany.
   [Bergmann, Andreas] 4TEEN4 Pharmaceut GmbH, D-16761 Hennigsdorf, Germany.
   [Simon, Tim-Philipp; Marx, Gernot] Univ Hosp RWTH Aachen, Dept Intens Care & Intermediate Care, D-52074 Aachen, Germany.
   [Luetgehetmann, Marc] Univ Med Ctr Hamburg Eppendorf, Inst Med Microbiol Virol & Hyg, D-20251 Hamburg, Germany.
RP Karakas, M (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, D-20251 Hamburg, Germany.; Karakas, M (corresponding author), Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, D-20251 Hamburg, Germany.
EM m.karakas@uke.de; d.jarczak@uke.de;
   martin.becker@stud.uke.uni-hamburg.de; k.roedl@uke.de; m.addo@uke.de;
   fhein@adrenomed.com; bergmann@sphingotec.de; jzimmermann@adrenomed.com;
   tsimon@ukaachen.de; gmarx@ukaachen.de; mluetgehetmann@uke.edu;
   nierhaus@uke.de; s.kluge@uke.de
OI Jarczak, Dominik/0000-0003-0480-2089; Addo, Marylyn/0000-0003-2836-9224
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Blet A, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0255-0
   Deniau B, 2020, EUR J HEART FAIL, V22, P290, DOI 10.1002/ejhf.1601
   Geven C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024475
   Geven C, 2018, BRIT J CLIN PHARMACO, V84, P2129, DOI 10.1111/bcp.13655
   Geven C, 2018, SHOCK, V50, P132, DOI 10.1097/SHK.0000000000001103
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hamid SA, 2006, J MOL CELL CARDIOL, V41, P360, DOI 10.1016/j.yjmcc.2006.05.017
   Hinrichs S, 2018, P NATL ACAD SCI USA, V115, pE8727, DOI 10.1073/pnas.1721635115
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Magliocca A, 2020, EUR J HEART FAIL, V22, P300, DOI 10.1002/ejhf.1649
   Muller HC, 2010, THORAX, V65, P1077, DOI 10.1136/thx.2010.135996
   Nagaya N, 2002, J CARDIOVASC PHARM, V39, P754, DOI 10.1097/00005344-200205000-00017
   Nakamura R, 2004, CIRCULATION, V110, P426, DOI 10.1161/01.CIR.0000136085.34185.83
   Nakamura R, 2002, CARDIOVASC RES, V56, P373, DOI 10.1016/S0008-6363(02)00594-1
   Nickel L, 2017, BUNDESGESUNDHEITSBLA, V60, P804, DOI 10.1007/s00103-017-2574-1
   Okumura H, 2004, CIRCULATION, V109, P242, DOI 10.1161/01.CIR.0000109214.30211.7C
   Ocaranza MP, 2016, HYPERTENSION, V68, P552, DOI 10.1161/HYPERTENSIONAHA.116.07471
   Pfefferle S, 2020, EUROSURVEILLANCE, V25, P18, DOI 10.2807/1560-7917.ES.2020.25.9.2000152
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Takagi K, 2020, EUR J HEART FAIL, V22, P279, DOI 10.1002/ejhf.1600
   Tolppanen H, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-016-0229-2
   Trincot CE, 2019, CIRC RES, V124, P101, DOI 10.1161/CIRCRESAHA.118.313835
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Voors AA, 2019, EUR J HEART FAIL, V21, P163, DOI 10.1002/ejhf.1366
   WHO, NOV COR COVID 19
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu M. A., 2020, COVID 19 KEY ROLE PU, DOI [10.1101/2020.05.17.20104877, DOI 10.1101/2020.05.17.20104877]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD AUG
PY 2020
VL 10
IS 8
AR 1171
DI 10.3390/biom10081171
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OC0NE
UT WOS:000578859000001
PM 32796765
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marciniec, K
   Chrobak, E
   Dabrowska, A
   Bebenek, E
   Kadela-Tomanek, M
   Pecak, P
   Boryczka, S
AF Marciniec, Krzysztof
   Chrobak, Elwira
   Dabrowska, Aleksandra
   Bebenek, Ewa
   Kadela-Tomanek, Monika
   Pecak, Pawel
   Boryczka, Stanislaw
TI Phosphate Derivatives of 3-Carboxyacylbetulin: SynThesis, In Vitro
   Anti-HIV and Molecular Docking Study
SO BIOMOLECULES
LA English
DT Article
DE triterpenes; anti-HIV; SARS-CoV-2; bevirimat
ID GENERAL FORCE-FIELD; ANTIVIRAL ACTIVITY; AIDS AGENTS; DEFICIENCY;
   BEVIRIMAT; POTENT; TRITERPENOIDS; CHLOROQUINE; INHIBITOR; TOXICITY
AB Lupane-type pentacyclic triterpenes such as betulin and betulinic acid play an important role in the search for new therapies that would be effective in controlling viral infections. The aim of this study was the synthesis and evaluation of in vitro anti-HIV-1 activity for phosphate derivatives of 3-carboxyacylbetulin3-5as well as an in silico study of new compounds as potential ligands of the C-terminal domain of the HIV-1 capsid-spacer peptide 1 (CA-CTD-SP1) as a molecular target of HIV-1 maturation inhibitors. In vitro studies showed that 28-diethoxyphosphoryl-3-O-(3 ',3 '-dimethylsuccinyl)betulin (compound3), the phosphate analog of bevirimat (betulinic acid derivative, HIV-1 maturation inhibitor), has IC50(half maximal inhibitory concentration) equal to 0.02 mu M. Compound3inhibits viral replication at a level comparable to bevirimat and is also more selective (selectivity indices = 1250 and 967, respectively). Molecular docking was used to examine the probable interaction between the phosphate derivatives of 3-carboxyacylbetulin and C-terminal domain (CTD) of the HIV-1 capsid (CA)-spacer peptide 1 (SP1) fragment of Gag protein, designated as CTD-SP1. Compared with interactions between bevirimat (BVM) and the protein, an increased number of strong interactions between ligand3and the protein, generated by the phosphate group, were observed. These compounds might have the potential to also inhibit SARS-CoV2 proteins, in as far as the intrinsically imprecise docking scores suggest.
C1 [Marciniec, Krzysztof; Chrobak, Elwira; Bebenek, Ewa; Kadela-Tomanek, Monika; Pecak, Pawel; Boryczka, Stanislaw] Med Univ Silesia, Dept Organ Chem, Fac Pharmaceut Sci Sosnowiec, 4 Jagiellonska Str, PL-41200 Sosnowiec, Poland.
   [Dabrowska, Aleksandra] Natl Med Inst, 30-34 Chelmska Str, PL-00725 Warsaw, Poland.
RP Chrobak, E (corresponding author), Med Univ Silesia, Dept Organ Chem, Fac Pharmaceut Sci Sosnowiec, 4 Jagiellonska Str, PL-41200 Sosnowiec, Poland.
EM kmarciniec@sum.edu.pl; ebebenek@sum.edu.pl; aleksandra_dabrowska@o2.pl;
   ebebenek@sum.edu.pl; mkadela@sum.edu.pl; pawel.marek.pecak@gmail.com;
   boryczka@sum.edu.pl
OI Chrobak, Elwira/0000-0001-9038-3444; Pecak, Pawel/0000-0002-6232-3126;
   Bebenek, Ewa/0000-0001-5592-4161
FU Medical University of Silesia [KNW-1-055/K/9/O]; Wroclaw Centre for 818
   Networking and Supercomputing (Wroclaw University of Technology, Poland)
   [382]; Czestochowa University of Technology by the MICLAB project
   [POIG.02.03.00.24-093/13]
FX This work was supported by the Medical University of Silesia (grant
   KNW-1-055/K/9/O). Energy-minimization calculations have been carried out
   using resources provided by Wroclaw Centre for 818 Networking and
   Supercomputing (http://wcss.pl; Wroclaw University of Technology,
   Poland), Grant No. 382. The authors are grateful to Czestochowa
   University of Technology for granting access to HPC platform provided by
   the MICLAB project no.POIG.02.03.00.24-093/13.
CR ACD, 2015, ACD LABS 2015 REL BU
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Biron KK, 2006, ANTIVIR RES, V71, P154, DOI 10.1016/j.antiviral.2006.05.002
   Boojamra C.G, 2015, U.S. Patent, Patent No. [2015/0025039 A1, 20150025039]
   Boryczka S, 2019, Patent Application, Patent No. [No. P.430836, 430836]
   Broganelli P, 2012, DERMATOL THER, V25, P468, DOI 10.1111/j.1529-8019.2012.01477.x
   Chen YZ, 2001, J MOL GRAPH MODEL, V20, P199, DOI 10.1016/S1093-3263(01)00109-7
   Chrobak E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205209
   Chu Chung K., 2006, Antiviral Chemistry & Chemotherapy, V17, P285
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Dassault Systemes BIOVIA, 2016, DISC STUD MOD ENV RE
   Dracinsky M, 2008, BIOORGAN MED CHEM, V16, P6778, DOI 10.1016/j.bmc.2008.05.058
   Dzubak P, 2006, NAT PROD REP, V23, P394, DOI 10.1039/b515312n
   Feng Q, 2016, U.S. Patent, Patent No. [2016/9428542 B2, 20169428542]
   Frisch M.J., 2016, GAUSSIAN 16 REV B 01
   Ghannay S, 2020, MONATSH CHEM, V151, P267, DOI 10.1007/s00706-020-02550-4
   Goswami T., 2020, MOL DOCKING STUDY RE, DOI [10.26434/chemrxiv.12033774.v1, DOI 10.26434/CHEMRXIV.12033774.V1]
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hashimoto F, 1997, BIOORGAN MED CHEM, V5, P2133, DOI 10.1016/S0968-0896(97)00158-2
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jarzyna R, 1997, PHARMACOL RES, V35, P79, DOI 10.1006/phrs.1996.0108
   Kadioglu O, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255943, DOI 10.2471/BLT.20.255943]
   Kostalova E, 2015, CLIN CHIM ACTA, V440, P214, DOI 10.1016/j.cca.2014.11.026
   Laemmle A, 2015, MOL GENET METAB, V114, P438, DOI 10.1016/j.ymgme.2015.01.002
   Lai M., 2001, FIELDS VIROLOGY, P1163
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Martin David E., 2008, Antiviral Chemistry & Chemotherapy, V19, P107
   McCallister S, 2008, ANTIVIR THER, V13, pA10
   Mishra S.S., 2017, PHARM CHEM J, V4, P143
   Nitz T.J, 2012, U.S. Patent, Patent No. [2012/0046291 A1, 20120046291]
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Ribeiro JV, 2016, SCI REP-UK, V6, DOI 10.1038/srep26536
   Rut W., 2020, BIORXIV, DOI [10.1101/2020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   Sun IC, 1998, BIOORG MED CHEM LETT, V8, P1267, DOI 10.1016/S0960-894X(98)00202-9
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Urano E, 2016, ANTIMICROB AGENTS CH, V60, P190, DOI 10.1128/AAC.02121-15
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Vempati UD, 2007, MOL CELL BIOL, V27, P1771, DOI 10.1128/MCB.00287-06
   VISCIDI R, 1988, J CLIN MICROBIOL, V26, P453, DOI 10.1128/JCM.26.3.453-458.1988
   Wagner JM, 2016, ELIFE, V5, DOI 10.7554/eLife.17063
   Wang D, 2015, ACTA PHARM SIN B, V5, P493, DOI 10.1016/j.apsb.2015.05.004
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   WHO, 2018, MAN EP KEY FACTS MAJ
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xiao SL, 2018, MED RES REV, V38, P951, DOI 10.1002/med.21484
   Yu WB, 2012, J COMPUT CHEM, V33, P2451, DOI 10.1002/jcc.23067
   Zanella A, 2000, BEST PRACT RES CL HA, V13, P57, DOI 10.1053/beha.1999.0057
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhou Jing, 2004, Retrovirology, V1, P15, DOI 10.1186/1742-4690-1-15
NR 60
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD AUG
PY 2020
VL 10
IS 8
AR 1148
DI 10.3390/biom10081148
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OA5DI
UT WOS:000577805300001
PM 32764519
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, K
   Tian, ML
   Zeng, Y
   Wang, LW
   Luo, S
   Xia, W
   Zhang, XY
   Zha, Y
AF Zhang, Kui
   Tian, Maolu
   Zeng, Yang
   Wang, Linwen
   Luo, Sha
   Xia, Wei
   Zhang, Xiangyan
   Zha, Yan
TI The combined therapy of a traditional Chinese medicine formula and
   Western medicine for a critically ill case infected with COVID-19
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Chinese herbal medicine; COVID-19; SARS-CoV-2; Traditional Chinese
   medicine
ID WUHAN
AB Objective: Presentation of a case illustrating the benefits of traditional Chinese medicine (TCM) for treatment of Coronavirus disease 2019 (COVID-19) in critically ill patients.
   Clinical features and outcome: A 58-year-old woman presented with cough, fever, dizziness, chest tightness, polypnea and poor appetite. She was admitted to Guizhou Provincial People's hospital, and diagnosed with critically ill type of COVID-19 in February 2020. According to the patient's symptoms and signs, the TCM syndrome differentiation was qi deficiency, dampness-stasis and toxin accumulation. Then she received the combined therapy of a modified Chinese herbal formula and Western medicine. During a twelve-day period of treatment, her respiratory distress and appetite quickly improved. Abnormal laboratory indicators were resumed in time and lung lesions in CT scan largely absorbed. No side effects associated with this Chinese herbal formula were found. Before discharge, two consecutive nasopharyngeal swabs were shown to be negative for severe acute respiratory coronavirus 2 (SARS-CoV-2).
   Conclusions: Our case report suggests that collaborative treatments with traditional Chinese medicine prove beneficial in the management of COVID-19 in critically ill patients. In order to give optimal care for this COVID-19 crisis for the whole world, Chinese medicine practitioners and Western medical doctors should work together in frontline.
C1 [Zhang, Kui; Zeng, Yang; Wang, Linwen; Luo, Sha; Xia, Wei] Guizhou Prov Peoples Hosp, Dept Tradit Chinese Med, Guiyang, Guizhou, Peoples R China.
   [Tian, Maolu; Zha, Yan] Guizhou Prov Peoples Hosp, Inst Nephrit & Urinary Dis, Dept Nephrol, Guiyang, Guizhou, Peoples R China.
   [Zhang, Xiangyan] Guizhou Prov Peoples Hosp, Dept Pulm Med, NHC Key Lab Pulm Immunol Dis, Guiyang, Peoples R China.
RP Zha, Y (corresponding author), 83 Zhongshan East Rd, Guiyang 550002, Peoples R China.
EM zhayansy@163.com
FU National natural science foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81960892, 81160450]; Guizhou Clinical
   Research Center for Kidney Disease [QKHPTRC[2020]2201]
FX National natural science foundation of China -regional funds (81960892
   and 81160450); Guizhou Clinical Research Center for Kidney Disease
   (QKHPTRC[2020]2201).
CR Chan CC, 2020, CHIN J INTEGR MED, V26, P59, DOI 10.1007/s11655-019-3067-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2019, CHIN J INTEGR MED, V25, P922, DOI 10.1007/s11655-019-3033-7
   Cheng Q, 2020, TIANJIN J TRADIT CHI, P1
   Huang H, 2020, J HUNAN U CHIN MED, V40, P255
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu JP, 2004, J ALTERN COMPLEM MED, V10, P1041, DOI 10.1089/acm.2004.10.1041
   Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 0
Z9 0
U1 2
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD AUG
PY 2020
VL 52
AR 102473
DI 10.1016/j.ctim.2020.102473
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA OA1IW
UT WOS:000577549300027
PM 32951723
OA Green Published
DA 2021-01-01
ER

PT J
AU Alessandrini, F
   Caucci, S
   Onofri, V
   Melchionda, F
   Tagliabracci, A
   Bagnarelli, P
   Di Sante, L
   Turchi, C
   Menzo, S
AF Alessandrini, Federica
   Caucci, Sara
   Onofri, Valerio
   Melchionda, Filomena
   Tagliabracci, Adriano
   Bagnarelli, Patrizia
   Di Sante, Laura
   Turchi, Chiara
   Menzo, Stefano
TI Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive
   Parallel Sequencing
SO GENES
LA English
DT Article
DE SARS-CoV-2; viral genome; massively parallel sequencing; nasopharyngeal
   swab; COVID-19
AB Deep knowledge of the genetic features of SARS-CoV-2 is essential to track the ongoing pandemic through different geographical areas and to design and develop early diagnostic procedures, therapeutic strategies, public health interventions, and vaccines. We describe protocols and first results of the Ion AmpliSeq (TM) SARS-CoV-2 Research Panel by a massively parallel sequencing (MPS) assay. The panel allows for targeted sequencing by overlapping amplicons, thereby providing specific, accurate, and high throughput analysis. A modified reverse transcription reaction, which consists of the use of a SARS-CoV-2 specific primers pool from the Ion AmpliSeq SARS-CoV-2 Research Panel, was assessed in order to promote viral RNA specific reverse transcription. The aim of this study was to evaluate the effectiveness of the Ion AmpliSeq (TM) SARS-CoV-2 Research Panel in sequencing the entire viral genome in different samples. SARS-CoV-2 sequence data were obtained from ten viral isolates and one nasopharyngeal swab from different patients. The ten isolate samples amplified with 12 PCR cycles displayed high mean depth values compared to those of the two isolates amplified with 20 PCR cycles. High mean depth values were also obtained for the nasopharyngeal swab processed by use of a target-specific reverse transcription. The relative depth of coverage (rDoC) analysis showed that when 12 PCR cycles were used, all target regions were amplified with high sequencing coverage, while in libraries amplified at 20 cycles, a poor uniformity of amplification, with absent or low coverage of many target regions, was observed. Our results show that the Ion AmpliSeq SARS-CoV-2 Research Panel can achieve rapid and high throughput SARS-CoV-2 whole genome sequencing from 10 ng of DNA-free viral RNA from isolates and from 1 ng of DNA-free viral RNA from a nasopharyngeal swab using 12 PCR cycles for library amplification. The modified RT-PCR protocol yielded superior results on the nasopharyngeal swab compared to the reverse transcription reaction set up according to the manufacturer's instructions.
C1 [Alessandrini, Federica; Melchionda, Filomena; Tagliabracci, Adriano; Turchi, Chiara] Polytech Univ Marche, Dept Biomed Sci & Publ Hlth, Legal Med Unit, I-60126 Ancona, Italy.
   [Caucci, Sara; Bagnarelli, Patrizia; Di Sante, Laura; Menzo, Stefano] Polytech Univ Marche, Dept Biomed Sci & Publ Hlth, Virol Unit, I-60126 Ancona, Italy.
   [Onofri, Valerio] AOU Osped Riuniti, Legal Med Unit, I-60126 Ancona, Italy.
RP Turchi, C (corresponding author), Polytech Univ Marche, Dept Biomed Sci & Publ Hlth, Legal Med Unit, I-60126 Ancona, Italy.
EM f.alessandrini@univpm.it; s.caucci@pm.univpm.it;
   valerio.onofri@ospedaliriuniti.marche.it; f.melchionda@pm.univpm.it;
   a.tagliabracci@univpm.it; p.bagnarelli@staff.univpm.it;
   l.disante@staff.univpm.it; c.turchi@univpm.it; s.menzo@univpm.it
OI Tagliabracci, Adriano/0000-0002-4434-0475; Alessandrini,
   Federica/0000-0001-9066-0616; Menzo, Stefano/0000-0002-4425-3750;
   Turchi, Chiara/0000-0001-9211-810X
FU Fondo per il finanziamento di Dipartimenti universitari di eccellenza
   2018-2022 of Department of Biomedical Sciences and Public Health,
   Polytechnic University of Marche
FX This research received financial support from "Fondo per il
   finanziamento di Dipartimenti universitari di eccellenza 2018-2022 of
   Department of Biomedical Sciences and Public Health, Polytechnic
   University of Marche".
CR Bartolini B, 2020, EMERG INFECT DIS, V26, P1842, DOI 10.3201/eid2608.201525
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Capobianchi MR, 2020, CLIN MICROBIOL INFEC, V26, P954, DOI 10.1016/j.cmi.2020.03.025
   Goletic T., 2020, BIORXIV
   Karacan I, 2020, NORTH CLIN ISTANB, V7, P203, DOI 10.14744/nci.2020.90532
   Lai A., 2020, VIRUSES, V12, P798
   Licastro D, 2020, J VIROL, V94, DOI 10.1128/JVI.00543-20
   McNamara R.P., 2020, BIORXIV
   Rimoldi SG, 2020, SCI TOTAL ENVIRON, V744, DOI 10.1016/j.scitotenv.2020.140911
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao MF, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00751-4
   Zehender G, 2020, J MED VIROL, V92, P1637, DOI 10.1002/jmv.25794
NR 14
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD AUG
PY 2020
VL 11
IS 8
AR 929
DI 10.3390/genes11080929
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA OA6QN
UT WOS:000577907200001
PM 32806776
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, JA
AF Singh, Jerome Amir
TI The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; vaccine trials; ethics; public health; global health
ID MALARIA VACCINE; RACE; IMMUNOGENICITY; SAFETY
AB In response to provocative comments by 2 European clinicians and scientists, the World Health Organization Director General has declared that Africa will not host COVID-19 vaccine trials. Such a stance risks stigmatizing COVID-19 vaccine trials in Africa and depriving Africa of critical research. To the contrary, there is a critical need for Africa to host COVID-19 vaccine trials on public health, scientific, and ethics grounds.
C1 [Singh, Jerome Amir] Ctr AIDS Programme Res South Africa, Durban, South Africa.
RP Singh, JA (corresponding author), Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.
EM singhj9@ukzn.ac.za
OI Singh, Jerome Amir/0000-0002-6275-6853
FU Centre for the AIDS Programme of Research in South Africa; HIV
   Prevention Trial Network; Bill and Melinda Gates FoundationBill &
   Melinda Gates Foundation
FX J. A. S. is supported by the Centre for the AIDS Programme of Research
   in South Africa; the HIV Prevention Trial Network; and the Bill and
   Melinda Gates Foundation. No specific funding was received for writing
   this article.
CR [Anonymous], 2020, DRAFT LANDSC COVID 1
   Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6
   BBC, 2020, BBC
   Behr M., 2020, IOL             0425
   Braveman P, 2003, J EPIDEMIOL COMMUN H, V57, P254, DOI 10.1136/jech.57.4.254
   Busari S, 2020, CNN
   CHRISTY C, 1995, PEDIATRICS, V96, P584
   CIOMS, 2016, INT ETH GUID HLTH RE
   Cleary K., 2020, SPOTLIGHT
   Du SQ, 2020, J MED VIROL, V92, P1615, DOI 10.1002/jmv.25866
   Editorial Staff, 2020, AFRICAN BRIEFIN 0424
   Euronews and AP, 2020, EURONEWS AP     0404
   Express, 2020, EXPRESS
   Pollitt KJG, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00267-3
   Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004
   Goussanou W., 2020, SCIDEVNET
   Haralambieva LH, 2014, VACCINE, V32, P1946, DOI 10.1016/j.vaccine.2014.01.090
   Ho U., 2020, DAILY MAVERICK
   Hosseinipour Mina C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciz1239
   Institute for Health Metrics and Evaluation (IHME, 2018, FIND GLOB BURD DIS S
   Kurupati R, 2016, ONCOTARGET, V7, P62898, DOI 10.18632/oncotarget.11704
   McQuillan GM, 2007, J INFECT DIS, V196, P1459, DOI 10.1086/522866
   Namubiru L., 2020, GUARDIAN
   National Institutes of Health, 2019, GUID REV INCL BAS SE
   Ndwandwe D, 2020, HUM VACC IMMUNOTHER, V16, P972, DOI 10.1080/21645515.2019.1693720
   Nigeria National Centre for Disease Control, 2020, UPD COVID 2019 OUTBR
   Pelak K, 2010, J INFECT DIS, V201, P1141, DOI 10.1086/651382
   Pratt B, 2019, J EMPIR RES HUM RES, V14, P169, DOI 10.1177/1556264619833858
   Quach H, 2016, CELL, V167, P643, DOI 10.1016/j.cell.2016.09.024
   SHARMA S, 2020, VIRUSES-BASEL, V12, DOI DOI 10.3390/V12030324
   Singh JA, 2020, S AFR MED J, V110
   Stoute JA, 2006, AM J TROP MED HYG, V75, P166, DOI 10.4269/ajtmh.2006.75.166
   Tadokera R, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4828-z
   Thera MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001465
   United Nations Economic Commission for Africa, 2020, COVID 19 AFR PROT LI
   United Nations Economic Commission for Africa (UNECA), 2020, TRAD POL AFR TACKL C
   United Nations Human Settlements Programme (UN-Habitat), 2016, WORLD CIT REP 2016 U
   WMA, 2013, WMA DECL HELS ETH PR
   World Health Organization, 2019, WORLD HLTH STAT 2019
   Zuckerman D., 2009, PENN CTR GUIDE BIOET, P243
NR 40
TC 1
Z9 1
U1 3
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2020
VL 222
IS 3
BP 351
EP 355
DI 10.1093/infdis/jiaa303
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5VC
UT WOS:000577172300003
PM 32492144
OA Green Published
DA 2021-01-01
ER

PT J
AU Malkovsky, M
AF Malkovsky, Miroslav
TI Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy
   for Severe Coronavirus Disease 2019
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Malkovsky, Miroslav] Univ Wisconsin, Dept Med Microbiol & Immunol, Sch Med & Publ Hlth, 1550 Linden Dr, Madison, WI 53706 USA.
RP Malkovsky, M (corresponding author), Univ Wisconsin, Dept Med Microbiol & Immunol, Sch Med & Publ Hlth, 1550 Linden Dr, Madison, WI 53706 USA.
EM mmalkovs@wisc.edu
OI Malkovsky, Miroslav/0000-0002-5056-5224
CR Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Knaup H, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2220-9
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
NR 9
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2020
VL 222
IS 3
BP 509
EP 510
DI 10.1093/infdis/jiaa312
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5VC
UT WOS:000577172300021
PM 32473010
OA Green Published
DA 2021-01-01
ER

PT J
AU Zeng, QL
   Ji, FP
   Zhang, JY
AF Zeng, Qing-Lei
   Ji, Fanpu
   Zhang, Ji-Yuan
TI Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy
   for Severe Coronavirus Disease 2019 Response
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
DE Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19);
   Mortality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);
   Survival rate; Viral shedding
C1 [Zeng, Qing-Lei] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Eastern Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Ji, Fanpu] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Infect Dis, Xian, Shaanxi, Peoples R China.
   [Zhang, Ji-Yuan] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Treatment & Res Ctr Infect Dis, Beijing, Peoples R China.
RP Zeng, QL (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Eastern Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
EM zengqinglei2009@163.com
RI Zeng, Qing-Lei/ABD-6706-2020; Zeng, Qing-Lei/ABG-3295-2020
OI Zeng, Qing-Lei/0000-0002-2094-4784; 
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970517]; Zhongyuan (Henan) Thousand
   Outstanding Talents Plan [ZYQR201912179]; Foundation for Distinguished
   Young Talents of Zhengzhou University Medical School [2020ZQLMS]; Key
   Scientific Research Project of Henan Higher Education Institutions of
   China [20B320028]
FX This work was supported by the National Natural Science Foundation of
   China (grant 81970517), Zhongyuan (Henan) Thousand Outstanding Talents
   Plan (grant ZYQR201912179), the Foundation for Distinguished Young
   Talents of Zhengzhou University Medical School (grant 2020ZQLMS), and
   the Key Scientific Research Project of Henan Higher Education
   Institutions of China (grant 20B320028).
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Rubin R, 2020, JAMA-J AM MED ASSOC, V323, P2114, DOI 10.1001/jama.2020.7456
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
NR 10
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2020
VL 222
IS 3
BP 510
EP 511
DI 10.1093/infdis/jiaa313
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5VC
UT WOS:000577172300022
PM 32473012
OA Green Published
DA 2021-01-01
ER

PT J
AU Dawson, L
   Earl, J
   Livezey, J
AF Dawson, Liza
   Earl, Jake
   Livezey, Jeffrey
TI Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials:
   Too Risky, Too Soon
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
DE SARS-CoV-2; COVID-19; coronavirus; vaccines; human challenge studies;
   risk-taking; public trust; ethics
C1 [Dawson, Liza; Earl, Jake] Walter Reed Army Inst Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
   [Livezey, Jeffrey] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA.
RP Dawson, L (corresponding author), Walter Reed Army Inst Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
EM liza.dawson.civ@mail.mil
CR 1 Day Sooner, COVID 19 HUM CHALL T
   Bennett JW, 2013, NEW ENGL J MED, V369, P1381, DOI 10.1056/NEJMc1301936
   Bidad N, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1550-7
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Elliott C, 2008, NEW ENGL J MED, V358, P2316, DOI 10.1056/NEJMp0801872
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Fernandez Lynch H, 2020, BIOETHICS, DOI 10.1111/bioe.12704
   Innis BL, 2019, VACCINE, V37, P4823, DOI 10.1016/j.vaccine.2019.06.080
   Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2
   Khamsi R, 2020, NATURE, V580, P578, DOI 10.1038/d41586-020-01063-8
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   McDonald M, 2008, J EMPIR RES HUM RES, V3, P35, DOI 10.1525/jer.2008.3.4.35
   Miller FG, 2009, J MED ETHICS, V35, P445, DOI 10.1136/jme.2008.026062
   Onishi N, 2015, NY TIMES
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rozynska J, 2015, BIOETHICS, V29, P451, DOI 10.1111/bioe.12146
   Simon AE, 2007, AM J PREV MED, V32, P370, DOI 10.1016/j.amepre.2007.01.007
   Steinbrook R., 2008, OXFORD TXB CLIN RES, P110
   Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278
   Thaler R. H., 2009, NUDGE IMPROVING DECI
   Vekemans J, 2009, VACCINE, V27, pG67, DOI 10.1016/j.vaccine.2009.10.013
   Walker RL, 2018, J MED PHILOS, V43, P83, DOI 10.1093/jmp/jhx033
NR 24
TC 3
Z9 3
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2020
VL 222
IS 3
BP 514
EP 516
DI 10.1093/infdis/jiaa314
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5VC
UT WOS:000577172300025
PM 32496536
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mazzini, S
   Musso, L
   Dallavalle, S
   Artali, R
AF Mazzini, Stefania
   Musso, Loana
   Dallavalle, Sabrina
   Artali, Roberto
TI Putative SARS-CoV-2 M(pro)Inhibitors from an In-House Library of Natural
   and Nature-Inspired Products: A Virtual Screening and Molecular Docking
   Study
SO MOLECULES
LA English
DT Article
DE COVID-19; coronavirus; infectious diseases; natural products library;
   molecular docking; molecular modeling
ID PARTICLE MESH EWALD; FORCE-FIELD; DYNAMICS; VISUALIZATION; CAMPTOTHECIN;
   OPTIMIZATION; GROMACS; DESIGN
AB A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has been the cause of a recent global pandemic. The highly contagious nature of this life-threatening virus makes it imperative to find therapies to counteract its diffusion. The main protease (M-pro) of SARS-CoV-2 is a promising drug target due to its indispensable role in viral replication inside the host. Using a combined two-steps approach of virtual screening and molecular docking techniques, we have screened an in-house collection of small molecules, mainly composed of natural and nature-inspired compounds. The molecules were selected with high structural diversity to cover a wide range of chemical space into the enzyme pockets. Virtual screening experiments were performed using the blind docking mode of the AutoDock Vina software. Virtual screening allowed the selection of structurally heterogeneous compounds capable of interacting effectively with the enzymatic site of SARS-CoV-2 M-pro. The compounds showing the best interaction with the protein were re-scored by molecular docking as implemented in AutoDock, while the stability of the complexes was tested by molecular dynamics. The most promising candidates revealed a good ability to fit into the protein binding pocket and to reach the catalytic dyad. There is a high probability that at least one of the selected scaffolds could be promising for further research
C1 [Mazzini, Stefania; Musso, Loana; Dallavalle, Sabrina] Univ Milan, Dept Food Environm & Nutr Sci, Via Celoria 2, I-20133 Milan, Italy.
   [Artali, Roberto] Scientia Advice Roberto Artali, I-20832 Desio, MB, Italy.
RP Dallavalle, S (corresponding author), Univ Milan, Dept Food Environm & Nutr Sci, Via Celoria 2, I-20133 Milan, Italy.
EM stefania.mazzini@unimi.it; loana.musso@unimi.it;
   sabrina.dallavalle@unimi.it; roberto.artali@scientia-advice.com
OI Artali, Roberto/0000-0002-6289-5546; MAZZINI,
   STEFANIA/0000-0002-8220-0502
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Arun KG, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/10799893.2020.1715432, 10.1080/07391102.2020.1779819]
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bobrowski T., 2020, COMPUTATIONAL 1 MODE, P1, DOI [10.26434/chemrxiv.12153594.v1, DOI 10.26434/CHEMRXIV.12153594.V1]
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cananzi S, 2011, BIOORGAN MED CHEM, V19, P4971, DOI 10.1016/j.bmc.2011.06.056
   Cincinelli R, 2013, EUR J MED CHEM, V63, P387, DOI 10.1016/j.ejmech.2013.02.022
   Cincinelli R, 2011, TETRAHEDRON LETT, V52, P5972, DOI 10.1016/j.tetlet.2011.08.143
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dal Pozzo A, 2010, BIOORGAN MED CHEM, V18, P64, DOI 10.1016/j.bmc.2009.11.019
   Dallavalle S, 2001, J MED CHEM, V44, P3264, DOI 10.1021/jm0108092
   Dallavalle S, 2006, J MED CHEM, V49, P5177, DOI 10.1021/jm060285b
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dassault Systemes BIOVIA, 2019, DASS SYST BIOVIA BIO
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dhavan AA, 2016, BEILSTEIN J ORG CHEM, V12, P1624, DOI 10.3762/bjoc.12.159
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Gul S., 2020, SILICO IDENTIFICATIO, P1, DOI [10.26434/chemrxiv.12123204, DOI 10.26434/CHEMRXIV.12123204]
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Li Z, 2020, FEP BASED SCREENING, DOI [10.1101/2020.03.23.004580, DOI 10.1101/2020.03.23.004580]
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Maier H., 2015, METHOD MOL BIOL, P1282
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851
   Oprea TI, 2000, J COMPUT AID MOL DES, V14, P251, DOI 10.1023/A:1008130001697
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rackers JA, 2018, J CHEM THEORY COMPUT, V14, P5273, DOI 10.1021/acs.jctc.8b00529
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Satija N, 2007, ANN NY ACAD SCI, V1102, P26, DOI 10.1196/annals.1408.002
   Sekiou O., 2020, PREPRINT, DOI [10.26434/chemrxiv.12181404.v1, DOI 10.26434/CHEMRXIV.12181404.V1]
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Singam E.R.A., 2020, STRUCTURE BASED VIRT, P1, DOI [10.26434/chemrxiv.12143394.v1, DOI 10.26434/CHEMRXIV.12143394.V1]
   SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19
   STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208
   Sunil K., 2010, MOL BIOL SARS COR
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsuji M, 2020, FEBS OPEN BIO, V10, P995, DOI 10.1002/2211-5463.12875
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
NR 59
TC 2
Z9 2
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2020
VL 25
IS 16
AR 3745
DI 10.3390/molecules25163745
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OA4XC
UT WOS:000577789100001
PM 32824454
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nilsson, MI
   Mikhail, A
   Lan, L
   Di Carlo, A
   Hamilton, B
   Barnard, K
   Hettinga, BP
   Hatcher, E
   Tarnopolsky, MG
   Nederveen, JP
   Bujak, AL
   May, L
   Tarnopolsky, MA
AF Nilsson, Mats I.
   Mikhail, Andrew
   Lan, Lucy
   Di Carlo, Alessia
   Hamilton, Bethanie
   Barnard, Kristin
   Hettinga, Bart P.
   Hatcher, Erin
   Tarnopolsky, Milla G.
   Nederveen, Joshua P.
   Bujak, Adam L.
   May, Linda
   Tarnopolsky, Mark A.
TI A Five-Ingredient Nutritional Supplement and Home-Based Resistance
   Exercise Improve Lean Mass and Strength in Free-Living Elderly
SO NUTRIENTS
LA English
DT Article
DE sarcopenia; resistance exercise; multi-ingredient supplement; whey;
   creatine; omega-3; vitamin D; randomized clinical trial; COVID-19
ID DIFFERENT FIBER TYPES; SKELETAL-MUSCLE; OLDER-ADULTS; PHYSICAL-ACTIVITY;
   PROTEIN-SYNTHESIS; GRIP STRENGTH; ANABOLIC RESPONSE; VITAMIN-D;
   SARCOPENIA; RISK
AB Old age is associated with lower physical activity levels, suboptimal protein intake, and desensitization to anabolic stimuli, predisposing for age-related muscle loss (sarcopenia). Although resistance exercise (RE) and protein supplementation partially protect against sarcopenia under controlled conditions, the efficacy of home-based, unsupervised RE (HBRE) and multi-ingredient supplementation (MIS) is largely unknown. In this randomized, placebo-controlled and double-blind trial, we examined the effects of HBRE/MIS on muscle mass, strength, and function in free-living, older men. Thirty-two sedentary men underwent twelve weeks of home-based resistance band training (3 d/week), in combination with daily intake of a novel five-nutrient supplement ('Muscle5'; M5,n= 16, 77.4 +/- 2.8 y) containing whey, micellar casein, creatine, vitamin D, and omega-3 fatty acids, or an isocaloric/isonitrogenous placebo (PLA;n= 16, 74.4 +/- 1.3 y), containing collagen and sunflower oil. Appendicular and total lean mass (ASM; +3%, TLM; +2%), lean mass to fat ratios (ASM/% body fat; +6%, TLM/% body fat; +5%), maximal strength (grip; +8%, leg press; +17%), and function (5-Times Sit-to-Stand time; -9%) were significantly improved in the M5 group following HBRE/MIS therapy (pre vs. post tests;p< 0.05). Fast-twitch muscle fiber cross-sectional areas of the quadriceps muscle were also significantly increased in the M5 group post intervention (Type IIa; +30.9%, Type IIx, +28.5%,p< 0.05). Sub-group analysis indicated even greater gains in total lean mass in sarcopenic individuals following HBRE/MIS therapy (TLM; +1.65 kg/+3.4%,p< 0.05). We conclude that the Muscle5 supplement is a safe, well-tolerated, and effective complement to low-intensity, home-based resistance exercise and improves lean mass, strength, and overall muscle quality in old age.
C1 [Nilsson, Mats I.; Mikhail, Andrew; Lan, Lucy; Di Carlo, Alessia; Hamilton, Bethanie; Barnard, Kristin; Hatcher, Erin; Tarnopolsky, Milla G.; Nederveen, Joshua P.; May, Linda; Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat, Med Ctr, Hamilton, ON L8N 3Z5, Canada.
   [Nilsson, Mats I.; Hettinga, Bart P.; Bujak, Adam L.; Tarnopolsky, Mark A.] McMaster Univ, Exerkine Corp, Med Ctr, Hamilton, ON L8N 3Z5, Canada.
   [Mikhail, Andrew] McMaster Univ, Dept Kinesiol, Hamilton, ON L8N 3Z5, Canada.
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Dept Pediat, Med Ctr, Hamilton, ON L8N 3Z5, Canada.; Tarnopolsky, MA (corresponding author), McMaster Univ, Exerkine Corp, Med Ctr, Hamilton, ON L8N 3Z5, Canada.
EM mnilsson7714@gmail.com; mikhaiai@mcmaster.ca; lucy.lan2012@gmail.com;
   dicarlae@mcmaster.ca; hamiltob@mcmaster.ca; barnardk@hhsc.ca;
   adambujak01@gmail.com; hatchere@hhsc.ca; millaskier@gmail.com;
   nedervj@mcmaster.ca; adambujak01@gmail.com; maylind@mcmaster.ca;
   tarnopol@mcmaster.ca
OI Lan, Lucy/0000-0003-4474-6018; Nilsson, Mats/0000-0001-5656-5578;
   tarnopolsky, mark/0000-0003-0312-3746
FU Buck Institute [2017-0471]; CIHRCanadian Institutes of Health Research
   (CIHR) [143325]; Ontario Graduate Scholarship (OGS)Ontario Graduate
   Scholarship; CIHR Canada Graduate Scholarship (CGS)Canadian Institutes
   of Health Research (CIHR)
FX This work was supported by Buck Institute 2017-0471/Astellas
   Pharmaceuticals (baseline data only), and a CIHR grant (#143325) awarded
   to MAT (full study). Exerkine Corporation provided support in the form
   of salaries for authors M.I.N., B.P.H. and A.L.B. The specific roles of
   these authors are articulated in the author contributions section. A.M.
   received an Ontario Graduate Scholarship (OGS) and CIHR Canada Graduate
   Scholarship (CGS) during the course of the study. The funders of this
   study did not have additional roles in the study design, data collection
   and analyses, decision to publish, or preparation of the manuscript.
CR Agborsangaya CB, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1161
   Alway SE, 2008, EXERC SPORT SCI REV, V36, P51, DOI 10.1097/JES.0b013e318168e9dc
   Alway SE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00246
   Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Atherton PJ, 2010, AMINO ACIDS, V38, P1533, DOI 10.1007/s00726-009-0377-x
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   Barazzoni R, 2020, CLIN NUTR, V39, P1631, DOI 10.1016/j.clnu.2020.03.022
   Barbat-Artigas S., 2016, J NUTR HEALTH AGING, V16, P67
   Barberi L, 2013, BIOGERONTOLOGY, V14, P273, DOI 10.1007/s10522-013-9429-4
   Beaudart C, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0349-4
   Beaudart C, 2014, J CLIN ENDOCR METAB, V99, P4336, DOI 10.1210/jc.2014-1742
   Bell KE, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00107
   Bell KE, 2018, APPL PHYSIOL NUTR ME, V43, P299, DOI 10.1139/apnm-2017-0533
   Bell KE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181387
   Bello-Chavolla O.Y., 2020, J CLIN ENDOCR METAB, V105
   Benardot D, 2016, MED SCI SPORT EXER, V48, P543
   Bloemberg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035273
   BORTZ WM, 1984, WESTERN J MED, V141, P691
   Breen L, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-68
   Brose A, 2003, J GERONTOL A-BIOL, V58, P11
   Candow DG, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00124
   Cermak NM, 2012, AM J CLIN NUTR, V96, P1454, DOI 10.3945/ajcn.112.037556
   Cesari M, 2005, J AM GERIATR SOC, V53, P1675, DOI 10.1111/j.1532-5415.2005.53501.x
   Cesari M, 2009, J AM GERIATR SOC, V57, P251, DOI 10.1111/j.1532-5415.2008.02126.x
   Churchward-Venne TA, 2014, BIOFACTORS, V40, P199, DOI 10.1002/biof.1138
   Cimas M, 2018, EUR J PAIN, V22, P333, DOI 10.1002/ejp.1123
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Constandt B, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114144
   Crozier SJ, 2005, J NUTR, V135, P376
   Cruz-Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169
   Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   DEFRONZO RA, 1981, DIABETES CARE, V4, P493, DOI 10.2337/diacare.4.4.493
   Dickinson JM, 2013, EXERC SPORT SCI REV, V41, P216, DOI 10.1097/JES.0b013e3182a4e699
   Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003
   Drey M, 2011, WIEN MED WOCHENSCHR, V161, P402, DOI 10.1007/s10354-011-0002-y
   Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589
   FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029
   FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501
   Fielding RA, 2002, J AM GERIATR SOC, V50, P655, DOI 10.1046/j.1532-5415.2002.50159.x
   Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003
   Fitz Gerald S.J., 2004, J PHYS ACT HEALTH, V1, P7, DOI DOI 10.1123/JPAH.1.1.7
   Fry CS, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-11
   Gorissen SHM, 2018, P NUTR SOC, V77, P20, DOI [10.1017/S002966511700194X, 10.1017/s002966511700194x]
   Granacher U, 2013, SPORTS MED, V43, P627, DOI 10.1007/s40279-013-0041-1
   GRIMBY G, 1992, J APPL PHYSIOL, V73, P2517
   Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221
   Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221
   Hamer M, 2020, BRAIN BEHAV IMMUN, V87, P184, DOI 10.1016/j.bbi.2020.05.059
   Hirani V, 2015, J AM MED DIR ASSOC, V16, P607, DOI 10.1016/j.jamda.2015.02.006
   Hofmann M, 2016, EUR J APPL PHYSIOL, V116, P885, DOI 10.1007/s00421-016-3344-8
   Howe TE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000333.pub2
   Howe TE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004963.pub3
   Hunter GR, 2004, SPORTS MED, V34, P329, DOI 10.2165/00007256-200434050-00005
   Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x
   Katzmarzyk PT, 2002, MED SCI SPORT EXER, V34, P740, DOI 10.1097/00005768-200205000-00002
   Kreider RB, 2017, J INT SOC SPORT NUTR, V14, DOI 10.1186/s12970-017-0173-z
   Kryger AI, 2007, SCAND J MED SCI SPOR, V17, P422, DOI 10.1111/j.1600-0838.2006.00575.x
   Kumar V, 2009, J PHYSIOL-LONDON, V587, P211, DOI 10.1113/jphysiol.2008.164483
   Lacroix A, 2017, SPORTS MED, V47, P2341, DOI 10.1007/s40279-017-0747-6
   Landi F, 2013, AGE AGEING, V42, P203, DOI 10.1093/ageing/afs194
   Landi F, 2012, CLIN NUTR, V31, P652, DOI 10.1016/j.clnu.2012.02.007
   LEXELL J, 1983, MUSCLE NERVE, V6, P588, DOI 10.1002/mus.880060809
   LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3
   Liao CD, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007115
   Liu CJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002759.pub2
   Liu-Ambrose T, 2004, J AM GERIATR SOC, V52, P657, DOI 10.1111/j.1532-5415.2004.52200.x
   Lugaresi R, 2013, J INT SOC SPORT NUTR, V10, DOI 10.1186/1550-2783-10-26
   Martin SA, 2009, EXERC SPORT SCI REV, V37, P157, DOI 10.1097/JES.0b013e3181b7b57b
   Maruya Kohei, 2016, J Phys Ther Sci, V28, P3183
   Marzetti E, 2006, EXP GERONTOL, V41, P1234, DOI 10.1016/j.exger.2006.08.011
   Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5
   Mazzetti SA, 2000, MED SCI SPORT EXER, V32, P1175, DOI 10.1097/00005768-200006000-00023
   Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000465
   Metter EJ, 2002, J GERONTOL A-BIOL, V57, pB359, DOI 10.1093/gerona/57.10.B359
   Moreira-Pfrimer LDF, 2009, ANN NUTR METAB, V54, P291, DOI 10.1159/000235874
   Morton RW, 2018, BRIT J SPORT MED, V52, P376, DOI 10.1136/bjsports-2017-097608
   Naclerio F, 2016, SPORTS MED, V46, P125, DOI 10.1007/s40279-015-0403-y
   Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009
   Nieman DC, 2011, BRIT J SPORT MED, V45, P987, DOI 10.1136/bjsm.2010.077875
   Nilsson MI, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020040
   Nilsson MI, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210863
   O'Bryan KR, 2020, BRIT J SPORT MED, V54, P573, DOI 10.1136/bjsports-2018-099889
   Oesen S, 2015, EXP GERONTOL, V72, P99, DOI 10.1016/j.exger.2015.08.013
   Orr R, 2006, J GERONTOL A-BIOL, V61, P78, DOI 10.1093/gerona/61.1.78
   Peterson MD, 2011, MED SCI SPORT EXER, V43, P249, DOI 10.1249/MSS.0b013e3181eb6265
   Peterson MD, 2010, AGEING RES REV, V9, P226, DOI 10.1016/j.arr.2010.03.004
   Phillips SM, 2016, APPL PHYSIOL NUTR ME, V41, P565, DOI 10.1139/apnm-2015-0550
   Power SE, 2014, J NUTR HEALTH AGING, V18, P561, DOI 10.1007/s12603-014-0449-9
   Rantanen T, 1999, JAMA-J AM MED ASSOC, V281, P558, DOI 10.1001/jama.281.6.558
   Reidy PT, 2013, J NUTR, V143, P410, DOI 10.3945/jn.112.168021
   Roberts HC, 2011, AGE AGEING, V40, P423, DOI 10.1093/ageing/afr051
   Roberts KC, 2015, HEALTH PROMOT CHRON, V35, DOI 10.24095/hpcdp.35.6.01
   Rolland Y, 2011, CLIN GERIATR MED, V27, P423, DOI 10.1016/j.cger.2011.03.008
   Roubenoff R, 2001, CAN J APPL PHYSIOL, V26, P78, DOI 10.1139/h01-006
   Sandri M, 2013, BIOGERONTOLOGY, V14, P303, DOI 10.1007/s10522-013-9432-9
   Santilli V, 2014, CLIN CASES MINER BON, V11, P177, DOI 10.11138/ccmbm/2014.11.3.177
   Sasaki H, 2007, AM J MED, V120, P337, DOI 10.1016/j.amjmed.2006.04.018
   Simpson RJ, 2015, PROG MOL BIOL TRANSL, V135, P355, DOI 10.1016/bs.pmbts.2015.08.001
   Simpson RJ, 2012, AGEING RES REV, V11, P404, DOI 10.1016/j.arr.2012.03.003
   Smith Gordon I, 2016, Curr Nutr Rep, V5, P99, DOI 10.1007/s13668-016-0161-y
   Smith GI, 2011, AM J CLIN NUTR, V93, P402, DOI 10.3945/ajcn.110.005611
   Song Y, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082655
   Sousa-Santos AR, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0625-y
   Statistics Canada, 2018, TABL 13 10 0096 13 P
   Statistics Canada, 2018, TABL 13 10 0096 20 B
   Symons TB, 2011, J NUTR HEALTH AGING, V15, P376, DOI 10.1007/s12603-010-0319-z
   Tarnopolsky M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000991
   Tarnopolsky MA, 2008, APPL PHYSIOL NUTR ME, V33, P213, DOI 10.1139/H07-142
   Tarnopolsky MA, 2011, MUSCLE NERVE, V43, P717, DOI 10.1002/mus.21945
   Timmons JF, 2020, J AM GERIATR SOC, V68, P163, DOI 10.1111/jgs.16209
   Traylor DA, 2018, ADV NUTR, V9, P171, DOI 10.1093/advances/nmy003
   Tsekoura M, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120480
   Tudor-Locke C, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-80
   Turner JE, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4234765
   Van Ancum JM, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0812-5
   van Vliet S, 2015, J NUTR, V145, P1981, DOI 10.3945/jn.114.204305
   Volpi E, 2013, J GERONTOL A-BIOL, V68, P677, DOI 10.1093/gerona/gls229
   Wilkes EA, 2009, AM J CLIN NUTR, V90, P1343, DOI 10.3945/ajcn.2009.27543
   Wilkinson DJ, 2013, J PHYSIOL-LONDON, V591, P2911, DOI 10.1113/jphysiol.2013.253203
   Wilson TM, 2000, AM J PHYSIOL-HEART C, V278, pH829
   Woods JA, 2009, J AM GERIATR SOC, V57, P2183, DOI 10.1111/j.1532-5415.2009.02563.x
   Wyss M, 2000, PHYSIOL REV, V80, P1107
   Yan Z, 2020, REDOX BIOL, V32, DOI 10.1016/j.redox.2020.101508
   Zabetakis I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051466
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 125
TC 1
Z9 1
U1 9
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2020
VL 12
IS 8
AR 2391
DI 10.3390/nu12082391
PG 28
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA OA4ZX
UT WOS:000577796400001
PM 32785021
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mansour, O
   Keller, S
   Katz, M
   Townsend, JL
AF Mansour, Omar
   Keller, Sara
   Katz, Morgan
   Townsend, Jennifer L.
TI Outpatient Parenteral Antimicrobial Therapy in the Time of COVID-19: The
   Urgent Need for Better Insurance Coverage
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE coronavirus; home infusion; infection prevention; nursing homes;
   pandemic
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19), are placing unprecedented pressure on every health care system. Patients who require weeks of intravenous antibiotic therapy after hospital discharge due to severe bacterial infections, generally referred to as outpatient parenteral antibiotic therapy (OPAT), are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the health care system. To reduce the risk of COVID-19 among this vulnerable patient population, providers overseeing OPAT care need to consider the relative safety of the different OPAT sites of care. Home-based OPAT should be emphasized to minimize hospital stays and prevent skilled nursing facility admissions. Medicare reimbursement policies need to urgently change to provide comprehensive coverage of home infusion services.
C1 [Mansour, Omar] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Mansour, Omar] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD USA.
   [Keller, Sara; Katz, Morgan] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   [Keller, Sara] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Keller, Sara] Johns Hopkins Univ, Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA.
   [Townsend, Jennifer L.] Johns Hopkins Bayview Med Ctr, Div Infect Dis, Baltimore, MD 21224 USA.
RP Townsend, JL (corresponding author), Johns Hopkins Bayview Med Ctr, 5200 Eastern Ave,MFL Ctr Tower 381, Baltimore, MD 21224 USA.
EM jholme27@jhmi.edu
OI TOWNSEND, Jennifer/0000-0002-7587-3493; Keller, Sara/0000-0001-9660-4367
CR Barnett M.L., 2020, JAMA HLTH FORUM, V1, DOI [10.1001/jamahealthforum.2020.0369, DOI 10.1001/JAMAHEALTHFORUM.2020.0369]
   Centers for Disease Control and Prevention, PREP COVID 19 LONG T
   Centers for Disease Control and Prevention, COVID 19 RAC ETHN MI
   Hamad Y, ANN INTERN MED
   Hamad Y, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz363
   Keller S, 2015, CLIN INFECT DIS, V61, P1890, DOI 10.1093/cid/civ750
   Mansour O, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz471
   Mansour O, 2018, J ANTIMICROB CHEMOTH, V73, P3181, DOI 10.1093/jac/dky294
NR 8
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD AUG
PY 2020
VL 7
IS 8
AR ofaa287
DI 10.1093/ofid/ofaa287
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5UP
UT WOS:000577171000024
PM 32832575
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mertens, J
   Laghrib, Y
   Kenyon, C
AF Mertens, Jonathan
   Laghrib, Yassine
   Kenyon, Chris
TI A Case of Steroid-Responsive, COVID-19 Immune Reconstitution
   Inflammatory Syndrome Following the Use of Granulocyte
   Colony-Stimulating Factor
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE ARDS; COVID-19; granulocyte-colony stimulating factor; immune
   reconstitution inflammatory syndrome; IRIS; SARS-CoV-2
ID TUBERCULOSIS; TRIAL
AB We present a case report of a 54-year-old male with metastasized nasopharyngeal carcinoma presenting to the hospital with dyspnea, anorexia and fever. Examination revealed chemotherapy-induced pancytopenia. The patient tested positive for SARSCoV-2, but respiratory complications were mild. The patient was treated with granulocyte-colony stimulating factor (G-CSF) leading to amelioration of the neutropenia. However, severe acute respiratory distress syndrome (ARDS) occurred, prompting the diagnosis of immune reconstitution inflammatory syndrome (IRIS). GCSF is currently investigated as additional therapy in ARDS, but this case report emphasizes that risks and benefits must be carefully assessed. To our knowledge, this is the first case report of IRIS-induced ARDS in a COVID-19 patient.
C1 [Mertens, Jonathan; Laghrib, Yassine] Univ Hosp Antwerp, Dept Internal Med, Antwerp, Belgium.
   [Kenyon, Chris] Inst Trop Med, Dept Clin Sci, HIV STI Unit, Antwerp, Belgium.
   [Kenyon, Chris] Univ Cape Town, Div Infect Dis & HIV Med, Anzio Rd, ZA-7700 Observatory, South Africa.
RP Mertens, J (corresponding author), Univ Ziekenhuis Antwerpen, Antwerp, Belgium.
EM jonathan.mertens@student.uantwerpen.be
CR Calligaro G, 2011, CURR OPIN PULM MED, V17, P180, DOI 10.1097/MCP.0b013e328344f692
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Herold S, 2014, AM J RESP CRIT CARE, V189, P609, DOI 10.1164/rccm.201311-2041LE
   Heuser M, 2007, SEMIN HEMATOL, V44, P148, DOI 10.1053/j.seminhematol.2007.04.002
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   LECHNER AJ, 1994, AM J PHYSIOL, V266, pL561
   Lyman GH, 2018, ANN ONCOL, V29, P1903, DOI 10.1093/annonc/mdy311
   Lyman GH, 2013, ANN ONCOL, V24, P2475, DOI 10.1093/annonc/mdt226
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1
   Meintjes G, 2010, AIDS, V24, P2381, DOI 10.1097/QAD.0b013e32833dfc68
   Meintjes G, 2009, CLIN CHEST MED, V30, P797, DOI 10.1016/j.ccm.2009.08.013
   Meintjes G, 2008, CURR OPIN HIV AIDS, V3, P468, DOI 10.1097/COH.0b013e3282fe6e84
   Mhaskar R, 2014, COCHRANE DB SYST REV, V2014
   Nemunaitis J, 1997, DRUGS, V54, P709, DOI 10.2165/00003495-199754050-00004
   Paine R, 2012, CRIT CARE MED, V40, P90, DOI 10.1097/CCM.0b013e31822d7bf0
   Presneill JJ, 2002, AM J RESP CRIT CARE, V166, P138, DOI 10.1164/rccm.2009005
   Rosler Barbara, 2016, Mol Cell Pediatr, V3, P29, DOI 10.1186/s40348-016-0055-5
NR 18
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD AUG
PY 2020
VL 7
IS 8
AR ofaa376
DI 10.1093/ofid/ofaa376
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5UP
UT WOS:000577171000053
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rivera, CG
   Mahoney, MV
   Stevens, RW
   Abu Saleh, O
AF Rivera, Christina G.
   Mahoney, Monica, V
   Stevens, Ryan W.
   Abu Saleh, Omar
TI Out of Sight but Not Out of Mind: Caring for Patients Receiving OPAT
   During the SARS-CoV-2 Pandemic
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; OPAT; SARS-2-CoV
ID ANTIMICROBIAL THERAPY
AB In an effort to "flatten the curve" of SARS-CoV-2, society is urged to practice social distancing. However, the management of other disease states may require some patients to undergo outpatient parenteral antimicrobial therapy (OPAT). Practical considerations for OPAT management during an infectious pandemic are reviewed. These include shortening durations of therapy, utilizing the oral route, avoiding medications requiring therapeutic drug monitoring, selecting antimicrobials with long durations, decreasing frequency of laboratory blood draws, and performing tele-health visits.
C1 [Rivera, Christina G.; Stevens, Ryan W.] Mayo Clin, Dept Pharm, Rochester, MN USA.
   [Mahoney, Monica, V] Beth Israel Deaconess Med Ctr, Specialty Pharm, Boston, MA 02215 USA.
   [Abu Saleh, Omar] Mayo Clin, Div Infect Dis, Rochester, MN USA.
RP Rivera, CG (corresponding author), 200 First St SW, Rochester, MN 55905 USA.
EM rivera.christina@mayo.edu
OI Rivera, Christina/0000-0002-8308-3264
FU Mayo Clinic Midwest Pharmacy Research group
FX Mayo Clinic Midwest Pharmacy Research group provided funding of the
   publication fee.
CR Allison GM, 2014, CLIN INFECT DIS, V58, P812, DOI 10.1093/cid/cit920
   Chastre J, 2003, JAMA-J AM MED ASSOC, V290, P2588, DOI 10.1001/jama.290.19.2588
   Gjika E, 2019, ANN RHEUM DIS, V78, P1114, DOI 10.1136/annrheumdis-2019-215116
   Gordon AL, 2020, AGE AGEING, V49, P701, DOI 10.1093/ageing/afaa113
   Hamad Y, 2020, ANN INTERN MED
   Huck D, 2014, J ANTIMICROB CHEMOTH, V69, P228, DOI 10.1093/jac/dkt303
   Iversen K, 2019, NEW ENGL J MED, V380, P415, DOI 10.1056/NEJMoa1808312
   Johnson JA, 2015, OPEN FORUM INFECT DI, V2, pXXX
   Li HK, 2019, NEW ENGL J MED, V380, P425, DOI 10.1056/NEJMoa1710926
   Norris AH, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy745
   Rappo U, 2018, OPEN FORUM INFECT DI, V6, pXXX
   Sawyer RG, 2015, NEW ENGL J MED, V372, P1996, DOI 10.1056/NEJMoa1411162
   Schmidt M, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx086
   Seaton RA, 2019, J ANTIMICROB CHEMOTH, V74, P2119, DOI 10.1093/jac/dkz122
   Streifel AC, CLIN INFECT DIS
   Tan SJ, 2017, J ANTIMICROB CHEMOTH, V72, P2898, DOI 10.1093/jac/dkx203
   Wald-Dickler N, 2019, CLIN INFECT DIS, V69, P1476, DOI 10.1093/cid/ciy1134
   Yahav D, 2019, CLIN INFECT DIS, V69, P1091, DOI 10.1093/cid/ciy1054
NR 18
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD AUG
PY 2020
VL 7
IS 8
AR ofaa309
DI 10.1093/ofid/ofaa309
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5UP
UT WOS:000577171000044
PM 32782914
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Martorana, A
   Gentile, C
   Lauria, A
AF Martorana, Annamaria
   Gentile, Carla
   Lauria, Antonino
TI In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH
   Endogenous Defences in the Control of the Pandemic Coronavirus Infection
SO VIRUSES-BASEL
LA English
DT Article
DE coronavirus; COVID-19; SARS-CoV-2 main protease; DRUDIT web service;
   molecular docking; HIV-protease; NADH
ID INDUCED-FIT DOCKING; TISSUE DISTRIBUTION; ACCURATE DOCKING; RECEPTOR;
   GLIDE; PATHOGENESIS; DRUGS
AB COVID-19 is a pandemic health emergency faced by the entire world. The clinical treatment of the severe acute respiratory syndrome (SARS) CoV-2 is currently based on the experimental administration of HIV antiviral drugs, such as lopinavir, ritonavir, and remdesivir (a nucleotide analogue used for Ebola infection). This work proposes a repurposing process using a database containing approximately 8000 known drugs in synergy structure- and ligand-based studies by means of the molecular docking and descriptor-based protocol. The proposed in silico findings identified new potential SARS CoV-2 main protease (M-PRO) inhibitors that fit in the catalytic binding site of SARS CoV-2 M-PRO. Several selected structures are NAD-like derivatives, suggesting a relevant role of these molecules in the modulation of SARS CoV-2 infection in conditions of cell chronic oxidative stress. Increased catabolism of NAD(H) during protein ribosylation in the DNA damage repair process may explain the greater susceptibility of the elderly population to the acute respiratory symptoms of COVID-19. The molecular modelling studies proposed herein agree with this hypothesis.
C1 [Martorana, Annamaria; Gentile, Carla; Lauria, Antonino] Univ Palermo, Dipartimento Sci & Tecnol Biol Chim & Farmaceut, Viale Sci Ed 17, I-90128 Palermo, Italy.
RP Lauria, A (corresponding author), Univ Palermo, Dipartimento Sci & Tecnol Biol Chim & Farmaceut, Viale Sci Ed 17, I-90128 Palermo, Italy.
EM annamaria.martorana@unipa.it; carla.gentile@unipa.it;
   antonino.lauria@unipa.it
RI ; Lauria, Antonino/I-3412-2013
OI GENTILE, Carla/0000-0001-5861-3342; Lauria,
   Antonino/0000-0002-5116-6815; MARTORANA, Annamaria/0000-0002-9560-1882
CR [Anonymous], 2017, MAESTR VERS 10 2
   [Anonymous], 2017, SCHRODINGER RELEASE
   [Anonymous], 2017, SCHROD SUIT 2017 2 P
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P44879, DOI 10.18632/oncotarget.9821
   Kupferschmidt K., 2020, SCIENCE, DOI [10.11 26/science.abb8497, DOI 10.1126/SCIENCE.ABB8497, 10.1126/science.abb8497]
   Lamb NJ, 1999, CRIT CARE MED, V27, P1738, DOI 10.1097/00003246-199909000-00007
   Lauria A, 2020, BIOINFORMATICS, V36, P1562, DOI 10.1093/bioinformatics/btz783
   Lauria A, 2009, COMPUT BIOL CHEM, V33, P386, DOI 10.1016/j.compbiolchem.2009.07.010
   Lauria A, 2009, QSAR COMB SCI, V28, P387, DOI 10.1002/qsar.200810062
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo HJ, 2013, MED CHEM RES, V22, P4970, DOI 10.1007/s00044-013-0509-4
   Martorana A, 2016, CURR TOP MED CHEM, V16, P2088, DOI 10.2174/1568026616666160216153457
   Massudi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042357
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schmidt R, 2004, EUR RESPIR J, V24, P994, DOI 10.1183/09031936.04.00120703
   Sherman W, 2006, CHEM BIOL DRUG DES, V67, P83, DOI 10.1111/j.1747-0285.2005.00327.x
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Wang HW, 2008, J MOL GRAPH MODEL, V27, P512, DOI 10.1016/j.jmgm.2008.09.002
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yaku K, 2018, AGEING RES REV, V47, P1, DOI 10.1016/j.arr.2018.05.006
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong HZ, 2009, J MOL GRAPH MODEL, V28, P336, DOI 10.1016/j.jmgm.2009.08.012
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 36
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD AUG
PY 2020
VL 12
IS 8
AR 805
DI 10.3390/v12080805
PG 15
WC Virology
SC Virology
GA OC1UD
UT WOS:000578946500001
PM 32722574
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zar, HJ
   Moore, DP
   Andronikou, S
   Argent, AC
   Avenant, T
   Cohen, C
   Green, RJ
   Itzikowitz, G
   Jeena, P
   Nicol, MP
   Pillay, A
   Reubenson, G
   Masekela, R
   Madhi, SA
AF Zar, H. J.
   Moore, D. P.
   Andronikou, S.
   Argent, A. C.
   Avenant, T.
   Cohen, C.
   Green, R. J.
   Itzikowitz, G.
   Jeena, P.
   Nicol, M. P.
   Pillay, A.
   Reubenson, G.
   Masekela, R.
   Madhi, S. A.
TI Prevention of community-acquired pneumonia in children: South African
   Thoracic Society guidelines (part 4)
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; ANTIRETROVIRAL TREATMENT STRATEGIES;
   RESPIRATORY SYNCYTIAL VIRUS; HIV-INFECTED CHILDREN; VITAMIN-D; ISONIAZID
   PROPHYLAXIS; ZINC SUPPLEMENTATION; DEVELOPING-COUNTRIES; CHILDHOOD
   PNEUMONIA; UNINFECTED CHILDREN
AB Background. More comprehensive immunisation regimens, strengthening of HIV prevention and management programmes and improved socioeconomic conditions have impacted on the epidemiology of paediatric community-acquired pneumonia (CAP) in South Africa (SA).
   Objectives. To summarise effective preventive strategies to reduce the burden of childhood CAP.
   Methods. An expert subgroup reviewed existing SA guidelines and new publications focusing on prevention. Published evidence on pneumonia prevention informed the revisions; in the absence of evidence, expert opinion was used. Evidence was graded using the British Thoracic Society (BTS) grading system.
   Recommendations. General measures for prevention include minimising exposure to tobacco smoke or air pollution, breastfeeding, optimising nutrition, optimising maternal health from pregnancy onwards, adequate antenatal care and improvement in socioeconomic and living conditions. Prevention of viral transmission, including SARS-CoV-2, can be achieved by hand hygiene, environmental decontamination, use of masks and isolation of infected people. Specific preventive measures include vaccines as contained in the Expanded Programme on Immunisation schedule, isoniazid prophylaxis for tuberculosis, co-trimoxazole prophylaxis for HIV-infected infants and children who are immunosuppressed, and timely diagnosis of HIV, as well as antiretroviral therapy (ART) initiation. HIV-infected children treated with ART from early infancy, and HIV-exposed children, have similar immunogenicity and immune responses to most childhood vaccines as HIV-unexposed infants.
   Validation. These recommendations are based on available published evidence supplemented by the consensus opinion of SA paediatric experts, and are consistent with those in published international guidelines.
C1 [Zar, H. J.; Andronikou, S.; Argent, A. C.; Itzikowitz, G.] Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa.
   [Zar, H. J.; Andronikou, S.; Argent, A. C.; Itzikowitz, G.] Univ Cape Town, Fac Hlth Sci, Cape Town, South Africa.
   [Zar, H. J.] Univ Cape Town, South African Med Res Council, Unit Child & Adolescent Hlth, Cape Town, South Africa.
   [Moore, D. P.] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Dept Paediat & Child Hlth, Johannesburg, South Africa.
   [Moore, D. P.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [Andronikou, S.] Univ Penn, Dept Pediat Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Andronikou, S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Avenant, T.; Green, R. J.] Univ Pretoria, Dept Paediat & Child Hlth, Fac Hlth Sci, Pretoria, South Africa.
   [Cohen, C.] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa.
   [Jeena, P.; Pillay, A.; Masekela, R.] Univ KwaZulu Natal, Dept Paediat & Child Hlth, Nelson R Mandela Sch Med, Sch Clin Med,Coll Hlth Sci, Durban, South Africa.
   [Nicol, M. P.] Univ Cape Town, Div Med Microbiol, Dept Pathol, Fac Hlth Sci, Cape Town, South Africa.
   [Nicol, M. P.] Univ Western Australia, Sch Biomed Sci, Div Infect & Immun, Perth, WA, Australia.
   [Reubenson, G.] Univ Witwatersrand, Rahima Moosa Mother & Child Hosp, Dept Paediat & Child Hlth, Fac Hlth Sci, Johannesburg, South Africa.
   [Madhi, S. A.] Univ Witwatersrand, South African Med Res Council, Vaccine & Infect Dis Analyt Unit, Johannesburg, South Africa.
   [Madhi, S. A.] Univ Witwatersrand, Dept Sci & Technol, South African Res Chair Vaccine Preventable Dis, Natl Res Fdn,Fac Hlth Sci, Johannesburg, South Africa.
RP Zar, HJ (corresponding author), Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa.; Zar, HJ (corresponding author), Univ Cape Town, Fac Hlth Sci, Cape Town, South Africa.; Zar, HJ (corresponding author), Univ Cape Town, South African Med Res Council, Unit Child & Adolescent Hlth, Cape Town, South Africa.
EM heather.zar@uct.ac.za
RI ; Nicol, Mark/J-4987-2014
OI Avenant, Theunis/0000-0003-2367-6479; Nicol, Mark/0000-0002-1366-4805
FU South African Medical Research Council
FX HJZ and SAM are supported by the South African Medical Research Council.
CR Admasie A, 2018, J ENVIRON PUBLIC HEA, V2018, DOI 10.1155/2018/9320603
   Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005
   [Anonymous], 2008, Wkly Epidemiol Rec, V83, P373
   Barger-Kamate B, 2016, CLIN INFECT DIS, V63, pS187, DOI 10.1093/cid/ciw546
   Baumgartner J, 2011, INDOOR AIR, V21, P479, DOI 10.1111/j.1600-0668.2011.00730.x
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR
   Bhandari N, 2002, BRIT MED J, V324, P1358, DOI 10.1136/bmj.324.7350.1358
   Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7
   Bocchini JA, 2007, PEDIATRICS, V120, P650, DOI 10.1542/peds.2007-1734
   Brewer TF, 2000, CLIN INFECT DIS, V31, pS64, DOI 10.1086/314072
   Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829
   Charan J, 2012, J PHARMACOL PHARMACO, V3, P300, DOI 10.4103/0976-500X.103685
   Choudhary N, 2012, INDIAN PEDIATR, V49, P449, DOI 10.1007/s13312-012-0073-x
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Cohen C, 2018, CLIN INFECT DIS, V66, P95, DOI 10.1093/cid/cix740
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Daniels B, 2019, LANCET GLOB HEALTH, V7, pE1717, DOI 10.1016/S2214-109X(19)30422-X
   Doherty T, 2011, B WORLD HEALTH ORGAN, V89, P62, DOI 10.2471/BLT.10.079798
   Dzanibe S, 2017, J INFECT DIS, V215, P415, DOI 10.1093/infdis/jiw566
   Gibbs K, 2016, CHEST, V149, P552, DOI 10.1378/chest.15-1858
   Green RJ, 2010, SAMJ S AFR MED J, V100, P320, DOI 10.7196/SAMJ.4016
   Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hoest C, 2017, VACCINE, V35, P443, DOI 10.1016/j.vaccine.2016.11.075
   HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304
   Izu A, 2017, B WORLD HEALTH ORGAN, V95, P618, DOI 10.2471/BLT.16.187849
   Jallow S, 2017, J CLIN VIROL, V94, P50, DOI 10.1016/j.jcv.2017.07.009
   Jallow S, 2017, EXPERT REV VACCINES, V16, P453, DOI 10.1080/14760584.2017.1307740
   Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Kuhn L, 2015, S AFR J HIV MED, V16, P87, DOI [10.4102/SAJHIVMED.V16I1.377, 10.4102/sajhivmed.v16i1.377]
   Lamberti LM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S18
   Lee GY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111614
   Little P, 2015, LANCET, V386, P1631, DOI 10.1016/S0140-6736(15)60127-1
   Lockman S, 2017, LANCET GLOB HEALTH, V5, pE491, DOI [10.1016/S2214-109X(17)30143-2, 10.1016/s2214-109x(17)30143-2]
   Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038
   Madhi SA, 2005, PEDIATR INFECT DIS J, V24, P410, DOI 10.1097/01.inf.0000160942.84169.14
   Madhi SA, 2002, PEDIATR INFECT DIS J, V21, P393, DOI 10.1097/00006454-200205000-00009
   Madhi SA, 2007, VACCINE, V25, P2451, DOI 10.1016/j.vaccine.2006.09.019
   Madhi SA, 2013, AIDS, V27, P369, DOI 10.1097/QAD.0b013e32835ab5b2
   Madhi SA, 2011, NEW ENGL J MED, V365, P21, DOI 10.1056/NEJMoa1011214
   Madhi SA, 2010, J INFECT DIS, V202, P355, DOI 10.1086/653704
   Marlow R, 2018, VACCINE, V36, P2300, DOI 10.1016/j.vaccine.2018.03.021
   McAnerney JM, 2012, J INFECT DIS, V206, pS153, DOI 10.1093/infdis/jis575
   McIlleron H, 2017, J ANTIMICROB CHEMOTH, V72, P2028, DOI 10.1093/jac/dkx112
   Moore DP, 2010, PEDIATR INFECT DIS J, V29, P1099, DOI 10.1097/INF.0b013e3181eaefff
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Morris SK, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-106
   Mutsaerts EAML, 2019, J INFECT DIS, V220, P1529, DOI 10.1093/infdis/jiz348
   National Department of Health, 2019, 2019 ART CLIN GUID M
   Ntshoe GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055682
   Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531
   Nunes MC, 2016, JAMA PEDIATR, V170, P840, DOI 10.1001/jamapediatrics.2016.0921
   Oliwa JN, 2015, LANCET RESP MED, V3, P235, DOI 10.1016/S2213-2600(15)00028-4
   Omer SB, 2018, PEDIATR INFECT DIS J, V37, P436, DOI [10.1097/inf.0000000000001914, 10.1097/INF.0000000000001914]
   Schaaf HS, 2013, SAMJ S AFR MED J, V103, P714, DOI [10.7196/SAMJ.7189, 10.7196/samj.7189]
   Schaltz-Buchholzer F, 2019, J INFECT DIS, V219, P624, DOI 10.1093/infdis/jiy544
   Seddon JA, 2013, CLIN INFECT DIS, V57, P1676, DOI 10.1093/cid/cit655
   Simani OE, 2019, EXPERT REV VACCINES, V18, P95, DOI 10.1080/14760584.2019.1547195
   Simani OE, 2014, AIDS, V28, P531, DOI 10.1097/QAD.0000000000000127
   Simani OE, 2013, AIDS, V27, P1583, DOI 10.1097/QAD.0b013e32835fae26
   Soofie N, 2016, CLIN INFECT DIS, V63, pS165, DOI 10.1093/cid/ciw545
   Steyn K, 1997, S AFR MED J, V87, P460
   Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032
   Tsaban G, 2017, VACCINE, V35, P2882, DOI 10.1016/j.vaccine.2017.04.032
   van den Biggelaar AHJ, 2016, EXPERT REV VACCINES, V15, P69, DOI 10.1586/14760584.2016.1105136
   von Gottberg A, 2006, B WORLD HEALTH ORGAN, V84, P811, DOI 10.2471/BLT.06.030361
   von Gottberg A, 2012, VACCINE, V30, P565, DOI 10.1016/j.vaccine.2011.11.066
   Walker Jeanette H, 2004, J Emerg Nurs, V30, P367, DOI 10.1016/j.jen.2004.04.006
   Wang Y, 2018, HUM VACC IMMUNOTHER, V14, P1003, DOI 10.1080/21645515.2017.1409316
   Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110
   Wayse V, 2004, EUR J CLIN NUTR, V58, P563, DOI 10.1038/sj.ejcn.1601845
   WHO, 2019, WKLY EPIDEMIOL REC, V94, P85
   Willmott M, 2016, ARCH DIS CHILD, V101, P42, DOI 10.1136/archdischild-2015-308875
   World Health Organization, 2017, WKLY EPIDEMIOL REC, V92, P205
   World Health Organization, 1999, WHO GUID EP PREP RES
   Wright AL, 1998, PEDIATRICS, V101, P837, DOI 10.1542/peds.101.5.837
   Zar HJ, 2015, SAMJ S AFR MED J, V105, P525, DOI [10.7196/SAMJnew.8040, 10.7196/SAMJNEW.8040]
   Zar HJ, 2007, BRIT MED J, V334, P136, DOI 10.1136/bmj.39000.486400.55
NR 81
TC 1
Z9 1
U1 1
U2 1
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD AUG
PY 2020
VL 110
IS 8
BP 741
EP 746
DI 10.7196/SAMJ.2020.v110i8.15024
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ4YR
UT WOS:000577102900022
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Nnaji, CA
   Iwu, CJ
   Ndwandwe, DE
   Jordan, P
   Wiysonge, CS
AF Nnaji, C. A.
   Iwu, C. J.
   Ndwandwe, D. E.
   Jordan, P.
   Wiysonge, C. S.
TI Convalescent plasma or hyperimmune immunoglobulin for people with
   COVID-19
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
AB Convalescent plasma is being considered as a potential therapy for COVID-19. We highlight and contextualise the findings of a recent Cochrane rapid review that evaluated the effectiveness and safety of convalescent plasma or hyperimmune immunoglobulin transfusion in the treatment of people with COVID-19. The review found low-certainty evidence of the therapeutic effectiveness and safety of convalescent plasma. As the novel coronavirus continues to spread in South Africa (SA), convalescent plasma may offer a therapeutic ray of hope for mitigating the morbidity and mortality burdens of the disease. Further investigation of the clinical benefits of the therapy in well-designed studies is needed to provide more evidence that will guide COVID-19 treatment decision-making in the SA context.
C1 [Nnaji, C. A.; Ndwandwe, D. E.; Wiysonge, C. S.] South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.
   [Nnaji, C. A.; Wiysonge, C. S.] Univ Cape Town, Sch Publ Hlth & Family Med, Fac Hlth Sci, Cape Town, South Africa.
   [Iwu, C. J.; Jordan, P.] Stellenbosch Univ, Dept Nursing & Midwifery, Fac Med & Hlth Sci, Cape Town, South Africa.
   [Wiysonge, C. S.] Stellenbosch Univ, Dept Global Hlth, Fac Med & Hlth Sci, Cape Town, South Africa.
RP Nnaji, CA (corresponding author), South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.; Nnaji, CA (corresponding author), Univ Cape Town, Sch Publ Hlth & Family Med, Fac Hlth Sci, Cape Town, South Africa.
EM nnjchu001@myuct.ac.za
CR [Anonymous], 2020, IOL NEWS
   Barro L, 2018, VOX SANG, V113, P726, DOI 10.1111/vox.12705
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Mkhize Z., 2020, UPDATE COVID 19
   Sullivan HC, 2020, TRANSFUS MED REV, V34, P145, DOI 10.1016/j.tmrv.2020.04.001
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Wadvalla BA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1623
   Winkler AM, 2015, CURR OPIN HEMATOL, V22, P521, DOI 10.1097/MOH.0000000000000191
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD AUG
PY 2020
VL 110
IS 8
BP 759
EP 760
DI 10.7196/SAMJ.2020.v110i8.15032
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ4YR
UT WOS:000577102900027
PM 32880303
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Koukouraki, S
   Kapsoritakis, N
   Bourogianni, O
AF Koukouraki, S.
   Kapsoritakis, N.
   Bourogianni, O.
TI COVID-19 pandemic: Implications for radionuclide therapy in Nuclear
   Medicine departments
SO HELLENIC JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE COVID-19 pandemic; Radionuclide therapy; Cancer patients
C1 [Koukouraki, S.; Kapsoritakis, N.; Bourogianni, O.] Univ Crete, Sch Med, Dept Nucl Med, Iraklion, Greece.
   [Koukouraki, S.; Kapsoritakis, N.; Bourogianni, O.] Univ Hosp, Dept Nucl Med, Iraklion, Greece.
RP Koukouraki, S (corresponding author), Univ Crete, Sch Med, Iraklion, Greece.; Koukouraki, S (corresponding author), Univ Hosp, Dept Nucl Med, Iraklion, Greece.
EM koukour@uoc.gr
CR Buscombe JR, 2020, NUCL MED COMMUN, V41, P499, DOI 10.1097/MNM.0000000000001206
   Desai H, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0678-6
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   National Health Service England, 2020, CLIN GUID MAN NONC P
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
NR 5
TC 0
Z9 0
U1 0
U2 0
PU HELLENIC SOC NUCLEAR MEDICINE
PI THESSALONIKI
PA 51 HERMU ST, THESSALONIKI, 546 23, GREECE
SN 1790-5427
J9 HELL J NUCL MED
JI Hell. J. Nucl. Med.
PD AUG
PY 2020
VL 23
SU S
BP 31
EP 34
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NZ0CW
UT WOS:000576758100006
DA 2021-01-01
ER

PT J
AU Giannoula, E
   Vrachimis, A
   Giovanella, L
   Chatzipavlidou, V
   Iakovou, I
AF Giannoula, Evanthia
   Vrachimis, Alexis
   Giovanella, Luca
   Chatzipavlidou, Vasiliki
   Iakovou, Ioannis
TI Nuclear thyroidology in pandemic times: The paradigm shift of COVID-19
SO HELLENIC JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
ID DRUG-INDUCED AGRANULOCYTOSIS; SUBACUTE THYROIDITIS; DIAGNOSIS
AB Since its outbreak in Wuhan, China the SARS-CoV-2 has become a public health emergency of international concern, impacting all areas of daily life, including medical care. Although not in the front line nuclear medicine practice should adjust their standard operating procedures. The adaptations and the flexibility that nuclear thyroidology, among other fields of nuclear medicine, should show during the pandemic, must focus not only in minimizing the risk of infection to staff, patients, and family members, but also in controlling the transmission of the virus while continuing to provide health care services which do not jeopardize patients' prognosis and quality of life. Favorable prognosis and indolent symptoms of most cases of thyroid diseases, allows postponements and rescheduling as well as alternative procedures, provided that they are cautiously considered for each case individually. The objective of the current paper is to provide guidance on how diagnostic and therapeutic management of patients with thyroid diseases can be safely and effectively adjusted during pandemic, in nuclear medicine settings.
C1 [Giannoula, Evanthia; Iakovou, Ioannis] Univ Hosp AHEPA, Acad Dept Nucl Med, Sch Med, Thessaloniki 54621, Greece.
   [Vrachimis, Alexis] Univ Hosp European Univ, German Oncol Ctr, Nucl Med Dept, Limassol, Cyprus.
   [Giovanella, Luca] Oncol Inst Southern Switzerland, Nucl Med Dept, Bellinzona, Switzerland.
   [Chatzipavlidou, Vasiliki] Theagenio Canc Hosp, Nucl Med & PET CT Dept, Thessaloniki, Greece.
RP Iakovou, I (corresponding author), Univ Hosp AHEPA, Acad Dept Nucl Med, Sch Med, Thessaloniki 54621, Greece.
EM iiakovou@auth.gr
CR Aggarwal N, 2016, CLIN ENDOCRINOL, V85, P949, DOI 10.1111/cen.13133
   Ancker OV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010010
   Andres E, 2020, MEDICINES, V7, P15
   Bartlett DL, 2020, ANN SURG ONCOL, V27, P1717, DOI 10.1245/s10434-020-08461-2
   Boelaert K, 2020, EUR J ENDOCRINOL
   Brancatella A, 2020, J CLIN ENDOCR METAB, V105, P2367, DOI 10.1210/clinem/dgaa276
   British Thyroid Foundation (BTF) and Thyroid Cancer Forum-UK (TCF-UK), BTA SFE STAT REG ISS
   British Thyroid Foundation (BTF) and Thyroid Cancer Forum-UK (TCF-UK), BTA SFE ADV PAT THYR
   Dean DS, 2008, BEST PRACT RES CL EN, V22, P901, DOI 10.1016/j.beem.2008.09.019
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Desailloud R, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-5
   Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575
   European Centre for Disease Prevention and Control, 2020, CONT TRAC PUBL HLTH
   Espinoza PG, 2010, CLIN NUCL MED, V35, P862, DOI 10.1097/RLU.0b013e3181f49adc
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang HL, 2020, NUCL MED COMMUN, V41, P297, DOI 10.1097/MNM.0000000000001183
   lakovou I, 2020, J CLIN MED, V9, P384
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Li M, 2020, CLIN THYROIDOL, V32, P156, DOI DOI 10.1089/CT.2020;32.156-158)
   Maier TM, 2015, J NUCL MED, V56, P190, DOI 10.2967/jnumed.114.150284
   Mostafaei S, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152855
   Nakamura H, 2013, J CLIN ENDOCR METAB, V98, P4776, DOI 10.1210/jc.2013-2569
   National Public Health Organization, 2020, DAIL EP SURV REP NEW
   NHS, CAR PEOPL HIGH CLIN
   Nishihara E, 2008, INTERNAL MED, V47, P725, DOI 10.2169/internalmedicine.47.0740
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Paez D, 2020, EUR J NUCL MED MOL I, V47, P1615, DOI 10.1007/s00259-020-04825-8
   Public Health England, GUID SHIELD PROT PEO
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Romesser PB, 2016, RADIOTHER ONCOL, V118, P286, DOI 10.1016/j.radonc.2015.12.008
   Sato J, 2017, ENDOCRINE, V55, P218, DOI 10.1007/s12020-016-1122-3
   Spitzweg C, 2017, INTERNIST, V58, P1011, DOI 10.1007/s00108-017-0306-0
   Stahel PF, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00235-9
   Stamatiou DP, 2016, ONCOL LETT, V11, P1635, DOI 10.3892/ol.2016.4144
   Tsirouki T, 2016, CLIN OPHTHALMOL, V10, P2277, DOI 10.2147/OPTH.S118555
   Vicente N, 2017, DRUGS R&D, V17, P91, DOI 10.1007/s40268-017-0172-1
   VOLPE R, 1986, MOL BIOL MED, V3, P25
   Vrachimis A, 2020, EUR J ENDOCRINOL
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 41
TC 0
Z9 0
U1 0
U2 0
PU HELLENIC SOC NUCLEAR MEDICINE
PI THESSALONIKI
PA 51 HERMU ST, THESSALONIKI, 546 23, GREECE
SN 1790-5427
J9 HELL J NUCL MED
JI Hell. J. Nucl. Med.
PD AUG
PY 2020
VL 23
SU S
BP 41
EP 50
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NZ0CW
UT WOS:000576758100008
DA 2021-01-01
ER

PT J
AU Hogan, RB
   Iii, RBH
   Cannon, T
   Rappai, M
   Studdard, J
   Paul, D
   Dooley, TP
AF Hogan, Reed B., II
   Hogan Iii, Reed B., III
   Cannon, Tim
   Rappai, Maria
   Studdard, John
   Paul, Doug
   Dooley, Thomas P.
TI Dual-histamine receptor blockade with cetirizine - famotidine reduces
   pulmonary symptoms in COVID-19 patients
SO PULMONARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
DE COVID; ARDS; Histamine; Antihistamine; Lung; Cytokine storm
ID COMBINED H-1
AB Background: The COVID-19 pandemic due to SARS-CoV-2 infection can produce Acute Respiratory Distress Syndrome as a result of a pulmonary cytokine storm. Antihistamines are safe and effective treatments for reducing inflammation and cytokine release. Combinations of Histamine-1 and Histamine-2 receptor antagonists have been effective in urticaria, and might reduce the histamine-mediated pulmonary cytokine storm in COVID-19. Can a combination of Histamine-1 and Histamine-2 receptor blockers improve COVID-19 inpatient outcomes?
   Methods: A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a single medical center of 110 high-acuity patients that were treated with cetirizine 10 mg b.i.d. and famotidine 20 mg b.i.d. plus standard-of-care.
   Results: Of all patients, including those with Do Not Resuscitate directives, receiving the dual-histamine receptor blockade for at least 48 h, the combination drug treatment resulted in a 16.4% rate of intubation, a 7.3% rate of intubation after a minimum of 48 h of treatment, a 15.5% rate of inpatient mortality, and 11.0 days duration of hospitalization. The drug combination exhibited beneficial reductions in inpatient mortality and symptom progression when compared to published reports of COVID-19 inpatients. Concomitant medications were assessed and hydroxychloroquine was correlated with worse outcomes.
   Conclusions: This physician-sponsored cohort study of cetirizine and famotidine provides proof-of-concept of a safe and effective method to reduce the progression in symptom severity, presumably by minimizing the histamine-mediated cytokine storm. Further clinical studies in COVID-19 are warranted of the repurposed offlabel combination of two historically-safe histamine receptor blockers.
C1 [Hogan, Reed B., II; Hogan Iii, Reed B., III] GI Associates, 2510 Lakeland Dr, Flowood, MS 39232 USA.
   [Cannon, Tim; Rappai, Maria; Studdard, John] Jackson Pulm Associates PA, Jackson, MS USA.
   [Paul, Doug] Med Mkt Econ MME, Oxford, MS USA.
   [Paul, Doug] Univ Mississippi, Oxford, MS USA.
   [Dooley, Thomas P.] Trends Pharma Dev LLC, 7100 Cabin Lane, Pinson, AL 35126 USA.
RP Hogan, RB (corresponding author), GI Associates, 2510 Lakeland Dr, Flowood, MS 39232 USA.; Dooley, TP (corresponding author), Trends Pharma Dev LLC, 7100 Cabin Lane, Pinson, AL 35126 USA.
EM reed.hogan@gi.md; tom@tomdooley.org
CR Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Branco ACCC, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/9524075
   Cao YH, 2020, J MED VIROL, V92, P1449, DOI [10.1002/jmv.25822, 10.1080/10962247.2020.1815895]
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   DORSCH W, 1982, AGENTS ACTIONS, V12, P113, DOI 10.1007/BF01965120
   Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053
   Hassoun Y, 2019, ANN ALLERG ASTHMA IM, V123, P407, DOI 10.1016/j.anai.2019.06.022
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jang Y, 2018, ARCH VIROL, V163, P3015, DOI 10.1007/s00705-018-3973-9
   Janowitz T, 2020, GUT, V69, P1592, DOI 10.1136/gutjnl-2020-321852
   Kmiecik T, 2012, ARCH MED SCI, V8, P154, DOI 10.5114/aoms.2012.27295
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mohammadi E, 2018, GASTROENTEROLOGY, V154, pS72
   MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404
   Norrie JD, 2020, LANCET, V395, P1525, DOI 10.1016/S0140-6736(20)31023-0
   PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   SIELAFF TD, 1987, SURGERY, V102, P350
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Wan KS, 2009, J DERMATOL TREAT, V20, P194, DOI 10.1080/09546630802607495
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 1
Z9 1
U1 2
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1094-5539
J9 PULM PHARMACOL THER
JI Pulm. Pharmacol. Ther.
PD AUG
PY 2020
VL 63
AR 101942
DI 10.1016/j.pupt.2020.101942
PG 7
WC Pharmacology & Pharmacy; Respiratory System
SC Pharmacology & Pharmacy; Respiratory System
GA NY8UG
UT WOS:000576658500003
PM 32871242
OA Green Published
DA 2021-01-01
ER

PT J
AU Cherian, R
   Chandra, B
   Tung, ML
   Vuylsteke, A
AF Cherian, Robin
   Chandra, Bharatendu
   Tung, Moon Ley
   Vuylsteke, Alain
TI COVID-19 conundrum: clinical phenotyping based on pathophysiology as a
   promising approach to guide therapy in a novel illness
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID GAS-EXCHANGE
C1 [Cherian, Robin] Natl Univ Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore.
   [Chandra, Bharatendu] Natl Univ Singapore Hosp, Div Neurol, Singapore, Singapore.
   [Tung, Moon Ley] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore.
   [Vuylsteke, Alain] Royal Papworth Hosp NHS Trust, Dept Anaesthesia & Crit Care, Cambridge, England.
RP Cherian, R (corresponding author), Natl Univ Heart Ctr, Dept Cardiol, Cardiac Crit Care, NUHS Tower Block,Level 9,1E Kent Ridge Rd, Singapore 119228, Singapore.
EM robin_cherian@nuhs.edu.sg
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bos LDJ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01768-2020
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Maggiorini R, 1997, EUR RESPIR J, V10, P727
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Mauri T, 2020, CRIT CARE MED, V48, P1129, DOI 10.1097/CCM.0000000000004386
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Oudkerk M, 2020, RADIOLOGY, DOI [10.1148/radiol.2020201629]., DOI 10.1148/RADIOL.2020201629]]
   Petersson J, 2014, EUR RESPIR J, V44, P1023, DOI 10.1183/09031936.00037014
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Sciagra R, 2020, EUR J NUCL MED MOL I, V47, P2211, DOI 10.1007/s00259-020-04868-x
   SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448
   Soldati G, 2020, J ULTRAS MED, V39, P2483, DOI 10.1002/jum.15338
   Tee A, 2020, INTENS CARE MED, V46, P1660, DOI 10.1007/s00134-020-06085-4
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wagner PD, 2015, EUR RESPIR J, V45, P227, DOI 10.1183/09031936.00039214
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu Y, 2020, QJM-INT J MED, V113, P539, DOI 10.1093/qjmed/hcaa121
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 25
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD AUG 1
PY 2020
VL 56
IS 2
PG 4
WC Respiratory System
SC Respiratory System
GA NW4AM
UT WOS:000574951300050
DA 2021-01-01
ER

PT J
AU Cherian, R
   Chandra, B
   Tung, ML
   Vuylsteke, A
AF Cherian, Robin
   Chandra, Bharatendu
   Tung, Moon Ley
   Vuylsteke, Alain
TI COVID-19 conundrum: clinical phenotyping based on pathophysiology as a
   promising approach to guide therapy in a novel illness
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID GAS-EXCHANGE
C1 [Cherian, Robin] Natl Univ Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore.
   [Chandra, Bharatendu] Natl Univ Singapore Hosp, Div Neurol, Singapore, Singapore.
   [Tung, Moon Ley] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore.
   [Vuylsteke, Alain] Royal Papworth Hosp NHS Trust, Dept Anaesthesia & Crit Care, Cambridge, England.
RP Cherian, R (corresponding author), Natl Univ Heart Ctr, Dept Cardiol, Cardiac Crit Care, NUHS Tower Block,Level 9,1E Kent Ridge Rd, Singapore 119228, Singapore.
EM robin_cherian@nuhs.edu.sg
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bos LDJ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01768-2020
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Maggiorini R, 1997, EUR RESPIR J, V10, P727
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Mauri T, 2020, CRIT CARE MED, V48, P1129, DOI 10.1097/CCM.0000000000004386
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Petersson J, 2014, EUR RESPIR J, V44, P1023, DOI 10.1183/09031936.00037014
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Sciagra R, 2020, EUR J NUCL MED MOL I, V47, P2211, DOI 10.1007/s00259-020-04868-x
   SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448
   Soldati G, 2020, J ULTRAS MED, V39, P2483, DOI 10.1002/jum.15338
   Tee A, 2020, INTENS CARE MED, V46, P1660, DOI 10.1007/s00134-020-06085-4
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wagner PD, 2015, EUR RESPIR J, V45, P227, DOI 10.1183/09031936.00039214
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu Y, 2020, QJM-INT J MED, V113, P539, DOI 10.1093/qjmed/hcaa121
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 25
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD AUG 1
PY 2020
VL 56
IS 2
PG 4
WC Respiratory System
SC Respiratory System
GA NW4AM
UT WOS:000574951300056
DA 2021-01-01
ER

PT J
AU Cherian, R
   Chandra, B
   Tung, ML
   Vuylsteke, A
AF Cherian, Robin
   Chandra, Bharatendu
   Tung, Moon Ley
   Vuylsteke, Alain
TI COVID-19 conundrum: clinical phenotyping based on pathophysiology as a
   promising approach to guide therapy in a novel illness
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID GAS-EXCHANGE
C1 [Cherian, Robin] Natl Univ Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore.
   [Chandra, Bharatendu] Natl Univ Singapore Hosp, Div Neurol, Singapore, Singapore.
   [Tung, Moon Ley] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore.
   [Vuylsteke, Alain] Royal Papworth Hosp NHS Trust, Dept Anaesthesia & Crit care, Cambridge, England.
RP Cherian, R (corresponding author), Natl Univ Heart Ctr, Dept Cardiol, Cardiac Crit Care, NUHS Tower Block,Level 9,1E Kent Ridge Rd, Singapore 119228, Singapore.
EM robin_cherian@nuhs.edu.sg
OI Vuylsteke, Alain/0000-0002-6749-9251; Tung, Moon
   Ley/0000-0002-5436-1720; BHARATENDU, CHANDRA/0000-0002-6777-4137
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bos LDJ, 2020, EUR RESPIR J, V56
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Maggiorini R, 1997, EUR RESPIR J, V10, P727
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Mauri T, 2020, CRIT CARE MED, V48, P1129, DOI 10.1097/CCM.0000000000004386
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Petersson J, 2014, EUR RESPIR J, V44, P1023, DOI 10.1183/09031936.00037014
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Sciagra R, 2020, EUR J NUCL MED MOL I, V47, P2211, DOI 10.1007/s00259-020-04868-x
   SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448
   Soldati G, 2020, J ULTRAS MED, V39, P2483, DOI 10.1002/jum.15338
   Tee A, 2020, INTENS CARE MED, V46, P1660, DOI 10.1007/s00134-020-06085-4
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wagner PD, 2015, EUR RESPIR J, V45, P227, DOI 10.1183/09031936.00039214
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu Y, 2020, QJM-INT J MED, V113, P539, DOI 10.1093/qjmed/hcaa121
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 25
TC 1
Z9 1
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD AUG 1
PY 2020
VL 56
IS 2
AR 2002135
DI 10.1183/13993003.02135-2020
PG 4
WC Respiratory System
SC Respiratory System
GA NW4AM
UT WOS:000574951300035
PM 32675212
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cherian, R
   Chandra, B
   Tung, ML
   Vuylsteke, A
AF Cherian, Robin
   Chandra, Bharatendu
   Tung, Moon Ley
   Vuylsteke, Alain
TI COVID-19 conundrum: clinical phenotyping based on pathophysiology as a
   promising approach to guide therapy in a novel illness
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID GAS-EXCHANGE
C1 [Cherian, Robin] Natl Univ Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore.
   [Chandra, Bharatendu] Natl Univ Singapore Hosp, Div Neurol, Singapore, Singapore.
   [Tung, Moon Ley] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore.
   [Vuylsteke, Alain] Royal Papworth Hosp NHS Trust, Dept Anaesthesia & Crit Care, Cambridge, England.
RP Cherian, R (corresponding author), Natl Univ Heart Ctr, Dept Cardiol, NUHS Tower Block,Level 9,1E Kent Ridge Rd, Singapore 119228, Singapore.
EM robin_cherian@nuhs.edu.sg
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bos LDJ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01768-2020
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Maggiorini R, 1997, EUR RESPIR J, V10, P727
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Mauri T, 2020, CRIT CARE MED, V48, P1129, DOI 10.1097/CCM.0000000000004386
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Petersson J, 2014, EUR RESPIR J, V44, P1023, DOI 10.1183/09031936.00037014
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Sciagra R, 2020, EUR J NUCL MED MOL I, V47, P2211, DOI 10.1007/s00259-020-04868-x
   SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448
   Soldati G, 2020, J ULTRAS MED, V39, P2483, DOI 10.1002/jum.15338
   Tee A, 2020, INTENS CARE MED, V46, P1660, DOI 10.1007/s00134-020-06085-4
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wagner PD, 2015, EUR RESPIR J, V45, P227, DOI 10.1183/09031936.00039214
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu Y, 2020, QJM-INT J MED, V113, P539, DOI 10.1093/qjmed/hcaa121
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 25
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD AUG 1
PY 2020
VL 56
IS 2
PG 4
WC Respiratory System
SC Respiratory System
GA NW4AM
UT WOS:000574951300039
DA 2021-01-01
ER

PT J
AU Bojti, PP
   Stang, R
   Gunda, B
   Sipos, I
   Bereczki, D
AF Bojti Peter Pal
   Stang Rita
   Gunda Bence
   Sipos Ildiko
   Bereczki Daniel
TI Effects of COVID-19 pandemic on acute ischemic stroke care
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE acute stroke; thrombolytic therapy; coronavirus; COVID-19 pandemic;
   health care systems
AB Introduction: Early international observations report decreased number of acute ischemic stroke admissions and prolonged onset-to-treatment times during COVID-19 pandemic. Aim: Our goal was to assess the effect of COVID-19 pandemic on Hungarian acute ischemic stroke care.
   Method: We compared demographical and clinical characteristics, rate of intravenous and endovascular therapies and therapeutic time parameters of acute ischemic strokes admitted to a university stroke centre in a COVID-epidemic period (01/03/2020-30/04/2020) and an identical period of 2019.
   Results: 86 patients were admitted during the COVID-period and 97 in the control period. Demographical and clinical characteristics of these periods were well-balanced. In the COVID-period, the proportion of patients arriving beyond 24 hours after onset increased by 13% (p = 0.046), the rate of endovascular interventions remained unchanged (8%), the rate of intravenous thrombolysis decreased from 26% to 16%, the mean onset-to-treatment time of thrombolysis increased by 20 minutes, while the mean door-to-treatment time increased by only 5 minutes. Behind the shift of arrival time categories, multivariable (year of examination, NIHSS, age) logistic regression shows that the year of examination might play a leading role (p = 0.096).
   Conclusion: In the COVID-period, admissions for acute ischemic strokes decreased by 11% and the proportion of cases certainly untreatable by reperfusion therapies (arriving beyond 24 hours after onset) increased significantly. While the rate of endovascular interventions remained unchanged, the absolute rate of intravenous thrombolysis decreased by 10% and the mean onset-to-treatment time showed a tendency to increase. In these changes, the COVID-epidemic itself and related out-of-hospital factors might play a leading role.
C1 [Bojti Peter Pal; Stang Rita; Gunda Bence; Sipos Ildiko; Bereczki Daniel] Semmelweis Egyet, Neurol Klin, Altalanos Orvostud Kar, Budapest, Hungary.
   [Bereczki Daniel] MTA SE Neuroepidemiol Kutatocsoport, Budapest, Hungary.
   [Bereczki Daniel] European Acad Neurol, EANcore COVID 19 Task Force, Vienna, Austria.
RP Bojti, PP (corresponding author), Balassa U 6, H-1083 Budapest, Hungary.
EM bojti.peter-pal@med.semmelweis-univ.hu
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Feral-Pierssens AL, 2020, EUR J EMERG MED, V27, P233, DOI 10.1097/MEJ.0000000000000717
   Galarza M, 2020, NEUROSURGERY, V87, pE186, DOI 10.1093/neuros/nyaa155
   Hemphill NM, 2020, CAN J CARDIOL, V36, P1130, DOI 10.1016/j.cjca.2020.04.038
   Hungarian Government, TAJ OLD KOR
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Morelli N, 2020, ERA EUR NEUROL, V14, P1, DOI DOI 10.1159/000507666
   National Public Health Center, KOZP COVID 19 KOR 20
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Semmelweis University Budapest, TAJ AZ UJ KOR
   van der Worp B, INCREASE RISK DEATH
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Waqas M, 2020, J NEUROINTERV SURG, V12, P260, DOI 10.1136/neurintsurg-2019-015172
   Warren CS, 2020, PSYCHOL TODAY   0317
   Zhao J, 2020, STROKE, V51, P1356, DOI 10.1161/STROKEAHA.120.029701
   Zitelny E, 2020, CARDIOVASC PATHOL, V48, DOI 10.1016/j.carpath.2020.107232
NR 18
TC 0
Z9 0
U1 0
U2 0
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD AUG
PY 2020
VL 161
IS 34
BP 1395
EP 1399
DI 10.1556/650.2020.31936
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NW9HL
UT WOS:000575326700001
PM 32804669
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chen, BZ
   Xia, R
AF Chen, Binzhen
   Xia, Rong
TI Early experience with convalescent plasma as immunotherapy for COVID-19
   in China: Knowns and unknowns
SO VOX SANGUINIS
LA English
DT Article
DE COVID-19 convalescent plasma (CCP); therapy; COVID-19; SARS-CoV-2
ID SPANISH INFLUENZA; BLOOD-PRODUCTS; PNEUMONIA
AB Background and objectives In the absence of a vaccine or specific drug treatment options for coronavirus disease (COVID-19), attention has been shifted in China to the possible therapeutic use of convalescent plasma. COVID-19 convalescent plasma (CCP) is currently under investigation. We summarized clinical studies and other research data available as of 5 May 2020 on CCP therapy according to theClinical Treatment Guideline of COVID-19 Convalescent Plasmain China, as well as clinical experience at the First Affiliated Hospital of Zhejiang University, as part of a comprehensive anti-epidemic strategy. Materials and methods As of 5 May 2020, when the epidemic was well-controlled in China, healthcare databases and sources of English literature relating to convalescent plasma were searched and reviewed. Sources of clinical and methodological heterogeneity were identified. Results As of 5 May 2020, up to 2000 samples of CCP had been collected across China and administered to 700 COVID-19 patients. From donors, 200-400 ml of plasma was collected at each donation, with antibody titres > 1:160. We identified three clinical studies for COVID-19 in China. Analyses showed a statistically significant improvement in clinical outcomes compared with untreated cases (P < 0.001). No adverse effects were reported. Conclusion From initial studies, convalescent plasma therapy appears effective and safe for COVID-19. However, there is clearly a need for well-designed RCTs (randomized controlled trials) or other formal studies to further evaluate the efficacy and any potential adverse effects of CCP.
C1 [Chen, Binzhen; Xia, Rong] Fudan Univ, Huashan Hosp, Dept Transfus Med, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China.
RP Xia, R (corresponding author), Fudan Univ, Huashan Hosp, Dept Transfus Med, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China.
EM xiarongcn@126.com
OI Chen, Binzhen/0000-0003-3512-1526
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670173] Funding Source: Medline
CR Ankcorn M, 2019, J HEPATOL, V71, P434, DOI 10.1016/j.jhep.2019.04.008
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Brown JF, 2018, J INFECT DIS, V218, P555, DOI 10.1093/infdis/jiy199
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Florescu DF, 2015, CLIN INFECT DIS, V61, P969, DOI 10.1093/cid/civ395
   Garraud O, 2016, PRESSE MED, V45, pE243, DOI 10.1016/j.lpm.2016.06.015
   Gong J, 2020, CORRELATION ANAL DIS
   Guo XZJ, 2017, SEMIN IMMUNOPATHOL, V39, P541, DOI 10.1007/s00281-017-0636-y
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Liang T., 2020, HDB COVID 19 PREVENT
   Logtenberg SJ, 2007, ANN INTERN MED, V146, P686, DOI 10.7326/0003-4819-146-9-200705010-00020
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   National Health Commission of The People's Republic of China, 2020, CLIN TREATM COVID 19
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   U.S. National Library of Medicine, 2020, STUD FOUND COVID 19
   van Griensven J, 2016, NEW ENGL J MED, V375, P2307, DOI 10.1056/NEJMc1609116
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang HN, 2020, CLIN CARDIOL, V43, P450, DOI 10.1002/clc.23341
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
NR 37
TC 3
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD AUG
PY 2020
VL 115
IS 6
BP 507
EP 514
DI 10.1111/vox.12968
PG 8
WC Hematology
SC Hematology
GA NX7SJ
UT WOS:000575905800007
PM 32516839
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gordy, JT
   Mazumdar, K
   Dutta, NK
AF Gordy, James T.
   Mazumdar, Kaushiki
   Dutta, Noton K.
TI Accelerating Drug Development through Repurposed FDA-Approved Drugs for
   COVID-19: Speed Is Important, Not Haste
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Letter
DE coronavirus disease 2019; COVID-19; severe acute respiratory syndrome
   coronavirus-2; SARS-CoV-2; treatment; antiviral drugs; FDA-approved
   drugs; host-directed therapy; pathogen-directed therapy
C1 [Gordy, James T.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD USA.
   [Mazumdar, Kaushiki] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Dutta, Noton K.] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA.
RP Dutta, NK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA.
EM ndutta1@jhmi.edu
OI Gordy, James/0000-0003-2588-0756; Mazumdar,
   Kaushiki/0000-0002-1036-1980; Dutta, Noton/0000-0002-5066-3342
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Ayman F, 2020, IDENTIFICATION FDA A
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Lasry A, 2020, MMWR-MORBID MORTAL W, V69, P451, DOI 10.15585/mmwr.mm6915e2
   Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-01295-8
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Vishal M, 2020, DRUG REPURPOSING APP
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
NR 27
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2020
VL 64
IS 8
AR e00857-20
DI 10.1128/AAC.00857-20
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA NU8WI
UT WOS:000573917700013
PM 32423954
DA 2021-01-01
ER

PT J
AU Salgado-Benvindo, C
   Thaler, M
   Tas, A
   Ogando, NS
   Bredenbeek, PJ
   Ninaber, DK
   Wang, Y
   Hiemstra, PS
   Snijder, EJ
   van Hemert, MJ
AF Salgado-Benvindo, Clarisse
   Thaler, Melissa
   Tas, Ali
   Ogando, Natacha S.
   Bredenbeek, Peter J.
   Ninaber, Dennis K.
   Wang, Ying
   Hiemstra, Pieter S.
   Snijder, Eric J.
   van Hemert, Martijn J.
TI Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering
   with Early Steps of the Replication Cycle
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; SARS-CoV-2; suramin; antiviral agents; coronavirus; drug
   repurposing
ID VIRUS-REPLICATION; DENGUE VIRUS; CORONAVIRUS; BINDING; PATHOGENESIS;
   DEPENDS; PROTEIN; SARS
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that originated in Wuhan, China, in December 2019 has impacted public health, society, the global economy, and the daily lives of billions of people in an unprecedented manner. There are currently no specific registered antiviral drugs to treat or prevent SARS-CoV-2 infections. Therefore, drug repurposing would be the fastest route to provide at least a temporary solution while better, more specific drugs are being developed. Here, we demonstrate that the antiparasitic drug suramin inhibits SARS-CoV-2 replication, protecting Vero E6 cells with a 50% effective concentration (EC50) of similar to 20 mu M, which is well below the maximum attainable level in human serum. Suramin also decreased the viral load by 2 to 3 logs when Vero E6 cells or cells of a human lung epithelial cell line (Calu-3 2B4 [referred to here as "Calu-3"]) were treated. Time-of-addition and plaque reduction assays performed on Vero E6 cells showed that suramin acts on early steps of the replication cycle, possibly preventing binding or entry of the virus. In a primary human airway epithelial cell culture model, suramin also inhibited the progression of infection. The results of our preclinical study warrant further investigation and suggest that it is worth evaluating whether suramin provides any benefit for COVID-19 patients, which obviously requires safety studies and well-designed, properly controlled randomized clinical trials.
C1 [Salgado-Benvindo, Clarisse; Thaler, Melissa; Tas, Ali; Ogando, Natacha S.; Bredenbeek, Peter J.; Snijder, Eric J.; van Hemert, Martijn J.] Leiden Univ, Dept Med Microbiol, Med Ctr, Leiden, Netherlands.
   [Ninaber, Dennis K.; Wang, Ying; Hiemstra, Pieter S.] Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands.
RP van Hemert, MJ (corresponding author), Leiden Univ, Dept Med Microbiol, Med Ctr, Leiden, Netherlands.
EM M.J.van_Hemert@lumc.nl
OI Ogando, Natacha/0000-0002-3577-4909; Salgado Benvindo da Silva,
   Clarisse/0000-0002-2244-7992; Thaler, Melissa/0000-0002-5590-4918; van
   Hemert, Martijn/0000-0002-2617-9243
FU Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES [88881.171440/2018-01]; Ministry of Education, Brazil;
   China Scholarship CouncilChina Scholarship Council; Leiden University
   Fund (LUF); Bontius Foundation
FX C.S.-B. was supported by the Coordination for the Improvement of Higher
   Education Personnel (CAPES) (process no. 88881.171440/2018-01), Ministry
   of Education, Brazil. Y.W. was supported in part by a grant from the
   China Scholarship Council. Part of this research was supported by the
   Leiden University Fund (LUF), the Bontius Foundation, and donations from
   the crowdfunding initiative "wake up to corona."
CR Aguilar JS, 1999, VIROLOGY, V258, P141, DOI 10.1006/viro.1999.9723
   Albulescu IC, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030314
   Albulescu IC, 2017, ANTIVIR RES, V143, P230, DOI 10.1016/j.antiviral.2017.04.016
   Albulescu IC, 2015, ANTIVIR RES, V121, P39, DOI 10.1016/j.antiviral.2015.06.013
   Amatngalim GD, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01009-2017
   Basavannacharya C, 2014, BIOCHEM BIOPH RES CO, V453, P539, DOI 10.1016/j.bbrc.2014.09.113
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X
   Fulcher M Leslie, 2013, Methods Mol Biol, V945, P109, DOI 10.1007/978-1-62703-125-7_8
   Garson JA, 1999, J MED VIROL, V57, P238
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hiemstra PS, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00742-2019
   Ho YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133511
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   KAPLAN LD, 1987, AM J MED, V82, P615, DOI 10.1016/0002-9343(87)90108-2
   Kovacikova K, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.02532-19
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Ren PJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep42902
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   SCHER HI, 1992, CANCER RES, V52, P64
   Scholte FEM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071047
   Schrumpf JA, 2020, J INNATE IMMUN, V12, P74, DOI 10.1159/000497415
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sims AC, 2005, J VIROL, V79, P15511, DOI 10.1128/JVI.79.24.15511-15524.2005
   Tan CW, 2017, ANTIVIR RES, V143, P186, DOI 10.1016/j.antiviral.2017.04.017
   VOOGD TE, 1993, PHARMACOL REV, V45, P177
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wiedemar N, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01168-19
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, COR DIS 2019 COVID 1
   YAHI N, 1994, J BIOL CHEM, V269, P24349
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 41
TC 3
Z9 3
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2020
VL 64
IS 8
AR e00900-20
DI 10.1128/AAC.00900-20
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA NU8WN
UT WOS:000573918200008
PM 32513797
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Callahan, CJ
   Lee, R
   Zulauf, KE
   Tamburello, L
   Smith, KP
   Previtera, J
   Cheng, AN
   Green, A
   Azim, AA
   Yano, A
   Doraiswami, N
   Kirby, JE
   Arnaout, RA
AF Callahan, Cody J.
   Lee, Rose
   Zulauf, Katelyn E.
   Tamburello, Lauren
   Smith, Kenneth P.
   Previtera, Joe
   Cheng, Annie
   Green, Alex
   Azim, Ahmed Abdul
   Yano, Amanda
   Doraiswami, Nancy
   Kirby, James E.
   Arnaout, Ramy A.
TI Open Development and Clinical Validation of Multiple 3D-Printed
   Nasopharyngeal Collection Swabs: Rapid Resolution of a Critical COVID-19
   Testing Bottleneck
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; virological testing; diagnostic testing;
   epidemiology
AB The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a severe international shortage of the nasopharyngeal swabs that are required for collection of optimal specimens, creating a critical bottleneck blocking clinical laboratories' ability to perform high-sensitivity virological testing for SARS-CoV-2. To address this crisis, we designed and executed an innovative, cooperative, rapid-response translational-research program that brought together health care workers, manufacturers, and scientists to emergently develop and clinically validate new swabs for immediate mass production by 3D printing. We performed a multistep preclinical evaluation of 160 swab designs and 48 materials from 24 companies, laboratories, and individuals, and we shared results and other feed- back via a public data repository (http://github.com/rarnaout/Covidswab/). We validated four prototypes through an institutional review board (IRB)-approved clinical trial that involved 276 outpatient volunteers who presented to our hospital's drive-through testing center with symptoms suspicious for COVID-19. Each participant was swabbed with a reference swab (the control) and a prototype, and SARS-CoV-2 reverse transcriptase PCR (RT-PCR) results were compared. All prototypes displayed excellent concordance with the control (kappa = 0.85 to 0.89). Cycle threshold (C-T) values were not significantly different between each prototype and the control, supporting the new swabs' noninferiority (Mann-Whitney U [MWU] test, P> 0.05). Study staff preferred one of the prototypes over the others and preferred the control swab overall. The total time elapsed between identification of the problem and validation of the first prototype was 22 days. Contact information for ordering can be found at http://printedswabs.org . Our experience holds lessons for the rapid development, validation, and deployment of new technology for this pandemic and beyond.
C1 [Callahan, Cody J.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
   [Lee, Rose; Zulauf, Katelyn E.; Smith, Kenneth P.; Cheng, Annie; Green, Alex; Kirby, James E.; Arnaout, Ramy A.] Beth Israel Deaconess Med Ctr, Clin Microbiol Labs, Div Clin Pathol, Dept Pathol, Boston, MA 02215 USA.
   [Lee, Rose; Azim, Ahmed Abdul] Beth Israel Deaconess Med Ctr, Div Infect Dis, Dept Med, Boston, MA USA.
   [Zulauf, Katelyn E.; Smith, Kenneth P.; Green, Alex; Kirby, James E.; Arnaout, Ramy A.] Harvard Med Sch, Boston, MA 02115 USA.
   [Tamburello, Lauren] Beth Israel Deaconess Med Ctr, Div Urol Surg, Dept Surg, Boston, MA USA.
   [Previtera, Joe] Beth Israel Deaconess Med Ctr, Div Resp Therapy, Boston, MA USA.
   [Yano, Amanda] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
   [Doraiswami, Nancy] Beth Israel Deaconess Med Ctr, Div Perioperat Serv, Dept Cent Proc, Boston, MA USA.
   [Azim, Ahmed Abdul] Beth Israel Deaconess Med Ctr, Div Infect Control, Hosp Epidemiol, Silverman Inst Healthcare Qual & Safety, Boston, MA USA.
   [Arnaout, Ramy A.] Beth Israel Deaconess Med Ctr, Div Clin Informat, Dept Med, Boston, MA 02215 USA.
RP Arnaout, RA (corresponding author), Beth Israel Deaconess Med Ctr, Clin Microbiol Labs, Div Clin Pathol, Dept Pathol, Boston, MA 02215 USA.; Arnaout, RA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Arnaout, RA (corresponding author), Beth Israel Deaconess Med Ctr, Div Clin Informat, Dept Med, Boston, MA 02215 USA.
EM rarnaout@bidmc.harvard.edu
FU National Institute of Allergy and Infectious Diseases training grant
   [T32AI007061]; National Institute of Allergy and Infectious Diseases of
   the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [F32AI124590];
   Harvard Catalyst, The Harvard Clinical and Translational Science Center
   (National Center for Advancing Translational Sciences, National
   Institutes of Health) [UL 1TR002541]; Harvard University; EnvisionTec;
   Carbon3D; Origin; HP
FX K.E.Z. was supported by a National Institute of Allergy and Infectious
   Diseases training grant (T32AI007061). K.P.S. was supported by the
   National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health under award number F32AI124590. This work was
   conducted with support from Harvard Catalyst, The Harvard Clinical and
   Translational Science Center (National Center for Advancing
   Translational Sciences, National Institutes of Health award UL
   1TR002541), and financial contributions from Harvard University and its
   affiliated academic health care centers. This work was supported by
   Carbon3D, EnvisionTec, Origin, and HP to cover the cost of the IRB and
   PCR testing.
CR Abbott, 2020, ABB REALTIME SARS CO
   Arnaout RA, COVIDSWAB
   Azzi L, 2020, J INFECTION, V81, pE45, DOI 10.1016/j.jinf.2020.04.005
   Becton Dickinson and Company, 2017, BD GRAM STAIN KITS R
   Bessetti J., 2007, INTRO PCR INHIBITORS
   Centers for Disease Control and Prevention, 2020, DSR05201 SOP CTR DIS
   Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043
   Johns Hopkins Coronavirus Resource Center, COVID 19 MAP
   Kodzius R, 2012, SENSOR ACTUAT B-CHEM, V161, P349, DOI 10.1016/j.snb.2011.10.044
   Kwiecien R, 2011, DTSCH ARZTEBL INT, V108, P515, DOI 10.3238/arztebl.2011.0515
   Lakhani KR, 2013, NAT BIOTECHNOL, V31, P108, DOI 10.1038/nbt.2495
   Lee J, 2016, PROCEDIA COMPUT SCI, V91, P492, DOI 10.1016/j.procs.2016.07.128
   Mak RH, 2019, JAMA ONCOL, V5, P654, DOI 10.1001/jamaoncol.2019.0159
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   Miller JM, 2013, J CLIN MICROBIOL, V51, P3910, DOI 10.1128/JCM.02023-13
   Pere H, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00721-20
   Tack P, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0236-4
   Thomas K., 2020, NY TIMES
   Tu Y-P, 2020, PATIENT COLLECTED TO, DOI 10.1101/2020.04.01.20050005v1
   Wikipedia contributors, 2020, A B TEST WIK FREE EN
   Wikipedia contributors, 2020, ROUND ROB TOURN WIK
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 22
TC 6
Z9 6
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2020
VL 58
IS 8
AR e00876-20
DI 10.1128/JCM.00876-20
PG 10
WC Microbiology
SC Microbiology
GA NU8WW
UT WOS:000573919100018
PM 32393482
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Craney, AR
   Velu, PD
   Satlin, MJ
   Fauntleroy, KA
   Callan, K
   Robertson, A
   La Spina, M
   Lei, B
   Chen, AQ
   Alston, T
   Rozman, A
   Loda, M
   Rennert, H
   Cushing, M
   Westblade, LF
AF Craney, Arryn R.
   Velu, Priya D.
   Satlin, Michael J.
   Fauntleroy, Kathy A.
   Callan, Katrina
   Robertson, Amy
   La Spina, Marisa
   Lei, Beryl
   Chen, Anqi
   Alston, Tricia
   Rozman, Anna
   Loda, Massimo
   Rennert, Hanna
   Cushing, Melissa
   Westblade, Lars F.
TI Comparison of Two High-Throughput Reverse Transcription-PCR Systems for
   the Detection of Severe Acute Respiratory Syndrome Coronavirus 2
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE coronavirus disease 19 (COVID-19); high throughput; platform; reverse
   transcription-PCR (RT-PCR); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); system
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as the cause of a worldwide pandemic. Many commercial SARS-CoV-2 reverse transcription-PCR (RT-PCR) assays have received Emergency Use Authorization from the U.S. Food and Drug Administration. However, there are limited data describing their performance, in particular the performance of high-throughput SARS-CoV-2 RT-PCR systems. We analyzed the diagnostic performance of two high-throughput systems: cobas 6800 and Panther Fusion, and their associated RT-PCR assays, with a collection of 389 nasopharyngeal specimens. The overall agreement between the platforms was 96.4% (375/389). Cohen's kappa analysis rated the strength of agreement between the two platforms as "almost perfect" (kappa = 0.922; standard error, 0.051). Furthermore, there was no significant difference between corresponding cycle threshold values generated on the two systems (P value = 0.88; Student's t test). Taken together, these data imply that the two platforms can be considered comparable in terms of their clinical performance. We believe that this information will be useful for those who have already adopted these platforms or are seeking to implement high-throughput RT-PCR testing to stem the SARS-CoV-2 pandemic.
C1 [Craney, Arryn R.; Velu, Priya D.; Loda, Massimo; Rennert, Hanna; Cushing, Melissa; Westblade, Lars F.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Satlin, Michael J.; Westblade, Lars F.] Weill Cornell Med, Div Infect Dis, Dept Med, New York, NY 10065 USA.
   [Fauntleroy, Kathy A.; Callan, Katrina; Robertson, Amy; La Spina, Marisa; Lei, Beryl; Chen, Anqi; Alston, Tricia; Rozman, Anna] NewYork Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA.
RP Westblade, LF (corresponding author), Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.; Westblade, LF (corresponding author), Weill Cornell Med, Div Infect Dis, Dept Med, New York, NY 10065 USA.
EM law9067@med.cornell.edu
CR Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Cepheid Inc., 2020, XPERT XPRESS SARS CO
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Harrington A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00798-20
   Hologic, 2020, PANTHER FUSION SARS
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Moran A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00772-20
   NYC Department of Health and Mental Hygiene, 2020, COVID 19 DAT
   Patel R, 2020, AM SOC MICR COVID 19, V11, DOI 10.1128/mBio.00722-20
   Rhoads DD, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00760-20
   Roche Diagnostics, 2020, COBAS SARS COV 2 EUA
   US Food and Drug Administration, 2020, EM US AUTH
   WHO, 2020, COR DIS COVID 19 PAN
NR 13
TC 12
Z9 12
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2020
VL 58
IS 8
AR e00890-20
DI 10.1128/JCM.00890-20
PG 6
WC Microbiology
SC Microbiology
GA NU8WW
UT WOS:000573919100032
PM 32381643
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hogan, CA
   Garamani, N
   Lee, AS
   Tung, JK
   Sahoo, MK
   Huang, CH
   Stevens, B
   Zehnder, J
   Pinsky, BA
AF Hogan, Catherine A.
   Garamani, Natasha
   Lee, Andrew S.
   Tung, Jack K.
   Sahoo, Malaya K.
   Huang, ChunHong
   Stevens, Bryan
   Zehnder, James
   Pinsky, Benjamin A.
TI Comparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed
   Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal
   Specimens
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE COVID-19; laboratory-developed test; Mesa Accula; point-of-care test;
   SARS-CoV-2
AB Several point-of-care (POC) molecular tests have received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The test performance characteristics of the Accula (Mesa Biotech) SARS-CoV-2 POC test need to be evaluated to inform its optimal use. The aim of this study was to assess the test performance of the Accula SARS-CoV-2 test. The performance of the Accula test was assessed by comparing results of 100 nasopharyngeal swab samples previously characterized by the Stanford Health Care EUA laboratory-developed test (SHC-LDT), targeting the envelope (E) gene. Assay concordance was assessed by overall percent agreement, positive percent agreement (PPA), negative percent agreement (NPA), and Cohen's kappa coefficient. Overall percent agreement between the assays was 84.0% (95% confidence interval [CI], 75.3 to 90.6%), PPA was 68.0% (95% CI, 53.3 to 80.5%), and the kappa coefficient was 0.68 (95% CI, 0.54 to 0.82). Sixteen specimens detected by the SHC-LDT were not detected by the Accula test and showed low viral load burden, with a median cycle threshold value of 37.7. NPA was 100% (95% CI, 94.2 to 100%). Compared to the SHC-LDT, the Accula SARS-CoV-2 test showed excellent negative agreement. However, positive agreement was low for samples with low viral load. The false-negative rate of the Accula POC test calls for a more thorough evaluation of POC test performance characteristics in clinical settings and for confirmatory testing in individuals with moderate to high pretest probability of SARS-CoV-2 who test negative on Accula.
C1 [Hogan, Catherine A.; Garamani, Natasha; Lee, Andrew S.; Tung, Jack K.; Sahoo, Malaya K.; Huang, ChunHong; Stevens, Bryan; Zehnder, James; Pinsky, Benjamin A.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
   [Hogan, Catherine A.; Stevens, Bryan; Pinsky, Benjamin A.] Stanford Hlth Care, Clin Virol Lab, Stanford, CA 94304 USA.
   [Pinsky, Benjamin A.] Stanford Univ, Div Infect Dis & Geog Med, Dept Med, Sch Med, Stanford, CA 94305 USA.
RP Pinsky, BA (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.; Pinsky, BA (corresponding author), Stanford Hlth Care, Clin Virol Lab, Stanford, CA 94304 USA.; Pinsky, BA (corresponding author), Stanford Univ, Div Infect Dis & Geog Med, Dept Med, Sch Med, Stanford, CA 94305 USA.
EM bpinsky@stanford.edu
OI Pinsky, Benjamin/0000-0001-8751-4810
CR [Anonymous], 2020, KAISER HLTH NEWS
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   CDC, 2020, EV TEST PERS COR DIS
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Food and Drug Administration, 2020, POL COR DIS 2019 TES
   Food and Drug Administration, 2020, EM US AUTH
   Harrington A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00798-20
   Hogan CA, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104410
   Hogan CA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104383
   Hogan CA, 2020, JAMA-J AM MED ASSOC, V323, P1967, DOI 10.1001/jama.2020.5445
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lieberman JA, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00821-20
   Mesa Biotech, 2020, DOC LIB ACC SARS COV
   Moran A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00772-20
   Nalla AK, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00557-20
   Rhoads DD, 2020, J CLIN MICROBIOL, DOI [10.1128/JCM.00760-20., DOI 10.1128/JCM.00760.20]
   Sharfstein JM, 2020, JAMA-J AM MED ASSOC, V323, P1437, DOI 10.1001/jama.2020.3864
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P515, DOI 10.1038/d41587-020-00010-2
   WHO, 2020, COR DIS COVID 19 TEC
   Zhen W, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00783-20
NR 20
TC 3
Z9 3
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2020
VL 58
IS 8
AR e01072-20
DI 10.1128/JCM.01072-20
PG 5
WC Microbiology
SC Microbiology
GA NU8WW
UT WOS:000573919100013
PM 32461285
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhen, W
   Smith, E
   Manji, R
   Schron, D
   Berry, GJ
AF Zhen, Wei
   Smith, Elizabeth
   Manji, Ryhana
   Schron, Deborah
   Berry, Gregory J.
TI Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of
   SARS-CoV-2
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE COVID-19; EUA; SARS-CoV-2; molecular diagnostics; nasopharyngeal;
   near-patient testing
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread across the globe. As part of the worldwide response, many molecular diagnostic platforms have been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA) to identify SARS-CoV-2 positive patients. Our objective was to evaluate three sample-to-answer molecular diagnostic platforms (Cepheid Xpert Xpress SARS-CoV-2 (Xpert Xpress), Abbott ID NOW COVID-19 [ID NOW), and GenMark ePlex SARS-CoV-2 Test [ePlex]) to determine analytical sensitivity, clinical performance, and workflow for the detection of SARS-CoV-2 in nasopharyngeal swabs from 108 symptomatic patients. We found that Xpert Xpress had the lowest limit of detection (100% detection at 100 copies/ml), followed by ePlex (100% detection at 1,000 copies/ml), and ID NOW (20,000 copies/ml). Xpert Xpress also had highest positive percent agreement (PPA) compared to our reference standard (98.3%) followed by ePlex (91.4%) and ID NOW (87.7%). All three assays showed 100% negative percent agreement (NPA). In the workflow analysis, ID NOW produced the lowest time to result per specimen (similar to 17 min) compared to Xpert Xpress (similar to 46 min) and ePlex (similar to 1.5 h), but what ID NOW gained in rapid results, it lost in analytical and clinical performance. ePlex had the longest time to results and showed a slight improvement in PPA over ID NOW. Information about the clinical and analytical performance of these assays, as well as workflow, will be critical in making informed and timely decisions on testing platforms.
C1 [Zhen, Wei; Smith, Elizabeth; Manji, Ryhana; Berry, Gregory J.] Northwell Hlth Labs, Infect Dis Diagnost, Lake Success, NY 11042 USA.
   [Schron, Deborah; Berry, Gregory J.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, East Garden City, NY 11549 USA.
RP Berry, GJ (corresponding author), Northwell Hlth Labs, Infect Dis Diagnost, Lake Success, NY 11042 USA.; Berry, GJ (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, East Garden City, NY 11549 USA.
EM gberry1@northwell.edu
CR CDC, 2020, GROUPS HIGH RISK SEV
   CDC, 2020, LOC CONF COVID 19 CA
   Center for Systems Science and Engineering Johns Hopkins Coronavirus Resource Center, 2020, COVID 19 DASHB CTR S
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   FINNEY DJ, 1948, BIOMETRIKA, V35, P191, DOI 10.1093/biomet/35.1-2.191
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   WHO-China Joint Mission, 2020, REP WHO CHIN JOINT M
NR 12
TC 27
Z9 27
U1 4
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2020
VL 58
IS 8
AR e00783-20
DI 10.1128/JCM.00783-20
PG 7
WC Microbiology
SC Microbiology
GA NU8WW
UT WOS:000573919100035
PM 32332061
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Michelena, X
   Borrell, H
   Lopez-Corbeto, M
   Lopez-Lasanta, M
   Moreno, E
   Pascual-Pastor, M
   Erra, A
   Serrat, M
   Espartal, E
   Anton, S
   Anez, GA
   Caparros-Ruiz, R
   Pluma, A
   Trallero-Araguas, E
   Barcelo-Bru, M
   Almirall, M
   De Agustin, JJ
   Llados, J
   Julia, A
   Marsal, S
AF Michelena, Xabier
   Borrell, Helena
   Lopez-Corbeto, Mireia
   Lopez-Lasanta, Maria
   Moreno, Estefania
   Pascual-Pastor, Maria
   Erra, Alba
   Serrat, Mayte
   Espartal, Esther
   Anton, Susana
   Anez, Gustavo Adolfo
   Caparros-Ruiz, Raquel
   Pluma, Andrea
   Trallero-Araguas, Ernesto
   Barcelo-Bru, Mireia
   Almirall, Miriam
   De Agustin, Juan Jose
   Llados, Jordi
   Julia, Antonio
   Marsal, Sara
TI Incidence of COVID-19 in a cohort of adult and paediatric patients with
   rheumatic diseases treated with targeted biologic and synthetic
   disease-modifying anti-rheumatic drugs
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Article
DE COVID-19; Targeted disease modifying anti-rheumatic drugs; Rheumatic
   diseases; Epidemiology; Pediatric rheumatology
ID INFECTION; ARTHRITIS; RISK
AB Objectives: To investigate the incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases receiving targeted biologic and synthetic disease modifying anti-rheumatic drugs (tDMARDs) and to explore the possible effect of these treatments in the clinical expression of COVID-19.
   Methods: A cross-sectional study comprising of a telephone survey and electronic health records review was performed including all adult and paediatric patients with rheumatic diseases treated with tDMARDs in a large rheumatology tertiary centre in Barcelona, Spain. Demographics, disease activity, COVID-19 related symptoms and contact history data were obtained from the start of the 2020 pandemic. Cumulative incidence of confirmed cases (SARS-CoV-2 positive PCR test) was compared to the population estimates for the same city districts from a governmental COVID-19 health database. Suspected cases were defined following WHO criteria and compared to those without compatible symptoms.
   Results: 959 patients with rheumatic diseases treated with tDMARDs were included. We identified 11 confirmed SARS-CoV-2 positive cases in the adult cohort and no confirmed positive cases in the paediatric cohort. COVID-19 incidence rates of the rheumatic patient cohort were very similar to that of the general population [(0.48% (95% CI 0.09 to 0.87%)] and [0.58% (95% CI 0.56 to 0.60%)], respectively. We found significant differences in tDMARDs proportions between the suspected and non-suspected cases (p=0.002).
   Conclusion: Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Michelena, Xabier; Borrell, Helena; Lopez-Corbeto, Mireia; Lopez-Lasanta, Maria; Moreno, Estefania; Pascual-Pastor, Maria; Erra, Alba; Serrat, Mayte; Espartal, Esther; Anton, Susana; Anez, Gustavo Adolfo; Caparros-Ruiz, Raquel; Pluma, Andrea; Trallero-Araguas, Ernesto; Barcelo-Bru, Mireia; Almirall, Miriam; De Agustin, Juan Jose; Llados, Jordi; Julia, Antonio; Marsal, Sara] Vall dHebron Univ Hosp, Vall dHebron Res Inst, Rheumatol Dept, Rheumatol Res Grp, Barcelona, Spain.
   [Michelena, Xabier] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
RP Marsal, S (corresponding author), Vall dHebron Univ Hosp, Vall dHebron Res Inst, Rheumatol Dept, Rheumatol Res Grp, Barcelona, Spain.
EM sara.marsal@vhir.org
RI Almirall, Miriam/ABG-8960-2020; Michelena, Xabier/AAL-8322-2020
OI Almirall, Miriam/0000-0002-4874-8013; Michelena,
   Xabier/0000-0002-5352-919X; Trallero-Araguas,
   Ernesto/0000-0003-3365-4521
FU Carlos III Institute of Health, Ministry of Economy and Competitiveness
   (Spain) [COV20_00357]; European Union ERDF funds (European Regional
   Development Fund)European Union (EU)
FX The project received a research grant from the Carlos III Institute of
   Health, Ministry of Economy and Competitiveness (Spain), awarded on the
   2020 call under the COVID-19 initiative, with reference COV20_00357,
   co-funded with European Union ERDF funds (European Regional Development
   Fund)".
CR American College of Rheumatology (ACR), COVID 19 CLIN GUID A
   [Anonymous], DAD DIAR INF COR SAR
   Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Dixon WG, 2012, ANN RHEUM DIS, V71, P1128, DOI 10.1136/annrheumdis-2011-200702
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524
   European League Against Rheumatism (EULAR), EULAR COVID 19 DAT
   European League Against Rheumatism (EULAR), EULAR GUID PAT COVID
   Favalli EG, 2020, J RHEUMATOL, V47, P1296, DOI 10.3899/jrheum.200507
   Feldman AM, 2011, ASIAN J LAW ECON, V2, DOI 10.2202/2154-4611.1033
   Fernandez-Diaz C, 2018, SEMIN ARTHRITIS RHEU, V48, P22, DOI 10.1016/j.semarthrit.2017.12.012
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Filocamo Giovanni, 2020, J Rheumatol, DOI 10.3899/jrheum.200483
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Gianfrancesco M, 2020, LANCET RHEUMATOL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Manfredi A, 2020, INTERN MED J, V50, P1085, DOI 10.1111/imj.14670
   McGonagle D, 2020, AUTOIMMUN REV, DOI [10.1016/j.autrev.2020.102537:102537., DOI 10.1016/J.AUTREV.2020.102537:102537]
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   National Institute for Health and Care Excellence (NICE), COVID 19 RAP GUID RH
   Paediatric Rheumatology European Association (PRES), PRES REC COR OUTBR
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   Schulze-Koops H, 2020, ANN RHEUM DIS, V79, P840, DOI 10.1136/annrheumdis-2020-217628
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, 2020, GLOB SURV COVID 19 C
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
NR 34
TC 21
Z9 19
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD AUG
PY 2020
VL 50
IS 4
BP 564
EP 570
DI 10.1016/j.semarthrit.2020.05.001
PG 7
WC Rheumatology
SC Rheumatology
GA NT6JA
UT WOS:000573043500007
PM 32425260
OA Green Published
DA 2021-01-01
ER

PT J
AU Sharmeen, S
   Elghawy, A
   Zarlasht, F
   Yao, QP
AF Sharmeen, Saika
   Elghawy, Ahmed
   Zarlasht, Fnu
   Yao, Qingping
TI COVID-19 in rheumatic disease patients on immunosuppressive agents
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Article
DE COVID-19; Rheumatic disease; DMARDs; Biologics; SARS CoV-2
ID MACROPHAGE ACTIVATION SYNDROME; CLINICAL-COURSE; PATHOGENESIS;
   TOCILIZUMAB; SARS-COV-2; ANTIBODIES; INFECTION; ARTHRITIS; SERIES
AB Objective: To analyze clinical characteristics and outcome of COVID-19 patients with underlying rheumatic diseases (RD) on immunosuppressive agents.
   Method: A case series of COVID-19 patients with RD on disease modifying anti-rheumatic drugs (DMARDs) were studied by a retrospective chart review. A literature search identified 9 similar studies of single cases and case series, which were also included.
   Results: There were 4 COVID-19 inpatients with RD from our hospital, and the mean age was 57 +/- 21 years. Two patients had a mild infection, and 2 developed severe COVID-19 related respiratory complications, including 1 patient on secukinumab requiring mechanical ventilation and 1 patient on rituximab developing viral pneumonia requiring supplemental oxygenation. All 4 patients had elevated acute phase reactants, 2 patients had mild COVID-19 with lymphopenia, and 2 patients had severe COVID-19 with normal lymphocyte counts, and high levels of IL-6. None of the patients exhibited an exacerbation of their underlying RD. In the literature, there were 9 studies of COVID-19 involving 197 cases of various inflammatory RD. Most patients were on DMARDs or biologics, of which TNF alpha inhibitors were most frequently used. Two tocilizumab users had a mild infection. Two patients were on rituximab with 1 severe COVID-19 requiring mechanical ventilation. Six patients were on secukinumab with 1 hospitalization. Of the total 201 cases, 12 died, with an estimated mortality of 5.9%
   Conclusion: Patients with RD are susceptible to COVID-19. Various DMARDs or biologics may affect the viral disease course differently. Patients on hydroxychloroquine, TNF alpha antagonists or tocilizumab may have a mild viral illness. Rituximab or secukinumab could worsen the viral disease. Further study is warranted. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Sharmeen, Saika; Elghawy, Ahmed; Zarlasht, Fnu; Yao, Qingping] SUNY Stony Brook, Renaissance Sch Med, Dept Med, Div Rheumatol Allergy & Immunol, Stony Brook, NY 11794 USA.
RP Yao, QP (corresponding author), SUNY Stony Brook, Dept Med, Div Rheumatol Allergy & Immunol, Stony Brook, NY 11794 USA.
EM qingping.yao@stonybrookmedicine.edu
CR Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Chowdhury MDS, 2020, ACAD EMERG MED, V27, P493, DOI 10.1111/acem.14005
   De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802
   Duret PM, 2020, ANN RHEUM DIS, V79, P1250, DOI [10.1136/annrheumdis-2020-217362, 10.1080/17843286.2020.1812830]
   Favalli EG, 2020, ANN RHEUM DIS, V79, P718, DOI 10.1136/annrheumdis-2020-eular.3197
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715
   Grom AA, 2016, NAT REV RHEUMATOL, V12, P259, DOI 10.1038/nrrheum.2015.179
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guilpain P, 2020, ANN RHEUM DIS   0420, DOI [10.1136/annr- heumdis-2020-217549, DOI 10.1136/ANNR-HEUMDIS-2020-217549, 10.1136/annr-heumdis-2020-217549.]
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kostik MM, 2015, SEMIN ARTHRITIS RHEU, V44, P417, DOI 10.1016/j.semarthrit.2014.09.004
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO, DOI [10.1101/2020.04.16.2006592063., DOI 10.1101/2020.04.16.2006592063]
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Monteagudo Luke Adam, 2020, ACR Open Rheumatol, V2, P276, DOI 10.1002/acr2.11135
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Moutsopoulos HM, 2020, ANN RHEUM DIS, V79, P1253, DOI 10.1136/annrheumdis-2020-217562
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Ruperto N, 2012, NEW ENGL J MED, V367, P2396, DOI 10.1056/NEJMoa1205099
   Sciascia S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103469
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   TANG JJ, 2020, J INFECTION, DOI DOI 10.1016/J.JINF.2020.03.019
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 42
TC 4
Z9 4
U1 3
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD AUG
PY 2020
VL 50
IS 4
BP 680
EP 686
DI 10.1016/j.semarthrit.2020.05.010
PG 7
WC Rheumatology
SC Rheumatology
GA NT6JA
UT WOS:000573043500024
PM 32512263
OA Green Published
DA 2021-01-01
ER

PT J
AU Belkhadir, J
AF Belkhadir, Jamal
TI COVID-19 and diabetes from IDF MENA region
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Diabetes; COVID-19; MENA region
AB The whole world are facing the current COVID-19 pandemic, the most serious health crisis in modern times. All countries with the support of national and international agencies are making great efforts to fight this devastating pandemic with disastrous medical, economic and social consequences. This pandemic affects all people but it's serious in case of diabetes, elderly and in chronic and complicated diseases. The current work on the theme "COVID-19 and Diabetes" attempts to bring together all the data available at MENA level through medical and scientific publications. It also includes all the efforts made by the governments and the responses of associations and their efforts in this field. Even if it is admitted that diabetes with its comorbidity represents a high risk factor for severe forms and mortality, the health consequences of the epidemic, does not seem as dramatic in terms of both morbidity and mortality of COVID-19 with diabetes in the majority of MENA countries. If the crises continues longer, the supply of insulin, oral drugs, self monitoring equipment of diabetes and other tools, will be affected. To this, we must expect great difficulties in supplying food for many countries. Certainely, it is important to remember that containment and hygiene measures, associated with other factors such as the young average age of the population, the higher temperature in these countries, the differences in the immune status of populations and the role of BCG vaccine have something to do with it. All of this deserves to be studied in depth. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Belkhadir, Jamal] Chair IDF MENA Reg, Rabat, Morocco.
RP Belkhadir, J (corresponding author), Chair IDF MENA Reg, Rabat, Morocco.
CR Al Nsour M, 2020, JMIR PUBLIC HLTH SUR, V6, P86, DOI 10.2196/18503
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Ghosal Samit, 2020, DIABETES METABOLIC S, V14, P319
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Hanif S, 2020, DIABETIC MED, V37, P1094, DOI 10.1111/dme.14312
   Hassanein M, 2019, DIABETES RES CLIN PR, V151, P275, DOI 10.1016/j.diabres.2019.02.020
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Mahmoud Ibrahim, 2020, BMJ OPEN DIAB RES CA, V2020, DOI [10.1136/bmjdrc-2020-001248, DOI 10.1136/BMJDRC-2020-001248.E001248]
   Mehra MR, 2020, HYDROXYCHLOROQUINE C, DOI [10.1016/S0140-6736(20)31180-6, DOI 10.1016/S0140-6736(20)31180-6, 10.1016/S0140-6736(20)31180-6.]
   Shiying Shao, 2020, PHARMACOL THERAPEUT, V209, P107503
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD AUG
PY 2020
VL 166
AR 108277
DI 10.1016/j.diabres.2020.108277
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NT3KU
UT WOS:000572845000042
PM 32592837
OA Bronze
DA 2021-01-01
ER

PT J
AU Hwang, Y
   Khasag, A
   Jia, WP
   Jenkins, A
   Huang, CN
   Yabe, D
   Kim, DM
   Kadowaki, T
   Lee, MK
AF Hwang, Yerin
   Khasag, Altaisaikhan
   Jia, Weiping
   Jenkins, Alicia
   Huang, Chien-Ning
   Yabe, Daisuke
   Kim, Doo-Man
   Kadowaki, Takashi
   Lee, Moon-Kyu
TI Diabetes and COVID-19: IDF perspective in the Western Pacific region
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Diabetes; COVID-19
AB The World Health Organization (WHO) declared a pandemic, the highest risk level in the infectious disease alert phase, on 11 March 2020. In the Western Pacific Region (WPR), 192,016 confirmed cases with 7125 deaths had been reported as of 8 June 2020.
   In people with diabetes COVID-19 can be more difficult to treat due to the wide fluctuations in blood glucose levels or presence of comorbidities such as diabetes complications, including cardiovascular disease and renal damage, which are recognized risks for adverse outcomes. National diabetes associations and governments have established guidelines for subjects with diabetes in relation to COVID-19, and are trying to supply emergency and their regularly required medical products for them.
   The WPR is so large and composed of such diverse countries and COVID-19 situations, no one conclusion or program applies. Instead we could see a diverse COVID-19 pandemic pro file in the WPR, and several creative diagnostic and therapeutic measures undertaken. This includes drive-through screening facilities, high-speed RT-PCR technologies, convalescent patients' plasma therapy, which potentially had some positive contributions in combatting COVID-19 in the WPR as well as globally. Although the numbers of confirmed cases are currently decreasing in the region, the COVID-19 pandemic is not over, and many experts are recommending to prepare measures for potential second or third waves of COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Hwang, Yerin] Sungkyunkwan Univ, Sch Med, Dept Social & Prevent Med, Suwon, South Korea.
   [Khasag, Altaisaikhan] Hlth Sci Univ Mongolia, Ulaanbaatar, Mongolia.
   [Jia, Weiping] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Shanghai Diabet Inst, Shanghai, Peoples R China.
   [Jenkins, Alicia] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia.
   [Huang, Chien-Ning] Chung Shang Med Univ Hosp, Inst Med, Taichung, Taiwan.
   [Yabe, Daisuke] Gifu Univ, Grad Sch Med, Dept Diabet & Endocrinol, Gifu, Japan.
   [Kim, Doo-Man] Hallym Univ, Sch Med, Dept Endocrinol & Metab, Seoul, South Korea.
   [Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Diabet & Metab Dis, Tokyo, Japan.
   [Kadowaki, Takashi] Toranomon Gen Hosp, Tokyo, Japan.
   [Lee, Moon-Kyu] Soonchunhyang Univ, Gumi Hosp, Dept Internal Med, Div Endocrinol & Metab,Coll Med, Gumi, South Korea.
   [Lee, Moon-Kyu] IDF Western Pacific Reg, Seoul, South Korea.
RP Lee, MK (corresponding author), Soonchunhyang Univ, Gumi Hosp, Dept Internal Med, Div Endocrinol & Metab,Coll Med, Gumi, South Korea.; Lee, MK (corresponding author), IDF Western Pacific Reg, Seoul, South Korea.
EM leemk4132@gmail.com
CR Andrikopoulos S, 2020, DIABETES RES CLIN PR, V165, DOI 10.1016/j.diabres.2020.108246
   [Anonymous], 2020, FIGHTING COVID 19 CH
   Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020
   Venkatesh Nisha, 2020, J Diabetes Sci Technol, V14, P803, DOI 10.1177/1932296820929708
   World Health Organization, WHO W PAC REG ACT PL
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   中华医学会糖尿病学分会, 2020, [中华糖尿病杂志, Chinese Journal of Diabetes Mellitus], V12, P73
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD AUG
PY 2020
VL 166
AR 108278
DI 10.1016/j.diabres.2020.108278
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NT3KU
UT WOS:000572845000003
PM 32592842
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chatterjee, SS
   Malathesh, BC
   Das, S
   Singh, OP
AF Chatterjee, Seshadri Sekhar
   Malathesh, Barikar C.
   Das, Soumitra
   Singh, Om Prakash
TI Interactions of recommended COVID-19 drugs with commonly used
   psychotropics
SO ASIAN JOURNAL OF PSYCHIATRY
LA English
DT Letter
DE Hydroxychloroquine; Psychotropics; Drug interaction; COVID-19;
   Ritonavir/Lopinavir
ID LOPINAVIR/RITONAVIR
C1 [Chatterjee, Seshadri Sekhar] Diamond Harbour Med Coll, Dept Psychiat, Diamond Harbour, W Bengal, India.
   [Malathesh, Barikar C.] NIMHANS, Dept Psychiat, Bengaluru, India.
   [Das, Soumitra] NWMH, Melbourne, Vic, Australia.
   [Singh, Om Prakash] West Bengal Univ Hlth Sci, Dept Psychiat, Kolkata, India.
RP Malathesh, BC (corresponding author), NIMHANS, Dept Psychiat, Bengaluru, India.
EM bc.malathesh@gmail.com
RI Chatterjee, Seshadri Sekhar/AAI-9523-2020; Barikar,
   Malathesh/AAC-4211-2019
OI Chatterjee, Seshadri Sekhar/0000-0002-5554-2216; Barikar,
   Malathesh/0000-0001-9107-1717; Singh, Om Prakash/0000-0001-7672-3676
CR Beach SR, 2018, PSYCHOSOMATICS, V59, P105, DOI 10.1016/j.psym.2017.10.009
   Chatterjee SS, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102071
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   English BA, 2012, CURR PSYCHIAT REP, V14, P376, DOI 10.1007/s11920-012-0284-9
   FDA, 2020, COR COVID 19 UPD FDA
   Govt of India, 2020, REV GUID CLIN MAN CO
   Haas SJ, 2007, DRUG SAFETY, V30, P47, DOI 10.2165/00002018-200730010-00005
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sheehan NL, 2006, ANN PHARMACOTHER, V40, P147, DOI 10.1345/aph.1G418
   Tandon R, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.102100
NR 10
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1876-2018
EI 1876-2026
J9 ASIAN J PSYCHIATR
JI Asian J. Psychiatr.
PD AUG
PY 2020
VL 52
AR 102173
DI 10.1016/j.ajp.2020.102173
PG 2
WC Psychiatry
SC Psychiatry
GA NU4ZK
UT WOS:000573651300035
PM 32446195
OA Green Published
DA 2021-01-01
ER

PT J
AU Vaira, LA
   Hopkins, C
   Petrocelli, M
   Lechien, JR
   Chiesa-Estomba, CM
   Salzano, G
   Cucurullo, M
   Salzano, FA
   Saussez, S
   Boscolo-Rizzo, P
   Biglioli, F
   De Riu, G
AF Vaira, L. A.
   Hopkins, C.
   Petrocelli, M.
   Lechien, J. R.
   Chiesa-Estomba, C. M.
   Salzano, G.
   Cucurullo, M.
   Salzano, F. A.
   Saussez, S.
   Boscolo-Rizzo, P.
   Biglioli, F.
   De Riu, G.
TI Smell and taste recovery in coronavirus disease 2019 patients: a 60-day
   objective and prospective study
SO JOURNAL OF LARYNGOLOGY AND OTOLOGY
LA English
DT Article
DE COVID-19; Ageusia; Anosmia; Gustatory Dysfunction; SARS-CoV-2;
   Coronavirus; Hypogeusia; Smell; Taste
ID DYSFUNCTION
AB Background The long-term recovery rate of chemosensitive functions in coronavirus disease 2019 patients has not yet been determined. Method A multicentre prospective study on 138 coronavirus disease 2019 patients was conducted. Olfactory and gustatory functions were prospectively evaluated for 60 days. Results Within the first 4 days of coronavirus disease 2019, 84.8 per cent of patients had chemosensitive dysfunction that gradually improved over the observation period. The most significant increase in chemosensitive scores occurred in the first 10 days for taste and between 10 and 20 days for smell. At the end of the observation period (60 days after symptom onset), 7.2 per cent of the patients still had severe dysfunctions. The risk of developing a long-lasting disorder becomes significant at 10 days for taste (odds ratio = 40.2, 95 per cent confidence interval = 2.204-733.2,p= 0.013) and 20 days for smell (odds ratio = 58.5, 95 per cent confidence interval = 3.278-1043.5,p= 0.005). Conclusion Chemosensitive disturbances persisted in 7.2 per cent of patients 60 days after clinical onset. Specific therapies should be initiated in patients with severe olfactory and gustatory disturbances 20 days after disease onset.
C1 [Vaira, L. A.; De Riu, G.] Univ Hosp Sassari, Maxillofacial Surg Operat Unit, Sassari, Italy.
   [Hopkins, C.] Kings Coll London, ENT Dept, London, England.
   [Petrocelli, M.] Bellaria Maggiore Hosp, Unazienda Sanitaria Locale AUSL, Maxillofacial Surg Operat Unit, Bologna, Italy.
   [Lechien, J. R.; Chiesa-Estomba, C. M.; Saussez, S.] Young Otolaryngologists Int Federat Otorhinolaryn, COVID 19 Task Force, Bologna, Italy.
   [Lechien, J. R.] Univ Mons UMons, UMONS Res Inst Hlth Sci & Technol, Fac Med, Dept Human & Expt Oncol, Mons, Belgium.
   [Chiesa-Estomba, C. M.] Donostia Univ Hosp, Biodonostia Hlth Res Inst, Osakidetza, Dept Otorhinolaryngol, San Sebastian, Spain.
   [Salzano, G.] Univ Hosp Naples Federico II, Maxillofacial Surg Unit, Naples, Italy.
   [Cucurullo, M.; Biglioli, F.] Univ Milan, San Paolo Hosp, Azienda Socio Sanit Territoriale ASST Santi Paolo, Maxillofacial Surg Dept, Milan, Italy.
   [Salzano, F. A.] Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Otolaryngol Operat Unit, Salerno, Italy.
   [Boscolo-Rizzo, P.] Univ Padua, Dept Neurosci, Sect Otolaryngol, Treviso, Italy.
RP Vaira, LA (corresponding author), Viale San Pietro 43-B, I-07100 Sassari, Italy.
EM luigi.vaira@gmail.com
RI Vaira, Luigi Angelo/AAS-7736-2020
OI Vaira, Luigi Angelo/0000-0002-7789-145X; BOSCOLO RIZZO,
   PAOLO/0000-0002-4635-7959
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   CAIN WS, 1988, LARYNGOSCOPE, V98, P83
   Calvo-Henriquez C, 2020, EUR ARCH OTORHINOLAR
   Heilmann S, 2004, AM J RHINOL, V18, P29, DOI 10.1177/194589240401800107
   Hopkins C, 2020, INT FORUM ALLERGY RH, V10, P926, DOI 10.1002/alr.22608
   Hopkins C, 2020, RHINOLOGY, V58, P295, DOI 10.4193/Rhin20.116
   Hummel T, 2002, LARYNGOSCOPE, V112, P2076, DOI 10.1097/00005537-200211000-00031
   Hummel T, 2017, EUR ARCH OTO-RHINO-L, V274, P2819, DOI 10.1007/s00405-017-4576-x
   Lechien JR, 2020, HEAD NECK-J SCI SPEC, V42, P1583, DOI 10.1002/hed.26279
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lechien JR, 2020, RHINOLOGY
   Lechien JR, 2020, ANN INTERN MED
   Maglitto F, 2020, EUR J PLAST SURG, V43, P865, DOI 10.1007/s00238-020-01705-0
   Massarelli O, 2018, HEAD NECK-J SCI SPEC, V40, P467, DOI 10.1002/hed.25000
   Moein ST, 2020, INT FORUM ALLERGY RH, V10, P944, DOI 10.1002/alr.22587
   Rodrigo SG, 2016, EPJ APPL METAMATERIA, V3, DOI 10.1051/epjam/2016013
   Russell Beth, 2020, Ecancermedicalscience, V14, ped98, DOI 10.3332/ecancer.2020.ed98
   Sorokowska A, 2017, RHINOLOGY, V55, P17, DOI 10.4193/Rhin16.195
   Spinato G, 2020, JAMA-J AM MED ASSOC, V323, P2089, DOI 10.1001/jama.2020.6771
   Vaira L.A., 2020, INT FORUM ALLERGY RH
   Vaira LA, 2020, LARYNGOSCOPE, V130, P1787, DOI 10.1002/lary.28692
   Vaira LA, 2020, J OTOLARYNGOL-HEAD N, V49, DOI 10.1186/s40463-020-00449-y
   Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1560, DOI 10.1002/hed.26269
   Vaira LA, 2020, BRIT J ORAL MAX SURG, V58, P615, DOI 10.1016/j.bjoms.2020.04.024
   Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1570, DOI 10.1002/hed.26228
   Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1252, DOI 10.1002/hed.26204
   Veyseller B, 2014, INDIAN J OTOLARYNGOL, V66, P31, DOI 10.1007/s12070-013-0632-z
   Xydakis M.S., 2020, LANCET INFECT DIS
   Yan CH, 2020, NEUROSURGERY, V87, pE91, DOI 10.1093/neuros/nyz559
NR 29
TC 4
Z9 4
U1 3
U2 3
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022-2151
EI 1748-5460
J9 J LARYNGOL OTOL
JI J. Laryngol. Otol.
PD AUG
PY 2020
VL 134
IS 8
BP 703
EP 709
AR PII S0022215120001826
DI 10.1017/S0022215120001826
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NS7AB
UT WOS:000572409000009
PM 32782030
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Saha, A
   Sharma, AR
   Bhattacharya, M
   Sharma, G
   Lee, SS
   Chakraborty, C
AF Saha, Abinit
   Sharma, Ashish Ranjan
   Bhattacharya, Manojit
   Sharma, Garima
   Lee, Sang-Soo
   Chakraborty, Chiranjib
TI Probable Molecular Mechanism of Remdesivir for the Treatment of
   COVID-19: Need to Know More
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE SARS-CoV-2; Remdesivir; COVID-19; Therapeutic molecule
AB COVID-19 is now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as 'molecule of hope' for the treatment of this disease. USFDA gave emergency approval to this drug for the treatment of COVID-19. The molecular mechanism is unknown. In this pa per, we tried to describe the probable molecular mechanism of remdesivir to inhibit the RNA synthesis of SARS-CoV-2. However, more detail mechanism is needed to understand mechanism of action of remdesivir. (c) 2020 IMSS. Published by Elsevier Inc.
C1 [Saha, Abinit; Chakraborty, Chiranjib] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
   [Sharma, Ashish Ranjan; Lee, Sang-Soo] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si, Gangwon Do, South Korea.
   [Bhattacharya, Manojit] Fakir Mohan Univ, Dept Zool, VyasaVihar, Balasore, Odisha, India.
   [Sharma, Garima] Kangwon Natl Univ, Neuropsychopharmacol & Toxicol Program, Coll Pharm, Gangwon Do, South Korea.
RP Chakraborty, C (corresponding author), Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
EM 123sslee@gmail.com
OI Chkraborty, Chiranjib/0000-0002-3958-239X
FU Hallym University Research Fund; Basic Science Research Program through
   the National Research Foundation of Korea (NRF) - Ministry of Education
   [NRF-2017R1A2B4012944]
FX This research was supported by Hallym University Research Fund and by
   the Basic Science Research Program through the National Research
   Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF-2017R1A2B4012944).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, 2019 NOVEL CORONAVIR
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Warren TK, 2017, DISCOVERY SYNTHESIS
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
NR 11
TC 15
Z9 15
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD AUG
PY 2020
VL 51
IS 6
BP 585
EP 586
DI 10.1016/j.arcmed.2020.05.001
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NR4HY
UT WOS:000571526400016
PM 32439198
OA Green Published
DA 2021-01-01
ER

PT J
AU Dahan, S
   Segal, G
   Katz, I
   Hellou, T
   Tietel, M
   Bryk, G
   Amital, H
   Shoenfeld, Y
   Dagan, A
AF Dahan, Shani
   Segal, Gad
   Katz, Itai
   Hellou, Tamar
   Tietel, Michal
   Bryk, Gabriel
   Amital, Howard
   Shoenfeld, Yehuda
   Dagan, Amir
TI Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal
   Correlation
SO ISRAEL MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
DE autoimmunity; coronavirus disease-2019 (COVID-19); ferritin;
   hyperferritinemic syndrome; macrophage activating syndrome (MAS)
ID IRON-METABOLISM; CYTOKINES; SERUM; HYPERFERRITINEMIA; ELEMENTS; THERAPY;
   CELLS
AB Background: Ferritin, the cellular protein storage for iron, has emerged as a key molecule in the immune system, orchestrating the cellular defense against inflammation. At the end of 2019, the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) rapidly spread throughout China and other countries around the world, resulting in a viral pandemic.
   Objectives: To evaluate the correlation between ferritin and disease severity in coronavirus disease-2019 (COVID-19).
   Methods: In this cross-sectional study, we obtained clinical and laboratory data regarding 39 hospitalized patients with confirmed COVID-19 from two hospitals in Israel.
   Results: A significant increase in ferritin levels was demonstrated in patients with moderate and severe disease, compared to patients with mild disease (P = 0.006 and 0.005, respectively). Severe patients had significantly higher levels of ferritin (2817.6 ng/ml) than non-severe patients (708.6 ng/ml) P = 0.02.
   Conclusions: In this preliminary cross-sectional study, elevated ferritin levels were shown to correlate with disease severity in 39 patients from Israel with confirmed COVID-19 infection. Our results further strengthen the hypothesis that severe COVID-19 disease might be due to an underlying dysregulated hyperimmune response. In order to identify these patients early and prioritized resources, we believe that all patients with COVID-19 should be screened for hyperferritinemia.
C1 [Dahan, Shani; Hellou, Tamar; Tietel, Michal; Dagan, Amir] Assuta Ashdod Med Ctr, Dept Internal Med B, IL-7747629 Ashdod, Israel.
   [Dagan, Amir] Assuta Ashdod Med Ctr, Dept Rheumatol, Ashdod, Israel.
   Assuta Ashdod Med Ctr, Div Labs, Ashdod, Israel.
   Ben Gurion Univ Negev, Beer Sheva, Israel.
   [Amital, Howard] Sheba Med Ctr, Dept Internal Med B, Tel Hashomer, Israel.
   [Segal, Gad; Bryk, Gabriel] Sheba Med Ctr, Dept Internal Med T, Tel Hashomer, Israel.
   [Katz, Itai; Amital, Howard; Shoenfeld, Yehuda] Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Hashomer, Israel.
   [Dahan, Shani; Segal, Gad; Katz, Itai; Shoenfeld, Yehuda] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
RP Dahan, S (corresponding author), Assuta Ashdod Med Ctr, Dept Internal Med B, IL-7747629 Ashdod, Israel.
EM shish.dahan@gmail.com
CR ADDISON GM, 1972, J CLIN PATHOL, V25, P326, DOI 10.1136/jcp.25.4.326
   Agmon-Levin N, 2013, LUPUS, V22, P1327, DOI 10.1177/0961203313504633
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arosio P, 2010, BBA-GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005
   Bishara R, 2016, CLIN RHEUMATOL, V35, P795, DOI 10.1007/s10067-014-2829-2
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Colafrancesco S, 2014, ISR MED ASSOC J, V16, P662
   FAHMY M, 1993, BIOCHEM J, V296, P175, DOI 10.1042/bj2960175
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   FINCH CA, 1986, WESTERN J MED, V145, P657
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Hintze KJ, 2005, P NATL ACAD SCI USA, V102, P15048, DOI 10.1073/pnas.0505148102
   HIRAYAMA M, 1993, HEPATOLOGY, V18, P874, DOI 10.1002/hep.1840180420
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   JACOBS A, 1975, NEW ENGL J MED, V292, P951, DOI 10.1056/NEJM197505012921805
   Kanduc D, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108426
   KONIJN AM, 1981, BRIT J HAEMATOL, V49, P361, DOI 10.1111/j.1365-2141.1981.tb07238.x
   Laufberger V, 1937, B SOC CHIM BIOL, V19, P1575
   McIntosh K, CORONAVIRUS DIS 2019
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143
   Orbach H, 2007, ANN NY ACAD SCI, V1109, P385, DOI 10.1196/annals.1398.044
   da Rosa GP, 2020, CLIN EXP RHEUMATOL, V38, P370
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Rosario C, 2014, ISR MED ASSOC J, V16, P664
   Rosario C, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-185
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Ruscitti P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01130
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sharif K, 2018, CLIN EXP IMMUNOL, V191, P149, DOI 10.1111/cei.13069
   Smirnov IM, 1999, AM J PHYSIOL-LUNG C, V277, pL257
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505
   Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261
   Tu GW, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1284-7
   Wan S., 2020, CHARACTERISTICS LYMP
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011
   WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6
   WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, NOV COR 2019 NCOV TE
   World Health Organization, DIR GEN REM MED BRIE
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zandman-Goddard G, 2008, ISR MED ASSOC J, V10, P83
   Zandman-Goddard G, 2007, AUTOIMMUN REV, V6, P457, DOI 10.1016/j.autrev.2007.01.016
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 55
TC 2
Z9 2
U1 1
U2 1
PU ISRAEL MEDICAL ASSOC JOURNAL
PI RAMAT GAN
PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136,
   ISRAEL
SN 1565-1088
J9 ISR MED ASSOC J
JI Isr. Med. Assoc. J.
PD AUG
PY 2020
VL 22
IS 8
BP 428
EP 434
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS4CZ
UT WOS:000572212900006
PM 32812717
DA 2021-01-01
ER

PT J
AU McKay, D
   Minaya, C
   Storch, EA
AF McKay, Dean
   Minaya, Charlene
   Storch, Eric A.
TI Conducting exposure and response prevention treatment for contamination
   fears during COVID-19: The behavioral immune system impact on clinician
   approaches to treatment
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE COVID-19; Coronavirus; Contamination fear; Obsessive-Compulsive
   Disorder; Clinicians; Exposure with response prevention
ID INTOLERANCE; THERAPY
AB The coronavirus disease 2019 (COVID-19) pandemic sparked significant anxiety regarding viral rates and means of transmission. Heightened concerns about contamination have prompted new hygienic strategies to vigilantly guard against infection, including hand washing immediately after touching foreign objects or suspected contaminants. This has presented a critical challenge for the delivery of exposure and response prevention (ERP) therapy to individuals with contamination fears due to Obsessive Compulsive Disorder (OCD), as providers must manage not only their clients' attitudes and reactions but their own as well. In this investigation, self-identified anxiety and OCD treatment specialists (N = 139) provided demographic information, including their anxiety and OCD caseloads, and completed measures related to intolerance of uncertainty (IUS-SF; Carlton a al., 2007), beliefs about exposure therapy (TBES; Deacon a al., 2013), and emotional reactions to physical sensations (The Chills; Maruskin a al., 2012). We tested the hypothesis that intolerance of uncertainty and activation of the behavioral immune system (BIS; Schaller & Park, 2011), a mechanism theoretically activated by the prominent emergence of pathogens to protect against illness would predict attitudes toward exposure. The Chills Scale was used to assess BIS activation, a broad assessment of vasoconstriction responses associated with different emotional reactions, and includes a subscale (coldness) that evaluates vasoconstriction associated with defense against pathogens. Both coldness and OCD caseload, but not anxiety caseload or subscales of intolerance of uncertainty, emerged as significant predictors of clinicians' beliefs about exposure; increases in OCD caseload were also related to decreases in negative beliefs about exposure. Findings are useful in determining methods for aiding clinicians in developing effective approaches to contamination fears during and post-pandemic that include addressing their own BIS-related concerns and mapping out means for social behavioral norms associated with engaging in exposure treatment.
C1 [McKay, Dean; Minaya, Charlene] Fordham Univ, Bronx, NY 10458 USA.
   [Storch, Eric A.] Baylor Coll Med, Houston, TX 77030 USA.
RP McKay, D (corresponding author), Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
EM mckay@fordham.edu
OI McKay, Dean/0000-0003-1158-5043
CR Blake S, 2016, INT J EVID BASED COA, P1
   Carleton RN, 2007, J ANXIETY DISORD, V21, P105, DOI 10.1016/j.janxdis.2006.03.014
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, 2020, INT REC US HOUS SUSP
   Deacon BJ, 2013, J ANXIETY DISORD, V27, P259, DOI 10.1016/j.janxdis.2013.02.004
   Farrell NR, 2013, J ANXIETY DISORD, V27, P763, DOI 10.1016/j.janxdis.2013.03.007
   Jacoby RJ, 2013, J ANXIETY DISORD, V27, P535, DOI 10.1016/j.janxdis.2013.07.008
   Kupfer TR, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0207
   Mancusi L., 2020, BEHAV AVOIDANCE TASK
   Maruskin LA, 2012, J PERS SOC PSYCHOL, V103, P135, DOI 10.1037/a0028117
   Mckay D, 2020, J ANXIETY DISORD, V73, DOI 10.1016/j.janxdis.2020.102233
   Mckay D, 2015, PSYCHIAT RES, V225, P236, DOI 10.1016/j.psychres.2014.11.058
   Richard D. C. S., 2006, HDB EXPOSURE THERAPI, P409
   Saluja S, 2019, Q J EXP PSYCHOL, V72, P2705, DOI 10.1177/1747021819862500
   Schaller M, 2011, CURR DIR PSYCHOL SCI, V20, P99, DOI 10.1177/0963721411402596
   Storch E.A., 2020, IMPACT COVID 19 EXPO
   Zoellner LA, 2011, PSYCHOL TRAUMA-US, V3, P300, DOI 10.1037/a0024642
NR 17
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD AUG
PY 2020
VL 74
AR 102270
DI 10.1016/j.janxdis.2020.102270
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA NR7FV
UT WOS:000571727500015
PM 32650220
OA Green Published
DA 2021-01-01
ER

PT J
AU Afriyie, DK
   Asare, GA
   Amponsah, SK
   Godman, B
AF Afriyie, Daniel Kwame
   Asare, George Awuku
   Amponsah, Seth Kwabena
   Godman, Brian
TI COVID-19 pandemic in resource-poor countries: challenges, experiences
   and opportunities in Ghana
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Novel SARS-CoV-2; COVID-19; Ghana; challenges; opportunities
ID CORONAVIRUS
AB The novel coronavirus, SARS-CoV-2, which causes COVID-19, is seen world-wide. In developing countries, adequate health facilities and staff numbers are a concern. Ghana recorded its first 2 cases of COVID-19 on 12 March 2020. On 30 March 2020, a partial lockdown for 14 days was imposed and later extended along with other measures. By the end of the initial lockdown, 19 April 2020, an estimated 86,000 people had been traced and 68,591 tests performed. Of the 68,591 tests, there were 1,042 (1.5%) positive cases, 9 deaths, and 99 recoveries, with Ghana ranked number one among African countries in administering tests per million people. Ghana's effective track and trace system, as well as lockdown and other measures, have helped limit mortality with only 85 recorded deaths by 23 June 2020. Scientists from three facilities of the University of Ghana have also successfully sequenced the genomes of COVID-19 from 15 confirmed cases, and the Food and Drugs Authority in Ghana have also helped address shortages by fast-tracking certification of hand sanitizers and local production of 3.6 million standardized personal protective equipment. There has also been the development of prototypes of locally-manufactured mechanical ventilators to meet local need at intensive care units. Most people have also resorted to changing diets and the use of supplements to boost their immune system. Although initial results are encouraging, further research is needed to understand the dynamics of COVID-19 in Ghana and provide additional guidance.
C1 [Afriyie, Daniel Kwame] Ghana Police Hosp, Pharm Dept, PMB CT 104, Cantonments, Accra, Ghana.
   [Asare, George Awuku] Univ Ghana, Sch Biomed & Allied Hlth Sci, Dept Med Lab Sci, Accra, Ghana.
   [Amponsah, Seth Kwabena] Univ Ghana, Dept Med Pharmacol, Med Sch, Accra, Ghana.
   [Godman, Brian] Strathclyde Univ, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland.
   [Godman, Brian] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Clin Pharmacol, Huddinge, Sweden.
   [Godman, Brian] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Div Publ Hlth Pharm & Management, Pretoria, South Africa.
RP Afriyie, DK (corresponding author), Ghana Police Hosp, Pharm Dept, PMB CT 104, Cantonments, Accra, Ghana.
EM copdan78@gmail.com
CR Abena PM, 2020, AM J TROP MED HYG, V102, P1184, DOI 10.4269/ajtmh.20-0290
   Beigel JH, 2020, ACTT 1 STUDY GROUP M, DOI DOI 10.1056/NEJM0A2007764.ACCESSED
   Classfm, 2020, BACKL 18000 COVID 19
   Debrah EK, 2020, CHLOROQUINE CORONAVI
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   El-Sadr WM, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2008193
   Ghana News Agency, 2020, SUCC TEST REG CONTR
   Ghana News Agency, 2020, GHAN LOC MAD MECH VE
   Ghana News Agency, 2020, GHAN TOPS AFR RANK C
   Godman B, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00108
   Godman B, 2020, CURR MED RES OPIN, V36, P301, DOI 10.1080/03007995.2019.1700947
   Haque M, 2020, BANGLADESH J MED SCI, V19, pS1, DOI 10.3329/bjms.v19i0.47610
   Institute for Health Metrics and Evaluation (IHME), 2020, NEW COVID 19 FOR US
   Institute for Health Metrics and Evaluation (IHME), 2020, NEW COVID 19 FOR EUR
   Kirby T, 2020, LANCET RESP MED, V8, P547, DOI 10.1016/S2213-2600(20)30228-9
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YX, 2020, SYST REV-LONDON, V9, DOI [10.1186/s13643-020-01432-4, 10.1186/s13643-020-01343-4]
   Ngnenbe T, 2020, CO READY DELIVER PPE
   Nuffield Department of Population Health, 2020, RECOVERY TRIAL NO CL
   Nyabor J, 2020, COVID 19 1400 AM EVA
   Palombi L, 2018, MULTIDISCIPLINARY TE, P3
   Shaban ARA, 2020, GHANA CORONAVIRUS 80
   Thornton J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1637
   United Nations Africa Renewal, 2020, COR UPD RES
   WHO, 2020, WHO COR DIS COVID 20
   WHO, 2020, COR DIS COVID 19 SIT
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2020, OP CONS CAS MAN COVI
   World Health Organization (WHO), 2020, COR AFR COULD NEXT E
   Zurek K., 2020, COVID 19 PRESIDENT A
   Zurek K, 2020, CORONAVIRUS GHANA HA
NR 31
TC 0
Z9 0
U1 2
U2 2
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD AUG
PY 2020
VL 14
IS 8
BP 838
EP 843
DI 10.3855/jidc.12909
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA NR3TB
UT WOS:000571485000006
PM 32903226
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Uyaroglu, OA
   Guven, GS
   Gullu, I
AF Uyaroglu, Oguz Abdullah
   Guven, Gulay Sain
   Gullu, Ibrahim
TI Can Levamisole be used in the treatment of COVID-19 patients presenting
   with diarrhea?
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Levamisole; COVID-19; diarrhea
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China, on Jan 7, 2020. Over the following months, the virus rapidly spread throughout the world. Coronavirus Disease 2019 (COVID-19) can involve the gastrointestinal tract, including symptoms like nausea, vomiting and diarrhea and shedding of the SARS-CoV-2 in feces. Angiotensin-converting enzyme 2 (ACE2) protein, which has been proven to be a cell receptor for SARS-CoV-2, is expressed in the glandular cells of gastric, duodenal, and rectal epithelia, supporting the entry of SARS-CoV-2 into the host cells. According to the literature, rates of COVID-19 patients reporting diarrhea were between 7 14%. Diarrhea in the course of COVID-19 disease can cause dehydration and hospitalization. Although no antiviral drug was specifically designed for the treatment of diarrhea, several molecules could have beneficial effects by reducing viral replication. In this letter, we discussed the Levamisole, which is an anthelmintic agent with immunomodulatory effects, could be used effectively both for antiviral therapy and especially in COVID-19 patients with diarrhea.
C1 [Uyaroglu, Oguz Abdullah; Guven, Gulay Sain] Hacettepe Univ, Fac Med, Dept Internal Med, Div Gen Internal Med, TR-06100 Ankara, Turkey.
   [Gullu, Ibrahim] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey.
RP Uyaroglu, OA (corresponding author), Hacettepe Univ, Fac Med, Dept Internal Med, Div Gen Internal Med, TR-06100 Ankara, Turkey.
EM oguzuyaroglu@hotmail.com
CR Afazeli Siamack, 2020, EV EFF LEV FORM BUD
   Ain Shams University, 2020, LEVAMISOLE ISOPRINOS
   Chethan GE, 2019, TROP ANIM HEALTH PRO, V51, P1455, DOI 10.1007/s11250-019-01833-1
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   D'Amico F, 2020, CLIN GASTROENTEROL H, V18, P1663, DOI 10.1016/j.cgh.2020.04.001
   El Dauroti Mohamed, 2020, LEV IS TREATM COVID1
   Gao QY, 2020, J DIGEST DIS, V21, P125, DOI 10.1111/1751-2980.12851
   Gupta M, 2016, INDIAN J DERMATOL VE, V82, P230, DOI 10.4103/0378-6323.175927
   Parasa S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11335
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Scheinfeld N, 2004, AM J CLIN DERMATOL, V5, P97, DOI 10.2165/00128071-200405020-00004
   Taal BG, 2001, BRIT J CANCER, V85, P1437, DOI 10.1054/bjoc.2001.2117
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
NR 14
TC 0
Z9 0
U1 0
U2 0
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD AUG
PY 2020
VL 14
IS 8
BP 844
EP 846
DI 10.3855/jidc.13101
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA NR3TB
UT WOS:000571485000007
PM 32903227
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kang, YJ
   Cho, JH
   Lee, MH
   Kim, YJ
   Park, CS
AF Kang, Yun Jin
   Cho, Jin Hee
   Lee, Min Hyeong
   Kim, Yeon Ji
   Park, Chan-Soon
TI The diagnostic value of detecting sudden smell loss among asymptomatic
   COVID-19 patients in early stage: The possible early sign of COVID-19
SO AURIS NASUS LARYNX
LA English
DT Article
DE SARS-CoV-2; COVID-19; Anosmia; Hyposmia; Olfactory dysfunction;
   Gustatory dysfunction
ID OLFACTORY LOSS; CORONAVIRUS INFECTION; IDENTIFICATION; THERAPY
AB Importance: The newly emerged coronavirus disease 19 (COVID-19), is threatening the world. Olfactory or gustatory dysfunction is reported as one of the symptoms worldwide. As reported so far, different clinical features have been reported according to outbreak sites and gender; most of the patients, who complained of anosmia or hyposmia, were Europeans. We had a fast review for novel articles about COVID-19 infection and olfactory function.
   Observations: Rapid reviews for COVID-19 or other viral infection and olfactory and/or gustatory dysfunctions were done in this review. Up to date, a lot of reports have shown that olfactory dysfunction is related to viral infections but no exact mechanism, clinical course, and definite treatment have been discovered, which is also same in COVID-19. In general, intranasal steroid (INS) and oral steroid for short time help improve the recovery of the olfactory function in case of olfactory dysfunction after virus infection. Considering severe respiratory complications and immunocompromised state of COVID-19, the use of steroid should be limited and cautious because we do not have enough data to support the usage of steroid to treat olfactory dysfunction in the clinical course of COVID-19.
   Conclusions and relevance: In the days of pandemic COVID-19, we should keep in mind that olfactory dysfunctions, even without other upper respiratory infection or otolaryngologic symptoms, might be the early signs of COVID-19. (C) 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.
C1 [Kang, Yun Jin; Lee, Min Hyeong; Kim, Yeon Ji; Park, Chan-Soon] Catholic Univ Korea, Coll Med, Dept Otolaryngol Head & Neck Surg, St Vincents Hosp, Seoul, South Korea.
   [Cho, Jin Hee] Catholic Univ Korea, Coll Med, Dept Otolaryngol Head & Neck Surg, Yeouido St Marys Hosp, Seoul, South Korea.
RP Park, CS (corresponding author), Catholic Univ Korea, Coll Med, Dept Otolaryngol Head & Neck Surg, St Vincents Hosp, Seoul, South Korea.
EM pcs0112@catholic.ac.kr
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Beltran-Corbellini a, 2020, EUR J NEUROL
   Bousquet J, 2020, ALLERGY
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Damm M, 2014, LARYNGOSCOPE, V124, P826, DOI 10.1002/lary.24340
   de Haro-Licer J, 2013, ACTA OTORRINOLAR ESP, V64, P331, DOI [10.1016/j.otorri.2013.04.003, 10.1016/j.otoeng.2013.10.004]
   DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5
   Eliezer M, 2020, JAMA OTOLARYNGOL HEA
   Finsterer J, 2020, J MED VIROL
   Gane S., 2020, RHINOLOGY
   Giacomelli A, 2020, CLIN INFECT DIS
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heidari F, 2020, RHINOLOGY
   Hopkins C, 2020, RHINOLOGY
   Hummel T, 2017, RHINOLOGY, V54, P7, DOI 10.4193/Rhino16.248
   HUMMEL T, 2011, GMS CURR TOP OTORHIN, V10, P4, DOI DOI 10.3205/CT0000077
   Hwang Chi-Shin, 2006, Acta Neurol Taiwan, V15, P26
   KCDC, 2020, UPD COVID 19 KOR 6 A
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lefevre N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01052
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Mao L, 2020, JAMA NEUROL
   Moein ST, 2020, INT FORUM ALLERGY RH, V10, P944, DOI 10.1002/alr.22587
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Organization WHO, 2018, WHO MIDDL E REP SYND
   Sastre J, 2012, J INVEST ALLERG CLIN, V22, P1
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Soler ZM, 2020, INT FORUM ALLERGY RH
   Spinato G., 2020, JAMA
   Stenner M, 2008, LARYNGOSCOPE, V118, P1681, DOI 10.1097/MLG.0b013e31817c1368
   Suzuki M, 2007, LARYNGOSCOPE, V117, P272, DOI 10.1097/01.mlg.0000249922.37381.1e
   Trotier D, 2007, CHEM SENSES, V32, P285, DOI 10.1093/chemse/bjl057
   van Riel D, 2015, J PATHOL, V235, P277, DOI 10.1002/path.4461
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wilder-Smith A, 2005, EMERG INFECT DIS, V11, P1142, DOI 10.3201/eid1107.041165
   Wu YC, 2020, J CHIN MED ASS, V2020
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yamagishi Masuo, 1994, Rhinology (Utrecht), V32, P113
   Yan C. H., 2020, INT FORUM ALLERGY RH
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Young BE, 2020, JAMA
   Zayet S, 2020, INFECTION, DOI 10.1007/s15010-020-01442-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0385-8146
EI 1879-1476
J9 AURIS NASUS LARYNX
JI Auris Nasus Larynx
PD AUG
PY 2020
VL 47
IS 4
BP 565
EP 573
DI 10.1016/j.anl.2020.05.020
PG 9
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NN5YI
UT WOS:000568863400006
PM 32553562
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Voisin, O
   le Lorc'h, E
   Mahe, A
   Azria, P
   Borie, MF
   Hubert, S
   Menage, E
   Guillerm, JC
   Mourad, JJ
AF Voisin, Olivier
   le Lorc'h, Erwan
   Mahe, Annabelle
   Azria, Philippe
   Borie, Marie-Francoise
   Hubert, Sidonie
   Menage, Elodie
   Guillerm, Jean-Christophe
   Mourad, Jean-Jacques
TI Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin
   Treatment in the Context of COVID-19 Infection
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID CHLOROQUINE; SAFETY
AB Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention. Even as the efficacy of this combination is under evaluation, clinicians have begun to use it largely. As these medications are known to prolong the QT interval, we analyzed serial electrocardiograms recorded in patients hospitalized for COVID-19 pneumonia and treated with HCQ + AZ. Fifty consecutive patients received the combination of HCQ (600 mg/d for 10 days) and AZ (500 mg/d on day 1 and 250 mg/d from day 2 to day 5). Twelve-lead electrocardiograms were recorded before treatment, at day 3, at day 5, and at discharge. The median age of patients was 68 years (interquartile range, 53-81 years); 28 (56%) were men. The main comorbidities were hypertension (36%; n=18) and diabetes (16%; n=8). The mean corrected QT (QTc) interval was 408 ms at baseline and increased up to 437 ms at day 3 and to 456 ms at day 5. Thirty-eight patients (76%) presented short-term modifications of the QTc duration (>30 ms). Treatment discontinuation was decided in 6 patients (12%), leading to QTc normalization in 5 of them. No deaths and no cardiac arrhythmic events were observed in this cohort. Our report confirms that a short duration treat-ment with HCQ + AZ modifies the QTc interval. The treatment had to be discontinued for QTc modifications in 12% of patients. Nevertheless, in inpatients hospitalized for COVID-19, we did not observe any clinically relevant consequences of these transitory modifications. In conclusion, when patients are treated with HCQ + AZ, cardiac monitoring should be regularly performed and hospital settings allow monitoring under in safe conditions. (C) 2020 Mayo Foundation for Medical Education and Research
C1 [Voisin, Olivier; le Lorc'h, Erwan; Mahe, Annabelle; Azria, Philippe; Borie, Marie-Francoise; Hubert, Sidonie; Menage, Elodie; Guillerm, Jean-Christophe; Mourad, Jean-Jacques] Grp Hosp Paris St Joseph, Dept Internal Med, 185 Rue Raymond Losserand, F-75014 Paris, France.
RP Mourad, JJ (corresponding author), Grp Hosp Paris St Joseph, Dept Internal Med, 185 Rue Raymond Losserand, F-75014 Paris, France.
EM jjmourad@hpsj.fr
OI Mourad, Jean-Jacques/0000-0003-0877-8311
CR [Anonymous], COVID 19 CHLOR HYDR
   [Anonymous], 85 WHO
   ANSM, MED UT CHEZ PAT ATT
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Fossa AA, 2007, AM J TROP MED HYG, V77, P929, DOI 10.4269/ajtmh.2007.77.929
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Haugaa KH, 2013, MAYO CLIN PROC, V88, P315, DOI 10.1016/j.mayocp.2013.01.013
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Juurlink DN, 2014, CAN MED ASSOC J, V186, P1127, DOI 10.1503/cmaj.140572
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Lakkireddy DR, 2020, CIRCULATION, V141, pE823, DOI 10.1161/CIRCULATIONAHA.120.047063
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Li Matthew, 2017, P T, V42, P473
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mzayek Fawaz, 2007, PLoS Clin Trials, V2, pe6, DOI 10.1371/journal.pctr.0020006
   Pukrittayakamee S, 2014, ANTIMICROB AGENTS CH, V58, P3354, DOI 10.1128/AAC.02794-13
   Ursing J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01846-19
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
NR 21
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD AUG
PY 2020
VL 95
IS 8
BP 1696
EP 1700
DI 10.1016/j.mayocp.2020.05.005
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK2NF
UT WOS:000566572900020
PM 32753141
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Al-Lami, RA
   Urban, RJ
   Volpi, E
   Algburi, AMA
   Baillargeon, J
AF Al-Lami, Rasha A.
   Urban, Randall J.
   Volpi, Elena
   Algburi, Ammar M. A.
   Baillargeon, Jacques
TI Sex Hormones and Novel Corona Virus Infectious Disease (COVID-19)
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; STEROID-HORMONES; SUSCEPTIBILITY; FRAILTY
AB Given the rapid spread of the coronavirus disease 2019 (COVID-19) pandemic and its overwhelming effect on health care systems and the global economy, innovative therapeutic strategies are urgently needed. The proposed primary culprit of COVID-19 is the intense inflammatory response-an augmented immune response and cytokine storm-severely damaging the lung tissue and rendering some patients' conditions severe enough to require assisted ventilation. Sex differences in the response to inflammation have been documented and can be attributed, at least in part, to sex steroid hormones. Moreover, age-associated decreases in sex steroid hormones, namely, estrogen and testosterone, may mediate proinflammatory increases in older adults that could increase their risk of COVID-19 adverse outcomes. Sex hormones can mitigate the inflammation response and might provide promising therapeutic potential for patients with COVID-19. In this article, we explore the possible anti-inflammatory effects of estrogen and testosterone and the anabolic effect of testosterone, with particular attention to the potential therapeutic role of hormone replacement therapy in older men and women with COVID-19. (C) 2020 Mayo Foundation for Medical Education and Research
C1 [Al-Lami, Rasha A.; Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Populat Hlth, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Urban, Randall J.; Volpi, Elena] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.
   [Algburi, Ammar M. A.] Al Yarmouk Teaching Hosp, Baghdad, Iraq.
RP Al-Lami, RA (corresponding author), Univ Texas Med Branch, Dept Prevent Med & Populat Hlth, 301 Univ Blvd, Galveston, TX 77555 USA.
EM raallami@utmb.edu
OI Al-Lami, Rasha A./0000-0002-8815-0614; Baillargeon,
   Jacques/0000-0002-3297-653X
CR Almoosa KF, 2014, ENDOCR PRACT, V20, P1057, DOI 10.4158/EP14003.OR
   [Anonymous], COR DIS 2019 COVID 1
   Baillargeon J, 2018, CHRON RESP DIS, V16, DOI 10.1177/1479972318793004
   Baillargeon J, 2016, CLIN RHEUMATOL, V35, P2983, DOI 10.1007/s10067-016-3330-x
   Biswas DK, 2005, SCI STKE, V2005, ppe27, DOI DOI 10.1126/stke.2882005pe27
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Dillon EL, 2010, CLIN NUTR, V29, P697, DOI 10.1016/j.clnu.2010.03.010
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gaskins AJ, 2012, AM J EPIDEMIOL, V175, P423, DOI 10.1093/aje/kwr343
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hel Z, 2010, ENDOCR REV, V31, P79, DOI 10.1210/er.2009-0018
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Kritas SK, 2020, J BIOL REGUL HOMEOST, V34
   Li HF, 2011, AGING DIS, V2, P466
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Morley JE, 2005, REV ENDOCR METAB DIS, V6, P101, DOI 10.1007/s11154-005-6722-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Stocco C, 2012, STEROIDS, V77, P27, DOI 10.1016/j.steroids.2011.10.013
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Traish A, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120549
   Tsilidis KK, 2013, ANDROLOGY-US, V1, P919, DOI 10.1111/j.2047-2927.2013.00129.x
   Wadman M, SCIENCE
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 32
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD AUG
PY 2020
VL 95
IS 8
BP 1710
EP 1714
DI 10.1016/j.mayocp.2020.05.013
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK2NF
UT WOS:000566572900024
PM 32753145
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tichy, EM
   Francis, JR
AF Tichy, Eric M.
   Francis, James R.
TI Impactful Policy Action to Reduce Drug Costs in Managing Critically Ill
   Patients with COVID-19
SO MAYO CLINIC PROCEEDINGS
LA English
DT Letter
ID SHORTAGES
C1 [Tichy, Eric M.; Francis, James R.] Mayo Clin, Rochester, MN 55905 USA.
RP Tichy, EM (corresponding author), Mayo Clin, Rochester, MN 55905 USA.
OI Tichy, Eric/0000-0003-1431-0416
CR Choo EK, 2020, MAYO CLIN PROC, V95, P1112, DOI 10.1016/j.mayocp.2020.04.001
   Gupta R, 2017, J MANAG CARE SPEC PH, V23, P1066, DOI 10.18553/jmcp.2017.23.10.1066
   Sharma D, 2020, THER INNOV REGUL SCI, V54, P424, DOI 10.1007/s43441-019-00072-8
   Tichy EM, 2020, AM J HLTH SYST PHARM
   Vijayvargiya P, 2020, MAYO CLIN P
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD AUG
PY 2020
VL 95
IS 8
BP 1808
EP 1809
DI 10.1016/j.mayocp.2020.06.042
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK2NF
UT WOS:000566572900040
PM 32753159
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ahmadi, P
   Hartjen, P
   Kohsar, M
   Kummer, S
   Schmiedel, S
   Bockmann, JH
   Fathi, A
   Huber, S
   Haag, F
   zur Wiesch, JS
AF Ahmadi, Parimah
   Hartjen, Philip
   Kohsar, Matin
   Kummer, Silke
   Schmiedel, Stefan
   Bockmann, Jan-Hendrik
   Fathi, Anahita
   Huber, Samuel
   Haag, Friedrich
   Schulze zur Wiesch, Julian
TI Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The
   CD73(-)Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
SO CELLS
LA English
DT Article
DE COVID-19; purinergic signaling; CD73; CD39; cytotoxic lymphocytes;
   granzyme B; perforin; SARS-CoV-2; cytokines
ID T-CELLS; ACTIVATION; IMMUNITY; CD73; EXPRESSION; RESPONSES; CD39
AB The ectonucleotidases CD39 and CD73 regulate immune responses by balancing extracellular ATP and adenosine in inflammation and are likely to be involved in the pathophysiology of COVID-19. Here, we analyzed CD39 and CD73 on different lymphocyte populations in a small cohort of COVID-19 patients and in healthy individuals. We describe a significantly lower level of expression of CD73 on cytotoxic lymphocyte populations, including CD8(+)T, natural killer T (NKT), and natural killer (NK) cells, during COVID-19. Interestingly, the decrease of CD73 on CD8(+)T cells and NKT cells correlated with serum ferritin levels. Furthermore, we observed distinct functional differences between the CD73(+)and CD73(-)subsets of CD8(+)T cells and NKT cells with regard to cytokine/toxin secretion. In COVID-19 patients, the majority of the CD73(-)CD8(+)T cells were capable of secreting granzyme B, perforin, tumor necrosis factor (TNF-alpha) or interferon-gamma (IFN-gamma). To conclude, in this first study of CD39 and CD73 expression of lymphocytes in COVID-19, we show that CD8(+)T cells and NKT cells lacking CD73 possess a significantly higher cytotoxic effector functionality compared to their CD73(+)counterparts. Future studies should investigate differences of cellular CD39 and CD73 expression in patients at different disease stages and their potential as prognostic markers or targets for immunomodulatory therapies.
C1 [Ahmadi, Parimah; Kohsar, Matin; Kummer, Silke; Schmiedel, Stefan; Bockmann, Jan-Hendrik; Fathi, Anahita; Huber, Samuel; Schulze zur Wiesch, Julian] Univ Med Ctr Hamburg Eppendorf, Sect Infect Dis, Dept Med 1, Martinistr 52, D-20246 Hamburg, Germany.
   [Hartjen, Philip] Univ Med Ctr Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, Martinistr 52, D-20246 Hamburg, Germany.
   [Bockmann, Jan-Hendrik; Fathi, Anahita; Schulze zur Wiesch, Julian] Hamburg Lubeck Borstel Riems, German Ctr Infect Res, D-23538 Lubeck, Germany.
   [Haag, Friedrich] Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Martinistr 52, D-20246 Hamburg, Germany.
RP zur Wiesch, JS (corresponding author), Univ Med Ctr Hamburg Eppendorf, Sect Infect Dis, Dept Med 1, Martinistr 52, D-20246 Hamburg, Germany.; zur Wiesch, JS (corresponding author), Hamburg Lubeck Borstel Riems, German Ctr Infect Res, D-23538 Lubeck, Germany.
EM p.ahmadi@uke.de; p.hartjen@uke.de; Matin.Kohsar@stud.uke.uni-hamburg.de;
   silkekum@gmail.com; s.schmiedel@uke.de; j.bockmann@uke.de;
   a.fathi@uke.de; s.huber@uke.de; haag@uke.de; j.schulze-zur-wiesch@uke.de
OI Huber, Samuel/0000-0001-9325-8227; Haag, Friedrich/0000-0001-6555-3106;
   Fathi, Anahita/0000-0002-9351-9471
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German
   Research Foundation (DFG) [SFB1328, SFB841]; German Center for Infection
   Research
FX This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation) SFB1328, A12 (P.A., J.S.z.W., S.H. and F.H.),
   SFB841 (J.S.z.W. and S.K.) and German Center for Infection Research
   (J.S.z.W., J.B. and A.F.). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abouelkhair MA, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110012
   Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005
   Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938
   Kim ES, 2017, J LEUKOCYTE BIOL, V101, P1263, DOI [10.1189/jlb.5A0816-346R, 10.1189/jlb.5a0816-346r]
   Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002
   Moncrieffe H, 2010, J IMMUNOL, V185, P134, DOI 10.4049/jimmunol.0803474
   Ohta A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00109
   Peric S, 2020, WIEN KLIN WOCHENSCHR, V132, P356, DOI 10.1007/s00508-020-01672-3
   Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802
   Schneider E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01729
   Schuler PJ, 2013, AIDS, V27, P1545, DOI 10.1097/QAD.0b013e328360c7f3
   Slaats J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005973
   Tai NW, 2013, J IMMUNOL, V191, P2926, DOI 10.4049/jimmunol.1300547
   Tak E, 2014, J AM SOC NEPHROL, V25, P547, DOI 10.1681/ASN.2012101014
   Toth I, 2013, J LEUKOCYTE BIOL, V94, P551, DOI 10.1189/jlb.0113018
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2019, REP WHO CHIN JOINT M
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang W, 2018, PURINERG SIGNAL, V14, P443, DOI 10.1007/s11302-018-9628-1
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10
NR 31
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD AUG
PY 2020
VL 9
IS 8
AR 1750
DI 10.3390/cells9081750
PG 16
WC Cell Biology
SC Cell Biology
GA NM3TR
UT WOS:000568023200001
PM 32707842
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Di Lorito, C
   Bosco, A
   Goldberg, SE
   Nair, R
   O'Brien, R
   Howe, L
   van der Wardt, V
   Pollock, K
   Booth, V
   Logan, P
   Godfrey, M
   Dunlop, M
   Horne, J
   Harwood, RH
AF Di Lorito, Claudio
   Bosco, Alessandro
   Goldberg, Sarah E.
   Nair, Roshan
   O'Brien, Rebecca
   Howe, Louise
   van der Wardt, Veronika
   Pollock, Kristian
   Booth, Vicky
   Logan, Pip
   Godfrey, Maureen
   Dunlop, Marianne
   Horne, Jane
   Harwood, Rowan H.
TI Protocol for the process evaluation of the Promoting Activity,
   Independence and Stability in Early Dementia (PrAISED), following
   changes required by the COVID-19 pandemic
SO BMJ OPEN
LA English
DT Article
DE geriatric medicine; dementia; rehabilitation medicine; sports medicine
ID MILD COGNITIVE IMPAIRMENT; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE;
   EXERCISE; PEOPLE; INTERVENTION; PERFORMANCE; CARERS
AB Introduction The Promoting Activity, Independence and Stability in Early Dementia (PrAISED) randomised controlled trial (RCT) is evaluating a home-based, face-to-face, individually tailored, activity and exercise programme for people living with dementia. Social distancing requirements following the COVID-19 pandemic necessitated rapid changes to intervention delivery.
   Methods and analysis A mixed-methods process evaluation will investigate how the changes were implemented and the impact that these have on participants' experience. Animplementation studywill investigate how the intervention was delivered during the pandemic. Astudy on the mechanisms of impact and contextwill investigate how these changes were experienced by the PrAISED participants, their carers and the therapists delivering the intervention. The study will commence in May 2020.
   Ethics and dissemination The PrAISED RCT and process evaluation have received ethical approval number 18/YH/0059. The PrAISED process evaluation will enable us to understand how distancing and isolation affected participants, their activity and exercise routines and whether the therapy programme could be continued with remote support. This will be valuable both in explaining trial results and also contribute to understanding and designing new ways of delivering home-based services and rehabilitation interventions for people with dementia and their carers.
C1 [Di Lorito, Claudio; O'Brien, Rebecca; Howe, Louise; Booth, Vicky; Logan, Pip; Godfrey, Maureen; Dunlop, Marianne; Horne, Jane] Univ Nottingham, Div Rehabil Ageing & Wellbeing, Nottingham, England.
   [Bosco, Alessandro; Nair, Roshan] Univ Nottingham, Div Psychiat & Appl Psychol, Nottingham, England.
   [Goldberg, Sarah E.; Pollock, Kristian; Harwood, Rowan H.] Univ Nottingham, Sch Hlth Sci, Nottingham, England.
   [van der Wardt, Veronika] Philipps Univ Marburg, Marburg, Hessen, Germany.
RP Di Lorito, C (corresponding author), Univ Nottingham, Div Rehabil Ageing & Wellbeing, Nottingham, England.
EM claudio.dilorito@nottingham.ac.uk
OI Booth, Vicky/0000-0002-5338-0196; Di Lorito, Claudio/0000-0002-8953-0117
FU United Kingdom National Institute for Health Research (NIHR)National
   Institute for Health Research (NIHR) [RP-PG-0614-20007]
FX This protocol presents independent research funded by the United Kingdom
   National Institute for Health Research (NIHR) under its Programme Grants
   for Applied Research funding scheme (RP-PG-0614-20007). The views
   expressed are those of the authors and not necessarily those of the
   National Health Service, the NIHR or the Department of Health and Social
   Care.
CR Alzheimer's Research UK, 2019, DEM
   Alzheimer's Society, 2020, FACTS MED
   Bajwa RK, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3871-9
   Blankevoort CG, 2010, DEMENT GERIATR COGN, V30, P392, DOI 10.1159/000321357
   Booth V, 2018, CLIN REHABIL, V32, P855, DOI 10.1177/0269215518758149
   Bosco A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221507
   Bosco A, 2019, ARCH GERONTOL GERIAT, V81, P59, DOI 10.1016/j.archger.2018.11.003
   BRODATY H, 1990, AUST NZ J PSYCHIAT, V24, P351, DOI 10.3109/00048679009077702
   Di Lorito C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051544
   Di Lorito C, 2019, MATURITAS, V122, P8, DOI 10.1016/j.maturitas.2019.01.001
   Di Lorito C, 2019, MATURITAS, V121, P101, DOI 10.1016/j.maturitas.2019.01.008
   Ferguson N., 2020, IMPACT NONPHARMACEUT
   Forbes D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub4
   Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117
   Gaugler JE, 2005, J AM GERIATR SOC, V53, P2098, DOI 10.1111/j.1532-5415.2005.00495.x
   Giebel CM, 2015, AGING MENT HEALTH, V19, P63, DOI 10.1080/13607863.2014.915920
   Giebel CM, 2014, INT PSYCHOGERIATR, V26, P1283, DOI 10.1017/S1041610214000775
   Graham C, 1997, INT J GERIATR PSYCH, V12, P931, DOI 10.1002/(SICI)1099-1166(199709)12:9<931::AID-GPS666>3.3.CO;2-#
   Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903
   Hauer K, 2012, J AM GERIATR SOC, V60, P8, DOI 10.1111/j.1532-5415.2011.03778.x
   Hawton A, 2011, QUAL LIFE RES, V20, P57, DOI 10.1007/s11136-010-9717-2
   Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019
   Hoffmann K, 2016, J ALZHEIMERS DIS, V50, P443, DOI 10.3233/JAD-150817
   IBM Corp, 2017, IBM SPSS STAT WIND V
   Lamb SE, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1675
   Lewis F, 2014, OFFICE HLTH EC CONSU
   Logan P, 2019, EMRAN, P2059
   Lowery D, 2014, INT J GERIATR PSYCH, V29, P819, DOI 10.1002/gps.4062
   Martyr A, 2012, DEMENT GERIATR COGN, V33, P189, DOI 10.1159/000338233
   Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258
   Nelson J, 2017, QUAL RES, V17, P554, DOI 10.1177/1468794116679873
   NVivo, 2018, NVIVO QUAL DAT AN SO
   Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359
   Potter R, 2011, INT J GERIATR PSYCH, V26, P1000, DOI 10.1002/gps.2641
   Prick AE, 2017, J AGING PHYS ACTIV, V25, P539, DOI 10.1123/japa.2016-0038
   Public Health England, 2020, GUID SOC DIST EV UK
   Rolland Y, 2007, J AM GERIATR SOC, V55, P158, DOI 10.1111/j.1532-5415.2007.01035.x
   Schwenk M, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-73
   Schwenk M, 2010, NEUROLOGY, V74, P1961, DOI 10.1212/WNL.0b013e3181e39696
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Suzuki T, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-128
   Telenius EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126102
   The Chartered Society of Physiotherapy, COVID 19 GUID RAP IM
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 44
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD AUG
PY 2020
VL 10
IS 8
AR e039305
DI 10.1136/bmjopen-2020-039305
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NL4JC
UT WOS:000567383300015
PM 32859666
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bamias, G
   Lagou, S
   Gizis, M
   Karampekos, G
   Kyriakoulis, KG
   Pontas, C
   Mantzaris, GJ
AF Bamias, Giorgos
   Lagou, Styliani
   Gizis, Michalis
   Karampekos, George
   Kyriakoulis, Konstantinos G.
   Pontas, Christos
   Mantzaris, Gerassimos J.
TI The Greek Response to COVID-19: A True Success Story from an IBD
   Perspective
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE Greece; SARS-CoV-2; COVID-19; IBD
ID CARE
AB Background: After the first case of infection with the novel coronavirus, SARS-CoV-2, in China, an outbreak rapidly spread, finally evolving into a global pandemic. The new disease was named coronavirus disease 2019 (COVID-19) and by May 10, 2020, it has affected more than 4 million people worldwide and caused more than 270,000 deaths.
   Methods: We describe the Greek experience regarding the response to COVID-19, with particular focus on 2 COVID-19 reference hospitals in the metropolitan area of Athens, the capital of Greece.
   Results: The first case of SARS-CoV-2 infection in Greece was reported on February 26, 2020, and prompted a decisive response from the Greek government. The primary focus was containment of virus spread, considering shortage of ICU beds. A general lockdown was implemented early on, and the national Health Care System underwent massive re-structuring. Our 2 gastrointestinal (GI) centers, which provide care for more than 1500 inflammatory bowel disease (IBD) patients, are located in hospitals that were transformed to COVID-19 reference centers. To maintain sufficient care for our patients, while also contributing to the fight against COVID-19, we undertook specific measures. These included provision of telemedicine services, electronic prescriptions and home delivery of medications, isolation of infusion units and IBD clinics in COVID-free zones of the hospitals, in addition to limiting endoscopies to emergencies only. Such practices allowed us to avoid interruption of appropriate therapies for IBD patients. In fact, within the SECURE-IBD database, there have been only 4 Greek IBD patients, to date, who have been reported as positive for SARS-CoV-2.
   Conclusion: Timely application of preventive measures and strict compliance to guidelines limited the spread of COVID-19 in Greece and minimally impacted our IBD community, without interfering with therapeutic management.
C1 [Bamias, Giorgos; Lagou, Styliani; Gizis, Michalis; Kyriakoulis, Konstantinos G.] Natl & Kapodistrian Univ Athens, Sotiria Hosp, Acad Dept Internal Med 3, GI Unit, Athens, Greece.
   [Karampekos, George; Pontas, Christos; Mantzaris, Gerassimos J.] GHA Evaggelismos Ophthalmiatre Athinon Polyklin, Dept Gastroenterol, Athens, Greece.
RP Bamias, G (corresponding author), Sotiria Hosp, Acad Dept Internal Med 3, GI Unit, Mesogeion 152, Athens 11527, Greece.
EM gbamias@gmail.com
CR Allocca M, 2020, CLIN GASTROENTEROL H
   Blake H, 2020, INT J ENV RES PUBLIC, V17
   Grasselli G, 2020, JAMA
   Hanzel J, 2020, CLIN GASTROENTEROL H
   Hong Z, 2020, J MED INTERNET RES, V22, DOI 10.2196/19577
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Motwani K, 2020, CLIN J GASTROENTEROL, V13, P732, DOI 10.1007/s12328-020-01141-4
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Wu Z, 2020, JAMA
   Zheng Z., 2020, J INFECT
NR 11
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD AUG
PY 2020
VL 26
IS 8
BP 1144
EP 1148
DI 10.1093/ibd/izaa143
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NO0YQ
UT WOS:000569213000013
PM 32476001
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Arranz, EM
   Ferrer, CS
   Ramirez, LG
   Garcia, JLR
   Sanchez-Azofra, M
   Cordon, JP
   Noci, J
   Zabana, Y
   Barreiro-de Acosta, M
   Martin-Arranz, MD
AF Martin Arranz, Eduardo
   Suarez Ferrer, Cristina
   Garcia Ramirez, Laura
   Rueda Garcia, Jose Luis
   Sanchez-Azofra, Maria
   Poza Cordon, Joaquin
   Noci, Jesus
   Zabana, Yamile
   Barreiro-de Acosta, Manuel
   Dolores Martin-Arranz, Maria
CA GETECCU
   Spanish Working Grp Crohns Dis Ulc
TI Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease
   Units: Results From a National Survey
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE COVID-19; inflammatory bowel disease; coronavirus; quality of care
AB Background: The outbreak of COVID-19 has rapidly evolved into a pandemic that has represented a challenge to health systems worldwide. Inflammatory bowel disease (IBD) units have been forced to change their practices to address the disease and to ensure the quality of care.
   Methods: We conducted a national survey among IBD gastroenterologist members of the Spanish Working Group on Crohn's Disease and Colitis regarding changes of practice, IBD treatments, and diagnosis and treatment of COVID-19.
   Results: We received 54 answers from Spanish hospitals. One hundred percent of the IBD units rescheduled onsite visits to telematic consultation, and elective endoscopic and surgical procedures were delayed. Protective measures were also taken in the infusion units (100% of health centers) and hospital pharmacies, with 40.7% sending subcutaneous medications to patients. No switching between intravenous and subcutaneous anti-tumor necrosis factor drugs were made. We also found that 96.1% of IBD units advised their patients to maintain treatment if they were asymptomatic for COVID-19. For patients with COVID-19 symptoms, 92.6% of IBD units referred them to primary care or the emergency department. In addition, 7.5% of IBD units made a COVID-19 diagnosis through polymerase chain reaction and/or chest x-ray. Modifications in IBD treatment and treatment recommended for COVID-19 are also discussed.
   Conclusions: We report a representative national survey of changes made in the structure, diagnosis of COVID-19, and modifications in IBD treatments within IBD units.
C1 [Martin Arranz, Eduardo; Suarez Ferrer, Cristina; Rueda Garcia, Jose Luis; Sanchez-Azofra, Maria; Poza Cordon, Joaquin; Noci, Jesus; Dolores Martin-Arranz, Maria] Hosp Univ La Paz, Gastroenterol Dept, Paseo Castellana 261, Madrid 28046, Spain.
   [Martin Arranz, Eduardo; Dolores Martin-Arranz, Maria] Hosp La Paz, Inst Hlth Res IdiPaz, Madrid, Spain.
   [Garcia Ramirez, Laura] Hosp Univ La Paz, Fdn Invest Biomed, Madrid, Spain.
   [Zabana, Yamile] Hosp Univ Mutua Terrassa, Gastroenterol Dept, Barcelona, Spain.
   [Zabana, Yamile] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Barreiro-de Acosta, Manuel] Hosp Univ Clin Santiago, Gastroenterol Unit, Santiago De Compostela, Spain.
RP Arranz, EM (corresponding author), Hosp Univ La Paz, Gastroenterol Dept, Paseo Castellana 261, Madrid 28046, Spain.
EM emarranz@salud.madrid.org
RI Zabana, Yamile/ABF-7648-2020
OI Barreiro de Acosta, Manuel/0000-0001-5915-1477
CR Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Crespo J, 2020, REV ESP ENFERM DIG, V112, P397, DOI 10.17235/reed.2020.7141/2020
   Fiorino G, 2020, J CROHNS COLITIS, V14, P1330, DOI 10.1093/ecco-jcc/jjaa058
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Johns Hopkins University and Medicine, MAPS TRENDS
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
   Rodriguez-Lago I, 2020, GASTROENTEROLOGY, V159, P781, DOI 10.1053/j.gastro.2020.04.043
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 12
TC 2
Z9 2
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD AUG
PY 2020
VL 26
IS 8
BP 1149
EP 1154
DI 10.1093/ibd/izaa142
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NO0YQ
UT WOS:000569213000014
PM 32495826
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Urashima, M
   Otani, K
   Hasegawa, Y
   Akutsu, T
AF Urashima, Mitsuyoshi
   Otani, Katharina
   Hasegawa, Yasutaka
   Akutsu, Taisuke
TI BCG Vaccination and Mortality of COVID-19 across 173 Countries: An
   Ecological Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE urbanization; Bacillus Calmette-Guerin; BCG; vaccination; coronavirus
   disease 2019; COVID-19; SARS-CoV-2; ecological study; morbidity;
   mortality
AB Ecological studies have suggested fewer COVID-19 morbidities and mortalities in Bacillus Calmette-Guerin (BCG)-vaccinated countries than BCG-non-vaccinated countries. However, these studies obtained data during the early phase of the pandemic and did not adjust for potential confounders, including PCR-test numbers per population (PCR-tests). Currently-more than four months after declaration of the pandemic-the BCG-hypothesis needs reexamining. An ecological study was conducted by obtaining data of 61 factors in 173 countries, including BCG vaccine coverage (%), using morbidity and mortality as outcomes, obtained from open resources. 'Urban population (%)' and 'insufficient physical activity (%)' in each country was positively associated with morbidity, but not mortality, after adjustment for PCR-tests. On the other hand, recent BCG vaccine coverage (%) was negatively associated with mortality, but not morbidity, even with adjustment for percentage of the population >= 60 years of age, morbidity, PCR-tests and other factors. The results of this study generated a hypothesis that a national BCG vaccination program seems to be associated with reduced mortality of COVID-19, although this needs to be further examined and proved by randomized clinical trials.
C1 [Urashima, Mitsuyoshi; Otani, Katharina; Hasegawa, Yasutaka; Akutsu, Taisuke] Jikei Univ, Div Mol Epidemiol, Sch Med, Tokyo 1058461, Japan.
   [Otani, Katharina] Siemens Healthcare KK, Adv Therapies Innovat Dept, Tokyo 1418644, Japan.
   [Hasegawa, Yasutaka] Hitachi Ltd, Res & Dev Grp, Tokyo 1858601, Japan.
RP Urashima, M (corresponding author), Jikei Univ, Div Mol Epidemiol, Sch Med, Tokyo 1058461, Japan.
EM urashima@jikei.ac.jp; katharina@jikei.ac.jp; yhearth102523@jikei.ac.jp;
   t-akutsu@jikei.ac.jp
OI Urashima, Mitsuyoshi/0000-0002-7395-5831
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Ebina-Shibuya R., 2020, RESPIROLOGY, DOI [10.1111/resp.13885 32558034, DOI 10.1111/RESP.13885 32558034]
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Hisaka A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061904
   Kim JH, 2019, KOREAN J ANESTHESIOL, V72, P558, DOI 10.4097/kja.19087
   Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378
   Koti M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001119
   Lapostolle F, 2020, EUR J EMERG MED, V27, P274, DOI 10.1097/MEJ.0000000000000723
   Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661
   Murray CJL, 2006, LANCET, V368, P2211, DOI 10.1016/S0140-6736(06)69895-4
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Patel AP, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01227-y
   Pereira IG, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17145115
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Rentsch Christopher T, 2020, medRxiv, DOI 10.1101/2020.05.12.20099135
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sharma A.R., 2020, ALLERGOL IMMUNOPATH, DOI [10.1016/j.aller.2020.05.00232653224, DOI 10.1016/J.ALLER.2020.05.00232653224]
   ten Doesschate T, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04521-w
   Weng CH, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001569
   Yates T., 2020, CARE DIABETES, DOI [10.1016/j.pcd.2020.05.011, DOI 10.1016/J.PCD.2020.05.011]
NR 26
TC 0
Z9 0
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2020
VL 17
IS 15
AR 5589
DI 10.3390/ijerph17155589
PG 20
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA NL4ML
UT WOS:000567392000001
PM 32756371
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saravi, SSS
   Beer, JH
AF Saravi, Seyed Soheil Saeedi
   Beer, Juerg H.
TI Apelin-potential therapy for COVID-19?
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Apelin; COVID-19; Renin-angiotensin system
ID ANGIOTENSIN-CONVERTING ENZYME; RENIN-ANGIOTENSIN; EXPRESSION; ACE2
AB We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio.
C1 [Saravi, Seyed Soheil Saeedi; Beer, Juerg H.] Univ Zurich, Ctr Mol Cardiol, CH-8952 Schlieren, Switzerland.
   [Saravi, Seyed Soheil Saeedi; Beer, Juerg H.] Cantonal Hosp Baden, Dept Internal Med, Ergel 1, CH-5404 Baden, Switzerland.
RP Beer, JH (corresponding author), Cantonal Hosp Baden, Dept Internal Med, Ergel 1, CH-5404 Baden, Switzerland.
EM hansjuerg.beer@ksb.ch
OI Beer, Jurg Hans/0000-0002-7199-0406
CR Brame AL, 2015, HYPERTENSION, V65, P834, DOI 10.1161/HYPERTENSIONAHA.114.05099
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Dielis AWJH, 2005, HYPERTENSION, V46, P1236, DOI 10.1161/01.HYP.0000193538.20705.23
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fan XF, 2015, CHEST, V147, P969, DOI 10.1378/chest.14-1426
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Japp AG, 2010, CIRCULATION, V121, P1818, DOI 10.1161/CIRCULATIONAHA.109.911339
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Milne S, 2020, LANCET RESP MED, V8, pE50, DOI 10.1016/S2213-2600(20)30224-1
   Read C, 2016, BIOCHEM PHARMACOL, V116, P63, DOI 10.1016/j.bcp.2016.07.018
   Sabry MM, 2019, ARCH PHYSIOL BIOCHEM, V125, P244, DOI 10.1080/13813455.2018.1453521
   Sato T, 2013, J CLIN INVEST, V123, P5203, DOI 10.1172/JCI69608
   Siddiquee K, 2011, J HYPERTENS, V29, P724, DOI 10.1097/HJH.0b013e32834347de
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Sriram K, 2020, CLIN PHARMACOL THER, V108, P236, DOI 10.1002/cpt.1863
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Yan JL, 2020, CELL MOL LIFE SCI, V77, P2919, DOI 10.1007/s00018-020-03461-7
   Yang PR, 2015, TRENDS PHARMACOL SCI, V36, P560, DOI 10.1016/j.tips.2015.06.002
   Zhang HB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1882-z
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 20
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD AUG
PY 2020
VL 145
BP 84
EP 87
DI 10.1016/j.yjmcc.2020.06.007
PG 4
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA NL5DG
UT WOS:000567435700009
PM 32562701
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Min, JS
   Kim, GW
   Kwon, S
   Jin, YH
AF Min, Jung Sun
   Kim, Geon-Woo
   Kwon, Sunoh
   Jin, Young-Hee
TI A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus
   RNA-Dependent RNA Polymerase Activity
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE Middle East respiratory syndrome; coronavirus; RNA-dependent RNA
   polymerase; cell-based reporter assay; nucleoside analog; remdesivir
ID ACUTE RESPIRATORY SYNDROME; HEPATITIS-C; STATISTICAL PARAMETER; LETHAL
   MUTAGENESIS; T-705 FAVIPIRAVIR; VIRUS; MECHANISM; RIBAVIRIN; SARS;
   POTENCY
AB Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19) are emerging zoonotic diseases caused by coronavirus (CoV) infections. The viral RNA-dependent RNA polymerase (RdRp) has been suggested as a valuable target for antiviral therapeutics because the sequence homology of CoV RdRp is highly conserved. We established a cell-based reporter assay for MERS-CoV RdRp activity to test viral polymerase inhibitors. The cell-based reporter system was composed of the bicistronic reporter construct and the MERS-CoV nsp12 plasmid construct. Among the tested nine viral polymerase inhibitors, ribavirin, sofosbuvir, favipiravir, lamivudine, zidovudine, valacyclovir, vidarabine, dasabuvir, and remdesivir, only remdesivir exhibited a dose-dependent inhibition. Meanwhile, the Z-factor and Z '-factor of this assay for screening inhibitors of MERS-CoV RdRp activity were 0.778 and 0.782, respectively. Ribavirin and favipiravir did not inhibit the MERS-CoV RdRp activity, and non-nucleoside HCV RdRp inhibitor, dasabuvir, partially inhibited MERS-CoV RdRp activity. Taken together, the cell-based reporter assay for MERS-CoV RdRp activity confirmed remdesivir as a direct inhibitor of MERS-CoV RdRp in cells. A cell-based MERS-CoV RdRp activity reporter assay is reliable and accurate for screening MERS-CoV RdRp-specific inhibitors. It may provide a valuable platform for developing antiviral drugs for emerging CoV infections.
C1 [Min, Jung Sun; Kim, Geon-Woo; Kwon, Sunoh] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.
   [Min, Jung Sun; Kim, Geon-Woo; Kwon, Sunoh; Jin, Young-Hee] Korea Res Inst Chem Technol, Ctr Convergent Res Emerging Virus Infect, Daejeon 34114, South Korea.
   [Jin, Young-Hee] Korea Inst Oriental Med, KM Applicat Ctr, Daegu 41062, South Korea.
RP Kwon, S (corresponding author), Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.; Kwon, S; Jin, YH (corresponding author), Korea Res Inst Chem Technol, Ctr Convergent Res Emerging Virus Infect, Daejeon 34114, South Korea.; Jin, YH (corresponding author), Korea Inst Oriental Med, KM Applicat Ctr, Daegu 41062, South Korea.
EM jsmin1019@kiom.re.kr; azard3142@kiom.re.kr; sunohkwon@kiom.re.kr;
   jinohee@kiom.re.kr
RI Kwon, Sunoh/AAW-3496-2020; JIN, YOUNG-HEE/AAW-3506-2020
OI Kwon, Sunoh/0000-0002-0942-8164; JIN, YOUNG-HEE/0000-0001-9916-1418;
   KIM, GEON-WOO/0000-0003-0432-8268
FU National Research Council of Science & Technology (NST) - Korea
   government (MSIT) [CRC-16-01-KRICT, NSN1621350]; 'National Research
   Council of Science & Technology (NST)-Korea Institute of Oriental
   Medicine (KIOM)' Postdoctoral Research Fellowship for Young Scientists
   at the Korea Institute of Oriental Medicine in South Korea
FX This study was supported by the National Research Council of Science &
   Technology (NST) grant [grant numbers CRC-16-01-KRICT and NSN1621350]
   funded by the Korea government (MSIT). J.S.M. and G.-W.K. were supported
   by the `National Research Council of Science & Technology (NST)-Korea
   Institute of Oriental Medicine (KIOM)' Postdoctoral Research Fellowship
   for Young Scientists at the Korea Institute of Oriental Medicine in
   South Korea.
CR Adedeji AO, 2014, ANTIMICROB AGENTS CH, V58, P4894, DOI 10.1128/AAC.02994-14
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Akaberi Dario, 2018, Infection Ecology & Epidemiology, V8, P1528117, DOI 10.1080/20008686.2018.1528117
   Anderson P., 2010, CLIN MED REV THER, V2, P115, DOI [10.4137/cmrt.s4557, DOI 10.4137/CMRT.S4557]
   Baranovich T, 2013, J VIROL, V87, P3741, DOI 10.1128/JVI.02346-12
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015
   Dash S, 2019, VIRAL POLYMERASES: STRUCTURES, FUNCTIONS, AND ROLES AS ANTIVIRAL DRUG TARGETS, P211, DOI 10.1016/B978-0-12-815422-9.00008-5
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Durai P, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.76
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   Fung A, 2014, ANTIMICROB AGENTS CH, V58, P3636, DOI 10.1128/AAC.02666-14
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gentile I, 2014, REV RECENT CLIN TRIA, V9, P115, DOI 10.2174/1574887109666140529222602
   Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   James J.S., 1998, TREAT NEWS, V7
   Johnson S, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012713.pub2
   Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672
   Lee JC, 2010, ANAL BIOCHEM, V403, P52, DOI 10.1016/j.ab.2010.04.004
   Liang RY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120721
   Mehand MS, 2018, ANTIVIR RES, V159, P63, DOI 10.1016/j.antiviral.2018.09.009
   Stedman C, 2014, THER ADV GASTROENTER, V7, P131, DOI 10.1177/1756283X13515825
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sui YX, 2007, J BIOMOL SCREEN, V12, P229, DOI 10.1177/1087057106296498
   Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357
   Turner TL, 2014, CLINICOECONOMIC OUTC, V6, P217, DOI 10.2147/CEOR.S60710
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Wang YQ, 2018, J THORAC DIS, V10, pS2260, DOI 10.21037/jtd.2018.03.80
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 40
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2399
DI 10.3390/jcm9082399
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA NL0TL
UT WOS:000567138400001
PM 32727069
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Read, J
   Renton, J
   Harrop, C
   Geekie, J
   Dowrick, C
AF Read, John
   Renton, Julia
   Harrop, Christopher
   Geekie, Jim
   Dowrick, Christopher
TI A survey of UK general practitioners about depression, antidepressants
   and withdrawal: implementing the 2019 Public Health England report
SO THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
LA English
DT Article
DE Antidepressants; Withdrawal; General Practitioners; Primary Care;
   Depression; Training
ID BELIEFS; PLACEBO; PEOPLE; METAANALYSIS
AB Background: In 2019, a literature review indicated that more than half of people who try to come off antidepressants experience withdrawal effects. Both the National Institute of Health and Care Excellence and the Royal College of Psychiatrists updated their positions in line with that review, and Public Health England published a 152-page report calledDependence and withdrawal associated with some prescribed medicines: an evidence review. The report made several recommendations relevant to general practice.
   Method: In order to facilitate implementation of these recommendations, an online survey was designed to explore United Kingdom general practitioner (GP) experiences, opinions, knowledge and needs in relation to depression, ADs and withdrawal. A total of 66 GPs had completed the survey when COVID-19 occurred.
   Results: In keeping with previous findings, this small sample of GPs had a predominantly psycho-social perspective on the causes of, and treatments for, depression. They broadly considered ADs effective for moderate/severe depression and ineffective for minimal/mild depression, for which they preferred psychological therapies and social prescribing. There was a marked lack of consistency in GPs' knowledge about the incidence and duration of withdrawal effects. Only a minority (29%) felt their knowledge about withdrawal was 'adequate' and fewer (17%) believed this about their 'Ability to distinguish between withdrawal effects and return of the original problem (e.g. depression)'. Two-thirds (68%) would like more training on these matters.
   Conclusion: It is hoped that even this small sample will be helpful when designing, and seeking funding for, GP training programmes, and when implementing the PHE recommendations for support services, based in the primary care system, for the millions of people contemplating or initiating withdrawal from ADs every year in the UK.
C1 [Read, John] Univ East London, Sch Psychol, Water Lane, London E15 4LZ, England.
   [Renton, Julia; Harrop, Christopher] West London NHS Trust, London, England.
   [Geekie, Jim] NHS Educ Scotland, Edinburgh, Midlothian, Scotland.
   [Geekie, Jim] NHS Lothian, Edinburgh, Midlothian, Scotland.
   [Dowrick, Christopher] Univ Liverpool, Primary Med Care, Liverpool, Merseyside, England.
   [Dowrick, Christopher] Aintree Pk Grp Practice, Liverpool, Merseyside, England.
RP Read, J (corresponding author), Univ East London, Sch Psychol, Water Lane, London E15 4LZ, England.
EM john@uel.ac.uk
CR American Psychiatric Association, 2010, PRACTICE GUIDELINE T, P39
   Antonuccio D, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/965908
   British National Formulary, 2020, ANTIDEPRESSANTS
   Cipriani A, 2018, LANCET, V391, P1357, DOI 10.1016/S0140-6736(17)32802-7
   Davies J, 2019, ADDICT BEHAV, V97, P111, DOI 10.1016/j.addbeh.2018.08.027
   de Wattignar S., 2009, J MENT HEALTH, V18, P1
   Dowrick C, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7140
   Dowrick Christopher, 2009, DEPRESSION NEW APPRO
   Fava GA, 2018, PSYCHOTHER PSYCHOSOM, V87, P195, DOI 10.1159/000491524
   Fava GA, 2015, PSYCHOTHER PSYCHOSOM, V84, P72, DOI 10.1159/000370338
   Gibson K, 2014, INT J MENT HEALTH, V43, P81, DOI 10.2753/IMH0020-7411430105
   Gotzsche PC, 2013, DEADLY MED ORG CRIME
   Groot PC, 2018, PSYCHOSIS, V10, P142, DOI 10.1080/17522439.2018.1469163
   Hagmayer Y, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01303
   Healey D, 2004, LET THEM EAT PROZAC
   Horowitz MA, 2019, LANCET PSYCHIAT, V6, P538, DOI 10.1016/S2215-0366(19)30032-X
   IACOBUCCI G, 2019, BMJ, V367
   Jakobsen JC, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-016-1173-2
   Karasz A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X616373
   Kendrick T, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04338-7
   Khan A, 2002, INT J NEUROPSYCHOPH, V5, P193, DOI 10.1017/S1461145702002912
   Khan A, 2015, WORLD PSYCHIATRY, V14, P294, DOI 10.1002/wps.20241
   Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045
   Mahase E., 2020, BMJ, V368
   Maund E, 2019, ANN FAM MED, V17, P52, DOI 10.1370/afm.2336
   Moncrieff J, 2015, WORLD PSYCHIATRY, V14, P302, DOI 10.1002/wps.20243
   Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999
   Moret C, 2009, J PSYCHOPHARMACOL, V23, P967, DOI 10.1177/0269881108093582
   National Institute for Health and Care Excellence (NICE), 2009, DEPR AD REC MAN
   NICE, 2019, ANT TREATM AD
   Ogden E, 2016, THESIS
   Organisation for Economic Cooperation and Development (OECD), 2017, ANT DRUGS CONS 2000, DOI [10.1787/health_glance-2017-graph181-en, DOI 10.1787/HEALTH_GLANCE-2017-GRAPH181-EN]
   Pilkington PD, 2013, J AFFECT DISORDERS, V150, P356, DOI 10.1016/j.jad.2013.04.019
   Pratt LA, 2017, ANTIDEPRESSANT USE P
   Read J, 2015, ACTA PSYCHIAT SCAND, V131, P434, DOI 10.1111/acps.12390
   Read J, 2013, ACTA PSYCHIAT SCAND, V128, P422, DOI 10.1111/acps.12146
   Read J, 2018, CURR DRUG SAF, V13, P176, DOI 10.2174/1574886313666180605095130
   Read J, 2017, PSYCHIAT RES, V256, P423, DOI 10.1016/j.psychres.2017.07.003
   Read J, 2015, J AFFECT DISORDERS, V174, P150, DOI 10.1016/j.jad.2014.11.009
   Read J, 2014, J AFFECT DISORDERS, V168, P236, DOI 10.1016/j.jad.2014.06.010
   Read J, 2014, PSYCHIAT RES, V216, P67, DOI 10.1016/j.psychres.2014.01.042
   Royal College of Psychiatrists, 2019, POS STAT ANT DEPR PS
   SVENSON O, 1981, ACTA PSYCHOL, V47, P143, DOI 10.1016/0001-6918(81)90005-6
   Taylor S, 2019, DEPENDENCE WITHDRAWA
   Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779
   Uher R, 2009, BRIT J PSYCHIAT, V195, P202, DOI 10.1192/bjp.bp.108.061960
   Wilson J, 2001, FAM PRACT, V18, P84, DOI 10.1093/fampra/18.1.84
NR 47
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2045-1253
EI 2045-1261
J9 THER ADV PSYCHOPHARM
JI Ther. Adv. Psychopharm.
PD AUG
PY 2020
VL 10
AR 2045125320950124
DI 10.1177/2045125320950124
PG 14
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA NJ9QK
UT WOS:000566378100001
PM 32922735
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Palermo, NE
   Sadhu, AR
   McDonnell, ME
AF Palermo, Nadine E.
   Sadhu, Archana R.
   McDonnell, Marie E.
TI Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE diabetes; pancreatic and gastrointestinal hormones; diabetic
   ketoacidosis
ID INTRAVENOUS REGULAR INSULIN; HYPERGLYCEMIC CRISES; TYPE-1;
   HOSPITALIZATIONS; CORONAVIRUS; PREVENTION; MANAGEMENT; MORTALITY;
   DIAGNOSIS; TRENDS
AB Context: While individuals with diabetes appear to be at similar risk for SARS-CoV-2 infection to those without diabetes, they are more likely to suffer severe consequences, including death. Diabetic ketoacidosis (DKA) is a common and potentially lethal acute complication of diabetes arising from a relative insulin deficiency, which occurs more often in those with type 1 diabetes and in the setting of moderate to severe illness. Early reports indicate that among patients with pre-existing diabetes, DKA may be a common complication of severe COVID-19 and a poor prognostic sign.
   Case Description: This clinical perspective explores the key elements of caring for individuals with DKA during the COVID-19 pandemic through 2 cases. Topics addressed include diagnosis, triage, and the fundamental principles of treatment with a focus on the importance of characterizing DKA severity and medical complexity to determine the best approach.
   Conclusions: As discussed, some tenets of DKA management may require flexibility in the setting of COVID-19 due to important public health goals, such as preventing transmission to highest risk individuals, reducing healthcare worker exposure to infected patients, and preserving personal protective equipment. Evidence for alternative treatment strategies is explored, with special attention placed on treatment options that may be more relevant during the pandemic, including use of subcutaneous insulin therapy. Finally, DKA is often a preventable condition. We include evidence-based strategies and guidance designed to empower clinicians and patients to avoid this serious complication when possible.
C1 [Palermo, Nadine E.; McDonnell, Marie E.] Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.
   [Palermo, Nadine E.; McDonnell, Marie E.] Harvard Med Sch, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.
   [Sadhu, Archana R.] Houston Methodist Hosp, Houston, TX 77030 USA.
   [Sadhu, Archana R.] Weill Cornell Med Coll, Houston, TX 77030 USA.
RP McDonnell, ME (corresponding author), Brigham & Womens Hosp, Diabet Program, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.
EM mmdonnell@bwh.harvard.edu
CR Alhassan S, 2019, J DIABETES, V11, P410, DOI 10.1111/1753-0407.12885
   Andrade-Castellanos CA, 2016, COCHRANE DB SYST REV, V2016
   Barker JM, 2004, DIABETES CARE, V27, P1399, DOI 10.2337/diacare.27.6.1399
   Benoit SR, 2018, MMWR-MORBID MORTAL W, V67, P362, DOI 10.15585/mmwr.mm6712a3
   BEVILACQUA S, 1987, METABOLISM, V36, P502, DOI 10.1016/0026-0495(87)90051-5
   CDC, STAY HOM YOUR SICK
   Chee YJ, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108166
   Chen YQ, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0146-2
   Della Manna T, 2005, DIABETES CARE, V28, P1856, DOI 10.2337/diacare.28.8.1856
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Ersoz HO, 2006, INT J CLIN PRACT, V60, P429, DOI 10.1111/j.1368-5031.2006.00786.x
   Fayfman M, 2017, MED CLIN N AM, V101, P587, DOI 10.1016/j.mcna.2016.12.011
   FDA, FDA REV LAB SGLT2 IN
   Foundation JDR, COR TYP 1 DIAB WHAT
   GAMBA G, 1991, REV INVEST CLIN, V43, P234
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamblin PS, 2019, J CLIN ENDOCR METAB, V104, P3077, DOI 10.1210/jc.2019-00139
   Hsia E, 2012, J CLIN ENDOCR METAB, V97, P3132, DOI 10.1210/jc.2012-1244
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jefferies CA, 2015, PEDIATR CLIN N AM, V62, P857, DOI 10.1016/j.pcl.2015.04.002
   Kaiser UB, 2020, J CLIN ENDOCR METAB, V105, P1
   Karajgikar ND, 2019, ENDOCR PRACT, V25, P407, DOI 10.4158/EP-2018-0398
   Karoli R, 2011, INDIAN J PHARMACOL, V43, P398, DOI 10.4103/0253-7613.83109
   Kim NY, 2020, DIABETES METAB J, V44, P349, DOI 10.4093/dmj.2020.0091
   Kitabchi AE, 2009, DIABETES CARE, V32, P1335, DOI 10.2337/dc09-9032
   Korytkowski M, 2020, J CLIN ENDOCR METAB, V105, P3076, DOI 10.1210/clinem/dgaa342
   Laffel LM, 2018, PEDIATR DIABETES, V19, P193, DOI 10.1111/pedi.12741
   Larsson HE, 2011, DIABETES CARE, V34, P2347, DOI 10.2337/dc11-1026
   Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057
   Limenta M, 2019, CLIN DRUG INVEST, V39, P683, DOI 10.1007/s40261-019-00794-5
   Masini M, 2005, DIABETES CARE, V28, P940, DOI 10.2337/diacare.28.4.940
   McDonnell ME, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1015-3
   Misra S, 2015, DIABETIC MED, V32, P14, DOI 10.1111/dme.12604
   Moghissi ES, 2009, DIABETES CARE, V32, P1119, DOI 10.2337/dc09-9029
   MUNRO JF, 1973, BRIT MED J, V2, P578, DOI 10.1136/bmj.2.5866.578
   Novonordisk Savings Program, COVID 19 NOV NORD IN
   Nyenwe EA, 2016, METABOLISM, V65, P507, DOI 10.1016/j.metabol.2015.12.007
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Peters AL, 2020, DIABETES TECHNOL THE, V22, P449, DOI 10.1089/dia.2020.0187
   Peters AL, 2016, DIABETES CARE, V39, P532, DOI 10.2337/dc15-1995
   Petzold A, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0654-x
   ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610
   Singh AK, 2020, DIABETES METAB SYND, V14, P303, DOI 10.1016/j.dsx.2020.04.004
   Steenkamp DW, 2013, CURR DIABETES REP, V13, P130, DOI 10.1007/s11892-012-0342-z
   Stentz FB, 2004, DIABETES, V53, P2079, DOI 10.2337/diabetes.53.8.2079
   Stratigou T, 2019, DIABETES METAB SYND, V13, P1639, DOI 10.1016/j.dsx.2019.03.022
   Umpierrez GE, 2004, DIABETES CARE, V27, P1873, DOI 10.2337/diacare.27.8.1873
   Umpierrez GE, 2004, AM J MED, V117, P291, DOI 10.1016/j.amjmed.2004.05.010
   Umpierrez GE, 2006, DIABETES CARE, V29, P2755, DOI 10.2337/dc06-1870
   Vellanki P, 2018, DIABETES CARE, V41, P1839, DOI 10.2337/dci18-0004
   Wagner David V, 2017, J Diabetes Sci Technol, V11, P468, DOI 10.1177/1932296817695337
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Zhong VW, 2018, DIABETES CARE, V41, P1870, DOI 10.2337/dc17-1583
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720
NR 57
TC 4
Z9 4
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD AUG
PY 2020
VL 105
IS 8
BP 2819
EP 2829
DI 10.1210/clinem/dgaa360
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NJ3DE
UT WOS:000565927300092
PM 32556147
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dell'Era, V
   Dosdegani, R
   Valletti, PA
   Garzaro, M
AF Dell'Era, Valeria
   Dosdegani, Riccardo
   Valletti, Paolo Aluffi
   Garzaro, Massimiliano
TI Epistaxis in hospitalized patients with COVID-19
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Epistaxis; pandemics; COVID-19; hemorrhage; heparin; oxygen therapy
AB Spontaneous epistaxis in patients with COVID-19 can represent a clinical challenge with respect to both the risk of contamination and the treatment options. We herein present the data of 30 patients with COVID-19 who developed spontaneous epistaxis while hospitalized at Eastern Piedmont Hospital during March and April 2020. All patients received low-molecular-weight heparin during their hospital stay and required supplementary oxygen therapy either by a nasal cannula or continuous positive airway pressure. Both conditions can represent risk factors for developing epistaxis. Prevention of crust formation in patients with rhinitis using a nasal lubricant should be recommended. If any treatment is required, appropriate self-protection is mandatory.
C1 [Dell'Era, Valeria; Valletti, Paolo Aluffi; Garzaro, Massimiliano] Univ Piemonte Orientale, ENT Div, Corso Mazzini 18, I-28100 Novara, Italy.
   [Dosdegani, Riccardo] St Andrea Hosp, ENT Div, Vercelli, Italy.
RP Dell'Era, V (corresponding author), Univ Piemonte Orientale, ENT Div, Corso Mazzini 18, I-28100 Novara, Italy.
EM valeria.dellera@gmail.com
OI Dell'Era, Valeria/0000-0002-2171-4120
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   D'Aguanno V, 2020, OTOLARYNG HEAD NECK, V163, P75, DOI 10.1177/0194599820926497
   El-Anwar MW, 2020, AURIS NASUS LARYNX, V47, P559, DOI 10.1016/j.anl.2020.06.003
   Garzaro G, 2020, MED LAV, V111, P184, DOI 10.23749/mdl.v111i3.9767
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Miyamoto K, 2008, RESP CARE, V53, P503
   Poiroux L, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0472-9
   STRUMPF DA, 1989, CHEST, V95, P1141, DOI 10.1378/chest.95.5.1141
   Tabassom A, 2020, STATPEARLS
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD AUG
PY 2020
VL 48
IS 8
AR 0300060520951040
DI 10.1177/0300060520951040
PG 4
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NL1GV
UT WOS:000567173200001
PM 32865072
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lazzerini, PE
   Acampa, M
   Laghi-Pasini, F
   Bertolozzi, I
   Finizola, F
   Vanni, F
   Natale, M
   Bisogno, S
   Cevenini, G
   Cartocci, A
   Giabbani, B
   Migliacci, N
   D'Errico, A
   Dokollari, A
   Maccherini, M
   Boutjdir, M
   Capecchi, PL
AF Lazzerini, Pietro Enea
   Acampa, Maurizio
   Laghi-Pasini, Franco
   Bertolozzi, Iacopo
   Finizola, Francesco
   Vanni, Francesca
   Natale, Mariarita
   Bisogno, Stefania
   Cevenini, Gabriele
   Cartocci, Alessandra
   Giabbani, Beatrice
   Migliacci, Nicola
   D'Errico, Antonio
   Dokollari, Alexander
   Maccherini, Massimo
   Boutjdir, Mohamed
   Capecchi, Pier Leopoldo
TI Cardiac Arrest Risk During Acute Infections Systemic Inflammation
   Directly Prolongs QTc Interval via Cytokine-Mediated Effects on
   Potassium Channel Expression
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE communicable diseases; heart arrest; inflammation; potassium channels;
   Torsades de pointes
ID C-REACTIVE PROTEIN; AMERICAN-HEART-ASSOCIATION; RHEUMATOID-ARTHRITIS;
   SUDDEN-DEATH; PNEUMONIA; STATEMENT; SEPSIS
AB Background: During acute infections, the risk of malignant ventricular arrhythmias is increased, partly because of a higher propensity to develop QTc prolongation. Although it is generally believed that QTc changes almost exclusively result from concomitant treatment with QT-prolonging antimicrobials, direct effects of inflammatory cytokines on ventricular repolarization are increasingly recognized. We hypothesized that systemic inflammation per se can significantly prolong QTc during acute infections, via cytokine-mediated changes in K(+)channel expression. Methods: We evaluated (1) the frequency of QTc prolongation and its association with inflammatory markers, in patients with different types of acute infections, during active disease and remission; (2) the prevalence of acute infections in a cohort of consecutive patients with Torsades de Pointes; (3) the relationship between K(+)channel mRNA levels in ventricles and peripheral blood mononuclear cells and their changes in patients with acute infection over time. Results: In patients with acute infections, regardless of concomitant QT-prolonging antimicrobial treatments, QTc was significantly prolonged but rapidly normalized in parallel to CRP (C-reactive protein) and cytokine level reduction. Consistently in the Torsades de Pointes cohort, concomitant acute infections were highly prevalent (30%), despite only a minority (25%) of these cases were treated with QT-prolonging antimicrobials. KCNJ2 K(+)channel expression in peripheral blood mononuclear cell, which strongly correlated to that in ventricles, inversely associated to CRP and IL (interleukin)-1 changes in acute infection patients. Conclusions: During acute infections, systemic inflammation rapidly induces cytokine-mediated ventricular electrical remodeling and significant QTc prolongation, regardless concomitant antimicrobial therapy. Although transient, these changes may significantly increase the risk of life-threatening ventricular arrhythmia in these patients. It is timely and warranted to transpose these findings to the current coronavirus disease 2019 (COVID-19) pandemic, in which both increased amounts of circulating cytokines and cardiac arrhythmias are demonstrated along with a frequent concomitant treatment with several QT-prolonging drugs.
C1 [Lazzerini, Pietro Enea; Laghi-Pasini, Franco; Finizola, Francesco; Vanni, Francesca; Natale, Mariarita; Bisogno, Stefania; Giabbani, Beatrice; Migliacci, Nicola; D'Errico, Antonio; Capecchi, Pier Leopoldo] Univ Siena, Dept Med Sci Surg & Neurosci, Viale Bracci, I-53100 Siena, Italy.
   [Cevenini, Gabriele; Cartocci, Alessandra] Univ Siena, Dept Med Biotechnol, Siena, Italy.
   [Acampa, Maurizio] Univ Hosp Siena, Stroke Unit, Siena, Italy.
   [Dokollari, Alexander; Maccherini, Massimo] Univ Hosp Siena, Dept Cardiac Surg, Siena, Italy.
   [Bertolozzi, Iacopo] Hosp Carrara, Dept Internal Med, Cardiol Intens Therapy Unit, Bergamo, Italy.
   [Dokollari, Alexander] Univ Toronto, St Michael Hosp, Dept Cardiovasc Surg, Toronto, ON, Canada.
   SUNY Downstate Med Ctr, VA New York Harbor Healthcare Syst, Brooklyn, NY USA.
   [Boutjdir, Mohamed] NYU Sch Med, New York, NY USA.
RP Lazzerini, PE (corresponding author), Univ Siena, Dept Med Sci Surg & Neurosci, Viale Bracci, I-53100 Siena, Italy.
EM lazzerini7@unisi.it
RI Cartocci, Alessandra/AAB-5831-2020; Acampa, Maurizio/I-3062-2019;
   CEVENINI, Gabriele/S-1973-2018
OI Cartocci, Alessandra/0000-0002-1818-6275; Acampa,
   Maurizio/0000-0003-4149-1785; Lazzerini, Pietro
   Enea/0000-0001-6721-1214; CEVENINI, Gabriele/0000-0002-7212-573X
FU Ministero dell'Istruzione, dell'Universita e della Ricerca, Progetti di
   Rilevante Interesse NazionaleMinistry of Education, Universities and
   Research (MIUR)Research Projects of National Relevance (PRIN)
   [2017XZMBYX]; Ministero dell'Istruzione, dell'Universita e della
   Ricerca, Bando 2017 [2017XZMBYX]
FX This work was funded by Ministero dell'Istruzione, dell'Universita e
   della Ricerca, Progetti di Rilevante Interesse Nazionale, and Bando
   2017, protocollo 2017XZMBYX.
CR Adlan AM, 2015, J RHEUMATOL, V42, P421, DOI 10.3899/jrheum.140861
   Albert CM, 2002, CIRCULATION, V105, P2595, DOI 10.1161/01.CIR.0000017493.03108.1C
   Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321
   Capecchi PL, 2019, HEART RHYTHM, V16, P1273, DOI 10.1016/j.hrthm.2019.02.017
   Carr GE, 2012, CHEST, V141, P1528, DOI 10.1378/chest.11-1547
   Chiladakis J, 2010, PACE, V33, P553, DOI 10.1111/j.1540-8159.2009.02657.x
   Danielsson B, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034560
   Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704
   El-Sherif N, 2018, PACE, V41, P414, DOI 10.1111/pace.13296
   Empana JP, 2010, ARTERIOSCL THROM VAS, V30, P2047, DOI 10.1161/ATVBAHA.110.208785
   Feske S, 2015, ANNU REV IMMUNOL, V33, P291, DOI 10.1146/annurev-immunol-032414-112212
   Gao G, 2014, J AM COLL CARDIOL, V63, P2261, DOI 10.1016/j.jacc.2014.02.588
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grant AO, 2009, CIRC-ARRHYTHMIA ELEC, V2, P185, DOI 10.1161/CIRCEP.108.789081
   Gupta A, 2007, AM HEART J, V153, P891, DOI 10.1016/j.ahj.2007.01.040
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650
   Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15
   Kobayashi H, 2018, J RHEUMATOL, V45, P1620, DOI 10.3899/jrheum.180065
   Lazzerini PE, 2020, CIRCULATION, V142, P7, DOI 10.1161/CIRCULATIONAHA.120.047293
   Lazzerini PE, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011006
   Lazzerini PE, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010595
   Lazzerini PE, 2019, NAT REV IMMUNOL, V19, P63, DOI 10.1038/s41577-018-0098-z
   Lazzerini PE, 2017, HEART, V103, P1821, DOI 10.1136/heartjnl-2016-311079
   Lazzerini PE, 2017, EUR HEART J, V38, P1717, DOI 10.1093/eurheartj/ehw208
   Lazzerini Pietro Enea, 2015, Front Cardiovasc Med, V2, P26, DOI 10.3389/fcvm.2015.00026
   Lazzerini PE, 2015, ARTHRIT CARE RES, V67, P332, DOI 10.1002/acr.22455
   Leoni D, 2017, CLIN MICROBIOL INFEC, V23, P730, DOI 10.1016/j.cmi.2016.11.018
   Lepojarvi ES, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203363
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li XR, 2016, J CARDIOVASC PHARM, V67, P252, DOI 10.1097/FJC.0000000000000341
   Maradit-Kremers H, 2005, ARTHRITIS RHEUM-US, V52, P402, DOI 10.1002/art.20853
   Mason JW, 2017, J ANTIMICROB CHEMOTH, V72, P1272, DOI 10.1093/jac/dkw591
   Morgan RW, 2017, J CRIT CARE, V40, P128, DOI 10.1016/j.jcrc.2017.03.023
   Ozdemir R, 2016, J TROP PEDIATRICS, V62, P377, DOI 10.1093/tropej/fmw021
   Petkova-Kirova PS, 2006, AM J PHYSIOL-HEART C, V290, pH2098, DOI 10.1152/ajpheart.00097.2005
   Pujades-Rodriguez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151245
   Shahreyar M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.26
   Soto-Gomez N, 2013, AM J MED, V126, P43, DOI 10.1016/j.amjmed.2012.08.005
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JX, 2004, J BIOL CHEM, V279, P13289, DOI 10.1074/jbc.C400025200
   Wasserstrum Y, 2016, INTERN MED J, V46, P1204, DOI 10.1111/imj.13170
   Wu KC, 2012, CIRC-CARDIOVASC IMAG, V5, P178, DOI 10.1161/CIRCIMAGING.111.968024
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zurolo E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-280
NR 46
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3149
EI 1941-3084
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD AUG
PY 2020
VL 13
IS 8
DI 10.1161/CIRCEP.120.008627
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NI6RQ
UT WOS:000565478900017
PM 32654514
DA 2021-01-01
ER

PT J
AU Casey, RT
   Valk, GD
   Schalin-Jantti, C
   Grossman, AB
   Thakker, RV
AF Casey, Ruth T.
   Valk, Gerlof D.
   Schalin-Jantti, Camilla
   Grossman, Ashley B.
   Thakker, Rajesh, V
TI ENDOCRINOLOGY IN THE TIME OF COVID-19 Clinical management of
   neuroendocrine neoplasms (NENs)
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID ENETS CONSENSUS GUIDELINES; TUMORS; RECEPTOR
AB In viral pandemics, most specifically Covid-19, many patients with neuroendocrine neoplasms (NENs), including phaeochromocytomas, paragangliomas and medullary thyroid carcinoma, may develop Covid-19 in a mild or severe form, or be concerned about the influence of viral infection relative to their anti-tumoral therapy. In general, newly presenting patients should be assessed, and patients recently receiving chemotherapy, targeted therapy or radionuclide therapy, or showing tumour growth, should be closely followed. For previously diagnosed patients, who have indolent disease, some delay in routine follow-up or treatment may not be problematic. However, patients developing acute secretory syndromes due to functional neuroendocrine neoplasms (such as of the pancreas, intestine or lung), phaeochromocytomas and paragangliomas, will require prompt treatment. Patients with life-threatening Covid-19-related symptoms should be urgently treated and long-term anti-tumoral treatments may be temporarily delayed. In patients with especially aggressive NENs, a careful judgement should be made regarding the severity of any Covid-19 illness, tumour grade, and the immunosuppressant effects of any planned chemotherapy, immunotherapy (e.g. interferon-alpha), targeted therapy or related treatment. In other cases, especially patients with completely resected NENs, or who are under surveillance for a genetic disorder, a telephone or delayed consultation may be in order, balancing the risk of a delay against that of the possible development of Covid-19.
C1 [Casey, Ruth T.] Cambridge Univ Hosp NHS Fdn Trust, Wolfson Diabet & Endocrinol Clin, Cambridge, England.
   [Casey, Ruth T.] Univ Cambridge, Dept Med Genet, Cambridge, England.
   [Valk, Gerlof D.] Univ Med Ctr Utrecht, ENETS Ctr Excellence, Dept Endocrine Oncol, Utrecht, Netherlands.
   [Schalin-Jantti, Camilla] Univ Helsinki, Abdominal Ctr, Div Endocrinol, Helsinki, Finland.
   [Schalin-Jantti, Camilla] Helsinki Univ Hosp, Helsinki, Finland.
   [Grossman, Ashley B.] Royal Free Hosp ENETs Ctr Excellence, London, England.
   [Grossman, Ashley B.] Barts & London Queen Marys Sch Med & Dent, Ctr Endocrinol, London, England.
   [Grossman, Ashley B.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
   [Thakker, Rajesh, V] Univ Oxford, Acad Endocrine Unit, Radcliffe Dept Med, Oxford, England.
RP Thakker, RV (corresponding author), Univ Oxford, Acad Endocrine Unit, Radcliffe Dept Med, Oxford, England.
EM rajesh.thakker@ndm.ox.ac.uk
FU GIST Support UK; Wellcome Trust Investigator AwardWellcome Trust
   [106995/Z/15/Z]; National Institute for Health Research (NIHR) Oxford
   Biomedical Research Centre ProgrammeNational Institute for Health
   Research (NIHR); NIHRNational Institute for Health Research (NIHR)
   [NF-SI-0514-10091]
FX R T C is supported by a grant from GIST Support UK; and R V T is
   supported by a Wellcome Trust Investigator Award (grant number
   106995/Z/15/Z), National Institute for Health Research (NIHR) Oxford
   Biomedical Research Centre Programme), and NIHR Senior Investigator
   Award (grant number NF-SI-0514-10091).
CR Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI 10.1056/NEJMoa1316158
   Condron ME, 2019, SURGERY, V165, P158, DOI 10.1016/j.surg.2018.04.093
   Gonzalez CD, 2010, CURR DRUG SAF, V5, P79, DOI 10.2174/157488610789869157
   Dasari A, 2017, JAMA ONCOL, V3, P1335, DOI 10.1001/jamaoncol.2017.0589
   Falconi M, 2016, NEUROENDOCRINOLOGY, V103, P153, DOI 10.1159/000443171
   Garcia-Carbonero R, 2016, NEUROENDOCRINOLOGY, V103, P186, DOI 10.1159/000443172
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofland J, 2020, ENDOCR REV, V41, P371, DOI 10.1210/endrev/bnz004
   Kaltsas G, 2017, NEUROENDOCRINOLOGY, V105, P245, DOI 10.1159/000461583
   Lamberti G, 2020, J CLIN ENDOCR METAB, V105, P194, DOI 10.1210/clinem/dgz035
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Nolting S, 2019, CANCERS, V11, DOI 10.3390/cancers11101505
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Ramage JK, 2012, GUT, V61, P6, DOI 10.1136/gutjnl-2011-300831
   Rindi G, 2018, MODERN PATHOL, V31, P1770, DOI 10.1038/s41379-018-0110-y
   Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510
   Seymour N, 2013, CAN J ANESTH, V60, P492, DOI 10.1007/s12630-012-9879-1
   Sorbye H, 2018, ENDOCRIN METAB CLIN, V47, P683, DOI 10.1016/j.ecl.2018.05.001
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335
NR 22
TC 2
Z9 2
U1 0
U2 0
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD AUG
PY 2020
VL 183
IS 2
BP G79
EP G88
DI 10.1530/EJE-20-0424
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NI7RP
UT WOS:000565546600010
PM 32554825
OA Bronze
DA 2021-01-01
ER

PT J
AU Gittoes, NJ
   Criseno, S
   Appelman-Dijkstra, NM
   Bollerslev, J
   Canalis, E
   Rejnmark, L
   Hassan-Smith, Z
AF Gittoes, Neil J.
   Criseno, Sherwin
   Appelman-Dijkstra, Natasha M.
   Bollerslev, Jens
   Canalis, Ernesto
   Rejnmark, Lars
   Hassan-Smith, Zaki
TI ENDOCRINOLOGY IN THE TIME OF COVID-19 Management of calcium metabolic
   disorders and osteoporosis
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID EMERGENCY MANAGEMENT
AB Endocrinologists have had to make rapid changes to services so that resources can be focused on the COVID-19 response to help prevent spread of the virus. Herein we provide pragmatic advice on the management of commonly encountered calcium metabolic problems and osteoporosis. Non-urgent elective appointments should be postponed, and remote consultations and digital health solutions promoted. Patients should be empowered to self-manage their conditions safely. Patients, their caregivers and healthcare providers should be directed to assured national or international online resources and specific patient groups. For patients in acute hospital settings, existing emergency guidance on the management of hyper- and hypo-calcaemia should be followed. An approach to osteoporosis management is outlined. IV zoledronic acid infusions can be delayed for 6-9 months during the pandemic. Patients established on denosumab, teriparatide and abaloparatide should continue planned therapy. In the event of supply issues with teriparatide or abaloparatide, pausing this treatment in the short term is likely to be relatively harmless, whereas delaying denosumab may cause an immediate increased risk of fracture. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use of resources and resilience of healthcare systems in its aftermath.
C1 [Gittoes, Neil J.; Criseno, Sherwin; Hassan-Smith, Zaki] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Dept Endocrinol, Birmingham, W Midlands, England.
   [Gittoes, Neil J.; Criseno, Sherwin; Hassan-Smith, Zaki] Birmingham Hlth Partners, Ctr Endocrinol Diabet & Metab, Birmingham, W Midlands, England.
   [Gittoes, Neil J.; Hassan-Smith, Zaki] Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham, W Midlands, England.
   [Appelman-Dijkstra, Natasha M.] Leiden Univ, Ctr Bone Qual, Med Ctr, Leiden, Netherlands.
   [Bollerslev, Jens] Oslo Univ Hosp, Sect Specialized Endocrinol, Oslo, Norway.
   [Bollerslev, Jens] Univ Oslo, Fac Med, Oslo, Norway.
   [Canalis, Ernesto] UConn Hlth, Dept Orthopaed, Farmington, CT USA.
   [Canalis, Ernesto] UConn Hlth, Dept Med, Farmington, CT USA.
   [Rejnmark, Lars] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
RP Gittoes, NJ (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Dept Endocrinol, Birmingham, W Midlands, England.; Gittoes, NJ (corresponding author), Birmingham Hlth Partners, Ctr Endocrinol Diabet & Metab, Birmingham, W Midlands, England.; Gittoes, NJ (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham, W Midlands, England.
EM Neil.Gittoes@uhb.nhs.uk
OI Rejnmark, Lars/0000-0002-2152-4247
CR Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3
   Dancer RCA, 2015, THORAX, V70, P617, DOI 10.1136/thoraxjnl-2014-206680
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Turner J, 2016, ENDOCR CONNECT, V5, pG7, DOI 10.1530/EC-16-0056
   Walsh J, 2016, ENDOCR CONNECT, V5, pG9, DOI 10.1530/EC-16-0055
NR 8
TC 2
Z9 2
U1 1
U2 1
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD AUG
PY 2020
VL 183
IS 2
BP G57
EP G65
DI 10.1530/EJE-20-0385
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NI7RP
UT WOS:000565546600008
PM 32396134
OA Bronze
DA 2021-01-01
ER

PT J
AU Pandey, AT
   Pandey, I
   Zamboni, P
   Gemmati, D
   Kanase, A
   Singh, AV
   Singh, MP
AF Pandey, Aprajita Tiwari
   Pandey, Ishan
   Zamboni, Paolo
   Gemmati, Donato
   Kanase, Anurag
   Singh, Ajay Vikram
   Singh, Mohan Prasad
TI Traditional Herbal Remedies with a Multifunctional Therapeutic Approach
   as an Implication in COVID-19 Associated Co-Infections
SO COATINGS
LA English
DT Article
DE viral infection; antifungal; antibiotics; multidrug resistant; plant
   extracts; immunomodulators; surface coatings
AB Co-infection in patients with viral infection as a predisposing factor is less focused on during epidemic outbreaks, resulting in increased morbidity and mortality. Recent studies showed that patients with coronavirus disease 2019 (COVID-19) often have both bacterial and fungal co-infections. In this study, sputum samples of 120 OPD (outdoor patients) suffering from respiratory tract infection (RTI) but negative for tuberculosis infection were collected with informed consent. Morphological, biochemical, and resistance criteria were used to classify isolates and to distinguish multidrug resistant (MDR) isolates, which were further classified on a molecular basis. We found that the isolates, including MDR strains, showed remarkable sensitivity against acetone and methanol extracts ofMoringa oleifera, Adhatoda vasica, andCassia fistula. The results strongly confirmed that multifactorial infections can produce MDR characteristics against antimicrobial drugs, which gave insight into the use of herbal drugs with their age-old traditional importance as having antiviral, antibacterial, antifungal, anti-inflammatory, and immunomodulatory effects. We conclude that apart from this, the anti-infective potential of these plants can be used in the future in the form of products such as cosmetics, pharmaceutical coatings, surface coatings, drug delivery vehicle coatings, and other bioengineered coatings for public use. Future studies are required to assess therapeutics for co-infective resistant strains and nosocomial infections with immune-enhancing effects, thereby promoting their function in holistic treatment and therapy of COVID-19 patients.
C1 [Pandey, Aprajita Tiwari; Singh, Mohan Prasad] Univ Allahabad, Ctr Biotechnol, Nehru Sci Complex, Prayagraj 211002, Uttar Pradesh, India.
   [Pandey, Ishan] Moti Lal Nehru Med Coll, Dept Pathol, Prayagraj 211001, Uttar Pradesh, India.
   [Zamboni, Paolo] Ferrara Univ Hosp, Unit Translat Surg, I-44124 Ferrara, Italy.
   [Zamboni, Paolo] Ferrara Univ Hosp, Vasc Dis Ctr, I-44124 Ferrara, Italy.
   [Gemmati, Donato] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44124 Ferrara, Italy.
   [Gemmati, Donato] Univ Ferrara, Ctr Hemostasis & Thrombosis, I-44124 Ferrara, Italy.
   [Kanase, Anurag] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA.
   [Singh, Ajay Vikram] German Fed Inst Risk Assessment BfR, Dept Chem & Prod Safety, Max Dohrn Str 8-10, D-10589 Berlin, Germany.
RP Singh, MP (corresponding author), Univ Allahabad, Ctr Biotechnol, Nehru Sci Complex, Prayagraj 211002, Uttar Pradesh, India.; Singh, AV (corresponding author), German Fed Inst Risk Assessment BfR, Dept Chem & Prod Safety, Max Dohrn Str 8-10, D-10589 Berlin, Germany.
EM tiwari.aprajita2011@gmail.com; ishan.pandey411@gmail.com;
   zambo@unife.it; cet@unife.it; anuragkanase@gmail.com;
   Ajay-Vikram.Singh@bfr.bund.de; mpsingh.16@gmail.com
RI Singh, Mohan Prasad/F-7059-2011
OI Singh, Mohan Prasad/0000-0002-6236-856X; Kanase,
   Anurag/0000-0002-1260-3138; Zamboni, Paolo/0000-0002-7107-888X; Gemmati,
   Donato/0000-0001-6213-6120
CR Amiri MRJ, 2018, ETHIOP J HEALTH SCI, V28, P683, DOI 10.4314/ejhs.v28i6.2
   Ansari MHD, 2020, CURR NANOSCI, V16, P27, DOI 10.2174/1573413715666190409101305
   Atef N.M, 2019, B NAT RES CENT, V43, P144, DOI [10.1186/s42269-019-0184-9, DOI 10.1186/S42269-019-0184-9]
   Bag A, 2020, TREATMENT COVID 19 P, DOI [10.26434/chemrxiv.12038604.v1, DOI 10.26434/CHEMRXIV.12038604.V1]
   Bahorun T, 2005, AFR J BIOTECHNOL, V4, P1530
   Bengoechea JA, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012560
   Budayanti NS, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00064
   Chaerunisaa Anis Yohana, 2020, Toxicol Rep, V7, P649, DOI 10.1016/j.toxrep.2020.04.013
   Chartier L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021212
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cox Michael J, 2020, Lancet Microbe, V1, pe11, DOI 10.1016/S2666-5247(20)30009-4
   Das K, 2010, J MED PLANTS RES, V4, P104
   Duin D.V., 2010, INFECT DIS CLIN N AM, V2, P377
   EILERT U, 1981, PLANTA MED, V42, P55, DOI 10.1055/s-2007-971546
   Gangwar A. K., 2014, International Journal of Herbal Medicine, V2, P88
   Gemmati D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103474
   Holt J.G., 1994, BERGEYS MANUAL DETER
   Hudzicki J., 2009, AM SOC MICROBIOL
   Jacobs E, 2009, INT J ANTIMICROB AG, V33, P52, DOI 10.1016/j.ijantimicag.2008.07.017
   Jyotirmoy S, 2016, IJHRMLP, V2, P24
   Killedar SG, 2014, INT J PHARM INVESTIG, V4, P215, DOI 10.4103/2230-973X.143128
   Kwon J.W, 2020, MEDPAGE TODAY
   Lockett CT, 2000, INT J FOOD SCI NUTR, V51, P195, DOI [10.1080/09637480050029700, 10.1080/096374899101238]
   Lopes LC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005267
   MacIntyre CR, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3548-0
   Meignanalakshmi S., 2013, HYGELA J DRUGS MED, V1, P1
   Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041
   Nostro A, 2006, PHYTOTHER RES, V20, P187, DOI 10.1002/ptr.1830
   Obeidat M., 2012, Research Journal of Microbiology, V7, P59, DOI 10.3923/jm.2012.59.67
   Prasannabalaji N., 2012, Asian Pacific Journal of Tropical Disease, pS291
   Rastogi Sanjeev, 2020, J Ayurveda Integr Med, DOI 10.1016/j.jaim.2020.04.002
   Razmavar S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/521287
   Shelar A, 2019, MED CHEM, V15, P781, DOI 10.2174/1573406415666190430142637
   Shukla S, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02398
   Singh AV, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901862
   Singh AV, 2020, LANGMUIR, V36, P5435, DOI 10.1021/acs.langmuir.9b03665
   Singh AV, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11040448
   Singh Ajay Vikram, 2019, Expert Opin Drug Deliv, V16, P1259, DOI 10.1080/17425247.2019.1676228
   Singh R.M, 2013, J MAT ENV SCI, V1, P117
   Siyanbola T. O., 2015, Canadian Journal of Pure & Applied Sciences, V9, P3229
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stevenson JE, 2007, ANTIMICROB AGENTS CH, V51, P195, DOI 10.1128/AAC.00222-06
   Terraneo S, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.09.002
   Thirumal M, 2012, CRIT REV PHARM SCI, V1, P43
   Vishwanath S, 2013, IRAN J MICROBIOL, V5, P323
   Wang LM, 2016, 3 BIOTECH, V6, DOI 10.1007/s13205-016-0473-z
   Wijetunge W.M.A.N.K, 2015, IJMS INT J MULTIDISC, V2, P71, DOI [10.4038/ijms.v2i2.76, DOI 10.4038/IJMS.V2I2.76]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zafar Afia, 2008, J Ayub Med Coll Abbottabad, V20, P7
   Zahirah N, 2018, FRONT PHARMACOL, V9, P1
   Zapata A, 2015, CURR MICROBIOL, V70, P907, DOI 10.1007/s00284-015-0801-2
   Zheng Z, 2003, CHINESE J RESP CRITI, V2, P270
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou PC, 2020, INFECT CONT HOSP EP, V41, P1124, DOI 10.1017/ice.2020.156
NR 54
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-6412
J9 COATINGS
JI Coatings
PD AUG
PY 2020
VL 10
IS 8
AR 761
DI 10.3390/coatings10080761
PG 14
WC Materials Science, Coatings & Films
SC Materials Science
GA NH4JY
UT WOS:000564639200001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kriegova, E
   Fillerova, R
   Kvapil, P
AF Kriegova, Eva
   Fillerova, Regina
   Kvapil, Petr
TI Direct-RT-qPCR Detection of SARS-CoV-2 without RNA Extraction as Part of
   a COVID-19 Testing Strategy: From Sample to Result in One Hour
SO DIAGNOSTICS
LA English
DT Article
DE 2019-nCoV; diagnostics; one-step direct RT-PCR; screening tests;
   point-of-care testing
AB Due to the lack of protective immunity in the general population and the absence of effective antivirals and vaccines, the Coronavirus disease 2019 (COVID-19) pandemic continues in some countries, with local epicentres emerging in others. Due to the great demand for effective COVID-19 testing programmes to control the spread of the disease, we have suggested such a testing programme that includes a rapid RT-qPCR approach without RNA extraction. The Direct-One-Step-RT-qPCR (DIOS-RT-qPCR) assay detects severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than one hour while maintaining the high sensitivity and specificity required of diagnostic tools. This optimised protocol allows for the direct use of swab transfer media (14 mu L) without the need for RNA extraction, achieving comparable sensitivity to the standard method that requires the time-consuming and costly step of RNA isolation. The limit of detection for DIOS-RT-qPCR was lower than seven copies/reaction, which translates to 550 virus copies/mL of swab. The speed, ease of use and low price of this assay make it suitable for high-throughput screening programmes. The use of fast enzymes allows RT-qPCR to be performed under standard laboratory conditions within one hour, making it a potential point-of-care solution on high-speed cycling instruments. This protocol also implements the heat inactivation of SARS-CoV-2 (75 degrees C for 10 min), which renders samples non-infectious, enabling testing in BSL-2 facilities. Moreover, we discuss the critical steps involved in developing tests for the rapid detection of COVID-19. Implementing rapid, easy, cost-effective methods can help control the worldwide spread of the COVID-19 infection.
C1 [Kriegova, Eva; Fillerova, Regina] Palacky Univ Olomouc, Fac Med & Dent, OLGEN, Dept Immunol, Olomouc 77515, Czech Republic.
   [Kriegova, Eva; Fillerova, Regina] Univ Hosp, Olomouc 77515, Czech Republic.
   [Kvapil, Petr] Inst Appl Biotechnol As, Prague 10800, Czech Republic.
RP Kriegova, E (corresponding author), Palacky Univ Olomouc, Fac Med & Dent, OLGEN, Dept Immunol, Olomouc 77515, Czech Republic.; Kriegova, E (corresponding author), Univ Hosp, Olomouc 77515, Czech Republic.
EM regina.fillerova@fnol.cz; regina.fillerova@fnol.cz; kvapil@ibiotech.cz
OI Kriegova, Eva/0000-0002-8969-4197
FU internal grant agency of Palacky University [IGA UP_2020_016]; Ministry
   of Health of the Czech Republic (MH CZ-DRO (FNOL)) [00098892];
   Biobanking and Biomolecular Resources Research Infrastructure of the
   Czech Republic [CZ.02.1.01/0.0/0.0/16_013/0001674]
FX This work was supported by the internal grant agency of Palacky
   University (IGA UP_2020_016) and in part by the Ministry of Health of
   the Czech Republic (MH CZ-DRO (FNOL, 00098892) and the Biobanking and
   Biomolecular Resources Research Infrastructure of the Czech Republic
   (CZ.02.1.01/0.0/0.0/16_013/0001674).
CR Arizti-Sanz J, 2020, INTEGRATED SAMPLE IN, DOI [10.1101/2020.05.28.119131, DOI 10.1101/2020.05.28.119131]
   Beltran-Pavez C, 2020, SARS COV 2 DETECTION, DOI [10.1101/2020.03.28.013508, DOI 10.1101/2020.03.28.013508]
   Bruce Emily A, 2020, bioRxiv, DOI 10.1101/2020.03.20.001008
   Centers for Disease Control and Prevention, RES US ONL 2019 NOV
   Centers for Disease Control and Prevention, SPEC COLL GUID
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Fomsgaard AS, 2020, ALTERNATIVE WORKFLOW, DOI [10.1101/2020.03.27.20044495, DOI 10.1101/2020.03.27.20044495]
   Grant PR, 2020, BIORXIV, DOI [10.1101/2020.04.06.028316, DOI 10.1101/2020.04.06.028316]
   Hasan MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236564
   Joung Julia, 2020, medRxiv, DOI 10.1101/2020.05.04.20091231
   Kampf G, 2020, J HOSP INFECT, V105, P348, DOI 10.1016/j.jhin.2020.03.025
   Kubina R, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10060434
   Li L, 2019, INT J INFECT DIS, V85, P167, DOI 10.1016/j.ijid.2019.06.007
   Lista M.J., 2020, RESILIENT SARS COV 2, DOI [10.1101/2020.04.22.20074351v1, DOI 10.1101/2020.04.22.20074351V1]
   Lu RF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082826
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   US FDA, POL COR DIS 2019 TES
   Wikramaratna P., 2020, ESTIMATING FALSE NEG, DOI [10.1101/2020.04.05.20053355, DOI 10.1101/2020.04.05.20053355]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organisation Laboratory, BIOS GUID REL COR DI
   World Health Organization, 1 DAT STAB RES SARS
   Wylie LA, 2020, SALIVA IS MORE SENSI, DOI [10.1101/2020.04.16.20067835, DOI 10.1101/2020.04.16.20067835]
   Yang Yang M, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Zhang Y., 2020, RAPID MOL DETECTION, DOI [10.1101/2020.02.26.20028373, DOI 10.1101/2020.02.26.20028373]
NR 26
TC 1
Z9 1
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD AUG
PY 2020
VL 10
IS 8
AR 605
DI 10.3390/diagnostics10080605
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH5YS
UT WOS:000564746000001
PM 32824767
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Deshpande, S
   Balaji, S
AF Deshpande, Sanjay
   Balaji, Sarath
TI MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive
   Measure?
SO INDIAN PEDIATRICS
LA English
DT Letter
ID MEASLES; ANTIBODIES; MUMPS
C1 [Deshpande, Sanjay] Manipal Hosp, Pediat & Pediat Infect Dis, Bengaluru, Karnataka, India.
   [Balaji, Sarath] Inst Child Hlth, Dept Pulmonol, Chennai, Tamil Nadu, India.
RP Deshpande, S (corresponding author), Manipal Hosp, Pediat & Pediat Infect Dis, Bengaluru, Karnataka, India.
EM deshpande.sanjay29@gmail.com
CR Caprari S, 2015, VIRUSES-BASEL, V7, P5388, DOI 10.3390/v7102882
   Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20
   Gohil DJ, 2016, VIRAL IMMUNOL, V29, P159, DOI 10.1089/vim.2015.0070
   Okada H, 2001, ARCH VIROL, V146, P859, DOI 10.1007/s007050170121
   Raut SK, 2007, CLIN VACCINE IMMUNOL, V14, P1370, DOI 10.1128/CVI.00246-07
   Shanker V, 2020, INDIAN PEDIATR, V57, P380
   Sidiq KR, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00120
NR 7
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD AUG
PY 2020
VL 57
IS 8
BP 773
EP 773
DI 10.1007/s13312-020-1941-4
PG 1
WC Pediatrics
SC Pediatrics
GA NH8IF
UT WOS:000564906600032
PM 32710535
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Iglesias-Sanchez, PP
   Witt, GFV
   Cabrera, FE
   Jambrino-Maldonado, C
AF Iglesias-Sanchez, Patricia P.
   Vaccaro Witt, Gustavo Fabian
   Cabrera, Francisco E.
   Jambrino-Maldonado, Carmen
TI The Contagion of Sentiments during the COVID-19 Pandemic Crisis: The
   Case of Isolation in Spain
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE sentiment analysis; health crisis; isolation; confinement; emergency
   response; contagion of emotions; COVID-19
ID PUBLIC-HEALTH CRISES; MEDIA
AB This study examines how confinement measures established during the COVID-19 pandemic crisis affected the emotions of the population. For this purpose, public sentiment on social media and digital ecosystems in Spain is analyzed. We identified affective tones towards media and citizens published on social media focusing on six basic emotions: anger, fear, joy, sadness, disgust and uncertainty. The main contribution of this work is the evidence of contagious sentiments and, consequently, the possibility of using this new dimension of social media as a form of a "collective therapy". This paper contributes to understanding the impact of confinement measures in a pandemic from the point of view of emotional health. This analysis provides a set of practical implications that can guide conceptual and empirical work in health crisis management with an alternative approach, especially useful for decision-making processes facing emergency responses and health crises, even in an unprecedented global health crisis such as the traumatic events caused by the COVID-19 disease.
C1 [Iglesias-Sanchez, Patricia P.; Jambrino-Maldonado, Carmen] Univ Malaga, Dept Econ & Business Adm, Malaga 29071, Spain.
   [Vaccaro Witt, Gustavo Fabian; Cabrera, Francisco E.] Univ Malaga, Appl Social Res Ctr CISA, Biomed Res Inst IBIMA, Dept Languages & Comp Sci, Malaga 29071, Spain.
RP Jambrino-Maldonado, C (corresponding author), Univ Malaga, Dept Econ & Business Adm, Malaga 29071, Spain.
EM patricia.iglesias@uma.es; fabianvaccaro@uma.es; fecabrera@uma.es;
   mcjambrino@uma.es
RI Jambrino Maldonado, Carmen/H-6297-2017
OI Jambrino Maldonado, Carmen/0000-0001-8444-0967; Cabrera, Francisco
   E./0000-0001-6286-577X; Iglesias Sanchez, Patricia/0000-0002-5591-2248
FU Programa Operativo FEDER Andalucia 2014-2020 [UMA18-FEDERJA-148]; Plan
   Propio-Universidad de Malaga
FX The research was funded by Programa Operativo FEDER Andalucia 2014-2020
   under grant number UMA18-FEDERJA-148 and Plan Propio-Universidad de
   Malaga.
CR Ashton K, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016089
   Bird S, 2009, NATURAL LANGUAGE PRO
   Coombs WT, 2014, J COMMUN MANAG, V18, P40, DOI 10.1108/JCOM-03-2013-0015
   DiStaso MW, 2015, PUBLIC RELAT REV, V41, P222, DOI 10.1016/j.pubrev.2014.11.014
   EPANECHN.VA, 1969, THEOR PROBAB APPL+, V14, P153, DOI 10.1137/1114019
   ERIKSSON M, 2018, INT J STRATEGIC COMM, V12, P526, DOI DOI 10.1080/1553118X.2018.1510405
   Gruzd A., 2011, P 44 HAW INT C SYST, P1, DOI DOI 10.1109/HICSS.2011.259
   Hoyt Robert Eugene, 2016, JMIR Public Health Surveill, V2, pe157, DOI 10.2196/publichealth.5810
   Pelaez JI, 2018, KNOWL-BASED SYST, V162, P252, DOI 10.1016/j.knosys.2018.07.023
   Kirwan M, 2017, PSYCHIAT RES, V254, P40, DOI 10.1016/j.psychres.2017.04.028
   Litwin R, 2017, EAT WEIGHT DISORD-ST, V22, P97, DOI 10.1007/s40519-016-0301-9
   Lyu JC, 2012, PUBLIC RELAT REV, V38, P799, DOI 10.1016/j.pubrev.2012.07.006
   Na K, 2018, J HEALTH COMMUN, V23, P791, DOI 10.1080/10810730.2018.1527877
   National Institute of Statistics, 2019, STAT MICR IND, P1
   Neubaum G, 2017, MEDIA PSYCHOL, V20, P502, DOI 10.1080/15213269.2016.1211539
   Pelaez JI, 2019, KNOWL-BASED SYST, V172, P33, DOI 10.1016/j.knosys.2019.02.009
   Pizzoli SMF, 2020, JMIR RES PROTOC, V9, DOI 10.2196/19236
   Roberts H, 2016, PUBLIC RELAT REV, V42, P214, DOI 10.1016/j.pubrev.2015.07.013
   Rodin P, 2019, J CONTING CRISIS MAN, V27, P237, DOI 10.1111/1468-5973.12254
   Thelwall M, 2010, J AM SOC INF SCI TEC, V61, P2544, DOI 10.1002/asi.21416
   Weick KE, 1995, SENSEMAKING ORG
NR 21
TC 2
Z9 2
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2020
VL 17
IS 16
AR 5918
DI 10.3390/ijerph17165918
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA NI5TF
UT WOS:000565413100001
PM 32824110
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lanza, F
   Seidita, V
   Chella, A
AF Lanza, Francesco
   Seidita, Valeria
   Chella, Antonio
TI Agents and robots for collaborating and supporting physicians in
   healthcare scenarios
SO JOURNAL OF BIOMEDICAL INFORMATICS
LA English
DT Article
DE Multi-agent systems; Robots in therapy; Robots in Emergency Care for
   COVID-19; Patient monitoring; Human-robot interaction
ID SYSTEMS
AB Monitoring patients through robotics telehealth systems is an interesting scenario where patients' conditions, and their environment, are dynamic and unknown variables. We propose to improve telehealth systems' features to include the ability to serve patients with their needs, operating as human caregivers. The objective is to support the independent living of patients at home without losing the opportunity to monitor their health status. Application scenarios are several, and they spread from simple clinical assisting scenarios to an emergency one. For instance, in the case of a nursing home, the system would support in continuously monitoring the elderly patients. In contrast, in the case of an epidemic diffusion, such as COVID-19 pandemic, the system may help in all the early triage phases, significantly reducing the risk of contagion. However, the system has to let medical assistants perform actions remotely such as changing therapies or interacting with patients that need support. The paper proposes and describes a multi-agent architecture for intelligent medical care. We propose to use the beliefs-desires-intentions agent architecture, part of it is devised to be deployed in a robot. The result is an intelligent system that may allow robots the ability to select the most useful plan for unhandled situations and to communicate the choice to the physician for his validation and permission.
C1 [Lanza, Francesco; Seidita, Valeria; Chella, Antonio] Univ Palermo, Dipartimento Ingn, Viale Sci, I-90128 Palermo, Italy.
   [Seidita, Valeria; Chella, Antonio] CNR, Ist Calcolo & Reti Ad Alte Prestaz ICAR, Via Ugo La Malfa 153, I-90146 Palermo, Italy.
RP Lanza, F (corresponding author), Univ Palermo, Dipartimento Ingn, Viale Sci, I-90128 Palermo, Italy.
EM francesco.lanza@unipa.it; valeria.seidita@unipa.it;
   antonio.chella@unipa.it
OI LANZA, Francesco/0000-0003-4382-6366
CR Antoniou G, 2003, IN HAND I S, P67
   Ardizzone E, 2009, IEEE T INF TECHNOL B, V13, P87, DOI 10.1109/TITB.2008.2007108
   Babar MA, 2004, 2004 AUSTRALIAN SOFTWARE ENGINEERING CONFERENCE, PROCEEDINGS, P309, DOI 10.1109/ASWEC.2004.1290484
   Bertucco M, 2019, I IEEE EMBS C NEUR E, P53, DOI 10.1109/NER.2019.8717085
   Bordini R.H., 2007, WILEY SERIES AGENT T
   Bordini RH, 2006, LECT NOTES COMPUT SC, V3900, P143
   Bratman M.E., 1987, INTENTION PLANS PRAC, V10
   BRATMAN ME, 1990, SYS DEV FDN, P15
   Bruegge B., 2003, OBJECT ORIENTED SOFT
   Casey D., 2015, 15 ANN SCH NURS MIDW
   Casey D, 2016, LECT NOTES COMPUT SC, V9758, P318, DOI 10.1007/978-3-319-41264-1_44
   Chella Antonio, 2019, Engineering Multi-Agent Systems. 6th International Workshop, EMAS 2018. Revised Selected Papers: Lecture Notes in Artificial Intelligence (LNAI 11375), P320, DOI 10.1007/978-3-030-25693-7_17
   Chella A., 2019, HUMAN ROBOT TEAMING, V2352
   Chella A., 2019, COGNITIVE ARCHITECTU, V2418, P82
   Chella A., 2018, REPRESENTING DEVELOP, V2215, P147
   Chella A., 2018, P 6 INT WORKSH ENG M
   Courreges F, 2004, P ANN INT IEEE EMBS, V26, P5371
   D'Onofrio G., 2015, 6 FOR IT AMB ASS LIV
   Dobrica L, 2002, IEEE T SOFTWARE ENG, V28, P638, DOI 10.1109/TSE.2002.1019479
   Eeles P., IBM RATIONAL DEVELOP
   Endres F, 2014, IEEE T ROBOT, V30, P177, DOI 10.1109/TRO.2013.2279412
   Ferber J., 1999, MULTIAGENT SYSTEMS I, V1
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Gambino O, 2018, J BIOMED INFORM, V88, P37, DOI 10.1016/j.jbi.2018.10.009
   Healthy, 2019, HLTH PROSP LIV ALL E
   Janoscova R., 2012, IMEA, V2012, P24
   Kazman R., 1994, P ICSE, V16, P81
   Koceska N, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19040834
   Lanza F, 2020, PROCEEDINGS OF THE 35TH ANNUAL ACM SYMPOSIUM ON APPLIED COMPUTING (SAC'20), P823, DOI 10.1145/3341105.3374083
   Lassing N., 1999, P 1 BENELUX C SOFTW, P47
   Lee Ren-Guey, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6004
   Liou JC, 2019, PROCEEDINGS OF 2019 IEEE EURASIA CONFERENCE ON BIOMEDICAL ENGINEERING, HEALTHCARE AND SUSTAINABILITY (IEEE ECBIOS 2019), P13, DOI 10.1109/ECBIOS.2019.8807821
   Liu J., 2018, MULTIAGENT ROBOTIC S
   Luperto M., 2019, 2019 IEEE RSJ INT C, P1
   Luperto M., 2018, P IJCAI, P5841
   Luperto M., 2018, ROBOTS ASSISTED LIVI
   Hai NDX, 2019, INT CONF SYST SCI EN, P506, DOI 10.1109/ICSSE.2019.8823334
   Ota J, 2006, ADV ENG INFORM, V20, P59, DOI 10.1016/j.aei.2005.06.002
   Papadopoulos I., ARXIV180311243
   Papadopoulos I, 2018, CONTEMP NURSE, V54, P425, DOI 10.1080/10376178.2018.1519374
   Papadopoulos I, 2018, J NURS SCHOLARSHIP, V50, P653, DOI 10.1111/jnu.12422
   Patidar A, 2015, 2015 2ND INTERNATIONAL CONFERENCE ON COMPUTING FOR SUSTAINABLE GLOBAL DEVELOPMENT (INDIACOM), P967
   Policy Department for Economic Scientific and Quality of Life Policies, 2019, ROB HEALTHC SOL PROB
   Rao A. S., 1995, ICMAS-95 Proceedings. First International Conference on Multi-Agent Systems, P312
   Rao A. S., 1996, Agents Breaking Away. 7th European Workshop on Modelling Autonomous Agents in a Multi-Agent World, MAAMAW '96 Proceedings, P42
   Recupero D.R., EU PROJECT NETWORKIN
   Redmon J., ARXIV180402767
   Salatino C, 2017, STUD HEALTH TECHNOL, V242, P484, DOI 10.3233/978-1-61499-798-6-484
   Salatino C, 2016, LECT NOTES COMPUT SC, V9758, P326, DOI 10.1007/978-3-319-41264-1_45
   Savaglio C, 2020, FUTURE GENER COMP SY, V102, P1038, DOI 10.1016/j.future.2019.09.016
   Stefano A, 2015, LECT NOTES COMPUT SC, V9279, P579, DOI 10.1007/978-3-319-23231-7_52
   Stone P, 2000, AUTON ROBOT, V8, P345, DOI 10.1023/A:1008942012299
   Su CJ, 2011, APPL SOFT COMPUT, V11, P315, DOI 10.1016/j.asoc.2009.11.022
   Van Cu Pham, 2020, Advanced Information Networking and Applications. Proceedings of the 34th International Conference on Advanced Information Networking and Applications (AINA-2020). Advances in Intelligent Systems and Computing (1151), P369, DOI 10.1007/978-3-030-44041-1_34
   Vuono A, 2018, PROCEEDINGS OF THE 17TH INTERNATIONAL CONFERENCE ON AUTONOMOUS AGENTS AND MULTIAGENT SYSTEMS (AAMAS' 18), P1835
   Wooldridge M., 2000, AGENT ORIENTED SOFTW
   Wooldridge Michael, 2003, REASONING RATIONAL A
   Yang GZ, 2020, SCI ROBOT, V5, DOI 10.1126/scirobotics.abb5589
NR 58
TC 0
Z9 0
U1 7
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1532-0464
EI 1532-0480
J9 J BIOMED INFORM
JI J. Biomed. Inform.
PD AUG
PY 2020
VL 108
AR 103483
DI 10.1016/j.jbi.2020.103483
PG 11
WC Computer Science, Interdisciplinary Applications; Medical Informatics
SC Computer Science; Medical Informatics
GA NH3TJ
UT WOS:000564595700008
PM 32603793
OA Green Published
DA 2021-01-01
ER

PT J
AU Bruce, E
   Barlow-Pay, F
   Short, R
   Vilches-Moraga, A
   Price, A
   McGovern, A
   Braude, P
   Stechman, MJ
   Moug, S
   McCarthy, K
   Hewitt, J
   Ben Carter
   Myint, PK
AF Bruce, Eilidh
   Barlow-Pay, Fenella
   Short, Roxanna
   Vilches-Moraga, Arturo
   Price, Angeline
   McGovern, Aine
   Braude, Philip
   Stechman, Michael J.
   Moug, Susan
   McCarthy, Kathryn
   Hewitt, Jonathan
   Ben Carter
   Myint, Phyo Kyaw
TI Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
   Important Outcomes in Hospitalised Patients with COVID-19
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE covid-19; SARS-CoV-2; non-steroidal anti-inflammatory drugs; NSAIDs
AB Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from aggressive inflammation initiated by viral replication. There has been much speculation about the potential role of non-steroidal inflammatory drugs (NSAIDs), which increase the expression of angiotensin-converting enzyme 2 (ACE2), a binding target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter the host cell, which could lead to poorer outcomes in COVID-19 disease. The aim of this study was to examine the association between routine use of NSAIDs and outcomes in hospitalised patients with COVID-19. This was a multicentre, observational study, with data collected from adult patients with COVID-19 admitted to eight UK hospitals. Of 1222 patients eligible to be included, 54 (4.4%) were routinely prescribed NSAIDs prior to admission. Univariate results suggested a modest protective effect from the use of NSAIDs, but in the multivariable analysis, there was no association between prior NSAID use and time to mortality (adjusted HR (aHR) = 0.89, 95% CI 0.52-1.53,p= 0.67) or length of stay (aHR 0.89, 95% CI 0.59-1.35,p= 0.58). This study found no evidence that routine NSAID use was associated with higher COVID-19 mortality in hospitalised patients; therefore, patients should be advised to continue taking these medications until further evidence emerges. Our findings suggest that NSAID use might confer a modest benefit with regard to survival. However, as this finding was underpowered, further research is required.
C1 [Bruce, Eilidh; Myint, Phyo Kyaw] Aberdeen Royal Infirm, Aberdeen AB25 2ZN, Scotland.
   [Bruce, Eilidh; Myint, Phyo Kyaw] Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen AB25 2ZN, Scotland.
   [Barlow-Pay, Fenella; Moug, Susan] Royal Alexandra Hosp, Paisley PA2 9PJ, Renfrew, Scotland.
   [Short, Roxanna; Ben Carter] Kings Coll London, Dept Biostat & Hlth Informat, London WC2R 2LS, England.
   [Vilches-Moraga, Arturo; Price, Angeline] Salford Royal NHS Trust, Salford M6 8HD, Lancs, England.
   [McGovern, Aine] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland.
   [Braude, Philip; McCarthy, Kathryn] North Bristol NHS Trust, Bristol BS10 5NB, Avon, England.
   [Stechman, Michael J.; Hewitt, Jonathan] Cardiff Univ, Sch Med, Cardiff CF10 3AT, S Glam, Wales.
RP Myint, PK (corresponding author), Aberdeen Royal Infirm, Aberdeen AB25 2ZN, Scotland.; Myint, PK (corresponding author), Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen AB25 2ZN, Scotland.
EM eilidh.bruce@nhs.net; Fenella.barlow-pay@nhs.net;
   roxanna.short@kcl.ac.uk; Arturo.Vilches-Moraga@srft.nhs.uk;
   angeline.price@srft.nhs.uk; aine.mcgovern@nhs.net;
   philip.braude@nbt.nhs.uk; Michael.stechman@wales.nhs.uk;
   susanmoug@nhs.net; kathryn.mccarthy@nbt.nhs.uk; Hewittj2@cardiff.ac.uk;
   ben.carter@kcl.ac.uk; phyo.myint@abdn.ac.uk
RI ; myint, phyo/G-5730-2013
OI Carter, Ben/0000-0003-0318-8865; myint, phyo/0000-0003-3852-6158;
   Hewitt, Jonathan/0000-0002-7924-1792; Barlow-Pay,
   Fenella/0000-0003-4312-1905; Moug, Susan/0000-0001-9969-9760
CR Amici C, 2006, ANTIVIR THER, V11, P1021
   Basille D, 2018, AM J RESP CRIT CARE, V198, P128, DOI 10.1164/rccm.201802-0229LE
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9
   Capuano A, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104849
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gomez-Acebo I, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6019-z
   Gracia-Ramos AE, 2020, ARCH MED RES
   Hewitt J, 2020, LANCET PUBLIC HEALTH, V5, pE444, DOI 10.1016/S2468-2667(20)30146-8
   Heyneman CA, 2000, DRUGS, V60, P555, DOI 10.2165/00003495-200060030-00004
   Honvo G, 2019, DRUG AGING, V36, P45, DOI 10.1007/s40266-019-00661-0
   Kassambara A., SURVMINER DRAWING SU
   Lanas A., 2014, CLIN GASTROENTEROL H, V13
   MAASSENVANDENBRINK, 2020, J HEADACHE PAIN, V21, DOI DOI 10.1186/S10194-020-01106-5
   Pan YJ, 2014, NEPHROLOGY, V19, P655, DOI 10.1111/nep.12318
   PERGOLIZZI JV, 2020, PAIN THER, DOI DOI 10.1080/00325481.2020.1725352
   R Core Team, 2019, R LANG ENV STAT COMP
   Rinott E, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.06.003
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   StataCorp, 2017, STAT STAT SOFTW
   Voiriot G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060786
   Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306
   Yousefifard M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13557
   Zhang XY, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0673-8
NR 24
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2586
DI 10.3390/jcm9082586
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH7AN
UT WOS:000564819000001
PM 32785086
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Morris, SE
   Moment, A
   Thomas, JD
AF Morris, Sue E.
   Moment, Amanda
   Thomas, Jane deLima
TI Caring for Bereaved Family Members During the COVID-19 Pandemic: Before
   and After the Death of a Patient
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Bereavement; bereavement care; palliative care; end-of-life care; grief;
   COVID-19; family members; cognitive behavior therapy
ID COMPLICATED GRIEF; OF-LIFE; CARE; PREDICTORS; CAREGIVERS; OUTCOMES;
   QUALITY; CANCER; LENGTH; IMPACT
AB Bereavement care is considered an integral component of quality end-of-life care endorsed by the palliative care movement. However, few hospitals and health care institutions offer universal bereavement care to all families of patients who die. The current coronavirus disease 2019 pandemic has highlighted this gap and created a sense of urgency, from a public health perspective, for institutions to provide support to bereaved family members. In this article, drawing on the palliative care and bereavement literature, we offer suggestions about how to incorporate palliative care tools and psychological strategies into bereavement care for families during this pandemic. (C) 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Morris, Sue E.; Thomas, Jane deLima] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,JF8, Boston, MA 02115 USA.
   [Moment, Amanda] Brigham & Womens Hosp, Dept Care Continuum Management, 75 Francis St, Boston, MA 02115 USA.
RP Morris, SE (corresponding author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,JF8, Boston, MA 02115 USA.
EM Sue_morris@dfci.harvard.edu
OI Thomas, Jane/0000-0002-6197-2861
CR Ambuel Bruce, 2004, J Palliat Med, V7, P473, DOI 10.1089/1096621041349536
   Aoun SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121101
   Beck J. S., 2011, COGNITIVE BEHAV THER
   Bradley EH, 2004, AM J PSYCHIAT, V161, P2257, DOI 10.1176/appi.ajp.161.12.2257
   Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2
   Collins A, 2014, BMJ SUPPORT PALLIAT, V4, P68, DOI 10.1136/bmjspcare-2012-000419
   HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
   Kentish-Barnes N, 2015, EUR RESPIR J, V45, P1341, DOI 10.1183/09031936.00160014
   Litz BT, 2014, BEHAV RES THER, V61, P23, DOI 10.1016/j.brat.2014.07.005
   Lobb EA, 2010, DEATH STUD, V34, P673, DOI 10.1080/07481187.2010.496686
   Lundorff M, 2017, J AFFECT DISORDERS, V212, P138, DOI 10.1016/j.jad.2017.01.030
   Malkinson R., 2007, COGNITIVE GRIEF THER
   Midland D., 2015, FAST FACTS CONCEPTS
   Morris SE., 2018, OVERCOMING GRIEF SEL
   Morris S, 2019, J ENVIRON SCI HEAL A, V54, P1233, DOI [10.1080/10934529.2019.1633855, 10.1080/07347332.2019.1703065]
   Morris SE, 2020, J PALLIAT MED, V23, P1030, DOI 10.1089/jpm.2019.0467
   Morris SE, 2015, J PALLIAT MED, V18, P915, DOI 10.1089/jpm.2015.0080
   National Consensus Project for Quality Palliative Care, 2018, CLIN PRACT GUID QUAL
   Neimeyer RA, 2012, TECHNIQUEGRIEF THE
   Palmer WW, 2017, AM J HOSP PALLIAT ME, V34, P880, DOI 10.1177/1049909116662459
   Prigerson HG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000121
   Shear MK, 2016, JAMA PSYCHIAT, V73, P685, DOI 10.1001/jamapsychiatry.2016.0892
   Stroebe M, 2007, LANCET, V370, P1960, DOI 10.1016/S0140-6736(07)61816-9
   Wachterman MW, 2016, JAMA INTERN MED, V176, P1095, DOI 10.1001/jamainternmed.2016.1200
   Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604
   Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863
NR 26
TC 10
Z9 11
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD AUG
PY 2020
VL 60
IS 2
BP E70
EP E74
DI 10.1016/j.jpainsymman.2020.05.002
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA NI0RK
UT WOS:000565066200014
PM 32387574
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pettus, K
   Cleary, JF
   de Lima, L
   Ahmed, E
   Radbruch, L
AF Pettus, Katherine
   Cleary, James F.
   de Lima, Liliana
   Ahmed, Ebtesam
   Radbruch, Lukas
TI Availability of Internationally Controlled Essential Medicines in the
   COVID-19 Pandemic
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Essential medicines; palliative care; morphine; COVID-19; breathlessness
AB Section 2 of the 2019 World Health Organization Model List of Essential Medicines includes opioid analgesics formulations commonly used for the control of pain and respiratory distress, as well as sedative and anxiolytic substances such as midazolam and diazepam. These medicines, essential to palliative care, are regulated under the international drug control conventions overseen by United Nations specialized agencies and treaty bodies and under national drug control laws. Those national laws and regulations directly affect bedside availability of Internationally Controlled Essential Medicines (ICEMs). The complex interaction between national regulatory systems and global supply chains (now impacted by COVID-19 pandemic) directly affects bedside availability of ICEMs and patient care. Despite decades of global civil society advocacy in the United Nations system, ICEMs have remained chronically unavailable, inaccessible, and unaffordable in low- and-middle-income countries, and there are recent reports of shortages in high-income countries as well. The most prevalent symptoms in COVID-19 are breathlessness, cough, drowsiness, anxiety, agitation, and delirium. Frequently used medicines include opioids such as morphine or fentanyl and midazolam, all of them listed as ICEMs. This paper describes the issues related to the lack of availability and limited access to ICEMs during the COVID-19 pandemic in both intensive and palliative care patients in countries of all income levels and makes recommendations for improving access. (C) 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Pettus, Katherine; de Lima, Liliana] Int Assoc Hosp & Palliat Care, Houston, TX USA.
   [Cleary, James F.] Indiana Univ, Walther Ctr Global Palliat Care, Indianapolis, IN 46204 USA.
   [Ahmed, Ebtesam] St Johns Univ, New York, NY USA.
   [Radbruch, Lukas] Univ Hosp, Bonn, Germany.
RP Pettus, K (corresponding author), 5535 Mem Dr, Houston, TX 77007 USA.
EM Kpettus@iahpc.com
CR American Society of Health System Pharmacists, 2020, RE REQ IMM INCR ALL
   [Anonymous], 2020, BUSINESS INSIDER
   [Anonymous], FRANCE 24
   British Broadcasting Service, 2020, COR LOC SHORT INT CA
   European University Hospital Alliance, 2020, U HOSP URG CALL MOR
   Foley KM, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P981
   International Narcotics Control Board (INCB), 2016, AV INT CONTR DRUGS E
   Knaul FM, 2018, LANCET, V391, P1391, DOI 10.1016/S0140-6736(17)32513-8
   Lohman D, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-8
   Lovell N, 2020, J PAIN SYMPTOM MANAG, V2020
   Pettus K, 2018, J PAIN PALLIAT CARE, V32, P124, DOI 10.1080/15360288.2018.1488792
   Scholten WK, 2019, AM J PUBLIC HEALTH, V109, P52, DOI 10.2105/AJPH.2018.304753
   United Nations Office on Drugs and Crime, 1961, SINGL CONV NARC DRUG
   WHO, 2019, WHO MOD LIST ESS MED
NR 14
TC 3
Z9 3
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD AUG
PY 2020
VL 60
IS 2
BP E48
EP E51
DI 10.1016/j.jpainsymman.2020.04.153
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA NI0RK
UT WOS:000565066200011
PM 32387575
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Berzal-Herranz, A
   Romero-Lopez, C
AF Berzal-Herranz, Alfredo
   Romero-Lopez, Cristina
TI Two Examples of RNA Aptamers with Antiviral Activity. Are Aptamers the
   Wished Antiviral Drugs?
SO PHARMACEUTICALS
LA English
DT Article
DE aptamers; antiviral RNAs; viral RNA genome; functional RNA domains; RNA
   tools; RNA structure; function
ID IN-VITRO SELECTION; ANTI-VEGF APTAMER; VIRUS; TRANSLATION; MOLECULES;
   DNA; REPLICATION; INHIBITION; ENRICHMENT; PEGAPTANIB
AB The current Covid-19 pandemic has pointed out some major deficiencies of the even most advanced societies to fight against viral RNA infections. Once more, it has been demonstrated that there is a lack of efficient drugs to control RNA viruses. Aptamers are efficient ligands of a great variety of molecules including proteins and nucleic acids. Their specificity and mechanism of action make them very promising molecules for interfering with the function encoded in viral RNA genomes. RNA viruses store essential information in conserved structural genomic RNA elements that promote important steps for the consecution of the infective cycle. This work describes two well documented examples of RNA aptamers with antiviral activity against highly conserved structural domains of the HIV-1 and HCV RNA genome, respectively, performed in our laboratory. They are two good examples that illustrate the potential of the aptamers to fill the therapeutic gaps in the fight against RNA viruses.
C1 [Berzal-Herranz, Alfredo; Romero-Lopez, Cristina] PTS Granada, Inst Parasitol & Biomed Lopez Neyra, IPBLN CSIC, Av Conocimiento 17, Granada 18016, Spain.
RP Berzal-Herranz, A (corresponding author), PTS Granada, Inst Parasitol & Biomed Lopez Neyra, IPBLN CSIC, Av Conocimiento 17, Granada 18016, Spain.
EM aberzalh@ipb.csic.es; cristina_romero@ipb.csic.es
RI Berzal-Herranz, Alfredo/K-8614-2014
OI Berzal-Herranz, Alfredo/0000-0003-3722-7973
CR Berkhout B, 2011, RNA BIOL, V8, P225, DOI 10.4161/rna.8.2.14801
   Berzal-Herranz A., 2019, P 5 INT EL C MED CHE, DOI [10.3390/ECMC2019-06415, DOI 10.3390/ECMC2019-06415]
   Berzal-Herranz A, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12010038
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Fernandez-Sanles A, 2015, MOLECULES, V20, P16030, DOI 10.3390/molecules200916030
   Gopinath SCB, 2007, ANAL BIOANAL CHEM, V387, P171, DOI 10.1007/s00216-006-0826-2
   Kendra JA, 2018, J BIOL CHEM, V293, P17536, DOI 10.1074/jbc.RA118.005606
   Ku TH, 2015, SENSORS-BASEL, V15, P16281, DOI 10.3390/s150716281
   Kumar PKR, 2016, BIOSENSORS-BASEL, V6, DOI 10.3390/bios6030040
   Marton S, 2013, J VIRAL HEPATITIS, V20, P103, DOI 10.1111/j.1365-2893.2012.01629.x
   Marton S, 2012, PHARMACEUTICALS-BASE, V5, P49, DOI 10.3390/ph5010049
   Marton S, 2010, MOLECULES, V15, P4610, DOI 10.3390/molecules15074610
   Moomau C, 2016, J BIOL CHEM, V291, P15788, DOI 10.1074/jbc.M116.735613
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Odeh F, 2020, MOLECULES, V25, DOI 10.3390/molecules25010003
   Raddatz MSL, 2008, ANGEW CHEM INT EDIT, V47, P5190, DOI 10.1002/anie.200800216
   Rajendran M, 2008, ANAL BIOANAL CHEM, V390, P1067, DOI 10.1007/s00216-007-1735-8
   Romero-Lopez C, 2007, CELL MOL LIFE SCI, V64, P2994, DOI 10.1007/s00018-007-7345-y
   Romero-Lopez C, 2005, BIOL CHEM, V386, P183, DOI 10.1515/BC.2005.023
   Romero-Lopez C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041479
   Romero-Lopez C, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02093
   Romero-Lopez C, 2017, MOLECULES, V22, DOI 10.3390/molecules22050861
   Romero-Lopez C, 2013, REV MED VIROL, V23, P340, DOI 10.1002/rmv.1756
   Romero-Lopez C, 2012, ANTIVIR RES, V94, P131, DOI 10.1016/j.antiviral.2012.02.015
   Romero-Lopez C, 2009, J GEN VIROL, V90, P1659, DOI 10.1099/vir.0.008821-0
   Sanchez-Luque FJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06242
   SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P
   THEISSEN G, 1989, ANAL BIOCHEM, V179, P98, DOI 10.1016/0003-2697(89)90207-8
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Torres-Chavolla E, 2009, BIOSENS BIOELECTRON, V24, P3175, DOI 10.1016/j.bios.2008.11.010
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
NR 35
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD AUG
PY 2020
VL 13
IS 8
AR 157
DI 10.3390/ph13080157
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NI9WI
UT WOS:000565696000001
PM 32707768
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Plog, J
   Wu, JW
   Dias, YJ
   Mashayek, F
   Cooper, LF
   Yarin, AL
AF Plog, Jevon
   Wu, Jingwei
   Dias, Yasmin J.
   Mashayek, Farzad
   Cooper, Lyndon F.
   Yarin, Alexander L.
TI Reopening dentistry after COVID-19: Complete suppression of
   aerosolization in dental procedures by viscoelastic Medusa Gorgo
SO PHYSICS OF FLUIDS
LA English
DT Article
ID AIRBORNE TRANSMISSION; INFECTION
AB The aerosol transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has impacted the delivery of health care and essentially stopped the provision of medical and dental therapies. Dentistry uses rotary, ultrasonic, and laser-based instruments that produce water-based aerosols in the daily, routine treatment of patients. Abundant aerosols are generated, which reach health care workers and other patients. Viruses, including SARS-CoV-2 virus and related coronavirus disease (COVID-19) pandemic, continued expansion throughout the USA and the world. The virus is spread by both droplet (visible drops) and aerosol (practically invisible drops) transmission. The generation of aerosols in dentistry-an unavoidable part of most dental treatments-creates a high-risk situation. The US Centers for Disease Control and The Occupational Safety and Health Administration consider dental procedures to be of "highest risk" in the potential spreading of SARS-CoV-2 and other respiratory viruses. There are several ways to reduce or eliminate the virus: (i) cease or postpone dentistry (public and personal health risk), (ii) screen patients immediately prior to dental treatment (by appropriate testing, if any), (iii) block/remove the virus containing aerosol by engineering controls together with stringent personal protective equipment use. The present work takes a novel, fourth approach. By altering the physical response of water to the rotary or ultrasonic forces that are used in dentistry, the generation of aerosol particles and the distance any aerosol may spread beyond the point of generation can be markedly suppressed or completely eliminated in comparison to water for both the ultrasonic scaler and dental handpiece.
C1 [Plog, Jevon; Wu, Jingwei; Dias, Yasmin J.; Mashayek, Farzad; Yarin, Alexander L.] Univ Illinois, Dept Mech & Ind Engn, 842 W Taylor St, Chicago, IL 60607 USA.
   [Cooper, Lyndon F.] Univ Illinois, Dept Oral Biol, 801 S Paulina St 402E, Chicago, IL 60607 USA.
RP Yarin, AL (corresponding author), Univ Illinois, Dept Mech & Ind Engn, 842 W Taylor St, Chicago, IL 60607 USA.
EM ayarin@uic.edu
OI Wu, Jingwei/0000-0002-5753-9344; Cooper, Lyndon/0000-0002-6577-781X
FU UIC College of Dentistry
FX This work was supported by discretionary funds of the UIC College of
   Dentistry.
CR [Anonymous], 1999, LANCET, V354, pSIV1, DOI DOI 10.1016/S0140-6736(99)90354-9
   BENJAMIN TB, 1954, PROC R SOC LON SER-A, V225, P505, DOI 10.1098/rspa.1954.0218
   BENTLEY CD, 1994, J AM DENT ASSOC, V125, P579, DOI 10.14219/jada.archive.1994.0093
   Bird R. B., 1987, DYNAMICS POLYM LIQUI
   Bourouiba L, 2014, J FLUID MECH, V745, P537, DOI 10.1017/jfm.2014.88
   da Silva LH, 2017, BRAZ ORAL RES, V31, P133, DOI 10.1590/1807-3107BOR-2017.vol31.0058
   Dbouk T, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0011960
   de Gennes P. G., 1979, SCALING CONCEPTS POL
   DEAN M, 1994, LANCET, V343, P1027, DOI 10.1016/S0140-6736(94)90135-X
   DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018
   Denry I, 2010, MATERIALS, V3, P351, DOI 10.3390/ma3010351
   Doi M., 1986, THEORY POLYM DYNAMIC
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Guzzi G, 2005, LANCET, V366, P894, DOI 10.1016/S0140-6736(05)67316-3
   Harrel SK, 2004, J AM DENT ASSOC, V135, P429, DOI 10.14219/jada.archive.2004.0207
   HOLBROOK WP, 1978, BRIT DENT J, V144, P245, DOI 10.1038/sj.bdj.4804072
   Jiang SH, 2017, ANGEW CHEM INT EDIT, V56, P3285, DOI 10.1002/anie.201611787
   Keulers B, 2005, LANCET, V366, P894, DOI 10.1016/S0140-6736(05)67317-5
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   Michael Faraday, 1831, PHILOS T R SOC LONDO, V121, P299, DOI [10.1098/rstl.1831.0018, DOI 10.1098/RSTL.1831.0018]
   Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140-6736(19)31146-8
   Roberts W. A., 1857, LANCET, V70, P654, DOI [10.1016/s0140-6736(02)36507-3, DOI 10.1016/S0140-6736(02)36507-3]
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051
   Scharfman BE, 2016, EXP FLUIDS, V57, DOI 10.1007/s00348-015-2078-4
   Seto WH, 2015, J HOSP INFECT, V89, P225, DOI 10.1016/j.jhin.2014.11.005
   Sirignano W. A., 2010, FLUID DYNAMICS TRANS
   Spagnuolo G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062094
   Stelter M, 2000, J RHEOL, V44, P595, DOI 10.1122/1.551102
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   Thompson W, 2019, LANCET, V394, P10
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Watt RG, 2019, LANCET, V394, P261, DOI 10.1016/S0140-6736(19)31133-X
   Yarin A.L., 2017, COLLISION PHENOMENA
   Yarin A. L., 2020, Provisional Patent Application UIC, Patent No. [2020-172-01, 202017201]
   Yarin A. L., 2014, FUNDAMENTALS APPL MI
   Yarin AL, 2004, J RHEOL, V48, P101, DOI 10.1122/1.1631423
   Yarin L. P., 2004, COMBUSTION 2 PHASE R
   Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117
   Zussman E, 2007, J DENT RES, V86, P281, DOI 10.1177/154405910708600316
NR 39
TC 2
Z9 2
U1 7
U2 7
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1070-6631
EI 1089-7666
J9 PHYS FLUIDS
JI Phys. Fluids
PD AUG 1
PY 2020
VL 32
IS 8
AR 083111
DI 10.1063/5.0021476
PG 12
WC Mechanics; Physics, Fluids & Plasmas
SC Mechanics; Physics
GA NI3OI
UT WOS:000565265200001
PM 32904886
OA Bronze
DA 2021-01-01
ER

PT J
AU Firat, O
   Yalcin, N
   Demirkan, K
AF Firat, Oguzhan
   Yalcin, Nadir
   Demirkan, Kutay
TI COVID-19 & antiepileptic drugs: Should we pay attention?
SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
LA English
DT Letter
C1 [Firat, Oguzhan; Yalcin, Nadir; Demirkan, Kutay] Hacettepe Univ, Fac Pharm, Dept Clin Pharm, Ankara, Turkey.
RP Firat, O (corresponding author), Hacettepe Univ, Fac Pharm, Dept Clin Pharm, Ankara, Turkey.
EM oguzhan.firat@hacettepe.edu.tr
RI Yalcin, Nadir/AAJ-9513-2020
CR Asadi-Pooya AA, 2020, SEIZURE-EUR J EPILEP, V79, P49, DOI 10.1016/j.seizure.2020.05.005
   Birbeck GL, 2012, EPILEPSIA, V53, P207, DOI 10.1111/j.1528-1167.2011.03335.x
   Liverpul drug interactions group, 2020, INT EXP COVID 19 THE
NR 3
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1059-1311
EI 1532-2688
J9 SEIZURE-EUR J EPILEP
JI Seizure
PD AUG
PY 2020
VL 80
BP 240
EP 241
DI 10.1016/j.seizure.2020.07.005
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NI2II
UT WOS:000565178800050
PM 32663783
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ahmed, SAKS
   Ajisola, M
   Azeem, K
   Bakibinga, P
   Chen, YF
   Choudhury, NN
   Fayehun, O
   Griffiths, F
   Harris, B
   Kibe, P
   Lilford, RJ
   Omigbodun, A
   Rizvi, N
   Sartori, J
   Smith, S
   Watson, SI
   Wilson, R
   Yeboah, G
   Aujla, N
   Azam, SI
   Diggle, PJ
   Gill, P
   Iqbal, R
   Kabaria, C
   Kisia, L
   Kyobutungi, C
   Madan, JJ
   Mberu, B
   Mohamed, SF
   Nazish, A
   Odubanjo, O
   Osuh, ME
   Owoaje, E
   Oyebode, O
   de Albuquerque, JP
   Rahman, O
   Tabani, K
   Taiwo, OJ
   Tregonning, G
   Uthman, OA
   Yusuf, R
AF Ahmed, Syed A. K. Shifat
   Ajisola, Motunrayo
   Azeem, Kehkashan
   Bakibinga, Pauline
   Chen, Yen-Fu
   Choudhury, Nazratun Nayeem
   Fayehun, Olufunke
   Griffiths, Frances
   Harris, Bronwyn
   Kibe, Peter
   Lilford, Richard J.
   Omigbodun, Akinyinka
   Rizvi, Narjis
   Sartori, Jo
   Smith, Simon
   Watson, Samuel, I
   Wilson, Ria
   Yeboah, Godwin
   Aujla, Navneet
   Azam, Syed Iqbal
   Diggle, Peter J.
   Gill, Paramjit
   Iqbal, Romaina
   Kabaria, Caroline
   Kisia, Lyagamula
   Kyobutungi, Catherine
   Madan, Jason J.
   Mberu, Blessing
   Mohamed, Shukri F.
   Nazish, Ahsana
   Odubanjo, Oladoyin
   Osuh, Mary E.
   Owoaje, Eme
   Oyebode, Oyinlola
   Porto de Albuquerque, Joao
   Rahman, Omar
   Tabani, Komal
   Taiwo, Olalekan John
   Tregonning, Grant
   Uthman, Olalekan A.
   Yusuf, Rita
CA Improving Hlth Slums Collaborative
TI Impact of the societal response to COVID-19 on access to healthcare for
   non-COVID-19 health issues in slum communities of Bangladesh, Kenya,
   Nigeria and Pakistan: results of pre-COVID and COVID-19 lockdown
   stakeholder engagements
SO BMJ GLOBAL HEALTH
LA English
DT Article
DE health policy; health systems; public health; other infection; disease;
   disorder; or injury; qualitative study
ID MODEL
AB Introduction With COVID-19, there is urgency for policymakers to understand and respond to the health needs of slum communities. Lockdowns for pandemic control have health, social and economic consequences. We consider access to healthcare before and during COVID-19 with those working and living in slum communities. Methods In seven slums in Bangladesh, Kenya, Nigeria and Pakistan, we explored stakeholder perspectives and experiences of healthcare access for non-COVID-19 conditions in two periods: pre-COVID-19 and during COVID-19 lockdowns. Results Between March 2018 and May 2020, we engaged with 860 community leaders, residents, health workers and local authority representatives. Perceived common illnesses in all sites included respiratory, gastric, waterborne and mosquitoborne illnesses and hypertension. Pre-COVID, stakeholders described various preventive, diagnostic and treatment services, including well-used antenatal and immunisation programmes and some screening for hypertension, tuberculosis, HIV and vectorborne disease. In all sites, pharmacists and patent medicine vendors were key providers of treatment and advice for minor illnesses. Mental health services and those addressing gender-based violence were perceived to be limited or unavailable. With COVID-19, a reduction in access to healthcare services was reported in all sites, including preventive services. Cost of healthcare increased while household income reduced. Residents had difficulty reaching healthcare facilities. Fear of being diagnosed with COVID-19 discouraged healthcare seeking. Alleviators included provision of healthcare by phone, pharmacists/drug vendors extending credit and residents receiving philanthropic or government support; these were inconsistent and inadequate. Conclusion Slum residents' ability to seek healthcare for non-COVID-19 conditions has been reduced during lockdowns. To encourage healthcare seeking, clear communication is needed about what is available and whether infection control is in place. Policymakers need to ensure that costs do not escalate and unfairly disadvantage slum communities. Remote consulting to reduce face-to-face contact and provision of mental health and gender-based violence services should be considered.
C1 [Ahmed, Syed A. K. Shifat; Choudhury, Nazratun Nayeem; Yusuf, Rita] Independent Univ Bangladesh, Ctr Hlth Populat & Dev, Dhaka, Bangladesh.
   [Ajisola, Motunrayo] Univ Ibadan, Natl Inst Hlth Res Project, Ibadan, Oyo State, Nigeria.
   [Azeem, Kehkashan; Rizvi, Narjis; Azam, Syed Iqbal; Iqbal, Romaina; Nazish, Ahsana; Tabani, Komal] Aga Khan Univ, Community Hlth Sci Dept, Karachi, Pakistan.
   [Bakibinga, Pauline; Kibe, Peter; Kabaria, Caroline; Kisia, Lyagamula; Kyobutungi, Catherine; Mberu, Blessing; Mohamed, Shukri F.] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Chen, Yen-Fu; Griffiths, Frances; Harris, Bronwyn; Smith, Simon; Watson, Samuel, I; Wilson, Ria; Aujla, Navneet; Gill, Paramjit; Mohamed, Shukri F.; Oyebode, Oyinlola; Uthman, Olalekan A.] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry, W Midlands, England.
   [Fayehun, Olufunke] Univ Ibadan, Fac Social Sci, Dept Sociol, Ibadan, Oyo State, Nigeria.
   [Griffiths, Frances] Univ Witwatersrand, Sch Publ Hlth, Ctr Hlth Policy, Johannesburg, South Africa.
   [Lilford, Richard J.; Sartori, Jo; Watson, Samuel, I] Univ Birmingham, Inst Appl Hlth Res, Coll Med & Dent Sci, Birmingham, W Midlands, England.
   [Omigbodun, Akinyinka] Univ Ibadan, Coll Med, Fac Clin Sci, Dept Obstet & Gynaecol, Ibadan, Oyo State, Nigeria.
   [Yeboah, Godwin; Porto de Albuquerque, Joao; Tregonning, Grant] Univ Warwick, Inst Global Sustainable Dev, Coventry, W Midlands, England.
   [Diggle, Peter J.] Univ Lancaster, Lancaster Med Sch, Lancaster, England.
   [Madan, Jason J.] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry, W Midlands, England.
   [Odubanjo, Oladoyin] Nigerian Acad Sci, Lagos, Nigeria.
   [Osuh, Mary E.] Univ Ibadan, Coll Med, Dept Periodontol & Community Dent, Fac Dent, Ibadan, Oyo State, Nigeria.
   [Owoaje, Eme] Univ Ibadan, Fac Publ Hlth, Coll Med, Dept Community Med, Ibadan, Oyo State, Nigeria.
   [Rahman, Omar] Univ Liberal Arts Bangladesh, Dhaka, Bangladesh.
   [Taiwo, Olalekan John] Univ Ibadan, Dept Geog, Fac Social Sci, Ibadan, Oyo State, Nigeria.
RP Griffiths, F (corresponding author), Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry, W Midlands, England.
EM f.e.griffiths@warwick.ac.uk
RI Yeboah, Godwin/D-5080-2015
OI Yeboah, Godwin/0000-0003-4618-3175; Griffiths,
   Frances/0000-0002-4173-1438; Ahmed, Syed A K Shifat/0000-0001-8166-7971;
   Fayehun, Olufunke/0000-0002-3769-2130; Ajisola,
   Motunrayo/0000-0002-1704-0944
FU National Institute for Health Research (NIHR) Global Health Research
   Unit on Improving Health in Slums using UK aid from the UK Government to
   support global health researchNational Institute for Health Research
   (NIHR); UK Government
FX This research was funded by the National Institute for Health Research
   (NIHR) Global Health Research Unit on Improving Health in Slums using UK
   aid from the UK Government to support global health research. The views
   expressed in this publication are those of the author(s) and not
   necessarily those of the NIHR or the UK Department of Health and Social
   Care.
CR Adhikari Bipin, 2019, Wellcome Open Res, V4, P87, DOI 10.12688/wellcomeopenres.15298.2
   Africanews, 2020, AFRICANEWS      0405
   Alif A, 2020, DHAKA TRIBUNE
   Andrade RD, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1597
   [Anonymous], 2019, IMMUNE NETW, V19, pe34
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Butt Amna Subhan, 2015, Euroasian J Hepatogastroenterol, V5, P43, DOI 10.5005/jp-journals-10018-1129
   Chandan JS, 2020, LANCET PUBLIC HEALTH, V5, pE309, DOI 10.1016/S2468-2667(20)30112-2
   Devnath B, 2020, CRITICAL COVID 19 PA
   Dubey S, 2020, DIABETES METAB SYND, V14, P779, DOI 10.1016/j.dsx.2020.05.035
   Farha L, 2020, COVID 19 GUIDANCE NO
   Fayehun F, 2020, CONVERSATION
   Figueroa ME, 2017, J HEALTH COMMUN, V22, P5, DOI 10.1080/10810730.2016.1231725
   Fuhrman S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002624
   Garda World News Alerts, 2020, GARDA WORLD NEWS ALE
   Gillani W, 2020, DANGEROUS THEORIES N
   Glandon D, 2017, HEALTH POLICY PLANN, V32, P1457, DOI 10.1093/heapol/czx123
   Government of Pakistan, 2020, ECC HAS APPR RS 29 7
   Griffiths F, 2020, DIGIT HEALTH, V6, DOI 10.1177/2055207620919594
   Hall Brian J, 2020, Asian J Psychiatr, V53, P102179, DOI 10.1016/j.ajp.2020.102179
   IFRC OCHA WHO, 2020, COVID 19 INCL MARG V
   Improving Health in Slums Collaborative, 2020, HEALTHC ACC US UNPUB, P2020
   International Monetary Fund, 2020, POL RESP COVID 19 PO
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Kagwe M, 2020, 1 CASE CORONAVIRUS D
   Kee KF, 2020, 2 INT HDB INTERNET R, P351
   Kim Andrew Wooyoung, 2020, medRxiv, DOI 10.1101/2020.06.13.20130120
   Kluge HHP, 2020, LANCET, V395, P1678, DOI 10.1016/S0140-6736(20)31067-9
   Levesque JF, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-18
   Lilford R, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001267
   Lusambili A, 2020, PPP, V14, P35, DOI DOI 10.3351/PPP.2020.6344577346
   Maclin BJ, 2020, GLOB PUBLIC HEALTH, V15, P734, DOI 10.1080/17441692.2020.1716036
   Manderson L, 2020, MED ANTHROPOL, V39, P367, DOI 10.1080/01459740.2020.1746301
   McIntyre D, 2009, HEALTH ECON POLICY L, V4, P179, DOI 10.1017/S1744133109004836
   Naidoo R, 2020, NATURE, V583, P198, DOI 10.1038/d41586-020-01999-x
   NIHR Global Health Research Unit on Improving Health in Slums, 2020, COVID 19 SLUM SETT N
   Omigbodun A, 2020, NIHR ARC W MIDLANDS, V2, P3
   Otu A, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010339
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Rawal LB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184967
   Samuels F, 2017, HEALTH POLICY PLANN, V32, P1015, DOI 10.1093/heapol/czx037
   Satterthwaite D, 2019, J URBAN HEALTH, V96, P112, DOI 10.1007/s11524-018-0264-4
   Sharif MM, 2020, OPINION SLUMS ARE NE
   Simonovic D, 2020, STATES MUST COMBAT D
   Subbaraman R, 2014, SOC SCI MED, V119, P155, DOI 10.1016/j.socscimed.2014.08.021
   Sverdlik A, 2011, ENVIRON URBAN, V23, P123, DOI 10.1177/0956247811398604
   Vaughan Adam, 2020, New Sci, V246, P8, DOI 10.1016/S0262-4079(20)30704-1
   Wasdani KP, 2020, LOCAL ENVIRON, V25, P414, DOI 10.1080/13549839.2020.1754375
   WHO, 2020, WHO AV 3 CS CLOS SPA
   Wilkinson A, 2020, ENVIRON URBAN, V32, P503, DOI 10.1177/0956247820922843
   World Health Organization, 2020, RISK COMM COMM ENG R
   World Health Organization, 2020, WHO2019NCOVIPCPPEUSE
   World Health Organization, 2020, WHO COR DIS COVID 19
   Zaman Mohammad Mostafa, 2016, Indian J Public Health, V60, P17, DOI 10.4103/0019-557X.177290
NR 54
TC 2
Z9 2
U1 5
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2059-7908
J9 BMJ GLOB HEALTH
JI BMJ Glob. Health
PD AUG
PY 2020
VL 5
IS 8
AR e003042
DI 10.1136/bmjgh-2020-003042
PG 17
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NH0GM
UT WOS:000564358100009
PM 32819917
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yang, R
   Lan, JM
   Huang, BY
   Ruhan, A
   Lu, MQ
   Wang, W
   Wang, WL
   Li, WH
   Deng, Y
   Wong, G
   Tan, WJ
AF Yang, Ren
   Lan, Jiaming
   Huang, Baoying
   Ruhan, A.
   Lu, Mingqing
   Wang, Wen
   Wang, Wenling
   Li, Wenhui
   Deng, Yao
   Wong, Gary
   Tan, Wenjie
TI Lack of antibody-mediated cross-protection between SARS-CoV-2 and
   SARS-CoV infections
SO EBIOMEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; CoV; Cross-neutralization; ACE2
ID FUNCTIONAL RECEPTOR; CORONAVIRUS; BINDING; SPIKE
AB Background: The novel coronavirus (SARS-CoV-2) shares approximately 80% whole genome sequence identity and 66% spike (S) protein identity with that of SARS-CoV. The cross-neutralization between these viruses is currently not well-defined.
   Methods: Here, by using the live SARS-CoV-2 virus infection assay as well as HIV-1 based pseudotyped-virus carrying the spike (S) gene of the SARS-CoV-2 (ppSARS-2) and SARS-CoV (ppSARS), we examined whether infections with SARS-CoV and SARS-CoV-2 can induce cross-neutralizing antibodies.
   Findings: We confirmed that SARS-CoV-2 infects cells via angiotensin converting enzyme 2 (ACE2), the functional receptor for SARS-CoV, and we also found that the recombinant receptor binding domain (RBD) of the S protein of SARS-CoV effectively inhibits ppSARS-2 entry in Huh7.5 cells. However, convalescent sera from SARS-CoV and SARS-CoV-2 patients showed high neutralizing activity only against the homologous virus, with no or limited cross-neutralization activity against the other pseudotyped virus. Similar results were also observed in vaccination studies in mice.
   Interpretation: Our study demonstrates that although both SARS-CoV and SARS-CoV-2 use ACE2 as a cellular receptor, the neutralization epitopes are not shared by these two closely-related viruses, highlighting challenges towards developing a universal vaccine against SARS-CoV related viruses. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
C1 [Yang, Ren; Huang, Baoying; Ruhan, A.; Wang, Wen; Wang, Wenling; Deng, Yao; Tan, Wenjie] China CDC, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing 102206, Peoples R China.
   [Lan, Jiaming; Lu, Mingqing; Wong, Gary] Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China.
   [Wang, Wenling] Natl Inst Biol Sci, Beijing 102206, Peoples R China.
   [Wong, Gary] Laval Univ, Dept Microbiol Infectiol & Immunol, Quebec City, PQ G1V 4G2, Canada.
RP Deng, Y; Tan, WJ (corresponding author), China CDC, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing 102206, Peoples R China.; Wong, G (corresponding author), Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China.
EM dengyao31@163.com; garyckwong@ips.ac.cn; tanwj28@163.com
FU National Key Research and Development Program of China [2016YFD0500301];
   National Major Project for Control and Prevention of Infectious Disease
   in China [2016ZX10004001-003]; One Belt and One Road Major Project for
   infectious diseases [2018ZX10101004-003]; IP; FMX; CASChinese Academy of
   Sciences
FX The study was supported by the National Key Research and Development
   Program of China (Nos. 2016YFD0500301) and the National Major Project
   for Control and Prevention of Infectious Disease in China (Nos.
   2016ZX10004001-003) to WT, and the One Belt and One Road Major Project
   for infectious diseases (2018ZX10101004-003) to GW. GW is supported by a
   G4 grant from IP, FMX and CAS. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515
   Casadevall A, 2018, CURR OPIN IMMUNOL, V53, P74, DOI 10.1016/j.coi.2018.04.011
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deng Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0056-7
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Niu PH, 2018, SCI CHINA LIFE SCI, V61, P1280, DOI 10.1007/s11427-018-9343-8
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   Spruth M, 2006, VACCINE, V24, P652, DOI 10.1016/j.vaccine.2005.08.055
   The World Health Organization (WHO), 2020, COVID 19
   VanBlargan LA, 2016, MICROBIOL MOL BIOL R, V80, DOI 10.1128/MMBR.00024-15
   Wang Q, 2020, CELL
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhao GY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-266
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2020
VL 58
AR 102890
DI 10.1016/j.ebiom.2020.102890
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NG7VH
UT WOS:000564188600009
PM 32707445
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Navinya, C
   Patidar, G
   Phuleria, HC
AF Navinya, Chimurkar
   Patidar, Girish
   Phuleria, Harish C.
TI Examining Effects of the COVID-19 National Lockdown on Ambient Air
   Quality Across Urban India
SO AEROSOL AND AIR QUALITY RESEARCH
LA English
DT Article
DE COVID-19; Urban air pollution; India; Lockdown; PM2.5
ID IMPACT; PM2.5; EMISSIONS; DELHI; NO2
AB Lockdown seems the most effective way to prevent the spread of Coronavirus disease (COVID-19) as no vaccine is currently available in the market to cure it. Thus, India has enforced nation-wide lockdown from 25th March to lower the spread of this contagious virus and associated illness. This study aims to quantify the changes in pollution levels as well as meteorology during the 6-weeks COVID-19 lockdown over 17 cities of India for 5 major criteria pollutants using publicly available air quality data. Hourly averaged data is accessed from the air quality monitoring stations during the lockdown and immediate pre-lockdown periods and also corresponding data from the previous year (2019). During the lockdown, PM2.5, PM10, NO2, and CO reduced significantly with relatively small changes in meteorological conditions compared to the pre-lockdown period. The highest decline is observed over Ahmedabad (68%), Delhi (71%), Bangalore (87%), and Nagpur (63%) for PM2.5, PM10, NO2, and CO, respectively. The Northern region shows the highest decline for all the pollutants with most days below NAAQS during lockdown & mdash;86%, 68%, and 100% compared to 18%, 0%, and 38% in 2019 for PM2.5, PM10, and NO2, respectively. The smaller cities Dewas and Jorapokhar show lesser improvement with only 3% and 16% improvement in days under NAAQS for PM2.5. SO2 is the least affected pollutant with little improvement. The major decline is observed during 7 & ndash;10 am and 7 & ndash;10 pm hours of the day for PM2.5, PM10, NO2, and CO with more than 40% reduction. The meteorological changes are very small and heterogeneous over India showing a similar extent of changes compared to the previous year but the pollution levels have reduced significantly. Thus, the sharp decline in pollutant concentration during the similar to 6 weeks period national lockdown can be attributed to the reduced economic and transport activities.
C1 [Navinya, Chimurkar; Patidar, Girish; Phuleria, Harish C.] Indian Inst Technol, Interdisciplinary Program Climate Studies, Mumbai 400076, Maharashtra, India.
   [Phuleria, Harish C.] Indian Inst Technol, Environm Sci & Engn Dept, Mumbai 400076, Maharashtra, India.
RP Phuleria, HC (corresponding author), Indian Inst Technol, Interdisciplinary Program Climate Studies, Mumbai 400076, Maharashtra, India.; Phuleria, HC (corresponding author), Indian Inst Technol, Environm Sci & Engn Dept, Mumbai 400076, Maharashtra, India.
EM phuleria@iitb.ac.in
CR Bao R, 2020, SCI TOTAL ENVIRON, V731, DOI 10.1016/j.scitotenv.2020.139052
   Bathmanabhan S, 2010, ATMOS POLLUT RES, V1, P184, DOI 10.5094/APR.2010.024
   Boucher O, 2004, CLIM DYNAM, V22, P597, DOI 10.1007/s00382-004-0402-4
   Central Pollution Control Board (CPCB), 2020, CPCB AIR QUAL DAT PO
   Central Pollution Control Board (CPCB), 2011, GUID MEAS AMB POLL, VI
   Chaloulakou A, 2003, ATMOS ENVIRON, V37, P649, DOI 10.1016/S1352-2310(02)00898-1
   Chauhan A, 2020, ENVIRON RES, V187, DOI 10.1016/j.envres.2020.109634
   Chen QX, 2020, AEROSOL AIR QUAL RES, V20, P1541, DOI 10.4209/aaqr.2020.05.0224
   Cleophas T.J., 2011, STAT ANAL CLIN DATA, P41, DOI [10.1007/978-94-007-1211-9_15, DOI 10.1007/978-94-007-1211-9_15]
   Dantas G, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139085
   Das A, 2004, ENERG CONVERS MANAGE, V45, P2603, DOI 10.1016/j.enconman.2003.08.019
   Dutheil F, 2020, ENVIRON POLLUT, V263, DOI 10.1016/j.envpol.2020.114466
   Filonchyk M, 2020, AEROSOL AIR QUAL RES, V20, P1530, DOI 10.4209/aaqr.2020.05.0226
   Gautam S, 2020, B ENVIRON CONTAM TOX, V104, P724, DOI 10.1007/s00128-020-02877-y
   Ghei D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200371
   Goyal P, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-216
   Goyal SK, 2006, ENVIRON MONIT ASSESS, V119, P557, DOI 10.1007/s10661-005-9043-2
   Gupta I, 2012, SCI WORLD J, DOI 10.1100/2012/585791
   He G, 2020, COVID 19 CITY LOCKDO, DOI [10.1101/2020.03.29.20046649, DOI 10.1101/2020.03.29.20046649]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   India Meteorological Department (IMD), 2020, NEW NORM DAT ONS PRO
   Isaifan RJ, 2020, GLOB J ENVIRON SCI M, V6, P275, DOI 10.22034/gjesm.2020.03.01
   Jain S, 2020, AEROSOL AIR QUAL RES, V20, P1222, DOI 10.4209/aaqr.2020.04.0171
   Kerimray A, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.139179
   Kothawale DR, 2010, CLIM RES, V42, P89, DOI 10.3354/cr00857
   Lani J., 2010, ANOVA ANAL VARIANCE
   Li L, 2020, SCI TOTAL ENVIRON, V732, DOI 10.1016/j.scitotenv.2020.139282
   Liu F, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc2992
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mahapatra PS, 2014, THEOR APPL CLIMATOL, V117, P133, DOI 10.1007/s00704-013-0984-z
   Mahato S, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.139086
   McNeill VF, 2020, ACS EARTH SPACE CHEM, V4, P674, DOI 10.1021/acsearthspacechem.0c00093
   Ministry of Home Affairs (MHA), 2020, 4032020DMIA MHA GOV
   Ministry of Home Affairs (MHA), 2020, GOV IND ISS ORD PRES
   Myllyvirta L, 2020, 11000 AIR POLLUTION
   Nadzir MSM, 2020, AEROSOL AIR QUAL RES, V20, P1237, DOI 10.4209/aaqr.2020.04.0163
   NASA, 2020, AIRB NITR DIOX PLUMM
   Navinya CD, 2020, AEROSOL AIR QUAL RES, V20, P1329, DOI 10.4209/aaqr.2019.12.0615
   Pandey A, 2014, ATMOS ENVIRON, V98, P123, DOI 10.1016/j.atmosenv.2014.08.039
   Ramachandra TV, 2009, ATMOS ENVIRON, V43, P5510, DOI 10.1016/j.atmosenv.2009.07.015
   Schiermeier Q, 2020, NATURE, V580, P313, DOI 10.1038/d41586-020-01049-6
   Sharma SK, 2014, URBAN CLIM, V10, P656, DOI 10.1016/j.uclim.2013.11.002
   Sharma S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138878
   Shrestha A.M., 2020, LOCKDOWN CAUSED COVI, DOI [10.31223/osf.io/edt4j., DOI 10.31223/OSF.IO/EDT4J]
   Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164
   Tobias A, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138540
   Venter Z.S., 2020, COVID 19 LOCKDOWNS C, DOI [10.1101/2020.04.10.20060673., DOI 10.1101/2020.04.10.20060673, 10.1101/2020.04.10.20060673]
   Wallace J, 2009, SCI TOTAL ENVIRON, V407, P5085, DOI 10.1016/j.scitotenv.2009.05.050
   Wang PF, 2020, RESOUR CONSERV RECY, V158, DOI 10.1016/j.resconrec.2020.104814
   WHO, 2020, COR DIS COVID 19 SIT
   Wu J, 2018, CLIM DYNAM, V51, P2039, DOI 10.1007/s00382-017-3997-y
   Xu KJ, 2020, AEROSOL AIR QUAL RES, V20, P915, DOI 10.4209/aaqr.2020.04.0150
NR 53
TC 5
Z9 5
U1 0
U2 0
PU TAIWAN ASSOC AEROSOL RES-TAAR
PI TAICHUNG COUNTY
PA CHAOYANG UNIV TECH, DEPT ENV ENG & MGMT, PROD CTR AAQR, NO 168, JIFONG E
   RD, WUFONG TOWNSHIP, TAICHUNG COUNTY, 41349, TAIWAN
SN 1680-8584
EI 2071-1409
J9 AEROSOL AIR QUAL RES
JI Aerosol Air Qual. Res.
PD AUG
PY 2020
VL 20
IS 8
BP 1759
EP 1771
DI 10.4209/aaqr.2020.05.0256
PG 13
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA NH5FA
UT WOS:000564694500005
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Al Rihani, SB
   Smith, MK
   Bikmetov, R
   Deodhar, M
   Dow, P
   Turgeon, J
   Michaud, V
AF Al Rihani, Sweilem B.
   Smith, Matt K.
   Bikmetov, Ravil
   Deodhar, Malavika
   Dow, Pamela
   Turgeon, Jacques
   Michaud, Veronique
TI Risk of Adverse Drug Events Following the Virtual Addition of COVID-19
   Repurposed Drugs to Drug Regimens of Frail Older Adults with
   Polypharmacy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE adverse drug events; COVID-19; polypharmacy; older adults; simulation
ID QT-INTERVAL PROLONGATION; TORSADE-DE-POINTES; SEDATIVE LOAD;
   AZITHROMYCIN; CHLOROQUINE; METABOLISM
AB Determination of the risk-benefit ratio associated with the use of novel coronavirus disease 2019 (COVID-19) repurposed drugs in older adults with polypharmacy is mandatory. Our objective was to develop and validate a strategy to assess risk for adverse drug events (ADE) associated with COVID-19 repurposed drugs using hydroxychloroquine (HCQ) and chloroquine (CQ), alone or in combination with azithromycin (AZ), and the combination lopinavir/ritonavir (LPV/r). These medications were virtually added, one at a time, to drug regimens of 12,383 participants of the Program of All-Inclusive Care for the Elderly. The MedWise Risk Score (MRSTM) was determined from 198,323 drug claims. Results demonstrated that the addition of each repurposed drug caused a rightward shift in the frequency distribution of MRS(TM)values (p< 0.05); the increase was due to an increase in the drug-induced Long QT Syndrome (LQTS) or CYP450 drug interaction burden risk scores. Increases in LQTS risk observed with HCQ + AZ and CQ + AZ were of the same magnitude as those estimated when terfenadine or terfenadine + AZ, used as positive controls for drug-induced LQTS, were added to drug regimens. The simulation-based strategy performed offers a way to assess risk of ADE for drugs to be used in people with underlying medical comorbidities and polypharmacy at risk of COVID-19 infection without exposing them to these drugs.
C1 [Al Rihani, Sweilem B.; Smith, Matt K.; Bikmetov, Ravil; Deodhar, Malavika; Dow, Pamela; Turgeon, Jacques; Michaud, Veronique] Tabula Rasa HealthCare Precis, Pharmacotherapy Res & Dev Inst, Orlando, FL 32827 USA.
   [Turgeon, Jacques; Michaud, Veronique] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
RP Michaud, V (corresponding author), Tabula Rasa HealthCare Precis, Pharmacotherapy Res & Dev Inst, Orlando, FL 32827 USA.; Michaud, V (corresponding author), Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
EM srihani@trhc.com; mksmith@trhc.com; rbikmetov@trhc.com;
   mdeodhar@trhc.com; pdow@trhc.com; jturgeon@trhc.com; vmichaud@trhc.com
RI Rihani, Sweilem B. Al/ABA-4623-2020; Rihani, Sweilem B. Al/ABA-4636-2020
OI Rihani, Sweilem B. Al/0000-0003-2415-4664; Turgeon,
   Jacques/0000-0002-7978-9280
CR Al Rihani S.B., POTENTIAL COVID 19 T
   Arunachalam Karuppiah, 2018, J Clin Med Res, V10, P384, DOI 10.14740/jocmr3338w
   Bankes DL, 2020, PHARMACY-BASEL, V8, DOI 10.3390/pharmacy8020087
   Bauman JL, 2020, PHARMACOTHERAPY, V40, P387, DOI 10.1002/phar.2387
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Boustani MA, 2008, AGING HLTH, V4, P311, DOI [DOI 10.2217/1745509X.4.3.311, 10.2217/1745509X.4.3.311]
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chorin E., 2020, HEART RHYTHM, DOI [10.1016/j.hrthm.2020.05.01432407884, DOI 10.1016/J.HRTHM.2020.05.01432407884]
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Cicali B., 2018, BENEF Q, V34, P49
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   DEMAZIERE J, 1995, J TOXICOL-CLIN TOXIC, V33, P369, DOI 10.3109/15563659509028925
   Department of Health and Human Services Hoechst Marion Roussel Inc. Baker Norton Pharmaceuticals Inc., 1997, FED REGISTER, V62, P1889
   Doan J, 2013, ANN PHARMACOTHER, V47, P324, DOI 10.1345/aph.1R621
   Drici MD, 1998, JAMA-J AM MED ASSOC, V280, P1774, DOI 10.1001/jama.280.20.1774
   Food Drug Administration HHS, 2005, NOTICE FED REG, V70, P61133
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gowda RM, 2004, INT J CARDIOL, V95, P219, DOI 10.1016/j.ijcard.2003.04.034
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harpaz Rave, 2010, AMIA Annu Symp Proc, V2010, P281
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Jankelson L, 2020, HEART RHYTHM, V17, P1472, DOI 10.1016/j.hrthm.2020.05.008
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Linjakumpu T, 2003, INT J GERIATR PSYCH, V18, P542, DOI 10.1002/gps.846
   MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Michaud V, 2020, RISK DRUG INDUCED LO, DOI [10.1101/2020.04.21.20066761, DOI 10.1101/2020.04.21.20066761]
   Milberg P, 2002, J PHARMACOL EXP THER, V303, P218, DOI 10.1124/jpet.102.037911
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Oakes B., AGEISM LEAVES OLDER
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Ross SB, 2020, J AM GERIATR SOC, V68, P1636, DOI 10.1111/jgs.16623
   Sarganas G, 2014, EUROPACE, V16, P101, DOI 10.1093/europace/eut214
   Simko J, 2008, INFECTION, V36, P194, DOI 10.1007/s15010-007-7211-8
   Simpson TF, VENTRICULAR ARRHYTHM
   Skipper C.P., HYDROXYCHLOROQUINE N
   Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055
   Szekely Y., 2019, CHLOROQUINE INDUCED
   Taipale HT, 2011, DRUG AGING, V28, P913, DOI 10.2165/11597800-000000000-00000
   Taipale HT, 2010, AM J GERIATR PHARMAC, V8, P460, DOI 10.1016/j.amjopharm.2010.10.004
   Turgeon J, 2019, U.S. Patent WO, Patent No. 2019089725
   Turgeon J, 2017, U.S. Patent WO, Patent No. 2017213825
   U.S. Food and Drug Administration, REQ EM US AUTH US CH
   U.S. Food and Drug Administration, 2020, FDA CAUT US HYDR CHL
   U.S. Food and Drug Administration, EM US AUTH EUA EM US
   WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532
   World Health Organization, 2017, P MAL POL ADV COMM M
   World Health Organization, PNEM UNK CAUS EM PRE
   World Health Organization, SOLIDARITY
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yeh RF, 2006, JAIDS-J ACQ IMM DEF, V42, P52
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 60
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2591
DI 10.3390/jcm9082591
PG 19
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH7ZJ
UT WOS:000564883600001
PM 32785135
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nawabi, J
   Morotti, A
   Wildgruber, M
   Boulouis, G
   Kraehling, H
   Schlunk, F
   Can, E
   Kniep, H
   Thomalla, G
   Psychogios, M
   Hamm, B
   Fiehler, J
   Hanning, U
   Sporns, P
AF Nawabi, Jawed
   Morotti, Andrea
   Wildgruber, Moritz
   Boulouis, Gregoire
   Kraehling, Hermann
   Schlunk, Frieder
   Can, Elif
   Kniep, Helge
   Thomalla, Goetz
   Psychogios, Marios
   Hamm, Bernd
   Fiehler, Jens
   Hanning, Uta
   Sporns, Peter
TI Clinical and Imaging Characteristics in Patients with SARS-CoV-2
   Infection and Acute Intracranial Hemorrhage
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE intracranial hemorrhage; SARS-CoV-2; COVID-19; imaging characteristics
ID NERVOUS-SYSTEM VASCULITIS; SARS-CORONAVIRUS
AB Background and Purpose: Intracranial hemorrhage has been observed in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19), but the clinical, imaging, and pathophysiological features of intracranial bleeding during COVID-19 infection remain poorly characterized. This study describes clinical and imaging characteristics of patients with COVID-19 infection who presented with intracranial bleeding in a European multicenter cohort. Methods: This is a multicenter retrospective, observational case series including 18 consecutive patients with COVID-19 infection and intracranial hemorrhage. Data were collected from February to May 2020 at five designated European special care centers for COVID-19. The diagnosis of COVID-19 was based on laboratory-confirmed diagnosis of SARS-CoV-2. Intracranial bleeding was diagnosed on computed tomography (CT) of the brain within one month of the date of COVID-19 diagnosis. The clinical, laboratory, radiologic, and pathologic findings, therapy and outcomes in COVID-19 patients presenting with intracranial bleeding were analyzed. Results: Eighteen patients had evidence of acute intracranial bleeding within 11 days (IQR 9-29) of admission. Six patients had parenchymal hemorrhage (33.3%), 11 had subarachnoid hemorrhage (SAH) (61.1%), and one patient had subdural hemorrhage (5.6%). Three patients presented with intraventricular hemorrhage (IVH) (16.7%). Conclusion: This study represents the largest case series of patients with intracranial hemorrhage diagnosed with COVID-19 based on key European countries with geospatial hotspots of SARS-CoV-2. Isolated SAH along the convexity may be a predominant bleeding manifestation and may occur in a late temporal course of severe COVID-19.
C1 [Nawabi, Jawed; Can, Elif; Hamm, Bernd] Charite Univ Med Berlin, Dept Radiol CCM, Campus Mitte, D-14195 Berlin, Germany.
   [Nawabi, Jawed; Schlunk, Frieder; Can, Elif; Hamm, Bernd] Humboldt Univ, D-14195 Berlin, Germany.
   [Nawabi, Jawed; Schlunk, Frieder; Can, Elif; Hamm, Bernd] Free Univ Berlin, D-14195 Berlin, Germany.
   [Morotti, Andrea] ASST Valcamon, Neurol Unit, I-25040 Brescia, Italy.
   [Wildgruber, Moritz] Klinikum Univ LMU, Klin & Poliklin Radiol, D-81377 Munich, Germany.
   [Boulouis, Gregoire] Univ Paris, Pediat Radiol Dept, Necker Enfants Malad, F-75015 Paris, France.
   [Boulouis, Gregoire] Univ Paris, GHU Paris, St Anne Hosp, Inst Psychiat & Neurosci Paris IPNP,UMR S1266,INS, F-75015 Paris, France.
   [Kraehling, Hermann] Univ Hosp Muenster, Dept Radiol, D-48149 Munster, Germany.
   [Schlunk, Frieder] Charite Univ Med Berlin, Dept Neuroradiol, D-14195 Berlin, Germany.
   [Schlunk, Frieder] Berlin Inst Hlth, D-14195 Berlin, Germany.
   [Kniep, Helge; Fiehler, Jens; Hanning, Uta; Sporns, Peter] Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Neuroradiol, D-20251 Hamburg, Germany.
   [Thomalla, Goetz] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, D-20251 Hamburg, Germany.
   [Psychogios, Marios; Sporns, Peter] Univ Hosp Basel, Clin Radiol & Nucl Med, Dept Neuroradiol, CH-4031 Basel, Switzerland.
RP Nawabi, J (corresponding author), Charite Univ Med Berlin, Dept Radiol CCM, Campus Mitte, D-14195 Berlin, Germany.; Nawabi, J (corresponding author), Humboldt Univ, D-14195 Berlin, Germany.; Nawabi, J (corresponding author), Free Univ Berlin, D-14195 Berlin, Germany.
EM jawed.nawabi@charite.de; andrea.morotti85@gmail.com;
   moritz.Wildgruber@med.uni-muenchen.de; gregoireboulouis@gmail.com;
   Hermann.Kraehling@ukmuenster.de; frieder.schlunk@charite.de;
   elif.can@charite.de; h.kniep@uke.de; thomalla@uke.de;
   marios.psychogios@usb.ch; b.hamm@charite.de; fiehler@uke.de;
   u.hanning@uke.de; peter.sporns@hotmail.de
OI Nawabi, Jawed/0000-0002-1137-0643
CR Barboza Miguel A, 2014, J Vasc Interv Neurol, V7, P17
   Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC
   Boulouis G, 2017, STROKE, V48, P1248, DOI 10.1161/STROKEAHA.116.016194
   Broderick JP, 2017, STROKE, V48, P2007, DOI 10.1161/STROKEAHA.117.017866
   Cariddi LP, 2020, J NEUROL, V267, P3157, DOI 10.1007/s00415-020-10001-7
   Cavayas YA, 2018, PERFUSION-UK, V33, P42, DOI 10.1177/0267659118766435
   Cuvinciuc V, 2010, AM J NEURORADIOL, V31, P1355, DOI 10.3174/ajnr.A1986
   Fanou EM, 2017, STROKE, V48, P1085, DOI 10.1161/STROKEAHA.116.016289
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Forman R, 2017, NEUROLOGY, V88, P286
   Franceschi AM, 2020, AM J NEURORADIOL, V41, P1173, DOI 10.3174/ajnr.A6595
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   GREENAN TJ, 1992, RADIOLOGY, V182, P65, DOI 10.1148/radiology.182.1.1727311
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Jain R, 2003, AM J NEURORADIOL, V24, P971
   Jin HJ, 2020, STROKE VASC NEUROL, V5, P146, DOI [10.1136/svn-2020-000382, 10.1136/svn-2020-000482]
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Kumar TP, 2019, MOL NEUROBIOL, V56, P1992, DOI 10.1007/s12035-018-1213-7
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Mahammedi A, 2020, RADIOLOGY, V297, pE270, DOI 10.1148/radiol.2020201933
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marsh EB, 2012, NEUROLOGIST, V18, P233, DOI 10.1097/NRL.0b013e31825c6d23
   Mavragani A, 2020, JMIR PUBLIC HLTH SUR, V6, P233, DOI 10.2196/18941
   Merkler Alexander E, 2020, medRxiv, DOI 10.1101/2020.05.18.20105494
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Pinna P, 2020, J NEUROL SCI, V415, DOI 10.1016/j.jns.2020.116969
   ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P725, DOI 10.1001/archneur.1984.04050180047016
   Salvarani C, 2012, CURR OPIN RHEUMATOL, V24, P46, DOI 10.1097/BOR.0b013e32834d6d76
   Salvarani C, 2011, ARTHRITIS RHEUM-US, V63, P3598, DOI 10.1002/art.30594
   Sharlala H, 2009, CURR RHEUMATOL REP, V10, DOI 10.1007/s11926-008-0073-y
   Sharma R, 2018, J MED IMAG RADIAT ON, V62, P451, DOI 10.1111/1754-9485.12726
   Sweidan AJ, 2020, STROKE VASC NEUROL, V5, P29, DOI 10.1136/svn-2019-000274
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Younger DS, 2019, NEUROL CLIN, V37, P441, DOI 10.1016/j.ncl.2019.01.002
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 39
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2543
DI 10.3390/jcm9082543
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH3SU
UT WOS:000564594200001
PM 32781623
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cascella, M
   Mauro, I
   De Blasio, E
   Crispo, A
   Del Gaudio, A
   Bimonte, S
   Cuomo, A
   Ascierto, PA
AF Cascella, Marco
   Mauro, Immacolata
   De Blasio, Elvio
   Crispo, Anna
   Del Gaudio, Alfredo
   Bimonte, Sabrina
   Cuomo, Arturo
   Ascierto, Paolo Antonio
TI Rapid and Impressive Response to a Combined Treatment with Single-Dose
   Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS
SO MEDICINA-LITHUANIA
LA English
DT Article
DE case report; cytokines; immunotherapy; inflammation; COVID-19; acute
   respiratory distress syndrome (ARDS)
AB Treatment of acute respiratory distress syndrome (ARDS) due to COVID-19 pneumonia (CARDS) represents a clinical challenge, requiring often invasive mechanical ventilation (IMV). Since the pathogenesis of CARDS it probably involves a direct viral attack to pulmonary and endothelium cells, and immune-mediated inflammation with dysfunctional coagulation, it was suggested to interfere with interleukin-6 (IL-6) activity by using the IL-6 receptor monoclonal antibody tocilizumab (TCZ). We reported the case of a 54-year-old 100 kg male COVID-19 patient (BMI 29) with severe respiratory insufficiency featuring dyspnea and hypoxia (SpO(2)89% on room; PaO(2)53 mmHg). Despite treatment with antiviral and non-invasive ventilation (NIV), after 24 h there was a progressive worsening of clinical conditions with higher fever (40 degrees C), increased dyspnea, and hypoxia (PaO2/FiO(2)or P/F ratio of 150). The patient was at the limit to be sedated and intubated for IMV. He was treated with tocilizumab (8 mg/Kg i.v., single shot 800 mg) and NIV in the prone positioning. After only 96 h, the clinical, laboratory, and imaging findings showed incredible improvement. There was an important gain in oxygenation (P/F 300), a decrease of C-reactive protein values, and a decrease of the fever. Both the neutrophil-to-lymphocyte ratio (NLR) and the derived NLR ratio dropped down to 44%. Chest imaging confirmed the favorable response. This case suggested that for CARDS management efforts are needed for reducing its underlying inflammatory processes. Through a multiprofessional approach, the combination of IL-6-targeting therapies with calibrated ventilatory strategies may represent a winning strategy for improving outcomes.
C1 [Cascella, Marco; Bimonte, Sabrina; Cuomo, Arturo] Fdn G Pascale, Div Anesthesia & Pain Med, Ist Nazl Tumori, IRCCS, I-80131 Naples, Italy.
   [Mauro, Immacolata] Osped Mauro Scarlato, Pneumol Unit, I-84018 Scafati, SA, Italy.
   [De Blasio, Elvio] Multidisciplinary Emergency Unit COVID 19 Campani, I-80100 Naples, Italy.
   [Crispo, Anna] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Epidemiol & Biostat Unit, I-80131 Naples, Italy.
   [Del Gaudio, Alfredo] IRCCS Casa Sollievo Sofferenza, DSC Anestesia & Rianimaz 2, I-71013 San Giovanni Rotondo, FG, Italy.
   [Ascierto, Paolo Antonio] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Dev Therapeut Unit, I-80131 Naples, Italy.
RP Crispo, A (corresponding author), Fdn G Pascale, IRCCS, Ist Nazl Tumori, Epidemiol & Biostat Unit, I-80131 Naples, Italy.
EM m.cascella@istitutotumori.na.it; i.mauro@aslsalerno.it;
   elvio.deblasio@gmail.com; a.crispo@istitutotumori.na.it;
   freddydelgaudio@libero.it; s.bimonte@istitutotumori.na.it;
   a.cuomo@istitutotumori.na.it; p.ascierto@istitutotumori.na.it
RI Crispo, Anna/ABA-7435-2020; cascella, Marco/N-1316-2018
OI cascella, Marco/0000-0002-5236-3132; Crispo, Anna/0000-0002-8455-3328;
   bimonte, sabrina/0000-0002-5408-9675
CR Cao W, 2020, CELL RES, V30, P367, DOI 10.1038/s41422-020-0327-4
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Chad T, 2020, CLIN MED, V20, pE97, DOI 10.7861/clinmed.2020-0179
   Ciceri F., 2020, CRIT CARE RESUSC
   Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gattinoni L, 2020, INTENS CARE MED, V46, P1438, DOI 10.1007/s00134-020-06103-5
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Quartuccio L, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104444
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rojas-Marte G, 2020, QJM-INT J MED, V113, P546, DOI 10.1093/qjmed/hcaa206
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Stroud CRG, 2019, J ONCOL PHARM PRACT, V25, P551, DOI 10.1177/1078155217745144
   Tanaka T, 2014, SEMIN IMMUNOL, V26, P88, DOI 10.1016/j.smim.2014.01.009
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 22
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD AUG
PY 2020
VL 56
IS 8
AR 377
DI 10.3390/medicina56080377
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NG6FH
UT WOS:000564077100001
PM 32727107
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gramegna, M
   Baldetti, L
   Beneduce, A
   Pannone, L
   Falasconi, G
   Calvo, F
   Pazzanese, V
   Sacchi, S
   Pagnesi, M
   Moroni, F
   Ajello, S
   Melisurgo, G
   Agricola, E
   Camici, PG
   Scandroglio, AM
   Landoni, G
   Ciceri, F
   Zangrillo, A
   Cappelletti, AM
AF Gramegna, Mario
   Baldetti, Luca
   Beneduce, Alessandro
   Pannone, Luigi
   Falasconi, Giulio
   Calvo, Francesco
   Pazzanese, Vittorio
   Sacchi, Stefania
   Pagnesi, Matteo
   Moroni, Francesco
   Ajello, Silvia
   Melisurgo, Giulio
   Agricola, Eustachio
   Camici, Paolo G.
   Scandroglio, Anna Mara
   Landoni, Giovanni
   Ciceri, Fabio
   Zangrillo, Alberto
   Cappelletti, Alberto Maria
TI ST-Segment-Elevation Myocardial Infarction During COVID-19 Pandemic
   Insights From a Regional Public Service Healthcare Hub
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE acute coronary syndrome; coronavirus; myocardial infarction; pandemic;
   severe acute respiratory syndrome coronavirus 2
AB Background: Coronavirus disease 2019 (COVID-19) pandemic has led to a fast and radical transformation in social, economic, and healthcare networks. COVID-19 outbreak may thus have profound indirect consequences on clinical presentation and management of patients with ST-segment-elevation myocardial infarction (STEMI). Aim of this study was to assess clinical features of patients with STEMI during COVID-19 pandemic. Methods: This single-center, prospective study from a regional public service healthcare hub in Milan included all consecutive patients with STEMI admitted to our institute from February 21 to April 1, 2020 (during COVID-19 pandemic). These patients were compared with a historical cohort of patients admitted for STEMI during the analogous time period (February 21 to April 1) in 2018 and 2019, in terms of time from symptoms onset to hospital admission, clinical characteristics, and in-hospital outcomes. Results: A total of 26 patients were admitted for STEMI during the study period, and 7 (26.9%) of these patients tested positive for severe acute respiratory syndrome coronavirus 2. On admission, medical therapy, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers use, was similar between cohorts. Median (interquartile range) time from symptoms onset to hospital admission was significantly longer in 2020 as compared to the historical cohort (15.0 [2.0-48.0] versus 2.0 [1.0-3.0] hours;P<0.01). A higher proportion of patients presenting with late presentation STEMI was observed in 2020 compared with the historical cohort (50.0% versus 4.8%;P<0.01). Primary percutaneous coronary intervention resulted indicated in 80.8% of patients in 2020 compared with 100% in the historical cohort (P=0.06). In-hospital death, thromboembolism, mechanical ventilation, or hemodynamic decompensation needing inotropic or mechanical support were similar between years. Conclusions: These preliminary results from a cardiovascular regional public service healthcare hub demonstrate a significantly longer time from symptoms onset to hospital admission among patients with STEMI during COVID-19 pandemic compared with the same time period in the previous 2 years.
C1 [Gramegna, Mario; Baldetti, Luca; Pannone, Luigi; Falasconi, Giulio; Calvo, Francesco; Pazzanese, Vittorio; Sacchi, Stefania; Pagnesi, Matteo; Moroni, Francesco; Cappelletti, Alberto Maria] IRCCS San Raffaele Sci Inst, Cardiac Intens Care Unit, Via Olgettina 60, I-20132 Milan, Italy.
   [Beneduce, Alessandro] IRCCS San Raffaele Sci Inst, Intervent Cardiol Unit, Milan, Italy.
   [Ajello, Silvia; Melisurgo, Giulio; Scandroglio, Anna Mara] IRCCS San Raffaele Sci Inst, Cardiac Surg Intens Care Unit, Milan, Italy.
   [Agricola, Eustachio] IRCCS San Raffaele Sci Inst, Cardiac Imaging Unit, Milan, Italy.
   [Landoni, Giovanni; Zangrillo, Alberto] IRCCS San Raffaele Sci Inst, Anesthesia & Intens Care, Milan, Italy.
   [Ciceri, Fabio] IRCCS San Raffaele Sci Inst, Hematol Dept, Milan, Italy.
   [Agricola, Eustachio; Camici, Paolo G.; Landoni, Giovanni; Ciceri, Fabio; Zangrillo, Alberto] Univ Vita Salute San Raffaele, Milan, Italy.
RP Gramegna, M (corresponding author), IRCCS San Raffaele Sci Inst, Cardiac Intens Care Unit, Via Olgettina 60, I-20132 Milan, Italy.
EM gramegna.mario@hsr.it
RI Gramegna, Mario/ABF-3698-2020
OI Gramegna, Mario/0000-0002-9709-6082; Beneduce,
   Alessandro/0000-0003-2130-1964; Pannone, Luigi/0000-0001-9769-1511;
   Pazzanese, Vittorio/0000-0003-0631-4230; Moroni,
   Francesco/0000-0002-6101-1403; Agricola, Eustachio/0000-0002-4834-2187;
   LANDONI, Giovanni/0000-0002-8594-5980; ZANGRILLO,
   Alberto/0000-0002-7687-7648
CR Alkhalil M, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.007287
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Chieffo A, 2020, EUR HEART J, V41, P1839, DOI 10.1093/eurheartj/ehaa381
   Ciceri Fabio, 2020, Crit Care Resusc, V22, P95
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   Han YL, 2020, CIRCULATION, V141, pE810, DOI 10.1161/CIRCULATIONAHA.120.047011
   Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393
   Kannan VD, 2014, MED CARE, V52, P336, DOI 10.1097/MLR.0000000000000100
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Ministero della Salute 2020, 2020, COVID 19 SIT IT
   Moroni Francesco, 2020, JACC Case Rep, V2, P1620, DOI 10.1016/j.jaccas.2020.04.010
   Parmet WE, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2004211
   Parpia AS, 2016, EMERG INFECT DIS, V22, P433, DOI 10.3201/eid2203.150977
   Pisano A, 2020, J CARDIOTHOR VASC AN, V34, P1698, DOI 10.1053/j.jvca.2020.03.043
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Rubinson L, 2013, MED CARE, V51, P259, DOI 10.1097/MLR.0b013e31827da8ea
   Stefanini GG, 2020, CIRCULATION, V141, P1597, DOI 10.1161/CIRCULATIONAHA.120.047070
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   TCTMD.com, 2020, MYST MISS STEM COVID
   Thygesen K, 2018, CIRCULATION, V138, pE618, DOI 10.1161/CIR.0000000000000617
   Vogel B, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0090-3
   Yang CZ, 2020, JAMA CARDIOL, V5, P743, DOI 10.1001/jamacardio.2020.0934
   Zangrillo A, 2020, CRIT CARE RESUSC
   Zangrillo Alberto, 2020, Crit Care Resusc, V22, P91
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 26
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD AUG
PY 2020
VL 13
IS 8
DI 10.1161/CIRCINTERVENTIONS.120.009413
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NF8VJ
UT WOS:000563570400012
PM 32791953
DA 2021-01-01
ER

PT J
AU Singh, S
   Prakash, C
   Ramakrishna, S
AF Singh, Sunpreet
   Prakash, Chander
   Ramakrishna, Seeram
TI Three-dimensional printing in the fight against novel virus COVID-19:
   Technology helping society during an infectious disease pandemic
SO TECHNOLOGY IN SOCIETY
LA English
DT Article
DE Three-dimensional printing; COVID-19; Pandemic; Personal protective
   equipment; Society; Safety
ID DRUG-DELIVERY; 3D; PNEUMONIA; RELEASE
AB Indeed, the scientific milestones set by the ever-emerging three-dimensional printing (3DP) technologies are tremendous. Till now, the innovative 3DP technologies have benefitted the aerospace, automobile, textile, pharmaceutical, and biomedical sectors by developing pre-requisite designed and customized performance standards of the end-user products. As the scientific world, at this moment, is expediting efforts to fight against the highly damaging novel coronavirus (COVID-19) pandemic, the 3DP technologies are facilitating creative solutions in terms of personal protective equipment (PPE), medical equipment (such as ventilators and other respiratory devices), and other health and welfare tools to aid the personal hygiene as well as safe environment for humans by restricting the communication of risks. Various sources (including journal articles, news articles, white papers of the government and other non-profit organizations, commercial enterprises, as well as academic institutions have been reviewed for the collection of the information relevant to COVID-19 and 3DP. This communication presents the recent applications of the 3DP technologies aiding in developing innovative products designed to save the lives of millions of people around the world. Moreover, the potential of 3DP technologies in developing test swabs and controlled medicines has been highlighted. The literature reviewed in the present study indicated that the fused filament fabrication (FFF) is one of the most preferred technologies and contribute about 62% in the overall production of the protective gears developed through overall class of 3DP.
C1 [Singh, Sunpreet; Ramakrishna, Seeram] Natl Univ Singapore, Mech Engn, Singapore, Singapore.
   [Prakash, Chander] Lovely Profess Univ, Sch Mech Engn, Phagwara, India.
RP Singh, S (corresponding author), Natl Univ Singapore, Mech Engn, Singapore, Singapore.
EM snprt.singh@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Al-Awadhi AM, 2020, J BEHAV EXP FINANC, V27, DOI 10.1016/j.jbef.2020.100326
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, TOP 9 VENDORS PERSON
   [Anonymous], 2020, 3D PRINTING COMMUNIT
   [Anonymous], 2020, FAQS SHORT SURG MASK
   [Anonymous], 2020, 3D PRINTING COVID 19
   [Anonymous], 2019, COR DIS 2019 COVID 2
   [Anonymous], 2020, PRIVATE TECH COMPANI
   [Anonymous], 2020, INFECT PREVENTION CO
   [Anonymous], 2020, SHORT PERS PROT EQ E
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baldwin R., 2020, EC TIME COVID 19, P59
   Bennett I., 2020, RAPID DEPLOYMENT 3D, DOI [10.1101/2020.05.25.20112201., DOI 10.1101/2020.05.25.20112201]
   Boulos MKN, 2020, INT J HEALTH GEOGR, V19, DOI 10.1186/s12942-020-00202-8
   Brida M, 2020, INT J CARDIOL, V310, P170, DOI 10.1016/j.ijcard.2020.04.006
   Burroughs B, 2020, TECHNOL SOC, V62, DOI 10.1016/j.techsoc.2020.101277
   Callahan CL, 2020, RAPID OPEN DEV CLIN, DOI [10.1101/2020.04.14.20065094, DOI 10.1101/2020.04.14.20065094]
   Callahan CJ, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00876-20
   Cavallo L., 2020, PROSTHESIS, V2, P46, DOI [10.3390/prosthesis2020005, DOI 10.3390/prosthesis2020005]
   Clifton W, 2020, 3D PRINT ADDIT MANUF, V7, P97, DOI 10.1089/3dp.2020.0101
   Corsini L, 2019, TECHNOL SOC, V58, DOI 10.1016/j.techsoc.2019.02.003
   Cote J., 2020, COVID 19 NOVEL INITI, DOI [10.21203/rs.3.rs-31671/v1., DOI 10.21203/RS.3.RS-31671/V1]
   Cox JL, 2020, LAB MED, V51, pE45, DOI 10.1093/labmed/lmaa031
   Dickinson A., 2020, PERSONAL RESPIRATOR, DOI [10.31224/osf.io/rvcs3., DOI 10.31224/OSF.IO/RVCS3]
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fang L., 2020, LANCET, V8, P21
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Feeley SR, 2014, J SUSTAIN DEV, V7, P1, DOI [10.5539/jsd.v7n5p1, DOI 10.5539/JSD.V7N5P1]
   Fitzgerald S, 2015, NEUROL TODAY, V15, P26, DOI DOI 10.1097/01.NT.0000472137.66046.B5
   Fox S, 2017, TECHNOL SOC, V51, P1, DOI 10.1016/j.techsoc.2017.07.003
   Fox S, 2014, TECHNOL SOC, V39, P18, DOI 10.1016/j.techsoc.2014.07.001
   Gallup N., 2020, PARAMETRIC NASOPHARY, DOI [10.20944/preprints202005.0310.v1., DOI 10.20944/PREPRINTS202005.0310.V1]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Hamburg MA, 2008, TECHNOL SOC, V30, P383, DOI 10.1016/j.techsoc.2008.04.002
   Harmooshi N. Nazari, 2020, ENV CONCERN REGARDIN, DOI [10.2139/ssrn.3563403., DOI 10.2139/SSRN.3563403]
   Ishack S, 2020, AM J MED, V133, pE385, DOI 10.1016/j.amjmed.2020.04.002
   Ji W, 2020, J MED VIROL, V22, P1
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jonathan G, 2016, INT J PHARMACEUT, V499, P376, DOI 10.1016/j.ijpharm.2015.12.071
   Larraneta E, 2020, 3D PRINT ADDIT MANUF, V7, P100, DOI 10.1089/3dp.2020.0106
   Li F, 2017, ANAL CHEM, V89, P4701, DOI 10.1021/acs.analchem.7b00409
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Naddeo V, 2020, ENVIRON SCI-WAT RES, V6, P1213, DOI 10.1039/d0ew90015j
   Nicholson K., 2020, MODIFIED FULL FACE S
   Pearce J., 2020, DISTRIBUTED MANUFACT, DOI [10.20944/preprints202004.0054.v1., DOI 10.20944/PREPRINTS202004.0054.V1.]
   Pereira A., 2004, 200400310 ARXIV
   Prasad LK, 2016, DRUG DEV IND PHARM, V42, P1019, DOI 10.3109/03639045.2015.1120743
   Qu GB, 2020, ENVIRON SCI TECHNOL, V54, P3730, DOI 10.1021/acs.est.0c01102
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruiz Estrada MA, 2020, 3560681 SSRN, DOI [10.2139/ssrn.3560681, DOI 10.2139/SSRN.3560681]
   Shende P, 2018, BIOMED PHARMACOTHER, V107, P146, DOI 10.1016/j.biopha.2018.07.167
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Solanki NG, 2018, J PHARM SCI-US, V107, P390, DOI 10.1016/j.xphs.2017.10.021
   Williams E, 2020, MED J AUSTRALIA, V213, P276, DOI [10.5694.mja2.50726, 10.5694/mja2.50726]
   Xing JF, 2015, CHEM SOC REV, V44, P5031, DOI 10.1039/c5cs00278h
   Zhang CH, 2008, J CONTROL RELEASE, V131, P128, DOI 10.1016/j.jconrel.2008.07.026
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
NR 60
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0160-791X
EI 1879-3274
J9 TECHNOL SOC
JI Technol. Soc.
PD AUG
PY 2020
VL 62
AR 101305
DI 10.1016/j.techsoc.2020.101305
PG 8
WC Social Issues; Social Sciences, Interdisciplinary
SC Social Issues; Social Sciences - Other Topics
GA NE9UZ
UT WOS:000562950700006
PM 32834232
OA Green Published
DA 2021-01-01
ER

PT J
AU Osho, AA
   Moonsamy, P
   Hibbert, KA
   Shelton, KT
   Trahanas, JM
   Attia, RQ
   Bloom, JP
   Onwugbufor, MT
   D'Alessandro, DA
   Villavicencio, MA
   Sundt, TM
   Crowley, JC
   Raz, Y
   Funamoto, M
AF Osho, Asishana A.
   Moonsamy, Philicia
   Hibbert, Kathryn A.
   Shelton, Kenneth T.
   Trahanas, John M.
   Attia, Rizwan Q.
   Bloom, Jordan P.
   Onwugbufor, Michael T.
   D'Alessandro, David A.
   Villavicencio, Mauricio A.
   Sundt, Thoralf M.
   Crowley, Jerome C.
   Raz, Yuval
   Funamoto, Masaki
TI Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure
   in COVID-19 Patients Early Experience From a Major Academic Medical
   Center in North America
SO ANNALS OF SURGERY
LA English
DT Article
DE ARDS; COVID-19; extracorporeal membrane oxygenation; VV-ECMO
ID ECMO
AB and Background Data: VV ECMO can be utilized as an advanced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical care management and optimal mechanical ventilation. Anticipating a need for such therapies during the pandemic, our center created a targeted protocol for ECMO therapy in COVID-19 patients that allows us to provide this life-saving therapy to our sickest patients without overburdening already stretched resources or excessively exposing healthcare staff to infection risk. Methods: As a major regional referral program, we used the framework of our well-established ECMO service-line to outline specific team structures, modified patient eligibility criteria, cannulation strategies, and management protocols for the COVID-19 ECMO program. Results: During the first month of the COVID-19 outbreak in Massachusetts, 6 patients were placed on VV ECMO for refractory hypoxemic respiratory failure. The median (interquartile range) age was 47 years (43-53) with most patients being male (83%) and obese (67%). All cannulations were performed at the bedside in the intensive care unit in patients who had undergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective ventilation, paralysis, prone positioning, and inhaled nitric oxide. At the time of this report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic stroke. 67% of patients (4/6) have been successfully decannulated, including 2 that have been successfully extubated and one who was discharged from the hospital. The median duration of VV ECMO therapy for patients who have been decannulated is 12 days (4-18 days). Conclusions: This is 1 the first case series describing VV ECMO outcomes in COVID-19 patients. Our initial data suggest that VV ECMO can be successfully utilized in appropriately selected COVID-19 patients with advanced respiratory failure.
C1 [Osho, Asishana A.; Moonsamy, Philicia; Trahanas, John M.; Attia, Rizwan Q.; Bloom, Jordan P.; Onwugbufor, Michael T.; D'Alessandro, David A.; Villavicencio, Mauricio A.; Sundt, Thoralf M.; Funamoto, Masaki] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
   [Hibbert, Kathryn A.; Raz, Yuval] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
   [Shelton, Kenneth T.; Crowley, Jerome C.] Massachusetts Gen Hosp, Div Cardiac Anesthesia, Boston, MA 02114 USA.
RP Osho, AA (corresponding author), Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
EM Asishana.Osho@mgh.harvard.edu
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jayaraman AL, 2017, ANN CARD ANAESTH, V20, pS11, DOI 10.4103/0971-9784.197791
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Namendys-Silva SA, 2020, HEART LUNG, V49, P348, DOI 10.1016/j.hrtlng.2020.03.012
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
NR 8
TC 6
Z9 6
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD AUG
PY 2020
VL 272
IS 2
BP E75
EP E78
DI 10.1097/SLA.0000000000004084
PG 4
WC Surgery
SC Surgery
GA NE6GN
UT WOS:000562697800015
PM 32675503
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Whitelaw, S
   Mamas, MA
   Topol, E
   Van Spall, HGC
AF Whitelaw, Sera
   Mamas, Mamas A.
   Topol, Eric
   Van Spall, Harriette G. C.
TI Applications of digital technology in COVID-19 pandemic planning and
   response
SO LANCET DIGITAL HEALTH
LA English
DT Article
AB With high transmissibility and no effective vaccine or therapy, COVID-19 is now a global pandemic. Government-coordinated efforts across the globe have focused on containment and mitigation, with varying degrees of success. Countries that have maintained low COVID-19 per-capita mortality rates appear to share strategies that include early surveillance, testing, contact tracing, and strict quarantine. The scale of coordination and data management required for effective implementation of these strategies has-in most successful countries-relied on adopting digital technology and integrating it into policy and health care. This Viewpoint provides a framework for the application of digital technologies in pandemic management and response, highlighting ways in which successful countries have adopted these technologies for pandemic planning, surveillance, testing, contact tracing, quarantine, and health care.
C1 [Whitelaw, Sera; Van Spall, Harriette G. C.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Van Spall, Harriette G. C.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Mamas, Mamas A.] Univ Manchester, Inst Populat Hlth, Manchester, Lancs, England.
   [Mamas, Mamas A.] Keele Univ, Keele Cardiac Res Grp, Stoke On Trent, Staffs, England.
   [Topol, Eric] Scripps Res Translat Inst, La Jolla, CA USA.
   [Van Spall, Harriette G. C.] Populat Hlth Res Inst, Hamilton, ON L8L 0A3, Canada.
RP Van Spall, HGC (corresponding author), Populat Hlth Res Inst, Hamilton, ON L8L 0A3, Canada.
EM harriette.vanspall@phri.ca
RI Mamas, Mamas/A-2549-2019
OI Mamas, Mamas/0000-0001-9241-8890
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR)
FX HGCV receives research funding from the Canadian Institutes of Health
   Research.
CR [Anonymous], BUSINESS INSIDER
   [Anonymous], 2020, WASHINGTON POST
   [Anonymous], 2020, NY TIMES
   [Anonymous], WALL STREET J
   [Anonymous], 2020, CTV NEWS
   Bever Lindsey, 2014, WASHINGTON POST
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   GSMA, STAT MOB INT CONN 20
   James G., 2017, INTRO STAT LEARNING
   Li L, 2020, RADIOLOGY, V296, pE65, DOI 10.1148/radiol.2020200905
   McCall B, 2020, LANCET DIGIT HEALTH, V2, pE166, DOI 10.1016/S2589-7500(20)30054-6
   Miller AC, 2018, CLIN INFECT DIS, V67, P388, DOI 10.1093/cid/ciy073
   Naude W., ARTIFICIAL INTELLIGE
   Naude W, 2020, AI SOC, V35, P761, DOI 10.1007/s00146-020-00978-0
   Steyerberg EW, 2016, J CLIN EPIDEMIOL, V69, P245, DOI 10.1016/j.jclinepi.2015.04.005
   Torous J, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/18848
   Wallis L, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1327686
   Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 13
Z9 14
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2589-7500
J9 LANCET DIGIT HEALTH
JI Lancet Digit. Health
PD AUG
PY 2020
VL 2
IS 8
BP E435
EP E440
DI 10.1016/S2589-7500(20)30142-4
PG 6
WC Medical Informatics; Medicine, General & Internal
SC Medical Informatics; General & Internal Medicine
GA NE7RG
UT WOS:000562799500013
PM 32835201
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Luccarelli, J
   Fernandez-Robles, C
   Fernandez-Robles, C
   Horvath, RJ
   Berg, S
   McCoy, TH
   Seiner, SJ
   Henry, ME
AF Luccarelli, James
   Fernandez-Robles, Claudia
   Fernandez-Robles, Carlos
   Horvath, Ryan J.
   Berg, Sheri
   McCoy, Thomas H.
   Seiner, Stephen J.
   Henry, Michael E.
TI Modified Anesthesia Protocol for Electroconvulsive Therapy Permits
   Reduction in Aerosol-Generating Bag-Mask Ventilation during the COVID-19
   Pandemic
SO PSYCHOTHERAPY AND PSYCHOSOMATICS
LA English
DT Article
DE General anesthesia; Mechanical ventilation; COVID-19; Cohort studies;
   Electroconvulsive therapy
ID OXYGEN-SATURATION; HYPERVENTILATION; PREOXYGENATION; MANAGEMENT;
   MORTALITY; BENEFITS; ECT
AB Introduction:Electroconvulsive therapy (ECT) is a critical procedure in psychiatric treatment, but as typically delivered involves the use of bag-mask ventilation (BMV), which during the COVID-19 pandemic exposes patients and treatment staff to potentially infectious aerosols.Objective:To demonstrate the utility of a modified anesthesia protocol for ECT utilizing preoxygenation by facemask and withholding the use of BMV for only those patients who desaturate during the apneic period.Methods:This chart review study analyzes patients who were treated with ECT using both the traditional and modified anesthesia protocols.Results:A total of 106 patients were analyzed, of whom 51 (48.1%) required BMV using the new protocol. Of clinical factors, only patient BMI was significantly associated with the requirement for BMV. Mean seizure duration reduced from 52.0 +/- 22.4 to 46.6 +/- 17.1 s, but seizure duration was adequate in all cases. No acute physical, respiratory, or psychiatric complications occurred during treatment.Conclusions:A modified anesthesia protocol reduces the use of BMV by more than 50%, while retaining adequate seizure duration.
C1 [Luccarelli, James; Fernandez-Robles, Carlos; McCoy, Thomas H.; Henry, Michael E.] Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St Wacc 812, Boston, MA 02114 USA.
   [Luccarelli, James; Seiner, Stephen J.] McLean Hosp, Dept Psychiat, 115 Mill St, Belmont, MA 02178 USA.
   [Fernandez-Robles, Claudia] Yale Sch Med, Dept Anesthesiol, New Haven, CT USA.
   [Horvath, Ryan J.; Berg, Sheri] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Luccarelli, J (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St Wacc 812, Boston, MA 02114 USA.
EM jluccarelli@partners.org
OI Luccarelli, James/0000-0002-1606-3917
FU National Institute of Mental HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R25MH094612]
FX This work was supported by the National Institute of Mental Health
   (R25MH094612; J.L.). The funder had no role in the design and conduct of
   the study; collection, management, analysis, and interpretation of the
   data; preparation, review, or approval of the manuscript; and decision
   to submit the manuscript for publication.
CR A S A H M C M M A H Al E., 2010, HLTH TECHNOL ASSESS, V14
   Benumof JL, 1997, ANESTHESIOLOGY, V87, P979, DOI 10.1097/00000542-199710000-00034
   Bryson EO, 2017, ANESTH ANALG, V124, P1943, DOI 10.1213/ANE.0000000000001873
   Chan MTV, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18614-1
   COFFEY CE, 1995, BIOL PSYCHIAT, V37, P777, DOI 10.1016/0006-3223(95)00053-J
   Committ AP, 2001, PRACTICE ELECTROCONV
   de Arriba-Arnau A, 2017, J AFFECT DISORDERS, V217, P225, DOI 10.1016/j.jad.2017.04.007
   Driver BE, 2018, ANN EMERG MED, V71, P381, DOI 10.1016/j.annemergmed.2017.09.017
   Espinoza RT, 2020, J ECT
   Flexman AM, 2020, J NEUROSURG ANESTHES
   Gomez-Arnau J, 2018, GEN HOSP PSYCHIAT, V50, P54, DOI 10.1016/j.genhosppsych.2017.09.003
   Kimball D, 2011, WEST J EMERG MED, V12, P365, DOI 10.5811/westjem.2010.11.1922
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Linder JA, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05315-1
   Luccarelli J, 2020, BRAIN STIMUL, V13, P523, DOI 10.1016/j.brs.2019.12.007
   Mirzakhani H, 2016, ANESTH ANALG, V123, P587, DOI 10.1213/ANE.0000000000001218
   Munk-Olsen T, 2007, BRIT J PSYCHIAT, V190, P435, DOI 10.1192/bjp.bp.106.026740
   Nimmagadda U, 2017, ANESTH ANALG, V124, P507, DOI 10.1213/ANE.0000000000001589
   Nishihara F, 2003, J ECT, V19, P211, DOI 10.1097/00124509-200312000-00006
   PANDE AC, 1990, BIOL PSYCHIAT, V27, P799, DOI 10.1016/0006-3223(90)90597-U
   Sackeim HA, 2017, JAMA PSYCHIAT, V74, P779, DOI 10.1001/jamapsychiatry.2017.1670
   Saito S, 2003, J ECT, V19, P26, DOI 10.1097/00124509-200303000-00006
   Sienaert P, 2020, AM J GERIATR PSYCHIA
   Slade EP, 2017, JAMA PSYCHIAT, V74, P798, DOI 10.1001/jamapsychiatry.2017.1378
   Sriganesh K, 2018, J NEUROSURG ANESTH, V30, P314, DOI 10.1097/ANA.0000000000000456
   Surve Rohini, 2015, J Anaesthesiol Clin Pharmacol, V31, P99, DOI 10.4103/0970-9185.150555
   SWINDELLS SR, 1987, BRIT J PSYCHIAT, V150, P695, DOI 10.1192/bjp.150.5.695
   Torring N, 2017, ACTA PSYCHIAT SCAND, V135, P388, DOI 10.1111/acps.12721
   van Doremalen N, 2020, N ENGL J MED
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
   Zhu Y, 2019, EUR J ANAESTH, V36, P309, DOI 10.1097/EJA.0000000000000944
NR 32
TC 1
Z9 1
U1 3
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0033-3190
EI 1423-0348
J9 PSYCHOTHER PSYCHOSOM
JI Psychother. Psychosom.
PD AUG
PY 2020
VL 89
IS 5
BP 314
EP 319
DI 10.1159/000509113
PG 6
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA NE9KE
UT WOS:000562921500005
PM 32554959
DA 2021-01-01
ER

PT J
AU Montaner, J
   Barragan-Prieto, A
   Perez-Sanchez, S
   Escudero-Martinez, I
   Moniche, F
   Sanchez-Miura, JA
   Ruiz-Bayo, L
   Gonzalez, A
AF Montaner, Joan
   Barragan-Prieto, Ana
   Perez-Sanchez, Soledad
   Escudero-Martinez, Irene
   Moniche, Francisco
   Sanchez-Miura, Jose Antonio
   Ruiz-Bayo, Lidia
   Gonzalez, Alejandro
TI Break in the Stroke Chain of Survival due to COVID-19
SO STROKE
LA English
DT Article
DE acute disease; coronavirus; diagnosis; pandemics; reperfusion; stroke
AB Background and Purpose: Emergency measures to treat patients with coronavirus disease 2019 (COVID-19) and contain the outbreak is the main priority in each of our hospitals; however, these measures are likely to result in collateral damage among patients with other acute diseases. Here, we investigate whether the COVID-19 pandemic affects acute stroke care through interruptions in the stroke chain of survival. Methods: A descriptive analysis of acute stroke care activity before and after the COVID-19 outbreak is given for a stroke network in southern Europe. To quantify the impact of the pandemic, the number of stroke code activations, ambulance transfers, consultations through telestroke, stroke unit admissions, and reperfusion therapy times and rates are described in temporal relationship with the rising number of COVID-19 cases in the region. Results: Following confinement of the population, our stroke unit activity decreased sharply, with a 25% reduction in admitted cases (mean number of 58 cases every 15 days in previous months to 44 cases in the 15 days after the outbreak,P<0.001). Consultations to the telestroke network declined from 25 every 15 days before the outbreak to 7 after the outbreak (P<0.001). The increasing trend in the prehospital diagnosis of stroke activated by 911 calls stopped abruptly in the region, regressing to 2019 levels. The mean number of stroke codes dispatched to hospitals decreased (78% versus 57%,P<0.001). Time of arrival from symptoms onset to stroke units was delayed >30 minutes, reperfusion therapy cases fell, and door-to-needle time started 16 minutes later than usual. Conclusions: The COVID-19 pandemic is disruptive for acute stroke pathways. Bottlenecks in the access and delivery of patients to our secured stroke centers are among the main challenges. It is critical to encourage patients to continue seeking emergency care if experiencing acute stroke symptoms and to ensure that emergency professionals continue to use stroke code activation and telestroke networks.
C1 [Montaner, Joan; Barragan-Prieto, Ana; Perez-Sanchez, Soledad; Sanchez-Miura, Jose Antonio; Ruiz-Bayo, Lidia] Hosp Univ Virgen Macarena, Dept Neurol, Seville, Spain.
   [Montaner, Joan; Gonzalez, Alejandro] Inst Biomed Sevilla IBiS, Neurovasc Res Lab, Vall Hebron Inst Res VHIR, Barcelona, Spain.
   [Escudero-Martinez, Irene; Moniche, Francisco] Hosp Univ Virgen Rocio, Dept Neurol, Seville, Spain.
   [Gonzalez, Alejandro] Hosp Univ Virgen Rocio, Dept Radiol, Intervent Neuroradiol, Seville, Spain.
   [Sanchez-Miura, Jose Antonio] Seville Crit Care & Emergency Unit, Seville, Spain.
RP Montaner, J (corresponding author), Univ Seville, Hosp Univ Virgen Rocio, Neurovasc Res Grp, Inst Biomed Seville,IBiS,CSIC, Av Manuel Siurot S-N, Seville 41013, Spain.
EM jmontaner-ibis@us.es
RI IBiS, Neurovascular/P-5842-2016; Montaner, Joan/D-3063-2015; Prieto, Ana
   Barragan/AAV-1034-2020; Gonzalez, Alejandro/F-2241-2015
OI IBiS, Neurovascular/0000-0001-9511-0672; Montaner,
   Joan/0000-0003-4845-2279; Gonzalez, Alejandro/0000-0003-0373-7780;
   Barragan Prieto, Ana/0000-0002-9348-4643
FU Spanish Neurovascular Disease Research Network (INVICTUS+)
   [RD16/0019/0015]
FX The Neurovascular Research Group is part of the Spanish Neurovascular
   Disease Research Network (INVICTUS+, RD16/0019/0015).
CR [Anonymous], 2020, STROKE, DOI [DOI 10.1161/STR0KEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bustamante A, 2017, STROKE, V48, P2419, DOI 10.1161/STROKEAHA.117.017076
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Gonzalez-Pinto T, 2020, EUR J NEUROL, V27, pE35, DOI 10.1111/ene.14286
   Khosravani H, 2020, STROKE, V51, P1891, DOI 10.1161/STROKEAHA.120.029838
   Lee SY, 2019, YONSEI MED J, V60, P796, DOI 10.3349/ymj.2019.60.8.796
   Legido-Quigley H, 2020, LANCET PUBLIC HEALTH, V5, pE251, DOI 10.1016/S2468-2667(20)30060-8
   Qureshi AI, 2020, INT J STROKE, V15, P540, DOI 10.1177/1747493020923234
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   World Health Organization, COR DIS COVID 2019 S
   Zhao J, 2020, STROKE, V51, P1356, DOI 10.1161/STROKEAHA.120.029701
NR 12
TC 12
Z9 12
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD AUG
PY 2020
VL 51
IS 8
BP 2307
EP 2314
DI 10.1161/STROKEAHA.120.030106
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA NE6ZZ
UT WOS:000562751900032
PM 32466738
OA Green Published
DA 2021-01-01
ER

PT J
AU Diegoli, H
   Magalhaes, PSC
   Martins, SCO
   Moro, CHC
   Franca, PHC
   Safanelli, J
   Nagel, V
   Venancio, VG
   Liberato, RB
   Longo, AL
AF Diegoli, Henrique
   Magalhaes, Pedro S. C.
   Martins, Sheila C. O.
   Moro, Carla H. C.
   Franca, Paulo H. C.
   Safanelli, Juliana
   Nagel, Vivian
   Venancio, Vanessa G.
   Liberato, Rafaela B.
   Longo, Alexandre L.
TI Decrease in Hospital Admissions for Transient Ischemic Attack, Mild, and
   Moderate Stroke During the COVID-19 Era
SO STROKE
LA English
DT Article
DE coronavirus; epidemiology; health services research; incidence;
   subarachnoid hemorrhage
ID GLOBAL BURDEN; JOINVILLE; MORTALITY; OUTBREAK; TRENDS; CARE
AB Background and Purpose: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, doctors and public authorities have demonstrated concern about the reduction in quality of care for other health conditions due to social restrictions and lack of resources. Using a population-based stroke registry, we investigated the impact of the onset of the COVID-19 pandemic in stroke admissions in Joinville, Brazil. Methods: Patients admitted after the onset of COVID-19 restrictions in the city (defined as March 17, 2020) were compared with those admitted in 2019. We analyzed differences between stroke incidence, types, severity, reperfusion therapies, and time from stroke onset to admission. Statistical tests were also performed to compare the 30 days before and after COVID-19 to the same period in 2019. Results: We observed a decrease in total stroke admissions from an average of 12.9/100 000 per month in 2019 to 8.3 after COVID-19 (P=0.0029). When compared with the same period in 2019, there was a 36.4% reduction in stroke admissions. There was no difference in admissions for severe stroke (National Institutes of Health Stroke Scale score >8), intraparenchymal hemorrhage, and subarachnoid hemorrhage. Conclusions: The onset of COVID-19 was correlated with a reduction in admissions for transient, mild, and moderate strokes. Given the need to prevent the worsening of symptoms and the occurrence of medical complications in these groups, a reorganization of the stroke-care networks is necessary to reduce collateral damage caused by COVID-19.
C1 [Diegoli, Henrique; Magalhaes, Pedro S. C.; Moro, Carla H. C.; Longo, Alexandre L.] Hosp Sao Jose, Stroke Unit, 488 Dr Placido Olimpio Oliveira St, BR-89202165 Joinville, SC, Brazil.
   [Martins, Sheila C. O.] Hosp Moinhos Vento, Dept Neurol, Porto Alegre, RS, Brazil.
   [Franca, Paulo H. C.] Univ Regiao Joinville Univille, Postgrad Program Hlth & Environm, Joinville, SC, Brazil.
   [Safanelli, Juliana; Nagel, Vivian; Venancio, Vanessa G.; Liberato, Rafaela B.] Joinville Stroke Registry, Joinville, SC, Brazil.
RP Diegoli, H (corresponding author), Hosp Sao Jose, Stroke Unit, 488 Dr Placido Olimpio Oliveira St, BR-89202165 Joinville, SC, Brazil.
EM henrique.diegoli@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469; Diegoli,
   Henrique/0000-0002-3970-019X
FU Health Secretariat in Joinville
FX All data were obtained from the Joinville Stroke Registry, which is
   funded by the Health Secretariat in Joinville.
CR [Anonymous], CID EST JOINV
   [Anonymous], 2020, STROKE, V51, P1910, DOI [DOI 10.1161/STROKEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   Bersano A, 2020, NEUROLOGY, V94, P905, DOI 10.1212/WNL.0000000000009508
   Cabral NL, 2009, J NEUROL NEUROSUR PS, V80, P749, DOI 10.1136/jnnp.2008.164475
   Cabral NL, 2016, NEUROEPIDEMIOLOGY, V46, P273, DOI 10.1159/000445060
   Camara dos Deputados do Brasil, 2020, MED PROV 926 2020
   Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413
   Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4
   Governo do Estado de Santa Catarina, 2020, AT EST SANT CAT
   Instituto Brasileiro de Geografia e Estatistica (IBGE), POP BRAS
   Lavallee PC, 2007, LANCET NEUROL, V6, P953, DOI 10.1016/S1474-4422(07)70248-X
   Lee KK, 2018, J STROKE, V20, P2, DOI 10.5853/jos.2017.02894
   Lee SY, 2019, YONSEI MED J, V60, P796, DOI 10.3349/ymj.2019.60.8.796
   Mandelzweig L, 2006, STROKE, V37, P1248, DOI 10.1161/01.STR.0000217200.61167.39
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314
   Ministerio da Saude do Brasil, 2020, PAIN COR
   Morelli N, 2020, EUR NEUROL, V83, P213, DOI 10.1159/000507666
   Rothwell PM, 2007, LANCET, V370, P1432, DOI 10.1016/S0140-6736(07)61448-2
   Royal College of Physicians and National Health Service England, 2020, CLIN GUID MAN STROK
   Secretaria da Saude de Joinville, 2020, DAD CAS COR MUN JOIN
   Secretaria da Saude de Joinville, 2020, AT OF COR MUN JOINV
   Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550
   Supremo Tribunal Federal, 2020, MED CAUT ACELAR ACAO
   THORNTON J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1406
   Worp B, LIKELY INCREASE RISK
NR 26
TC 12
Z9 12
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD AUG
PY 2020
VL 51
IS 8
BP 2315
EP 2321
DI 10.1161/STROKEAHA.120.030481
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA NE6ZZ
UT WOS:000562751900033
PM 32530738
OA Green Published
DA 2021-01-01
ER

PT J
AU Hajdu, SD
   Pittet, V
   Puccinelli, F
   Ben Hassen, W
   Ben Maacha, M
   Blanc, R
   Bracco, S
   Broocks, G
   Bartolini, B
   Casseri, T
   Clarencon, F
   Naggara, O
   Eugene, F
   Ferre, JC
   Guedon, A
   Houdart, E
   Krings, T
   Lehmann, P
   Limbucci, N
   Machi, P
   Macho, J
   Mandruzzato, N
   Nappini, S
   Nawka, MT
   Nicholson, P
   Marto, JP
   Pereira, V
   Correia, MA
   Pinho-e-Melo, T
   Ramos, JN
   Raz, E
   Ferreira, P
   Reis, J
   Shapiro, M
   Shotar, E
   van Horn, N
   Piotin, M
   Saliou, G
AF Hajdu, Steven D.
   Pittet, Valerie
   Puccinelli, Francesco
   Ben Hassen, Wagih
   Ben Maacha, Malek
   Blanc, Raphael
   Bracco, Sandra
   Broocks, Gabriel
   Bartolini, Bruno
   Casseri, Tommaso
   Clarencon, Frederic
   Naggara, Olivier
   Eugene, Francois
   Ferre, Jean-Christophe
   Guedon, Alexis
   Houdart, Emmanuel
   Krings, Timo
   Lehmann, Pierre
   Limbucci, Nicola
   Machi, Paolo
   Macho, Juan
   Mandruzzato, Nicolo
   Nappini, Sergio
   Nawka, Marie Teresa
   Nicholson, Patrick
   Marto, Joao Pedro
   Pereira, Vitor
   Correia, Manuel A.
   Pinho-e-Melo, Teresa
   Nuno Ramos, Joao
   Raz, Eytan
   Ferreira, Patricia
   Reis, Joao
   Shapiro, Maksim
   Shotar, Eimad
   van Horn, Noel
   Piotin, Michel
   Saliou, Guillaume
TI Acute Stroke Management During the COVID-19 Pandemic Does Confinement
   Impact Eligibility for Endovascular Therapy?
SO STROKE
LA English
DT Article
DE COVID-19; goal; groin; pandemic; standard of care
ID GUIDELINES
AB During the coronavirus disease 2019 (COVID-19) pandemic, the World Health Organization recommended measures to mitigate the outbreak such as social distancing and confinement. Since these measures have been put in place, anecdotal reports describe a decrease in the number of endovascular therapy (EVT) treatments for acute ischemic stroke due to large vessel occlusion. The purpose of our study was to determine the effect on EVT for patients with acute ischemic stroke during the COVID-19 confinement. In this retrospective, observational study, data were collected from November 1, 2019, to April 15, 2020, at 17 stroke centers in countries where confinement measures have been in place since March 2020 for the COVID-19 pandemic (Switzerland, Italy, France, Spain, Portugal, Germany, Canada, and United States). This study included 1600 patients treated by EVT for acute ischemic stroke. Date of EVT and symptom onset-to-groin puncture time were collected. Mean number of EVTs performed per hospital per 2-week interval and mean stroke onset-to-groin puncture time were calculated before confinement measures and after confinement measures. Distributions (non-normal) between the 2 groups (before COVID-19 confinement versus after COVID-19 confinement) were compared using 2-sample Wilcoxon rank-sum test. The results show a significant decrease in mean number of EVTs performed per hospital per 2-week interval between before COVID-19 confinement (9.0 [95% CI, 7.8-10.1]) and after COVID-19 confinement (6.1 [95% CI, 4.5-7.7]), (P<0.001). In addition, there is a significant increase in mean stroke onset-to-groin puncture time (P<0.001), between before COVID-19 confinement (300.3 minutes [95% CI, 285.3-315.4]) and after COVID-19 confinement (354.5 minutes [95% CI, 316.2-392.7]). Our preliminary analysis indicates a 32% reduction in EVT procedures and an estimated 54-minute increase in symptom onset-to-groin puncture time after confinement measures for COVID-19 pandemic were put into place.
C1 [Hajdu, Steven D.; Puccinelli, Francesco; Bartolini, Bruno; Saliou, Guillaume] Lausanne Univ Hosp, Dept Intervent & Diagnost Radiol, Rue Bugnon 47, CH-1011 Lausanne, Switzerland.
   [Pereira, Vitor] Univ Lausanne, Ctr Primary Care & Publ Hlth, Lausanne, Switzerland.
   [Ben Hassen, Wagih; Naggara, Olivier] St Anne Hosp, Dept Neuroradiol, Paris, France.
   [Ben Maacha, Malek; Blanc, Raphael; Machi, Paolo] Fondat Rothschild Hosp, Intervent Neuroradiol, Paris, France.
   [Bracco, Sandra; Casseri, Tommaso] Univ Hosp Siena, Unit Neuroimaging & Neurointervent, Siena, Italy.
   [Broocks, Gabriel; Nawka, Marie Teresa; van Horn, Noel] Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Neuroradiol, Hamburg, Germany.
   [Clarencon, Frederic; Shotar, Eimad] Hop La Pitie Salpetriere, Dept Neuroradiol, Paris, France.
   [Eugene, Francois; Ferre, Jean-Christophe] Ctr Hosp Univ Rennes, Dept Neuroradiol, Rennes, France.
   [Guedon, Alexis; Houdart, Emmanuel] Lariboisiere Hosp, Dept Neuroradiol, Paris, France.
   [Krings, Timo; Nicholson, Patrick; Pereira, Vitor] Toronto Western Hosp, Joint Dept Med Imaging, Div Neuroradiol, Toronto, ON, Canada.
   [Lehmann, Pierre] Marseille Hosp, Dept Neuroradiol, Marseille, France.
   [Limbucci, Nicola; Nappini, Sergio] Careggi Univ Hosp, Dept Intervent Neuroradiol, Florence, Italy.
   [Machi, Paolo; Mandruzzato, Nicolo] Geneva Univ Hosp, Serv Diagnost & Intervent Neuroradiol, Geneva, Switzerland.
   [Macho, Juan] Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain.
   [Marto, Joao Pedro; Nuno Ramos, Joao] Hosp Egas Moniz, Ctr Hosp Lisboa Ocidental, Dept Neurol, Lisbon, Portugal.
   [Marto, Joao Pedro; Nuno Ramos, Joao] Hosp Egas Moniz, Ctr Hosp Lisboa Ocidental, Dept Neuroradiol, Lisbon, Portugal.
   [Correia, Manuel A.; Pinho-e-Melo, Teresa] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Dept Neurol, Lisbon, Portugal.
   [Correia, Manuel A.; Pinho-e-Melo, Teresa] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Dept Neuroradiol, Lisbon, Portugal.
   [Raz, Eytan; Shapiro, Maksim] Hosp Sao Jose, Ctr Hosp Lisboa Cent Lisbon, NYU Langone Hlth New York, Lisbon, Portugal.
   [Ferreira, Patricia; Reis, Joao] Hosp Sao Jose, Ctr Hosp Lisboa Cent Lisbon, Stroke Unit, Lisbon, Portugal.
   [Ferreira, Patricia; Reis, Joao] Hosp Sao Jose, Ctr Hosp Lisboa Cent Lisbon, Dept Neuroradiol, Lisbon, Portugal.
RP Hajdu, SD (corresponding author), Lausanne Univ Hosp, Dept Intervent & Diagnost Radiol, Rue Bugnon 47, CH-1011 Lausanne, Switzerland.
EM steven.hajdu@chuv.ch
RI Hassen, Wagih Ben/ABH-8248-2020; van Horn, Noel/AAW-5274-2020; Eugene,
   Francois/ABD-5110-2020
OI van Horn, Noel/0000-0001-5764-1982; NAPPINI, Sergio/0000-0002-2607-5815
CR [Anonymous], 2020, STROKE, V51, P1910, DOI [DOI 10.1161/STROKEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Maas MB, 2013, J STROKE CEREBROVASC, V22, P241, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.004
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Rodriguez-Leor O, 2020, REC INTERV CARDIOL, V2, P82, DOI DOI 10.24875/RECIC.M20000120
   Sebastian S, 2019, STROKE, V50, P2216, DOI 10.1161/STROKEAHA.119.025872
   Turc G, 2019, EUR STROKE J, V4, P6, DOI 10.1177/2396987319832140
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
NR 12
TC 4
Z9 4
U1 6
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD AUG
PY 2020
VL 51
IS 8
BP 2593
EP 2596
DI 10.1161/STROKEAHA.120.030794
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA NE6ZZ
UT WOS:000562751900069
PM 32716828
OA Green Published
DA 2021-01-01
ER

PT J
AU Barcelo, D
AF Barcelo, Damia
TI An environmental and health perspective for COVID-19 outbreak:
   Meteorology and air quality influence, sewage epidemiology indicator,
   hospitals disinfection, drug therapies and recommendations
SO JOURNAL OF ENVIRONMENTAL CHEMICAL ENGINEERING
LA English
DT Article
DE COVID-19; Air quality index; Meteorological conditions; Sewage
   epidemiology; Hospital disinfection; Drug therapies
AB This Opinion Paper wishes to provide a summary of recent findings and solutions for a better understanding of the environmental and health problems associated with COVID-19. The list of topics covered is large: meteorology and air quality factors with correlation number of infections, sewage waters as a way to reveal the scale of COVID-19 outbreak, current hospital disinfection procedures and new eco-friendly technologies and list of drug therapies recommend waiting for the desired vaccine to come. During the last two months we did notice an increase in the scientific literature regarding COVID-19 with a partial vision of this problem. The current Opinion Paper is one of the first attempts, to my understanding, to summarize and integrate environmental and human health aspects related to the monitoring, fate and treatment solutions for COVID-19. That being said I believe that this Opinion Paper can serve as multipurpose document, not only for scientists of different disciplines but for social media and citizens in general.
C1 [Barcelo, Damia] IDAEA CSIC, Dept Environm Chem, Water & Soil Qual Res Grp, C Jordi Girona 18-26, Barcelona 08034, Spain.
   [Barcelo, Damia] Catalan Inst Water Res ICRA, C Emili Grahit 101, Girona 17003, Spain.
   [Barcelo, Damia] Zhejiang A&F Univ, Coll Environm & Resources Sci, Hangzhou 311300, Peoples R China.
RP Barcelo, D (corresponding author), IDAEA CSIC, Dept Environm Chem, Water & Soil Qual Res Grp, C Jordi Girona 18-26, Barcelona 08034, Spain.
EM dbcqam@cid.csic.es
CR Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Casanova L, 2009, WATER RES, V43, P1893, DOI 10.1016/j.watres.2009.02.002
   Coccia M, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138474
   Conticini E, 2020, ENVIRON POLLUT, V261, DOI 10.1016/j.envpol.2020.114465
   Daughton C, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138149
   Fu LF, 2020, SCI TOTAL ENVIRON, V722, DOI 10.1016/j.scitotenv.2020.137895
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerba CP, 2017, WATER RES, V108, P25, DOI 10.1016/j.watres.2016.11.020
   Gil-Santos Eduardo, 2020, NAT NANOTECHNOL, DOI [10.1038/s41565-020-0672-yh.tt, DOI 10.1038/S41565-020-0672-YH.TT]
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hart OE, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138875
   Hoogeveen MJ, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138543
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lai ACK, 2018, J HAZARD MATER, V358, P389, DOI 10.1016/j.jhazmat.2018.07.003
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lisa M., 2015, ENVIRON SCI TECH LET, V2, P76
   Mao K, 2020, ENVIRON SCI TECHNOL, V54, P3733, DOI 10.1021/acs.est.0c01174
   Medema G., 2020, PRESENCE SARS CORONA, DOI [10.1101/2020.03.29, DOI 10.1101/2020.03.29]
   Nunez-Delgado A, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138647
   Ogen Y, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138605
   Qu GB, 2020, ENVIRON SCI TECHNOL, V54, P3730, DOI 10.1021/acs.est.0c01102
   Rowan NJ, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138532
   Sasan Faridi, 2020, SCI TOTAL ENVIRON, V725
   Tobias A, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138540
   Tosepu R, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138436
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wurtzer S, 2020, TIME COURSE QUANTITA, DOI [10.1101/2020.04.12.20062679, DOI 10.1101/2020.04.12.20062679]
   Yang Y, 2020, INFECT CONT HOSP EP, V41, P872, DOI 10.1017/ice.2020.97
   Ye YY, 2016, ENVIRON SCI TECHNOL, V50, P5077, DOI 10.1021/acs.est.6b00876
   Zhang C, 2019, CHEM ENG J, V355, P399, DOI 10.1016/j.cej.2018.08.158
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou Y., 2020, SCI TOTAL ENVIRON, V724
NR 32
TC 15
Z9 15
U1 22
U2 50
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2213-3437
J9 J ENVIRON CHEM ENG
JI J. Environ. Chem. Eng.
PD AUG
PY 2020
VL 8
IS 4
AR 104006
DI 10.1016/j.jece.2020.104006
PG 4
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA ND7IQ
UT WOS:000562077000018
PM 32373461
OA Green Published
DA 2021-01-01
ER

PT J
AU Rathod, S
   Dubey, A
   Bashir, B
   Sivananthan, G
   Leylek, A
   Chowdhury, A
   Koul, R
AF Rathod, Shrinivas
   Dubey, Arbind
   Bashir, Bashir
   Sivananthan, Gokulan
   Leylek, Ahmet
   Chowdhury, Amitava
   Koul, Rashmi
TI Bracing for impact with new 4R's in the COVID-19 pandemic - A provincial
   thoracic radiation oncology consensus
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
DE Lung cancer; COVID-19
ID CELL LUNG-CANCER; PROPHYLACTIC CRANIAL IRRADIATION; RANDOMIZED-TRIAL;
   OPEN-LABEL; STAGE-I; RADIOTHERAPY; PHASE-3; CHEMOTHERAPY; THERAPY
AB As COVID-19 pandemic continues to explode, cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic radiation regimen in a Canadian province with 4 new R's of COVID era. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Rathod, Shrinivas; Dubey, Arbind; Bashir, Bashir; Leylek, Ahmet; Chowdhury, Amitava; Koul, Rashmi] CancerCare Manitoba, Winnipeg, MB, Canada.
   [Rathod, Shrinivas; Dubey, Arbind; Bashir, Bashir; Leylek, Ahmet; Chowdhury, Amitava; Koul, Rashmi] Univ Manitoba, Winnipeg, MB, Canada.
   [Sivananthan, Gokulan] Western Manitoba Canc Ctr, Brandon, MB, Canada.
RP Rathod, S (corresponding author), CancerCare Manitoba, Winnipeg, MB, Canada.; Rathod, S (corresponding author), Univ Manitoba, Winnipeg, MB, Canada.
EM srathod@cancercare.mb.ca
CR Achard V, 2020, INT J RAD ONCOL BIOL
   Bezjak A, 2019, J CLIN ONCOL, V37, P1316, DOI 10.1200/JCO.18.00622
   Bradley JD, 2020, J CLIN ONCOL, V38, P706, DOI 10.1200/JCO.19.01162
   De Ruysscher D, 2016, ANN ONCOL, V27, P1818, DOI 10.1093/annonc/mdw263
   Faivre-Finn C, 2017, LANCET ONCOL, V18, P1116, DOI 10.1016/S1470-2045(17)30318-2
   Filippi AR, 2020, INT J RAD ONCOL BIOL
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Krengli M, 2020, ADV RAD ONCOL
   Le Pechoux C, 2009, LANCET ONCOL, V10, P467, DOI 10.1016/S1470-2045(09)70101-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336
   Rathod S, 2017, INT J RADIAT ONCOL, V99, pS103, DOI 10.1016/j.ijrobp.2017.06.246
   Rathod S, 2019, EUR J CANCER, V110, P110, DOI 10.1016/j.ejca.2019.01.003
   Rathod S, 2019, AM J CLIN ONCOL-CANC, V42, P123, DOI 10.1097/COC.0000000000000489
   Rivera AON, 2020, ADV RAD ONCOL
   Rodrigues G, 2011, PRACT RADIAT ONCOL, V1, P60, DOI 10.1016/j.prro.2011.01.005
   Simcock R, 2020, CLIN TRANSL RAD ONCO
   Slotman B, 2007, NEW ENGL J MED, V357, P664, DOI 10.1056/NEJMoa071780
   Slotman BJ, 2015, LANCET, V385, P36, DOI 10.1016/S0140-6736(14)61085-0
   Stahl JM, 2017, LUNG CANCER, V103, P11, DOI 10.1016/j.lungcan.2016.11.009
   Stevens R, 2015, COCHRANE DB SYST REV, P1, DOI 10.1002/14651858.CD002143.pub4
   Swaminath A, 2017, CLIN LUNG CANCER, V18, P250, DOI 10.1016/j.cllc.2016.08.002
   Takahashi T, 2017, LANCET ONCOL, V18, P663, DOI 10.1016/S1470-2045(17)30230-9
   Timmerman RD, 2018, JAMA ONCOL, V4, P1263, DOI 10.1001/jamaoncol.2018.1251
   Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403
   Videtic GM, 2019, INT J RADIAT ONCOL, V103, P1077, DOI 10.1016/j.ijrobp.2018.11.051
NR 26
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD AUG
PY 2020
VL 149
BP 124
EP 127
DI 10.1016/j.radonc.2020.03.045
PG 4
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA ND2JN
UT WOS:000561731500027
PM 32342864
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kirsch, DG
   Diehn, M
   Cucinotta, FA
   Weichselbaum, R
AF Kirsch, David G.
   Diehn, Maximilian
   Cucinotta, Francis A.
   Weichselbaum, Ralph
TI Response Letter: Radiation therapy for COVID-19 pneumopathy
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
C1 [Kirsch, David G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA.
   [Kirsch, David G.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA.
   [Diehn, Maximilian] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA.
   [Diehn, Maximilian] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
   [Diehn, Maximilian] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.
   [Cucinotta, Francis A.] Univ Nevada, Dept Hlth Phys & Diagnost Sci, Las Vegas, NV 89154 USA.
   [Weichselbaum, Ralph] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.
RP Kirsch, DG (corresponding author), Duke Univ, Med Ctr, DUMC Box 91006, Durham, NC 27708 USA.
EM david.kirsch@duke.edu
RI Cucinotta, Francis/AAZ-5941-2020
OI Diehn, Maximilian/0000-0003-2032-0581
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   BAYLIN GJ, 1946, AM J ROENTGENOL, V55, P473
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Kirkby C, 2020, RADIOTHER ONCOL
   Kirsch DG, 2020, RADIOTHER ONCOL
   Oppenheimer A, 1943, AM J ROENTGENOL RADI, V49, P635
   Rockx B., 2020, SCIENCE
   Salomaa S, 2020, INT J RADIAT BIOL, V96, P1224, DOI 10.1080/09553002.2020.1762020
   Trott KR, 2020, RADIOTHER ONCOL
NR 9
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD AUG
PY 2020
VL 149
BP 238
EP 239
DI 10.1016/j.radonc.2020.05.048
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA ND2JN
UT WOS:000561731500044
PM 32505722
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abdullah, A
   Neurath, MF
   Atreya, R
AF Abdullah, Abdullah
   Neurath, Markus F.
   Atreya, Raja
TI Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis
   Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral
   Hyperinflammatory Response and Avoid Aggravated Outcomes?
SO VISCERAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Ulcerative colitis; Infliximab; Anti-TNF antibody;
   Cytokine storm
ID ALPHA; INHIBITION
AB The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, represents a potentially major challenge to patients with immune-mediated inflammatory diseases who are treated with immunomodulatory therapies. We report the case of an 18-year-old ulcerative colitis patient in sustained clinical remission who 4 days after application of her ongoing therapy with the anti-TNF antibody infliximab developed mild respiratory and abdominal symptoms. The patient was subsequently diagnosed with COVID-19 but did not need hospitalization. The clinical symptoms completely resolved within 1 week after onset and there was no change in ulcerative colitis activity. The recently applied anti-TNF therapy did not lead to exacerbation of the infectious symptoms. Current recommendations strongly favor continuation of effective maintenance anti-TNF therapy in inflammatory bowel disease patients, as there is no evidence for aggravated CO-VID-19 upon infection. It is unclear whether anti-TNF treatment might even have assisted in preventing worsening of COVID-19 and improving outcome. Further data in the group of immune-mediated inflammatory disease patients under anti-TNF therapy are urgently needed.
C1 [Abdullah, Abdullah; Neurath, Markus F.; Atreya, Raja] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Ulmenweg 18, DE-91054 Erlangen, Germany.
   [Abdullah, Abdullah; Neurath, Markus F.; Atreya, Raja] Deutsch Zentrum Immuntherapie, Erlangen, Germany.
RP Atreya, R (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Ulmenweg 18, DE-91054 Erlangen, Germany.
EM raja.atreya@uk-erlangen.de
FU DFGGerman Research Foundation (DFG) [SFB1181, SFB/TRR241]; German
   Research Foundation (DFG)German Research Foundation (DFG)
FX This study was supported by funding from DFG-SFB1181 (Project No. C02)
   (R. Atreya) and DFG-SFB/TRR241 (Project No. C02) (R. Atreya). The German
   Research Foundation (DFG) funds the Heisenberg Professorship of R.
   Atreya.
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Atreya R, 2014, NAT MED, V20, P313, DOI 10.1038/nm.3462
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, SECURE IBD DATABASE
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Leal RF, 2015, GUT, V64, P233, DOI 10.1136/gutjnl-2013-306518
   Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
   Kennedy NA, 2020, GUT
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI
   Neurath MF, 2020, GUT
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Schett G, 2020, NEW ENGL J MED, V20, P271, DOI DOI 10.1056/NEJMOA2002032
   Shi XL, 2013, CRIT CARE, V17, DOI 10.1186/cc13171
   Tursi A, 2020, GUT, V69, P1364, DOI 10.1136/gutjnl-2020-321240
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 28
TC 1
Z9 1
U1 2
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 2297-4725
EI 2297-475X
J9 VISC MED
JI Visc. Med.
PD AUG
PY 2020
VL 36
IS 4
BP 338
EP 342
DI 10.1159/000508740
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA ND6DH
UT WOS:000561987700013
PM 32999889
OA Green Published
DA 2021-01-01
ER

PT J
AU Sachdeva, M
   Uppal, NN
   Hirsch, JS
   Ng, JH
   Malieckal, D
   Fishbane, S
   Jhaveri, KD
AF Sachdeva, Mala
   Uppal, Nupur N.
   Hirsch, Jamie S.
   Ng, Jia H.
   Malieckal, Deepa
   Fishbane, Steven
   Jhaveri, Kenar D.
CA Northwell COVID-19 Res Consortium
   Northwell Nephrology COVID-19 Res
TI COVID-19 in Hospitalized Patients on Chronic Peritoneal Dialysis: A Case
   Series
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Coronavirus disease 2019; Nephrology; Peritoneal dialysis; End-stage
   kidney disease
AB Background:The COVID-19 pandemic has affected the end-stage kidney disease (ESKD) population, with high mortality rates reported among patients on hemodialysis. However, the degree to which it has affected the peritoneal dialysis (PD) population in the United States has not yet been elucidated. In this report, we describe the clinical characteristics, presentations, clinical course, and outcomes of ESKD patients on PD hospitalized with COVID-19.Methods:We describe the characteristics, presentation, and outcomes of adult ESKD patients on chronic PD hospitalized with CO-VID-19 in our 13 major hospitals in the NY health system using descriptive statistical analysis.Results:Of 419 hospitalized patients with ESKD, 11 were on chronic PD therapy (2.6%). Among those 11, 3 patients required mechanical ventilation, 2 of whom died. Of the entire cohort, 9 of the 11 patients (82%) were discharged alive. While fever was a common presentation, more than half of our patients also presented with diarrhea. Interestingly, 3 patients were diagnosed with culture-negative peritonitis during their hospitalization. Seven patients reported positive SARS-CoV-2 exposure from a member of their household.Conclusion:Hospitalized patients on PD with COVID-19 had a relatively mild course, and majority of them were discharged home.
C1 [Sachdeva, Mala; Uppal, Nupur N.; Hirsch, Jamie S.; Ng, Jia H.; Malieckal, Deepa; Fishbane, Steven; Jhaveri, Kenar D.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med, Div Kidney Dis & Hypertens, Great Neck, NY USA.
   [Hirsch, Jamie S.] Feinstein Inst Med Res, Inst Hlth Innovat & Outcomes Res, Manhasset, NY USA.
   [Hirsch, Jamie S.] Northwell Hlth, Dept Informat Serv, New Hyde Pk, NY USA.
RP Sachdeva, M (corresponding author), Northwell Hlth, Div Kidney Dis & Hypertens, Donald & Barbara Zucker Sch Med Hofstra Northwell, 100 Community Dr, Great Neck, NY 11021 USA.
EM msachdeva@northwell.edu
OI Jhaveri, Kenar D/0000-0003-1578-0524
CR Alberici F., 2020, KIDNEY INT
   Fisher M, 2020, KIDNEY360
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Valeri AM, 2020, J AM SOC NEPHROL, V31, P1409, DOI 10.1681/ASN.2020040470
   Vischini G, 2020, KIDNEY INT, V98, P237, DOI 10.1016/j.kint.2020.05.005
   Workbook, 2020, NYS COVID 19 TRACK
   Xiong F, 2020, J AM SOC NEPHROL, V31, P1387, DOI 10.1681/ASN.2020030354
NR 9
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
EI 1421-9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PD AUG
PY 2020
VL 51
IS 8
BP 669
EP 673
DI 10.1159/000510259
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA ND5TO
UT WOS:000561962400009
PM 32731215
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kong, Q
   Wu, Y
   Gu, Y
   Lv, Q
   Qi, FF
   Gong, SR
   Chen, XP
AF Kong, Qi
   Wu, Yue
   Gu, Yu
   Lv, Qi
   Qi, Feifei
   Gong, Shuran
   Chen, Xiuping
TI Analysis of the molecular mechanism of Pudilan (PDL) treatment for
   COVID-19 by network pharmacology tools
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE SARS-CoV-2 infection; COVID-19; Traditional Chinese herbs; Targeted
   therapy; Network pharmacology
ID INJURY
AB Background: Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified.
   Methods: We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform.
   Results: PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-gamma (IFN-gamma), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-beta 1 (TGF beta 1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate.
   Conclusion: PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.
C1 [Kong, Qi; Wu, Yue; Gu, Yu; Lv, Qi; Qi, Feifei; Gong, Shuran] Chinese Acad Med Sci CAMS, Inst Lab Anim Sci, 5 Panjiayuan Nanli, Beijing 100021, Peoples R China.
   [Kong, Qi; Wu, Yue; Gu, Yu; Lv, Qi; Qi, Feifei; Gong, Shuran] Chinese Minist Hlth, Peking Union Med Coll PUMC, Key Lab Human Dis Comparat Med,Comparat Med Ctr, Beijing Key Lab Anim Models Emerging & Reemerging, 5 Panjiayuan Nanli, Beijing 100021, Peoples R China.
   [Chen, Xiuping] Qingdao Univ, Med Coll, Qingdao 266071, Peoples R China.
RP Kong, Q (corresponding author), Chinese Acad Med Sci CAMS, Inst Lab Anim Sci, 5 Panjiayuan Nanli, Beijing 100021, Peoples R China.; Kong, Q (corresponding author), Chinese Minist Hlth, Peking Union Med Coll PUMC, Key Lab Human Dis Comparat Med,Comparat Med Ctr, Beijing Key Lab Anim Models Emerging & Reemerging, 5 Panjiayuan Nanli, Beijing 100021, Peoples R China.; Chen, XP (corresponding author), Qingdao Univ, Med Coll, Qingdao 266071, Peoples R China.
EM kongqi@cnilas.org; chenxiu0725@qq.com
OI Kong, Qi/0000-0003-2867-7382
FU CAMS Initiative for Innovative Medicine of China [2016-I2M-2-006];
   National Mega Projects of China for Major Infectious Diseases
   [2017ZX10304402]
FX This work was supported by the CAMS Initiative for Innovative Medicine
   of China (2016-I2M-2-006), and National Mega Projects of China for Major
   Infectious Diseases (2017ZX10304402).
CR Chen G., 2019, J CLIN INVEST, P2020
   Deng W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0176-0
   Dong L., 2020, SHANDONG MED, V60, P1
   Feng L, 2018, J ETHNOPHARMACOL, V214, P292, DOI 10.1016/j.jep.2017.07.009
   Guo X, 2020, MATH FDN COMPUT, V3, P263, DOI 10.3934/mfc.2020010
   H.P.H. Committee, 2020, EXP CONS NOV COR PNE
   Huang L, 2018, NUCLEIC ACIDS RES, V46, pD1117, DOI 10.1093/nar/gkx1028
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kong Q., 2020, MOL CANCER, P1
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Lim Y.X., 2016, DISEASES, V4
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tian G, 2020, BIOMED PHARMACOTHER, V124, DOI 10.1016/j.biopha.2020.109833
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Wang F., 2020, JCI INSIGHT
   Wang Lian-Xin, 2019, Zhongguo Zhong Yao Za Zhi, V44, P5277, DOI 10.19540/j.cnki.cjcmm.20191105.501
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Yang N, 2016, INT IMMUNOPHARMACOL, V34, P92, DOI 10.1016/j.intimp.2016.02.028
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Zhai XT, 2016, J ETHNOPHARMACOL, V194, P153, DOI 10.1016/j.jep.2016.09.013
   Zhang D, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104882
   Zhong YX, 2012, VIRUSES-BASEL, V4, P980, DOI 10.3390/v4060980
NR 31
TC 6
Z9 6
U1 11
U2 12
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD AUG
PY 2020
VL 128
AR 110316
DI 10.1016/j.biopha.2020.110316
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA ND2MV
UT WOS:000561740200009
PM 32505821
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Fantini, J
   Chahinian, H
   Yahi, N
AF Fantini, Jacques
   Chahinian, Henri
   Yahi, Nouara
TI Synergistic antiviral effect of hydroxychloroquine and azithromycin in
   combination against SARS-CoV-2: What molecular dynamics studies of
   virus-host interactions reveal
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Coronavirus; Pandemic; SARS-CoV-2; Ganglioside; Azithromycin;
   Chloroquine
ID MEMBRANE MICRODOMAINS; CORONAVIRUS; PROTEIN; SPIKE; GLYCOSPHINGOLIPIDS;
   IDENTIFICATION; COMPLEX; ENTRY; HIV-1
AB The emergence of SARS-coronavirus-2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19). Hydroxychloroquine (CLQ-OH)/azithromycin (ATM) combination therapy is currently being tested for the treatment of COVID-19, with promising results. However, the molecular mechanism of action of this combination is not yet established. Using molecular dynamics (MD) simulations, this study shows that the drugs act in synergy to prevent any close contact between the virus and the plasma membrane of host cells. Unexpected molecular similarity is shown between ATM and the sugar moiety of GM1, a lipid raft ganglioside acting as a host attachment cofactor for respiratory viruses. Due to this mimicry, ATM interacts with the ganglioside-binding domain of SARS-CoV-2 spike protein. This binding site shared by ATM and GM1 displays a conserved amino acid triad Q-134/F-135/N137 located at the tip of the spike protein. CLQ-OH molecules are shown to saturate virus attachment sites on gangliosides in the vicinity of the primary coronavirus receptor, angiotensin-converting enzyme2 (ACE-2). Taken together, these data show that ATM is directed against the virus, whereas CLQ-OH is directed against cellular attachment cofactors. We conclude that both drugs act as competitive inhibitors of SARS-CoV-2 attachment to the host-cell membrane. This is consistent with a synergistic antiviral mechanism at the plasma membrane level, where therapeutic intervention is likely to be most efficient. This molecular mechanism may explain the beneficial effects of CLQ-OH/ATM combination therapy in patients with COVID-19. Incidentally, the data also indicate that the conserved Q-134/F-135/N-137 triad could be considered as a target for vaccine strategies. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Fantini, Jacques] INSERM, UMR S 1072, F-13015 Marseille, France.
   [Chahinian, Henri; Yahi, Nouara] Aix Marseille Univ, F-13015 Marseille, France.
RP Fantini, J (corresponding author), INSERM, UMR S 1072, F-13015 Marseille, France.
EM jm.fantini@gmail.com
CR Berntsson RPA, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3058
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Di Scala C, 2017, METHODS MOL BIOL, V1583, P7, DOI 10.1007/978-1-4939-6875-6_2
   Di Scala C, 2016, SCI REP-UK, V6, DOI 10.1038/srep28781
   Fantini J, 2015, BRAIN LIPIDS SYNAPTI
   Fantini Jacques, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402005392
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Fantini J, 2016, SCI REP-UK, V6, DOI 10.1038/srep21907
   Fantini J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00120
   Fantini J, 2011, BBA-BIOMEMBRANES, V1808, P2343, DOI 10.1016/j.bbamem.2011.06.017
   Flores A, 2019, P NATL ACAD SCI USA, V116, P18098, DOI 10.1073/pnas.1908051116
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999
   Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   Huta BP, 2016, CHEMMEDCHEM, V11, P277, DOI 10.1002/cmdc.201500494
   Lee J, 2019, J CHEM THEORY COMPUT, V15, P775, DOI 10.1021/acs.jctc.8b01066
   Li WT, 2017, P NATL ACAD SCI USA, V114, pE8508, DOI 10.1073/pnas.1712592114
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Matrosovich M, 2015, TOP CURR CHEM, V367, P1, DOI 10.1007/128_2013_466
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   McDonald G, 2014, J CLIN INVEST, V124, P712, DOI 10.1172/JCI69571
   Neu U, 2008, P NATL ACAD SCI USA, V105, P5219, DOI 10.1073/pnas.0710301105
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pawlowski AC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02680-0
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Verma DK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110650
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yahi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104751
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   ZEBALLOS RS, 1994, J CLIN LAB ANAL, V8, P378, DOI 10.1002/jcla.1860080607
NR 40
TC 12
Z9 12
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106020
DI 10.1016/j.ijantimicag.2020.106020
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400007
OA Green Published
DA 2021-01-01
ER

PT J
AU Montelongo-Jauregui, D
   Vila, T
   Sultan, AS
   Jabra-Rizk, MA
AF Montelongo-Jauregui, Daniel
   Vila, Taissa
   Sultan, Ahmed S.
   Jabra-Rizk, Mary Ann
TI Convalescent serum therapy for COVID-19: A 19th century remedy for a
   21st century disease
SO PLOS PATHOGENS
LA English
DT Article
ID INFECTION; PLASMA
C1 [Montelongo-Jauregui, Daniel; Vila, Taissa; Sultan, Ahmed S.; Jabra-Rizk, Mary Ann] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
   [Jabra-Rizk, Mary Ann] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
RP Montelongo-Jauregui, D (corresponding author), Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
EM dmontelongo@umaryland.edu
RI Vila, Taissa/AAY-3980-2020
OI Vila, Taissa/0000-0001-5600-4367; Sultan, Ahmed S./0000-0001-5286-4562
FU National Institute of Allergy and Infectious Diseases of the NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI130170]
FX The work in this publication was supported by the National Institute of
   Allergy and Infectious Diseases of the NIH under award number
   R01AI130170 (NIAID). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 1933, INT J ORTHOD DENT CH, V19, P328, DOI [10.1016/S0097-0522(33)90316-0, DOI 10.1016/S0097-0522(33)90316-0]
   [Anonymous], 2013, UEBER ZUSTANDEKOMMEN, DOI [10.17192/eb2013.0164, DOI 10.17192/EB2013.0164]
   [Anonymous], EPIDEMIOLOGY PREVENT
   [Anonymous], 1933, STATE J MED, V33, P2
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   CASADEVALL A, 1994, ANTIMICROB AGENTS CH, V38, P1695, DOI 10.1128/AAC.38.8.1695
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Epstein J, 2020, VOX SANG, V115, P485, DOI 10.1111/vox.12939
   Ev Behring, 2013, UNTERSUCHUNGEN ZUSTA, DOI [10.17192/eb2013.0165, DOI 10.17192/EB2013.0165]
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hung IEN, 2013, CHEST, V144, P464, DOI 10.1378/chest.12-2907
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Jancar S, 2005, TRENDS IMMUNOL, V26, P48, DOI 10.1016/j.it.2004.11.007
   Joyner Michael, 2020, medRxiv, DOI 10.1101/2020.05.12.20099879
   Katzelnick LC, 2017, VACCINE, V35, P4659, DOI 10.1016/j.vaccine.2017.07.045
   Kaufmann SHE, 2017, MBIO, V8, DOI 10.1128/mBio.00117-17
   Kohn JL, 1938, J AMER MED ASSOC, V111, P2361, DOI 10.1001/jama.1938.02790520017004
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lutz HU, 2012, ADV EXP MED BIOL, V750, P186, DOI 10.1007/978-1-4614-3461-0_14
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Moore JJ, 1914, J INFECT DIS, V15, P215, DOI 10.1093/infdis/15.1.215
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P655, DOI 10.1038/d41587-020-00011-1
   Smith DD, 1934, THESIS
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ye M, 2020, J MED VIROL, P1, DOI [10.1002/jmv.25577, DOI 10.1002/JMV.25577]
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
NR 38
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2020
VL 16
IS 8
AR e1008735
DI 10.1371/journal.ppat.1008735
PG 7
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA ND3GD
UT WOS:000561791300004
PM 32785259
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Choudhary, R
   Kaushik, A
   Sharma, JB
AF Choudhary, Rahul
   Kaushik, Atul
   Sharma, Jai Bharat
TI COVID-19 pandemic and stent thrombosis in a post percutaneous coronary
   intervention patient-a case report highlighting the selection of P2Y12
   inhibitor
SO CARDIOVASCULAR DIAGNOSIS AND THERAPY
LA English
DT Article
DE Stent thrombosis (ST); P2Y12 inhibitor; COV1D-19; acute coronary
   syndrome; case report
ID CLOPIDOGREL; TICAGRELOR
AB The current pandemic of novel coronavirus disease 2019 (COVII)-19) has posed a great threat to people's health worldwide, with specific implications on patients with underlying heart diseases. During this challenging period, nearly all major societies have recommended for conservative approach, even for patients with relatively stable acute cardiovascular diseases. Selection of specific antiplatelet therapy in an uncomplicated post percutaneous coronary intervention (PCI) patient can, at times, be crucial issue in such strained circumstances. We report a case of 64-year-old male, who was taken for urgent coronary angiogram (CAG) in view of non ST elevation acute coronary syndrome. Successful PCI with implantation of drug eluting stent was done for right coronary artery (RCA) and left anterior descending (LAD) artery lesions. On day 5th post-PCI, he developed acute inferior wall STEMI due to subacute stent thrombosis (ST), and despite all efforts, patient could not be saved as he didn't receive timely intervention. Increased travel time to emergency department due to lockdown because of COVID-19 and along with extra time required for donning of personal protection equipment (PPE) and other COVID-19 related safety measures prolonged the ischemic time. Potent P2Y12 inhibitor based dual antiplatelet therapy might have prevented this subacute ST, and thus mortality, as the patient was discharged on clopidogrel after PCI. While selecting specific P2Y12 inhibitor in a post PCI patient, apart from clinical condition of patient and complexity of procedure, we should also consider current COVID-19 pandemic. Current circumstances may favour ticagrelor over other P2Y12 inhibitors in view of its potent, rapid, and reversible antiplatelet action along with its optimistic effect in pneumonia.
C1 [Choudhary, Rahul; Kaushik, Atul; Sharma, Jai Bharat] All India Inst Med Sci, Jodhpur, Rajasthan, India.
RP Choudhary, R (corresponding author), All India Inst Med Sci, Jodhpur, Rajasthan, India.
EM drrahulchoudhary@yahoo.com
OI Choudhary, Rahul/0000-0002-5013-5734
CR Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731
   Ray Shuvanan, 2014, Indian Heart J, V66, P530, DOI 10.1016/j.ihj.2014.08.012
   Sahlen A, 2016, EUR HEART J, V37, P3335, DOI 10.1093/eurheartj/ehw284
   Sexton Travis R, 2018, JACC Basic Transl Sci, V3, P435, DOI 10.1016/j.jacbts.2018.05.005
   Storey RF, 2014, PLATELETS, V25, P517, DOI 10.3109/09537104.2013.842965
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223-3652
EI 2223-3660
J9 CARDIOVASC DIAGN THE
JI Cardiovisc. Diagn. Ther.
PD AUG
PY 2020
VL 10
IS 4
BP 898
EP 901
DI 10.21037/cdt-20-485
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ND1QT
UT WOS:000561681200037
PM 32968646
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Martinelli, F
   Garbi, A
AF Martinelli, Fabio
   Garbi, Annalisa
TI Change in practice in gynecologic oncology during the COVID-19 pandemic:
   a social media survey
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
ID SURGERY
AB Objective COVID-19 has affected gynecologic cancer management. The goal of this survey was to evaluate changes that occurred in gynecologic oncology practice during the COVID-19 pandemic.
   Methods A anonymous survey consisting of 33 questions () regarding interaction between gynecologic cancers and COVID-19 was distributed online via social media from April 9 to April 30, 2020. Basic descriptive statistics were applied. Analytics of survey-diffusion and generated-interest (visualizations, engagement rates, response rate) were analyzed.
   Results The survey received 20 836 visualizations, generating an average engagement rates by reach of 4.7%. The response rate was 30%. A total of 86% of respondents completed the survey, for a total of 187 physicians surveyed across 49 countries. The majority (143/187; 76%) were gynecologic oncologists, and most were <= 50 years old (146/187; 78%). A total of 49.7% (93/187) were facing the early phase of the COVID-19 pandemic, while 26.7% (50/187) and 23.5% (44/187) were in the peak and plateau phases, respectively. For 97.3% (182/187) of respondents COVID-19 affected or changed their respective clinical practice. Between 16% (27/165) (before surgery) and 25% (26/102) (before medical treatment) did not perform any tests to rule out COVID-19 infection among patients. The majority of respondents did not alter indications of treatment if patients were COVID-19-negative, while treatments were generally postponed in COVID-19-positive patients. Treatments were considered priority for: early stage high-risk uterine cancers (85/187; 45%), newly diagnosed epithelial ovarian cancer (76/187; 41%), and locally advanced cervical cancer (76/187; 41%). Treatment of early stage low-grade endometrioid endometrial cancer was deferred according to 49% (91/187) of respondents, with hormonal treatment as the option of therapy (31%; 56/178). A total of 77% (136/177) of respondents reported no changes in (surgical) treatment for early stage cervical cancer in COVID-19-negative patients, while treatment was postponed by 54% (96/177) of respondent, if the patient tested COVID-19-positive. Neoadjuvant chemotherapy for advanced ovarian cancers was considered by over one-third of respondents as well as hypofractionation of radiation treatment for locally advanced cervical cancers.
   Conclusion COVID-19 affected the treatment of gynecologic cancers patients, both in terms of prioritization and identification of strategies to reduce hospital access and length of stay. Social media is a reliable tool to perform fast-tracking, worldwide surveys.
C1 [Martinelli, Fabio] Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, I-20133 Milan, Italy.
   [Garbi, Annalisa] European Inst Oncol, Gynecol Oncol, Milan, Lombardia, Italy.
RP Martinelli, F (corresponding author), Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, I-20133 Milan, Italy.
EM Martinelli@istitutotumori.mi.it
RI Martinelli, Fabio/J-4151-2013
OI Martinelli, Fabio/0000-0002-4863-1747
CR Alanzi T, 2019, INT J TELEMED APPL, V2019, DOI 10.1155/2019/6323962
   Coleridge SL, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005343.pub4
   Cripe JC, 2019, GYNECOL OBSTET INVES, V84, P50, DOI 10.1159/000491089
   Dostalek L, 2018, INT J GYNECOL CANCER, V28, P1226, DOI 10.1097/IGC.0000000000001314
   Dusek G., 2015, INT J DOCTORAL STUDI, V10, P279, DOI DOI 10.28945/2296
   Fan WH, 2014, SCI CHINA INFORM SCI, V57, DOI 10.1007/s11432-012-4737-x
   Garg G, 2011, GYNECOL ONCOL, V121, P143, DOI 10.1016/j.ygyno.2010.12.337
   Harter P, 2019, CANCER-AM CANCER SOC, V125, P4573, DOI 10.1002/cncr.32514
   Lin LL, 2020, INT J GYNECOL CANCER, V30, P409, DOI 10.1136/ijgc-2020-001227
   Alcazar JL, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e86
   Lyons YA, 2020, INT J GYNECOL CANCER, V30, P845, DOI 10.1136/ijgc-2019-001124
   Nair N, 2018, GYNECOL ONCOL REP, V26, P71, DOI 10.1016/j.gore.2018.10.003
   Pluym ID, 2020, AM J PERINAT, V37, P890, DOI 10.1055/s-0039-1701027
   Ramirez PT, 2020, INT J GYNECOL CANC
   Ukoha C, 2019, J MED INTERNET RES, V21, DOI 10.2196/14684
   Venkatesh V, 2003, MIS QUART, V27, P425
   Vercellino GF, 2019, ARCH GYNECOL OBSTET, V300, P191, DOI 10.1007/s00404-019-05164-2
   Visser NCM, 2017, OBSTET GYNECOL, V130, P803, DOI 10.1097/AOG.0000000000002261
NR 18
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD AUG
PY 2020
VL 30
IS 8
BP 1101
EP 1107
DI 10.1136/ijgc-2020-001585
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA NC6GH
UT WOS:000561315100004
PM 32513664
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Liu, M
   Caputi, TL
   Dredze, M
   Kesselheim, AS
   Ayers, JW
AF Liu, Michael
   Caputi, Theodore L.
   Dredze, Mark
   Kesselheim, Aaron S.
   Ayers, John W.
TI Internet Searches for Unproven COVID-19 Therapies in the United States
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Liu, Michael] Univ Oxford, Oxford, England.
   [Caputi, Theodore L.] Univ Calif San Diego, Ctr Data Driven Hlth, Qualcomm Inst, La Jolla, CA 92093 USA.
   [Dredze, Mark] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.
   [Kesselheim, Aaron S.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Ayers, John W.] Univ Calif San Diego, Sch Med, Dept Med, Div Infect Dis & Global Hlth, 9500 Gilman Dr,333 CRSF, La Jolla, CA 92093 USA.
RP Ayers, JW (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, Div Infect Dis & Global Hlth, 9500 Gilman Dr,333 CRSF, La Jolla, CA 92093 USA.
EM ayers.john.w@gmail.com
OI Liu, Michael/0000-0003-2724-8797
CR Ayers JW, 2014, JAMA-J AM MED ASSOC, V311, P1399, DOI 10.1001/jama.2014.1505
   Hyndman RJ, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i03
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Vigdor N, 2020, NY TIMES
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
NR 6
TC 18
Z9 18
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD AUG
PY 2020
VL 180
IS 8
BP 1116
EP 1118
DI 10.1001/jamainternmed.2020.1764
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC5OJ
UT WOS:000561264100017
PM 32347895
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fiehler, J
   Brouwer, P
   Diaz, C
   Hirsch, JA
   Kulcsar, Z
   Liebeskind, D
   Linfante, I
   Lylyk, P
   Mack, WJ
   Milburn, J
   Nogueira, R
   Orbach, DB
   Pumar, JMM
   Tanaka, M
   Taylor, A
AF Fiehler, Jens
   Brouwer, Patrick
   Diaz, Carlos
   Hirsch, Joshua A.
   Kulcsar, Zsolt
   Liebeskind, David
   Linfante, Italo
   Lylyk, Pedro
   Mack, William J.
   Milburn, James
   Nogueira, Raul
   Orbach, Darren B.
   Pumar, Jose Manuel Manuel
   Tanaka, Michihiro
   Taylor, Allan
TI COVID-19 and neurointerventional service worldwide: a survey of the
   European Society of Minimally Invasive Neurological Therapy (ESMINT),
   the Society of NeuroInterventional Surgery (SNIS), the Sociedad
   Iberolatinoamericana de Neuroradiologia Diagnostica y Terapeutica
   (SILAN), the Society of Vascular and Interventional Neurology (SVIN),
   and the World Federation of Interventional and Therapeutic
   Neuroradiology (WFITN)
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE stroke; intervention; standards; political; thrombectomy
AB Background This survey was focused on the provision of neurointerventional services, the current practices of managing patients under COVID-19 conditions, and the expectations for the future. Methods Invitations for this survey were sent out as a collaborative effort of the European Society of Minimally Invasive Neurological Therapy (ESMINT), the Society of NeuroInterventional Surgery (SNIS), the Sociedad Iberolatinoamericana de Neuroradiologia Diagnostica y Terapeutica (SILAN), the Society of Vascular and Interventional Neurology (SVIN), and the World Federation of Interventional and Therapeutic Neuroradiology (WFITN). Results Overall, 475 participants from 61 countries responded (six from Africa (1%), 81 from Asia (17%), 156 from Europe (33%), 53 from Latin America (11%), and 172 from North America (11%)). The majority of participants (96%) reported being able to provide emergency services, though 26% of these reported limited resources. A decrease in emergency procedures was reported by 69% of participants (52% in ischemic and hemorrhagic stroke, 11% ischemic, and 6% hemorrhagic stroke alone). Only 4% reported an increase in emergency cases. The emerging need for social distancing and the rapid adoption of remote communication was reflected in the interest in establishing case discussion forums (43%), general online forums (37%), and access to angio video streaming for live mentoring and support (33%). Conclusion Neurointerventional emergency services are available in almost all centers, while the number of emergency patients is markedly decreased. Half of the participants have abandoned neurointerventions in non-emergent situations. There are considerable variations in the management of neurointerventions and in the expectations for the future.
C1 [Fiehler, Jens] Univ Med Ctr Hamburg Eppendorf, Dept Neuroradiol, Martinistr 52, D-20251 Hamburg, Germany.
   [Brouwer, Patrick] Karolinska Univ Jukhuset, Neuroradiol, Stockholmslan, Sweden.
   [Diaz, Carlos] Univ Antioquia, Radiol, Medellin, Antioquia, Colombia.
   [Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA.
   [Kulcsar, Zsolt] Univ Hosp Zurich, Dept Neuroradiol, Zurich, Switzerland.
   [Liebeskind, David] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA.
   [Linfante, Italo] Baptist Cardiac & Vasc Inst, Miami, FL USA.
   [Lylyk, Pedro] Clin Inst ENERI, Intervent Neuroradiol, Buenos Aires, DF, Argentina.
   [Mack, William J.] Univ Southern Calif, Neurosurg, Los Angeles, CA 90007 USA.
   [Milburn, James] Ochsner Med Syst, Radiol, New Orleans, LA USA.
   [Nogueira, Raul] Emory Univ, Sch Med, Neurol, Atlanta, GA USA.
   [Orbach, Darren B.] Boston Childrens Hosp, Neurointervent Rdiol, Boston, MA USA.
   [Pumar, Jose Manuel Manuel] Hosp Clin Univ, Neuroradiol, Santiago De Compostela, Spain.
   [Tanaka, Michihiro] Kameda Med Ctr, Neurosurg, Kamogawa, Chiba, Japan.
   [Taylor, Allan] Univ Cape Town, Neurosurg, Cape Town, W Cape, South Africa.
RP Fiehler, J (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neuroradiol, Martinistr 52, D-20251 Hamburg, Germany.
EM fiehler@uke.de
OI Milburn, James/0000-0003-3403-2628; Kulcsar, Zsolt/0000-0002-6805-5150
CR Aggour M, 2020, J NEUROINTERV SURG, V12, P542, DOI 10.1136/neurintsurg-2020-016137
   Bambakidis NC, 2020, J NEUROSURG, V133, P10, DOI 10.3171/2020.3.JNS20965
   Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9
   Bechstein M, 2019, CLIN NEURORADIOL, DOI 10.1007/s00062-019-00870-5
   Fraser JF, 2020, J NEUROINTERV SURG, V12, P539, DOI 10.1136/neurintsurg-2020-016098
   Mahajan A, 2020, AM J NEURORADIOL, V41, P552, DOI 10.3174/ajnr.A6526
   Nguyen TN, 2020, STROKE, V51, P1896, DOI 10.1161/STROKEAHA.120.030100
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 9
TC 4
Z9 4
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD AUG
PY 2020
VL 12
IS 8
BP 726
EP 730
DI 10.1136/neurintsurg-2020-016349
PG 5
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA ND2TY
UT WOS:000561758700002
PM 32546635
OA Bronze, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Dogra, S
   Jain, R
   Cao, M
   Bilaloglu, S
   Zagzag, D
   Hochman, S
   Lewis, A
   Melmed, K
   Hochman, K
   Horwitz, L
   Galetta, S
   Berger, J
AF Dogra, Siddhant
   Jain, Rajan
   Cao, Meng
   Bilaloglu, Seda
   Zagzag, David
   Hochman, Sarah
   Lewis, Ariane
   Melmed, Kara
   Hochman, Katherine
   Horwitz, Leora
   Galetta, Steven
   Berger, Jeffrey
TI Hemorrhagic stroke and anticoagulation in COVID-19
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE COVID-19; Intracranial hemorrhage; Anticoagulation; Hemorrhagic stroke
ID INTRACEREBRAL HEMORRHAGE; MANAGEMENT
AB Background and Purpose: Patients with the Coronavirus Disease of 2019 (COVID-19) are at increased risk for thrombotic events and mortality. Various anticoagulation regimens are now being considered for these patients. Anticoagulation is known to increase the risk for adverse bleeding events, of which intracranial hemorrhage (ICH) is one of the most feared. We present a retrospective study of 33 patients positive for COVID-19 with neuroimaging-documented ICH and examine anticoagulation use in this population. Methods: Patients over the age of 18 with confirmed COVID-19 and radiographic evidence of ICH were included in this study. Evidence of hemorrhage was confirmed and categorized by a fellowship trained neuroradiologist. Electronic health records were analyzed for patient information including demographic data, medical history, hospital course, laboratory values, and medications. Results: We identified 33 COVID-19 positive patients with ICH, mean age 61.6 years (range 37-83 years), 21.2% of whom were female. Parenchymal hemorrhages with mass effect and herniation occurred in 5 (15.2%) patients, with a 100% mortality rate. Of the remaining 28 patients with ICH, 7 (25%) had punctate hemorrhages, 17 (60.7%) had small-moderate size hemorrhages, and 4 (14.3%) had a large single site of hemorrhage without evidence of herniation. Almost all patients received either therapeutic dose anticoagulation (in 22 [66.7%] patients) or prophy-lactic dose (in 3 [9.1] patients) prior to ICH discovery. Conclusions: Anticoagulation therapy may be considered in patients with COVID-19 though the risk of ICH should be taken into account when developing a treatment regimen. (c) 2020 Elsevier Inc. All rights reserved.
C1 [Dogra, Siddhant; Jain, Rajan] NYU, Dept Radiol, Langone Hlth, 560 1St Ave, New York, NY 10016 USA.
   [Jain, Rajan; Zagzag, David; Lewis, Ariane] NYU, Dept Neurosurg, Langone Hlth, 550 1St Ave, New York, NY 10016 USA.
   [Cao, Meng; Hochman, Katherine] NYU, Dept Med, Langone Hlth, 550 1St Ave, New York, NY 10016 USA.
   [Bilaloglu, Seda; Horwitz, Leora] NYU, Dept Populat Hlth, Langone Hlth, New York, NY USA.
   [Zagzag, David] NYU, Dept Pathol, Langone Hlth, 550 1St Ave, New York, NY 10016 USA.
   [Hochman, Sarah] NYU, Dept Infect Dis, Langone Hlth, New York, NY USA.
   [Lewis, Ariane; Melmed, Kara; Galetta, Steven] NYU, Dept Neurol, Langone Hlth, New York, NY 10016 USA.
   [Berger, Jeffrey] NYU, Dept Cardiol, Langone Hlth, New York, NY USA.
RP Dogra, S (corresponding author), NYU, Sch Med, Radiol & Neurosurg, 660 First Ave,2nd Floor, New York, NY 10016 USA.
EM Siddhant.dogra@nyulangone.org; rajan.jain@nyulangone.org;
   meng.cao@nyulangone.org; seda.bilaloglu@nyulangone.org;
   David.zagzag@nyulangone.org; sarah.hochman@nyulangone.org;
   Ariane.lewis@nyulangone.org; kara.melmed@nyulangone.org;
   Katherine.hochman@nyulangone.org; Leora.Horwitz@nyulangone.org;
   Steven.galetta@nyulangone.org; Jeffrey.berger@nyulangone.org
RI Horwitz, Leora/ABD-1292-2020; Melmed, Kara/AAS-3287-2020
OI Melmed, Kara/0000-0003-4084-8586; Lewis, Ariane/0000-0002-0756-7320;
   Hochman, Katherine/0000-0002-1724-9465; Hochman,
   Sarah/0000-0003-2011-0453; Dogra, Siddhant/0000-0003-2386-7849; Jain,
   Rajan/0000-0002-4879-0457
CR Alquwaizani M, 2013, CURR EMERG HOSP ME R, V1, P83, DOI 10.1007/s40138-013-0014-6
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Boon GJAM, 2020, RES PRACT THROMB HAE, V4, P958, DOI 10.1002/rth2.12404
   Connors JM, 2020, BLOOD
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dybdahl D, 2019, CLIN MED INSIGHTS-BL, V12, DOI 10.1177/1179545X19863814
   Heit JJ, 2017, J STROKE, V19, P11, DOI 10.5853/jos.2016.00563
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Jain R, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116923
   Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438
   Liotta EM, 2013, J STROKE CEREBROVASC, V22, P1151, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.015
   Purrucker JC, 2016, JAMA NEUROL, V73, P169, DOI 10.1001/jamaneurol.2015.3682
   Sharifi-Razavi A., 2020, NEW MICROBES NEW INF, V35, DOI [10.1016/j.nmni.2020.100669, DOI 10.1016/J.NMNI.2020.100669]
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 17
Z9 18
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD AUG
PY 2020
VL 29
IS 8
AR 104984
DI 10.1016/j.jstrokecerebrovasdis.2020.104984
PG 6
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA ND3MV
UT WOS:000561808800030
PM 32689588
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Garcia-Salido, A
   Leoz-Gordillo, I
   de Azagra-Garde, AM
   Nieto-Moro, M
   Iglesias-Bouzas, MI
   Garcia-Teresa, MA
   Cabrero-Hernandez, M
   Caro-Paton, GD
   Valdovinos, AG
   Gonzalez-Brabin, A
   Serrano-Gonzalez, A
AF Garcia-Salido, Alberto
   Leoz-Gordillo, Ines
   Martinez de Azagra-Garde, Amelia
   Nieto-Moro, Montserrat
   Iglesias-Bouzas, Maria Isabel
   Garcia-Teresa, Maria Angeles
   Cabrero-Hernandez, Marta
   De Lama Caro-Paton, Gema
   Gochi Valdovinos, Ainhoa
   Gonzalez-Brabin, Anthony
   Serrano-Gonzalez, Ana
TI Children in Critical Care Due to Severe Acute Respiratory Syndrome
   Coronavirus 2 Infection: Experience in a Spanish Hospital
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE children; coronavirus disease 2019; mechanical ventilation; noninvasive
   ventilation; pediatric critical care; severe acute respiratory syndrome
   coronavirus 2
ID COVID-19
AB Objectives: Spain has been one of the countries most severely affected by the coronavirus disease 2019. This study aims to describe a series of children admitted to a PICU due to coronavirus disease 2019 infection.
   Design: Prospective observational study.
   Setting: Tertiary hospital in Madrid, Spain.
   Patients: Children admitted to the PICU with severe acute respiratory syndrome coronavirus 2 (severe acute respiratory syndrome coronavirus 2) infection, from March 1, 2020, to April 15, 2020.
   Interventions: Observational study.
   Measurements and Main Results: Epidemiologic data, previous clinical characteristics, support therapy needed, imaging tests, laboratory observations on admission, and pharmacologic therapy. Eleven children were admitted to the PICU, with suspected coronavirus disease 2019; the polymerase chain reaction test was positive in seven. The median age was 100.7 months (range, 0.5-162). Five were admitted from the emergency department and two from the ward. The Pediatric Sequential Organ Failure Assessment score was 3 (range, 0-9), and Pediatric Risk of Mortality II score was 4 (range, 0-16). All children were previously healthy except one (allogeneic hematopoietic stem cell transplantation). Respiratory symptoms and fever were prevalent. A chest radiograph led to a pneumonia diagnosis. Not all patients presented with lymphopenia on admission.d-Dimer and ferritin were elevated. All patients needed oxygen therapy through a nasal cannula; five patients received high-flow nasal cannula therapy, which was later substituted with noninvasive ventilation in four. Mechanical ventilation was necessary in two patients on the first day of PICU admission. Two children required mechanical ventilation and inotropic support. Tocilizumab was applied in two intubated children. Also, four children received heparin. No patients died.
   Conclusions: On the whole, the children were previously healthy and are more than 1 year old. Respiratory symptoms were the leading cause of PICU admission, making respiratory support the principal therapy. Patients requiring mechanical ventilation showed deterioration on the first day of admission. These children seemed to require close monitoring, and multicenter studies are necessary.
C1 [Garcia-Salido, Alberto; Leoz-Gordillo, Ines; Martinez de Azagra-Garde, Amelia; Nieto-Moro, Montserrat; Iglesias-Bouzas, Maria Isabel; Garcia-Teresa, Maria Angeles; Cabrero-Hernandez, Marta; De Lama Caro-Paton, Gema; Gochi Valdovinos, Ainhoa; Gonzalez-Brabin, Anthony; Serrano-Gonzalez, Ana] Hosp Infantil Univ Nino Jesus, Pediat Crit Care Unit, Madrid, Spain.
RP Garcia-Salido, A (corresponding author), Hosp Infantil Univ Nino Jesus, Pediat Crit Care Unit, Madrid, Spain.
EM citopensis@yahoo.es
RI Garcia-Salido, Alberto/D-2294-2019
OI Garcia-Salido, Alberto/0000-0002-8038-7430
CR [Anonymous], 2020, SIT COVID 19 ESP
   Cai J, 2020, CLIN INFECT DIS
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Peeri NC, 2020, INT J EPIDEMIOL
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Tagarro A, 2020, JAMA PEDIAT
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 9
TC 3
Z9 3
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1529-7535
EI 1947-3893
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD AUG
PY 2020
VL 21
IS 8
BP E576
EP E580
DI 10.1097/PCC.0000000000002475
PG 5
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA NC7ZX
UT WOS:000561434200014
PM 32459790
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Daly, ML
   Zimmer, A
   Stickling, J
   Daikeler, T
   Grossmann, FF
AF Daly, Mary Louise
   Zimmer, Andrea
   Stickling, Julia
   Daikeler, Thomas
   Grossmann, Florian F.
TI COVID-19 driven care changes in high risk patients from an outpatient to
   a community setting A cross-sectional study
SO PFLEGE
LA English
DT Article
DE Drug administration routes; patient preference; chronic disease;
   COVID-19; outpatient clinics
ID RHEUMATOID-ARTHRITIS; SELF-EFFICACY; PREFERENCES; SATISFACTION;
   EXPERIENCE; THERAPIES; DISEASE
AB Background: COVID-19 has led to a change in care for patients with chronic conditions, involving a transfer of drug administration from an outpatient to a community setting.Aim: To investigate patient preferences for treatment settings in the light of the current pandemic. Methods: Patients, who prior to the pandemic had attended two different outpatient clinics in a university hospital for their infusions or injections, were interviewed by telephone. The semi-structured interviews were analyzed using qualitative and quantitative methods. Results: Out of 49 patients with either anti-inflammatory or immunoglobulin treatments (response rate: 83%), 24 (49.0%) switched from subcutaneous (sc) injections in the hospital to the community setting, 18 (36.7%) from intravenous infusions (iv) in the hospital to sc administration at home and 7 (14.3 %) moved to iv at home. During the pandemic 38 (80.9%) wanted to continue their treatment at home, but after the pandemic 22 (46.8%) would opt to go back to the hospital. Satisfaction was high with both settings, slightly favoring drug administration in hospital. Qualitative data shows that patients while emphasizing the importance of the relationship with the healthcare team, had increased concerns about safety as a result of COVID-19. Conclusions: The experience during the COVID-19 pandemic has increased self-management-skills in some patients, but long-term follow-up is needed. It has repercussions for future shared decision making for patients and their healthcare teams.
C1 [Daly, Mary Louise] Univ Hosp Basel, Med Outpatient Dept, Basel, Switzerland.
   [Zimmer, Andrea] Univ Hosp Basel, Neurol Clin & Policlin, Basel, Switzerland.
   [Stickling, Julia] Univ Basel, Inst Nursing Sci, Dept Publ Hlth, Basel, Switzerland.
   [Daikeler, Thomas] Univ Hosp Basel, Rheumatol Clin, Basel, Switzerland.
   [Grossmann, Florian F.] Univ Hosp Basel, Dept Med, Div Nursing, Hebelstr 2, CH-4031 Basel, Switzerland.
RP Grossmann, FF (corresponding author), Univ Hosp Basel, Dept Med, Div Nursing, Hebelstr 2, CH-4031 Basel, Switzerland.
EM florian.grossmann@usb.ch
RI Grossmann, Florian F/E-7291-2017
OI Grossmann, Florian F/0000-0001-7804-8870
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Barton JL, 2009, PATIENT PREFER ADHER, V3, P335
   Bolge SC, 2017, PATIENT PREFER ADHER, V11, P661, DOI 10.2147/PPA.S121032
   Brady TJ, 2011, ARTHRIT CARE RES, V63, pS473, DOI 10.1002/acr.20567
   De Mits S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166607
   Dumusc Alexandre, 2020, Rev Med Suisse, V16, P831
   Garratt AM, 2014, RHEUMATOLOGY, V53, P1161, DOI 10.1093/rheumatology/ket374
   Gaylis NB, 2017, PATIENT PREFER ADHER, V11, P1543, DOI 10.2147/PPA.S136567
   Grisanti L, 2019, ARTHRIT CARE RES, V71, P1234, DOI 10.1002/acr.23758
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   IBM Corporation, 2013, IBM SPSS STAT WIND V
   Kuitwaard K, 2017, J PERIPHER NERV SYST, V22, P425, DOI 10.1111/jns.12242
   Mayring P., 1991, QUALITATIVE INHALTSA
   Mccain Jack, 2016, Manag Care, V25, P28
   McCormack B., 2016, PERSON CTR PRACTICE
   Michaud Kaleb, 2020, ACR Open Rheumatol, V2, P335, DOI 10.1002/acr2.11148
   Roland D., 2020, PEDIATR RES, DOI [10.1038/s4139-020-0947-x, DOI 10.1038/S4139-020-0947-X]
   Scarpato S, 2010, RHEUMATOLOGY, V49, P289, DOI 10.1093/rheumatology/kep354
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715
   Spichiger Eilsabeth, 2006, Pflege, V19, P45, DOI 10.1024/1012-5302.19.1.45
   Stamm T, 2010, Z RHEUMATOL, V69, P198, DOI 10.1007/s00393-009-0573-9
   Stoner KL, 2015, PATIENT, V8, P145, DOI 10.1007/s40271-014-0075-y
   Swissethics, 2020, QUAL OD BEW FORSCH
   Sylwestrzak G, 2014, AM HEALTH DRUG BENEF, V7, P71
   van Vollenhoven R, 2019, NAT REV RHEUMATOL, V15, P180, DOI 10.1038/s41584-019-0170-5
   Voutilainen A, 2016, J ADV NURS, V72, P946, DOI 10.1111/jan.12875
   World Health Organization, 2016, STRENGTH PEOPL CTR H
NR 29
TC 0
Z9 0
U1 1
U2 1
PU VERLAG HANS HUBER
PI BERN 9
PA LANGGASS-STRASSE 76, CH-3000 BERN 9, SWITZERLAND
SN 1012-5302
EI 1664-283X
J9 PFLEGE
JI Pflege
PD AUG
PY 2020
VL 33
IS 4
BP 219
EP 227
DI 10.1024/1012-5302/a000753
PG 9
WC Nursing
SC Nursing
GA NC6ZO
UT WOS:000561365700005
PM 32811324
DA 2021-01-01
ER

PT J
AU Wiwanitkit, V
AF Wiwanitkit, Viroj
TI Convalescent plasma therapy in the treatment of COVID-19: Some
   considerations: Correspondence
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Letter
DE COVID-19; Convalescent; Plasma
C1 [Wiwanitkit, Viroj] Dr DY Patil Univ, Pune, Maharashtra, India.
RP Wiwanitkit, V (corresponding author), Dr DY Patil Univ, Pune, Maharashtra, India.
EM wviroj@yahoo.com
CR Bongiovanni M, 2020, INFECT DIS-NOR, V52, P581, DOI 10.1080/23744235.2020.1769177
   Hoang VT, 2020, J MED VIROL, V92, P2366, DOI 10.1002/jmv.26056
   Islam A., 2020, INT J SURG, VS1743-9191, P30462
NR 3
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD AUG
PY 2020
VL 80
BP 26
EP 26
DI 10.1016/j.ijsu.2020.06.029
PG 1
WC Surgery
SC Surgery
GA NC3ZS
UT WOS:000561153700010
PM 32585194
OA Green Published
DA 2021-01-01
ER

PT J
AU Alvarez, JC
   Moine, P
   Etting, I
   Annane, D
   Larabi, IA
AF Alvarez, Jean-Claude
   Moine, Pierre
   Etting, Isabelle
   Annane, Djillali
   Larabi, Islam Amine
TI Quantification of plasma remdesivir and its metabolite GS-441524 using
   liquid chromatography coupled to tandem mass spectrometry. Application
   to a Covid-19 treated patient
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE Covid-19; GS-441524; LC-MS/MS; remdesivir
AB Objectives: A method based on liquid chromatography coupled to triple quadrupole mass spectrometry detection using 50 mu L of plasma was developed and fully validated for quantification of remdesivir and its active metabolites GS-441524.
   Methods: A simple protein precipitation was carried out using 75 mu L of methanol containing the internal standard (IS) remdesivir-C-13(6) and 5 mu L ZnSO4 1 M. After separation on Kinetex (R) 2.6 mu m Polar C18 100A LC column (100 x 2.1 mm i.d.), both compounds were detected by a mass spectrometer with electrospray ionization in positive mode. The ion transitions used were m/z 603.3 -> m/z 200.0 and m/z 229.0 for remdesivir, m/z 292.2 -> m/z 173.1 and m/z 147.1 for GS-441524 and m/z 609.3 -> m/z 206.0 for remdesivir-C-13(6).
   Results: Calibration curves were linear in the 1-5000 mu g/L range for remdesivir and 5-2500 for GS-441524, with limit of detection set at 0.5 and 2 mu g/L and limit of quantification at 1 and 5 mu g/L, respectively. Precisions evaluated at 2.5, 400 and 4000 mu g/L for remdesivir and 12.5, 125, 2000 mu g/L for GS441524 were lower than 14.7% and accuracy was in the [89.6-110.2%] range. A slight matrix effect was observed, compensated by IS. Higher stability of remdesivir and metabolite was observed on NaF-plasma. After 200 mg IV single administration, remdesivir concentration decrease rapidly with a half-life less than 1 h while GS-441524 appeared rapidly and decreased slowly until H-24 with a half-life around 12 h.
   Conclusions: This method would be useful for therapeutic drug monitoring of these compounds in Covid-19 pandemic.
C1 [Alvarez, Jean-Claude] Univ Versailles St Quentin En Yvelines, Lab Pharmacol Toxicol, Hop Raymond Poincare, AP HP,Inserm U 1173, 104 Blvd R Poincare, F-92380 Garches, France.
   [Moine, Pierre; Annane, Djillali] Paris Saclay Univ Versailles St Quentin En Yvelin, Raymond Poincare Hosp, AP HP, Inserm U 1173,Intens Care Unit, Garches, France.
   [Etting, Isabelle; Larabi, Islam Amine] Paris Saclay Univ Versailles St Quentin En Yvelin, Raymond Poincare Hosp, AP HP, Dept Pharmacol & Toxicol,Inserm U 1173, Garches, France.
RP Alvarez, JC (corresponding author), Univ Versailles St Quentin En Yvelines, Lab Pharmacol Toxicol, Hop Raymond Poincare, AP HP,Inserm U 1173, 104 Blvd R Poincare, F-92380 Garches, France.
EM jean-claude.alvarez@aphp.fr
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   European Medicines Agency, 2011, GUID BIOAN METH VAL
   European Medicines Agency Science Medicines Health, 2020, SCI MED HLTH
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Kakodkar P, 2020, CUREUS, V12, DOI 10.7759/cureus.7560
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
NR 13
TC 0
Z9 0
U1 17
U2 18
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD AUG
PY 2020
VL 58
IS 9
BP 1461
EP 1468
DI 10.1515/cclm-2020-0612
PG 8
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA NB7SR
UT WOS:000560715100020
PM 32573468
OA Bronze
DA 2021-01-01
ER

PT J
AU Hosoki, K
   Chakraborty, A
   Sur, S
AF Hosoki, Koa
   Chakraborty, Abhijit
   Sur, Sanjiv
TI Molecular mechanisms and epidemiology of COVID-19 from an allergist's
   perspective
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE ACE2; asthma; allergic rhinitis; COVID-19; severe acute respiratory
   syndrome coronavirus 2; receptor-binding domain; TMPRSS2
ID ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; INDUCED
   ASTHMA EXACERBATIONS; CORONAVIRUS SPIKE PROTEIN; KAWASAKI-LIKE DISEASE;
   SARS-CORONAVIRUS; TRACT INFECTIONS; SYNCYTIAL VIRUS; PROTEOLYTIC
   ACTIVATION; TRANSMISSION DYNAMICS
AB The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.
C1 [Hosoki, Koa; Chakraborty, Abhijit; Sur, Sanjiv] Baylor Coll Med, Dept Med Immunol Allergy & Rheumatol, Houston, TX 77030 USA.
RP Sur, S (corresponding author), Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ssur@BCM.EDU
OI Hosoki, Koa/0000-0003-4228-2176
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [5R01HL145477-02,
   3R01HL145477-01S1]; Department of DefenseUnited States Department of
   Defense [PR171425 W81XWH-18-1-0743]
FX This research was supported by the National Heart, Lung, and Blood
   Institute (grant nos. 5R01HL145477-02 and 3R01HL145477-01S1) and the
   Department of Defense (grant no. PR171425 W81XWH-18-1-0743).
CR Abd-Elsayed A, 2020, ANESTH ANALG, V131, P4, DOI 10.1213/ANE.0000000000004841
   ABDULAI I, 2020, CELL, V181, DOI DOI 10.1016/J.AGSY.2020.102812
   [Anonymous], 2020, DRAFT LANDSC COVID 1
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Bae S, 2020, ANN INTERN MED, V173, pW22, DOI 10.7326/M20-1342
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   Broszeit F, 2019, CELL REP, V27, P3284, DOI 10.1016/j.celrep.2019.05.048
   Canonica GW, 2008, WORLD ALLERGY ORGAN, V1, P138, DOI 10.1097/WOX.0b013e3181865faf
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carenzo L, 2020, ANAESTHESIA, V75, P928, DOI 10.1111/anae.15072
   Centers for Disease Control and Prevention, GROUPS HIGH RISK SEV
   Centers for Disease Control and Prevention, 2018, SUMM HLTH STAT TABL
   Centers for Disease Control and Prevention, INT GUID COLL HANDL
   Centers for Disease Control and Prevention, HOSP RAT CHAR PAT HO
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Chow EJ, 2020, JAMA-J AM MED ASSOC, V323, P2087, DOI 10.1001/jama.2020.6637
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chung JY, 2007, J MED VIROL, V79, P1238, DOI 10.1002/jmv.20926
   Codispoti CD, 2020, ANN ALLERG ASTHMA IM, V125, P208, DOI 10.1016/j.anai.2020.05.009
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123
   Coomes EA, 2020, INTERLEUKIN 6 COVID, DOI [10.1101/2020.03.30.20048058, DOI 10.1101/2020.03.30.20048058]
   Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9
   COVID-19 Treatment Guidelines Panel, COVID 19 TREATM GUID
   COWART BJ, 1993, J ALLERGY CLIN IMMUN, V91, P747, DOI 10.1016/0091-6749(93)90194-K
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Dhawale VS, 2016, TOXICOL APPL PHARM, V306, P17, DOI 10.1016/j.taap.2016.06.026
   Ding QL, 2012, J ASTHMA, V49, P557, DOI 10.3109/02770903.2012.685540
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Duan K, 2020, FEASIBILITY CONVALES, DOI [10.1101/2020.03, DOI 10.1101/2020.03.16.20036145, 10.1101/2020.03.16.20036145.]
   El-Ekiaby A, 2006, AM J RESP CRIT CARE, V174, P508, DOI 10.1164/rccm.200603-431OC
   Fauver Joseph R, 2020, medRxiv, DOI 10.1101/2020.03.25.20043828
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerna G, 2006, J MED VIROL, V78, P938, DOI 10.1002/jmv.20645
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Griggs TF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0567-0
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047
   Haller O, 2015, TRENDS MICROBIOL, V23, P154, DOI 10.1016/j.tim.2014.12.003
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hamming I, 2007, J PATHOL, V212, P1, DOI 10.1002/path.2162
   Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang N, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4775-8
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Infectious Diseases Society of America, IDSA COVID 19 ANT TE
   Iwabuchi K, 2020, COVID 19 3 CASES IMP
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC
   Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009
   Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC
   Jeon S, ANTIMICROB AGENTS CH, DOI [10.1128/AAC.00810-20, DOI 10.1128/AAC.00810-20]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johns Hopkins University, COR COVID 19 GLOB CA
   JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kawasaki T, 2006, P JPN ACAD B-PHYS, V82, P59, DOI 10.2183/pjab.82.59
   Kesic MJ, 2012, RESP RES, V13, P82
   Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816
   Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030
   Ko M., 2020, SCREENING FDA APPROV, DOI [10.1101/2020.02.25.965582, DOI 10.1101/2020.02.25.965582]
   Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33
   Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981
   Kuo HC, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-38
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Kuruvilla ME, 2019, CLIN REV ALLERG IMMU, V56, P219, DOI 10.1007/s12016-018-8712-1
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leach CL, 2006, J AEROSOL MED, V19, P117, DOI 10.1089/jam.2006.19.117
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Liu XP, 2020, INFLUENZA OTHER RESP, V14, P472, DOI 10.1111/irv.12740
   Loisel DA, 2016, CLIN EXP ALLERGY, V46, P112, DOI 10.1111/cea.12642
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Ma KL, 2020, COVID 19 MYOCARDITIS, DOI [10.1101/2020.03.19.20034124, DOI 10.1101/2020.03.19.20034124]
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Magalhaes GS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00058
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m641
   Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032
   Matsuyama S, INHALED CORTICOSTERO, DOI [10.1101/2020.0'3.11.087016, DOI 10.1101/2020.0'3.11.087016]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meissner HC, 2016, NEW ENGL J MED, V374, P1793, DOI 10.1056/NEJMc1601509
   Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Montgomery MT, AM J RESP CRIT CARE, DOI [10.1164/rcern.202003-08210C, DOI 10.1164/RCERN.202003-0821OC]
   National Institute of Allergy and Infectious Diseases, COVLD 19 MERS SARS
   Nave R, 2013, INT J GEN MED, V6, P99, DOI 10.2147/IJGM.S39134
   New York State Department of Health, NYSDOH COVID 19 TRAC
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328
   Perrier A, 2019, J BIOL CHEM, V294, P14406, DOI 10.1074/jbc.RA119.008964
   Peters U, 2018, J ALLERGY CLIN IMMUN, V141, P1169, DOI 10.1016/j.jaci.2018.02.004
   Price D, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0083-6
   Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052
   Ravanetti L, 2019, J ALLERGY CLIN IMMUN, V143, P1355, DOI 10.1016/j.jaci.2018.08.051
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE346, DOI 10.1111/jdv.16533
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Rydzewski B, 2000, ACTA OTO-LARYNGOL, V120, P323
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Sandell C, 2010, J ALLERGY CLIN IMMUN, V144, P1624
   Schaper F, 2015, CYTOKINE GROWTH F R, V26, P475, DOI 10.1016/j.cytogfr.2015.07.004
   Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x
   Shanawani H, 2006, CLIN CHEST MED, V27, P17, DOI 10.1016/j.ccm.2005.11.002
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi T, 2015, J GLOB HEALTH, V5, P203, DOI 10.7189/jogh.05.020416
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569
   Slejko JF, 2014, J ALLERGY CLIN IMMUN, V133, P1579, DOI 10.1016/j.jaci.2013.10.028
   Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5
   Stuck BA, 2015, J ALLERGY CLIN IMMUN, V136, P1460, DOI 10.1016/j.jaci.2015.08.003
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Taher YA, 2008, J ALLERGY CLIN IMMUN, V121, P983, DOI 10.1016/j.jaci.2007.11.021
   Tan WC, 2003, AM J MED, V115, P272, DOI 10.1016/S0002-9343(03)00353-X
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Torigoe M, 2018, CLIN IMMUNOL, V195, P1, DOI 10.1016/j.clim.2018.07.003
   Tsai YJ, 2013, ALLERGY ASTHMA PROC, V34, P467, DOI 10.2500/aap.2013.34.3697
   Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x
   Van Bever HP, 2004, PEDIAT ALLERG IMM-UK, V15, P206, DOI 10.1111/j.1399-3038.2004.00137.x
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6
   Walk PA, 2002, EUR RESPIR J, V10, P68
   Wallace DJ, 2015, AM J RESP CRIT CARE, V191, P410, DOI 10.1164/rccm.201409-1746OC
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901
   Weinheimer VK, 2012, J INFECT DIS, V206, P1685, DOI 10.1093/infdis/jis455
   Werder RB, 2018, J ALLERGY CLIN IMMUN, V141, P1607, DOI 10.1016/j.jaci.2017.07.051
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, SOL CLIN TRIAL COVID
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, SCIENCE, DOI [10.1126/seience.abe2241., 10.1126/seience.abe2241, DOI 10.1126/SEIENCE.ABE2241]
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao SL, 2017, J ASTHMA, V54, P476, DOI 10.1080/02770903.2016.1236943
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang F, 2020, MYOCARDIAL INJURY IS, DOI [10.1101/2020.03.21.20040121, DOI 10.1101/2020.03.21.20040121]
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang T, PANGOLIN HOMOLOGY AS, DOI [10.1101/2020.02.10.050253, DOI 10.1101/2020.02.10.050253]
   Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Zhu J, 2019, J ALLERGY CLIN IMMUN, V143, P114, DOI 10.1016/j.jaci.2018.04.003
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P469, DOI 10.1097/INF.0000000000002700
NR 201
TC 2
Z9 2
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD AUG
PY 2020
VL 146
IS 2
BP 285
EP 299
DI 10.1016/j.jaci.2020.05.033
PG 15
WC Allergy; Immunology
SC Allergy; Immunology
GA MZ0TA
UT WOS:000558835000013
PM 32624257
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Valent, P
   Akin, C
   Bonadonna, P
   Brockow, K
   Niedoszytko, M
   Nedoszytko, B
   Butterfield, JH
   Alvarez-Twose, I
   Sotlar, K
   Schwaab, J
   Jawhar, M
   Reiter, A
   Castells, M
   Sperr, WR
   Kluin-Nelemans, HC
   Hermine, O
   Gotlib, J
   Zanotti, R
   Broesby-Olsen, S
   Horny, HP
   Triggiani, M
   Siebenhaar, F
   Orfao, A
   Metcalfe, DD
   Arock, M
   Hartmann, K
AF Valent, Peter
   Akin, Cem
   Bonadonna, Patrizia
   Brockow, Knut
   Niedoszytko, Marek
   Nedoszytko, Boguslaw
   Butterfield, Joseph H.
   Alvarez-Twose, Ivan
   Sotlar, Karl
   Schwaab, Juliana
   Jawhar, Mohamad
   Reiter, Andreas
   Castells, Mariana
   Sperr, Wolfgang R.
   Kluin-Nelemans, Hanneke C.
   Hermine, Olivier
   Gotlib, Jason
   Zanotti, Roberta
   Broesby-Olsen, Sigurd
   Horny, Hans-Peter
   Triggiani, Massimo
   Siebenhaar, Frank
   Orfao, Alberto
   Metcalfe, Dean D.
   Arock, Michel
   Hartmann, Karin
TI Risk and management of patients with mastocytosis and MCAS in the
   SARS-CoV-2 (COVID-19) pandemic: Expert opinions
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Mast cells; mastocytosis; tryptase; KIT D816V; coronavirus; COVID-19;
   SARS-CoV-2; mast cell activation syndrome
ID CELL ACTIVATION SYNDROMES; MAST-CELLS; CLASSIFICATION; INFECTION;
   MIDOSTAURIN; DISORDERS; DIAGNOSIS; EFFICACY; CRITERIA; SAFETY
AB The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19 induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.
C1 [Valent, Peter; Sperr, Wolfgang R.] Med Univ Vienna, Dept Internal Med 1, Div Haematol, Vienna, Austria.
   [Valent, Peter; Sperr, Wolfgang R.] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Akin, Cem] Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA.
   [Bonadonna, Patrizia] Verona Univ Hosp, Allergy Unit, Verona, Italy.
   [Brockow, Knut] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany.
   [Niedoszytko, Marek] Med Univ Gdansk, Dept Allergol, Gdansk, Poland.
   [Nedoszytko, Boguslaw] Med Univ Gdansk, Dept Dermatol, Gdansk, Poland.
   [Butterfield, Joseph H.] Mayo Clinic, Div Allerg Dis, Rochester, MN USA.
   [Alvarez-Twose, Ivan] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo, Spain.
   [Alvarez-Twose, Ivan] Hosp Virgen del Valle, CIBERONC, Toledo, Spain.
   [Sotlar, Karl] Paracelsus Med Univ Salzburg, Inst Pathol, Salzburg, Austria.
   [Schwaab, Juliana; Jawhar, Mohamad; Reiter, Andreas] Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany.
   [Castells, Mariana] Harvard Med Sch, Mastocytosis Ctr, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Kluin-Nelemans, Hanneke C.] Univ Groningen, Univ Med Ctr Groningen, Dept Haematol, Groningen, Netherlands.
   [Hermine, Olivier] Univ Paris 05, Imagine Inst, Sorbonne Paris Cite, Ctr Natl Reference Mastocytoses, Paris, France.
   [Gotlib, Jason] Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA.
   [Zanotti, Roberta] Univ Verona, Dept Med, Sect Hematol, Verona, Italy.
   [Broesby-Olsen, Sigurd] Odense Univ Hosp, Dept Dermatol, Odense, Denmark.
   [Broesby-Olsen, Sigurd] Odense Univ Hosp, Allergy Ctr, Odense, Denmark.
   [Horny, Hans-Peter] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany.
   [Triggiani, Massimo] Univ Salerno, Div Allergy & Clin Immunol, Salerno, Italy.
   [Siebenhaar, Frank] Charite Univ Med Berlin, Dermatol Allergol, Dept Dermatol & Allergy, Berlin, Germany.
   [Siebenhaar, Frank] Free Univ Berlin, Berlin, Germany.
   [Siebenhaar, Frank] Humboldt Univ, Berlin, Germany.
   [Siebenhaar, Frank] Berlin Inst Hlth, Berlin, Germany.
   [Orfao, Alberto] Univ Salamanca, Serv Cent Citometria, Ctr Invest Canc, IBMCC,CSICUSAL,IBSAL,CIBERONC, Salamanca, Spain.
   [Orfao, Alberto] Univ Salamanca, Dept Med, Salamanca, Spain.
   [Metcalfe, Dean D.] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany.
   [Arock, Michel] Pierre & Marie Curie Univ UPMC, Dept Hematol Biol, Pitie Salpetriere Hosp, Paris, France.
   [Hartmann, Karin] Univ Basel, Div Allergy, Dept Dermatol, Basel, Switzerland.
   [Hartmann, Karin] Univ Basel, Dept Biomed, Basel, Switzerland.
RP Valent, P (corresponding author), Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.; Valent, P (corresponding author), Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM peter.valent@meduniwien.ac.at
RI Hartmann, Karin/N-4865-2015; Valent, Peter/B-8533-2016; Nedoszytko,
   Boguslaw/AAY-5079-2020; Niedoszytko, Marek/U-1250-2018
OI Hartmann, Karin/0000-0002-4595-8226; Valent, Peter/0000-0003-0456-5095;
   Niedoszytko, Marek/0000-0003-1089-1911
FU Austrian Science Fund (FWF)Austrian Science Fund (FWF) [P32470-B,
   F4704B20]; Charles and Ann Johnson Foundation; Division of Intramural
   Research, National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID)
FX P.V. was supported by the Austrian Science Fund (FWF; projects P32470-B
   and F4704B20). J.G. is supported by the Charles and Ann Johnson
   Foundation. D.D.M. is supported by the Division of Intramural Research,
   National Institute of Allergy and Infectious Diseases.
CR Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035
   Akoto C, 2017, CLIN EXP ALLERGY, V47, P351, DOI 10.1111/cea.12879
   Arock M, 2015, LEUKEMIA, V29, P1223, DOI 10.1038/leu.2015.24
   Arock M, 2015, EUR J HAEMATOL, V94, P474, DOI 10.1111/ejh.12544
   Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237
   Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835
   Carter SJ, 2020, OBESITY, V28, P1176, DOI 10.1002/oby.22838
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cruse G, 2010, J IMMUNOL, V184, P7108, DOI 10.4049/jimmunol.0900802
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Dawicki W, 2007, CURR OPIN IMMUNOL, V19, P31, DOI 10.1016/j.coi.2006.11.006
   Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559
   Gavillet M, 2020, LEUKEMIA RES, V92, DOI 10.1016/j.leukres.2020.106353
   Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034
   Horny H. P., 2017, WHO CLASSIFICATION T, P62
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jakovac H, 2020, AM J PHYSIOL-ENDOC M, V318, pE589, DOI 10.1152/ajpendo.00138.2020
   Jendoubi F, 2020, CLIN EXP ALLERGY, V50, P654, DOI 10.1111/cea.13592
   Kluin-Nelemans HC, 2003, BLOOD, V102, P4270, DOI 10.1182/blood-2003-05-1699
   Kritas SK, 2020, J BIOL REGUL HOMEOST, V34
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696
   Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039
   Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0
   Mayerhofer M, 2007, INT J IMMUNOPATH PH, V20, P421, DOI 10.1177/039463200702000301
   McCartney D M, 2020, Ir Med J, V113, P58
   Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097
   Phelan AL, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.1007., DOI 10.1001/JAMA.2020.1007]
   Reiter A, 2020, BLOOD, V135, P1365, DOI 10.1182/blood.2019000932
   Sabato V, 2018, J CLIN IMMUNOL, V38, P457, DOI 10.1007/s10875-018-0506-y
   St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108
   Sundstrom JB, 2007, BLOOD, V109, P5293, DOI 10.1182/blood-2006-11-058438
   Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760
   Ustun C, 2014, J CLIN ONCOL, V32, P3264, DOI 10.1200/JCO.2014.55.2018
   VALENT F, 2019, J ALLERGY CLIN IMMUN, V7, DOI DOI 10.1136/FMCH-2019-000198
   Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x
   Valent P, 2017, ANN ONCOL, V28, P2367, DOI 10.1093/annonc/mdx290
   Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045
   Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8
   Valent P, 2013, ALLERGY, V68, P417, DOI 10.1111/all.12126
   Valent P, 2019, INT J MOL SCI, V20
   Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893
   Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760
   Valent P, 2010, BLOOD, V116, P5812, DOI 10.1182/blood-2010-08-292144
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YL, 2020, ANN PALLIAT MED, V9, P428, DOI 10.21037/apm.2020.03.26
NR 52
TC 1
Z9 1
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD AUG
PY 2020
VL 146
IS 2
BP 300
EP 306
DI 10.1016/j.jaci.2020.06.009
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA MZ0TA
UT WOS:000558835000014
PM 32561389
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Camiolo, M
   Gauthier, M
   Kaminski, N
   Ray, A
   Wenzel, SE
AF Camiolo, Matthew
   Gauthier, Marc
   Kaminski, Naftali
   Ray, Anuradha
   Wenzel, Sally E.
TI Expression of SARS-CoV-2 receptor ACE2 and coincident host response
   signature varies by asthma inflammatory phenotype
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE COVID-19; ACE2; coronavirus; SARS-CoV-2; asthma; interferon; viral
   response; Type-2 low
ID GENE-EXPRESSION; CORONAVIRUS; CYTOSCAPE; ONTOLOGY; PACKAGE; TOOL
AB Background: More than 300 million people carry a diagnosis of asthma, with data to suggest that they are at a higher risk for infection or adverse outcomes from severe acute respiratory syndrome coronavirus 2. Asthma is remarkably heterogeneous, and it is currently unclear how patient-intrinsic factors may relate to coronavirus disease 2019.
   Objective: We sought to identify and characterize subsets of patients with asthma at increased risk for severe acute respiratory syndrome coronavirus 2 infection.
   Methods: Participants from 2 large asthma cohorts were stratified using clinically relevant parameters to identify factors related to angiotensin-converting enzyme-2 (ACE2) expression within bronchial epithelium. ACE-2 correlated gene signatures were used to interrogate publicly available databases to identify upstream signaling events and novel therapeutic targets.
   Results: Stratifying by type 2 inflammatory biomarkers, we identified subjects who demonstrated low peripheral blood eosinophils accompanied by increased expression of the severe acute respiratory syndrome coronavirus 2 receptor ACE2 in bronchial epithelium. Genes highly correlated with ACE2 overlapped with type 1 and 2 IFN signatures, normally induced by viral infections. T-cell recruitment and activation within bronchoalveolar lavage cells of ACE2-high subjects was reciprocally increased. These patients demonstrated characteristics corresponding to risk factors for severe coronavirus disease 2019, including male sex, history of hypertension, low peripheral blood, and elevated bronchoalveolar lavage lymphocytes.
   Conclusions: ACE2 expression is linked to upregulation of viral response genes in a subset of type 2 low patients with asthma with characteristics resembling known risk factors for severe coronavirus disease 2019. Therapies targeting the IFN family and T-cell activating factors may therefore be of benefit in a subset of patients.
C1 [Camiolo, Matthew; Gauthier, Marc; Ray, Anuradha; Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.
   [Kaminski, Naftali] Yale Sch Med, Pulm Crit Care & Sleep Med, New Haven, CT USA.
   [Ray, Anuradha; Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA.
   [Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Environm Med & Occupat Hlth, Pittsburgh, PA USA.
RP Wenzel, SE (corresponding author), Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Environm Med & Occupat Hlth, Pittsburgh, PA USA.; Wenzel, SE (corresponding author), Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Environm Med & Occupat Hlth, 4126 Publ Hlth,130 DeSoto St, Pittsburgh, PA 15261 USA.
EM swenzel@pitt.edu
OI Camiolo, Matthew/0000-0002-9085-6552
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P01AI106684,
   R01HL113956, R01AI048927, U10HL109152, F32HL14741501]
FX This study was supported by the National Institutes of Health (NIH)
   (grant no. P01AI106684 to A.R. and S.E.W., grant no. R01HL113956 to
   A.R., and grant no. R01AI048927 to A.R.), NIH grant number U10HL109152
   (to S.E.W.), and NIH grant number F32HL14741501 (to M.C.).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bhakta NR, 2018, AM J RESP CRIT CARE, V197, P313, DOI 10.1164/rccm.201706-1070OC
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Buhl AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01162
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Charrad M, 2014, J STAT SOFTW, V61, P1
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   ENCODE Project Consortium, 2011, PLOS BIOL, V9
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Garg S, 2020, MMWR MORB MORTAL WKL, V69
   Gauthier M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94580
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jackson DJ, J ALLERGY CLIN IMMUN, DOI [10.1016/j.jaci.2020.04.009, DOI 10.1016/J.JACI.2020.04009]
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kalinka Alex T, 2011, Bioinformatics, V27, P2011, DOI 10.1093/bioinformatics/btr311
   Kanneganti TD, 2018, NAT REV IMMUNOL, V18, P483, DOI 10.1038/s41577-018-0027-1
   Kreft L, 2017, NUCLEIC ACIDS RES, V45, pW490, DOI 10.1093/nar/gkx376
   Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466
   Laresgoiti U, 2013, NUCLEIC ACIDS RES, V41, P10185, DOI 10.1093/nar/gkt821
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Lesurf R, 2016, NUCLEIC ACIDS RES, V44, pD126, DOI 10.1093/nar/gkv1203
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li Q, 2020, ECLINICALMEDICINE
   Li XiaoChen, 2020, Journal of Allergy and Clinical Immunology, V146, P110, DOI 10.1016/j.jaci.2020.04.006
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu J, 2020, NEUTROPHIL TO LYMPHO, DOI [10.1101/2020.02.10.20021584, DOI 10.1101/2020.02.10.20021584]
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Modena BD, 2017, AM J RESP CRIT CARE, V195, P1449, DOI 10.1164/rccm.201607-1407OC
   Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC
   Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639
   PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0
   Queen D, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00317
   Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911
   Ray A, 2020, PHYSIOL REV, V100, P983, DOI 10.1152/physrev.00023.2019
   Roan F, 2019, J CLIN INVEST, V129, P1441, DOI 10.1172/JCI124606
   Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752
   Rouillard A.D., 2016, DATABASE-OXFORD, V2016
   Sajuthi Satria P, 2020, bioRxiv, DOI 10.1101/2020.04.09.034454
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stathias V, 2020, NUCLEIC ACIDS RES, V48, pD431, DOI 10.1093/nar/gkz1023
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Trifilo MJ, 2003, J VIROL, V77, P4004, DOI 10.1128/JVI.77.7.4004-4014.2003
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678
   Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 52
TC 3
Z9 3
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD AUG
PY 2020
VL 146
IS 2
BP 315
EP +
DI 10.1016/j.jaci.2020.05.051
PG 17
WC Allergy; Immunology
SC Allergy; Immunology
GA MZ0TA
UT WOS:000558835000016
PM 32531372
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, J
   Zheng, XB
   Huang, YY
   Shan, H
   Huang, J
AF Liu, Jing
   Zheng, Xiaobin
   Huang, Yiying
   Shan, Hong
   Huang, Jin
TI Successful use of methylprednisolone for treating severe COVID-19
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID CORTICOSTEROIDS; THERAPY
C1 [Liu, Jing; Zheng, Xiaobin; Huang, Yiying; Huang, Jin] Sun Yat Sen Univ, Dept Pulm & Crit Care Med, Zhuhai, Peoples R China.
   [Liu, Jing; Shan, Hong; Huang, Jin] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Provincial Key Lab Biomed Imaging, Zhuhai, Peoples R China.
   [Liu, Jing; Shan, Hong; Huang, Jin] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Peoples R China.
   [Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai, Peoples R China.
RP Huang, J (corresponding author), Sun Yat Sen Univ, Dept Pulm & Crit Care Med, Zhuhai, Peoples R China.; Shan, H; Huang, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Provincial Key Lab Biomed Imaging, Zhuhai, Peoples R China.; Shan, H; Huang, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Peoples R China.; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai, Peoples R China.
EM shanhong@mail.sysu.edu.cn; hjin@mail.sysu.edu.cn
FU Natural Science Foundation of Guangdong Province of ChinaNational
   Natural Science Foundation of Guangdong Province [2020A1515011147];
   Scientific Research Foundation of Guangdong Province [A2020176]
FX This work was supported by grants from Natural Science Foundation of
   Guangdong Province of China (Grant No. 2020A1515011147 to J.L.) and
   Scientific Research Foundation of Guangdong Province (Grant No. A2020176
   to X.Z.).
CR Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/ERI.11.56, 10.1586/eri.11.56]
   Garg S., 2020, MMWR-MORBID MORTAL W, P69
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Li XiaoChen, 2020, Journal of Allergy and Clinical Immunology, V146, P110, DOI 10.1016/j.jaci.2020.04.006
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
NR 7
TC 10
Z9 10
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD AUG
PY 2020
VL 146
IS 2
BP 325
EP 327
DI 10.1016/j.jaci.2020.05.021
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA MZ0TA
UT WOS:000558835000017
PM 32479759
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, YZ
   Salwi, S
   Drolet, BC
AF Liu, Yangzi
   Salwi, Sanjana
   Drolet, Brian C.
TI Multivalue ethical framework for fair global allocation of a COVID-19
   vaccine
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE distributive justice; clinical ethics
AB The urgent drive for vaccine development in the midst of the current COVID-19 pandemic has prompted public and private organisations to invest heavily in research and development of a COVID-19 vaccine. Organisations globally have affirmed the commitment of fair global access, but the means by which a successful vaccine can be mass produced and equitably distributed remains notably unanswered. Barriers for low-income countries include the inability to afford vaccines as well as inadequate resources to vaccinate, barriers that are exacerbated during a pandemic. Fair distribution of a pandemic vaccine is unlikely without a solid ethical framework for allocation. This piece analyses four allocation paradigms: ability to develop or purchase; reciprocity; ability to implement; and distributive justice, and synthesises their ethical considerations to develop an allocation model to fit the COVID-19 pandemic.
C1 [Liu, Yangzi; Salwi, Sanjana] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA.
   [Drolet, Brian C.] Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, Nashville, TN USA.
RP Liu, YZ (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA.
EM yangzi.liu@vanderbilt.edu
OI Liu, Yangzi/0000-0002-4524-2623
CR [Anonymous], 2020, COMMITMENT CALL ACTI
   Biddison LD, 2014, CHEST, V146, pE145S, DOI 10.1378/chest.14-0742
   Bollyky TJ, 2020, JAMA-J AM MED ASSOC, V323, P2462, DOI 10.1001/jama.2020.6641
   Carter A, 2018, PUBLIC LAW REV, V29, P11
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fidler DP, 2008, EMERG INFECT DIS, V14, P88, DOI 10.3201/eid1401.070700
   Fidler DP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000247
   Khamsi R., 2020, NATURE
   Lee BY, 2011, HEALTH AFFAIR, V30, P1141, DOI 10.1377/hlthaff.2010.0778
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019
   Morris L, 2020, WASHINGTON POST
   Persad G, 2009, LANCET, V373, P423, DOI 10.1016/S0140-6736(09)60137-9
   Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0
   Sofaer N, 2014, BIOETHICS, V28, P456, DOI 10.1111/bioe.12039
   Switzerland World Health Organization, 2012, DEV IMPL NAT DEPL VA
   White D., 2020, ALLOCATION SCARCE CR
   White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046
   Zerhouni E, 2019, CELL, V179, P13, DOI 10.1016/j.cell.2019.08.026
NR 19
TC 3
Z9 3
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD AUG
PY 2020
VL 46
IS 8
BP 499
EP 501
DI 10.1136/medethics-2020-106516
PG 3
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NB9GJ
UT WOS:000560823300003
PM 32532826
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Richards, AD
AF Richards, Adair D.
TI Ethical guidelines for deliberately infecting volunteers with COVID-19
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE research ethics; public policy; policy guidelines; Inst; review boards;
   review Cttes; informed consent; ethics committees; consultation
AB Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments for and against such methods and provides suggested broad guidelines for regulators, researchers and ethics committees when considering these matters. It concludes that it may be possible to maintain current ethical standards yet still permit human challenge trials in a context where delay is critical. The implications are that regulators and researchers need to work together now to design robust but short trials and streamline ethics approval processes so that they are in place when applications for trials are made.
C1 [Richards, Adair D.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
RP Richards, AD (corresponding author), Univ Warwick, Coventry CV4 7AL, W Midlands, England.
EM Adair.Richards@warwick.ac.uk
CR Bentham J., 1999, INTRO PRINCIPLES MOR
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786
   Jefferson A, 2014, PHILOS COMPASS, V9, P672, DOI 10.1111/phc3.12161
   Miller FG, 2001, CLIN INFECT DIS, V33, P1028, DOI 10.1086/322664
   Schonecker D, 2015, I KANTS GROUNDWORK M
   Sengupta Amit, 2009, Indian J Med Ethics, V6, P118
   Siebre JE, 2012, PLANNING ETHICALLY R
   Thombre AC, 2017, INT CONF COMPUT
   Wertheimer A, 2002, BLACKWELL GUIDE SOCI, P55
   Wertheimer A., 2010, RETHINKING ETHICS CL
   World Health Organization, 2020, DRAFT LANDSC COVID 1
NR 13
TC 4
Z9 4
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD AUG
PY 2020
VL 46
IS 8
BP 502
EP 504
DI 10.1136/medethics-2020-106322
PG 3
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NB9GJ
UT WOS:000560823300004
PM 32461245
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lu, YJ
   Cai, H
   Lu, MJ
   Ma, YM
   Li, AZ
   Gao, YL
   Zhou, JY
   Gu, H
   Li, JR
   Gu, JY
AF Lu, Yunjian
   Cai, Hui
   Lu, Mijia
   Ma, Yuanmei
   Li, Anzhong
   Gao, Youling
   Zhou, Jiyong
   Gu, Howard
   Li, Jianrong
   Gu, Jinyan
TI Porcine Epidemic Diarrhea Virus Deficient in RNA Cap Guanine-N-7
   Methylation Is Attenuated and Induces Higher Type I and III Interferon
   Responses
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE Porcine epidemic diarrhea virus; RNA methylation; coronavirus
ID MESSENGER-RNA; CORONAVIRUS NSP14; HEPATITIS-VIRUS; RATIONAL DESIGN;
   UNITED-STATES; METHYLTRANSFERASE; BINDING; VACCINE; EXORIBONUCLEASE;
   REPLICATION
AB The 5' cap methylation of viral RNA plays important roles in RNA stability, efficient translation, and immune evasion. Thus, RNA cap methylation is an attractive target for antiviral discovery and development of new live attenuated vaccines. For coronaviruses, RNA cap structure is first methylated at the guanine-N-7 (G-N-7) position by nonstructural protein 14 (nsp14), which facilitates and precedes the subsequent ribose 2'-O methylation by the nsp16-nsp10 complex. Using porcine epidemic diarrhea virus (PEDV), an Alphacoronavirus, as a model, we showed that G-N-7 methyltransferase (G-N-7 MTase) of PEDV nsp14 methylated RNA substrates in a sequence-unspecific manner. PEDV nsp14 can efficiently methylate RNA substrates with various lengths in both neutral and alkaline pH environments and can methylate cap analogs (GpppA and GpppG) and single-nucleotide GTP but not ATP, CTP, or UTP. Mutations to the S-adenosyl-L-methionine (SAM) binding motif in the nsp14 abolished the G-N-7 MTase activity and were lethal to PEDV. However, recombinant rPEDV-D350A with a single mutation ( D350A) in nsp14, which retained 29.0% of G-N-7 MTase activity, was viable. Recombinant rPEDV-D350A formed a significantly smaller plaque and had significant defects in viral protein synthesis and viral replication in Vero CCL-81 cells and intestinal porcine epithelial cells (IPEC-DQ). Notably, rPEDV-D350A induced significantly higher expression of both type I and III interferons in IPEC-DQ cells than the parental rPEDV. Collectively, our results demonstrate that G-N-7 MTase activity of PEDV modulates viral replication, gene expression, and innate immune responses.
   IMPORTANCE Coronaviruses (CoVs) include a wide range of important human and animal pathogens. Examples of human CoVs include severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), and the most recently emerged SARS-CoV-2. Examples of pig CoVs include porcine epidemic diarrhea virus (PEDV), porcine deltacoronavirus (PDCoV), and swine enteric alphacoronavirus (SeACoV). There are no vaccines or antiviral drugs for most of these viruses. All known CoVs encode a bifunctional nsp14 protein which possesses ExoN and guanine-N-7 methyltransferase (G-N-7 MTase) activities, responsible for replication fidelity and RNA cap G-N-7 methylation, respectively. Here, we biochemically characterized G-N-7 MTase of PEDV nsp14 and found that G-N-7 MTase-deficient PEDV was defective in replication and induced greater responses of type I and III interferons. These findings highlight that CoV G-N-7 MTase may be a novel target for rational design of live attenuated vaccines and antiviral drugs.
C1 [Lu, Yunjian; Gu, Jinyan] Nanjing Agr Univ, Coll Vet Med, Nanjing, Jiangsu, Peoples R China.
   [Lu, Yunjian; Cai, Hui; Lu, Mijia; Ma, Yuanmei; Li, Anzhong; Gao, Youling; Li, Jianrong] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA.
   [Zhou, Jiyong] Zhejiang Univ, MOA Key Lab Anim Virol, Dept Vet Med, Hangzhou, Zhejiang, Peoples R China.
   [Zhou, Jiyong] Zhejiang Univ, Ctr Vet Med Sci, Hangzhou, Zhejiang, Peoples R China.
   [Gu, Howard] Ohio State Univ, Coll Med, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA.
   [Cai, Hui] Pfizer Inc, Pearl River, NY USA.
   [Ma, Yuanmei] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
   [Ma, Yuanmei] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
   [Gao, Youling] Zhejiang Wanli Univ, Coll Biol & Environm Sci, Ningbo, Zhejiang, Peoples R China.
RP Gu, JY (corresponding author), Nanjing Agr Univ, Coll Vet Med, Nanjing, Jiangsu, Peoples R China.; Li, JR (corresponding author), Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA.
EM li.926@osu.edu; gjy@zju.edu.cn
FU Key Research & Development Program of China [2016YFD0500102]; Department
   of Veterinary Biosciences at The Ohio State University
FX J. Gu was supported by Key Research & Development Program of China
   (2016YFD0500102). Work in J. Li's lab was supported by start-up funds
   from the Department of Veterinary Biosciences at The Ohio State
   University.
CR Ahola T, 1999, J VIROL, V73, P10061, DOI 10.1128/JVI.73.12.10061-10069.1999
   AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507
   Almazan F, 2006, J VIROL, V80, P10900, DOI 10.1128/JVI.00385-06
   Alonso C, 2014, VET RES, V45, DOI 10.1186/s13567-014-0073-z
   Becares M, 2016, J VIROL, V90, P5399, DOI 10.1128/JVI.03259-15
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Case JB, 2016, J VIROL, V90, P7248, DOI 10.1128/JVI.00542-16
   Chen Y, 2013, J VIROL, V87, P6296, DOI 10.1128/JVI.00061-13
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Cougot N, 2004, TRENDS BIOCHEM SCI, V29, P436, DOI 10.1016/j.tibs.2004.06.008
   COUSSEMENT W, 1982, VET PATHOL, V19, P46, DOI 10.1177/030098588201900108
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Deng XF, 2019, J VIROL, V93, DOI [10.1128/JVI.02000-18, 10.1128/jvi.02000-18]
   Dong HP, 2008, J VIROL, V82, P4295, DOI 10.1128/JVI.02202-07
   Dong HP, 2007, J VIROL, V81, P4412, DOI 10.1128/JVI.02455-06
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283
   Fehr Anthony R, 2020, Methods Mol Biol, V2099, P53, DOI 10.1007/978-1-0716-0211-9_5
   Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9
   FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305
   Hou YX, 2019, J VIROL, V93, DOI 10.1128/JVI.00406-19
   Ivanov KA, 2004, J VIROL, V78, P7833, DOI 10.1128/JVI.78.14.7833-7838.2004
   Jin X, 2013, VIRUS RES, V176, P45, DOI 10.1016/j.virusres.2013.05.001
   Kwon HJ, 2013, BIOORGAN MED CHEM, V21, P4706, DOI 10.1016/j.bmc.2013.04.085
   LAI MMC, 1981, J VIROL, V38, P661, DOI 10.1128/JVI.38.2.661-670.1981
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   Li L, 2017, ANTIVIR RES, V140, P76, DOI 10.1016/j.antiviral.2017.01.012
   Li SH, 2013, J VIROL, V87, P5812, DOI 10.1128/JVI.02806-12
   Lugari A, 2010, J BIOL CHEM, V285, P33230, DOI 10.1074/jbc.M110.120014
   Ma YM, 2016, VET MICROBIOL, V186, P90, DOI 10.1016/j.vetmic.2016.02.004
   Ma YM, 2015, MBIO, V6, DOI 10.1128/mBio.00064-15
   Ma YM, 2014, J VIROL, V88, P2913, DOI 10.1128/JVI.03420-13
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3
   McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   MUTHUKRISHNAN S, 1976, BIOCHEMISTRY-US, V15, P5761, DOI 10.1021/bi00671a012
   Narayanan K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/971296
   Pan YF, 2017, VET MICROBIOL, V211, P15, DOI 10.1016/j.vetmic.2017.09.020
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rahmeh AA, 2009, J VIROL, V83, P11043, DOI 10.1128/JVI.01426-09
   Saha N, 2001, VIROLOGY, V287, P40, DOI 10.1006/viro.2001.1006
   Sang YM, 2010, J INTERF CYTOK RES, V30, P801, DOI 10.1089/jir.2010.0016
   Stadler J, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0454-1
   Stevenson GW, 2013, J VET DIAGN INVEST, V25, P649, DOI 10.1177/1040638713501675
   Sun J, 2014, J VIROL, V88, P12348, DOI 10.1128/JVI.01095-14
   Sun RQ, 2012, EMERG INFECT DIS, V18, P161, DOI 10.3201/eid1801.111259
   Tian PF, 2014, EMERG INFECT DIS, V20, P1735, DOI 10.3201/eid2010.140338
   van Vliet ALW, 2002, EMBO J, V21, P6571, DOI 10.1093/emboj/cdf635
   Wang D, 2016, VIRUS RES, V226, P7, DOI 10.1016/j.virusres.2016.05.026
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Wang YL, 2018, VIROLOGY, V518, P210, DOI 10.1016/j.virol.2018.02.022
   Yu J, 2018, VIRUS RES, V247, P47, DOI 10.1016/j.virusres.2018.01.013
   Zhang Q., 2018, REMOTE SENSING, V10, P1, DOI DOI 10.1109/TGRS.2018.2830100
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang Y, 2014, J VIROL, V88, P11411, DOI 10.1128/JVI.00876-14
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 68
TC 1
Z9 1
U1 4
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2020
VL 94
IS 16
AR e00447-20
DI 10.1128/JVI.00447-20
PG 20
WC Virology
SC Virology
GA NA7YZ
UT WOS:000560035300003
PM 32461321
DA 2021-01-01
ER

PT J
AU Jamrozik, E
   Selgelid, MJ
AF Jamrozik, Euzebiusz
   Selgelid, Michael J.
TI COVID-19 human challenge studies: ethical issues
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID CORONAVIRUS INFECTION; RISK
AB COVID-19 poses an extraordinary threat to global public health and an effective vaccine could provide a key means of overcoming this crisis. Human challenge studies involve the intentional infection of research participants and can accelerate or improve vaccine development by rapidly providing estimates of vaccine safety and efficacy. Human challenge studies of low virulence coronaviruses have been done in the past and human challenge studies with severe acute respiratory syndrome coronavirus 2 have been proposed. These studies of coronaviruses could provide considerable benefits to public health; for instance, by improving and accelerating vaccine development. However, human challenge studies of severe acute respiratory syndrome coronavirus 2 in particular might be controversial, in part, for ethical reasons. The ethical issues raised by such studies thus warrant early consideration involving, for example, broad consultation with the community. This Personal View provides preliminary analyses of relevant ethical considerations regarding human challenge studies of severe acute respiratory syndrome coronavirus 2, including the potential benefits to public health and to participants, the risks and uncertainty for participants, and the third-party risks (ie, to research staff and the wider community). We argue that these human challenge studies can reasonably be considered ethically acceptable insofar as such studies are accepted internationally and by the communities in which they are done, can realistically be expected to accelerate or improve vaccine development, have considerable potential to directly benefit participants, are designed to limit and minimise risks to participants, and are done with strict infection control measures to limit and reduce third-party risks.
C1 [Jamrozik, Euzebiusz; Selgelid, Michael J.] Monash Univ, Monash Bioeth Ctr, Melbourne, Vic 3800, Australia.
   [Jamrozik, Euzebiusz; Selgelid, Michael J.] Monash Univ, WHO Collaborating Ctr Bioeth, Melbourne, Vic, Australia.
   [Jamrozik, Euzebiusz] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia.
RP Jamrozik, E (corresponding author), Monash Univ, Monash Bioeth Ctr, Melbourne, Vic 3800, Australia.
EM zeb.jamrozik@monash.edu
FU Welcome TrustWellcome Trust [210551/Z/18/Z]
FX Our ethical analyses in this paper were informed by a project supported
   by the Welcome Trust (210551/Z/18/Z). The funder of the study had no
   role in the writing of the manuscript or the decision to submit for
   publication.
CR [Anonymous], 2004, SUMM PROB SARS CAS O
   Bambery B, 2018, PUBLIC HEALTH ETH-UK, V11, P221, DOI 10.1093/phe/phx021
   Bambery B, 2016, PUBLIC HEALTH ETH-UK, V9, P92, DOI 10.1093/phe/phv026
   Baumgaertner E., 2018, ETHICISTS CALL MORE
   Binik A, 2020, BIOETHICS, V34, P420, DOI 10.1111/bioe.12736
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Darton TC, 2015, LANCET INFECT DIS, V15, P840, DOI 10.1016/S1473-3099(15)00068-7
   Durbin AP, 2017, J INFECT DIS, V216, pS971, DOI 10.1093/infdis/jix491
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Evers DL, 2015, SCI ENG ETHICS, V21, P1049, DOI 10.1007/s11948-014-9579-z
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   HIGGINS PG, 1983, ANTIMICROB AGENTS CH, V24, P713, DOI 10.1128/AAC.24.5.713
   Jamrozik E, 2020, HUMAN CHALLENGE STUD
   Jamrozik E, BIOETHICS
   KRZYZANOWSKI M, 1990, AM J EPIDEMIOL, V131, P412, DOI 10.1093/oxfordjournals.aje.a115516
   Lederer Susan E., 2008, OXFORD TXB CLIN RES, P9
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   London AJ, 2019, HASTINGS CENT REP, V49, P31, DOI 10.1002/hast.1034
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Marshall E, 2004, SCIENCE, V303, P944, DOI 10.1126/science.303.5660.944
   Memoli MJ, 2015, CLIN INFECT DIS, V60, P693, DOI 10.1093/cid/ciu924
   Miller FG, 2009, J MED ETHICS, V35, P445, DOI 10.1136/jme.2008.026062
   Organization WH and Sciences CfIOoM, 2016, INT ETH GUID HLTH RE
   Palacios R, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3843-0
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   PRINCE GA, 1986, J VIROL, V57, P721, DOI 10.1128/JVI.57.3.721-728.1986
   Roestenberg M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00297
   Roestenberg M, 2018, LANCET INFECT DIS, V18, pE312, DOI 10.1016/S1473-3099(18)30177-4
   Roland D, 2020, WANTED PEOPLE WILLIN
   Salhe H, 2020, SCIENCE, DOI [10.1126/science.abc3517, DOI 10.1126/SCIENCE.ABC3]
   Schaefer G, 2020, COVID 19 VCCINE DEV
   Selgelid MJ, 2016, BASIC BIOETH, P175
   Selgelid Michael J, 2018, Indian J Med Ethics, V3, P263, DOI 10.20529/IJME.2018.073
   Shah SK, 2018, SCIENCE, V360, P158, DOI 10.1126/science.aaq0917
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Thombre AC, 2017, INT CONF COMPUT
   TYRRELL DAJ, 1979, POSTGRAD MED J, V55, P117, DOI 10.1136/pgmj.55.640.117
   Vannice KS, 2019, VACCINE, V37, P863, DOI 10.1016/j.vaccine.2018.12.040
   Verity R, 2020, LANCET INFECT DIS, DOI [10.1016/51473-3099(20)30243-7, DOI 10.1016/51473-3099(20)30243-7]
   WHO, 2009, INFL LIK ILLN US MEX
   WHO, 2019, MIDDL E RESP SYNDR C
   WHO, 2020, COORD GLOB RES ROADM
   Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8
   Wong JY, 2013, EPIDEMIOLOGY, V24, P830, DOI 10.1097/EDE.0b013e3182a67448
   World Health Organization, 2014, ETH ISS REL STUD DES
   World Health Organization (WHO), 2000, WHO REP GLOB SURV EP
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
NR 48
TC 15
Z9 15
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD AUG
PY 2020
VL 20
IS 8
BP E198
EP E203
DI 10.1016/S1473-3099(20)30438-2
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA NA3ZL
UT WOS:000559753300009
PM 32479747
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ton, AT
   Gentile, F
   Hsing, M
   Ban, FQ
   Cherkasov, A
AF Ton, Anh-Tien
   Gentile, Francesco
   Hsing, Michael
   Ban, Fuqiang
   Cherkasov, Artem
TI Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease
   by Deep Docking of 1.3 Billion Compounds
SO MOLECULAR INFORMATICS
LA English
DT Article
DE SARS-CoV-2; COVID-19; deep learning; virtual screening; protease
   inhibitors
ID SARS; DESIGN; DISCOVERY; CORONAVIRUSES; VALIDATION; 3CL(PRO)
AB The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.
C1 [Ton, Anh-Tien; Gentile, Francesco; Hsing, Michael; Ban, Fuqiang; Cherkasov, Artem] Univ British Columbia, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.
RP Cherkasov, A (corresponding author), Univ British Columbia, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.
EM acherkasov@prostatecentre.com
OI Gentile, Francesco/0000-0001-8299-1976
FU CIHR Canadian 2019 Novel Coronavirus (2019-nCoV)Canadian Institutes of
   Health Research (CIHR) [DC0190GP] Funding Source: Medline; NIDCD NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Deafness &
   Other Communication Disorders (NIDCD) [F32 DC000190] Funding Source:
   Medline
CR Abuhammad A, 2017, J MOL RECOGNIT, V30, DOI 10.1002/jmr.2644
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ashtawy HM, 2015, IEEE ACM T COMPUT BI, V12, P335, DOI 10.1109/TCBB.2014.2351824
   Bemis GW, 1996, J MED CHEM, V39, P2887, DOI 10.1021/jm9602928
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015
   Chaput L, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0167-x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Das PK, 2016, ANTIMICROB AGENTS CH, V60, P7382, DOI 10.1128/AAC.01421-16
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gentile F., 2019, BIORXIV
   Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P5684, DOI 10.1016/j.bmcl.2008.08.082
   Ghosh AK, 2006, ANNU REP MED CHEM, V41, P183, DOI 10.1016/S0065-7743(06)41011-3
   Gordon C.J., 2020, J BIOL CHEM
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Lee H, 2014, BIOORGAN MED CHEM, V22, P167, DOI 10.1016/j.bmc.2013.11.041
   Li G., 2020, NAT REV DRUG DISCOV
   Li Y., 2020, BIORXIV
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Liu X, 2020, SMART MATER STRUCT, V2020, P1
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Lyu J, 2019, NATURE, V566, P224, DOI 10.1038/s41586-019-0917-9
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ragoza M, 2017, J CHEM INF MODEL, V57, P942, DOI 10.1021/acs.jcim.6b00740
   Shah F, 2011, J CHEM INF MODEL, V51, P852, DOI 10.1021/ci200029y
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Torres PHM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184574
   Tuley A, 2018, BIOCHEMISTRY-US, V57, P3326, DOI 10.1021/acs.biochem.8b00315
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu Z., 2020, BIORXIV
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang H., 2020, DEEP LEARNING BASED
   Zhang HP, 2019, PEERJ, V7, DOI 10.7717/peerj.7362
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 47
TC 83
Z9 84
U1 20
U2 36
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
PD AUG
PY 2020
VL 39
IS 8
AR 2000028
DI 10.1002/minf.202000028
PG 7
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA NA3TQ
UT WOS:000559737300001
PM 32162456
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Caccamo, N
   Sullivan, LC
   Brooks, AG
   Dieli, F
AF Caccamo, Nadia
   Sullivan, Lucy C.
   Brooks, Andrew G.
   Dieli, Francesco
TI Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy
   of patients with severe COVID-19
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE SARS-CoV-2; COVID-19; T-cell immunotherapy; HLA-E-restricted CD8 T cells
C1 [Caccamo, Nadia; Dieli, Francesco] Univ Palermo, Cent Lab Adv Diag & Biomed Res, Palermo, Italy.
   [Caccamo, Nadia; Dieli, Francesco] Univ Palermo, Dept Biomed Neurosci & Adv Diag, Palermo, Italy.
   [Sullivan, Lucy C.; Brooks, Andrew G.] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
RP Dieli, F (corresponding author), Univ Palermo, Cent Lab Adv Diag & Biomed Res, Palermo, Italy.; Dieli, F (corresponding author), Univ Palermo, Dept Biomed Neurosci & Adv Diag, Palermo, Italy.
EM francesco.dieli@unipa.it
OI Dieli, Francesco/0000-0002-6685-352X; Sullivan, Lucy/0000-0003-2907-4989
CR Bian Y, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006384
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hanley B, 2020, BRIT J HAEMATOL, V189, P1062, DOI 10.1111/bjh.16780
   Hansen SG, 2016, SCIENCE, V351, P714, DOI 10.1126/science.aac9475
   La Manna MP, 2020, AM J RESP CELL MOL, V62, P430, DOI 10.1165/rcmb.2019-0261OC
   Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Petrie EJ, 2008, J EXP MED, V205, P725, DOI 10.1084/jem.20072525
   Prezzemolo T, 2018, EUR J IMMUNOL, V48, P293, DOI 10.1002/eji.201747184
   Walters LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05459-z
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2020
VL 190
IS 4
BP E185
EP E187
DI 10.1111/bjh.16895
PG 3
WC Hematology
SC Hematology
GA NA4YY
UT WOS:000559825300003
PM 32480418
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brown, SM
   Peltan, ID
   Webb, B
   Kumar, N
   Starr, N
   Grissom, C
   Buckel, WR
   Srivastava, R
   Harris, ES
   Leither, L
   Johnson, SA
   Paine, R
   Greene, T
AF Brown, Samuel M.
   Peltan, Ithan D.
   Webb, Brandon
   Kumar, Naresh
   Starr, Nathan
   Grissom, Colin
   Buckel, Whitney R.
   Srivastava, Raj
   Harris, Estelle S.
   Leither, LindsayM.
   Johnson, Stacy A.
   Paine, Robert, III
   Greene, Tom
TI Hydroxychloroquine versus Azithromycin for Hospitalized Patients with
   Suspected or Confirmed COVID-19 (HAHPS) Protocol for a Pragmatic,
   Open-Label, Active Comparator Trial
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
DE COVID-19; clinical trial; hydroxychloroquine
ID COMMUNITY-ACQUIRED PNEUMONIA; BALANCED CRYSTALLOIDS; RANDOMIZED-TRIAL;
   OXYGEN-THERAPY; CARE; VARIABILITY; SALINE; DRUG; LIFE
AB Coronavirus disease (COVID-19) is a potentially fatal illness with no proven therapy beyond excellent supportive care. Treatments are urgently sought. Adaptations to traditional trial logistics and design to allow rapid implementation, evaluation of trials within a global trials context, flexible interim monitoring, and access outside traditional research hospitals (even in settings where formal placebos are unavailable) may be helpful. Thoughtful adaptations to traditional trial designs, especially within the global context of related studies, may also foster collaborative relationships among government, community, and the research enterprise. Here, we describe the protocol for a pragmatic, active comparator trial in as many as 300 patients comparing two current "off-label" treatments for COVID-19-hydroxychloroquine and azithromycin-in academic and nonacademic hospitals in Utah. We developed the trial in response to local pressures for widespread, indiscriminate off-label use of these medications. We used a hybrid Bayesian-frequentist design for interim monitoring to allow rapid, contextual assessment of the available evidence. We also developed an inference grid for interpreting the range of possible results from this trial within the context of parallel trials and prepared for a network meta-analysis of the resulting data. This trial was prospectively registered (ClinicalTrials.gov Identifier NCT04329832) before enrollment of the first patient.
C1 [Brown, Samuel M.; Peltan, Ithan D.; Kumar, Naresh; Grissom, Colin; Leither, LindsayM.] Intermt Med Ctr, Pulm & Crit Care Med, Murray, UT USA.
   [Webb, Brandon; Kumar, Naresh] Intermt Med Ctr, Infect Dis, Murray, UT USA.
   [Starr, Nathan] Intermt Med Ctr, Hosp Med, Murray, UT USA.
   [Brown, Samuel M.; Peltan, Ithan D.; Grissom, Colin; Harris, Estelle S.; Leither, LindsayM.; Paine, Robert, III] Univ Utah, Pulm & Crit Care Med, Salt Lake City, UT USA.
   [Webb, Brandon] Univ Utah, Infect Dis, Salt Lake City, UT USA.
   [Srivastava, Raj] Univ Utah, Dept Pediat, Inpatient Med, Salt Lake City, UT USA.
   [Johnson, Stacy A.] Univ Utah, Hosp Med, Salt Lake City, UT USA.
   [Greene, Tom] Univ Utah, Biostat, Salt Lake City, UT USA.
   [Webb, Brandon] Stanford Univ, Infect Dis, Stanford, CA 94305 USA.
   [Buckel, Whitney R.] Intermt Healthcare, Serv Pharm, Murray, UT USA.
   [Srivastava, Raj] Intermt Healthcare, Healthcare Delivery Inst, Murray, UT USA.
RP Brown, SM (corresponding author), Intermt Med Ctr, 5121 S Cottonwood St, Murray, UT 84107 USA.
EM samuel.brown@imail.org
RI Brown, Samuel/E-6846-2015
OI Brown, Samuel/0000-0003-1206-6261; Buckel, Whitney/0000-0001-9505-2572;
   KUMAR, NARESH/0000-0001-5984-4142
FU National Institute of General Medical Sciences (NIGMS)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [K23GM129661]; NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL144624]; Intermountain Research and
   Medical Foundation
FX Supported by National Institute of General Medical Sciences (NIGMS)
   grant K23GM129661 (I.D.P.). S.M.B. is supported by NHLBI grant
   R01HL144624. The HAHPS trial is supported by the Intermountain Research
   and Medical Foundation and departmental funds.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   [Anonymous], 2020, CLIN CAR SEV AC RESP
   Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Colantuoni E, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5748
   Dean NC, 2012, ANN EMERG MED, V59, P35, DOI 10.1016/j.annemergmed.2011.07.032
   Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.3.CO;2-L
   Gibson PG, 2017, LANCET, V390, P659, DOI 10.1016/S0140-6736(17)31281-3
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Ginde AA, 2019, NEW ENGL J MED, V381, P2529, DOI 10.1056/NEJMoa1911124
   Harrell F, 2020, STAT DESIGN ANAL PLA, P2020
   Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7
   Hart JL, 2015, JAMA INTERN MED, V175, P1019, DOI 10.1001/jamainternmed.2015.0372
   Hobbs BP, 2008, J BIOPHARM STAT, V18, P54, DOI 10.1080/10543400701668266
   Infectious Diseases Society of America, 2020, INF DIS SOC AM GUID
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kawamura K, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2866-1
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Lamontagne F, 2020, JAMA-J AM MED ASSOC, V323, P938, DOI 10.1001/jama.2020.0930
   Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109
   Menzel M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28698
   Mills EJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2914
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   National Academies of Sciences Engineering and Medicine Health and Medicine Division; Board on Health Sciences Policy Board on Global Health, 2017, INT CLIN RES EP RESP
   Niforatos JD, 2020, HYDROXYCHLOROQUINE U
   Novack V, 2020, CRIT CARE MED, V48, P158, DOI 10.1097/CCM.0000000000004104
   O'Connor CM, 2003, JAMA-J AM MED ASSOC, V290, P1459, DOI 10.1001/jama.290.11.1459
   Peltan ID, 2017, CRIT CARE MED, V45, P1011, DOI 10.1097/CCM.0000000000002436
   Peschken CA, 2020, J RHEUMATOL, V47, P787, DOI 10.3899/jrheum.200395
   Postma DF, 2015, NEW ENGL J MED, V372, P1312, DOI 10.1056/NEJMoa1406330
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Roche L., 2020, DESERET NEWS
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Self WH, 2018, ANN EMERG MED, V72, P457, DOI 10.1016/j.annemergmed.2018.03.039
   Self WH, 2018, NEW ENGL J MED, V378, P819, DOI 10.1056/NEJMoa1711586
   Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584
   Shepherd Katie, 2020, WASHINGTON POST
   Simonis FD, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.25
   Song FJ, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4909
   Strle F, 2002, WIEN KLIN WOCHENSCHR, V114, P396
   Svanstrom H, 2013, NEW ENGL J MED, V368, P1704, DOI 10.1056/NEJMoa1300799
   Thompson B Taylor, 2007, Proc Am Thorac Soc, V4, P577, DOI 10.1513/pats.200706-072JK
   U.S. Food and Drug Administration, 2020, FACT SHEET HLTH PROV
   Walkey AJ, 2012, CHEST, V141, P1153, DOI 10.1378/chest.11-1908
   Wong CH, 2019, BIOSTATISTICS, V20, P273, DOI 10.1093/biostatistics/kxx069
   Wright JT, 2015, NEW ENGL J MED, V373, P2103, DOI 10.1056/NEJMoa1511939
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao X, 2020, CLIN INFECT DIS
   Young PJ, 2017, CRIT CARE RESUSC, V19, P344
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 55
TC 3
Z9 3
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD AUG
PY 2020
VL 17
IS 8
BP 1008
EP 1015
DI 10.1513/AnnalsATS.202004-309SD
PG 8
WC Respiratory System
SC Respiratory System
GA MY8AS
UT WOS:000558638400017
PM 32425051
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Raman, L
   Bartlett, RH
   Paden, ML
AF Raman, Lakshmi
   Bartlett, Robert H.
   Paden, Matthew L.
TI Choice of ECMO as a Therapy in COVID-19?
SO ASAIO JOURNAL
LA English
DT Letter
C1 [Raman, Lakshmi] Univ Texas Southwestern Med Ctr Dallas, Div Pediat Crit Care, Dallas, TX 75390 USA.
   [Bartlett, Robert H.] Extracorporeal Life Support Org, Ann Arbor, MI USA.
   [Paden, Matthew L.] Emory Univ, Div Pediat Crit Care, Atlanta, GA 30322 USA.
RP Raman, L (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Div Pediat Crit Care, Dallas, TX 75390 USA.
CR Angouras DC, 2020, ASAIO J, V66, pE110, DOI 10.1097/MAT.0000000000001233
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD AUG
PY 2020
VL 66
IS 8
BP E112
EP E112
DI 10.1097/MAT.0000000000001235
PG 1
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA MZ4HL
UT WOS:000559082900005
PM 32740365
DA 2021-01-01
ER

PT J
AU Luo, J
   Rizvi, H
   Egger, JV
   Preeshagul, IR
   Wolchok, JD
   Hellmann, MD
AF Luo, Jia
   Rizvi, Hira
   Egger, Jacklynn, V
   Preeshagul, Isabel R.
   Wolchok, Jedd D.
   Hellmann, Matthew D.
TI Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung
   Cancers
SO CANCER DISCOVERY
LA English
DT Article
ID T-CELLS
AB The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers.
   SIGNIFICANCE: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes.
C1 [Luo, Jia; Rizvi, Hira; Egger, Jacklynn, V; Preeshagul, Isabel R.; Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10065 USA.
   [Wolchok, Jedd D.; Hellmann, Matthew D.] Weill Cornell Med Ctr, Dept Med, New York, NY USA.
   [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
   [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, New York, NY 10065 USA.
   [Wolchok, Jedd D.; Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, New York, NY 10065 USA.
RP Hellmann, MD (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM hellmanm@mskcc.org
OI Preeshagul, Isabel/0000-0002-4504-4520; Egger,
   Jacklynn/0000-0002-2180-4169
FU Memorial Sloan Kettering Cancer Center [P30-CA008748]; Druckenmiller
   Center for Lung Cancer Research at Memorial Sloan Kettering Cancer
   Center; Ludwig Collaborative, Memorial Sloan Kettering Cancer Center;
   Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [T32-CA009207, K30-UL1TR00457]; Damon
   Runyon Cancer Research Foundation [CI-98-18]
FX This work was supported by Memorial Sloan Kettering Cancer Center
   Support Grant/Core Grant No. P30-CA008748, the Druckenmiller Center for
   Lung Cancer Research at Memorial Sloan Kettering Cancer Center, and the
   Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan
   Kettering Cancer Center; J. Luo was supported in part by T32-CA009207
   and K30-UL1TR00457 grants from the NIH; J.D. Wolchok is a member of the
   Parker Institute for Cancer Immunotherapy; M.D. Hellmann is a Damon
   Runyon Clinical Investigator supported in part by the Damon Runyon
   Cancer Research Foundation Grant No. CI-98-18 and is a member of the
   Parker Institute for Cancer Immunotherapy. The authors thank Jean W.
   Liew, Jai Madhok, and Leon Castaneda for helpful discussions related to
   this analysis. The authors thank Daniel W. Kelly, Tobias M. Hohl, Mini
   Kamboj, Ying Taur, Elizabeth V. Robilotti, and the Thoracic Oncology
   Service attendings (Charles M. Rudin, Mark G. Kris, Gregory J. Riely,
   Helena A. Yu, Bob T. Li, Jamie E. Chaft, Paul K. Paik, Alexander E.
   Drilon, Marjorie G. Zauderer, Stephen R. Veach, Robert M. Daly, Juliana
   Eng, Azadeh Namakydoust, Afsheen Iqbal, Kenneth K. Ng, John J. Fiore,
   Piro Lito, Michael D. Offin, W. Victoria Lai, and Kathryn C. Arbour) for
   identifying patients and details for this analysis.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Barlesi FF S, AACR VIRT ANN M
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bonomi L, 2020, J THORAC ONCOL, V15, pE83, DOI 10.1016/j.jtho.2020.03.021
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Dai MF, 2020, FRACTALS, V28, DOI 10.1142/S0218348X2050067X
   Fairfax BP, 2020, NAT MED, V26, P193, DOI 10.1038/s41591-019-0734-6
   Garassino MC, 2020, AACR VIRT ANN M
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079
   Hung CH, 2020, MATERIALS, V13, DOI 10.3390/ma13020414
   Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330
   Koralnik IJ, 2019, NEW ENGL J MED, V380, P1667, DOI 10.1056/NEJMe1904140
   Lewis MA, 2020, N ENGL J MED
   Lewnard JA, 2020, INCIDENCE CLIN OUTCO, DOI 10.1101/2020.04.12.20062943
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lovly CM, 2020, RAPIDLY FATAL PNEUMO, DOI 10.1101/2020.04.29.20085738
   Ma XT, 2020, CELL ONCOL, V43, P751, DOI 10.1007/s13402-020-00512-w
   MEHTA V, 2020, CANCER DISCOV, DOI DOI 10.1080/01635581.2020.1778746
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Muus C, 2020, BIORXIV
   Patanavanich R, 2020, NICOTINE TOB RES
   Robilotti EV, 2020, DETERMINANTS SEVERIT
   Smith JC, 2020, BIORXIV
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8
   Wu Z, 2020, JAMA
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 35
TC 46
Z9 46
U1 5
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD AUG
PY 2020
VL 10
IS 8
BP 1121
EP 1128
DI 10.1158/2159-8290.CD-20-0596
PG 8
WC Oncology
SC Oncology
GA MY8SM
UT WOS:000558688700021
PM 32398243
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Polychrones, J
AF Polychrones, J.
TI Drug Information Association (DIA) 2020 Virtual Global Annual Meeting
   (June 14-18, 2020)
SO DRUGS OF TODAY
LA English
DT Article
DE ACTIV Partnership; Decentralized clinical trials; Electronic health
   records; Digital Research Networks; Statistical data monitoring; Key
   risk indicators; Quality tolerance limits; Digital health technology;
   Patient-focused drug development; Prescription drug use-related
   software; Patient-reported outcomes
AB At the 56th Global Annual Meeting of the Drug Information Association (DIA), attendees met virtually during the height of the global COVID-19 pandemic for "rapid cross-stakeholder, cross-border collaboration" to support health worldwide. Sessions included presenters and speakers from regulatory, patient advocacy and academia sectors, with patients at the forefront of those discussions. This report covers various presentations and panel discussions from the 4-day meeting that focus on COVID-19, innovative trial designs spurred by a need to adapt amid a pandemic, digital health, novel products inspiring new regulatory standards, clinical trials, data collection and management, the need for more and better data and the ever-increasing importance of the patient perspective.
C1 [Polychrones, J.] Clarivate, Woodbridge, VA 22191 USA.
RP Polychrones, J (corresponding author), Clarivate, Woodbridge, VA 22191 USA.
EM jaime.polychrones@clarivate.com
NR 0
TC 0
Z9 0
U1 1
U2 1
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD AUG
PY 2020
VL 56
IS 8
BP 541
EP 554
DI 10.1358/dot.2020.56.8.3195003
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MY9DN
UT WOS:000558719400005
PM 33025949
DA 2021-01-01
ER

PT J
AU Elledge, CR
   Beriwal, S
   Chargari, C
   Chopra, S
   Erickson, BA
   Gaffney, DK
   Jhingran, A
   Klopp, AH
   Small, W
   Yashar, CM
   Viswanathan, AN
AF Elledge, Christen R.
   Beriwal, Sushil
   Chargari, Cyrus
   Chopra, Supriya
   Erickson, Beth A.
   Gaffney, David K.
   Jhingran, Anuja
   Klopp, Ann H.
   Small, William, Jr.
   Yashar, Catheryn M.
   Viswanathan, Akila N.
TI Radiation therapy for gynecologic malignancies during the COVID-19
   pandemic: International expert consensus recommendations
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; SIMULTANEOUS INTEGRATED BOOST; ADVANCED PELVIC
   MALIGNANCIES; COURSE PALLIATIVE RADIATION; EXTERNAL-BEAM RADIOTHERAPY;
   LOCALLY ADVANCED-CARCINOMA; DOSE-RATE BRACHYTHERAPY; MODULATED ARC
   THERAPY; PHASE-II TRIAL; TREATMENT TIME
AB Objective. To develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic.
   Methods. An international committee of ten experts in gynecologic radiation oncology convened to provide consensus recommendations for patients with gynecologic malignancies referred for radiation therapy. Treatment priority groups were established. A review of the relevant literature was performed and different clinical scenarios were categorized into three priority groups. For each stage and clinical scenario in cervical, endometrial. vulvar, vaginal and ovarian cancer, specific recommendations regarding dose, technique, and timing were provided by the panel.
   Results. Expert review and discussion generated consensus recommendations to guide radiation oncologists treating gynecologic malignancies during the COVID-19 pandemic. Priority scales for cervical, endometrial, vulvar, vaginal, and ovarian cancers are presented. Both radical and palliative treatments are discussed. Management of COVID-19 positive patients is considered. Hypofractionated radiation therapy should be used when feasible and recommendations regarding radiation dose, timing, and technique have been provided for external beam and brachytherapy treatments. Concurrent chemotherapy may be limited in some countries, and consideration of radiation alone is recommended.
   Conclusions. The expert consensus recommendations provide guidance for delivering radiation therapy during the COVID-19 pandemic. Specific recommendations have been provided for common clinical scenarios encountered in gynecologic radiation oncology with a focus on strategies to reduce patient and staff exposure to COVID-19. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Elledge, Christen R.; Viswanathan, Akila N.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA.
   [Beriwal, Sushil] Univ Pittsburgh, Dept Radiat Oncol, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA.
   [Chargari, Cyrus] Gustave Roussy, Dept Radiat Oncol, Canc Campus, Villejuif, France.
   [Chopra, Supriya] Homi Bhabha Natl Inst, Tata Mem Ctr, Adv Ctr Treatment Res & Educ Canc, Dept Radiat Oncol, Kharghar, Navi Mumbai, India.
   [Erickson, Beth A.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
   [Gaffney, David K.] Univ Utah, Huntsman Canc Inst, Dept Radiat Oncol, Salt Lake City, UT USA.
   [Jhingran, Anuja; Klopp, Ann H.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
   [Small, William, Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL USA.
   [Yashar, Catheryn M.] Univ Calif San Diego, Dept Radiat Oncol, San Diego, CA 92103 USA.
RP Viswanathan, AN (corresponding author), 401 N Broadway,Suite 1440, Baltimore, MD 21287 USA.
EM anv@jhu.edu
CR Al-Rashdan A., 2020, ADV RAD ONCOLOGY
   Albuquerque K, 2020, INT J RADIAT ONCOL, V106, P464, DOI 10.1016/j.ijrobp.2019.10.042
   Albuquerque K, 2019, BRACHYTHERAPY, V18, P429, DOI 10.1016/j.brachy.2019.02.008
   Banna G, 2020, ESMO OPEN, V5
   Beriwal S, 2012, BRACHYTHERAPY, V11, P68, DOI 10.1016/j.brachy.2011.06.008
   Blake P, 2003, BEST PRACT RES CL OB, V17, P649, DOI 10.1016/S1521-6934(03)00042-7
   Bloemers MCWM, 2012, MED DOSIM, V37, P310, DOI 10.1016/j.meddos.2011.11.005
   BOULWARE RJ, 1979, INT J RADIAT ONCOL, V5, P333, DOI 10.1016/0360-3016(79)91212-4
   Boyle J, 2014, GYNECOL ONCOL, V135, P239, DOI 10.1016/j.ygyno.2014.08.037
   Braunstein L.Z., 2020, ADV RAD ONCOLOGY
   Brewster DJ, 2020, MED J AUSTRALIA, V212, P472, DOI 10.5694/mja2.50598
   Brown AP, 2013, GYNECOL ONCOL, V130, P300, DOI 10.1016/j.ygyno.2013.04.469
   Brown TB, 2005, AM FAM PHYSICIAN, V71, P85
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Cattaneo R, 2014, INT J RADIAT ONCOL, V88, P866, DOI 10.1016/j.ijrobp.2013.11.247
   Chapman BV, 2017, INT J RADIAT ONCOL, V97, P107, DOI 10.1016/j.ijrobp.2016.09.023
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen W., 2020, ADV RAD ONCOLOGY
   Chen Y. L., 2020, ADV RAD ONCOLOGY
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chopra S, 2020, INT J RADIAT ONCOL, V106, P310, DOI 10.1016/j.ijrobp.2019.10.037
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Cormio G, 2010, EUR J CANCER CARE, V19, P302, DOI 10.1111/j.1365-2354.2008.01011.x
   D'Souza D, 2014, BRACHYTHERAPY, V13, P225, DOI 10.1016/j.brachy.2014.02.001
   De Felice F., 2020, OFFICIAL J ASS COLOP
   De Felice F, 2020, RADIOTHER ONCOL, V147, P84, DOI 10.1016/j.radonc.2020.03.020
   Dinh T.-K.T., 2020, ADV RAD ONCOLOGY
   Dolly D, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00031
   DSilva D.F., 2020, BR J ANAESTH
   Escher AR, 2020, CUREUS, V12, DOI 10.7759/cureus.7345
   Faul C., 1997, EUR J CANCER, V33, pS205
   Faul CM, 1997, INT J RADIAT ONCOL, V38, P381, DOI 10.1016/S0360-3016(97)82500-X
   Feng CH, 2016, J APPL CLIN MED PHYS, V17, P76, DOI 10.1120/jacmp.v17i5.6123
   Frey JN, 2016, INT J GYNECOL CANCER, V26, P575, DOI 10.1097/IGC.0000000000000637
   Gaffney DK, 2016, INT J RADIAT ONCOL, V95, P1191, DOI 10.1016/j.ijrobp.2016.02.043
   Gay HA, 2019, PRACT RADIAT ONCOL, V9, P305, DOI 10.1016/j.prro.2019.03.007
   Ferreira JAG, 2015, REP PRACT ONCOL RADI, V20, P328, DOI 10.1016/j.rpor.2015.05.010
   Graboyes EM, 2019, JAMA OTOLARYNGOL, V145, P166, DOI 10.1001/jamaoto.2018.2716
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   HALLE JS, 1986, INT J RADIAT ONCOL, V12, P1947, DOI 10.1016/0360-3016(86)90130-6
   Hamilton VA, 2012, HEART LUNG, V41, P167, DOI 10.1016/j.hrtlng.2011.09.001
   Harkenrider MM, 2018, INT J RADIAT ONCOL, V101, P1069, DOI 10.1016/j.ijrobp.2018.04.049
   Haviland JS, 2016, RADIOTHER ONCOL, V121, P420, DOI 10.1016/j.radonc.2016.08.027
   HEAPS JM, 1990, GYNECOL ONCOL, V38, P309, DOI 10.1016/0090-8258(90)90064-R
   Hendry J, 2017, INT J RADIAT ONCOL, V99, P1313
   HODSON DI, 1983, GYNECOL ONCOL, V16, P112, DOI 10.1016/0090-8258(83)90016-1
   HOMESLEY HD, 1986, OBSTET GYNECOL, V68, P733
   Huang J, 2003, J CLIN ONCOL, V21, P555, DOI 10.1200/JCO.2003.04.171
   Jurgenliemk-Schulz IM, 2019, SEMIN RADIAT ONCOL, V29, P158, DOI 10.1016/j.semradonc.2018.11.002
   Kang JaV A., 2013, PEREZ BRADYS PRINCIP
   Kemmerer E, 2013, INT J RADIAT ONCOL, V85, P129, DOI 10.1016/j.ijrobp.2012.02.058
   Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048
   Kim DH, 2013, RADIAT ONCOL J, V31, P216, DOI 10.3857/roj.2013.31.4.216
   Klopp A, 2014, PRACT RADIAT ONCOL, V4, P137, DOI 10.1016/j.prro.2014.01.003
   Klopp AH, 2009, GYNECOL ONCOL, V115, P6, DOI 10.1016/j.ygyno.2009.06.035
   Krengli M., 2020, ADV RAD ONCOLOGY
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lin SM, 2017, ONCOTARGET, V8, P85203, DOI 10.18632/oncotarget.19617
   Macchia G, 2016, INT J RADIAT ONCOL, V96, P606, DOI 10.1016/j.ijrobp.2016.07.004
   Macchia G, 2014, ACTA ONCOL, V53, P251, DOI 10.3109/0284186X.2013.819997
   Manuel MM, 2016, RADIOTHER ONCOL, V120, P486, DOI 10.1016/j.radonc.2016.05.019
   Mariani A, 2002, GYNECOL ONCOL, V87, P112, DOI 10.1006/gyno.2002.6789
   Matei D, 2019, NEW ENGL J MED, V380, P2317, DOI 10.1056/NEJMoa1813181
   Miyamoto DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065048
   Moore DH, 2012, GYNECOL ONCOL, V124, P529, DOI 10.1016/j.ygyno.2011.11.003
   Niazi TM, 2005, INT J RADIAT ONCOL, V63, P1108, DOI 10.1016/j.ijrobp.2005.04.036
   Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2
   Onsrud M, 2001, GYNECOL ONCOL, V82, P167, DOI 10.1006/gyno.2001.6233
   Papachristofilou A., 2020, ADV RAD ONCOLOGY
   Parthasarathy A, 2006, GYNECOL ONCOL, V103, P1095, DOI 10.1016/j.ygyno.2006.06.030
   PEREZ CA, 1995, INT J RADIAT ONCOL, V32, P1275, DOI 10.1016/0360-3016(95)00220-S
   Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606
   Qin Lu, 2020, Mycology-An International Journal On Fungal Biology, V11, DOI 10.1080/21501203.2020.1727578
   Raffetto N, 2003, ANTICANCER RES, V23, P3105
   Rahimi F., 2020, ARCH MED RES
   Rivera A., 2020, ADV RAD ONCOLOGY
   Sapienza LG, 2019, CLIN TRANSL RAD ONCO, V14, P40, DOI 10.1016/j.ctro.2018.11.007
   Schwarz JK, 2015, BRACHYTHERAPY, V14, P587, DOI 10.1016/j.brachy.2015.06.002
   Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387
   Shankar Abhishek, 2020, Asian Pac J Cancer Prev, V21, P569, DOI 10.31557/APJCP.2020.21.3.569
   Sharma M, 2016, J CANCER RES THER, V12, P103, DOI 10.4103/0973-1482.148676
   Small W, 2012, BRACHYTHERAPY, V11, P58, DOI 10.1016/j.brachy.2011.08.005
   Song SS, 2013, CANCER-AM CANCER SOC, V119, P325, DOI 10.1002/cncr.27652
   Sorbe B, 2009, INT J GYNECOL CANCER, V19, P873, DOI 10.1111/IGC.0b013e3181a6c9df
   Soyfer V, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-81
   SPANOS W, 1989, INT J RADIAT ONCOL, V17, P659, DOI 10.1016/0360-3016(89)90120-X
   SPANOS WJ, 1993, INT J RADIAT ONCOL, V25, P399, DOI 10.1016/0360-3016(93)90059-5
   te Grootenhuis NC, 2019, GYNECOL ONCOL, V154, P266, DOI 10.1016/j.ygyno.2019.05.010
   Tergas AI, 2016, CANCER INVEST, V34, P137, DOI 10.3109/07357907.2015.1131291
   UCLA, UCLA NEWSROOM
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Viswanathan AN, 2013, GYNECOL ONCOL, V130, P545, DOI 10.1016/j.ygyno.2013.05.036
   Viswanathan AN, 2012, BRACHYTHERAPY, V11, P47, DOI 10.1016/j.brachy.2011.07.002
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Wright J.L., 2020, ADV RAD ONCOLOGY
   Wu S., 2020, ADV RAD ONCOLOGY
   Yang C, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28248
   Yerramilli D., 2020, ADV RAD ONCOLOGY
   Zaorsky N.G., 2020, ADV RAD ONCOLOGY
NR 99
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD AUG
PY 2020
VL 158
IS 2
BP 244
EP 253
DI 10.1016/j.ygyno.2020.06.486
PG 10
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA MZ0CZ
UT WOS:000558793000004
PM 32563593
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU George, PM
   Wells, AU
   Jenkins, RG
AF George, Peter M.
   Wells, Athol U.
   Jenkins, R. Gisli
TI Pulmonary fibrosis and COVID-19: the potential role for antifibrotic
   therapy
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; QUALITY-OF-LIFE;
   INFLUENZA-VIRUS INFECTION; GROWTH-FACTOR-BETA; C-JUN; ACUTE
   EXACERBATION; TGF-BETA; PIRFENIDONE; INFLAMMATION
AB In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215 000 deaths. The symptoms associated with COVID-19 are diverse, ranging from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome. The major risk factors for severe COVID-19 are shared with idiopathic pulmonary fibrosis (IPF), namely increasing age, male sex, and comorbidities such as hypertension and diabetes. However, the role of antifibrotic therapy in patients with IPF who contract SARS-CoV-2 infection, and the scientific rationale for their continuation or cessation, is poorly defined. Furthermore, several licensed and potential antifibrotic compounds have been assessed in models of acute lung injury and viral pneumonia. Data from previous coronavirus infections such as severe acute respiratory syndrome and Middle East respiratory syndrome, as well as emerging data from the COVID-19 pandemic, suggest there could be substantial fibrotic consequences following SARS-CoV-2 infection. Antifibrotic therapies that are available or in development could have value in preventing severe COVID-19 in patients with IPF, have the potential to treat severe COVID-19 in patients without IPF, and might have a role in preventing fibrosis after SARS-CoV-2 infection.
C1 [George, Peter M.; Wells, Athol U.] Royal Brompton & Harefield NHS Fdn Trust, London, England.
   [George, Peter M.; Wells, Athol U.] Imperial Coll London, Natl Heart & Lung Inst, London, England.
   [Jenkins, R. Gisli] Univ Nottingham, Natl Inst Hlth Res, Biomed Res Ctr, Nottingham NG5 1PB, England.
RP Jenkins, RG (corresponding author), Univ Nottingham, Natl Inst Hlth Res, Biomed Res Ctr, Nottingham NG5 1PB, England.
EM gisli.jenkins@nottingham.ac.uk
CR Allen RJ, 2020, AM J RESP CRIT CARE, V201, P564, DOI 10.1164/rccm.201905-1017OC
   Andersen O, 1997, SCAND J IMMUNOL, V46, P331, DOI 10.1046/j.1365-3083.1997.d01-147.x
   Antonio GE, 2003, RADIOLOGY, V228, P810, DOI 10.1148/radiol.2283030726
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Asad M, 2020, IEEE J ELECTRON DEVI, V8, P457, DOI 10.1109/JEDS.2020.2988630
   Azuma A, 2005, AM J RESP CELL MOL, V32, P93, DOI 10.1165/rcmb.2003-0374OC
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Borthwick LA, 2016, SEMIN IMMUNOPATHOL, V38, P517, DOI 10.1007/s00281-016-0559-z
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   Burnham EL, 2013, CRIT CARE MED, V41, P445, DOI 10.1097/CCM.0b013e31826a5062
   Castelino FV, 2016, ARTHRITIS RHEUMATOL, V68, P2964, DOI 10.1002/art.39797
   Chen YJ, 2018, AM J PATHOL, V188, P1031, DOI 10.1016/j.ajpath.2017.12.014
   Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI
   Collard HR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-73
   Das Karuna M, 2017, Indian J Radiol Imaging, V27, P342, DOI 10.4103/ijri.IJRI_469_16
   Davey A, 2011, EUR RESPIR J, V38, P959, DOI 10.1183/09031936.00032111
   Desai SR, 1999, RADIOLOGY, V210, P29, DOI 10.1148/radiology.210.1.r99ja2629
   Ding XB, 2015, SHOCK, V43, P352, DOI 10.1097/SHK.0000000000000313
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fisher Mark, 2017, J Manag Care Spec Pharm, V23, pS17, DOI 10.18553/jmcp.2017.23.3-b.s17
   Flaherty KR, 2019, NEW ENGL J MED, V381, P1718, DOI 10.1056/NEJMoa1908681
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Gad ES, 2020, INFLAMMATION, V43, P123, DOI 10.1007/s10753-019-01101-2
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   George PM, 2019, LANCET RESP MED, V7, P271, DOI 10.1016/S2213-2600(18)30502-2
   George PM, 2014, CIRC RES, V114, P677, DOI 10.1161/CIRCRESAHA.114.302221
   George PM, 2012, PHARMACOL THERAPEUT, V135, P44, DOI 10.1016/j.pharmthera.2012.03.006
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamada N, 2005, J IMMUNOL, V175, P1224, DOI 10.4049/jimmunol.175.2.1224
   Herbert J, 2002, MOL MED, V8, P9, DOI 10.1007/BF03401998
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Horvath A, 2001, ANTIVIR RES, V52, P43, DOI 10.1016/S0166-3542(01)00158-9
   Hui DS, 2005, THORAX, V60, P401, DOI 10.1136/thx.2004.030205
   Hutchinson J, 2015, EUR RESPIR J, V46, P795, DOI 10.1183/09031936.00185114
   Iwata T, 2016, ANN THORAC SURG, V102, P1905, DOI 10.1016/j.athoracsur.2016.05.094
   Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183
   Jia XH, 2019, INT IMMUNOPHARMACOL, V67, P211, DOI 10.1016/j.intimp.2018.12.017
   Jia XH, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007428
   Jo HE, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01592-2016
   Job ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059623
   Jolly L, 2014, J BIOL CHEM, V289, P35246, DOI 10.1074/jbc.M114.582262
   Kanayama M, 2020, SURG TODAY, V50, P469, DOI 10.1007/s00595-019-01923-5
   King CS, 2017, LANCET RESP MED, V5, P72, DOI 10.1016/S2213-2600(16)30222-3
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1
   Kluwe J, 2010, GASTROENTEROLOGY, V138, P347, DOI 10.1053/j.gastro.2009.09.015
   Kobayashi T, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0261-z
   Le TTT, 2014, J IMMUNOL, V193, P3755, DOI 10.4049/jimmunol.1302470
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li Y, 2018, MOL IMMUNOL, V99, P134, DOI 10.1016/j.molimm.2018.05.003
   Liu M, 2007, FASEB J, V21, P1586, DOI 10.1096/fj.06-6589com
   Liu Y, 2020, ANTIHYPERTENSIVE ANG, DOI [10.1101/2020.03.20.20039586, DOI 10.1101/2020.03.20.20039586]
   Liu Y, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0405-7
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lou LM, 2019, INT J CLIN EXP PATHO, V12, P528
   Lukey PT, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01992-2018
   Ma FY, 2007, J AM SOC NEPHROL, V18, P472, DOI 10.1681/ASN.2006060604
   Ma YJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03046
   MacKinnon AC, 2012, AM J RESP CRIT CARE, V185, P537, DOI 10.1164/rccm.201106-0965OC
   Maher TM, 2020, LANCET RESP MED, V8, P147, DOI 10.1016/S2213-2600(19)30341-8
   Masclans JR, 2011, CHEST, V139, P1340, DOI 10.1378/chest.10-2438
   McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Meliopoulos VA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005804
   Menk M, 2018, J INFLAMM RES, V11, P169, DOI 10.2147/JIR.S160573
   Mercer PF, 2016, THORAX, V71, P701, DOI 10.1136/thoraxjnl-2015-207429
   Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020
   Moodley YP, 2003, AM J PATHOL, V163, P345, DOI 10.1016/S0002-9440(10)63658-9
   Nakagawa N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87446
   Nalysnyk L, 2012, EUR RESPIR REV, V21, P355, DOI 10.1183/09059180.00002512
   Nathan SD, 2017, LANCET RESP MED, V5, P33, DOI 10.1016/S2213-2600(16)30326-5
   Nita-Lazar M, 2015, MOL IMMUNOL, V65, P1, DOI 10.1016/j.molimm.2014.12.010
   O'Donoghue RJJ, 2012, EMBO MOL MED, V4, P939, DOI 10.1002/emmm.201100604
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pilling D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093730
   Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963
   Raghu G, 2018, JAMA-J AM MED ASSOC, V319, P2299, DOI 10.1001/jama.2018.6129
   Raghu G, 2014, LANCET RESP MED, V2, P566, DOI 10.1016/S2213-2600(14)70101-8
   Rathinasabapathy A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00180
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Savale L, 2014, EUR RESPIR J, V44, P1627, DOI 10.1183/09031936.00057914
   Sekihara K, 2020, SURG TODAY, V50, P905, DOI 10.1007/s00595-020-01978-9
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Simon-Blancal V, 2012, RESPIRATION, V83, P28, DOI 10.1159/000329891
   Song YL, 2008, INFECT IMMUN, V76, P2325, DOI 10.1128/IAI.01431-07
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Sreekanth GP, 2017, ANTIVIR RES, V141, P7, DOI 10.1016/j.antiviral.2017.02.003
   Swaney JS, 2010, BRIT J PHARMACOL, V160, P1699, DOI 10.1111/j.1476-5381.2010.00828.x
   Thille AW, 2013, LANCET RESP MED, V1, P395, DOI 10.1016/S2213-2600(13)70053-5
   van der Velden JLJ, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0117-2
   Vancheri C, 2010, EUR RESPIR J, V35, P496, DOI 10.1183/09031936.00077309
   Virakul S, 2016, MOL CELL ENDOCRINOL, V433, P94, DOI 10.1016/j.mce.2016.05.023
   Wang J, 2020, Zhonghua Shao Shang Za Zhi, V36, P691, DOI 10.3760/cma.j.cn501120-20200307-00132
   Wang YL, 2013, CARDIOLOGY, V126, P1, DOI 10.1159/000351179
   Wells AU, 2020, LANCET RESP MED, V8, P453, DOI 10.1016/S2213-2600(20)30036-9
   Wollin L, 2014, J PHARMACOL EXP THER, V349, P209, DOI 10.1124/jpet.113.208223
   Wootton SC, 2011, AM J RESP CRIT CARE, V183, P1698, DOI 10.1164/rccm.201010-1752OC
   Xie JJ, 2014, BBA-MOL BASIS DIS, V1842, P2479, DOI 10.1016/j.bbadis.2014.04.017
   Xu X, 2020, EFFECTIVE TREATMENT, DOI [10.12074/202003.00026, DOI 10.12074/202003.00026]
   Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR
   Zhang SP, 2016, ARCH VIROL, V161, P345, DOI 10.1007/s00705-015-2668-8
   Zhang T, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P496, DOI 10.3760/cma.j.cn112147-20200311-00312
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 108
TC 63
Z9 63
U1 6
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD AUG
PY 2020
VL 8
IS 8
BP 807
EP 815
DI 10.1016/S2213-2600(20)30225-3
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA MZ1FJ
UT WOS:000558867100020
PM 32422178
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Palmieri, V
   Papi, M
AF Palmieri, V.
   Papi, M.
TI Can graphene take part in the fight against COVID-19?
SO NANO TODAY
LA English
DT Article
ID OXIDE; CORONAVIRUS; INHIBITION; BACTERIA
AB The pneumonia outbreak of coronavirus disease 2019 (COVID-19) represents a global issue. The bidimensional material graphene has captured much attention due to promising antimicrobial applications and has also demonstrated antiviral efficacy. In response to this global outbreak, we summarized the current state of knowledge of graphene and virus interaction as well as possible successful applications to fight COVID-19. Antibody-conjugated graphene sheets can rapidly detect targeted virus proteins and can be useful for large population screening, but also for the development of environmental sensors and filters, given the low cost of graphene materials. Functionalized graphene has demonstrated a good viral capture capacity that, combined with heat or light-mediated inactivation, could be used as a disinfectant. Graphene sensors arrays can be implemented on standard utility textiles and drug efficacy screening. Thanks to its high versatility, we foresee that graphene may have a leading role in the fight against COVID-19. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Palmieri, V.; Papi, M.] Univ Cattolica Sacro Cuore, Dipartimento Neurosci, Largo Francesco Vito 1, I-00168 Rome, Italy.
   [Palmieri, V.; Papi, M.] Fdn Policlin Univ A Gemelli IRCSS, Rome, Italy.
   [Palmieri, V.] Natl Res Council CNR, Inst Complex Syst ISC, Rome, Italy.
RP Palmieri, V (corresponding author), Univ Cattolica Sacro Cuore, Dipartimento Neurosci, Largo Francesco Vito 1, I-00168 Rome, Italy.
EM valentina.palmieri@unicatt.it; massimiliano.papi@unicatt.it
RI Palmieri, Valentina/H-7836-2012
OI Palmieri, Valentina/0000-0002-6358-9647
CR Akhavan O, 2012, J PHYS CHEM C, V116, P9653, DOI 10.1021/jp301707m
   Chauhan N., J MAT
   Chen YN, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040430
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   Deokar AR, 2017, BIOCONJUGATE CHEM, V28, P1115, DOI 10.1021/acs.bioconjchem.7b00030
   Donskyi IS, 2019, NANOSCALE, V11, P15804, DOI 10.1039/c9nr05273a
   Du T, 2018, ACS APPL BIO MAT, V1, P1286, DOI DOI 10.1021/acsabm.8b00154
   Du XX, 2019, MAT SCI ENG C-MATER, V105, DOI 10.1016/j.msec.2019.110052
   Fadeel B, 2018, ACS NANO, V12, P10582, DOI 10.1021/acsnano.8b04758
   Frost R., NANO LETT
   Huang JL, 2016, ANAL CHIM ACTA, V913, P121, DOI 10.1016/j.aca.2016.01.050
   Iannazzo D, 2018, BIOCONJUGATE CHEM, V29, P3084, DOI 10.1021/acs.bioconjchem.8b00448
   Jang H., ANGEW CHEM INT ED
   Jones ST, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax9318
   Joshi SR, 2020, MAT SCI ENG C-MATER, V108, DOI 10.1016/j.msec.2019.110465
   Kinnamon DS, 2018, J ELECTROCHEM SOC, V165, pB3084, DOI 10.1149/2.0131808jes
   Li Q., 2019, ADV OPT MAT, V7, DOI [10.1021/acsbiomaterials.6b00812., DOI 10.1021/ACSBIOMATERIALS.6B00812]
   Li Y, 2006, J HOSP INFECT, V62, P58, DOI 10.1016/j.jhin.2005.04.015
   Mycroft-West C, 2020, 2019 CORONAVIRUS SAR
   Naskalska A, 2019, J VIROL, V93, DOI 10.1128/JVI.00355-19
   Palmieri V, 2019, NANOSCALE HORIZ, V4, P273, DOI 10.1039/c8nh00318a
   Palmieri V, 2017, ACS BIOMATER SCI ENG, V3, P619, DOI 10.1021/acsbiomaterials.6b00812
   Palmieri V, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/aa6150
   Palmieri V, 2016, EXPERT REV MED DEVIC, V13, P1013, DOI 10.1080/17434440.2016.1245612
   Ren XM, 2018, ENVIRON SCI-NANO, V5, P1298, DOI 10.1039/c7en01258f
   Rui LF, 2015, BBA-BIOMEMBRANES, V1848, P1203, DOI 10.1016/j.bbamem.2015.02.018
   Sametband M., ACS APPL MAT
   Seah I, 2020, EYE
   Smith M., 2020, REPURPOSING THERAPEU, DOI 10.26434/chemrxiv.11871402.v3
   Sohrabi C., 2020, INT J SURG
   Song ZY, 2015, SMALL, V11, P1171, DOI 10.1002/smll.201401706
   Stanford MG, 2019, ACS NANO, V13, P11912, DOI 10.1021/acsnano.9b05983
   Steinberg RS, 2017, ACS NANO, V11, P5670, DOI 10.1021/acsnano.7b01106
   Ting D, 2018, ACS APPL NANO MATER, V1, P5451, DOI 10.1021/acsanm.8b00779
   Xie Z., 2014, PLOS ONE, V9
   Yang XX, 2017, NANOSCALE, V9, P16086, DOI 10.1039/c7nr06520e
   Ye SY, 2015, ACS APPL MATER INTER, V7, P21571, DOI 10.1021/acsami.5b06876
   Yip L, 2019, J OCCUP ENVIRON HYG, V16, P341, DOI 10.1080/15459624.2019.1591626
   Ziem B, 2017, NANOSCALE, V9, P3774, DOI 10.1039/c7nr00611j
   Ziem B, 2016, ADV HEALTHC MATER, V5, P2922, DOI 10.1002/adhm.201600812
NR 40
TC 14
Z9 14
U1 22
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1748-0132
EI 1878-044X
J9 NANO TODAY
JI Nano Today
PD AUG
PY 2020
VL 33
AR 100883
DI 10.1016/j.nantod.2020.100883
PG 4
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA MX5WL
UT WOS:000557793000012
PM 32382315
OA Green Published
DA 2021-01-01
ER

PT J
AU Akindele, AJ
   Agunbiade, FO
   Sofidiya, MO
   Awodele, O
   Sowemimo, A
   Ade-Ademilua, O
   Akinleye, MO
   Ishola, IO
   Orabueze, I
   Salu, OB
   Oreagba, IA
   Asekun, OT
   Odukoya, O
AF Akindele, Abidemi J.
   Agunbiade, Foluso O.
   Sofidiya, Margaret O.
   Awodele, Olufunsho
   Sowemimo, Abimbola
   Ade-Ademilua, Omobolanle
   Akinleye, Moshood O.
   Ishola, Ismail O.
   Orabueze, Ifeoma
   Salu, Olumuyiwa B.
   Oreagba, Ibrahim A.
   Asekun, Olayinka T.
   Odukoya, Olukemi
CA ACEDHARS UNILAG COVID 19 Response
TI COVID-19 Pandemic: A Case for Phytomedicines
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE COVID-19; phytomedicines; therapeutic management; strategic
   interventions; safety; collaboration
ID MEDICINAL-PLANTS; CHLOROQUINE; INHIBITOR
AB Coronavirus disease 2019 (COVID-19) is an infection caused by a newly discovered coronavirus which was identified in Wuhan, China. The race is on globally to repurpose drugs for COVID-19 and develop a safe and effective vaccine against the disease. There is an urgent need to search for effective remedies against COVID-19 from the rich and extensive flora of Africa and the world. A literature search was conducted to obtain information on drugs with the potential for effectiveness in the treatment of COVID-19 based mostly on outcomes of preclinical studies and a few clinical investigations. This was considered important to this perspective as some of the identified mechanisms of action may be related to potential anti-COVID-19 actions of phytomedicines. The findings from the literature search were also used to establish the need for exploration of phytomedicines in the fight against COVID-19. This perspective identifies the need to preserve the rich tradition of herbal medicine in Africa, repositioning it by inculcating all aspects of discovery, development, and chemical evaluation of pharmaceuticals from medicinal plants for effective management of prevalent diseases. The identified mechanisms of action of current drugs under consideration for the treatment of COVID-19 include preventing fusion of SARS-CoV-2 with human cells; decrease acidity in endosomes, cell membrane-derived vesicles for transportation of the virus within the host cell and within which the virus can replicate; and blockade of the production of proinflammatory cytokines. Phytomedicines may possibly elicit either one or a combination of these effects. The case for the exploration of phytomedicines against COVID-19 is strengthened by the emergence of a number of conventional drugs from medicinal plants and the emergence of botanicals with proven efficacy for some medical conditions. Caution against indiscriminate use of medicinal plants in the guise of treating COVID-19 has been highlighted and the need for reliable preclinical and clinical studies.
C1 [Akindele, Abidemi J.; Agunbiade, Foluso O.; Sofidiya, Margaret O.; Awodele, Olufunsho; Sowemimo, Abimbola; Ade-Ademilua, Omobolanle; Akinleye, Moshood O.; Ishola, Ismail O.; Orabueze, Ifeoma; Salu, Olumuyiwa B.; Oreagba, Ibrahim A.; Asekun, Olayinka T.; Odukoya, Olukemi] Univ Lagos UNILAG, African Ctr Excellence Drug Res Herbal Med Dev &, Lagos, Nigeria.
   [Akindele, Abidemi J.; Awodele, Olufunsho; Ishola, Ismail O.; Oreagba, Ibrahim A.] Univ Lagos, Coll Med, Fac Basic Med Sci, Dept Pharmacol Therapeut & Toxicol, Lagos, Nigeria.
   [Agunbiade, Foluso O.; Asekun, Olayinka T.] Univ Lagos, Fac Sci, Dept Chem, Lagos, Nigeria.
   [Sofidiya, Margaret O.; Sowemimo, Abimbola; Orabueze, Ifeoma; Odukoya, Olukemi] Univ Lagos, Fac Pharm, Dept Pharmacognosy, Lagos, Nigeria.
   [Ade-Ademilua, Omobolanle] Univ Lagos, Fac Sci, Dept Bot, Lagos, Nigeria.
   [Akinleye, Moshood O.] Univ Lagos, Fac Pharm, Dept Pharmaceut Chem, Lagos, Nigeria.
   [Salu, Olumuyiwa B.] Univ Lagos, Coll Med, Fac Basic Med Sci, Dept Med Microbiol & Parasitol, Lagos, Nigeria.
RP Akindele, AJ (corresponding author), Univ Lagos UNILAG, African Ctr Excellence Drug Res Herbal Med Dev &, Lagos, Nigeria.
EM jakindele@unilag.edu.ng
RI Agunbiade, Foluso O./N-4184-2013; Agunbiade, Foluso/AAY-8016-2020;
   Akindele, Abidemi/O-9150-2014
OI Agunbiade, Foluso O./0000-0002-6467-8561; Akindele,
   Abidemi/0000-0002-9007-0437; Asekun, Olayinka/0000-0002-3875-003X
CR Akintonwa A, 2009, J ETHNOPHARMACOL, V125, P461, DOI 10.1016/j.jep.2009.07.013
   Ampel NM, 2020, NEJM J WATCH
   [Anonymous], 2020, NAT PLANTS, V6, P177, DOI 10.1038/s41477-020-0628-0
   Awodele O, 2010, INT J BIOMEDICAL PHA, V4, P76
   Awodele O, 2018, W AFR J PHARM, V29, P1
   Brown JC, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz078
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Cohen M, 2012, AUST FAM PHYSICIAN, V41, P495
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   FARNSWORTH NR, 1985, B WORLD HEALTH ORGAN, V63, P965
   Fischer WA, 2018, LANCET INFECT DIS, V18, pE183, DOI 10.1016/S1473-3099(17)30677-1
   Frie K., 2020, CHLOROQUINE HYDROXYC
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gadano AB, 2006, J ETHNOPHARMACOL, V103, P246, DOI 10.1016/j.jep.2005.08.043
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hurt S., 2019, AFRIGETICS BOT
   Ilori MO, 1996, J DIARRHOEAL DIS RES, V14, P283
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   National Institute for Health Care and Excellence (NICE), 2014, COUNT OPT OST JOINT, P177
   Nigeria Centre for Disease Control (NCDC), 2020, UPD COVID 19 COR DIS
   Olatokunboh AO, 2009, AFR J PHARM PHARMACO, V3, P319
   Oyelami OA, 2005, J ALTERN COMPLEM MED, V11, P369, DOI 10.1089/acm.2005.11.369
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 1985, INT TRADITIONAL MED, V1, P1
   WHO, 2020, BAC CALM GUER BCG VA
   Wu CL, 2017, ARCH CLIN PSYCHOL, V8, P15, DOI [10.6550/ACP.0802.002, DOI 10.6550/ACP.0802.002]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 41
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934-578X
EI 1555-9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD AUG
PY 2020
VL 15
IS 8
DI 10.1177/1934578X20945086
PG 9
WC Chemistry, Medicinal; Food Science & Technology
SC Pharmacology & Pharmacy; Food Science & Technology
GA NA4VD
UT WOS:000559815400001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lee, SA
   Mathis, AA
   Jobe, MC
   Pappalardo, EA
AF Lee, Sherman A.
   Mathis, Amanda A.
   Jobe, Mary C.
   Pappalardo, Emily A.
TI Clinically significant fear and anxiety of COVID-19: A psychometric
   examination of the Coronavirus Anxiety Scale
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Coronavirus (COVID-19); Anxiety; Mental health screener
ID ACUTE RESPIRATORY SYNDROME; PSYCHOLOGICAL IMPACT; EPIDEMIC; OUTBREAK;
   CHINA; SARS
AB The present study examined the psychometric properties of the Coronavirus Anxiety Scale (CAS) using an online survey of 398 adult Amazon MTurk workers in the U.S. Confirmatory factor analyses demonstrated that the CAS measures a reliable (alpha = 0.92), unidimensional construct with a structure that was shown to be invariant across gender, race, and age. Construct validity was demonstrated with correlations between CAS scores and demographics, coronavirus diagnosis, history of anxiety, coronavirus fear, functional impairment, alcohol/drug coping, religious coping, hopelessness, suicidal ideation, as well as social attitudes (e.g., satisfaction with President Trump). The CAS also demonstrated solid discrimination ability for functional impairment (AUC = 0.88), while the original cut score of >= 9 (76% sensitivity and 90% specificity) showed the strongest diagnostic effectiveness among scores. Overall, these findings are largely consistent with the results of the first CAS investigation and support the validity of this mental health screener for COVID-19 related research and practice.
C1 [Lee, Sherman A.; Mathis, Amanda A.; Jobe, Mary C.; Pappalardo, Emily A.] Christopher Newport Univ, Dept Psychol, 1 Ave Arts, Newport News, VA 23606 USA.
RP Lee, SA (corresponding author), Christopher Newport Univ, Dept Psychol, 1 Ave Arts, Newport News, VA 23606 USA.
EM sherman.lee@cnu.edu
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Asmundson GJG, 2020, J ANXIETY DISORD, V70, DOI 10.1016/j.janxdis.2020.102196
   Association American Psychological, 2013, DIAGN STAT MAN MENT
   Barger P., 2011, IND ORG PSYCHOL, V49, P11, DOI DOI 10.1145/1809400.1809422
   Barlow D. H., 1991, PSYCHOL INQ, V2, P58, DOI [10.1207/s15327965pli0201_15, DOI 10.1207/S15327965PLI0201_15]
   Bergkvist L, 2007, J MARKETING RES, V44, P175, DOI 10.1509/jmkr.44.2.175
   Brown T.A., 2015, CONFIRMATORY FACTOR
   Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980
   Bunnell BE, 2013, J ANXIETY DISORD, V27, P84, DOI 10.1016/j.janxdis.2012.09.001
   Byrne B. M., 2001, STRUCTURAL EQUATION
   Chong MY, 2004, BRIT J PSYCHIAT, V185, P127, DOI 10.1192/bjp.185.2.127
   Cosmides L., 2000, HDB EMOTIONS, P91, DOI DOI 10.1007/978-94-007-1951-4
   Ekman P., 2003, EMOTIONS REVEALED RE
   Fang J., 2020, WASHINGTON POST
   Jacobsen PB, 2005, CANCER-AM CANCER SOC, V103, P1494, DOI 10.1002/cncr.20940
   Johnson A, 2020, EARLY DATA SHOWS AFR
   Jost JT, 2017, SOC COGNITION, V35, P324, DOI 10.1521/soco.2017.35.4.324
   Khatri N, 2014, CLIN INTERV AGING, V9, P765, DOI 10.2147/CIA.S57832
   Kvasny L, 2006, INFORM SYST J, V16, P23, DOI 10.1111/j.1365-2575.2006.00207.x
   Kyriazos T.A., 2018, PSYCHOLOGY, V9, P1095, DOI DOI 10.4236/PSYCH.2018.95069
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   LEE SA, 2020, DEATH STUD, DOI DOI 10.1080/07481187.2020
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Madrigal LA, 2018, J CLIN SPORT PSYCHOL, V12, P201, DOI 10.1123/jcsp.2016-0036
   Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461
   Nail PR, 2009, SOC JUSTICE RES, V22, P231, DOI 10.1007/s11211-009-0098-z
   Ohman A., 2000, HDB EMOTIONS, P573
   Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba
   Shean G, 2008, J GENET PSYCHOL, V169, P281, DOI 10.3200/GNTP.169.3.281-292
   Simundic Ana-Maria, 2009, EJIFCC, V19, P203
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stockman F, 2020, NY TIMES
   Tabachnick B. G., 2001, USING MULTIVARIATE S
   Van Dam NT, 2013, ANXIETY STRESS COPIN, V26, P70, DOI 10.1080/10615806.2011.631525
   WEINSTEIN MC, 1989, MED CARE, V27, P593, DOI 10.1097/00005650-198906000-00003
   Wheaton MG, 2012, COGNITIVE THER RES, V36, P210, DOI 10.1007/s10608-011-9353-3
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Yip PSF, 2010, CRISIS, V31, P86, DOI 10.1027/0227-5910/a000015
NR 40
TC 17
Z9 17
U1 12
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD AUG
PY 2020
VL 290
AR 113112
DI 10.1016/j.psychres.2020.113112
PG 7
WC Psychiatry
SC Psychiatry
GA MY5OQ
UT WOS:000558466900052
PM 32460185
OA Green Published
DA 2021-01-01
ER

PT J
AU Zijp, TR
   Toren-Wielema, ML
   Panday, PNV
   Kosterink, JGW
   Berger, SP
   Touw, DJ
AF Zijp, Tanja R.
   Toren-Wielema, Martha L.
   Nannan Panday, Prashant V.
   Kosterink, Jos G. W.
   Berger, Stefan P.
   Touw, Daan J.
TI Important Interactions of Immunosuppressants With Experimental Therapies
   for Novel Coronavirus Disease (COVID-19): How to Act
SO THERAPEUTIC DRUG MONITORING
LA English
DT Letter
ID CYCLOSPORINE; TACROLIMUS; PHARMACOKINETICS
C1 [Zijp, Tanja R.; Toren-Wielema, Martha L.; Nannan Panday, Prashant V.; Kosterink, Jos G. W.; Touw, Daan J.] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
   [Zijp, Tanja R.; Toren-Wielema, Martha L.; Nannan Panday, Prashant V.; Kosterink, Jos G. W.; Berger, Stefan P.; Touw, Daan J.] Univ Groningen, Groningen, Netherlands.
   [Berger, Stefan P.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands.
   [Berger, Stefan P.] Univ Med Ctr Groningen, UMC Groningen Comprehens Transplant Ctr, Groningen, Netherlands.
RP Zijp, TR (corresponding author), Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.; Zijp, TR (corresponding author), Univ Groningen, Groningen, Netherlands.
OI Touw, Daniel/0000-0002-1429-4789
CR Badri P, 2015, AM J TRANSPLANT, V15, P1313, DOI 10.1111/ajt.13111
   Badri PS, 2016, THER DRUG MONIT, V38, P640, DOI 10.1097/FTD.0000000000000315
   Cao B, 2020, NEW ENGL J MED, V382
   Dolman GE, 2018, BMJ CASE REP, DOI [10.6002/ect.2017.0013, DOI 10.6002/ECT.2017.0013]
   FINIELZ P, 1993, NEPHRON, V65, P333, DOI 10.1159/000187506
   Floren LC, 1999, CLIN PHARMACOL THER, V65, P159, DOI 10.1016/S0009-9236(99)80167-2
   Katzenmaier S, 2011, CLIN PHARMACOL THER, V90, P666, DOI 10.1038/clpt.2011.164
   Kovarik JM, 2005, J CLIN PHARMACOL, V45, P514, DOI 10.1177/0091270005275368
   van Maarseveen EM, 2013, TRANSPLANTATION, V95, P397, DOI 10.1097/TP.0b013e3182734651
   Yilmaz M, 2017, EXP CLIN TRANSPLANT, DOI [10.6002/ect.2017.0013, DOI 10.6002/ECT.2017.0013]
NR 10
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0163-4356
EI 1536-3694
J9 THER DRUG MONIT
JI Ther. Drug Monit.
PD AUG
PY 2020
VL 42
IS 4
BP 652
EP 653
DI 10.1097/FTD.0000000000000766
PG 2
WC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
SC Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology
GA MZ7YZ
UT WOS:000559344000021
PM 32433189
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Li, L
   Yang, R
   Wang, J
   Lv, QL
   Ren, M
   Zhao, L
   Chen, HW
   Xu, HX
   Xie, SL
   Xie, J
   Lin, H
   Li, WJ
   Fang, P
   Gong, L
   Wang, L
   Wu, YY
   Liu, Z
AF Li, Ling
   Yang, Ru
   Wang, Jue
   Lv, Qilu
   Ren, Ming
   Zhao, Lei
   Chen, Hanwei
   Xu, Haixia
   Xie, Songli
   Xie, Jin
   Lin, Hui
   Li, Wenjuan
   Fang, Peng
   Gong, Li
   Wang, Lan
   Wu, Yanyun
   Liu, Zhong
TI Feasibility of a pilot program forCOVID-19 convalescent plasma
   collection in Wuhan, China
SO TRANSFUSION
LA English
DT Article
AB BACKGROUND A novel coronavirus has caused an international outbreak. Currently, there are no specific therapeutic agents for coronavirus infections. Convalescent plasma (CP) therapy is a potentially effective treatment option. METHODS Patients who had recovered from COVID-19 and had been discharged from the hospital for more than 2 weeks were recruited. COVID-19 convalescent plasma (CCP)-specific donor screening and selection were performed based on the following criteria: 1) aged 18-55 years; 2) eligible for blood donation; 3) diagnosed with COVID-19; 4) had two consecutive negative COVID-19 nasopharyngeal swab tests based on PCR (at least 24 hr apart) prior to hospital discharge; 5) had been discharged from the hospital for more than 2 weeks; and 6) had no COVID-19 symptoms prior to convalescent plasma donation. In addition, preference was given to CCP donors who had a fever lasting more than 3 days or a body temperature exceeding 38.5 degrees C (101.3 degrees F), and who donated 4 weeks after the onset of symptoms. CCP collection was performed using routine plasma collection procedures via plasmapheresis. In addition to routine donor testing, the CCP donors & apos; plasma was also tested for SARS-CoV-2 nucleic acid and S-RBD-specific IgG antibody. RESULTS Of the 81 potential CCP donors, 64 (79%) plasma products were collected. There were 18 female donors and 46 male donors. There were 34 first-time blood donors and 30 repeat donors. The average time between CCP collection and initial symptom onset was 49.1 days, and the average time between CCP collection and hospital discharge was 38.7 days. The average volume of CCP collected was 327.7 mL. All Alanine transaminase (ALT) testing results met blood donation requirements. HIV Ag/Ab, anti-HCV, anti-syphilis, and HBsAg were all negative; NAT for HIV, HBV, and HCV were also negative. In addition, all of the CCP donors & apos; plasma units were negative for SARS-CoV-2 RNA. Of the total 64 CCP donors tested, only one had an S-RBD-specific IgG titer of 1:160, all others had a titer of >= 1:320. CONCLUSION Based on a feasibility study of a pilot CCP program in Wuhan, China, we demonstrated the success and feasibility of CCP collection. In addition, all of the CCP units collected had a titer of >= 1:160 for S-RBD-specific IgG antibody, which met the CCP quality control requirements based on the Chinese national guidelines for CCP.
C1 [Li, Ling; Wang, Jue; Lv, Qilu; Xu, Haixia; Li, Wenjuan; Fang, Peng; Gong, Li; Liu, Zhong] Chinese Acad Med Sci & Peking Union Med Coll, Clin Transfus Res Ctr, Inst Blood Transfus, Chengdu, Sichuan, Peoples R China.
   [Li, Ling; Wang, Jue; Lv, Qilu; Xu, Haixia; Li, Wenjuan; Fang, Peng; Gong, Li; Liu, Zhong] CAMS, Key Lab Transfus Adverse React, Chengdu, Sichuan, Peoples R China.
   [Yang, Ru; Ren, Ming; Zhao, Lei; Chen, Hanwei; Xie, Songli; Xie, Jin; Lin, Hui; Wang, Lan] Wuhan Blood Ctr, Wuhan, Hubei, Peoples R China.
   [Li, Wenjuan; Fang, Peng; Gong, Li] Anhui Med Univ, Hefei, Peoples R China.
   [Wu, Yanyun] Univ Miami, Miami, FL 33136 USA.
RP Wang, L (corresponding author), Baofeng 1st Rd, Wuhan, Hubei, Peoples R China.; Wu, YY (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.; Liu, Z (corresponding author), 26 Huacai Rd, Chengdu, Sichuan, Peoples R China.
EM wlan66@126.com; yxw1366@med.miami.edu; liuz@ibt.pumc.edu.cn
RI Liu, Zhong/ABH-8584-2020
FU the CAMS Innovation Fund for Medical Sciences (CIFMS) [2017-I2M-1-009,
   2016-I2M-3-024] Funding Source: Medline
CR Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Cascella M, 2020, FEATURES EVALUATION
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   FDA - Food and Drug Administration, INV COVID 19 CONV PL
   Garraud O, 2017, TRANSFUS APHER SCI, V56, P31, DOI 10.1016/j.transci.2016.12.014
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, ANTIVIR RES, V150, P202, DOI 10.1016/j.antiviral.2018.01.002
   LI L, 2020, TRANSFUSION 0706, DOI DOI 10.1111/TRF.15918
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   National Health Commission of the Peoples Republic of China, COVID 19 TREATM PLAN
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   World Health Organization, COR DIS COVID 19 OUT
NR 14
TC 1
Z9 1
U1 4
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD AUG
PY 2020
VL 60
IS 8
BP 1773
EP 1777
DI 10.1111/trf.15921
PG 5
WC Hematology
SC Hematology
GA MZ2CR
UT WOS:000558928600024
PM 32491199
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hao, SR
   Yan, R
   Zhang, SY
   Lian, JS
   Cai, H
   Zhang, XL
   Zheng, L
   Jia, HY
   Hu, JH
   Yu, GD
   Gu, JQ
   Ye, CY
   Jin, CL
   Lu, YF
   Xin, JJ
   Sheng, JF
   Yang, YD
AF Hao, Shao-rui
   Yan, Ren
   Zhang, Shan-yan
   Lian, Jiang-shan
   Cai, Huan
   Zhang, Xiao-li
   Zheng, Lin
   Jia, Hong-yu
   Hu, Jian-hua
   Yu, Guo-dong
   Gu, Jue-qing
   Ye, Chan-yuan
   Jin, Ci-liang
   Lu, Ying-feng
   Xin, Jiao-jiao
   Sheng, Ji-fang
   Yang, Yi-da
TI Interferon-alpha 2b spray inhalation did not shorten virus shedding time
   of SARS-CoV-2 in hospitalized patients: a preliminary matched
   case-control study
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); Propensity score match; Interferon (IFN);
   R184
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS; INFECTION; RIBAVIRIN; RESPONSES;
   MODEL
AB Background Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development. Methods Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-alpha 2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors. Results A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%,P=0.006), dyspnea (8.8% vs. 25.0%,P=0.025), or diarrhea (4.4% vs. 19.4%,P=0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d,P=0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%,P=0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%,P=0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%,P=0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%,P=0.027) was higher and the hospitalization time (16 vs. 21 d,P=0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d,P=0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d,P=0.206). Conclusions IFN-alpha 2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.
C1 [Hao, Shao-rui; Yan, Ren; Zhang, Shan-yan; Lian, Jiang-shan; Cai, Huan; Zhang, Xiao-li; Zheng, Lin; Jia, Hong-yu; Hu, Jian-hua; Yu, Guo-dong; Gu, Jue-qing; Ye, Chan-yuan; Jin, Ci-liang; Lu, Ying-feng; Xin, Jiao-jiao; Sheng, Ji-fang; Yang, Yi-da] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Dept Infect Dis Sch Med,Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis,Natl Cl, Hangzhou 310003, Zhejiang, Peoples R China.
RP Yang, YD (corresponding author), Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Dept Infect Dis Sch Med,Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis,Natl Cl, Hangzhou 310003, Zhejiang, Peoples R China.
EM yidayang65@zju.edu.cn
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Cinatl J, 2004, EXPERT OPIN BIOL TH, V4, P827, DOI 10.1517/14712598.4.6.827
   Danesh A, 2011, VIROLOGY, V409, P102, DOI 10.1016/j.virol.2010.10.002
   Dusheiko G, 1997, HEPATOLOGY, V26, pS112, DOI 10.1002/hep.510260720
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Ge ZY, 2020, J ZHEJIANG UNIV-SC B, V21, P361, DOI 10.1631/jzus.B2010010
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Mantlo Emily, 2020, bioRxiv, DOI 10.1101/2020.04.02.022764
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Ren WB, 2019, J ZHEJIANG UNIV-SC B, V20, P39, DOI 10.1631/jzus.B1800211
   Shi Y, 2020, J ZHEJIANG UNIV-SC B, V21, P343, DOI 10.1631/jzus.B2000083
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Thiel V, 2008, CYTOKINE GROWTH F R, V19, P121, DOI 10.1016/j.cytogfr.2008.01.001
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD AUG
PY 2020
VL 21
IS 8
BP 628
EP 636
DI 10.1631/jzus.B2000211
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA NA9BU
UT WOS:000560113000004
PM 32748578
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Khan, S
   Ali, A
   Shi, HW
   Siddique, R
   Shabana
   Nabi, G
   Hu, JJ
   Wang, TJ
   Dong, M
   Zaman, W
   Han, G
AF Khan, Suliman
   Ali, Ashaq
   Shi, Hongwei
   Siddique, Rabeea
   Shabana
   Nabi, Ghulam
   Hu, Junjie
   Wang, Tiejun
   Dong, Men
   Zaman, Wajid
   Han, Guang
TI COVID-19: Clinical aspects and therapeutics responses
SO SAUDI PHARMACEUTICAL JOURNAL
LA English
DT Article
DE COVID-19; Therapeutics; Mild symptoms; TCM; Recoveries
ID CORONAVIRUS; PNEUMONIA; MEDICINE
AB COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retro-spective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recov-ery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Khan, Suliman; Siddique, Rabeea] Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.
   [Khan, Suliman; Siddique, Rabeea] Henan Med Key Lab Translat Cerebrovasc Dis, Zhengzhou, Peoples R China.
   [Ali, Ashaq; Shabana; Dong, Men] Chinese Acad Sci, Wuhan Inst Virol, Xiao Hong Shan 44, Wuhan, Peoples R China.
   [Ali, Ashaq; Shabana; Dong, Men] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Shi, Hongwei] Wuhan Univ, Sch Life Sci, Key State Lab Virol, Wuhan, Peoples R China.
   [Nabi, Ghulam] Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Pro, Shijiazhuang 050024, Hebei, Peoples R China.
   [Hu, Junjie] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China.
   [Wang, Tiejun] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Breast Surg, Wuhan, Peoples R China.
   [Zaman, Wajid] Chinese Acad Sci, Inst Bot, State Key Lab Systemat & Evolutionary Bot, Beijing 100093, Peoples R China.
   [Han, Guang] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan, Peoples R China.
RP Khan, S (corresponding author), Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.; Khan, S (corresponding author), Henan Med Key Lab Translat Cerebrovasc Dis, Zhengzhou, Peoples R China.; Han, G (corresponding author), Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan, Peoples R China.
EM suliman.khan18@mails.ucas.ac.cn; hg7913@hotmail.com
RI Zaman, Wajid/J-6491-2019; Ali, Ashaq/ABF-3123-2020
OI Zaman, Wajid/0000-0001-6864-2366; Ali, Ashaq/0000-0003-3224-2891; Khan,
   Suliman/0000-0003-4954-0748
FU Second Affiliated Hospital of Zhengzhou University, Zhengzhou China;
   Chinese Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation
FX This project received the funding from the Postdoctoral research grants
   from the Second Affiliated Hospital of Zhengzhou University, Zhengzhou
   China and the Chinese Postdoctoral Science Foundation (for S.K.).
CR Ashraf M.A., 2020, COVID 19 IRAN COMPRE, DOI 10.1101
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Conti P, 2020, J BIOL REGUL HOMEOST
   Dong L, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/637969
   Duan ZP, 2011, CHINESE MED J-PEKING, V124, P2925, DOI 10.3760/cma.j.issn.0366-6999.2011.18.024
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamza M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1778534
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khan S, 2020, CLIN MICROBIOL INFEC, V26, P399, DOI 10.1016/j.cmi.2020.02.005
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li Yueping, 2020, Med (N Y), V1, P105, DOI 10.1016/j.medj.2020.04.001
   Liu Q, 2020, EFFECT ARBIDOL HYDRO, DOI [10.1101/2020.04.11.20056523, DOI 10.1101/2020.04.11.20056523]
   Noelle Breslin MD, 2020, AM J OBSTET GYN 0409, DOI [10.1016, DOI 10.1016/J.AJOGMF.2020.100118]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
NR 18
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-0164
EI 2213-7475
J9 SAUDI PHARM J
JI Saudi Pharm. J.
PD AUG
PY 2020
VL 28
IS 8
BP 1004
EP 1008
DI 10.1016/j.jsps.2020.06.022
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MX0OH
UT WOS:000557427600013
PM 32788835
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Copcu, HE
AF Copcu, Hasim Eray
TI Potential Using of Fat-derived Stromal Cells in the Treatment of Active
   Disease, and also, in Both Pre- and Post-Periods in COVID-19
SO AGING AND DISEASE
LA English
DT Article
DE COVID 19; stromal cells; stem cell; ADSC; adipose tissue
ID RENIN-ANGIOTENSIN SYSTEM; MESENCHYMAL STEM-CELLS; HUMAN ADIPOSE-TISSUE;
   VASCULAR FRACTION; DELIVERY; THERAPY
AB The whole world is fighting with the COVID-19 pandemic, which traps people home, causing high business and economic losses, and above all, leads to very serious deaths. The lack of a valid, accepted treatment protocol and vaccine that leads to continued treatment searches. Leng et al published their article in the Aging and Disease journal, which demonstrates that mesenchy mal stem cells (MSCs) can be used for COVID-19 treatment.Adipose tissue is one of the most important MSCs sources in the body, and adipose derived stromal cells (ADSCs) from adipose tissue are also one of the most valuable components of stromal vascular fraction (SVF). Finally, Gentile and Sterodimas, have also published their article for the potential use of SVF in COVID-19 treatment in Aging and Disease journal. Their publication has been a guide in many ways. Adipose tissuederived stromal cells have three main features: Immunomodulatory, anti-inflammatory and regenerative. Immunomodulator effects are used as a preventive in patients prone to disease; its anti-inflammatory effects may allow them to be used as a therapeutic during active disease period and finally regenerative effects to repair postdisease sequale. Those cells can be obtained not only enzymatically, but also mechanically with very benefits. They can be delivered not only systemically through the IV route but also to the target organ with a carrier. While suggesting any adipose tissue-derived treatment method possibility, the relation of adipose tissue COVID-19 should not be ignored. Because, COVID-19 shows its effect through ACE-2 and adipose tissue is very rich and important tissue in terms of ACE-2.
C1 [Copcu, Hasim Eray] Mest Hlth Serv, Aesthet & Plast Surg, Izmir, Turkey.
RP Copcu, HE (corresponding author), Mest Hlth Serv, Cumhuriyet Bulv 161-A-1-2, Izmir, Turkey.
EM ecopcu@gmail.com
CR Al-Ghadban S, 2020, PHYSIOLOGY, V35, P125, DOI 10.1152/physiol.00021.2019
   Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Chen J., 2020, ENGINEERING
   Engeli S, 1999, J HYPERTENS, V17, P555, DOI 10.1097/00004872-199917040-00014
   Fukui E, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5179172
   Garg RK, 2014, STEM CELL TRANSL MED, V3, P1079, DOI 10.5966/sctm.2014-0007
   Gentile P, 2020, AGING DIS, V11, P465, DOI 10.14336/AD.2020.0422
   Ghiasloo M, 2020, AESTHETIC SURG J
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Hoogduijn MJ, 2019, STEM CELL TRANSL MED, V8, P1126, DOI 10.1002/sctm.19-0073
   JARRELL BE, 1986, SURGERY, V100, P392
   Ji FP, 2020, STEM CELL TRANSL MED, V9, P813, DOI 10.1002/sctm.20-0083
   Jia X, 2020, 2 THINGS COVID 19 MI
   Karlsson C, 1998, J CLIN ENDOCR METAB, V83, P3925, DOI 10.1210/jc.83.11.3925
   Khoury M, 2020, EUROPEAN RESP J
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003
   Lopes-Pacheco M, 2020, CELL BIOL TOXICOL, V36, P83, DOI 10.1007/s10565-019-09493-5
   Morestin H, 1915, B MEM SOC CHIR PARIS, V41, P1631
   Ozturk S, 2020, J DIGIT IMAGING, V33, P958, DOI 10.1007/s10278-020-00343-z
   Pahlavani M, 2017, COMPR PHYSIOL, V7, P1137, DOI 10.1002/cphy.c160031
   Ryan PM, 2020, OBESITY, V28, P1191, DOI 10.1002/oby.22843
   Schildberg FA, 2018, CYTOM PART A, V93A, P871, DOI 10.1002/cyto.a.23600
   Sese B, 2019, PLAST RECONSTR SURG, V144, P1079, DOI 10.1097/PRS.0000000000006155
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Shetty Rohit, 2020, Indian J Ophthalmol, V68, P693, DOI 10.4103/ijo.IJO_639_20
   Silva JD, 2018, CRIT CARE MED, V46, pE132, DOI 10.1097/CCM.0000000000002833
   Slamkova M, 2016, Endocr Regul, V50, P229, DOI 10.1515/enr-2016-0025
   Sun ZW, 2018, J THORAC DIS, V10, P1084, DOI 10.21037/jtd.2018.01.46
   Ullah M, 2019, ISCIENCE, V15, P421, DOI 10.1016/j.isci.2019.05.004
   Zimmerlin L, 2013, CYTOM PART A, V83A, P134, DOI 10.1002/cyto.a.22227
   Zimmerlin L, 2013, CYTOTHERAPY, V15, P102, DOI 10.1016/j.jcyt.2012.10.009
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 34
TC 0
Z9 0
U1 2
U2 2
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD AUG
PY 2020
VL 11
IS 4
BP 730
EP 736
DI 10.14336/AD.2020.0621
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA MV9JM
UT WOS:000556664900002
PM 32765938
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schwartz, MD
   Emerson, SG
   Punt, J
   Goff, WD
AF Schwartz, Michael D.
   Emerson, Stephen G.
   Punt, Jennifer
   Goff, Willow D.
TI Decreased Naive T-cell Production Leading to Cytokine Storm as Cause of
   Increased COVID-19 Severity with Comorbidities
SO AGING AND DISEASE
LA English
DT Article
DE COVID-19; SARS-CoV-2; naive T cells; type 2 diabetes; cytokine storm
ID RECOVERY
AB Aging, type 2 diabetes, and male gender are major risk factors leading to increased COVID-19 morbidity and mortality. Thymic production and the export of naive T cells decrease with aging through the effects of androgens in males and in type 2 diabetes. Furthermore, with aging, recovery of naive T-cell populations after bone marrow transplantation is delayed and associated with an increased risk of chronic graft vs. host disease. Severe COVID-19 and SARS infections are notable for severe T-cell depletion. In COVID-19, there is unique suppression of interferon signaling by infected respiratory tract cells with intact cytokine signaling. A decreased naive T-cell response likely, contributes to an excessive inflammatory response and increases the odds of a cytokine storm. Treatments that improve naive T-cell production may prove to be vital COVID-19 therapies, especially for these high-risk groups.
C1 [Schwartz, Michael D.] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA.
   [Emerson, Stephen G.] Columbia Univ, Immunol & Med, New York, NY 10027 USA.
   [Punt, Jennifer] Univ Penn, Sch Vet Med, Immunol, Pathobiol, Philadelphia, PA 19104 USA.
   [Goff, Willow D.] Colgate Univ, Hamilton, NY 13346 USA.
RP Schwartz, MD (corresponding author), Univ S Florida, Lehigh Valley Hlth Network, Morsani Sch Med, Trexlertown, PA 18057 USA.
EM Michael.Schwartz@lvh.com
CR Blanco-Melo D., 2020, CELL
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dohner H, 2013, HAEMATOLOGICA, V98, P233, DOI 10.3324/haematol.2012.072264
   Dworacki G, 2015, IMMUNOLOGY, V146, P456, DOI 10.1111/imm.12522
   Fulzele S, 2020, AGING DIS, V11, P509, DOI 10.14336/AD.2020.0428
   Goldberg GL, 2009, J IMMUNOL, V182, P5846, DOI 10.4049/jimmunol.0801458
   Heng TSP, 2005, J IMMUNOL, V175, P2982, DOI 10.4049/jimmunol.175.5.2982
   Hung IF-N, 2020, LANCET
   Montecino-Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096
   Montopoli M, 2020, ANN ONCOL
   Palmer DB, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00316
   Perales MA, 2012, BLOOD, V120, P4882, DOI 10.1182/blood-2012-06-437236
   Pido-Lopez J, 2001, CLIN EXP IMMUNOL, V125, P409, DOI 10.1046/j.1365-2249.2001.01640.x
   Roux E, 2000, BLOOD, V96, P2299
   Soares MV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00334
   Xiang L, 2020, SMALL METHODS, V4, DOI 10.1002/smtd.202000160
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
NR 17
TC 0
Z9 0
U1 1
U2 1
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD AUG
PY 2020
VL 11
IS 4
BP 742
EP 745
DI 10.14336/AD.2020.0619
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA MV9JM
UT WOS:000556664900004
PM 32765940
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Das, UN
AF Das, Undurti N.
TI Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal
   Stem Cells in COVID-19
SO AGING AND DISEASE
LA English
DT Article
DE COVID-19; immune check point inhibitory therapy; cytokines;
   inflammation; bioactive lipids; mesenchymal stem cells
ID POLYUNSATURATED FATTY-ACIDS; INDUCED DIABETES-MELLITUS; ACUTE LUNG
   INJURY; PROSTAGLANDIN E-2; ARACHIDONIC-ACID; INDUCED CYTOTOXICITY;
   RESOLUTION; PROMOTE; MACROPHAGES; PROLIFERATION
AB It is proposed that the beneficial action of mesenchymal stem cells (MSCs) in COVID-19 and other inflammatory diseases could be attributed to their ability to secrete bioactive lipids (BALs) such as prostaglandin E2 (PGE2) and lipoxin A4 (LXA4) and other similar BALs. This implies that MSCs that have limited or low capacity to secrete BALs may be unable to bring about their beneficial actions. This proposal implies that pretreatment of MSCs with BALs enhance their physiological action or improve their (MSCs) anti-inflammatory and disease resolution capacity to a significant degree. Thus, the beneficial action of MSCs reported in the management of COVID-19 could be attributed to their ability to secrete BALs, especially PGE2 and LXA4. Since PGE2, LXA4 and their precursors AA (arachidonic acid), dihomo-gamma-linolenic acid (DGLA) and gammalinolenic acid (GLA) inhibit the production of pro-inflammatory IL-6 and TNF-alpha, they could be employed to treat cytokine storm seen in COVID-19, immune check point inhibitory (ICI) therapy, sepsis and ARDS (acute respiratory disease). This is further supported by the observation that GLA, DGLA and AA inactivate enveloped viruses including COVID-19. Thus, infusions of appropriate amounts of GLA, DGLA, AA, PGE2 and LXA4 are of significant therapeutic benefit in COVID-19, ICI therapy and other inflammatory conditions including but not limited to sepsis. AA is the precursor of both PGE2 and LXA4 suggesting that AA is most suited for such preventive and therapeutic approach.
C1 [Das, Undurti N.] UND Life Sci, 2221 NW 5th St, Battle Ground, WA 98604 USA.
   [Das, Undurti N.] Gayatri Vidya Parishad Med Coll & Hosp, BioSci Res Ctr, Visakhapatnam 530048, Andhra Pradesh, India.
   [Das, Undurti N.] Gayatri Vidya Parishad Med Coll & Hosp, Dept Med, Visakhapatnam 530048, Andhra Pradesh, India.
RP Das, UN (corresponding author), UND Life Sci, 2221 NW 5th St, Battle Ground, WA 98604 USA.
EM undurti@lipidworld.com
CR Abdelmawgoud H, 2018, ADV CLIN EXP MED, V27, P873, DOI 10.17219/acem/73720
   An JH, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1684-9
   Augello A, 2005, EUR J IMMUNOL, V35, P1482, DOI 10.1002/eji.200425405
   Bai YH, 2019, MED SCI MONITOR, V25, P3069, DOI 10.12659/MSM.914860
   Chan MMY, 2010, J IMMUNOL, V184, P6418, DOI 10.4049/jimmunol.0903816
   Chen PM, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-49
   Cheng X, 2016, FREE RADICAL BIO MED, V93, P52, DOI 10.1016/j.freeradbiomed.2016.01.026
   Chiossone L, 2016, STEM CELLS, V34, P1909, DOI 10.1002/stem.2369
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657
   Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013
   Das UN, 2018, J ADV RES, V11, P57, DOI 10.1016/j.jare.2018.01.001
   Das UN, 2011, MOLECULAR BASIS OF HEALTH AND DISEASE, P1, DOI 10.1007/978-94-007-0495-4_1
   Das UN, 2010, J INFLAMM RES, V3, P143, DOI 10.2147/JIR.S9425
   Diaz MF, 2015, J EXP MED, V212, P665, DOI 10.1084/jem.20142235
   Duffy MM, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt75
   Engela AU, 2013, CLIN EXP IMMUNOL, V174, P449, DOI 10.1111/cei.12199
   Fang XH, 2015, J IMMUNOL, V195, P875, DOI 10.4049/jimmunol.1500244
   Gundala NKV, 2018, BIOCHEM BIOPH RES CO, V496, P105, DOI 10.1016/j.bbrc.2018.01.007
   Gundala NKV, 2017, NUTRITION, V35, P61, DOI 10.1016/j.nut.2016.10.004
   Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627
   Hoggatt J, 2013, NATURE, V495, P365, DOI 10.1038/nature11929
   Holopainen M, 2019, BBA-MOL CELL BIOL L, P1350, DOI 10.1016/j.bbalip.2019.06.010
   Hyvarinen K, 2018, FRONT IMMUNOL, V8, P771
   Kalim KW, 2013, MOL IMMUNOL, V53, P274, DOI 10.1016/j.molimm.2012.08.014
   Kim DS, 2018, STEM CELL REV REP, V14, P286, DOI 10.1007/s12015-017-9793-6
   Li F, 2010, SIAM J IMAGING SCI, V3, P1, DOI 10.1137/090748421
   Li MF, 2014, CLIN EXP IMMUNOL, V178, P516, DOI 10.1111/cei.12423
   Liu XX, 2012, J IMMUNOL, V189, P1182, DOI 10.4049/jimmunol.1102996
   Loynes CA, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8320
   Naveen KVG, 2017, BIOFACTORS, V43, P251, DOI [10.1002/biof.1336, DOI 10.1002/BIOF.1336]
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Park HJ, 2018, BIOCHEM BIOPH RES CO, V498, P988, DOI 10.1016/j.bbrc.2018.03.096
   PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z
   Poloso NJ, 2013, MOL IMMUNOL, V54, P284, DOI 10.1016/j.molimm.2012.12.010
   Rogerio AP, 2012, J IMMUNOL, V189, P1983, DOI 10.4049/jimmunol.1101665
   Rozenberg A, 2016, STEM CELL TRANSL MED, V5, P1506, DOI 10.5966/sctm.2015-0243
   Siresha B, 2019, LIPIDS HLTH DIS, V18, P214
   Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997
   Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541
   Suresh Y, 2003, NUTRITION, V19, P213, DOI 10.1016/S0899-9007(02)00855-9
   Suresh Y, 2003, NUTRITION, V19, P93, DOI 10.1016/S0899-9007(02)00856-0
   Suresh Y, 2001, PROSTAG LEUKOTR ESS, V64, P37, DOI 10.1054/plef.2000.0236
   Vane JR, 2003, THROMB RES, V110, P255, DOI 10.1016/S0049-3848(03)00379-7
   Vasandan AB, 2016, SCI REP-UK, V6, DOI 10.1038/srep38308
   Wang BS, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0744-6
   Wang L, 2012, J DENT RES, V91, P1003, DOI 10.1177/0022034512460404
   Wang LX, 2016, BOUND VALUE PROBL, DOI 10.1186/s13661-016-0584-9
   Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5
   Yang FY, 2018, CELL TRANSPLANT, V27, P1352, DOI 10.1177/0963689718780304
   Yang HM, 2018, RES VET SCI, V119, P19, DOI 10.1016/j.rvsc.2018.05.011
   Ylostalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191
   Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340
   Zhang ZY, 2019, EBIOMEDICINE, V45, P341, DOI 10.1016/j.ebiom.2019.06.016
NR 54
TC 1
Z9 1
U1 3
U2 3
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD AUG
PY 2020
VL 11
IS 4
BP 746
EP 755
DI 10.14336/AD.2020.0521
PG 10
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA MV9JM
UT WOS:000556664900005
PM 32765941
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kow, CS
   Sunter, W
   Bain, A
   Zaidi, STR
   Hasan, SS
AF Kow, Chia Siang
   Sunter, Wendy
   Bain, Amie
   Zaidi, Syed Tabish Razi
   Hasan, Syed Shahzad
TI Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A
   Practical Guide
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Article
ID INTERNATIONAL NORMALIZED RATIO; DIRECT ORAL ANTICOAGULANTS; ACUTE VENOUS
   THROMBOEMBOLISM; MOLECULAR-WEIGHT HEPARINS; ED AMERICAN-COLLEGE;
   SELF-MANAGEMENT; ATRIAL-FIBRILLATION; ANTITHROMBOTIC THERAPY; STROKE
   PREVENTION; CHEST GUIDELINE
AB Many healthcare resources have been and continue to be allocated to the management of patients with COVID-19. Therefore, the ongoing care of patients receiving oral anticoagulation with warfarin is likely to be compromised amid this unprecedented crisis. This article discusses a stepwise algorithm for the management of outpatient warfarin therapy. Alternative management strategies are presented and discussed, including alternative pharmacological therapy options and self-monitoring. Our algorithm aims to help clinicians safely optimize the treatment of patients requiring anticoagulation therapy in the context of the global response to the current pandemic.
C1 [Kow, Chia Siang] Int Med Univ, Sch Postgrad Studies, Kuala Lumpur, Malaysia.
   [Sunter, Wendy] Calderdale & Huddersfield NHS Fdn Trust, Anticoagulant Serv, Huddersfield, W Yorkshire, England.
   [Bain, Amie; Hasan, Syed Shahzad] Univ Huddersfield, Dept Pharm, Huddersfield, W Yorkshire, England.
   [Bain, Amie] Sheffield Teaching Hosp NHS Fdn Trust, Dept Pharm, Sheffield, S Yorkshire, England.
   [Zaidi, Syed Tabish Razi] Univ Leeds, Sch Healthcare, Leeds, W Yorkshire, England.
   [Zaidi, Syed Tabish Razi] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
RP Hasan, SS (corresponding author), Univ Huddersfield, Dept Pharm, Huddersfield, W Yorkshire, England.
EM s.hasan@hud.ac.uk
RI Hasan, Syed Shahzad/V-9082-2018
OI Hasan, Syed Shahzad/0000-0002-4058-2215; Bain, Amie/0000-0003-3591-7380
CR Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507
   Ansell J, 2005, INT J CARDIOL, V99, P37, DOI 10.1016/j.ijcard.2003.11.008
   Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670
   Baglin T, 2012, J THROMB HAEMOST, V10, P1702, DOI [10.1111/j.1538-7836.2012.04806.x, 10.1111/j.1538-7836.2012.04662.x]
   Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903
   Bereznicki Luke R E, 2014, Int J Pharm Pract, V22, P84, DOI 10.1111/ijpp.12035
   BLACK IW, 1994, CIRCULATION, V89, P2509, DOI 10.1161/01.CIR.89.6.2509
   BSH Haemostasis and Thrombosis Task Force, 2020, INR TEST OUT PAT WAR
   Buller HR, 2013, NEW ENGL J MED, V369, P1406, DOI 10.1056/NEJMoa1306638
   Buller HR, 2012, NEW ENGL J MED, V366, P1287, DOI 10.1056/NEJMoa1113572
   Carris NW, 2015, CARDIOVASC THER, V33, P98, DOI 10.1111/1755-5922.12115
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Davidson BL, 2007, J THROMB HAEMOST, V5, P1191, DOI 10.1111/j.1538-7836.2007.02565.x
   Dong E, 2020, LANCET INFECT DIS
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Eyre H, 2004, CA-CANCER J CLIN, V54, P190, DOI 10.3322/canjclin.54.4.190
   Fitzmaurice DA, 2005, BRIT MED J, V331, P1057, DOI 10.1136/bmj.38618.580903.AE
   Frydman A, 1996, HAEMOSTASIS, V26, P24
   Gardiner C, 2005, BRIT J HAEMATOL, V128, P242, DOI 10.1111/j.1365-2141.2004.05300.x
   Gurwitz JH, 1997, ARCH INTERN MED, V157, P978, DOI 10.1001/archinte.157.9.978
   Heidbuchel H, 2015, EUROPACE, V17, P1467, DOI 10.1093/europace/euv309
   Heneghan CJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003839.pub3
   Holbrook A, 2012, CHEST, V141, pE152S, DOI 10.1378/chest.11-2295
   Ieko M, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0144-5
   January CT, 2019, J AM COLL CARDIOL, V74, P104, DOI 10.1016/j.jacc.2019.01.011
   Jennings I, 2014, BRIT J HAEMATOL, V167, P600, DOI 10.1111/bjh.13070
   Jun M, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4323
   Kalcik M, 2017, CLIN APPL THROMB-HEM, V23, P187, DOI 10.1177/1076029615595881
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301
   Keeling D, 2012, BRIT J HAEMATOL, V157, P47, DOI 10.1111/j.1365-2141.2012.09037.x
   Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
   Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   LE DT, 1994, ANN INTERN MED, V120, P552, DOI 10.7326/0003-4819-120-7-199404010-00004
   Lip GYH, 2018, CHEST, V154, P1121, DOI 10.1016/j.chest.2018.07.040
   Massicotte Anne, 2014, Can Pharm J (Ott), V147, P25, DOI 10.1177/1715163513513869
   Maxmen A, 2020, NATURE, V580, P173, DOI 10.1038/d41586-020-00983-9
   McAlister FA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-016980
   Mekaj YH, 2015, THER CLIN RISK MANAG, V11, DOI [10.2147/TCRM.S84210, 10.2147/TCRM.S92222]
   Moiz B, 2018, CLIN APPL THROMB-HEM, V24, P1153, DOI 10.1177/1076029617752247
   Moll S, 2019, RES PRACT THROMB HAE, V3, P152, DOI 10.1002/rth2.12178
   Morris C, 2020, BBC NEWS
   Morris TA, 2007, CHEST, V132, P1131, DOI 10.1378/chest.06-2518
   Nagler M, 2013, J THROMB HAEMOST, V11, P197, DOI 10.1111/jth.12050
   Nishimura RA, 2017, CIRCULATION, V135, pE1159, DOI 10.1161/CIR.0000000000000503
   Nutescu EA, 2009, ANN PHARMACOTHER, V43, P1064, DOI 10.1345/aph.1L194
   Padrini R, 2019, EUR J DRUG METAB PH, V44, P1, DOI 10.1007/s13318-018-0501-y
   Park M, 2020, EUR J IMMUNOL, V50, P308, DOI 10.1002/eji.202070035
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Pozzi M, 2016, VASC HEALTH RISK MAN, V12, P387, DOI 10.2147/VHRM.S85031
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Public Health England, 2020, GUID PRIOR SARS COV
   Robertson L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010957.pub2
   Rose A, 2011, CHEST, V140, P359, DOI 10.1378/chest.10-2738
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Ryan F, 2009, J THROMB HAEMOST, V7, P1284, DOI 10.1111/j.1538-7836.2009.03497.x
   Schulman S, 2014, CIRCULATION, V129, P764, DOI 10.1161/CIRCULATIONAHA.113.004450
   Schulman S, 2009, NEW ENGL J MED, V361, P2342, DOI 10.1056/NEJMoa0906598
   Siebenhofer A, 2004, THROMB HAEMOSTASIS, V91, P225, DOI 10.1160/TH03-09-0598
   Siebenhofer A, 2008, THROMB HAEMOSTASIS, V100, P1089, DOI 10.1160/TH08-06-0361
   Tejan-Sie SA, 2003, J AM COLL CARDIOL, V42, P1638, DOI 10.1016/j.jacc.2003.06.008
   Thrombosis UK, ANT COV 19
   Trikha R, 2017, CARDIOLOGY, V136, P115, DOI 10.1159/000447530
   Verhovsek Madeleine, 2008, BMC Geriatr, V8, P13, DOI 10.1186/1471-2318-8-13
   Verret L, 2012, PHARMACOTHERAPY, V32, P871, DOI 10.1002/j.1875-9114.2012.01116
   Ward A, 2015, BRIT J GEN PRACT, V65, pE428, DOI 10.3399/bjgp15X685633
   Wells PS, 2014, JAMA-J AM MED ASSOC, V311, P717, DOI 10.1001/jama.2014.65
   Witt DM, 2018, BLOOD ADV, V2, P3257, DOI 10.1182/bloodadvances.2018024893
   Zirlik A, 2017, J THROMB THROMBOLYS, V43, P365, DOI 10.1007/s11239-016-1446-0
NR 70
TC 0
Z9 0
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PD AUG
PY 2020
VL 20
IS 4
BP 301
EP 309
DI 10.1007/s40256-020-00415-z
PG 9
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA MW4JF
UT WOS:000557004600001
PM 32458370
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chigurupati, R
   Panchal, N
   Henry, AM
   Batal, H
   Sethi, A
   D'innocenzo, R
   Mehra, P
   Krishnan, DG
   Roser, SM
AF Chigurupati, Radhika
   Panchal, Neeraj
   Henry, Andrew M.
   Batal, Hussam
   Sethi, Amit
   D'innocenzo, Richard
   Mehra, Pushkar
   Krishnan, Deepak G.
   Roser, Steven M.
TI Considerations for Oral and Maxillofacial Surgeons in COVID-19 Era: Can
   We Sustain the Solutions to Keep Our Patients and Healthcare Personnel
   Safe?
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID CORONAVIRUS
AB Several uncertainties exist regarding how we will conduct our clinical, didactic, business, and social activities as the coronavirus disease 2019 (COVID-19) global pandemic abates and social distancing guidelines are relaxed. We anticipate changes in how we interact with our patients and other providers, how patient workflow is designed, the methods used to conduct our teaching sessions, and how we perform procedures in different clinical settings. The objective of the present report is to review some of the changes to consider in the clinical and academic oral and maxillofacial surgery workflow and, allow for a smoother transition, with less risk to our patients and healthcare personnel. New infection control policies should be strictly enforced and monitored in all clinical and nonclinical settings, with an overall goal to decrease the risk of exposure and transmission. Screening for COVID-19 symptoms, testing when indicated, and establishing the epidemiologic linkage will be crucial to containing and preventing new COVID-19 cases until a vaccine or an alternate solution is available. Additionally, the shortage of essential supplies such as drugs and personal protective equipment, the design and ventilation of workspaces and waiting areas, the increase in overhead costs, and the possible absence of staff, if quarantine is necessary, must be considered. This shift in our workflow and patient care paths will likely continue in the short-term at least through 2021 or the next 12 to 24 months. Thus, we must prioritize surgery, balancing patient preferences and healthcare personnel risks. We have an opportunity now to make changes and embrace telemedicine and other collaborative virtual platforms for teaching and clinical care. It is crucial that we maintain COVID-19 awareness, proper surveillance in our microenvironments, good clinical judgment, and ethical values to continue to deliver high-quality, economical, and accessible patient care. (C) 2020 American Association of Oral and Maxillofacial Surgeons
C1 [Chigurupati, Radhika; Henry, Andrew M.; Mehra, Pushkar] Boston Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Boston, MA USA.
   [Chigurupati, Radhika; Henry, Andrew M.] Boston Univ, Henry M Goldman Sch Dent Med, Boston, MA 02215 USA.
   [Panchal, Neeraj] Univ Penn, Sch Dent Med, Dept Oral & Maxillofacial Surg, Philadelphia Vet Affairs Med Ctr,Penn Presbyteria, Philadelphia, PA 19104 USA.
   [Batal, Hussam; D'innocenzo, Richard] Boston Univ, Dept Oral & Maxillofacial Surg, Boston, MA 02215 USA.
   [Batal, Hussam] Boston Med Ctr, Boston, MA USA.
   [Sethi, Amit] Boston Univ, Dept Oral & Maxillofacial Surg, Henry M Goldman Sch Dent Med, Boston, MA 02215 USA.
   [D'innocenzo, Richard] Boston Univ, Dept Dent, Boston, MA 02215 USA.
   [D'innocenzo, Richard] Boston Univ, Henry M Goldman Sch Dent Med, Predoctoral Educ, Boston, MA 02215 USA.
   [Mehra, Pushkar] Boston Univ, Henry M Goldman Sch Dent Med, Hosp Affairs, Boston, MA 02215 USA.
   [Krishnan, Deepak G.] Univ Cincinnati, Med Ctr, Dept Surg, Cincinnati, OH 45267 USA.
   [Krishnan, Deepak G.] Univ Cincinnati, Med Ctr, Sect Oral & Maxillofacial Surg, Cincinnati, OH 45267 USA.
   [Krishnan, Deepak G.] Cincinnati Childrens Hosp & Med Ctr, Sect Oral & Maxillofacial Surg, Cincinnati, OH USA.
   [Roser, Steven M.] Emory Univ, Sch Med, Dept Surg, Surg, Atlanta, GA 30322 USA.
   [Roser, Steven M.] Emory Univ, Sch Med, Dept Surg, Div Oral & Maxillofacial Surg, Atlanta, GA 30322 USA.
RP Chigurupati, R (corresponding author), Boston Univ, Dept Oral & Maxillofacial Surg, Boston Med Ctr, Henry M Goldman Sch Dent Med, Boston, MA 02118 USA.
EM rchiguru@bu.edu
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 1994, MMWR Recomm Rep, V43, P1
   Arduino PG, 2020, ORAL DIS, DOI 10.1111/odi.13362
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Caplan AL, 2020, PERSPECTIVE MEDSCAPE
   Centers for Disease Control and Preventions, 2018, US PAPRS CLIN HEALTH
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Daugherty EL, 2008, RESP CARE, V53, P201
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Eggers M, 2015, INFECT DIS THER, V4, P491, DOI 10.1007/s40121-015-0091-9
   Ellis R, 2020, BRIT J ORAL MAX SURG, V58, P577, DOI 10.1016/j.bjoms.2020.04.002
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Fonner A, INTERIM GUIDANCE DEN
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Joynt GM, 2020, LANCET INFECT DIS, V20, P635, DOI 10.1016/S1473-3099(20)30237-1
   Kariwa H, 2006, DERMATOLOGY, V212, P119, DOI 10.1159/000089211
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kirk-Bayley J, 2020, USE POVIDONE IODINE
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Liu SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147306
   LIU Y, 2020, NATURE 0427, DOI DOI 10.1038/S41586-020-2271-3
   Lu D, 2020, J HOSP INFECT, V104, P454, DOI 10.1016/j.jhin.2020.02.018
   Nathavitharana RR, 2020, J HOSP MED, V15, P299, DOI 10.12788/jhm.3439
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patel RJ, 2020, HEAD NECK-J SCI SPEC, V42, P1168, DOI 10.1002/hed.26189
   Prachand VN, 2020, J AM COLL SURGEONS, V231, P281, DOI 10.1016/j.jamcollsurg.2020.04.011
   Pramesh CS, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2011595
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286
   Roberts Vanessa, 2014, Can J Respir Ther, V50, P87
   Rubin R, 2020, JAMA-J AM MED ASSOC, V323, P1760, DOI 10.1001/jama.2020.5427
   Shuman AG, 2020, HEAD NECK-J SCI SPEC, V42, P1214, DOI 10.1002/hed.26193
   Siddarth D, 2020, WEYL GE COVID 19 RAP
   Stahel PF, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00235-9
   Streifel AJ, 1999, HOSP EPIDEMIOLOGY IN
   Tay JK, 2020, JAMA OTOLARYNGOL, V146, P517, DOI 10.1001/jamaoto.2020.0764
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vukkadala N, 2020, LARYNGOSCOPE, V130, P2537, DOI 10.1002/lary.28672
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, MOD TRANSM VIR CAUS
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xu K, 2020, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V55, pE001, DOI 10.3760/cma.j.issn.1673-0860.2020.0001
NR 50
TC 2
Z9 2
U1 4
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
EI 1531-5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD AUG
PY 2020
VL 78
IS 8
BP 1241
EP 1256
DI 10.1016/j.joms.2020.05.027
PG 16
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA MU6HM
UT WOS:000555772300012
PM 32479811
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kohan, HG
   Jamali, F
AF Kohan, Hamed Gilzad
   Jamali, Fakhreddin
TI Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their
   Effects on the Renin-Angiotensin System and Angiotensin-Converting
   Enzyme-2
SO JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; CYTOKINE STORM; DISEASE
   INTERACTIONS; INTERFERON BETA-1A; DOUBLE-BLIND; OPEN-LABEL;
   HYDROXYCHLOROQUINE; RECEPTOR; THERAPY
AB COVID-19 infection is associated with systemic inflammation, and sometimes hyperinflammatory responses with cytokine storm. This plays a major role in COVID-19 severity and poor disease prognosis, even death. Higher levels of inflammatory hallmarks including C-reactive protein, ferritin, D-dimers, and cytokines such as interleukin (IL) -6, IL-10 and tumor necrosis factor- alpha (TNF-alpha) have been reported. Many anti-viral drugs have been tried, but none were proven fully effective. Supportive care and management of the complications that are caused mainly by inflammation might be the key to greater survival rates and shorter hospitalization (e.g., the use of remdesivir, lopinavir, ritonavir, umifenovir (arbidol), oseltamivir, ganciclovir, favipiravir, darunavir, hydroxychloroquine, chloroquine, colchicine, azithromycin, anakinra, canakinumab, tocilizumab, siltuximab, sarilumab, Type 1 interferon, interferon beta-1 alpha, interferon alpha-2b, baricitinib, ruxolitinib, fedratinib, methylprednisolone and dexamethasone). However, the efficacy of these treatments still needs well-planned clinical trials. In such trials, careful attention must be paid to the duration of the treatment, the onset of beneficial effects, and the severity of the disease, otherwise, the outcomes may still remain inconclusive. Herein, we present a review of the current drugs, which are being used in the management of the disease and their anti-inflammatory properties. We also investigated if these drugs directly interact with Angiotensin-Converting Enzyme (ACE 2), which is a crucial component of the virus entry to the cells.
C1 [Kohan, Hamed Gilzad] Western New England Univ, Coll Pharm & Hlth Sci, Springfield, MA 01119 USA.
   [Jamali, Fakhreddin] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada.
RP Kohan, HG (corresponding author), Western New England Univ, Coll Pharm & Hlth Sci, Springfield, MA 01119 USA.; Jamali, F (corresponding author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada.
EM hamed.gilzadkohan@wne.edu; fjamali@ualberta.ca
OI Gilzad Kohan, Hamed/0000-0002-8028-0481
CR Abdin SM, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118054
   Abdulaziz N, 2018, CURR OPIN RHEUMATOL, V30, P249, DOI 10.1097/BOR.0000000000000500
   Al-Salama ZT, 2018, DRUGS, V78, P761, DOI 10.1007/s40265-018-0908-4
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Ancuta C, 2020, JOINT BONE SPINE, V87, P235, DOI 10.1016/j.jbspin.2019.12.003
   Angelidis C, 2018, CURR PHARM DESIGN, V24, P659, DOI 10.2174/1381612824666180123110042
   Antwi-Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038
   Aouba A, 2020, ANN RHEUMATIC DIS
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Asghar W, 2017, INFLAMMOPHARMACOLOGY
   Banjanac M, 2012, PHARMACOL RES, V66, P357, DOI 10.1016/j.phrs.2012.06.011
   Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736
   Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404
   Benucci M, 2020, J MED VIROL, V92, P2368, DOI 10.1002/jmv.26062
   Bird NL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129768
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   Burmester GR, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210310
   Cai Q, 2020, ENGINEERING
   Cantini F, 2020, J INFECT, VS0163-4453, P30228
   Caruso C, 2019, CANCER DISCOV, V9, P1332, DOI 10.1158/2159-8290.CD-NB2019-102
   Casper C, 2015, CLIN CANCER RES, V21, P4294, DOI 10.1158/1078-0432.CCR-15-0134
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cj Jorgensen S, 2020, PHARMACOTHERAPY
   CLARK P, 1993, ANN INTERN MED, V119, P1067, DOI 10.7326/0003-4819-119-11-199312010-00002
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Corral P, 2020, J CLIN PHARMACOL, V60, P978, DOI 10.1002/jcph.1684
   Costedoat-Chalumeau N, 2014, PRESSE MED, V43, pE167, DOI 10.1016/j.lpm.2014.03.007
   Crisafulli S, 2020, BIODRUGS CLIN IMMUNO, V2020, P1
   Crossman D, 2018, J THORAC DIS, V10, pS3084, DOI 10.21037/jtd.2018.07.50
   Dalbeth N, 2014, CLIN THER, V36, P1465, DOI 10.1016/j.clinthera.2014.07.017
   Daneshtalab N, 2004, J CLIN PHARMACOL, V44, P245, DOI 10.1177/0091270003262951
   Daneshtalab N, 2006, J CLIN PHARMACOL, V46, P1344, DOI 10.1177/0091270006292163
   Dastan F, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106688
   De Meyer S, 2020, INT J INFECT DIS, V97, P7, DOI 10.1016/j.ijid.2020.05.085
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Della-Torre E, 2020, ANN RHEUMATIC DIS
   Detert J, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-412
   Dey R, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105806
   Dolgin E, 2020, NAT BIOTECHNOL, V38, P510, DOI [10.1038/s41587-020-0520-5, 10.1038/s41587-020-0528-x]
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   El Azab SR, 2002, BRIT J ANAESTH, V88, P496, DOI 10.1093/bja/88.4.496
   Elli EM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01186
   Everett BM, 2019, CIRCULATION, V139, P1289, DOI 10.1161/CIRCULATIONAHA.118.038010
   Everett BM, 2018, J AM COLL CARDIOL, V71, P2392, DOI 10.1016/j.jacc.2018.03.002
   Fadel R, 2020, CLIN INFECT DIS OFFI
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Faraji F, 2019, COMPLEMENT THER MED, V45, P275, DOI 10.1016/j.ctim.2019.04.010
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Franco R, 2020, J IMMUNOLOGY
   Franzetti M, 2020, INT J INFECT DIS, V97, P215, DOI 10.1016/j.ijid.2020.05.050
   Garcia LF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01441
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gemcioglu E, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102196
   Gensel JC, 2017, SCI REP-UK, V7, DOI 10.1038/srep40144
   Ghasami K, 2016, IRAN J IMMUNOL, V13, P16, DOI IJIv13i1A3
   Gilzad-Kohan MH, 2012, EUR J PHARM SCI, V47, P387, DOI 10.1016/j.ejps.2012.06.003
   Goker Bagca B, 2020, CYTOKINE GROWTH FACT
   Goldman FD, 2000, BLOOD, V95, P3460, DOI 10.1182/blood.V95.11.3460.011k26_3460_3466
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guirguis MS, 2003, J PHARM SCI, V92, P1077, DOI 10.1002/jps.10381
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hanafy S, 2012, J PHARM PHARM SCI, V15, P361, DOI 10.18433/J30300
   Hanafy S, 2011, INFLAMMATION, V34, P609, DOI 10.1007/s10753-010-9269-1
   Haroon M, 2010, JOINT BONE SPINE, V77, P232, DOI 10.1016/j.jbspin.2010.02.008
   Haydar D, 2019, J IMMUNOL, V203, P1021, DOI 10.4049/jimmunol.1801228
   Hu B., 2020, J MED VIROLOGY, DOI 10.002/jmv.26232
   Hu CF, 2017, CURR MED CHEM, V24, P2241, DOI 10.2174/0929867324666170316115938
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUANG YL, 1995, J INTERF CYTOK RES, V15, P317, DOI 10.1089/jir.1995.15.317
   Hughes JH, CPT PHARMACOMETRICS
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156
   Johnson RM, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2648
   Khademi M, 2000, J NEUROIMMUNOL, V103, P202, DOI 10.1016/S0165-5728(99)00184-8
   Kingsbury SR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-64
   Kolilekas L, 2020, J MED VIROL, V92, P2866, DOI 10.1002/jmv.26165
   KOVARSKY J, 1984, ARTHRITIS RHEUM, V27, P1315, DOI 10.1002/art.1780271119
   Kulmatycki KM, 2005, J PHARM PHARM SCI, V8, P602
   Kulmatycki KM, 2001, CYTOKINE, V14, P1, DOI 10.1006/cyto.2000.0827
   Kuprash DV, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1237, DOI 10.1134/S0006297916110018
   Kyburz D, 2006, NAT CLIN PRACT RHEUM, V2, P458, DOI 10.1038/ncprheum0292
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Lamb YN, 2018, DRUGS, V78, P929, DOI 10.1007/s40265-018-0929-z
   Lan T, 2015, J CLIN TRANSL HEPATO, V3, P271, DOI 10.14218/JCTH.2015.00024
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee EB, 2018, IMMUNOTHERAPY-UK, V10, P57, DOI 10.2217/imt-2017-0075
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liantinioti G, 2018, CURR PHARM DESIGN, V24, P690, DOI 10.2174/1381612824666180116095658
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015
   Lin SJ, 2016, INT IMMUNOPHARMACOL, V40, P318, DOI 10.1016/j.intimp.2016.09.012
   Ling S, 2009, J CLIN PHARMACOL, V49, P301, DOI 10.1177/0091270008328099
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Liu Xiaoshun, 2004, Expert Rev Cardiovasc Ther, V2, P653, DOI 10.1586/14779072.2.5.653
   Guo LY, 2020, APMIS, V128, P423, DOI 10.1111/apm.13047
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Magro G, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198070
   Mansouri N, 2020, IMMUNOL INVEST, DOI 10.1080/08820139.2020.1789655
   Mayo PR, 2000, BRIT J CLIN PHARMACO, V50, P605, DOI 10.1046/j.1365-2125.2000.00314.x
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Nikolaus S, 2003, GUT, V52, P1286, DOI 10.1136/gut.52.9.1286
   Palanques-Pastor T, 2020, EUROPEAN J HOSP PHAR
   Pani A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106053
   Pietila KO, 1996, EUR HEART J, V17, P1345
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Price CC, 2020, CHEST, VS0012-3692, P31670
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Rakonczay Z, 2003, EUR J PHARMACOL, V464, P217, DOI 10.1016/S0014-2999(03)01380-3
   Ramakrishna R, 2010, ASIA-PAC J CLIN ONCO, V6, P210, DOI 10.1111/j.1743-7563.2010.01295.x
   Ramirez J, 2018, EXPERT OPIN DRUG SAF, V17, P727, DOI 10.1080/14740338.2018.1486819
   Richardson PJ, 2020, LANCET INFECT DIS
   Rojas-Marte GR, 2020, QJM MONTHLY J ASS PH
   Roskoski R, 2016, PHARMACOL RES, V111, P784, DOI 10.1016/j.phrs.2016.07.038
   Rossi JF, 2015, CLIN CANCER RES, V21, P1248, DOI 10.1158/1078-0432.CCR-14-2291
   Rubbert-Roth A, 2018, RHEUMATOL THER, V5, P21, DOI 10.1007/s40744-018-0102-x
   Saber-Ayad M, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050096
   Sacre K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3895
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Sanaee F, 2011, BRIT J CLIN PHARMACO, V72, P787, DOI 10.1111/j.1365-2125.2011.04019.x
   Seif F, 2020, INT ARCH ALLERGY IMM, V181, P467, DOI 10.1159/000508247
   Sellebjerg F, 2004, DAN MED BULL, V51, P167
   Selvaraj Vijairam, 2020, R I Med J (2013), V103, P39
   Setti L, 2020, INT J ENV RES PUBLIC, V17
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   So C, 2020, RESPIROL CASE REP, V8, DOI 10.1002/rcr2.596
   South AM, 2019, CLIN SCI, V133, P55, DOI 10.1042/CS20171550
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   Suba Z, 2020, J PHARM PHARM SCI, V23, P75, DOI 10.18433/jpps31069
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Taylor PC, 2017, NEW ENGL J MED, V376, P652, DOI 10.1056/NEJMoa1608345
   TETT S, 1990, BAILLIERE CLIN RHEUM, V4, P467, DOI 10.1016/S0950-3579(05)80004-4
   Thompson PL, 2018, J THORAC DIS, V10, P695, DOI 10.21037/jtd.2018.01.119
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Ucciferri C, 2020, LANCET RHEUMATOLOGY
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Wallace DJ, 2018, LANCET, V392, P222, DOI 10.1016/S0140-6736(18)31363-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Weiss U, 2008, NATURE, V454, P427, DOI 10.1038/454427a
   Wu CH, 2018, ARTERIOSCL THROM VAS, V38, pE108, DOI 10.1161/ATVBAHA.118.311282
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Wu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep10501
   Xie MK, 2020, INT J LEGAL MED, DOI 10.1007/s00414-020-02277-1
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang A Y, 2019, Zhonghua Xue Ye Xue Za Zhi, V40, P1003, DOI 10.3760/cma.j.issn.0253-2727.2019.12.006
   Yao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004
   Yeleswaram S, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108517
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuwala K, 2018, J CONTROL RELEASE, V275, P53, DOI 10.1016/j.jconrel.2018.02.012
NR 182
TC 2
Z9 2
U1 7
U2 7
PU CANADIAN SOC PHARMACEUTICAL SCIENCES
PI EDMONTON
PA 3118 DENTISTRY-PHARMACY CENTRE UNIV ALBERTA CAMPUS, EDMONTON, ALBERTA
   T6G2N8, CANADA
SN 1482-1826
J9 J PHARM PHARM SCI
JI J. Pharm. Pharm. Sci.
PD AUG 1
PY 2020
VL 23
BP 259
EP 277
DI 10.18433/jpps31346
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MV1FX
UT WOS:000556108700001
PM 32735768
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Guaraldi, G
   Meschiari, M
   Cozzi-Lepri, A
   Milic, J
   Tonelli, R
   Menozzi, M
   Franceschini, E
   Cuomo, G
   Orlando, G
   Borghi, V
   Santoro, A
   Di Gaetano, M
   Puzzolante, C
   Carli, F
   Bedini, A
   Corradi, L
   Fantini, R
   Castaniere, I
   Tabbi, L
   Girardis, M
   Tedeschi, S
   Giannella, M
   Bartoletti, M
   Pascale, R
   Dolci, G
   Brugioni, L
   Pietrangelo, A
   Cossarizza, A
   Pea, F
   Clini, E
   Salvarani, C
   Massari, M
   Viale, PL
   Mussini, C
AF Guaraldi, Giovanni
   Meschiari, Marianna
   Cozzi-Lepri, Alessandro
   Milic, Jovana
   Tonelli, Roberto
   Menozzi, Marianna
   Franceschini, Erica
   Cuomo, Gianluca
   Orlando, Gabriella
   Borghi, Vanni
   Santoro, Antonella
   Di Gaetano, Margherita
   Puzzolante, Cinzia
   Carli, Federica
   Bedini, Andrea
   Corradi, Luca
   Fantini, Riccardo
   Castaniere, Ivana
   Tabbi, Luca
   Girardis, Massimo
   Tedeschi, Sara
   Giannella, Maddalena
   Bartoletti, Michele
   Pascale, Renato
   Dolci, Giovanni
   Brugioni, Lucio
   Pietrangelo, Antonello
   Cossarizza, Andrea
   Pea, Federico
   Clini, Enrico
   Salvarani, Carlo
   Massari, Marco
   Viale, Pier Luigi
   Mussini, Cristina
TI Tocilizumab in patients with severe COVID-19: a retrospective cohort
   study
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID MONOCLONAL-ANTIBODY; PHARMACODYNAMICS; PHARMACOKINETICS; RECEPTOR
AB Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment.
   Methods This retrospective, observational cohort study included adults (>= 18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable. The primary endpoint was a composite of invasive mechanical ventilation or death. Treatment groups were compared using Kaplan-Meier curves and Cox regression analysis after adjusting for sex, age, recruiting centre, duration of symptoms, and baseline Sequential Organ Failure Assessment (SOFA) score.
   Findings Of 1351 patients admitted, 544 (40%) had severe COVID-19 pneumonia and were included in the study. 57 (16%) of 365 patients in the standard care group needed mechanical ventilation, compared with 33 (18%) of 179 patients treated with tocilizumab (p=0.41; 16 [18%] of 88 patients treated intravenously and 17 [19%] of 91 patients treated subcutaneously). 73 (20%) patients in the standard care group died, compared with 13 (7%; p<0.0001) patients treated with tocilizumab (six [7%] treated intravenously and seven [8%] treated subcutaneously). After adjustment for sex, age, recruiting centre, duration of symptoms, and SOFA score, tocilizumab treatment was associated with a reduced risk of invasive mechanical ventilation or death (adjusted hazard ratio 0.61, 95% CI 0.40-0.92; p=0.020). 24 (13%) of 179 patients treated with tocilizumab were diagnosed with new infections, versus 14 (4%) of 365 patients treated with standard of care alone (p<0.0001).
   Interpretation Treatment with tocilizumab, whether administered intravenously or subcutaneously, might reduce the risk of invasive mechanical ventilation or death in patients with severe COVID-19 pneumonia. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Guaraldi, Giovanni; Meschiari, Marianna; Menozzi, Marianna; Franceschini, Erica; Cuomo, Gianluca; Orlando, Gabriella; Borghi, Vanni; Santoro, Antonella; Di Gaetano, Margherita; Puzzolante, Cinzia; Carli, Federica; Bedini, Andrea; Corradi, Luca; Dolci, Giovanni; Mussini, Cristina] Azienda Osped Univ Policlin Modena, Dept Infect Dis, Modena, Italy.
   [Tonelli, Roberto; Fantini, Riccardo; Castaniere, Ivana; Tabbi, Luca; Clini, Enrico] Azienda Osped Univ Policlin Modena, Resp Dis Unit, Modena, Italy.
   [Girardis, Massimo] Azienda Osped Univ Policlin Modena, Dept Anaesthesia & Intens Care Unit, Modena, Italy.
   [Brugioni, Lucio; Pietrangelo, Antonello] Azienda Osped Univ Policlin Modena, Internal Med Dept, Modena, Italy.
   [Guaraldi, Giovanni; Milic, Jovana; Girardis, Massimo; Salvarani, Carlo; Mussini, Cristina] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, I-41124 Modena, Italy.
   [Milic, Jovana; Tonelli, Roberto; Castaniere, Ivana] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy.
   [Pietrangelo, Antonello; Cossarizza, Andrea; Clini, Enrico] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy.
   [Cozzi-Lepri, Alessandro] UCL, Ctr Clin Res Epidemiol Modelling & Evaluat, Inst Global Hlth, London, England.
   [Tedeschi, Sara; Giannella, Maddalena; Bartoletti, Michele; Pascale, Renato; Viale, Pier Luigi] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.
   [Pea, Federico] Univ Udine, Azienda Osped Univ Santa Maria Misericordia, Inst Clin Pharmacol, Udine, Italy.
   [Salvarani, Carlo] Azienda USL IRCCS Reggio Emilia, Dept Rheumatol, Reggio Nellemilia, Italy.
   [Massari, Marco] Azienda USL IRCCS Reggio Emilia, Infect Dis Unit, Reggio Nellemilia, Italy.
RP Mussini, C (corresponding author), Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, I-41124 Modena, Italy.
EM cristina.mussini@unimore.it
RI Girardis, Massimo/K-8974-2016; Clini, Enrico/ABE-6642-2020
OI Girardis, Massimo/0000-0002-2453-0829; Clini,
   Enrico/0000-0002-1515-5094; Franceschini, Erica/0000-0001-6922-5759
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Davidson AC, 2016, THORAX, V71, P1, DOI 10.1136/thoraxjnl-2015-208209
   Dostalek M, 2013, CLIN PHARMACOKINET, V52, P83, DOI 10.1007/s40262-012-0027-4
   Gill KL, 2016, CLIN PHARMACOKINET, V55, P789, DOI 10.1007/s40262-015-0361-4
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hennigan Stephanie, 2008, Ther Clin Risk Manag, V4, P767
   Higgs A, 2018, BRIT J ANAESTH, V120, P323, DOI 10.1016/j.bja.2017.10.021
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jain Aditi, 2016, J Anaesthesiol Clin Pharmacol, V32, P364, DOI 10.4103/0970-9185.168165
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lodi S, 2019, AM J EPIDEMIOL, V188, P1569, DOI 10.1093/aje/kwz100
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Nicastri E, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.11.2000230
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849
   Swerdlow DI, 2012, LANCET, V379, P1214, DOI 10.1016/S0140-6736(12)60110-X
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zayet S, 2020, INFECTION, DOI 10.1007/s15010-020-01442-3
   Zhang XP, 2013, INT J CLIN PHARM TH, V51, P443, DOI 10.5414/CP201819
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 39
TC 126
Z9 126
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD AUG
PY 2020
VL 2
IS 8
BP E474
EP E484
DI 10.1016/S2665-9913(20)30173-9
PG 11
WC Rheumatology
SC Rheumatology
GA MV7RH
UT WOS:000556549600017
PM 32835257
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Klopfenstein, T
   Zayet, S
   Lohse, A
   Balblanc, JC
   Badie, J
   Royer, PY
   Toko, L
   Mezher, C
   Kadiane-Oussou, NJ
   Bossert, M
   Bozgan, AM
   Charpentier, A
   Roux, MF
   Contreras, R
   Mazurier, I
   Dussert, P
   Gendrin, V
   Conrozier, T
AF Klopfenstein, T.
   Zayet, S.
   Lohse, A.
   Balblanc, J-C
   Badie, J.
   Royer, P-Y
   Toko, L.
   Mezher, C.
   Kadiane-Oussou, N. J.
   Bossert, M.
   Bozgan, A-M
   Charpentier, A.
   Roux, M-F
   Contreras, R.
   Mazurier, I
   Dussert, P.
   Gendrin, V
   Conrozier, T.
CA HNF Hosp Tocilizumab Multidiscipli
TI Tocilizumab therapy reduced intensive care unit admissions and/or
   mortality in COVID-19 patients
SO MEDECINE ET MALADIES INFECTIEUSES
LA English
DT Article
DE Tocilizumab; COVID-19; SARS-CoV-2; Mortality; Intensive care unit
AB Introduction. - No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
   Method. - We conducted a retrospective case-control study in the Nord Franche-Comte Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions.
   Results. - Patients with TCZ (n = 20) had a higher Charlson comorbidity index (5.3 [+/- 2.4] vs 3.4 [+/- 2.6], P = 0.014), presented with more severe forms (higher level of oxygen therapy at 13 L/min vs 6 L/min, P< 0.001), and had poorer biological findings (severe lymphopenia: 676/mm(3) vs 914/mm(3), P= 0.037 and higher CRP level: 158 mg/L vs 105 mg/L, P = 0.017) than patients without TCZ (n = 25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P= 0.002).
   Conclusion. - Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Klopfenstein, T.; Zayet, S.; Royer, P-Y; Toko, L.; Kadiane-Oussou, N. J.; Gendrin, V] Nord Franche Comte Hosp, Infect Dis Dept, F-90400 Trevenans, France.
   [Lohse, A.; Balblanc, J-C; Bossert, M.; Bozgan, A-M; Charpentier, A.; Conrozier, T.] Nord Franche Comte Hosp, Rheumatol Dept, F-90400 Trevenans, France.
   [Badie, J.; Mezher, C.] Nord Franche Comte Hosp, Intens Care Unit Dept, F-90400 Trevenans, France.
   [Roux, M-F; Contreras, R.] Nord Franche Comte Hosp, Pharmacol Dept, F-90400 Trevenans, France.
   [Mazurier, I; Dussert, P.] Nord Franche Comte Hosp, Biol Dept, F-90400 Trevenans, France.
RP Klopfenstein, T; Zayet, S (corresponding author), Nord Franche Comte Hosp, Infect Dis Dept, F-90400 Trevenans, France.
EM timothee.klopfenstein@hnfc.fr; souhail.zayet@gmail.com
CR Bernard Stoecklin S, 2020, EURO SURVEILL B EUR, V25
   Corman V.M., 2020, EURO SURVEILL B EUR, V25
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Henry B.M., 2019, CLIN CHEM LAB MED
   Michot J -M, 2020, ANN ONCOL
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Phua J., 2020, LANCET RESP MED
   Roumier M, 2020, INTERLEUKIN 6 BLOCKA
   Sanders JM, 2020, JAMA
   Siddiqi HK, 2020, J HEART LUNG TRANSPL
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Xu Xiaoling, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED
   Ye Q., 2020, J INFECT
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 17
TC 40
Z9 41
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0399-077X
J9 MED MALADIES INFECT
JI Med. Mal. Infect.
PD AUG
PY 2020
VL 50
IS 5
BP 397
EP 400
DI 10.1016/j.medmal.2020.05.001
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA MU6SW
UT WOS:000555801900003
PM 32387320
OA Green Published
DA 2021-01-01
ER

PT J
AU Freudenberg, LS
   Dittmer, U
   Herrmann, K
AF Freudenberg, Lutz S.
   Dittmer, Ulf
   Herrmann, Ken
TI Impact of COVID-19 on Nuclear Medicine in Germany, Austria and
   Switzerland: An International Survey in April 2020
SO NUKLEARMEDIZIN-NUCLEAR MEDICINE
LA English
DT Article
DE COVID-19; nuclear medicine; impact; survey
AB Introduction Preparations of health systems to accommodate large number of severely ill COVID-19 patients in March/April 2020 has a significant impact on nuclear medicine departments. Materials and Methods A web-based questionnaire was designed to differentiate the impact of the pandemic on inpatient and outpatient nuclear medicine operations and on public versus private health systems, respectively. Questions were addressing the following issues: impact on nuclear medicine diagnostics and therapy, use of recommendations, personal protective equipment, and organizational adaptations. The survey was available for 6 days and closed on April 20, 2020. Results 113 complete responses were recorded. Nearly all participants (97 %) report a decline of nuclear medicine diagnostic procedures. The mean reduction in the last three weeks for PET/CT, scintigraphies of bone, myocardium, lung thyroid, sentinel lymph-node are -14.4 %, -47.2 %, -47.5 %, -40.7 %, -58.4 %, and -25.2 % respectively. Furthermore, 76 % of the participants report a reduction in therapies especially for benign thyroid disease (-41.8 %) and radiosynoviorthesis (-53.8 %) while tumor therapies remained mainly stable. 48 % of the participants report a shortage of personal protective equipment. Conclusions Nuclear medicine services are notably reduced 3 weeks after the SARS-CoV-2 pandemic reached Germany, Austria and Switzerland on a large scale. We must be aware that the current crisis will also have a significant economic impact on the healthcare system. As the survey cannot adapt to daily dynamic changes in priorities, it serves as a first snapshot requiring follow-up studies and comparisons with other countries and regions.
C1 [Freudenberg, Lutz S.; Herrmann, Ken] Univ Hosp Essen, Clin Nucl Med, Essen, Germany.
   [Dittmer, Ulf] Univ Hosp Essen, Inst Virol, Essen, Germany.
   [Freudenberg, Lutz S.] Zentrum Radiol & Nukl Med Rheinland, Dept Nucl Med, Korschenbroich, Germany.
RP Freudenberg, LS (corresponding author), ZRN Rheinland, Nukl Med, Uberseite 88, D-41352 Korschenbroich, Germany.
EM l.freudenberg@zrn-info.de
CR Amparore D, 2020, MINERVA UROL NEFROL, V72, P505, DOI 10.23736/S0393-2249.20.03868-0
   [Anonymous], 2020, NATURE NEWS
   Czernin J, 2020, J NUCL MED, V61, P626, DOI 10.2967/jnumed.120.245738
   Hellwig D, 2017, NUKLEARMED-NUCL MED, V56, P55, DOI 10.3413/Nukmed-0880-17-02
   Krause BJ, 2020, NUKLEARMED-NUCL MED, V59, pE1, DOI 10.1055/a-1147-6722
   Lam WWC, 2020, EUR J NUCL MED MOL I, V47, P1645, DOI 10.1007/s00259-020-04790-2
   Lutje S, 2020, NUKLEARMED-NUCL MED, V59, P276, DOI 10.1055/a-1152-2341
   Paez D, 2020, EUR J NUCL MED MOL I, V47, P1615, DOI 10.1007/s00259-020-04825-8
   Robert-Koch-Institut, COVID 19 COR SARS CO
   The European Centre for Disease Prevention and Control, RAP RISK ASS COR DIS
   Vidick T, 2020, QUANTUM-AUSTRIA, V4
   Wieder H, 2012, NUKLEARMED-NUCL MED, V51, P154, DOI 10.3413/Nukmed-0467-12-01
   World Health Organization, WHO CORONAVIRUS DIS
NR 13
TC 6
Z9 6
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0029-5566
EI 2567-6407
J9 NUKLEARMED-NUCL MED
JI Nuklearmedizin
PD AUG
PY 2020
VL 59
IS 04
BP 294
EP 299
DI 10.1055/a-1163-3096
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA MU7FF
UT WOS:000555834600002
PM 32344438
DA 2021-01-01
ER

PT J
AU Shuman, AG
   Fox, ER
   Unguru, Y
AF Shuman, Andrew G.
   Fox, Erin R.
   Unguru, Yoram
TI COVID-19 and Drug Shortages: A Call to Action
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
AB The ever-vulnerable medication supply chain is being further strained by the COVID-19 pandemic. Pharmacists in all settings, including managed care, will need to prepare for a potential exacerbation of existing and new drug shortages in the midst of unprecedented crisis. We summarize the major issues, discuss potential mitigation strategies, and call on our colleagues to respond with the resilience necessary to protect our patients. Copyright (C) 2020, Academy of Managed Care Pharmacy. All rights reserved.
C1 [Shuman, Andrew G.] Univ Michigan, Sch Med, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA.
   [Shuman, Andrew G.] Univ Michigan, Sch Med, Michigan Inst Clin & Hlth Res, Ann Arbor, MI 48109 USA.
   [Fox, Erin R.] Univ Utah Hlth, Dept Pharm, Salt Lake City, UT 84132 USA.
   [Unguru, Yoram] Herman & Walter Samuelson Childrens Hosp Sinai, Div Pediat Hematol Oncol, Baltimore, MD USA.
   [Unguru, Yoram] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA.
RP Fox, ER (corresponding author), Univ Utah Hlth, Dept Pharm, Drug Informat & Support Serv, 50 N Med Dr,A050, Salt Lake City, UT 84132 USA.
EM Erin.Fox@hsc.utah.edu
CR Alexander GC, 2020, JAMA
   AMCP, 2020, AMCP SIGNS PHARM SUP
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210
   Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776
   Mazer-Amirshahi M, 2017, J CRIT CARE, V41, P283, DOI 10.1016/j.jcrc.2017.06.005
   McLaughlin M, 2013, J MANAGE CARE PHARM, V19, P783, DOI 10.18553/jmcp.2013.19.9.783
   Mehra B, 2020, JAMA HLTH FORUM 0410
   Rosoff PM, 2012, ARCH INTERN MED, V172, P1494, DOI 10.1001/archinternmed.2012.4367
   SILVERMAN E., 2020, STAT
   Liu VX, 2020, JAMA
   U.S. Food and Drug Administration, FDA DRUG SHORT
   U.S. Food and Drug Administration, 2020, COR COVID 19 SUPPL C
   U.S. Food and Drug Administratrion, 2012, FOOD DRUG ADM SAF IN
   U.S. Food & Drug Administration, 2019, DRUG SHORT ROOT CAUS
   Unguru Y, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv392
NR 16
TC 0
Z9 0
U1 7
U2 7
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD AUG
PY 2020
VL 26
IS 8
BP 945
EP 947
PG 3
WC Health Care Sciences & Services; Pharmacology & Pharmacy
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA MU2QE
UT WOS:000555517900004
PM 32715960
DA 2021-01-01
ER

PT J
AU Mattingly, TJ
   Hogue, MD
AF Mattingly, T. Joseph, II
   Hogue, Michael D.
TI Pharmacy's Call for Authorities to Aggressively Enforce Laws Addressing
   Price Gouging
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
AB Early reports of potential treatment for coronavirus disease (COVID-19) have raised concerns related to pharmaceutical distribution. Despite the lack of high-quality evidence, the mere hope of effectiveness of potential treatments, such as hydroxychloroquine, has led to surges in demand for these products, and many pharmacists are already informally reporting shortages through social channels. As manufacturers and wholesale distributors struggle to fulfill orders for drugs such as hydroxychloroquine, short-term price increases may seem reasonable in a free market when demand increases. However, any price increases by manufacturers, wholesale distributors, and pharmacies might be seen as exploitive gouging of consumers during a declared emergency. In addition to concerns of price gouging, increases in prescription drug utilization during the pandemic may lead to increases in spending for all payers as members may be treated for COVID-19. This article explores pharmaceutical supply chain and drug pricing nuances that may cause problems for payers and pharmacies as the country battles this global pandemic. Copyright (C) 2020, Academy of Managed Care Pharmacy. All rights reserved.
C1 [Mattingly, T. Joseph, II] Univ Maryland, Dept Pharmaceut Hlth Serv Res, Sch Pharm, Baltimore, MD 21201 USA.
   [Hogue, Michael D.] Loma Linda Univ, Sch Pharm, Loma Linda, CA 92350 USA.
   [Hogue, Michael D.] Loma Linda Univ, Ctr Interprofess Educ, Loma Linda, CA 92350 USA.
RP Mattingly, TJ (corresponding author), Univ Maryland, Sch Pharm, 220 Arch St,12th Fl, Baltimore, MD 21201 USA.
EM jmattingly@rx.umaryland.edu
RI Mattingly, T. Joseph/C-9368-2014
OI Mattingly, T. Joseph/0000-0001-7786-5780
CR Anderson GE, 2019, HLTH AFFAIRS BLOG, DOI [10.1.377/hblog201.9021.5.708286/full/, DOI 10.1377/HBLOG20190215.708286/FULL]
   [Anonymous], 2020, HLTH INS PROV RESP C
   Berchick ER, 2019, HLTH INSURANCE COVER
   Centers for Disease Control and Prevention, INF HNIC THER OPT CO
   Centers for Medicare m Medicaid Services, 2020, NADAC NAT AV DRUG AC
   Centers for Medicare & Medicaid Services, FED UPP LIM
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Hodge JG, 2012, J LAW MED ETHICS, V40, P690, DOI 10.1111/j.1748-720X.2012.00700.x
   IBM Watson Health, 2019, IBM MICR REDBOOK ONL
   Levy J, 2018, VALUE HEALTH, V21, P677, DOI 10.1016/j.jval.2017.06.013
   Luo J, 2019, ANN INTERN MED, V171, P605, DOI 10.7326/M18-1138
   Mairgiott TA, 2017, VALUE DIRECT INDIR D
   Tatelbaurn J., 2020, FEARS US DRUG SHORTA
NR 13
TC 0
Z9 0
U1 5
U2 6
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD AUG
PY 2020
VL 26
IS 8
BP 952
EP 955
DI 10.18553/jmcp.2020.20166
PG 4
WC Health Care Sciences & Services; Pharmacology & Pharmacy
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA MU2QE
UT WOS:000555517900005
PM 32329404
DA 2021-01-01
ER

PT J
AU Spyropoulos, AC
   Levy, JH
   Ageno, W
   Connors, JM
   Hunt, BJ
   Iba, T
   Levi, M
   Samama, CM
   Thachil, J
   Giannis, D
   Douketis, JD
AF Spyropoulos, Alex C.
   Levy, Jerrold H.
   Ageno, Walter
   Connors, Jean Marie
   Hunt, Beverley J.
   Iba, Toshiaki
   Levi, Marcel
   Samama, Charles Marc
   Thachil, Jecko
   Giannis, Dimitrios
   Douketis, James D.
CA Int Soc Thrombosis Haemostasis
TI Scientific and Standardization Committee communication: Clinical
   guidance on the diagnosis, prevention, and treatment of venous
   thromboembolism in hospitalized patients with COVID-19
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE anticoagulant; antithrombotic therapy; coronavirus disease 2019;
   hospitalization; SARS-CoV-2
ID RISK-ASSESSMENT MODEL; MEDICAL PATIENTS; ANTITHROMBOTIC THERAPY;
   PROPHYLAXIS; VTE; THROMBOPROPHYLAXIS; MANAGEMENT
C1 [Spyropoulos, Alex C.] Northwell Hlth Lenox Hill Hosp, Feinstein Inst Med Res, New York, NY 10075 USA.
   [Spyropoulos, Alex C.] Northwell Hlth Lenox Hill Hosp, Donald & Barbara Zucker Sch Med Hofstra Northwell, New York, NY 10075 USA.
   [Spyropoulos, Alex C.] Northwell Hlth Lenox Hill Hosp, Dept Med Anticoagulat & Clin Thrombosis Serv, 130 E 77th St, New York, NY 10075 USA.
   [Levy, Jerrold H.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC USA.
   [Levy, Jerrold H.] Duke Univ, Sch Med, Dept Crit Care, Durham, NC USA.
   [Levy, Jerrold H.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA.
   [Ageno, Walter] Univ Insubria, Dept Med & Surg, Varese, Italy.
   [Connors, Jean Marie] Harvard Med Sch, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
   [Hunt, Beverley J.] Guys & St Thomas NHS Fdn Trust, Thrombosis & Haemophilia Ctr, London, England.
   [Iba, Toshiaki] Juntendo Univ, Dept Emergency & Disaster Med, Tokyo, Japan.
   [Levi, Marcel] Univ Coll London Hosp NHS Fdn Trust, Dept Med, London, England.
   [Levi, Marcel] Univ Coll London Hosp NHS Fdn Trust, Cardiometab Programme NIHR UCLH UCL BRC, London, England.
   [Samama, Charles Marc] Ctr Univ Paris, Cochin Hosp, GHU, AP HP,Dept Anaesthesia Intens Care & Perioperat M, Paris, France.
   [Thachil, Jecko] Manchester Univ Hosp, Dept Haematol, Manchester, Lancs, England.
   [Giannis, Dimitrios] Feinstein Inst Med Res, Manhasset, NY USA.
   [Douketis, James D.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
RP Spyropoulos, AC (corresponding author), Northwell Hlth Lenox Hill Hosp, Dept Med Anticoagulat & Clin Thrombosis Serv, 130 E 77th St, New York, NY 10075 USA.; Spyropoulos, AC (corresponding author), Northwell Hlth Lenox Hill Hosp, Donald & Barbara Zucker Sch Med Hofstra Northwell, Feinstein Inst Med Res, 130 E 77th St, New York, NY 10075 USA.
EM aspyropoul@northwell.edu
RI Giannis, Dimitrios/AAQ-3483-2020; Levi, Marcel/AAZ-8559-2020
OI Giannis, Dimitrios/0000-0001-9246-976X; Hunt,
   Beverley/0000-0002-4709-0774
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Bikdeli B, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009042
   Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096
   Cohoon KP, 2018, J THROMB HAEMOST, V16, P1278, DOI 10.1111/jth.14146
   Cohoon KP, 2020, RES PRACT THROMB HAE, V4, DOI 10.1002/rth2.12358
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Greene MT, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.03.031
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Ho KM, 2013, CIRCULATION, V128, P1003, DOI 10.1161/CIRCULATIONAHA.113.002690
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   MacDougall K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041002
   Mahan CE, 2014, THROMB HAEMOSTASIS, V112, P692, DOI 10.1160/TH14-03-0239
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   OBE BH, PRACTICAL GUIDANCE P
   Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010
   Rosenberg D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001152
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Spyropoulos Alex C, 2020, TH Open, V4, pe59, DOI 10.1055/s-0040-1705137
   Spyropoulos AC, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029619886022
   Spyropoulos AC, 2017, THROMB HAEMOSTASIS, V117, P1662, DOI 10.1160/TH17-03-0168
   Spyropoulos AC, 2011, CHEST, V140, P706, DOI 10.1378/chest.10-1944
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
NR 35
TC 59
Z9 61
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD AUG
PY 2020
VL 18
IS 8
BP 1859
EP 1865
DI 10.1111/jth.14929
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA MT6DH
UT WOS:000555063100008
PM 32459046
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Peng, L
   Xiao, K
   Ottaviani, S
   Stebbing, J
   Wang, YJ
AF Peng, Ling
   Xiao, Kui
   Ottaviani, Silvia
   Stebbing, Justin
   Wang, Ying-Jie
TI A real-world disproportionality analysis of FDA Adverse Event Reporting
   System (FAERS) events for baricitinib
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Article
DE Baricitinib; JAK inhibitor; pharmacovigilance; FAERS; adverse event
AB Background Baricitinib is approved for the treatment of rheumatoid arthritis (RA). The authors retrospectively investigated adverse events (AEs) by data-mining a self-reporting database to better understand toxicities, especially since it has been used during the coronavirus disease 2019 (COVID-19) pandemic. Methods A reporting odds ratio (ROR) was used to detect the risk signals from the data in the US Food and Drug Administration (FDA) adverse event reporting system database (FAERS). The definition relied on system organ class (SOCs) and preferred terms (PTs) by the Medical Dictionary for Regulatory Activities (MedDRA). Results The search retrieved 1,598 baricitinib-associated cases within the reporting period: 86 PTs with significant disproportionality were retained. Infections including 'herpes zoster,' 'oral herpes,' and 'herpes virus infection' were found at a similar rate to those reported in trials, and such events were rare. Reports emerged for several thrombotic adverse events, while these events were also rare. Unexpected safety signals as opportunistic infections were detected. Serious outcomes as death and life-threatening outcomes accounted for 9.76% of the reported cases. Conclusions The incidence of these AEs does not appear above the background expected. These data are consistent with routine clinical observations and suggest the importance of pharmacovigilance.
C1 [Peng, Ling] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Radiotherapy, Hangzhou, Zhejiang, Peoples R China.
   [Xiao, Kui] Cent South Univ, Xiangya Hosp 2, Dept Pulm & Crit Care Med, Changsha, Hunan, Peoples R China.
   [Ottaviani, Silvia; Stebbing, Justin] Imperial Coll London, Dept Surg & Canc, Div Canc, London, England.
   [Wang, Ying-Jie] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp1,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
RP Wang, YJ (corresponding author), Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp1,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.; Stebbing, J (corresponding author), Imperial Coll Imperial Healthcare NHS Trust, Charing Cross Hosp, 1st Floor,Fulham Palace Rd, London W6 8RF, England.
EM j.stebbing@imperial.ac.uk; yingjiewang@zju.edu.cn
OI Ottaviani, Silvia/0000-0002-8830-9947; Stebbing,
   Justin/0000-0002-1117-6947; Xiao, Kui/0000-0001-6519-713X
FU Natural Science Foundation of Zhejiang Province, ChinaNatural Science
   Foundation of Zhejiang Province [LY19H160041]
FX This study was partially supported by the Natural Science Foundation of
   Zhejiang Province, China (grant no. LY19H160041).
CR Banerjee S, 2017, DRUGS, V77, P521, DOI 10.1007/s40265-017-0701-9
   Bechman K, 2019, RHEUMATOLOGY OXFORD, V58
   Dai J, 2019, MINI-REV MED CHEM, V19, P1531, DOI 10.2174/1389557519666190617152011
   Golomb BA, 2018, DRUG SAFETY, V41, P403, DOI 10.1007/s40264-017-0620-4
   Harigai M., 2019, RHEUMATOLOGY OXFO S1, V58
   Hazell L, 2006, DRUG SAF, V29
   Honda S, 2020, EXPERT OPIN DRUG SAF, V19, P545, DOI 10.1080/14740338.2020.1743263
   Huang F, 2018, BIODRUGS, V32, P415, DOI 10.1007/s40259-018-0304-3
   Jamilloux Y, 2019, AUTOIMMUN REV, V18
   Le Berre C, 2020, GASTROENTEROLOGY, V158, P76, DOI 10.1053/j.gastro.2019.08.058
   Lindquist M, 2000, DRUG SAF, V23
   Lippi G, 2020, CLIN CHEM LAB MED, V58
   Markham A, 2017, DRUGS, V77, P697, DOI 10.1007/s40265-017-0723-3
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rothman KJ, 2004, PHARMACOEPIDEMIOL DR, V13
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Scott IC, 2018, DRUG SAF, V41, P645
   Smolen JS, 2019, J RHEUMATOL, V46, P7, DOI 10.3899/jrheum.171361
   Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Taylor PC, 2019, J CLIN MED, V8
   Taylor PC, 2017, N ENGL J MED, V376
   TV A, 2019, BIODRUGS, V33
   Vallejo-Yague E, 2020, DRUG SAFETY, V43, P881, DOI 10.1007/s40264-020-00958-9
   Widdifield J, 2013, ARTHRITIS CARE RES H, V65, P353
   Xie WH, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2019-215841
   Zink RC, 2013, CHIN J NAT MEDICINES, V11, P314, DOI 10.1016/S1875-5364(13)60035-7
NR 29
TC 5
Z9 5
U1 4
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD NOV 1
PY 2020
VL 19
IS 11
BP 1505
EP 1511
DI 10.1080/14740338.2020.1799975
EA AUG 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OK5BS
UT WOS:000555219700001
PM 32693646
OA Bronze
DA 2021-01-01
ER

PT J
AU Wong, LP
   Alias, H
   Wong, PF
   Lee, HY
   AbuBakar, S
AF Wong, Li Ping
   Alias, Haridah
   Wong, Pooi-Fong
   Lee, Hai Yen
   AbuBakar, Sazaly
TI The use of the health belief model to assess predictors of intent to
   receive the COVID-19 vaccine and willingness to pay
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE COVID-19 vaccination; willingness to pay; intention; health belief
   model; Malaysia
ID INFLUENZA VACCINATION; DECISION
AB Background The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. Methods A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP. Results A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean +/- standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD +/- 79.2) [US$30.66 +/- 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes. Conclusions The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP.
C1 [Wong, Li Ping; Alias, Haridah] Univ Malaya, Dept Social & Prevent Med, Ctr Epidemiol & Evidence Based Practice, Fac Med, Blocks N&O,Level 5, Kuala Lumpur 50603, Malaysia.
   [Wong, Pooi-Fong] Univ Malaya, Dept Pharmacol, Fac Med, Kuala Lumpur, Malaysia.
   [Lee, Hai Yen; AbuBakar, Sazaly] Univ Malaya, Trop Infect Dis Res & Educ Ctr TIDREC, Kuala Lumpur, Malaysia.
   [AbuBakar, Sazaly] Univ Malaya, Dept Med Microbiol, Fac Med, Kuala Lumpur, Malaysia.
RP Wong, LP (corresponding author), Univ Malaya, Dept Social & Prevent Med, Ctr Epidemiol & Evidence Based Practice, Fac Med, Blocks N&O,Level 5, Kuala Lumpur 50603, Malaysia.
EM wonglp@ummc.edu.my
RI WONG, POOI-FONG PF/B-5234-2010; abubakar, sazaly/B-3957-2010; Wong, Li
   Ping/B-2782-2010
OI WONG, POOI-FONG PF/0000-0002-6705-2521; abubakar,
   sazaly/0000-0002-9267-1420; Wong, Li Ping/0000-0002-0107-0532
FU Ministry of Education Malaysia under Long Term Research Grant Scheme
   (LRGS MRUN Phase 1) [LRGS MRUN/F1/01/2018]; Higher Institution Centre of
   Excellence (HICOE) Program [MO002-2019]
FX The study was financially supported by the Ministry of Education
   Malaysia under Long Term Research Grant Scheme (LRGS MRUN Phase 1: LRGS
   MRUN/F1/01/2018) and in partial support from Higher Institution Centre
   of Excellence (HICOE) Program under Project MO002-2019.
CR Becker M, 1974, HLTH ED MONOGRAPHS, V2, P324, DOI [10.1177/109019817400200401, DOI 10.1177/109019817400200407]
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Champion V. L., 2008, HLTH BEHAV HLTH ED T, P45
   Dube Eve, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.9e239605f4d320c6ad27ce2aea5aaad2
   Ess SM, 2002, CLIN INFECT DIS, V35, P294, DOI 10.1086/341419
   Glanz K., 2008, HLTH BEHAV HLTH ED T
   Hosmer D., 2013, APPL LOGISTIC REGRES, V3rd
   Iwashita Y, 2010, JPN J PUBLIC HLTH, V57
   Jayasooria D, 2016, UKM ETHIC STUDIES PA
   Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396
   Kim S, 2019, HEALTH COMMUN, V34, P21, DOI 10.1080/10410236.2017.1384353
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Palache A, 2011, VACCINE, V29, P9459, DOI 10.1016/j.vaccine.2011.10.030
   Rajamoorthy Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215125
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Schmidt J, 2020, J ACAD MARKET SCI, V48, P499, DOI 10.1007/s11747-019-00666-6
   Shahrabani S, 2010, INT J ENV RES PUB HE, V7, P853, DOI 10.3390/ijerph7030853
   Shahrabani S, 2009, EUR J HEALTH ECON, V10, P227, DOI 10.1007/s10198-008-0124-3
   Tsutsui Y, 2012, J SOCIO-ECON, V41, P594, DOI 10.1016/j.socec.2012.05.001
   Verelst F, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0820
   World Health Organization, 127 WHO
   Yeo HY, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0163-2
   Zainudin EN, 2018, IIUM MED J MALAYSIA, V17
NR 24
TC 2
Z9 2
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD SEP 1
PY 2020
VL 16
IS 9
BP 2204
EP 2214
DI 10.1080/21645515.2020.1790279
EA AUG 2020
PG 11
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NU9MN
UT WOS:000555144000001
PM 32730103
OA Bronze
DA 2021-01-01
ER

PT J
AU Pirro, F
   Caldarola, G
   Chiricozzi, A
   Tambone, S
   Mariani, M
   Calabrese, L
   D'Urso, DF
   De Simone, C
   Peris, K
AF Pirro, Federico
   Caldarola, Giacomo
   Chiricozzi, Andrea
   Tambone, Sara
   Mariani, Marco
   Calabrese, Laura
   D'Urso, Dario Francesco
   De Simone, Clara
   Peris, Ketty
TI The impact of COVID-19 pandemic in a cohort of Italian psoriatic
   patients treated with biological therapies
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article; Early Access
DE Psoriasis; biological therapies; COVID-19; SARS-CoV-2; anxiety;
   depression; stress
AB Background The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide. Objective To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics. Methods A telephone survey was conducted in May 4-10 2020 about the Italian lockdown period (March 9-May 3 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS). Results 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity. Conclusion Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.
C1 [Pirro, Federico; Caldarola, Giacomo; Chiricozzi, Andrea; Tambone, Sara; Calabrese, Laura; D'Urso, Dario Francesco; De Simone, Clara; Peris, Ketty] Univ Cattolica Sacro Cuore, Dermatol, Largo F Vito 1, I-00135 Rome, Italy.
   [Pirro, Federico; Caldarola, Giacomo; Chiricozzi, Andrea; Tambone, Sara; Calabrese, Laura; D'Urso, Dario Francesco; De Simone, Clara; Peris, Ketty] Fdn Policlin Univ A Gemelli IRCCS, Dermatol, Rome, Italy.
   [Mariani, Marco] Univ Cattolica Sacro Cuore, Univ Dept Hlth Sci & Publ Hlth, Sect Hyg, Rome, Italy.
RP De Simone, C (corresponding author), Univ Cattolica Sacro Cuore, Dermatol, Largo F Vito 1, I-00135 Rome, Italy.
EM psoriasi@policlinicogemelli.it
OI Pirro, Federico/0000-0001-6629-9613; Calabrese,
   Laura/0000-0001-5238-2336; Chiricozzi, Andrea/0000-0002-6739-0387
CR Amerio P, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13434
   [Anonymous], WHAT IBD PAT SHOULD
   [Anonymous], COVID 19 GUID RHEUM
   Burtscher J, 2020, SCAND J MED SCI SPOR, V30, P1544, DOI 10.1111/sms.13706
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Fleming P, 2017, J EUR ACAD DERMATOL, V31, P798, DOI 10.1111/jdv.13891
   Freeman EE, 2020, J AM ACAD DERMATOL, V82
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Gisondi P, 2020, J AM ACAD DERMATOL, V83, P285, DOI 10.1016/j.jaad.2020.04.085
   Hall JMF, 2012, DERMAT RES PRACT, DOI 10.1155/2012/403908
   Kutlu O, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13383
   Mauro V, 2020, INTERN EMERG MED, V15, P787, DOI [10.1007/s11739-020-02395-z, 10.1024/0300-9831/a000674]
   Moccia L, 2020, BRAIN BEHAV IMMUN, V87, P75, DOI 10.1016/j.bbi.2020.04.048
   Ozaras R, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13632
   Prignano F, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0753-1
   RAMADI KB, 2020, J DERMATOL TREAT, V31, DOI DOI 10.1016/J.CELREP.2020.107734
   Ricardo JW, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13687
   Rismiller K, 2020, J DERMATOL TREAT, V31, P441, DOI 10.1080/09546634.2020.1762843
   Smith BW, 2008, INT J BEHAV MED, V15, P194, DOI 10.1080/10705500802222972
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Torres T, 2020, AM J CLIN DERMATOL, V21, P307, DOI 10.1007/s40257-020-00514-2
   Villani A, 2020, J DERMATOL TREAT, V31
   Walton M, 2020, EUR HEART J-ACUTE CA, V9, P241, DOI 10.1177/2048872620922795
   WAN JY, 2020, J AM ACAD DERMATOL, V83
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 27
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1800578
EA AUG 2020
PG 5
WC Dermatology
SC Dermatology
GA MT8ID
UT WOS:000555210900001
PM 32705945
OA Bronze
DA 2021-01-01
ER

PT J
AU Sanchis-Gomar, F
   Lavie, CJ
   Morin, DP
   Perez-Quilis, C
   Laukkanen, JA
   Perez, MV
AF Sanchis-Gomar, Fabian
   Lavie, Carl J.
   Morin, Daniel P.
   Perez-Quilis, Carme
   Laukkanen, Jari A.
   Perez, Marco, V
TI Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only,
   or Drug to Prevent Infection?
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Article
ID INJURY; RATS
AB Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.
C1 [Sanchis-Gomar, Fabian; Perez-Quilis, Carme] Univ Valencia, Fac Med, Incl Biomed Res Inst, Dept Physiol,INCLIVA Biomed Res Inst, Av Blasco Ibanez 15, Valencia 46010, Spain.
   [Sanchis-Gomar, Fabian; Perez, Marco, V] Stanford Univ, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA.
   [Lavie, Carl J.; Morin, Daniel P.] Univ Queensland, Ochsner Clin Sch, John Ochsner Heart & Vasc Inst, Sch Med, New Orleans, LA USA.
   [Laukkanen, Jari A.] Univ Eastern Finland, Inst Clin Med, Dept Med, Kuopio, Finland.
   [Laukkanen, Jari A.] Cent Finland Hlth Care Dist, Dept Med, Jyvaskyla, Finland.
RP Sanchis-Gomar, F (corresponding author), Univ Valencia, Fac Med, Incl Biomed Res Inst, Dept Physiol,INCLIVA Biomed Res Inst, Av Blasco Ibanez 15, Valencia 46010, Spain.; Sanchis-Gomar, F (corresponding author), Stanford Univ, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA.
EM fabian.sanchis@uv.es
RI Laukkanen, Jari/I-4528-2017
OI Laukkanen, Jari/0000-0002-3738-1586; Sanchis-Gomar,
   Fabian/0000-0003-0424-4208
FU Subprograma Atraccio de Talent-Contractes Postdoctorals de la
   Universitat de Valencia
FX Fabian Sanchis-Gomar is supported by a postdoctoral contract granted by
   'Subprograma Atraccio de Talent-Contractes Postdoctorals de la
   Universitat de Valencia'.
CR Aimo A, 2020, EUR J PREV CARDIOL, DOI 10.1177/2047487320919233
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Carpenter A, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00085
   CHORIN E, 2020, NAT MED 0424, DOI DOI 10.1101/2020.04.02.20047050
   Gehi AK, 2006, JAMA-J AM MED ASSOC, V296, P2839, DOI 10.1001/jama.296.23.2839
   Halici Z, 2007, EUR J PHARMACOL, V566, P215, DOI 10.1016/j.ejphar.2007.03.046
   Sr DH, 2020, AM J CARDIOVASC DRUG, V20, P549, DOI 10.1007/s40256-020-00401-5
   Heijman J, 2013, N-S ARCH PHARMACOL, V386, P571, DOI 10.1007/s00210-013-0865-0
   Hirasawa Y, 2009, CIRC J, V73, P639, DOI 10.1253/circj.CJ-08-0794
   Ide T, 1999, CIRCULATION, V100, P690, DOI 10.1161/01.CIR.100.7.690
   Ito H, 2002, CYTOKINE, V17, P197, DOI 10.1006/cyto.2001.0996
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kadioglu O, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255943, DOI 10.2471/BLT.20.255943]
   Karnatovskaia LV, 2012, J CRIT CARE, V27, P447, DOI 10.1016/j.jcrc.2011.10.009
   Kochav SM, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008719
   Lippi G, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3989
   Matsumori A, 1997, CIRCULATION, V96, P1386, DOI 10.1161/01.CIR.96.5.1386
   Megens RTA, 2012, THROMB HAEMOSTASIS, V107, P597, DOI 10.1160/TH11-09-0650
   Nakaya H, 2009, CIRC J, V73, P622, DOI 10.1253/circj.CJ-09-0038
   Oral H, 1999, AM J CARDIOL, V83, P388, DOI 10.1016/S0002-9149(98)00874-1
   Polat B, 2013, N-S ARCH PHARMACOL, V386, P635, DOI 10.1007/s00210-013-0862-3
   Rali Aniket S., 2020, US CARDIOL REV, V14, pe01
   Salata C, 2016, J ANTIMICROB CHEMOTH, V71, P280, DOI 10.1093/jac/dkv305
   Salata C, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv032
   Stadler K, 2008, AM J RESP CELL MOL, V39, P142, DOI 10.1165/rcmb.2007-0217OC
   Wong AW, 2020, CHEST, V158, P1069, DOI 10.1016/j.chest.2020.04.019
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
NR 27
TC 2
Z9 2
U1 3
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PD OCT
PY 2020
VL 20
IS 5
BP 413
EP 418
DI 10.1007/s40256-020-00429-7
EA AUG 2020
PG 6
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA OB4KK
UT WOS:000554436400001
PM 32737841
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wei, TZ
   Wang, H
   Wu, XQ
   Lu, Y
   Guan, SH
   Dong, FQ
   Dong, CL
   Zhu, GL
   Bao, YZ
   Zhang, J
   Wang, GY
   Li, HY
AF Wei Tian-zi
   Wang Hao
   Wu Xue-qing
   Lu Yi
   Guan Sheng-hui
   Dong Feng-quan
   Dong Chen-le
   Zhu Gu-li
   Bao Yu-zhou
   Zhang Jian
   Wang Guan-yu
   Li Hai-ying
TI In SilicoScreening of Potential Spike Glycoprotein Inhibitors of
   SARS-CoV-2 with Drug Repurposing Strategy
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; drug repurposing; virtual screening; Chinese
   medicine
ID TRADITIONAL CHINESE MEDICINE; WESTERN MEDICINE; INTEGRATIVE CHINESE;
   CORONAVIRUS; COVID-19
AB Objective To select potential molecules that can target viral spike proteins, which may potentially interrupt the interaction between the human angiotension-converting enzyme 2 (ACE2) receptor and viral spike protein by virtual screening. Methods The three-dimensional (3D)-coordinate file of the receptor-binding domain (RBD)-ACE2 complex for searching a suitable docking pocket was firstly downloaded and prepared. Secondly, approximately 15,000 molecular candidates were prepared, including US Food and Drug Administration (FDA)-approved drugs from DrugBank and natural compounds from Traditional Chinese Medicine Systems Pharmacology (TCMSP), for the docking process. Then, virtual screening was performed and the binding energy in Autodock Vina was calculated. Finally, the top 20 molecules with high binding energy and their Chinese medicine (CM) herb sources were listed in this paper. Results It was found that digitoxin, a cardiac glycoside in DrugBank and bisindigotin in TCMSP had the highest docking scores. Interestingly, two of the CM herbs containing the natural compounds that had relatively high binding scores,Forsythiae fructusandIsatidis radix, are components of Lianhua Qingwen (& x83b2;& x82b1;& x6e05;& x761f;), a CM formula reportedly exerting activity against severe acute respiratory syndrome (SARS)-Cov-2. Moreover, raltegravir, an HIV integrase inhibitor, was found to have a relatively high binding score. Conclusions A class of compounds, which are from FDA-approved drugs and CM natural compounds, that had high binding energy with RBD of the viral spike protein. Our work provides potential candidates for other researchers to identify inhibitors to prevent SARS-CoV-2 infection, and highlights the importance of CM and integrative application of CM and Western medicine on treating COVID-19.
C1 [Wei Tian-zi; Guan Sheng-hui; Wang Guan-yu] Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Guangdong, Peoples R China.
   [Wei Tian-zi; Lu Yi; Zhang Jian] Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Guangdong, Peoples R China.
   [Wei Tian-zi] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.
   [Wang Hao; Wu Xue-qing; Zhu Gu-li] Shenzhen Univ Gen Hosp, Dept Obstet & Gynecol, Shenzhen 518055, Guangdong, Peoples R China.
   [Wang Hao; Wu Xue-qing; Dong Feng-quan; Zhu Gu-li; Bao Yu-zhou; Li Hai-ying] Shenzhen Univ, Clin Med Acad, Shenzhen 518055, Guangdong, Peoples R China.
   [Dong Feng-quan; Bao Yu-zhou; Li Hai-ying] Shenzhen Univ Gen Hosp, Dept Cardiol, Shenzhen 518055, Guangdong, Peoples R China.
   [Dong Chen-le] Wenzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
   [Wang Guan-yu] Guangdong Prov Key Lab Computat Sci & Mat Design, Shenzhen 518055, Guangdong, Peoples R China.
   [Wang Guan-yu] Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Guangdong, Peoples R China.
RP Wang, GY (corresponding author), Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Guangdong, Peoples R China.; Zhang, J (corresponding author), Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Guangdong, Peoples R China.; Li, HY (corresponding author), Shenzhen Univ, Clin Med Acad, Shenzhen 518055, Guangdong, Peoples R China.; Li, HY (corresponding author), Shenzhen Univ Gen Hosp, Dept Cardiol, Shenzhen 518055, Guangdong, Peoples R China.; Wang, GY (corresponding author), Guangdong Prov Key Lab Computat Sci & Mat Design, Shenzhen 518055, Guangdong, Peoples R China.; Wang, GY (corresponding author), Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Guangdong, Peoples R China.
EM zhangjian@sustech.edu.cn; wanggy@sustech.edu.cn;
   lihaiying111@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61773196]; Special Scientific Research
   Project on COVID-19 Epidemic Prevention and Control in Guangdong
   Universities [2020KZDZX1182]; Guangdong Provincial Key Laboratory Funds
   [2017B030301018, 2019B030301001]; Shenzhen Research Funds
   [JCYJ20170817104740861]; Shenzhen Peacock Plan [KQTD2016053117035204];
   Center for Computational Science and Engineering of Southern University
   of Science and Technology, China
FX Supported by National Natural Science Foundation of China (No.
   61773196), Special Scientific Research Project on COVID-19 Epidemic
   Prevention and Control in Guangdong Universities (No. 2020KZDZX1182),
   Guangdong Provincial Key Laboratory Funds (Nos. 2017B030301018,
   2019B030301001), Shenzhen Research Funds (No. JCYJ20170817104740861),
   Shenzhen Peacock Plan (No. KQTD2016053117035204), and by Center for
   Computational Science and Engineering of Southern University of Science
   and Technology, China
CR [Anonymous], 1986, DICT TRAD CHIN DRUGS
   [Anonymous], 2016, DISC STUD MOD ENV RE
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Di Pierro M, 2015, J CHEM THEORY COMPUT, V11, P5624, DOI 10.1021/acs.jctc.5b00648
   Dobos G, 2011, CHIN J INTEGR MED, V17, P11, DOI 10.1007/s11655-011-0601-x
   Elbaz HA, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-4
   Gao LQ, 2020, CHIN J INTEGR MED, V26, P527, DOI 10.1007/s11655-020-3476-x
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Jiao Q, 2003, CHIN J INTEGR MED, V9, P175, DOI 10.1007/BF02838027
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li RF, 2020, PHARM RES
   Li XH, 2003, CHIN J INTEGR MED, V9, P263, DOI 10.1007/BF02838611
   Lin L, 2003, CHIN J INTEGR MED, V9, P162, DOI 10.1007/BF02838024
   Liu BY, 2004, CHIN J INTEGR MED, V10, P117, DOI 10.1007/BF02836381
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Menger L, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23082
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang RB, 2003, CHIN J INTEGR MED, V9, P259, DOI 10.1007/BF02838610
   Wei XY, 2005, J NAT PROD, V68, P427, DOI 10.1021/NP049662i
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang K, 2020, AM J EMERG MED
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 33
TC 2
Z9 2
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD SEP
PY 2020
VL 26
IS 9
BP 663
EP 669
DI 10.1007/s11655-020-3427-6
EA AUG 2020
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NF2SH
UT WOS:000554424700002
PM 32740825
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU To, KLA
   Fok, YYY
AF To, Ka Lun Aaron
   Fok, Yuen Ying Yvonne
TI Homeopathic Clinical Features of 18 Patients in COVID-19 Outbreaks in
   Hong Kong
SO HOMEOPATHY
LA English
DT Article
DE homeopathy; COVID-19; Hong Kong; China; clinical features
ID COMBINATION REMEDY; THERAPY; FEVER
AB Background Hong Kong is geographically located in the province of Guangdong which, after Hubei, has been the region of China second-most affected by the COVID-19 pandemic. Compared to the pathognomonic symptoms of the named disease, homeopathic symptoms are always more helpful for homeopathic prescriptions. Aim This study reports and summarizes the homeopathic symptoms observed in 18 confirmed/suspected epidemiologically related cases in cluster outbreaks of COVID-19 in Hong Kong in early 2020. Methods Homeopathic symptoms from this case series were collected from 18 consecutive patients who, in addition to their concurrent conventional treatment or traditional Chinese medicine, actively sought help from homeopathy as an adjunctive measure for symptomatic relief from COVID-19. Cases were categorized according to outbreak clusters, focusing mainly on the homeopathic symptoms. In the analysis, frequency of all homeopathic medicines, common rubrics in all the cases, common rubrics in each of the top-ranked remedies, and differentiating symptoms for each top-ranked remedy were determined. Results Homeopathic symptoms of 18 cases, each identified as mild and belonging to one of six separate clusters, are reported. Eighteen common symptoms screened out of 79 selected rubrics constituted two sets of homeopathic symptom pictures:Bryonia alba(n = 4) andGelsemium sempervirens(n = 12). Eight and seven differentiating features, respectively, were identified forBryonia albaandGelsemium sempervirens. Conclusion The common symptoms of 18 mild COVID-19 cases constituted two sets of homeopathic symptom pictures, indicatingBryonia albaorGelsemium sempervirens; they were indicated in 4 and 12 cases, respectively, out of the 18 in total.
C1 [To, Ka Lun Aaron; Fok, Yuen Ying Yvonne] Hong Kong Assoc Homeopathy, Hong Kong, Peoples R China.
RP Fok, YYY (corresponding author), Hong Kong Assoc Homeopathy, Epidemiol & Biostat, Prince Edward, 4-F Union Pk Ctr,771-775 Nathan Rd, Hong Kong, Peoples R China.
EM yvonne.fok@chinesehomeopathy.com
CR Bracho G, 2010, HOMEOPATHY, V99, P156, DOI 10.1016/j.homp.2010.05.009
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hahnemann S, 1801, HEILUNG VERHUTUNG SC
   Jacobs J, 2007, HOMEOPATHY, V96, P22, DOI 10.1016/j.homp.2006.10.004
   Jacobs J, 2018, HOMEOPATHY, V107, P157, DOI 10.1055/s-0038-1649487
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Nair KRJ, 2014, IND J RES HOM, V8, P160
   National Health Commission of the People's Republic of China, DIAGN TREATM PROT CO
   Saeed-ul-Hassan S, 2013, TROP J PHARM RES, V12, P767, DOI 10.4314/tjpr.v12i5.16
   Schroyens F, 2007, RELATED REMEDY RADAR
   van Erp V MA, 1996, BR HOM J, V85, P66
   Wadhwani GG, 2013, HOMEOPATHY, V102, P193, DOI 10.1016/j.homp.2013.02.001
   Winston J, 1999, FACES HOMEOPATHY
   World Health Organization, COR COVID 19 CHIN
   World Health Organization, COR COVID 19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang Q, 2013, WHO TRADITIONAL MED
NR 17
TC 1
Z9 1
U1 3
U2 3
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1475-4916
EI 1476-4245
J9 HOMEOPATHY
JI Homeopathy
PD AUG
PY 2020
VL 109
IS 03
BP 146
EP 162
DI 10.1055/s-0040-1710545
PG 17
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA MS6IV
UT WOS:000554378000006
PM 32503061
OA Other Gold
DA 2021-01-01
ER

PT J
AU Bani-Sadr, F
   Hentzien, M
   Pascard, M
   N'Guyen, Y
   Servettaz, A
   Andreoletti, L
   Kanagaratnam, L
   Jolly, D
AF Bani-Sadr, Firouze
   Hentzien, Maxime
   Pascard, Madeline
   N'Guyen, Yohan
   Servettaz, Amelie
   Andreoletti, Laurent
   Kanagaratnam, Lukshe
   Jolly, Damien
TI Corticosteroid therapy for patients with COVID-19 pneumonia: a
   before-after study
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; SARS-CoV-2; COVID-19 pneumonia; Corticosteroid
AB Anti-inflammatory drugs such as corticosteroids may beneficially modulate the host inflammatory response to coronavirus disease 2019 (COVID-19) pneumonia. The aim of this study was to evaluate the impact of addition of corticosteroids to the hospital protocol for treatment of suspected or confirmed COVID-19 pneumonia on rates of death or intensive care unit (ICU) admission. A before-after study was performed to evaluate the effect of addition of corticosteroids to our institution's COVID-19 treatment protocol on hospital mortality. A total of 257 patients with a COVID-19 diagnosis were included in this study between 3 March 2020 and 14 April 2020. As corticosteroids were widely used after 27 March 2020, two periods were considered for the purposes of this study: the 'before' period from 3-20 March 2020 (n = 85); and the 'after' period from 26 March-14 April 2020 (n = 172). The 'after' period was associated with a lower risk of death [adjusted hazard ratio (aHR) = 0.47, 95% confidence interval (CI) 0.23-0.97; P = 0.04] and a lower risk of ICU admission or of death before ICU admission (aHR = 0.37, 95% CI 0.21-0.64; P = 0.0005) by multivariate analysis adjusted for age, National Early Warning score and institutionalisation status. In conclusion, addition of corticosteroids to our institution's COVID-19 treatment protocol was associated with a significant reduction in hospital mortality in the 'after' period. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Bani-Sadr, Firouze; Hentzien, Maxime; N'Guyen, Yohan; Servettaz, Amelie] Reims Univ Hosp, Dept Internal Med Clin Immunol & Infect Dis, Reims, France.
   [Pascard, Madeline; Kanagaratnam, Lukshe; Jolly, Damien] Reims Univ Hosp, Dept Res & Publ Hlth, Reims, France.
   [Andreoletti, Laurent] Reims Univ Hosp, Dept Virol, Reims, France.
RP Bani-Sadr, F (corresponding author), CHU Robert Debre, Dept Internal Med Infect Dis & Clin Immunol, Rue Gen Koenig, F-51092 Reims, France.
EM fbanisadr@chu-reims.fr
RI Zixuan, Huang/ABI-3557-2020
OI HENTZIEN, Maxime/0000-0003-2729-9420
CR BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104
   Busse KH, 2008, JAIDS-J ACQ IMM DEF, V48, P561, DOI 10.1097/QAI.0b013e31817bebeb
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Rubin GD, 2020, CHEST, V158, P106, DOI 10.1016/j.chest.2020.04.003
   Williams B., NATL EARLY WARNING S
   World Health Organization, 2020, CLIN MAN COVID 19
   Xu J, 2020, CLIN INFECT DIS
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 10
TC 4
Z9 4
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106077
DI 10.1016/j.ijantimicag.2020.106077
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400035
PM 32634602
OA Green Published
DA 2021-01-01
ER

PT J
AU He, J
   Hu, LJ
   Huang, XJ
   Wang, CR
   Zhang, ZM
   Wang, Y
   Zhang, DM
   Ye, WC
AF He, Jun
   Hu, Lijun
   Huang, Xiaojun
   Wang, Chenran
   Zhang, Zhimin
   Wang, Ying
   Zhang, Dongmei
   Ye, Wencai
TI Potential of coronavirus 3C-like protease inhibitors for the development
   of new anti-SARS-CoV-2 drugs: Insights from structures of protease and
   inhibitors
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Coronavirus; SARS; MERS; COVID-19; 3C-like protease; 3CL(pro) inhibitor
ID COV 3CL PROTEASE; EAST RESPIRATORY SYNDROME; SARS-COV;
   CHEMICAL-SYNTHESIS; IDENTIFICATION; COMBINATION; DERIVATIVES; MECHANISM;
   DESIGN
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), which belong to the same Betacoronavirus genus, induces severe acute respiratory disease that is a threat to human health. Since the outbreak of infection by SARS-CoV-2 began, which causes coronavirus disease 2019 (COVID-19), the disease has rapidly spread worldwide. Thus, a search for effective drugs able to inhibit SARS-CoV-2 has become a global pursuit. The 3C-like protease (3CL(pro)), which hydrolyses viral polyproteins to produce functional proteins, is essential for coronavirus replication and is considered an important therapeutic target for diseases caused by coronaviruses, including COVID-19. Many 3CL(pro) inhibitors have been proposed and some new drug candidates have achieved success in preclinical studies. In this review, we briefly describe recent developments in determining the structure of 3CL(pro) and its function in coronavirus replication and summarise new insights into 3CL(pro) inhibitors and their mechanisms of action. The clinical application prospects and limitations of 3CL(pro) inhibitors for COVID-19 treatment are also discussed. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [He, Jun; Hu, Lijun; Huang, Xiaojun; Wang, Chenran; Wang, Ying; Zhang, Dongmei; Ye, Wencai] Jinan Univ, Inst Tradit Chinese Med & Nat Prod, Coll Pharm, Guangzhou 510632, Peoples R China.
   [He, Jun] Jinan Univ, Inst Lab Anim Sci, Guangzhou 510632, Peoples R China.
   [Hu, Lijun; Huang, Xiaojun; Wang, Chenran; Wang, Ying; Zhang, Dongmei; Ye, Wencai] Jinan Univ, Guangdong Prov Key Lab Pharmacodynam Constituents, Coll Pharm, Guangzhou, Peoples R China.
   [Zhang, Zhimin] Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ MOE, Coll Pharm, Guangzhou, Peoples R China.
RP Zhang, DM; Ye, WC (corresponding author), Jinan Univ, Inst Tradit Chinese Med & Nat Prod, Coll Pharm, Guangzhou 510632, Peoples R China.; Zhang, DM; Ye, WC (corresponding author), Jinan Univ, Guangdong Prov Key Lab Pharmacodynam Constituents, Coll Pharm, Guangzhou, Peoples R China.
EM dmzhang701@jnu.edu.cn; chywc@aliyun.com
FU National Key R&D Program of China [2017YFC1703800]; Innovative and
   Research Teams Project of the Guangdong Pearl River Talents Program
   [2017BT01Y036]; Science and Technology Key Project of Guangdong
   Province, China [2020B1111110004, 202020 012620800001]; Basic and
   Applied Basic Research Fund of Guangdong Province [2019A1515011994]
FX This study was supported by the National Key R&D Program of China [No.
   2017YFC1703800], the Innovative and Research Teams Project of the
   Guangdong Pearl River Talents Program [No. 2017BT01Y036], the Science
   and Technology Key Project of Guangdong Province, China [2020B1111110004
   and 202020 012620800001] and the Basic and Applied Basic Research Fund
   of Guangdong Province [2019A1515011994].
CR Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2020, EMERG INFECT DIS, P26, DOI [10.3201/eid2607.200282., DOI 10.3201/EID2607.200282]
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Boulos MKN, 2020, INT J HEALTH GEOGR, V19, DOI 10.1186/s12942-020-00202-8
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chuck CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013197
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong SJ, 2020, J MED VIROL, V92, P1542, DOI 10.1002/jmv.25768
   Fischer A, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11923239., DOI 10.26434/CHEMRXIV.11923239]
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Ho BL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144865
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Hu TC, 2009, VIROLOGY, V388, P324, DOI 10.1016/j.virol.2009.03.034
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Konno H, 2017, BIOORG MED CHEM LETT, V27, P2746, DOI 10.1016/j.bmcl.2017.04.056
   Konno H, 2016, BIOORGAN MED CHEM, V24, P1241, DOI 10.1016/j.bmc.2016.01.052
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Kumar V, 2016, BIOORGAN MED CHEM, V24, P3035, DOI 10.1016/j.bmc.2016.05.013
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim L, 2019, PROG BIOPHYS MOL BIO, V143, P52, DOI 10.1016/j.pbiomolbio.2018.08.009
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Nga PT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002215
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Rut W., 2020, SUBSTRATE SPECIFICIT, DOI [10.1101/2020.03.07.9819282020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sisay M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104779
   Theerawatanasirikul S, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104697
   Tomar S, 2015, J BIOL CHEM, V290, P19403, DOI 10.1074/jbc.M115.651463
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang L, 2017, EUR J MED CHEM, V137, P450, DOI 10.1016/j.ejmech.2017.05.045
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu RJ, 2019, EUR J MED CHEM, V167, P472, DOI 10.1016/j.ejmech.2019.02.002
   Ye G, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020240
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang SN, 2010, PROTEIN CELL, V1, P371, DOI 10.1007/s13238-010-0044-8
   Zhou JW, 2019, FASEB J, V33, P14575, DOI 10.1096/fj.201901624RR
NR 52
TC 2
Z9 2
U1 8
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106055
DI 10.1016/j.ijantimicag.2020.106055
PG 10
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400028
PM 32534187
OA Green Published
DA 2021-01-01
ER

PT J
AU Homolak, J
   Kodvanj, I
AF Homolak, J.
   Kodvanj, I.
TI Widely available lysosome targeting agents should be considered as
   potential therapy for COVID-19
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; Lysosomotropic agents; Endosome; Antiviral; Drug repurposing
ID PUMP INHIBITOR LANSOPRAZOLE; VIRUS-INFECTION; DRUGS; AZITHROMYCIN;
   MACROLIDES; ENTRY; INDOMETHACIN; HEPATOCYTES; MECHANISMS; PNEUMONIA
AB While the coronavirus disease 2019 (COVID-19) pandemic advances, the scientific community continues to struggle in the search for treatments. Several improvements have been made, including discovery of the clinical efficacy of chloroquine (CQ) in patients with COVID-19, but effective treatment protocols remain elusive. In the search for novel treatment options, many scientists have used the in-silico approach to identify compounds that could interfere with the key molecules involved in entrance, replication or dissemination of severe acute respiratory syndrome coronavirus-2. However, most of the identified molecules are not available as pharmacological agents at present, and assessment of their safety and efficacy could take many months. This review took a different approach based on the proposed pharmacodynamic model of CQ in COVID-19. The main mechanism of action responsible for the favourable outcome of patients with COVID-19 treated with CQ seems to be related to a pH-modulation-mediated effect on endolysosomal trafficking, a characteristic of chemical compounds often called `lysosomotropic agents' because of the physico-chemical properties that enable them to diffuse passively through the endosomal membrane and undergo protonation-based trapping in the lumen of the acidic vesicles. This review discusses lysosomotropic and lysosome targeting drugs that are already in clinical use and are characterized by good safety profiles, low cost and wide availability. Some of these drugs-particularly azithromycin and other macrolides, indomethacin and some other non-steroidal anti-inflammatory drugs, proton pump inhibitors and fluoxetine - could provide additional therapeutic benefits in addition to the potential antiviral effect that is still to be confirmed by well-controlled clinical trials. As some of these drugs have probably been used empirically in the treatment of COVID-19, it is hoped that colleagues worldwide will publish patient data to enable evaluation of the potential efficacy of these agents in the clinical context, and rapid implementation in therapeutic protocols if they are shown to have a beneficial effect on clinical outcome. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Homolak, J.; Kodvanj, I.] Univ Zagreb, Sch Med, Dept Pharmacol, Salata 11, Zagreb 10000, Croatia.
RP Homolak, J (corresponding author), Univ Zagreb, Sch Med, Dept Pharmacol, Salata 11, Zagreb 10000, Croatia.
EM homolakjan@gmail.com
RI Homolak, Jan/AAM-4333-2020; Kodvanj, Ivan/AAI-9407-2020
OI Homolak, Jan/0000-0003-1508-3243; Kodvanj, Ivan/0000-0002-1359-3701
CR Agelidis AM, 2015, FUTURE VIROL, V10, P1145, DOI 10.2217/fvl.15.85
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Amici C, 2015, CELL MICROBIOL, V17, P1391, DOI 10.1111/cmi.12446
   Asada M, 2009, ANTIVIR RES, V83, P191, DOI 10.1016/j.antiviral.2009.05.003
   Bauer L, 2019, ACS INFECT DIS, V5, P1609, DOI 10.1021/acsinfecdis.9b00179
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Chamoun-Emanuelli AM, 2019, SCI REP, V9, P1
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   Dartois V, 2014, NAT REV MICROBIOL, V12, P159, DOI 10.1038/nrmicro3200
   Dayer MR, ARXIV200304524
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hallifax D, 2007, DRUG METAB DISPOS, V35, P1325, DOI 10.1124/dmd.107.015131
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Hitchings A, 2019, TOP 100 DRUGS CLIN P
   Hu YB, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0041-1
   Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067
   Jia J, 2005, BRIT J PHARMACOL, V144, P80, DOI 10.1038/sj.bjp.0705984
   Kazmi F, 2013, DRUG METAB DISPOS, V41, P897, DOI 10.1124/dmd.112.050054
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee YY, 2015, ONCOTARGET, V6, P35040, DOI 10.18632/oncotarget.5319
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu XH, 2012, COMPR PSYCHIAT, V53, P15, DOI 10.1016/j.comppsych.2011.02.003
   Long Jason, 2015, F1000Res, V4, P30, DOI 10.12688/f1000research.6085.1
   Lu S., 2017, PLOS ONE, V12
   Lu ZN, 2017, CANCER CHEMOTH PHARM, V80, P925, DOI 10.1007/s00280-017-3426-2
   Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305
   Marceau F, 2012, TOXICOL APPL PHARM, V259, P1, DOI 10.1016/j.taap.2011.12.004
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015
   Mazzon Michela, 2019, F1000Res, V8, DOI 10.12688/f1000research.19694.1
   Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010
   Novoa RR, 2005, BIOL CELL, V97, P147, DOI 10.1042/BC20040058
   Nujic K, 2012, CELL IMMUNOL, V279, P78, DOI 10.1016/j.cellimm.2012.09.007
   Paessler S, 2018, FRONT BIOSCI-LANDMRK, V23, P947, DOI 10.2741/4627
   Park SC, 2020, PSYCHIAT INVEST, V17, P85, DOI 10.30773/pi.2020.0058
   Persson HL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-83
   Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sasaki T, 2005, EUR J PHARMACOL, V509, P201, DOI 10.1016/j.ejphar.2004.12.042
   Sasaki Takahiko, 2011, Ther Adv Respir Dis, V5, P91, DOI 10.1177/1753465810392264
   Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014
   Schump MD, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01639-16
   Scott CC, 2011, BIOESSAYS, V33, P103, DOI 10.1002/bies.201000108
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shkurupii VA, 2006, B EXP BIOL MED+, V141, P487, DOI 10.1007/s10517-006-0206-0
   Siekmeier R, 2015, ADV EXP MED BIOL, V839, P13, DOI 10.1007/5584_2014_50
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Song Y, 2020, GUT, V69, P1143, DOI 10.1136/gutjnl-2020-320891
   Staring J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216259
   Terrier O, 2020, BROADSPECTRUM ANTIVI, P7202
   Vallecillo-Hernandez J, 2018, SCI REP, V8, P1
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   White JM, 2016, TRAFFIC, V17, P593, DOI 10.1111/tra.12389
   Wong EHC, 2014, LANCET RESP MED, V2, P657, DOI 10.1016/S2213-2600(14)70107-9
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
   Xiao CF, 2020, PSYCHIAT INVEST, V17, P175, DOI 10.30773/pi.2020.0047
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu T, 2020, INDOMETHACIN HAS POT, P8
   Yu M, 2015, CANCER SCI, V106, P1438, DOI 10.1111/cas.12756
   Zarogoulidis P, 2012, EUR J CLIN PHARMACOL, V68, P479, DOI 10.1007/s00228-011-1161-x
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zheng WN, 2019, CELL REP, V27, P1875, DOI 10.1016/j.celrep.2019.04.053
   Zuo J, 2012, ANTIMICROB AGENTS CH, V56, P4838, DOI 10.1128/AAC.00983-12
NR 73
TC 4
Z9 4
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106044
DI 10.1016/j.ijantimicag.2020.106044
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400018
PM 32522674
OA Green Published
DA 2021-01-01
ER

PT J
AU Hong, SI
   Ryu, BH
   Chong, YP
   Lee, S
   Kim, S
   Kim, HC
   Hong, KW
   Bae, IG
   Cho, OH
AF Hong, Sun In
   Ryu, Byung-Han
   Chong, Yong Pil
   Lee, Seungjun
   Kim, Sunjoo
   Kim, Ho Cheol
   Hong, Kyung-Wook
   Bae, In-Gyu
   Cho, Oh-Hyun
TI Five severe COVID-19 pneumonia patients treated with triple combination
   therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon
   beta-1b
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Letter
C1 [Hong, Sun In; Ryu, Byung-Han; Kim, Ho Cheol; Hong, Kyung-Wook; Bae, In-Gyu; Cho, Oh-Hyun] Gyeongsang Natl Univ, Dept Internal Med, Changwon Hosp, Coll Med, 11 Samjeongja Ro, Chang Won 51472, South Korea.
   [Chong, Yong Pil] Univ Ulsan, Div Infect Dis, Dept Internal Med, Coll Med,Asan Med Ctr, Seoul, South Korea.
   [Lee, Seungjun; Kim, Sunjoo] Gyeongsang Natl Univ, Dept Lab Med, Changwon Hosp, Coll Med, Chang Won, South Korea.
   [Kim, Ho Cheol; Bae, In-Gyu; Cho, Oh-Hyun] Gyeongsang Natl Univ, Gyeongsang Inst Hlth Sci, Coll Med, Jinju, South Korea.
RP Cho, OH (corresponding author), Gyeongsang Natl Univ, Dept Internal Med, Changwon Hosp, Coll Med, 11 Samjeongja Ro, Chang Won 51472, South Korea.
EM zenmd@naver.com
OI Kim, Sunjoo/0000-0001-8099-8891; Chong, Yong Pil/0000-0003-1672-3185
FU National Research Foundation of KoreaNational Research Foundation of
   Korea; Korean government (MSIT)Korean Government
   [NRF-018R1D1A1B07040831]
FX This work was supported by the National Research Foundation of Korea
   grant, funded by the Korean government (MSIT) (No.
   NRF-018R1D1A1B07040831).
CR Arashiro T, 2020, EMERG INFECT DIS, V26, P1346, DOI 10.3201/eid2606.200452
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 4
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106052
DI 10.1016/j.ijantimicag.2020.106052
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400025
PM 32544570
OA Green Published
DA 2021-01-01
ER

PT J
AU Pawar, AY
AF Pawar, Ashish Yashwantrao
TI Combating devastating COVID-19 by drug repurposing
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Drug repurposing; Coronavirus
ID RESPIRATORY SYNDROME CORONAVIRUS; ENTRY; ANTIBIOTICS; CHLOROQUINE;
   INHIBIT; CELLS
AB Despite advances in drug discovery, viral infections remain a major challenge for scientists across the globe. The recent pandemic of COVID-19 (coronavirus disease 2019), caused by a viral infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has created a disastrous situation all over the world. As no drugs are available to treat this life-threatening disease and the mortality rate due to COVID-19 is high, there is an utmost need to attempt to treat the infection using drug repurposing. Some countries are against the use of these drugs because of adverse effects associated with drug repurpos-ing and lack of statistically significant clinical data, but they have been found to be effective in some countries to treat COVID-19 patients (off-label/investigational). This article emphasises possible drug can-didates in the treatment of COVID-19. Most of these drugs were found to be effective in in vitro studies. There is a need to re-assess in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on a priority basis. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Pawar, Ashish Yashwantrao] Mahatma Gandhi Vidyamandirs Pharm Coll, Dept Pharmaceut Sci, Nasik 422003, Maharashtra, India.
RP Pawar, AY (corresponding author), Mahatma Gandhi Vidyamandirs Pharm Coll, Dept Pharmaceut Sci, Nasik 422003, Maharashtra, India.
EM pawarashish23@gmail.com
CR [Anonymous], 2020, GUARDIAN
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Burkard C, 2015, PLOS PATHOG, V11, DOI [10.1371/journal.ppat.1004709., DOI 10.1371/JOURNAL.PPAT.1004709]
   Burkard C, 2015, J VIROL, V89, P4434, DOI 10.1128/JVI.03274-14
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2016, INT J ANTIMICROB AG, V48, P349, DOI 10.1016/j.ijantimicag.2016.07.004
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hemila H, 1999, INT J TUBERC LUNG D, V3, P756
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Joseph T., INT PULMONOLOGISTS C
   Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Padmanabhan S., 2020, POTENTIAL DUAL THERA, DOI [10.13140/RG.2.2.28124.74882, DOI 10.13140/RG.2.2.28124.74882]
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu X, 2020, 20200300026 CHINAXIV
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 22
TC 10
Z9 10
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 105984
DI 10.1016/j.ijantimicag.2020.105984
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400002
PM 32305589
OA Green Published
DA 2021-01-01
ER

PT J
AU Perez-Garcia, LA
   Mejias-Carpio, IE
   Delgado-Noguera, LA
   Manzanarez-Motezuma, JP
   Escalona-Rodriguez, MA
   Sordillo, EM
   Mogollon-Rodriguez, EA
   Hernandez-Pereira, CE
   Marquez-Colmenarez, MC
   Paniz-Mondolfi, AE
AF Perez-Garcia, Luis A.
   Mejias-Carpio, Isis E.
   Delgado-Noguera, Lourdes A.
   Manzanarez-Motezuma, Jean P.
   Escalona-Rodriguez, Maria A.
   Sordillo, Emilia M.
   Mogollon-Rodriguez, Euler A.
   Hernandez-Pereira, Carlos E.
   Marquez-Colmenarez, Marilianna C.
   Paniz-Mondolfi, Alberto E.
TI Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian
   crisis
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Ivermectin; Venezuela; Multipurpose; Humanitarian; Crisis; Endemic;
   Epidemic
ID SANITATION; HYGIENE; WATER
AB Ivermectin (IVM) is a robust antiparasitic drug with an excellent tolerance and safety profile. Historically it has been the drug of choice for onchocerciasis and lymphatic filariasis global elimination programs. IVM is an oral insecticide and is a standard treatment against intestinal helminths and ectoparasites. The current humanitarian crisis in Venezuela is a regional public health threat that requires immediate action. The public health system in Venezuela has crumbled because of a 70% shortage of medicines in public hospitals, low vaccination campaigns, and the mass exodus of medical personnel. Herein we discuss the repurposing of IVM to attenuate the burden imposed by the most prevalent neglected tropical diseases (NTDs) in Venezuela, including soil-transmitted helminths, ectoparasites and, possibly, vectorborne diseases, such as malaria. In addition, novel experimental evidence has shown that IVM is active and efficacious in vitro against Chagas disease, Leishmaniases, arboviruses, and SARS-CoV-2. In crisis-hit Venezuela, all these infectious diseases are public health emergencies that have long been ignored and require immediate attention. The versatility of IVM could serve as a powerful tool to tackle the multiple overlapping endemic and emergent diseases that currently affect Venezuela. The repurposing of this multipurpose drug would be a timely therapeutic approach to help mitigate the tremendous burden of NTDs nationwide. (C) 2020 Published by Elsevier B.V.
C1 [Perez-Garcia, Luis A.; Delgado-Noguera, Lourdes A.; Manzanarez-Motezuma, Jean P.; Escalona-Rodriguez, Maria A.; Mogollon-Rodriguez, Euler A.; Hernandez-Pereira, Carlos E.; Marquez-Colmenarez, Marilianna C.] Inst Invest Biomed IDB Barquisimeto, Venezuelan Sci Incubator & Zoonosis & Emerging Pa, Div Infect Dis, Lara, Venezuela.
   [Mejias-Carpio, Isis E.] Global WASH, Houston, TX USA.
   [Sordillo, Emilia M.; Paniz-Mondolfi, Alberto E.] Icahn Sch Med Mt Sinai, Dept Pathol Mol & CellBased Med, New York, NY 10029 USA.
RP Paniz-Mondolfi, AE (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol Mol & CellBased Med, New York, NY 10029 USA.
EM alberto.paniz-mondolfi@mountsinai.org
OI Manzanarez Motezuma, Jean Pilade/0000-0003-4111-5667; Delgado - Noguera,
   Lourdes/0000-0003-0910-5434; Perez, Luis/0000-0002-2230-3171;
   Hernandez-Pereira, Carlos E./0000-0003-4377-5175
CR Ault S, 2011, WORKSH INT DEW INT P, P1
   Botto C, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1313-z
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chaccour C, 2019, LANCET, V393, P1480, DOI 10.1016/S0140-6736(18)32613-8
   Crump A, 2017, J ANTIBIOT, V70, P495, DOI 10.1038/ja.2017.11
   dos Santos AR, 2009, BIOORGAN MED CHEM, V17, P496, DOI 10.1016/j.bmc.2008.12.003
   Freeman MC, 2013, AM J TROP MED HYG, V89, P875, DOI 10.4269/ajtmh.13-0237
   Grillet ME, 2019, LANCET INFECT DIS, V19, pE149, DOI 10.1016/S1473-3099(18)30757-6
   Heukelbach J, 2004, ARZNEIMITTELFORSCH, V54, P416
   Kobylinski KC, 2014, AM J TROP MED HYG, V91, P655, DOI 10.4269/ajtmh.14-0187
   Kobylinski KC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-381
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Moser W, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4307
   Nery SV, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3532-6
   Incani RN, 2017, ACTA TROP, V167, P64, DOI 10.1016/j.actatropica.2016.12.014
   Palmeirim MS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006458
   Paniz-Mondolfi AE, 2019, EMERG INFECT DIS, V25, P625, DOI 10.3201/eid2504.181305
   Pinilla YT, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006221
   Speare R, 2004, B WORLD HEALTH ORGAN, V82, P562
   Ventegodt S., 2015, MENT HOLIST HEAL SOM, P119
   Whitley L, 2019, INT J HYG ENVIR HEAL, V222, P1133, DOI 10.1016/j.ijheh.2019.08.001
NR 21
TC 1
Z9 1
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106037
DI 10.1016/j.ijantimicag.2020.106037
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400014
PM 32479893
OA Green Published
DA 2021-01-01
ER

PT J
AU Sharma, A
   Tiwari, S
   Deb, MK
   Marty, JL
AF Sharma, Atul
   Tiwari, Swapnil
   Deb, Manas Kanti
   Marty, Jean Louis
TI Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global
   pandemic and treatment strategies
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Coronavirus; SARS-CoV-2; Chloroquine; Severe acute respiratory syndrome;
   Antiviral agents; Biosensor
ID CLINICAL CHARACTERISTICS; CONVALESCENT PLASMA; VIRAL-INFECTIONS;
   IN-VITRO; SARS; CHLOROQUINE; INFLUENZA; PNEUMONIA; PROTEIN; LOCALIZATION
AB The emergence and rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a potentially fatal disease, is swiftly leading to public health crises worldwide. The origin of SARS-CoV-2 infection was first reported in people exposed to a seafood market in Wuhan City, China in December 2019. It has been suggested that the infection is likely to be of zoonotic origin and transmitted to humans through a not-yet-known intermediary. As of 22 May 2020, the World Health Organization reported that there were approximately 4,995,996 confirmed cases and 327,821 deaths. SARS-CoV-2 is transmitted via inhalation or direct contact with droplets from infected people. It has an incubation period ranging from 2 to >= 14 days. The rate of spread of SARS-CoV-2 is greater than that for severe acute respiratory syndrome coronavirus and Middle East respiratory coronavirus. The symptoms are similar to influenza (i.e. breathlessness, sore throat and fatigue) and infected cases are isolated and treated. Infection is mild in most cases, but in elderly (>50 years) patients and those with cardiac and respiratory disorders, it may progress to pneumonia, acute respiratory distress syndrome and multi-organ failure. People with strong immunity or those who have developed herd immunity are asymptomatic. The fatality rate ranges from 3% to 4%. Recommended methods for diagnosis of COVID-19 are molecular tests (e.g. polymerase chain reaction) on respiratory secretions, chest scan and common laboratory diagnosis. Currently, treatment is essentially supportive, and the role of antiviral agents is yet to be established as a vaccine is not yet available. This review will focus on epidemiology, symptoms, transmission, pathogenesis, ongoing available treatments and future perspectives of SARS-CoV-2. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Sharma, Atul] Monash Univ, Sch Chem, Melbourne, Vic 3800, Australia.
   [Tiwari, Swapnil; Deb, Manas Kanti] Pt Ravishankar Shukla Univ, Sch Studies Chem, Raipur 492010, Chhattisgarh, India.
   [Marty, Jean Louis] Univ Perpignan Via Domitia, Biocapteurs Anal Environm, 52 Ave Paul Alduy, F-66860 Perpignan, France.
   [Marty, Jean Louis] Sensbiotech, 21rue Nogarede, F-66400 Ceret, France.
RP Sharma, A (corresponding author), Monash Univ, Sch Chem, Melbourne, Vic 3800, Australia.
EM a.sharmard@gmail.com
OI Sharma, Atul/0000-0003-0877-1275
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, REC INV COVID 19 CON
   [Anonymous], 2020, 51 WHO
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Baidya A, 2020, J MED SCI CLIN RES, V8, P94
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Boelaert JR, 2001, J CLIN VIROL, V20, P137, DOI 10.1016/S1386-6532(00)00140-2
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cai QX, 2020, ALLERGY, V75, P1742, DOI 10.1111/all.14309
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Casanova L, 2009, WATER RES, V43, P1893, DOI 10.1016/j.watres.2009.02.002
   Cascella M, 2020, FEATURES EVALUATION
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Denis M, 2020, TRANSDISCIPLINARY IN, P1
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dorward J, 2020, THERE IS CURRENTLY N
   Du GS, 2016, ANAL BIOCHEM, V514, P2, DOI 10.1016/j.ab.2016.09.006
   Duan K, 2020, P NAT ACAD SCI, V4, P168
   Duddu P., 2020, CORONAVIRUS TREATMEN
   Dutra RF, 2007, CLIN CHIM ACTA, V376, P114, DOI 10.1016/j.cca.2006.07.029
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gunalan Vithiagaran, 2011, BMC Res Notes, V4, P446, DOI 10.1186/1756-0500-4-446
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu L, 2020, RISK FACTORS ASS CLI
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang RR, 2016, SCI REP-UK, V6, DOI 10.1038/srep31103
   Ji S, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109652
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jianping J, 2020, RANDOMIZED OPEN BLAN
   Johnson & Johnson, 2020, LACK EV SUPP US DAR
   Khan A, 2020, NANOMATERIALS AIR RE, P61
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Kosyna FK, 2015, BIOL CHEM, V396, P1357, DOI 10.1515/hsz-2015-0171
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Lee SJ, 2011, NAT REV NEPHROL, V7, P718, DOI 10.1038/nrneph.2011.150
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Y, 2020, EXPLORATORY RANDOMIZ
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu JL, 2016, VIROL SIN, V31, P279, DOI 10.1007/s12250-016-3756-y
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Mishra GK, 2015, BIOSENS BIOELECTRON, V67, P532, DOI 10.1016/j.bios.2014.09.033
   Morales-Narvaez E, 2020, BIOSENS BIOELECTRON, V163, DOI 10.1016/j.bios.2020.112274
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   National Health Commission, 2020, DIAGN TREATM NOV COR
   Nawaz MH, 2018, ANAL CHIM ACTA, V1026, P1, DOI 10.1016/j.aca.2018.04.032
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Peiris J. S. M., 2012, Medical microbiology: a guide to microbial infections: pathogenesis, immunity, laboratory investigation and control, P587
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Qu GB, 2020, ENVIRON SCI TECHNOL, V54, P3730, DOI 10.1021/acs.est.0c01102
   Rathi S, 2020, LANCET INFECT DIS
   Reperant LA, 2017, VACCINE, V35, P4470, DOI 10.1016/j.vaccine.2017.04.082
   Reperant LA, 2013, CURR TOP MICROBIOL, V365, P49, DOI 10.1007/82_2012_269
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Segler MHS, 2018, NATURE, V555, P604, DOI 10.1038/nature25978
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Sharma A, 2016, RSC ADV, V6, P65579, DOI 10.1039/c6ra10942j
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sorrell FJ, 2016, STRUCTURE, V24, P401, DOI 10.1016/j.str.2015.12.015
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1090
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Timani KA, 2005, VIRUS RES, V114, P23, DOI 10.1016/j.virusres.2005.05.007
   University of Oxford, 2020, STUD CAND COVID 19 V
   US Food and Drug Administration, 2020, DAT SHEET HLTH CAR P
   van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052
   Varki A, 1997, FASEB J, V11, P248
   Vastag B, 2003, JAMA-J AM MED ASSOC, V290, P1695, DOI 10.1001/jama.290.13.1695
   Venkateswaran TV, 2020, INDIA EXPLORE NOVEL
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wagstaff KM, 2011, J BIOMOL SCREEN, V16, P192, DOI 10.1177/1087057110390360
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Weber DJ, 2016, AM J INFECT CONTROL, V44, pE91, DOI 10.1016/j.ajic.2015.11.018
   White NJ, 2014, LANCET, V383, P723, DOI 10.1016/S0140-6736(13)60024-0
   WHO, 2020, 22 WHO
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, MOD TRANSM VIR CAUS
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, BAC CALM GUER BCG VA
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   World Health Organization, 2019, STAT MIDDL E RESP SY
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, SARS STAT SUMM PROB
   World Health Organization, 2015, 21 WHO
   Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001
   Xu Kaijin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P147, DOI 10.3785/j.issn.1008-9292.2020.02.02
   Yao X, 2020, CLIN INFECT DIS
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
   Zhao CS, 2006, BIOORGAN MED CHEM, V14, P2552, DOI 10.1016/j.bmc.2005.11.033
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhu GK, 2020, DISCRETE DYN NAT SOC, V2020, DOI 10.1155/2020/6152041
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 132
TC 9
Z9 10
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106054
DI 10.1016/j.ijantimicag.2020.106054
PG 13
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400027
PM 32534188
OA Green Published
DA 2021-01-01
ER

PT J
AU Vankadari, N
AF Vankadari, Naveen
TI Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by
   blocking trimerization of the spike glycoprotein
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Coronavirus; Antiviral; Spike glycoprotein; Molecular dynamics; COVID-19
AB The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a global public health emergency, and new therapeutics are needed. This article reports the potential drug target and mecha-nism of action of Arbidol (umifenovir) to treat coronavirus disease 2019 (COVID-19). Molecular dynamics and structural analysis were used to show how Arbidol targets the SARS-CoV-2 spike glycoprotein and impedes its trimerization, which is key for host cell adhesion and hijacking, indicating the potential of Arbidol to treat COVID-19. It is hoped that knowledge of the potential drug target and mechanism of action of Arbidol will help in the development of new therapeutics for SARS-CoV-2. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Vankadari, Naveen] Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.
   [Vankadari, Naveen] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
RP Vankadari, N (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.; Vankadari, N (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
EM Naveen.vankadari@monash.edu
OI Vankadari, Naveen/0000-0001-9363-080X
CR Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
NR 9
TC 31
Z9 31
U1 14
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 105998
DI 10.1016/j.ijantimicag.2020.105998
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400003
PM 32360231
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Yu, R
   Chen, L
   Lan, R
   Shen, R
   Li, P
AF Yu, Ran
   Chen, Liang
   Lan, Rong
   Shen, Rong
   Li, Peng
TI Computational screening of antagonists against the SARS-CoV-2 (COVID-19)
   coronavirus by molecular docking
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE 2019-nCoV; AutoDock Vina; chloroquine; remdesivir; ribavirin; luteolin
ID PHENOLIC-ACIDS; SPIKE; EVOLUTION; POTENT
AB In the current spread of novel coronavirus (SARS-CoV-2), antiviral drug discovery is of great importance. AutoDock Vina was used to screen potential drugs by molecular docking with the structural protein and non-structural protein sites of new coronavirus. Ribavirin, a common antiviral drug, remdesivir, chloro-quine and luteolin were studied. Honeysuckle is generally believed to have antiviral effects in traditional Chinese medicine. In this study, luteolin (the main flavonoid in honeysuckle) was found to bind with a high affinity to the same sites of the main protease of SARS-CoV-2 as the control molecule. Chloro-quine has been proved clinically effective and can bind to the main protease; this may be the antiviral mechanism of this drug. The study was restricted to molecular docking without validation by molecular dynamics simulations. Interactions with the main protease may play a key role in fighting against viruses. Luteolin is a potential antiviral molecule worthy of attention. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Yu, Ran; Chen, Liang; Lan, Rong; Shen, Rong] Beijing Polytech, Dept Bioengn, Beijing 100176, Peoples R China.
   [Li, Peng] SDIC Xinkai Water Environm Investment Co Ltd, Beijing 101101, Peoples R China.
RP Yu, R (corresponding author), Beijing Polytech, Dept Bioengn, Beijing 100176, Peoples R China.
EM yuran1230@hotmail.com
FU Beijing Municipal Commission of EducationBeijing Municipal Commission of
   Education [KM202010858002]
FX The authors wish to thank the general projects of scientific research
   plan of the Beijing Municipal Commission of Education for financial
   support under the project KM202010858002.
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101608
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Du J, 2019, MAT SCI ENG C-MATER, V102, P247, DOI 10.1016/j.msec.2019.04.031
   El Zowalaty ME, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100124
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hsu HF, 2016, IND CROP PROD, V89, P543, DOI 10.1016/j.indcrop.2016.05.010
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Konno H, 2017, BIOORG MED CHEM LETT, V27, P2746, DOI 10.1016/j.bmcl.2017.04.056
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Lee JJ, 2018, J ETHNOPHARMACOL, V227, P97, DOI 10.1016/j.jep.2018.08.027
   Li C, 2019, J PHARMACEUT BIOMED, V163, P105, DOI 10.1016/j.jpba.2018.08.058
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li SW, 2013, BIOMEDICINE-TAIWAN, V3, P43, DOI 10.1016/j.biomed.2012.12.007
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Liu MZ, 2020, AQUACULTURE, V519, DOI 10.1016/j.aquaculture.2019.734882
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang F, 2015, J ETHNOPHARMACOL, V170, P1, DOI 10.1016/j.jep.2015.05.011
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xiang KL, 2020, PHYTOCHEMISTRY, V173, DOI 10.1016/j.phytochem.2020.112298
   Zhang B, 2018, J PHARMACEUT BIOMED, V148, P1, DOI 10.1016/j.jpba.2017.09.023
   Zhao L, 2020, BIOORG CHEM, V96, DOI 10.1016/j.bioorg.2020.103651
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 39
TC 28
Z9 28
U1 16
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 2020
VL 56
IS 2
AR 106012
DI 10.1016/j.ijantimicag.2020.106012
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MU2XY
UT WOS:000555538400005
PM 32389723
OA Green Published
DA 2021-01-01
ER

PT J
AU Jiang, YC
   Chen, J
   Cen, FL
   Li, X
   Song, Z
   Peng, M
   Liu, XY
AF Jiang, Yichun
   Chen, Jun
   Cen, Fulan
   Li, Xu
   Song, Zhi
   Peng, Mian
   Liu, Xueyan
TI Importance of respiratory airway management as well as psychological and
   rehabilitative treatments to COVID-19 patients
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE 2019 coronavirus disease (COVID-19); Mechanical ventilation; Respiratory
   airway care; Psychological therapy; Rehabilitative therapy
ID CHINA
AB The clinical therapy for severe 2019 coronavirus disease (i.e., COVID-19) sufferers is relatively challenging. Herein, the processes involving salvage of a critical COVID-19 patient were retrospectively analyzed. The condition of an obese female critical COVID-19 sufferer progressively worsened in the initial period after admission. According to her symptoms and examination reports, endotracheal intubation and mechanical ventilation were timely conducted and meanwhile high-dose sedatives and analgesics were administrated. In the later therapeutic phase, however, sedative and analgesic dosages were gradually reduced, and psychological and rehabilitative therapies were conducted, concomitantly with enhancement of airway care to facilitate sputum expectoration. Eventually, the endotracheal tube was feasibly removed after intubation for 18 days and subsequently replaced with noninvasive ventilation and a high-flow nasal cannula oxygen therapy. Intensive airway care alongside psychological and rehabilitative therapies can shorten the mechanical ventilation time and improve the prognosis of COVID-19 sufferers. (c) 2020 Published by Elsevier Inc.
C1 [Jiang, Yichun; Chen, Jun; Liu, Xueyan] Shenzhen Peoples Hosp, Dept Crit Care Med, Shenzhen, Peoples R China.
   [Chen, Jun] Nanjing Univ Sci & Technol, Sch Environm & Biol Engn, Nanjing, Peoples R China.
   [Cen, Fulan] Shenzhen Third Peoples Hosp, Shenzhen, Peoples R China.
   [Li, Xu] Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China.
   [Song, Zhi] Shenzhen Univ, Gen Hosp, Shenzhen, Peoples R China.
   [Peng, Mian] Shenzhen Univ, Affiliated Hosp 3, Shenzhen, Peoples R China.
RP Liu, XY (corresponding author), Shenzhen Peoples Hosp, Dept Crit Care Med, Shenzhen, Peoples R China.
EM 13554843721@163.com
FU Shenzhen Municipal Health Commission [SZXJ2017027]
FX This work was supported by the Shenzhen Municipal Health Commission (NO:
   SZXJ2017027).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Health Emergency Office, NOV COR PNEUM EP SIT
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Xiao CF, 2020, PSYCHIAT INVEST, V17, P175, DOI 10.30773/pi.2020.0047
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 8
TC 1
Z9 1
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD AUG
PY 2020
VL 38
IS 8
DI 10.1016/j.ajem.2020.04.055
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA MR0XM
UT WOS:000553316500029
PM 32601006
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jockusch, S
   Tao, CJ
   Li, XX
   Anderson, TK
   Chien, MC
   Kumar, S
   Russo, JJ
   Kirchdoerfer, RN
   Ju, JY
AF Jockusch, Steffen
   Tao, Chuanjuan
   Li, Xiaoxu
   Anderson, Thomas K.
   Chien, Minchen
   Kumar, Shiv
   Russo, James J.
   Kirchdoerfer, Robert N.
   Ju, Jingyue
TI A library of nucleotide analogues terminate RNA synthesis catalyzed by
   polymerases of coronaviruses that cause SARS and COVID-19
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; RNA-Dependent RNA polymerase; Nucleotide
   analogues; Exonuclease
ID CHRONIC HEPATITIS-B; REVERSE-TRANSCRIPTASE; DNA-POLYMERASE; IN-VITRO;
   VIRUS; ENTECAVIR; CIDOFOVIR; EXCISION; PHARMACOKINETICS; EXORIBONUCLEASE
AB SARS-CoV-2, a member of the coronavirus family, is responsible for the current COVID-19 worldwide pandemic. We previously demonstrated that five nucleotide analogues inhibit the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), including the active triphosphate forms of Sofosbuvir, Alovudine, Zidovudine, Tenofovir alafenamide and Emtricitabine. We report here the evaluation of a library of nucleoside triphosphate analogues with a variety of structural and chemical features as inhibitors of the RdRps of SARS-CoV and SARS-CoV-2. These features include modifications on the sugar (2' or 3' modifications, carbocyclic, acyclic, or dideoxynucleotides) or on the base. The goal is to identify nucleotide analogues that not only terminate RNA synthesis catalyzed by these coronavirus RdRps, but also have the potential to resist the viruses' exonuclease activity. We examined these nucleotide analogues for their ability to be incorporated by the RdRps in the polymerase reaction and to prevent further incorporation. While all 11 molecules tested displayed incorporation, 6 exhibited immediate termination of the polymerase reaction (triphosphates of Carbovir, Ganciclovir, Stavudine and Entecavir; 3'-OMe-UTP and Biotin-16-dUTP), 2 showed delayed termination (Cidofovir diphosphate and 2'-OMe-UTP), and 3 did not terminate the polymerase reaction (2'-F-dUTP, 2'-NH2-dUTP and Desthiobiotin-16-UTP). The coronaviruses possess an exonuclease that apparently requires a 2'-OH at the 3'-terminus of the growing RNA strand for proofreading. In this study, all nucleoside triphosphate analogues evaluated form Watson-Crick-like base pairs. The nucleotide analogues demonstrating termination either lack a 2'-OH, have a blocked 2'-OH, or show delayed termination. Thus, these nucleotide analogues are of interest for further investigation to evaluate whether they can evade the viral exonuclease activity. Prodrugs of five of these nucleotide analogues (Cidofovir, Abacavir, Valganciclovir/Ganciclovir, Stavudine and Entecavir) are FDA-approved medications for treatment of other viral infections, and their safety profiles are well established. After demonstrating potency in inhibiting viral replication in cell culture, candidate molecules can be rapidly evaluated as potential therapies for COVID-19.
C1 [Jockusch, Steffen; Tao, Chuanjuan; Li, Xiaoxu; Chien, Minchen; Kumar, Shiv; Russo, James J.; Ju, Jingyue] Columbia Univ, Ctr Genome Technol & Biomol Engn, New York, NY 10027 USA.
   [Jockusch, Steffen] Columbia Univ, Dept Chem, New York, NY 10027 USA.
   [Tao, Chuanjuan; Li, Xiaoxu; Chien, Minchen; Kumar, Shiv; Russo, James J.; Ju, Jingyue] Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
   [Ju, Jingyue] Columbia Univ, Dept Pharmacol, New York, NY 10027 USA.
   [Anderson, Thomas K.; Kirchdoerfer, Robert N.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
   [Anderson, Thomas K.; Kirchdoerfer, Robert N.] Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA.
RP Ju, JY (corresponding author), Columbia Univ, Ctr Genome Technol & Biomol Engn, New York, NY 10027 USA.; Kirchdoerfer, RN (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
EM rnkirchdoerf@wisc.edu; dj222@columbia.edu
OI Kirchdoerfer, Robert/0000-0002-5974-2709; Jockusch,
   Steffen/0000-0002-4592-5280
FU Columbia University; Jack Ma Foundation; National Institute of Allergy
   and Infectious DiseaseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI123498]
FX This research is supported by Columbia University, a grant from the Jack
   Ma Foundation, a generous gift from the Columbia Engineering Member of
   the Board of Visitors Dr. Bing Zhao, and Fast Grants to J.J. and a
   National Institute of Allergy and Infectious Disease grant AI123498 to
   R.N.K.
CR Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   Akyurek LM, 2001, MOL THER, V3, P779, DOI 10.1006/mthe.2001.0315
   Alanazi AS, 2019, ACS MED CHEM LETT, V10, P2, DOI 10.1021/acsmedchemlett.8b00586
   Anderson PL, 2011, J ANTIMICROB CHEMOTH, V66, P240, DOI 10.1093/jac/dkq447
   AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Chien Minchen, 2020, bioRxiv, DOI 10.1101/2020.03.18.997585
   Cundy KC, 1999, CLIN PHARMACOKINET, V36, P127, DOI 10.2165/00003088-199936020-00004
   De Clercq E, 2002, ANTIVIR RES, V55, P1, DOI 10.1016/S0166-3542(02)00008-6
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Dustin LB, 2016, CLIN MICROBIOL INFEC, V22, P826, DOI 10.1016/j.cmi.2016.08.025
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   Elfiky AA, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117715
   Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868
   Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   HO HT, 1989, ANTIMICROB AGENTS CH, V33, P844, DOI 10.1128/AAC.33.6.844
   HUANG P, 1992, J BIOL CHEM, V267, P2817
   Jockusch S, 2020, BIORXIV, DOI [10.1101/2020.04.03.022939, DOI 10.1101/2020.04.03.022939]
   Ju J., 2020, NUCLEOTIDE ANALOGUES, DOI [10.1101/2020.03.12.989186, DOI 10.1101/2020.03.12.989186]
   Ju JY, 2006, P NATL ACAD SCI USA, V103, P19635, DOI 10.1073/pnas.0609513103
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lanier R, 2010, VIRUSES-BASEL, V2, P2740, DOI 10.3390/v2122740
   Lauridsen LH, 2012, CHEMBIOCHEM, V13, P19, DOI 10.1002/cbic.201100648
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Magee WC, 2005, ANTIMICROB AGENTS CH, V49, P3153, DOI 10.1128/AAC.49.8.3153-3162.2005
   Matthews SJ, 2006, CLIN THER, V28, P184, DOI 10.1016/j.clinthera.2006.02.012
   MATTHEWS T, 1988, REV INFECT DIS, V10, pS490
   Mazzucco CE, 2008, ANTIMICROB AGENTS CH, V52, P598, DOI 10.1128/AAC.01122-07
   McKenna C.E., 1989, ACS SYM SER, V401, P1, DOI [10.1021/bk-1989-0401.ch001, DOI 10.1021/BK-1989-0401.CH001]
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Oberg B, 2006, ANTIVIR RES, V71, P90, DOI 10.1016/j.antiviral.2006.05.012
   Ray AS, 2002, J BIOL CHEM, V277, P40479, DOI 10.1074/jbc.M205303200
   Rivkina A, 2002, PHARMACOTHERAPY, V22, P721, DOI 10.1592/phco.22.9.721.34058
   Selisko B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020059
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tchesnokov EP, 2008, J BIOL CHEM, V283, P34218, DOI 10.1074/jbc.M806797200
   te Velthuis AJW, 2014, CELL MOL LIFE SCI, V71, P4403, DOI 10.1007/s00018-014-1695-z
   Trost LC, 2015, ANTIVIR RES, V117, P115, DOI 10.1016/j.antiviral.2015.02.007
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 46
TC 4
Z9 4
U1 19
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2020
VL 180
AR 104857
DI 10.1016/j.antiviral.2020.104857
PG 8
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA MR1VK
UT WOS:000553379200018
PM 32562705
OA Green Published
DA 2021-01-01
ER

PT J
AU Gorzalski, AJ
   Tian, HL
   Laverdure, C
   Morzunov, S
   Verma, SC
   VanHooser, S
   Pandori, MW
AF Gorzalski, Andrew J.
   Tian, Honglin
   Laverdure, Chris
   Morzunov, Sergey
   Verma, Subhash C.
   VanHooser, Stephanie
   Pandori, Mark W.
TI High-Throughput Transcription-mediated amplification on the Hologic
   Panther is a highly sensitive method of detection for SARS-CoV-2
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE SARS-CoV-2; RT-PCR; TMA; Transcription mediated amplification; Aptima;
   Sensitivity
AB Background: As the demand for laboratory testing for SARS-CoV-2 increases, additional varieties of testing methodologies are being considered. While real time polymerase chain reaction (RT-PCR) has performed as the main method for virus detection, other methods are becoming available, including transcription mediated amplification (TMA). The Hologic Aptima SARS-CoV-2 Assay utilizes TMA as a target amplification mechanism, and it has only recently received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA).
   Objectives: We sought to compare the sensitivity and specificity of the Aptima SARS-CoV-2 Assay to RT-PCR as a means of SARS-CoV-2 detection in a diagnostic setting.
   Study design: We performed a limit-of-detection study (LoD) to assess the analytical sensitivity of TMA and RTPCR. This preceded a comparison of the methods using previously evaluated clinical specimens (nasopharyngeal swabs) using 116 human specimens tested by both methodologies. Specimens included sixty-one (61) specimens found reactive by real-time PCR, fifty-one (51) found non-reactive, and four (4) deemed inconclusive.
   Results: The Aptima SARS-CoV-2 Assay showed a markedly higher analytical sensitivity than RT-PCR by LoD study. Evaluation of clinical specimens resulted in fewer inconclusive results by the SARS-CoV-2 assay, leading to potentially higher clinical sensitivity.
   Conclusions: Higher analytical sensitivity may explain TMA's ability to ascertain for the presence of SARS-CoV-2 genome in human specimens deemed inconclusive by real-time PCR. TMA provides an effective, highly sensitive means of detection of SARS-CoV-2 in nasopharyngeal specimens.
C1 [Gorzalski, Andrew J.; Tian, Honglin; Laverdure, Chris; Morzunov, Sergey; VanHooser, Stephanie; Pandori, Mark W.] Nevada State Publ Hlth Lab, Reno, NV 89503 USA.
   [Verma, Subhash C.] Univ Nevada, Sch Med, Dept Microbiol & Immunol, Reno, NV 89557 USA.
   [Pandori, Mark W.] Univ Nevada, Sch Med, Dept Pathol & Lab Med, Reno, NV 89557 USA.
RP Pandori, MW (corresponding author), Nevada State Publ Hlth Lab, Reno, NV 89503 USA.
EM mpandori@unr.edu
OI PANDORI, MARK/0000-0003-0334-1946
CR [Anonymous], 2020, COVID 19 PUBLIC HLTH
   Bordi L, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104416
   Hatzakis A, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0627-y
   Hofmann WP, 2005, J CLIN VIROL, V32, P289, DOI 10.1016/j.jcv.2004.08.011
   Lu XY, 2020, EMERG INFECT DIS, V26, P1654, DOI 10.3201/eid2608.201246
   Okamaoto Kiyoko, 2020, Jpn J Infect Dis, V73, P366, DOI 10.7883/yoken.JJID.2020.108
   Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhen W., 2020, J CLIN MICROBIOL, DOI [10.1128/JCM.00743-20pii:JCM.00743-20, DOI 10.1128/JCM.00743-20PII:JCM.00743-20]
NR 9
TC 2
Z9 2
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2020
VL 129
AR 104501
DI 10.1016/j.jcv.2020.104501
PG 3
WC Virology
SC Virology
GA MQ5ZM
UT WOS:000552972500025
PM 32619959
OA Green Published
DA 2021-01-01
ER

PT J
AU Quartuccio, L
   Sonaglia, A
   McGonagle, D
   Fabris, M
   Peghin, M
   Pecori, D
   De Monte, A
   Bove, T
   Curcio, F
   Bassi, F
   De Vita, S
   Tascini, C
AF Quartuccio, Luca
   Sonaglia, Arianna
   McGonagle, Dennis
   Fabris, Martina
   Peghin, Maddalena
   Pecori, Davide
   De Monte, Amato
   Bove, Tiziana
   Curcio, Francesco
   Bassi, Flavio
   De Vita, Salvatore
   Tascini, Carlo
TI Profiling COVID-19 pneumonia progressing into the cytokine storm
   syndrome: Results from a single Italian Centre study on tocilizumab
   versus standard of care
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Coronavirus; COVID-19; Tocilizumab; Cytokine; Intensive care
ID CELLS
AB Objective: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-threatening pneumonia that often occurs in the setting of increased inflammation or "cytokine storm". Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear, and the aim of our study is to address this point.
   Methods: Between February 29 to April 6, 2020, 111 consecutive hospitalized patients with COVID-19 pneumonia were evaluated in a single centre retrospective study. Patients were divided in two groups: 42 severe cases (TOCI) with adverse prognostic features including raised CRP and IL-6 levels, who underwent anti-cytokine treatments, mostly tocilizumab, and 69 standard of care patients (SOC).
   Results: In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62% of cases were ventilated and there were three deaths (17.8 +/- 10.6 days, mean follow up) with 7/26 cases remaining on ventilators, without improvement, and 17/26 developed bacterial superinfection. One fatality occurred in the 15 TOCI cases treated on noninvasive ventilation and one serious bacterial superinfection. Of the 69 cases in SOC, there was no fatalities and no bacterial complications. The TOCI group had higher baseline CRP and IL-6 elevations (p < 0.0001 for both) and higher neutrophils and lower lymphocyte levels (p = 0.04 and p = 0.001, respectively) with the TOCI ventilated patients having higher markers than non-ventilated TOCI patients.
   Conclusion: Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI cases compared to ward based TOCI. Despite the confounding factors, this suggests that therapy time in anticytokine randomized trials will be key.
C1 [Quartuccio, Luca; Sonaglia, Arianna; De Vita, Salvatore] Univ Udine, Dept Med Dame, ASUFC, Clin Rheumatol, Udine, Italy.
   [McGonagle, Dennis] Leeds Teaching Hosp, Natl Inst Hlth Res NIHR Leeds Biomed Res Ctr BRC, Leeds, W Yorkshire, England.
   [Fabris, Martina; Curcio, Francesco] ASUFC, Inst Clin Pathol, Udine, Italy.
   [Peghin, Maddalena; Pecori, Davide; De Monte, Amato; Tascini, Carlo] ASUFC, Infect Dis Unit, Udine, Italy.
   [Bove, Tiziana; Bassi, Flavio] ASUFC, Dept Anesthesia & Intens Care, Udine, Italy.
   [Bove, Tiziana] Univ Udine, Dept Med, Anesthesia & Intens Care Clin, Udine, Italy.
RP Quartuccio, L (corresponding author), Univ Udine, Dept Med Dame, ASUFC, Clin Rheumatol, Udine, Italy.
EM luca.quartuccio@asufc.sanita.fvg.it
OI , Salvatore/0000-0002-2757-3373
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen X., 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa449ciaa449, DOI 10.1093/CID/CIAA449CIAA449]
   Ciceri F., 2020, CRIT CARE RESUSC
   De Luna G, 2020, AM J HEMATOL, V95, P876, DOI 10.1002/ajh.25833
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   LIU Y, 2020, CLIN INFECT DIS, DOI DOI 10.1093/CID/CIAA248
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Qin C., 2020, CHINA J INFECT, DOI [10.1016/j.jinf.2020.04.002, DOI 10.1016/J.JINF.2020.04.002]
   Quartuccio L, 2020, JOINT BONE SPINE, V87, P191, DOI 10.1016/j.jbspin.2020.03.011
   Quartuccio L, 2017, J RHEUMATOL, V44, P1106, DOI 10.3899/jrheum.170462
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   Udugama B., 2020, DIAGNOSING COVID 19, DOI [10.1021/acsnano.0c02624acsnano.0c02624, DOI 10.1021/ACSNANO.0C02624ACSNANO.0C02624]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu X, 2020, EFFECTIVE TREATMENT
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang ZG, 2020, AGING-US, V12, P6037, DOI 10.18632/aging.102999
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
NR 31
TC 26
Z9 26
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2020
VL 129
AR 104444
DI 10.1016/j.jcv.2020.104444
PG 7
WC Virology
SC Virology
GA MQ5ZM
UT WOS:000552972500018
OA Green Published
DA 2021-01-01
ER

PT J
AU Galloway, JB
   Norton, S
   Barker, RD
   Brookes, A
   Carey, I
   Clarke, BD
   Jina, R
   Reid, C
   Russell, MD
   Sneep, R
   Sugarman, L
   Williams, S
   Yates, M
   Teo, J
   Shah, AM
   Cantle, F
AF Galloway, James B.
   Norton, Sam
   Barker, Richard D.
   Brookes, Andrew
   Carey, Ivana
   Clarke, Benjamin D.
   Jina, Raeesa
   Reid, Carole
   Russell, Mark D.
   Sneep, Ruth
   Sugarman, Leah
   Williams, Sarah
   Yates, Mark
   Teo, James
   Shah, Ajay M.
   Cantle, Fleur
TI A clinical risk score to identify patients with COVID-19 at high risk of
   critical care admission or death: An observational cohort study
SO JOURNAL OF INFECTION
LA English
DT Article
AB Background: The COVID-19 pandemic continues to escalate. There is urgent need to stratify patients. Understanding risk of deterioration will assist in admission and discharge decisions, and help selection for clinical studies to indicate where risk of therapy-related complications is justified.
   Methods: An observational cohort of patients acutely admitted to two London hospitals with COVID-19 and positive SARS-CoV-2 swab results was assessed. Demographic details, clinical data, comorbidities, blood parameters and chest radiograph severity scores were collected from electronic health records. Endpoints assessed were critical care admission and death. A risk score was developed to predict outcomes.
   Findings: Analyses included 1,157 patients. Older age, male sex, comorbidities, respiratory rate, oxygenation, radiographic severity, higher neutrophils, higher CRP and lower albumin at presentation predicted critical care admission and mortality. Non-white ethnicity predicted critical care admission but not death. Social deprivation was not predictive of outcome. A risk score was developed incorporating twelve characteristics: age>40, male, non-white ethnicity, oxygen saturations<93%, radiological severity score>3, neutrophil count>8.0 x10(9)/L, CRP>40 mg/L, albumin<34 g/L, creatinine>100 mu mol/L, diabetes mellitus, hypertension and chronic lung disease. Risk scores of 4 or higher corresponded to a 28-day cumulative incidence of critical care admission or death of 40.7% (95% CI: 37.1 to 44.4), versus 12.4% (95% CI: 8.2 to 16.7) for scores less than 4.
   Interpretation: Our study identified predictors of critical care admission and death in people admitted to hospital with COVID-19. These predictors were incorporated into a risk score that will inform clinical care and stratify patients for clinical trials. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
C1 [Galloway, James B.; Norton, Sam; Clarke, Benjamin D.; Russell, Mark D.; Yates, Mark] Kings Coll London, Ctr Rheumat Dis, London, England.
   [Brookes, Andrew; Jina, Raeesa; Reid, Carole; Sneep, Ruth; Sugarman, Leah; Williams, Sarah; Cantle, Fleur] Kings Coll Hosp London, Dept Emergency Med, London, England.
   [Barker, Richard D.] Kings Coll Hosp London, Dept Resp Med, London, England.
   [Carey, Ivana] Kings Coll Hosp London, Inst Liver Studies, London, England.
   [Shah, Ajay M.] Kings Coll London, Sch Cardiovasc Med & Sci, British Heart Fdn Ctr, London, England.
   [Teo, James] Kings Coll Hosp London, Dept Neurosci, London, England.
RP Galloway, JB (corresponding author), Weston Educ Ctr, Cutcombe Rd, London SE5 9RJ, England.
EM james.galloway@kcl.ac.uk
RI Teo, James T/ABA-1819-2020; Norton, Sam J/A-1898-2009; Teo, James
   TH/D-9696-2011
OI Teo, James T/0000-0002-6899-8319; Norton, Sam J/0000-0003-1714-9963;
   Teo, James TH/0000-0002-6899-8319
FU British Heart FoundationBritish Heart Foundation [CH/1999001/11735];
   National Institute for Health Research (NIHR) Biomedical Research Centre
   at Guy's & St Thomas' NHS Foundation Trust and King's College London;
   King's College Hospital NHS Foundation Trust [IS-BRC-1215-20006]
FX We are grateful for the work of the King's College Hospital Information
   and Communication Technology Department. AMS is supported by the British
   Heart Foundation (CH/1999001/11735) and the National Institute for
   Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas'
   NHS Foundation Trust and King's College London with King's College
   Hospital NHS Foundation Trust (IS-BRC-1215-20006). We would like to
   thank all the clinicians managing the patients.
CR Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Carver C., 2020, COMP ACCURACY OROPHA
   Coronavirus.data.gov.uk, 2020, COR COVID 19 UK
   Dixon-Woods Mary, 2006, BMC Med Res Methodol, V6, P35, DOI 10.1186/1471-2288-6-35
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Geoportal.statistics.gov.uk, 2019, IND MULT DEPR DEC 20
   Gov.uk, 2020, STAY HOM GUID HOUS P
   Guan WJ, 2020, N ENGL J MED
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Icnarc.org, 2020, ICNARC REP COVID 19
   Ico.org.uk, 2012, AN MAN DAT PROT RISK
   Kinross P, 2020, EURO SURVEILL, V25
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Oldroyd J, 2005, POSTGRAD MED J, V81, P486, DOI 10.1136/pgmj.2004.029124
   Pareek M., 2020, LANCET
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Wong H, 2019, ADDIT MANUF, V29, DOI 10.1016/j.addma.2019.100829
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
NR 18
TC 14
Z9 14
U1 5
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD AUG
PY 2020
VL 81
IS 2
BP 282
EP 288
DI 10.1016/j.jinf.2020.05.064
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA MR1QE
UT WOS:000553365200074
PM 32479771
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cantini, F
   Niccoli, L
   Matarrese, D
   Nicastri, E
   Stobbione, P
   Goletti, D
AF Cantini, Fabrizio
   Niccoli, Laura
   Matarrese, Daniela
   Nicastri, Emanuele
   Stobbione, Paolo
   Goletti, Delia
TI Baricitinib therapy in COVID-19: A pilot study on safety and clinical
   impact
SO JOURNAL OF INFECTION
LA English
DT Letter
C1 [Cantini, Fabrizio; Niccoli, Laura] Hosp Prato, Dept Rheumatol, Azienda USL Toscana Ctr, Piazza Osped 1, Prato, Italy.
   [Matarrese, Daniela] Hosp Prato, Azienda USL Toscana Ctr, Prato, Italy.
   [Nicastri, Emanuele; Goletti, Delia] IRCCS, Natl Inst Infect Dis, Via Portuense 292, I-292 Rome 00149, Italy.
   [Stobbione, Paolo] AOS Antonio & Biagio & C Arrigo, Rheumatol Unit, Alessandria, Italy.
   [Goletti, Delia] IRCCS, Dept Epidemiol & Preclin Res, L Spallanzani Natl Inst Infect Dis INMI, Via Portuense 292, I-00149 Rome, Italy.
RP Cantini, F (corresponding author), Hosp Prato, Dept Rheumatol, Azienda USL Toscana Ctr, Piazza Osped 1, Prato, Italy.
EM fbrzcantini@gmail.com; daniela.matarrese@usicentro.toscana.it;
   emanuele.nicastri@inmi.it; pstobbione@ospedale.al.it;
   delia.goletti@inmi.it
OI Goletti, Delia/0000-0001-8360-4376; Matarrese,
   Daniela/0000-0002-3479-4545
FU Italian Ministry of Health "Ricerca Corrente" Linea 1
FX This work was partly supported by the Italian Ministry of Health
   "Ricerca Corrente" Linea 1.
CR Bechman K, 2019, RHEUMATOLOGY, V58, P1755, DOI 10.1093/rheumatology/kez087
   Cao B, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041399
   Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Goletti D, 2018, RESPIROLOGY, V23, P455, DOI 10.1111/resp.13272
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li R, 2020, J INFECTION, V80, P469, DOI 10.1016/j.jinf.2020.02.013
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521
   Xu X., 2020, CHINAXIV20200300026V
NR 10
TC 69
Z9 71
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD AUG
PY 2020
VL 81
IS 2
BP 318
EP 322
DI 10.1016/j.jinf.2020.04.017
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA MR1QE
UT WOS:000553365200079
PM 32333918
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Xie, Y
   Cao, S
   Dong, H
   Li, QY
   Chen, EZ
   Zhang, WK
   Yang, LY
   Fu, SZ
   Wang, RL
AF Xie, Yun
   Cao, Song
   Dong, Hui
   Li, Qingyun
   Chen, Erzhen
   Zhang, Wenkai
   Yang, Luyu
   Fu, Shouzhi
   Wang, Ruilan
TI Effect of regular intravenous immunoglobulin therapy on prognosis of
   severe pneumonia in patients with COVID-19
SO JOURNAL OF INFECTION
LA English
DT Letter
C1 [Xie, Yun; Wang, Ruilan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Crit Care Med, 650 New Songjiang Rd, Shanghai 201600, Peoples R China.
   [Cao, Song; Dong, Hui; Zhang, Wenkai; Yang, Luyu; Fu, Shouzhi] Wuhan Univ, Wuhan Third Hosp, Dept Crit Care Med, 216 Guanshan Ave, Wuhan 430070, Hubei, Peoples R China.
   [Li, Qingyun] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Dept Resp, Sch Med, 197 Ruijin Two Rd, Shanghai 200020, Peoples R China.
   [Chen, Erzhen] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Sch Med, 197 Ruijin Two Rd, Shanghai 200020, Peoples R China.
RP Wang, RL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Crit Care Med, 650 New Songjiang Rd, Shanghai 201600, Peoples R China.; Yang, LY; Fu, SZ (corresponding author), Wuhan Univ, Wuhan Third Hosp, Dept Crit Care Med, 216 Guanshan Ave, Wuhan 430070, Hubei, Peoples R China.
EM wangyusun@hotmail.com
CR Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999
   Diebel LN, 2005, J TRAUMA, V59, P1099, DOI 10.1097/01.ta.0000187797.38327.78
   Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010
   Hung IEN, 2013, CHEST, V144, P464, DOI 10.1378/chest.12-2907
   Mustafa S, 2018, J INFECT PUBLIC HEAL, V11, P9, DOI 10.1016/j.jiph.2017.08.009
   Rockman S, 2017, EBIOMEDICINE, V19, P119, DOI 10.1016/j.ebiom.2017.04.010
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tagami T, 2015, CLIN INFECT DIS, V61, P385, DOI 10.1093/cid/civ307
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang X., 2020, LANCET RESP MED, DOI [10.1016/S2213-2600(20)30079-5, DOI 10.1016/S2213-2600(20)30079-5.]
NR 10
TC 36
Z9 38
U1 4
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD AUG
PY 2020
VL 81
IS 2
BP 340
EP 343
DI 10.1016/j.jinf.2020.03.044
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA MR1QE
UT WOS:000553365200089
PM 32283154
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jung, J
   Oh, DK
   Ahn, JH
   Hong, SB
   Sung, H
   Kim, MN
   Kim, SH
AF Jung, Jiwon
   Oh, Dong Kyu
   Ahn, Jee Hwan
   Hong, Sang-Bum
   Sung, Heungsup
   Kim, Mi-Na
   Kim, Sung-Han
TI Re: Low-dose corticosteroid therapy does not delay viral clearance in
   patients with COVID-19
SO JOURNAL OF INFECTION
LA English
DT Letter
C1 [Jung, Jiwon; Kim, Sung-Han] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul, South Korea.
   [Jung, Jiwon; Kim, Sung-Han] Asan Med Ctr, Off Infect Control, Seoul, South Korea.
   [Oh, Dong Kyu; Ahn, Jee Hwan; Hong, Sang-Bum] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea.
   [Sung, Heungsup; Kim, Mi-Na] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul, South Korea.
RP Kim, SH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul, South Korea.; Kim, SH (corresponding author), Asan Med Ctr, Off Infect Control, Seoul, South Korea.
EM kimsunghanmd@hotmail.com
FU National Research Founda-tion of Korea (NRF) - Ministry of Science and
   ICT, South Korea [NRF-2019R1G1A1100017]
FX This study was supported by the National Research Founda-tion of Korea
   (NRF) grant funded by the Ministry of Science and ICT, South Korea (No.
   NRF-2019R1G1A1100017).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Centers for Diseases Control and Prevention, 2019, DISC TRANSM BAS PREC
   Fang X, 2020, J INFECT
   KBS World Radio, 2020, KBS WORLD RADIO 0229
   Korea Centers for Disease Control and Prevention, 2020, MAN GUID COR DIS 19
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   NPR, 2020, MYST WUH REC COR PAT
   Wu Y, 2020, LANCET GASTROENTEROL
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD AUG
PY 2020
VL 81
IS 2
BP E79
EP E81
DI 10.1016/j.jinf.2020.05.004
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MR1QE
UT WOS:000553365200020
PM 32389783
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Liang, JL
   Pitsillou, E
   Karagiannis, C
   Darmawan, KK
   Ng, K
   Hung, A
   Karagiannis, TC
AF Liang, Julia
   Pitsillou, Eleni
   Karagiannis, Chris
   Darmawan, Kevion K.
   Ng, Ken
   Hung, Andrew
   Karagiannis, Tom C.
TI Interaction of the prototypical alpha-ketoamide inhibitor with the
   SARS-CoV-2 main protease active site in silico: Molecular dynamic
   simulations highlight the stability of the ligand-protein complex
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Coronavirus; COVID-19; SARS-CoV-2; SARS-CoV-2 main protease;
   alpha-ketoamide; molecular docking; molecular dynamics simulations
ID FORCE-FIELD; CORONAVIRUS; SARS; DOCKING; GROMACS; BINDING; TOOL
AB The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes an illness known as COVID-19, which has been declared a global pandemic with over 2 million confirmed cases and 137,000 deaths in 185 countries and regions at the time of writing (16 April 2020), over a quarter of these cases being in the United States. In the absence of a vaccine, or an approved effective therapeutic, there is an intense interest in repositioning available drugs or designing small molecule antivirals. In this context, in silico modelling has proven to be an invaluable tool. An important target is the SARS-CoV-2 main protease (M-Pro), involved in processing translated viral proteins. Peptidomimetic alpha-ketoamides represent prototypical inhibitors of M-Pro. A recent attempt at designing a compound with enhanced pharmacokinetic properties has resulted in the synthesis and evaluation of the alpha-ketoamide 13b analogue. Here, we performed molecular docking and molecular dynamics simulations to further characterize the interaction of alpha-ketoamide 13b with the active site of the SARS-CoV-2 M-Pro. We included the widely used antibiotic, amoxicillin, for comparison. Our findings indicate that alpha-ketoamide 13b binds more tightly (predicted GlideScore = -8.7 and -9.2 kcal/mol for protomers A and B, respectively), to the protease active site compared to amoxicillin (-5.0 and -4.8 kcal/mol). Further, molecular dynamics simulations highlight the stability of the interaction of the alpha-ketoamide 13b ligand with the SARS-CoV-2 M-Pro (Delta G = -25.2 and -22.3 kcal/mol for protomers A and B). In contrast, amoxicillin interacts unfavourably with the protease (Delta G = + 32.8 kcal/mol for protomer A), with unbinding events observed in several independent simulations. Overall, our findings are consistent with those previously observed, and highlight the need to further explore the alpha-ketoamides as potential antivirals for this ongoing COVID-19 pandemic.
C1 [Liang, Julia; Pitsillou, Eleni; Karagiannis, Tom C.] Monash Univ, Cent Clin Sch, Dept Diabet, Epigen Med, Melbourne, Vic 3004, Australia.
   [Liang, Julia; Pitsillou, Eleni; Karagiannis, Chris; Darmawan, Kevion K.; Hung, Andrew] RMIT Univ, Coll Sci Engn & Hlth, Sch Sci, Melbourne, Vic 3001, Australia.
   [Karagiannis, Chris; Ng, Ken] Univ Melbourne, Fac Vet & Agr Sci, Sch Agr & Food, Parkville, Vic 3052, Australia.
   [Karagiannis, Tom C.] Univ Melbourne, Dept Clin Pathol, Parkville, Vic 3052, Australia.
RP Karagiannis, TC (corresponding author), Monash Univ, Cent Clin Sch, Dept Diabet, Melbourne, Vic 3004, Australia.
EM tom.karagiannis@monash.edu
OI Liang, Julia/0000-0002-3031-3169; Darmawan, Kevion/0000-0001-7441-7368
FU McCord Research (Iowa, USA); Australian Government Research Training
   Program ScholarshipsAustralian Government; Australian
   GovernmentAustralian GovernmentCGIAR; Spartan High Performance Computing
   service (University of Melbourne); Partnership for Advanced Computing in
   Europe (PRACE)
FX We would like to acknowledge intellectual and financial support by
   McCord Research (Iowa, USA). JL and KKD are supported by Australian
   Government Research Training Program Scholarships. We are indebted to
   Alfonso Perez Escuredo (crowdfightcovid) for enabling access to
   supercomputing facilities and to Matthew Gasperetti (Hypernet Labs;
   Galileo), for enabling cloud computing for this project. We thank the
   National Computing Infrastructure (NCI), and the Pawsey Supercomputing
   Centre in Australia (funded by the Australian Government). Further, we
   thank the Spartan High Performance Computing service (University of
   Melbourne), and the Partnership for Advanced Computing in Europe (PRACE)
   for awarding the access to Piz Daint, hosted at the Swiss National
   Supercomputing Centre (CSCS), Switzerland.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Baud D., 2020, LANCET INFECT DIS
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Bochevarov AD, 2013, INT J QUANTUM CHEM, V113, P2110, DOI 10.1002/qua.24481
   Brown SP, 2009, J MED CHEM, V52, P3159, DOI 10.1021/jm801444x
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cho AE, 2005, J COMPUT CHEM, V26, P915, DOI 10.1002/jcc.20222
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dong E, 2020, LANCET INFECT DIS
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mossel EC, 2008, VIROLOGY, V372, P127, DOI 10.1016/j.virol.2007.09.045
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Rajgor DD, 2020, LANCET INFECT DIS
   Robert K., 2012, COMPUT SCI DISCOV, V5
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger, 2018, MAESTR, V11
   Thompson DC, 2008, J CHEM INF MODEL, V48, P1081, DOI 10.1021/ci700470c
   Uhal BD, 2011, AM J PHYSIOL-LUNG C, V301, pL269, DOI 10.1152/ajplung.00222.2010
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Walls A.C., 2020, CELL
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WHO, 2020, 1 WHO, P1
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhang L., 2020, SCIENCE NEW YORK NY
   Zhang L, 2020, MED CHEM RES, V29, P575, DOI 10.1007/s00044-020-02509-4
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 52
TC 2
Z9 2
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1476-9271
EI 1476-928X
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD AUG
PY 2020
VL 87
AR 107292
DI 10.1016/j.compbiolchem.2020.107292
PG 8
WC Biology; Computer Science, Interdisciplinary Applications
SC Life Sciences & Biomedicine - Other Topics; Computer Science
GA MQ2GJ
UT WOS:000552715000028
PM 32485652
OA Green Published
DA 2021-01-01
ER

PT J
AU Papamichalis, P
   Papadogoulas, A
   Katsiafylloudis, P
   Skoura, AL
   Papamichalis, M
   Neou, E
   Papadopoulos, D
   Karagiannis, S
   Zafeiridis, T
   Babalis, D
   Komnos, A
AF Papamichalis, Panagiotis
   Papadogoulas, Antonios
   Katsiafylloudis, Periklis
   Skoura, Apostolia-Lemonia
   Papamichalis, Michail
   Neou, Evangelia
   Papadopoulos, Dimitrios
   Karagiannis, Spyridon
   Zafeiridis, Tilemachos
   Babalis, Dimitris
   Komnos, Apostolos
TI Combination of thrombolytic and immunosuppressive therapy for
   coronavirus disease 2019: A case report
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Coronavirus disease 2019; Acute respiratory distress syndrome;
   Recombinant tissue plasminogen activator; Tocilizumab; D-dimer
ID COAGULATION
AB In a proportion of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a multisystem syndrome characterized by hyperinflammation, acute respiratory distress syndrome (ARDS), and hypercoagulability. A 68-year-old man with coronavirus disease 2019 (COVID-19) was admitted to the intensive care unit with respiratory failure, cytokine release syndrome (CRS), and skin ischemia - microthrombosis. Specific coagulation and inflammatory markers (D-dimer, ferritin, and Creactive protein), along with the clinical picture, triggered the trial of recombinant tissue plasminogen activator (rt-PA) and tocilizumab. This was followed by resolution of the skin ischemia and CRS, while respiratory parameters improved. No major complications associated with rt-PA or tocilizumab occurred. The combination of rt-PA with targeted anti-inflammatory treatment could be a new therapeutic option for patients with COVID-19, ARDS, hyperinflammation, and increased blood viscosity. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Papamichalis, Panagiotis; Papadogoulas, Antonios; Katsiafylloudis, Periklis; Skoura, Apostolia-Lemonia; Neou, Evangelia; Papadopoulos, Dimitrios; Karagiannis, Spyridon; Zafeiridis, Tilemachos; Komnos, Apostolos] Gen Hosp Larissa, Intens Care Unit, Tsakalof 1, Larisa 41221, Greece.
   [Papamichalis, Michail] Univ Gen Hosp Larissa, Dept Cardiol, Larisa, Greece.
   [Babalis, Dimitris] Gen Hosp Larissa, Emergency Dept, Larisa, Greece.
RP Papamichalis, P (corresponding author), Gen Hosp Larissa, Intens Care Unit, Tsakalof 1, Larisa 41221, Greece.
EM ppapamih@med.uth.gr
RI PANAGIOTIS, PAPAMICHALIS/ABC-2362-2020
OI PANAGIOTIS, PAPAMICHALIS/0000-0001-7296-419X
CR Danzi GB, 2020, EUR HEART J
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Jacobs K, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-112615
   Lippi G, 2020, THROMB HAEMOST
   Liu J, 2020, RES PRACT THROMB HAE, V4, P518, DOI 10.1002/rth2.12353
   MacLaren R, 2007, PHARMACOTHERAPY, V27, P860, DOI 10.1592/phco.27.6.860
   Moore BH, 2020, J TRAUMA ACUTE CARE
   Poggiali Erika, 2020, Eur J Case Rep Intern Med, V7, P001646, DOI 10.12890/2020_001646
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   WHO, 2020, CLIN MAN SEV AC RESP
   Xiaoling X, 2020, CHINAXIV
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2020
VL 97
BP 90
EP 93
DI 10.1016/j.ijid.2020.05.118
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA MQ1ZD
UT WOS:000552696000017
PM 32497796
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Franzetti, M
   Pozzetti, U
   Carugati, M
   Pandolfo, A
   Molteni, C
   Faccioli, P
   Castaldo, G
   Longoni, E
   Ormas, V
   Iemoli, E
   Piconi, S
AF Franzetti, Marco
   Pozzetti, Ugo
   Carugati, Manuela
   Pandolfo, Alessandro
   Molteni, Chiara
   Faccioli, Paolo
   Castaldo, Gioacchino
   Longoni, Ernesto
   Ormas, Valentina
   Iemoli, Enrico
   Piconi, Stefania
TI Interleukin-1 receptor antagonist anakinra in association with
   remdesivir in severe COVID-19: A case report
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Novel coronavirus disease 2019 (COVID-19); Cytokine-release syndrome;
   Interleukin-1 receptor antagonist; Anakinra; Remdesivir
AB We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
C1 [Franzetti, Marco; Pandolfo, Alessandro; Molteni, Chiara; Castaldo, Gioacchino; Longoni, Ernesto; Piconi, Stefania] A Manzoni Hosp, Infect Dis Unit, Via Eremo 9, I-23900 Lecce, Italy.
   [Pozzetti, Ugo] A Manzoni Hosp, Med Dept, Lecce, Italy.
   [Carugati, Manuela] Duke Univ, Div Infect Dis, Durham, NC USA.
   [Carugati, Manuela] ATS Brianza, Lecce, Italy.
   [Faccioli, Paolo] Alessandro Manzoni Hosp, Radiol Unit, Lecce, Italy.
   [Ormas, Valentina] Manzoni Hosp, Intens Care Unit, Lecce, Italy.
   [Iemoli, Enrico] L Sacco Hosp Vialba, Infect Dis Dept 1, Milan, Italy.
   [Iemoli, Enrico] L Sacco Hosp Vialba, Clin Immunol Unit, Milan, Italy.
RP Franzetti, M (corresponding author), A Manzoni Hosp, Infect Dis Unit, Via Eremo 9, I-23900 Lecce, Italy.
EM m.franzetti@asst-lecco.it
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Campbell L, 2011, RHEUMATOLOGY, V50, P552, DOI 10.1093/rheumatology/keq343
   Cohen SB, 2004, ANN RHEUM DIS, V63, P1062, DOI 10.1136/ard.2003.016014
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Conti P, 2020, J BIOL REGUL HOMEOST, V34, P23812
   Giamarellos-Bourboulis E. J., 2020, CELL HOST MICROBE
   Grein J, 2020, NEW ENGL J MED, V382
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Livingston E., 2020, JAMA
   Lopalco G, 2016, CLIN EXP RHEUMATOL, V34, P531
   Lukaszewicz AC, 2009, CRIT CARE MED, V37, P2746, DOI 10.1097/CCM.0b013e3181ab858a
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Sonmez HE, 2018, CLIN RHEUMATOL, V37, P3329, DOI 10.1007/s10067-018-4095-1
   Tanaka S, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0541-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang JR, 2020, J MED VIROL, V92, P1681, DOI 10.1002/jmv.25940
NR 19
TC 10
Z9 11
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2020
VL 97
BP 215
EP 218
DI 10.1016/j.ijid.2020.05.050
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA MQ1ZD
UT WOS:000552696000043
PM 32422376
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arshad, S
   Kilgore, P
   Chaudhry, ZS
   Jacobsen, G
   Wang, DD
   Huitsing, K
   Brar, I
   Alangaden, GJ
   Ramesh, MS
   McKinnon, JE
   O'Neill, W
   Zervos, M
AF Arshad, Samia
   Kilgore, Paul
   Chaudhry, Zohra S.
   Jacobsen, Gordon
   Wang, Dee Dee
   Huitsing, Kylie
   Brar, Indira
   Alangaden, George J.
   Ramesh, Mayur S.
   McKinnon, John E.
   O'Neill, William
   Zervos, Marcus
CA Henry Ford COVID 19 Task Force
TI Treatment with hydroxychloroquine, azithromycin, and combination in
   patients hospitalized with COVID-19
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Hydroxychloroquine; Mortality; COVID-19; SARS-COV-2; Coronavirus;
   Therapy
ID CHLOROQUINE
AB Significance: The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.
   Objective: The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.
   Design: Multi-center retrospective observational study.
   Setting: The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largestofhospitalsisan802-bed quaternaryacademicteachinghospital inurbanDetroit,Michigan.
   Participants: Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48 h unless expired within 24 h.
   Exposure: Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.
   Main outcome: The primary outcome was in-hospital mortality.
   Results: Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age >= 65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine + azithromycin 71% compared to neither treatment (p < 0.001).
   Conclusions and relevance: In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
C1 [Arshad, Samia; Chaudhry, Zohra S.; Huitsing, Kylie; Brar, Indira; Alangaden, George J.; Ramesh, Mayur S.; McKinnon, John E.; Zervos, Marcus] Henry Ford Hosp, Infect Dis, Detroit, MI 48202 USA.
   [Kilgore, Paul] Wayne State Univ, Eugene Applebaum Coll Pharm, Detroit, MI USA.
   [Kilgore, Paul; Alangaden, George J.; Zervos, Marcus] Wayne State Univ, Sch Med, Detroit, MI USA.
   [Wang, Dee Dee; O'Neill, William] Henry Ford Hosp, Div Cardiovasc Dis & Struct Heart, Detroit, MI 48202 USA.
   [Jacobsen, Gordon] Henry Ford Hosp, Publ Hlth Sci, Detroit, MI 48202 USA.
RP Zervos, M (corresponding author), Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA.
EM MZervos1@hfhs.org
OI Chaudhry, Zohra S/0000-0002-8733-2264; Ramesh, Mayur/0000-0002-1677-3994
FU Henry Ford Health System
FX Internal Support Henry Ford Health System.
CR Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Cao B, 2020, NEW ENGL J MED, V382
   CDC, 2020, COR DIS 2019 COVID 1
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   FDA, 2020, FDA CAUT AG US HYDR
   Gandhi M, 2020, ENGL J MED, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grein J, 2020, NEW ENGL J MED, V382
   Grissom CK, 2010, DISASTER MED PUBLIC, V4, P277, DOI 10.1001/dmp.2010.40
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jung HJ, 2010, ARTHRITIS RHEUM-US, V62, P863, DOI 10.1002/art.27289
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mc McCullough PA, 2020, BAYLOR U MED CTR P
   McCreary Erin K, 2020, OPEN FORUM INFECT DI, V7
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   NIH, 2020, ANTIVIRAL THERAPY
   Pagliano P, 2020, CLIN INFECT DIS, V71, P887, DOI 10.1093/cid/ciaa320
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu B, 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.04.27.20073379, DOI 10.1101/2020.04.27.20073379]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 69
Z9 69
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2020
VL 97
BP 396
EP 403
DI 10.1016/j.ijid.2020.06.099
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA MQ1VR
UT WOS:000552686700032
PM 32623082
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Salazar, E
   Perez, KK
   Ashraf, M
   Chen, J
   Castillo, B
   Christensen, PA
   Eubank, T
   Bernard, DW
   Eagar, TN
   Long, SW
   Subedi, S
   Olsen, RJ
   Leveque, C
   Schwartz, MR
   Dey, M
   Chavez-East, C
   Rogers, J
   Shehabeldin, A
   Joseph, D
   Williams, G
   Thomas, K
   Masud, F
   Talley, C
   Dlouhy, KG
   Lopez, BV
   Hampton, C
   Lavinder, J
   Gollihar, JD
   Maranhao, AC
   Ippolito, GC
   Saavedra, MO
   Cantu, CC
   Yerramilli, P
   Pruitt, L
   Musser, JM
AF Salazar, Eric
   Perez, Katherine K.
   Ashraf, Madiha
   Chen, Jian
   Castillo, Brian
   Christensen, Paul A.
   Eubank, Taryn
   Bernard, David W.
   Eagar, Todd N.
   Long, S. Wesley
   Subedi, Sishir
   Olsen, Randall J.
   Leveque, Christopher
   Schwartz, Mary R.
   Dey, Monisha
   Chavez-East, Cheryl
   Rogers, John
   Shehabeldin, Ahmed
   Joseph, David
   Williams, Guy
   Thomas, Karen
   Masud, Faisal
   Talley, Christina
   Dlouhy, Katharine G.
   Lopez, Bevin V.
   Hampton, Curt
   Lavinder, Jason
   Gollihar, Jimmy D.
   Maranhao, Andre C.
   Ippolito, Gregory C.
   Saavedra, Matthew O.
   Cantu, Concepcion C.
   Yerramilli, Prasanti
   Pruitt, Layne
   Musser, James M.
TI Treatment of Coronavirus Disease 2019 (COVID-19) Patients with
   Convalescent Plasma
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID SARS; THERAPY
AB Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and no proven treatments are available. Convalescent plasma therapy has been used with varying degrees of success to treat severe microbial infections for >100 years. Patients (n = 25) with severe and/or life-threatening COVID-19 disease were enrolled at the Houston Methodist hospitals from March 28, 2020, to April 14, 2020. Patients were transfused with convalescent plasma, obtained from donors with confirmed severe acute respiratory syndrome coronavirus 2 infection who had recovered. The primary study outcome was safety, and the secondary outcome was clinical status at day 14 after transfusion. Clinical improvement was assessed on the basis of a modified World Health Organization six-point ordinal scale and laboratory parameters. Viral genome sequencing was performed on donor and recipient strains. At day 7 after transfusion with convalescent plasma, nine patients had at least a one-point improvement in clinical scale, and seven of those were discharged. By day 14 after transfusion, 19 (76%) patients had at least a one-point improvement in clinical status, and 11 were discharged. No adverse events as a result of plasma transfusion were observed. Whole genome sequencing data did not identify a strain genotype-disease severity correlation. The data indicate that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.
C1 [Salazar, Eric; Perez, Katherine K.; Chen, Jian; Castillo, Brian; Christensen, Paul A.; Bernard, David W.; Eagar, Todd N.; Long, S. Wesley; Subedi, Sishir; Olsen, Randall J.; Leveque, Christopher; Schwartz, Mary R.; Dey, Monisha; Chavez-East, Cheryl; Rogers, John; Shehabeldin, Ahmed; Joseph, David; Williams, Guy; Thomas, Karen; Musser, James M.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA.
   [Salazar, Eric; Bernard, David W.; Eagar, Todd N.; Long, S. Wesley; Olsen, Randall J.; Musser, James M.] Houston Methodist Hosp, Dept Pharm, Houston, TX 77030 USA.
   [Masud, Faisal] Houston Methodist Hosp, Dept Anesthesiol & Crit Care, Houston, TX 77030 USA.
   [Ashraf, Madiha; Masud, Faisal] Houston Methodist Hosp, Dept Clin Med, Div Infect Dis, Houston, TX 77030 USA.
   [Perez, Katherine K.; Eubank, Taryn] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
   [Long, S. Wesley; Olsen, Randall J.; Saavedra, Matthew O.; Cantu, Concepcion C.; Yerramilli, Prasanti; Pruitt, Layne; Musser, James M.] Houston Methodist Res Inst, Ctr Mol & Translat Human Infect Dis, Houston, TX USA.
   [Talley, Christina; Dlouhy, Katharine G.; Lopez, Bevin V.; Hampton, Curt] Houston Methodist Res Inst, Acad Off Clin Trials, Houston, TX USA.
   [Lavinder, Jason; Maranhao, Andre C.; Ippolito, Gregory C.] Univ Texas Austin, Dell Med Sch, Dept Mol Biosci, Austin, TX 78712 USA.
   [Cantu, Concepcion C.] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX 78712 USA.
   [Gollihar, Jimmy D.] Univ Texas Austin, Army Res Lab South, Combat Capabil Dev Command CCDC, Austin, TX 78712 USA.
RP Musser, JM (corresponding author), Houston Methodist Hosp, 6565 Fannin St, Houston, TX 77030 USA.
EM jmmusser@houstonmethodist.org
RI Long, S. Wesley/A-9651-2008
OI Long, S. Wesley/0000-0003-3043-5307; Ippolito,
   Gregory/0000-0002-7565-7002; Perez, Katherine/0000-0002-7535-997X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI146771-01, AI139369-01]; Fondren
   Foundation, Houston Methodist Hospital and Research Institute; National
   Institute of Allergy and Infectious Diseases/NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [75N93019C00050]; Army Research Office [W911NF-12-1-0390]
FX Supported by NIH grants AI146771-01 and AI139369-01; the Fondren
   Foundation, Houston Methodist Hospital and Research Institute (J.M.M.);
   National Institute of Allergy and Infectious Diseases/NIH, contract
   75N93019C00050 (J.L. and G.C.I.); and Army Research Office Cooperative
   Agreement W911NF-12-1-0390 (J.D.G.).
CR Brufsky A, 2020, J MED VIROL, V92, P1386, DOI 10.1002/jmv.25902
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghosal S., 2020, CLIN RES REV, V14, P311
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hodcroft E. B, 2020, SWISS MED WEEKLY, V150, pw20212
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Long SW, 2020, BIORXIV
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Piva S, 2020, J CRIT CARE, V58, P29, DOI 10.1016/j.jcrc.2020.04.004
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhao J, 2020, RELATIONSHIP THEABOB
NR 41
TC 33
Z9 34
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2020
VL 190
IS 8
BP 1680
EP 1690
DI 10.1016/j.ajpath.2020.05.014
PG 11
WC Pathology
SC Pathology
GA MQ1RI
UT WOS:000552675100010
PM 32473109
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Montopoli, M
   Zumerle, S
   Vettor, R
   Rugge, M
   Zorzi, M
   Catapano, CV
   Carbone, GM
   Cavalli, A
   Pagano, F
   Ragazzi, E
   Prayer-Galetti, T
   Alimonti, A
AF Montopoli, M.
   Zumerle, S.
   Vettor, R.
   Rugge, M.
   Zorzi, M.
   Catapano, C., V
   Carbone, G. M.
   Cavalli, A.
   Pagano, F.
   Ragazzi, E.
   Prayer-Galetti, T.
   Alimonti, A.
TI Androgen-deprivation therapies for prostate cancer and risk of infection
   by SARS-CoV-2: a population-based study (N=4532)
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE androgen-deprivation therapy; COVID-19; prostate cancer
ID POTENTIAL TARGET; PROTEASE TMPRSS2; CORONAVIRUS; PNEUMONIA; VIRUS
AB Background: Cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on binding of the viral spike (S) proteins to angiotensin-converting enzyme 2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is up-regulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First-or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections.
   Materials and methods: We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the coronavirus disease 2019 (COVID-19) pandemic. The parameters used for each COVID-19-positive patient were sex, hospitalization, admission to intensive care unit, death, tumor diagnosis, prostate cancer diagnosis, and ADT.
   Results: There were evaluable 9280 SARS-CoV-2-positive patients in Veneto on 1 April 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2-positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared with patients who did not receive ADT (OR 4.05;95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT with patients with any other type of cancer (OR 4.86; 95% CI 1.88-12.56).
   Conclusion: Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections compared with noncancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.
C1 [Montopoli, M.; Ragazzi, E.] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy.
   [Montopoli, M.; Zumerle, S.; Pagano, F.; Alimonti, A.] Fdn Ric Biomed Avanzata, VIMM Veneto Inst Mol Med, Padua, Italy.
   [Zumerle, S.; Vettor, R.; Rugge, M.; Alimonti, A.] Univ Padua, Dept Med, Padua, Italy.
   [Rugge, M.; Zorzi, M.] Veneto Tumour Registry Azienda Zero, Padua, Italy.
   [Catapano, C., V; Carbone, G. M.; Alimonti, A.] Univ Svizzera Italiana, Inst Oncol Res, Oncol Inst Southern Switzerland, Bellinzona, Switzerland.
   [Cavalli, A.] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland.
   [Prayer-Galetti, T.] Azienda Osped Padova, Dept Oncol & Gastroenterol Sci, Urol Unit, Padua, Italy.
   [Alimonti, A.] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Zurich, Switzerland.
RP Alimonti, A (corresponding author), Univ Svizzera Italiana, Inst Oncol Res, Via Vela 6, CH-6500 Bellinzona, Switzerland.
EM andrea.alimonti@ior.iosi.ch
OI Alimonti, Andrea/0000-0002-9362-2313
FU European Research Council Consolidator GrantEuropean Research Council
   (ERC) [683136]; Swiss Cancer League [4267]; Swiss National Science
   Foundation (SNSF)Swiss National Science Foundation (SNSF) [176045];
   Prostate Cancer Foundation [19CHAL08]; Italian Association for Cancer
   Research Investigator GrantAssociazione Italiana per la Ricerca sul
   Cancro (AIRC) [22030]
FX This work was supported by the following grants to AA: European Research
   Council Consolidator Grant [grant number 683136]; Swiss Cancer League
   [grant number 4267]; Swiss National Science Foundation (SNSF) [grant
   number 176045], Prostate Cancer Foundation [grant number 19CHAL08]; and
   Italian Association for Cancer Research Investigator Grant [grant number
   22030].
CR Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Choi SY, 2009, TRENDS MOL MED, V15, P303, DOI 10.1016/j.molmed.2009.05.003
   COVID-19 Map, COVID 19 MAP
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Faivre EJ, 2017, MOL CANCER RES, V15, P35, DOI 10.1158/1541-7786.MCR-16-0221
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ianculescu I, 2012, J BIOL CHEM, V287, P4000, DOI 10.1074/jbc.M111.300194
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lucas J, 2008, J PATHOL, V215, P118, DOI 10.1002/path.2330
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Shaw GL, 2016, EUR UROL, V70, P214, DOI 10.1016/j.eururo.2015.10.042
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Sheskin DJ, 2004, HDB PARAMETRIC NONPA
   Shin WJ, 2017, EXPERT OPIN DRUG DIS, V12, P1139, DOI 10.1080/17460441.2017.1372417
   Shinde D, 2019, EUR UROL ONCOL, V2, P415, DOI 10.1016/j.euo.2018.08.024
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Xu ZY, 2018, ONCOGENE, V37, P6259, DOI 10.1038/s41388-018-0409-7
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 79
Z9 81
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD AUG
PY 2020
VL 31
IS 8
BP 1040
EP 1045
DI 10.1016/j.annonc.2020.04.479
PG 6
WC Oncology
SC Oncology
GA MQ7PX
UT WOS:000553086700011
PM 32387456
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Deer, TR
   Sayed, D
   Pope, JE
   Chakravarthy, KV
   Petersen, E
   Moeschler, SM
   Abd-Elsayed, A
   Amirdelfan, K
   Mekhail, N
AF Deer, Timothy R.
   Sayed, Dawood
   Pope, Jason E.
   Chakravarthy, Krishnan V.
   Petersen, Erika
   Moeschler, Susan M.
   Abd-Elsayed, Alaa
   Amirdelfan, Kasra
   Mekhail, Nagy
CA ASPN COVID Workgrp
TI Emergence From the COVID-19 Pandemic and the Care of Chronic Pain:
   Guidance for the Interventionalist
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID COMPREHENSIVE MEDICAL-MANAGEMENT; REFRACTORY CANCER PAIN; DRUG-RELATED
   TOXICITY; BACTERIAL TRANSMISSION; PREVALENCE; TELEMEDICINE
AB BACKGROUND: The current coronavirus disease 2019 (COVID-19) pandemic led to a significant disruption in the care of pain from chronic and subacute conditions. The impact of this cessation of pain treatment may have unintended consequences of increased pain, reduced function, increased reliance on opioid medications, and potential increased morbidity, due to the systemic impact of untreated disease burden. This may include decreased mobility, reduction in overall health status, and increase of opioid use with the associated risks. METHODS: The article is the study of the American Society of Pain and Neuroscience (ASPN) COVID-19 task force to evaluate the policies set forth by federal, state, and local agencies to reduce or eliminate elective procedures for those patients with pain from spine, nerve, and joint disease. The impact of these decisions, which were needed to reduce the spread of the pandemic, led to a delay in care for many patients. We hence review an emergence plan to reinitiate this pain-related care. The goal is to outline a path to work with federal, state, and local authorities to combat the spread of the pandemic and minimize the deleterious impact of pain and suffering on our chronic pain patients. RESULTS: The article sets forth a strategy for the interventional pain centers to reemerge from the current pandemic and to set a course for future events. CONCLUSIONS: The COVID-19 pandemic represents an overwhelming challenge to interventional pain physicians and their patients. In addition to urgent actions needed for disease mitigation, the ASPN recommends a staged return to pain management professionals' workflow.
C1 [Deer, Timothy R.] Spine & Nerve Ctr Virginias, Dept Pain Med, Charleston, WV USA.
   [Deer, Timothy R.] West Virginia Univ, Sch Med, Dept Anesthesiol & Pain Med, Morgantown, WV 26506 USA.
   [Sayed, Dawood] Univ Kansas, Med Ctr, Dept Anesthesiol & Pain Med, Kansas City, KS 66103 USA.
   [Pope, Jason E.] Evolve Restorat Ctr, Santa Rosa, CA USA.
   [Chakravarthy, Krishnan V.] Univ Calif San Diego, Dept Anesthesiol, Div Pain Med, San Diego, CA 92103 USA.
   [Chakravarthy, Krishnan V.] Vet Affairs VA San Diego Healthcare, Div Pain Med, Dept Anesthesiol, San Diego, CA USA.
   [Petersen, Erika] Univ Arkansas Med Sci, Dept Neurosurg, Little Rock, AR 72205 USA.
   [Moeschler, Susan M.] Mayo Clin, Div Pain Med, Rochester, MN USA.
   [Abd-Elsayed, Alaa] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI USA.
   [Amirdelfan, Kasra] IPM Med Grp Inc, Walnut Creek, CA USA.
   [Mekhail, Nagy] Cleveland Clin, Dept Anesthesiol, Cleveland, OH 44106 USA.
RP Deer, TR (corresponding author), Spine & Nerve Ctr Virginias, 400 Ct St,Suite 100, Charleston, WV 25304 USA.
EM doctdeer@aol.com
OI Petersen, Erika/0000-0002-8548-1450
FU American Society of Pain and Neuroscience
FX Funded by the American Society of Pain and Neuroscience.
CR Agencia Estatal Boletin Ofical del Estado, BOEA20203692 AG EST
   American College of Surgeons, COVID 19 GUID TRIAG
   American Enterprise Institute, NAT COR RESP ROAD MA
   [Anonymous], LOC RES EL SURG GUID
   Association of State and Territorial Health Officials, ADM PREP STRAT MAN S
   Barry DT, 2012, J PSYCHIATR RES, V46, P118, DOI 10.1016/j.jpsychires.2011.09.004
   Bednarski BK, 2018, DIS COLON RECTUM, V61, P77, DOI 10.1097/DCR.0000000000000945
   Canon S, 2014, J TELEMED TELECARE, V20, P427, DOI 10.1177/1357633X14555610
   Centers for Disease Control and Prevention, SCREEN TRIAG INT
   Centers for Disease Control and Prevention, SER TEST COVID 19
   Centers for Disease Control and Prevention, INF CONTR BAS TRANSM
   Centers for Disease Control and Prevention, GUID INF PREV ORTH P
   Centers for Disease Control and Prevention (CDC), INT US GUID RISK ASS
   Centers for Medicare & Medicaid Services, NON EL MED SERV TRE
   Centers for Medicare & Medicaid Services, COR COVID 19 PARTN T
   Centers for Medicare & Medicaid Services, MED TEL HLTH CAR FAC
   Centers for Medicare & Medicaid Services, OP AM AG REOP FAC NO
   Chang HY, 2014, AM J EMERG MED, V32, P421, DOI 10.1016/j.ajem.2014.01.015
   Cohen SP, 2020, PAIN MED
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Fisher EM, 2014, J OCCUP ENVIRON HYG, V11, pD115, DOI 10.1080/15459624.2014.902954
   Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001
   Li Y, 2020, EUR RADIOL, V30, P6186, DOI 10.1007/s00330-020-06969-5
   Loftus RW, 2015, ANESTH ANALG, V120, P853, DOI 10.1213/ANE.0000000000000505
   Motov Sergey M, 2016, Anesthesiol Clin, V34, P271, DOI 10.1016/j.anclin.2016.01.006
   Pennsylvania Department of Health, INT PENNS CRIS STAND
   Prachand VN, 2020, J AM COLL SURG
   Rowlands J, 2014, AM J INFECT CONTROL, V42, P698, DOI 10.1016/j.ajic.2014.02.021
   Samcam I, 2016, PAIN MANAGEMENT
   Shanthanna H, 2020, ANAESTHESIA, V75, P935, DOI 10.1111/anae.15076
   Smith C, 2018, PAIN MED, V19, P1293, DOI 10.1093/pm/pny016
   Smith TJ, 2005, ANN ONCOL, V16, P825, DOI 10.1093/annonc/mdi156
   Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118
   State Governor of Illinois, 20 STAT GOV ILL
   State Governor of Montana, 22020 STAT GOV MONT
   State Governor of New York, 202 STAT GOV NEW YOR
   State Governor of Tennessee, 20 STAT GOV TENN
   Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859
   White House (USA), GUID OP AM AG
   Williams Aaron M, 2018, Mhealth, V4, P11, DOI 10.21037/mhealth.2018.04.03
NR 40
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD AUG
PY 2020
VL 131
IS 2
BP 387
EP 394
DI 10.1213/ANE.0000000000005000
PG 8
WC Anesthesiology
SC Anesthesiology
GA MP0ME
UT WOS:000551907100026
PM 32452905
OA Green Published
DA 2021-01-01
ER

PT J
AU Iaccarino, G
   Grassi, G
   Borghi, C
   Ferri, C
   Salvetti, M
   Volpe, M
AF Iaccarino, Guido
   Grassi, Guido
   Borghi, Claudio
   Ferri, Claudio
   Salvetti, Massimo
   Volpe, Massimo
CA SARS-RAS Investigators
TI Age and Multimorbidity Predict Death Among COVID-19 Patients Results of
   the SARS-RAS Study of the Italian Society of Hypertension
SO HYPERTENSION
LA English
DT Article
DE COVID-19; hypertension; Italy; multimorbidity; odds ratio
AB Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66 +/- 0.4 years) were recorded. At least 1 preexisting condition was observed in 73.4% of patients, with hypertension being the most represented (54.9%). One hundred eighty-eight deaths were recorded (11.8%; mean age, 79.6 +/- 0.9 years). In nonsurvivors, older age, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery diseases, and heart failure were more represented than in survivors. The Charlson Comorbidity Index was significantly higher in nonsurvivors compared with survivors (4.3 +/- 0.15 versus 2.6 +/- 0.05;P<0.001). ACE (angiotensin-converting enzyme) inhibitors, diuretics, and beta-blockers were more frequently used in nonsurvivors than in survivors. After correction by multivariate analysis, only age (P=0.0001), diabetes mellitus (P=0.004), chronic obstructive pulmonary disease (P=0.011), and chronic kidney disease (P=0.004) but not hypertension predicted mortality. Charlson Comorbidity Index, which cumulates age and comorbidities, predicts mortality with an exponential increase in the odds ratio by each point of score. In the COVID-19 outbreak, mortality is predicted by age and the presence of comorbidities. Our data do not support a significant interference of hypertension and antihypertensive therapy on COVID-19 lethality.
C1 [Iaccarino, Guido] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy.
   [Grassi, Guido] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy.
   [Borghi, Claudio] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.
   [Ferri, Claudio] Univ Aquila, Dept Clin Med Publ Hlth Life & Environm Sci, Laquila, Italy.
   [Salvetti, Massimo] Univ Brescia, Dept Clin & Expt Sci, Med 2, ASST Spedali Civili Brescia, Brescia, Italy.
   [Volpe, Massimo] Sapienza Univ, Clin & Mol Med Dept, St Andrea Hosp, Rome, Italy.
   [Volpe, Massimo] IRCCS Neuromed, Pozzilli, IS, Italy.
RP Iaccarino, G (corresponding author), Federico II Univ Naples, Dept Adv Biomed Sci, Via Pansini 5, I-80138 Naples, Italy.
EM guiaccar@unina.it
RI ; Salvetti, Massimo/E-9929-2010
OI Volpe, Massimo/0000-0002-9642-8380; Ferri, Claudio/0000-0002-3594-2503;
   Salvetti, Massimo/0000-0001-8101-1374; BORGHI,
   CLAUDIO/0000-0001-8039-8781; GRASSI, GUIDO/0000-0003-1922-6547
FU Italian Society of Hypertension/Italian League against hypertension
FX The Phase IV Observational Study to Associate Hypertension and
   Hypertensinon Treatment to COVID-19 (SARS-RAS) study is supported by an
   unconditioned grant from the Italian Society of Hypertension/Italian
   League against hypertension.
CR [Anonymous], 2020, COVID 19 GDS CARATTE
   Battistoni A, 2020, EUR HEART J-CARD PHA, V6, P248, DOI 10.1093/ehjcvp/pvaa030
   Cano IP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217030
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Di Bari M, 1999, J HYPERTENS, V17, P1633
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hanff TC, 2020, CLIN INFECT DIS, V71, P870, DOI 10.1093/cid/ciaa329
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iaccarino G, 2020, HIGH BLOOD PRESS CAR, V27, P105, DOI 10.1007/s40292-020-00380-3
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rossi GP, 2020, ELIFE, V9, DOI 10.7554/eLife.57278
   Santulli G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122061
   Sarzani R, 2020, EUR J PREV CARDIOL, DOI 10.1177/2047487320918421
   Supe S, 2016, BRIT J PHARMACOL, V173, P1618, DOI 10.1111/bph.13462
   Tocci G, 2015, J HUM HYPERTENS, V29, P696, DOI 10.1038/jhh.2015.4
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Williams B, 2018, J HYPERTENS, V36, P1953, DOI 10.1097/HJH.0000000000001940
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 37
TC 31
Z9 31
U1 8
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD AUG
PY 2020
VL 76
IS 2
BP 366
EP 372
DI 10.1161/HYPERTENSIONAHA.120.15324
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MP0ND
UT WOS:000551909600022
PM 32564693
OA Green Published
DA 2021-01-01
ER

PT J
AU Guo, XM
   Zhu, YL
   Hong, Y
AF Guo, Xiaoming
   Zhu, Yueli
   Hong, Yuan
TI Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone
   System Inhibitors Therapy in Patients With Hypertension A Meta-Analysis
SO HYPERTENSION
LA English
DT Letter
DE global health; humans; hypertension; pandemics; renin-angiotensin system
AB Supplemental Digital Content is available in the text.
C1 [Guo, Xiaoming; Hong, Yuan] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China.
   [Zhu, Yueli] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurol, Hangzhou, Peoples R China.
RP Hong, Y (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China.
EM hy0904@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81870964]; Zhejiang Provincial Natural
   Science Foundation of ChinaNatural Science Foundation of Zhejiang
   Province [LY17H090012]
FX This work was supported by the National Natural Science Foundation of
   China (81870964) and Zhejiang Provincial Natural Science Foundation of
   China (LY17H090012).
CR He XL, 2007, SHOCK, V28, P106, DOI 10.1097/SHK.0b013e3180310f3a
   Igase M, 2008, HYPERTENS RES, V31, P553, DOI 10.1291/hypres.31.553
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 5
TC 23
Z9 23
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD AUG
PY 2020
VL 76
IS 2
BP E13
EP E14
DI 10.1161/HYPERTENSIONAHA.120.15572
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MP0ND
UT WOS:000551909600002
PM 32458694
DA 2021-01-01
ER

PT J
AU Wang, JZ
   Zhang, RY
   Bai, J
AF Wang, Jing-Zhang
   Zhang, Rui-Ying
   Bai, Jing
TI An anti-oxidative therapy for ameliorating cardiac injuries of
   critically ill COVID-19-infected patients
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE COVID-19; Cardiac injury; Antiviral immunity; Reactive oxygen species;
   Antioxidant
C1 [Wang, Jing-Zhang; Zhang, Rui-Ying; Bai, Jing] Hebei Univ Engn, Coll Med, Affiliated Hosp, Handan 056002, Peoples R China.
RP Wang, JZ (corresponding author), Hebei Univ Engn, Coll Med, Affiliated Hosp, Handan 056002, Peoples R China.
EM jingzhangwang@hebeu.edu.cn
FU Hebei Provincial Social Science Fund Project [HB19SH020]
FX Hebei Provincial Social Science Fund Project (No. HB19SH020).
CR Erol N, 2019, INFLAMMATION, V42, P1585, DOI 10.1007/s10753-019-01020-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Loffredo L, 2019, INT J CARDIOL, V293, P56, DOI 10.1016/j.ijcard.2019.05.014
   Perrone LA, 2013, J INFECT DIS, V207, P1576, DOI 10.1093/infdis/jit062
NR 5
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD AUG 1
PY 2020
VL 312
BP 137
EP 138
DI 10.1016/j.ijcard.2020.04.009
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MP2SB
UT WOS:000552057800033
PM 32321655
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, Y
   Lipner, SR
AF Wang, Yu
   Lipner, Shari R.
TI Retrospective analysis of smell and taste disturbances associated with
   dermatologic medications reported to the United States Food and Drug
   Administration and relevance to COVID-19 infections
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Wang, Yu] SUNY Stony Brook, Med Sch, New York, NY USA.
   [Lipner, Shari R.] Weill Cornell Med, Dept Dermatol, New York, NY USA.
RP Lipner, SR (corresponding author), 1305 York Ave, New York, NY 10021 USA.
EM shl9032@med.cornell.edu
CR Damiani G, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12876
   DUHRA P, 1988, CLIN EXP DERMATOL, V13, P126, DOI 10.1111/j.1365-2230.1988.tb00677.x
   Halpern SM, 1996, BRIT J DERMATOL, V134, P378, DOI 10.1111/j.1365-2133.1996.tb07641.x
   HEISE E, 1990, EUR ARCH OTO-RHINO-L, V247, P382, DOI 10.1007/BF00179013
   Suri R, 2018, CHEST, V154, pE45, DOI 10.1016/j.chest.2017.12.011
   Tuccori M, 2011, DRUG SAFETY, V34, P849, DOI 10.2165/11593120-000000000-00000
   Xydakis MS, 2020, LANCET INFECT DIS, V20, P1015, DOI 10.1016/S1473-3099(20)30293-0
NR 7
TC 1
Z9 1
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2020
VL 83
IS 2
BP 682
EP 684
DI 10.1016/j.jaad.2020.05.057
PG 4
WC Dermatology
SC Dermatology
GA MP5FI
UT WOS:000552229600106
PM 32425285
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rudnicka, L
   Glowacka, P
   Goldust, M
   Sikora, M
   Sar-Pomian, M
   Rakowska, A
   Samochocki, Z
   Olszewska, M
AF Rudnicka, Lidia
   Glowacka, Paulina
   Goldust, Mohamad
   Sikora, Mariusz
   Sar-Pomian, Marta
   Rakowska, Adriana
   Samochocki, Zbigniew
   Olszewska, Malgorzata
TI Cyclosporine therapy during the COVID-19 pandemic
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Rudnicka, Lidia; Glowacka, Paulina; Sikora, Mariusz; Sar-Pomian, Marta; Rakowska, Adriana; Samochocki, Zbigniew; Olszewska, Malgorzata] Med Univ Warsaw, Dept Dermatol, Koszykowa 82A, PL-02008 Warsaw, Poland.
   [Goldust, Mohamad] Univ Rome G Marconi, Dept Dermatol, Rome, Italy.
   [Goldust, Mohamad] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany.
   [Goldust, Mohamad] Univ Hosp Basel, Dept Dermatol, Basel, Switzerland.
RP Rudnicka, L (corresponding author), Med Univ Warsaw, Dept Dermatol, Koszykowa 82A, PL-02008 Warsaw, Poland.
EM lidiarudnicka@gmail.com
RI Rudnicka, Lidia/L-7529-2019
OI Rudnicka, Lidia/0000-0002-8308-1023
CR Colombo D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/941767
   de Wilde AH, 2018, VIROLOGY, V522, P46, DOI 10.1016/j.virol.2018.06.011
   Elston DM, 2020, J AM ACAD DERMATOL, V82, P819, DOI 10.1016/j.jaad.2020.02.031
   Ianevski A, 2018, ANTIVIR RES, V154, P174, DOI 10.1016/j.antiviral.2018.04.016
   Rudnicka L, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13361
   Russell CD, 2013, J INFECTION, V67, P84, DOI 10.1016/j.jinf.2013.01.004
NR 6
TC 10
Z9 10
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2020
VL 83
IS 2
BP E151
EP E152
DI 10.1016/j.jaad.2020.04.153
PG 2
WC Dermatology
SC Dermatology
GA MP5FI
UT WOS:000552229600024
PM 32376422
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aaby, P
   Benn, CS
   Flanagan, KL
   Klein, SL
   Kollmann, TR
   Lynn, DJ
   Shann, F
AF Aaby, Peter
   Benn, Christine Stabell
   Flanagan, Katie L.
   Klein, Sabra L.
   Kollmann, Tobias R.
   Lynn, David J.
   Shann, Frank
TI The non-specific and sex-differential effects of vaccines
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Article
ID DIPHTHERIA-TETANUS-PERTUSSIS; NEONATAL BCG VACCINATION; FEMALE-MALE
   MORTALITY; MEASLES VACCINATION; INFLUENZA VACCINE; HOSPITALIZATION;
   INFECTION; SURVIVAL; DISEASE; IMPACT
AB The textbook view of vaccination is that it functions to induce immune memory of the specific pathogen components of the vaccine, leading to a quantitatively and qualitatively better response if the host is exposed to infection with the same pathogen. However, evidence accumulated over the past few decades increasingly suggests that vaccines can also have non-specific effects on unrelated infections and diseases, with important implications for childhood mortality particularly in low-income settings. Furthermore, many of these non-specific effects, as well as the pathogen-specific effects, of vaccines show differences between the sexes. Here, members of the Optimmunize consortium discuss the evidence for and potential mechanisms of non-specific and sex-differential effects of vaccines, as well as their potential policy implications. Given that the non-specific effects of some vaccines are now being tested for their ability to protect against COVID-19, the authors also comment on the broader implications of these trials.
   The contributors Peter Aaby was trained as an anthropologist but has built a large health surveillance system in Guinea-Bissau since 1978, focusing on the high levels of child mortality there. Crowding and intensive exposure to measles were key determinants of child mortality. This led to vaccine research and the discovery of the non-specific effects of measles vaccine. Christine Stabell Benn is a professor in global health at the University of Southern Denmark. She conducts epidemiological and immunological studies of vaccines and vitamin A, with a focus on their real-life effects on overall health in Africa and Denmark. She formulated the hypothesis that these health interventions with immunomodulatory effects interact, often in a sex-differential manner. Katie L. Flanagan is Director of Infectious Diseases for north/north-west Tasmania, an adjunct professor at the University of Tasmania and RMIT University and an adjunct associate professor at Monash University. She is Honorary Secretary of the Australasian Society for Infectious Diseases (ASID), Chair of the ASID Vaccination Special Interest Group and a member of the Australian Technical Advisory Group on Immunisation. Her current research focuses on using systems vaccinology to study the sex-differential and non-targeted effects of vaccines. Sabra L. Klein is a professor of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. She is an expert on sex and gender differences in immune responses and susceptibility to infection. She is the immediate past president of the Organization for the Study of Sex Differences, a principal investigator of the Johns Hopkins Specialized Center for Research Excellence in sex and age differences in immunity to influenza and a co-director of the Johns Hopkins Center for Women's Health, Sex, and Gender Research. Tobias R. Kollmann is a paediatric infectious disease clinician and systems vaccinologist at Telethon Kids Institute and Perth Children's Hospital in Perth, Australia. His expertise centres on newborn infectious diseases, immune ontogeny and early-life vaccine responses, using cutting-edge technology and analytics to extract the most information out of the typically small biological samples obtainable in early life. David J. Lynn is Director of the Computational and Systems Biology Program and an EMBL Australia group leader at the South Australian Health and Medical Research Institute. He is also a professor at the Flinders University College of Medicine and Public Health. He leads a research programme in systems immunology, investigating how pathogenic and commensal microorganisms modulate the immune system in different contexts, including vaccination. Frank Shann worked as a paediatrician in Papua New Guinea and then for 20 years was Director of Intensive Care at the Royal Children's Hospital in Melbourne, Australia. He is a professorial fellow in the Department of Paediatrics, University of Melbourne, engaged in research on the non-specific effects of vaccines.
   In this Viewpoint article, members of the Optimmunize consortium discuss the evidence for non-specific and sex-differential effects of vaccines and how this information might inform vaccine design and policy, including in relation to the COVID-19 pandemic.
C1 [Aaby, Peter] Bandim Hlth Project, Bissau, Guinea Bissau.
   [Benn, Christine Stabell] Odense Univ Hosp, Bandim Hlth Project, Dept Clin Res, OPEN, Odense, Denmark.
   [Benn, Christine Stabell] Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark.
   [Flanagan, Katie L.] Univ Tasmania, Hobart, Tas, Australia.
   [Flanagan, Katie L.] RMIT Univ, Melbourne, Vic, Australia.
   [Flanagan, Katie L.] Monash Univ, Melbourne, Vic, Australia.
   [Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
   [Kollmann, Tobias R.] Telethon Kids Inst, Perth, WA, Australia.
   [Lynn, David J.] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Lynn, David J.] Flinders Univ S Australia, Adelaide, SA, Australia.
   [Shann, Frank] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
RP Aaby, P (corresponding author), Bandim Hlth Project, Bissau, Guinea Bissau.; Benn, CS (corresponding author), Odense Univ Hosp, Bandim Hlth Project, Dept Clin Res, OPEN, Odense, Denmark.; Benn, CS (corresponding author), Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark.; Flanagan, KL (corresponding author), Univ Tasmania, Hobart, Tas, Australia.; Flanagan, KL (corresponding author), RMIT Univ, Melbourne, Vic, Australia.; Flanagan, KL (corresponding author), Monash Univ, Melbourne, Vic, Australia.; Klein, SL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.; Kollmann, TR (corresponding author), Telethon Kids Inst, Perth, WA, Australia.; Lynn, DJ (corresponding author), South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.; Lynn, DJ (corresponding author), Flinders Univ S Australia, Adelaide, SA, Australia.; Shann, F (corresponding author), Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
EM p.aaby@bandim.org; cbenn@health.sdu.dk; katie.flanagan@ths.tas.gov.au;
   sklein2@jhu.edu; tkollm@mac.com; david.lynn@sahmri.com;
   fshann@unimelb.edu.au
OI Lynn, David/0000-0003-4664-1404; Kollmann, Tobias/0000-0003-2403-9762
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI118608] Funding Source: Medline;
   Wellcome TrustWellcome Trust Funding Source: Medline
CR Aaby P, 2019, CLIN MICROBIOL INFEC, V25, P1459, DOI 10.1016/j.cmi.2019.08.011
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2016, PEDIATR INFECT DIS J, V35, P1247, DOI 10.1097/INF.0000000000001269
   Aaby P, 2014, NAT IMMUNOL, V15, P895, DOI 10.1038/ni.2961
   Aaby P, 2014, CLIN INFECT DIS, V59, P484, DOI 10.1093/cid/ciu354
   Aaby P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000707
   Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Andersen A, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00013
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Bardenheier BH, 2017, CLIN INFECT DIS, V65, P729, DOI 10.1093/cid/cix442
   Benn C. S., LANCET INFECT DIS
   Benn CS, 2016, EBIOMEDICINE, V10, P312, DOI 10.1016/j.ebiom.2016.07.016
   Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004
   Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525
   Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115
   Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
   Flanagan KL, 2011, VACCINE, V29, P2349, DOI 10.1016/j.vaccine.2011.01.071
   FLOCH F, 1976, ANN INST PASTEUR IMM, VC127, P173
   Freyne B, 2014, ARCH DIS CHILD, V99, P182, DOI 10.1136/archdischild-2013-305655
   Gofrit ON, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224433
   Guallar-Garrido S, 2020, IMMUNOTARGETS THER, V9, P1, DOI 10.2147/ITT.S202006
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2016, MBIO, V7, DOI 10.1128/mBio.00514-16
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Kollmann TR, 2020, SCIENCE, V368, P612, DOI 10.1126/science.aaz9447
   Kuhtreiber WM, 2019, TRENDS ENDOCRIN MET, V30, P80, DOI 10.1016/j.tem.2018.11.006
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Noho-Konteh F, 2016, CLIN INFECT DIS, V63, P1213, DOI 10.1093/cid/ciw492
   Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6
   Rieckmann A, 2017, INT J EPIDEMIOL, V46, P695, DOI 10.1093/ije/dyw120
   Benitez MLR, 2019, APPL MICROBIOL BIOT, V103, P7903, DOI 10.1007/s00253-019-10057-0
   Sala G, 2020, ASS BCG VACCINATION, DOI [10.1101/2020.03.30.20048165, DOI 10.1101/2020.03.30.20048165]
   Shann Frank, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa292
   Shann F, 2013, CLIN THER, V35, P109, DOI 10.1016/j.clinthera.2013.01.007
   Shet A., 2020, DIFFERENTIAL COVID 1, DOI [10.1101/2020.04.01.20049478, DOI 10.1101/2020.04.01.20049478]
   Sorup S, 2014, JAMA-J AM MED ASSOC, V311, P826, DOI 10.1001/jama.2014.470
   Stensballe LG, 2017, ARCH DIS CHILD, V102, P224, DOI 10.1136/archdischild-2016-310760
   Uthayakumar D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02869
   Wardhana, 2011, Acta Med Indones, V43, P185
   Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2
   Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930
   Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989
   Zivkovic I, 2018, BIOLOGICALS, V52, P18, DOI 10.1016/j.biologicals.2018.01.007
   Zivkovic I, 2015, VACCINE, V33, P5546, DOI 10.1016/j.vaccine.2015.09.006
NR 51
TC 7
Z9 6
U1 16
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
PD AUG
PY 2020
VL 20
IS 8
BP 464
EP 470
DI 10.1038/s41577-020-0338-x
PG 7
WC Immunology
SC Immunology
GA MQ1WG
UT WOS:000552688200008
PM 32461674
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Antonoff, M
   Backhus, L
   Boffa, DJ
   Broderick, SR
   Brown, LM
   Carrott, P
   Clark, JM
   Cooke, D
   David, E
   Facktor, M
   Farjah, F
   Grogan, E
   Isbell, J
   Jones, DR
   Kidane, B
   Kim, AW
   Keshavjee, S
   Krantz, S
   Lui, N
   Martin, L
   Meguid, RA
   Meyerson, SL
   Mullett, T
   Nelson, H
   Odell, DD
   Phillips, JD
   Puri, V
   Rusch, V
   Shulman, L
   Varghese, TK
   Wakeam, E
   Wood, DE
AF Antonoff, Mara
   Backhus, Leah
   Boffa, Daniel J.
   Broderick, Stephen R.
   Brown, Lisa M.
   Carrott, Phillip
   Clark, James M.
   Cooke, David
   David, Elizabeth
   Facktor, Matt
   Farjah, Farhood
   Grogan, Eric
   Isbell, James
   Jones, David R.
   Kidane, Biniam
   Kim, Anthony W.
   Keshavjee, Shaf
   Krantz, Seth
   Lui, Natalie
   Martin, Linda
   Meguid, Robert A.
   Meyerson, Shari L.
   Mullett, Tim
   Nelson, Heidi
   Odell, David D.
   Phillips, Joseph D.
   Puri, Varun
   Rusch, Valerie
   Shulman, Lawrence
   Varghese, Thomas K.
   Wakeam, Elliot
   Wood, Douglas E.
CA Thoracic Surg Outcomes Res Network
TI COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A
   Consensus Statement From Thoracic Surgery Outcomes Research Network
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID BODY RADIATION-THERAPY
AB The extraordinary demands of managing the COVID-19 pandemic has disrupted the world's ability to care for patients with thoracicmalignancies. As a hospital'sCOVID-19 population increases and hospital resources are depleted, the ability to provide surgical care is progressively restricted, forcing surgeons to prioritize among their cancer populations. Representatives from multiple cancer, surgical, and research organizations have come together to provide a guide for triaging patients with thoracic malignancies as the impact of COVID-19 evolves as each hospital. (C) 2020 by The Society of Thoracic Surgeons and the American Association for Thoracic Surgery.
C1 [Boffa, Daniel J.] POB 208062, New Haven, CT 06520 USA.
RP Boffa, DJ (corresponding author), POB 208062, New Haven, CT 06520 USA.
EM daniel.boffa@yale.edu
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Cao C, 2019, J THORAC DIS, V11, P5187, DOI 10.21037/jtd.2019.12.12
   Grotenhuis BA, 2010, J GASTROINTEST SURG, V14, P476, DOI 10.1007/s11605-009-1109-y
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Khorfan R, 2020, ANN THORAC SURG, V110, P228, DOI 10.1016/j.athoracsur.2020.01.073
   Kim JY, 2012, ANN THORAC SURG, V93, P207, DOI 10.1016/j.athoracsur.2011.05.021
   Levinsky NC, 2020, J THORAC CARDIOV SUR, V159, P2555, DOI 10.1016/j.jtcvs.2019.09.169
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Rosen JE, 2016, J THORAC CARDIOV SUR, V152, P44, DOI 10.1016/j.jtcvs.2016.03.060
   Samson P, 2017, ANN THORAC SURG, V103, P1070, DOI 10.1016/j.athoracsur.2016.09.053
   Samson P, 2015, ANN THORAC SURG, V99, P1906, DOI 10.1016/j.athoracsur.2015.02.022
   Semenkovich TR, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.31
NR 15
TC 16
Z9 16
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD AUG
PY 2020
VL 110
IS 2
BP 692
EP 696
DI 10.1016/j.athoracsur.2020.03.005
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA MR8NP
UT WOS:000553847900058
PM 32278755
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lu, XY
   Wang, LJ
   Sakthivel, SK
   Whitaker, B
   Murray, J
   Kamili, S
   Lynch, B
   Malapati, L
   Burke, SA
   Harcourt, J
   Tamin, A
   Thornburg, NJ
   Villanueva, JM
   Lindstrom, S
AF Lu, Xiaoyan
   Wang, Lijuan
   Sakthivel, Senthilkumar K.
   Whitaker, Brett
   Murray, Janna
   Kamili, Shifaq
   Lynch, Brian
   Malapati, Lakshmi
   Burke, Stephen A.
   Harcourt, Jennifer
   Tamin, Azaibi
   Thornburg, Natalie J.
   Villanueva, Julie M.
   Lindstrom, Stephen
TI US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe
   Acute Respiratory Syndrome Coronavirus 2
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID SARS CORONAVIRUS; PNEUMONIA; ASSAY
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent associated with coronavirus disease, which emerged in late 2019. In response, we developed a diagnostic panel consisting of 3 real-time reverse transcription PCR assays targeting the nucleocapsid gene and evaluated use of these assays for detecting SARS-CoV-2 infection. All assays demonstrated a linear dynamic range of 8 orders of magnitude and an analytical limit of detection of 5 copies/reaction of quantified RNA transcripts and 1 x 10(-1.5) 50% tissue culture infectious dose/mL of cell-cultured SARS-CoV-2. All assays performed comparably with nasopharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. We obtained no false-positive amplifications with other human coronaviruses or common respiratory pathogens. Results from all 3 assays were highly correlated during clinical specimen testing. On February 4, 2020, the Food and Drug Administration issued an Emergency Use Authorization to enable emergency use of this panel.
C1 [Lu, Xiaoyan; Whitaker, Brett; Burke, Stephen A.; Harcourt, Jennifer; Tamin, Azaibi; Thornburg, Natalie J.; Villanueva, Julie M.; Lindstrom, Stephen] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30329 USA.
   [Wang, Lijuan; Kamili, Shifaq] Synergy Amer Inc, Atlanta, GA USA.
   [Sakthivel, Senthilkumar K.; Murray, Janna; Lynch, Brian] Eagle Contracting, Atlanta, GA USA.
   [Malapati, Lakshmi] Leidos, Atlanta, GA USA.
   [Burke, Stephen A.] Battelle Mem Inst, Atlanta, GA USA.
RP Lindstrom, S (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30329 USA.
EM sq15@cdc.gov
CR Al-Abdely HM, 2019, EMERG INFECT DIS, V25, P753, DOI 10.3201/eid2504.181595
   [Anonymous], PNEUM UNK CAUS CHIN
   Centers for Disease Control and Prevention, CDC 2019 NOV COR 201
   Centers for Disease Control and Prevention, HLTH AL NETW UPD INT
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan KH, 2004, EMERG INFECT DIS, V10, P294, DOI 10.3201/eid1002.030610
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   COVID 19 Investigation, 2020, NAT MED, V26, P861, DOI 10.1038/s41591-020-0877-5
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Grant PR, 2003, NEW ENGL J MED, V349, P2468, DOI 10.1056/NEJM200312183492522
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu XY, 2014, J CLIN MICROBIOL, V52, P67, DOI 10.1128/JCM.02533-13
   Moreno JL, 2008, J VIROL, V82, P3882, DOI 10.1128/JVI.02622-07
   Nalla A.K., 2020, J CLIN MICROBIOL
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, COR DIS 2019 COVID 1
   Zhang Y- Z., 2020, VIROLOGICAL
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 24
TC 18
Z9 18
U1 2
U2 3
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2020
VL 26
IS 8
BP 1654
EP 1665
DI 10.3201/eid2608.201246
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MO0MZ
UT WOS:000551232700002
PM 32396505
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Szabados, B
   Abu-Ghanem, Y
   Grant, M
   Choy, J
   Bex, A
   Powles, T
AF Szabados, Bernadett
   Abu-Ghanem, Yasmin
   Grant, Michael
   Choy, Julia
   Bex, Axel
   Powles, Thomas
TI Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer
   Patients Treated with Immune Checkpoint Inhibitors
SO EUROPEAN UROLOGY
LA English
DT Article
DE COVID-19; Immune checkpoint inhibition; Cancer
AB Preliminary data suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with higher mortality among cancer patients, particularly in those on systemic therapy. It is unclear whether this applies to patients receiving immune checkpoint inhibitors (ICIs). In this case series, 74 patients from a single institution with genitourinary (GU) cancer on ICI were followed up during a 12-wk period. During this period, 11 patients (15%) developed symptoms consistent with coronavirus disease 2019 (COVID-19) and four (5%) tested positive. Two patients had metastatic urothelial cancer (treated with atezolizumab) and two had metastatic renal cancer (treated with ipilimumab and nivolumab). All had additional risk factors associated with COVID-19 mortality and two received steroids within 1 mo of infection. Two patients developed symptoms requiring hospitalisation. All four are alive 32-45 d after their first symptoms and 28-38 d after testing positive. These patients all had multiple risk factors associated with severe COVID-19. These data suggest that the higher risk of COVID-19 death associated with systemic therapy in cancer may not apply to patients on ICIs. Assessment of COVID-19 severity in these patients can be complicated by the underlying cancer and its treatment. (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Szabados, Bernadett; Grant, Michael; Choy, Julia; Powles, Thomas] Queen Mary Univ London, Barts Canc Ctr, London, England.
   [Abu-Ghanem, Yasmin; Grant, Michael; Bex, Axel] UCL Div Surg & Intervent Sci, Royal Free London NHS Fdn Trust, Ctr Kidney Canc, London, England.
RP Powles, T (corresponding author), Queen Mary Univ London, Barts Canc Ctr, Ctr Expt Canc Med, Charterhouse Sq, London EC1 M 6BQ, England.
EM t.powles@qmul.ac.uk
CR Assi T, 2019, IMMUNOTHERAPY-UK, V11, P591, DOI 10.2217/imt-2018-0169
   Gillessen S, 2020, EUR UROL, V77, P667, DOI 10.1016/j.eururo.2020.03.026
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   National Institute for Health and Care Excellence, 2020, INT TREATM CHANG OPT
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Su Q, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00108
   UK Government, 2020, COR COVID 19 GUID SU
   Yu JY, 2020, J BIOMED OPT, V25, DOI 10.1117/1.JBO.25.5.056501
   Zhang L, 2020, ANN ONCOLO, V20, P1, DOI DOI 10.1002/tcr.202000041
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 4
Z9 4
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD AUG
PY 2020
VL 78
IS 2
BP 276
EP 280
DI 10.1016/j.eururo.2020.05.024
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA MO1FG
UT WOS:000551280300041
PM 32534910
OA Green Published
DA 2021-01-01
ER

PT J
AU Lavi, E
   Cong, L
AF Lavi, Ehud
   Cong, Lin
TI Type I astrocytes and microglia induce a cytokine response in an
   encephalitic murine coronavirus infection
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Coronavirus; Mouse hepatitis virus; Cytokines; Astrocytes; Microglia;
   COVID-19
ID SPIKE GLYCOPROTEIN GENE; DEMYELINATION; VIRUS; MUTATIONS; STORM; MICE
AB The pathogenesis of viral infections involves an immune response by cytokines, causing a deleterious effect on organ function, in addition to tissue destruction due to viral replication. Clinical symptoms and laboratory findings of the human coronavirus disease COVID-19, caused by the novel coronavirus SARS CoV-2, indicate cytokine involvement. Our laboratory showed that an experimental murine coronavirus (MHV-A59) can be transmitted into the brain by intranasal or intracerebral exposure and that neurovirulence is mediated by cytokine secretion. In this study we investigated which cells in the brain produce cytokines, thus functioning as the braids innate immune system. Using tissue cultures of microglia, and clonal populations of astrocytes, we found that microglia and type I astrocytes (but not types II and III), produced pro-inflammatory cytokines in response to MHV-A59 infection. A molecularly closely related, non-encephalitic strain of the virus (MHV-2) caused in vitro infection, but without cytokine induction. Furthermore, immunofluorescence and immunohistochemistry revealed that type I astrocytes and microglia have perivascular foot processes necessary for the formation of the perivascular glymphatic system, the anatomical site of the braids innate immune system. Cytokine secretion by type I astrocytes and microglia, as part of the braids glymphatic and innate immune system, contributes to the pathogenesis of an encephalitic coronavirus infection, and indicates the rationale for anti-cytokine therapies for COVID-19.
C1 [Lavi, Ehud] Weill Cornell Med, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA.
   New York Presbyterian Hosp, New York, NY 10065 USA.
RP Lavi, E (corresponding author), Weill Cornell Med, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA.
EM ehl2005@med.cornell.edu
CR ALLIOT F, 1984, BRAIN RES, V306, P283, DOI 10.1016/0006-8993(84)90377-9
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Bevrouti R., 2020, J NEUROL NEUROSUR PS, DOI [10.1136/jnnp-2020-323586, DOI 10.1136/JNNP-2020-323586.APRIL]
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Das Sarma J, 2000, J VIROL, V74, P9206, DOI 10.1128/JVI.74.19.9206-9213.2000
   Das Sarma J, 2001, J NEUROVIROL, V7, P432
   Das Sarma J, 2001, EXP MOL PATHOL, V71, P1
   Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005
   ffrench-Costant C, 1986, NATURE, V323, P335
   Fu L, 2004, J NEUROVIROL, V10, P41, DOI 10.1080/13550280490262229
   Fu Li, 2005, P849, DOI 10.1007/0-387-25518-4_49
   Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LAVI E, 1988, LAB INVEST, V58, P31
   LAVI E, 1984, J VIROL, V51, P563, DOI 10.1128/JVI.51.2.563-566.1984
   Lavi E, 1999, J NEUROPATH EXP NEUR, V58, P1197, DOI 10.1097/00005072-199912000-00001
   LAVI E, 1984, NEUROLOGY, V34, P597, DOI 10.1212/WNL.34.5.597
   Lavi E., 1989, DEV MED VIROLOGY KLU, P101
   Li Y, 2004, J VIROL, V78, P3398, DOI 10.1128/JVI.78.7.3398-3406.2004
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Negi N, 2018, INT REV IMMUNOL, V37, P57, DOI 10.1080/08830185.2017.1357719
   Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Peiris J.S.M., 2003, LANCET, V1361, P1
   Seidman KJN, 1997, BRAIN RES, V753, P18, DOI 10.1016/S0006-8993(96)01481-3
   SUZUMURA A, 1986, SCIENCE, V232, P991, DOI 10.1126/science.3010460
   Toscano G., 2020, NEJM
   Wang X., 2020, INT J INFECT DIS
NR 30
TC 5
Z9 5
U1 3
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD AUG
PY 2020
VL 115
AR 104474
DI 10.1016/j.yexmp.2020.104474
PG 6
WC Pathology
SC Pathology
GA MO4LR
UT WOS:000551499900034
PM 32454103
OA Green Published
DA 2021-01-01
ER

PT J
AU Braun, P
   Haffner, S
   Woodcock, BG
AF Braun, Peter
   Haffner, Steffen
   Woodcock, Barry G.
TI COVID-19 pandemic predictions using the modified Bateman SIZ model and
   observational data for Heidelberg, Germany: Effect of vaccination with a
   SARS-CoV-2 vaccine, coronavirus testing and application of the
   Corona-Warn-App
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE COVID-19 disease; prediction scenarios; SIZ model; SIR model; modified
   Bateman model; interventional measures; SARS-CoV-2 vaccine; testing for
   coronavirus; Corona-Warn-App; lock-down; Heidelberg
AB Aims of the study: Published data show that the current progression of the COVID-19 pandemic in Heidelberg, Germany, despite the current lockdown, could continue into 2021 and become more severe. We have used the modified Bateman SIZ algorithm to predict the effects of interventional measures to control the COVID-19 pandemic. Materials and methods: Model parameters, e.g., doubling time and rate of decrease in the number of infectious persons were obtained from published reports. Predictions were made for the status quo on June 1, 2020, and for interventional measures obtained for 4 scenarios. These included vaccination of the whole population using a SARS-CoV-2 vaccine having an efficacy of 50% and 100%, mass-testing for COVID-19 coronavirus and application of the Corona-Warn-App. Results: The principle findings were 1) without new measures to control the pandemic, the daily number of infectious persons could reach a peak of > 4,500 daily within 18 months when > 67,000 persons would have been infected. This could be prevented by using a vaccine with 50% efficacy which was almost equally effective as a vaccine with 100% efficacy. Application of the Corona-Warn-App was the most effective method and more effective than testing for COVID-19. The methodology used has been described in detail to enable other researchers to apply the modified Bateman SIZ model to obtain predictions for COVID-19 outbreaks in other regions. Application of the model has been verified by independent investigators using different commercial software packages. Conclusion: The modified Bateman SIZ model has been verified and used to predict the course of the COVID-19 pandemic in Heidelberg. Lockdown measures alone are insufficient to control the pandemic during 2021. Vaccination, diagnostic tests, and use of the Corona-Warn-App with quarantine could successfully control the spread of the coronavirus infection in the community. The Corona-Warn-App applied correctly may be the most effective. The model showed that vaccination with 50% efficacy is almost as effective as vaccination with 100% efficacy.
C1 [Braun, Peter; Woodcock, Barry G.] Arbeitsgemeinschaft Immunoglobuline Anticanc Anti, Rodermark, Germany.
   [Haffner, Steffen] Paul Ehrlich Inst, Langen, Germany.
RP Braun, P (corresponding author), AGIGAAT, POB 200232, D-63308 Rodermark, Germany.
EM braun-roedermark@t-online.de
CR Bateman H, 1910, P CAMB PHILOS SOC, V15, P423
   Karlsen T, 2020, ABO BLOOD GROUP LOCU
   La<ss>mann A., CORONA VIRUS VORHERS
   Merle U, 2020, INT J CLIN PHARM TH, V58, P366, DOI 10.5414/CP203824
   Woodcock BG, 2020, INT J CLIN PHARM TH, V58, P363, DOI 10.5414/CP203820
NR 5
TC 4
Z9 4
U1 10
U2 10
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-1965
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD AUG
PY 2020
VL 58
IS 8
BP 417
EP 425
DI 10.5414/CP203846
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MO2CM
UT WOS:000551340800002
PM 32646540
DA 2021-01-01
ER

PT J
AU Chao, JY
   Derespina, KR
   Herold, BC
   Goldman, DL
   Aldrich, M
   Weingarten, J
   Ushay, HM
   Cabana, MD
   Medar, SS
AF Chao, Jerry Y.
   Derespina, Kim R.
   Herold, Betsy C.
   Goldman, David L.
   Aldrich, Margaret
   Weingarten, Jacqueline
   Ushay, Henry M.
   Cabana, Michael D.
   Medar, Shivanand S.
TI Clinical Characteristics and Outcomes of Hospitalized and Critically Ill
   Children and Adolescents with Coronavirus Disease 2019 at a Tertiary
   Care Medical Center in New York City
SO JOURNAL OF PEDIATRICS
LA English
DT Article
AB Objective To describe the clinical profiles and risk factors for critical illness in hospitalized children and adolescents with coronavirus disease 2019 (COVID-19).
   Study design Children 1 month to 21 years of age with COVID-19 from a single tertiary care children's hospital between March 15 and April 13, 2020 were included. Demographic and clinical data were collected.
   Results In total, 67 children tested positive for COVID-19; 21 (31.3%) were managed as outpatients. Of 46 admitted patients, 33 (72%) were admitted to the general pediatric medical unit and 13 (28%) to the pediatric intensive care unit (PICU). Obesity and asthma were highly prevalent but not significantly associated with PICU admission (P =.99). Admission to the PICU was significantly associated with higher C-reactive protein, procalcitonin, and pro-B type natriuretic peptide levels and platelet counts (P <.05 for all). Patients in the PICU were more likely to require high-flow nasal cannula (P =.0001) and were more likely to have received Remdesivir through compassionate release (P <.05). Severe sepsis and septic shock syndromes were observed in 7 (53.8%) patients in the PICU. Acute respiratory distress syndrome was observed in 10 (77%) PICU patients, 6 of whom (46.2%) required invasive mechanical ventilation for a median of 9 days. Of the 13 patients in the PICU, 8 (61.5%) were discharged home, and 4 (30.7%) patients remain hospitalized on ventilatory support at day 14. One patient died after withdrawal of life-sustaining therapy because of metastatic cancer.
   Conclusions We describe a higher than previously recognized rate of severe disease requiring PICU admission in pediatric patients admitted to the hospital with COVID-19.
C1 [Chao, Jerry Y.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Anesthesiol, Bronx, NY 10467 USA.
   [Derespina, Kim R.; Weingarten, Jacqueline; Ushay, Henry M.; Medar, Shivanand S.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Crit Care Med, Bronx, NY 10467 USA.
   [Herold, Betsy C.; Goldman, David L.; Aldrich, Margaret] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Infect Dis, Bronx, NY 10467 USA.
   [Cabana, Michael D.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Gen Pediat, Bronx, NY 10467 USA.
   [Medar, Shivanand S.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Cardiol, Bronx, NY 10467 USA.
RP Medar, SS (corresponding author), Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Crit Care Med & Cardiol, 3411 Wayne Ave,Suite 808B, Bronx, NY 10467 USA.
EM shivanandmedar@gmail.com
RI Medar, Shivanand S/AAW-2293-2020
FU NIH/National Center for Advancing Translational Science (NCATS)
   Einstein-Montefiore CTSAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR001073]; Department of
   Anesthesiology, Albert Einstein College of Medicine, Montefiore Medical
   Center, Children's Hospital at Montefiore; Department of Pediatrics,
   Albert Einstein College of Medicine, Montefiore Medical Center,
   Children's Hospital at Montefiore
FX Supported by NIH/National Center for Advancing Translational Science
   (NCATS) Einstein-Montefiore CTSA (UL1TR001073) and the Departments of
   Anesthesiology and Pediatrics, Albert Einstein College of Medicine,
   Montefiore Medical Center, Children's Hospital at Montefiore. M.C.
   serves on the Editorial Board of The Journal of Pediatrics and is a
   member of the United States Preventive Services Task Force (USPSTF).
   This manuscript does not necessarily represent the views of the USPSTF.
   The other authors declare no conflicts of interest.
CR Andrist E, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0748
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI [10.1001/jama.2020.4326, DOI 10.1001/JAMA.2020.5394]
   BARWISE A, 2020, PEDIATRICS, V48
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grunwell JR, 2018, PEDIATR CRIT CARE ME, V19, pE585, DOI 10.1097/PCC.0000000000001695
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keenan HT, 2002, PEDIATRICS, V109, P40, DOI 10.1542/peds.109.1.40
   Keet CA, 2017, J ALLERGY CLIN IMMUN, V140, P822, DOI 10.1016/j.jaci.2017.01.036
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Lee H, 2009, POPUL RES POLICY REV, V28, P505, DOI 10.1007/s11113-008-9115-4
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weiss SL, 2020, PEDIATR CRIT CARE ME, V21, pE52, DOI 10.1097/PCC.0000000000002198
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 23
TC 38
Z9 38
U1 10
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD AUG
PY 2020
VL 223
BP 14
EP 19
DI 10.1016/j.jpeds.2020.05.006
PG 6
WC Pediatrics
SC Pediatrics
GA MO1GM
UT WOS:000551283500005
PM 32407719
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Antonoff, M
   Backhus, L
   Boffa, DJ
   Broderick, SR
   Brown, LM
   Carrott, P
   Clark, JM
   Cooke, D
   David, E
   Facktor, M
   Farjah, F
   Grogan, E
   Isbell, J
   Jones, DR
   Kidane, B
   Kim, AW
   Keshavjee, S
   Krantz, S
   Lui, N
   Martin, L
   Meguid, RA
   Meyerson, SL
   Mullett, T
   Nelson, H
   Odell, DD
   Phillips, JD
   Puri, V
   Rusch, V
   Shulman, L
   Varghese, TK
   Wakeam, E
   Wood, DE
AF Antonoff, Mara
   Backhus, Leah
   Boffa, Daniel J.
   Broderick, Stephen R.
   Brown, Lisa M.
   Carrott, Phillip
   Clark, James M.
   Cooke, David
   David, Elizabeth
   Facktor, Matt
   Farjah, Farhood
   Grogan, Eric
   Isbell, James
   Jones, David R.
   Kidane, Biniam
   Kim, Anthony W.
   Keshavjee, Shaf
   Krantz, Seth
   Lui, Natalie
   Martin, Linda
   Meguid, Robert A.
   Meyerson, Shari L.
   Mullett, Tim
   Nelson, Heidi
   Odell, David D.
   Phillips, Joseph D.
   Puri, Varun
   Rusch, Valerie
   Shulman, Lawrence
   Varghese, Thomas K.
   Wakeam, Elliot
   Wood, Douglas E.
CA Thoracic Surg Outcomes Res Network
TI COVID-19 guidance for triage of operations for thoracic malignancies: A
   consensus statement from Thoracic Surgery Outcomes Research Network
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID BODY RADIATION-THERAPY
AB The extraordinary demands of managing the COVID-19 pandemic has disrupted the world's ability to care for patients with thoracic malignancies. As a hospital ' s COVID-19 population increases and hospital resources are depleted, the ability to provide surgical care is progressively restricted, forcing surgeons to prioritize among their cancer populations. Representatives from multiple cancer, surgical, and research organizations have come together to provide a guide for triaging patients with thoracic malignancies as the impact of COVID-19 evolves as each hospital.
C1 [Boffa, Daniel J.] POB 208062, New Haven, CT 06520 USA.
RP Boffa, DJ (corresponding author), POB 208062, New Haven, CT 06520 USA.
EM daniel.boffa@yale.edu
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Cao C, 2019, J THORAC DIS, V11, P5187, DOI 10.21037/jtd.2019.12.12
   Grotenhuis BA, 2010, J GASTROINTEST SURG, V14, P476, DOI 10.1007/s11605-009-1109-y
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Khorfan R, 2020, ANN THORAC SURG, V110, P228, DOI 10.1016/j.athoracsur.2020.01.073
   Kim JY, 2012, ANN THORAC SURG, V93, P207, DOI 10.1016/j.athoracsur.2011.05.021
   Levinsky NC, 2020, J THORAC CARDIOV SUR, V159, P2555, DOI 10.1016/j.jtcvs.2019.09.169
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Rosen JE, 2016, J THORAC CARDIOV SUR, V152, P44, DOI 10.1016/j.jtcvs.2016.03.060
   Samson P, 2017, ANN THORAC SURG, V103, P1070, DOI 10.1016/j.athoracsur.2016.09.053
   Samson P, 2015, ANN THORAC SURG, V99, P1906, DOI 10.1016/j.athoracsur.2015.02.022
   Semenkovich TR, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.31
NR 15
TC 5
Z9 5
U1 2
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD AUG
PY 2020
VL 160
IS 2
BP 601
EP 605
DI 10.1016/j.jtcvs.2020.03.061
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA MN3QB
UT WOS:000550758000048
PM 32689703
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chakhtoura, M
   Napoli, N
   Fuleihan, GE
AF Chakhtoura, M.
   Napoli, N.
   Fuleihan, G. El Hajj
TI Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID SEASONAL INFLUENZA-A; D SUPPLEMENTATION; PREVENTION; VACCINE
C1 [Chakhtoura, M.; Fuleihan, G. El Hajj] Amer Univ Beirut, Med Ctr, Calcium Metab & Osteoporosis Program, POB 113-6044-C8, Beirut, Lebanon.
   [Chakhtoura, M.; Fuleihan, G. El Hajj] Amer Univ Beirut, Med Ctr, Scholars Hlth Res Program SHARP, Beirut, Lebanon.
   [Napoli, N.] Univ Campus Biomed Roma, Unit Endocrinol & Diabet, Dept Med, Via Alvaro di Portillo 21, I-00128 Rome, Italy.
   [Napoli, N.] Washington Univ, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
RP Chakhtoura, M (corresponding author), Amer Univ Beirut, Med Ctr, Calcium Metab & Osteoporosis Program, POB 113-6044-C8, Beirut, Lebanon.
EM mc39@aub.edu.lb
CR Aglipay M, 2017, JAMA-J AM MED ASSOC, V318, P245, DOI 10.1001/jama.2017.8708
   Bassatne A, 2019, METABOLISM, V92, P193, DOI 10.1016/j.metabol.2018.12.010
   BELL NH, 1985, J CLIN INVEST, V76, P1, DOI 10.1172/JCI111930
   Bischoff-Ferrari HA, 2016, JAMA INTERN MED, V176, P175, DOI 10.1001/jamainternmed.2015.7148
   Bouillon R, 2019, ENDOCR REV, V40, P1109, DOI 10.1210/er.2018-00126
   Calton EK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141770
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chakhtoura M, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115112
   D'Avolio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051359
   Darling A. L., 2020, VITAMIN D STATUS BOD, DOI [10.1101/2020.04.29.20084277, DOI 10.1101/2020.04.29.20084277]
   De Smet D, 2020, VITAMIN D DEFICIENCY, DOI [DOI 10.1101/2020.05.01.20079376, 10.1101/2020.05.01.20079376]
   Ebadi M, 2020, EUR J CLIN NUTR, V74, P856, DOI 10.1038/s41430-020-0661-0
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Fuleihan GE, 2015, J BONE MINER RES, V30, P1119, DOI 10.1002/jbmr.2536
   Garg M, 2020, ALIMENT PHARM THER, V51, P1438, DOI 10.1111/apt.15796
   Ginde AA, 2019, NEW ENGL J MED, V381, P2529, DOI 10.1056/NEJMoa1911124
   Goncalves-Mendes N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00065
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Greiller CL, 2015, NUTRIENTS, V7, P4240, DOI 10.3390/nu7064240
   Gruber-Bzura BM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082419
   Pham H, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16173020
   Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840
   Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Kriesel JD, 1999, VACCINE, V17, P1883, DOI 10.1016/S0264-410X(98)00476-9
   Langlois PL, 2018, CLIN NUTR, V37, P1238, DOI 10.1016/j.clnu.2017.05.006
   Loeb M, 2019, INFLUENZA OTHER RESP, V13, P176, DOI 10.1111/irv.12615
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Pereira-Santos M, 2015, OBES REV, V16, P341, DOI 10.1111/obr.12239
   Principi N, 2013, HUM VACC IMMUNOTHER, V9, P969, DOI 10.4161/hv.23540
   Putzu A, 2017, J CRIT CARE, V38, P109, DOI 10.1016/j.jcrc.2016.10.029
   Rafiq S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010059
   Rhodes JM, 2020, ALIMENT PHARM THER, V51, P1434, DOI 10.1111/apt.15777
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704
   Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sundaram ME, 2012, ADV NUTR, V3, P517, DOI 10.3945/an.112.002162
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Urashima M, 2014, FOOD FUNCT, V5, P2365, DOI [10.1039/c4fo00371c, 10.1039/C4FO00371C]
   Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094
   Yamshchikov AV, 2009, ENDOCR PRACT, V15, P438, DOI 10.4158/EP09101.ORR
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhou J, 2018, PEDIATR INFECT DIS J, V37, P749, DOI 10.1097/INF.0000000000001890
   ZHU F, 2020, J MED VIROL, DOI DOI 10.1002/JMV.25822
NR 45
TC 5
Z9 5
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD AUG
PY 2020
VL 109
AR 154276
DI 10.1016/j.metabol.2020.154276
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MO3AE
UT WOS:000551402400006
PM 32470350
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Soliz, J
   Schneider-Gasser, EM
   Arias-Reyes, C
   Aliaga-Raduan, F
   Poma-Machicao, L
   Zubieta-Calleja, G
   Furuya, WI
   Trevizan-Bau, P
   Dhingra, RR
   Dutschmann, M
AF Soliz, Jorge
   Schneider-Gasser, Edith M.
   Arias-Reyes, Christian
   Aliaga-Raduan, Fernanda
   Poma-Machicao, Liliana
   Zubieta-Calleja, Gustavo
   Furuya, Werner, I
   Trevizan-Bau, Pedro
   Dhingra, Rishi R.
   Dutschmann, Mathias
TI Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant
   treatment of COVID-19?
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE Silent hypoxemia; High-altitude hypoxia; Hypoxic acclimatization; Acute
   respiratory distress; Respiratory system
ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; RESPIRATORY SYNDROME CORONAVIRUS;
   ACUTE MOUNTAIN-SICKNESS; HIGH-ALTITUDE ILLNESS; ACUTE LUNG INJURY;
   CAROTID-BODY; FUNCTIONAL ADAPTATION; IMPROVED SURVIVAL; REFLEX CONTROL;
   POTENTIAL ROLE
AB A very recent epidemiological study provides preliminary evidence that living in habitats located at 2500 m above sea level (mass) might protect from the development of severe respiratory symptoms following infection with the novel SARS-CoV-2 virus. This epidemiological finding raises the question of whether physiological mechanisms underlying the acclimatization to high altitude identifies therapeutic targets for the effective treatment of severe acute respiratory syndrome pivotal to the reduction of global mortality during the COVID-19 pandemic. This article compares the symptoms of acute mountain sickness (AMS) with those of SARS-CoV-2 infection and explores overlapping patho-physiological mechanisms of the respiratory system including impaired oxygen transport, pulmonary gas exchange and brainstem circuits controlling respiration. In this context, we also discuss the potential impact of SARS-CoV-2 infection on oxygen sensing in the carotid body. Finally, since erythropoietin (EPO) is an effective prophylactic treatment for AMS, this article reviews the potential benefits of implementing FDA-approved erythropoietin-based (EPO) drug therapies to counteract a variety of acute respiratory and non-respiratory (e.g. excessive inflammation of vascular beds) symptoms of SARS-CoV-2 infection.
C1 [Soliz, Jorge; Arias-Reyes, Christian; Aliaga-Raduan, Fernanda; Poma-Machicao, Liliana] Univ Laval, Inst Univ Cardiol & Pneumol Quebec IUCPQ, Fac Med, Quebec City, PQ, Canada.
   [Schneider-Gasser, Edith M.] Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Winterthurerstr 260, Zurich, Switzerland.
   [Soliz, Jorge; Zubieta-Calleja, Gustavo] High Altitude Pulm & Pathol Inst IPPA, La Paz, Bolivia.
   [Furuya, Werner, I; Trevizan-Bau, Pedro; Dhingra, Rishi R.; Dutschmann, Mathias] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
   [Furuya, Werner, I; Trevizan-Bau, Pedro; Dutschmann, Mathias] Univ Melbourne, Florey Dept Neurosci, Melbourne, Vic, Australia.
RP Soliz, J (corresponding author), Inst Univ Cardiol Pneumol Quebec IUCPQ, 2725 Chemin St Foy, Quebec City, PQ G1V 4G5, Canada.
EM jorge.soliz@criucpq.ulaval.ca
OI Dhingra, Rishi/0000-0002-4684-5215; Dutschmann,
   Mathias/0000-0002-0692-746X; Furuya, Werner/0000-0002-7244-2313
FU "Fonds de recherche du Quebec-Sante" (FRQ-S) [FQ121919]; IUCPQ
   Foundation; NHMRCNational Health and Medical Research Council of
   Australia [APP1165529]
FX Jorge Soliz is supported by the "Fonds de recherche du Quebec-Sante"
   (FRQ-S; FQ121919) and the IUCPQ Foundation. Mathias Dutschmann is
   currently supported by a NHMRC project grant (APP1165529).
CR Alnaeeli Mawadda, 2012, Anat Res Int, V2012, P953264, DOI 10.1155/2012/953264
   Arias-Reyes C, 2020, RESP PHYSIOL NEUROBI, V277, DOI 10.1016/j.resp.2020.103443
   Ballot O., 1985, J APPL PHYSIOL
   Banks WA, 2004, EUR J PHARMACOL, V505, P93, DOI 10.1016/j.ejphar.2004.10.035
   Basnyat B, 2003, LANCET, V361, P1967, DOI 10.1016/S0140-6736(03)13591-X
   Beall CM, 1998, AM J PHYS ANTHROPOL, V106, P385, DOI 10.1002/(SICI)1096-8644(199807)106:3<385::AID-AJPA10>3.0.CO;2-X
   Beall CM, 2007, P NATL ACAD SCI USA, V104, P8655, DOI 10.1073/pnas.0701985104
   Beleslin-Cokic BB, 2004, BLOOD, V104, P2073, DOI 10.1182/blood-2004-02-0744
   Beleslin-Cokic BB, 2011, CYTOKINE, V54, P129, DOI 10.1016/j.cyto.2011.01.015
   Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007
   Bhatraju PK, 2020, N ENGL J MED
   Bikdeli B., 2020, J AM COLL CARDIOL
   BIRCHER HP, 1994, J WILDERNESS MED, V5, P302, DOI 10.1580/0953-9859-5.3.302
   Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101
   BRUNNER MJ, 1982, CIRC RES, V51, P624, DOI 10.1161/01.RES.51.5.624
   BUEMI M, 1993, NEPHRON, V64, P333, DOI 10.1159/000187347
   Caucio L, 2008, J TRAUMA, V65, P297
   Chawla S, 2014, RESONANCE, V19, P538, DOI 10.1007/s12045-014-0057-3
   Chen JM, 2015, BIOCHEM INSIGHTS, V8, P25, DOI [10.4137/BCI.S30753, 10.4137/BCICI.S30753]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001
   Chung J, 2017, ELIFE, V6, DOI 10.7554/eLife.24767
   Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533
   Cuzzocrea S, 2005, ARTHRITIS RHEUM, V52, P940, DOI 10.1002/art.20875
   Dang ZC, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112470
   Dehnert C, 2017, THER UMSCH, V74, P535, DOI 10.1024/0040-5930/a000954
   Doobay MF, 2007, AM J PHYSIOL-REG I, V292, pR373, DOI 10.1152/ajpregu.00292.2006
   Du Y, 2020, AM J RESP CRIT CARE, P2020
   Duan LP, 2020, ENERGY TECHNOL-GER, V8, DOI 10.1002/ente.201901401
   Dunham-Snary KJ, 2017, CHEST, V151, P181, DOI 10.1016/j.chest.2016.09.001
   Elliot-Portal E, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy072
   FRISANCHO AR, 1975, SCIENCE, V187, P313, DOI 10.1126/science.1089311
   Gamboa J, 2003, RESP PHYSIOL NEUROBI, V135, P1, DOI 10.1016/S1569-9048(03)00065-X
   Gasmi A, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108409
   Gassmann M, 2003, ADV EXP MED BIOL, V543, P323
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450
   Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hadadi A, 2020, J MED VIROL, V92, P915, DOI 10.1002/jmv.25839
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Heo K, 2014, J KOREAN MED SCI, V29, P416, DOI 10.3346/jkms.2014.29.3.416
   Hochachka PW, 2000, ADV EXP MED BIOL, V475, P25
   HONIG A, 1989, AM J PHYSIOL, V257, pR1282
   Jelkmann W, 2007, EUR J HAEMATOL, V78, P183, DOI 10.1111/j.1600-0609.2007.00818.x
   Joseph V, 2000, AM J PHYSIOL-REG I, V278, pR806
   Juul SE, 2009, PEDIATR RES, V65, P485, DOI 10.1203/PDR.0b013e31819d90c8
   Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007
   KARIM F, 1993, J PHYSIOL-LONDON, V466, P599
   Kedzierewicz Romain, 2013, Rev Prat, V63, P18
   Korkmaz Tanzer, 2014, BMC Res Notes, V7, P267, DOI 10.1186/1756-0500-7-267
   Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9
   Kumar Prem, 2007, Shengli Xuebao, V59, P128
   Lei Y., 2020, CLIN FEATURES IMPORT, DOI 10.1101/2020.03.09.20033126.
   LeonVelarde F, 1997, AM J PHYSIOL-REG I, V272, pR90
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Li YL, 2006, J PHYSIOL-LONDON, V575, P215, DOI 10.1113/jphysiol.2006.110700
   Lippi G, 2010, SEMIN THROMB HEMOST, V36, P537, DOI 10.1055/s-0030-1255448
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu W., 2020, COVID 19 ATTACKS 1 B
   Lopez-Barneo J, 2016, AM J PHYSIOL-CELL PH, V310, pC629, DOI 10.1152/ajpcell.00265.2015
   LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613
   Marini J. J., 2020, JAMA
   Martin D, 2008, POSTGRAD MED J, V84, P622, DOI 10.1136/pgmj.2008.068296
   Mazzuero G, 2008, HIGH ALT MED BIOL, V9, P241, DOI 10.1089/ham.2007.1074
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Moeini M, 2013, INT J PREVENTIVE MED, V4, P648
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Mortola JP, 1996, RESP PHYSIOL, V106, P21, DOI 10.1016/0034-5687(96)00064-3
   Nairz M, 2012, MICROBES INFECT, V14, P238, DOI 10.1016/j.micinf.2011.10.005
   Nairz M, 2011, IMMUNITY, V34, P61, DOI 10.1016/j.immuni.2011.01.002
   Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ortiz-Prado E., 2020, CLIN MOL EPIDEMIOLOG, DOI 10.20944/preprints202004.0283.v1
   Powell FL, 1998, RESP PHYSIOL, V112, P123, DOI 10.1016/S0034-5687(98)00026-7
   Prabhakar NR, 2016, PFLUG ARCH EUR J PHY, V468, P71, DOI 10.1007/s00424-015-1719-z
   Qin C, 2020, CLIN INFECT DIS
   Read R, 2020, COVID 19 ATTACKS 1 B, pv2, DOI 10.26434/chemrxiv.12120912.v2
   Richalet JP, 2012, AM J RESP CRIT CARE, V185, P192, DOI 10.1164/rccm.201108-1396OC
   Rocha J, 2015, INFLAMMATION, V38, P312, DOI 10.1007/s10753-014-0035-7
   Rupert JL, 2006, HIGH ALT MED BIOL, V7, P150, DOI 10.1089/ham.2006.7.150
   Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609
   Scharte M, 2003, CRIT CARE MED, V31, pS651, DOI 10.1097/01.CCM.0000098036.90796.ED
   SCHMIDT M, 1985, BIOMED BIOCHIM ACTA, V44, P695
   Seaborn T, 2011, NEUROSCI LETT, V502, P33, DOI 10.1016/j.neulet.2011.07.019
   Smedley T, 2013, BRIT J PAIN, V7, P85, DOI 10.1177/2049463713489539
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.7343
   Soliz J, 2005, J PHYSIOL-LONDON, V568, P559, DOI 10.1113/jphysiol.2005.093328
   Soliz J, 2007, J PHYSIOL-LONDON, V583, P329, DOI 10.1113/jphysiol.2007.133454
   Sonoda A, 2014, EXP THER MED, V8, P1443, DOI 10.3892/etm.2014.1960
   Spindler KR, 2012, TRENDS MICROBIOL, V20, P282, DOI 10.1016/j.tim.2012.03.009
   Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521
   Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc
   Storz JF, 2008, HIGH ALT MED BIOL, V9, P148, DOI 10.1089/ham.2007.1079
   Swenson ER, 2012, COMPR PHYSIOL, V2, P2753, DOI 10.1002/cphy.c100029
   Sylvester JT, 2012, PHYSIOL REV, V92, P367, DOI 10.1152/physrev.00041.2010
   Tansey EA, 2008, ADV PHYSIOL EDUC, V32, P11, DOI 10.1152/advan.00005.2007
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Turhan AH, 2016, EXP LUNG RES, V42, P199, DOI 10.1080/01902148.2016.1190424
   Veit F, 2013, AM J RESP CRIT CARE, V187, P569, DOI 10.1164/rccm.201301-0133ED
   WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295
   Xenocostas A, 2005, EUR J CLIN PHARMACOL, V61, P189, DOI 10.1007/s00228-005-0896-7
   Xie J, 2020, MAYO CLIN P
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yang X., 2020, LANCET RESP MED
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924
   Zhang RF, 2009, AM J PHYSIOL-LUNG C, V297, pL631, DOI 10.1152/ajplung.90415.2008
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XL, 2019, ANN CLIN LAB SCI, V49, P257
   Zhu M, 2019, TRANSPL P, V51, P972, DOI 10.1016/j.transproceed.2019.01.059
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zubieta-Calleja GR, 2007, J PHYSIOL PHARMACOL, V58, P811
NR 114
TC 4
Z9 4
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD AUG
PY 2020
VL 279
AR 103476
DI 10.1016/j.resp.2020.103476
PG 8
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA MP2EJ
UT WOS:000552022200014
PM 32522574
OA Green Published
DA 2021-01-01
ER

PT J
AU Masiero, S
   Maccarone, MC
   Magro, G
AF Masiero, Stefano
   Maccarone, Maria Chiara
   Magro, Giacomo
TI Balneotherapy and human immune function in the era of COVID-19
SO INTERNATIONAL JOURNAL OF BIOMETEOROLOGY
LA English
DT Letter
ID SPA THERAPY; WATER
C1 [Masiero, Stefano] Univ Padua, Dept Neurosci, Rehabil Unit, Via Giustiniani 3, I-35128 Padua, Italy.
   [Masiero, Stefano; Maccarone, Maria Chiara; Magro, Giacomo] Univ Padua, Phys Med & Rehabil Sch, Padua, Italy.
RP Masiero, S (corresponding author), Univ Padua, Dept Neurosci, Rehabil Unit, Via Giustiniani 3, I-35128 Padua, Italy.; Masiero, S (corresponding author), Univ Padua, Phys Med & Rehabil Sch, Padua, Italy.
EM stef.masiero@unipd.it
OI Masiero, Stefano/0000-0002-0361-4898
CR Antonelli M, 2018, INT J BIOMETEOROL, V62, P913, DOI 10.1007/s00484-018-1504-8
   Blazickova S, 2000, INT J CLIN PHARM RES, V20, P41
   Cucu A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00882
   Galvez I, 2019, INT J HYPERTHER, V35, P340, DOI 10.1080/02656736.2018.1502896
   Galvez I, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061687
   Galvez I, 2017, ENDOCR METAB IMMUNE, V17, P78, DOI 10.2174/1871530317666170320113613
   Lee YB, 2014, ANN DERMATOL, V26, P221, DOI 10.5021/ad.2014.26.2.221
   Ortega E, 2017, INT J BIOMETEOROL, V61, P1777, DOI 10.1007/s00484-017-1361-x
   Piao CN, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325820902338
   Rinaldi L, 2006, LAB INVEST, V86, P391, DOI 10.1038/labinvest.3700391
   Ruhle PF, 2017, AUTOIMMUNITY, V50, P133, DOI 10.1080/08916934.2017.1284819
   Vitale M, 2018, B SOC ESP HIDROL MED, V33, P68, DOI [10.23853/bsehm.2018.0588, DOI 10.23853/BSEHM.2018.0588]
NR 12
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0020-7128
EI 1432-1254
J9 INT J BIOMETEOROL
JI Int. J. Biometeorol.
PD AUG
PY 2020
VL 64
IS 8
BP 1433
EP 1434
DI 10.1007/s00484-020-01914-z
PG 2
WC Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences;
   Physiology
SC Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric
   Sciences; Physiology
GA MN3UZ
UT WOS:000550770900016
PM 32300868
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wright, FL
   Vogler, TO
   Moore, EE
   Moore, HB
   Wohlauer, MV
   Urban, S
   Nydam, TL
   Moore, PK
   McIntyre, RC
AF Wright, Franklin L.
   Vogler, Thomas O.
   Moore, Ernest E.
   Moore, Hunter B.
   Wohlauer, Max, V
   Urban, Shane
   Nydam, Trevor L.
   Moore, Peter K.
   McIntyre, Robert C., Jr.
TI Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe
   COVID-19 Infection
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID INTRAVASCULAR COAGULATION; TRAUMA; VALIDATION; THROMBOSIS; MORTALITY
AB BACKGROUND: COVID-19 predisposes patients to a prothrombotic state with demonstrated microvascular involvement. The degree of hypercoagulability appears to correlate with outcomes; however, optimal criteria to assess for the highest-risk patients for thrombotic events remain unclear; we hypothesized that deranged thromboelastography measurements of coagulation would correlate with thromboembolic events.
   STUDY DESIGN: Patients admitted to an ICU with COVID-19 diagnoses who had thromboelastography analyses performed were studied. Conventional coagulation assays, D-dimer levels, and viscoelastic measurements were analyzed using a receiver operating characteristic curve to predict thromboembolic outcomes and new-onset renal failure.
   RESULTS: Forty-four patients with COVID-19 were included in the analysis. Derangements in coagulation laboratory values, including elevated D-dimer, fibrinogen, prothrombin time, and partial thromboplastin time, were confirmed; viscoelastic measurements showed an elevated maximum amplitude and low lysis of clot at 30 minutes. A complete lack of lysis of clot at 30 minutes was seen in 57% of patients and predicted venous thromboembolic events with an area under the receiver operating characteristic curve of 0.742 (p = 0.021). A D-dimer cutoff of 2,600 ng/mL predicted need for dialysis with an area under the receiver operating characteristic curve of 0.779 (p = 0.005). Overall, patients with no lysis of clot at 30 minutes and a D-dimer > 2,600 ng/mL had a venous thromboembolic event rate of 50% compared with 0% for patients with neither risk factor (p = 0.008), and had a hemodialysis rate of 80% compared with 14% (p = 0.004).
   CONCLUSIONS: Fibrinolysis shutdown, as evidenced by elevated D-dimer and complete failure of clot lysis at 30 minutes on thromboelastography predicts thromboembolic events and need for hemodialysis in critically ill patients with COVID-19. Additional clinical trials are required to ascertain the need for early therapeutic anticoagulation or fibrinolytic therapy to address this state of fibrinolysis shutdown. ((C) 2020 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.)
C1 [Wright, Franklin L.; Moore, Ernest E.; Moore, Hunter B.; Wohlauer, Max, V; Nydam, Trevor L.; McIntyre, Robert C., Jr.] Univ Colorado, UCHlth, Dept Surg, Anschutz Med Campus, Aurora, CO USA.
   [Moore, Peter K.] Univ Colorado, UCHlth, Dept Med, Anschutz Med Campus, Aurora, CO USA.
   [Vogler, Thomas O.] Univ Colorado, UCHlth, Sch Med, Anschutz Med Campus, Aurora, CO USA.
   [Urban, Shane] Univ Colorado Hosp, Aurora, CO USA.
   [Moore, Ernest E.] Denver Hlth, Ernest E Moore Shock Trauma Ctr, Dept Surg, Denver, CO USA.
RP Wright, FL (corresponding author), Univ Colorado, Sch Med, Dept Surg, Div GI Trauma & Endocrine Surg, 12631 E 17th Ave,C313, Aurora, CO 80045 USA.
EM Franklin.Wright@cuanschutz.edu
OI Wright, Franklin/0000-0002-4433-5385
FU NIH/National Center for Research Resources CCSTI grant [UL1 RR025780]
FX REDCap is provided through the Colorado Clinical & Translational
   Sciences Institute (CCTSI) with the Development and Informatics Service
   Center grant support (NIH/National Center for Research Resources CCSTI
   grant UL1 RR025780).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bakhtiari K, 2004, CRIT CARE MED, V32, P2416, DOI 10.1097/01.CCM.0000147769.07699.E3
   BIEMOND BJ, 1995, CLIN SCI, V88, P587, DOI 10.1042/cs0880587
   Boonyawat K, 2015, SEMIN THROMB HEMOST, V41, P68, DOI 10.1055/s-0034-1398386
   Brill JB, 2017, J TRAUMA ACUTE CARE, V83, P413, DOI 10.1097/TA.0000000000001618
   Choudhury R, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00305-4
   Coleman JR, 2019, AM J SURG, V218, P1065, DOI 10.1016/j.amjsurg.2019.08.024
   COLLEN D, 1987, J CELL BIOCHEM, V33, P77, DOI 10.1002/jcb.240330202
   Cotton BA, 2012, J TRAUMA ACUTE CARE, V72, P1470, DOI 10.1097/TA.0b013e31824d56ad
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Gary JL, 2016, J ORTHOP TRAUMA, V30, P294, DOI 10.1097/BOT.0000000000000523
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   GREENE R, 1987, AM J ROENTGENOL, V148, P501, DOI 10.2214/ajr.148.3.501
   Harahsheh Y, 2019, CRIT CARE MED, V47, P826, DOI 10.1097/CCM.0000000000003730
   HARDAWAY RM, 1965, MIL MED, V130, P451, DOI 10.1093/milmed/130.5.451
   Hardaway RM, 2001, AM SURGEON, V67, P377
   HARDAWAY RM, 1962, ANN SURG, V155, P241
   HARDAWAY RM, 1963, JAMA-J AM MED ASSOC, V183, P597
   HARDAWAY RM, 1963, ANN SURG, V157, P305
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kuiper GJAJM, 2016, THROMB J, V14, DOI 10.1186/s12959-016-0076-2
   Leeper CM, 2017, ANN SURG, V266, P508, DOI 10.1097/SLA.0000000000002355
   McCrath DJ, 2005, ANESTH ANALG, V100, P1576, DOI 10.1213/01.ANE.0000155290.86795.12
   Meizoso JP, 2017, J AM COLL SURGEONS, V224, P575, DOI 10.1016/j.jamcollsurg.2016.12.018
   Moore HB, 2020, J TRAUMA ACUTE CARE, V88, P713, DOI 10.1097/TA.0000000000002694
   Moore HB, 2019, ANESTH ANALG, V129, P762, DOI 10.1213/ANE.0000000000004234
   Moore HB, 2016, J AM COLL SURGEONS, V222, P347, DOI 10.1016/j.jamcollsurg.2016.01.006
   Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341
   Myers SP, 2019, J TRAUMA ACUTE CARE, V86, P20, DOI 10.1097/TA.0000000000002061
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Roberts DJ, 2019, J TRAUMA ACUTE CARE, V86, P206, DOI 10.1097/TA.0000000000002099
   Schmitt FCF, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0499-6
   Subramaniam S, 2018, FRONT BIOSCI-LANDMRK, V23, P1060, DOI 10.2741/4633
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang ZF, 2011, THROMB RES, V127, P198, DOI 10.1016/j.thromres.2010.11.032
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 40
TC 47
Z9 47
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD AUG
PY 2020
VL 231
IS 2
BP 193
EP 203
DI 10.1016/j.jamcollsurg.2020.05.007
PG 11
WC Surgery
SC Surgery
GA MM6ZS
UT WOS:000550303800001
PM 32422349
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Huang, M
   Yang, Y
   Shang, FT
   Zheng, YS
   Zhao, WJ
   Luo, L
   Han, XD
   Lin, AH
   Zhao, HS
   Gu, Q
   Shi, Y
   Li, J
   Xu, XX
   Liu, KX
   Deng, YJ
   Cao, Q
   Wang, WW
AF Huang, Mao
   Yang, Yi
   Shang, Futai
   Zheng, Yishan
   Zhao, Wenjing
   Luo, Liang
   Han, Xudong
   Lin, Aihua
   Zhao, Hongsheng
   Gu, Qing
   Shi, Yi
   Li, Jun
   Xu, Xingxiang
   Liu, Kexi
   Deng, YiJun
   Cao, Quan
   Wang, Weiwei
TI Clinical Characteristics and Predictors of Disease Progression in Severe
   Patients with COVID-19 Infection in Jiangsu Province, China: A
   Descriptive Study
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE COVID-19; Severe patients; Disease progression; Critical care
ID INFLUENZA; WUHAN
AB Background: We studied patients with coronavirus disease 2019 (COVID-19) infected by severe acute respiratory syndrome coronavirus 2, a virus that originated in Wuhan, China, and is spreading over the country including Jiangsu Province. We studied the clinical characteristics and therapies of severe cases in Jiangsu Province.
   Methods: A multicenter retrospective cohort study was conducted to analyze clinical, laboratory data and treatment of 60 severe cases with COVID-19 infection in Jiangsu Province between January 24, 2020 and April 20, 2020. The improvement and deterioration subgroups were compared to identify predictors of disease progression.
   Results: A total of 653 infected cases with COVID-19 were reported in Jiangsu Province, of which 60 severe cases were included in this study. Up until April 20, 2020, the mortality of severe patients was 0%. The median age was 57 years. The average body mass index of these patients was 25 kg/m(2). White blood cell counts decreased in 45.0% of patients, lymphopenia in 63.3%, thrombocytopenia in 13.3% and procalcitonin levels in 88.3% of the patients were less than 0.5 ng/mL. There were no statistically significant differences in immunoglobulin therapy and GCs therapy between the improvement and deterioration subgroups. Logistic regression analysis identified higher levels of troponin T (odds ratio [OR]: 1.04; 95% confidence interval [CI]: 1.00-1.08; P = 0.04), antiviral therapy with aerosol inhalation of interferon (OR: 6.33; 95% CI: 1.18-33.98; P = 0.03), and the application of non-invasive mechanical ventilation (OR: 1.99; 95%CI: 1.17-3.41; P = 0.01) as predictors of disease progression, whereas higher lymphocyte count (OR: 0.11; 95% CI: 0.02-0.57; P = 0.01) and early prone ventilation were associated with improvement (OR: 0.11; 95% CI: 0.01-0.98; P = 0.04).
   Conclusions: COVID-19 infection had a low mortality rate in Jiangsu Province, China. The higher levels of troponin T and lower lymphocyte count were predictors of disease progression. Early prone ventilation may be an effective treatment for severe cases.
C1 [Huang, Mao] Nanjing Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Nanjing, Peoples R China.
   [Yang, Yi] Southeast Univ, Zhongda Hosp, Dept Crit Care Med, Nanjing, Peoples R China.
   [Shang, Futai] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Crit Care Med, Huaian, Peoples R China.
   [Zheng, Yishan] Nanjing 2 Hosp, Dept Crit Care Med, Nanjing, Peoples R China.
   [Zhao, Wenjing] Xuzhou Med Univ, Affiliated Hosp, Dept Crit Care Med, Xuzhou, Jiangsu, Peoples R China.
   [Luo, Liang] Wuxi Peoples Hosp, Dept Crit Care Med, Wuxi, Jiangsu, Peoples R China.
   [Han, Xudong] Nantong Univ, Peoples Hosp Nantong City 3, Dept Crit Care Med, Nantong, Peoples R China.
   [Lin, Aihua] Suqian Peoples Hosp, Nanjing Gulou Hosp Grp, Dept Crit Care Med, Suqian, Peoples R China.
   [Zhao, Hongsheng] Nantong Univ, Affiliated Hosp, Dept Crit Care Med, Nantong, Peoples R China.
   [Gu, Qing] Nanjing Univ, Med Sch, Nanjing Drum Tower Hosp, Dept Crit Care Med, Nanjing, Peoples R China.
   [Shi, Yi] Nanjing Jinlin Hosp, Dept Pulm & Crit Care Med, Nanjing, Peoples R China.
   [Li, Jun] Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Peoples R China.
   [Xu, Xingxiang] Northern Jiangsu Peoples Hosp, Dept Pulm & Crit Care Med, Yangzhou, Jiangsu, Peoples R China.
   [Liu, Kexi] Lianyungang First Peoples Hosp, Dept Crit Care Med, Lianyungang, Peoples R China.
   [Deng, YiJun] Yancheng First Peoples Hosp, Dept Crit Care Med, Yancheng, Peoples R China.
   [Cao, Quan; Wang, Weiwei] Nanjing Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Nanjing, Peoples R China.
RP Wang, WW (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Nanjing, Peoples R China.
EM wangweiwei199203@163.com
CR Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   [Anonymous], 2020, CHINESE J INTEGRATIV, P1
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Beigel H, 2005, NEW ENGL J MED, V353, P1374
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman V.M., 2020, EURO SURVEILLANCE B, V25
   Eurosurveillance Editorial Team, 2020, EURO SURVEILLANCE B
   General office of the national health commission Office of the national administration of traditional Chinese medicine, 2020, CLIN ED GEN PRACTICE, V18, P100
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang C, 2020, LANCET LONDON ENGLAN
   Huang C, 2020, LANCET
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   LEGALL JR, 1986, CRIT CARE MED, V14, P754
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Lu H., 2020, J MED VIROL
   Lu R, 2020, LANCET LONDON ENGLAN
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M477
   Minodier L, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0448-4
   Olson G, 2020, JAMA
   Phan LT, 2020, N ENGL J MED
   Phelan A.L., 2020, JAMA
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rothe C, 2020, N ENGL J MED
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Sjoding MW, 2018, CHEST, V153, P361, DOI 10.1016/j.chest.2017.11.037
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Uyeki TM, 2020, NEW ENGL J MED, V382
   Wang C, 2020, LANCET LONDON ENGLAN
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WW, 2017, AM J INFECT CONTROL, V45, P59, DOI 10.1016/j.ajic.2016.08.008
   World Health Organization, NOV COR 2019 NCOV SI
   Wu JT, 2020, LANCET
   Yang Y, 2015, CRIT CARE MED, V43, P339, DOI 10.1097/CCM.0000000000000695
   Zhu N, 2020, N ENGL J MED
NR 34
TC 3
Z9 3
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD AUG
PY 2020
VL 360
IS 2
BP 120
EP 128
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA MN3IX
UT WOS:000550739300005
PM 32709280
OA Bronze
DA 2021-01-01
ER

PT J
AU Di Cosimo, S
   Malfettone, A
   Perez-Garcia, JM
   Llombart-Cussac, A
   Miceli, R
   Curigliano, G
   Cortes, J
AF Di Cosimo, Serena
   Malfettone, Andrea
   Perez-Garcia, Jose M.
   Llombart-Cussac, Antonio
   Miceli, Rosalba
   Curigliano, Giuseppe
   Cortes, Javier
TI Immune checkpoint inhibitors: a physiology-driven approach to the
   treatment of coronavirus disease 2019
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE COVID-19; SARS-CoV-2; Cytokine storm; AntiePD-1; AntieIL-6R;
   Pembrolizumab; Tocilizumab
ID BLOCKADE
AB While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Di Cosimo, Serena] Fdn IRCCS Ist Nazl Tumori, Dept Appl Res & Technol Dev, Biomarker Unit, Milan, Italy.
   [Malfettone, Andrea; Perez-Garcia, Jose M.; Llombart-Cussac, Antonio; Cortes, Javier] Medica Sci Innovat Res MedSIR, Ridgewood, NJ USA.
   [Malfettone, Andrea; Perez-Garcia, Jose M.; Llombart-Cussac, Antonio; Cortes, Javier] Medica Sci Innovat Res MedSIR, Barcelona, Spain.
   [Perez-Garcia, Jose M.; Cortes, Javier] Quironsalud Grp, IOB Inst Oncol, Madrid, Spain.
   [Perez-Garcia, Jose M.; Cortes, Javier] Quironsalud Grp, IOB Inst Oncol, Barcelona, Spain.
   [Llombart-Cussac, Antonio] Univ Catolica Valencia San Vicente Martir, Hosp Arnau Vilanova, Valencia, Spain.
   [Miceli, Rosalba] Fdn IRCCS Ist Nazl Tumori, Dept Clin Epidemiol & Trial Org, Milan, Italy.
   [Curigliano, Giuseppe] IRCCS, Ist Europeo Oncol, Milan, Italy.
   [Curigliano, Giuseppe] Univ Milan, Sch Med, Milan, Italy.
   [Cortes, Javier] Vall DHebron Inst Oncol VHIO, Barcelona, Spain.
RP Cortes, J (corresponding author), Hosp Ruber Internac, Quironsalud Grp, IOB Inst Oncol, Calle Maso 38, Madrid 28034, Spain.
EM jacortes@vhio.net
RI Curigliano, Giuseppe/D-3371-2018
OI Curigliano, Giuseppe/0000-0003-1781-2518; Llombart Cussac,
   Antonio/0000-0003-4515-8293
CR Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115
   Bayle A, 2020, ANN ONCOL, V31, P959, DOI 10.1016/j.annonc.2020.03.290
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P105, DOI 10.2217/imt-2019-0200
   Billerbeck E, 2017, SCIENCE, V357, P204, DOI 10.1126/science.aal1962
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chong CR, 2020, CLIN INFECT DIS, V70, P193, DOI 10.1093/cid/ciz202
   Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   Hotchkiss RS, 2019, INTENS CARE MED, V45, P1360, DOI 10.1007/s00134-019-05704-z
   Hotchkiss RS, 2019, CRIT CARE MED, V47, P632, DOI 10.1097/CCM.0000000000003685
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yu J, 2020, JAMA ONCOL, DOI [10.1001/ja-maoncol.2020.0980, DOI 10.1001/JA-MAONCOL.2020.0980]
   Zheng H, 2020, CURR EYE RES, V45, P1043, DOI [10.1080/02713683.2020.1716986, 10.1080/10408398.2020.1740645]
   Zheng M., 2020, CELL MOL IMMUNOL, P1
   Zheng Y, 2020, INFECT DIS EXCEPT HI
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD AUG
PY 2020
VL 135
BP 62
EP 65
DI 10.1016/j.ejca.2020.05.026
PG 4
WC Oncology
SC Oncology
GA MM4NX
UT WOS:000550136400010
PM 32544799
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Souza, IL
   Fernandes, I
   Taranto, P
   Buzaid, AC
   Schvartsman, G
AF Souza, Ive L.
   Fernandes, Italo
   Taranto, Patricia
   Buzaid, Antonio C.
   Schvartsman, Gustavo
TI Immune-related pneumonitis with nivolumab and ipilimumab during the
   coronavirus disease 2019 (COVID-19) pandemic
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Letter
DE Adverse drug reactions; Immunotherapy; PD-1; Pneumonitis; COVID-19
C1 [Souza, Ive L.; Fernandes, Italo; Taranto, Patricia; Buzaid, Antonio C.; Schvartsman, Gustavo] Hosp Israelita Albert Einstein, Ave Albert Einstein 627-520, BR-05651901 Sao Paulo, SP, Brazil.
RP Schvartsman, G (corresponding author), Hosp Israelita Albert Einstein, Ave Albert Einstein 627-520, BR-05651901 Sao Paulo, SP, Brazil.
EM gustavo.schvartsman@einstein.br
CR [Anonymous], 2020, EP SIT
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Simpson S, 2020, RADIOLOGY, V2, pe200152, DOI [10.1148/ryct.2020200152, DOI 10.1148/RYCT.2020200152]
   Zhong LD, 2020, ADV EXP MED BIOL, V1244, P255, DOI 10.1007/978-3-030-41008-7_13
NR 8
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD AUG
PY 2020
VL 135
BP 147
EP 149
DI 10.1016/j.ejca.2020.06.004
PG 3
WC Oncology
SC Oncology
GA MM4NX
UT WOS:000550136400021
PM 32585589
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhai, XF
   Sun, JM
   Yan, ZQ
   Zhang, J
   Zhao, J
   Zhao, ZZ
   Gao, Q
   He, WT
   Veit, M
   Su, S
AF Zhai, Xiaofeng
   Sun, Jiumeng
   Yan, Ziqing
   Zhang, Jie
   Zhao, Jin
   Zhao, Zongzheng
   Gao, Qi
   He, Wan-Ting
   Veit, Michael
   Su, Shuo
TI Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike
   Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and
   Putative Intermediate Hosts
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; SARS-CoV-2;
   angiotensin-converting enzyme 2; livestock
ID EVOLUTION; SARS-COV-2; INFECTION; SITE
AB The emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulted in a pandemic. Here, we used X-ray structures of human ACE2 bound to the receptor-binding domain (RBD) of the spike protein (S) from SARS-CoV-2 to predict its binding to ACE2 proteins from different animals, including pets, farm animals, and putative intermediate hosts of SARSCoV-2. Comparing the interaction sites of ACE2 proteins known to serve or not serve as receptors allows the definition of residues important for binding. From the 20 amino acids in ACE2 that contact S, up to 7 can be replaced and ACE2 can still function as the SARS-CoV-2 receptor. These variable amino acids are clustered at certain positions, mostly at the periphery of the binding site, while changes of the invariable residues prevent S binding or infection of the respective animal. Some ACE2 proteins even tolerate the loss or acquisition of N-glycosylation sites located near the S interface. Of note, pigs and dogs, which are not infected or are not effectively infected and have only a few changes in the binding site, exhibit relatively low levels of ACE2 in the respiratory tract. Comparison of the RBD of S of SARS-CoV-2 with that from bat coronavirus strain RaTG13 (Bat-CoV-RaTG13) and pangolin coronavirus (Pangolin-CoV) strain hCoV-19/pangolin/Guangdong/1/2019 revealed that the latter contains only one substitution, whereas Bat-CoV-RaTG13 exhibits five. However, ACE2 of pangolin exhibits seven changes relative to human ACE2, and a similar number of substitutions is present in ACE2 of bats, raccoon dogs, and civets, suggesting that SARS-CoV-2 may not be especially adapted to ACE2 of any of its putative intermediate hosts. These analyses provide new insight into the receptor usage and animal source/origin of SARS-CoV-2.
   IMPORTANCE SARS-CoV-2 is threatening people worldwide, and there are no drugs or vaccines available to mitigate its spread. The origin of the virus is still unclear, and whether pets and livestock can be infected and transmit SARS-CoV-2 are important and unknown scientific questions. Effective binding to the host receptor ACE2 is the first prerequisite for infection of cells and determines the host range. Our analysis provides a framework for the prediction of potential hosts of SARS-CoV-2. We found that ACE2 from species known to support SARS-CoV-2 infection tolerate many amino acid changes, indicating that the species barrier might be low. Exceptions are dogs and especially pigs, which revealed relatively low ACE2 expression levels in the respiratory tract. Monitoring of animals is necessary to prevent the generation of a new coronavirus reservoir. Finally, our analysis also showed that SARS-CoV-2 may not be specifically adapted to any of its putative intermediate hosts.
C1 [Zhai, Xiaofeng; Sun, Jiumeng; Yan, Ziqing; Zhang, Jie; Zhao, Jin; Gao, Qi; He, Wan-Ting; Su, Shuo] Nanjing Agr Univ, Coll Vet Med, Engn Lab Anim Immun Jiangsu Prov, Nanjing, Peoples R China.
   [Veit, Michael] Free Univ Berlin, Fac Vet, Ctr Infect Med, Inst Virol, Berlin, Germany.
   [Zhao, Zongzheng] Acad Mil Med Sci, Inst Mil Vet, Changchun, Peoples R China.
RP Su, S (corresponding author), Nanjing Agr Univ, Coll Vet Med, Engn Lab Anim Immun Jiangsu Prov, Nanjing, Peoples R China.; Veit, M (corresponding author), Free Univ Berlin, Fac Vet, Ctr Infect Med, Inst Virol, Berlin, Germany.
EM michael.veit@fu-berlin.de; shuosu@njau.edu.cn
OI Veit, Michael/0000-0002-7638-1829
FU National Key Research and Development Program of China [2017YFD0500101];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [Y0201900459]; China
   Association for Science and Technology Youth Talent Lift Project
   (2017-2019); Six Talent Peaks Project of Jiangsu Province of China
   [NY-045]; Natural Science Foundation of Jiangsu ProvinceNatural Science
   Foundation of Jiangsu Province [BK20170721]; Young Top-Notch Talents of
   National TenThousand Talents Program; Sino-German cooperation and
   exchange project in international cooperation and Cultivation Project in
   2019; Bioinformatics Center of Nanjing Agricultural University; German
   Research Foundation (DFG)German Research Foundation (DFG)
FX This work was financially supported by the National Key Research and
   Development Program of China (grant no. 2017YFD0500101), the Fundamental
   Research Funds for the Central Universities (grant no. Y0201900459), the
   China Association for Science and Technology Youth Talent Lift Project
   (2017-2019), Six Talent Peaks Project of Jiangsu Province of China
   (grant no. NY-045), the Natural Science Foundation of Jiangsu Province
   (grant no. BK20170721), the Young Top-Notch Talents of National
   TenThousand Talents Program, Sino-German cooperation and exchange
   project in international cooperation and Cultivation Project in 2019,
   and the Bioinformatics Center of Nanjing Agricultural University.
   Experimental work in the lab of M.V. is financed by the German Research
   Foundation (DFG).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hou YX, 2010, ARCH VIROL, V155, P1563, DOI 10.1007/s00705-010-0729-6
   Hu B, 2017, BLOOD, V130
   KAWAOKA Y, 1984, VIROLOGY, V139, P303, DOI 10.1016/0042-6822(84)90376-3
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu P, 2020, ARE PANGOLINS INTERM, DOI [10.1101/2020.1102.1118.954628, DOI 10.1101/2020.1102.1118.954628]
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Schjoldager KTBG, 2011, J BIOL CHEM, V286, P40122, DOI 10.1074/jbc.M111.287912
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wahba L, 2020, MSPHERE, V5, DOI [10.1128/mSphere.00160-20, DOI 10.1128/MSPHERE.00160-20]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang Q, 2020, VIROL SIN, V35, P337, DOI 10.1007/s12250-020-00212-7
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou H, 2020, NOVEL BAT CORONAVIRU, DOI [10.1101/2020.2003.2002.974139, DOI 10.1101/2020.2003.2002.974139]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 43
TC 18
Z9 17
U1 5
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2020
VL 94
IS 15
AR e00831-20
DI 10.1128/JVI.00831-20
PG 16
WC Virology
SC Virology
GA MM5CA
UT WOS:000550173300002
PM 32404529
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Longpre-Poirier, C
   Jodoin, VD
   Miron, JP
   Lesperance, P
AF Longpre-Poirier, Christophe
   Jodoin, Veronique Desbeaumes
   Miron, Jean-Philippe
   Lesperance, Paul
TI "Remote Monitoring of Intranasal Ketamine Self-Administration as
   Maintenance Therapy in Treatment-Resistant Depression (TRD): A Novel
   Strategy for Vulnerable and At-Risk Populations to COVID-19?"
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Letter
C1 [Longpre-Poirier, Christophe; Jodoin, Veronique Desbeaumes; Miron, Jean-Philippe; Lesperance, Paul] Univ Montreal, Ctr Hosp Univ Montreal CHUM, Unit Neuromodulat Psychiat UNP CLP VDJ JPM & PL, Montreal, PQ, Canada.
   [Longpre-Poirier, Christophe; Jodoin, Veronique Desbeaumes; Miron, Jean-Philippe; Lesperance, Paul] Univ Montreal, Ctr Rech CHUM CRCHUM CLP VDJ JPM & PL, Montreal, PQ, Canada.
   [Longpre-Poirier, Christophe; Jodoin, Veronique Desbeaumes; Miron, Jean-Philippe; Lesperance, Paul] Univ Montreal, Dept Psychiat CHUM CLP VDJ JPM & PL, Montreal, PQ, Canada.
RP Longpre-Poirier, C (corresponding author), Univ Montreal, Ctr Hosp Univ Montreal CHUM, Unit Neuromodulat Psychiat UNP CLP VDJ JPM & PL, Montreal, PQ, Canada.; Longpre-Poirier, C (corresponding author), Univ Montreal, Ctr Rech CHUM CRCHUM CLP VDJ JPM & PL, Montreal, PQ, Canada.; Longpre-Poirier, C (corresponding author), Univ Montreal, Dept Psychiat CHUM CLP VDJ JPM & PL, Montreal, PQ, Canada.
RI Miron, Jean-Philippe/ABA-4686-2020
OI Miron, Jean-Philippe/0000-0002-5277-541X
CR Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001
   Nacoti M, 2020, NEJM CATAL INNOV CAR, V1
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Ribeiro CMD, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0855-x
   Short B, 2018, LANCET PSYCHIAT, V5, P65, DOI 10.1016/S2215-0366(17)30272-9
NR 5
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2020
VL 28
IS 8
BP 892
EP 893
DI 10.1016/j.jagp.2020.04.024
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA ML8KW
UT WOS:000549708700019
PM 32446640
OA Green Published
DA 2021-01-01
ER

PT J
AU Burhan, AM
   Safi, A
   Blair, M
   O'Reilly, R
AF Burhan, Amer M.
   Safi, Ajmal
   Blair, Mervin
   O'Reilly, Richard
TI Electroconvulsive Therapy for Geriatric Depression in the COVID-19 Era:
   Reflection on the Ethics
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Letter
ID MORTALITY
C1 [Burhan, Amer M.; Safi, Ajmal; Blair, Mervin] Parkwood Inst, Clin Neuropsychiat & Therapeut Brain Stimulat Res, London, ON, Canada.
   [Burhan, Amer M.; O'Reilly, Richard] Schulich Sch Med & Dent, Dept Psychiat, London, ON, Canada.
   [Burhan, Amer M.; O'Reilly, Richard] Parkwood Inst Mental Hlth Care Bldg, Therapeut Brain Stimulat Clin, London, ON, Canada.
RP Burhan, AM (corresponding author), Parkwood Inst, Clin Neuropsychiat & Therapeut Brain Stimulat Res, London, ON, Canada.; Burhan, AM (corresponding author), Schulich Sch Med & Dent, Dept Psychiat, London, ON, Canada.; Burhan, AM (corresponding author), Parkwood Inst Mental Hlth Care Bldg, Therapeut Brain Stimulat Clin, London, ON, Canada.
CR Galvez V, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0592-y
   Geduldig ET, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0674-5
   GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184
   International society for ECT and neu- rostimulation, 2020, INT SOC ECT NEUROSTI
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Ryan J, 2008, BRIT J PSYCHIAT, V192, P12, DOI 10.1192/bjp.bp.107.039164
   Schulz R, 2000, ARCH INTERN MED, V160, P1761, DOI 10.1001/archinte.160.12.1761
   Tor Phern Chern, 2020, J ECT, DOI 10.1097/YCT.0000000000000690
   Uppal V, 2010, BJA EDUC, V10, P192, DOI 10.1093/bjaceaccp/mkq039
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
NR 10
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2020
VL 28
IS 8
BP 900
EP 902
PG 3
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA ML8KW
UT WOS:000549708700023
PM 32425472
OA Green Published
DA 2021-01-01
ER

PT J
AU Brownstone, ND
   Thibodeaux, QG
   Reddy, VD
   Myers, BA
   Chan, SY
   Bhutani, T
   Liao, W
AF Brownstone, Nicholas D.
   Thibodeaux, Quinn G.
   Reddy, Vidhatha D.
   Myers, Bridget A.
   Chan, Stephanie Y.
   Bhutani, Tina
   Liao, Wilson
TI Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis:
   Successful Recovery in Two Patients After Infection with Severe Acute
   Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
SO DERMATOLOGY AND THERAPY
LA English
DT Article
DE Biologics; COVID-19; Infection; Pandemic; Psoriasis; SARS-CoV-2; Virus
ID SERIOUS INFECTION; RISK
AB The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.
C1 [Brownstone, Nicholas D.; Thibodeaux, Quinn G.; Reddy, Vidhatha D.; Myers, Bridget A.; Chan, Stephanie Y.; Bhutani, Tina; Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, Psoriasis & Skin Treatment Ctr, San Francisco, CA 94143 USA.
RP Brownstone, ND (corresponding author), Univ Calif San Francisco, Dept Dermatol, Psoriasis & Skin Treatment Ctr, San Francisco, CA 94143 USA.
EM nicholas.brownstone@ucsf.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI119125] Funding Source: Medline
CR Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   Gooderham Melinda, 2018, Curr Probl Dermatol, V53, P15, DOI 10.1159/000478074
   *JHONS HOPK COR RE, COVID 19 MAP
   Kalb RE, 2015, JAMA DERMATOL, V151, P961, DOI 10.1001/jamadermatol.2015.0718
   Quartuccio L, 2019, J ADV RES, V15, P87, DOI 10.1016/j.jare.2018.09.003
   *SAN, BIOL MED TARG DIS SO
   Wu ZY, 2020, J INTELL MANUF, V31, P1559, DOI 10.1007/s10845-020-01534-9
   Yiu ZZN, 2019, BRIT J DERMATOL, V180, P894, DOI 10.1111/bjd.17421
   Yiu ZZN, 2018, J INVEST DERMATOL, V138, P534, DOI 10.1016/j.jid.2017.10.005
NR 9
TC 2
Z9 2
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 2193-8210
EI 2190-9172
J9 DERMATOLOGY THER
JI Dermatol. Ther.
PD AUG
PY 2020
VL 10
IS 4
BP 881
EP 885
DI 10.1007/s13555-020-00394-8
PG 5
WC Dermatology
SC Dermatology
GA ML7CZ
UT WOS:000549620600030
PM 32468230
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Essid, N
   Allouche, M
   Lazzem, M
   Harrath, AH
   Mansour, L
   Alwasel, S
   Mahmoudi, E
   Beyrem, H
   Boufahja, F
AF Essid, Naceur
   Allouche, Mohamed
   Lazzem, Mounira
   Harrath, Abdel Halim
   Mansour, Lamjed
   Alwasel, Saleh
   Mahmoudi, Ezzeddine
   Beyrem, Hamouda
   Boufahja, Fehmi
TI Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19
   drug treatment
SO MARINE POLLUTION BULLETIN
LA English
DT Article
DE COVID-19; Ivermectin; Ecotoxicity; Meiobenthic nematodes
ID LIVING MARINE NEMATODES; ENVIRONMENTAL RISK; COMMUNITY; CONTAMINATION;
   BIODIVERSITY; COLONIZATION; ASSEMBLAGES; MEIOFAUNA; SEDIMENTS; ECOLOGY
AB At the end of March 2020, ivermectin was confirmed as a drug for COVID-19 treatment. A significant amount of ivermectin could deposit into sediments of the semi-closed Mediterranean Sea, where three European COVID-19 epicenters are located: Italy, Spain, and France. Meiobenthic nematodes were exposed to three ivermectin doses (1.8 ng.g(-1), 9 ng.g(-1), and 18 ng.g(-1)) for 10 days. Ivermectin caused a great reduction in abundance. However, the diversity indices decreased only at high doses. Ivermectin disadvantaged the 1B-Cr-Id functional type (non-selective deposit feeders and nematodes with circular or indistinct amphids) and benefited the 2A-REL-Sp type (epistrate feeders and nematodes with rounded or elongated loop amphids). Thus, Trophic Diversity and Amphideal Diversity index values increased with sedimentary ivermectin enrichment. Large amphideal foveas were more efficient for 2A-REL-Sp nematodes to avoid ivermectin. The responses of the functional type 2A-REL-Sp and corresponding taxa predict post-COVID-19 environmental concerns and the bioaccumulation of ivermectin in seafoods.
C1 [Essid, Naceur; Allouche, Mohamed; Lazzem, Mounira; Mahmoudi, Ezzeddine; Beyrem, Hamouda; Boufahja, Fehmi] Univ Carthage, Fac Sci Bizerte, Coastal Ecol & Ecotoxicol Unit, Lab Environm Biomonitoring, Zarzouna 7021, Tunisia.
   [Harrath, Abdel Halim; Mansour, Lamjed; Alwasel, Saleh] King Saud Univ, Coll Sci, Zool Dept, Box 2455, Riyadh 11451, Saudi Arabia.
RP Boufahja, F (corresponding author), Univ Carthage, Fac Sci Bizerte, Coastal Ecol & Ecotoxicol Unit, Lab Environm Biomonitoring, Zarzouna 7021, Tunisia.
EM fehmiboufahja@yahoo.fr
RI MANSOUR, Lamjed/AAO-6201-2020; Alwasel, Saleh/AAD-4023-2019; Harrath,
   Abdel Halim/K-2166-2014
OI MANSOUR, Lamjed/0000-0002-9415-9383; Harrath, Abdel
   Halim/0000-0002-2170-1303; ESSID, Naceur/0000-0001-6080-8165
FU Deanship of Scientific Research at King Saud UniversityKing Saud
   University [RG-254]
FX The authors extend their appreciation to the Deanship of Scientific
   Research at King Saud University for funding the Research group RG-254
   and to RSSU at King Saud University for their technical support.
CR Abd El-Aziz TM, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104327
   ALBERTIN.J, 1974, AQUACULTURE, V4, P13, DOI 10.1016/0044-8486(74)90015-5
   Allouche M, 2020, ENVIRON POLLUT, V263, DOI 10.1016/j.envpol.2020.114529
   Allouche M, 2020, ENVIRON SCI POLLUT R, V27, P11403, DOI 10.1007/s11356-020-07655-1
   Allouche M, 2020, J KING SAUD UNIV SCI, V32, P1339, DOI 10.1016/j.jksus.2019.11.025
   Beyrem H, 2007, ECOTOX ENVIRON SAFE, V68, P412, DOI 10.1016/j.ecoenv.2006.12.007
   Beyrem H, 2010, MAR ENVIRON RES, V69, P248, DOI 10.1016/j.marenvres.2009.10.018
   Bezerra T. N., 2019, NEMYS WORLD DATABASE
   Boeckner MJ, 2009, HYDROBIOLOGIA, V624, P91, DOI 10.1007/s10750-008-9669-5
   Boonstra H, 2011, ARCH ENVIRON CON TOX, V60, P77, DOI 10.1007/s00244-010-9526-1
   Boucher G, 1997, CORAL REEFS, V16, P177, DOI 10.1007/s003380050072
   Boufahja F, 2015, J NEMATOL, V47, P198
   Boufahja F, 2015, CAH BIOL MAR, V56, P39
   Buchanan J.B., 1971, INT BIOL PROGRAMME H, V16
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cesaroni L., 2017, MICROSCOPIE, P31
   Clarke K. R., 2001, CHANGES MARINE COMMU
   CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x
   COULL BC, 1992, OCEANOGR MAR BIOL, V30, P191
   Davies IM, 1998, AQUACULTURE, V163, P29, DOI 10.1016/S0044-8486(98)00211-7
   Davies IM, 1997, AQUACULTURE, V158, P263, DOI 10.1016/S0044-8486(97)00209-3
   Decraemer W, 2014, HBK ZOOL, P1
   FABIANO M, 1994, HYDROBIOLOGIA, V277, P71, DOI 10.1007/BF00016755
   FITZHUGH GR, 1985, B MAR SCI, V36, P436
   Guo Y, 2001, J MAR BIOL ASSOC UK, V81, P755, DOI 10.1017/S0025315401004568
   HALLEY BA, 1993, VET PARASITOL, V48, P109, DOI 10.1016/0304-4017(93)90149-H
   Hedfi A, 2007, B ENVIRON CONTAM TOX, V79, P345, DOI 10.1007/s00128-007-9261-0
   HEIP C, 1985, OCEANOGR MAR BIOL, V23, P399
   Hermi M, 2009, ARCH ENVIRON CON TOX, V56, P426, DOI 10.1007/s00244-008-9217-3
   Lee MR, 2005, MAR ENVIRON RES, V59, P1, DOI 10.1016/j.marenvres.2004.01.002
   Louati H, 2013, ENVIRON SCI POLLUT R, V20, P300, DOI 10.1007/s11356-012-0860-x
   Mahmoudi E, 2007, J EXP MAR BIOL ECOL, V343, P217, DOI 10.1016/j.jembe.2006.12.017
   Mahmoudi E, 2005, MAR POLLUT BULL, V50, P1197, DOI 10.1016/j.marpolbul.2005.04.018
   Mesa L, 2020, SCI TOTAL ENVIRON, V706, DOI 10.1016/j.scitotenv.2019.135692
   Moens T, 1997, J MAR BIOL ASSOC UK, V77, P211, DOI 10.1017/S0025315400033889
   Platt H.M., 1983, SYNOPSES BRIT FAU 1, V28
   Platt H.M., 1988, SYNOPSES BRIT FAUN 2, V38
   Raes M, 2007, CORAL REEFS, V26, P113, DOI 10.1007/s00338-006-0184-8
   Sanderson H, 2007, AQUAT TOXICOL, V85, P229, DOI 10.1016/j.aquatox.2007.08.011
   Schratzberger M, 1998, MAR ECOL PROG SER, V164, P83, DOI 10.3354/meps164083
   Schratzberger M, 2004, MAR BIOL, V145, P69, DOI 10.1007/s00227-004-1302-1
   Schweitzer N, 2010, AQUAT TOXICOL, V97, P304, DOI 10.1016/j.aquatox.2009.12.017
   Seinhorst J. W., 1959, Nematologica, V4, P67
   Semprucci F, 2018, MAR ENVIRON RES, V135, P114, DOI 10.1016/j.marenvres.2018.02.001
   Thain JE, 1997, AQUACULTURE, V159, P47, DOI 10.1016/S0044-8486(97)00210-X
   Vitiello P., 1979, Rapports et Proces-Verbaux des Reunions Commission Internationale pour l'Exploration Scientifique de la Mer Mediterranee Monaco, V25-26, P279
   Warwick R.M., 1998, SYNOPSIS BRIT FAUN 3, V53
   Whitworth J, 2020, T ROY SOC TROP MED H, V114, P227, DOI 10.1093/trstmh/traa025
   Wieser, 1953, ZOOL ARCH, V4, P439
   Wilcox J.R., 1979, BIOL BULL, V146, P424
NR 50
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0025-326X
EI 1879-3363
J9 MAR POLLUT BULL
JI Mar. Pollut. Bull.
PD AUG
PY 2020
VL 157
AR 111375
DI 10.1016/j.marpolbul.2020.111375
PG 9
WC Environmental Sciences; Marine & Freshwater Biology
SC Environmental Sciences & Ecology; Marine & Freshwater Biology
GA MK1FD
UT WOS:000548531100021
PM 32658716
OA Green Published
DA 2021-01-01
ER

PT J
AU Feng, ZL
   Glasser, JW
   Hill, AN
AF Feng, Zhilan
   Glasser, John W.
   Hill, Andrew N.
TI On the benefits of flattening the curve: A perspective
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Epidemic curves; Peak magnitude and timing; Total infections; Impact of
   mitigation measures
AB The many variations on a graphic illustrating the impact of non-pharmaceutical measures to mitigate pandemic influenza that have appeared in recent news reports about COVID-19 suggest a need to better explain the mechanism by which social distancing reduces the spread of infectious diseases. And some reports understate one benefit of reducing the frequency or proximity of interpersonal encounters, a reduction in the total number of infections. In hopes that understanding will increase compliance, we describe how social distancing (a) reduces the peak incidence of infections, (b) delays the occurrence of this peak, and (c) reduces the total number of infections during epidemics. In view of the extraordinary efforts underway to identify existing medications that are active against SARS-COV-2 and to develop new antiviral drugs, vaccines and antibody therapies, any of which may have community-level effects, we also describe how pharmaceutical interventions affect transmission.
C1 [Feng, Zhilan] Purdue Univ, Dept Math, W Lafayette, IN 47907 USA.
   [Feng, Zhilan] Natl Sci Fdn, Div Math Sci, Alexandria, VA USA.
   [Glasser, John W.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Hill, Andrew N.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Glasser, JW (corresponding author), 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM jglasser@cdc.gov
FU National Science FoundationNational Science Foundation (NSF)
   [DMS-1814545]; Independent Research/Development Program
FX ZF acknowledges support from the National Science Foundation via
   DMS-1814545 and the Independent Research/Development Program.
CR Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Nash A., 2015, MIMS PATHOGENESIS IN, P365
   Qualls N, 2017, MMWR RECOMM REP, V66, P1, DOI 10.15585/mmwr.rr6601a1
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
NR 6
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD AUG
PY 2020
VL 326
AR 108389
DI 10.1016/j.mbs.2020.108389
PG 3
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA ML3QG
UT WOS:000549384100004
PM 32473161
OA Green Published
DA 2021-01-01
ER

PT J
AU Safavi, F
   Nourbakhsh, B
   Azimi, AR
AF Safavi, Farinaz
   Nourbakhsh, Bardia
   Azimi, Amir Reza
TI B-cell depleting therapies may affect susceptibility to acute
   respiratory illness among patients with multiple sclerosis during the
   early COVID-19 epidemic in Iran
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE Multiple Sclerosis; COVID-19; DMTs; B-cell depleting therapies
ID INFECTION RISK; INTERFERON; HEALTH
AB Objective: To determine whether the course of COVID-19 is more severe in patients with MS and if MS disease-modifying treatments (DMTs) affect the risk of contracting the disease.
   Methods: In a cross-sectional survey, data were collected by sending a questionnaire to 2000 patients with a demyelinating disease through an online portal system. Collected data included the current MS DMT and patient-reported disability level, history of recent sick contact, recent fever, respiratory symptoms, diagnosis with COVID-19, and the disposition after the diagnosis. We defined a COVID-19-suspect group as patients having fever and cough or fever and shortness of breath, or a presumptive diagnosis based on suggestive chest computed tomography. We calculated the proportion of COVID-19-suspect patients and compared their demographics, clinical characteristics, and DMT categories with the rest of survey-responders, using univariable and multivariable models.
   Results: Out of 712 patients, 34 (4.8%) fulfilled our criteria for being in the COVID-19-suspect group. Only two patients required hospitalization. No patient required intensive care. In a multivariable model, disease duration (p-value=0.017), DMT category (p-value=0.030), and history of sick contact (p-values<0.001) were associated with the risk of being in the COVID-19-suspect group. Being on B-cell depleting antibodies (as compared to non-cell depleting, non-cell trafficking inhibitor DMTs) was associated with a 2.6-fold increase in the risk of being in the COVID-19-suspect group. (RR: 3.55, 95%CI: 1.45, 8.68, p-value=0.005).
   Conclusions: The course of infection in patients with MS suspected of having COVID-19 was mild to moderate, and all patients had a full recovery. B-cell depleting antibodies may increase the susceptibility to contracting COVID-19.
C1 [Safavi, Farinaz] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Nourbakhsh, Bardia] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
   [Azimi, Amir Reza] Univ Tehran Med Sci, MS Res Ctr, Neurosci Inst, Tehran, Iran.
RP Azimi, AR (corresponding author), Univ Tehran Med Sci, Dept Neurol, Sina Hosp, Imam Khomeini Ave, Tehran, Iran.
EM a-azimi@sina.tums.ac.ir
CR Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2
   Borriello G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102165
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839
   De Stefano N, 2020, NAT REV NEUROL, V16, P463, DOI 10.1038/s41582-020-0378-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Luna G., 2019, JAMA NEUROL, V7, DOI [10.1001/jamaneurol.2019.3365. 77, DOI 10.1001/JAMANEUROL.2019.3365.77]
   Najjar E, 2020, J NEUROIMMUNOL, V343, DOI 10.1016/j.jneuroim.2020.577230
   Nelson Richard E, 2015, Int J MS Care, V17, P221, DOI 10.7224/1537-2073.2014-035
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wijnands JMA, 2017, MULT SCLER J, V23, P1506, DOI 10.1177/1352458516681198
   Wijnands JMA, 2018, J NEUROL NEUROSUR PS, V89, P1050, DOI 10.1136/jnnp-2017-317493
   Williamson EM, 2015, CNS DRUGS, V29, P229, DOI 10.1007/s40263-015-0226-2
   Winkelmann A, 2016, NAT REV NEUROL, V12, P217, DOI 10.1038/nrneurol.2016.21
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
NR 22
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD AUG
PY 2020
VL 43
AR 102195
DI 10.1016/j.msard.2020.102195
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA MK3FA
UT WOS:000548668100013
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Braus, M
   Morton, B
AF Braus, Mallory
   Morton, Brenda
TI Art Therapy in the Time of COVID-19
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE art therapy; trauma; COVID-19
AB We are fighting two invisible enemies: COVID-19 and mental health challenges due to unmitigated stress and trauma as we follow directions to avoid the spread of the virus. To address the mental health challenges, art therapy is offered as a tool to support individuals during periods of isolation. Art therapy is a wonderful self-care activity that can benefit individuals throughout the life span.
C1 [Braus, Mallory; Morton, Brenda] George Fox Univ, Sch Educ, Newberg Campus, Newberg, OR 97132 USA.
RP Morton, B (corresponding author), George Fox Univ, Sch Educ, 414 North Meridian, Newberg, OR 97132 USA.
EM bmorton@georgefox.edu
CR Allen AB, 2014, GERONTOLOGIST, V54, P190, DOI 10.1093/geront/gns204
   Barnard LK, 2011, REV GEN PSYCHOL, V15, P289, DOI 10.1037/a0025754
   Ceausu F., 2018, REV ARTISTIC ED, V16, P203, DOI [10.2478/RAE-2018-0022, DOI 10.2478/RAE-2018-0022]
   Foa EB, 2008, EFFECTIVE TREATMENTS
   Hass-Cohen N., 2008, ART THERAPY CLIN NEU
   Johnson D. R., 2009, EFFECTIVE TREATMENTS, P600
   Malchiodi C, 2007, ART THERAPY SOURCE B
   Moon B., 2006, ETHICAL ISSUES ART T
   Williams P. R., 2018, CANADIAN ART THERAPY, V31, P23, DOI [10.1080/08322473.2018.1454687, DOI 10.1080/08322473.2018.1454687]
NR 9
TC 1
Z9 1
U1 8
U2 8
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD AUG
PY 2020
VL 12
SU 1
SI SI
BP S267
EP S268
DI 10.1037/tra0000746
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EW
UT WOS:000548599700099
PM 32478544
DA 2021-01-01
ER

PT J
AU Gurwitch, RH
   Salem, H
   Nelson, MM
   Comer, JS
AF Gurwitch, Robin H.
   Salem, Hanan
   Nelson, Melanie M.
   Comer, Jonathan S.
TI Leveraging Parent-Child Interaction Therapy and Telehealth Capacities to
   Address the Unique Needs of Young Children During the COVID-19 Public
   Health Crisis
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE COVID-19; PCIT; telehealth
ID DISASTERS; YOUTH; TIME; HOME
AB COVID-19 and related efforts to mitigate its spread have dramatically transformed the structure and predictability of modern childhood, resulting in growing concerns children may be particularly vulnerable to serious mental health consequences. Worldwide stay-at-home directives and emergency changes in healthcare policy and reimbursement have smoothed the trail for broad implementation of technology-based remote mental health services for children. Parent-Child Interaction Therapy (PCIT) is particularly well-positioned to address some of the most pressing child and parental needs that arise during stressful times, and telehealth formats of PCIT, such as Internet-delivered PCIT (iPCIT), have already been supported in controlled trials. This commentary explores PCIT implementation during the COVID-19 public health crisis and the challenges encountered in the move toward Internet-delivered services.
C1 [Gurwitch, Robin H.] Duke Univ, Med Ctr, Ctr Child & Family Hlth, 1121 West Chapel Hill St,Suite 100, Durham, NC 27703 USA.
   [Salem, Hanan; Comer, Jonathan S.] Florida Int Univ, Ctr Children & Families, Miami, FL 33199 USA.
   [Nelson, Melanie M.] Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL USA.
RP Gurwitch, RH (corresponding author), Duke Univ, Med Ctr, Ctr Child & Family Hlth, 1121 West Chapel Hill St,Suite 100, Durham, NC 27703 USA.
EM robin.gurwitch@duke.edu
CR Brinkmeyer MY, 2003, EVIDENCE-BASED PSYCHOTHERAPIES FOR CHILDREN AND ADOLESCENTS, P204
   Chaffin M, 2004, J CONSULT CLIN PSYCH, V72, P500, DOI 10.1037/0022-006X.72.3.500
   Cluver L, 2020, LANCET, V395, pE64, DOI 10.1016/S0140-6736(20)30736-4
   Cohen-Silver R., 2020, FLATT CURV FOR PAND
   Comer JS, 2017, J CONSULT CLIN PSYCH, V85, P909, DOI 10.1037/ccp0000230
   Comer JS, 2015, COGN BEHAV PRACT, V22, P302, DOI 10.1016/j.cbpra.2014.07.003
   DePierro Jonathan, 2019, Psychol Trauma, DOI 10.1037/tra0000532
   Eyberg SM, 2011, PARENT CHILD INTERAC
   Furr JM, 2010, J CONSULT CLIN PSYCH, V78, P765, DOI 10.1037/a0021482
   Gurwitch R. H., 2017, EVIDENCE BASED TREAT, P341, DOI [10.1007/978-3-319-46138-0_16, DOI 10.1007/978-3-319-46138-0_16]
   Kar N, 2009, WORLD J PEDIATR, V5, P5, DOI 10.1007/s12519-009-0001-x
   Kerns CE, 2014, J AFFECT DISORDERS, V167, P50, DOI 10.1016/j.jad.2014.05.040
   Lieneman CC, 2017, PSYCHOL RES BEHAV MA, V10, P239, DOI 10.2147/PRBM.S91200
   Morland LA, 2015, INT REV PSYCHIATR, V27, P504, DOI 10.3109/09540261.2015.1082986
   SAMHSA, 2018, DIS TECHN ASS CTR SU
   Scheeringa MS, 2008, J CLIN CHILD ADOLESC, V37, P508, DOI 10.1080/15374410802148178
   U.S. Department of Health and Human Services, 2020, SECR AZ ANN HIST EXP
   Vernberg EM, 2008, PROF PSYCHOL-RES PR, V39, P381, DOI 10.1037/a0012663
NR 18
TC 2
Z9 2
U1 12
U2 13
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD AUG
PY 2020
VL 12
SU 1
SI SI
BP S82
EP S84
DI 10.1037/tra0000863
PG 3
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EW
UT WOS:000548599700030
PM 32538646
DA 2021-01-01
ER

PT J
AU Haller, M
   Norman, SB
   Davis, BC
   Capone, C
   Browne, K
   Allard, CB
AF Haller, Moira
   Norman, Sonya B.
   Davis, Brittany C.
   Capone, Christy
   Browne, Kendall
   Allard, Carolyn B.
TI A Model for Treating COVID-19-Related Guilt, Shame, an Moral Injury
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE moral injury; COVID-19; guilt; shame; intervention
ID TRAUMA-RELATED GUILT; THERAPY
AB During the unprecedented COVID-19 pandemic, people around the world have faced a myriad of heart-rending and ethically difficult scenarios (e.g., not being able to tend to a sick or dying loved one) that may lead to subsequent guilt, shame, or moral injury. Trauma-informed guilt reduction therapy is a brief intervention that helps clients accurately appraise their role in a stressful event (such as those experienced during the COVID-19 pandemic) and find positive ways to express important values going forward. Future studies of trauma-informed guilt reduction therapy with those affected by COVID-19 will be helpful for clarifying its effectiveness with this population.
C1 [Haller, Moira; Allard, Carolyn B.] Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.
   [Haller, Moira; Norman, Sonya B.] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA.
   [Norman, Sonya B.] Natl Ctr PTSD, White River Jct, VT USA.
   [Davis, Brittany C.] James A Haley Vet Hosp, Tampa, FL 33612 USA.
   [Davis, Brittany C.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL 33620 USA.
   [Capone, Christy] Providence Vet Affairs Med Ctr, Providence, RI USA.
   [Capone, Christy] Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Sch Med, Providence, RI 02912 USA.
   [Browne, Kendall] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Addict Treatment & Educ, Seattle, WA USA.
   [Browne, Kendall] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Allard, Carolyn B.] Alliant Int Univ, Calif Sch Profess Psychol, Dept Clin Psychol, San Diego, CA USA.
RP Haller, M (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.
EM mohaller@health.ucsd.edu
OI Allard, Carolyn/0000-0002-7803-2243; Norman, Sonya/0000-0002-4751-1882
FU CDMPR Grants [W81XWH-15-1-0330, W81XWH-15-1-0331]
FX This work was supported by CDMPR Grants W81XWH-15-1-0330 (pricncipal
   investigator: Sonya B. Norman) and W81XWH-15-1-0331 (principal
   investigator: Christy Capone). Some of the authors (Sonya B. Norman,
   Brittany C. Davis, Christy Capone, Kendall Browne, and Carolyn B.
   Allard) receive royalties from Elsevier Press.
CR Browne KC, 2015, J TRAUMA STRESS, V28, P134, DOI 10.1002/jts.21999
   Bryan CJ, 2013, DEPRESS ANXIETY, V30, P55, DOI 10.1002/da.22002
   Griffin BJ, 2019, J TRAUMA STRESS, V32, P350, DOI 10.1002/jts.22362
   Kubany ES, 1995, J PSYCHOPATHOL BEHAV, V17, P353, DOI 10.1007/BF02229056
   Kubany ES, 2004, J CONSULT CLIN PSYCH, V72, P3, DOI 10.1037/0022-006X.72.1.3
   Kubany ES, 2003, PSYCHOL REC, V53, P51
   Norman SB, 2018, J PSYCHIATR RES, V100, P56, DOI 10.1016/j.jpsychires.2018.02.003
   Norman Sonya, 2019, TRAUMA INFORM GUILT
   Norman SB, 2014, COGN BEHAV PRACT, V21, P78, DOI 10.1016/j.cbpra.2013.08.001
   Shanafelt T, 2020, JAMA-J AM MED ASSOC, V323, P2133, DOI 10.1001/jama.2020.5893
   Tangney JP, 2007, ANNU REV PSYCHOL, V58, P345, DOI 10.1146/annurev.psych.56.091103.070145
   Wilkins K. C., 2013, ANX DEPR ASS AM ANN
   Williamson Victoria, 2020, Occup Med (Lond), V70, P317, DOI 10.1093/occmed/kqaa052
NR 13
TC 3
Z9 3
U1 3
U2 4
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD AUG
PY 2020
VL 12
SU 1
SI SI
BP S174
EP S176
DI 10.1037/tra0000742
PG 3
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EW
UT WOS:000548599700064
PM 32551775
DA 2021-01-01
ER

PT J
AU Johnson, MT
   Johnson, EA
   Webber, L
   Nettle, D
AF Johnson, Matthew Thomas
   Johnson, Elliott Aidan
   Webber, Laura
   Nettle, Daniel
TI Mitigating Social and Economic Sources of Trauma: The Need for Universal
   Basic Income During the Coronavirus Pandemic
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE economic shock; unpredictability; trauma; universal basic income
ID POSTTRAUMATIC-STRESS-DISORDER
AB The COVID-19 pandemic is projected to cause an economic shock larger than the global financial crisis of 2007-2008 and a recession as great as anything seen since the Great Depression in 1930s. The social and economic consequences of lockdowns and social distancing measures, such as unemployment, broken relationships and homelessness. create potential for intergenerational trauma extending decades into the future. In this article, we argue that, in the absence of a vaccine, governments need to introduce universal basic income as a means of mitigating this trauma.
C1 [Johnson, Matthew Thomas; Johnson, Elliott Aidan] Univ Lancaster, Dept Polit Philosophy & Relig, Lancaster LA1 4YL, England.
   [Webber, Laura] HealthLumen Ltd, London, England.
   [Nettle, Daniel] Newcastle Univ, Inst Populat Hlth Sci, Newcastle Upon Tyne, Tyne & Wear, England.
RP Johnson, MT (corresponding author), Univ Lancaster, Dept Polit Philosophy & Relig, Lancaster LA1 4YL, England.
EM m.johnson@lancs.ac.uk
RI Johnson, Matthew Thomas/H-3658-2017
OI Johnson, Matthew Thomas/0000-0002-9987-7050; Johnson,
   Elliott/0000-0002-0937-6894; Nettle, Daniel/0000-0001-9089-2599
CR American Psychological Association, 2020, TRAUMA
   American Psychological Association, 2013, REC EM DIS
   Bjornsdotter M, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00024
   Dreman S., 1991, J TRAUMA STRESS, V4, P113, DOI DOI 10.1002/JTS.2490040109
   Duxbury F, 2006, BRIT J GEN PRACT, V56, P294
   Foroohar R., 2020, FINANCIAL TIMES
   Gibson M., 2018, UNIVERSAL BASIC INCO
   GOODMAN L, 1991, AM PSYCHOL, V46, P1219, DOI 10.1037/0003-066X.46.11.1219
   Gopinath G., 2020, GREAT LOCKDOWN WORST
   Johnson E. A., 2020, EVID POLICY, DOI [10.1332/174426420X15820274674068, DOI 10.1332/174426420X15820274674068]
   Johnson MT, 2019, SOC THEOR HEALTH, V17, P253, DOI 10.1057/s41285-018-0076-3
   Kangas O., 2019, BASIC INCOME EXPT 20
   Khoury L, 2010, DEPRESS ANXIETY, V27, P1077, DOI 10.1002/da.20751
   McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3
   Ng K., 2020, INDEPENDENT
   Painter A, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6473
   PETTIT P, 2007, BASIC INCOME STUDIES, V2, P1, DOI DOI 10.2202/1932-0183.1082
   Sheahan A., 2003, BASIC INCOME GUARANT
   Thoits PA, 2010, J HEALTH SOC BEHAV, V51, pS41, DOI 10.1177/0022146510383499
   Webber L, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3377
   Widerquist K, 2013, EXPLOR BASIC INCOME, P1, DOI 10.1057/9781137313096
   Yang2020, 2020, FREEDOM DIVIDEND
NR 22
TC 1
Z9 1
U1 11
U2 11
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD AUG
PY 2020
VL 12
SU 1
SI SI
BP S191
EP S192
DI 10.1037/tra0000739
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EW
UT WOS:000548599700070
PM 32551770
OA Green Accepted
DA 2021-01-01
ER

PT J
AU Stojanovic, M
   El-Khatib, Z
   Brandic, AR
   Maalouf, W
AF Stojanovic, Milos
   El-Khatib, Ziad
   Brandic, Alma Rovis
   Maalouf, Wadih
TI Lions Quest Skills for Adolescence Implementation During COVID-19
   Challenges in Croatia
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE online teaching; social emotional learning; COVID-19; Croatia; Lions
   Quest Skills for Adolescence
AB Globally, the Coronavirus-2019 (COVID-19) pandemic situation has affected the education system. forcing students to start distance learning. Consequently, education of students reverted to online platforms or TV station broadcasts. Extracurricular programs have also experienced a setback given the natural prioritization of mandatory school subjects. Meanwhile, the United Nations Office on Drugs and Crime (UNODC) was implementing a teacher-led extracurricular activity for children of age 10-15 years to prevent substance use and other negative life and social consequences (Lions Quest Skills for Adolescence [LQSFA]). Due to the COVID-19 pandemic, LQSFA was difficult to sustain, partly as it was considered extracurricular and partly given its interactive requirement that was difficult to apply through distance learning. Nevertheless. schools' facilitators managed to adapt the program information sharing and communication strategies with the student groups and identified essential sessions allowing continuity of program implementation and utilization of critical program skills during COVID-19 pandemic. The practical implication of the facilitators' assessment of the relevance, value, motivation and feasibility of the implementation of the LQSFA program within the current COVID- 19 circumstances calls for the eminent need for adaptation of its implementation modality to meet the current educational delivery circumstances.
C1 [Stojanovic, Milos] United Nat Off Drugs & Crime UNODC, Programme Off Serbia, Belgrade, Serbia.
   [El-Khatib, Ziad] United Nat Off Drugs & Crime UNODC, Drug Prevent & Hlth Branch, Vienna, Austria.
   [El-Khatib, Ziad] Univ Quebec Abitibi Temiscamingue UQAT, World Hlth Programme, Rouyn Noranda, PQ, Canada.
   [Brandic, Alma Rovis] Educ & Teacher Training Agcy, High Sch Dept, Zagreb, Croatia.
   [Maalouf, Wadih] United Nat Off Drugs & Crime UNODC, Prevent Treatment & Rehabil Sect, Drug Prevent & Hlth Branch, Room D 1419,POB 500, A-1400 Vienna, Austria.
RP Maalouf, W (corresponding author), United Nat Off Drugs & Crime UNODC, Prevent Treatment & Rehabil Sect, Drug Prevent & Hlth Branch, Room D 1419,POB 500, A-1400 Vienna, Austria.
EM wadih.maalouf@un.org
RI Maalouf, Wadih/AAY-1383-2020; El-Khatib, Ziad/B-5161-2017
OI Maalouf, Wadih/0000-0003-1820-3693; El-Khatib, Ziad/0000-0003-0756-7280
CR Maalouf W, 2019, PREV SCI, V20, P555, DOI 10.1007/s11121-019-01012-6
   UNODC, 2018, INT STAND DRUG US PR
NR 2
TC 0
Z9 0
U1 3
U2 3
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD AUG
PY 2020
VL 12
SU 1
SI SI
BP S274
EP S275
DI 10.1037/tra0000843
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EW
UT WOS:000548599700102
PM 32496105
DA 2021-01-01
ER

PT J
AU Yamaguchi, K
   Takebayashi, Y
   Miyamae, M
   Komazawa, A
   Yokoyama, C
   Ito, M
AF Yamaguchi, Keiko
   Takebayashi, Yoshitake
   Miyamae, Mitsuhiro
   Komazawa, Asami
   Yokoyama, Chika
   Ito, Masaya
TI Role of Focusing on the Positive Side During COVID-19 Outbreak: Mental
   Health Perspective From Positive Psychology
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE positive emotion; COVID-19; pandemic; strength
ID THERAPY
AB This paper discusses how positive emotions can help maintain and improve mental health during the COVID-19 outbreak. taking into account examples of social interaction and positive psychology research efforts in Japanese context.
C1 [Yamaguchi, Keiko; Takebayashi, Yoshitake; Miyamae, Mitsuhiro; Komazawa, Asami; Yokoyama, Chika; Ito, Masaya] Natl Ctr Neurol & Psychiat, Natl Ctr Cognit Behav Therapy & Res, Tokyo, Japan.
   [Takebayashi, Yoshitake] Fukushima Med Univ, Sch Med, Dept Hlth Risk Commun, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
   [Miyamae, Mitsuhiro] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo, Japan.
RP Takebayashi, Y (corresponding author), Fukushima Med Univ, Sch Med, Dept Hlth Risk Commun, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
EM ytake2@fmu.ac.jp
OI Takebayashi, Yoshitake/0000-0002-6366-0087; Yamaguchi,
   Keiko/0000-0002-1954-7503; Ito, Masaya/0000-0003-2295-9733
CR Fava GA, 2017, DEPRESS ANXIETY, V34, P801, DOI 10.1002/da.22629
   Hoshino G., 2020, I WAS STAYING HOME M
   Ito M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15819
   Komazawa A., 2017, 19 ANN M JAP PSYCH A
   LOOI MK, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1447
   Padesky CA, 2012, CLIN PSYCHOL PSYCHOT, V19, P283, DOI 10.1002/cpp.1795
   Quoidbach J, 2010, PERS INDIV DIFFER, V49, P368, DOI 10.1016/j.paid.2010.03.048
   Santos L., 2020, HAPPINESS LAB L SANT
   Strampe L., 2020, ANIMAL CROSSING NEW
   Yamaguchi K, 2018, PSYCHOL PSYCHOTHER-T, V91, P509, DOI 10.1111/papt.12176
NR 10
TC 1
Z9 1
U1 17
U2 17
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD AUG
PY 2020
VL 12
SU 1
SI SI
BP S49
EP S50
DI 10.1037/tra0000807
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EW
UT WOS:000548599700017
PM 32525365
DA 2021-01-01
ER

PT J
AU Dastan, F
   Nadji, SA
   Saffaei, A
   Marjani, M
   Moniri, A
   Jamaati, H
   Hashemian, SM
   Baghaei, P
   Abedini, A
   Varahram, M
   Yousefian, S
   Tabarsi, P
AF Dastan, Farzaneh
   Nadji, Seyed Alireza
   Saffaei, Ali
   Marjani, Majid
   Moniri, Afshin
   Jamaati, Hamidreza
   Hashemian, Seyed MohammadReza
   Baghaei, Parvaneh
   Abedini, Atefeh
   Varahram, Mohammad
   Yousefian, Sahar
   Tabarsi, Payam
TI Subcutaneous administration of interferon beta-1a for COVID-19: A
   non-controlled prospective trial
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Interferon Beta-1a; COVID-19; Coronavirus; Pulmonary infection
ID I INTERFERONS; CORONAVIRUS; EXPRESSION
AB Background: Recently, a new coronavirus spreads rapidly throughout the countries and resulted in a worldwide epidemic. Interferons have direct antiviral and immunomodulatory effects. Antiviral effects may include inhibition of viral replication, protein synthesis, virus maturation, or virus release from infected cells. Previous studies have shown that some coronaviruses are susceptible to interferons. The aim of this study was to evaluate the therapeutic effects of IFN-beta-1a administration in COVID-19.
   Methods: In this prospective non-controlled trial, 20 patients included. They received IFN-beta-1a at a dose of 44 mu g subcutaneously every other day up to 10 days. All patients received conventional therapy including Hydroxychloroquine, and lopinavir/ritonavir. Demographic data, clinical symptoms, virological clearance, and imaging findings recorded during the study.
   Results: The mean age of the patients was 58.55 +/- 13.43 years. Fever resolved in all patients during first seven days. Although other symptoms decreased gradually. Virological clearance results showed a significant decrease within 10 days. Imaging studies showed significant recovery after 14-day period in all patients. The mean time of hospitalization was 16.8 +/- 3.4 days. There were no deaths or significant adverse drug reactions in the 14-day period.
   Conclusions: Our findings support the use of IFN-beta-1a in combination with hydroxychloroquine and lopinavir/ritonavir in the management of COVID-19.
C1 [Dastan, Farzaneh; Yousefian, Sahar] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Tehran, Iran.
   [Dastan, Farzaneh; Jamaati, Hamidreza; Hashemian, Seyed MohammadReza; Abedini, Atefeh; Yousefian, Sahar] Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr CRDRC, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Nadji, Seyed Alireza; Moniri, Afshin] Shahid Beheshti Univ Med Sci, Virol Res Ctr, Natl Inst TB & Lung Dis, Tehran, Iran.
   [Saffaei, Ali] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Student Res Comm, Tehran, Iran.
   [Marjani, Majid; Baghaei, Parvaneh; Tabarsi, Payam] Shahid Beheshti Univ Med Sci, Clin TB & Epidemiol Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Daarabad St,Niyavaran St, Tehran, Iran.
   [Varahram, Mohammad] Shahid Beheshti Univ Med Sci, Mycobacteriol Res Ctr, Natl Res Inst TB & Lung Dis, Tehran, Iran.
RP Tabarsi, P (corresponding author), Shahid Beheshti Univ Med Sci, Clin TB & Epidemiol Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Daarabad St,Niyavaran St, Tehran, Iran.
EM tabarsi@nritld.ac.ir
RI Marjani, Majid/H-5191-2012
OI Marjani, Majid/0000-0003-1466-8645
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Bellingan G, 2014, LANCET RESP MED, V2, P98, DOI 10.1016/S2213-2600(13)70259-5
   Blanco-Melo D., 2020, CELL
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Davidson S, 2015, J INTERF CYTOK RES, V35, P252, DOI 10.1089/jir.2014.0227
   Gonzalez-Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133
   Hadjadj J., 2020, IMPAIRED TYPE 1 INTE
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Jamaati H., 2020, IRAN J PHARM RES
   Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x
   Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015
   Medrano RFV, 2017, ONCOTARGET, V8, P71249, DOI 10.18632/oncotarget.19531
   Muller L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00304
   Osterlund P, 2005, J VIROL, V79, P9608, DOI 10.1128/JVI.79.15.9608-9617.2005
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Teijaro JR, 2016, CURR OPIN VIROL, V16, P31, DOI 10.1016/j.coviro.2016.01.001
   Wu Z, 2020, JAMA
   Xia SM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5370706
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
NR 22
TC 13
Z9 13
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD AUG
PY 2020
VL 85
AR 106688
DI 10.1016/j.intimp.2020.106688
PG 5
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA MJ5QA
UT WOS:000548143500084
PM 32544867
OA Green Published
DA 2021-01-01
ER

PT J
AU Aggarwal, G
   Henry, BM
   Aggarwal, S
   Bangalore, S
AF Aggarwal, Gaurav
   Henry, Brandon Michael
   Aggarwal, Saurabh
   Bangalore, Sripal
TI Cardiovascular Safety of Potential Drugs for the Treatment of
   Coronavirus Disease 2019
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID AZITHROMYCIN; RISK
AB Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Aggarwal, Gaurav] Jersey City Med Ctr, Jersey City, NJ USA.
   [Henry, Brandon Michael] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Aggarwal, Saurabh] Unitypoint Clin, Des Moines, IA USA.
   [Bangalore, Sripal] NYU, Sch Med, New York, NY USA.
RP Bangalore, S (corresponding author), 550 First Ave, New York, NY 10016 USA.
EM sripalbangalore@gmail.com
OI Bangalore, Sripal/0000-0001-9485-0652; Aggarwal,
   Gaurav/0000-0002-8180-9287
CR Aggarwal G, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100617
   [Anonymous], 2013, Med Lett Drugs Ther, V55, P28
   Bacchiega BC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005038
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chaubey SK, 2009, SEX HEALTH, V6, P254, DOI 10.1071/SH09005
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Cheng YJ, 2015, J AM COLL CARDIOL, V66, P2173, DOI 10.1016/j.jacc.2015.09.029
   Chinello P, 2017, PLOS NEGLECT TROP D, V11, DOI [10.1371/journal.pntd.0006034, DOI 10.1371/JOURNAL.PNTD.0006034]
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   El-Dosouky II, 2016, J INDIAN COLL CARDIO, V6, P16
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   LADIPO GOA, 1983, INT J CARDIOL, V4, P198, DOI 10.1016/0167-5273(83)90136-5
   Lee DH, 2004, AM J CLIN NUTR, V80, P1194
   Lee Jae Hak, 2010, Korean Circ J, V40, P604, DOI 10.4070/kcj.2010.40.11.604
   Limsreng S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160306
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Rao GA, 2014, ANN FAM MED, V12, P121, DOI 10.1370/afm.1601
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Reffelmann T, 2006, CIRCULATION, V114, pE357, DOI 10.1161/CIRCULATIONAHA.105.600627
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055
   Svanstrom H, 2013, NEW ENGL J MED, V368, P1704, DOI 10.1056/NEJMoa1300799
   Teragawa H, 1996, JPN HEART J, V37, P905
   Thome R, 2013, IMMUNOL LETT, V153, P50, DOI 10.1016/j.imlet.2013.07.004
   Trac MH, 2016, CAN MED ASSOC J, V188, pE120, DOI 10.1503/cmaj.150901
   Trifiro G, 2017, CAN MED ASSOC J, V189, pE560, DOI 10.1503/cmaj.160355
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang ZJ, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.115.003560
NR 30
TC 5
Z9 5
U1 2
U2 2
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD AUG 1
PY 2020
VL 128
BP 147
EP 150
DI 10.1016/j.amjcard.2020.04.054
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MJ0VB
UT WOS:000547812800022
PM 32425199
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yu, JW
   Wang, L
   Bao, LD
AF Yu, Jiu-wang
   Wang, Lu
   Bao, Li-dao
TI Exploring the active compounds of traditional Mongolian medicine in
   intervention of novel coronavirus (COVID-19) based on molecular docking
   method
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Mongolian medicine; Phillyrin; Chlorogenic acid; COVID-19; S-protein;
   ACE2; SARS-CoV-2
ID RECEPTOR; PROTEIN
AB Objective: This article intends to use molecular docking technology to find potential inhibitors that can respond to COVID-19 from active compounds in Mongolian medicine.
   Methods: Mongolian medicine with anti-inflammatory and antiviral effects is selected from Mongolian medicine prescription preparations. TCMSP, ETCM database and document mining methods were used to collect active compounds. Swiss TargetPrediction and SuperPred server were used to find targets of compounds with smiles number. Drugbank and Genecard database were used to collect antiviral drug targets. Then the above targets were compared and analyzed to screen out antiviral targets of Mongolia medicine. Metascape database platform was used to enrich and analyze the GO (Gene ontology) annotation and KEGG pathway of the targets. In view of the high homology of gene sequences between SARS-CoV-2 S-protein RBD domain and SARS virus, as well as their similarities in pathogenesis and clinical manifestations, we established SARS-CoV-2 S-protein model using Swiss-Model. The ZDOCK protein docking software was applied to dock the S-protein with the human angiotensin ACE2 protein to find out the key amino acids of the binding site. Taking ACE2 as the receptor, the molecular docking between the active ingredients and the target protein was studied by AutoDock molecular docking software. The interaction between ligand and receptor is applied to provide a choice for screening anti-COVID-19 drugs.
   Results: A total of 253 active components were predicted. Metascape analysis showed that key candidate targets were significantly enriched in multiple pathways related to different toxins. These key candidate targets were mainly derived from phillyrin and chlorogenic acid. Through the protein docking between S-protein and ACE2, it is found that Glu329/Gln325 and Gln42/Asp38 in ACE2 play an important role in the binding process of the two. The results of molecular docking virtual calculation showed that phillyrin and chlorogenic acid could stably combine with Gln325 and Gln42/Asp38 in ACE2, respectively, which hindered the combination between Sprotein and ACE2.
   Conclusion: Phillyrin and chlorogenic acid can effectively prevent the combination of SARS-CoV-2 S-protein and ACE2 at the molecular level. Phillyrin and chlorogenic acid can be used as potential inhibitors of COVID-19 for further research and development.
C1 [Yu, Jiu-wang; Wang, Lu; Bao, Li-dao] Inner Mongolia Med Univ, Affiliated Hosp, Dept Pharm, Hohhot 010059, Inner Mongolia, Peoples R China.
RP Bao, LD (corresponding author), Inner Mongolia Med Univ, Affiliated Hosp, Hohhot 010059, Inner Mongolia, Peoples R China.
EM Nowitzki_2011@163.com
CR Arun V., 2015, International Journal of Advanced Intelligence Paradigms, V7, P342
   Chen Shaohua, 2008, FOOD SCI TECHNOLOGY, V33, P195
   Cotton M., 1993, LANCET, V382, P1993
   Duan H, 2019, CURR MOL MED, V19, P303, DOI 10.2174/1566524019666190405094125
   Duan Hongyan, 2009, J MODERN INTEGRATIVE, V18, P1214
   Dunkel M, 2008, NUCLEIC ACIDS RES, V36, pW55, DOI 10.1093/nar/gkn307
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Haiqing Xu., 2020, J LIAONING U TRADITI, V22, P164
   Hu Zongfu, 2006, Food Science, China, V27, P128
   Jianyong W., 2019, MED DIET HLTH, V16, P29
   Jiarui Wu, 2017, CHINESE J EXPT PRESC, V23, P179
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Haiyan, 2017, STRAIT PHARM J, V29, P46
   [李丽静 LI Lijing], 2005, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V11, P585
   [李营营 Li Yingying], 2018, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V35, P143
   Linjian Duan, 2012, CHINESE GEN PRACTITI, V15, P2082
   MA Z, 2020, NATURAL PRODUCT RES, V34
   Mao Lihua, 2018, JIANGSU SCI TECHNOLO, V35, P47
   Mo Hongying, 2005, J BASIC MED TRADITIO, V11, P194
   National Health Committee, 2020, DIAGN TREATM PLAN PN
   Normile Dennis, 2020, SCIENCE, DOI [10.1126/science:aba8542., DOI 10.1126/SCIENCE:ABA8542]
   Pan XL, 2014, INFLAMM RES, V63, P597, DOI 10.1007/s00011-014-0731-7
   Pan Zhaozhao, 2011, J PEDIAT TRADITIONAL, V7, P9
   Peng GQ, 2011, P NATL ACAD SCI USA, V108, P10696, DOI 10.1073/pnas.1104306108
   Qin Likui, 2016, EFFECT YINQIAOSAN RE
   Qu HH, 2008, J PHARM PHARMACOL, V60, P261, DOI 10.1211/jpp.60.2.0016
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ren Yajun, 2014, J CHINESE MATERIA ME, V39, P2295
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Sheng Xie-Huang, 2008, Chinese Journal of Natural Medicines, V6, P232, DOI 10.3724/SP.J.1009.2008.00232
   Tang Juri, 2012, UNIVERSITIES, V9, P114
   Wang Guanjie, 2013, PREPARATION YINQIAO
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan W., 2019, COMPUTER METHODS PRO, V95, P249
   Zefeng Wang, 2020, SHANXI TRADITIONAL C, V36, P45
   Zhang Haochao, 2017, FOOD PHARMACEUTICALS, V19, P222
   Zhang TianHong, 2020, Psychol Med, P1, DOI 10.1017/S0033291720000756
   Zhao Mengjiao, 2016, WORLD LATEST MED INF, V16, P33
   Zheng C. S., 2017, ZHENGGU, V29, P20
   林丽美, 2008, [中国中药杂志, China Journal of Chinese Materia Medica], V33, P473
NR 40
TC 4
Z9 4
U1 6
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD AUG
PY 2020
VL 71
AR 104016
DI 10.1016/j.jff.2020.104016
PG 10
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA MH7XU
UT WOS:000546937800020
PM 32421102
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cagnacci, A
   Bonaccorsi, G
   Gambacciani, M
AF Cagnacci, A.
   Bonaccorsi, G.
   Gambacciani, M.
CA Italian Menopause Soc
TI Reflections and recommendations on the COVID-19 pandemic: Should hormone
   therapy be discontinued?
SO MATURITAS
LA English
DT Letter
C1 [Cagnacci, A.] Obstet & Gynecol Clin, Genoa, Italy.
   [Bonaccorsi, G.] Obstet & Gynecol Clin, Ferrara, Italy.
   [Gambacciani, M.] Obstet & Gynecol Clin, Pisa, Italy.
RP Cagnacci, A (corresponding author), Univ Genoa, Osped Policlin San Martino IRCCS, Dipartimento Neurosci Riabilitaz Oftalmol Genet &, Ginecol & Ostetricia, Largo Benzi 10, I-16132 Genoa, Italy.
EM angelo.cagnacci@unige.it
RI Cagnacci, Angelo/Q-7432-2016
OI Cagnacci, Angelo/0000-0003-2714-623X
CR Cagnacci A, 2020, AM J OBSTET GYNECOL, V223, P453, DOI 10.1016/j.ajog.2020.05.039
   Cattaneo M., 2020, THROMB HAEMOSTASIS, DOI [10.1055/s-0040-1712097, DOI 10.1055/S-0040-474]
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Fruzzetti F, 2020, EUR J CONTRACEP REPR, V25, P231, DOI 10.1080/13625187.2020.1766016
   Ramirez I, 2020, MATURITAS, V137, P57, DOI 10.1016/j.maturitas.2020.04.019
   Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD AUG
PY 2020
VL 138
BP 76
EP 77
DI 10.1016/j.maturitas.2020.05.022
PG 2
WC Geriatrics & Gerontology; Obstetrics & Gynecology
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA MH7GY
UT WOS:000546894000011
PM 32565009
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yager, EJ
AF Yager, Eric J.
TI Antibody-dependent enhancement and COVID-19: Moving toward acquittal
SO CLINICAL IMMUNOLOGY
LA English
DT Letter
DE COVID-19; Coronavirus; Antiviral antibodies; Viral immunity; Vaccines
C1 [Yager, Eric J.] Albany Coll Pharm & Hlth Sci, Dept Basic & Clin Sci, 106 New Scotland Ave, Albany, NY 12208 USA.
RP Yager, EJ (corresponding author), Albany Coll Pharm & Hlth Sci, Dept Basic & Clin Sci, 106 New Scotland Ave, Albany, NY 12208 USA.
EM eric.yager@acphs.edu
CR Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   Joyner Michael, 2020, medRxiv, DOI 10.1101/2020.05.12.20099879
   Leung GM, 2006, EPIDEMIOL INFECT, V134, P211, DOI 10.1017/S0950268805004826
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Nguyen AA, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108459
   Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 10
TC 1
Z9 1
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD AUG
PY 2020
VL 217
AR 108496
DI 10.1016/j.clim.2020.108496
PG 2
WC Immunology
SC Immunology
GA MK4EK
UT WOS:000548738300021
PM 32526272
DA 2021-01-01
ER

PT J
AU Faivre-Finn, C
   Fenwick, JD
   Franks, KN
   Harrow, S
   Hatton, MQF
   Hiley, C
   McAleese, JJ
   McDonald, F
   O'Hare, J
   Peedell, C
   Pope, T
   Powell, C
   Rulach, R
   Toy, E
AF Faivre-Finn, C.
   Fenwick, J. D.
   Franks, K. N.
   Harrow, S.
   Hatton, M. Q. F.
   Hiley, C.
   McAleese, J. J.
   McDonald, F.
   O'Hare, J.
   Peedell, C.
   Pope, T.
   Powell, C.
   Rulach, R.
   Toy, E.
TI Reduced Fractionation in Lung Cancer Patients Treated with
   Curative-intent Radiotherapy during the COVID-19 Pandemic
SO CLINICAL ONCOLOGY
LA English
DT Article
DE COVID-19; fractionation; lung cancer; radiotherapy
ID BODY RADIATION-THERAPY; CHEST-WALL TOXICITY; CONCURRENT CHEMOTHERAPY;
   THORACIC RADIOTHERAPY; RISK-FACTORS; TRIAL; EXPERIENCE; MANAGEMENT;
   PHASE-2
AB Patients treated with curative-intent lung radiotherapy are in the group at highest risk of severe complications and death from COVID-19. There is therefore an urgent need to reduce the risks associated with multiple hospital visits and their anti-cancer treatment. One recommendation is to consider alternative dose-fractionation schedules or radiotherapy techniques. This would also increase radiotherapy service capacity for operable patients with stage I-III lung cancer, who might be unable to have surgery during the pandemic.
   Here we identify reduced-fractionation for curative-intent radiotherapy regimes in lung cancer, from a literature search carried out between 20/03/2020 and 30/03/2020 as well as published and unpublished audits of hypofractionated regimes from UK centres. Evidence, practical considerations and limitations are discussed for early-stage NSCLC, stage III NSCLC, early-stage and locally advanced SCLC. We recommend discussion of this guidance document with other specialist lung MDT members to disseminate the potential changes to radiotherapy practices that could be made to reduce pressure on other departments such as thoracic surgery. It is also a crucial part of the consent process to ensure that the risks and benefits of undergoing cancer treatment during the COVID-19 pandemic and the uncertainties surrounding toxicity from reduced fractionation have been adequately discussed with patients. Furthermore, centres should document all deviations from standard protocols, and we urge all colleagues, where possible, to join national/international data collection initiatives (such as COVID-RT Lung) aimed at recording the impact of the COVID-19 pandemic on lung cancer treatment and outcomes. (C) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Faivre-Finn, C.] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England.
   [Faivre-Finn, C.] Univ Manchester, Manchester, Lancs, England.
   [Fenwick, J. D.] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England.
   [Fenwick, J. D.] Clatterbridge Canc Ctr, Dept Phys, Wirral, Merseyside, England.
   [Franks, K. N.] St James Univ Hosp, Leeds Canc Ctr, Leeds, W Yorkshire, England.
   [Franks, K. N.] Univ Leeds, Leeds, W Yorkshire, England.
   [Harrow, S.; Rulach, R.] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
   [Harrow, S.; Rulach, R.] Univ Glasgow, Glasgow, Lanark, Scotland.
   [Hatton, M. Q. F.] Weston Pk Hosp, Broomhall, Sheffield, S Yorkshire, England.
   [Hiley, C.] UCL, CRUK Lung Canc Ctr Excellence, London, England.
   [Hiley, C.] Univ Coll London Hosp NHS Fdn Trust, Dept Clin Oncol, London, England.
   [McAleese, J. J.; O'Hare, J.] Belfast City Hosp, Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland.
   [McDonald, F.] Royal Marsden NHS Fdn Trust, London, England.
   [Peedell, C.] James Cook Univ Hosp, Middlesbrough, Cleveland, England.
   [Powell, C.] Singleton Hosp, South West Wales Canc Ctr, Swansea, W Glam, Wales.
   [Powell, C.] Velindre Canc Ctr, Cardiff, Wales.
   [Pope, T.] Clatterbridge Canc Ctr, Wirral, Merseyside, England.
   [Toy, E.] Exeter Hosp, Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England.
RP Faivre-Finn, C (corresponding author), Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England.
EM Corinne.Finn@christie.nhs.uk
OI Faivre-Finn, Corinne/0000-0001-5617-9781
FU NIHR Manchester Biomedical Research CentreNational Institute for Health
   Research (NIHR)
FX C. Faivre-Finn was supported by the NIHR Manchester Biomedical Research
   Centre. The authors would like to thank Dr Kate Wicks for her assistance
   in preparing this manuscript.
CR Amini A, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-33
   Andolino DL, 2011, INT J RADIAT ONCOL, V80, P692, DOI 10.1016/j.ijrobp.2010.03.020
   Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697
   Asai K, 2012, INT J RADIAT ONCOL, V84, P768, DOI 10.1016/j.ijrobp.2012.01.027
   Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543
   Bongers EM, 2011, J THORAC ONCOL, V6, P2052, DOI 10.1097/JTO.0b013e3182307e74
   Cannon DM, 2013, J CLIN ONCOL, V31, P4343, DOI 10.1200/JCO.2013.51.5353
   Chen HB, 2019, J THORAC ONCOL, V14, P1332, DOI 10.1016/j.jtho.2019.04.018
   Cho WK, 2016, CANCER RES TREAT, V48, P1187, DOI 10.4143/crt.2015.391
   Faivre-Finn C, 2017, LANCET ONCOL, V18, P1116, DOI 10.1016/S1470-2045(17)30318-2
   Fenwick JD, 2009, CLIN ONCOL-UK, V21, P343, DOI 10.1016/j.clon.2008.12.011
   Global Initiative for Chronic Obstructive Lung Disease, 2020, GLOB STRAT DIAGN MAN
   Gronberg BH, 2016, ACTA ONCOL, V55, P591, DOI 10.3109/0284186X.2015.1092584
   Hatton MQF, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2017-019903
   Iqbal MS, 2019, CLIN ONCOL-UK, V31, pE1, DOI 10.1016/j.clon.2018.10.006
   Iyengar P, 2016, INT J RADIAT ONCOL, V96, pE451, DOI 10.1016/j.ijrobp.2016.06.1763
   Landau DB, 2016, INT J RADIAT ONCOL, V95, P1367, DOI 10.1016/j.ijrobp.2016.03.031
   Lester JF, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e20551
   Ma JT, 2019, INT J RADIAT ONCOL, V103, P843, DOI 10.1016/j.ijrobp.2018.11.036
   Maguire J, 2014, EUR J CANCER, V50, P2939, DOI 10.1016/j.ejca.2014.07.009
   Manyam BV, 2019, PRACT RADIAT ONCOL, V9, pE187, DOI 10.1016/j.prro.2018.11.011
   May R, 2020, CARING PEOPLE HIGHES
   MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336
   Nambu A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-68
   National Comprehensive Cancer Network, NCCN GUID NONSM CELL
   National Comprehensive Cancer Network, NCCN GUID SMALL CELL
   National Institute for Health and Care Excellence, 2020, NICE GUID NG162
   National Institute for Health and Care Excellence, 2019, NICE GUID NG122
   Paximadis P, 2018, CLIN LUNG CANCER, V19, pE559, DOI 10.1016/j.cllc.2018.03.017
   Prewett SL, 2012, CLIN ONCOL-UK, V24, P402, DOI 10.1016/j.clon.2012.03.005
   Robinson SD, 2020, RADIOTHER ONCOL, V143, P37, DOI 10.1016/j.radonc.2019.08.025
   Rulach R, 2020, CLIN ONCOL-UK, V32, P250, DOI 10.1016/j.clon.2019.09.055
   Simone CB, 2020, PRACT RADIAT ONCOL, V10, P158, DOI 10.1016/j.prro.2020.02.009
   Singh AK, 2019, INT J RADIAT ONCOL, V105, P752, DOI 10.1016/j.ijrobp.2019.08.019
   Stahl JM, 2017, LUNG CANCER, V103, P11, DOI 10.1016/j.lungcan.2016.11.009
   Tekatli H, 2017, J THORAC ONCOL, V12, P974, DOI 10.1016/j.jtho.2017.02.021
   Tekatli H, 2016, J THORAC ONCOL, V11, P1081, DOI 10.1016/j.jtho.2016.03.008
   Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403
   UK SABR Consortium, 2019, UK SABR CONS GUID V6
   Verma V, 2019, RADIOTHER ONCOL, V131, P145, DOI 10.1016/j.radonc.2018.12.006
   Verma V, 2017, INT J RADIAT ONCOL, V97, P362, DOI 10.1016/j.ijrobp.2016.10.041
   Videtic GMM, 2003, INT J RADIAT ONCOL, V57, P709, DOI 10.1016/S0360-3016(03)00635-7
   Videtic GM, 2019, INT J RADIAT ONCOL, V103, P1077, DOI 10.1016/j.ijrobp.2018.11.051
   Videtic GMM, 2017, PRACT RADIAT ONCOL, V7, P295, DOI 10.1016/j.prro.2017.04.014
   Videtic GMM, 2015, INT J RADIAT ONCOL, V93, P757, DOI 10.1016/j.ijrobp.2015.07.2260
   Westover KD, 2015, INT J RADIAT ONCOL, V93, P72, DOI 10.1016/j.ijrobp.2015.05.004
   Woody NM, 2015, INT J RADIAT ONCOL, V92, P325, DOI 10.1016/j.ijrobp.2015.01.045
   Xia B, 2015, INT J RADIAT ONCOL, V91, P517, DOI 10.1016/j.ijrobp.2014.09.042
   Zeng KL, 2018, INT J RADIAT ONCOL, V102, pE719, DOI 10.1016/j.ijrobp.2018.07.1932
NR 49
TC 6
Z9 6
U1 3
U2 3
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936-6555
EI 1433-2981
J9 CLIN ONCOL-UK
JI Clin. Oncol.
PD AUG
PY 2020
VL 32
IS 8
BP 481
EP 489
DI 10.1016/j.clon.2020.05.001
PG 9
WC Oncology
SC Oncology
GA MH4CK
UT WOS:000546679100002
PM 32405158
OA Green Published, Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Curigliano, G
   Cardoso, MJ
   Poortmans, P
   Gentilini, O
   Pravettoni, G
   Mazzocco, K
   Houssami, N
   Pagani, O
   Senkus, E
   Cardoso, F
AF Curigliano, Giuseppe
   Cardoso, Maria Joao
   Poortmans, Philip
   Gentilini, Oreste
   Pravettoni, Gabriella
   Mazzocco, Ketti
   Houssami, Nehmat
   Pagani, Olivia
   Senkus, Elzbieta
   Cardoso, Fatima
CA Editorial Board Breast
TI Recommendations for triage, prioritization and treatment of breast
   cancer patients during the COVID-19 pandemic
SO BREAST
LA English
DT Article
ID RADIATION-THERAPY; CONSERVING SURGERY; RADIOTHERAPY HYPOFRACTIONATION;
   FOLLOW-UP; IRRADIATION; RCT
AB The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated disease (COVID-19) outbreak seriously challenges globally all health care systems and professionals. Expert projections es- timate that despite social distancing and lockdown being practiced, we have yet to feel the full impact of COVID-19. In this manuscript we provide guidance to prepare for the impact of COVID-19 pandemic on breast cancer patients and advise on how to triage, prioritize and organize diagnostic procedures, sur- gical, radiation and medical treatments. (C) 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Curigliano, Giuseppe; Pravettoni, Gabriella; Mazzocco, Ketti] IRCCS, Dept Early Drug Dev, Ist Europeo Oncol, Milan, Italy.
   [Curigliano, Giuseppe; Pravettoni, Gabriella; Mazzocco, Ketti] Univ Milan, Milan, Italy.
   [Cardoso, Maria Joao; Cardoso, Fatima] Champalimaud Fdn, Breast Unit, Champalimaud Clin Ctr, Lisbon, Portugal.
   [Cardoso, Maria Joao] Nova Med Sch, Lisbon, Portugal.
   [Poortmans, Philip] Iridium Kankernetwerk, Dept Radiat Oncol, Antwerp, Belgium.
   [Poortmans, Philip] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.
   [Gentilini, Oreste] San Raffaele Univ, Breast Surg, Milan, Italy.
   [Gentilini, Oreste] Res Hosp, Milan, Italy.
   [Houssami, Nehmat] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
   [Pagani, Olivia] Geneva Univ Hosp, Serv Interdisciplinaire Cancerol, Swiss Grp Clin Canc Res SAKK, Hop Riviera Chablais Rennaz Vaud, Geneva, Switzerland.
   [Senkus, Elzbieta] Med Univ Gdansk, Gdansk, Poland.
RP Curigliano, G (corresponding author), Univ Milan, Dept Oncol & Haematooncol, European Inst Oncol IRCCS, Div Early Drug Dev Innovat Therapies, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy.
EM giuseppe.curigliano@ieo.it
RI Gentilini, Oreste Davide/AAN-7577-2020; Houssami, Nehmat/ABC-1103-2020;
   Pagani, Olivia/ABF-3164-2020; Curigliano, Giuseppe/D-3371-2018
OI Gentilini, Oreste Davide/0000-0002-4489-1867; Houssami,
   Nehmat/0000-0002-3641-952X; Curigliano, Giuseppe/0000-0003-1781-2518;
   Cardoso, Maria Joao/0000-0002-8137-3700
CR ACS (American College of Surgeons), 2020, COVID 19 GUID TRIAG
   American College of Surgeons (ACS), 2020, COVID 19 REC MAN EL
   Annunziata MA, 2020, SUPPORT CARE CANCER, V28, P3921, DOI 10.1007/s00520-019-05244-8
   [Anonymous], 2020, CLIN GUID MAN CANC P
   ASBrS, 2020, REC PRIOR TREATM TRI
   ASBrS ACR, 2020, ASBRS ACR JOINT STAT
   ASCO, 2020, CAR IND CANC COVID 1
   ASPS ASPS, 2020, STAT BREAST REC FAC
   Bartelink H, 2015, LANCET ONCOL, V16, P47, DOI 10.1016/S1470-2045(14)71156-8
   Biganzoli L, 2020, BREAST, V51, P65, DOI 10.1016/j.breast.2020.02.003
   Bortolato B, 2017, CANCER TREAT REV, V52, P58, DOI 10.1016/j.ctrv.2016.11.004
   Brunt AM, 2018, INT J RADIAT ONCOL, V102, P1603, DOI 10.1016/j.ijrobp.2018.08.049
   Brunt AM, 2018, RADIOTHER ONCOL, V127, pS311, DOI 10.1016/S0167-8140(18)30905-8
   Brunt AM, 2016, RADIOTHER ONCOL, V120, P114, DOI 10.1016/j.radonc.2016.02.027
   Cardoso F, 2019, ANN ONCOL, V30, P1674, DOI 10.1093/annonc/mdz189
   Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Coles CE, 2017, LANCET, V390, P1048, DOI 10.1016/S0140-6736(17)31145-5
   D'Ippolito S, 2017, ANN ONCOL, V28
   Deming W.E., 1986, OUT CRISIS
   Earl HM, 2019, LANCET, V393, P2599, DOI 10.1016/S0140-6736(19)30650-6
   ECCO, 2020, STAT COVID 19 EUR CA
   Extance A, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1174
   Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3
   Hill EM, 2019, PSYCHO-ONCOLOGY, V28, P553, DOI 10.1002/pon.4975
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Kunkler IH, 2015, LANCET ONCOL, V16, P266, DOI 10.1016/S1470-2045(14)71221-5
   Leong N, 2017, INT J RADIAT ONCOL, V99, P1166, DOI 10.1016/j.ijrobp.2017.07.043
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Livi L, 2015, EUR J CANCER, V51, P451, DOI 10.1016/j.ejca.2014.12.013
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Reis JC, 2020, CNS SPECTRUMS, V25, P79, DOI 10.1017/S1092852918001621
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   UEDA M, 2020, J NATL COMPR CANC NE, V10, DOI DOI 10.3389/FONC.2020.00327
   van Maaren MC, 2017, BRIT J CANCER, V117, P179, DOI 10.1038/bjc.2017.159
   Veronesi U, 2013, LANCET ONCOL, V14, P1269, DOI 10.1016/S1470-2045(13)70497-2
   Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260
NR 39
TC 40
Z9 40
U1 3
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD AUG
PY 2020
VL 52
BP 8
EP 16
DI 10.1016/j.breast.2020.04.006
PG 9
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA MG9YY
UT WOS:000546389500002
PM 32334323
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Gasparri, ML
   Gentilini, OD
   Lueftner, D
   Kuehn, T
   Kaidar-Person, O
   Poortmans, P
AF Gasparri, Maria Luisa
   Gentilini, Oreste Davide
   Lueftner, Diana
   Kuehn, Thorsten
   Kaidar-Person, Orit
   Poortmans, Philip
TI Changes in breast cancer management during the Corona Virus Disease 19
   pandemic: An international survey of the European Breast Cancer Research
   Association of Surgical Trialists (EUBREAST)
SO BREAST
LA English
DT Article
DE Breast cancer; Breast surgery; Chemotherapy; COVID-19; Radiation therapy
AB Background: Corona Virus Disease 19 (COVID-19) had a worldwide negative impact on healthcare sys- tems, which were not used to coping with such pandemic. Adaptation strategies prioritizing COVID-19 patients included triage of patients and reduction or re-allocation of other services. The aim of our survey was to provide a real time international snapshot of modi fications of breast cancer management during the COVID-19 pandemic. Methods: A survey was developed by a multidisciplinary group on behalf of European Breast Cancer Research Association of Surgical Trialists and distributed via breast cancer societies. One reply per breast unit was requested. Results: In ten days, 377 breast centres from 41 countries completed the questionnaire. RT-PCR testing for SARS-CoV-2 prior to treatment was reported by 44.8% of the institutions. The estimated time interval between diagnosis and treatment initiation increased for about 20% of institutions. Indications for pri- mary systemic therapy were modi fied in 56% (211/377), with upfront surgery increasing from 39.8% to 50.7% (p < 0.002) and from 33.7% to 42.2% (p < 0.016) in T1cN0 triple-negative and ER-negative/HER2- positive cases, respectively. Sixty-seven percent considered that chemotherapy increases risks for developing COVID-19 complications. Fifty-one percent of the responders reported modi fications in chemotherapy protocols. Gene-expression pro file used to evaluate the need for adjuvant chemotherapy increased in 18.8%. In luminal-A tumours, a large majority (68%) recommended endocrine treatment to postpone surgery. Postoperative radiation therapy was postponed in 20% of the cases. Conclusions: Breast cancer management was considerably modi fied during the COVID-19 pandemic. Our data provide a base to investigate whether these changes impact oncologic outcomes. (C) 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Gasparri, Maria Luisa] Univ Italian Switzerland USI, Dept Gynecol & Obstet, Osped Regionale Lugano, Lugano, Switzerland.
   [Gasparri, Maria Luisa] Ente Osped Cantonale EOC, Ctr Senol Svizzera Italiana CSSI, Lugano, Switzerland.
   [Gentilini, Oreste Davide] San Raffaele Univ Hosp, Breast Surg Unit, Milan, Italy.
   [Lueftner, Diana] Charite, Humboldt Univ Berlin, Dept Hematol Oncol & Tumour Immunol, Berlin, Germany.
   [Kuehn, Thorsten] Klinikum Esslingen, Interdisciplinary Breast Ctr, Dept Gynecol & Obstet, Esslingen, Germany.
   [Kaidar-Person, Orit] Sheba Hosp Tel Hashomer, Oncol Inst, Breast Radiat Unit, Ramat Gan, Israel.
   [Poortmans, Philip] Iridium Kankernetwerk, Dept Radiat Oncol, Antwerp, Belgium.
   [Poortmans, Philip] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.
RP Gasparri, ML (corresponding author), Univ Svizzera Italiana USI, Osped Regionale Lugano, Dept Gynecol & Obstet, Ctr Senol Svizzera Italiana CSSI,Ente Osped Canto, Lugano, Switzerland.
EM marialuisa.gasparri@eoc.ch
OI GASPARRI, Maria Luisa/0000-0002-9482-9527
CR American College of Surgeons, COVID 19 EL TRIAG GU
   [Anonymous], 2020, INTERCOLLEGIATE GEN
   Biganzoli L, 2020, BREAST, V51, P65, DOI 10.1016/j.breast.2020.02.003
   Cannistra SA, 2020, J CLIN ONCOL, V38, P2206, DOI 10.1200/JCO.20.00858
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   James W., 2020, COMMUNICATION   0413
   Joseph JP, 2020, EUR SURG, V52, P188, DOI 10.1007/s10353-020-00644-1
   Lewis MA, 2020, NEW ENGL J MED, V382, P2285, DOI 10.1056/NEJMp2006588
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 18
TC 3
Z9 3
U1 5
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD AUG
PY 2020
VL 52
BP 110
EP 115
DI 10.1016/j.breast.2020.05.006
PG 6
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA MG9YY
UT WOS:000546389500015
PM 32502796
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ahmad, S
   Navid, A
   Farid, R
   Abbas, G
   Ahmad, F
   Zaman, N
   Parvaiz, N
   Azam, SS
AF Ahmad, Sajjad
   Navid, Afifa
   Farid, Rabia
   Abbas, Ghulam
   Ahmad, Faisal
   Zaman, Naila
   Parvaiz, Nousheen
   Azam, Syed Sikander
TI Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus
   Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy
   against Avenging Zoonotics
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Coronavirus disease (COVID-19); Vaccinomics; Non-structural protein 8;
   3C-like proteinase; Spike glycoprotein
ID PROTEIN-STRUCTURE; CODON USAGE; PREDICTION; ACTIVATION; REFINEMENT;
   EXPRESSION; SOFTWARE; IMMUNITY; TOPOLOGY; ADHESINS
AB The emergence and rapid expansion of the coronavirus disease (COVID-19) require the development of effective countermeasures especially a vaccine to provide active acquired immunity against the virus. This study pre- sented a comprehensive vaccinomics approach applied to the complete protein data published so far in the National Center for Biotechnological Information (NCBI) coronavirus data hub. We identified non-structural protein 8 (Nsp8), 3C -like proteinase, and spike glycoprotein as potential targets for immune responses to COVID- 19. Epitopes prediction illustrated both B -cell and T -cell epitopes associated with the mentioned proteins. The shared B and T -cell epitopes: DRDAAMQRK and QARSEDKRA of Nsp8, EDMLNPNYEDL and EFTPFDVVR of 3C - like proteinase, and VNNSYECDIPI of the spike glycoprotein are regions of high potential interest and have a high likelihood of being recognized by the human immune system. The vaccine construct of the epitopes shows stimulation of robust primary immune responses and high level of interferon gamma. Also, the construct has the best conformation with respect to the tested innate immune receptors involving vigorous molecular mechanics and solvation energy. Designing of vaccination strategies that target immune response focusing on these con- served epitopes could generate immunity that not only provide cross protection across Betacoronaviruses but additionally resistant to virus evolution.
C1 [Ahmad, Sajjad; Navid, Afifa; Farid, Rabia; Abbas, Ghulam; Ahmad, Faisal; Zaman, Naila; Parvaiz, Nousheen; Azam, Syed Sikander] Quaid I Azam Univ, Natl Ctr Bioinformat NCB, Computat Biol Lab, Islamabad 45320, Pakistan.
RP Azam, SS (corresponding author), Quaid I Azam Univ, Natl Ctr Bioinformat, Islamabad 45320, Pakistan.
EM syedazam2008@gmail.com
RI Ahmad, Sajjad/ABG-7863-2020
OI Ahmad, Sajjad/0000-0003-0754-1742
FU Pakistan-United States Science and Technology Cooperation Program
FX Authors are highly grateful to the Pakistan-United States Science and
   Technology Cooperation Program (Grant No. Pak-US/2017/360) for granting
   financial assistance.
CR Abbas G, 2020, EUR J PHARM SCI, V142, DOI 10.1016/j.ejps.2019.105160
   Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Ahmad S, 2019, EUR J PHARM SCI, V132, P1, DOI 10.1016/j.ejps.2019.02.023
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   Aminov RI, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00158
   Andleeb S, 2016, RSC ADV, V6, P79651, DOI 10.1039/c6ra19162b
   Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Angov E, 2011, BIOTECHNOL J, V6, P650, DOI 10.1002/biot.201000332
   Baldauf KJ, 2015, TOXINS, V7, P974, DOI 10.3390/toxins7030974
   Barh D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052773
   Biovia D.S., 2017, DISCOVERY STUDIO VIS
   Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017
   Bouvet M, 2014, J BIOL CHEM, V289, P25783, DOI 10.1074/jbc.M114.577353
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Case D, 2014, AMBER, V14, P29
   Case D. A., 2016, AMBER16 PACKAGE
   Chen JE, 2015, BIOINFORMATICS, V31, P1484, DOI 10.1093/bioinformatics/btu841
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Dombkowski AA, 2014, FEBS LETT, V588, P206, DOI 10.1016/j.febslet.2013.11.024
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0
   Flores BN, 2019, CELL REP, V27, P1133, DOI 10.1016/j.celrep.2019.03.093
   Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161
   Garg A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-62
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guan PP, 2003, NUCLEIC ACIDS RES, V31, P3621, DOI 10.1093/nar/gkg510
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han XZ, 2014, VACCINE, V32, P297, DOI 10.1016/j.vaccine.2013.09.004
   Haq FU, 2017, J MOL GRAPH MODEL, V74, P143, DOI DOI 10.1016/j.jmgm.2017.03.002
   Hart BL, 2011, PHILOS T R SOC B, V366, P3406, DOI 10.1098/rstb.2011.0092
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x
   Hossain T, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3783714
   Hou T., 2011, ACCURACY BINDING FRE, P69
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hubbard R.E., 2001, HYDROGEN BONDS PROTE, V164, P2399
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   Janeway Jr C.A., 2001, IMMUNOBIOL IMMUNE SY
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Kaliappan S., 2016, UCSF CHIMERA SUPERIM
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Kuzmanic A, 2010, BIOPHYS J, V98, P861, DOI 10.1016/j.bpj.2009.11.011
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   LEMAK AS, 1994, MOL SIMULAT, V13, P177, DOI 10.1080/08927029408021981
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Lui S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/240769
   MacLean RC, 2019, SCIENCE, V365, P1082, DOI 10.1126/science.aax3879
   Maiorov V.N., 1994, SIGNIFICANCE ROOT ME
   Martins MA, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029504
   Mazel-Sanchez B, 2018, J VIROL, V92, DOI [10.1128/JVI.00425-18, 10.1128/jvi.00425-18]
   Miknis ZJ, 2009, J VIROL, V83, P3007, DOI 10.1128/JVI.01505-08
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Mora-Bermudez F, 2016, ELIFE, V5, DOI 10.7554/eLife.18683
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759
   Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027
   Naz K, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2713-9
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Peiris JSM, 2007, CLIN MICROBIOL REV, V20, P243, DOI 10.1128/CMR.00037-06
   ProtParam E., 2017, EXPASY PROTPARAM TOO
   Rapin N., 2012, C IMMSIM 10 1 SERVER
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009
   Sachdeva G, 2005, BIOINFORMATICS, V21, P483, DOI 10.1093/bioinformatics/bti028
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Seone C., 2015, SCIENCEDAILY YOUR SO, V14, P1
   Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x
   Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579
   Sugiarto H, 2004, BIOCHEM BIOPH RES CO, V323, P721, DOI 10.1016/j.bbrc.2004.08.162
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849
   Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang Chen, 2020, LANCET
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wellman-Labadie O, 2008, COMP BIOCHEM PHYS B, V149, P640, DOI 10.1016/j.cbpb.2008.01.001
   Wizemann TM, 1999, EMERG INFECT DIS, V5, P395, DOI 10.3201/eid0503.990310
   Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 95
TC 2
Z9 2
U1 9
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD AUG 1
PY 2020
VL 151
AR 105387
DI 10.1016/j.ejps.2020.105387
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MG2VA
UT WOS:000545892700001
PM 32454128
OA Green Published
DA 2021-01-01
ER

PT J
AU Ojha, R
   Gupta, N
   Naik, B
   Singh, S
   Verma, VK
   Prusty, D
   Prajapati, VK
AF Ojha, Rupal
   Gupta, Nidhi
   Naik, Biswajit
   Singh, Satyendra
   Verma, Vijay Kumar
   Prusty, Dhaneswar
   Prajapati, Vijay Kumar
TI High throughput and comprehensive approach to develop multiepitope
   vaccine against minacious COVID-19
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Adjuvant; Coronavirus; Multi-epitope; Vaccine; Immune response
ID ACUTE RESPIRATORY SYNDROME; SUBUNIT VACCINE; CORONAVIRUS; PROTEIN;
   SERVER; STRATEGY; DESIGN; ALPHA
AB The ongoing enigmatic COVID-19 outbreak, first reported from Wuhan, China, on last day of the year 2019, which has spread to 213 countries, territories/areas till 28th April 2020, threatens hundreds of thousands human souls. This devastating viral infection has stimulated the urgent development of viable vaccine against COVID-19 across the research institutes around the globe. The World Health Organization (WHO) has also confirmed that the recent pandemic is causing Public Health Emergency of International apprehension. Moreover, the earlier two pathogenic SARS-CoV and MERS-CoV and many others yet to be identified pose a universal menace. Here, in this piece of work, we have utilized an in silico structural biology and advanced immunoinformatic strategies to devise a multi-epitope subunit vaccine against ongoing COVID-19 infection. The engineered vaccine sequence is adjuvanted with beta-3 defensin and comprised of B -cell epitopes, HTL epitopes and CTL epitopes. This is very likely that the vaccine will be able to elicit the strong immune response. Further, specific binding of the en- gineered vaccine and immune cell receptor TLR3 was estimated by molecular interaction studies. Strong in- teraction in the binding groove as well as good docking scores affirmed the stringency of engineered vaccine. The interaction is stable with minimal deviation in root -mean square deviation and root -mean -square fluctuation was confirmed by the molecular dynamics simulation experiment. The immune -simulation by C-ImmSim server, which mimics the natural immune environment, yielded more potent immune response data of B -cells, Th cells, Tc cells and IgG for vaccine. The encouraging data obtained from the various in-silico works indicated this vaccine as an effective therapeutic against COVID-19.
C1 [Ojha, Rupal; Gupta, Nidhi; Naik, Biswajit; Singh, Satyendra; Prusty, Dhaneswar; Prajapati, Vijay Kumar] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH-8, Ajmer, Rajasthan, India.
   [Verma, Vijay Kumar] Cent Univ Rajasthan, Sch Life Sci, Dept Microbiol, Ajmer 305817, Rajasthan, India.
RP Prajapati, VK (corresponding author), Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH-8, Ajmer, Rajasthan, India.
EM vkprajapati@curaj.ac.in
OI Prajapati, Vijay/0000-0001-6510-0596; Naik, Biswajit/0000-0003-3732-5063
FU UGCUniversity Grants Commission, India
FX RO is thankful to UGC for providing university fellowship. VKP is
   thankful to the Central University of Rajasthan for providing
   computational facility
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adedeji AO, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00235-16
   Beck B, 2020, PREDICTING COMMERCIA
   Benkert P, 2009, NUCLEIC ACIDS RES, V37, pW510, DOI 10.1093/nar/gkp322
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055
   Chan-Yeung M, 2003, BRIT MED J, V326, P850, DOI 10.1136/bmj.326.7394.850
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   DEVRIES SJ, 2010, J MOL BIOL, V5, P883, DOI DOI 10.1038/NPROT.2010.32
   Dikhit MR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01763
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gupta N, 2020, INT J BIOL MACROMOL, V152, P535, DOI 10.1016/j.ijbiomac.2020.02.297
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ismail MM, 2003, AVIAN DIS, V47, P515, DOI 10.1637/5917
   Kallberg M, 2014, METHODS MOL BIOL, V1137, P17, DOI 10.1007/978-1-4939-0366-5_2
   Kao DJ, 2009, CHEM BIOL DRUG DES, V74, P33, DOI 10.1111/j.1747-0285.2009.00825.x
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Lewis R., 2020, DNA SCI BLOG
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Mohan T, 2013, VACCINE, V31, P1707, DOI 10.1016/j.vaccine.2013.01.041
   Muruato LA, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00206-17
   Ojha R, 2020, INT J BIOL MACROMOL, V156, P548, DOI 10.1016/j.ijbiomac.2020.04.097
   Ojha R, 2019, ACS OMEGA, V4, P13069, DOI 10.1021/acsomega.9b00944
   Ojha R, 2019, J CELL PHYSIOL, V234, P6437, DOI 10.1002/jcp.27380
   Ojha R, 2018, INT J BIOL MACROMOL, V118, P834, DOI 10.1016/j.ijbiomac.2018.06.112
   Ong E., 2020, COVID 19 CORONAVIRUS
   Pandey RK, 2019, J CELL PHYSIOL, V234, P8717, DOI 10.1002/jcp.27531
   Pearson W. R, 2013, CURRENT PROTOCOLS BI
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Saha Sudipto, 2007, V409, P387, DOI 10.1007/978-1-60327-118-9_29
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Shen WJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23113034
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tomar S, 2015, J BIOL CHEM, V290, P19403, DOI 10.1074/jbc.M115.651463
   Totura AL, 2015, MBIO, V6, DOI 10.1128/ mBio.00638-1571
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Yano A, 2005, VACCINE, V23, P2322, DOI 10.1016/j.vaccine.2005.01.031
   Yi XJ, 2015, PROCEEDINGS OF THE 2015 FIRST INTERNATIONAL CONFERENCE ON RELIABILITY SYSTEMS ENGINEERING 2015 ICRSE
   Zhou P, 2018, NATURE, V556, P255, DOI 10.1038/s41586-018-0010-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Zumla A, 2019, LANCET INFECT DIS, V19, P1054, DOI 10.1016/S1473-3099(19)30477-3
NR 50
TC 4
Z9 5
U1 20
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD AUG 1
PY 2020
VL 151
AR 105375
DI 10.1016/j.ejps.2020.105375
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MG2UC
UT WOS:000545890200001
PM 32417398
OA Green Published
DA 2021-01-01
ER

PT J
AU Bellinvia, S
   Edwards, CJ
   Schisano, M
   Banfi, P
   Fallico, M
   Murabito, P
AF Bellinvia, Salvatore
   Edwards, Christopher J.
   Schisano, Matteo
   Banfi, Paolo
   Fallico, Matteo
   Murabito, Paolo
TI The unleashing of the immune system in COVID-19 and sepsis: the calm
   before the storm?
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Covid-19; Immune dysregulation; Inflammatory receptors; Cytokine storm;
   Sepsis; Checkpoint inhibitors
ID TOLL-LIKE RECEPTORS; ANTI-PD-1/PD-L1 THERAPY; SARS CORONAVIRUS;
   RESPONSES; DISEASE; CANCER; INFLAMMATION; EXPRESSION; PNEUMONIA; CHINA
AB The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.
C1 [Bellinvia, Salvatore; Edwards, Christopher J.] Univ Hosp Southampton NHS Fdn Trust, Dept Rheumatol, Southampton, Hants, England.
   [Bellinvia, Salvatore; Edwards, Christopher J.] Univ Hosp Southampton NHS Fdn Trust, NIHR Clin Res Facil, Southampton, Hants, England.
   [Schisano, Matteo] Univ Catania, AOU Policlin Vittorio Emanuele, Reg Referral Ctr Rare Lung Dis, Dept Clin & Expt Med, Catania, Italy.
   [Banfi, Paolo] IRCCS Fdn Don Carlo Gnocchi, Milan, Italy.
   [Fallico, Matteo] Univ Catania, AOU Policlin Vittorio Emanuele, Dept Ophthalmol, Catania, Italy.
   [Murabito, Paolo] Univ Catania, Univ Hosp G Rodolico, Dept Anaesthesia & Intens Care, Via Santa Sofia 78, I-95123 Catania, Italy.
RP Bellinvia, S (corresponding author), Univ Hosp Southampton NHS Fdn Trust, Dept Rheumatol, Southampton, Hants, England.; Bellinvia, S (corresponding author), Univ Hosp Southampton NHS Fdn Trust, NIHR Clin Res Facil, Southampton, Hants, England.
EM salvo.bellinvia@libero.it
OI Murabito, Paolo/0000-0002-2662-1898; Bellinvia,
   Salvatore/0000-0002-0697-3191; FALLICO, MATTEO/0000-0003-2639-1321
CR Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010
   Boomer JS, 2014, VIRULENCE, V5, P45, DOI [10.4161/viru.26516, 10.4161/viru.27794]
   Busch LM, 2020, INTENS CARE MED EXP, V8, DOI 10.1186/s40635-019-0290-x
   Cavaillon JM, 2014, CRIT CARE, V18, DOI 10.1186/cc13787
   Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese Clinical Trial Registry, 2020, MULT RAND CONTR TRIA
   Davies Roger, 2018, J Intensive Care Soc, V19, P326, DOI 10.1177/1751143718765407
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Demaret J, 2013, CYTOM PART B-CLIN CY, V84B, P59, DOI 10.1002/cyto.b.21043
   Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875
   Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103
   Espinosa G, 2002, ANN RHEUM DIS, V61, P195, DOI 10.1136/ard.61.3.195
   Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603
   Fuentes E, 2017, AN ACAD BRAS CIENC, V89, P285, DOI 10.1590/0001-3765201720160487
   Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000
   Gillis A, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0260-3
   Gomez HG, 2014, CRIT CARE MED, V42, P771, DOI 10.1097/CCM.0000000000000100
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guignant C, 2011, CRIT CARE, V15, DOI 10.1186/cc10112
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibrahim YF, 2020, INFLAMMOPHARMACOLOGY, V28, P215, DOI 10.1007/s10787-019-00628-y
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Johnson DB, 2017, CANCER-AM CANCER SOC, V123, P1904, DOI 10.1002/cncr.30642
   Kruttgen A, 2012, J INTERF CYTOK RES, V32, P60, DOI 10.1089/jir.2011.0062
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li Q, 2003, INFECT IMMUN, V71, P4873, DOI 10.1128/IAI.71.9.4873-4882.2003
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA
   Martin S, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00020
   Matsuda N, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0147-2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Pacha O, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0328-z
   Patil NK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112413
   Pawelec G, 2018, EXP GERONTOL, V105, P4, DOI 10.1016/j.exger.2017.10.024
   de Heredia FP, 2012, P NUTR SOC, V71, P332, DOI 10.1017/S0029665112000092
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rao M, 2017, INT J INFECT DIS, V56, P221, DOI 10.1016/j.ijid.2017.01.028
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shoenfeld Y, 2006, ANN RHEUM DIS, V65, P2, DOI 10.1136/ard.2005.045443
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   World Health Organization, COR DIS COVID 19 OUT
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu HP, 2009, INFLAMM RES, V58, P385, DOI 10.1007/s00011-009-0003-0
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Ye B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.42
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhang Y, 2010, CRIT CARE, V14, DOI 10.1186/cc9354
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou S, 2018, THER CLIN RISK MANAG, V14, P167, DOI 10.2147/TCRM.S155488
NR 64
TC 1
Z9 2
U1 5
U2 5
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD AUG
PY 2020
VL 69
IS 8
BP 757
EP 763
DI 10.1007/s00011-020-01366-6
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA MD5KQ
UT WOS:000544010400007
PM 32468151
OA Bronze
DA 2021-01-01
ER

PT J
AU Hormati, A
   Ghadir, MR
   Zamani, F
   Khodadadi, J
   Khodadust, F
   Afifian, M
   Aminnejad, R
   Ahmadpour, S
AF Hormati, Ahmad
   Ghadir, Mohammad Reza
   Zamani, Farhad
   Khodadadi, Javad
   Khodadust, Fatemeh
   Afifian, Mahboubeh
   Aminnejad, Reza
   Ahmadpour, Sajjad
TI Are there any association between COVID-19 severity and
   immunosuppressive therapy?
SO IMMUNOLOGY LETTERS
LA English
DT Letter
C1 [Hormati, Ahmad; Ghadir, Mohammad Reza; Ahmadpour, Sajjad] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran.
   [Hormati, Ahmad; Zamani, Farhad] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran.
   [Khodadadi, Javad] Qom Univ Med Sci, Sch Med, Dept Infect Dis, Kamkar Arabnia Hosp, Qom, Iran.
   [Khodadust, Fatemeh] Mazandaran Univ Med Sci, Fac Pharm, Dept Radiopharm, Sari, Iran.
   [Afifian, Mahboubeh] Univ Tehran Med Sci, Hlth Informat Technol, Tehran, Iran.
   [Aminnejad, Reza] Qom Univ Med Sci, Dept Anisthesiol & Cirit Care, Qom, Iran.
   [Aminnejad, Reza] Shahid Beheshti Univ Med Sci, Dept Anisthesiol & Cirit Care, Tehran, Iran.
RP Ahmadpour, S (corresponding author), Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran.
EM sajjadahmadpour@yahoo.com
RI Zamani, Farhad/ABH-8503-2020; Ahmadpour, sajjad/ABB-2229-2020
CR Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Xu X, 20200300026V1 CHINAX
NR 5
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD AUG
PY 2020
VL 224
BP 12
EP 13
DI 10.1016/j.imlet.2020.05.002
PG 2
WC Immunology
SC Immunology
GA MC5WX
UT WOS:000543358000002
PM 32473971
OA Green Published
DA 2021-01-01
ER

PT J
AU Ietto, G
AF Ietto, Giuseppe
TI SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and
   therapeutic approach using trivalent vaccine (tetanus, diphtheria and
   Bordetella pertussis)
SO MEDICAL HYPOTHESES
LA English
DT Article
DE SARS - CoV-2; Covid-19; Coronavirus; Vaccine; Toxoids; ARDS; Epidemic
   infection; Pandemic infection; Immunotherapy
ID CELLS
AB The novel coronavirus Covid-19 follows transmission route and clinical presentation of all community-acquired coronaviruses. Instead, the rate of transmission is significative higher, with a faster spread of the virus responsible of the worldwide outbreak and a significative higher mortality rate due to the development of a severe lung injury. Most noteworthy is the distribution of death rate among age groups. Children and younger people are almost protected from severe clinical presentation.
   Possible explanation of this phenomenon could be the ability of past vaccinations (especially tetanic, diphtheria toxoids and inactivated bacteria as pertussis) to stimulate immune system and to generate a scattered immunity against non-self antigens in transit, as coronaviruses and other community-circulating viruses and make immune system readier to develop specific immunity against Covid-19.
   The first support to this hypothesis is the distribution of mortality rate during historical pandemics ("Spanish flu" 1918, "Asian flu" 1956 and "the Hong Kong flu" 1968) among age groups before and after the introduction of vaccines.
   The immunological support to the hypothesis derives from recent studies about immunotherapy for malignancies, which propose the use of oncolytic vaccines combined with toxoids in order to exploit CD4+ memory T cell recall in supporting the ongoing anti-tumour response.
   According to this hypothesis vaccine formulations (tetanus, diphtheria, Bordetella pertussis) could be readministrate after the first contact with Covid-19, better before the development of respiratory severe illness and of course before full-blown ARDS (Acute Respiratory Distress Syndrome).
   The CD4 + memory exploiting could help immune system to recall immunity of already know antigens against coronaviruses, avoiding or limiting "lung crash" until virus specific immunity develops and making it faster and prolonged.
   Finally, this administration could be helpful not only in already infected patients, but also before infection. In fact, people could have an immune system more ready when the contact with the Covid-19 will occur.
C1 [Ietto, Giuseppe] Univ Insubria, Via Pietro Verri 12, I-21100 Varese, Italy.
RP Ietto, G (corresponding author), Univ Insubria, Via Pietro Verri 12, I-21100 Varese, Italy.
EM giuseppe.ietto@gmail.com
RI Ietto, Giuseppe/AAM-4618-2020
OI Ietto, Giuseppe/0000-0001-5029-8173
CR Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0
   DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539
   Durgeau A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00014
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357
   McIntosh K., 2020, CORONAVIRUSES TOPIC
   McIntosh K., 2020, CORONAVIRUS DIS 2019
   Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320
   Ostroumov D, 2018, CELL MOL LIFE SCI, V75, P689, DOI 10.1007/s00018-017-2686-7
   Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395
   Tahtinen S, 2020, CANC RES
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
NR 13
TC 2
Z9 2
U1 7
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD AUG
PY 2020
VL 141
AR 109779
DI 10.1016/j.mehy.2020.109779
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MA8VW
UT WOS:000542189700028
PM 32387756
OA Green Published
DA 2021-01-01
ER

PT J
AU Banach, M
   Penson, PE
   Fras, Z
   Vrablik, M
   Pella, D
   Reiner, Z
   Nabavi, SM
   Sahebkar, A
   Kayikcioglu, M
   Daccord, M
AF Banach, Maciej
   Penson, Peter E.
   Fras, Zlatko
   Vrablik, Michal
   Pella, Daniel
   Reiner, Zeljko
   Nabavi, Seyed Mohammad
   Sahebkar, Amirhossein
   Kayikcioglu, Meral
   Daccord, Magdalena
CA FH Europe Int Lipid Expert Panel
TI Brief recommendations on the management of adult patients with familial
   hypercholesterolemia during the COVID-19 pandemic
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Cholesterol; Coronavirus; Covid-19; Prevention; Risk stratification;
   Statins; Therapy
ID CARDIOVASCULAR RISK
AB Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations on the management of adult patients with FH during the COVID-19 pandemic. We discuss the implications of COVID-19 infections for FH patients, the importance of continuing lipid-lowering therapy where possible, issues relating to safety monitoring and service delivery. We summarise the evidence for additional benefits of statins and other lipid-lowering drugs during viral infections. The recommendations do not override in any way the individual responsibility of physicians to make appropriate and accurate decisions taking into account the condition of a given patient and the doses, rules, and regulations applicable to drugs and devices at the time of their prescription/use.
C1 [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Chair Nephrol & Hypertens, Lodz, Poland.
   [Banach, Maciej] Polish Mothers Mem Hosp Res Inst PMMHRI, Lodz, Poland.
   [Banach, Maciej] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland.
   [Penson, Peter E.] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool, Merseyside, England.
   [Fras, Zlatko] Univ Ljubljana, Univ Med Ctr Ljubljana, Ctr Prevent Cardiol, Div Med,Med Fac, Ljubljana, Slovenia.
   [Vrablik, Michal] Charles Univ Prague, Fac Med 1, Dept Internal Med 3, Prague, Czech Republic.
   [Vrablik, Michal] Gen Fac Hosp Prague, Prague, Czech Republic.
   [Pella, Daniel] Safarik Univ, East Slovak Inst Cardiovasc Dis, Dept Cardiol, Kosice, Slovakia.
   [Pella, Daniel] Safarik Univ, Fac Med, Kosice, Slovakia.
   [Reiner, Zeljko] Zagreb Univ, Univ Hosp Ctr Zagreb, Sch Med, Dept Internal Dis, Zagreb, Croatia.
   [Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Baqiyatallah Hosp, Tehran, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran.
   [Kayikcioglu, Meral] Ege Univ, Sch Med, Dept Cardiol, Izmir, Turkey.
   [Daccord, Magdalena] FH Europe, Budapest, Hungary.
RP Daccord, M (corresponding author), FH Europe, Budapest, Hungary.; Banach, M (corresponding author), Med Univ Lodz, WAM Univ Hosp Lodz, Dept Hypertens, Zeromskiego 113, PL-90549 Lodz, Poland.
EM maciej.banach@icloud.com; md@fheurope.org
RI Sahebkar, Amirhossein/B-5124-2018; Banach, Maciej/A-1271-2009; Penson,
   Peter/E-5353-2010
OI Banach, Maciej/0000-0001-6690-6874; Penson, Peter/0000-0001-6763-1489
FU Sanofi; Valeant; AKCEA; AmgenAmgen; AMRYT; Link Medical; Napp;
   Sanofi-AventisSanofi-Aventis; PfizerPfizer; MSD; Amryt Pharma
FX MB -speakers bureau: Abbott/Mylan, Abbott Vascular, Actavis, Akcea,
   Amgen, Biofarm, KRKA, MSD, Polpharma, Sanofi-Aventis, Servier and
   Valeant; consultant to Abbott Vascular, Akcea, Amgen, Daichii Sankyo,
   Esperion, Freia Pharmaceuticals, Lilly, MSD, Polfarmex, Resverlogix,
   Sanofi-Aventis; Grants from Sanofi and Valeant; PEP owns four shares in
   AstraZeneca PLC and has received honoraria and/or travel reimbursement
   for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, Sanofi;
   ZF has received reimbursements for lectures, advice and
   research/institutional grant support from Sanofi-Aventis, as well as
   reimbursements by Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim,
   Krka, Novo Nordisk, Pfizer, Sanofi-Aventis, and Servier; MV has received
   research support and consulting fees from Amgen, Pfizer, Sanofi, and
   MSD; and nonfinancial support from Amgen and Sanofi; ZR has received
   honoraria from Sanofi-Aventis; MK has received honoraria (for lectures
   and consultancy) from Abbott and Menarini, and research funding from
   Amryt Pharma, Amgen, and Sanofi, and has participated in clinical trials
   with Amgen, Medicines Company, Regenerone, and Sanofi within the last 2
   years. All other authors have noting to disclose.
CR [Anonymous], 2020, COR DIS 2019 COVID 2
   Banach M, 2019, CARDIOVASC RES, V115, pE26, DOI 10.1093/cvr/cvy301
   Bianconi Vanessa, 2020, Trends Cardiovasc Med, DOI 10.1016/j.tcm.2020.03.004
   Cook NR, 2018, J AM COLL CARDIOL, V72, P287, DOI 10.1016/j.jacc.2018.04.060
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Guo HC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170123
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Jeon JH, 2018, ARCH VIROL, V163, P3119, DOI 10.1007/s00705-018-3967-7
   Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503
   Leipold R, 2017, EUR J PREV CARDIOL, V24, P1843, DOI 10.1177/2047487317730473
   Mach F, 2020, EUR HEART J, V41, P111, DOI 10.1093/eurheartj/ehz455
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Momtazi-Borojeni AA, 2019, EUR HEART J-CARD PHA, V5, P237, DOI 10.1093/ehjcvp/pvz022
   Nikolic D, 2020, EXPERT OPIN DRUG SAF, V19, P601, DOI 10.1080/14740338.2020.1747431
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Rosenson RS, 2017, J AM COLL CARDIOL, V70, P1290, DOI 10.1016/j.jacc.2017.07.752
   Solnica B, 2020, ARCH MED SCI, V16, P237, DOI 10.5114/aoms.2020.93253
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Vallejo-Vaz AJ, 2018, ATHEROSCLEROSIS, V277, P234, DOI 10.1016/j.atherosclerosis.2018.08.051
   Vallejo-Vaz AJ, 2015, ATHEROSCLEROSIS, V243, P257, DOI 10.1016/j.atherosclerosis.2015.09.021
   Vuorio A, 2020, J INTERN MED, V287, P746, DOI 10.1111/joim.13070
NR 21
TC 5
Z9 5
U1 6
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD AUG
PY 2020
VL 158
AR 104891
DI 10.1016/j.phrs.2020.104891
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MA7XE
UT WOS:000542124500012
PM 32389859
OA Green Published
DA 2021-01-01
ER

PT J
AU Viecca, M
   Radovanovic, D
   Forleo, GB
   Santus, P
AF Viecca, Maurizio
   Radovanovic, Dejan
   Forleo, Giovanni Battista
   Santus, Pierachille
TI Enhanced platelet inhibition treatment improves hypoxemia in patients
   with severe Covid-19 and hypercoagulability. A case control, proof of
   concept study
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Coronavirus; Covid-19; Respiratory failure; Antiplatelet; Coagulation;
   D-dimer
ID SEPSIS; LUNG
AB Patients affected by severe coronavirus induced disease-2019 (Covid-19) often experience hypoxemia due to alveolar involvement and endothelial dysfunction, which leads to the formation of micro thrombi in the pulmonary capillary vessels. Both hypoxemia and a prothrombotic diathesis have been associated with more severe disease and increased risk of death. To date, specific indications to treat this condition are lacking.
   This was a single center, investigator initiated, compassionate use, proof of concept, case control, phase IIb study (NCT04368377) conducted in the Intermediate Respiratory Care Unit of L. Sacco University Hospital in Milano, Italy. Our objective was to explore the effects of the administration of anti-platelet therapy on arterial oxygenation and clinical outcomes in patients with severe Covid-19 with hypercoagulability.
   We enrolled five consecutive patients with laboratory confirmed SARS-CoV-2 infection, severe respiratory failure requiring helmet continuous positive airway pressure (CPAP), bilateral pulmonary infiltrates and a prothrombotic state identified as a D-dimer > 3 times the upper limit of normal. Five patients matched for age, Ddimer value and SOFA score formed the control group.
   Beyond standard of care, treated patients received 25 mu g/Kg/body weight tirofiban as bolus infusion, followed by a continuous infusion of 0.15 mu g/Kg/body weight per minute for 48 hours. Before tirofiban, patients received acetylsalicylic acid 250 mg infusion and oral clopidogrel 300 mg; both were continued at a dose of 75 mg daily for 30 days. Fondaparinux2.5 mg/day sub-cutaneous was given for the duration of the hospital stay. All controls were receiving prophylactic or therapeutic dose heparin, according to local standard operating procedures.
   Treated patients consistently experienced a mean (SD) reduction in A-a 02 gradient of -32.6 mmHg (61.9, P = 0.154), -52.4 mmHg (59.4, P = 0.016) and -151.1 mmHg (56.6, P = 0.011; P = 0.047 vs. controls) at 24, 48 hours and 7 days after treatment. Pa02/Fi02 ratio increased by 52 mmHg (50, P = 0.172), 64 mmHg (47, P = 0.040) and 112 mmHg (51, P = 0.036) after 24, 48 hours and 7 days, respectively. All patients but one were successfully weaned from CPAP after 3 days. This was not true for the control group. No major adverse events were observed.
   Antiplatelet therapy might be effective in improving the ventilation/perfusion ratio in Covid-19 patients with severe respiratory failure. The effects might be sustained by the prevention and interference on forming clots in lung capillary vessels and by modulating megakaryocytes' function and platelet adhesion. Randomized clinical trials are urgently needed to confirm these results.
C1 [Viecca, Maurizio; Forleo, Giovanni Battista] ASST Fatebenefratelli Sacco, Osped L Sacco, Dept Cardiol, Via GB Grassi 74, I-20157 Milan, Italy.
   [Radovanovic, Dejan; Santus, Pierachille] ASST Fatebenefratelli Sacco, Osped L Sacco, Div Resp Dis, Via GB Grassi 74, I-20157 Milan, Italy.
   [Santus, Pierachille] Univ Milan, Dept Biomed & Clin Sci DIBIC, Milan, Italy.
RP Santus, P (corresponding author), Univ Milan, Dept Biomed & Clin Sci DIBIC, Div Resp Dis, Osped L Sacco,ASST Fatebenefratelli Sacco, Via GB Grassi 74, I-20157 Milan, Italy.
EM maurizio.viecca@asst-fbf.sacco.it; dejan.radovanovic@asst-fbf-sacco.it;
   giovanni.forleo@asst-fbf-sacco.it; pierachille.santus@unimi.it
CR Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI 10.1016/j.jacc.2014.09.017
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Carsana L, 2020, PULMONARY POSTMORTEM, DOI [10.1101/2020.04.19.20054262, DOI 10.1101/2020.04.19.20054262]
   Cazenave JP, 1997, BAILLIERE CLIN HAEM, V10, P163, DOI 10.1016/S0950-3536(97)80056-X
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   HELMHOLZ HF, 1979, CHEST, V75, P748, DOI 10.1378/chest.75.6.748
   Lefrancais E, 2017, NATURE, V544, P105, DOI 10.1038/nature21706
   LI S, 2020, JAMA CARDIOL, V272, DOI DOI 10.1001/JAMACARDIO.2020.1017
   MACNAUGHTON PD, 1994, AM J RESP CRIT CARE, V150, P770, DOI 10.1164/ajrccm.150.3.8087351
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Panigada M., 2020, J THROMB HAEMOST, DOI [10.1111/jth., DOI 10.1111/JTH.]
   PATRONO C, 1990, Circulation, V81, pI12
   Petersson J, 2014, EUR RESPIR J, V44, P1023, DOI 10.1183/09031936.00037014
   Radovanovic D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041191
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   SEEGER W, 1988, CIRC RES, V62, P651, DOI 10.1161/01.RES.62.4.651
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Tan CW, 2020, AM J HEMATOL, V95, pE156, DOI 10.1002/ajh.25822
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   WHO. World Health Organization (WHO), 2020, WHO NOV COR 2019 NCO
   Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872
   Yau JW, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0124-z
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zucker-Franklin D, 2000, AM J PATHOL, V157, P69, DOI 10.1016/S0002-9440(10)64518-X
NR 28
TC 11
Z9 11
U1 16
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD AUG
PY 2020
VL 158
AR 104950
DI 10.1016/j.phrs.2020.104950
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MA7XE
UT WOS:000542124500028
PM 32450344
OA Green Published
DA 2021-01-01
ER

PT J
AU Cruz, MV
   Bellorin, O
   Srivatana, V
   Afaneh, C
AF Vigiola Cruz, Mariana
   Bellorin, Omar
   Srivatana, Vesh
   Afaneh, Cheguevara
TI Safety and Efficacy of Bedside Peritoneal Dialysis Catheter Placement in
   the COVID-19 Era: Initial Experience at a New York City Hospital
SO WORLD JOURNAL OF SURGERY
LA English
DT Article
ID COMPLICATIONS; 1ST
AB Introduction Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is common in critically ill patients with COVID-19. Unparalleled numbers of patients with AKI and shortage of dialysis machines and operative resources prompted consideration of expanded use of urgent-start peritoneal dialysis (PD) and evaluation of the safety and efficacy of bedside surgical placement of PD catheters. Study design Bedside, open PD catheter insertions were performed in early April 2020, at a large academic center in New York City. Patients with SARS-CoV-2 infection and AKI and ambulatory patients with chronic kidney disease and impending need for RRT were included. Detailed surgical technique is described. Results Fourteen catheters were placed at the bedside over 2 weeks, 11 in critically ill COVID-19 patients and three in ambulatory patients. Mean patient age was 61.9 years (43-83), and mean body mass index was 27.1 (20-37.6); four patients had prior abdominal surgery. All catheters were placed successfully without routine radiographic studies or intraoperative complications. One patient (7%) experienced primary nonfunction of the catheter requiring HD. One patient had limited intraperitoneal bleeding while anticoagulated, which was managed by mechanical compression of the abdominal wall and temporarily holding anticoagulation. All other catheters had an adequate function at 3-18 days of follow-up. Conclusions Bedside placement of PD catheters is safe and effective in ICU and outpatient clinic settings. Our surgical protocols allowed for optimization of critical hospital resources, minimization of hazardous exposure to healthcare providers and a broader application of urgent-start PD in selected patients. Long-term follow-up is warranted.
C1 [Vigiola Cruz, Mariana; Bellorin, Omar; Afaneh, Cheguevara] New York Presbyterian Hosp Weill Cornell Med, Dept Surg, 525 East 68th St Box 294, New York, NY 10065 USA.
   [Srivatana, Vesh] New York Presbyterian Hosp Weill Cornell Med, Dept Hypertens & Nephrol, New York, NY USA.
RP Cruz, MV (corresponding author), New York Presbyterian Hosp Weill Cornell Med, Dept Surg, 525 East 68th St Box 294, New York, NY 10065 USA.
EM mav9206@med.cornell.edu
CR Al-Hwiesh A, 2018, THER APHER DIAL, V22, P371, DOI 10.1111/1744-9987.12660
   Alp E, 2006, J HOSP INFECT, V62, P1, DOI 10.1016/j.jhin.2005.01.014
   American Society of Nephrology, 2020, REC CAR HOSP PAT COV
   Arramreddy R, 2014, AM J KIDNEY DIS, V63, P390, DOI 10.1053/j.ajkd.2013.09.018
   Burgner A, 2020, CLIN J AM SOC NEPHRO, V15, P720, DOI 10.2215/CJN.03750320
   Chionh CY, 2013, CLIN J AM SOC NEPHRO, V8, P1649, DOI 10.2215/CJN.01540213
   Crabtree JH, 2009, AM SURGEON, V75, P140
   Danielsson A, 2007, PERITON DIALYSIS INT, V27, P153
   Di Saverio S, 2020, J TRAUMA ACUTE CARE, DOI 10.1097/TA.0000000000002727
   Dias DB, 2020, PERIT DIAL INT
   Durvasula R, AM J KIDNEY DIS
   George N, 2016, PERITON DIALYSIS INT, V36, P655, DOI 10.3747/pdi.2015.00097
   Ghaffari A, 2013, PERITON DIALYSIS INT, V33, P611, DOI 10.3747/pdi.2013.00017
   Ikizler TA, 2020, NAT REV NEPHROL, V16, P311, DOI 10.1038/s41581-020-0280-y
   Lew SQ, 2019, AM J KIDNEY DIS, V74, P95, DOI 10.1053/j.ajkd.2019.01.023
   Liu FXQ, 2015, PERITON DIALYSIS INT, V35, P406, DOI 10.3747/pdi.2013.00204
   Liu FX, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000293
   McCormick BB, 2007, J AM SOC NEPHROL, V18, P3023, DOI 10.1681/ASN.2007070796
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Sun ML, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01724-w
   Tan CW, 2020, AM J HEMATOL, V95, pE156, DOI 10.1002/ajh.25822
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813
   Vigneswaran Y, 2020, J GASTROINTEST SURG, V24, P1686, DOI 10.1007/s11605-020-04592-9
   Watnick S, 2020, CLIN J AM SOC NEPHRO, V15, P710, DOI 10.2215/CJN.03540320
NR 26
TC 4
Z9 4
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0364-2313
EI 1432-2323
J9 WORLD J SURG
JI World J.Surg.
PD AUG
PY 2020
VL 44
IS 8
BP 2464
EP 2470
DI 10.1007/s00268-020-05600-4
PG 7
WC Surgery
SC Surgery
GA MD9YX
UT WOS:000544322800003
PM 32458021
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rothan, HA
   Stone, S
   Natekar, J
   Kumari, P
   Arora, K
   Kumar, M
AF Rothan, Hussin A.
   Stone, Shannon
   Natekar, Janhavi
   Kumari, Pratima
   Arora, Komal
   Kumar, Mukesh
TI The FDA-approved gold drug auranofin inhibits novel coronavirus
   (SARS-COV-2) replication and attenuates inflammation in human cells
SO VIROLOGY
LA English
DT Article
DE SARS-COV-2; COVID-19; Auranofin; Antiviral; Anti-inflammatory
ID REPURPOSING AURANOFIN; CYTOKINES; COVID-19; PROTEIN; MODEL
AB SARS-COV-2 has recently emerged as a new public health threat Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-00V-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease.
C1 [Rothan, Hussin A.; Stone, Shannon; Natekar, Janhavi; Kumari, Pratima; Arora, Komal; Kumar, Mukesh] Georgia State Univ, Coll Arts & Sci, Dept Biol, 145 Piedmont Ave SE, Atlanta, GA 30303 USA.
RP Rothan, HA; Kumar, M (corresponding author), Georgia State Univ, Coll Arts & Sci, Dept Biol, 145 Piedmont Ave SE, Atlanta, GA 30303 USA.
EM hrothan@gsu.edu; mkumar8@gsu.edu
RI Rothan, Hussin/AAV-9877-2020; Kumar, Mukesh/N-8814-2015
OI Kumar, Mukesh/0000-0003-0970-4875; ROTHAN, HUSSIN/0000-0002-7300-6388;
   Kumari, Pratima/0000-0001-5248-7007
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R21NS099838]; Office of the Director, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R21OD024896]
FX This work was supported by a grant (R21NS099838) from National Institute
   of Neurological Disorders and Stroke, grant (R21OD024896) from the
   Office of the Director, National Institutes of Health, and Institutional
   funds.
CR Azouz F, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020162
   Capparelli EV, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01947-16
   Chirullo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.473
   Diaz RS, 2019, INT J ANTIMICROB AG, V54, P592, DOI 10.1016/j.ijantimicag.2019.08.001
   Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296
   Han S, 2008, ARCH PHARM RES, V31, P67, DOI 10.1007/s12272-008-1122-9
   Harbut MB, 2015, P NATL ACAD SCI USA, V112, P4453, DOI 10.1073/pnas.1504022112
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hou GX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0159-4
   Kim JA, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020072
   Kim NH, 2007, IMMUNOLOGY, V122, P607, DOI 10.1111/j.1365-2567.2007.02679.x
   KRAUSE K, 2019, FRONT MICROBIOL, V10, DOI DOI 10.3389/FMICB.2019
   Kumar M, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0750-4
   Leitsch D, 2017, INT J PARASITOL-DRUG, V7, P321, DOI 10.1016/j.ijpddr.2017.09.001
   Lewis MG, 2011, AIDS, V25, P1347, DOI 10.1097/QAD.0b013e328347bd77
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lugea A, 2017, GASTROENTEROLOGY, V153, P1674, DOI 10.1053/j.gastro.2017.08.036
   May HC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00336
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Natekar JP, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010009
   OH BM, 2017, CELL DEATH DIS, V8, DOI DOI 10.1038/CDDIS.2017
   Rigobello MP, 2009, FREE RADICAL BIO MED, V47, P710, DOI 10.1016/j.freeradbiomed.2009.05.027
   Roder C, 2015, DRUGS R&D, V15, P13, DOI 10.1007/s40268-015-0083-y
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rothan HA, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030148
   Rothan HA, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02089
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Siu KL, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-3
   Sung SC, 2009, VIROLOGY, V387, P402, DOI 10.1016/j.virol.2009.02.021
   Tang BSF, 2005, J VIROL, V79, P6180, DOI 10.1128/JVI.79.10.6180-6193.2005
   Thangamani S, 2016, INT J ANTIMICROB AG, V47, P195, DOI 10.1016/j.ijantimicag.2015.12.016
   Varghese E, 2014, CANCERS, V6, P2243, DOI 10.3390/cancers6042243
   WALZ DT, 1983, AM J MED, V75, P90, DOI 10.1016/0002-9343(83)90481-3
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wiederhold NP, 2017, VIRULENCE, V8, P138, DOI 10.1080/21505594.2016.1196301
NR 35
TC 13
Z9 14
U1 6
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD AUG
PY 2020
VL 547
BP 7
EP 11
DI 10.1016/j.virol.2020.05.002
PG 5
WC Virology
SC Virology
GA MA2WK
UT WOS:000541778600002
PM 32442105
OA Green Published
DA 2021-01-01
ER

PT J
AU Ali, I
   Alharbi, OML
AF Ali, Imran
   Alharbi, Omar M. L.
TI COVID-19: Disease, management, treatment, and social impact
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE SARS-CoV-2; COVID-19; Prevention and management; Treatment; Social
   impact
ID ANTIVIRAL ACTIVITIES; CORONAVIRUS; WUHAN; SARS; IDENTIFICATION;
   REMDESIVIR; EFFICACY; INHIBIT; EXTRACT; VIRUS
AB COVID-19 was originated from Wuhan city of Hubei Province in China in December 2019. Since then it has spread in more than 210 countries and territories. It is a viral disease due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. The patients show flu-like symptoms with a dry cough, sore throat, high fever, and breathing problems. The disease due to SARS-CoV-2 was named as COVID-19. About 2.2 million people have been infected with more than 0.15 million deaths globally. The United States of America is the most affected country with the highest patients of about 0.7 million. Despite great efforts, there is no treatment of this disease. However, prevention and management are the best options. This article describes SARS-CoV-2, disease, prevention and management, treatment and social impact on society. It was analyzed that a combination of antiviral drugs with hydroxyl-chloroquine and azithromycin (with the consultation of a medical practitioner) may be the best option to treat the patients, depending on the patient's conditions and symptoms. However, Unani therapy may be useful along with allopathic treatment. It is urgently advised and requested that all the persons should follow the preventive measures, managements and quarantine strictly without any religious discrepancy otherwise the situation may be the worst. Also, there is an urgent requirement to educate our new generation for science and technology to fight against any such disaster in future; if any. There is no need to be panic and proper prevention and management are essential to combat this disease. This article may be useful to create awareness among the public, to prevent, manage and treat COVID-19.
C1 [Ali, Imran] Taibah Univ, Coll Sci, Dept Chem, Al Medina Al Munawara 41477, Saudi Arabia.
   [Ali, Imran] Jamia Millia Islamia, Dept Chem, New Delhi 11025, India.
   [Alharbi, Omar M. L.] Taibah Univ, Coll Sci, Dept Biol, Al Medina Al Munawara 41477, Saudi Arabia.
RP Ali, I (corresponding author), Taibah Univ, Coll Sci, Dept Chem, Al Medina Al Munawara 41477, Saudi Arabia.; Ali, I (corresponding author), Jamia Millia Islamia, Dept Chem, New Delhi 11025, India.
EM drimran.chiral@gmail.com
RI Ali, Prof. & Dr. Imran/F-7710-2010
OI Ali, Prof. & Dr. Imran/0000-0001-6511-8374
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Anagha K., 2014, J CURR MICROBIOL APP, V3, P657
   [Anonymous], 2020, NY TIMES
   [Anonymous], 2020, CARINGLY YOURS  0128
   Asl N.N., 2007, J MED PLANT, V6, P1
   BANO N, 2017, J BIOEQUIV BIOAVAILA, V9, P387, DOI DOI 10.4172/jbb.1000330
   Bayan L, 2014, AVICENNA J PHYTOMEDI, V4, P1
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Chang JS, 2013, J ETHNOPHARMACOL, V145, P146, DOI 10.1016/j.jep.2012.10.043
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Fatima M, 2016, J MICROBIOL BIOTECHN, V26, P151, DOI 10.4014/jmb.1508.08024
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   Ghoke SS, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2238-1
   Hashemipour MA, 2014, WOUNDS, V26, P47
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jaimes JA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010083
   Jiang ZY, 2013, BIOORG MED CHEM LETT, V23, P2123, DOI 10.1016/j.bmcl.2013.01.118
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kim HY, 2010, ANTIVIR THER, V15, P697, DOI 10.3851/IMP1615
   KONOWALCHUK J, 1978, APPL ENVIRON MICROB, V35, P1219, DOI 10.1128/AEM.35.6.1219-1220.1978
   Lee JB, 2012, FOOD CHEM, V134, P2164, DOI 10.1016/j.foodchem.2012.04.016
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mathie RT, 2013, HOMEOPATHY, V102, P187, DOI 10.1016/j.homp.2013.04.001
   Miladi S, 2012, NAT PROD RES, V26, P1027, DOI 10.1080/14786419.2010.550263
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Omer MO, 2014, PHARMACOGN RES, V6, P6, DOI 10.4103/0974-8490.122911
   Praditya D, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00912
   Ren L.-L., 2020, CHINESE MED J
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Wan Y., 2020, J VIROL, V94
   Wang LQ, 2015, ACTA PHARM SIN B, V5, P310, DOI [10.1016//j.apsb.2015.05.005, 10.1016/j.apsb.2015.05.005]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WEBER ND, 1992, PLANTA MED, V58, P417, DOI 10.1055/s-2006-961504
   Xu Z., 2020, BIORXIV
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 49
TC 28
Z9 28
U1 4
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD AUG 1
PY 2020
VL 728
AR 138861
DI 10.1016/j.scitotenv.2020.138861
PG 6
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA LZ1SJ
UT WOS:000541009200027
PM 32344226
OA Green Published
DA 2021-01-01
ER

PT J
AU Chakraborty, I
   Maity, P
AF Chakraborty, Indranil
   Maity, Prasenjit
TI COVID-19 outbreak: Migration, effects on society, global environment and
   prevention
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE COVID-19; Pandemics; Global health; Economic; Prevention
ID CORONAVIRUS 2019-NCOV; CHLOROQUINE; CLIMATE
AB The COVID-19 pandemic is considered as the most crucial global health calamity of the century and the greatest challenge that the humankind faced since the 2nd World War. In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China and was named by the World Health Organization as COVID-19 (coronavirus disease 2019). A new class of corona virus, known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has been found to be responsible for occurrence of this disease. As far as the history of human civilization is concerned there are instances of severe outbreaks of diseases caused by a number of viruses. According to the report of the World Health Organization (WHO as of April 18 2020), the current outbreak of COVID-19, has affected over 2164111 people and killed more than 146,198 people in more than 200 countries throughout the world. Till now there is no report of any clinically approved antiviral drugs or vaccines that are effective against COVID-19. It has rapidly spread around the world, posing enormous health, economic, environmental and social challenges to the entire human population. The coronavirus outbreak is severely disrupting the global economy. Almost all the nations are struggling to slow down the transmission of the disease by testing & treating patients, quarantining suspected persons through contact tracing, restricting large gatherings, maintaining complete or partial lock down etc. This paper describes the impact of COVID-19 on society and global environment, and the possible ways in which the disease can be controlled has also been discussed therein.
C1 [Chakraborty, Indranil] Kharagpur Coll, Dept Chem, Kharagpur 721305, W Bengal, India.
   [Maity, Prasenjit] Sabang Sajanikanta Mahavidyalaya, Dept Chem, Paschim Midnapore 721166, W Bengal, India.
RP Maity, P (corresponding author), Sabang Sajanikanta Mahavidyalaya, Dept Chem, Paschim Midnapore 721166, W Bengal, India.
EM prasenjitchem89@gmail.com
OI MAITY, DR. PRASENJIT/0000-0002-0612-0228
CR Afelt A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00702
   de Oliveira JFA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01209-1
   Allocati N, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.48
   [Anonymous], 2004, SUMM PROB SARS CAS O
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Bremer S., 2019, OXFORD RES ENCY NAT, DOI [10.1093/acrefore/9780199389407.013.354, DOI 10.1093/ACREFORE/9780199389407.013.354]
   Coutts A, 2010, URBAN POLICY RES, V28, P27, DOI 10.1080/08111140903437716
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Field CB, 2014, CLIMATE CHANGE 2014: IMPACTS, ADAPTATION, AND VULNERABILITY, PT A: GLOBAL AND SECTORAL ASPECTS, P1
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu W., 2020, CHEMBIOCHEM, DOI [10.1002/cbic.2020 0 0 047, DOI 10.1002/CBIC.2020]
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   OECD Interim Economic Assessment, 2020, COR WORLD EC RISK
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Rawat Mukesh, CORONAVIRUS INDIA TR
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Ruscio BA, 2015, INT J CIRCUMPOL HEAL, V74, DOI 10.3402/ijch.v74.27913
   Shindell D, 2017, SCIENCE, V356, P493, DOI 10.1126/science.aak9521
   Wang Chen, 2020, LANCET
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Yoo J.H., 2020, J KOREAN MED SCI, P35, DOI [10.3346/jkms.2020.35.56, DOI 10.3346/JKMS.2020.35.56]
NR 25
TC 77
Z9 80
U1 71
U2 82
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD AUG 1
PY 2020
VL 728
AR 138882
DI 10.1016/j.scitotenv.2020.138882
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA LZ1SJ
UT WOS:000541009200001
PM 32335410
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Nikhat, S
   Fazil, M
AF Nikhat, Sadia
   Fazil, Mohammad
TI Overview of Covid-19; its prevention and management in the light of
   Unani medicine
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE SARS-CoV-2; Covid-19; Unani medicine; Waba; Influenza; Nazla-e-wabaiya
ID ESSENTIAL OIL; TRIBOLIUM-CASTANEUM; FUMIGANT TOXICITY; EXTRACTS;
   CONSTITUENTS; REPELLENT; BEETLE; DRUGS; COLD
AB Since December 2019, a respiratory pandemic named as coronavirus disease 2019 (Covid-19) caused by a new coronavirus named as SARS-CoV-2, has taken the world by storm. The symptoms are fever, malaise, and cough which resolve in a few days in most cases; but may progress to respiratory distress and organ failure. Transmission is through droplet infection or fomites, but other modes such as airborne transmission and oro-fecal transmission are also speculated. Research is underway to develop effective vaccines and medicines for the disease. In such a scenario, we present the measures described in Unani system of medicine for health protection during epidemics. Unani is a traditional system of medicine developed during the middle ages, which employs natural drugs of herbal, animal and mineral origin for treatment. In Unani medicine, during an epidemic, apart from isolation and quarantine, three measures are of utmost importance, (i) purification of surroundings using certain herbal drugs as fumigants or sprays, (ii) health promotion and immune-modulation, and (iii) use of health-protecting drugs and symptom-specific drugs. Drugs such as loban (Styrax benzoides W. G. Craib), sandroos (Hymenaea verrucosa Gaertn.) za'fran (Crocus sativus L.), vinegar etc. are prescribed in various forms. Scientific researches on these drugs reveal the presence of a number of pharmacologically active substances, which may provide a new insight into the management of infections and epidemics.
C1 [Nikhat, Sadia] Jamia Hamdard, Sch Unani Med Educ & Res, Dept Ilaj Bit Tadbeer, New Delhi 110062, India.
   [Fazil, Mohammad] CCRUM, HAK Inst Literary & Hist Res Unani Med, Jamia Millia Islamia Campus, New Delhi 110025, India.
RP Fazil, M (corresponding author), CCRUM, HAK Inst Literary & Hist Res Unani Med, Jamia Millia Islamia Campus, New Delhi 110025, India.
EM sadianikhat@jamiahamdard.ac.in; fazilmd00@gmail.com
RI Fazil, Mohammad/AAV-2473-2020; Nikhat, Sadia/AAS-7700-2020
OI Fazil, Mohammad/0000-0002-6708-6027; Nikhat, Sadia/0000-0003-4761-0976
CR Acharya Krishna Prasad, 2020, Clin Epidemiol Glob Health, DOI 10.1016/j.cegh.2020.03.001
   Adedeji W A, 2016, Ann Ib Postgrad Med, V14, P56
   Al-Massarani SM, 2017, SAUDI PHARM J, V25, P750, DOI 10.1016/j.jsps.2016.10.012
   Amini M, 2017, FOOD CHEM, V235, P290, DOI 10.1016/j.foodchem.2017.05.067
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anfinrud Philip, 2020, medRxiv, DOI 10.1101/2020.04.02.20051177
   [Anonymous], 2009, UNANI PHARMACOPOEI 1
   [Anonymous], 2006, NATL FORMULARY UNANI
   Arain IU, 2016, ANN KING EDWARD MED, V22, P8, DOI 10.21649/akemu.v22i1.789
   Bachrouch O, 2010, B INSECTOL, V63, P129
   Baghdadi I.H., 2004, KITAB AL MUKHTARAT F
   Bassiri-Jahromi S, 2018, ONCOL REV, V12, P1, DOI 10.4081/oncol.2018.345
   Bhat G. A., 2016, ENVIRON POLICY LAW, V46, P137
   Bhatwalkar SB, 2019, J AYURVEDA INTEGR ME, V10, P203, DOI 10.1016/j.jaim.2019.05.002
   Bukhari SI, 2018, BIOMED PHARMACOTHER, V98, P733, DOI 10.1016/j.biopha.2017.12.090
   Cagno V, 2015, J ETHNOPHARMACOL, V176, P252, DOI 10.1016/j.jep.2015.10.042
   Cambra L.M.A., 2018, AM RES J ENGLISH LIT, V4, DOI [10.21694/2378-9026.18015., DOI 10.21694/2378-9026.18015]
   Chaleshtori FS, 2018, J EVID-BASED INTEGR, V23, DOI 10.1177/2515690X17751314
   Chaubey Mukesh Kumar, 2013, Pakistan Journal of Biological Sciences, V16, P517, DOI 10.3923/pjbs.2013.517.523
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Civljak R, 2020, CROAT MED J, V61, P1, DOI 10.3325/cmj.2020.61.1
   Crowther A, 2015, J ARCHAEOL SCI, V53, P374, DOI 10.1016/j.jas.2014.10.008
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Deponti G.N., 2017, J CRIT CARE, V42, P399, DOI [10.1016/j.jcrc.2017.09.091, DOI 10.1016/J.JCRC.2017.09.091]
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Ezz Eldin Hayam Mohamed, 2019, J Parasit Dis, V43, P351, DOI 10.1007/s12639-019-01098-3
   Foster W.D., 1970, HIST MED BACTERIOLOG, DOI [10.1016/c2013-0-04334-4, DOI 10.1016/C2013-0-04334-4]
   Fu JT, 2015, J INSECT SCI, V15, DOI 10.1093/jisesa/iev112
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hamauzu Y, 2005, J AGR FOOD CHEM, V53, P928, DOI 10.1021/jf0494635
   Hayes D, 2016, CRIT REV FOOD SCI, V56, P1231, DOI 10.1080/10408398.2012.760516
   He X., 2020, TEMPORAL DYNAMICS VI, DOI [10.1101/2020.03.15.20036707, DOI 10.1101/2020.03.15.20036707]
   Ho CW, 2017, FOOD CHEM, V221, P1621, DOI 10.1016/j.foodchem.2016.10.128
   Hong EH, 2015, BIOMOL THER, V23, P345, DOI 10.4062/biomolther.2015.019
   Husain A, 2010, MED J ISLAM WORLD AC, V18, P27
   Imani G., 2020, J HERBMED PHARM, V9, DOI [10.15171/jhp.2020.xx, DOI 10.15171/JHP.2020.XX]
   Islam A, 2018, INTELLECT DISCOURSE, V26, P23
   Jabri MA, 2016, BIOMED PHARMACOTHER, V84, P1937, DOI 10.1016/j.biopha.2016.11.008
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Jones D. S., 2020, NEW ENGL J MED, V382, P1
   Kim J, 2016, PESTIC BIOCHEM PHYS, V133, P35, DOI 10.1016/j.pestbp.2016.03.007
   Kim MJ, 2016, J FOOD COMPOS ANAL, V49, P19, DOI 10.1016/j.jfca.2016.03.004
   Kim SI, 2007, VET PARASITOL, V145, P377, DOI 10.1016/j.vetpar.2006.12.021
   Komakech R, 2019, INTEGR MED RES, V8, P181, DOI 10.1016/j.imr.2019.07.002
   Lemenih M, 2003, J ARID ENVIRON, V55, P465, DOI 10.1016/S0140-1963(03)00053-3
   Lim SH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020437
   Ling L, 2020, ANAESTH CRIT CARE PA, V39, P163, DOI 10.1016/j.accpm.2020.02.002
   Ludwiczuk A, 2017, PHARMACOGNOSY: FUNDAMENTALS, APPLICATIONS AND STRATEGIES, P233, DOI 10.1016/B978-0-12-802104-0.00011-1
   MARIDASS M, 2008, ETHNOBOTANICAL LEAFL, V12, P868
   McKibbin W. J., 2020, 192020 CAMA, DOI [10.2139/ssrn.3547729, DOI 10.2139/SSRN.3547729]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menkir Tigist Ferede, 2020, medRxiv, DOI 10.1101/2020.03.23.20038331
   Mohr KI, 2016, CURR TOP MICROBIOL, V398, P237, DOI 10.1007/82_2016_499
   Nigar Z, 2013, ANC SCI LIFE, V33, P119, DOI 10.4103/0257-7941.139054
   OBER WB, 1982, B NEW YORK ACAD MED, V58, P418
   Orav A, 2010, PROCEDIA CHEM, V2, P161, DOI 10.1016/j.proche.2009.12.023
   Oza MJ, 2017, J PHARM PHARMACOL, V69, P755, DOI 10.1111/jphp.12715
   Pandith SA, 2018, PHYTOCHEM REV, V17, P573, DOI 10.1007/s11101-018-9551-7
   Parsley NC, 2018, PHYTOCHEMISTRY, V152, P61, DOI 10.1016/j.phytochem.2018.04.014
   Qadeer A., 2001, TAREEKH E TIB WA AKH
   Rahmani AH, 2015, PHARMACOGN RES, V7, P217, DOI 10.4103/0974-8490.157956
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Razi Z., 2008, KITAB AL HAWI
   Razi Z., 1991, KITAB AL MANSOORI
   Rehman S.Z., 1991, DAUR E JADEED AUR TI
   Rodriguez-Morales AJ, 2020, J PURE APPL MICROBIO, V14, P5, DOI 10.22207/JPAM.14.1.02
   Rushd I., 1987, KITAB AL KULLIYAT
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Sabatini J, 2020, INT J TEST, V20, P1, DOI 10.1080/15305058.2018.1551224
   Sagheer M, 2013, PAK J ZOOL, V45, P1735
   Sahasranaman A., 2020, SSRN ELECT J, DOI [10.2139/ssrn, DOI 10.2139/SSRN.3558548]
   Samarqandi N., 2010, SHARAH ASBAB
   Saxena S, 2017, J CLIN DIAGN RES, V11, pZC47, DOI 10.7860/JCDR/2017/23558.9355
   Sina I., 1878, AL QANOON FIL TIBB
   Subbarayappa BV, 2001, J BIOSCIENCE, V26, P135, DOI 10.1007/BF02703637
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Vahid-Dastjerdi E, 2014, IRAN J MICROBIOL, V6, P269
   Vairappan C.S., 2015, J TROP BIOL CONSERV, V12, P127
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Verma RS, 2015, J ESSENT OIL RES, V27, P477, DOI 10.1080/10412905.2015.1039664
   VOHORA SB, 1986, J ETHNOPHARMACOL, V16, P201, DOI 10.1016/0378-8741(86)90090-5
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zeinali M, 2019, IRAN J BASIC MED SCI, V22, P334, DOI 10.22038/ijbms.2019.34365.8158
   Zhang JS, 2011, J AGR FOOD CHEM, V59, P9910, DOI 10.1021/jf202266n
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 91
TC 8
Z9 8
U1 8
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD AUG 1
PY 2020
VL 728
AR 138859
DI 10.1016/j.scitotenv.2020.138859
PG 9
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA LZ1SJ
UT WOS:000541009200011
PM 32334163
OA Green Published
DA 2021-01-01
ER

PT J
AU Andreani, J
   Le Bideau, M
   Duflot, I
   Jardot, P
   Rolland, C
   Boxberger, M
   Wurtz, N
   Rolain, JM
   Colson, P
   La Scola, B
   Raoult, D
AF Andreani, Julien
   Le Bideau, Marion
   Duflot, Isabelle
   Jardot, Priscilla
   Rolland, Clara
   Boxberger, Manon
   Wurtz, Nathalie
   Rolain, Jean-Marc
   Colson, Philippe
   La Scola, Bernard
   Raoult, Didier
TI In vitro testing of combined hydroxychloroquine and azithromycin on
   SARS-CoV-2 shows synergistic effect
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE 2019-nCoV; SARS-CoV-2; COVID-19; Hydroxychloroquine; Azithromycin; Vero
   E6
ID RESPIRATORY SYNDROME CORONAVIRUS; Q-FEVER; CHLOROQUINE; INFECTION;
   CELLS; INHIBITION; DOXYCYCLINE; PNEUMONIA; CHILDREN; DRUG
AB Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
C1 [Andreani, Julien; Le Bideau, Marion; Duflot, Isabelle; Jardot, Priscilla; Rolland, Clara; Boxberger, Manon; Wurtz, Nathalie; Rolain, Jean-Marc; Colson, Philippe; La Scola, Bernard; Raoult, Didier] IHU Mediterranee Infect, Marseille, France.
   [Andreani, Julien; Le Bideau, Marion; Duflot, Isabelle; Jardot, Priscilla; Rolland, Clara; Boxberger, Manon; Wurtz, Nathalie; Rolain, Jean-Marc; Colson, Philippe; La Scola, Bernard; Raoult, Didier] Aix Marseille Univ, AP HM, MEPHI, IRD, Marseille, France.
RP La Scola, B; Raoult, D (corresponding author), IHU Mediterranee Infect, Marseille, France.
EM bernard.la-scola@univ-amu.fr; didier.raoult@gmail.com
RI Rolain, Jean-Marc/Y-3788-2019
OI Rolain, Jean-Marc/0000-0002-2402-4467; BOXBERGER,
   Manon/0000-0002-7740-0518; Rolland, Clara/0000-0002-2058-1696
FU French Government under the "Investissements d'avenir" (Investments for
   the Future) programFrench National Research Agency (ANR) [Mediterranee
   Infection 10-IAHU-03]; Region Provence-Alpes-Cote d'AzurRegion
   Provence-Alpes-Cote d'Azur; European funding FEDER PRIMI
FX This research was funded by the French Government under the
   "Investissements d'avenir" (Investments for the Future) program managed
   by the Agence Nationale de la Recherche (ANR, French National Agency for
   Research), (reference: Mediterranee Infection 10-IAHU-03), by Region
   Provence-Alpes-Cote d'Azur and European funding FEDER PRIMI.
CR Amrane S., 2020, TRAVEL MED INFECT DI, DOI [10.1016/j.tmaid.2020.101663, DOI 10.1016/J.TMAID.2020.101663]
   Armstrong N, 2017, J CHROMATOGR B, V1060, P166, DOI 10.1016/j.jchromb.2017.06.011
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Boulos A, 2004, ANTIMICROB AGENTS CH, V48, P747, DOI 10.1128/AAC.48.3.747-752.2004
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Fenollar F, 2007, NEW ENGL J MED, V356, P55, DOI 10.1056/NEJMra062477
   Fleming-Dutra KE, 2018, PEDIATR INFECT DIS J, V37, P52, DOI 10.1097/INF.0000000000001708
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li CF, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00394-19
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lusamba KN, 2015, PHYSL REP, V3
   Morens DM, 2009, J INFECT DIS, V200, P1018, DOI 10.1086/644537
   Morgene MF, 2018, VIROLOGY, V523, P27, DOI 10.1016/j.virol.2018.07.025
   Nabirotchkin S., 2020, FOCUSING UNFOLDED PR, DOI DOI 10.20944/PREPRINTS202003.0302.V1
   OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327
   Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167
   RAOULT D, 1990, ANTIMICROB AGENTS CH, V34, P1512, DOI 10.1128/AAC.34.8.1512
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang C, 2019, IEEE IND ELEC, P2020, DOI 10.1109/IECON.2019.8927477
   Wang YZ, 2016, ANTIVIR RES, V125, P1, DOI 10.1016/j.antiviral.2015.11.003
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 42
Z9 43
U1 11
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD AUG
PY 2020
VL 145
AR 104228
DI 10.1016/j.micpath.2020.104228
PG 4
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LY9GI
UT WOS:000540835800019
PM 32344177
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kalita, P
   Padhi, AK
   Zhang, KYJ
   Tripathi, T
AF Kalita, Parismita
   Padhi, Aditya K.
   Zhang, Kam Y. J.
   Tripathi, Timir
TI Design of a peptide-based subunit vaccine against novel coronavirus
   SARS-CoV-2
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE Adjuvant; COVID-19; Immunogenic epitopes; Peptide vaccine; SARS-CoV-2;
   Subunit vaccine
ID SARS; COVID-19
AB Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. We advocate this vaccine must be synthesized and tested urgently as a public health priority.
C1 [Kalita, Parismita; Tripathi, Timir] North Eastern Hill Univ, Mol & Struct Biophys Lab, Dept Biochem, Shillong 793022, Meghalaya, India.
   [Kalita, Parismita] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
   [Padhi, Aditya K.; Zhang, Kam Y. J.] RIKEN, Ctr Biosyst Dynam Res, Lab Struct Bioinformat, Yokohama, Kanagawa 2300045, Japan.
RP Tripathi, T (corresponding author), North Eastern Hill Univ, Mol & Struct Biophys Lab, Dept Biochem, Shillong 793022, Meghalaya, India.
EM timir.tripathi@gmail.com
RI ; Tripathi, Timir/G-4197-2012
OI Kalita, Parismita/0000-0002-4123-0975; Tripathi,
   Timir/0000-0001-5559-289X
CR Abdelmageed M.I., 2020, BIORXIV 2020
   Al-amri SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44875
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2020, NIH CLIN TRIAL INVES
   [Anonymous], 2020, CLOVER BIOPHARMACEUT
   [Anonymous], 2020, INFORM CLINICIANS TH
   [Anonymous], 2020, MODERNAS WORK POTENT
   Beau H.D., 2020, SLASHDOTMEDIA
   Bhatia MS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1803964
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061196
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cyranoski David, 2020, Nature, DOI 10.1038/d41586-020-00938-0
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Feng E., 2020, NATL PUBLIC RADIO NE, P2020
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Kalita P, 2019, INT J BIOL MACROMOL, V138, P224, DOI 10.1016/j.ijbiomac.2019.07.024
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mishra S., 2020, CHEMRXIV 2020, DOI [10.26434/chemrxiv.12029523.v2, DOI 10.26434/CHEMRXIV.12029523.V2]
   Mukerjee S., 2020, FIRST CORONAVIRUS DR
   Poon LLM, 2003, J CLIN VIROL, V28, P233, DOI 10.1016/j.jcv.2003.08.004
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Seema M., 2020, CHEMRXIV 2020
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, DRAFT LANDSCAPE COVI
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang JY, 2020, P NATL ACAD SCI USA, V117, P1496, DOI 10.1073/pnas.1914677117
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 38
TC 21
Z9 21
U1 33
U2 47
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD AUG
PY 2020
VL 145
AR 104236
DI 10.1016/j.micpath.2020.104236
PG 8
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LY9GI
UT WOS:000540835800026
PM 32376359
OA Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Giron, CC
   Laaksonen, A
   da Silva, FLB
AF Giron, Carolina Correa
   Laaksonen, Aatto
   Barroso da Silva, Fernando L.
TI On the interactions of the receptor-binding domain of SARS-CoV-1 and
   SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor
   ACE2
SO VIRUS RESEARCH
LA English
DT Article
DE Epitopes; Binding affinity; Antibody development; Host-pathogen
   interaction; Electrostatic interactions; Antigenic analysis; Computer
   simulation; pH effect; Coronavirus; SARS-CoV-2; ACE2; Protein-protein
   interaction
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; PH; DETERMINANTS;
   GLYCOPROTEIN; SIMULATIONS; INFECTION; OUTBREAK; SYSTEM; ENTRY
AB A new betacoronavirus named SARS-CoV-2 has emerged as a new threat to global health and economy. A promising target for both diagnosis and therapeutics treatments of the new disease named COVID-19 is the coronavirus (CoV) spike (S) glycoprotein. By constant-pH Monte Carlo simulations and the PROCEEDpKa method, we have mapped the electrostatic epitopes for four monoclonal antibodies and the angiotensin-converting enzyme 2 (ACE2) on both SARS-CoV-1 and the new SARS-CoV-2 S receptor binding domain (RBD) proteins. We also calculated free energy of interactions and shown that the S RBD proteins from both SARS viruses binds to ACE2 with similar affinities. However, the affinity between the S RBD protein from the new SARS-CoV-2 and ACE2 is higher than for any studied antibody previously found complexed with SARS-CoV-1. Based on physical chemical analysis and free energies estimates, we can shed some light on the involved molecular recognition processes, their clinical aspects, the implications for drug developments, and suggest structural modifications on the CR3022 antibody that would improve its binding affinities for SARS-CoV-2 and contribute to address the ongoing international health crisis.
C1 [Giron, Carolina Correa] Univ Fed Triangulo Mineiro, Dept Saude Colet, Rua Vigario Carlos, BR-38025350 Uberaba, MG, Brazil.
   [Giron, Carolina Correa; Barroso da Silva, Fernando L.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Ciencias Biomol, Av Cafe S-No,Campus USP, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Laaksonen, Aatto] Stockholm Univ, Dept Mat & Environm Chem, Arrhenius Lab, SE-10691 Stockholm, Sweden.
   [Laaksonen, Aatto] Nanjing Tech Univ, State Key Lab Mat Oriented & Chem Engn, Nanjing 210009, Peoples R China.
   [Laaksonen, Aatto] Petru Poni Inst Macromol Chem, Ctr Adv Res Bionanoconjugates & Biopolymers, Aleea Grigore Ghica Voda 41A, Iasi 700487, Romania.
   [Laaksonen, Aatto] Lulea Univ Technol, Dept Engn Sci & Math, Div Energy Sci, SE-97187 Lulea, Sweden.
   [Barroso da Silva, Fernando L.] North Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA.
RP da Silva, FLB (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Ciencias Biomol, Av Cafe S-No,Campus USP, BR-14040903 Ribeirao Preto, SP, Brazil.
EM flbarroso@usp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [Fapesp 2015/16116-3]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq); Swedish
   Science Council; Ministry of Research and Innovation of Romania (CNCS
   -UEFISCDI within PNCDI III) [PN-III-P4-ID-PCCF-2016-0050]
FX This work has been supported in part by the "Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo" [Fapesp 2015/16116-3 (F.L.B.d.S.)] and
   the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [(F.L.B.d.S.)]. F.L.B.d.S. is also deeply thankful to resources provided
   by the Swedish National Infrastructure for Computing (SNIC) at NSC. It
   is also a pleasure to acknowledge initial discussions with Zhenlin Yang
   (Zhongshan Hospital, Fudan University, China) that also provided us some
   preliminary modeled structures used for our first tests. A. Laaksonen
   acknowledges Swedish Science Council for financial support, and partial
   support from a grant from Ministry of Research and Innovation of Romania
   (CNCS -UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0050, within
   PNCDI III).
CR Ahani A., 2020, J SOFT COMPUT DECIS, V7, P19
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0
   da Silva FLB, 2020, ANNU REV FOOD SCI T, V11, P365, DOI 10.1146/annurev-food-032519-051640
   da Silva FLB, 2019, J CHEM THEORY COMPUT, V15, P3875, DOI 10.1021/acs.jctc.9b00202
   da Silva FLB, 2018, BIOCHEM BIOPH RES CO, V498, P264, DOI 10.1016/j.bbrc.2017.07.027
   da Silva FLB, 2017, J CHEM THEORY COMPUT, V13, P2915, DOI 10.1021/acs.jctc.6b01114
   da Silva FLB, 2016, SOFT MATTER, V12, P5600, DOI 10.1039/c6sm00860g
   Barroso daSilva Fernando Luis, 2017, Biophys Rev, V9, P699, DOI 10.1007/s12551-017-0311-5
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Binder K., 1986, MONTE CARLO METHODS
   Bottcher-Friebertshauser E., 2018, ACTIVATION VIRUSES H, DOI [10.1007/978-3-319-75474-1., DOI 10.1007/978-3-319-75474-1.]
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chen YJ, 2015, J CHEM THEORY COMPUT, V11, P3919, DOI 10.1021/acs.jctc.5b00261
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chun S, 2018, RSC ADV, V8, P17334, DOI 10.1039/c8ra00888d
   Delboni LA, 2016, FOOD HYDROCOLLOID, V55, P89, DOI 10.1016/j.foodhyd.2015.11.010
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Du LY, 2014, J VIROL, V88, P7045, DOI 10.1128/JVI.00433-14
   EISENBERG D, 1982, FARADAY SYMP CHEM S, P109, DOI 10.1039/fs9821700109
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Ferre G, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4978623
   Fossepre M., BIOMOLECULAR MODELIN, V2
   Viso JF, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006082
   Frenkel D., 2001, UNDERSTANDING MOL SI
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Greber U.F., 2019, ADV EXPT MED BIOL, V1215, DOI [10.1007/978-3-030-14741-9, DOI 10.1007/978-3-030-14741-9]
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hyltegren K, 2020, J CHEM THEORY COMPUT, V16, P1843, DOI 10.1021/acs.jctc.9b01041
   Ibrahim B, 2018, VIRUS RES, V251, P86, DOI 10.1016/j.virusres.2018.05.009
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jonsson B, 2007, ROY SOC CH, P129, DOI 10.1039/9781847557698-00127
   KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kmiecik S, 2016, CHEM REV, V116, P7898, DOI 10.1021/acs.chemrev.6b00163
   Kurut A, 2012, J PHYS CHEM LETT, V3, P731, DOI 10.1021/jz201680m
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   LAMARRE A, 1989, CAN J MICROBIOL, V35, P972, DOI 10.1139/m89-160
   Leach A.R., 1996, MOL MODELLING PRINCI
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Maier H.J., METHOD MOL BIOL, V1282, DOI [10.1007/978-1-4939-2438-7, DOI 10.1007/978-1-4939-2438-7.]
   Mendonca DC, 2019, CYTOSKELETON, V76, P457, DOI 10.1002/cm.21569
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   O'Kennedy R, 2017, TRAC-TREND ANAL CHEM, V89, P53, DOI 10.1016/j.trac.2017.01.009
   Peiris J.S.M., 2016, CORONAVIRUSES CLIN V, P1243, DOI [10.1128/9781555819439.ch52, DOI 10.1128/9781555819439.CH52]
   Persson BA, 2010, BIOPHYS CHEM, V151, P187, DOI 10.1016/j.bpc.2010.06.005
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poveda-Cuevas SA, 2020, J CHEM INF MODEL, V60, P944, DOI 10.1021/acs.jcim.9b00895
   Poveda-Cuevas SA, 2018, ACS OMEGA, V3, P16212, DOI 10.1021/acsomega.8b02081
   Ramaraj T, 2012, BBA-PROTEINS PROTEOM, V1824, P520, DOI 10.1016/j.bbapap.2011.12.007
   Rapaport D.C., 2004, ART MOL DYNAMICS SIM, DOI [10.1017/CBO9780511816581, DOI 10.1017/CBO9780511816581]
   Teixeira AAR, 2010, J CHEM THEORY COMPUT, V6, P3259, DOI 10.1021/ct1003093
   Sato H, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00042
   Sharma D, 2015, J VIROL, V89, P1489, DOI 10.1128/JVI.02027-14
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Srivastava D, 2017, LANGMUIR, V33, P11417, DOI 10.1021/acs.langmuir.7b02271
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van Gunsteren WF, 2012, MOL SIMULAT, V38, P1271, DOI 10.1080/08927022.2012.701744
   Van Regenmortel MHV, 2014, J MOL RECOGNIT, V27, P627, DOI 10.1002/jmr.2394
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wevers BA, 2010, FUTURE VIROL, V5, P145, DOI 10.2217/FVL.10.4
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2
   Wu ZY, 2020, JAMA SURG, V155, P1142, DOI 10.1001/jamasurg.2020.4132
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yoshida K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40461-5
   Yuan M., 2020, SCIENCE, DOI [10.1126/science.abb7269.eabb7269, DOI 10.1126/SCIENCE.ABB7269.EABB7269]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
NR 87
TC 5
Z9 5
U1 59
U2 68
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD AUG
PY 2020
VL 285
AR 198021
DI 10.1016/j.virusres.2020.198021
PG 13
WC Virology
SC Virology
GA LY2MP
UT WOS:000540355300021
PM 32416259
OA Green Published
DA 2021-01-01
ER

PT J
AU Onawole, AT
   Sulaiman, KO
   Kolapo, TU
   Akinde, FO
   Adegoke, RO
AF Onawole, Abdulmujeeb T.
   Sulaiman, Kazeem O.
   Kolapo, Temitope U.
   Akinde, Fatimo O.
   Adegoke, Rukayat O.
TI COVID-19: CADD to the rescue
SO VIRUS RESEARCH
LA English
DT Article
DE COVID-19; Coronavirus; CARD; Zoonotic diseases; SARS-CoV-2; Virtual
   screening
ID DRUG DISCOVERY; PROTEIN; DOCKING; DESIGN
AB The recent outbreak of the deadly COVID-19 disease, being caused by the novel coronavirus (SARS-CoV-2), has put the world on red alert as it keeps spreading and recording more fatalities. Research efforts are being carried out to curtail the disease from spreading as it has been declared as of global health emergency. Hence, there is an exigent need to identify and design drugs that are capable of curing the infection and hinder its continual spread across the globe. Herein, a computer-aided drug design tool known as the virtual screening method was used to screen a database of 44 million compounds to find compounds that have the potential to inhibit the surface glycoprotein responsible for virus entry and binding. The consensus scoring approach selected three compounds with promising physicochemical properties and favorable molecular interactions with the target protein. These selected compounds can undergo lead optimization to be further developed as drugs that can be used in treating the COVID-19 disease.
C1 [Onawole, Abdulmujeeb T.] King Fahd Univ Petr & Minerals, Dept Chem, Dhahran 31261, Saudi Arabia.
   [Sulaiman, Kazeem O.] Univ Saskatchewan, Dept Chem, 110 Sci Pl, Saskatoon, SK S7N 5C9, Canada.
   [Kolapo, Temitope U.] Univ Ilorin, Dept Vet Parasitol & Entomol, PMB 1515, Ilorin, Nigeria.
   [Kolapo, Temitope U.] Univ Saskatchewan, Dept Vet Microbiol, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.
   [Akinde, Fatimo O.] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China.
   [Adegoke, Rukayat O.] Ladoke Akintola Univ Technol, Dept Pure & Appl Biol, PMB 4000, Ogbomosho, Nigeria.
RP Sulaiman, KO (corresponding author), Univ Saskatchewan, Dept Chem, 110 Sci Pl, Saskatoon, SK S7N 5C9, Canada.
EM kosulaiman2008@yahoo.com
CR Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Bajusz D, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0069-3
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Biovia D.S., 2015, DISCOVERY STUDIO MOD
   Burley SK, 2018, PROTEIN SCI, V27, P316, DOI 10.1002/pro.3331
   Cerqueira NMFSA, 2015, ARCH BIOCHEM BIOPHYS, V582, P56, DOI 10.1016/j.abb.2015.05.011
   Charifson PS, 1999, J MED CHEM, V42, P5100, DOI 10.1021/jm990352k
   Chen HM, 2018, DRUG DISCOV TODAY, V23, P1241, DOI 10.1016/j.drudis.2018.01.039
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Clark DE, 2008, EXPERT OPIN DRUG DIS, V3, P841, DOI 10.1517/17460441.3.8.841
   Clark RD, 2002, J MOL GRAPH MODEL, V20, P281, DOI 10.1016/S1093-3263(01)00125-5
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Forino M, 2005, J MED CHEM, V48, P2278, DOI 10.1021/jm048962u
   Gralinski LE, 2020, VIRUSES, V12, P1
   Grosdidier A, 2009, J COMPUT CHEM, V30, P2021, DOI 10.1002/jcc.21202
   Haddad Y, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007449
   Huang SY, 2010, PHYS CHEM CHEM PHYS, V12, P12899, DOI 10.1039/c0cp00151a
   Jendele L, 2019, NUCLEIC ACIDS RES, V47, pW345, DOI 10.1093/nar/gkz424
   Jimenez J, 2018, J CHEM INF MODEL, V58, P287, DOI 10.1021/acs.jcim.7b00650
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   Kapetanovic IM, 2008, CHEM-BIOL INTERACT, V171, P165, DOI 10.1016/j.cbi.2006.12.006
   Kiss R., 2012, J CHEMINFORMATICS, V4, pP17, DOI [DOI 10.1186/1758-2946-4-S1-P17, 10.1186/1758-2946-4-S1-P17]
   Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Krieger Elmer, 2012, STRUCTURAL BIOINFORM, P507, DOI 10.1007/978-1-61779-588-6
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leelananda SP, 2016, BEILSTEIN J ORG CHEM, V12, P2694, DOI 10.3762/bjoc.12.267
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922.01.28.922922]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lipinski CA, 2016, ADV DRUG DELIVER REV, V101, P34, DOI 10.1016/j.addr.2016.04.029
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   Manas ES, 2017, J COMPUT AID MOL DES, V31, P249, DOI 10.1007/s10822-016-0004-3
   Maynard A.T., 2016, QUANTIFYING VISUALIZ, DOI [10.1021/acs.jmedchem.5b00948, DOI 10.1021/ACS.JMEDCHEM.5B00948]
   Melo CC, 2019, EUR J MED CHEM, V163, P649, DOI 10.1016/j.ejmech.2018.11.062
   Mori M, 2012, VIRUS RES, V169, P377, DOI 10.1016/j.virusres.2012.05.011
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Onawole AT, 2018, COMPUT BIOL CHEM, V72, P170, DOI 10.1016/j.compbiolchem.2017.11.006
   Onawole AT, 2017, J MOL GRAPH MODEL, V73, P54, DOI 10.1016/j.jmgm.2017.01.018
   Peng J, 2011, PROTEINS, V79, P161, DOI 10.1002/prot.23175
   Pereira P., 2020, VIRUS RES, V278, DOI [10.1016/j.virusres.2020.197867, DOI 10.1016/J.VIRUSRES.2020.197867.197867]
   Qiao J, 2018, COMP MATER SCI, V141, P180, DOI 10.1016/j.commatsci.2017.09.034
   Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7
   Sanguinetti MC, 2006, NATURE, V440, P463, DOI 10.1038/nature04710
   Skalic M, 2019, BIOINFORMATICS, V35, P1237, DOI 10.1093/bioinformatics/bty758
   Sousou J, 2015, JNP-J NURSE PRACT, V11, P131, DOI 10.1016/j.nurpra.2014.09.019
   Stevens E., 2014, MED CHEM MODERN DRUG
   Sulaiman KO, 2019, J BIOMOL STRUCT DYN, V37, P3029, DOI 10.1080/07391102.2018.1506362
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   World Health Organization, 2020, COR LAT WHO OFF NAM
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiang ZX, 2006, CURR PROTEIN PEPT SC, V7, P217, DOI 10.2174/138920306777452312
   Yang HB, 2018, J CHEM INF MODEL, V58, P2051, DOI 10.1021/acs.jcim.8b00532
   Yang JM, 2005, J CHEM INF MODEL, V45, P1134, DOI 10.1021/ci050034w
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 67
TC 2
Z9 2
U1 19
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD AUG
PY 2020
VL 285
AR 198022
DI 10.1016/j.virusres.2020.198022
PG 12
WC Virology
SC Virology
GA LY2MP
UT WOS:000540355300014
PM 32417181
OA Green Published
DA 2021-01-01
ER

PT J
AU Shinwari, ZK
   Qaiser, M
   Nasar, MQ
   Ali, A
AF Shinwari, Zabta K.
   Qaiser, Muhammad
   Nasar, Muhammad Qasim
   Ali, Amjad
TI INDIGENOUS KNOWLEDGE BASED HERBAL MEDICINE FOR CORONA (COVID-19)
   TREATMENT
SO PAKISTAN JOURNAL OF BOTANY
LA English
DT Article
DE Corona virus; Cholroquine; Herbal medicine; Viral infection
ID HEPATITIS-B-VIRUS; ANTIVIRAL ACTIVITY; INFLUENZA-VIRUS; PLANT; EXTRACT;
   ANTIINFLUENZA; NANOPARTICLES; FLAVONOIDS; LEAVES
AB Current Corona virus Covid-19 crisis has infected more than 1.8 million humans in last three months and it is increasing exponentially every day. Some of the allopathic medicines (Cholroquine, Lopinover, Oseltamivir and Retenover etc.) used for other purposes like Malaria have shown good results in Corona. Plants species were reported to be effective in coronavirus (SARS-CoV), which causes a serious type of pneumonia. In similar way, Plant materials are a good source of bioactive compounds/phytochemicals that can be utilized not only for strengthening our immune system but also killing the pathogens. Due to chemical diversity and natural affability of natural products, either in the form of standardized extract or as a pure compound based on ethnopharmacological properties plays a s significant role in new drug development. Though, we have summarized medicinal plants that have a role in anti-viral activities, but there is an immediate need to find out more and more medicinal plants for anti-viral activities.
C1 [Shinwari, Zabta K.] Natl Council Tibb, Islamabad, Pakistan.
   [Qaiser, Muhammad] Univ Karachi, Bot Garden, Karachi 75270, Pakistan.
   [Nasar, Muhammad Qasim] Agr Res Inst, Quetta Balochistan, Pakistan.
   [Ali, Amjad] Univ Cattolica Sacro Cuore, Via Emilia Parmense, Piacenza, Italy.
RP Shinwari, ZK (corresponding author), Natl Council Tibb, Islamabad, Pakistan.
CR Afridi S., 2020, MAT SCI ENG C
   Ahmad S, 2020, PAK J BOT, V52, P519, DOI 10.30848/PJB2020-2(19)
   Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   Ali M, 2018, PHYTOTHER RES, V32, P199, DOI 10.1002/ptr.5957
   Amber R, 2017, J PHARM PHARMACOL, V69, P109, DOI 10.1111/jphp.12669
   Andleeb R, 2020, SAUDI J BIOL SCI, V27, P335, DOI 10.1016/j.sjbs.2019.10.002
   Arbab AH, 2017, EXP THER MED, V14, P626, DOI 10.3892/etm.2017.4530
   Ashraf A, 2020, PAK J BOT, V52, P531, DOI 10.30848/PJB2020-2(3)
   Ashraf A, 2017, PAK J PHARM SCI, V30, P567
   Bayan L, 2014, AVICENNA J PHYTOMEDI, V4, P1
   Bedoya LM, 2001, J ETHNOPHARMACOL, V77, P113, DOI 10.1016/S0378-8741(01)00265-3
   Bergenstrom A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0079-5
   Bodinet C, 2002, PLANTA MED, V68, P896, DOI 10.1055/s-2002-34919
   Cary DC, 2018, AIDS RES HUM RETROV, V34, P31, DOI [10.1089/AID.2017.0232, 10.1089/aid.2017.0232]
   Chang JS, 2005, ANTIVIR RES, V66, P29, DOI 10.1016/j.antiviral.2004.12.006
   Chavan R, 2014, INT J PHARM SCI REV, V25, P231
   Chung CY, 2016, ANTIVIR RES, V130, P58, DOI 10.1016/j.antiviral.2016.03.012
   Damle M., 2014, International Journal of Herbal Medicine, V2, P132
   De Ruiz R.E.L., 1994, FITOTERAPIA, V65, P181
   Du J, 2003, PHYTOCHEMISTRY, V62, P1235, DOI 10.1016/S0031-9422(02)00753-7
   Emmanuel R, 2017, MICROB PATHOGENESIS, V113, P295, DOI 10.1016/j.micpath.2017.10.055
   Hafid AF, 2017, ASIAN PAC J TROP BIO, V7, P633, DOI 10.1016/j.apjtb.2017.06.003
   Hameed S, 2019, NANOMEDICINE-UK, V14, P655, DOI 10.2217/nnm-2018-0279
   Huang KL, 2006, WORLD J GASTROENTERO, V12, P5721, DOI 10.3748/wjg.v12.i35.5721
   Hussain W, 2017, FUTURE VIROL, V12, P299, DOI 10.2217/fvl-2016-0110
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kasithevar Muthupandi, 2017, Journal of Interdisciplinary Nanomedicine, V2, P131, DOI 10.1002/jin2.26
   Kernan MR, 1997, J NAT PROD, V60, P635, DOI 10.1021/np960613i
   Khalil AT, 2017, HEALTH SECUR, V15, P268, DOI 10.1089/hs.2016.0072
   Khan MA, 2014, PAK J BOT, V46, P185
   Kinoshita E., 2012, BIOSCIENCE BIOTECH B
   Kiyohara H, 2012, PHYTOMEDICINE, V19, P111, DOI 10.1016/j.phymed.2011.07.004
   Kuroyanagi M, 2012, CHEM PHARM BULL, V60, P892, DOI 10.1248/cpb.c12-00264
   Lee JB, 2012, FOOD CHEM, V134, P2164, DOI 10.1016/j.foodchem.2012.04.016
   Liu AL, 2008, PLANTA MED, V74, P847, DOI 10.1055/s-2008-1074558
   Mallhi TH, 2019, J PHARM POLICY PRACT, V12, DOI 10.1186/s40545-019-0199-5
   McCaughey Conall, 2010, Ulster Med J, V79, P46
   Mohamed HEA, 2020, NANOMEDICINE-UK, V15, P467, DOI 10.2217/nnm-2019-0368
   Mustafa G., 2017, BIOACTIVE COMPOUNDS
   Omoruyi BE, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-215
   Porter RS, 2017, PHYTOTHER RES, V31, P533, DOI 10.1002/ptr.5782
   Rajasekaran D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079293
   Rashed K, 2013, J APPL IND SCI, V1, P49
   Rebensburg S, 2016, SCI REP-UK, V6, DOI 10.1038/srep20394
   Rehman NU, 2015, PAK J BOT, V47, P1195
   Rehman S, 2018, MICROB PATHOGENESIS, V121, P198, DOI 10.1016/j.micpath.2018.05.023
   Saleem H, 2020, PROCESSES, V8, DOI 10.3390/pr8030336
   SERKEDJIEVA J, 1990, PHYTOTHER RES, V4, P97, DOI 10.1002/ptr.2650040305
   Shah S.M, 2019, LEISHMANIASIS LUNGS, DOI [10.30848/PJB2019-6(39), DOI 10.30848/PJB2019-6(39)]
   Sun HD, 1996, J NAT PROD, V59, P525, DOI 10.1021/np960149h
   Ullah I, 2017, PAK J BOT, V49, P1949
   Ullah I, 2017, PAK J BOT, V49, P1561
   Wang RR, 2006, J ETHNOPHARMACOL, V105, P269, DOI 10.1016/j.jep.2005.11.008
   Xu HX, 1996, J NAT PROD, V59, P643, DOI 10.1021/np960165e
   Yaseen G, 2019, PAK J BOT, V51, P657, DOI 10.30848/PJB2019-2(31)
   Zhao YY, 2013, J ETHNOPHARMACOL, V148, P403, DOI 10.1016/j.jep.2013.04.018
   Zohra T, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-018-2416-1
   Zuo Guo-Ying, 2005, Antiviral Chemistry & Chemotherapy, V16, P393
NR 58
TC 0
Z9 0
U1 29
U2 50
PU PAKISTAN BOTANICAL SOC
PI KARACHI
PA DEPT OF BOTANY UNIV KARACHI, 32 KARACHI, PAKISTAN
SN 0556-3321
EI 2070-3368
J9 PAK J BOT
JI Pak. J. Bot.
PD AUG
PY 2020
VL 52
IS 4
BP 1427
EP 1434
DI 10.30848/PJB2020-4(13)
PG 8
WC Plant Sciences
SC Plant Sciences
GA LR9CI
UT WOS:000535992800035
DA 2021-01-01
ER

PT J
AU Wang, KG
   Tan, F
   Zhou, R
   Liu, D
   Ni, Z
   Liu, JS
   Luo, FM
AF Wang, Kaige
   Tan, Fen
   Zhou, Rui
   Liu, Dan
   Ni, Zhong
   Liu, Jiasheng
   Luo, Fengming
TI Therapeutic response to corticosteroids in a critically ill patient with
   COVID-19 A case report
SO MEDICINE
LA English
DT Article
DE corticosteroids use; critically ill patient; COVID-19; SARS-CoV2
AB Introduction: Since the coronavirus disease 2019 (COVID-19) outbreak in Wuhan in late 2019, controversy on the use of corticosteroids for COVID-19 has obtained increasing attention. We present 1 critically ill patient who had a rapid therapeutic response to moderate-dose corticosteroids. Patient concerns: A 53-year-old critically ill woman from Wuhan suffered with COVID-19. Diagnosis: The chest computed tomography scan was suggestive of COVID-19. The diagnosis was confirmed by a real-time reverse transcription polymerase chain reaction test for SARS-CoV-2. The critically ill status was characterized by worsening dyspnea, progressing bilateral lung consolidation, and poor oxygenation (SiO2/FiO(2):110 mm Hg). Interventions: The patient was treated with a moderate dose of intravenous corticosteroids and high-flow nasal cannula oxygen therapy. Outcomes: After the initiation of corticosteroids, the patient rapidly improved over the following 6 days. Serial chest computed tomography scans showed good absorption of the consolidations. The patient was discharged on Day 17 of hospitalization without obvious adverse effects. Conclusions: Early use of moderate-dose corticosteroids over a short period may enhance recovery from COVID-19 in critically ill patients.
C1 [Wang, Kaige; Liu, Dan; Ni, Zhong; Luo, Fengming] Sichuan Univ, West China Hosp, Dept Pulm & Crit Care Med, Chengdu 610041, Peoples R China.
   [Tan, Fen; Zhou, Rui] Cent South Univ, Xiangya Hosp 2, Resp Dis Res Inst Hunan Prov, Dept Pulm & Crit Care Med, Changsha, Peoples R China.
   [Liu, Jiasheng] Wuhan Univ, Dept Gastrointestinal Surg, Renmin Hosp, Wuhan, Peoples R China.
RP Luo, FM (corresponding author), Sichuan Univ, West China Hosp, Dept Pulm & Crit Care Med, Chengdu 610041, Peoples R China.
EM luofengming@hotmail.com
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P473, DOI 10.3760/cma.j.cn112147-112147-20200321-00392
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lee FEH, 2011, CHEST, V140, P1155, DOI 10.1378/chest.11-0047
   Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   World Health Organisation, 2020, 115 WHO
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 11
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 31
PY 2020
VL 99
IS 31
DI 10.1097/MD.0000000000021597
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA NE6EZ
UT WOS:000562693800145
PM 32756215
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gupta, AK
   Khan, MS
   Choudhury, S
   Mukhopadhyay, A
   Sakshi
   Rastogi, A
   Thakur, A
   Kumari, P
   Kaur, M
   Shalu
   Saini, C
   Sapehia, V
   Barkha
   Patel, PK
   Bhamare, KT
   Kumar, M
AF Gupta, Amit Kumar
   Khan, Md. Shoaib
   Choudhury, Shubham
   Mukhopadhyay, Adhip
   Sakshi
   Rastogi, Amber
   Thakur, Anamika
   Kumari, Pallawi
   Kaur, Manmeet
   Shalu
   Saini, Chanchal
   Sapehia, Vandna
   Barkha
   Patel, Pradeep Kumar
   Bhamare, Kailash T.
   Kumar, Manoj
TI CoronaVR: A Computational Resource and Analysis of Epitopes and
   Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; 2019-nCoV; COVID-19; epitopes; therapeutics; primers
ID IMMUNE-RESPONSES; SPIKE PROTEIN; NUCLEOCAPSID PROTEIN; GLOBAL HEALTH;
   CODON USAGE; SARS; 2019-NCOV; PREDICTION; VACCINE; IDENTIFICATION
AB In December 2019, the Chinese city of Wuhan was the center of origin of a pneumonia-like disease outbreak with an unknown causative pathogen. The CDC, China, managed to track the source of infection to a novel coronavirus (2019-nCoV; SARS-CoV-2) that shares approximately 79.6% of its genome with SARS-CoV. The World Health Organization (WHO) initially declared COVID-19 as a Public Health Emergency of International Concern (PHEIC) and later characterized it as a global pandemic on March 11, 2020. Due to the novel nature of this virus, there is an urgent need for vaccines and therapeutics to control the spread of SARS-CoV-2 and its associated disease, COVID-19. Global efforts are underway to circumvent its further spread and treat COVID-19 patients through experimental vaccine formulations and therapeutic interventions, respectively. In the absence of any effective therapeutics, we have devised h bioinformatics-based approaches to accelerate global efforts in the fight against SARS-CoV-2 and to assist researchers in the initial phase of vaccine and therapeutics development. In this study, we have performed comprehensive meta-analyses and developed an integrative resource, "CoronaVR" (http://bioinfo.imtech.res.in/manojk/coronavr/). Predominantly, we identified potential epitope-based vaccine candidates, siRNA-based therapeutic regimens, and diagnostic primers. The resource is categorized into the main sections "Genomes," "Epitopes," "Therapeutics," and Primers." The genome section harbors different components, viz, genomes, a genome browser, phylogenetic analysis, codon usage, glycosylation sites, and structural analysis. Under the umbrella of epitopes, sub-divisions, namely cross-protective epitopes, B-cell (linear/discontinuous), T-cell (CD4(+)/CD8(+)), CTL, and MHC binders, are presented. The therapeutics section has different sub-sections like siRNA, miRNAs, and sgRNAs. Further, experimentally confirmed and designed diagnostic primers are earmarked in the primers section. Our study provided a set of shortlisted B-cell and T-cell (CD4(+) and CD8(+)) epitopes that can be experimentally tested for their incorporation in vaccine formulations. The list of selected primers can be used in testing kits to identify SARS-CoV-2, while the recommended siRNAs, sgRNAs, and miRNAs can be used in therapeutic regimens. We foresee that this resource will help in advancing the research against coronaviruses.
C1 [Gupta, Amit Kumar; Khan, Md. Shoaib; Choudhury, Shubham; Mukhopadhyay, Adhip; Sakshi; Rastogi, Amber; Thakur, Anamika; Kumari, Pallawi; Kaur, Manmeet; Shalu; Saini, Chanchal; Sapehia, Vandna; Barkha; Patel, Pradeep Kumar; Bhamare, Kailash T.; Kumar, Manoj] CSIR, Inst Microbial Technol, Virol Unit, Sect 39-A, Chandigarh, India.
   [Gupta, Amit Kumar; Khan, Md. Shoaib; Choudhury, Shubham; Mukhopadhyay, Adhip; Sakshi; Rastogi, Amber; Thakur, Anamika; Kumari, Pallawi; Kaur, Manmeet; Shalu; Saini, Chanchal; Sapehia, Vandna; Barkha; Patel, Pradeep Kumar; Bhamare, Kailash T.; Kumar, Manoj] CSIR, Inst Microbial Technol, Bioinformat Ctr, Sect 39-A, Chandigarh, India.
   [Mukhopadhyay, Adhip; Sakshi; Rastogi, Amber; Thakur, Anamika; Kumar, Manoj] Acad Sci & Innovat Res AcSIR, Ghaziabad, India.
RP Kumar, M (corresponding author), CSIR, Inst Microbial Technol, Virol Unit, Sect 39-A, Chandigarh, India.; Kumar, M (corresponding author), CSIR, Inst Microbial Technol, Bioinformat Ctr, Sect 39-A, Chandigarh, India.; Kumar, M (corresponding author), Acad Sci & Innovat Res AcSIR, Ghaziabad, India.
EM manojk@imtech.res.in
OI MUKHOPADHYAY, ADHIP/0000-0002-0925-5486; Choudhury,
   Shubham/0000-0002-4509-4683
FU Council of Scientific and Industrial Research (CSIR), Government of
   IndiaCouncil of Scientific & Industrial Research (CSIR) - India
   [OLP0501, OLP0143]; Council of Scientific and Industrial Research
   (CSIR)Council of Scientific & Industrial Research (CSIR) - India
   [OLP0501, OLP0143]
FX This work was supported by the Council of Scientific and Industrial
   Research (CSIR), Government of India (Grant Numbers OLP0501 and
   OLP0143). Funding for open access charge: Council of Scientific and
   Industrial Research (CSIR) (OLP0501 and OLP0143).
CR Adedeji AO, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00235-16
   Ahmed F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023443
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Benvenuto D, 2020, PATHOG GLOB HEALTH, V114, P64, DOI 10.1080/20477724.2020.1725339
   Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Buels R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0924-1
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Casais R, 2003, J VIROL, V77, P9084, DOI 10.1128/JVI.77.16.9084-9089.2003
   Castells M, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0780-y
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2017, ONCOTARGET, V8, P110337, DOI 10.18632/oncotarget.22738
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Chesler DA, 2002, CYTOKINE GROWTH F R, V13, P441, DOI 10.1016/S1359-6101(02)00044-8
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Dhanda SK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01369
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2010, VIRAL IMMUNOL, V23, P211, DOI 10.1089/vim.2009.0090
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P123, DOI 10.1038/s41579-020-0332-0
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Gkirtzou K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011843
   Goo J, 2020, VIRUS RES, V278, DOI 10.1016/j.virusres.2020.197863
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Gupta AK, 2020, DATABASE-OXFORD, DOI 10.1093/database/baz159
   Gupta AK, 2016, SCI REP-UK, V6, DOI 10.1038/srep32713
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HORI S, 1989, J MOL CELL CARDIOL, V21, P203, DOI 10.1016/0022-2828(89)90862-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hurst KR, 2013, J VIROL, V87, P9159, DOI 10.1128/JVI.01275-13
   Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Julenius K, 2007, GLYCOBIOLOGY, V17, P868, DOI 10.1093/glycob/cwm050
   Kaur K, 2016, SCI REP-UK, V6, DOI 10.1038/srep30870
   Kickbusch I, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m406
   Kim MK, 2011, EUR J MED CHEM, V46, P5698, DOI 10.1016/j.ejmech.2011.09.005
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Le SQ, 2008, MOL BIOL EVOL, V25, P1307, DOI 10.1093/molbev/msn067
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lo YMD, 2020, CLIN CHEM, V66, P503, DOI 10.1093/clinchem/hvaa038
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   McKeever TM, 2004, AM J PUBLIC HEALTH, V94, P985, DOI 10.2105/AJPH.94.6.985
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Moura G, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-r28
   Nagpal G, 2017, METHODS MOL BIOL, V1632, P75, DOI 10.1007/978-1-4939-7138-1_5
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Perrier A, 2019, J BIOL CHEM, V294, P14406, DOI 10.1074/jbc.RA119.008964
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Puigbo P, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-38
   Qiu TY, 2020, J GENET GENOMICS, V47, P115, DOI 10.1016/j.jgg.2020.01.003
   Qureshi A, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-305
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Ryu S, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020006
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Srivastava S, 2018, INFECT DRUG RESIST, V11, P2377, DOI 10.2147/IDR.S175114
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   Sullivan CS, 2007, METHOD ENZYMOL, V427, P3, DOI 10.1016/S0076-6879(07)27001-6
   Tanner JA, 2005, CHEM BIOL, V12, P303, DOI 10.1016/j.chembiol.2005.01.006
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Watts Charlotte H, 2020, Nature, V578, P363, DOI 10.1038/d41586-020-00457-y
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yi CY, 2020, CELL MOL IMMUNOL, V17, P621, DOI 10.1038/s41423-020-0458-z
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Yoon H, 2015, BIOINFORMATICS, V31, P1472, DOI 10.1093/bioinformatics/btu832
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao S, 2008, BIOSYSTEMS, V92, P207, DOI 10.1016/j.biosystems.2008.01.006
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2019, LANCET INFECT DIS, V19, P1054, DOI 10.1016/S1473-3099(19)30477-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 125
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUL 31
PY 2020
VL 11
AR 1858
DI 10.3389/fmicb.2020.01858
PG 21
WC Microbiology
SC Microbiology
GA ND1OZ
UT WOS:000561676600001
PM 32849449
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kelly, JA
   Olson, AN
   Neupane, K
   Munshi, S
   San Emeterio, J
   Pollack, L
   Woodside, MT
   Dinman, JD
AF Kelly, Jamie A.
   Olson, Alexandra N.
   Neupane, Krishna
   Munshi, Sneha
   San Emeterio, Josue
   Pollack, Lois
   Woodside, Michael T.
   Dinman, Jonathan D.
TI Structural and functional conservation of the programmed-1 ribosomal
   frameshift signal of SARS coronavirus 2 (SARS-CoV-2)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); coronavirus; programmed-1 ribosomal
   frameshifting (-1 PRF); translation; RNA; RNA structure; virus; (+)
   ssRNA; inhibitor; small molecule inhibitor; mRNA pseudoknot
ID CONFORMATIONAL PLASTICITY; LIGAND
AB Approximately 17 years after the severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic, the world is currently facing the COVID-19 pandemic caused by SARS corona virus 2 (SARS-CoV-2). According to the most optimistic projections, it will take more than a year to develop a vaccine, so the best short-term strategy may lie in identifying virus-specific targets for small molecule-based interventions. All coronaviruses utilize a molecular mechanism called programmed -1 ribosomal frameshift (-1 PRF) to control the relative expression of their proteins. Previous analyses of SARS-CoV have revealed that it employs a structurally unique three-stemmed mRNA pseudoknot that stimulates high -1 PRF rates and that it also harbors a -1 PRF attenuation element. Altering -1 PRF activity impairs virus replication, suggesting that this activity may be therapeutically targeted. Here, we comparatively analyzed the SARS-CoV and SARS-CoV-2 frameshift signals. Structural and functional analyses revealed that both elements promote similar -1 PRF rates and that silent coding mutations in the slippery sites and in all three stems of the pseudoknot strongly ablate -1 PRF activity. We noted that the upstream attenuator hairpin activity is also functionally retained in both viruses, despite differences in the primary sequence in this region. Small-angle X-ray scattering analyses indicated that the pseudoknots in SARS-CoV and SARS-CoV-2 have the same conformation. Finally, a small molecule previously shown to bind the SARS-CoV pseudoknot and inhibit -1 PRF was similarly effective against -1 PRF in SARS-CoV-2, suggesting that such frameshift inhibitors may be promising lead compounds to combat the current COVID-19 pandemic.
C1 [Kelly, Jamie A.; Olson, Alexandra N.; Dinman, Jonathan D.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
   [Neupane, Krishna; Munshi, Sneha; Woodside, Michael T.] Univ Alberta, Dept Phys, Edmonton, AB, Canada.
   [San Emeterio, Josue; Pollack, Lois] Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.
RP Dinman, JD (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.; Woodside, MT (corresponding author), Univ Alberta, Dept Phys, Edmonton, AB, Canada.; Pollack, L (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.
EM lp26@cornell.edu; mwoodsid@ualberta.ca; dinman@umd.edu
OI Kelly, Jamie/0000-0003-2416-2496; Dinman, Jonathan/0000-0002-2402-9698
FU Defense Threat Reduction AgencyUnited States Department of
   DefenseDefense Threat Reduction Agency [HDTRA1-13-1-0005]; NIGMS,
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01 GM117177]; University of
   Maryland Coronavirus Research Program Seed Grant; Canadian Institutes of
   Health ResearchCanadian Institutes of Health Research (CIHR)
   [OV3-170709]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [P30
   GM133893, S10 OD012331, BER-BO 070, 2T32AI051967-06A1]; National Science
   FoundationNational Science Foundation (NSF) [DBI-1930046]; Department of
   EnergyUnited States Department of Energy (DOE) [BES-FWP-PS001]
FX This work was supported by Defense Threat Reduction Agency Grant
   HDTRA1-13-1-0005; NIGMS, National Institutes of Health Grant R01
   GM117177; a University of Maryland Coronavirus Research Program Seed
   Grant (to J. D. D.); Canadian Institutes of Health Research Grant
   OV3-170709 (to M. T. W.); and National Institutes of Health
   Institutional Training Grant 2T32AI051967-06A1 (to J. A. K.). The
   solution scattering work was supported by National Science Foundation
   Award DBI-1930046 (to L. P.). Support for work performed at Beamline LIX
   (16ID) of the Center for BioMolecular Structure at National Synchrotron
   Light Source II was provided by National Institutes of Health Grants P30
   GM133893, S10 OD012331, and BER-BO 070. National Synchrotron Light
   Source II is supported by Department of Energy Grant BES-FWP-PS001. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Ahn DG, 2011, ANTIVIR RES, V91, P1, DOI 10.1016/j.antiviral.2011.04.009
   Atkins JF, 2016, NUCLEIC ACIDS RES, V44, P7007, DOI 10.1093/nar/gkw530
   Baranov PV, 2005, VIROLOGY, V332, P498, DOI 10.1016/j.virol.2004.11.038
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   Brierley I, 2006, VIRUS RES, V119, P29, DOI 10.1016/j.virusres.2005.10.008
   Chen YL, 2019, J PHYS CHEM B, V123, P9773, DOI 10.1021/acs.jpcb.9b07502
   Cho CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062283
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Dinman JD, 2012, WIRES RNA, V3, P661, DOI 10.1002/wrna.1126
   Halma MTJ, 2019, P NATL ACAD SCI USA, V116, P19500, DOI 10.1073/pnas.1905258116
   Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803
   Ishimaru D, 2013, NUCLEIC ACIDS RES, V41, P2594, DOI 10.1093/nar/gks1361
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   Jacobs JL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh157
   Park SJ, 2011, J AM CHEM SOC, V133, P10094, DOI 10.1021/ja1098325
   Plant EP, 2005, PLOS BIOL, V3, P1012, DOI 10.1371/journal.pbio.0030172
   Plant EP, 2013, VIRUSES-BASEL, V5, P279, DOI 10.3390/v5010279
   Plant EP, 2010, J VIROL, V84, P4330, DOI 10.1128/JVI.02480-09
   PUGLISI JD, 1988, NATURE, V331, P283, DOI 10.1038/331283a0
   Ritchie DB, 2014, J AM CHEM SOC, V136, P2196, DOI 10.1021/ja410344b
   Ritchie DB, 2012, P NATL ACAD SCI USA, V109, P16167, DOI 10.1073/pnas.1204114109
   Rodnina MV, 2020, NUCLEIC ACIDS RES, V48, P1056, DOI 10.1093/nar/gkz783
   Yang L, 2020, J SYNCHROTRON RADIAT, V27, P804, DOI 10.1107/S1600577520002362
NR 24
TC 6
Z9 6
U1 6
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 31
PY 2020
VL 295
IS 31
BP 10741
EP 10748
DI 10.1074/jbc.AC120.013449
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NB3HM
UT WOS:000560405600018
PM 32571880
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Onweni, CL
   Zhang, YS
   Caulfield, T
   Hopkins, CE
   Fairweather, D
   Freeman, WD
AF Onweni, Chidinma L.
   Zhang, Yu Shrike
   Caulfield, Thomas
   Hopkins, Christopher E.
   Fairweather, De Lisa
   Freeman, William D.
TI ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and
   SARS-CoV-2 viral docking
SO CRITICAL CARE
LA English
DT Letter
DE ACE2; ACEI/ARB therapy; COVID-19
C1 [Onweni, Chidinma L.; Freeman, William D.] Mayo Clin, Dept Crit Care Med, Jacksonville, FL 32224 USA.
   [Zhang, Yu Shrike] Brigham & Womens Hosp, Div Engn Med, 75 Francis St, Boston, MA 02115 USA.
   [Caulfield, Thomas; Freeman, William D.] Mayo Clin, Dept Neurol Surg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
   [Caulfield, Thomas] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA.
   [Hopkins, Christopher E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Hopkins, Christopher E.] InVivo Biosyst, Eugene, OR USA.
   [Fairweather, De Lisa] Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USA.
   [Fairweather, De Lisa] Mayo Clin, Dept Immunol, Jacksonville, FL 32224 USA.
RP Freeman, WD (corresponding author), Mayo Clin, Dept Crit Care Med, Jacksonville, FL 32224 USA.; Freeman, WD (corresponding author), Mayo Clin, Dept Neurol Surg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM freeman.william1@mayo.edu
OI Freeman, M.D., William D./0000-0003-2326-0633
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI154927, R21 AI145356] Funding Source:
   Medline
CR Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Singh AK, 2020, DIABETES METAB SYND, V14, P283, DOI 10.1016/j.dsx.2020.03.016
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 5
TC 1
Z9 1
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUL 31
PY 2020
VL 24
IS 1
AR 475
DI 10.1186/s13054-020-03195-9
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA NA4BW
UT WOS:000559760700001
PM 32736573
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Boileve, A
   Stoclin, A
   Barlesi, F
   Varin, F
   Suria, S
   Rieutord, A
   Blot, F
   Netzer, F
   Scotte, F
AF Boileve, Alice
   Stoclin, Annabelle
   Barlesi, Fabrice
   Varin, Florent
   Suria, Stephanie
   Rieutord, Andre
   Blot, Francois
   Netzer, Florence
   Scotte, Florian
TI COVID-19 management in a cancer center: the ICU storm
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE COVID-19; Coronavirus; Cancer; Pandemic; Management; Intensive care unit
ID QUALITY-OF-LIFE
AB A novel coronavirus, SARS-CoV-2, was first reported as a respiratory illness in December 2019 in Wuhan, China. Since then, the World Health Organization (WHO) Emergency Committee declared a global health. COVID-19 has now spread worldwide and is responsible of more than 472,216 persons, out of 9,100,090 officially diagnosed worldwide since 23 of June. In the context of cancer patients, COVID-19 has a severe impact, regarding pulmonary infection but also cancer treatments in this fragile and immunocompromised population, and ICU admission for cancer patients in the context of COVID-19 requires ethical and clinical consideration. In our cancer center, intensivists, oncologists, pharmacists, and hospital administrators had to prepare for a substantial increase in critical care bed capacity (from 10 ICU beds, 6 medical intensive care beds, and 12 surgical intensive care beds, bed capacity was increased to 28 medical intensive care beds with ventilating capacity) and to adapt infrastructure (i.e., ICU beds), supplies (i.e., drugs, ventilators, protective materials), and staff (i.e., nurses and medical staff). Overall, thirty-three COVID-19 patients were admitted in our ICU, 17 cancer-free and 16 with cancer, and 23 required mechanical ventilation, resulting in 4 deaths (of them two patients with cancer). We report here management of a dedicated intensive care unit of a cancer center during the COVID-19 infection pandemic, considering resource allocation and redistribution of healthcare workers.
C1 [Boileve, Alice; Barlesi, Fabrice] Gustave Roussy Canc Campus, Med Oncol Dept, 114 Rue Edouard Valliant, Villejuif, France.
   [Stoclin, Annabelle; Blot, Francois] Gustave Roussy Canc Campus, Intens Care Unit, Villejuif, France.
   [Stoclin, Annabelle; Blot, Francois; Scotte, Florian] Gustave Roussy Canc Campus, Interdisciplinary Canc Course Dept DIOPP, Villejuif, France.
   [Varin, Florent; Suria, Stephanie] Gustave Roussy Canc Campus, Dept Anesthesia, Villejuif, France.
   [Rieutord, Andre; Netzer, Florence] Gustave Roussy Canc Campus, Pharm Dept, Villejuif, France.
RP Boileve, A (corresponding author), Gustave Roussy Canc Campus, Med Oncol Dept, 114 Rue Edouard Valliant, Villejuif, France.
EM alice.boileve@gmail.com
OI Boileve, Alice/0000-0003-3708-4909
CR Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123
   [Anonymous], 2020, WORLDOMETER COVID 19
   [Anonymous], 2020, WHO CHINA JOINT MISS
   Balzer F, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0272-4
   Chen YM, 2004, LUNG CANCER-J IASLC, V45, P39, DOI 10.1016/j.lungcan.2004.01.002
   Davidson TA, 1999, AM J RESP CRIT CARE, V160, P1838, DOI 10.1164/ajrccm.160.6.9903058
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Schelling G, 2000, INTENS CARE MED, V26, P1304, DOI 10.1007/s001340051342
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zangrillo A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02928-0
NR 18
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT
PY 2020
VL 28
IS 10
BP 5037
EP 5044
DI 10.1007/s00520-020-05658-9
EA JUL 2020
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NL2KY
UT WOS:000559381200002
PM 32734394
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lu, IN
   Kulkarni, S
   Fisk, M
   Kostapanos, M
   Banham-Hall, E
   Kadyan, S
   Bond, S
   Norton, S
   Cope, A
   Galloway, J
   Hall, F
   Jayne, D
   Wilkinson, IB
   Cheriyan, J
AF Lu, Ing Ni
   Kulkarni, Spoorthy
   Fisk, Marie
   Kostapanos, Michalis
   Banham-Hall, Edward
   Kadyan, Sonakshi
   Bond, Simon
   Norton, Sam
   Cope, Andrew
   Galloway, James
   Hall, Frances
   Jayne, David
   Wilkinson, Ian B.
   Cheriyan, Joseph
TI muLTi-Arm Therapeutic study in pre-ICu patients admitted with
   Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured
   summary of a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; Protocol; Open-label; Adaptive
   trial; EDP1815; Dapagliflozin; Ambrisentan; Experimental drugs
AB ObjectivesTo determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min).Trial designRandomised, parallel arm, open-label, adaptive platform Phase 2/3 trial of potential disease modifying therapies in patients with late stage 1/stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical, laboratory and radiological assessment.ParticipantsPatients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a risk count (as defined below) >3 OR >= 3 if risk count includes "Radiographic severity score >3". A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x10(9)/L, age >40 years and CRP >40 mg/L.Patients should be considered an appropriate subject for intervention with immunomodulatory or other disease modifying agents in the opinion of the investigator and are able to swallow capsules or tablets. The complete inclusion and exclusion criteria as detailed in the Additional file 1 should be fulfilled. Drug specific inclusion and exclusion criteria will also be applied to the active arms. Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust. Other centres will be approached internationally in view of the evolving pandemic.Intervention and comparatorThere is increasing evidence of the role of immunomodulation in altering the course of COVID-19. Additionally, various groups have demonstrated the presence of pulmonary shunting in patients with COVID-19 as well as other cardiovascular complications. TACTIC-E will assess the efficacy of the novel immunomodulatory agent EDP1815 versus the approved cardio-pulmonary drugs, Dapagliflozin in combination with Ambrisentan versus the prevailing standard of care.EDP1815 will be given as 2 capsules twice daily (1.6 x 10(11) cells) for up to 7 days with the option to extend up to 14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. Ambrisentan 5mg and Dapagliflozin 10mg will be given in combination once daily orally for up to maximum of 14 days. Patients will be randomised in a 1:1:1 ratio across treatments. Each active arm will be compared with standard of care alone. Additional arms may be added as the trial progresses. No comparisons will be made between active arms in this platform trial.Main outcomesThe primary outcome is the incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min).
   RandomisationEligible patients will be randomised using a central web-based randomisation service (Sealed Envelope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or standard of care.Blinding (masking)This is an open-label trial. Data analysis will not be blinded.Numbers to be randomised (sample size)There is no fixed sample size for this study. There will be an early biomarker-based futility analysis performed at a point during the study. If this biomarker futility analysis is not conclusive, then a second futility analysis based on clinical endpoints will be performed after approximately 125 patients have been recruited per arm. Provisionally, further analyses of clinical endpoints will be performed after 229 patients per active arm and later 469 patients per arm have been recruited. Further additional analyses may be triggered by the independent data monitoring committee.Trial StatusTACTIC-E Protocol version number 1.0 date May 27(th), 2020. Recruitment starts on the 3(rd) of July 2020. The end trial date will be 18 months after the last patient's last visit and cannot be accurately predicted at this time.Trial registrationRegistered on EU Clinical Trials Register EudraCT Number: 2020-002229-27 registered: 9 June 2020.The trial was also registered on ClinicalTrials.gov (NCT04393246) on 19 May 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Lu, Ing Ni; Kulkarni, Spoorthy; Fisk, Marie; Kostapanos, Michalis; Banham-Hall, Edward; Kadyan, Sonakshi; Bond, Simon; Norton, Sam; Cope, Andrew; Galloway, James; Hall, Frances; Jayne, David; Wilkinson, Ian B.; Cheriyan, Joseph] Cambridge Univ Hosp NHS Fdn Trust, Clin Pharmacol, Cambridge, England.
RP Lu, IN (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Clin Pharmacol, Cambridge, England.
EM ing.lu@addenbrookes.nhs.uk
RI Norton, Sam J/A-1898-2009
OI Norton, Sam J/0000-0003-1714-9963; Kostapanos,
   Michalis/0000-0002-7513-5319
FU Cambridge University Hospitals NHS Foundation Trust;
   AstraZenecaAstraZeneca; Evelo Biosciences; National Institute for Health
   ResearchNational Institute for Health Research (NIHR)
FX The trial is sponsored by Cambridge University Hospitals NHS Foundation
   Trust. Trial funding and drug supply is provided by AstraZeneca and
   Evelo Biosciences. The trial is supported by the National Institute for
   Health Research. The funding bodies had no role in the design of the
   study and collection, analysis, and interpretation of data and in
   writing the manuscript.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 31
PY 2020
VL 21
IS 1
AR 690
DI 10.1186/s13063-020-04618-2
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NA4BQ
UT WOS:000559760100002
PM 32736592
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nanni, O
   Viale, P
   Vertogen, B
   Lilli, C
   Zingaretti, C
   Donati, C
   Masini, C
   Monti, M
   Serra, P
   Vespignani, R
   Grossi, V
   Biggeri, A
   Scarpi, E
   Galardi, F
   Bertoni, L
   Colamartini, A
   Falcini, F
   Altini, M
   Massa, I
   Gaggeri, R
   Martinelli, G
AF Nanni, Oriana
   Viale, Pierluigi
   Vertogen, Bernadette
   Lilli, Claudia
   Zingaretti, Chiara
   Donati, Caterina
   Masini, Carla
   Monti, Manuela
   Serra, Patrizia
   Vespignani, Roberto
   Grossi, Veruska
   Biggeri, Annibale
   Scarpi, Emanuela
   Galardi, Francesca
   Bertoni, Lucia
   Colamartini, Americo
   Falcini, Fabio
   Altini, Mattia
   Massa, Ilaria
   Gaggeri, Raffaella
   Martinelli, Giovanni
TI PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus
   observational support for prevention or early-phase treatment of
   Coronavirus disease (COVID-19): A structured summary of a study protocol
   for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomized controlled clinical trial; Protocol;
   Hydroxychloroquine; Prophylaxis; Prevention; Early treatment;
   Asymptomatic; Paucisymptomatic
AB ObjectivesHydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion and glycosylation of viral surface proteins. In addition to its antiviral activity, hydroxychloroquine has an immune-modulating activity that may synergistically enhance its antiviral effect in vivo, making it a potentially promising drug for the prevention and the cure of SARS-CoV-19. However, randomized controlled trials are needed to assess whether it can be used safely to treat COVID-19 patients or to prevent infection. The main objective of the present study is to evaluate the efficacy of hydroxychloroquine for (I) the prevention of COVID-19 or related symptoms in SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients.Trial designThis is a controlled, open label, cluster-randomized, superiority trial with parallel group design. Subjects will be randomized either to receive hydroxychloroquine or to observation (2:1).ParticipantsSARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled. Paucisymptomatic patients are defined as patients with a low number of mild symptoms. All subjects must be aged >= 18 years, male or female, must be willing and able to give informed consent and must not have any contraindications to take hydroxychloroquine (intolerance or previous toxicity for hydroxychloroquine/chloroquine, bradycardia or reduction in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness, current use of medications with known significant drug-drug interactions, and known prolonged QT syndrome or current use of drugs with known QT prolongation).The study is monocentric and will be conducted at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Subjects will be enrolled from a large epidemic region (North-Central Italy). The Public Health Departments of several Italian regions will collaborate by identifying potentially eligible subjects.Intervention and comparatorThe participants will be randomized (2:1 randomization) to receive either hydroxychloroquine (Arm A) or to Observation (Arm B). Hydroxychloroquine will be administered with the following schedule:Group1: A loading dose hydroxychloroquine 400 mg twice daily on day 1, followed by a weekly dose of hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, for a total of one month of treatment.Group 2: A loading dose hydroxychloroquine 400 mg twice daily on day 1 followed by 200 mg twice daily for a total of 5-7 days.The comparator in this trial is observation given that currently neither treatment is administered to asymptomatic or paucisymptomatic subjects, nor prophylaxis is available for contacts.
   Hydroxychloroquine will be shipped to subjects within 24 hours of randomization. Given the extraordinary nature of the COVID-19 pandemic, only telephonic interviews will be carried out and electronic Patient Reported Outcomes (ePRO) completed. During treatment, each subject will be contacted every other day for the first week and weekly thereafter (Group 2) or weekly (Group 1) by a study physician to assess early onset of any COVID-19 symptom or any adverse reaction to hydroxychloroquine and to check subject compliance. Furthermore, all subjects will receive periodic ePROs which may be completed through smartphone or tablets to record drug self-administration and onset of any symptom or adverse event. All subjects will be followed up for a total of 6 months by periodic telephonic interviews and ePROs.Main outcomesThe primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization.RandomizationAll household members and/or contacts of each COVID-19 index case, and the COVID-19 patient himself/herself, fulfilling all inclusion criteria will be grouped into a single cluster and this cluster will be randomized (2:1) to either arm A or arm B. Information on each subject will be recorded in specific data records.Randomization lists will be stratified according to the following factors regarding COVID-19 index cases:1. COVID-19 risk level on the basis of province of residence (high vs. low/intermediate);2. Index case is a healthcare professional (yes vs.no)3. Index case with COVID-19 treatment (yes vs. no)An independent statistician not otherwise involved in the trial will generate the allocation sequence, and COVID-19 response teams will be unaware of the allocation of clusters.Randomization will be performed through an interactive web-based electronic data-capturing database.An Independent Data Monitoring Committee has been established.Blinding (masking)This study is open label.Numbers to be randomized (sample size)For Group 1, a sample size of about 2000 SARS-CoV-2-exposed subjects such as household members and/or contacts of COVID-19 patients will take part in the study. Assuming around 1.5-2.0 asymptomatic household members and/or contacts for each COVID-19 patient, we expect to identify approximately 1000-1300 COVID-19 index cases to be randomized. An interim analysis on efficacy is planned using standard alpha-spending function.For Group 2, sufficient power for primary objective (negative swab within 14 days of randomization) will be reached given a sample size of 300 asymptomatic or paucisymptomatic COVID-19 subjects in home situations not treated for COVID-19 (25%-30% of about 1000-1300 expected index cases). Since up to date reduced evidence about COVID-19 infection epidemiology, the continuous update of diagnostic and therapeutic approaches, the sample size estimation could be updated after a one third of population will be recruited and eventually modified according to a substantial protocol amendment. An interim analysis at 100 enrolled COVID-19 patients is planned.We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates. The above reported sample size analysis is therefore to be considered conservative.Trial StatusThe current version of the PROTECT trial protocol is 'Final version, 15 April 2020'.
   The study started on 9(th) May 2020. The first patient was enrolled on 14(th) May 2020. Recruitment is expected to last through September 2020.Trial registrationThe PROTECT trial is registered in the EudraCT database (no. 2020-001501-24) and in ClinicalTrials.gov (NCT04363827), date of registration 24 April 2020.Full protocolThe full PROTECT protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interests of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol (Protocol final version, 15(th) April 2020). The study protocol has been reported in accordance with Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Nanni, Oriana; Vertogen, Bernadette; Lilli, Claudia; Zingaretti, Chiara; Donati, Caterina; Masini, Carla; Monti, Manuela; Serra, Patrizia; Vespignani, Roberto; Grossi, Veruska; Scarpi, Emanuela; Galardi, Francesca; Bertoni, Lucia; Colamartini, Americo; Falcini, Fabio; Altini, Mattia; Massa, Ilaria; Gaggeri, Raffaella; Martinelli, Giovanni] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy.
   [Viale, Pierluigi] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy.
   [Biggeri, Annibale] Univ Firenze, Dipartimento Stat Informat Applicaz G Parenti DIS, Florence, Italy.
RP Nanni, O (corresponding author), IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy.
EM oriana.nanni@irst.emr.it
FU IRST IRCCS
FX IRST IRCCS is funding this trial and will have full oversight of the
   design of the study, collection, analysis, and interpretation of data
   and drafting of the manuscript.
NR 0
TC 3
Z9 3
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 31
PY 2020
VL 21
IS 1
AR 689
DI 10.1186/s13063-020-04527-4
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NA4BQ
UT WOS:000559760100001
PM 32736597
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wilkinson, T
   Dixon, R
   Page, C
   Carroll, M
   Griffiths, G
   Ho, LP
   De Soyza, A
   Felton, T
   Lewis, KE
   Phekoo, K
   Chalmers, JD
   Gordon, A
   McGarvey, L
   Doherty, J
   Read, RC
   Shankar-Hari, M
   Martinez-Alier, N
   O'Kelly, M
   Duncan, G
   Walles, R
   Sykes, J
   Summers, C
   Singh, D
AF Wilkinson, Tom
   Dixon, Rupert
   Page, Clive
   Carroll, Miles
   Griffiths, Gareth
   Ho, Ling-Pei
   De Soyza, Anthony
   Felton, Timothy
   Lewis, Keir E.
   Phekoo, Karen
   Chalmers, James D.
   Gordon, Anthony
   McGarvey, Lorcan
   Doherty, Jillian
   Read, Robert C.
   Shankar-Hari, Manu
   Martinez-Alier, Nuria
   O'Kelly, Michael
   Duncan, Graeme
   Walles, Roelize
   Sykes, James
   Summers, Charlotte
   Singh, Dave
CA ACCORD Collaborators
TI ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform
   Study to Assess the Efficacy and Safety of Multiple Candidate Agents for
   the Treatment of COVID-19 in Hospitalised Patients: A structured summary
   of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; randomised; platform study; master protocol; phase II
AB ObjectivesStage 1: To evaluate the safety and efficacy of candidate agents as add-on therapies to standard of care (SoC) in patients hospitalised with COVID-19 in a screening stage.Stage 2: To confirm the efficacy of candidate agents selected on the basis of evidence from Stage 1 in patients hospitalised with COVID-19 in an expansion stage.Trial designACCORD is a seamless, Phase 2, adaptive, randomised controlled platform study, designed to rapidly test candidate agents in the treatment of COVID-19. Designed as a master protocol with each candidate agent being included via its own sub-protocol, initially randomising equally between each candidate and a single contemporaneous SoC arm (which can adapt into 2:1). Candidate agents currently include bemcentinib, MEDI3506, acalabrutinib, zilucoplan and nebulised heparin. For each candidate a total of 60 patients will be recruited in Stage 1. If Stage 1 provides evidence of efficacy and acceptable safety the candidate will enter Stage 2 where a total of approximately 126 patients will be recruited into each study arm sub-protocol. Enrollees and outcomes will not be shared across the Stages; the endpoint, analysis and sample size for Stage 2 may be adjusted based on evidence from Stage 1. Additional arms may be added as new potential candidate agents are identified via candidate agent specific sub-protocols.ParticipantsThe study will include hospitalised adult patients (>= 18 years) with confirmed SARS-CoV-2 infection, the virus that causes COVID-19, that clinically meet Grades 3 (hospitalised - mild disease, no oxygen therapy), Grades 4 (hospitalised, oxygen by mask or nasal prongs) and 5 (hospitalised, non-invasive ventilation or high flow oxygen) of the WHO Working Group on the Clinical Characteristics of COVID-19 9-point category ordinal scale.Participants will be recruited from England, Northern Ireland, Wales and Scotland.Intervention and comparatorComparator is current standard of care (SoC) for the treatment of COVID-19. Current candidate experimental arms include bemcentinib, MEDI3506, acalabrutinib, zilucoplan and nebulised heparin with others to be added over time. Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein. ACCORD is linked with the UK national COVID therapeutics task force to help prioritise candidate agents.Main outcomesTime to sustained clinical improvement of at least 2 points (from randomisation) on the WHO 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale), whichever comes first, by Day 29 (this will also define the "responder" for the response rate analyses).RandomisationAn electronic randomization will be performed by Cenduit using Interactive Response Technology (IRT). Randomisation will be stratified by baseline severity grade. Randomisation will proceed with an equal allocation to each arm and a contemporaneous SoC arm (e.g. 1:1 if control and 1 experimental arm; 1:1:1 if two experimental candidate arms etc) but will be reviewed as the trial progresses and may be changed to 2:1 in favour of the candidate agents.
   Blinding (masking)The trial is open label and no blinding is currently planned in the study.Numbers to be randomised (sample size)This will be in the order of 60 patients per candidate agent for Stage 1, and 126 patients for Stage 2. However, sample size re-estimation may be considered after Stage 1. It is estimated that up to 1800 patients will participate in the overall study.Trial StatusMaster protocol version ACCORD-2-001 - Master Protocol (Amendment 1) 22(nd) April 2020, the trial has full regulatory approval and recruitment is ongoing in the bemcentinib (first patient recruited 6/5/2020), MEDI3506 (first patient recruited 19/5/2020), acalabrutinib (first patient recruited 20/5/2020) and zilucoplan (first patient recruited 19/5/2020) candidates (and SoC). The recruitment dates of each arm will vary between candidate agents as they are added or dropped from the trial, but will have recruited and reported within a year.Trial registrationEudraCT 2020-001736-95, registered 28(th) April 2020.Full protocolThe full protocol (Master Protocol with each of the candidate sub-protocols) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Wilkinson, Tom; Griffiths, Gareth; Read, Robert C.] Univ Southampton, Southampton, Hants, England.
   [Wilkinson, Tom; Read, Robert C.] NIHR Southampton Biomed Res Ctr, Southampton, Hants, England.
   [Dixon, Rupert; Martinez-Alier, Nuria; Walles, Roelize; Sykes, James] IQVIA, Reading, Berks, England.
   [Page, Clive; Shankar-Hari, Manu] Kings Coll London, London, England.
   [Carroll, Miles] Publ Hlth England, London, England.
   [Ho, Ling-Pei] Univ Oxford, NIHR Oxford Biomed Res Ctr, Oxford, England.
   [De Soyza, Anthony] Newcastle Univ, Fac Med Sci, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Felton, Timothy] Univ Manchester, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England.
   [Lewis, Keir E.] Swansea Univ, Swansea, W Glam, Wales.
   [Phekoo, Karen; Doherty, Jillian] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Chalmers, James D.] Univ Dundee, Dundee, Scotland.
   [Gordon, Anthony] Imperial Coll London, London, England.
   [McGarvey, Lorcan] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Martinez-Alier, Nuria] Evelina London Childrens Hosp Guys & St Thomas Ho, London, England.
   [O'Kelly, Michael] IQVIA, Dublin, Ireland.
   [Duncan, Graeme] IQVIA, Edinburgh, Midlothian, Scotland.
   [Summers, Charlotte] Univ Cambridge, Cambridge, England.
   [Singh, Dave] Univ Manchester, Manchester, Lancs, England.
RP Griffiths, G (corresponding author), Univ Southampton, Southampton, Hants, England.
EM G.O.Griffiths@soton.ac.uk
RI Summers, Charlotte/A-6973-2012
OI Summers, Charlotte/0000-0002-7269-2873
FU UKRI
FX The ACCORD trial platform is funded by UKRI. The funder will have no
   role in the study's design, collection, management, analysis and
   interpretation of data, writing of the report and the decision to submit
   the report for publication conception or in the data analysis.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 31
PY 2020
VL 21
IS 1
AR 691
DI 10.1186/s13063-020-04584-9
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NA4BQ
UT WOS:000559760100003
PM 32736596
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhou, DM
   Duyvesteyn, HME
   Chen, CP
   Huang, CG
   Chen, TH
   Shih, SR
   Lin, YC
   Cheng, CY
   Cheng, SH
   Huang, YC
   Lin, TY
   Ma, C
   Huo, JD
   Carrique, L
   Malinauskas, T
   Ruza, RR
   Shah, PNM
   Tan, TK
   Rijal, P
   Donat, RF
   Godwin, K
   Buttigieg, KR
   Tree, JA
   Radecke, J
   Paterson, NG
   Supasa, P
   Mongkolsapaya, J
   Screaton, GR
   Carroll, MW
   Gilbert-Jaramillo, J
   Knight, ML
   James, W
   Owens, RJ
   Naismith, JH
   Townsend, AR
   Fry, EE
   Zhao, YG
   Ren, JS
   Stuart, DI
   Huang, KYA
AF Zhou, Daming
   Duyvesteyn, Helen M. E.
   Chen, Cheng-Pin
   Huang, Chung-Guei
   Chen, Ting-Hua
   Shih, Shin-Ru
   Lin, Yi-Chun
   Cheng, Chien-Yu
   Cheng, Shu-Hsing
   Huang, Yhu-Chering
   Lin, Tzou-Yien
   Ma, Che
   Huo, Jiandong
   Carrique, Loic
   Malinauskas, Tomas
   Ruza, Reinis R.
   Shah, Pranav N. M.
   Tan, Tiong Kit
   Rijal, Pramila
   Donat, Robert F.
   Godwin, Kerry
   Buttigieg, Karen R.
   Tree, Julia A.
   Radecke, Julika
   Paterson, Neil G.
   Supasa, Piyada
   Mongkolsapaya, Juthathip
   Screaton, Gavin R.
   Carroll, Miles W.
   Gilbert-Jaramillo, Javier
   Knight, Michael L.
   James, William
   Owens, Raymond J.
   Naismith, James H.
   Townsend, Alain R.
   Fry, Elizabeth E.
   Zhao, Yuguang
   Ren, Jingshan
   Stuart, David, I
   Huang, Kuan-Ying A.
TI Structural basis for the neutralization of SARS-CoV-2 by an antibody
   from a convalescent patient
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article; Early Access
ID NANOLITRE CRYSTALLIZATION EXPERIMENTS; CRYO-EM STRUCTURE; SARS
   CORONAVIRUS; POTENT NEUTRALIZATION; PROTEIN; SPIKE
AB The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds the receptor binding domain (RBD) of the viral spike glycoprotein tightly (K(D)of 2 nM), and a 2.6-angstrom-resolution crystal structure of an RBD-EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues within this footprint are key to stabilizing the pre-fusion spike. Cryo-EM analyses of the pre-fusion spike incubated with EY6A Fab reveal a complex of the intact spike trimer with three Fabs bound and two further multimeric forms comprising the destabilized spike attached to Fab. EY6A binds what is probably a major neutralizing epitope, making it a candidate therapeutic for COVID-19.
   EY6A, a neutralizing antibody isolated from a patient convalescing from COVID-19, binds the receptor binding domain of the SARS-CoV-2 spike glycoprotein with high affinity, at a location away from the binding site for the ACE2 receptor, similar to the one recognized by CR3022.
C1 [Zhou, Daming; Duyvesteyn, Helen M. E.; Huo, Jiandong; Carrique, Loic; Malinauskas, Tomas; Ruza, Reinis R.; Shah, Pranav N. M.; Owens, Raymond J.; Naismith, James H.; Fry, Elizabeth E.; Zhao, Yuguang; Ren, Jingshan; Stuart, David, I] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Div Struct Biol, Oxford, England.
   [Chen, Cheng-Pin; Lin, Yi-Chun; Cheng, Chien-Yu; Cheng, Shu-Hsing] Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf, Taoyuan, Taiwan.
   [Chen, Cheng-Pin; Cheng, Chien-Yu] Natl Yang Ming Univ, Taipei, Taiwan.
   [Huang, Chung-Guei; Shih, Shin-Ru; Huang, Kuan-Ying A.] Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.
   [Huang, Chung-Guei; Shih, Shin-Ru] Chang Gung Mem Hosp, Dept Lab Med, Taoyuan, Taiwan.
   [Chen, Ting-Hua; Ma, Che] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Lin, Yi-Chun; Cheng, Shu-Hsing] Taipei Med Univ, Taipei, Taiwan.
   [Huang, Yhu-Chering; Lin, Tzou-Yien; Huang, Kuan-Ying A.] Chang Gung Mem Hosp, Dept Pediat, Div Pediat Infect Dis, Taoyuan, Taiwan.
   [Huo, Jiandong; Owens, Raymond J.; Naismith, James H.] Rosalind Franklin Inst, Harwell Campus, Didcot, Oxon, England.
   [Huo, Jiandong; Owens, Raymond J.; Naismith, James H.] Res Complex Harwell, Prot Prod UK, Harwell Sci & Innovat Campus, Didcot, Oxon, England.
   [Tan, Tiong Kit; Rijal, Pramila; Donat, Robert F.; Townsend, Alain R.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
   [Rijal, Pramila; Townsend, Alain R.; Stuart, David, I] Univ Oxford, Chinese Acad Med Sci, Ctr Translat Immunol, Oxford Inst, Oxford, England.
   [Godwin, Kerry; Buttigieg, Karen R.; Tree, Julia A.; Carroll, Miles W.] Publ Hlth England, Natl Infect Serv, Salisbury, Wilts, England.
   [Radecke, Julika; Paterson, Neil G.; Stuart, David, I] Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot, Oxon, England.
   [Supasa, Piyada; Mongkolsapaya, Juthathip; Screaton, Gavin R.; Carroll, Miles W.] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford, England.
   [Mongkolsapaya, Juthathip] Mahidol Univ, Siriraj Hosp, Fac Med, Dengue Hemorrhag Fever Res Unit,Off Res & Dev, Bangkok, Thailand.
   [Gilbert-Jaramillo, Javier; Knight, Michael L.; James, William] Univ Oxford, William Dunn Sch Pathol, Oxford, England.
RP Stuart, DI (corresponding author), Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Div Struct Biol, Oxford, England.; Huang, KYA (corresponding author), Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.; Huang, KYA (corresponding author), Chang Gung Mem Hosp, Dept Pediat, Div Pediat Infect Dis, Taoyuan, Taiwan.; Stuart, DI (corresponding author), Univ Oxford, Chinese Acad Med Sci, Ctr Translat Immunol, Oxford Inst, Oxford, England.; Stuart, DI (corresponding author), Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot, Oxon, England.
EM dave@strubi.ox.ac.uk; arthur1726@cgmh.org.tw
RI Malinauskas, Tomas/H-3133-2012; Naismith, James Henderson/AAB-8614-2020;
   Alex, Che/AAF-3280-2019; james, william/H-4289-2013
OI Malinauskas, Tomas/0000-0002-4847-5529; Naismith, James
   Henderson/0000-0001-6744-5061; Alex, Che/0000-0002-4741-2307; Chen,
   Cheng-Pin/0000-0002-0629-9790; Chen, Ting-Hua/0000-0001-8104-0562;
   Gilbert, Javier/0000-0003-1268-2304; Carrique, Loic/0000-0001-5332-8593;
   Shah, Pranav NM/0000-0003-1212-904X; james, william/0000-0002-2506-1198;
   Ren, Jingshan/0000-0003-4015-1404; Rijal, Pramila/0000-0002-9214-9851
FU Chang Gung Memorial HospitalChang Gung Memorial Hospital [BMRPE22];
   Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical
   Science (CIFMS), China [2018-I2M-2002]; Wellcome TrustWellcome Trust
   [101122/Z/13/Z, 090532/Z/09/Z, 095541/A/11/Z]; Cancer Research UKCancer
   Research UK [C375/A17721, C20724/A14414, C20724/A26752]; UK Medical
   Research CouncilMedical Research Council UK (MRC) [MR/N00065X/1]; EPA
   Cephalosporin Fund; Rosalind Franklin Institute EPSRC grant
   [EP/S025243/1]; National Institute for Health Research Biomedical
   Research Centre Funding SchemeNational Institute for Health Research
   (NIHR); Fast Grants (Mercatus Center); EPA Cephalosporin Early Career
   Teaching and Research Fellowship; Townsend-Jeantet Charitable Trust
   [1011770]
FX We acknowledge the BD FACSAria cell sorter service provided by the Core
   Instrument Center of Chang Gung University. The sorting of plasmablasts
   and production and characterization of human mAbs were supported by the
   Chang Gung Memorial Hospital (BMRPE22). This work was supported by the
   Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical
   Science (CIFMS), China (grant no. 2018-I2M-2002) to D.I.S., G.R.S. and
   A.R.T., which supported P.R.; E.E.F., H.M.E.D. and J. Ren are supported
   by the Wellcome Trust (101122/Z/13/Z); Y.Z. by Cancer Research UK
   (C375/A17721); and D.I.S. and E.E.F. by the UK Medical Research Council
   (MR/N00065X/1); J.H. is supported by a grant from the EPA Cephalosporin
   Fund; and PPUK is funded by the Rosalind Franklin Institute EPSRC grant
   no. EP/S025243/1 (J.H.N. and R.J.O.). The National Institute for Health
   Research Biomedical Research Centre Funding Scheme supports G.R.S. We
   are also grateful for a Fast Grant from Fast Grants (Mercatus Center) to
   support the isolation of human monoclonal antibodies to SARS-2. G.R.S.
   is also supported as a Wellcome Trust Senior Investigator (grant no.
   095541/A/11/Z). T.K.T. is funded by an EPA Cephalosporin Early Career
   Teaching and Research Fellowship and the Townsend-Jeantet Charitable
   Trust (charity no. 1011770). T.M. is supported by Cancer Research UK
   grants C20724/A14414 and C20724/A26752 to C. Siebold. This is a
   contribution from the UK Instruct-ERIC Centre. The Wellcome Centre for
   Human Genetics is supported by the Wellcome Trust (grant no.
   090532/Z/09/Z). Virus used for the neutralization assays was a gift from
   J. Druce at the Doherty Centre, Melbourne, Australia. We acknowledge the
   Diamond Light Source for time on Beamline I03 under proposal mx19946 and
   for electron microscope time at the UK National Electron Bio-Imaging
   Centre (eBIC), proposal BI26983, both COVID-19 Rapid Access. D.I.S. is a
   Jenner Investigator. We thank the teams, especially at the Diamond Light
   Source and Department of Structural Biology, Oxford University, that
   have enabled work to continue during the pandemic.
CR Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   CAI YH, 2020, ISCIENCE, V23, DOI DOI 10.1126/SCIENCE.ABD4251
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Corman VM, 2020, EUROSURVEILLANCE, V25
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gong YQ, 2020, EPIDEMIOL INFECT, V148, DOI [10.1017/S0950268820000771, 10.1080/22221751.2020.1782271]
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   Grist N. R., 1966, DIAGNOSTIC METHODS C
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang KYA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00736-9
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lv Z, 2020, SCIENCE, V369, P1505, DOI 10.1126/science.abc5881
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Neffleship Joanne E., 2009, V498, P245, DOI 10.1007/978-1-59745-196-3_16
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Roy S., 2020, PREPRINT, DOI [10.1101/2020.04.20.052290V1, DOI 10.1101/2020.04.20.052290V1]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808
   Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 50
TC 12
Z9 12
U1 9
U2 9
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
DI 10.1038/s41594-020-0480-y
EA JUL 2020
PG 25
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA MZ8CU
UT WOS:000559353900001
PM 32737466
OA Bronze
DA 2021-01-01
ER

PT J
AU Li, L
   Yang, R
   Wang, J
   Lv, QL
   Ren, M
   Zhao, L
   Chen, HW
   Xu, HX
   Xie, SL
   Xie, J
   Lin, H
   Li, WJ
   Fang, P
   Gong, L
   Wang, L
   Wu, YY
   Liu, Z
AF Li, Ling
   Yang, Ru
   Wang, Jue
   Lv, Qilu
   Ren, Ming
   Zhao, Lei
   Chen, Hanwei
   Xu, Haixia
   Xie, Songli
   Xie, Jin
   Lin, Hui
   Li, Wenjuan
   Fang, Peng
   Gong, Li
   Wang, Lan
   Wu, Yanyun
   Liu, Zhong
TI Feasibility of a pilot program forCOVID-19 convalescent plasma
   collection in Wuhan, China
SO TRANSFUSION
LA English
DT Article; Early Access
AB BACKGROUND A novel coronavirus has caused an international outbreak. Currently, there are no specific therapeutic agents for coronavirus infections. Convalescent plasma (CP) therapy is a potentially effective treatment option. METHODS Patients who had recovered from COVID-19 and had been discharged from the hospital for more than 2 weeks were recruited. COVID-19 convalescent plasma (CCP)-specific donor screening and selection were performed based on the following criteria: 1) aged 18-55 years; 2) eligible for blood donation; 3) diagnosed with COVID-19; 4) had two consecutive negative COVID-19 nasopharyngeal swab tests based on PCR (at least 24 hr apart) prior to hospital discharge; 5) had been discharged from the hospital for more than 2 weeks; and 6) had no COVID-19 symptoms prior to convalescent plasma donation. In addition, preference was given to CCP donors who had a fever lasting more than 3 days or a body temperature exceeding 38.5 degrees C (101.3 degrees F), and who donated 4 weeks after the onset of symptoms. CCP collection was performed using routine plasma collection procedures via plasmapheresis. In addition to routine donor testing, the CCP donors' plasma was also tested for SARS-CoV-2 nucleic acid and S-RBD-specific IgG antibody. RESULTS Of the 81 potential CCP donors, 64 (79%) plasma products were collected. There were 18 female donors and 46 male donors. There were 34 first-time blood donors and 30 repeat donors. The average time between CCP collection and initial symptom onset was 49.1 days, and the average time between CCP collection and hospital discharge was 38.7 days. The average volume of CCP collected was 327.7 mL. All Alanine transaminase (ALT) testing results met blood donation requirements. HIV Ag/Ab, anti-HCV, anti-syphilis, and HBsAg were all negative; NAT for HIV, HBV, and HCV were also negative. In addition, all of the CCP donors' plasma units were negative for SARS-CoV-2 RNA. Of the total 64 CCP donors tested, only one had an S-RBD-specific IgG titer of 1:160, all others had a titer of >= 1:320. CONCLUSION Based on a feasibility study of a pilot CCP program in Wuhan, China, we demonstrated the success and feasibility of CCP collection. In addition, all of the CCP units collected had a titer of >= 1:160 for S-RBD-specific IgG antibody, which met the CCP quality control requirements based on the Chinese national guidelines for CCP.
C1 [Li, Ling; Wang, Jue; Lv, Qilu; Xu, Haixia; Li, Wenjuan; Fang, Peng; Gong, Li; Liu, Zhong] Chinese Acad Med Sci & Peking Union Med Coll, Clin Transfus Res Ctr, Inst Blood Transfus, Chengdu, Sichuan, Peoples R China.
   [Li, Ling; Wang, Jue; Lv, Qilu; Xu, Haixia; Li, Wenjuan; Fang, Peng; Gong, Li; Liu, Zhong] CAMS, Key Lab Transfus Adverse React, Chengdu, Sichuan, Peoples R China.
   [Yang, Ru; Ren, Ming; Zhao, Lei; Chen, Hanwei; Xie, Songli; Xie, Jin; Lin, Hui; Wang, Lan] Wuhan Blood Ctr, Wuhan, Hubei, Peoples R China.
   [Li, Wenjuan; Fang, Peng; Gong, Li] Anhui Med Univ, Hefei, Peoples R China.
   [Wu, Yanyun] Univ Miami, Miami, FL 33136 USA.
RP Wang, L (corresponding author), Baofeng 1st Rd, Wuhan, Hubei, Peoples R China.; Wu, YY (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.; Liu, Z (corresponding author), 26 Huacai Rd, Chengdu, Sichuan, Peoples R China.
EM wlan66@126.com; yxw1366@med.miami.edu; liuz@ibt.pumc.edu.cn
RI Liu, Zhong/ABH-8584-2020
FU CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-I2M-CoV19-006,
   2016-I2M-3-024, 2017-I2M-1-009]; Non-profit Central Research Institute
   Fund of Chinese Academy of Medical Sciences [2018PT32016]; the CAMS
   Innovation Fund for Medical Sciences (CIFMS) [2017-I2M-1-009,
   2016-I2M-3-024] Funding Source: Medline
FX This work was supported by the CAMS Innovation Fund for Medical Sciences
   (CIFMS) (Grant Nos. 2020-I2M-CoV19-006, 2016-I2M-3-024, and
   2017-I2M-1-009). Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences (Grant No. 2018PT32016).
CR Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Cascella M, 2020, FEATURES EVALUATION
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   FDA - Food and Drug Administration, INV COVID 19 CONV PL
   Garraud O, 2017, TRANSFUS APHER SCI, V56, P31, DOI 10.1016/j.transci.2016.12.014
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, ANTIVIR RES, V150, P202, DOI 10.1016/j.antiviral.2018.01.002
   LI L, 2020, TRANSFUSION 0706, DOI DOI 10.1111/TRF.15918
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   National Health Commission of the Peoples Republic of China, COVID 19 TREATM PLAN
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   World Health Organization, COR DIS COVID 19 OUT
NR 14
TC 1
Z9 1
U1 4
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
DI 10.1111/trf.15921
EA JUL 2020
PG 5
WC Hematology
SC Hematology
GA MZ7ZL
UT WOS:000559345200001
PM 32491199
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cheng, DR
   Wen, JQ
   Liu, ZZ
   Lv, TF
   Chen, JS
AF Cheng, Dongrui
   Wen, Jiqiu
   Liu, Zhengzhao
   Lv, Tangfeng
   Chen, Jin-song
TI Coronavirus disease 2019 in renal transplant recipients: Report of two
   cases
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE COVID-19; immunosuppressant; methylprednisolone; renal transplant
   recipient; SARS-CoV-2
ID ACUTE-RESPIRATORY-SYNDROME
AB Coronavirus disease 2019 (COVID-19) has been a pandemic worldwide. The data about COVID-19 in renal transplant recipient are deficiency. Herein, we report two COVID-19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low-dose methylprednisolone-based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID-19 in renal transplant recipients.
C1 [Cheng, Dongrui; Wen, Jiqiu; Liu, Zhengzhao; Chen, Jin-song] Nanjing Univ, Jinling Hosp, Natl Clin Res Ctr Kidney Dis, Dept Nephrol, Nanjing, Peoples R China.
   [Cheng, Dongrui; Wen, Jiqiu; Liu, Zhengzhao; Lv, Tangfeng] Wuhan Huoshenshan Hosp, Nanjing, Peoples R China.
   [Lv, Tangfeng] Nanjing Univ, Jinling Hosp, Dept Pulm & Crit Care Med, Nanjing, Peoples R China.
RP Chen, JS (corresponding author), Nanjing Univ, Jinling Hosp, Natl Clin Res Ctr Kidney Dis, Dept Nephrol, Nanjing, Peoples R China.
EM chenjinsongkidney@hotmail.com
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE007, DOI 10.3760/cma.j.issn.1001-0939.2020.0007
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhong ZB, 2020, AM J TRANSPLANT, V20, P1916, DOI 10.1111/ajt.15928
NR 14
TC 6
Z9 6
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2020
VL 22
IS 5
AR e13329
DI 10.1111/tid.13329
EA JUL 2020
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OR6XJ
UT WOS:000559377100001
PM 32415905
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lopez-Pelayo, H
   Aubin, HJ
   Drummond, C
   Dom, G
   Pascual, F
   Rehm, J
   Saitz, R
   Scafato, E
   Gual, A
AF Lopez-Pelayo, Hugo
   Aubin, Henri-Jean
   Drummond, Colin
   Dom, Geert
   Pascual, Francisco
   Rehm, Jurgen
   Saitz, Richard
   Scafato, Emanuele
   Gual, Antoni
TI "The post-COVID era": challenges in the treatment of substance use
   disorder (SUD) after the pandemic
SO BMC MEDICINE
LA English
DT Article
DE Addictions; COVID-19; Substance use disorder; Stigma; Telemedicine;
   Harm-reduction
ID COST-EFFECTIVENESS; MENTAL-HEALTH; CANNABIS USE; IMPACT; INTERVENTIONS;
   PSYCHIATRY; EMPLOYMENT; REVIEWS
AB BackgroundCitizens affected by substance use disorders are high-risk populations for both SARS-CoV-2 infection and COVID-19-related mortality. Relevant vulnerabilities to COVID-19 in people who suffer substance use disorders are described in previous communications. The COVID-19 pandemic offers a unique opportunity to reshape and update addiction treatment networks.Main bodyRenewed treatment systems should be based on these seven pillars: (1) telemedicine and digital solutions, (2) hospitalization at home, (3) consultation-liaison psychiatric and addiction services, (4) harm-reduction facilities, (5) person-centered care, (6) promote paid work to improve quality of life in people with substance use disorders, and (7) integrated addiction care. The three "best buys" of the World Health Organization (reduce availability, increase prices, and a ban on advertising) are still valid. Additionally, new strategies must be implemented to systematically deal with (a) fake news concerning legal and illegal drugs and (b) controversial scientific information.ConclusionThe heroin pandemic four decades ago was the last time that addiction treatment systems were updated in many western countries. A revised and modernized addiction treatment network must include improved access to care, facilitated where appropriate by technology; more integrated care with addiction specialists supporting non-specialists; and reducing the stigma experienced by people with SUDs.
C1 [Lopez-Pelayo, Hugo; Gual, Antoni] Hosp Clin Barcelona, Grp Recerca Addicc Clin GRAC GRE, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Rossello 149, Barcelona 08036, Spain.
   [Lopez-Pelayo, Hugo] Socidrogalcohol Spanish Soc Drug & Alcohol Specia, Barcelona, Spain.
   [Aubin, Henri-Jean] Univ Paris Saclay, Dept Psychiat & Addictol, Route Orme Merisiers,RD 128, F-91190 Paris, France.
   [Aubin, Henri-Jean] INSERM 1018, Ctr Rech Epidemiol & Sante Populat CESP, Paris, France.
   [Aubin, Henri-Jean] Grp Hosp Univ, AP HP, Paris, France.
   [Drummond, Colin] Kings Coll London, Addict Dept, Addict Psychiat, Natl Addict Ctr,Inst Psychiat Psychol & Neurosci, 16 De Crespigny Pk, London SE5 8AF, England.
   [Drummond, Colin] European Federat Addict Soc EUFAS, 16 De Crespigny Pk, London SE5 8AF, England.
   [Dom, Geert] Antwerp Univ UA, CAPRI, Antwerp, Belgium.
   [Dom, Geert] Belgian Profess Psychiat Assoc, Antwerp, Belgium.
   [Dom, Geert] European Federat Addict Soc EUFAS, Antwerp, Belgium.
   [Dom, Geert] European Psychiat Assoc EPA, Prinsstr 13, B-2000 Antwerp, Belgium.
   [Pascual, Francisco] SOCIDROGALCOHOL, Barcelona, Spain.
   [Pascual, Francisco] CAARFE, Valencia, Spain.
   [Pascual, Francisco] Dept Biol Aplicada, Alicante, Spain.
   [Pascual, Francisco] UCA, Alicante, Spain.
   [Rehm, Jurgen] Ctr Addict & Mental Hlth CAMH, Inst Mental Hlth Policy Res, Toronto, ON, Canada.
   [Rehm, Jurgen] Ctr Addict & Mental Hlth CAMH, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada.
   [Rehm, Jurgen] Univ Toronto UofT, Dalla Lana Sch Publ Hlth, 155 Coll St, Toronto, ON, Canada.
   [Rehm, Jurgen] Univ Toronto UofT, Dept Psychiat, 155 Coll St, Toronto, ON, Canada.
   [Rehm, Jurgen] Tech Univ Dresden, Epidemiol Res Unit, Klin Psychol & Psychotherapie, Dresden, Germany.
   [Rehm, Jurgen] IM Sechenov First Moscow State Med Univ, Dept Int Hlth Projects, Inst Leadership & Hlth Management, Moscow, Russia.
   [Saitz, Richard] Boston Univ, Dept Community Hlth Sci CHS, Sch Publ Hlth, 715 Albany St, Boston, MA 02118 USA.
   [Saitz, Richard] Boston Univ, Clin Addict Res & Educ CARE Unit, Sect Gen Internal Med, Med,Sch Med, Boston, MA 02118 USA.
   [Saitz, Richard] Boston Med Ctr, Grayken Ctr Addict, Boston, MA 02118 USA.
   [Scafato, Emanuele] Ist Super Sanita, WHO Collaborating Ctr Res & Hlth, Osservatorio Nazl Alcol Promot Alcohol & Alcohol, Rome, Italy.
   [Scafato, Emanuele] EUFAS Ist Super Sanita, Soc Italiana Alcol SIA, Rome, Italy.
   [Gual, Antoni] Int Network Brief Intervent Alcohol & Other Drugs, Barcelona, Spain.
RP Lopez-Pelayo, H (corresponding author), Hosp Clin Barcelona, Grp Recerca Addicc Clin GRAC GRE, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Rossello 149, Barcelona 08036, Spain.; Lopez-Pelayo, H (corresponding author), Socidrogalcohol Spanish Soc Drug & Alcohol Specia, Barcelona, Spain.
EM hlopez@clinic.cat
RI Pascual, Francisco/ABG-4384-2020
OI Lopez-Pelayo, Hugo/0000-0002-3850-8374
FU UK Department of Health and Social Care (DHSC) National Institute of
   Health Research (NIHR) Biomedical Research Centre at South London and
   Maudsley NHS Foundation Trust; NIHR Applied Research Collaboration South
   London; NIHR Senior Investigator Award; Spanish Ministry of Science,
   Innovation and Universities, Instituto de Salud Carlos III through a
   "Juan Rodes" contract [JR19/00025]
FX CD is part funded by the UK Department of Health and Social Care (DHSC)
   National Institute of Health Research (NIHR) Biomedical Research Centre
   at South London and Maudsley NHS Foundation Trust, the NIHR Applied
   Research Collaboration South London, and is in receipt of an NIHR Senior
   Investigator Award. The views expressed here do not necessarily
   represent those of the DHSC or NIHR.; HLP works under CERCA
   Programme/Generalitat de Catalunya and receives funding from the Spanish
   Ministry of Science, Innovation and Universities, Instituto de Salud
   Carlos III through a "Juan Rodes" contract (JR19/00025).
CR Pale LA, 2019, REV PSIQUIATR SALUD, V12, P207, DOI 10.1016/j.rpsm.2018.09.003
   Algren MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139297
   American Society of Addiction Medicine, 2020, COVID 19 COR
   Barney A, 2020, J ADOLESCENT HEALTH, V67, P164, DOI 10.1016/j.jadohealth.2020.05.006
   Baxter AJ, 2019, J EPIDEMIOL COMMUN H, V73, P379, DOI 10.1136/jech-2018-210981
   Bellis MA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2766-x
   Boege I, 2015, EUR PSYCHIAT, V30, P583, DOI 10.1016/j.eurpsy.2015.01.009
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Bush PW, 2009, PSYCHIAT SERV, V60, P1024, DOI 10.1176/appi.ps.60.8.1024
   Campeny E, 2020, EUR NEUROPSYCHOPHARM, V33, P1, DOI 10.1016/j.euroneuro.2020.02.003
   Charlet K, 2017, ADDICT BIOL, V22, P1119, DOI 10.1111/adb.12414
   Chisholm D, 2018, J STUD ALCOHOL DRUGS, V79, P514, DOI 10.15288/jsad.2018.79.514
   Chou KL, 2011, J CLIN PSYCHIAT, V72, P1468, DOI 10.4088/JCP.10m06019gry
   ConFAc, CONF FED AS CANN
   Cornelis J, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1632-z
   COVID19 APHP Grp, 2020, LANCET, V395, P1760, DOI 10.1016/S0140-6736(20)31210-1
   de Goeij MCM, 2015, SOC SCI MED, V131, P131, DOI 10.1016/j.socscimed.2015.02.025
   Delaigue S, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.020414
   DiClemente CC, 2017, PSYCHOL ADDICT BEHAV, V31, P862, DOI 10.1037/adb0000318
   Dom G, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010122
   Drummond C, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2704
   Dubanowicz A, 2015, IMPACT EC RECESSION
   EMCDDA, EMCDDA PUBL UPD IMPL
   European Monitoring Centre for Drugs and Drug Addiction, 2020, EMCDDA UPD IMPL COVI
   European Monitoring Centre for Drugs and Drug Addiction, EU DRUG MARK IMP COV
   Ferreri F, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00051
   Friedrichs A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145817
   Garcia C., VOZPOPULI
   Goncalves-Bradley DC, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000356.pub4
   Government of Canada, EX PRACT PHARM PRESC
   Gupta M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13329
   Henkel Dieter, 2011, Curr Drug Abuse Rev, V4, P4
   Hoch E, 2016, EUR ADDICT RES, V22, P233, DOI 10.1159/000445716
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   International Labour Office, 2020, ILO COVID 19 CAUS DE
   IWSR, US BEV ALC IND RESP
   Kaner EFS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011479.pub2
   Kruse CS, 2020, J MED INTERNET RES, V22, DOI 10.2196/13252
   Lopez-Pelayo H, 2019, J PSYCHOSOM RES, V116, P75, DOI 10.1016/j.jpsychores.2018.11.020
   Luciano A, 2016, PSYCHIAT SERV, V67, P1130, DOI 10.1176/appi.ps.201500343
   Martin-Carrasco M, 2016, EUR ARCH PSY CLIN N, V266, P89, DOI 10.1007/s00406-016-0681-x
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Miyara M, 2020, QEIOS, DOI [10.32388/WPP19W.3., DOI 10.32388/WPP19W.3, 10.32388/WPP19W.3]
   Molfenter T, 2018, INT J TELEMED APPL, V2018, DOI 10.1155/2018/3932643
   NHS, 2020, CRIS RES INT HOM TRE
   Nordeck CD, 2018, DRUG ALCOHOL DEPEN, V186, P23, DOI 10.1016/j.drugalcdep.2017.12.043
   Paris M, 2018, AM J PUBLIC HEALTH, V108, P1535, DOI 10.2105/AJPH.2018.304571
   Peterson EC, 2020, QUANTUM-AUSTRIA, V4
   Rehm J, 2020, DRUG ALCOHOL REV, V39, P301, DOI 10.1111/dar.13074
   Rehm J, 2017, ADDICTION, V112, P968, DOI 10.1111/add.13757
   Roden JM, 2017, SOC SCI MED, V175, P127, DOI 10.1016/j.socscimed.2017.01.001
   SAMSHA, 2020, COR COVID 19
   Schmidt-Weitmann S, 2015, TELEMED E-HEALTH, V21, P48, DOI 10.1089/tmj.2013.0370
   Simou E, 2018, CHEST, V154, P58, DOI 10.1016/j.chest.2017.11.041
   Substance Abuse and Mental Health Services Administration, 2006, SUBST AB CLIN ISS IN
   UNSDG, SHAR RESP GLOB SOL R
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vieta E, 2020, REV PSIQUIATR SALUD, V13, P105, DOI 10.1016/j.rpsm.2020.04.004
   Volkow ND, 2020, NEW ENGL J MED, V382, P1289, DOI 10.1056/NEJMp1917360
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Witkiewitz K, 2019, ALCOHOL CLIN EXP RES, V43, P979, DOI 10.1111/acer.14018
   World Health Organisation, WHO RESP COUNTR
NR 62
TC 1
Z9 1
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUL 31
PY 2020
VL 18
IS 1
AR 241
DI 10.1186/s12916-020-01693-9
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX4MU
UT WOS:000557699200001
PM 32731868
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, J
   Zhang, S
   Wu, ZX
   Shang, Y
   Dong, X
   Li, G
   Zhang, LD
   Chen, YZ
   Ye, XF
   Du, HX
   Liu, YG
   Wang, T
   Huang, SS
   Chen, LM
   Wen, ZL
   Qu, JM
   Chen, DC
AF Liu, Jiao
   Zhang, Sheng
   Wu, Zhixiong
   Shang, You
   Dong, Xuan
   Li, Guang
   Zhang, Lidi
   Chen, Yizhu
   Ye, Xiaofei
   Du, Hangxiang
   Liu, Yongan
   Wang, Tao
   Huang, SiSi
   Chen, Limin
   Wen, Zhenliang
   Qu, Jieming
   Chen, Dechang
TI Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Risk factors; COVID-19; Development; Severe; Mortality
ID COMMUNITY-ACQUIRED PNEUMONIA; CORONAVIRUS; ADULTS; DIAGNOSIS; SEVERITY
AB Background Since December 2019, an outbreak of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) initially emerged in Wuhan, China, and has spread worldwide now. Clinical features of patients with COVID-19 have been described. However, risk factors leading to in-hospital deterioration and poor prognosis in COVID-19 patients with severe disease have not been well identified. Methods In this retrospective, single-center cohort study, 1190 adult inpatients (>= 18 years old) with laboratory-confirmed COVID-19 and determined outcomes (discharged or died) were included from Wuhan Infectious Disease Hospital from December 29, 2019 to February 28, 2020. The final follow-up date was March 2, 2020. Clinical data including characteristics, laboratory and imaging information as well as treatments were extracted from electronic medical records and compared. A multivariable logistic regression model was used to explore the potential predictors associated with in-hospital deterioration and death. Results 1190 patients with confirmed COVID-19 were included. Their median age was 57 years (interquartile range 47-67 years). Two hundred and sixty-one patients (22%) developed a severe illness after admission. Multivariable logistic regression demonstrated that higher SOFA score (OR 1.32, 95% CI 1.22-1.43, per score increase,p < 0.001 for deterioration and OR 1.30, 95% CI 1.11-1.53, per score increase,p = 0.001 for death), lymphocytopenia (OR 1.81, 95% CI 1.13-2.89p = 0.013 for deterioration; OR 4.44, 95% CI 1.26-15.87,p = 0.021 for death) on admission were independent risk factors for in-hospital deterioration from not severe to severe disease and for death in severe patients. On admission D-dimer greater than 1 mu g/L (OR 3.28, 95% CI 1.19-9.04,p = 0.021), leukocytopenia (OR 5.10, 95% CI 1.25-20.78), thrombocytopenia (OR 8.37, 95% CI 2.04-34.44) and history of diabetes (OR 11.16, 95% CI 1.87-66.57,p = 0.008) were also associated with higher risks of in-hospital death in severe COVID-19 patients. Shorter time interval from illness onset to non-invasive mechanical ventilation in the survivors with severe disease was observed compared with non-survivors (10.5 days, IQR 9.25-11.0 vs. 16.0 days, IQR 11.0-19.0 days,p = 0.030). Treatment with glucocorticoids increased the risk of progression from not severe to severe disease (OR 3.79, 95% CI 2.39-6.01,p < 0.001). Administration of antiviral drugs especially oseltamivir or ganciclovir is associated with a decreased risk of death in severe patients (OR 0.17, 95% CI 0.05-0.64,p < 0.001). Conclusions High SOFA score and lymphocytopenia on admission could predict that not severe patients would develop severe disease in-hospital. On admission elevated D-dimer, leukocytopenia, thrombocytopenia and diabetes were independent risk factors of in-hospital death in severe patients with COVID-19. Administration of oseltamivir or ganciclovir might be beneficial for reducing mortality in severe patients.
C1 [Liu, Jiao; Zhang, Sheng; Zhang, Lidi; Chen, Yizhu; Du, Hangxiang; Liu, Yongan; Wang, Tao; Huang, SiSi; Chen, Limin; Wen, Zhenliang; Chen, Dechang] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Crit Care Med, Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
   [Wu, Zhixiong] Fudan Univ, Dept Surg Intens Care Unit, Huadong Hosp, 221 West Yanan Rd, Shanghai 200040, Peoples R China.
   [Shang, You] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Crit Care Med, 1277 Jiefang Ave, Wuhan 430022, Peoples R China.
   [Dong, Xuan] Wuhan Jinyin Tan Hosp, TB & Resp Dept, 1 Yintan Rd, Wuhan 430023, Peoples R China.
   [Li, Guang] Renmin Hosp Wuhan Univ, Dept Crit Care Med, 238 Jiefang Rd, Wuhan 238, Peoples R China.
   [Ye, Xiaofei] Second Mil Med Univ, Dept Hlth Stat, 800 Xiangyin Rd, Shanghai, Peoples R China.
   [Qu, Jieming; Chen, Dechang] Shanghai Jiao Tong Univ, Dept Pulm & Crit Care Med, Ruijin Hosp, Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
RP Chen, DC (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Crit Care Med, Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.; Qu, JM; Chen, DC (corresponding author), Shanghai Jiao Tong Univ, Dept Pulm & Crit Care Med, Ruijin Hosp, Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM jmqu0906@163.com; chengdechangsh@hotmail.com
CR Adam SS, 2009, BLOOD, V113, P2878, DOI 10.1182/blood-2008-06-165845
   Aggarwal G, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100617
   Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134
   Grossmann V, 2015, DIABETES CARE, V38, P1356, DOI 10.2337/dc14-3008
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Kwiecinski JM, 2020, CURR OPIN MICROBIOL, V53, P51, DOI 10.1016/j.mib.2020.02.005
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Matsuyama R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3881-4
   Mendoza-Torres Evelyn, 2015, Ther Adv Cardiovasc Dis, V9, P217, DOI 10.1177/1753944715597623
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010
   Niessen F, 2008, NATURE, V452, P654, DOI 10.1038/nature06663
   Querol-Ribelles JM, 2004, CHEST, V126, P1087, DOI 10.1378/chest.126.4.1087
   Shilon Y, 2003, BLOOD COAGUL FIBRIN, V14, P745, DOI 10.1097/00001721-200312000-00009
   WHO, 2020, 15 WHO
   WHO, 2020, CLIN MAN SEV AC RESP
   Wuhan Municipal Health Commission, 2020, REP NOV COR INF PNEU
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zareifopoulos N, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1296
   Zhao Y, 2020, SINGLE CELL RNA EXPR
   Zhou F., 2020, LANCET
   Zhou F, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02406-2018
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 37
TC 5
Z9 5
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD JUL 31
PY 2020
VL 10
IS 1
AR 99
DI 10.1186/s13613-020-00706-3
PG 21
WC Critical Care Medicine
SC General & Internal Medicine
GA MU1YD
UT WOS:000555468000001
PM 32737627
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tomasiewicz, K
   Piekarska, A
   Stempkowska-Rejek, J
   Serafinska, S
   Gawkowska, A
   Parczewski, M
   Niscigorska-Olsen, J
   Lapinski, TW
   Zarebska-Michaluk, D
   Kowalska, JD
   Horban, A
   Flisiak, R
AF Tomasiewicz, Krzysztof
   Piekarska, Anna
   Stempkowska-Rejek, Justyna
   Serafinska, Sylwia
   Gawkowska, Aleksandra
   Parczewski, Milosz
   Niscigorska-Olsen, Jolanta
   Lapinski, Tadeusz W.
   Zarebska-Michaluk, Dorota
   Kowalska, Justyna D.
   Horban, Andrzej
   Flisiak, Robert
TI Tocilizumab for patients with severe COVID-19: a retrospective,
   multi-center study
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; tocilizumab; interleukin-6; therapy
AB Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. Methods This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. Results Twenty-eight patients were included (19 male), with a mean age of 61.7 +/- 12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 +/- 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p < 0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p <= 0.001). Lung changes improved in 21 (84%) patients within two weeks of treatment; 19 had minimal or no changes upon final examination. Conclusions Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients.
C1 [Tomasiewicz, Krzysztof; Stempkowska-Rejek, Justyna] Med Univ Lublin, Dept Infect Dis, Lublin, Poland.
   [Piekarska, Anna] Med Univ Lodz, Dept Infect Dis & Hepatol, Lodz, Poland.
   [Serafinska, Sylwia; Gawkowska, Aleksandra] Wroclaw Med Univ, Dept Infect Dis & Hepatol, Wroclaw, Poland.
   [Parczewski, Milosz; Niscigorska-Olsen, Jolanta] Pomeranian Med Univ, Dept Infect Trop Dis & Immune Deficiency, Szczecin, Poland.
   [Lapinski, Tadeusz W.; Flisiak, Robert] Med Univ Bialystok, Dept Infect Dis & Hepatol, Bialystok, Poland.
   [Zarebska-Michaluk, Dorota] Voivodeship Hosp, Dept Infect Dis, Kielce, Poland.
   [Zarebska-Michaluk, Dorota] Jan Kochanowski Univ Humanities & Sci, Kielce, Poland.
   [Kowalska, Justyna D.; Horban, Andrzej] Med Univ Warsaw, Dept Adults Infect Dis, Warsaw, Poland.
RP Flisiak, R (corresponding author), Med Univ Lodz, Dept Infect Dis & Hepatol, Lodz, Poland.
EM robert.flisiak1@gmail.com
RI Tomasiewicz, Krzysztof/AAX-3442-2020; Zarebska-Michaluk,
   Dorota/R-1325-2019
OI Zarebska-Michaluk, Dorota/0000-0003-0938-1084
FU Polish Association of Epidemiologists; Roche Poland
FX This work was supported by Polish Association of Epidemiologists and
   Infectiologists; medical writing was supported by Roche Poland.
CR Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Capra R, 2020, EUR J INTERNAL MED, V76
   Chen J, 2017, SCI REP, V7
   Day M., 2020, BMJ, V369, pm1549, DOI 10.1136/bmj.m1549
   Filocamo G, 2020, IJID, V96
   Flisiak R, 2020, POLISH ARCH INTERN M, V130
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Jones G, 2010, CLIN MED INSIGHTS-AR, V3, P81, DOI 10.4137/CMAMD.S4864
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Morena V, 2020, EUR J INTERNAL MED, V76
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Rogalska-Poska M, 2020, POL ARCH INTERN MED, V130
   Salehi S, 2020, J THORAC IMAGING, V35
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   The World Health Organization, 2019, 159 WHO
   van der Ver AJ, 2015, FRONT MED, V2
   Vitale A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00042
   Wu Zunyou, 2020, JAMA
   Xu X, 2020, P NATL ACAD SCI, V117
   Yang X, 2020, LANCET RESP MED, V8, pE26
   Zhang PX, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0084-5
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 5
Z9 5
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-7210
EI 1744-8336
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
DI 10.1080/14787210.2020.1800453
EA JUL 2020
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MT7NQ
UT WOS:000555157600001
PM 32693650
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Marski, K
   Meaiki, A
   Shanouda, M
AF Marski, Konrad
   Meaiki, Antonio
   Shanouda, Martin
TI Levamisole-adulterated cocaine poses a concern during the COVID-19
   pandemic
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article
DE COVID-19; SARS-Cov-2; adulterants; immunocompromise; cocaine
ID AGRANULOCYTOSIS
AB During the COVID-19 pandemic caused by the SARS-CoV-2 virus patients with compromised immune systems may be particularly vulnerable. Aside from known causes of immunocompromised states one cause which may have not received due attention is consumption of adulterated recreational drugs. Levamisole-adulterated cocaine poses a particular concern given that documented risk of agranulocytosis and severe neutropenia that may put those exposed at risk of bacterial superinfections and other complications as well as potentially increasing exposure. While oustanding questions remain these risks may warrant inclusion into patient counseling activities by clinicians.
C1 [Meaiki, Antonio; Shanouda, Martin] Med Univ Lodz, Lodz, Poland.
RP Meaiki, A (corresponding author), Med Univ Lodz, Lodz, Poland.
EM konrad.marski@mail.mcgill.ca
OI Meaiki, Antonio/0000-0002-6184-5440; Marski, Konrad/0000-0001-8231-9485;
   Shanouda, Martin/0000-0002-4171-0821
CR Aggrawal A., 2014, TXB FORENSIC MED TOX
   Carlson AQ, 2014, MEDICINE, V93, P290, DOI 10.1097/MD.0000000000000090
   Chen LY, 2008, CLIN EXP IMMUNOL, V151, P174, DOI 10.1111/j.1365-2249.2007.03541.x
   Czuchlewski DR, 2010, AM J CLIN PATHOL, V133, P466, DOI 10.1309/AJCPOPQNBP5THKP1
   Lee KC, 2012, MAYO CLIN PROC, V87, P581, DOI 10.1016/j.mayocp.2012.03.010
   Qaseem A, 2009, ANN INTERN MED, V150, P287
   Raheemullah A, 2019, J CLIN RHEUMATOL
   Tallarida CS, 2014, NEUROPHARMACOLOGY, V79, P590, DOI 10.1016/j.neuropharm.2014.01.002
   Tindle HA, 2020, NICOTINE TOB RES
   World Health Organization, 2019, LIST ESS MED
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
PD JUL 31
PY 2020
VL 38
IS 4
BP 580
EP 581
DI 10.1080/10550887.2020.1800890
EA JUL 2020
PG 2
WC Substance Abuse
SC Substance Abuse
GA OH9ZI
UT WOS:000555630500001
PM 32752939
DA 2021-01-01
ER

PT J
AU Fakhar, Z
   Faramarzi, B
   Pacifico, S
   Faramarzi, S
AF Fakhar, Zeynab
   Faramarzi, Bahar
   Pacifico, Severina
   Faramarzi, Shadab
TI Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main
   protease: An in-silico perspective of therapeutic targets against
   COVID-19 pandemic
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID 19; SARS-CoV-2; main protease; anthocyanin derivatives;
   pharmacophore modeling; virtual screening; docking workflow; ADMET; MD
   simulations
ID INFLUENZA-A; ANTIVIRAL ACTIVITY; ACCURATE DOCKING; VIRUS; FLAVONOIDS;
   GLIDE; MODEL; DYNAMICS; EXTRACTS; BINDING
AB A new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and become pandemic with thousands new deaths and infected cases globally. To treat the patients with coronavirus disease (COVID-19), currently no effective drug or vaccine is available. This necessity motivated us to explore potential lead compounds based natural products targeting main protease (M-pro) enzyme of SARS-CoV-2. The M(pro)enzyme plays a key role in mediating viral replication and transcription and thus being considered as an attractive drug target. Herein, comprehensive computational investigations were performed to identify new lead compounds against main protease enzyme. In this study, the candidate anthocyanin-derived compounds from PubChem database were filtered considering antiviral characteristics of anthocyanins. The structure-based pharmacophore modeling was developed based on the co-crystallized structure of the enzyme with its biological active inhibitor. The generated hypotheses were applied for virtual screening-based PHASE Screen Score. Docking based virtual screening work flow was used to generate hit compounds using HTVS, SP and XP based Glide Gscore. The obtained hit compounds were filtered using ADMET pharmacological and physicochemical properties screening. Molecular dynamics simulations were performed to explore the binding affinities of the considered compounds. Our study identified six best anthocyanin-derived natural compounds which could be used as promising lead compounds against main protease SARS-CoV-2 virus. Communicated by Ramaswamy H. Sarma
C1 [Fakhar, Zeynab] Univ Witwatersrand, Sch Chem, Mol Sci Inst, Johannesburg, South Africa.
   [Faramarzi, Bahar] Kermanshah Univ Med Sci, Fac Med, Kermanshah, Iran.
   [Pacifico, Severina; Faramarzi, Shadab] Univ Campania Luigi Vanvitelli, Dept Environm Biol & Pharmaceut Sci, Caserta, Italy.
   [Faramarzi, Shadab] Univ Hormozgan, Dept Physiol & Breeding Fruit Trees, Bandar Abbas, Iran.
RP Faramarzi, S (corresponding author), Univ Campania Luigi Vanvitelli, Dept Environm Biol & Pharmaceut Sci, Caserta, Italy.; Faramarzi, S (corresponding author), Univ Hormozgan, Dept Physiol & Breeding Fruit Trees, Bandar Abbas, Iran.
EM shadab.faramarzi@unicampania.it
FU University of Witwatersrand; National Research Foundation (NRF) through
   the South African Research Chairs Initiative of the Department of
   Science and Technology [64799]
FX ZF thanks the University of Witwatersrand and the National Research
   Foundation (NRF) through the South African Research Chairs Initiative of
   the Department of Science and Technology for a postdoctoral research
   fellowship (running under Grant No 64799 to OQM). Professor Orde Q.
   Munro is thanked for hosting the fellowship and providing access to the
   CHPC (Centre for High Performance Computing, www.chpc.ac.za) for the
   computational resources. We are also grateful to the CHPC
   (www.chpc.ac.za) for computational resources.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   Ben-Shabat S, 2020, DRUG DELIV TRANSL RE, V10, P354, DOI 10.1007/s13346-019-00691-6
   Case D., 2018, AMBER 2018
   Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;1033::AID-JSFA595&gt;3.0.CO;2-T, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1118::AID-JSFA570&gt;3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1063::AID-JSFA605&gt;3.0.CO;2-Q, 10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9]
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dixon SL, 2006, CHEM BIOL DRUG DES, V67, P370, DOI 10.1111/j.1747-0285.2006.00384.x
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   Fakhar Z, 2017, MOL BIOSYST, V13, P1223, DOI 10.1039/c7mb00110j
   Fakhar Z, 2016, J BIOMOL STRUCT DYN, V34, P2399, DOI 10.1080/07391102.2015.1117397
   Faramarzi S, 2015, PLANT FOOD HUM NUTR, V70, P324, DOI 10.1007/s11130-015-0497-2
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Harrach MF, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4872239
   Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P2371, DOI 10.1021/ct900275y
   Hayashi K, 2003, FOOD SCI TECHNOL RES, V9, P242, DOI 10.3136/fstr.9.242
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hosokawa K, 1997, PHYTOCHEMISTRY, V45, P167, DOI 10.1016/S0031-9422(96)00775-3
   Ikuta Kazufumi, 2013, Fukushima J Med Sci, V59, P35, DOI 10.5387/fms.59.35
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JOHANSEN OP, 1991, PHYTOCHEMISTRY, V30, P4137, DOI 10.1016/0031-9422(91)83481-Y
   JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001
   KAUL TN, 1985, J MED VIROL, V15, P71, DOI 10.1002/jmv.1890150110
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Kim H, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/2606583
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Knox YM, 2001, ACTA VIROL, V45, P209
   Kong JM, 2003, PHYTOCHEMISTRY, V64, P923, DOI 10.1016/S0031-9422(03)00438-2
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Langer T, 2010, MOL INFORM, V29, P470, DOI 10.1002/minf.201000022
   Li YL, 2002, J ETHNOPHARMACOL, V79, P365, DOI 10.1016/S0378-8741(01)00410-X
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu AL, 2008, PLANTA MED, V74, P847, DOI 10.1055/s-2008-1074558
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Loving K, 2009, J COMPUT AID MOL DES, V23, P541, DOI 10.1007/s10822-009-9268-1
   Maeda-Yamamoto M, 2012, J SCI FOOD AGR, V92, P2379, DOI 10.1002/jsfa.5644
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Mukhtar M, 2008, VIRUS RES, V131, P111, DOI 10.1016/j.virusres.2007.09.008
   Muthukumaran S, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1715260, 10.1080/07391102.2020.1785331]
   NAGAI T, 1995, BIOL PHARM BULL, V18, P295, DOI 10.1248/bpb.18.295
   Nichols WG, 2008, CLIN MICROBIOL REV, V21, P274, DOI 10.1128/CMR.00045-07
   Nikolaeva-Glomb L, 2014, NAT PROD COMMUN, V9, P51
   Nolkemper S, 2006, PLANTA MED, V72, P1378, DOI 10.1055/s-2006-951719
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s
   Pour PM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01207
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rojo LE, 2012, FOOD CHEM, V131, P387, DOI 10.1016/j.foodchem.2011.08.066
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Salam NK, 2009, J CHEM INF MODEL, V49, P2356, DOI 10.1021/ci900212v
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Sithisarn P, 2013, ANTIVIR RES, V97, P41, DOI 10.1016/j.antiviral.2012.10.004
   Smeriglio A, 2016, PHYTOTHER RES, V30, P1265, DOI 10.1002/ptr.5642
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+
   Swaminathan K, 2013, ANAL BIOANAL CHEM, V405, P6563, DOI 10.1007/s00216-013-7068-x
   Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923
   Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810
   Wu QF, 2010, FITOTERAPIA, V81, P429, DOI 10.1016/j.fitote.2009.12.005
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
NR 71
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1801510
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MT7VC
UT WOS:000555177000001
PM 32741312
OA Bronze
DA 2021-01-01
ER

PT J
AU Sharma, P
   Vijayan, V
   Pant, P
   Sharma, M
   Vikram, N
   Kaur, P
   Singh, TP
   Sharma, S
AF Sharma, Pradeep
   Vijayan, Viswanathan
   Pant, Pradeep
   Sharma, Mohita
   Vikram, Naval
   Kaur, Punit
   Singh, T. P.
   Sharma, Sujata
TI Identification of potential drug candidates to combat COVID-19: a
   structural study using the main protease (mpro) of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; drug repurposing; virtual screening; MD simulation; Corona
   virus; docking; Cobicistat
ID MOLECULAR-DYNAMICS; COMPLEX; SARS
AB The recent outbreak of the SARS-CoV-2 virus leading to the disease COVID 19 has become a global pandemic that is spreading rapidly and has caused a global health emergency. Hence, there is an urgent need of the hour to discover effective drugs to control the pandemic caused by this virus. Under such conditions, it would be imperative to repurpose already known drugs which could be a quick and effective alternative to discovering new drugs. The main protease (Mpro) of SARS-COV-2 is an attractive drug target because of its essential role in the processing of the majority of the non-structural proteins which are translated from viral RNA. Herein, we report the high-throughput virtual screening and molecular docking studies to search for the best potential inhibitors against Mpro from FDA approved drugs available in the ZINC database as well as the natural compounds from the Specs database. Our studies have identified six potential inhibitors of Mpro enzyme, out of which four are commercially available FDA approved drugs (Cobicistat, Iopromide, Cangrelor, and Fortovase) and two are from Specs database of natural compounds (Hopeaphenol and Cyclosieversiodide-A). While Cobicistat and Fortovase are known as HIV drugs, Iopromide is a contrast agent and Cangrelor is an anti-platelet drug. Furthermore, molecular dynamic (MD) simulations using GROMACS were performed to calculate the stability of the top-ranked compounds in the active site of Mpro. After extensive computational studies, we propose that Cobicistat and Hopeaphenol show potential to be excellent drugs that can form the basis of treating COVID-19 disease. Communicated by Ramaswamy H. Sarma
C1 [Sharma, Pradeep; Vijayan, Viswanathan; Kaur, Punit; Singh, T. P.; Sharma, Sujata] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
   [Pant, Pradeep] Univ Duisburg, Computat Biochem, Essen, Germany.
   [Sharma, Mohita] Tirupati Eye & Res Ctr, Noida, India.
   [Vikram, Naval] All India Inst Med Sci, Dept Med, New Delhi, India.
RP Sharma, S (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
EM sujatasharma.aiims@gmail.com
RI Pant, Pradeep/ABH-1881-2020
OI Pant, Pradeep/0000-0003-3890-1958
FU Department of Science and Technology (DST), SERBDepartment of Science &
   Technology (DOST), PhilippinesDepartment of Science & Technology
   (India); All India Institute of Medical sciences (AIIMS), New Delhi
FX Dr. Pradeep Sharma and Dr. Sujata Sharma thank All India Institute of
   Medical sciences (AIIMS), New Delhi for intramural grant. Dr.
   Viswanathan V thanks Department of Science and Technology (DST), SERB
   for National Postdoctoral Fellowship. Dr T. P. Singh thanks Department
   of Science and Technology (DST) for SERB Distinguished Research
   Professorship.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2017, SCHROD REL 2017 1 LI
   [Anonymous], 2017, SCHROD REL 2017 1 MA
   [Anonymous], 1987, SPECS DATABASE
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   DeLano W. L., 2002, CCP4 NEWSLETTER PROT, V40
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hess B., 1997, J COMPUT CHEM, V18, DOI [10.1002/(SICI)1096-987X(199709)18:121463::AID-JCC43.0.CO;2-H, DOI 10.1002/(SICI)1096-987X(199709)18:121463::AID-JCC43.0.CO;2-H]
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kawata M, 2001, CHEM PHYS LETT, V340, P165, DOI 10.1016/S0009-2614(01)00393-1
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kutzner C, 2007, J COMPUT CHEM, V28, P2075, DOI 10.1002/jcc.20703
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li Y., 2020, AM J ROENTGENOLOGY, V4
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Xue HQ, 2018, INT J BIOL SCI, V14, P1232, DOI 10.7150/ijbs.24612
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 47
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1798286
EA JUL 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MT8TL
UT WOS:000555240300001
PM 32741313
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Xiong, XL
   Qu, K
   Ciazynska, KA
   Hosmillo, M
   Carter, AP
   Ebrahimi, S
   Ke, ZL
   Scheres, SHW
   Bergamaschi, L
   Grice, GL
   Zhang, Y
   Nathan, JA
   Baker, S
   James, LC
   Baxendale, HE
   Goodfellow, I
   Doffinger, R
   Briggs, JAG
   Bradley, J
   Lyons, PA
   Smith, KGC
   Toshner, M
   Elmer, A
   Ribeiro, C
   Kourampa, J
   Jose, S
   Kennet, J
   Rowlands, J
   Meadows, A
   O'Brien, C
   Rastall, R
   Crucusio, C
   Hewitt, S
   Price, J
   Calder, J
   Laura, C
   Bucke, A
   Tordesillas, H
   Harris, J
   Ruffolo, V
   Domingo, J
   Graves, B
   Butcher, H
   Caputo, D
   Le Gresley, E
   Dunmore, BJ
   Martin, J
   Legchenko, E
   Treacy, C
   Huang, C
   Wood, J
   Sutcliffe, R
   Hodgson, J
   Shih, J
   Graf, S
   Tong, Z
   Mescia, F
   Tilly, T
   O'Donnell, C
   Hunter, K
   Pointon, L
   Pond, N
   Wylot, M
   Jones, E
   Fawke, S
   Bullman, B
   Bergamaschi, L
   Turner, L
   Jarvis, I
   Omarjee, O
   De Sa, A
   Marsden, J
   Betancourt, A
   Perera, M
   Epping, M
   Richoz, N
   Bower, G
   Sharma, R
   Nice, F
   Huhn, O
   Stark, H
   Walker, N
   Stirrups, K
   Ovington, N
   Dewhust, E
   Li, E
   Papadia, S
AF Xiong, Xiaoli
   Qu, Kun
   Ciazynska, Katarzyna A.
   Hosmillo, Myra
   Carter, Andrew P.
   Ebrahimi, Soraya
   Ke, Zunlong
   Scheres, Sjors H. W.
   Bergamaschi, Laura
   Grice, Guinevere L.
   Zhang, Ying
   Nathan, James A.
   Baker, Stephen
   James, Leo C.
   Baxendale, Helen E.
   Goodfellow, Ian
   Doffinger, Rainer
   Briggs, John A. G.
   Bradley, John
   Lyons, Paul A.
   Smith, Kenneth G. C.
   Toshner, Mark
   Elmer, Anne
   Ribeiro, Carla
   Kourampa, Jenny
   Jose, Sherly
   Kennet, Jane
   Rowlands, Jane
   Meadows, Anne
   O'Brien, Criona
   Rastall, Rebecca
   Crucusio, Cherry
   Hewitt, Sarah
   Price, Jane
   Calder, Jo
   Canna, Laura
   Bucke, Ashlea
   Tordesillas, Hugo
   Harris, Julie
   Ruffolo, Valentina
   Domingo, Jason
   Graves, Barbara
   Butcher, Helen
   Caputo, Daniela
   Le Gresley, Emma
   Dunmore, Benjamin J.
   Martin, Jennifer
   Legchenko, Ekaterina
   Treacy, Carmen
   Huang, Christopher
   Wood, Jennifer
   Sutcliffe, Rachel
   Hodgson, Josh
   Shih, Joy
   Graf, Stefan
   Tong, Zhen
   Mescia, Federica
   Tilly, Tobias
   O'Donnell, Ciara
   Hunter, Kelvin
   Pointon, Linda
   Pond, Nicole
   Wylot, Marta
   Jones, Emma
   Fawke, Stuart
   Bullman, Ben
   Bergamaschi, Laura
   Turner, Lori
   Jarvis, Isobel
   Omarjee, Ommar
   De Sa, Aloka
   Marsden, Joe
   Betancourt, Ariana
   Perera, Marianne
   Epping, Maddie
   Richoz, Nathan
   Bower, Georgie
   Sharma, Rahul
   Nice, Francesca
   Huhn, Oisin
   Stark, Hannah
   Walker, Neil
   Stirrups, Kathy
   Ovington, Nigel
   Dewhust, Eleanor
   Li, Emily
   Papadia, Sofia
CA CITIID-NIHR COVID-19 BioResource C
TI A thermostable, closed SARS-CoV-2 spike protein trimer
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article; Early Access
ID BEAM-INDUCED MOTION; CRYO-EM; CORONAVIRUS; VACCINE
AB The spike (S) protein of SARS-CoV-2 mediates receptor binding and cell entry and is the dominant target of the immune system. It exhibits substantial conformational flexibility. It transitions from closed to open conformations to expose its receptor-binding site and, subsequently, from prefusion to postfusion conformations to mediate fusion of viral and cellular membranes. S-protein derivatives are components of vaccine candidates and diagnostic assays, as well as tools for research into the biology and immunology of SARS-CoV-2. Here we have designed mutations in S that allow the production of thermostable, disulfide-bonded S-protein trimers that are trapped in the closed, prefusion state. Structures of the disulfide-stabilized and non-disulfide-stabilized proteins reveal distinct closed and locked conformations of the S trimer. We demonstrate that the designed, thermostable, closed S trimer can be used in serological assays. This protein has potential applications as a reagent for serology, virology and as an immunogen.
   The SARS-CoV-2 spike glycoprotein is flexible, and its receptor-binding domain (RBD) fluctuates between open and closed conformations. Disulfide bonds are engineered into the spike ectodomain to lock the RBD in the closed state, leading to a construct with high thermostability.
C1 [Xiong, Xiaoli; Qu, Kun; Ciazynska, Katarzyna A.; Carter, Andrew P.; Ke, Zunlong; Scheres, Sjors H. W.; Briggs, John A. G.; Papadia, Sofia] Med Res Council Lab Mol Biol, Struct Studies Div, Cambridge, England.
   [Hosmillo, Myra; Goodfellow, Ian; Dewhust, Eleanor] Univ Cambridge, Dept Pathol, Div Virol, Cambridge, England.
   [Ebrahimi, Soraya; Doffinger, Rainer; Li, Emily] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England.
   [Bergamaschi, Laura; Grice, Guinevere L.; Nathan, James A.; Baker, Stephen; Stark, Hannah; Walker, Neil] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis CIT, Cambridge, England.
   [Zhang, Ying] Sun Yat Sen Univ, Affiliated Hosp 7, Precis Med Ctr, Shenzhen, Guangdong, Peoples R China.
   [Zhang, Ying] Francis Crick Inst, London, England.
   [James, Leo C.; Stirrups, Kathy] Med Res Council Lab Mol Biol, Prot & Nucle Acid Chem Div, Cambridge, England.
   [Baxendale, Helen E.; Ovington, Nigel] Royal Papworth Hosp NHS Fdn Trust, Cambridge, England.
   [Nathan, James A.; Baker, Stephen; James, Leo C.; Baxendale, Helen E.; Bradley, John; Lyons, Paul A.; Smith, Kenneth G. C.; Toshner, Mark; Harris, Julie; Ruffolo, Valentina; Domingo, Jason; Graves, Barbara; Butcher, Helen; Caputo, Daniela; Le Gresley, Emma; Dunmore, Benjamin J.; Martin, Jennifer; Legchenko, Ekaterina; Treacy, Carmen; Huang, Christopher; Wood, Jennifer; Sutcliffe, Rachel; Hodgson, Josh; Shih, Joy; Graf, Stefan; Tong, Zhen; Mescia, Federica; Tilly, Tobias; Hunter, Kelvin; Pointon, Linda; Pond, Nicole; Wylot, Marta; Jones, Emma; Fawke, Stuart; Bullman, Ben; Bergamaschi, Laura; Turner, Lori; Jarvis, Isobel; Omarjee, Ommar; De Sa, Aloka; Marsden, Joe; Betancourt, Ariana; Perera, Marianne; Epping, Maddie; Sharma, Rahul] Univ Cambridge, Dept Med, Cambridge, England.
   [Nathan, James A.; Bradley, John] Natl Inst Hlth Res Cambridge Biomed Res Ctr, Cambridge, England.
   [Baker, Stephen; James, Leo C.; Lyons, Paul A.; Smith, Kenneth G. C.; Huang, Christopher; Hodgson, Josh; Mescia, Federica; O'Donnell, Ciara; Hunter, Kelvin; Pointon, Linda; Wylot, Marta; Jones, Emma; Bullman, Ben; Bergamaschi, Laura; Turner, Lori; Omarjee, Ommar; De Sa, Aloka; Betancourt, Ariana; Epping, Maddie] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Jeffrey Cheah Biomed Ctr, Cambridge BioMed Campus, Cambridge, England.
   [Goodfellow, Ian; Doffinger, Rainer; Briggs, John A. G.; Bradley, John; Elmer, Anne; Ribeiro, Carla; Kourampa, Jenny; Jose, Sherly; Price, Jane; Domingo, Jason] Natl Inst Hlth Res Clin Res Facil, Cambridge, England.
   [Lyons, Paul A.; Kennet, Jane] Univ Cambridge, Inst Metab Sci, Metab Res Labs, Cambridge, England.
   [Smith, Kenneth G. C.; Toshner, Mark; Ribeiro, Carla; Kourampa, Jenny; Jose, Sherly; Kennet, Jane; Rowlands, Jane; Meadows, Anne; O'Brien, Criona; Rastall, Rebecca; Crucusio, Cherry; Hewitt, Sarah; Price, Jane; Calder, Jo; Canna, Laura; Bucke, Ashlea; Tordesillas, Hugo; Ruffolo, Valentina; CITIID-NIHR COVID-19 BioResource C] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
   [Elmer, Anne; O'Brien, Criona; Crucusio, Cherry; Harris, Julie] Univ Cambridge, Dept Paediat, Cambridge, England.
   [Calder, Jo; Canna, Laura; Bucke, Ashlea; Tordesillas, Hugo; Graves, Barbara; Butcher, Helen; Caputo, Daniela; Le Gresley, Emma; Perera, Marianne; Epping, Maddie; Richoz, Nathan; Bower, Georgie; Sharma, Rahul; Nice, Francesca; Huhn, Oisin; Stark, Hannah; Walker, Neil; Stirrups, Kathy; Ovington, Nigel; Dewhust, Eleanor; Li, Emily; Papadia, Sofia] Natl Inst Hlth Res BioResource, Cambridge Biomed Campus, Cambridge, England.
   [O'Donnell, Ciara; Pointon, Linda] Univ Cambridge, Dept Psychiat, Cambridge, England.
   [Jarvis, Isobel; Omarjee, Ommar; Richoz, Nathan; Bower, Georgie] Univ Cambridge, Med Res Council Lab Mol Biol, Mol Immunity Unit, Cambridge, England.
   [Nice, Francesca] Univ Cambridge, Dept Oncol, Cambridge, England.
   [Betancourt, Ariana; Huhn, Oisin] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge, England.
RP Xiong, XL; Briggs, JAG (corresponding author), Med Res Council Lab Mol Biol, Struct Studies Div, Cambridge, England.
EM xiong@mrc-lmb.cam.ac.uk; jbriggs@mrc-lmb.cam.ac.uk
RI Mescia, Federica/ABE-1176-2020; Bergamaschi, Laura/ABE-1175-2020
OI Mescia, Federica/0000-0002-2759-4027; Ciazynska, Katarzyna
   A./0000-0002-9899-2428; Scheres, Sjors/0000-0002-0462-6540
FU European Research Council (ERC) under the European Union's Horizon 2020
   research and innovation programEuropean Research Council (ERC)
   [ERC-CoG-648432 MEMBRANEFUSION]; Medical Research Council as part of
   United Kingdom Research and Innovation [MC_UP_A025_1011,
   MC_UP_A025_1013, MC_UP_1201/16, MC_U105181010]; 100 Top Talents Program
   of Sun Yat-sen University; Wellcome Trust Senior FellowshipWellcome
   Trust [207498/Z/17/Z]
FX We thank the staff of the MRC-LMB for generous support during the
   COVID-19 pandemic lockdown. We thank the staff of the MRC-LMB EM
   Facility, in particular G. Sharov and G. Cannone, for supporting EM; J.
   Grimmett and T. Darling for supporting scientific computing; and P.
   Edwards for supporting cell culture. We thank T. Nakane for advice on
   image processing, K. Dent for assistance with sample screening, A.
   Fountain for assistance with primer design, C. Lu for assistance with
   bioinformatics, F. Coscia for assistance with EM grid preparation and R.
   Aricescu for advice on protein expression. We thank D. Mallery and D.
   Paul for performing exploratory experiments. We thank the Royal Papworth
   Hospital Clinical Staff and R&D team in supporting patient and staff
   recruitment, J. Gronlund for support with sample collection and Royal
   Papworth Hospital healthy staff donors for their participation in this
   research. This study was supported by funding from the European Research
   Council (ERC) under the European Union's Horizon 2020 research and
   innovation program (ERC-CoG-648432 MEMBRANEFUSION to J.A.G.B.), the
   Medical Research Council as part of United Kingdom Research and
   Innovation (MC_UP_A025_1011 to A.P.C., MC_UP_A025_1013 to S.H.W.S.,
   MC_U105181010 to L.C.J. and MC_UP_1201/16 to J.A.G.B.), 100 Top Talents
   Program of Sun Yat-sen University (to Y.Z.) and a Wellcome Trust Senior
   Fellowship (207498/Z/17/Z to I.G.).
CR Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   CAI YH, 2020, ISCIENCE, V23, DOI DOI 10.1126/SCIENCE.ABD4251
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kidmose RT, 2019, IUCRJ, V6, P526, DOI 10.1107/S2052252519007619
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu C., 2020, VIRAL ARCHITECTURE S, DOI [10.1101/2020.03.02.972927v1, DOI 10.1101/2020.03.02.972927V1]
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   McCallum M., 2020, CLOSING CORONAVIRUS, DOI [10.1101/2020.06.03.129817v1, DOI 10.1101/2020.06.03.129817V1]
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pancera M, 2017, CURR OPIN HIV AIDS, V12, P229, DOI 10.1097/COH.0000000000000360
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Shang J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007009
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Toelzer C., 2020, UNEXPECTED FREE FATT, DOI [10.1101/2020.06.18.158584v1, DOI 10.1101/2020.06.18.158584V1]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiong XL, 2018, J VIROL, V92
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang L., 2020, BIORXIV, DOI [10.1101/2020.06.12.148726v1, DOI 10.1101/2020.06.12.148726V1]
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2020, IUCRJ, V7, P253, DOI 10.1107/S2052252520000081
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
NR 46
TC 10
Z9 10
U1 11
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
DI 10.1038/s41594-020-0478-5
EA JUL 2020
PG 19
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA MU0TK
UT WOS:000555383400001
PM 32737467
OA Bronze
DA 2021-01-01
ER

PT J
AU Su, HX
   Yao, S
   Zhao, WF
   Li, MJ
   Liu, J
   Shang, WJ
   Xie, H
   Ke, CQ
   Hu, HC
   Gao, MN
   Yu, KQ
   Liu, H
   Shen, JS
   Tang, W
   Zhang, LK
   Xiao, GF
   Ni, L
   Wang, DW
   Zuo, JP
   Jiang, HL
   Bai, F
   Wu, Y
   Ye, Y
   Xu, YC
AF Su, Hai-xia
   Yao, Sheng
   Zhao, Wen-feng
   Li, Min-jun
   Liu, Jia
   Shang, Wei-juan
   Xie, Hang
   Ke, Chang-qiang
   Hu, Hang-chen
   Gao, Mei-na
   Yu, Kun-qian
   Liu, Hong
   Shen, Jing-shan
   Tang, Wei
   Zhang, Lei-ke
   Xiao, Geng-fu
   Ni, Li
   Wang, Dao-wen
   Zuo, Jian-ping
   Jiang, Hua-liang
   Bai, Fang
   Wu, Yan
   Ye, Yang
   Xu, Ye-chun
TI Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and
   bioactive ingredients
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE SARS-CoV-2; 3CL protease; traditional Chinese medicines; Shuanghuanglian
   oral liquid; baicalin; baicalein
ID SARS; CORONAVIRUS; INHIBITORS; DESIGN; OPTIMIZATION; REDUCTION;
   DISCOVERY; BAICALEIN; AGLYCONE; MODEL
AB Human infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and there is no cure currently. The 3CL protease (3CLpro) is a highly conserved protease which is indispensable for CoVs replication, and is a promising target for development of broad-spectrum antiviral drugs. In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian preparation, a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China. We showed that either the oral liquid of Shuanghuanglian, the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-2 3CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells. Baicalin and baicalein, two ingredients of Shuanghuanglian, were characterized as the first noncovalent, nonpeptidomimetic inhibitors of SARS-CoV-2 3CLpro and exhibited potent antiviral activities in a cell-based system. Remarkably, the binding mode of baicalein with SARS-CoV-2 3CLpro determined by X-ray protein crystallography was distinctly different from those of known 3CLpro inhibitors. Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues, the crucial S1/S2 subsites and the oxyanion loop, acting as a "shield" in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site. Overall, this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target, and gains evidence supporting the in vivo studies of Shuanghuanglian oral liquid as well as two natural products for COVID-19 treatment.
C1 [Su, Hai-xia; Zhao, Wen-feng; Xie, Hang; Hu, Hang-chen; Gao, Mei-na; Yu, Kun-qian; Shen, Jing-shan; Tang, Wei; Jiang, Hua-liang; Xu, Ye-chun] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.
   [Su, Hai-xia; Yao, Sheng; Liu, Jia; Hu, Hang-chen; Gao, Mei-na; Yu, Kun-qian; Liu, Hong; Shen, Jing-shan; Tang, Wei; Zuo, Jian-ping; Jiang, Hua-liang; Ye, Yang; Xu, Ye-chun] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Yao, Sheng; Liu, Jia; Ke, Chang-qiang; Liu, Hong; Zuo, Jian-ping; Ye, Yang] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Zhao, Wen-feng] China Pharmaceut Univ, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 210009, Peoples R China.
   [Zhao, Wen-feng] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.
   [Li, Min-jun] Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai Synchrotron Radiat Facil, Shanghai 201210, Peoples R China.
   [Shang, Wei-juan; Zhang, Lei-ke; Xiao, Geng-fu; Wu, Yan] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Ni, Li; Wang, Dao-wen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol, Wuhan 430030, Peoples R China.
   [Ni, Li; Wang, Dao-wen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med, Wuhan 430030, Peoples R China.
   [Jiang, Hua-liang; Bai, Fang] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.
   [Jiang, Hua-liang; Bai, Fang; Ye, Yang] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.
RP Xu, YC (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.; Ye, Y; Xu, YC (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Ye, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Wu, Y (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.; Bai, F (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.; Bai, F; Ye, Y (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.
EM baifang@shanghaitech.edu.cn; wuyan@wh.iov.cn; yye@simm.ac.cn;
   ycxu@simm.ac.cn
FU National Key R&D Program of China [2020YFC0841400, 2017YFB0202604,
   2016YFA0502301]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [91953000, 21877122];
   International Partnership Program of Chinese Academy of Sciences
   [153631KYSB20170043]; Chinese Academy of Engineering and Jack Ma
   Foundation [2020-CMKYGG-05]; Science and Technology Commission of
   Shanghai MunicipalityScience & Technology Commission of Shanghai
   Municipality (STCSM) [20431900200]
FX The authors sincerely thank Prof. Zi-he Rao and Prof. Hai-tao Yang for
   kindly providing the initial protein sample as well as substrate for the
   enzymatic assay of 3CLpro. We also thank the staff from beamlines BL17U1
   and BL18U1 at Shanghai Synchrotron Radiation Facility. This work was
   supported by the National Key R&D Program of China (nos. 2020YFC0841400,
   2017YFB0202604, and 2016YFA0502301), the National Natural Science
   Foundation of China (nos. 91953000 and 21877122), the International
   Partnership Program of Chinese Academy of Sciences (no.
   153631KYSB20170043), Chinese Academy of Engineering and Jack Ma
   Foundation (no. 2020-CMKYGG-05), and Science and Technology Commission
   of Shanghai Municipality (no. 20431900200).
CR Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   CHEN HL, 2016, J LIAONING U TRADIT, V18, P161
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dinda B, 2017, EUR J MED CHEM, V131, P68, DOI 10.1016/j.ejmech.2017.03.004
   Ding Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep45723
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fang PH, 2020, PHARMACOL REP, V72, P13, DOI 10.1007/s43440-019-00024-x
   Gao Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21843-7
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Guan SN, 2005, INF TRADIT CHIN MED, V22, P38
   Guo J, 2017, CHIN J CLIN RATION D, V21, P161
   Guo YP, 2015, CHIN MED-UK, V10, DOI 10.1186/s13020-015-0044-y
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kenny PW, 2017, J CHEM INF MODEL, V57, P2640, DOI 10.1021/acs.jcim.7b00313
   Law AHY, 2017, J ETHNOPHARMACOL, V209, P236, DOI 10.1016/j.jep.2017.07.015
   Li M, 2014, J ETHNOPHARMACOL, V156, P210, DOI 10.1016/j.jep.2014.08.031
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang J, 2013, ACTA CHIN MED PHARM, V41, P24
   Liang S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01466
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ma QH, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040079
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Ni L, 2020, FRONT MED-PRC, V14, P210, DOI 10.1007/s11684-020-0757-x
   Pedro L, 2016, J AM SOC MASS SPECTR, V27, P1520, DOI 10.1007/s13361-016-1417-x
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   Tang YL, 2018, MICROB PATHOGENESIS, V121, P318, DOI 10.1016/j.micpath.2018.06.004
   Wang QS, 2018, NUCL SCI TECH, V29, DOI 10.1007/s41365-018-0398-9
   Wang Y H, 1995, Zhongguo Zhong Xi Yi Jie He Za Zhi, V15, P347
   Woods LA, 2016, J MED CHEM, V59, P2192, DOI 10.1021/acs.jmedchem.5b01940
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhang FX, 2018, J PHARMACEUT BIOMED, V155, P216, DOI 10.1016/j.jpba.2018.03.066
   Zhang JM, 2008, BIOORG CHEM, V36, P229, DOI 10.1016/j.bioorg.2008.01.001
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 43
TC 7
Z9 7
U1 9
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD SEP
PY 2020
VL 41
IS 9
BP 1167
EP 1177
DI 10.1038/s41401-020-0483-6
EA JUL 2020
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA NI2JS
UT WOS:000554332300002
PM 32737471
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chikhale, RV
   Gupta, VK
   Eldesoky, GE
   Wabaidur, SM
   Patil, SA
   Islam, MA
AF Chikhale, Rupesh V.
   Gupta, Vivek K.
   Eldesoky, Gaber E.
   Wabaidur, Saikh M.
   Patil, Shripad A.
   Islam, Md Ataul
TI Identification of potential anti-TMPRSS2 natural products through
   homology modelling, virtual screening and molecular dynamics simulation
   studies
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; TMPRSS2; natural products; virtual screening;
   molecular docking; molecular dynamics
ID EPITHELIAL-CELLS; HUMAN HEPSIN; IN-VITRO; PROTEIN; SERINE; CORONAVIRUS;
   PROSTATE; VIRUS; TMPRSS2; ANTIINFLUENZA
AB Recent outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a pandemic of COVID-19. The absence of a therapeutic drug and vaccine is causing severe loss of life and economy worldwide. SARS-CoV and SARS-CoV-2 employ the host cellular serine protease TMPRSS2 for spike (S) protein priming for viral entry into host cells. A potential way to reduce the initial site of SARS-CoV-2 infection may be to inhibit the activity of TMPRSS2. In the current study, the three-dimensional structure of TMPRSS2 was generated by homology modelling and subsequently validated with a number of parameters. The structure-based virtual screening of Selleckchem database was performed through 'Virtual Work Flow' (VSW) to find out potential lead-like TMPRSS2 inhibitors. Camostat and bromhexine are known TMPRSS2 inhibitor drugs, hence these were used as control molecules throughout the study. Based on better dock score, binding-free energy and binding interactions compared to the control molecules, six molecules (Neohesperidin, Myricitrin, Quercitrin, Naringin, Icariin, and Ambroxol) were found to be promising against the TMPRSS2. Binding interactions analysis revealed a number of significant binding interactions with binding site amino residues of TMPRSS2. The all-atoms molecular dynamics (MD) simulation study indicated that all proposed molecules retain inside the receptor in dynamic states. The binding energy calculated from the MD simulation trajectories also favour the strong affinity of the molecules towards the TMPRSS2. Proposed molecules belong to the bioflavonoid class of phytochemicals and are reported to possess antiviral activity, our study indicates their possible potential for application in COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Chikhale, Rupesh V.] Univ East Anglia, Sch Pharm, Norwich, Norfolk, England.
   [Gupta, Vivek K.; Patil, Shripad A.] ICMR Natl JALMA Inst Leprosy & Other Mycobacteria, Dept Biochem, Agra, Uttar Pradesh, India.
   [Eldesoky, Gaber E.; Wabaidur, Saikh M.] King Saud Univ, Coll Sci, Dept Chem, Riyadh, Saudi Arabia.
   [Islam, Md Ataul] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.
   [Islam, Md Ataul] Univ Kwazulu Natal, Sch Hlth Sci, Durban, South Africa.
   [Islam, Md Ataul] Univ Pretoria, Dept Chem Pathol, Fac Hlth Sci, Pretoria, South Africa.
RP Gupta, VK (corresponding author), ICMR Natl JALMA Inst Leprosy & Other Mycobacteria, Dept Biochem, Agra, Uttar Pradesh, India.; Islam, MA (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.; Islam, MA (corresponding author), Univ Kwazulu Natal, Sch Hlth Sci, Durban, South Africa.; Islam, MA (corresponding author), Univ Pretoria, Dept Chem Pathol, Fac Hlth Sci, Pretoria, South Africa.
EM gupta.vk2@icmr.gov.in; ataul.islam80@gmail.com
RI Islam, Dr. Md Ataul/N-1637-2013
OI Islam, Dr. Md Ataul/0000-0001-6286-6262; Chikhale,
   Rupesh/0000-0001-5622-3981
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020/161]
FX The authors are grateful to the Researchers Supporting Project No.
   (RSP-2020/161), King Saud University, Riyadh, Saudi Arabia.
CR Alam MA, 2014, ADV NUTR, V5, P404, DOI 10.3945/an.113.005603
   Albrecht HH, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0113-4
   ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1
   Bahgat MM, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-27
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Benkert P, 2009, NUCLEIC ACIDS RES, V37, pW510, DOI 10.1093/nar/gkp322
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bhowmick S, 2020, J MOL STRUCT, V1216, DOI 10.1016/j.molstruc.2020.128316
   Bhowmick S, 2020, J MOL RECOGNIT, V33, DOI 10.1002/jmr.2838
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006
   Chen XR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073362
   Chen YW, 2010, AM J PATHOL, V176, P2986, DOI 10.2353/ajpath.2010.090665
   Choi HJ, 2012, PHYTOTHER RES, V26, P462, DOI 10.1002/ptr.3529
   Cournia Z, 2017, J CHEM INF MODEL, V57, P2911, DOI 10.1021/acs.jcim.7b00564
   Cataneo AHD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52626-3
   Dobos G, 2011, CHIN J INTEGR MED, V17, P11, DOI 10.1007/s11655-011-0601-x
   Frabasile S, 2017, SCI REP-UK, V7, DOI 10.1038/srep41864
   Friedrich NO, 2017, J CHEM INF MODEL, V57, P2719, DOI 10.1021/acs.jcim.7b00505
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gupta Nivedita, 2020, Indian J Med Res, V151, P236, DOI 10.4103/ijmr.IJMR_1035_20
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774
   Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Jangam CS, 2019, COMPUT BIOL CHEM, V83, DOI 10.1016/j.compbiolchem.2019.107136
   Jernigan DB, 2015, ANNU REV MED, V66, P361, DOI 10.1146/annurev-med-010714-112311
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kerzare D, 2016, J BRAZIL CHEM SOC, V27, P1998, DOI 10.5935/0103-5053.20160090
   Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297
   Koch KR, 2018, GEM INT J GEOMATHEMA, V9, P117, DOI 10.1007/s13137-017-0101-z
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860
   Lee MG, 1996, ARCH VIROL, V141, P1979, DOI 10.1007/BF01718208
   Lin BY, 1999, CANCER RES, V59, P4180
   Liu JJ, 2006, J CHROMATOGR A, V1103, P344, DOI 10.1016/j.chroma.2005.11.036
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mariani V, 2011, PROTEINS, V79, P37, DOI 10.1002/prot.23177
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Mathpati MM, 2020, J AYURVEDA INTEGR ME, V11, P89, DOI 10.1016/j.jaim.2018.06.004
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Micronutrient Information Center, 2017, IND 3 CARB LIN PAUL
   Molecular Operating Environment (MOE), 2016, 201308 MOE CHEM COMP
   Motlhatlego KE, 2018, S AFR J BOT, V115, P301, DOI 10.1016/j.sajb.2018.02.091
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Peramo A, 2016, MOL SIMULAT, V42, P1263, DOI 10.1080/08927022.2016.1183000
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Saha RK, 2009, BIOL PHARM BULL, V32, P1188, DOI 10.1248/bpb.32.1188
   Schrodinger, 2018, LIGPREP
   Selleckchem, 2014, INH SIGN PATHW
   Semwal DK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020090
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Somoza JR, 2003, STRUCTURE, V11, P1123, DOI 10.1016/S0969-2126(03)00148-5
   Song LF, 2019, J CHEM INF MODEL, V59, P3128, DOI 10.1021/acs.jcim.9b00105
   Vetter P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m627
   Wang X., 2020, TRANSCRIPTIONAL INHI, DOI [10.20944/preprints202003.0360.v1., DOI 10.20944/PREPRINTS202003.0360.V1, 10.20944/preprints202003.0360.v1]
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weiser T., 2008, CNS NEUROSCI THER, DOI [10.1111/j.1755-5949.2007.00032.x, DOI 10.1111/J.1755-5949.2007.00032.X]
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wong G, 2017, VIROL SIN, V32, P545, DOI 10.1007/s12250-017-4057-9
   World Health Organization (WHO), 2020, 54 WHO, V2019, P2633, DOI [10.1001/jama.2020.2633, DOI 10.1001/JAMA.2020.2633]
   Xiong W, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0459-9
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yang B, 2002, EUR RESPIR J, V19, P952, DOI 10.1183/09031936.02.00253302
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 78
TC 0
Z9 0
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1798813
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MT7WA
UT WOS:000555179400001
PM 32741259
OA Bronze
DA 2021-01-01
ER

PT J
AU Vijayan, V
   Pant, P
   Vikram, N
   Kaur, P
   Singh, TP
   Sharma, S
   Sharma, P
AF Vijayan, Viswanathan
   Pant, Pradeep
   Vikram, Naval
   Kaur, Punit
   Singh, T. P.
   Sharma, Sujata
   Sharma, Pradeep
TI Identification of promising drug candidates against NSP16 of SARS-CoV-2
   through computational drug repurposing study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; drug repurposing; virtual screening; MD simulation;
   coronavirus; docking
ID MOLECULAR-DYNAMICS; FORCE-FIELD; CORONAVIRUS; PROTEIN; RNA;
   METHYLTRANSFERASE; REPLICATION; ATTENUATION; SIMULATION; PARAMETERS
AB The recent outbreak of the SARS-CoV-2 virus leading to the disease COVID 19, a global pandemic has resulted in an unprecedented loss of life and economy worldwide. Hence, there is an urgent need to discover effective drugs to control this pandemic. NSP16 is a methyltransferase that methylates the ribose 2 '-O position of the viral nucleotide. Taking advantage of the recently solved structure of NSP16 with its inhibitor, S-Adenosylmethionine, we have virtually screened FDA approved drugs, drug candidates and natural compounds. The compounds with the best docking scores were subjected to molecular dynamics simulations followed by binding free energy calculations using the MM-PBSA method. The known drugs which were identified as potential inhibitors of NSP16 from SARS-CoV-2 included DB02498, DB03909, DB03186, Galuteolin, ZINC000029416466, ZINC000026985532, and ZINC000085537017. DB02498 (Carba-nicotinamide-adenine-dinucleotide) is an approved drug which has been used since the late 1960s in intravenous form to significantly lessen withdrawal symptoms from a variety of drugs and alcohol addicts and it has the best MM-PBSA binding free energy of-12.83 +/- 0.52 kcal/mol. The second best inhibitor, Galuteolin is a natural compound that inhibits tyrosinase enzyme with MM-PBSA binding free energy value of -11.21 +/- 0.47 kcal/mol. Detailed ligand and protein interactions were analyzed and common residues across SARS-CoV, SARS-CoV-2, and MERS-CoV were identified. We propose Carba-nicotinamide-adenine-dinucleotide and Galuteolin as the potential inhibitors of NSP16. The results in this study can be used for the treatment of COVID-19 and can also form the basis of rational drug design against NSP16 of SARS-CoV-2.
C1 [Vijayan, Viswanathan; Kaur, Punit; Singh, T. P.; Sharma, Sujata; Sharma, Pradeep] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
   [Pant, Pradeep] Indian Inst Technol Delhi, Dept Chem, New Delhi, India.
   [Pant, Pradeep] Univ Duisburg Essen, Computat Biochem, Essen, Germany.
   [Vikram, Naval] All India Inst Med Sci, Dept Med, New Delhi, India.
RP Sharma, P (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
EM pradeepbdk@gmail.com
RI Pant, Pradeep/ABH-1881-2020
OI Pant, Pradeep/0000-0003-3890-1958
FU All India Institute of Medical sciences (AIIMS), New Delhi; Department
   of Science and Technology (DST), SERBDepartment of Science & Technology
   (DOST), PhilippinesDepartment of Science & Technology (India)
FX Dr. Pradeep Sharma and Dr. Sujata Sharma thank All India Institute of
   Medical sciences (AIIMS), New Delhi for intramural grant. Dr.
   Viswanathan V thanks Department of Science and Technology (DST), SERB
   for National Postdoctoral Fellowship. Dr T. P. Singh thanks Department
   of Science and Technology (DST) for SERB Distinguished Research
   Professorship. The Supercomputing Facility for Bioinformatics &
   Computational Biology (SCFBio), IIT Delhi, is gratefully acknowledged
   for providing computational support.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Bennardo F, 2020, ORAL ONCOL, V106, DOI 10.1016/j.oraloncology.2020.104659
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Case D. A., 2014, AMBER 14
   CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045
   CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   da Costa VG, 2020, ARCH VIROL, V165, P1517, DOI 10.1007/s00705-020-04628-0
   DeLano W. L., 2002, CCP4 NEWSLETTER PROT, V40
   den Boon JA, 2010, CELL HOST MICROBE, V8, P77, DOI 10.1016/j.chom.2010.06.010
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gohlke H, 2004, J COMPUT CHEM, V25, P238, DOI 10.1022/jcc.10379
   Gupta M. K., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.2020.175130032238078, DOI 10.1080/07391102.2020.175130032238078]
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Hamelberg D, 2004, J CHEM PHYS, V120, P11919, DOI 10.1063/1.1755656
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hendaus M. A., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.2020.176769132396771, DOI 10.1080/07391102.2020.176769132396771]
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Khan S. A., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.2020.175129832238094, DOI 10.1080/07391102.2020.175129832238094]
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Menachery VD, 2014, VIRUS RES, V194, P191, DOI 10.1016/j.virusres.2014.09.009
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rosas-Lemus Monica, 2020, bioRxiv, DOI 10.1101/2020.04.17.047498
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sarma P., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.2020.175358032266867, DOI 10.1080/07391102.2020.175358032266867]
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Scuccimarri R, 2020, J RHEUMATOL, V47, P783, DOI 10.3899/jrheum.200369
   Sinha S. K., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.2020.176274132345124, DOI 10.1080/07391102.2020.176274132345124]
   Sodhi M, 2020, PHARMACOTHERAPY, V40, P487, DOI 10.1002/phar.2395
   Vanquelef E, 2011, NUCLEIC ACIDS RES, V39, pW511, DOI 10.1093/nar/gkr288
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 52
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1802349
EA JUL 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MT8CR
UT WOS:000555196700001
PM 32741322
OA Bronze
DA 2021-01-01
ER

PT J
AU Langdon-Embry, M
   Papadouka, V
   Cheng, I
   Almashhadani, M
   Ternier, A
   Zucker, JR
AF Langdon-Embry, Marisa
   Papadouka, Vikki
   Cheng, Iris
   Almashhadani, Mohammed
   Ternier, Alexandra
   Zucker, Jane R.
TI Rebound in Routine Childhood Vaccine Administration Following Decline
   During the COVID-19 Pandemic - New York City, March 1-June 27, 2020
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Langdon-Embry, Marisa; Papadouka, Vikki; Cheng, Iris; Almashhadani, Mohammed; Ternier, Alexandra; Zucker, Jane R.] CDC, Bur Immunizat, New York City Dept Hlth & Mental Hyg, Atlanta, GA 30333 USA.
   [Zucker, Jane R.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Zucker, JR (corresponding author), CDC, Bur Immunizat, New York City Dept Hlth & Mental Hyg, Atlanta, GA 30333 USA.; Zucker, JR (corresponding author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM jzucker@health.nyc.gov
CR Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1
   CDC, 2019, IMM INF SYST IIS SEN
   Metroka AE, 2016, PUBLIC HEALTH REP, V131, P583, DOI 10.1177/0033354916662217
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   Zucker JR, 2020, NEW ENGL J MED, V382, P1009, DOI 10.1056/NEJMoa1912514
NR 5
TC 2
Z9 2
U1 1
U2 1
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUL 31
PY 2020
VL 69
IS 30
BP 999
EP 1001
DI 10.15585/mmwr.mm6930a3
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MT3KI
UT WOS:000554866700004
PM 32734936
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kanhed, AM
   Patel, DV
   Teli, DM
   Patel, NR
   Chhabria, MT
   Yadav, MR
AF Kanhed, Ashish M.
   Patel, Dushyant, V
   Teli, Divya M.
   Patel, Nirav R.
   Chhabria, Mahesh T.
   Yadav, Mange Ram
TI Identification of potential Mpro inhibitors for the treatment of
   COVID-19 by using systematic virtual screening approach
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; Severe acute respiratory syndrome; Mpro; Virtual
   screening; Asinex BioDesign
ID GENERAL FORCE-FIELD; CORONAVIRUS
AB TheCoronavirusDisease (COVID-19) is caused because of novel coronavirus (SARS-CoV-2) pathogen detected in China for the first time, and from there it spread across the globe creating a worldwide pandemic of severe respiratory complications. The virus requires structural and non-structural proteins for its multiplication that are produced from polyproteins obtained by translation of its genomic RNA. These polyproteins are converted into structural and non-structural proteins mainly by the main protease (Mpro). A systematic screening of a drug library (having drugs and diagnostic agents which are approved by FDA or other world authorities) and the Asinex BioDesign library was carried out using pharmacophore and sequential conformational precision level filters using the Schrodinger Suite. From the screening of approved drug library, three antiviral agents ritonavir, nelfinavir and saquinavir were predicted to be the most potent Mpro inhibitors. Apart from these pralmorelin, iodixanol and iotrolan were also identified from the systematic screening. As iodixanol and iotrolan carry some limitations, structural modifications in them could lead to stable and safer antiviral agents. Screenings of Asinex BioDesign library resulted in 20 molecules exhibiting promising interactions with the target protein Mpro. They can broadly be categorized into four classes based on the nature of the scaffold, viz. disubstituted pyrazoles, cyclic amides, pyrrolidine-based compounds and miscellaneous derivatives. These could be used as potential molecules or hits for further drug development to obtain clinically useful therapeutic agents for the treatment of COVID-19.
   [GRAPHICS]
   .
C1 [Kanhed, Ashish M.] SVKMs NMIMS Univ, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Mumbai 400056, Maharashtra, India.
   [Patel, Dushyant, V; Patel, Nirav R.] Maharaja Sayajirao Univ Baroda, Fac Pharm, Kalabhavan Campus, Vadodara 390001, Gujarat, India.
   [Teli, Divya M.; Chhabria, Mahesh T.] LM Coll Pharm, Dept Pharmaceut Chem, Ahmadabad 380009, Gujarat, India.
   [Yadav, Mange Ram] Parul Univ, Waghodia Rd, Vadodara, Gujarat, India.
RP Yadav, MR (corresponding author), Parul Univ, Waghodia Rd, Vadodara, Gujarat, India.
EM mryadav11@yahoo.co.in
OI Patel, Dushyant/0000-0003-2984-3805
FU DST-INSPIRE, New Delhi [IF-150660]; UGC, New DelhiUniversity Grants
   Commission, India [25-1/2014-15(BSR)/7-129/2007/(BSR)]
FX Dushyant V. Patel gratefully acknowledges DST-INSPIRE, New Delhi, for
   awarding Research Fellowship (IF-150660). Nirav R. Patel is thankful to
   the UGC, New Delhi, for awarding Senior Research Fellowship [F. No.
   25-1/2014-15(BSR)/7-129/2007/(BSR)].
CR Adem S., 2020, IDENTIFICATION POTEN
   [Anonymous], 2016, IMPACT
   [Anonymous], 2020, PRIME
   [Anonymous], 2016, PROT PREP WIZ
   [Anonymous], 2020, GLID
   [Anonymous], 2020, LIGPREP
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   BIXON M, 1967, TETRAHEDRON, V23, P769, DOI 10.1016/0040-4020(67)85023-3
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296
   Goede A, 2005, BIOINFORMATICS, V21, P1751, DOI 10.1093/bioinformatics/bti295
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Loving K, 2009, J COMPUT AID MOL DES, V23, P541, DOI 10.1007/s10822-009-9268-1
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Rawat R, 2020, HEROMDANALYSIS AUTOM
   Rut W., 2020, SUBSTRATE SPECIFICIT
   Salam NK, 2009, J CHEM INF MODEL, V49, P2356, DOI 10.1021/ci900212v
   Siramshetty VB, 2018, NUCLEIC ACIDS RES, V46, pD1137, DOI 10.1093/nar/gkx1088
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Woelfel R., 2020, CLIN PRESENTATION VI
   World Health Organization, 2020, 89 WHO
   Yu WB, 2012, J COMPUT CHEM, V33, P2451, DOI 10.1002/jcc.23067
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang L, 2020, XRAY STRUCTURE MAIN
NR 34
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10130-1
EA JUL 2020
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA MS5OH
UT WOS:000554324600001
PM 32737681
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gandhi, M
   Beyrer, C
   Goosby, E
AF Gandhi, Monica
   Beyrer, Chris
   Goosby, Eric
TI Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum
   of SARS-CoV-2 to Protect the Wearer
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZING ANTIBODY;
   INFLUENZA-VIRUS; INFECTION; MODEL
AB Although the benefit of population-level public facial masking to protect others during the COVID-19 pandemic has received a great deal of attention, we discuss for one of the first times the hypothesis that universal masking reduces the "inoculum" or dose of the virus for the mask-wearer, leading to more mild and asymptomatic infection manifestations. Masks, depending on type, filter out the majority of viral particles, but not all. We first discuss the near-century-old literature around the viral inoculum and severity of disease (conceptualized as the LD50 or lethal dose of the virus). We include examples of rising rates of asymptomatic infection with population-level masking, including in closed settings (e.g., cruise ships) with and without universal masking. Asymptomatic infections may be harmful for spread but could actually be beneficial if they lead to higher rates of exposure. Exposing society to SARS-CoV-2 without the unacceptable consequences of severe illness with public masking could lead to greater community-level immunity and slower spread as we await a vaccine. This theory of viral inoculum and mild or asymptomatic disease with SARS-CoV-2 in light of population-level masking has received little attention so this is one of the first perspectives to discuss the evidence supporting this theory.
C1 [Gandhi, Monica; Goosby, Eric] Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
   [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth & Human Rights, Baltimore, MD USA.
RP Gandhi, M (corresponding author), Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
EM monica.gandhi@ucsf.edu
OI Gandhi, Monica/0000-0002-7025-1994
FU NIAID/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [2P30 AI027763]
FX Funding source for this perspective: NIAID/NIH 2P30 AI027763 (Gandhi,
   P.I.)
CR [Anonymous], 2020, WHO CORONAVIRUS DIS
   [Anonymous], 2020, GUARDIAN
   [Anonymous], 2020, ASS PRESS       0622
   [Anonymous], 2020, 7 NEWS BOSTON   0429
   [Anonymous], 2020, KGW
   Bouvier NM, 2010, VIRUSES-BASEL, V2, P1530, DOI 10.3390/v20801530
   Brown JD, 2009, J VET DIAGN INVEST, V21, P437, DOI 10.1177/104063870902100404
   Buitrago-Garcia D, 2020, ROLE ASYMPTOMATIC SA, DOI [10.1101/2020.04.25.20079103, DOI 10.1101/2020.04.25.20079103]
   Casadevall A, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00015-17
   Centers for Disease Control and Prevention, 2020, REG US CLOTH FAC COV
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2139, DOI 10.1093/cid/ciaa644
   Cline S., 2020, ASS PRESS       0609
   Davis N, 2020, GUARDIAN
   Doi A., 2020, SEROPREVALENCE NOVEL, DOI [10.1101/2020.04.26.20079822, DOI 10.1101/2020.04.26.20079822, 10.1101/2020.04.26.20079822.]
   Eikenberry SE, 2020, INFECT DIS MODEL, V5, P293, DOI 10.1016/j.idm.2020.04.001
   ENGELKING HM, 1989, VIRUS RES, V13, P213, DOI 10.1016/0168-1702(89)90017-8
   Gandhi M, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa131
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Gralinski LE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005504
   Hains DS, 2020, JAMA-J AM MED ASSOC, V323, P2424, DOI 10.1001/jama.2020.8438
   Handel A, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006505
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Ing AJ, 2020, THORAX, V75, P693, DOI 10.1136/thoraxjnl-2020-215091
   Kai D, 2020, UNIVERSAL MASKING IS
   Kim R, 2010, DIS AQUAT ORGAN, V91, P23, DOI 10.3354/dao02217
   LAPATRA SE, 1993, DIS AQUAT ORGAN, V16, P115, DOI 10.3354/dao016115
   Leslie M., 2020, SCIENCE
   Lyu W, 2020, HLTH AFF MILLWOOD
   McKenney DG, 2016, VIRUS RES, V214, P80, DOI 10.1016/j.virusres.2015.12.020
   Memoli MJ, 2015, CLIN INFECT DIS, V60, P693, DOI 10.1093/cid/ciu924
   Miller DS, 2013, LAB ANIM-UK, V47, P74, DOI 10.1258/la.2012.011157
   Mizumoto K, 2020, EURO SURVEILL, V25
   Niemietz B., 2020, NEW YORK DAILY NEWS
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   San Francisco Department of Public Health, 2020, ORD HLTH OFF CIT COU
   Smereka J, 2020, ANESTH ANALG
   Stutt ROJH, 2020, P ROY SOC A-MATH PHY, V476, DOI 10.1098/rspa.2020.0376
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tao XR, 2016, J VIROL, V90, P57, DOI 10.1128/JVI.02009-15
   Virlogeux V, 2015, EPIDEMIOLOGY, V26, P666, DOI 10.1097/EDE.0000000000000339
   Ward A., 2020, VOX             0518
   World Health Organization, 2020, ADV US MASKS CONT CO
   Yang RR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10182
   Yuan S, 2020, CLIN INFECT DIS
NR 47
TC 9
Z9 9
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2020
VL 35
IS 10
BP 3063
EP 3066
DI 10.1007/s11606-020-06067-8
EA JUL 2020
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA OC9OG
UT WOS:000554341200002
PM 32737790
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Canarutto, D
   Del Barba, P
   Di Frenna, M
   Del Tedesco, F
   Pajno, R
   Guarneri, MP
   Barera, G
AF Canarutto, Daniele
   Del Barba, Paolo
   Di Frenna, Marianna
   Del Tedesco, Federica
   Pajno, Roberta
   Guarneri, Maria Pia
   Barera, Graziano
TI Prolonged asymptomatic SARS-CoV-2 infection in a child receiving
   immunosuppressive therapy
SO PEDIATRIC PULMONOLOGY
LA English
DT Letter
C1 [Canarutto, Daniele; Del Barba, Paolo; Di Frenna, Marianna; Del Tedesco, Federica; Pajno, Roberta; Guarneri, Maria Pia; Barera, Graziano] IRCCS Osped San Raffaele, Pediat Dept, Milan, Italy.
   [Canarutto, Daniele; Del Tedesco, Federica; Barera, Graziano] Univ Vita Salute San Raffaele, Fac Med & Surg, Milan, Italy.
   [Canarutto, Daniele] IRCCS Osped San Raffaele, Pediat Immunohematol Unit, Milan, Italy.
   [Canarutto, Daniele] IRCCS Osped San Raffaele, BMT Program, Milan, Italy.
RP Canarutto, D (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.
EM canarutto.daniele@hsr.it
OI , Daniele/0000-0001-6999-8479
CR Del Barba P, 2020, PEDIATR PULM, V55, P1879, DOI 10.1002/ppul.24895
   Lin JL, 2020, PEDIATR PULM, V55, pE6, DOI 10.1002/ppul.24763
   Sieni E, 2020, BRIT J HAEMATOL, V189, pE222, DOI 10.1111/bjh.16781
   World Health Organization, 2020, HOM CAR PAT COVID 19
   Yilmaz O, 2020, PEDIATR PULM, V55, P1598, DOI 10.1002/ppul.24800
NR 5
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2020
VL 55
IS 10
BP 2504
EP 2505
DI 10.1002/ppul.24983
EA JUL 2020
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA NO0SF
UT WOS:000554037200001
PM 32735761
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Parente, A
   Manzia, TM
   Angelico, R
   Tirotta, F
   Muiesan, P
   Tisone, G
   dei Malatesta, MF
AF Parente, Alessandro
   Manzia, Tommaso Maria
   Angelico, Roberta
   Tirotta, Fabio
   Muiesan, Paolo
   Tisone, Giuseppe
   dei Malatesta, Marialuisa Framarino
TI COVID-19, liver transplant, and immunosuppression: Allies or foes?
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE COVID-19; liver transplant; liver transplantation
ID REPLICATION
AB Liver transplant (LT) recipients are considered at a particularly high risk for developing critical COVID-19 infection. To date, available data are heterogeneous and scarce and mortality in LT recipients seems to be higher compared to normal population, but whether this is caused by altered immunological status, immunosuppression (IS), or underlying comorbidities has not yet been fully clarified. Some evidences show that IS might play a role in the pathophysiology of this new disease. We searched all available data regarding LT recipients infected by COVID-19, focusing on the role of IS. To date, 244 LT recipients have been reported as COVID-19-positive. Trends among transplant physicians are to reduce overall IS, especially antimetabolite drugs, but the current available observations are still not enough to build strong evidences for recommendation and IS should be meticulously tailored case by case.
C1 [Parente, Alessandro; Tirotta, Fabio; Muiesan, Paolo] Univ Hosp Birmingham NHS Fdn Trust, Liver Unit, Birmingham, W Midlands, England.
   [Parente, Alessandro; Manzia, Tommaso Maria; Angelico, Roberta; Tisone, Giuseppe] Tor Vergata Univ Rome, Dept Hepatobiliary Surg, Rome, Italy.
   [Parente, Alessandro; Manzia, Tommaso Maria; Angelico, Roberta; Tisone, Giuseppe] Tor Vergata Univ Rome, Transplant Unit, Rome, Italy.
   [dei Malatesta, Marialuisa Framarino] Univ Sapienza Rome, Policlin Umberto I, Dept Gynecol Obstet & Urol Sci, Rome, Italy.
RP Parente, A (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Liver Unit, Mindelsohn Way, Birmingham B15 2TH, W Midlands, England.
EM aleparen@gmail.com
RI Parente, Alessandro/ABC-5073-2020; Manzia, Tommaso Maria/K-4467-2018
OI Parente, Alessandro/0000-0001-5506-224X; Framarino-dei-Malatesta,
   Marialuisa/0000-0001-7824-7511; Manzia, Tommaso
   Maria/0000-0002-4636-3478
CR Belli LS, 2020, LANCET GASTROENTEROL, V5, P724, DOI 10.1016/S2468-1253(20)30183-7
   Benitez C, 2013, HEPATOLOGY, V58, P1824, DOI 10.1002/hep.26426
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Gao F, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13335
   Grigoriu S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001492
   Hammami MB, 2020, AM J TRANSPLANT, V20, P2254, DOI 10.1111/ajt.15985
   Hoek RAS, 2020, TRANSPL INT, V33, P1099, DOI 10.1111/tri.13662
   Hann AJ, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13352
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Lagana SM, 2020, ARCH PATHOL LAB MED, V144, P929, DOI 10.5858/arpa.2020-0186-SA
   Lee BT, 2020, GASTROENTEROLOGY
   Ma-Lauer Y, 2020, ANTIVIR RES, V173, DOI 10.1016/j.antiviral.2019.104620
   Manzia TM, 2018, LIVER TRANSPLANT, V24, P1199, DOI 10.1002/lt.25293
   Massoumi H, 2020, LIVER TRANSPLANT, V26, P1198, DOI 10.1002/lt.25811
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Muller H, 2020, AM J TRANSPLANT, V20, P3255, DOI 10.1111/ajt.16107
   Patrono D, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13353
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Verma A, 2020, LIVER INT, V40, P1972, DOI 10.1111/liv.14552
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   Yi SG, 2020, TRANSPLANTATION, V104, P2208, DOI 10.1097/TP.0000000000003339
NR 31
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13417
DI 10.1111/tid.13417
EA JUL 2020
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA MS0DX
UT WOS:000553958800001
PM 32666588
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Desmazes-Dufeu, N
   Coltey, B
   Amari, L
   Gouitaa, M
   Touzery, C
   Reynaud-Gaubert, M
   Chanez, P
   Cassir, N
AF Desmazes-Dufeu, Nadine
   Coltey, Berengere
   Amari, Lyria
   Gouitaa, Marion
   Touzery, Camille
   Reynaud-Gaubert, Martine
   Chanez, Pascal
   Cassir, Nadim
TI Discordant courses of COVID-19 in a cohabiting couple of lung transplant
   recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE COVID-19; cystic fibrosis; immunosuppression; lung transplant;
   SARS-CoV-2; viral pneumonia
AB COVID-19 is a novel infectious disease caused by SARS-CoV-2 that emerged in late 2019 and which is now a pandemic. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 due to their chronic use of immunosuppressive drugs (ISDs) and to their associated conditions. Scarce data are available on the optimized management of ISDs in these patients and on its impact on presentation, clinical course, viral shedding, and outcome. We report here two cases of COVID-19 in a cohabiting couple of lung transplant recipients for cystic fibrosis, who had different ISDs management and who developed discordant courses of their disease. Our findings suggest that the degree of their immunosuppression might be a reason for their different course and that ISDs might prove partially protective.
C1 [Desmazes-Dufeu, Nadine; Coltey, Berengere; Amari, Lyria; Reynaud-Gaubert, Martine] Hop Nord Marseille, Assistance Publ Hop Marseille AP HM, Serv Pneumol, Equipe Transplantat Pulmonaire, Marseille, France.
   [Gouitaa, Marion; Chanez, Pascal] Aix Marseille Univ, AP HM, Clin Bronches Allergie & Sommeil, Marseille C2VN Ctr INSERM INRAE UMR1062, Marseille, France.
   [Touzery, Camille] Hop Nord Marseille, AP HM, Serv Radiol, Marseille, France.
   [Reynaud-Gaubert, Martine; Cassir, Nadim] Aix Marseille Univ UM63, Assistance Publ Hop Marseille AP HM, Microbes Evolut Phylogeny & Infect MEI, Inst Rech Dev IRD 198, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
RP Cassir, N (corresponding author), Aix Marseille Univ UM63, Assistance Publ Hop Marseille AP HM, Microbes Evolut Phylogeny & Infect MEI, Inst Rech Dev IRD 198, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
EM cassirnadim@gmail.com
OI Cassir, Nadim/0000-0002-5276-6986
CR Aigner C, 2020, J HEART LUNG TRANSPL, V39, P610, DOI 10.1016/j.healun.2020.04.004
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Cosgriff R, 2020, J CYST FIBROS, V19, P355, DOI 10.1016/j.jcf.2020.04.012
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoek RAS, 2020, TRANSPL INT, V33, P1099, DOI 10.1111/tri.13662
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Latif F, 2020, JAMA CARDIOL
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   LI PW, 2020, EUR J PREV CARDIOL, V27
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Travi G, 2020, AM J TRANSPLANT, V20, P2628, DOI 10.1111/ajt.16069
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   Wan SX, 2020, BRIT J HAEMATOL, V189, P428, DOI 10.1111/bjh.16659
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13410
DI 10.1111/tid.13410
EA JUL 2020
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA MS0EZ
UT WOS:000553961600001
PM 32654244
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ren, WL
   Sun, H
   Gao, GF
   Chen, JX
   Sun, S
   Zhao, RQ
   Gao, G
   Hu, YL
   Zhao, G
   Chen, YX
   Jin, X
   Fang, F
   Chen, JG
   Wang, Q
   Gong, ST
   Gao, W
   Sun, YF
   Su, JC
   He, AL
   Cheng, X
   Li, M
   Xia, CX
   Li, MH
   Sun, L
AF Ren, Wenlin
   Sun, Hunter
   Gao, George F.
   Chen, Jianxin
   Sun, Sean
   Zhao, Rongqing
   Gao, Guang
   Hu, Yalin
   Zhao, Gan
   Chen, Yuxin
   Jin, Xia
   Fang, Feng
   Chen, Jinggong
   Wang, Qi
   Gong, Sitao
   Gao, Wen
   Sun, Yufei
   Su, Junchi
   He, Ailiang
   Cheng, Xin
   Li, Min
   Xia, Chenxi
   Li, Maohua
   Sun, Le
TI Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of
   neutralizing responses in nonhuman primates
SO VACCINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Spike protein; Vaccine
AB The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000 confirmed cases and over 126,000 deaths worldwide. In this study, we examined the immunogenicity of CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein in mice, rabbits, and monkeys as a potential candidate for a COVID-19 vaccine. We demonstrate that the S1-Fc fusion protein is extremely immunogenic, as evidenced by strong antibody titers observed by day 7. Strong virus neutralizing activity was observed on day 14 in rabbits immunized with the S1-Fc fusion protein using a pseudovirus neutralization assay. Most importantly, in <20 days and three injections of the S1-Fc fusion protein, two monkeys developed higher virus neutralizing titers than a recovered COVID-19 patient in a live SARS-CoV-2 infection assay. Our data strongly suggests that the CHO-expressed SARS-CoV-2 S1-Fc recombinant protein could be a strong candidate for vaccine development against COVID-19. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Sun, Hunter; Sun, Sean; Zhao, Rongqing; Gao, Guang; Sun, Yufei; Su, Junchi; Sun, Le] AnyGo Technol Co LTD, D1117 Xinhua Int Plaza,89 Dayangfan Rd, Beijing, Peoples R China.
   [Ren, Wenlin; Fang, Feng; Wang, Qi; Gong, Sitao; Xia, Chenxi; Li, Maohua; Sun, Le] AbMax Biotechnol Co LTD, BDA, 99 Kechuang 14th St, Beijing 101111, Peoples R China.
   [Gao, George F.] Chinese Acad Sci, Inst Microbiol, Beijing, Peoples R China.
   [Chen, Jianxin; Chen, Jinggong; Gao, Wen; He, Ailiang] ZhenGe Biotechnol Co LTD, Shanghai, Peoples R China.
   [Hu, Yalin] SinoVac, Beijing, Peoples R China.
   [Zhao, Gan; Cheng, Xin] Advaccine Suzhou Biopharmaceut Co LTD, Suzhou, Jiangsu, Peoples R China.
   [Chen, Yuxin] Nanjing Univ, Dept Lab Medine, Med Sch, Nanjing 210008, Jiangsu, Peoples R China.
   [Jin, Xia; Li, Min] Fudan Univ, Coll Publ Hlth, Shanghai, Peoples R China.
RP Li, MH; Sun, L (corresponding author), AbMax Biotechnol Co LTD, BDA, 99 Kechuang 14th St, Beijing 101111, Peoples R China.
EM limh@antibodychina.com; sunl@antibodychina.com
FU Beijing Science and Technology Commission [Z201100001020002]; Bill &
   Melinda Gates FoundationBill & Melinda Gates Foundation [INV-005839]
FX This work is supported by Research Grants from Beijing Science and
   Technology Commission (Z201100001020002), and Bill & Melinda Gates
   Foundation (INV-005839) to Le Sun. The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. We thank Dr. Qiang Gao and his team from
   SinoVac for performing the live SARS-CoV-2 neutralizing assay, Dr.
   Jianqing Xu at Fudan Univ. for providing the ACE2-transfected HEK 293T
   cells, Dr. Pinliang Hu at Beijing Beyond Biotech. for purification of
   S1-Fc protein.
CR Ahmed SF, 2020, BIORXIV
   Amanat F, 2020, SEROLOGICAL ASSAY DE
   Chan JF-W, 2020, LANCET
   Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   Grant O. C., 2020, BIORXIV
   Huang C, 2020, LANCET
   Jefferis R, 2007, EXPERT OPIN BIOL TH, V7, P1401, DOI 10.1517/14712598.7.9.1401
   Lecrenier N, 2018, EXPERT REV VACCINES, V17, P619, DOI 10.1080/14760584.2018.1495565
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li X., 2020, J MED VIROL
   Miller J, 2001, PERCEPT PSYCHOPHYS, V63, P1399, DOI 10.3758/BF03194551
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhao R, 2020, CLIN INFECT DIS OFFI
NR 19
TC 4
Z9 4
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 31
PY 2020
VL 38
IS 35
BP 5653
EP 5658
DI 10.1016/j.vaccine.2020.06.066
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MO6KC
UT WOS:000551631300016
PM 32651113
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mercado, NB
   Zahn, R
   Wegmann, F
   Loos, C
   Chandrashekar, A
   Yu, JY
   Liu, JY
   Peter, L
   McMahan, K
   Tostanoski, LH
   He, X
   Martinez, DR
   Rutten, L
   Bos, R
   van Manen, D
   Vellinga, J
   Custers, J
   Langedijk, JP
   Kwaks, T
   Bakkers, MJG
   Zuijdgeest, D
   Huber, SKR
   Atyeo, C
   Fischinger, S
   Burke, JS
   Feldman, J
   Hauser, BM
   Caradonna, TM
   Bondzie, EA
   Dagotto, G
   Gebre, MS
   Hoffman, E
   Jacob-Dolan, C
   Kirilova, M
   Li, ZF
   Lin, ZJ
   Mahrokhian, SH
   Maxfield, LF
   Nampanya, F
   Nityanandam, R
   Nkolola, JP
   Patel, S
   Ventura, JD
   Verrington, K
   Wan, HH
   Pessaint, L
   Van Ry, A
   Blade, K
   Strasbaugh, A
   Cabus, M
   Brown, R
   Cook, A
   Zouantchangadou, S
   Teow, E
   Andersen, H
   Lewis, MG
   Cai, YF
   Chen, B
   Schmidt, AG
   Reeves, RK
   Baric, RS
   Lauffenburger, DA
   Alter, G
   Stoffels, P
   Mammen, M
   Van Hoof, J
   Schuitemaker, H
   Barouch, DH
AF Mercado, Noe B.
   Zahn, Roland
   Wegmann, Frank
   Loos, Carolin
   Chandrashekar, Abishek
   Yu, Jingyou
   Liu, Jinyan
   Peter, Lauren
   McMahan, Katherine
   Tostanoski, Lisa H.
   He, Xuan
   Martinez, David R.
   Rutten, Lucy
   Bos, Rinke
   van Manen, Danielle
   Vellinga, Jort
   Custers, Jerome
   Langedijk, Johannes P.
   Kwaks, Ted
   Bakkers, Mark J. G.
   Zuijdgeest, David
   Rosendahl Huber, Sietske K.
   Atyeo, Caroline
   Fischinger, Stephanie
   Burke, John S.
   Feldman, Jared
   Hauser, Blake M.
   Caradonna, Timothy M.
   Bondzie, Esther A.
   Dagotto, Gabriel
   Gebre, Makda S.
   Hoffman, Emily
   Jacob-Dolan, Catherine
   Kirilova, Marinela
   Li, Zhenfeng
   Lin, Zijin
   Mahrokhian, Shant H.
   Maxfield, Lori F.
   Nampanya, Felix
   Nityanandam, Ramya
   Nkolola, Joseph P.
   Patel, Shivani
   Ventura, John D.
   Verrington, Kaylee
   Wan, Huahua
   Pessaint, Laurent
   Van Ry, Alex
   Blade, Kelvin
   Strasbaugh, Amanda
   Cabus, Mehtap
   Brown, Renita
   Cook, Anthony
   Zouantchangadou, Serge
   Teow, Elyse
   Andersen, Hanne
   Lewis, Mark G.
   Cai, Yongfei
   Chen, Bing
   Schmidt, Aaron G.
   Reeves, R. Keith
   Baric, Ralph S.
   Lauffenburger, Douglas A.
   Alter, Galit
   Stoffels, Paul
   Mammen, Mathai
   Van Hoof, Johan
   Schuitemaker, Hanneke
   Barouch, Dan H.
TI Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
SO NATURE
LA English
DT Article; Early Access
ID LENGTH INFECTIOUS CDNA; REVERSE GENETICS; CORONAVIRUS; IMMUNOGENICITY;
   SPIKE; ANTIBODIES; PNEUMONIA; EFFICACY; IMMUNITY; CHINA
AB A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic(1-8). For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes(9,10). The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
   The protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccine expressing the SARS-CoV-2 spike protein in non-human primates is demonstrated.
C1 [Mercado, Noe B.; Chandrashekar, Abishek; Yu, Jingyou; Liu, Jinyan; Peter, Lauren; McMahan, Katherine; Tostanoski, Lisa H.; He, Xuan; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; Hoffman, Emily; Jacob-Dolan, Catherine; Kirilova, Marinela; Li, Zhenfeng; Lin, Zijin; Mahrokhian, Shant H.; Maxfield, Lori F.; Nampanya, Felix; Nityanandam, Ramya; Nkolola, Joseph P.; Patel, Shivani; Ventura, John D.; Verrington, Kaylee; Wan, Huahua; Reeves, R. Keith; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
   [Zahn, Roland; Wegmann, Frank; Rutten, Lucy; Bos, Rinke; van Manen, Danielle; Vellinga, Jort; Custers, Jerome; Langedijk, Johannes P.; Kwaks, Ted; Bakkers, Mark J. G.; Zuijdgeest, David; Rosendahl Huber, Sietske K.; Stoffels, Paul; Mammen, Mathai; Van Hoof, Johan; Schuitemaker, Hanneke] Janssen Vaccines & Prevent BV, Leiden, Netherlands.
   [Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
   [Loos, Carolin; Lauffenburger, Douglas A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Martinez, David R.; Baric, Ralph S.] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Atyeo, Caroline; Fischinger, Stephanie; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Dagotto, Gabriel; Gebre, Makda S.; Jacob-Dolan, Catherine; Schmidt, Aaron G.; Barouch, Dan H.] Harvard Med Sch, Boston, MA 02115 USA.
   [Pessaint, Laurent; Van Ry, Alex; Blade, Kelvin; Strasbaugh, Amanda; Cabus, Mehtap; Brown, Renita; Cook, Anthony; Zouantchangadou, Serge; Teow, Elyse; Andersen, Hanne; Lewis, Mark G.] Bioqual, Rockville, MD USA.
   [Cai, Yongfei; Chen, Bing] Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
   [Chen, Bing; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA.
RP Barouch, DH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA.
EM dbarouch@bidmc.harvard.edu
RI Cai, Yongfei/ABI-7748-2020; Mercado, Noe/ABE-8247-2020; Chandrashekar,
   Abishek/P-2610-2019
OI Cai, Yongfei/0000-0002-3628-3802; Mercado, Noe/0000-0001-7769-7326;
   Chandrashekar, Abishek/0000-0001-7821-5552; Hauser,
   Blake/0000-0002-0100-1684; Jacob-Dolan, Catherine/0000-0001-6641-0342;
   Mahrokhian, Shant/0000-0003-4094-8739; Gebre, Makda/0000-0001-8520-2178;
   Tostanoski, Lisa/0000-0001-9255-5684; Caradonna,
   Timothy/0000-0001-7138-4441
FU Department of Health and Human Services Biomedical Advanced Research and
   Development Authority (BARDA) [HHS0100201700018C]; Janssen Vaccines
   Prevention BV; Ragon Institute of MGH, MIT, and Harvard; Mark and Lisa
   Schwartz Foundation; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [OD024917, AI129797, AI124377, AI128751, AI126603, AI007151,
   AI152296, AI146779, 272201700036I-0-759301900131-1, AI100625, AI110700,
   AI132178, AI149644, AI108197]; Burroughs Wellcome Fund Postdoctoral
   Enrichment Program AwardBurroughs Wellcome Fund; Massachusetts
   Consortium on Pathogen Readiness (MassCPR)
FX We thank S. Blokland, Y. Choi, K. de Boer, I. de los Rios Oakes, E. van
   der Helm, D. Spek, I. Swart, M. Koning, A. Brandjes, N. van Dijk, A. de
   Wilde, M. Navis, R. van Schie, J. Verhagen, R. Vogels, R. van der Vlugt,
   A. Roos Broekhuijsen, B. Bart, J. Velasco, B. Finneyfrock, C. Shaver, J.
   Yalley-Ogunro, D. Wesemann, N. Kordana, M. Lifton, E. Borducchi, M.
   Silva, A. Richardson and C. Caron for advice, assistance and reagents.
   This project was funded in part by the Department of Health and Human
   Services Biomedical Advanced Research and Development Authority (BARDA)
   under contract HHS0100201700018C. We also acknowledge support from
   Janssen Vaccines & Prevention BV, the Ragon Institute of MGH, MIT, and
   Harvard, Mark and Lisa Schwartz Foundation, Massachusetts Consortium on
   Pathogen Readiness (MassCPR), and the National Institutes of Health
   (OD024917, AI129797, AI124377, AI128751, AI126603 to D.H.B.; AI007151
   and AI152296 to D.R.M.; AI146779 to A.G.S.;
   272201700036I-0-759301900131-1, AI100625, AI110700, AI132178, AI149644,
   AI108197 to R.S.B.). We also acknowledge a Burroughs Wellcome Fund
   Postdoctoral Enrichment Program Award to D.R.M.
CR Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06
   Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016
   Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   Baden LR, 2013, J INFECT DIS, V207, P240, DOI 10.1093/infdis/jis670
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]
   Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886
   Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025
   Brown EP, 2017, J IMMUNOL METHODS, V443, P33, DOI 10.1016/j.jim.2017.01.010
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Cox F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202820
   Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 31
Z9 29
U1 10
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2607-z
EA JUL 2020
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ7QM
UT WOS:000577298500002
PM 32731257
OA Bronze
DA 2021-01-01
ER

PT J
AU van Doremalen, N
   Lambe, T
   Spencer, A
   Belij-Rammerstorfer, S
   Purushotham, JN
   Port, JR
   Avanzato, VA
   Bushmaker, T
   Flaxman, A
   Ulaszewska, M
   Feldmann, F
   Allen, ER
   Sharpe, H
   Schulz, J
   Holbrook, M
   Okumura, A
   Meade-White, K
   Perez-Perez, L
   Edwards, NJ
   Wright, D
   Bissett, C
   Gilbride, C
   Williamson, BN
   Rosenke, R
   Long, D
   Ishwarbhai, A
   Kailath, R
   Rose, L
   Morris, S
   Powers, C
   Lovaglio, J
   Hanley, PW
   Scott, D
   Saturday, G
   de Wit, E
   Gilbert, SC
   Munster, VJ
AF van Doremalen, Neeltje
   Lambe, Teresa
   Spencer, Alexandra
   Belij-Rammerstorfer, Sandra
   Purushotham, Jyothi N.
   Port, Julia R.
   Avanzato, Victoria A.
   Bushmaker, Trenton
   Flaxman, Amy
   Ulaszewska, Marta
   Feldmann, Friederike
   Allen, Elizabeth R.
   Sharpe, Hannah
   Schulz, Jonathan
   Holbrook, Myndi
   Okumura, Atsushi
   Meade-White, Kimberly
   Perez-Perez, Lizzette
   Edwards, Nick J.
   Wright, Daniel
   Bissett, Cameron
   Gilbride, Ciaran
   Williamson, Brandi N.
   Rosenke, Rebecca
   Long, Dan
   Ishwarbhai, Alka
   Kailath, Reshma
   Rose, Louisa
   Morris, Susan
   Powers, Claire
   Lovaglio, Jamie
   Hanley, Patrick W.
   Scott, Dana
   Saturday, Greg
   de Wit, Emmie
   Gilbert, Sarah C.
   Munster, Vincent J.
TI ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
SO NATURE
LA English
DT Article; Early Access
ID ACUTE RESPIRATORY SYNDROME; IMMUNIZATION; MICE
AB The ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 induces an immune response in rhesus macaques and leads to reduced SARS-CoV-2 viral loads in respiratory tissues and an absence of pneumonia, but not to a reduction in nasal virus shedding, compared with unvaccinated animals.
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019(1,2)and is responsible for the coronavirus disease 2019 (COVID-19) pandemic(3). Vaccines are an essential countermeasure and are urgently needed to control the pandemic(4). Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS-CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated by the profiling of the IgG subclass and the expression of cytokines. Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques. We observed a significantly reduced viral load in the bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques that were challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated SARS-CoV-2-infected animals. However, there was no difference in nasal shedding between vaccinated and control SARS-CoV-2-infected macaques. Notably, we found no evidence of immune-enhanced disease after viral challenge in vaccinated SARS-CoV-2-infected animals. The safety, immunogenicity and efficacy profiles of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomized controlled clinical trials in humans.
C1 [van Doremalen, Neeltje; Purushotham, Jyothi N.; Port, Julia R.; Avanzato, Victoria A.; Bushmaker, Trenton; Schulz, Jonathan; Holbrook, Myndi; Okumura, Atsushi; Meade-White, Kimberly; Perez-Perez, Lizzette; Williamson, Brandi N.; de Wit, Emmie; Munster, Vincent J.] NIAID, Lab Virol, NIH, Hamilton, MT 59840 USA.
   [Lambe, Teresa; Spencer, Alexandra; Belij-Rammerstorfer, Sandra; Purushotham, Jyothi N.; Flaxman, Amy; Ulaszewska, Marta; Allen, Elizabeth R.; Sharpe, Hannah; Edwards, Nick J.; Wright, Daniel; Bissett, Cameron; Gilbride, Ciaran; Ishwarbhai, Alka; Kailath, Reshma; Rose, Louisa; Morris, Susan; Powers, Claire; Gilbert, Sarah C.] Univ Oxford, Jenner Inst, Oxford, England.
   [Feldmann, Friederike; Rosenke, Rebecca; Long, Dan; Lovaglio, Jamie; Hanley, Patrick W.; Scott, Dana; Saturday, Greg] NIAID, Rocky Mt Vet Branch, NIH, Hamilton, MT USA.
RP Munster, VJ (corresponding author), NIAID, Lab Virol, NIH, Hamilton, MT 59840 USA.; Gilbert, SC (corresponding author), Univ Oxford, Jenner Inst, Oxford, England.
EM sarah.gilbert@ndm.ox.ac.uk; vincent.munster@nih.gov
RI ; Lambe, Teresa/E-5733-2016; Munster, Vincent/I-7607-2018
OI Port, Julia Rebecca/0000-0002-0489-6591; Lambe,
   Teresa/0000-0001-7711-897X; Bissett, Cameron/0000-0003-3345-663X; Van
   Doremalen, Neeltje/0000-0003-4368-6359; Allen,
   Elizabeth/0000-0002-6406-4834; Wright, Daniel/0000-0002-8114-1838;
   Munster, Vincent/0000-0002-2288-3196; Spencer,
   Alexandra/0000-0001-7958-6961; Sharpe, Hannah/0000-0002-1194-2429
FU Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases (NIAID), National Institutes of Health (NIH)
   [1ZIAAI001179-01]; Department of Health and Social Care
FX We thank O. Abiona, B. Bailes, A. Carmody, K. Corbett, K. Cordova, J.
   Faris, H. Feldmann, S. Gerber, B. Graham, E. Haddock, R. Kissinger, M.
   Jones, M. Marsh, K. Menk, A. Mora, S. Seifert, L. Shupert, B. Smith, N.
   Thornburg, A. Weidow, M. Woods and K. C. Yinda for their assistance
   during this study. This work was supported by the Intramural Research
   Program of the National Institute of Allergy and Infectious Diseases
   (NIAID), National Institutes of Health (NIH) (1ZIAAI001179-01) and the
   Department of Health and Social Care using UK Aid funding managed by the
   NIHR.
CR Bewig B, 2000, BIOTECHNIQUES, V28, P870, DOI 10.2144/00285bm08
   Bliss CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21630-4
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   WHO, 2020, 113 WHO
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 52
Z9 49
U1 15
U2 15
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2608-y
EA JUL 2020
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ7QM
UT WOS:000577298500001
PM 32731258
OA Other Gold
DA 2021-01-01
ER

PT J
AU Xu, RD
   Shi, MF
   Li, J
   Song, P
   Li, N
AF Xu, Ruodan
   Shi, Mingfei
   Li, Jing
   Song, Ping
   Li, Ning
TI Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression
   System
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; virus-like particles; self-assemble; release
ID CELLS
AB Virus-like particle (VLP) is a self-assembled nanostructure incorporating key viral structural proteins. VLP resembles molecular and morphological features of authentic viruses but is non-infectious and non-replicating due to lack of genetic materials. Successful applications of VLP has been shown in vaccinological and virological research. As an accessibly safe and relevant substitute of naturally pathogenic viruses, the construction of SARS-CoV-2 VLPs is much in demand in the ongoing fight against 2019 Coronavirus disease (COVID-19) pandemics. In the current study, using mammalian expression system, which is advantageous in maintaining correct protein glycosylation patterns, we efficiently constructed SARS-CoV-2 VLPs. We showed that among four SARS-CoV-2 structural proteins, expression of membrane protein (M) and small envelope protein (E) are essential for efficient formation and release of SARS-CoV-2 VLPs. Moreover, the corona-like structure presented in SARS-CoV-2 VLPs from Vero E6 cells is more stable and unified, as compared to those from HEK-293T cells. Our data demonstrate that SARS-CoV-2 VLPs possess molecular and morphological properties of native virion particles, which endow such VLPs with a promising vaccine candidate and a powerful tool for the research of SARS-CoV-2.
C1 [Xu, Ruodan; Shi, Mingfei; Li, Ning] China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing, Peoples R China.
   [Li, Jing] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China.
   [Song, Ping] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China.
RP Li, N (corresponding author), China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing, Peoples R China.
EM lili.li.ning@gmail.com
FU Funding Program for National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81573587]; Fundamental
   Scientific Research of Central Public Welfare Foundation from China
   Academy of China Medical Sciences [YZ-202012]
FX This research was funded in part by a grant from the Funding Program for
   National Natural Science Foundation of China (81573587) and Fundamental
   Scientific Research of Central Public Welfare Foundation from China
   Academy of China Medical Sciences (YZ-202012).
CR Buonaguro L, 2006, J VIROL, V80, P9134, DOI 10.1128/JVI.00050-06
   Chen GL, 2020, JAMA-J AM MED ASSOC, V323, P1369, DOI 10.1001/jama.2020.2477
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Huang X, 2017, CVPR, V2, P3, DOI DOI 10.1002/JCB.26286
   Li CA, 2010, VACCINE, V28, P4294, DOI 10.1016/j.vaccine.2010.04.025
   Li L, 2005, CLIN INFECT DIS, V41, P815, DOI 10.1086/432720
   Li N, 2019, SCI BULL, V64, P180, DOI 10.1016/j.scib.2018.08.013
   Lopez-Macias Constantino, 2012, Hum Vaccin Immunother, V8, P411, DOI 10.4161/hv.18757
   Low JGH, 2014, VACCINE, V32, P5041, DOI 10.1016/j.vaccine.2014.07.011
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   Oberemok VV, 2020, INFLAMM RES, V69, P635, DOI 10.1007/s00011-020-01352-y
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Santi L, 2006, METHODS, V40, P66, DOI 10.1016/j.ymeth.2006.05.020
   Shiyu Dai H. W., 2018, J IMMUNO SCI, V2
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2
   Zhao QJ, 2012, NANOMED-NANOTECHNOL, V8, P1182, DOI 10.1016/j.nano.2012.01.007
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 24
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD JUL 30
PY 2020
VL 8
AR 862
DI 10.3389/fbioe.2020.00862
PG 6
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA ND0NF
UT WOS:000561604400001
PM 32850726
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vlachakis, PK
   Tentolouris, A
   Kanakakis, I
AF Vlachakis, Panayotis K.
   Tentolouris, Anastasios
   Kanakakis, Ioannis
TI Concerns for management of STEMI patients in the COVID-19 era: a paradox
   phenomenon
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE COVID-19; STEMI; Acute myocardial infarction; Acute coronary syndrome;
   Thrombolysis; Percutaneous coronary intervention
ID ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; ANGIOPLASTY; THERAPY
AB The pandemic of coronavirus disease 2019 (COVID-19) has become a public health emergency of international concern. During this time, the management of people with acute coronary syndromes (ACS) and COVID-19 has become a global issue, especially since preexisting cardiovascular disease is a risk factor for the presence and the severity of COVID-19. The number of people with ST- elevation myocardial infarction (STEMI) has decreased during the pandemic and delays in the time looking for medical care have been reported. In addition, the diagnosis of ACS may have been difficult due to possible underlying myocarditis or other clinical entities. Regarding management of people with STEMI, although the superiority of primary percutaneous coronary intervention (PCI) over thrombolysis is well established, the notable exposure risks due to absence of negative pressure in catheterization rooms and the increased difficulty in fine manipulation on guidewires under proper protection equipment may contribute to the relatively secondary role of PCI during the COVID-19 pandemic; thus, fibrinolytic therapy or robotic-assisted PCI in early presenting STEMI patients may have an alternative role during this period if prevention measures cannot be taken. Healthcare stuff should take the proper measures to avoid the spread of and their exposure to the virus.
C1 [Vlachakis, Panayotis K.; Kanakakis, Ioannis] Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens, Greece.
   [Tentolouris, Anastasios] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Sch Med, Dept Propaedeut Internal Med 1, 17 Agiou Thoma St, Athens 11527, Greece.
RP Tentolouris, A (corresponding author), Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Sch Med, Dept Propaedeut Internal Med 1, 17 Agiou Thoma St, Athens 11527, Greece.
EM antentol@med.uoa.gr
RI Vlachakis, Panayotis K./ABH-8221-2020
OI Vlachakis, Panayotis K./0000-0003-0736-4942
CR Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142
   Armstrong PW, 2013, NEW ENGL J MED, V368, P1379, DOI 10.1056/NEJMoa1301092
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558
   Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7
   Daniels MJ, 2020, CIRCULATION, V141, P1948, DOI 10.1161/CIRCULATIONAHA.120.047122
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Himbert D, 2005, INT J CARDIOL, V100, P109, DOI 10.1016/j.ijcard.2004.10.004
   Hu H, 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa190/5807656, DOI 10.1093/EURHEARTJ/EHAA190/5807656]
   Jing ZC, 2020, EUR HEART J, V41, P1791, DOI 10.1093/eurheartj/ehaa258
   Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035
   Meyer P, 2020, EUR HEART J, V41, P1860, DOI 10.1093/eurheartj/ehaa306
   Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433
   Rodriguez-Leor O, 2020, REC INTERV CARDIOL, V2, P82, DOI DOI 10.24875/RECIC.M20000120
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038]
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vlachakis PK, 2020, HELL J CARDIOL, V61, P46, DOI 10.1016/j.hjc.2020.04.001
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wegermann ZK, 2019, CURR CARDIOL REP, V21, DOI 10.1007/s11886-019-1218-5
   WHO, 2020, 178 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang L, 2020, EUR HEART J, V41, P1788, DOI 10.1093/eurheartj/ehaa266
NR 29
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD NOV
PY 2020
VL 50
IS 4
BP 809
EP 813
DI 10.1007/s11239-020-02236-y
EA JUL 2020
PG 5
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA OD4QN
UT WOS:000559246000001
PM 32734526
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rogerson, SJ
   Beeson, JG
   Laman, M
   Poespoprodjo, JR
   William, T
   Simpson, JA
   Price, RN
AF Rogerson, Stephen J.
   Beeson, James G.
   Laman, Moses
   Poespoprodjo, Jeanne Rini
   William, Timothy
   Simpson, Julie A.
   Price, Ric N.
CA ACREME Investigators
TI Identifying and combating the impacts of COVID-19 on malaria
SO BMC MEDICINE
LA English
DT Article
DE Malaria; COVID-19; Plasmodium; Elimination; Drug resistance
ID PLASMODIUM-FALCIPARUM; AFRICA; EBOLA
AB Background The COVID-19 pandemic has resulted in millions of infections, hundreds of thousands of deaths and major societal disruption due to lockdowns and other restrictions introduced to limit disease spread. Relatively little attention has been paid to understanding how the pandemic has affected treatment, prevention and control of malaria, which is a major cause of death and disease and predominantly affects people in less well-resourced settings. Main body Recent successes in malaria control and elimination have reduced the global malaria burden, but these gains are fragile and progress has stalled in the past 5 years. Withdrawing successful interventions often results in rapid malaria resurgence, primarily threatening vulnerable young children and pregnant women. Malaria programmes are being affected in many ways by COVID-19. For prevention of malaria, insecticide-treated nets need regular renewal, but distribution campaigns have been delayed or cancelled. For detection and treatment of malaria, individuals may stop attending health facilities, out of fear of exposure to COVID-19, or because they cannot afford transport, and health care workers require additional resources to protect themselves from COVID-19. Supplies of diagnostics and drugs are being interrupted, which is compounded by production of substandard and falsified medicines and diagnostics. These disruptions are predicted to double the number of young African children dying of malaria in the coming year and may impact efforts to control the spread of drug resistance. Using examples from successful malaria control and elimination campaigns, we propose strategies to re-establish malaria control activities and maintain elimination efforts in the context of the COVID-19 pandemic, which is likely to be a long-term challenge. All sectors of society, including governments, donors, private sector and civil society organisations, have crucial roles to play to prevent malaria resurgence. Sparse resources must be allocated efficiently to ensure integrated health care systems that can sustain control activities against COVID-19 as well as malaria and other priority infectious diseases. Conclusion As we deal with the COVID-19 pandemic, it is crucial that other major killers such as malaria are not ignored. History tells us that if we do, the consequences will be dire, particularly in vulnerable populations.
C1 [Rogerson, Stephen J.; Beeson, James G.] Univ Melbourne, Dept Med, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
   [Beeson, James G.] Burnet Inst, Melbourne, Vic, Australia.
   [Beeson, James G.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia.
   [Beeson, James G.] Monash Univ, Dept Microbiol, Clayton, Vic, Australia.
   [Laman, Moses] Papua New Guinea Inst Med Res, Madang, Madang Province, Papua N Guinea.
   [Poespoprodjo, Jeanne Rini] Papuan Hlth & Community Dev Fdn, Timika Malaria Res Program, Timika, Papua, Indonesia.
   [Poespoprodjo, Jeanne Rini] Mimika Dist Hlth Author, Timika, Papua, Indonesia.
   [Poespoprodjo, Jeanne Rini] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Child Hlth, Pediat Res Off, Yogyakarta, Indonesia.
   [Poespoprodjo, Jeanne Rini] Rumah Sakit Umum Daerah Kabupaten Mimika, Timika, Papua, Indonesia.
   [William, Timothy] Menzies Sch Hlth Res, Infect Dis Soc Sabah, Clin Res Unit, Kota Kinabalu, Sabah, Malaysia.
   [William, Timothy] Gleneagles Hosp, Kota Kinabalu, Sabah, Malaysia.
   [Simpson, Julie A.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
   [Price, Ric N.] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia.
   [Price, Ric N.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, Bangkok, Thailand.
   [Price, Ric N.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
RP Rogerson, SJ (corresponding author), Univ Melbourne, Dept Med, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
EM sroger@unimelb.edu.au
OI Price, Richard/0000-0003-2000-2874; Rogerson,
   Stephen/0000-0003-4287-1982
FU National Health and Medical Research Council of AustraliaNational Health
   and Medical Research Council of Australia [1173046, 1104975, 1092789,
   1143946, JAS 1100394]; Wellcome TrustWellcome Trust [200909]; NHMRC
   Independent Research Institute Infrastructure Support SchemeNational
   Health and Medical Research Council of Australia; Victorian State
   Government Operational Infrastructure grant; NHMRCNational Health and
   Medical Research Council of Australia [1134989]
FX Funding for the authors was provided by the National Health and Medical
   Research Council of Australia (Investigator Grant 1173046 to JGB, Senior
   Research Fellowship 1104975to JAS, Program Grant 1092789 to SJR and JGB,
   Project Grant 1143946 to SJR and Project Grant JAS 1100394) and the
   Wellcome Trust (Senior Clinical Fellowship 200909 to RNP). The Burnet
   Institute is supported by the NHMRC Independent Research Institute
   Infrastructure Support Scheme and a Victorian State Government
   Operational Infrastructure grant. All authors are members of the
   NHMRC-funded Centre for Research Excellence in Malaria Elimination
   (1134989).
CR Amimo F, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00219-6
   [Anonymous], 2020, LANCET, V395, P10238, DOI [10.1016/S0140-6736(20)31237-X, DOI 10.1016/S0140-6736(20)31237-X]
   Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981
   Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535
   Blitz MJ, 2020, AM J OBSTET GYNECOL, V223, P595, DOI 10.1016/j.ajog.2020.06.020
   Boseley S., 2020, GUARDIAN
   Cohen JM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-122
   Gates B, 2015, ASPIRATION ACTION WH
   Grepin KA, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h376
   Grillet ME, 2019, LANCET INFECT DIS, V19, pE149, DOI 10.1016/S1473-3099(18)30757-6
   Hamel MJ, 2015, LANCET INFECT DIS, V15, P75, DOI 10.1016/S1473-3099(15)70167-2
   Hamilton WL, 2019, LANCET INFECT DIS, V19, P943, DOI 10.1016/S1473-3099(19)30392-5
   Hsiang MS, 2020, LANCET, V395, P1361, DOI 10.1016/S0140-6736(20)30470-0
   Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1
   McLean ARD, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1172-x
   Najera JA, 1998, MALARIA EPIDEMICS DE
   Newton PN, 2020, LANCET GLOB HEALTH, V8, pE754, DOI 10.1016/S2214-109X(20)30136-4
   Parpia AS, 2016, EMERG INFECT DIS, V22, P433, DOI 10.3201/eid2203.150977
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Rahi M, 2020, AM J TROP MED HYG, V103, P28, DOI 10.4269/ajtmh.20-0394
   Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1
   Shretta R, 2017, MAJOR INFECT DIS
   van der Pluijm RW, 2019, LANCET INFECT DIS, V19, P952, DOI 10.1016/S1473-3099(19)30391-3
   van Huijsduijnen RH, 2018, CURR OPIN PHARMACOL, V42, P1, DOI 10.1016/j.coph.2018.05.006
   Walker PGT, 2015, LANCET INFECT DIS, V15, P825, DOI 10.1016/S1473-3099(15)70124-6
   WHO, 2019, WORLD MALARIA REPORT
   WHO, 2020, TAIL MAL INT COVID 1
   World Health Organization, 2014, WHOHTMGMP201410
   World Health Organization, 2015, GUID TREATM MAL
   World Health Organization (WHO), 2020, POT IMP HLTH SERV DI
   Yanow SK, 2020, AM J TROP MED HYG, V102, P1164, DOI 10.4269/ajtmh.20-0325
NR 31
TC 2
Z9 2
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUL 30
PY 2020
VL 18
IS 1
AR 239
DI 10.1186/s12916-020-01710-x
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX2FE
UT WOS:000557541100001
PM 32727467
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Han, L
   Wei, XX
   Zheng, YJ
   Zhang, LL
   Wang, XM
   Yang, HY
   Ma, X
   Zhao, LH
   Tong, XL
AF Han, Lin
   Wei, Xiu-Xiu
   Zheng, Yu-Jiao
   Zhang, Li-Li
   Wang, Xin-Miao
   Yang, Hao-Yu
   Ma, Xu
   Zhao, Lin-Hua
   Tong, Xiao-Lin
TI Potential mechanism prediction of Cold-Damp Plague Formula against
   COVID-19 via network pharmacology analysis and molecular docking
SO CHINESE MEDICINE
LA English
DT Article
DE COVID-19; Cold-Damp Plague Formula (CDPF); Network pharmacology;
   Molecular mechanism; Molecular docking
ID TRADITIONAL CHINESE MEDICINE; ACTIVATED PROTEIN-KINASE; CORONAVIRUS;
   BERBERINE; ANTIINFLUENZA; CYTOSCAPE; RELEVANCE; CYTOKINES; DATABASE;
   IL-10
AB Background Coronavirus disease 2019 (COVID-19) is a new global public health emergency. The therapeutic benefits of Cold-Damp Plague Formula (CDPF) against COVID-19, which was used to treat "cold-dampness stagnation in the lung" in Trial Versions 6 and 7 of the "Diagnosis and Treatment Protocol for COVID-19", have been demonstrated, but the effective components and their mechanism of action remain unclear. Methods In this study, a network pharmacology approach was employed, including drug-likeness evaluation, oral bioavailability prediction, protein-protein interaction (PPI) network construction and analysis, Gene Ontology (GO) terms, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, and virtual docking, to predict the bioactive components, potential targets, and molecular mechanism of CDPF for COVID-19 treatment. Results The active compound of herbs in CDPF and their candidate targets were obtained through database mining, and an herbs-ingredients-targets network was constructed. Subsequently, the candidate targets of the active compounds were compared to those relevant to COVID-19, to identify the potential targets of CDPF for COVID-19 treatment. Subsequently, the PPI network was constructed, which provided a basis for cluster analysis and hub gene screening. The seed targets in the most significant module were selected for further functional annotation. GO enrichment analysis identified four main areas: (1) cellular responses to external stimuli, (2) regulation of blood production and circulation, (3) free radical regulation, (4) immune regulation and anti-inflammatory effects. KEGG pathway analysis also revealed that CDPF could play pharmacological roles against COVID-19 through "multi components-multi targets-multi pathways" at the molecular level, mainly involving anti-viral, immune-regulatory, and anti-inflammatory pathways; consequently, a "CDPF-herbs-ingredients-targets-pathways-COVID-19" network was constructed. In hub target analysis, the top hub target IL6, and ACE2, the receptor via which SARS-CoV-2 typically enters host cells, were selected for molecular docking analyses, and revealed good binding activities. Conclusions This study revealed the active ingredients and potential molecular mechanism by which CDPF treatment is effective against COVID-19, and provides a reference basis for the wider application and further mechanistic investigations of CDPF in the fight against COVID-19.
C1 [Han, Lin; Zhang, Li-Li; Wang, Xin-Miao; Zhao, Lin-Hua; Tong, Xiao-Lin] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China.
   [Wei, Xiu-Xiu; Zheng, Yu-Jiao; Yang, Hao-Yu] Beijing Univ Chinese Med, Beijing 100029, Peoples R China.
   [Ma, Xu] Gansu Univ Chinese Med, Lanzhou 730000, Peoples R China.
RP Zhao, LH; Tong, XL (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China.
EM melonzhao@163.com; tongxiaolin@vip.163.com
FU Special Project for Emergency of the Ministry of Science and Technology
   [2020YFC0845000]
FX This work was funded by the Special Project for Emergency of the
   Ministry of Science and Technology (2020YFC0845000).
CR [Anonymous], MOL OP ENV MOE SOFTW
   Apweiler R, 2012, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/nar/gkr981
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436
   Chen X, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa449
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11
   Curcio MF, 2019, NITRIC OXIDE-BIOL CH, V93, P78, DOI 10.1016/j.niox.2019.09.004
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Ding YW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1585-7
   Ding ZH, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104759
   Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.3724/SP.J.1009.2019.000000, 10.1016/S1875-5364(20)30022-4]
   Duan ZP, 2011, CHINESE MED J-PEKING, V124, P2925, DOI 10.3760/cma.j.issn.0366-6999.2011.18.024
   Fajgenbaum D, 2018, HEMATOL-AM SOC HEMAT, P318, DOI 10.1182/asheducation-2018.1.318
   Faurie C, 2017, MED J AUSTRALIA, V207, DOI 10.5694/mja17.00098
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Ferrara F, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101481
   Gonzalez-Pinto T, 2020, EUR J NEUROL, V27, pE35, DOI 10.1111/ene.14286
   Gubernatorova EO, 2020, CYTOKINE GROWTH F R, V53, P13, DOI 10.1016/j.cytogfr.2020.05.009
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Jing YF, 2012, RES MAT BASIS RELATE
   Kaur S, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115327
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kong Q, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110316
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06-0006
   Li M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091880
   Lin YT, 2018, CELL PHYSIOL BIOCHEM, V51, P80, DOI 10.1159/000495166
   Ling JH., 2005, STUDIES CHEM CONSTIT
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu De-hui, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P685
   Liu XH, 2010, ENDOCR J, V57, P881, DOI 10.1507/endocrj.K10E-043
   Ma YX, 2019, APMIS, V127, P372, DOI 10.1111/apm.12928
   Ma ZY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02308
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   McKinstry KK, 2009, J IMMUNOL, V182, P7353, DOI 10.4049/jimmunol.0900657
   Metzemaekers M, 2020, J LEUKOCYTE BIOL, V107, P1167, DOI 10.1002/JLB.3AB0220-470R
   Mi DH, 2019, CNS NEUROSCI THER, V25, P323, DOI 10.1111/cns.13042
   National Administration of Traditional Chinese Medicine, GEN FORM COMM INT AC
   National Health Commission of the People's Republic of China, DIAGN TREATM PROT CO
   Nie CX, 2019, STUDY DIFFERENCES CH
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Otano I, 2020, THERANOSTICS, V10, P4481, DOI 10.7150/thno.41646
   Parekh NJ, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007778
   Rappaport N, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0359-2
   Ren X, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112932
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Saghazadeh A, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106560
   Savvides SN, 2020, NAT REV RHEUMATOL, V16, P189, DOI 10.1038/s41584-020-0388-2
   Schwartz SL, 2017, MOL BIOL CELL, V28, P3397, DOI 10.1091/mbc.E17-06-0350
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Simula L, 2020, CELL DEATH DIFF
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sordo-Bahamonde C, 2020, CANCERS, V12, DOI 10.3390/cancers12040893
   Sukocheva OA, 2020, ADV PROTEIN CHEM STR, V120, P123, DOI 10.1016/bs.apcsb.2019.11.003
   Sun Hua, 2018, Journal of Guangdong Pharmaceutical University, V34, P254
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tong T, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00326-w
   Tong Xiaolin, 2004, J Tradit Chin Med, V24, P266
   [仝小林 Tong Xiaolin], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P465
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Verrico CD, 2020, PAIN
   Violi F, 2020, THROMB HAEMOSTASIS, V120, P949, DOI 10.1055/s-0040-1710317
   Wang XL, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0886-6
   Weider T, 2020, THYROID, V30, P432, DOI 10.1089/thy.2019.0607
   Wen JS, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107566
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wong R, 2019, IMMUNOLOGY, V156, P120, DOI 10.1111/imm.13019
   Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200
   Xiao P, 2019, J EXP MED, V216, P337, DOI 10.1084/jem.20181198
   Xu J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062071
   Xu Y, 2018, STUDY COKE AROMA MAT
   Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100
   Yang RC, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104820
   Yi HY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00535
   Yuan SG, 2016, STRUCTURE, V24, P2041, DOI 10.1016/j.str.2016.11.012
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou Ji-yin, 2007, Yaoxue Xuebao, V42, P1243
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu GQ, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106473
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zhuang YaoDong, 2014, China Journal of Traditional Chinese Medicine and Pharmacy, V29, P969
NR 83
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
J9 CHIN MED-UK
JI Chin. Med.
PD JUL 30
PY 2020
VL 15
IS 1
AR 78
DI 10.1186/s13020-020-00360-8
PG 16
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA MX1BQ
UT WOS:000557462300001
PM 32754224
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kaminski, M
   Muth, A
   Bogdanski, P
AF Kaminski, Mikolaj
   Muth, Agnieszka
   Bogdanski, Pawel
TI Smoking, Vaping, and Tobacco Industry During COVID-19 Pandemic: Twitter
   Data Analysis
SO CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING
LA English
DT Article
DE Twitter; COVID-19; coronavirus; smoking; tobacco industry; social
   networking
ID COGNITIVE-DISSONANCE
AB The reports suggesting a beneficial effect of nicotine on coronavirus disease 2019 (COVID-19) severity may encourage smoking. We aimed to analyze tweets on COVID-19 and smoking coming from casual Twitter users and Twitter accounts representing the tobacco industry. We collected tweets on COVID-19 and smoking from January 1 to May 1, 2020, using Twitter application programming interface. We analyzed sentiment, likes, or retweet to followers ratios, and the posts coming from the casual users to find pieces of news that could affect the discourse. Tweets coming from industry were analyzed manually. We analyzedn = 33,890 tweets on COVID-19 and smoking. The sentiment of tweets was negative, hitting a nadir in mid-March, but became less negative in April when preprints suggesting benefits from smoking on COVID-19 were released. Similar trends were observed for the ratios of likes or retweets to followers. We found 58 messages from the tobacco industry concerning COVID-19. Twenty-two (37.9 percent) mentioned the efforts of tobacco companies to support the development of a COVID-19 vaccine. Two tweets included Food and Drug Administration statements that there is no evidence that vaping increases the risk of COVID-19. The occurrence of preprints suggesting benefits of smoking in COVID-19 might increase sentiment and reactions to tweets on tobacco products and the virus. The authors of potentially controversial articles should restrain from the promotion of their results before the completion of the peer-review process. Twitter presents a convenient tool to monitor e-discourse during a health crisis. The research community should monitor the tobacco industry's social media.
C1 [Kaminski, Mikolaj; Bogdanski, Pawel] Poznan Univ Med Sci, Dept Treatment Obes & Metab Disorders, Szamarzewskiego 84, PL-60569 Poznan, Poland.
   [Kaminski, Mikolaj; Bogdanski, Pawel] Poznan Univ Med Sci, Clin Dietet, Szamarzewskiego 84, PL-60569 Poznan, Poland.
   [Muth, Agnieszka] Poznan Univ Med Sci, Fac Med 1, Poznan, Poland.
RP Kaminski, M (corresponding author), Poznan Univ Med Sci, Dept Treatment Obes & Metab Disorders, Szamarzewskiego 84, PL-60569 Poznan, Poland.; Kaminski, M (corresponding author), Poznan Univ Med Sci, Clin Dietet, Szamarzewskiego 84, PL-60569 Poznan, Poland.
EM mikolaj.w.kaminski@gmail.com
RI Bogdanski, Pawel/ABB-2938-2020; Kaminski, Mikolaj/AAG-5495-2020
OI Bogdanski, Pawel/0000-0002-0563-1624; Kaminski,
   Mikolaj/0000-0002-4394-0460
CR Abd-Alrazaq A, 2020, J MED INTERNET RES, V22, DOI 10.2196/19016
   Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147
   Anon, 2020, FRANCE LIMITS NICOTI
   Anon. (2020) Timeline of the 2019-20 coronavirus pandemic, 2020, TIMELINE 2019 20 COR
   Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Changeux JP, 2020, CR BIOL, V343, P33, DOI 10.5802/crbiol.8
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Cialdini Robert B, 1993, INFLUENCE PSYCHOL PE
   De Queiroz G, 2020, PACKAGE TIDYTEXT TEX
   FARSALINOS K, 2020, INTERN EMERG ME 0509
   Farsalinos K, 2020, INTERN EMERG MED, V15, P845, DOI 10.1007/s11739-020-02355-7
   Festinger L., 2001, THEORY COGNITIVE DIS
   Fotuhi O, 2013, TOB CONTROL, V22, P52, DOI 10.1136/tobaccocontrol-2011-050139
   Garufi G, 2020, EUR J INTERN MED, V77, P121, DOI 10.1016/j.ejim.2020.04.042
   Harris JK, 2014, J MED INTERNET RES, V16, P162, DOI [10.2196/jmir.3622, 10.2196/jmir.2972]
   Hermida A, 2012, JOURNALISM STUD, V13, P815, DOI 10.1080/1461670X.2012.664430
   Hu M., 2004, P 10 ACM SIGKDD INT, P168, DOI [10.1145/1014052.1014073, DOI 10.1145/1014052.1014073]
   Kearney M, 2020, PACKAGE RTWEET COLLE
   Khalid A, 2020, SMOKERS ARENT QUITTI
   Kim AE, 2019, JAMA PEDIATR, V173, P690, DOI 10.1001/jamapediatrics.2019.0922
   Kim Yoonsang, 2020, Tob Control, DOI 10.1136/tobaccocontrol-2019-055427
   KLAYMAN J, 1987, PSYCHOL REV, V94, P211, DOI 10.1037/0033-295X.94.2.211
   Li Volti G, 2020, J CLIN MED, V9, P1321
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764
   MCMASTER C, 1991, ADDICT BEHAV, V16, P349, DOI 10.1016/0306-4603(91)90028-G
   Mendelsohn C., 2020, NO EVIDENCE VAPING I
   Miyara M, 2020, QEIOS, DOI [10.32388/WPP19W.3., DOI 10.32388/WPP19W.3, 10.32388/WPP19W.3]
   Moheimani RS, 2017, JAMA CARDIOL, V2, P278, DOI 10.1001/jamacardio.2016.5303
   Myers SA, 2014, WWW'14 COMPANION: PROCEEDINGS OF THE 23RD INTERNATIONAL CONFERENCE ON WORLD WIDE WEB, P493, DOI 10.1145/2567948.2576939
   Myslin M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2534
   Nilsson P, 2020, SMOKERS STOCK TOBACC
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Prochaska JJ, 2012, TOB CONTROL, V21, P447, DOI 10.1136/tc.2010.042507
   Rose SW, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5694
   Sinnenberg L, 2017, AM J PUBLIC HEALTH, V107, pE1, DOI 10.2105/AJPH.2016.303512
   Sussman R, 2020, VAPING SARS COV 2 CO
   Tiffany K., 2020, BLOOMBERG
   Unger JB, 2018, PREV MED, V114, P54, DOI 10.1016/j.ypmed.2018.06.006
   van der Tempel J, 2016, INT J PUBLIC HEALTH, V61, P249, DOI 10.1007/s00038-016-0791-2
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vazquez JC, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/120005
NR 43
TC 0
Z9 0
U1 4
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-2715
EI 2152-2723
J9 CYBERPSYCH BEH SOC N
JI Cyberpsychology Behav. Soc. Netw.
PD DEC 1
PY 2020
VL 23
IS 12
BP 811
EP 817
DI 10.1089/cyber.2020.0384
EA JUL 2020
PG 7
WC Psychology, Social
SC Psychology
GA PF6BZ
UT WOS:000558234700001
PM 32757951
OA Bronze
DA 2021-01-01
ER

PT J
AU Sachdeva, C
   Wadhwa, A
   Kumari, A
   Hussain, F
   Jha, P
   Kaushik, NK
AF Sachdeva, Cheryl
   Wadhwa, Anju
   Kumari, Anita
   Hussain, Firasat
   Jha, Preeti
   Kaushik, Naveen K.
TI In silicoPotential of Approved Antimalarial Drugs for Repurposing
   Against COVID-19
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; drug repurposing; antimalarial drugs; drug
   development; planetary health
ID SARS-COV; MECHANISM; TETRACYCLINES; CHLOROQUINE; DOXYCYCLINE;
   INHIBITION; ATOVAQUONE; SPIKE; HEME
AB Although the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is wreaking havoc and resulting in mortality and morbidity across the planet, novel treatments are urgently needed. Drug repurposing offers an innovative approach in this context. We report here new findings on thein silicopotential of several antimalarial drugs for repurposing against COVID-19. We conducted analyses by docking the compounds against two SARS-CoV-2-specific targets: (1) the receptor binding domain spike protein and (2) the main protease of the virus (M-Pro) using the Schrodinger software. Importantly, the docking analysis revealed that doxycycline (DOX) showed the most effective binding to the spike protein of SARS-CoV-2, whereas halofantrine and mefloquine bound effectively with the main protease among the antimalarial drugs evaluated in the present study. Thein silicoapproach reported here suggested that DOX could potentially be a good candidate for repurposing for COVID-19. In contrast, to decipher the actual potential of DOX and halofantrine against COVID-19, furtherin vitroandin vivostudies are called for. Drug repurposing warrants consideration as a viable research and innovation avenue as planetary health efforts to fight the COVID-19 continue.
C1 [Sachdeva, Cheryl; Kumari, Anita; Kaushik, Naveen K.] Amity Univ Uttar Pradesh, Amity Inst Virol & Immunol, Sect 25, Noida 201313, Uttar Pradesh, India.
   [Wadhwa, Anju; Hussain, Firasat] Univ Delhi, Dept Chem, North Campus,Univ Enclave, Delhi, India.
   [Jha, Preeti] Uppsala Univ, Dept Immunol Genet & Pathol, S-75185 Uppsala, Sweden.
RP Kaushik, NK (corresponding author), Amity Univ Uttar Pradesh, Amity Inst Virol & Immunol, Sect 25, Noida 201313, Uttar Pradesh, India.; Jha, P (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, S-75185 Uppsala, Sweden.
EM preeti.jha@igp.uu.se; nkkaushik@amity.edu
RI Jha, Dr. Preeti/F-4338-2019
OI Jha, Dr. Preeti/0000-0001-9943-5976; Kaushik, Naveen
   Kumar/0000-0002-4710-4662
CR Abdul-Fattah AM, 2002, INT J PHARM, V235, P17, DOI 10.1016/S0378-5173(01)00941-3
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Bahrami F, 2012, MINI-REV MED CHEM, V12, P44, DOI 10.2174/138955712798868977
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Bouchaud O, 2002, J TRAVEL MED, V9, P214, DOI 10.2310/7060.2002.24026
   Camarda G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11239-0
   CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L
   Chukwudi CU, 2016, ANTIMICROB AGENTS CH, V60, P4433, DOI 10.1128/AAC.00594-16
   Clemens DL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124078
   Dahl EL, 2006, ANTIMICROB AGENTS CH, V50, P3124, DOI 10.1128/AAC.00394-06
   Dai T, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01092-16
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Villiers KA, 2008, J INORG BIOCHEM, V102, P1660, DOI 10.1016/j.jinorgbio.2008.04.001
   Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418
   Dorman G, 2010, DRUGS, V70, P949, DOI 10.2165/11318390-000000000-00000
   Farber PM, 1998, FEBS LETT, V422, P311, DOI 10.1016/S0014-5793(98)00031-3
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Gane SB, 2020, RHINOLOGY, V58, P299, DOI 10.4193/Rhin20.114
   Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1
   Griffin MO, 2010, AM J PHYSIOL-CELL PH, V299, pC539, DOI 10.1152/ajpcell.00047.2010
   Haga S, 2010, ANTIVIR RES, V85, P551, DOI 10.1016/j.antiviral.2009.12.001
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Koromina M, 2019, OMICS, V23, P539, DOI 10.1089/omi.2019.0151
   Lan J, 2020, NATURE, V181
   Lipowsky HH, 2011, AM J PHYSIOL-HEART C, V300, pH415, DOI 10.1152/ajpheart.00923.2010
   Marten Norman W., 2005, P839, DOI 10.1007/0-387-25518-4_48
   Meli DN, 2006, INFECT IMMUN, V74, P3890, DOI 10.1128/IAI.01949-05
   Olafson KN, 2015, P NATL ACAD SCI USA, V112, P4946, DOI 10.1073/pnas.1501023112
   Peyriere H, 2018, J ANTIMICROB CHEMOTH, V73, P553, DOI 10.1093/jac/dkx420
   Phillips JM, 2017, J VIROL, V91, DOI 10.1128/JVI.01564-16
   Rodrigues VS, 2016, INT J ANTIMICROB AG, V48, P203, DOI 10.1016/j.ijantimicag.2016.04.029
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Schrodinger, 2017, MAESTRO11 1 LIGPREP
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Siregar JE, 2015, PARASITOL INT, V64, P295, DOI 10.1016/j.parint.2014.09.011
   Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334, DOI 10.1128/AAC.43.6.1334
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Van Nassauw Luc, 2008, Travel Med Infect Dis, V6, P253, DOI 10.1016/j.tmaid.2008.06.006
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang L. F., 2007, BATS CIVETS EMERGENC, DOI 10.1007/978-3-540-70962-6_13
   Warhurst DC, 2001, SE ASIAN J TROP MED, V32, P4
   White NJ, 1999, CLIN PHARMACOKINET, V37, P105, DOI 10.2165/00003088-199937020-00002
   Wong W, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.31
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
NR 47
TC 1
Z9 1
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD OCT 1
PY 2020
VL 24
IS 10
BP 568
EP 580
DI 10.1089/omi.2020.0071
EA JUL 2020
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA NW9WL
UT WOS:000558234400001
PM 32757981
OA Bronze
DA 2021-01-01
ER

PT J
AU Shawky, E
   Nada, AA
   Ibrahim, RS
AF Shawky, Eman
   Nada, Ahmed A.
   Ibrahim, Reham S.
TI Potential role of medicinal plants and their constituents in the
   mitigation of SARS-CoV-2: identifying related therapeutic targets using
   network pharmacology and molecular docking analyses
SO RSC ADVANCES
LA English
DT Article
ID ACUTE LUNG INJURY; ANTIINFLAMMATORY ACTIVITY; SARS-CORONAVIRUS;
   DISCOVERY; GENOME
AB Since the outbreak of Coronavirus disease (COVID-19) caused by SARS-CoV-2 in December 2019, there has been no vaccine or specific antiviral medication for treatment of the infection where supportive care and prevention of complications is the current management strategy. In this work, the potential use of medicinal plants and more than 16 500 of their constituents was investigated within two suggested therapeutic strategies in the fight against SARS-CoV-2 including prevention of SARS-CoV-2 RNA synthesis and replication, through targeting vital proteins and enzymes as well as modulation of the host's immunity through production of virulence factors. Molecular docking studies on the viral enzymes 3Clpro, PLpro and RdRp suggested rocymosin B, verbascoside, rutin, caftaric acid, luteolin 7-rutinoside, fenugreekine and cyanidin 3-(6 ''-malonylglucoside) as promising molecules for further drug development. Meanwhile, the medicinal plantsGlycyrrhiza glabra,Hibiscus sabdariffa,Cichorium intybus,Chrysanthemum coronarium,Nigella sativa,Anastatica hierochuntica,Euphorbia species,Psidium guajavaandEpilobium hirsutumwere enriched in compounds with the multi-targets PTGS2, IL2, IL1b, VCAM1 and TNF such as quercetin, ursolic acid, kaempferol, isorhamnetin, luteolin, glycerrhizin and apigenin. Enriched pathways of the molecular targets included cytokine-cytokine receptor interaction, TNF signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling pathway, NF-kappa B signaling pathway and JAK-STAT3 signaling pathway which are all closely related to inflammatory, innate and adaptive immune responses. The present study identified natural compounds targeting SARS-CoV-2 for furtherin vitroandin vivostudies and emphasizes the potential role of medicinal plants in the mitigation of SARS-CoV-2.
C1 [Shawky, Eman; Nada, Ahmed A.; Ibrahim, Reham S.] Alexandria Univ, Fac Pharm, Dept Pharmacognosy, Alexandria 21521, Egypt.
RP Shawky, E (corresponding author), Alexandria Univ, Fac Pharm, Dept Pharmacognosy, Alexandria 21521, Egypt.
EM shawkyeman@yahoo.com
CR Adedeji AO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036521
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bordoni L, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8020051
   Brune K, 2015, AM J PHYSIOL-LUNG C, V308, pL731, DOI 10.1152/ajplung.00309.2014
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   Chu Chung K., 2006, Antiviral Chemistry & Chemotherapy, V17, P285
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   Dawood HM, 2018, J ETHNOPHARMACOL, V224, P359, DOI 10.1016/j.jep.2018.06.009
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Farazuddin M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199612
   Fekri MS, 2019, DRUG CHEM TOXICOL, DOI 10.1080/01480545.2019.1606232
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   Frattaruolo L, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060186
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Garbi M. I., 2017, INT J HOME SCI, V3, P234
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hanley B, 2020, J CLIN PATHOL, V73, P239, DOI 10.1136/jclinpath-2020-206522
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibrahim RS, 2020, MED CHEM RES, V29, P707, DOI 10.1007/s00044-020-02516-5
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lee SA, 2019, J THORAC DIS, V11, P1287, DOI 10.21037/jtd.2019.04.14
   Leiva-Juarez MM, 2018, MUCOSAL IMMUNOL, V11, P21, DOI 10.1038/mi.2017.71
   Li C, 2015, J NUTR SCI VITAMINOL, V61, P375, DOI 10.3177/jnsv.61.375
   Li CN, 2020, IUBMB LIFE, V72, P632, DOI 10.1002/iub.2201
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Majdalawieh AF, 2015, INT IMMUNOPHARMACOL, V28, P295, DOI 10.1016/j.intimp.2015.06.023
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Rezagholizadeh L, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0128-6
   Rizvi W, 2014, ANC SCI LIFE, V34, P44, DOI 10.4103/0257-7941.150780
   Sahu KK, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.92
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Shen HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057055
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Smeitink J., 2020, HYPOTHESIS MPGES 1 D, DOI 10.20944/preprints202004.0180.v1
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sogo T, 2015, BIOFACTORS, V41, P58, DOI 10.1002/biof.1201
   Strzelecka M, 2005, J Physiol Pharmacol, V56 Suppl 1, P139
   Takashima K, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0150-x
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vaninov Natalie, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0305-6
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2014, EXP BIOL MED, V239, P1653, DOI 10.1177/1535370214537743
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang W, 2020, DEFINITION RISKS CYT, DOI [10.1101/2020.02.26.20026989, DOI 10.1101/2020.02.26.20026989]
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, NOV COR CHIN
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   World Health Organization, PNEUM UNKN CAUS CHIN
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu YH, 2017, CURR MED CHEM, V24, P4279, DOI 10.2174/0929867324666170815102917
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xie YC, 2013, BIOORGAN MED CHEM, V21, P7715, DOI 10.1016/j.bmc.2013.10.020
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yuan L, 2015, J BIOL CHEM, V290, P3172, DOI 10.1074/jbc.M114.619890
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang D., 2020, MOL BASIS TREATING C, DOI [10.21203/rs.3.rs-20828/v1, DOI 10.21203/RS.3.RS-20828/V1]
   Zhao J, 2019, CYTOKINE, V123, DOI 10.1016/j.cyto.2019.05.013
   Zhou J.-X., 2019, MEDICINES, V6, P55, DOI [10.3390/medicines6020055, DOI 10.3390/MEDICINES6020055]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 69
TC 1
Z9 1
U1 5
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD JUL 30
PY 2020
VL 10
IS 47
BP 27961
EP 27983
DI 10.1039/d0ra05126h
PG 23
WC Chemistry, Multidisciplinary
SC Chemistry
GA MV5YF
UT WOS:000556432400009
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Xiong, TY
   Huang, FY
   Liu, Q
   Peng, Y
   Xu, YN
   Wei, JF
   Li, N
   Bai, B
   Li, JH
   Prendergast, B
   Li, WM
   Chen, M
AF Xiong, Tian-Yuan
   Huang, Fang-Yang
   Liu, Qi
   Peng, Yong
   Xu, Yuan-Ning
   Wei, Jia-Fu
   Li, Nian
   Bai, Bei
   Li, Jun-Hua
   Prendergast, Bernard
   Li, Wei-Min
   Chen, Mao
TI Hypertension is a risk factor for adverse outcomes in patients with
   coronavirus disease 2019: a cohort study
SO ANNALS OF MEDICINE
LA English
DT Article
DE coronavirus disease; hypertension; intensive care; outcomes
ID ACE2
AB Background Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19. Methods This is a retrospective multi-centre study involving patients admitted between January 16th and March 10th 2020. The composite endpoint was defined as the presence of at least one of the following, intensive care unit (ICU) admission, or the need for mechanical ventilation, or death. Results A total of 472 consecutive cases admitted to 51 certified COVID-19 tertiary care hospitals were enrolled (median age was 43 [32-53.5] years and 53.0% were male). There were 101 (21.4%) patients presented with comorbidities, including hypertension (15.0%), diabetes mellitus (7.8%), coronary artery disease (2.6%), chronic obstructive pulmonary disease (1.3%) and cerebrovascular disease (1.9%). The composite endpoint occurred in 65 (13.8%) patients. Multivariate stepwise logistic regression analysis indicated that older age (odds ratio [OR] 1.39, 95% confidence interval (CI) 1.05-1.85, per 10-year increment), antecedent hypertension (OR 2.82, 95% CI 1.09-7.29), neutrophil counts (OR 1.33, 95% CI 1.14-1.56) and lactate dehydrogenase level (OR 1.01, 95% CI 1.00-1.01) were independently associated with the presence of composite endpoint. Hypertensive patients, compared with controls, had a greater chance of experiencing the composite endpoint (p < .001) and each individual endpoint, i.e. ICU admission (p < .001), mechanical ventilation (p < .001) and death (p = .012). In the stepwise regression analysis of anti-hypertensive medications, none of the therapy predicted the composite endpoint. Conclusions Hypertension is a common comorbidity in patients with COVID-19 and associated with adverse outcomes.KEY MESSAGES Hypertension was identified as the comorbidity associated with the prognosis of COVID-19 in this retrospective cohort. Patients with hypertension could experience an increased risk of the composite endpoint. Anti-hypertensive therapy did not affect patient outcomes.
C1 [Xiong, Tian-Yuan; Huang, Fang-Yang; Liu, Qi; Peng, Yong; Xu, Yuan-Ning; Wei, Jia-Fu; Chen, Mao] Sichuan Univ, West China Hosp, Dept Cardiol, 37 Guoxue St, Chengdu 610041, Peoples R China.
   [Li, Nian] Sichuan Univ, West China Hosp, Dept Med Affairs, Chengdu, Peoples R China.
   [Bai, Bei] Sichuan Univ, West China Hosp, Directors Off, Chengdu, Peoples R China.
   [Li, Jun-Hua] Hlth Commiss Sichuan Prov, Hlth Ind Div, Chengdu, Peoples R China.
   [Prendergast, Bernard] St Thomas Hosp, Dept Cardiol, Westminster Bridge Rd, London SE1 7EH, England.
   [Prendergast, Bernard] Cleveland Clin, London, England.
   [Li, Wei-Min] Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, 37 Guoxue St, Chengdu 610041, Peoples R China.
RP Chen, M (corresponding author), Sichuan Univ, West China Hosp, Dept Cardiol, 37 Guoxue St, Chengdu 610041, Peoples R China.; Prendergast, B (corresponding author), St Thomas Hosp, Dept Cardiol, Westminster Bridge Rd, London SE1 7EH, England.; Li, WM (corresponding author), Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, 37 Guoxue St, Chengdu 610041, Peoples R China.
EM bernard.prendergast@gstt.nhs.uk; weimi003@scu.edu.cn;
   hmaochen@vip.sina.com
CR Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   Busse LW, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02862-1
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang C, 2019, LANCET, V2020, P395
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta N, 2020, JAMA CARDIOLOGY
   Mertz D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5061
   National Health Commission of the People's Republic of China, NOV COR PNEUM DIAGN
   Rai A, 2020, J HYPERTENS, V38, P1878, DOI 10.1097/HJH.0000000000002456
   Roncon L, 2020, BRIT J ANAESTH, V125, pE254, DOI 10.1016/j.bja.2020.04.056
   Sanchis-Gomar F, 2020, MAYO CLIN PROC, V95, P1222, DOI 10.1016/j.mayocp.2020.03.026
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Zuin M, 2020, J INFECTION, V81, pE84, DOI 10.1016/j.jinf.2020.03.059
NR 21
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PD OCT 2
PY 2020
VL 52
IS 7
BP 361
EP 366
DI 10.1080/07853890.2020.1802059
EA JUL 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NM2HY
UT WOS:000555170800001
PM 32716217
OA Bronze
DA 2021-01-01
ER

PT J
AU Dressler, D
   Saberi, FA
AF Dressler, Dirk
   Adib Saberi, Fereshte
TI Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions
   from a German cohort
SO JOURNAL OF NEURAL TRANSMISSION
LA English
DT Article
DE Botulinum toxin; Therapy; Corona virus; SARS-CoV-2; COVID19; Pandemic;
   Dystonia; Spasticity; Hemifacial spasms; Pain conditions; Quality of
   life; Perception; Patient rights
AB The SARS-CoV-2 virus pandemic has provoked drastic countermeasures including shutdowns of public services. We wanted to describe the effects of a 6 week shutdown of a large German botulinum toxin (BT) outpatient clinics on patients and their well-being. 45 patients (age 61.9 +/- 9.8 years, 29 females, 16 males) receiving BT therapy (319.3 +/- 201.9MU-equivalent, treatment duration 8.3 +/- 5.5 years) were surveyed with a standardised questionnaire. The shutdown delayed BT therapy by 6.6 +/- 2.3 weeks. 93% of the patients noticed increased muscle cramps and 82% increased pain reducing their quality of life by 40.2 +/- 19.5%. For 23 patients with cervical dystonia this reduction was 41.1 +/- 18.3%, for 3 patients with blepharospasm 33.3 +/- 15.3%, for 9 patients with spasticity 37.8 +/- 15.6%, for 4 patients with pain conditions 37.4 +/- 35.7% and for 3 patients with hemifacial spasm 27.5 +/- 17.1%. After the shutdown 66% of patients perceived BT therapy as more important than before, 32% perceived it as unchanged. For all patients long-term availability of BT therapy was very important or important. 98% of the patients perceived the shutdown as inadequate and felt their patient rights not respected. The shutdown confirmed the considerable burden of disease caused by dystonia, spasticity, hemifacial spasm and various pain conditions and the importance of BT therapy to treat them. Any shutdown severely affects these patients and needs to be avoided.
C1 [Dressler, Dirk] Hannover Med Sch, Movement Disorders Sect, Dept Neurol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Adib Saberi, Fereshte] IAB Interdisciplinary Working Grp Movement Disord, Hamburg, Germany.
RP Dressler, D (corresponding author), Hannover Med Sch, Movement Disorders Sect, Dept Neurol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM dressler.dirk@mh-hannover.de
FU Projekt DEAL; IAB-Interdisciplinary Working Group for Movement Disorders
FX Open Access funding provided by Projekt DEAL. This study was made
   possible by an unrestricted educational grant from IAB-Interdisciplinary
   Working Group for Movement Disorders.
CR Dressler D, 2005, EUR NEUROL, V53, P3, DOI 10.1159/000083259
   Niedersachsisches Gesetz- und Verordnungsblatt, 2020, NIED VER BEK COR VIR, V4, P37
NR 2
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0300-9564
EI 1435-1463
J9 J NEURAL TRANSM
JI J. Neural Transm.
PD SEP
PY 2020
VL 127
IS 9
BP 1271
EP 1274
DI 10.1007/s00702-020-02235-6
EA JUL 2020
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MX5ND
UT WOS:000554753200001
PM 32734554
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Petersen, MW
   Meyhoff, TS
   Helleberg, M
   Kjaer, MBN
   Granholm, A
   Hjortso, CJS
   Jensen, TS
   Moller, MH
   Hjortrup, PB
   Wetterslev, M
   Vesterlund, GK
   Russell, L
   Jorgensen, VL
   Tjelle, K
   Benfield, T
   Ulrik, CS
   Andreasen, AS
   Mohr, T
   Bestle, MH
   Poulsen, LM
   Hitz, MF
   Hildebrandt, T
   Knudsen, LS
   Moller, A
   Solling, CG
   Brochner, AC
   Rasmussen, BS
   Nielsen, H
   Christensen, S
   Strom, T
   Cronhjort, M
   Wahlin, RR
   Jakob, S
   Cioccari, L
   Venkatesh, B
   Hammond, N
   Jha, V
   Myatra, SN
   Gluud, C
   Lange, T
   Perner, A
AF Petersen, Marie Warrer
   Meyhoff, Tine Sylvest
   Helleberg, Marie
   Kjaer, Maj-Brit Norregaard
   Granholm, Anders
   Hjortso, Carl Johan Steensen
   Jensen, Thomas Steen
   Moller, Morten Hylander
   Hjortrup, Peter Buhl
   Wetterslev, Mik
   Vesterlund, Gitte Kingo
   Russell, Lene
   Jorgensen, Vibeke Lind
   Tjelle, Klaus
   Benfield, Thomas
   Ulrik, Charlotte Suppli
   Andreasen, Anne Sofie
   Mohr, Thomas
   Bestle, Morten H.
   Poulsen, Lone Musaeus
   Hitz, Mette Friberg
   Hildebrandt, Thomas
   Knudsen, Lene Surland
   Moller, Anders
   Solling, Christoffer Grant
   Brochner, Anne Craveiro
   Rasmussen, Bodil Steen
   Nielsen, Henrik
   Christensen, Steffen
   Strom, Thomas
   Cronhjort, Maria
   Wahlin, Rebecka Rubenson
   Jakob, Stephan
   Cioccari, Luca
   Venkatesh, Balasubramanian
   Hammond, Naomi
   Jha, Vivekanand
   Myatra, Sheila Nainan
   Gluud, Christian
   Lange, Theis
   Perner, Anders
TI Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia
   (COVID STEROID) trial-Protocol and statistical analysis plan
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article
ID THERAPY
AB Introduction Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists. Methods The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving >= 10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals. Discussion The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.
C1 [Petersen, Marie Warrer; Meyhoff, Tine Sylvest; Kjaer, Maj-Brit Norregaard; Granholm, Anders; Hjortso, Carl Johan Steensen; Jensen, Thomas Steen; Moller, Morten Hylander; Hjortrup, Peter Buhl; Wetterslev, Mik; Vesterlund, Gitte Kingo; Russell, Lene; Perner, Anders] Copenhagen Univ Hosp, Dept Intens Care, Copenhagen, Denmark.
   [Petersen, Marie Warrer; Meyhoff, Tine Sylvest; Kjaer, Maj-Brit Norregaard; Granholm, Anders; Hjortso, Carl Johan Steensen; Jensen, Thomas Steen; Moller, Morten Hylander; Hjortrup, Peter Buhl; Wetterslev, Mik; Vesterlund, Gitte Kingo; Russell, Lene; Rasmussen, Bodil Steen; Perner, Anders] Collaborat Res Intens Care CRIC, Copenhagen, Denmark.
   [Helleberg, Marie] Copenhagen Univ Hosp, Dept Infect Dis, Copenhagen, Denmark.
   [Jorgensen, Vibeke Lind] Copenhagen Univ Hosp, Dept Thorac Anaesthesiol, Copenhagen, Denmark.
   [Tjelle, Klaus] Univ Copenhagen, Hvidovre Hosp, Dept Anaesthesia & Intens Care, Copenhagen, Denmark.
   [Benfield, Thomas] Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen, Denmark.
   [Ulrik, Charlotte Suppli] Univ Copenhagen, Hvidovre Hosp, Dept Resp Med, Copenhagen, Denmark.
   [Andreasen, Anne Sofie] Univ Copenhagen, Herlev Hosp, Dept Anaesthesia & Intens Care, Copenhagen, Denmark.
   [Mohr, Thomas] Univ Copenhagen, Gentofte Hosp, Dept Intens Care, Copenhagen, Denmark.
   [Bestle, Morten H.] Univ Copenhagen, Nordsjaellands Hosp, Dept Anaesthesia & Intens Care, Copenhagen, Denmark.
   [Poulsen, Lone Musaeus] Zealand Univ Hosp, Dept Anaesthesia & Intens Care, Koge, Denmark.
   [Hitz, Mette Friberg] Zealand Univ Hosp, Internal Med Dept, Endocrinol, Koge, Denmark.
   [Hildebrandt, Thomas] Zealand Univ Hosp, Dept Anaesthesia & Intens Care, Roskilde, Denmark.
   [Knudsen, Lene Surland] Zealand Univ Hosp, Dept Infect Dis, Roskilde, Denmark.
   [Moller, Anders] Nstved Slagelse Ringsted Hosp, Dept Anaesthesia & Intens Care, Slagelse, Denmark.
   [Solling, Christoffer Grant] Viborg Hosp, Dept Anaesthesia & Intens Care, Viborg, Denmark.
   [Brochner, Anne Craveiro] Kolding Cty Hosp, Dept Anaesthesia & Intens Care, Kolding, Denmark.
   [Rasmussen, Bodil Steen] Aalborg Univ Hosp, Dept Anaesthesia & Intens Care, Aalborg, Denmark.
   [Nielsen, Henrik] Aalborg Univ Hosp, Dept Infect Dis, Aalborg, Denmark.
   [Christensen, Steffen] Aarhus Univ Hosp, Dept Anaesthesia & Intens Care, Aarhus, Denmark.
   [Strom, Thomas] Odense Univ Hosp, Dept Anaesthesia & Intens Care, Odense, Denmark.
   [Cronhjort, Maria; Wahlin, Rebecka Rubenson] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden.
   [Jakob, Stephan; Cioccari, Luca] Univ Bern, Bern Univ Hosp, Dept Intens Care Med, Inselspital, Bern, Switzerland.
   [Venkatesh, Balasubramanian; Hammond, Naomi] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia.
   [Jha, Vivekanand] Univ New South Wales, George Inst Global Hlth, New Delhi, India.
   [Jha, Vivekanand] Manipal Acad Higher Educ, Manipal, Karnataka, India.
   [Myatra, Sheila Nainan] Homi Bhabha Natl Inst, Tata Mem Hosp, Dept Anaesthesia Crit Care & Pain, Mumbai, Maharashtra, India.
   [Gluud, Christian] Copenhagen Univ Hosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark.
   [Lange, Theis] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark.
RP Petersen, MW (corresponding author), Copenhagen Univ Hosp, Dept Intens Care, Copenhagen, Denmark.; Petersen, MW (corresponding author), Collaborat Res Intens Care CRIC, Copenhagen, Denmark.
EM marie.warrer.petersen.01@regionh.dk
RI Russell, Lene/I-8743-2019; Helleberg, Marie/ABC-8199-2020; Granholm,
   Anders/AAW-7623-2020
OI Russell, Lene/0000-0001-7352-8728; Helleberg, Marie/0000-0002-2370-1657;
   Granholm, Anders/0000-0001-5799-7655; Poulsen, Lone
   Musaeus/0000-0002-7030-3395; Lange, Theis/0000-0001-6807-8347; Solling,
   Christoffer/0000-0003-0721-926X; Hildebrandt,
   Thomas/0000-0001-7845-9899; Hjortso, Carl Johan
   Steensen/0000-0003-0413-9715; Benfield, Thomas/0000-0003-0698-9385;
   Cioccari, Luca/0000-0003-4993-427X; Kjaer, Maj-Brit/0000-0002-6536-0504;
   Jha, Vivekanand/0000-0002-8015-9470; Myatra, Sheila/0000-0001-6761-163X;
   Rasmussen, Bodil Steen/0000-0003-2190-145X
FU Rigshospitalet's Research Council [E-22703-06]; Novo Nordisk FondenNovo
   Nordisk Foundation [0062998]; PfizerPfizer [60473019]
FX Rigshospitalet's Research Council, Grant/Award Number: E-22703-06; Novo
   Nordisk Fonden, Grant/Award Number: 0062998; Pfizer, Grant/Award Number:
   60473019
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, 51 WHO
   Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Bhimraj A, 2020, CLIN INFECT DIS
   Bland JM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2622
   Cao B, 2020, NEW ENGL J MED, V382
   Center for Systems Science and Engineering at Johns Hopkins University, COR COVID 19 GLOB CA
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Copin MC, 2020, INTENS CARE MED, V46, P1124, DOI 10.1007/s00134-020-06057-8
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Horby P, EFFECT DEXAMETHASONE, DOI 10.1101/2020.06.22.20137273
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ICH Steering Committee, INT C HARM TECHN REQ
   International Committee of Medical Journal Editors, REC COND REP ED PUBL
   Jarvinen TLN, 2014, J CLIN EPIDEMIOL, V67, P769, DOI 10.1016/j.jclinepi.2013.11.011
   Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431
   Krag M, 2017, ACTA ANAESTH SCAND, V61, P859, DOI 10.1111/aas.12917
   Kryger Jensen A, 2019, ARXIV191012267STATME
   Loisa P, 2007, CRIT CARE, V11, DOI 10.1186/cc5696
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Perez A, 2014, J DIABETES, V6, P9, DOI 10.1111/1753-0407.12090
   Rygard SL, 2018, INTENS CARE MED, V44, P1003, DOI 10.1007/s00134-018-5197-6
   Schulz KF, 2011, INT J SURG, V9, P672, DOI [10.1016/j.ijsu.2011.09.004, 10.1016/j.jclinepi.2010.02.005]
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Smith FG, 2010, CRIT CARE, V14, DOI 10.1186/cc9266
   Sun SS, 2019, EXP THER MED, V18, P4637, DOI 10.3892/etm.2019.8167
   The Internation Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Expert Working Group, 2016, GUID GOOD CLIN PRA E
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
   Vesin A, 2013, INTENS CARE MED, V39, P1396, DOI 10.1007/s00134-013-2949-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, CLIN MAN SEV AC RESP
   World Medical Association, 2013, WMA DECL HELS ETH PR
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Y, 2020, SCI REP-UK, V10, DOI [10.1038/s41598-020-59732-7, 10.1038/s41598-020-58796-9]
NR 39
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD OCT
PY 2020
VL 64
IS 9
BP 1365
EP 1375
DI 10.1111/aas.13673
EA JUL 2020
PG 11
WC Anesthesiology
SC Anesthesiology
GA NK2AH
UT WOS:000553795500001
PM 32779728
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mikuls, TR
   Johnson, SR
   Fraenkel, L
   Arasaratnam, RJ
   Baden, LR
   Bermas, BL
   Chatham, W
   Cohen, S
   Costenbader, K
   Gravallese, EM
   Kalil, AC
   Weinblatt, ME
   Winthrop, K
   Mudano, AS
   Turner, A
   Saag, KG
AF Mikuls, Ted R.
   Johnson, Sindhu R.
   Fraenkel, Liana
   Arasaratnam, Reuben J.
   Baden, Lindsey R.
   Bermas, Bonnie L.
   Chatham, Winn
   Cohen, Stanley
   Costenbader, Karen
   Gravallese, Ellen M.
   Kalil, Andre C.
   Weinblatt, Michael E.
   Winthrop, Kevin
   Mudano, Amy S.
   Turner, Amy
   Saag, Kenneth G.
TI American College of Rheumatology Guidance for the Management of
   Rheumatic Disease in Adult Patients During the COVID-19 Pandemic:
   Version 2
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HERPES-ZOSTER; SERIOUS INFECTIONS;
   INCREASED RISK; ARTHRITIS; HYDROXYCHLOROQUINE; METHOTREXATE; CRITERIA;
   THERAPY; DISCONTINUATION
AB Objective To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic. Methods A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by e-mail and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus. Results To date, the task force has approved 80 guidance statements: 36 with moderate and 44 with high consensus. These were combined, resulting in 27 final guidance statements. Conclusion These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
C1 [Mikuls, Ted R.; Kalil, Andre C.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA.
   [Mikuls, Ted R.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA.
   [Johnson, Sindhu R.] Mt Sinai Hosp, Toronto Western Hosp, Toronto, ON, Canada.
   [Johnson, Sindhu R.] Univ Toronto, Toronto, ON, Canada.
   [Fraenkel, Liana] Berkshire Hlth Syst, Pittsfield, MA USA.
   [Fraenkel, Liana] Yale Univ, New Haven, CT USA.
   [Arasaratnam, Reuben J.; Bermas, Bonnie L.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Baden, Lindsey R.; Costenbader, Karen; Gravallese, Ellen M.; Weinblatt, Michael E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Chatham, Winn; Mudano, Amy S.; Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Cohen, Stanley] Metroplex Clin Res Ctr, Dallas, TX USA.
   [Winthrop, Kevin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Turner, Amy] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA.
RP Mikuls, TR (corresponding author), Univ Nebraska Med Ctr, Div Rheumatol, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM tmikuls@unmc.edu
OI Johnson, Sindhu R./0000-0003-0591-2976; Mikuls, Ted/0000-0002-0897-2272
FU American College of Rheumatology
FX Supported by the American College of Rheumatology.
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   American College of Rheumatology, 2020, COVID 19 PRACT ADV R
   American Heart Association, 2020, PAT TAK ACE I ARBS W
   Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013
   Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003
   Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   Bernatsky S, 2007, RHEUMATOLOGY, V46, P1157, DOI 10.1093/rheumatology/kem076
   Bichile T, 2014, PRESSE MED, V43, pE187, DOI 10.1016/j.lpm.2014.03.009
   Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Brook R, 1994, CLIN PRACTICE GUIDEL, P59
   Burner TW, 2009, CURR OPIN RHEUMATOL, V21, P50, DOI 10.1097/BOR.0b013e32831bc0c4
   Centers for Disease Control and Prevention, 2020, PROT YOURS OTH
   Centers for Disease Control and Prevention, 2020, WHAT DO YOU AR SICK
   Chen DY, 2017, EXP THER MED, V14, P6222, DOI 10.3892/etm.2017.5297
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   ClinicalTrials.gov. National Library of Medicine, 2020, EFF SAF EM AN RED HY
   ClinicalTrials.gov. National Library of Medicine, 2020, EV EFF SAF SAR HOSP
   ClinicalTrials.gov. National Library of Medicine, 2020, TREATM MOD SEV COR D
   ClinicalTrials.gov. National Library of Medicine, 2020, TOC VS CRRT MAN CYT
   ClinicalTrials.gov. National Library of Medicine, 2020, ANTIIL6 TREATM SER C
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   de Vries-Bouwstra JK, 2020, J RHEUMATOL, V47, P249, DOI 10.3899/jrheum.181173
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geraldino-Pardilla L, 2019, LUPUS, V28, P862, DOI 10.1177/0961203319851558
   Giwa A L, 2020, Pediatr Emerg Med Pract, V17, P1
   Grijalva CG, 2011, JAMA-J AM MED ASSOC, V306, P2331, DOI 10.1001/jama.2011.1692
   Hemingway H, 2008, ANN INTERN MED, V149, P221, DOI 10.7326/0003-4819-149-4-200808190-00003
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632
   LAROCHELLE GE, 1993, AM J MED, V95, P258, DOI 10.1016/0002-9343(93)90277-V
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Liu Z, 2020, J INFECTION, V6, P43
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mikuls TR, 2003, BEST PRACT RES CL RH, V17, P729, DOI 10.1016/S1521-6942(03)00041-X
   Mok CC, 2016, ARTHRIT CARE RES, V68, P1295, DOI 10.1002/acr.22837
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID MA
   National Institutes of Health, 2020, THER OPT COVID 19 CU
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Nurmohamed MT, 2015, NAT REV RHEUMATOL, V11, P693, DOI 10.1038/nrrheum.2015.112
   Pappas DA, 2015, ARTHRIT CARE RES, V67, P1671, DOI 10.1002/acr.22628
   Peart E, 2014, CURR OPIN RHEUMATOL, V26, P118, DOI 10.1097/BOR.0000000000000030
   Pimentel-Quiroz VR, 2019, LUPUS, V28, P1101, DOI 10.1177/0961203319860579
   Qin X, 2020, LANCET
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Richter A, 2016, ANN RHEUM DIS, V75, P1667, DOI 10.1136/annrheumdis-2015-207838
   Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sears SP, 2016, DRUGS REAL WORLD OUT, V3, P99, DOI [DOI 10.1007/s40801-016-0062-9, 10.1007/s40801-016-0062-9]
   Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022
   Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607
   Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Singh JA, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0609-5
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
   Smolen JS, 2014, LANCET, V383, P321, DOI 10.1016/S0140-6736(13)61751-1
   Smolen JS, 2013, LANCET, V381, P918, DOI 10.1016/S0140-6736(12)61811-X
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Strangfeld A, 2011, ANN RHEUM DIS, V70, P1914, DOI 10.1136/ard.2011.151043
   Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P171, DOI 10.1136/annrheumdis-2018-213271
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tsakonas E, 1998, LUPUS, V7, P80
   Tselios K, 2014, SEMIN ARTHRITIS RHEU, V43, P521, DOI 10.1016/j.semarthrit.2013.07.007
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tudesq JJ, 2018, AUTOIMMUN REV, V17, P115, DOI 10.1016/j.autrev.2017.11.015
   US Food and Drug Administration, 2020, COR COVID 19 UPD DAI
   US Food and Drug Administration, 2020, FDA ADV PAT US NONST
   US Food and Drug Administration, 2020, FDA DRUG SHORT
   van Vollenhoven RF, 2016, ANN RHEUM DIS, V75, P52, DOI 10.1136/annrheumdis-2014-205726
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, REP WHO CHIN JOINT M
   Winthrop KL, 2017, ARTHRITIS RHEUMATOL, V69, P1960, DOI 10.1002/art.40189
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu X, 2020, EFFECTIVE TREATMENT
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao X, 2020, CLIN INFECT DIS
   Younes A, 2011, ONCOLOGIST, V16, P730, DOI 10.1634/theoncologist.2010-0318
   Youssef J, 2016, RHEUM DIS CLIN N AM, V42, P157, DOI 10.1016/j.rdc.2015.08.004
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang N, 2012, CLIN EXP RHEUMATOL, V30, P962
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 99
TC 4
Z9 4
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD SEP
PY 2020
VL 72
IS 9
BP E1
EP E12
DI 10.1002/art.41437
EA JUL 2020
PG 12
WC Rheumatology
SC Rheumatology
GA NF3RY
UT WOS:000553792300001
PM 32734689
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, YH
   Zhou, Q
   Xu, MQ
   Kang, J
   Chen, YL
AF Wang, Yuhui
   Zhou, Qi
   Xu, Mengqi
   Kang, Jian
   Chen, Yaolong
TI Characteristics of Clinical Trials relating to COVID-19 registered at
   ClinicalTrials.gov
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article
DE characteristics analysis; clinical trial registration; COVID-19;
   SARS-CoV-2
AB What is known and objective Since the beginning of the COVID-19 outbreak in China in December 2019, the epidemic has continued to spread globally. Despite continuous reports of clinical trials being launched, no studies have yet systematically summarized and analysed their characteristics. Our objective is to do this by reviewing trials registered at ClinicalTrials.gov. Methods We searched the ClinicalTrials.gov database and retrieved all clinical trials on COVID-19 registered up to and including 3 April 2020. We summarized the characteristics of the trials, presenting the results of all trials, all intervention trials and drug intervention (including vaccines and traditional Chinese medicine) trials. Results and discussion We identified 306 COVID-19-related clinical trials. Seven of the studies had been withdrawn, leaving 299 active trials. Of the trials, 28.8% were planned to be conducted in Asia, 26.8% in Europe and 18.7% in North America. Most (73.0%) proposed trials expected to recruit fewer than 500 people, and only 22.1% of the studies included children (aged <18 years). About two-thirds (67.2%) of the studies were funded by the own resources of medical or research institutions. Of intervention trials, 73.9% used random allocation, and 73.4% used parallel assignment. Only 36.7% of the intervention trials used blinding. In terms of drug trials, 147 trials were drug intervention studies, covering 80 conventional drugs and seven traditional Chinese medicine drugs. Antiviral drugs and antimalarial drugs were the most commonly studied drugs with 52 and 45 trials registered, respectively. Five registered clinical trials were on vaccines. What is new and conclusion A large number of COVID-19-related trials have been registered within the first 4 months since the first infection was reported. These involve a large number of different drugs, the most common being antiviral drugs and antimalarial drugs. More attention should be paid to adequate blinding in future trials.
C1 [Wang, Yuhui; Kang, Jian] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou, Peoples R China.
   [Zhou, Qi] Lanzhou Univ, Sch Clin Med 1, Lanzhou, Peoples R China.
   [Zhou, Qi; Chen, Yaolong] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, 222 Tianshui South Rd, Lanzhou, Peoples R China.
   [Xu, Mengqi] Henan Ctr Dis Control & Prevent, Zhengzhou, Peoples R China.
   [Chen, Yaolong] Lanzhou Univ, Cochrane China Network, Lanzhou, Peoples R China.
   [Chen, Yaolong] Chinese GRADE Ctr, Lanzhou, Peoples R China.
   [Chen, Yaolong] Lanzhou Univ, Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.
RP Kang, J (corresponding author), Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou, Peoples R China.; Chen, YL (corresponding author), Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, 222 Tianshui South Rd, Lanzhou, Peoples R China.
EM kjlhy@tom.com; chenyaolong@lzu.edu.cn
OI Zhou, Qi/0000-0001-7884-7074
CR [Anonymous], 1997, NEW ENGL J MED, V336, P309, DOI DOI 10.1056/NEJM199701233360422
   Arnow KD, 2019, PSYCHIAT RES, V281, DOI 10.1016/j.psychres.2019.112552
   Califf RM, 2012, JAMA-J AM MED ASSOC, V307, P1838, DOI 10.1001/jama.2012.3424
   Chen CE, 2019, JAMA INTERN MED, V179, P838, DOI 10.1001/jamainternmed.2018.7235
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   De Angelis CD, 2006, HAEMATOLOGICA, V91, P293
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Duley L, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2378-5
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Norris Susan L, 2018, J Evid Based Med, V11, P133, DOI 10.1111/jebm.12314
   Pillamarapu M, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3592-0
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Wager E, 2014, EUR J ANAESTH, V31, P397, DOI 10.1097/EJA.0000000000000084
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   [项玉霞 Xiang Yuxia], 2020, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V25, P135
   Zarin DA, 2011, NEW ENGL J MED, V364, P852, DOI 10.1056/NEJMsa1012065
   Zhang XJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010643
NR 20
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD DEC
PY 2020
VL 45
IS 6
BP 1357
EP 1362
DI 10.1111/jcpt.13222
EA JUL 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OM7JJ
UT WOS:000553783600001
PM 32734670
OA Bronze
DA 2021-01-01
ER

PT J
AU Landecho, MF
   Yuste, JR
   Gandara, E
   Sunsundegui, P
   Quiroga, J
   Alcaide, AB
   Garcia-Layana, A
AF Landecho, M. F.
   Yuste, J. R.
   Gandara, E.
   Sunsundegui, P.
   Quiroga, J.
   Alcaide, A. B.
   Garcia-Layana, A.
TI COVID-19 retinal microangiopathy as an in vivo biomarker of systemic
   vascular disease?
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Article; Early Access
DE COVID-19 retinopathy; COVID-19 retinal microangiopathy; COVID-19
   vascular risk
AB Importance COVID-19 is caused by SARS-CoV-2, a betacoronavirus that uses the angiotensin-converting enzyme-related carboxypeptidase (ACE2) receptor to gain entry into cells. ACE2 receptor is widely expressed in multiple organs, including the retina, an extension of the central nervous system. The ACE2 receptor is involved in the diabetic and hypertensive retinopathy. Additionally, coronaviruses cause ocular infections in animals, including retinitis, and optic neuritis. Objective To assess whether there is any retinal disease associated with COVID-19. Design We have evaluated 27 asymptomatic subjects, with retinal fundoscopic, optical coherence tomography (OCT) and OCT angiography fourteen days after hospital discharge due to COVID-19 bilateral pneumonia. Results Cotton wool exudates were evident in six out of 27 patients evaluated, a 22%. Cotton wool exudates are a marker vascular disease severity in other medical context, that is diabetes and hypertension, and are associated with increased risk for acute vascular events. Whether antiaggregation therapy may play a role on fundoscopic-selected patients with COVID-19 requires prospective trials.
C1 [Landecho, M. F.; Yuste, J. R.; Sunsundegui, P.; Quiroga, J.; Alcaide, A. B.] Clin Univ Navarra, Covid19 Dept, Navarra, Spain.
   [Landecho, M. F.; Yuste, J. R.; Sunsundegui, P.; Quiroga, J.] Clin Univ Navarra, Internal Med Dept, Navarra, Spain.
   [Yuste, J. R.] Clin Univ Navarra, Microbiol & Infect Dis Div, Navarra, Spain.
   [Gandara, E.; Garcia-Layana, A.] Clin Univ Navarra, Ophtalmol Dept, Ave Pio XII 36, Navarra 31008, Spain.
   [Quiroga, J.] CIBEREHD, Navarra, Spain.
   [Alcaide, A. B.] Clin Univ Navarra, Pulm Med Dept, Navarra, Spain.
RP Garcia-Layana, A (corresponding author), Clin Univ Navarra, Ophtalmol Dept, Ave Pio XII 36, Navarra 31008, Spain.; Landecho, MF (corresponding author), Clin Univ Navarra, Internal Med Dept, Covid19 Dept, Ave Pio XII 36, Navarra 31008, Spain.
EM mflandecho@unav.es; aglayana@unav.es
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2
   Duan YQ, 2018, STEM CELLS, V36, P1430, DOI 10.1002/stem.2848
   Hess DC, 2020, TRANSL STROKE RES, V11, P322, DOI 10.1007/s12975-020-00818-9
   Jaworski C, 2000, OPTOMETRY VISION SCI, V77, P600, DOI 10.1097/00006324-200011000-00010
   Mahdjoubi A, 2020, INT OPHTHALMOL, V40, P1625, DOI 10.1007/s10792-020-01330-7
   Marinho PM, 2020, LANCET, V395, P1610, DOI 10.1016/S0140-6736(20)31014-X
   Raja H, 2020, DATA BRIEF, V29, DOI 10.1016/j.dib.2020.105342
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 15
TC 7
Z9 7
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
EI 1365-2796
J9 J INTERN MED
JI J. Intern. Med.
DI 10.1111/joim.13156
EA JUL 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR2YB
UT WOS:000553455600001
PM 32729633
OA Bronze
DA 2021-01-01
ER

PT J
AU Lara, OD
   O'Cearbhaill, RE
   Smith, MJ
   Sutter, ME
   Knisely, A
   McEachron, J
   Gabor, LR
   Jee, J
   Fehniger, JE
   Lee, YC
   Isani, SS
   Wright, JD
   Pothuri, B
AF Lara, Olivia D.
   O'Cearbhaill, Roisin E.
   Smith, Maria J.
   Sutter, Megan E.
   Knisely, Anne
   McEachron, Jennifer
   Gabor, Lisa R.
   Jee, Justin
   Fehniger, Julia E.
   Lee, Yi-Chun
   Isani, Sara S.
   Wright, Jason D.
   Pothuri, Bhavana
TI COVID-19 outcomes of patients with gynecologic cancer in New York City
SO CANCER
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); gynecologic cancer; outcomes;
   severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
AB Background New York City (NYC) is the epicenter of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]) in the United States. Clinical characteristics and outcomes of vulnerable populations, such as those with gynecologic cancer who develop COVID-19 infections, is limited. Methods Patients from 6 NYC-area hospital systems with known gynecologic cancer and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records. Results Records for 121 patients with gynecologic cancer and COVID-19 were abstracted; the median age at the COVID-19 diagnosis was 64.0 years (interquartile range, 51.0-73.0 years). Sixty-six of the 121 patients (54.5%) required hospitalization; among the hospitalized patients, 45 (68.2%) required respiratory intervention, 20 (30.3%) were admitted to the intensive care unit, and 9 (13.6%) underwent invasive mechanical ventilation. Seventeen patients (14.0%) died of COVID-19 complications. No patient requiring mechanical ventilation survived. On multivariable analysis, hospitalization was associated with an age >= 64 years (risk ratio [RR], 1.73; 95% confidence interval [CI], 1.18-2.51), African American race (RR, 1.56; 95% CI, 1.13-2.15), and 3 or more comorbidities (RR, 1.43; 95% CI, 1.03-1.98). Only recent immunotherapy use (RR, 3.49; 95% CI, 1.08-11.27) was associated with death due to COVID-19 on multivariable analysis; chemotherapy treatment and recent major surgery were not predictive of COVID-19 severity or mortality. Conclusions The case fatality rate among gynecologic oncology patients with a COVID-19 infection is 14.0%. Recent immunotherapy use is associated with an increased risk of mortality related to COVID-19 infection. Lay Summary
   The case fatality rate among gynecologic oncology patients with a coronavirus disease 2019 (COVID-19) infection is 14.0%; there is no association between cytotoxic chemotherapy and cancer-directed surgery and COVID-19 severity or death. As such, patients can be counseled regarding the safety of continued anticancer treatments during the pandemic. This is important because the ability to continue cancer therapies for cancer control and cure is critical.
C1 [Lara, Olivia D.; Smith, Maria J.; Sutter, Megan E.; Fehniger, Julia E.; Pothuri, Bhavana] NYU Langone Hlth, Dept Obstet & Gynecol, Perlmutter Canc Ctr, New York, NY 10016 USA.
   [O'Cearbhaill, Roisin E.; Jee, Justin] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Sutter, Megan E.] NYU Langone Hlth, Dept Populat Hlth, New York, NY 10016 USA.
   [Knisely, Anne; Wright, Jason D.] Columbia Univ, Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY USA.
   [McEachron, Jennifer; Lee, Yi-Chun] SUNY Downstate Med Ctr, Dept Obstet & Gynecol, Brooklyn, NY 11203 USA.
   [Gabor, Lisa R.; Isani, Sara S.] Montefiore Med Ctr, Dept Obstet & Gynecol & Womens Hlth, 111 E 210th St, Bronx, NY 10467 USA.
   [Gabor, Lisa R.; Isani, Sara S.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
RP Pothuri, B (corresponding author), NYU Langone Hlth, Dept Obstet & Gynecol, 240 E 38th St,19th Fl, New York, NY 10016 USA.
EM bhavana.pothuri@nyulangone.org
OI Pothuri, Bhavana/0000-0003-4578-2061; Sutter, Megan/0000-0001-9816-9549
FU Agency for Healthcare Research and QualityUnited States Department of
   Health & Human ServicesAgency for Healthcare Research & Quality
   [T32HS026120]; National Institutes of Health/National Cancer Institute
   Cancer Center Support Grant [P30 CA008748]
FX Megan E. Sutter is supported by the Agency for Healthcare Research and
   Quality (T32HS026120). Roisin E. O'Cearbhaill and Justin Jee were
   supported in part by National Institutes of Health/National Cancer
   Institute Cancer Center Support Grant P30 CA008748 (Memorial Sloan
   Kettering Cancer Center support group).
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Darmon M, 2019, INTENS CARE MED, V45, P977, DOI 10.1007/s00134-019-05653-7
   Gardiner D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063818
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   MA XT, 2020, JAMA ONCOL, DOI DOI 10.1001/JAMAONCOL.2020.0980
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005
   New York City Health, COVID 19 DAT
   NYC Health, COVID 19 DAT
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
   World Health Organization, WHO COR DIS COVID 19
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 29
TC 1
Z9 1
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 1
PY 2020
VL 126
IS 19
BP 4294
EP 4303
DI 10.1002/cncr.33084
EA JUL 2020
PG 10
WC Oncology
SC Oncology
GA NI5RA
UT WOS:000553393200001
PM 32729142
OA Bronze
DA 2021-01-01
ER

PT J
AU Ogbogu, U
   Hardcastle, L
AF Ogbogu, Ubaka
   Hardcastle, Lorian
TI Bioethics and practical justice in the post-COVID-19 era
SO DEVELOPING WORLD BIOETHICS
LA English
DT Article; Early Access
DE practical justice; justice; COVID-19; bioethics; biotechnology; ethics
ID DEVELOPING-COUNTRIES; CLINICAL-RESEARCH; PRINCIPLES
AB The ethical concept of justice, as it relates to the development and deployment of innovative health technologies, commands the fair and equitable distribution of burdens and benefits. In bioethics, specific guidance on practical strategies for achieving what this concept of justice demands are somewhat elusive. Drawing on issues of justice arising or likely to arise in the context of the search for a vaccine or cure for COVID-19, this paper argues for a focus on the concept of "practical justice" in post-pandemic bioethics work. To illustrate the value and promise of this concept, the paper reflects on an approach to achieving practical justice in health biotechnology research that is grounded in a commitment to offer technical assistance to developing and under-resourced nations.
C1 [Ogbogu, Ubaka] Univ Alberta, Fac Law, Edmonton, AB, Canada.
   [Ogbogu, Ubaka] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada.
   [Ogbogu, Ubaka] Univ Alberta, Hlth Law & Sci Policy, Edmonton, AB, Canada.
   [Hardcastle, Lorian] Univ Calgary, Fac Law, Dept Community Hlth Sci, Cumming Sch Med, Calgary, AB, Canada.
   [Hardcastle, Lorian] Univ Calgary, AMR One Hlth Consortium, OBrien Inst Publ Hlth, Calgary, AB, Canada.
   [Hardcastle, Lorian] Univ Calgary, Conjoint Hlth Res Eth Board, Calgary, AB, Canada.
RP Ogbogu, U (corresponding author), Univ Alberta, Fac Law, Edmonton, AB, Canada.; Ogbogu, U (corresponding author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada.
EM uogbogu@ualberta.ca
OI Hardcastle, Lorian/0000-0003-4057-4036
CR Aggleton P., 2019, PRACTICAL JUSTICE PR, P1
   Ahmed K, 2001, LANCET, V358, P815, DOI 10.1016/S0140-6736(01)06011-1
   Akst J., 2020, SCIENTIST
   Arendt H., 2018, HUMAN CONDITION, P8
   Bradley Jane, 2020, NY TIMES
   Busari S, 2020, CNN
   Canadian Institutes of Health Research, 2018, TRIC POL STAT ETH CO
   Chattopadhyay S., 2009, EUBIOS J ASIAN INT B, V18, P106
   Council for International Organizations of Medical Sciences, 2016, INT ETH GUID HLTH RE
   COVID-19 Clinical Res Coalition, 2020, LANCET, V395, P1322, DOI 10.1016/S0140-6736(20)30798-4
   Dauda B, 2016, J BIOETHIC INQ, V13, P281, DOI 10.1007/s11673-016-9706-4
   Department of Science and Technology, 2013, BIOEC STRAT
   Eggertson L, 2020, CAN MED ASSOC J, V192, pE438, DOI 10.1503/cmaj.1095862
   Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701
   Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709
   Engelhardt HT, 1998, J MED PHILOS, V23, P643
   Enserink M, 2009, SCIENCE, V326, P782, DOI 10.1126/science.326_782
   Faden R, 2013, J PRACT ETHICS, V1, P49
   Ferrer M, 2004, NAT BIOTECHNOL, V22, pDC8, DOI 10.1038/nbt1204supp-DC8
   International Society for Stem Cell Research, 2016, GUID STEM CELL RES C
   Macpherson CC, 2019, BIOETHICS, V33, P389, DOI 10.1111/bioe.12577
   Milum J., 2012, DEV WORLD BIOETH, V4, P42
   National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, BELM REP ETH PRINC G
   Nickerson J., 2020, CONVERSATION
   Pan American Health Organization, 2020, ETH GUID ISS RAIS NO
   Patton P., 2019, PRACTICAL JUSTICE PR
   Rabin R. C., 2020, NY TIMES
   Ravitsky V., 2020, POSTCOVID BIOETHICS
   Sedyaningsih ER, 2008, ANN ACAD MED SINGAP, V37, P482
   Servick K, 2020, SCIENCE
   Singh Rajesh Kumar, 2020, BLOOMBERG
   Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048
   The InterAcademy Partnership, 2019, HARN SCI ENG MED ADD
   Thorsteinsdottir H, 2004, NAT BIOTECHNOL, V22, pDC48, DOI 10.1038/nbt1204supp-DC48
   UNESCO, 2005, UN DECL BIOETH HUM R
   Wendland CL, 2008, AFR STUD REV, V51, P1, DOI 10.1353/arw.0.0084
   WHO, 2010, GLOB COD PRACT INT R
   WHO, 2005, INT HLTH REG
   Wolpe PR, 2017, NAT BIOTECHNOL, V35, P1050, DOI 10.1038/nbt.4007
   World Health Organization, 2011, INFL PREP FRAM
   World Health Organization, 2020, ETH COVID 19 RES ALL
   World Medical Association, 2008, DECL HELS ETH PRINC
NR 42
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1471-8731
EI 1471-8847
J9 DEV WORLD BIOETH
JI Dev. World Bioeth.
DI 10.1111/dewb.12279
EA JUL 2020
PG 5
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA MR4JW
UT WOS:000553556300001
PM 33210409
OA Bronze
DA 2021-01-01
ER

PT J
AU Al-Shar'i, NA
AF Al-Shar'i, Nizar A.
TI Tackling COVID-19: identification of potential main protease inhibitors
   via structural analysis, virtual screening, molecular docking and
   MM-PBSA calculations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; main protease; key interacting residues; pharmacophore
   modeling; docking
ID DYNAMICS; AMBER
AB The widespread of the COVID-19 disease, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), had severely affected the entire world. Unfortunately, no successful vaccines or antiviral drugs are currently available which leaves the scientific community under huge pressure to tackle this pandemic. Among the identified promising druggable targets, specific to this virus, is the main protease (M-pro) enzyme, which is vital for viral replication, transcription and packaging within the host cells. In this study, selective inhibition of the M(pro)was sought via thorough analysis of its available structural data in the Protein Data Bank. To this end, COVID-19 M(pro)crystal complexes were explored and the key interacting residues (KIRs) within its active site, that are expected to be vital for effective ligand binding, were identified. Based on these KIRs, 3D pharmacophore models were generated and used in virtual screening of different databases. Retrieved hits were docked into the active site of the enzyme and their MM-PBSA based free binding energies were calculated. Finally, ADMET descriptors were calculated to aid the selection of top scoring hits with best ADMET properties. Nine compounds with different chemotypes were identified as potential M(pro)inhibitors. Further, MD simulations of a virtual complex of M(pro)with one of the promising hits revealed stable binding which is indicative of good inhibitory potential. The identified compounds in this study are expected to support the global drug discovery efforts in fighting against this highly contagious virus by narrowing the searchable chemical space for potential effective therapeutics. Communicated by Ramaswamy H. Sarma
C1 [Al-Shar'i, Nizar A.] Jordan Univ Sci & Technol, Fac Pharm, Dept Med Chem & Pharmacognosy, POB 3030, Irbid 22110, Jordan.
RP Al-Shar'i, NA (corresponding author), Jordan Univ Sci & Technol, Fac Pharm, Dept Med Chem & Pharmacognosy, POB 3030, Irbid 22110, Jordan.
EM nashari@just.edu.jo
CR Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Al-Shar'i NA, 2021, ACTA PHARMACEUT, V71, P115, DOI 10.2478/acph-2021-0005
   Al-Shar'i NA, 2020, MED CHEM RES, V29, P356, DOI 10.1007/s00044-019-02486-3
   Al-Shar'i NA, 2019, J COMPUT AID MOL DES, V33, P799, DOI 10.1007/s10822-019-00226-8
   Al-Shar'i NA, 2016, J MOL GRAPH MODEL, V68, P147, DOI 10.1016/j.jmgm.2016.07.001
   Anson B. J., 2020, BROAD SPECTRUM INHIB, DOI [10.21203/rs.3.rs-26344/v1, DOI 10.21203/RS.3.RS-26344/V1]
   Biovia D. S., 2017, PIPELINE PILOT
   Biovia D. S., 2017, DISCOVERY STUDIO
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Case D., 2012, AMBER 12
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   DeLano W. L, 2016, PYMOL MOL GRAPHICS S
   Ezekwe EAD, 2016, TOXINS, V8, DOI 10.3390/toxins8040095
   Fadrna E, 2005, J BIOMOL STRUCT DYN, V23, P151, DOI 10.1080/07391102.2005.10531229
   FLETCHER R, 1964, COMPUT J, V7, P149, DOI 10.1093/comjnl/7.2.149
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Goldfarb D. S., 2009, METHOD USING LIFESPA
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   HAMMONDS KD, 1991, COMPUT PHYS COMMUN, V62, P336, DOI 10.1016/0010-4655(91)90105-T
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   John S, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S14-S4
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kadioglu O, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255943, DOI 10.2471/BLT.20.255943]
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Krammer A, 2005, J MOL GRAPH MODEL, V23, P395, DOI 10.1016/j.jmgm.2004.11.007
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Ma Chunlong, 2020, bioRxiv, DOI 10.1101/2020.04.20.051581
   Mastrangelo E, 2008, J MOL BIOL, V384, P673, DOI 10.1016/j.jmb.2008.09.064
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Meza JC, 2010, WIRES COMPUT STAT, V2, P719, DOI 10.1002/wics.117
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Muegge I, 2006, J MED CHEM, V49, P5895, DOI 10.1021/jm050038s
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Ridley D. D., 2009, INFORM RETRIEVAL SCI
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Spassov VZ, 2008, PROTEIN SCI, V17, P1955, DOI 10.1110/ps.036335.108
   Spassov VZ, 2008, PROTEIN ENG DES SEL, V21, P91, DOI 10.1093/protein/gzm083
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Watanabe K, 2007, NATURE, V449, P867, DOI 10.1038/nature06167
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization (WHO 2020 ), 2020, NOV COR CHIN DIS OUT
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 56
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1800514
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MT8KN
UT WOS:000555217100001
PM 32734828
OA Bronze
DA 2021-01-01
ER

PT J
AU Yang, JY
   Wang, W
   Chen, ZM
   Lu, SY
   Yang, FL
   Bi, ZF
   Bao, LL
   Mo, F
   Li, X
   Huang, Y
   Hong, WQ
   Yang, Y
   Zhao, Y
   Ye, F
   Lin, S
   Deng, W
   Chen, H
   Lei, H
   Zhang, ZQ
   Luo, M
   Gao, H
   Zheng, Y
   Gong, YQ
   Jiang, XH
   Xu, YF
   Lv, Q
   Li, D
   Wang, MN
   Li, FD
   Wang, SY
   Wang, GP
   Yu, P
   Qu, YJ
   Yang, L
   Deng, HX
   Tong, AP
   Li, J
   Wang, ZL
   Yang, JL
   Shen, GB
   Zhao, ZW
   Li, YH
   Luo, JW
   Liu, HQ
   Yu, WH
   Yang, ML
   Xu, JW
   Wang, JB
   Li, HY
   Wang, HX
   Kuang, DX
   Lin, PP
   Hu, ZT
   Guo, W
   Cheng, W
   He, YL
   Song, XR
   Chen, C
   Xue, ZH
   Yao, SH
   Chen, L
   Ma, XL
   Chen, SY
   Gou, ML
   Huang, WJ
   Wang, YC
   Fan, CF
   Tian, ZX
   Shi, M
   Wang, FS
   Dai, LZ
   Wu, M
   Li, G
   Wang, GY
   Peng, Y
   Qian, ZY
   Huang, CH
   Lau, JYN
   Yang, ZL
   Wei, YQ
   Cen, XB
   Peng, XZ
   Qin, C
   Zhang, K
   Lu, GW
   Wei, XW
AF Yang, Jingyun
   Wang, Wei
   Chen, Zimin
   Lu, Shuaiyao
   Yang, Fanli
   Bi, Zhenfei
   Bao, Linlin
   Mo, Fei
   Li, Xue
   Huang, Yong
   Hong, Weiqi
   Yang, Yun
   Zhao, Yuan
   Ye, Fei
   Lin, Sheng
   Deng, Wei
   Chen, Hua
   Lei, Hong
   Zhang, Ziqi
   Luo, Min
   Gao, Hong
   Zheng, Yue
   Gong, Yanqiu
   Jiang, Xiaohua
   Xu, Yanfeng
   Lv, Qi
   Li, Dan
   Wang, Manni
   Li, Fengdi
   Wang, Shunyi
   Wang, Guanpeng
   Yu, Pin
   Qu, Yajin
   Yang, Li
   Deng, Hongxin
   Tong, Aiping
   Li, Jiong
   Wang, Zhenling
   Yang, Jinliang
   Shen, Guobo
   Zhao, Zhiwei
   Li, Yuhua
   Luo, Jingwen
   Liu, Hongqi
   Yu, Wenhai
   Yang, Mengli
   Xu, Jingwen
   Wang, Junbin
   Li, Haiyan
   Wang, Haixuan
   Kuang, Dexuan
   Lin, Panpan
   Hu, Zhengtao
   Guo, Wei
   Cheng, Wei
   He, Yanlin
   Song, Xiangrong
   Chen, Chong
   Xue, Zhihong
   Yao, Shaohua
   Chen, Lu
   Ma, Xuelei
   Chen, Siyuan
   Gou, Maling
   Huang, Weijin
   Wang, Youchun
   Fan, Changfa
   Tian, Zhixin
   Shi, Ming
   Wang, Fu-Sheng
   Dai, Lunzhi
   Wu, Min
   Li, Gen
   Wang, Guangyu
   Peng, Yong
   Qian, Zhiyong
   Huang, Canhua
   Lau, Johnson Yiu-Nam
   Yang, Zhenglin
   Wei, Yuquan
   Cen, Xiaobo
   Peng, Xiaozhong
   Qin, Chuan
   Zhang, Kang
   Lu, Guangwen
   Wei, Xiawei
TI A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces
   protective immunity
SO NATURE
LA English
DT Article; Early Access
ID RECEPTOR-BINDING DOMAIN; MERS-COV; CORONAVIRUS; SPIKE; NEUTRALIZATION;
   ANTIBODIES; MICE; RESPONSES; ALUMINUM; SUBUNIT
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory disease called coronavirus disease 2019 (COVID-19), the spread of which has led to a pandemic. An effective preventive vaccine against this virus is urgently needed. As an essential step during infection, SARS-CoV-2 uses the receptor-binding domain (RBD) of the spike protein to engage with the receptor angiotensin-converting enzyme 2 (ACE2) on host cells(1,2). Here we show that a recombinant vaccine that comprises residues 319-545 of the RBD of the spike protein induces a potent functional antibody response in immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after the injection of a single vaccine dose. The sera from the immunized animals blocked the binding of the RBD to ACE2, which is expressed on the cell surface, and neutralized infection with a SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Notably, vaccination also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2. We found increased levels of RBD-specific antibodies in the sera of patients with COVID-19. We show that several immune pathways and CD4 T lymphocytes are involved in the induction of the vaccine antibody response. Our findings highlight the importance of the RBD domain in the design of SARS-CoV-2 vaccines and provide a rationale for the development of a protective vaccine through the induction of antibodies against the RBD domain.
   A recombinant vaccine that targets the receptor-binding domain of the spike protein of SARS-CoV-2 induces a potent antibody response in immunized mice, rabbits and non-human primates, and protects primates from infection with the virus.
C1 [Yang, Jingyun; Wang, Wei; Chen, Zimin; Yang, Fanli; Bi, Zhenfei; Mo, Fei; Li, Xue; Huang, Yong; Hong, Weiqi; Ye, Fei; Lin, Sheng; Chen, Hua; Lei, Hong; Zhang, Ziqi; Luo, Min; Zheng, Yue; Gong, Yanqiu; Jiang, Xiaohua; Li, Dan; Wang, Manni; Yang, Li; Deng, Hongxin; Tong, Aiping; Li, Jiong; Wang, Zhenling; Yang, Jinliang; Shen, Guobo; Zhao, Zhiwei; Luo, Jingwen; Lin, Panpan; Cheng, Wei; Song, Xiangrong; Chen, Chong; Xue, Zhihong; Yao, Shaohua; Chen, Lu; Ma, Xuelei; Chen, Siyuan; Gou, Maling; Dai, Lunzhi; Wu, Min; Peng, Yong; Qian, Zhiyong; Huang, Canhua; Wei, Yuquan; Cen, Xiaobo; Lu, Guangwen; Wei, Xiawei] Sichuan Univ, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr,West China Hosp, Chengdu, Peoples R China.
   [Yang, Jingyun; Wang, Wei; Chen, Zimin; Yang, Fanli; Bi, Zhenfei; Mo, Fei; Li, Xue; Huang, Yong; Hong, Weiqi; Ye, Fei; Lin, Sheng; Chen, Hua; Lei, Hong; Zhang, Ziqi; Luo, Min; Zheng, Yue; Gong, Yanqiu; Jiang, Xiaohua; Li, Dan; Wang, Manni; Yang, Li; Deng, Hongxin; Tong, Aiping; Li, Jiong; Wang, Zhenling; Yang, Jinliang; Shen, Guobo; Zhao, Zhiwei; Luo, Jingwen; Lin, Panpan; Cheng, Wei; Song, Xiangrong; Chen, Chong; Xue, Zhihong; Yao, Shaohua; Chen, Lu; Ma, Xuelei; Chen, Siyuan; Gou, Maling; Dai, Lunzhi; Wu, Min; Peng, Yong; Qian, Zhiyong; Huang, Canhua; Wei, Yuquan; Cen, Xiaobo; Lu, Guangwen; Wei, Xiawei] Sichuan Univ, Canc Ctr, Natl Clin Res Ctr Geriatr, West China Hosp, Chengdu, Peoples R China.
   [Lu, Shuaiyao; Yang, Yun; Zhao, Yuan; Liu, Hongqi; Yu, Wenhai; Yang, Mengli; Xu, Jingwen; Wang, Junbin; Li, Haiyan; Wang, Haixuan; Kuang, Dexuan; Peng, Xiaozhong] Chinese Acad Med Sci & Peking Union Med Coll, Natl Kunming Highlevel Biosafety Primate Res Ctr, Kunming, Yunnan, Peoples R China.
   [Bao, Linlin; Deng, Wei; Gao, Hong; Xu, Yanfeng; Lv, Qi; Li, Fengdi; Wang, Shunyi; Wang, Guanpeng; Yu, Pin; Qu, Yajin; Qin, Chuan] Chinese Acad Med Sci & Comparat Med Ctr, Peking Union Med Coll, Key Lab Human Dis Comparat Med,Inst Lab Anim Sci, Chinese Minist Hlth,Beijing Key Lab Anim Models E, Beijing, Peoples R China.
   [Li, Yuhua; Huang, Weijin; Wang, Youchun; Fan, Changfa] Natl Inst Food & Drug Control NIFDC, Beijing, Peoples R China.
   [Guo, Wei; He, Yanlin; Cen, Xiaobo] Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Natl Chengdu Ctr Safety Evaluat Drugs, State Key Lab Biotherapy,West CHina Hosp, Chengdu, Peoples R China.
   [Guo, Wei; He, Yanlin; Cen, Xiaobo] Sichuan Univ, West China Hosp, Canc Ctr, Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China.
   [Hu, Zhengtao; Tian, Zhixin] Tongji Univ, Sch Chem Sci & Engn, Shanghai Key Lab Chem Assessment & Sustainabil, Shanghai, Peoples R China.
   [Shi, Ming; Wang, Fu-Sheng] Peoples Liberat Army Gen Hosp, Med Ctr 5, Treatment & Res Ctr Infect Dis, Natl Clin Res Ctr Infect Dis, Beijing, Peoples R China.
   [Li, Gen; Zhang, Kang] Macau Univ Sci & Technol, Fac Med, Ctr Biomed & Innovat, Macau, Peoples R China.
   [Wang, Guangyu] Tsinghua Univ, Dept Comp Sci & Technol, Beijing, Peoples R China.
   [Lau, Johnson Yiu-Nam] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.
   [Yang, Zhenglin] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China.
   [Yang, Zhenglin] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Inst Lab Med, Chengdu, Peoples R China.
   [Peng, Xiaozhong] Chinese Acad Med Sci, Sch Basic Med, Peking Union Med Coll, State Key Lab Med Mol Biol, Beijing, Peoples R China.
   [Lu, Guangwen] Sichuan Univ, West China Hosp, Emergency Dept, State Key Lab Biotherapy, Chengdu, Peoples R China.
RP Lu, GW; Wei, XW (corresponding author), Sichuan Univ, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr,West China Hosp, Chengdu, Peoples R China.; Lu, GW; Wei, XW (corresponding author), Sichuan Univ, Canc Ctr, Natl Clin Res Ctr Geriatr, West China Hosp, Chengdu, Peoples R China.; Zhang, K (corresponding author), Macau Univ Sci & Technol, Fac Med, Ctr Biomed & Innovat, Macau, Peoples R China.; Lu, GW (corresponding author), Sichuan Univ, West China Hosp, Emergency Dept, State Key Lab Biotherapy, Chengdu, Peoples R China.
EM kang.zhang@gmail.com; lugw@scu.edu.cn; xiaweiwei@scu.edu.cn
RI qin, chuan/ABG-4508-2020; Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU National Key Research and Development Program of China [2016YFA0201402];
   National Natural Science Foundation Regional Innovation and Development
   [U19A2003]; National Major Scientific and Technological Special Project
   for 'Significant New Drugs Development' [2018ZX09733001]; Ministry of
   Science and Technology; National Health Commission; Ministry of
   Education of the People's Republic of ChinaMinistry of Education, China;
   National Key Research and Development Project of China [2016YFD0500304];
   West China Hospital Sichuan UniversitySichuan University
   [HX-2019-nCoV-004)]; Macao Science and Technology Development Fund
   (FDCT);  [2020YFS0010]
FX We thank Z. Li, G. Wei, Q. Chen, H. Yan, X. Zhou, X. Wu, F. Fu, H. Yang
   and X. Wu for assisting with the maintenance of the mouse facility, the
   collection of sera, and providing cell culture, ELISA assays and other
   technical support. This work was supported by the National Key Research
   and Development Program of China (2016YFA0201402), National Natural
   Science Foundation Regional Innovation and Development (U19A2003), the
   National Major Scientific and Technological Special Project for
   'Significant New Drugs Development' (2018ZX09733001), the projects for
   the vaccine by the Ministry of Science and Technology, National Health
   Commission, Ministry of Education of the People's Republic of China,
   Sichuan province, National Key Research and Development Project of China
   (2016YFD0500304). The special research fund on COVID-19 of Sichuan
   province (2020YFS0010), the special research fund on COVID-19 of West
   China Hospital Sichuan University (HX-2019-nCoV-004) and Macao Science
   and Technology Development Fund (FDCT).
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Contreras-Gomez A, 2014, BIOTECHNOL PROGR, V30, P1, DOI 10.1002/btpr.1842
   Cox MMJ, 2011, J INVERTEBR PATHOL, V107, pS31, DOI 10.1016/j.jip.2011.05.003
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Guo YJ, 2005, DNA CELL BIOL, V24, P510, DOI 10.1089/dna.2005.24.510
   Gupta M, 2001, J VIROL, V75, P4649, DOI 10.1128/JVI.75.10.4649-4654.2001
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu MQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00535-2
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Luo M, 2017, CELL RES, V27, P586, DOI 10.1038/cr.2017.14
   MacLeod MKL, 2011, P NATL ACAD SCI USA, V108, P7914, DOI 10.1073/pnas.1104588108
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Stadlmann J, 2017, NATURE, V549, P538, DOI 10.1038/nature24015
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang QH, 2014, CELL HOST MICROBE, V16, P328, DOI 10.1016/j.chom.2014.08.009
   Wang Y, 2020, J AM SOC MASS SPECTR, V31, P651, DOI 10.1021/jasms.9b00089
   Wang Y, 2019, CHEM COMMUN, V55, P7934, DOI 10.1039/c9cc04114a
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiao KJ, 2019, J PROTEOME RES, V18, P2885, DOI 10.1021/acs.jproteome.9b00191
   Xiao YH, 2013, VACCINE, V31, P319, DOI 10.1016/j.vaccine.2012.11.007
   Yang WM, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188486
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 35
TC 15
Z9 15
U1 43
U2 43
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2599-8
EA JUL 2020
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ7QS
UT WOS:000577299100001
PM 32726802
OA Bronze
DA 2021-01-01
ER

PT J
AU Braun, J
   Loyal, L
   Frentsch, M
   Wendisch, D
   Georg, P
   Kurth, F
   Hippenstiel, S
   Dingeldey, M
   Kruse, B
   Fauchere, F
   Baysal, E
   Mangold, M
   Henze, L
   Lauster, R
   Mall, MA
   Beyer, K
   Rohmel, J
   Voigt, S
   Schmitz, J
   Miltenyi, S
   Demuth, I
   Muller, MA
   Hocke, A
   Witzenrath, M
   Suttorp, N
   Kern, F
   Reimer, U
   Wenschuh, H
   Drosten, C
   Corman, VM
   Giesecke-Thiel, C
   Sander, LE
   Thiel, A
AF Braun, Julian
   Loyal, Lucie
   Frentsch, Marco
   Wendisch, Daniel
   Georg, Philipp
   Kurth, Florian
   Hippenstiel, Stefan
   Dingeldey, Manuela
   Kruse, Beate
   Fauchere, Florent
   Baysal, Emre
   Mangold, Maike
   Henze, Larissa
   Lauster, Roland
   Mall, Marcus A.
   Beyer, Kirsten
   Roehmel, Jobst
   Voigt, Sebastian
   Schmitz, Juergen
   Miltenyi, Stefan
   Demuth, Ilja
   Mueller, Marcel A.
   Hocke, Andreas
   Witzenrath, Martin
   Suttorp, Norbert
   Kern, Florian
   Reimer, Ulf
   Wenschuh, Holger
   Drosten, Christian
   Corman, Victor M.
   Giesecke-Thiel, Claudia
   Sander, Leif Erik
   Thiel, Andreas
TI SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
SO NATURE
LA English
DT Article
ID SARS CORONAVIRUS; IMMUNE-RESPONSE; PROTECTIVE IMMUNITY; EFFECTOR;
   NEUTRALIZATION; EPIDEMIOLOGY; INFECTION
AB A study of patients with COVID-19 and healthy donors found CD4(+)T cells that react to the spike protein of SARS-CoV-2 and human endemic coronaviruses; however, the effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined.
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic(1,2). Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4(+)T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4(+)T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4(+)T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
C1 [Braun, Julian; Loyal, Lucie; Dingeldey, Manuela; Kruse, Beate; Fauchere, Florent; Baysal, Emre; Mangold, Maike; Henze, Larissa; Lauster, Roland; Thiel, Andreas] Tech Univ Berlin, SiM Der Simulierte Mensch, Berlin, Germany.
   [Braun, Julian; Loyal, Lucie; Dingeldey, Manuela; Kruse, Beate; Fauchere, Florent; Baysal, Emre; Mangold, Maike; Henze, Larissa; Lauster, Roland; Thiel, Andreas] Charite Univ Med Berlin, Berlin, Germany.
   [Braun, Julian; Loyal, Lucie; Dingeldey, Manuela; Kruse, Beate; Fauchere, Florent; Baysal, Emre; Mangold, Maike; Henze, Larissa; Thiel, Andreas] Charite Univ Med Berlin, BIH Ctr Regenerat Therapies, Regenerat Immunol & Aging, Berlin, Germany.
   [Frentsch, Marco] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany.
   [Frentsch, Marco; Mall, Marcus A.] Berlin Inst Hlth BIH, Berlin, Germany.
   [Wendisch, Daniel; Georg, Philipp; Kurth, Florian; Hippenstiel, Stefan; Hocke, Andreas; Witzenrath, Martin; Suttorp, Norbert; Sander, Leif Erik] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany.
   [Kurth, Florian] Univ Med Ctr Hamburg Eppendorf, Bernhard Nocht Inst Trop Med, Dept Trop Med, Hamburg, Germany.
   [Kurth, Florian] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany.
   [Lauster, Roland] Tech Univ Berlin, Inst Biotechnol, Med Biotechnol, Berlin, Germany.
   [Mall, Marcus A.; Beyer, Kirsten; Roehmel, Jobst] Charite Univ Med Berlin, Dept Pediat Pulmonol Immunol & Crit Care Med, Berlin, Germany.
   [Voigt, Sebastian] Robert Koch Inst, Dept Infect Dis, Berlin, Germany.
   [Schmitz, Juergen; Miltenyi, Stefan] Miltenyi Biotec, Bergisch Gladbach, Germany.
   [Demuth, Ilja] Charite Univ Med Berlin, Interdisciplinary Metab Ctr, Biol Aging BoA Grp, Berlin, Germany.
   [Mueller, Marcel A.; Drosten, Christian; Corman, Victor M.] Charite Univ Med Berlin, Inst Virol, Berlin, Germany.
   [Kern, Florian] Brighton & Sussex Med Sch, Dept Clin & Expt Med, Brighton, E Sussex, England.
   [Kern, Florian; Reimer, Ulf; Wenschuh, Holger] JPT Peptide Technol, Berlin, Germany.
   [Giesecke-Thiel, Claudia] Max Planck Inst Mol Genet, Berlin, Germany.
RP Thiel, A (corresponding author), Tech Univ Berlin, SiM Der Simulierte Mensch, Berlin, Germany.; Thiel, A (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Thiel, A (corresponding author), Charite Univ Med Berlin, BIH Ctr Regenerat Therapies, Regenerat Immunol & Aging, Berlin, Germany.; Sander, LE (corresponding author), Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany.; Giesecke-Thiel, C (corresponding author), Max Planck Inst Mol Genet, Berlin, Germany.
EM giesecke@molgen.mpg.de; leif-erik.sander@charite.de;
   andreas.thiel@charite.de
OI Kurth, Florian/0000-0002-3807-473X; Fauchere,
   Florent/0000-0002-1955-6362
FU German Research FoundationGerman Research Foundation (DFG) [KFO339,
   SFB-TR84]; German Federal Ministry of Education and Research
   (BMBF-RAPID); Federal Ministery of Health through a resolution of the
   German Bundestag; German Federal Ministry of Education and Research
   (BMBF-CAPSyS)
FX We thank U. Klein and H.-P. Herzel for discussion; T. Kaiser and J.
   Kirsch from the Flow Cytometry Core Facility (FCCF) of the DRFZ for
   technical help; and B. Timmerman from the Sequencing Core Facility of
   the Max Planck Institute for Molecular Genetics for discussion. This
   work was supported by the German Research Foundation (KFO339 to J.B. and
   F.F., SFB-TR84 projects A4 and B6 to S.H., B8 to M.M., C6 to M.W., C8
   and C10 to L.E.S., and C9 to M.W. and N.S.) and by the German Federal
   Ministry of Education and Research (BMBF-RAPID to S.H. and C.D., and
   CAPSyS to M.W. and N.S.). This work was additionally funded by the
   Federal Ministery of Health through a resolution of the German Bundestag
   to A.T., J.B., L.H. and M.D.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Blom K, 2013, J IMMUNOL, V190, P2150, DOI 10.4049/jimmunol.1202234
   Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kohler S, 2012, EUR J IMMUNOL, V42, P2363, DOI 10.1002/eji.201142306
   Kurth F, 2020, INFECTION, V48, P619, DOI 10.1007/s15010-020-01464-x
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Libraty DH, 2007, VIROLOGY, V368, P317, DOI 10.1016/j.virol.2007.07.015
   LIDWELL OM, 1961, J HYG-CAMBRIDGE, V59, P309, DOI 10.1017/S0022172400038973
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Meng T, 2020, PREPRINT
   Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020
   Mitchison NA, 2004, NAT REV IMMUNOL, V4, P308, DOI 10.1038/nri1334
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Sattler A, 2009, BLOOD, V113, P1948, DOI 10.1182/blood-2008-02-139147
   Schoenbrunn A, 2012, J IMMUNOL, V189, P5985, DOI 10.4049/jimmunol.1201090
   Schulz AR, 2015, J IMMUNOL, V195, P4699, DOI 10.4049/jimmunol.1500598
   Tyrrell D. A. J, 1965, J COMMON COLDS RELAT
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang BM, 2004, BLOOD, V104, P200, DOI 10.1182/blood-2003-11-4072
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yang JB, 2009, INT IMMUNOL, V21, P63, DOI 10.1093/intimm/dxn124
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 38
TC 71
Z9 71
U1 7
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 12
PY 2020
VL 587
IS 7833
BP 270
EP +
DI 10.1038/s41586-020-2598-9
EA JUL 2020
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OQ5NQ
UT WOS:000576135900002
PM 32726801
OA Bronze
DA 2021-01-01
ER

PT J
AU Lin, S
   Chen, H
   Ye, F
   Chen, ZM
   Yang, FL
   Zheng, Y
   Cao, Y
   Qiao, JX
   Yang, SY
   Lu, GW
AF Lin, Sheng
   Chen, Hua
   Ye, Fei
   Chen, Zimin
   Yang, Fanli
   Zheng, Yue
   Cao, Yu
   Qiao, Jingxin
   Yang, Shengyong
   Lu, Guangwen
TI Crystal structure of SARS-CoV-2 nsp10/nsp16 2 '-O-methylase and its
   implication on antiviral drug design
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Letter
C1 [Lin, Sheng; Chen, Hua; Ye, Fei; Chen, Zimin; Yang, Fanli; Zheng, Yue; Cao, Yu; Qiao, Jingxin; Yang, Shengyong; Lu, Guangwen] Sichuan Univ, State Key Lab Biotherapy, West China Hosp Emergency Dept WCHED, Chengdu 610041, Sichuan, Peoples R China.
   [Lin, Sheng; Chen, Hua; Ye, Fei; Chen, Zimin; Yang, Fanli; Zheng, Yue; Cao, Yu; Qiao, Jingxin; Yang, Shengyong; Lu, Guangwen] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Lin, Sheng; Chen, Hua; Ye, Fei; Chen, Zimin; Yang, Fanli; Zheng, Yue; Cao, Yu; Qiao, Jingxin; Yang, Shengyong; Lu, Guangwen] Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Cao, Yu] Sichuan Univ, West China Hosp, Disaster Med Ctr, Chengdu 610041, Sichuan, Peoples R China.
RP Lu, GW (corresponding author), Sichuan Univ, State Key Lab Biotherapy, West China Hosp Emergency Dept WCHED, Chengdu 610041, Sichuan, Peoples R China.; Lu, GW (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Lu, GW (corresponding author), Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
EM lugw@scu.edu.cn
FU special research fund on COVID-19 of Sichuan Province [2020YFS0010];
   special research fund on COVID-19 of West China Hospital Sichuan
   University [HX-2019-nCoV-004]
FX We thank the staff of BL19U1 beamline at National Center for Protein
   Sciences Shanghai and Shanghai Synchrotron Radiation Facility (Shanghai,
   People's Republic of China) for assistance during data collection. This
   work was supported by the special research fund on COVID-19 of Sichuan
   Province (grant No. 2020YFS0010) and the special research fund on
   COVID-19 of West China Hospital Sichuan University (grant No.
   HX-2019-nCoV-004).
CR Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Viswanathan T., 2020, BIORXIV
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   World Health Organization, COR DIS COVID 19 OUT
NR 5
TC 2
Z9 2
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD JUL 29
PY 2020
VL 5
IS 1
AR 131
DI 10.1038/s41392-020-00241-4
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MX4JS
UT WOS:000557689900001
PM 32728018
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grau-Pujol, B
   Camprubi, D
   Marti-Soler, H
   Fernandez-Pardos, M
   Guinovart, C
   Munoz, J
AF Grau-Pujol, Berta
   Camprubi, Daniel
   Marti-Soler, Helena
   Fernandez-Pardos, Marc
   Guinovart, Caterina
   Munoz, Jose
TI Pre-exposure prophylaxis with hydroxychloroquine for high-risk
   healthcare workers during the COVID-19 pandemic: A structured summary of
   a study protocol for a multicentre, double-blind randomized controlled
   trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; pre-exposure;
   prophylaxis; hydroxychloroquine; healthcare workers; Spain;
   double-blinded
AB ObjectivesThe aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during an epidemic period.As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.Trial designMulticentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial.ParticipantsApproximately 440 healthcare workers of four Spanish hospitals (Hospital Clinic of Barcelona, Hospital de la Santa Creu i Sant Pau of Barcelona, Hospital Plato of Barcelona, Hospital General de Granollers, Barcelona) will be recruited. Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and confirmed cases of COVID-19.For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate. Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any contraindication to hydroxychloroquine treatment.Intervention and comparatorEligible participants will be allocated to one of the two study groups: Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine (R) tablet) daily the first four consecutive days, followed by 400 mg weekly for a period of 6 months.Control group: participants will receive placebo tablets with identical physical appearance to hydroxychloroquine 200 mg (Dolquine (R)) tablets following the same treatment schedule of the intervention group.Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines.Main outcomesThe primary endpoint will be the number of confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative SARS-CoV-2 PCR and serology at day 0.
   As secondary endpoints, we will obtain: i) the SARS-CoV-2 seroconversion in the PrEP group compared to placebo during the 6 months of follow-up in healthcare workers with negative serology at day 0; ii) the occurrence of any adverse event related with hydroxychloroquine treatment; iii) the incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers in the non-PrEP group, among the total of healthcare workers included in the non-PrEP group during the study period; iv) the risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19; v) a repository of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection.RandomisationParticipants meeting all eligibility requirements will be allocated to one of the two study arms (PrEP with hydroxychloroquine or non-PrEP control group) in a 1:1 ratio using simple randomisation with computer generated random numbers.Blinding (masking)Participants, doctors and nurses caring for participants, and investigators assessing the outcomes will be blinded to group assignment.Numbers to be randomised (sample size)Each intervention group will have 220 participants, giving a total of 440 participants.Trial StatusThe current protocol version is 1.5, 2(nd) of June 2020. Two hundred and seventy-fiveparticipants were recruited and completed first month follow-up until date. The estimated sample size could not be reached yet due to the declining national epidemic curve. Thus, 275 is the total number of participants included until date. The study has been suspended (26(th) of June) until new epidemic curve occurs.Trial registrationThis trial was registered on April 2(nd) 2020 at clinicaltrials.gov with the number NCT04331834.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Grau-Pujol, Berta; Camprubi, Daniel; Marti-Soler, Helena; Fernandez-Pardos, Marc; Guinovart, Caterina; Munoz, Jose] Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain.
   [Grau-Pujol, Berta] Fdn Mundo Sano, Barcelona, Spain.
   [Grau-Pujol, Berta] Ctr Invest Saude Manhica, Maputo, Mozambique.
RP Grau-Pujol, B (corresponding author), Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain.; Grau-Pujol, B (corresponding author), Fdn Mundo Sano, Barcelona, Spain.
EM berta.grau@isglobal.org
RI Guinovart, Caterina/ABH-2981-2020
OI Marti-Soler, Helena/0000-0002-7127-205X; Grau-Pujol,
   Berta/0000-0002-7320-0965; Camprubi, Daniel/0000-0003-4215-6030
FU ISGlobal; Hospital Clinic's International Health's department;
   Laboratorios Rubio
FX The study is currently supported by funds from ISGlobal and Hospital
   Clinic's International Health's department.; Laboratorios Rubio has
   partially contributed to the funding of this project and with the
   required doses of Hydroxychloroquine (Dolquine (R)). The funding body
   did not participate on the design of the study and collection, analysis,
   data interpretation or manuscript writing.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 29
PY 2020
VL 21
IS 1
AR 688
DI 10.1186/s13063-020-04621-7
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MX4NT
UT WOS:000557701900006
PM 32727613
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Perkins, GD
   Couper, K
   Connolly, B
   Baillie, JK
   Bradley, JM
   Dark, P
   De Soyza, A
   Gorman, E
   Gray, A
   Hamilton, L
   Hart, N
   Ji, C
   Lall, R
   McGowan, N
   Regan, S
   Simonds, AK
   Skilton, E
   Stallard, N
   Stimpson, E
   Yeung, J
   McAuley, DF
AF Perkins, Gavin D.
   Couper, Keith
   Connolly, Bronwen
   Baillie, J. Kenneth
   Bradley, Judy M.
   Dark, Paul
   De Soyza, Anthony
   Gorman, Ellen
   Gray, Alasdair
   Hamilton, Louisa
   Hart, Nicholas
   Ji, Chen
   Lall, Ranjit
   McGowan, Nicola
   Regan, Scott
   Simonds, Anita K.
   Skilton, Emma
   Stallard, Nigel
   Stimpson, Emily
   Yeung, Joyce
   McAuley, Daniel F.
TI RECOVERY- Respiratory Support: Respiratory Strategies for patients with
   suspected or proven COVID-19 respiratory failure; Continuous Positive
   Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured
   summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; continuous positive
   airway pressure; oxygen inhalation therapy; high-flow nasal oxygen
AB ObjectiveThe trial objective is to determine if Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) is clinically effective compared to standard oxygen therapy in patients with confirmed or suspected COVID-19.Trial designAdaptive (group-sequential), parallel group, pragmatic, superiority randomised controlled, open-label, multi-centre, effectiveness trial.ParticipantsThe trial is being conducted across approximately 60 hospitals across England, Wales, Scotland, and Northern Ireland. Inpatients at participating hospitals are eligible to participate if they have respiratory failure with suspected or proven COVID-19, and meet all of the inclusion criteria and none of the exclusion criteria.Inclusion criteria: 1) Adults >= 18 years; 2) Admitted to hospital with suspected or proven COVID-19; 3) Receiving oxygen with fraction of inspired oxygen (FiO(2)) >= 0.4 and peripheral oxygen saturation (SpO(2)) <= 94%; and 4) Plan for escalation to tracheal intubation if needed.Exclusion criteria: 1) Planned tracheal intubation and mechanical ventilation imminent within 1 hour; 2) Known or clinically apparent pregnancy; 3) Any absolute contraindication to CPAP or HFNO; 4) Decision not to intubate due to ceiling of treatment or withdrawal of treatment anticipated; and 5) Equipment for both CPAP and HFNO not available.Intervention and comparatorIntervention one: Continuous positive airway pressure delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion.Intervention two: High-flow nasal oxygen delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion.Comparator group: Standard care- oxygen delivered by face mask or nasal cannula (excluding the use of continuous positive airway pressure or high-flow nasal oxygen). Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion.Intervention delivery continues up to the point of death, tracheal intubation, or clinical determination that there is no ongoing need (palliation or improvement).Main outcomesThe primary outcome is a composite outcome comprising tracheal intubation or mortality within 30 days following randomisation.Secondary outcomes include tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay.RandomisationParticipants are randomised in a 1:1:1 ratio to receive either continuous positive airway pressure, high-flow nasal oxygen or standard care. Due to the challenging environment of study delivery, a specific intervention may not always be available at the hospital site. The study uses two integrated randomisation systems to allow, where required, the site to randomise between all three interventions, between CPAP and standard care, and between HFNO and standard care. System integration ensures maintenance of balance between interventions.Randomisation is performed using a telephone-based interactive voice response system to maintain allocation concealment. The randomisation sequence was computer-generated using the minimisation method. Participant randomisation is stratified by site, gender (M/F), and age (<50, >=50 years).Blinding (masking)The nature of the trial interventions precludes blinding of the researcher, patient and clinical team.
   Primary and secondary outcomes are all objective outcomes, thereby minimising the risk of detection bias.Numbers to be randomised (sample size)4002 participants (1334 to be randomized to each of the three study arms)Trial StatusCurrent protocol: Version 4.0, 29(th) May 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021.The trial has been awarded Urgent Public Health status by the National Institute of Health Research on 13(th) April 2020.Trial registrationISRCTN, ISRCTN16912075. Registered 6(th) April 2020, http://www.isrctn.com/ISRCTN16912075Full protocolThe full protocol (version 4.0, 29(th) May 2020) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Perkins, Gavin D.; Couper, Keith; Hamilton, Louisa; Ji, Chen; Lall, Ranjit; McGowan, Nicola; Regan, Scott; Skilton, Emma; Stimpson, Emily; Yeung, Joyce] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry, W Midlands, England.
   [Perkins, Gavin D.; Couper, Keith; Yeung, Joyce] Univ Hosp Birmingham NHS Fdn Trust, Crit Care Unit, Birmingham, W Midlands, England.
   [Connolly, Bronwen; Bradley, Judy M.; Gorman, Ellen; McAuley, Daniel F.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Baillie, J. Kenneth] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Baillie, J. Kenneth] Royal Infirm Edinburgh NHS Trust, Intens Care Unit, Edinburgh, Midlothian, Scotland.
   [Dark, Paul] Univ Manchester, Div Infect Immun & Resp Med, NIHR Manchester Biomed Res Ctr, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [De Soyza, Anthony] Newcastle Univ, Inst Cellular Med, NIHR Biomed Res Ctr Ageing, Newcastle Upon Tyne, Tyne & Wear, England.
   [De Soyza, Anthony] Freeman Rd Hosp, Dept Resp Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Gray, Alasdair] Royal Infirm Edinburgh NHS Trust, Emergency Med Res Grp Edinburgh, Edinburgh, Midlothian, Scotland.
   [Gray, Alasdair] Royal Infirm Edinburgh NHS Trust, Dept Emergency Med, Edinburgh, Midlothian, Scotland.
   [Hart, Nicholas] Kings Coll London, Ctr Human & Appl Physiol Sci, London, England.
   [Hart, Nicholas] Guys & St Thomas NHS Fdn Trust, Lane Fox Resp Serv, London, England.
   [Simonds, Anita K.] Royal Brompton & Harefield NHS Fdn Trust, Sleep & Ventilat Unit, London, England.
   [Stallard, Nigel] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry, W Midlands, England.
RP McAuley, DF (corresponding author), Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
EM d.f.mcauley@qub.ac.uk
RI Perkins, Gavin D/E-7613-2010
OI Baillie, John Kenneth/0000-0001-5258-793X; Dark,
   Paul/0000-0003-3309-0164; Ji, Chen/0000-0003-4919-3299
FU National Institute of Health ResearchNational Institute for Health
   Research (NIHR)
FX The study is funded by the National Institute of Health Research. The
   views expressed are those of the author(s) and not necessarily those of
   the NIHR or the Department of Health and Social Care. The study sponsor
   and funder have no role in the study design, data acquisition, data
   analysis or manuscript preparation.
NR 0
TC 2
Z9 2
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 29
PY 2020
VL 21
IS 1
AR 687
DI 10.1186/s13063-020-04617-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MX4NT
UT WOS:000557701900005
PM 32727624
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kolodny, O
   Berger, M
   Feldman, MW
   Ram, Y
AF Kolodny, Oren
   Berger, Michael
   Feldman, Marcus W.
   Ram, Yoav
TI A new perspective for mitigation of SARS-CoV-2 infection: priming the
   innate immune system for viral attack
SO OPEN BIOLOGY
LA English
DT Article
DE SARS-CoV-2; covid-19; priming; vaccines; innate immune system; trained
   immunity
ID INTERFERON-STIMULATED GENES; INFLUENZA-VIRUS INFECTION;
   TOLL-LIKE-RECEPTORS; BCG VACCINATION; COMMENSAL BACTERIA; RESPONSES;
   INDUCTION; RECOGNITION; COVID-19; MICROBIOME
AB The course of infection by SARS-CoV-2 frequently includes a long asymptomatic period, followed in some individuals by an immune dysregulation period that may lead to complications and immunopathology-induced death. This course of disease suggests that the virus often evades detection by the innate immune system. We suggest a novel therapeutic approach to mitigate the infection's severity, probability of complications and duration. We propose that priming an individual's innate immune system for viral attack shortly before it is expected to occur may allow pre-activation of the preferable trajectory of immune response, leading to early detection of the virus. Priming can be carried out, for example, by administering a standard vaccine or another reagent that elicits a broad anti-viral innate immune response. By the time that the expected SARS-CoV-2 infection occurs, activation cascades will have been put in motion and levels of immune factors needed to combat the infection will have been elevated. The infection would thus be cleared faster and with less complication than otherwise, alleviating adverse clinical outcomes at the individual level. Moreover, priming may also mitigate population-level risk by reducing need for hospitalizations and decreasing the infectious period of individuals, thus slowing the spread and reducing the impact of the epidemic. In view of the latter consideration, our proposal may have a significant epidemiological impact even if applied primarily to low-risk individuals, such as young adults, who often show mild symptoms or none, by shortening the period during which they unknowingly infect others. The proposed view is, at this time, an unproven hypothesis. Although supported by robust bio-medical reasoning and multiple lines of evidence, carefully designed clinical trials are necessary.
C1 [Kolodny, Oren] Hebrew Univ Jerusalem, Inst Life Sci, Dept Ecol Evolut & Behav, IL-9190401 Jerusalem, Israel.
   [Berger, Michael] Hebrew Univ Jerusalem, Lautenberg Ctr Immunol & Canc Res, Inst Med Res Israel Canada, Hadassah Med Sch, Jerusalem, Israel.
   [Feldman, Marcus W.] Stanford Univ, Dept Biol, Stanford, CA USA.
   [Ram, Yoav] Interdisciplinary Ctr Herzliya, Sch Comp Sci, Herzliyya, Israel.
RP Kolodny, O (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Ecol Evolut & Behav, IL-9190401 Jerusalem, Israel.
EM oren.kolodny@mail.huji.ac.il
RI Ram, Yoav/D-2344-2011
OI Ram, Yoav/0000-0002-9653-4458; kolodny, oren/0000-0002-0095-693X
FU Gordon and Betty Moore FoundationGordon and Betty Moore Foundation
   [GBMF9341]; US-Israel Binational Science Foundation (BSF)US-Israel
   Binational Science Foundation; Israeli Science FoundationIsrael Science
   Foundation [552/19, 3811/19]; Center for Computational, Evolutionary,
   and Human Genomics (CEHG) at Stanford University
FX This study was funded in part by the Gordon and Betty Moore Foundation
   (grant no. GBMF9341, DOI: 10.37807/GBMF9341; O.K.), by the US-Israel
   Binational Science Foundation (BSF; O.K.), by the Israeli Science
   Foundation (552/19 and 3811/19; YR), and the Center for Computational,
   Evolutionary, and Human Genomics (CEHG) at Stanford University.
CR Aaby P, 2019, CLIN MICROBIOL INFEC, V25, P1459, DOI 10.1016/j.cmi.2019.08.011
   Abt MC, 2013, CURR OPIN MICROBIOL, V16, P4, DOI 10.1016/j.mib.2012.12.002
   Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011
   Ahmed AE, TRAVEL MED INFECT DI
   Andreakos E, 2019, CURR OPIN IMMUNOL, V56, P67, DOI 10.1016/j.coi.2018.10.007
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Boe DM, 2017, CLIN EXP IMMUNOL, V187, P16, DOI 10.1111/cei.12881
   Boraschi D, 2014, IMMUNOL LETT, V162, P346, DOI 10.1016/j.imlet.2014.06.006
   Braciale TJ, 2013, IMMUNOL REV, V255, P5, DOI 10.1111/imr.12109
   Browne N, 2014, J INSECT PHYSIOL, V63, P21, DOI 10.1016/j.jinsphys.2014.02.006
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Conrath U, 2006, MOL PLANT MICROBE IN, V19, P1062, DOI 10.1094/MPMI-19-1062
   Conrath U, 2015, ANNU REV PHYTOPATHOL, V53, P97, DOI 10.1146/annurev-phyto-080614-120132
   Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Dhabhar FS, 2003, ANN NY ACAD SCI, V992, P205, DOI 10.1111/j.1749-6632.2003.tb03151.x
   Enard D, 2018, CELL, V175, P360, DOI 10.1016/j.cell.2018.08.034
   Enard D, 2016, ELIFE, V5, DOI 10.7554/eLife.12469
   Evans SE, 2010, AM J RESP CELL MOL, V42, P40, DOI 10.1165/rcmb.2008-0260OC
   Ferguson N, 2020, IMPACT NONPHARMACEUT, DOI [10.25561/77482, DOI 10.25561/77482]
   Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20
   GIFFORD GE, 1987, J NATL CANCER I, V78, P121, DOI 10.1093/jnci/78.1.121
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   HAYES MP, 1995, CYTOKINE, V7, P427, DOI 10.1006/cyto.1995.0058
   Hejblum BP, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004310
   Henriksen-Lacey M, 2011, EXPERT OPIN DRUG DEL, V8, P505, DOI 10.1517/17425247.2011.558081
   Hernandez PP, 2015, NAT IMMUNOL, V16, P698, DOI 10.1038/ni.3180
   Hoek KL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118528
   Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042
   Izumo T, 2010, INT IMMUNOPHARMACOL, V10, P1101, DOI 10.1016/j.intimp.2010.06.012
   Jensen KJ, 2015, J INFECT DIS, V211, P956, DOI 10.1093/infdis/jiu508
   Jung Y. C, 2017, SCI REP, V7, P1
   Kash JC, 2004, J VIROL, V78, P9499, DOI 10.1128/JVI.78.17.9499-9511.2004
   Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303
   Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042
   Kindler E, 2016, ADV VIRUS RES, V96, P219, DOI 10.1016/bs.aivir.2016.08.006
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Klinger D, 2020, SIGNIFICANTLY IMPROV
   Kobayashi N, 2011, INT IMMUNOPHARMACOL, V11, P199, DOI 10.1016/j.intimp.2010.11.019
   Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014
   Langley WA, 2010, J VIROL, V84, P8300, DOI 10.1128/JVI.00183-10
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332
   Li G, 2020, THERAPEUTIC OPTIONS
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liao M., 2020, LANDSCAPE LUNG BRONC
   Loo S, 2018, RESPIROLOGY, V23, P44
   MACKANESS GB, 1964, J EXP MED, V120, P105, DOI 10.1084/jem.120.1.105
   Martinez-Medina A, 2016, TRENDS PLANT SCI, V21, P818, DOI 10.1016/j.tplants.2016.07.009
   Maslov S, 2020, 2020 WINDOW OPPORTUN
   Mauch-Mani B, 2017, ANNU REV PLANT BIOL, V68, P485, DOI 10.1146/annurev-arplant-042916-041132
   Mays JW, 2012, J NEUROIMMUNOL, V243, P34, DOI 10.1016/j.jneuroim.2011.12.011
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menachery VD, 2013, IMMUNOL REV, V255, P256, DOI 10.1111/imr.12092
   Mifsud EJ, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00079
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Moret Y, 2003, P ROY SOC B-BIOL SCI, V270, P2475, DOI 10.1098/rspb.2003.2511
   Muneer A, 2020, COMP ANAL REVEALED R
   Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Nikolich-Zugich J, GEROSCIENCE
   Norton EB, 2010, J VIROL, V84, P2983, DOI 10.1128/JVI.01805-09
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Obermoser G, 2013, IMMUNITY, V38, P831, DOI 10.1016/j.immuni.2012.12.008
   Pasquali C, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00041
   Pfeiffer JK, 2016, SCIENCE, V351, DOI 10.1126/science.aad5872
   Powell ND, 2011, BRAIN BEHAV IMMUN, V25, P46, DOI 10.1016/j.bbi.2010.07.243
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Raison CL, 2013, MOL PSYCHIATR, V18, P15, DOI 10.1038/mp.2012.2
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006
   Shaman J, 2020, INITIAL SIMULATION S
   Sharma N, 2020, EMERGENCE OF PHARMACEUTICAL INDUSTRY GROWTH WITH INDUSTRIAL IOT APPROACH, P1, DOI 10.1016/B978-0-12-819593-2.00001-7
   Sinzinger AX, 2020, HUM VACC IMMUNOTHER, V16, P490, DOI 10.1080/21645515.2019.1663119
   Sorup S, 2016, VACCINE, V34, P6172, DOI 10.1016/j.vaccine.2016.11.005
   Sorup S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofv204
   Ssebambulidde K, 2020, PARASITES THEIR PROT
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665
   Takeda S, 2011, INT IMMUNOPHARMACOL, V11, P1976, DOI 10.1016/j.intimp.2011.08.007
   Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x
   Tate AT, 2012, OIKOS, V121, P1083, DOI 10.1111/j.1600-0706.2011.19725.x
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Thompson AJ, 2007, IMMUNOL CELL BIOL, V85, P435, DOI 10.1038/sj.icb.7100100
   Thompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920
   Tidbury HJ, 2012, P ROY SOC B-BIOL SCI, V279, P4505, DOI 10.1098/rspb.2012.1841
   Traniello JFA, 2002, P NATL ACAD SCI USA, V99, P6838, DOI 10.1073/pnas.102176599
   Tuvim MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004176
   Uricchio LH, 2019, NAT ECOL EVOL, V3, P977, DOI 10.1038/s41559-019-0890-6
   Verity R, 2020, ESTIMATES SEVERITY C
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Yap MW, 2012, ADV EXP MED BIOL, V770, P93
   Zanettini C., 2020, INFLUENZA VACCINATIO
   Zelaya H, 2015, INFLAMM RES, V64, P589, DOI 10.1007/s00011-015-0837-6
   Zhang N, 2015, CHINESE MED J-PEKING, V128, P2250, DOI 10.4103/0366-6999.162502
NR 101
TC 1
Z9 1
U1 6
U2 6
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
EI 2046-2441
J9 OPEN BIOL
JI Open Biol
PD JUL 29
PY 2020
VL 10
IS 7
AR 200138
DI 10.1098/rsob.200138
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MW2VL
UT WOS:000556901100001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lee, SY
   Lei, BW
   Mallick, B
AF Lee, Se Yoon
   Lei, Bowen
   Mallick, Bani
TI Estimation of COVID-19 spread curves integrating global data and
   borrowing information
SO PLOS ONE
LA English
DT Article
ID REPRODUCTION NUMBER; GROWTH-CURVES; MODELS; EPIDEMIOLOGY; HORSESHOE;
   INFLUENZA; INFERENCE; VARIANCE; DENGUE; SEIR
AB Currently, novel coronavirus disease 2019 (COVID-19) is a big threat to global health. The rapid spread of the virus has created pandemic, and countries all over the world are struggling with a surge in COVID-19 infected cases. There are no drugs or other therapeutics approved by the US Food and Drug Administration to prevent or treat COVID-19: information on the disease is very limited and scattered even if it exists. This motivates the use of data integration, combining data from diverse sources and eliciting useful information with a unified view of them. In this paper, we propose a Bayesian hierarchical model that integrates global data for real-time prediction of infection trajectory for multiple countries. Because the proposed model takes advantage of borrowing information across multiple countries, it outperforms an existing individual country-based model. As fully Bayesian way has been adopted, the model provides a powerful predictive tool endowed with uncertainty quantification. Additionally, a joint variable selection technique has been integrated into the proposed modeling scheme, which aimed to identify possible country-level risk factors for severe disease due to COVID-19.
C1 [Lee, Se Yoon; Lei, Bowen; Mallick, Bani] Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA.
RP Lee, SY (corresponding author), Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA.
EM seyoonlee@stat.tamu.edu
OI Lei, Bowen/0000-0001-7141-7485
FU National Cancer Institute of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA194391];
   NSFNational Science Foundation (NSF) [CCF-1934904]
FX Research reported in this publication was supported by National Cancer
   Institute of the National Institutes of Health under award number
   R01CA194391, and NSF grant no. NSF CCF-1934904. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anton H, 1988, CALCULUS ANAL GEOMET
   Armagan A, 2013, STAT SINICA, V23, P119, DOI 10.5705/ss.2011.048
   Bhadra A, 2019, STAT SCI, V34, P405, DOI 10.1214/19-STS700
   Birch CPD, 1999, ANN BOT-LONDON, V83, P713, DOI 10.1006/anbo.1999.0877
   Browne WJ, 2006, BAYESIAN ANAL, V1, P473, DOI 10.1214/06-BA117
   Cao J, 2016, J MATER CHEM A, V4, P10223, DOI 10.1039/c6ta03121h
   Cao LY, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11020204
   Carvalho C. M., 2009, J MACHINE LEARNING R, V5, P73
   Carvalho CM, 2010, BIOMETRIKA, V97, P465, DOI 10.1093/biomet/asq017
   CAUSTON DR, 1969, BIOMETRICS, V25, P401, DOI 10.2307/2528797
   Clayton D, 2013, STAT MODELS EPIDEMIO
   Davidian M., 1995, NONLINEAR MODELS REP, V62
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dowd J.B., 2020, P NATL ACAD SCI US
   Efron B, 2010, STAT SCI, V25, P145, DOI 10.1214/09-STS308
   Fineberg HV, 2009, EPIDEMIC SCI REAL TI
   Fitzmaurice G, 2009, CH CRC HANDB MOD STA, P1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gelman A., 2004, BAYESIAN DATA ANAL
   Gompertz B., 1825, PHILOS T ROY SOC LON, V115, P513, DOI [10.1098/RSTL.1825.0026, DOI 10.1098/RSTL.1825.0026]
   He ZR, 2018, INT J INFECT DIS, V74, P61, DOI 10.1016/j.ijid.2018.07.003
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   HILL BM, 1965, J AM STAT ASSOC, V60, P806, DOI 10.2307/2283247
   Hsieh YH, 2009, TROP MED INT HEALTH, V14, P628, DOI 10.1111/j.1365-3156.2009.02277.x
   Hsieh YH, 2004, EMERG INFECT DIS, V10, P1165, DOI 10.3201/eid1006.031023
   Hsieh YH, 2009, MODELING DYNAMICS IN, P216, DOI [10.1142/9789814261265_0009, DOI 10.1142/9789814261265_]
   Hsieh YH, 2010, INFLUENZA OTHER RESP, V4, P187, DOI 10.1111/j.1750-2659.2010.00147.x
   Hsieh YH, 2009, AM J TROP MED HYG, V80, P66, DOI 10.4269/ajtmh.2009.80.66
   Hu WB, 2006, ECOL MODEL, V196, P505, DOI 10.1016/j.ecolmodel.2006.02.028
   Huttenhower Curtis, 2006, Comput Syst Bioinformatics Conf, P341
   James W, 1992, BREAKTHROUGHS STAT, P443, DOI DOI 10.1007/978-1-4612-0919-5_30
   Jia L, 2020, PREDICTION ANAL CORO
   Kahm M, 2010, J STAT SOFTW, V33, P1
   Korobeinikov A, 2004, MATH MED BIOL, V21, P75
   Lenzerini M., 2002, P 21 ACM SIGMOD SIGA, P233, DOI DOI 10.1145/543613.543644
   Li Q, 2020, J INFECTION, V80, P472, DOI 10.1016/j.jinf.2020.02.014
   Li YS, 2010, BIOMETRICS, V66, P70, DOI 10.1111/j.1541-0420.2009.01227.x
   Lindley D.V., 1972, BAYESIAN STAT REV, V2
   Liu Z., 2020, PREDICTING CUMULATIV, DOI 10.1101/2020.03.11.20034314
   Malinverno A, 2004, GEOPHYSICS, V69, P1005, DOI 10.1190/1.1778243
   MCGILL R, 1978, AM STAT, V32, P12, DOI 10.2307/2683468
   Murray I., 2010, ELLIPTICAL SLICE SAM
   NELDER JA, 1962, BIOMETRICS, V18, P614, DOI 10.2307/2527907
   Pell B, 2018, EPIDEMICS-NETH, V22, P62, DOI 10.1016/j.epidem.2016.11.002
   Peng L., 2020, EPIDEMIC ANAL COVID
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   RICHARDS FJ, 1959, J EXP BOT, V10, P290, DOI 10.1093/jxb/10.2.290
   Rushton SP, 2006, EPIDEMIOL INFECT, V134, P521, DOI 10.1017/S0950268805005303
   Seber GA, 2003, NONLINEAR REGRESSION, V62, P63
   Shen XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060601
   Snijders T.A., 2011, MULTILEVEL ANAL INTR
   STONE M, 1965, BIOMETRIKA, V52, P623
   Thompson WW, 2006, J INFECT DIS, V194, pS82, DOI 10.1086/507558
   TIAO GC, 1965, BIOMETRIKA, V52, P37, DOI 10.1093/biomet/52.1-2.37
   Tiberiu H., 2014, APPL MATH COMPUT, V236, P184
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Tsoularis A, 2002, MATH BIOSCI, V179, P21, DOI 10.1016/S0025-5564(02)00096-2
   Wang XS, 2012, J THEOR BIOL, V313, P12, DOI 10.1016/j.jtbi.2012.07.024
   Wasserman L., 2013, ALL STAT CONCISE COU
   Werker AR, 1997, ANN BOT-LONDON, V79, P657, DOI 10.1006/anbo.1997.0387
   Wu K., 2020, ARXIV200305681
   Yaesoubi R, 2011, EUR J OPER RES, V215, P679, DOI 10.1016/j.ejor.2011.07.016
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
NR 64
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2020
VL 15
IS 7
AR e0236860
DI 10.1371/journal.pone.0236860
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MW2YL
UT WOS:000556908900019
PM 32726361
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Claeys, MJ
   Argacha, JF
   Collart, P
   Carlier, M
   Van Caenegem, O
   Sinnaeve, PR
   Desmet, W
   Dubois, P
   Stammen, F
   Gevaert, S
   Pourbaix, S
   Coussement, P
   Beauloye, C
   Evrard, P
   Brasseur, O
   Fierens, F
   Marechal, P
   Schelfaut, D
   Flore, V
   Hanet, C
AF Claeys, Marc J.
   Argacha, Jean-Francois
   Collart, Philippe
   Carlier, Marc
   Van Caenegem, Olivier
   Sinnaeve, Peter R.
   Desmet, Walter
   Dubois, Philippe
   Stammen, Francis
   Gevaert, Sofie
   Pourbaix, Suzanne
   Coussement, Patrick
   Beauloye, Christophe
   Evrard, Patrick
   Brasseur, Olivier
   Fierens, Frans
   Marechal, Patrick
   Schelfaut, Dan
   Flore, Vincent
   Hanet, Claude
TI Impact of COVID-19-related public containment measures on the ST
   elevation myocardial infarction epidemic in Belgium: a nationwide,
   serial, cross-sectional study
SO ACTA CARDIOLOGICA
LA English
DT Article; Early Access
DE STEMI; COVID-19; containment; pollution; PCI; mortality
ID ENVIRONMENTAL TRIGGERS
AB Aims The current study assessed the impact of COVID-19-related public containment measures (i.e. lockdown) on the ST elevation myocardial infarction (STEMI) epidemic in Belgium. Methods and results Clinical characteristics, reperfusion therapy modalities, COVID-19 status and in-hospital mortality of consecutive STEMI patients who were admitted to Belgian hospitals for percutaneous coronary intervention (PCI) were recorded during a three-week period starting at the beginning of the lockdown period on 13 March 2020. Similar data were collected for the same time period for 2017-2019. An evaluation of air quality revealed a 32% decrease in ambient NO(2)concentrations during lockdown (19.5 mu g/m(3) versus 13.2 mu g/m(3),p < .001). During the three-week period, there were 188 STEMI patients admitted for PCI during the lockdown versus an average 254 STEMI patients before the lockdown period (incidence rate ratio = 0.74,p = .001). Reperfusion strategy was predominantly primary PCI in both time periods (96% versus 95%). However, there was a significant delay in treatment during the lockdown period, with more late presentations (>12 h after onset of pain) (14% versus 7.6%,p = .04) and with longer door-to-balloon times (median of 45 versus 39 min,p = .02). Although the in-hospital mortality between the two periods was comparable (5.9% versus 6.7%), 5 of the 7 (71%) COVID-19-positive STEMI patients died. Conclusion The present study revealed a 26% reduction in STEMI admissions and a delay in treatment of STEMI patients. Less exposure to external STEMI triggers (such as ambient air pollution) and/or reluctance to seek medical care are possible explanations of this observation.
C1 [Claeys, Marc J.] Univ Antwerp Hosp, Dept Cardiol, Antwerp, Belgium.
   [Argacha, Jean-Francois] Univ Hosp Brussels, Dept Cardiol, Brussels, Belgium.
   [Collart, Philippe] Univ Libre Bruxelles, Sch Publ Hlth, Ctr Rech Epidemiol Biostat & Rech Clin, Brussels, Belgium.
   [Carlier, Marc] GHDC, Dept Cardiol, Charleroi, Belgium.
   [Van Caenegem, Olivier] Clin Univ St Luc, Div Cardiovasc Intens Care, Brussels, Belgium.
   [Sinnaeve, Peter R.; Desmet, Walter] Univ Hosp Leuven, Dept Cardiol, Leuven, Belgium.
   [Dubois, Philippe] CHU Charleroi, Dept Cardiol, Charleroi, Belgium.
   [Stammen, Francis] Hosp Roeselare, Dept Cardiol, Roeselare, Belgium.
   [Gevaert, Sofie] Ghent Univ Hosp, Dept Cardiol, Ghent, Belgium.
   [Pourbaix, Suzanne] CHR Citadelle Liege, Dept Cardiol, Liege, Belgium.
   [Coussement, Patrick] Hosp Sint Jan Brugge, Dept Cardiol, Brugge, Belgium.
   [Beauloye, Christophe] Clin Univ St Luc, Inst Rech Expt & Clin, Div Cardiol & Pole Cardiovasc Res, Brussels, Belgium.
   [Evrard, Patrick] Belgium Catholic Univ, Hosp Mt Godinne, Dept Intens Care, Brussels, Belgium.
   [Brasseur, Olivier] Brussels Environm, Lab Environm Res, Brussels, Belgium.
   [Fierens, Frans] Belgian Interreg Environm Agcy, Brussels, Belgium.
   [Marechal, Patrick] Univ Hosp Liege, Dept Cardiol, Liege, Belgium.
   [Schelfaut, Dan] OLV Aalst, Dept Cardiol, Aalst, Belgium.
   [Flore, Vincent] Hosp Maria Middelares, Dept Cardiol, Ghent, Belgium.
   [Hanet, Claude] Catholic Univ, Dept Cardiol, Hosp Mt Godinne, Brussels, Belgium.
RP Claeys, MJ (corresponding author), Univ Hosp Antwerp, Dept Cardiol, Wilrijkstr 1, B-2650 Edegem, Belgium.
EM marc.claeys@uantwerpen.be
RI Claeys, Marc/ABH-8781-2020
OI Claeys, Marc/0000-0002-6628-9543; Sinnaeve, Peter/0000-0003-4716-5892
FU Belgian government
FX The National STEMI Database is financially supported by the Belgian
   government.
CR Argacha JF, 2016, INT J CARDIOL, V223, P300, DOI 10.1016/j.ijcard.2016.07.191
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Claeys MJ, 2017, EUR HEART J, V38, P955, DOI 10.1093/eurheartj/ehw151
   Claeys MJ, 2015, ACTA CARDIOL, V70, P693, DOI [10.1080/AC.70.6.3120182, 10.2143/AC.70.6.3120182]
   Claeys MJ, 2011, ARCH INTERN MED, V171, P544, DOI 10.1001/archinternmed.2011.57
   DAVIES MJ, 1985, BRIT HEART J, V53, P363
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Henry TD, 2020, J AM COLL CARDIOL, V75, P25
   Jing ZC, 2020, EUR HEART J, V41, P1791, DOI 10.1093/eurheartj/ehaa258
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Lancet T., 2020, LANCET, V395, DOI 10.1016/S0140-6736(20)30644-9
   MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301
   Mittleman MA, 1997, JAMA-J AM MED ASSOC, V277, P1558
   Mustafic H, 2012, JAMA-J AM MED ASSOC, V307, P713, DOI 10.1001/jama.2012.126
   Nawrot TS, 2011, LANCET, V377, P732, DOI 10.1016/S0140-6736(10)62296-9
   Rodriguez-Leor O, 2020, REC INTERV CARDIOL, V2, P82, DOI DOI 10.24875/RECIC.M20000120
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Roffi M, 2020, EUROINTERVENTION, V16, P247, DOI 10.4244/EIJ-D-20-00528
   Tam CCF, 2020, CATHETER CARDIO INTE, DOI 10.1002/ccd.28943
   Townsend N, 2016, EUR HEART J, V37, P3232, DOI 10.1093/eurheartj/ehw334
   Warren-Gash C, 2011, J INFECT DIS, V203, P1710, DOI 10.1093/infdis/jir171
NR 21
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0001-5385
EI 1784-973X
J9 ACTA CARDIOL
JI Acta Cardiol.
DI 10.1080/00015385.2020.1796035
EA JUL 2020
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MT7CL
UT WOS:000555128500001
PM 32727305
OA Bronze
DA 2021-01-01
ER

PT J
AU AlAjmi, MF
   Azhar, A
   Owais, M
   Rashid, S
   Hasan, S
   Hussain, A
   Rehman, MT
AF AlAjmi, Mohamed F.
   Azhar, Asim
   Owais, Mohd
   Rashid, Summya
   Hasan, Sadaf
   Hussain, Afzal
   Rehman, Md Tabish
TI Antiviral potential of some novel structural analogs of standard drugs
   repurposed for the treatment of COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Remdesivir; Lopinavir; Theophylline; SARS-CoV-2; molecular dynamics
   simulation
ID RESPIRATORY SYNDROME CORONAVIRUS; PAPAIN-LIKE PROTEASE; HUMAN
   SERUM-ALBUMIN; CELL-CULTURE; REPLICATION; THEOPHYLLINE; INHIBITORS;
   INSIGHT; VIRUS
AB SARS-CoV-2 pandemic has claimed millions of lives across the world. As of June 2020, there is no FDA approved antiviral therapy to eradicate this dreadful virus. In this study, drug re-purposing and computational approaches were employed to identify high affinity inhibitors of SARS-CoV-2 Main protease (3CLpro), Papain-like protease (PLpro) and the receptor domain of Spike protein. Molecular docking on 40 derivatives of standard drugs (Remdesivir, Lopinavir and Theophylline) led to the identification of R10, R2 and L9 as potential inhibitors of 3CLpro, PLpro and Spike protein, respectively. The binding affinity of R10, R2 and L9 towards 3CLpro, PLpro and Spike protein were 4.03 x 10(6), 3.72 x 10(4)and 1.31 x 10(4)M(-1), respectively. These inhibitors interact with the active site or catalytic amino acid residues of 3CLpro, PLpro and Spike protein. We also examined the stability and dynamic behavior of protein-inhibitor complex by employing molecular dynamics simulation. RMSDs, RMSFs and variation in secondary structure of target proteins alone or in complex with their respective inhibitors were used to ascertain the integrity of proteins' structure during simulation. Moreover, physicochemical and ADMET properties of R10, R2 and L9 along with Remdesivir, Lopinavir and Theophylline were determined.In vitroandIn vivostudies are needed to further validate the potential of these derivatives before they can be developed into potential drug molecules. Communicated by Ramaswamy H. Sarma
C1 [AlAjmi, Mohamed F.; Hussain, Afzal; Rehman, Md Tabish] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh, Saudi Arabia.
   [Azhar, Asim; Owais, Mohd] Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Aligarh, Uttar Pradesh, India.
   [Rashid, Summya] Prince Sattam Bin AbdulAziz Univ, Coll Pharm Girls Sect, Dept Pharmacol & Toxicol, Al Kharj, Saudi Arabia.
   [Hasan, Sadaf] NYU, Sch Med, Dept Orthopaed Surg, New York, NY USA.
RP Rehman, MT (corresponding author), King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh, Saudi Arabia.; Azhar, A (corresponding author), Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Aligarh, Uttar Pradesh, India.
EM azharasim@gmail.com; mrehman@ksu.edu.sa
RI REHMAN, TABISH/H-8471-2012
OI REHMAN, TABISH/0000-0003-2341-900X
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020-122]
FX The authors acknowledge the generous support from Researchers Supporting
   Project number (RSP-2020-122), King Saud University, Riyadh, Saudi
   Arabia.
CR Al-Shabib NA, 2018, J MOL LIQ, V269, P511, DOI 10.1016/j.molliq.2018.07.122
   AlAjmi MF, 2018, INT J BIOL MACROMOL, V116, P173, DOI 10.1016/j.ijbiomac.2018.05.023
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Branka AC, 2000, PHYS REV E, V61, P4769, DOI 10.1103/PhysRevE.61.4769
   Calistri A, 2014, CELLS-BASEL, V3, P386, DOI 10.3390/cells3020386
   Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106
   de Wilde AH, 2017, VIRUS RES, V228, P7, DOI 10.1016/j.virusres.2016.11.011
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Ferreira LLG, 2019, DRUG DISCOV TODAY, V24, P1157, DOI 10.1016/j.drudis.2019.03.015
   Ishida T., 2020, EDELWEISS J BIOMEDIC, V2, DOI [10.33805/2690-2613.109, DOI 10.33805/2690-2613.109]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Khan MS, 2018, INT J BIOL MACROMOL, V120, P45, DOI 10.1016/j.ijbiomac.2018.07.112
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lim S, 2001, AM J RESP CRIT CARE, V164, P273, DOI 10.1164/ajrccm.164.2.2006043
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Parvez MK, 2019, SAUDI PHARM J, V27, P389, DOI 10.1016/j.jsps.2018.12.008
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Rehman MT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040819
   Rehman MT, 2016, J BIOMOL STRUCT DYN, V34, P1849, DOI 10.1080/07391102.2015.1094411
   Rehman MT, 2014, MOL PHARMACEUT, V11, P1785, DOI 10.1021/mp500116c
   Shamsi Anas, 2020, Biosci Rep, V40, DOI 10.1042/BSR20201256
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
NR 33
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1799865
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MT7GV
UT WOS:000555139900001
PM 32729392
OA Bronze
DA 2021-01-01
ER

PT J
AU Boelen, PA
   Eisma, MC
   Smid, GE
   de Keijser, J
   Lenferink, LIM
AF Boelen, Paul A.
   Eisma, Maarten C.
   Smid, Geert E.
   de Keijser, Jos
   Lenferink, Lonneke I. M.
TI Remotely Delivered Cognitive Behavior Therapy for Disturbed Grief During
   the COVID-19 Crisis: Challenges and Opportunities
SO JOURNAL OF LOSS & TRAUMA
LA English
DT Article; Early Access
DE Prolonged grief disorder; persistent complex bereavement disorder;
   videoconferencing; intervention; COVID-19; novel coronavirus
ID COMPLICATED GRIEF
AB Cognitive behavior therapy (CBT) interventions are effective in alleviating disturbed grief. CBT is typically delivered face-to-face. Government policy during the coronavirus (COVID-19) pandemic (quarantine and social distancing) may impede access to face-to-face therapy. Psychotherapy is now widely delivered remotely. In this article, various points of attention related to the application of CBT for disturbed grief using telephone or videoconferencing (or video calling) services are discussed. Additionally, we explore possible ways in which individual risk factors and stressors connected with COVID-19 can be addressed in treatment. Remote treatment brings challenges but also opportunities to help people in shifting from unhealthy to healthy grieving.
C1 [Boelen, Paul A.; Lenferink, Lonneke I. M.] Univ Utrecht, Fac Social Sci, Dept Clin Psychol, Utrecht, Netherlands.
   [Boelen, Paul A.; Smid, Geert E.] ARQ Natl Psychotrauma Ctr, Diemen, Netherlands.
   [Eisma, Maarten C.; de Keijser, Jos; Lenferink, Lonneke I. M.] Univ Groningen, Fac Behav & Social Sci, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands.
   [Smid, Geert E.] Univ Humanist Studies, Utrecht, Netherlands.
RP Boelen, PA (corresponding author), Univ Utrecht, Fac Social Sci, Dept Clin Psychol, Utrecht, Netherlands.
EM P.A.Boelen@uu.nl
RI Lenferink, Lonneke I.M./V-2058-2019
OI Lenferink, Lonneke I.M./0000-0003-1329-6413; Eisma,
   Maarten/0000-0002-6109-2274; Smid, Geert E./0000-0002-9616-5234; Boelen,
   Paul/0000-0003-4125-4739; de Keijser, Jos/0000-0003-1229-3042
CR American Psychiatric Association, 2013, DIAGNOSTIC AND STATI
   Boelen PA, 2006, J LOSS TRAUMA, V11, P1, DOI 10.1080/15325020500193655
   Boelen PA, 2006, CLIN PSYCHOL-SCI PR, V13, P109, DOI 10.1111/j.1468-2850.2006.00013.x
   Boss P., 2006, LOSS TRAUMA AND RESI
   Cummings JA, 2014, PROF PSYCHOL-RES PR, V45, P378, DOI 10.1037/a0037682
   Currier JM, 2010, INT J COGN THER, V3, P77, DOI 10.1521/ijct.2010.3.1.77
   Downar J, 2018, INTENS CARE MED, V44, P521, DOI 10.1007/s00134-017-5027-2
   Eisma MC, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113031
   Eisma MC, 2015, BEHAV THER, V46, P729, DOI 10.1016/j.beth.2015.05.007
   Johannsen M, 2019, J AFFECT DISORDERS, V253, P69, DOI 10.1016/j.jad.2019.04.065
   Kokou-Kpolou CK, 2020, PSYCHOL TRAUMA-US, V12, pS94, DOI 10.1037/tra0000798
   Morris SE, 2020, J PAIN SYMPTOM MANAG, V60, pE70, DOI 10.1016/j.jpainsymman.2020.05.002
   SMID GE, 2015, EUROPEAN J PSYCHOTRA, V6, P1, DOI DOI 10.3402/ejpt.v6.27324
   Smid GE, 2018, PSYCHIAT SERV, V69, P1050, DOI 10.1176/appi.ps.201700422
   Wagner B, 2006, DEATH STUD, V30, P429, DOI 10.1080/07481180600614385
   World Health Organization, 2018, INTERNATIONAL CLASSI
   Wright JH, 2020, PSYCHOTHER PSYCHOSOM, V89, P130, DOI 10.1159/000507376
NR 17
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1532-5024
EI 1532-5032
J9 J LOSS TRAUMA
JI J. Loss Trauma
DI 10.1080/15325024.2020.1793547
EA JUL 2020
PG 9
WC Psychology, Social
SC Psychology
GA MT7OL
UT WOS:000555159700001
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Garattini, SK
   Bin, A
   Donato, R
   Mansutti, M
   Rizzato, S
   Troiero, G
   Candoni, A
   Fanin, R
   Fasola, G
AF Garattini, S. K.
   Bin, A.
   Donato, R.
   Mansutti, M.
   Rizzato, S.
   Troiero, G.
   Candoni, A.
   Fanin, R.
   Fasola, G.
TI What to do in an oncology department to face the new COVID-19 era
   challenges?
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Medical oncology; COVID-19; Medical management; Pandemic
AB Italy was the first European country to be hit by COVID-19 pandemic. As a consequence, Italian oncologists had to guarantee essential treatments although minimizing exposure to the virus, and accidental infection, of patients and healthcare professionals. As Department of Medical Oncology of the University Hospital of Udine, in this short report, we describe the measures that we have taken, and gradually updated, since February 26, 2020. All accesses to our Oncology facilities are currently regulated by entrance check-points where patients are screened for infections following dedicated algorithms. Up to date, after 6 weeks of systematic execution of swabs no physician, nurse or other individual of the staff has been found positive to COVID-19. Only one patient admitted for therapy has been identified as COVID-19 positive. The aim of our work is to propose a model, made up of a set of operative procedures, that may be adopted by all the oncologists that daily struggle to guarantee safety and care in Oncology during this COVID-19 emergency.
C1 [Garattini, S. K.; Bin, A.; Donato, R.; Mansutti, M.; Rizzato, S.; Troiero, G.; Fasola, G.] ASUFC Univ Hosp Udine, Dept Oncol, I-33100 Udine, UD, Italy.
   [Candoni, A.; Fanin, R.] ASUFC Univ Hosp Udine, Dept Specialized Med, Haematolgy Clin, I-33100 Udine, UD, Italy.
   [Garattini, S. K.] Azienda Sanit Univ Integrata Udine, Dept Oncol, Piazzale Santa Maria della Misericordia 15, I-33100 Udine, UD, Italy.
RP Garattini, SK (corresponding author), ASUFC Univ Hosp Udine, Dept Oncol, I-33100 Udine, UD, Italy.; Garattini, SK (corresponding author), Azienda Sanit Univ Integrata Udine, Dept Oncol, Piazzale Santa Maria della Misericordia 15, I-33100 Udine, UD, Italy.
EM silvioken@hotmail.it; alessandra.bin@asufc.sanita.fvg.it;
   raffaela.donato@asufc.sanita.fvg.it; mauro.mansutti@asufc.sanita.fvg.it;
   simona.rizzato@asufc.sanita.fvg.it;
   graziella.troiero@asufc.sanita.fvg.it; anna.candoni@asufc.sanita.fvg.it;
   renato.fanin@asufc.sanita.fvg.it; gianpiero.fasola@asufc.sanita.fvg.it
RI Garattini, Silvio ken/ABB-1956-2020
OI Garattini, Silvio Ken/0000-0001-6420-0333
CR [Anonymous], 1990, EUR J CANC OXF ENGL, V2020
   [Anonymous], 2019, NOV COR PAT PNEUM CH
   ESMO, COVID 19 SUPP ONC PR
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Wu Z, 2020, JAMA
NR 6
TC 0
Z9 0
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD JUL 29
PY 2020
VL 37
IS 8
AR 75
DI 10.1007/s12032-020-01400-x
PG 6
WC Oncology
SC Oncology
GA MT0UW
UT WOS:000554686600001
PM 32728951
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alhatlani, BY
AF Alhatlani, Bader Y.
TI In silicoidentification of conservedcis-acting RNA elements in the
   SARS-CoV-2 genome
SO FUTURE VIROLOGY
LA English
DT Article
DE cis-acting RNA elements; RNA structure; RNA virus; SARS-CoV-2
ID PACKAGING SIGNAL; 5'-UNTRANSLATED REGION; STEM-LOOP; CORONAVIRUS;
   IDENTIFICATION; ALPHACORONAVIRUS; REPLICATION
AB Aim:The aim of this study was to computationally predict conserved RNA sequences and structures known ascis-acting RNA elements (CREs) in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome.Materials & methods:Bioinformatics tools were used to analyze and predict CREs by obtaining viral sequences from available databases.Results:Computational analysis revealed the presence of RNA stem-loop structures within the 3 ' end of the ORF1ab region analogous to previously identified SARS-CoV genomic packaging signals. Alignment-based RNA secondary structure predictions of the 5 ' end of the SARS-CoV-2 genome also identified conserved CREs.Conclusion:These CREs may be potential vaccine and/or antiviral therapeutic targets; however, further studies are warranted to confirm their roles in the SARS-CoV-2 life cycle.
C1 [Alhatlani, Bader Y.] Qassim Univ, Unayzah Community Coll, Dept Med Appl Sci, Unayzah, Saudi Arabia.
RP Alhatlani, BY (corresponding author), Qassim Univ, Unayzah Community Coll, Dept Med Appl Sci, Unayzah, Saudi Arabia.
EM balhatlani@qu.edu.sa
OI Alhatlani, Bader/0000-0003-0871-6313
CR Alhatlani B, 2015, VIRUS RES, V206, P134, DOI 10.1016/j.virusres.2015.02.002
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Chen SC, 2007, J VIROL, V81, P6771, DOI 10.1128/JVI.02231-06
   Chen SC, 2010, VIROLOGY, V401, P29, DOI 10.1016/j.virol.2010.02.007
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Darty K, 2009, BIOINFORMATICS, V25, P1974, DOI 10.1093/bioinformatics/btp250
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Escors D, 2003, J VIROL, V77, P7890, DOI 10.1128/JVI.77.14.7890-7902.2003
   FOSMIRE JA, 1992, J VIROL, V66, P3522, DOI 10.1128/JVI.66.6.3522-3530.1992
   Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000
   Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005
   Hsin WC, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0449-x
   King A.M.Q., 2011, VIRUS TAXONOMY
   Liu PH, 2007, RNA, V13, P763, DOI 10.1261/rna.261807
   Liu Y, 2009, BBA-GENE REGUL MECH, V1789, P495, DOI 10.1016/j.bbagrm.2009.09.007
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madhugiri R, 2016, ADV VIRUS RES, V96, P127, DOI 10.1016/bs.aivir.2016.08.007
   Madhugiri R, 2014, VIRUS RES, V194, P76, DOI 10.1016/j.virusres.2014.10.001
   Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031
   Qin L, 2003, ACTA PHARMACOL SIN, V24, P489
   Raman S, 2005, J VIROL, V79, P12434, DOI 10.1128/JVI.79.19.12434-12446.2005
   Rangan R, 2020, RNA, V26, P937, DOI 10.1261/rna.076141.120
   Sola I, 2011, RNA BIOL, V8, P237, DOI 10.4161/rna.8.2.14991
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Will S, 2012, RNA, V18, P900, DOI 10.1261/rna.029041.111
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Zaki AM, 2003, NEW ENGL J MED, V367, P1814
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 33
TC 1
Z9 1
U1 1
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD JUL
PY 2020
VL 15
IS 7
BP 409
EP 417
DI 10.2217/fvl-2020-0163
EA JUL 2020
PG 9
WC Virology
SC Virology
GA NC2WK
UT WOS:000553418600001
PM 33005212
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hermans, C
   Lambert, C
   Sogorb, A
   Wittebole, X
   Belkhir, L
   Yombi, JC
AF Hermans, Cedric
   Lambert, Catherine
   Sogorb, Amaury
   Wittebole, Xavier
   Belkhir, Leila
   Yombi, Jean Cyr
TI In-hospital management of persons with haemophilia and COVID-19:
   Practical guidance
SO HAEMOPHILIA
LA English
DT Article
DE COVID-19; guidance; haemophilia; SARS-CoV-2
AB A new disease (COVID-19) caused by a coronavirus (SARS-CoV-2) that appeared in China at the end of 2019 is currently spreading globally. This emerging virus is mainly responsible for respiratory tract infections and potentially fatal pneumonia, mainly in more frail patients. Persons with haemophilia of variable severity and from all parts of the world will likely be infected and develop COVID-19. We here propose practical guidance for the in-hospital specific management of haemophilia persons with COVID-19 including their possible transfer to the intensive care unit. Rapid identification of the haemophilia status, undelayed and regular liaison with the haemophilia team, proper therapy with factor concentrates or alternative treatments appear instrumental to prevent haemophilia-related complications in this setting. Information of patients and their families about COVID-19, psychological support and good appreciation of the impact of haemophilia on therapeutic decisions including end-of-life directives are also addressed.
C1 [Hermans, Cedric; Lambert, Catherine; Sogorb, Amaury] Catholic Univ Louvain, Clin Univ St Luc, Div Haematol, Haemostasis & Thrombosis Unit, Brussels, Belgium.
   [Wittebole, Xavier] Catholic Univ Louvain, Clin Univ St Luc, Div Intens Care, Brussels, Belgium.
   [Belkhir, Leila; Yombi, Jean Cyr] Catholic Univ Louvain, Clin Univ St Luc, Dept Internal Med, Div Infect Dis, Brussels, Belgium.
RP Hermans, C (corresponding author), Catholic Univ Louvain, UCLouvain, St Luc Univ Hosp, Div Adult Haematol,Haemostasis & Thrombosis Unit, Ave Hippocrate 10, B-1200 Brussels, Belgium.
EM cedric.hermans@uclouvain.be
OI Lambert, catherine/0000-0003-2222-0357
CR [Anonymous], 2020, 2019 NOVEL CORONAVIR
   [Anonymous], 2020, ETHICAL PRINCIPLES P
   [Anonymous], 2014, PHYSICAL ACTIVITY HE
   [Anonymous], 2020, UPDATED EHC COVID 19
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cui DY, 2020, HAEMOPHILIA, V26, pE214, DOI 10.1111/hae.14000
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Franchini M, 2014, SEMIN THROMB HEMOST, V40, P571, DOI 10.1055/s-0034-1381232
   Frias MA, 2011, PEDIATR CRIT CARE ME, V12, pE432, DOI 10.1097/PCC.0b013e31822f1b63
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01227-2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kwon SY, 2020, VOX SANG, V115, P601, DOI 10.1111/vox.12925
   Malfertheiner M V, 2017, Crit Care Resusc, V19, P45
   Mazza S, 2020, GUT, V69, P1148, DOI 10.1136/gutjnl-2020-321183
   Simpson S, 2020, J THORAC IMAG, V35, P219, DOI 10.1097/RTI.0000000000000524
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 3
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
EI 1365-2516
J9 HAEMOPHILIA
JI Haemophilia
PD SEP
PY 2020
VL 26
IS 5
BP 768
EP 772
DI 10.1111/hae.14045
EA JUL 2020
PG 5
WC Hematology
SC Hematology
GA NU0EM
UT WOS:000553224400001
PM 32384183
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pfeifer, M
   Hamer, OW
AF Pfeifer, M.
   Hamer, O. W.
TI COVID-19 pneumonia
SO INTERNIST
LA German
DT Article
DE Acute respiratory distress syndrome; Tomography; X-ray computed;
   Ventilation; mechanical; Antiviral agents; Dexamethasone
ID RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; LUNG INJURY;
   PROGRESSION; PRESSURE; SARS
AB Coronavirus disease 2019 (COVID-19) continues to pose a major global threat. Although a wide range of organ manifestations have now been described, the respiratory system remains in the forefront in terms of the course of infection. Severe pneumonia can develop and is generally prognostically relevant. The following article discusses currently known features of these pulmonary manifestations from a pathophysiological, symptomatological, and radiological perspective. With regard to pathophysiology, the complex nature of the acute pulmonary disease involving severe injury to the alveolar epithelium and pulmonary vascular endothelium resulting in severe respiratory failure in a proportion of patients is discussed. The differences from "classic" acute respiratory distress syndrome and the major effects these have on the treatment of COVID-19 are elucidated. Following a brief description of PCR-based pathogen identification and information on typical laboratory findings, imaging of COVID-19 pneumonia is described in greater details (typical findings, differential diagnoses, grading of the likelihood of COVID-19 pneumonia). This is followed by a description of symptoms, which develop in three phases. With regard to treatment, supportive and intensive care approaches are discussed, including O(2)administration and (non-)invasive ventilation. The article concludes with a summary of the insights gained into pharmacological therapies: thrombosis prevention on the one hand, and specific antiviral and immunomodulatory therapies (remdesivir, tocilizumab, anakinra, dexamethasone) on the other.
C1 [Pfeifer, M.] Univ Klinikum Regensburg, Klin & Poliklin Innere Med 2, Pneumol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
   [Pfeifer, M.; Hamer, O. W.] Klinikum Donaustauf, Donaustauf, Germany.
   [Pfeifer, M.] Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany.
   [Hamer, O. W.] Univ Klinikum Regensburg, Inst Rontgendiagnost, Regensburg, Germany.
RP Pfeifer, M (corresponding author), Univ Klinikum Regensburg, Klin & Poliklin Innere Med 2, Pneumol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM michael.pfeifer@ukr.de
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   BARACH A L, 1946, J Aviat Med, V17, P290
   Barach AL, 1938, ANN INTERN MED, V12, P754, DOI 10.7326/0003-4819-12-6-754
   Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP
   Cala-Garcia JD, 2020, IMMUNOTHERAPY-UK, V12, P1127, DOI 10.2217/imt-2020-0154
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Coyle Justin, 2020, JACC Case Rep, V2, P1331, DOI 10.1016/j.jaccas.2020.04.025
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Dohla M, 2020, PUBLIC HEALTH, V182, P170, DOI 10.1016/j.puhe.2020.04.009
   Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0
   Fichtner F, 2018, DTSCH ARZTEBL INT, V115, P840, DOI 10.3238/arztebl.2018.0840
   Fox SE, 2020, LANCET RESP MED, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gao C, 2020, CRIT CARE MED, V48, P451, DOI 10.1097/CCM.0000000000004207
   Gattinoni L, 2020, INTENSIVE CARE MED
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gillenwater S, 2020, NEW ENGL J MED, V383, P992, DOI 10.1056/NEJMc2022236
   Grant MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234765
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Han RB, 2020, ANIM BIOTECHNOL, DOI [10.1080/10495398.2020.1832104, 10.2214/AJR.20.22961]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ICNARC, 2020, ICNARC REP COVID 19
   Kanne JP, 2020, RADIOLOGY, V296, pE113, DOI 10.1148/radiol.2020200527
   Kim H, 2020, RADIOLOGY, V296, pE145, DOI 10.1148/radiol.2020201343
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Kolditz M, 2020, PNEUMOLOGIE, V74, P493, DOI 10.1055/a-1216-5739
   Langer F, 2020, HAMOSTASEOLOGIE, V40, P264, DOI 10.1055/a-1178-3551
   Lechien JR, 2020, ANN INTERN MED, V173, P672, DOI 10.7326/M20-2428
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   MASCHERONI D, 1988, INTENS CARE MED, V15, P8
   Munoz-Jimenez Alejandro, 2020, Reumatol Clin, DOI 10.1016/j.reuma.2020.04.009
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pfeifer M, 2020, PNEUMOLOGIE, V74, P337, DOI 10.1055/a-1157-9976
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Revel MP, 2020, EUR RADIOL, V30, P4903, DOI 10.1007/s00330-020-06865-y
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Schaible J, 2020, ROFO-FORTSCHR RONTG, V192, P513, DOI 10.1055/a-1164-7001
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Simpson S, 2020, J THORAC IMAG, V35, P219, DOI 10.1097/RTI.0000000000000524
   Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Vogel-Claussen J, 2020, ROFO-FORTSCHR RONTG, V192, P633, DOI 10.1055/a-1174-8378
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y, 2020, J MED VIROL, V92, P536, DOI 10.1002/jmv.25720
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Yoshida T, 2020, CURR OPIN CRIT CARE, V26, P59, DOI 10.1097/MCC.0000000000000691
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou SC, 2020, AM J ROENTGENOL, V214, P1287, DOI 10.2214/AJR.20.22975
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 67
TC 1
Z9 1
U1 7
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0020-9554
EI 1432-1289
J9 INTERNIST
JI Internist
PD AUG
PY 2020
VL 61
IS 8
SI SI
BP 793
EP 802
DI 10.1007/s00108-020-00854-5
EA JUL 2020
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA MU9TN
UT WOS:000553730700002
PM 32728817
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bloom, PP
   Pasricha, TS
   Andersson, KL
   Pratt, DS
   Hashemi, N
   Bhan, I
   Viveiros, K
AF Bloom, Patricia P.
   Pasricha, Trisha S.
   Andersson, Karin L.
   Pratt, Daniel S.
   Hashemi, Nikroo
   Bhan, Irun
   Viveiros, Kathleen
TI Hepatology Consultants Often Disagree on Etiology of Abnormal Liver
   Biochemistries in COVID-19 but Agree on Management
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article; Early Access
DE COVID-19; Hepatology consultation; Liver biochemistries; Diagnosis
AB Background Coronavirus disease 2019 (COVID-19) is associated with elevated liver biochemistries in approximately half of hospitalized patients, with many possible etiologies. Aim To assess agreement on the etiology of abnormal liver biochemistries and diagnostic recommendations in COVID-19. Methods Twenty hepatology consultations were reviewed by three senior hepatologists who provided a differential diagnosis and diagnostic recommendations. Kappa agreement on the primary etiology was calculated. Results Kappa agreement between hepatologists on the primary etiology of elevated liver biochemistries was 0.10 (p = 0.03). Agreement was greater around drug-induced liver injury 0.51 (p < 0.0001) and SARS-CoV-2-related liver injury 0.17 (p = 0.03). Serial liver biochemistries were recommended in all consultations over other evaluations. Conclusion In COVID-19, elevated liver biochemistries present a diagnostic challenge and can often be monitored conservatively.
C1 [Bloom, Patricia P.; Pasricha, Trisha S.; Andersson, Karin L.; Pratt, Daniel S.; Bhan, Irun] Massachusetts Gen Hosp, Div Gastroenterol, Dept Med, 15 Parkman St,Wang 5, Boston, MA 02140 USA.
   [Bloom, Patricia P.; Pasricha, Trisha S.; Andersson, Karin L.; Pratt, Daniel S.; Hashemi, Nikroo; Bhan, Irun; Viveiros, Kathleen] Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
   [Hashemi, Nikroo; Viveiros, Kathleen] Brigham Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA USA.
RP Bloom, PP (corresponding author), Massachusetts Gen Hosp, Div Gastroenterol, Dept Med, 15 Parkman St,Wang 5, Boston, MA 02140 USA.; Bloom, PP (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
EM ppbloom@med.umich.edu
OI Bloom, Patricia/0000-0003-3188-7188; Andersson,
   Karin/0000-0002-8497-1335
CR Bloom PP, 2020, HEPATOLOGY, DOI 10.1002/hep.31326
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Fix OK, 2020, HEPATOLOGY, V72, P287, DOI 10.1002/hep.31281
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jothimani D, 2020, J HEPATOL, V73, P1231, DOI 10.1016/j.jhep.2020.06.006
   Kwo PY, 2017, AM J GASTROENTEROL, V112, P18, DOI 10.1038/ajg.2016.517
   Piano S, 2020, LIVER INT, V40, P2394, DOI 10.1111/liv.14565
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Schaefer Esperance A K, 2020, Clin Liver Dis (Hoboken), V15, P175, DOI 10.1002/cld.967
NR 10
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
DI 10.1007/s10620-020-06495-w
EA JUL 2020
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MR7JG
UT WOS:000553766700003
PM 32729013
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bryce, S
   Heath, KN
   Issi, L
   Ryder, EF
   Rao, RP
AF Bryce, Samantha
   Heath, Kevin N.
   Issi, Luca
   Ryder, Elizabeth F.
   P. Rao, Reeta
TI UsingCOVID-19 as a teaching tool in a time of remote learning: A
   workflow for bioinformatic approaches to identifying candidates for
   therapeutic and vaccine development
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY EDUCATION
LA English
DT Article
DE active learning; cellular biology; computational biology; distance
   learning; immunology; inquiry-based teaching; integration of research
   into undergraduate teaching; molecular biology; virology
ID CORONAVIRUS; SARS-COV-2; PROTEINASE; ALBICANS; SEARCH
AB The COVID-19 pandemic has led to an urgent need for engaging computational alternatives to traditional laboratory exercises. Here we introduce a customizable and flexible workflow, designed with the SARS CoV-2 virus that causes COVID-19 in mind, as a means of reinforcing fundamental biology concepts using bioinformatics approaches. This workflow is accessible to a wide range of students in life science majors regardless of their prior bioinformatics knowledge, and all software is freely available, thus eliminating potential cost barriers. Using the workflow can thus provide a diverse group of students the opportunity to conduct inquiry-driven research. Here we demonstrate the utility of this workflow and outline the logical steps involved in the identification of therapeutic or vaccine targets against SARS CoV-2. We also provide an example of how the workflow may be adapted to other infectious microbes. Overall, our workflow anchors student understanding of viral biology and genomics and allows students to develop valuable bioinformatics expertise as well as to hone critical thinking and problem-solving skills, while also creating an opportunity to better understand emerging information surrounding the COVID-19 pandemic.
C1 [Bryce, Samantha; Issi, Luca; Ryder, Elizabeth F.; P. Rao, Reeta] Worcester Polytech Inst, Biol & Biotechnol Dept, Worcester, MA 01609 USA.
   [Heath, Kevin N.; Ryder, Elizabeth F.] Worcester Polytech Inst, Bioinformat & Computat Biol Program, Worcester, MA 01609 USA.
RP Rao, RP (corresponding author), Worcester Polytech Inst, Biol & Biotechnol Dept, Worcester, MA 01609 USA.
EM rpr@wpi.edu
OI Bryce, Samantha/0000-0002-3444-7252
FU National Center for Complementary and Integrative Health
   [1R15AT009926-01]; National Science FoundationNational Science
   Foundation (NSF) [1742446]
FX National Center for Complementary and Integrative Health, Grant/Award
   Number: 1R15AT009926-01; National Science Foundation, Grant/Award
   Number: 1742446
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Charles J., 2001, IMMUNOBIOLOGY IMMUNE
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Corum J., 2020, NY TIMES
   CUTFIELD SM, 1995, STRUCTURE, V3, P1261, DOI 10.1016/S0969-2126(01)00261-1
   Debarnot C, 2011, ACTA CRYSTALLOGR F, V67, P404, DOI 10.1107/S1744309111002867
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Fallon K, 1997, INFECT IMMUN, V65, P551, DOI 10.1128/IAI.65.2.551-556.1997
   Howard R. E., 1997, J COLL SCI TEACH, V26, P383
   Ke M, 2012, VIRUS RES, V167, P322, DOI 10.1016/j.virusres.2012.05.017
   Kerfeld CA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001014
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Leifert JA, 2003, DNA VACCINES
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Maria B, 2013, INT J INNOV SCI MATH, V21, P42
   Monto AS, 2020, J INFECT DIS, V222, P9, DOI 10.1093/infdis/jiaa161
   Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Reece AJ, 2017, J COLL SCI TEACH, V46, P83, DOI DOI 10.2505/4/jcst17_046_03_83
   Suits J, 2010, SCH SCI MATH, V104, P248
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wheeler D., 2007, BLAST QUICKSTART
   Wiesner TF, 2004, J ENG EDUC, V93, P195, DOI 10.1002/j.2168-9830.2004.tb00806.x
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
NR 31
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-8175
EI 1539-3429
J9 BIOCHEM MOL BIOL EDU
JI Biochem. Mol. Biol. Educ.
PD SEP
PY 2020
VL 48
IS 5
SI SI
BP 492
EP 498
DI 10.1002/bmb.21413
EA JUL 2020
PG 7
WC Biochemistry & Molecular Biology; Education, Scientific Disciplines
SC Biochemistry & Molecular Biology; Education & Educational Research
GA NV4BK
UT WOS:000553219800001
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Venketasubramanian, N
AF Venketasubramanian, Narayanaswamy
TI Stroke Care Services in Singapore During COVID-19 Pandemic-A National
   Perspective
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE stroke; services; COVID-19; Singapore; stroke unit
AB Stroke is a significant cause of admission to Singapore's acute care hospitals. Because of the current COVID-19 pandemic, there have been major changes in the stroke care system. On calling for the public ambulance, those suspected to have COVID-19 infection are taken to the National Center for Infectious Diseases. Otherwise, on arrival at the emergency room, all cases with fever or respiratory symptoms [COVID-19 suspect patients (CSPs)] are evaluated separately by staff wearing full personal protective equipment (PPE). Triage is not delayed. CSPs needing hyperacute therapies are sent to a specially prepared scanner; if not, imaging is deferred to the latter part of the day. CSPs are managed in isolation rooms, and sent to the acute stroke unit (ASU) if two consecutive COVID-19 swabs are negative. Investigation and rehabilitation are done within the room. ASU rounds are attended by essential members, communication by electronic means. Multidisciplinary team rounds have largely ceased, and discussions are via electronic platforms. Patient transfer and staff movement are minimized. All hospital staff wear face-masks, infection control is strictly enforced. Visitors are not allowed; staff make daily calls to update families. Mild stroke patients may be sent home with rehabilitation advice. Out-patient rehabilitation centers are closed. Patients return for out-patient visits only if needed; medications are sent to their home, and nurses make essential home visits. Stroke support and rehabilitation activities have started on-line. Continuing medical education activities are mainly by webinars. Stroke research has been severely hampered. Overall, evidence-based stroke care is delivered in a re-organized manner, with a clear eye on infection control.
C1 [Venketasubramanian, Narayanaswamy] Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore.
RP Venketasubramanian, N (corresponding author), Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore.
EM drnvramani@gmail.com
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Alqahtani SA, 2020, CUREUS, V12, DOI 10.7759/cureus.7808
   Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9
   Bhatia Rohit, 2020, Ann Indian Acad Neurol, V23, pS15, DOI 10.4103/aian.AIAN_302_20
   Bikson M, 2020, BRAIN STIMUL, V13, P1124, DOI 10.1016/j.brs.2020.05.010
   Boldrini P, 2020, EUR J PHYS REHAB MED, V56, P331, DOI 10.23736/S1973-9087.20.06373-X
   Carda S, 2020, EUR J PHYS REHAB MED, V56, P515, DOI 10.23736/S1973-9087.20.06317-0
   Chang MC, 2020, AM J PHYS MED REHAB, V99, P582, DOI 10.1097/PHM.0000000000001468
   Christopher S.Y.H., 2020, INT J CEREBROVASC DI, V3, P12, DOI [10.29011/2688-8734.000025, DOI 10.29011/2688-8734.000025]
   Dafer RM, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104881
   Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI 10.1016/S1474-4422(18)30499-X
   Goyal M, 2020, STROKE, V51, P2263, DOI 10.1161/STROKEAHA.120.030340
   Hess DC, 2020, TRANSL STROKE RES, V11, P322, DOI 10.1007/s12975-020-00818-9
   Khosravani H, 2020, STROKE, V51, P1891, DOI 10.1161/STROKEAHA.120.029838
   Kurz MW, 2020, STROKE, V51, P2273, DOI 10.1161/STROKEAHA.120.030091
   Larson AS, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016793
   Leira EC, 2020, NEUROLOGY, DOI [10.1212/WNL.000000000000971332385186, DOI 10.1212/WNL.000000000000971332385186]
   Leocani L, 2020, EUR J NEUROL, V27, pE50, DOI 10.1111/ene.14320
   Li Y, 2020, STROKE VASC NEUROL, DOI [10.1136/svn-2020-00043132616524, DOI 10.1136/SVN-2020-00043132616524]
   Lyden P, 2020, STROKE, V51, P1910, DOI 10.1161/STROKEAHA.120.030023
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Meschia JF, 2020, NEUROLOGY, V95, P29, DOI 10.1212/WNL.0000000000009698
   Morelli N, 2020, EUR NEUROL, V83, P213, DOI 10.1159/000507666
   Nguyen TN, 2020, STROKE, V51, P1896, DOI 10.1161/STROKEAHA.120.030100
   Pop R, 2020, EUR J NEUROL, V11, P1073, DOI [10.1111/ene.1431632399995, DOI 10.1111/ENE.1431632399995]
   Pranata R, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104949
   Qureshi AI, 2020, INT J STROKE, V15, P540, DOI 10.1177/1747493020923234
   Rai AT, 2020, J NEUROINTERV SURG, V12, P654, DOI 10.1136/neurintsurg-2020-016221
   Rodriguez-Pardo J, 2020, NEUROLOGIA, V35, P258, DOI 10.1016/j.nrl.2020.04.008
   Sheth SA, 2020, STROKE, V51, P2268, DOI 10.1161/STROKEAHA.120.030154
   Siegler JE, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104953
   Smith MS, 2020, STROKE, V51, P1902, DOI 10.1161/STROKEAHA.120.029863
   Sylaja PN, 2020, ANN NY ACAD SCI, V1473, P3, DOI 10.1111/nyas.14379
   Teo KC, 2020, STROKE, V51, P2228, DOI 10.1161/STROKEAHA.120.030105
   Venketasubramanian N, 2008, INT J STROKE, V3, P51, DOI 10.1111/j.1747-4949.2008.00181.x
   Venketasubramanian N, 2002, ANN ACAD MED SINGAP, V31, P452
   Venketasubramanian N, 2020, CEREBROVASC DIS, V49, P235, DOI 10.1159/000508370
   Venketasubramanian N, 2017, J STROKE, V19, P286, DOI 10.5853/jos.2017.00234
   Venketasubramanian N, 2017, INT J STROKE, V12, P297, DOI 10.1177/1747493016676620
   Wang XY, 2020, STROKE VASC NEUROL, V5, P180, DOI [10.1136/svn-2020-000400, 10.1136/svn-2020-000514]
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
   Zhao J, 2020, STROKE, V51, P1356, DOI 10.1161/STROKEAHA.120.029701
NR 44
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD JUL 28
PY 2020
VL 11
AR 780
DI 10.3389/fneur.2020.00780
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NC7LB
UT WOS:000561395600001
PM 32849231
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dong, R
   Chu, ZG
   Yu, FX
   Zha, Y
AF Dong, Rong
   Chu, Zhugang
   Yu, Fuxun
   Zha, Yan
TI Contriving Multi-Epitope Subunit of Vaccine for COVID-19:
   Immunoinformatics Approaches
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE immunoinformatics; epitope prediction; COVID-19; SARS-CoV-2; vaccine
ID B-CELL EPITOPES; IMMUNE-RESPONSE; PREDICTION; PROTEIN; WEB; BINDING;
   TARGET; SERVER; TOOL
AB COVID-19 has recently become the most serious threat to public health, and its prevalence has been increasing at an alarming rate. The incubation period for the virus is similar to 1-14 days and all age groups may be susceptible to a fatality rate of about 5.9%. COVID-19 is caused by a novel single-stranded, positive (+) sense RNA beta coronavirus. The development of a vaccine for SARS-CoV-2 is an urgent need worldwide. Immunoinformatics approaches are both cost-effective and convenient, asin silicopredictions can reduce the number of experiments needed. In this study, with the aid of immunoinformatics tools, we tried to design a multi-epitope vaccine that can be used for the prevention and treatment of COVID-19. The epitopes were computed by using B cells, cytotoxic T lymphocytes (CTL), and helper T lymphocytes (HTL) base on the proteins of SARS-CoV-2. A vaccine was devised by fusing together the B cell, HTL, and CTL epitopes with linkers. To enhance the immunogenicity, the beta-defensin (45 mer) amino acid sequence, and pan-HLA DR binding epitopes (13aa) were adjoined to the N-terminal of the vaccine with the help of the EAAAK linker. To enable the intracellular delivery of the modeled vaccine, a TAT sequence (11aa) was appended to C-terminal. Linkers play vital roles in producing an extended conformation (flexibility), protein folding, and separation of functional domains, and therefore, make the protein structure more stable. The secondary and three-dimensional (3D) structure of the final vaccine was then predicted. Furthermore, the complex between the final vaccine and immune receptors (toll-like receptor-3 (TLR-3), major histocompatibility complex (MHC-I), and MHC-II) were evaluated by molecular docking. Lastly, to confirm the expression of the designed vaccine, the mRNA of the vaccine was enhanced with the aid of the Java Codon Adaptation Tool, and the secondary structure was generated from Mfold. Then we performedin silicocloning. The final vaccine requires experimental validation to determine its safety and efficacy in controlling SARS-CoV-2 infections.
C1 [Dong, Rong; Zha, Yan] Guizhou Univ, Sch Med, Dept Biomed, Guiyang, Peoples R China.
   [Dong, Rong; Zha, Yan] Guizhou Prov Peoples Hosp, Dept Nephrol, Guiyang, Peoples R China.
   [Dong, Rong; Yu, Fuxun; Zha, Yan] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immunol Dis, Guiyang, Peoples R China.
   [Chu, Zhugang] Guizhou Prov Peoples Hosp, Dept Urinary Surg, Guiyang, Peoples R China.
RP Zha, Y (corresponding author), Guizhou Univ, Sch Med, Dept Biomed, Guiyang, Peoples R China.; Zha, Y (corresponding author), Guizhou Prov Peoples Hosp, Dept Nephrol, Guiyang, Peoples R China.; Zha, Y (corresponding author), Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immunol Dis, Guiyang, Peoples R China.
EM zhayan72@126.com
FU Special Fund for Basic Scientific Research Operating of Central Public
   Welfare Research Institutes; Chinese Academy of Medical Sciences
   [2019PT320003]; Guizhou High-Level Innovative Talents Program
   [QKHPTRC(2018)5636]
FX This work was partly supported by grants from the Special Fund for Basic
   Scientific Research Operating of Central Public Welfare Research
   Institutes, the Chinese Academy of Medical Sciences (2019PT320003), and
   Guizhou High-Level Innovative Talents Program [QKHPTRC(2018)5636].
CR Andreatta M, 2015, IMMUNOGENETICS, V67, P641, DOI 10.1007/s00251-015-0873-y
   Barh D, 2010, BIOINFORMATION, V5, P77, DOI 10.6026/97320630005077
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Chatterjee N, 2018, INT J BIOL MACROMOL, V118, P180, DOI 10.1016/j.ijbiomac.2018.06.080
   Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Ferdous S, 2019, MOL IMMUNOL, V114, P643, DOI 10.1016/j.molimm.2019.09.014
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gonzalez-Pech RA, 2019, BIOINFORMATICS, V35, P2697, DOI 10.1093/bioinformatics/bty1018
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hegde NR, 2018, EXPERT OPIN DRUG DIS, V13, P117, DOI 10.1080/17460441.2018.1413088
   Huang Jian, 2014, Methods Mol Biol, V1184, P237, DOI 10.1007/978-1-4939-1115-8_13
   Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Karpenko O, 2008, IMMUNOGENETICS, V60, P25, DOI 10.1007/s00251-007-0266-y
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Liu C, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P107, DOI 10.3760/cma.j.issn.1007-3418.2020.02.003
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Liu WL, 2003, PROG NAT SCI-MATER, V13, P844, DOI 10.1080/10020070312331344530
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   Lund O, 2004, IMMUNOGENETICS, V55, P797, DOI 10.1007/s00251-004-0647-4
   Mohan T, 2013, VACCINE, V31, P1707, DOI 10.1016/j.vaccine.2013.01.041
   Nabel GJ, 2002, VACCINE, V20, P1945, DOI 10.1016/S0264-410X(02)00074-9
   Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018
   Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Ojha R, 2019, J CELL PHYSIOL, V234, P6437, DOI 10.1002/jcp.27380
   Oli AN, 2020, IMMUNOTARGETS THER, V9, P13, DOI 10.2147/ITT.S241064
   Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110
   Pandey RK, 2018, VACCINE, V36, P4555, DOI 10.1016/j.vaccine.2018.05.082
   Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Peele K.A., 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1770127, DOI 10.1080/07391102.2020.1770127]
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Poran A., 2020, BIORXIV, DOI [10.1101/2020.04.06.027805, DOI 10.1101/2020.04.06.027805]
   Rana A, 2016, IMMUNOBIOLOGY, V221, P544, DOI 10.1016/j.imbio.2015.12.004
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Russell CD, 2017, CLIN MICROBIOL REV, V30, P481, DOI 10.1128/CMR.00090-16
   Sah R, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00169-20
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Sedeyn K, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007984
   Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2
   Sikora M, 2020, IMMUNOL LETT, V218, P1, DOI 10.1016/j.imlet.2019.12.002
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   The World Health Organization (WHO), 2020, COVID 19
   Tomar Namrata, 2014, Methods Mol Biol, V1184, P23, DOI 10.1007/978-1-4939-1115-8_3
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Walls AC, 2020, STRUCTURE FUNCTION A, DOI [10.1101/2020.02.19.956581, DOI 10.1101/2020.02.19.956581]
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wei Z Y, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, pE006, DOI 10.3760/cma.j.issn.cn112148-20200220-00106
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 82
TC 2
Z9 2
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 28
PY 2020
VL 11
AR 1784
DI 10.3389/fimmu.2020.01784
PG 18
WC Immunology
SC Immunology
GA NC7AJ
UT WOS:000561367800001
PM 32849643
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cadegiani, FA
   Wambier, CG
   Goren, A
AF Cadegiani, Flavio A.
   Wambier, Carlos G.
   Goren, Andy
TI Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May
   Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced
   Acute Respiratory Distress Syndrome (ARDS) in COVID-19
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; pandemic; spironolactone; ARDS (acute
   respiratory distress syndrome); androgen receptor antagonist; TMPRSS2
ID ANGIOTENSIN-ALDOSTERONE SYSTEM; MINERALOCORTICOID RECEPTOR BLOCKADE;
   ENZYME 2 ACE2; SARS CORONAVIRUS; HEART-FAILURE; INFLAMMATION; PROTEIN;
   INVOLVEMENT; INHIBITION; MODULATION
C1 [Cadegiani, Flavio A.] Univ Fed Sao Paulo, Dept Endocrinol, Sao Paulo, Brazil.
   [Cadegiani, Flavio A.] Corpornetria Inst, Brasilia, DF, Brazil.
   [Wambier, Carlos G.; Goren, Andy] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
   [Goren, Andy] Appl Biol Inc, Irvine, CA USA.
RP Cadegiani, FA (corresponding author), Univ Fed Sao Paulo, Dept Endocrinol, Sao Paulo, Brazil.; Cadegiani, FA (corresponding author), Corpornetria Inst, Brasilia, DF, Brazil.
EM flavio.cadegiani@unifesp.br
RI Cadegiani, Flavio/O-3289-2019
OI Cadegiani, Flavio/0000-0002-2699-4344
CR Abobaker A, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03208-w
   Alifano M, 2020, BIOCHIMIE, V174, P30, DOI 10.1016/j.biochi.2020.04.008
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   BROULIK PD, 1976, ENDOKRINOLOGIE, V68, P35
   Cadegiani FA, 2020, AM J PHYSIOL-ENDOC M, V318, pE587, DOI 10.1152/ajpendo.00136.2020
   Maya WDC, 2020, REPROD BIOMED ONLINE, V40, P763, DOI [10.1016/j.rbmo.2020.04.0091472-6483, 10.1016/j.rbmo.2020.04.009]
   Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Cardona GC, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116824
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Frantz ED, 2017, AM J PHYSIOL-ENDOC M, V313, pE473, DOI 10.1152/ajpendo.00078.2017
   DIETERICH HA, 2005, HUM PHYSIOL+, V31, P706, DOI DOI 10.1007/s10747-005-0119-8
   Dumanli GY, 2020, TURK J ANAESTHESIOL, V48, P254, DOI 10.5152/TJAR.2020.569
   Engeli S, 2005, HYPERTENSION, V45, P356, DOI 10.1161/01.HYP.0000154361.47683.d3
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Feraco A, 2013, J STEROID BIOCHEM, V137, P99, DOI 10.1016/j.jsbmb.2013.02.012
   Fraccarollo D, 2008, HYPERTENSION, V51, P905, DOI 10.1161/HYPERTENSIONAHA.107.100941
   Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9
   Georgianos PI, 2017, CURR VASC PHARMACOL, V15, P599, DOI 10.2174/1570161115666170201113817
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Goren A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13365
   Gross S, 2020, J MOL CELL CARDIOL, V144, P47, DOI 10.1016/j.yjmcc.2020.04.031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hajifathalian K, 2020, OBESITY, V28, P1606, DOI 10.1002/oby.22923
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hamming I, 2007, J PATHOL, V212, P1, DOI 10.1002/path.2162
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hermidorff MM, 2015, BIOCHEM CELL BIOL, V93, P83, DOI 10.1139/bcb-2014-0110
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2010, CIRC J, V74, P405, DOI 10.1253/circj.CJ-10-0045
   Ji WJ, 2016, NANOMEDICINE-UK, V11, P1393, DOI 10.2217/nnm-2016-0006
   Ji WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081090
   Jing F, 2013, MOL CELL ENDOCRINOL, V378, P23, DOI 10.1016/j.mce.2012.03.005
   Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859
   Kato Y, 2014, IMMUNOPHARM IMMUNOT, V36, P237, DOI 10.3109/08923973.2014.921690
   Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A
   Kim IC, 2020, EUR HEART J, V41, P1859, DOI 10.1093/eurheartj/ehaa288
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Kong EL, 2019, J CELL COMMUN SIGNAL, V13, P17, DOI 10.1007/s12079-018-0466-2
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   La Vignera S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082948
   Lacombe B, 2016, J VIROL, V90, P10972, DOI 10.1128/JVI.01722-16
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lee IC, 2020, J CHIN MED ASSOC, V83, P521, DOI 10.1097/JCMA.0000000000000319
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Lieber GB, 2013, EUR J PHARMACOL, V718, P290, DOI 10.1016/j.ejphar.2013.08.019
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Mungmunpuntipantip R, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16483
   Musa S, 2020, ARAB J GASTROENTEROL, V21, P3, DOI 10.1016/j.ajg.2020.03.002
   Nagase M, 2009, HYPERTENS RES, V32, P649, DOI 10.1038/hr.2009.86
   Nakano S, 2005, HYPERTENS RES, V28, P925, DOI 10.1291/hypres.28.925
   Natoli S, 2020, EUR J NEUROL, V27, P1764, DOI 10.1111/ene.14277
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Ozacmak HS, 2014, J SURG RES, V191, P350, DOI 10.1016/j.jss.2014.04.040
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Patel S, 2017, BIOMED PHARMACOTHER, V94, P317, DOI 10.1016/j.biopha.2017.07.091
   Pinheiro TD, 2017, J NUTR BIOCHEM, V48, P74, DOI 10.1016/j.jnutbio.2017.06.008
   Pirola CJ, 2020, J INFECTION, V81, P276, DOI 10.1016/j.jinf.2020.05.052
   Rafatian N, 2014, AM J PHYSIOL-REG I, V307, pR879, DOI 10.1152/ajpregu.00075.2014
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Schjoedt KJ, 2011, DAN MED BULL, V58
   Sert M, 2003, ACTA MED OKAYAMA, V57, P73
   Song J, 2020, J MED VIROL, V92, P2556, DOI 10.1002/jmv.26045
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   STEELMAN SL, 1969, STEROIDS, V14, P449, DOI 10.1016/S0039-128X(69)80007-3
   Taira M, 2008, EUR J PHARMACOL, V589, P264, DOI 10.1016/j.ejphar.2008.06.019
   Takeda Y, 2007, AM J HYPERTENS, V20, P1119, DOI 10.1016/j.amjhyper.2007.05.008
   te Riet L, 2015, CIRC RES, V116, P960, DOI 10.1161/CIRCRESAHA.116.303587
   Vecchiola A, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00223
   Verma D, 2016, P NATL ACAD SCI USA, V113, P3609, DOI 10.1073/pnas.1523686113
   Wambier CG, 2020, DRUG DEVELOP RES, V81, P771, DOI 10.1002/ddr.21688
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zhang L, 2014, LAB INVEST, V94, P839, DOI 10.1038/labinvest.2014.69
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu A, 2009, J HYPERTENS, V27, P800, DOI 10.1097/HJH.0b013e328325d861
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01302-4
NR 91
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUL 28
PY 2020
VL 7
AR 453
DI 10.3389/fmed.2020.00453
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC4SA
UT WOS:000561202400001
PM 32850920
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Farhat, RM
   Mousa, MA
   Daas, EJ
   Glassberg, MK
AF Farhat, Ryan M.
   Mousa, Mohammad A.
   Daas, Eshaan J.
   Glassberg, Marilyn K.
TI Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE coronavirus (2019-nCoV); SARS-CoV-2; transfusion safety; neutralizing
   antibody titers (NAT); convalescent plasma for COVID-19 therapy
ID PATIENT
AB The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.
C1 [Farhat, Ryan M.; Mousa, Mohammad A.; Daas, Eshaan J.; Glassberg, Marilyn K.] Univ Arizona, Coll Med Phoenix, Phoenix, AZ 85004 USA.
   [Glassberg, Marilyn K.] Univ Arizona, Coll Med Phoenix, Dept Med, Div Pulm Crit Care & Sleep Med, Phoenix, AZ USA.
RP Mousa, MA (corresponding author), Univ Arizona, Coll Med Phoenix, Phoenix, AZ 85004 USA.
EM momousa22@email.arizona.edu
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   [Anonymous], 2014, IQPP QUAL DON STAND
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Chun S, 2016, ANN LAB MED, V36, P393, DOI 10.3343/alm.2016.36.4.393
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Food and Drug Administration, 2020, INV COVID 19 CONV PL
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mora-Rillo M, 2015, LANCET RESP MED, V3, P554, DOI 10.1016/S2213-2600(15)00180-0
   Pandey S, 2012, TRANSFUSION, V52, p65S, DOI 10.1111/j.1537-2995.2012.03663.x
   Rajam Gowrisankar, 2010, Recent Pat Antiinfect Drug Discov, V5, P157
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Woelfel R., 2020, CLIN PRESENTATION VI, DOI [DOI 10.1101/2020.03.05.20030502, 10.1101/2020.03.05.20030502]
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
NR 27
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUL 28
PY 2020
VL 7
AR 435
DI 10.3389/fmed.2020.00435
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC9WK
UT WOS:000561560700001
PM 32850916
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Boucher, P
   Boucher, R
AF Boucher, Patrice
   Boucher, Roger
TI Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the
   Novelty, Diversity, and Quantity of Antigen
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE coronavirus; COVID-19; natural killer cells; vaccination; non-specific
   immunity; pandemic crisis
ID REPORTING SYSTEM VAERS; ADULTS 65 YEARS; ADVERSE EVENTS; VACCINE; OLDER;
   RESPONSES; AGE; CELLS
C1 [Boucher, Patrice] Ecole Technol Super, Software & Informat Technol Engn Dept, Montreal, PQ, Canada.
   [Boucher, Roger] Medicentre, La Salle, PQ, Canada.
RP Boucher, P (corresponding author), Ecole Technol Super, Software & Informat Technol Engn Dept, Montreal, PQ, Canada.
EM patrice.boucher.qc@gmail.com
CR Ebbo M, 2016, EBIOMEDICINE, V6, P222, DOI 10.1016/j.ebiom.2016.02.025
   Gnann JW, 2008, J PAIN, V9, pS31, DOI 10.1016/j.jpain.2007.10.007
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Haley PJ, 2003, TOXICOLOGY, V188, P49, DOI 10.1016/S0300-483X(03)00043-X
   Horowitz A, 2010, J IMMUNOL, V185, P2808, DOI 10.4049/jimmunol.1000844
   Kraicer-Melamed H, 2016, VACCINE, V34, P1540, DOI 10.1016/j.vaccine.2016.02.024
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Manzoli L, 2009, LANCET INFECT DIS, V9, P482, DOI 10.1016/S1473-3099(09)70153-7
   Moro PL, 2011, VACCINE, V29, P9404, DOI 10.1016/j.vaccine.2011.05.100
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J
   SCOTT P, 1995, CURR OPIN IMMUNOL, V7, P34, DOI 10.1016/0952-7915(95)80026-3
   Sukumaran L, 2015, CLIN INFECT DIS, V60, pE58, DOI 10.1093/cid/civ061
   Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Trinchieri G, 1995, Semin Immunol, V7, P83, DOI 10.1006/smim.1995.0012
   Turnbull FM, 2002, CLIN INFECT DIS, V34, P447, DOI 10.1086/338462
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Wardhana, 2011, Acta Med Indones, V43, P185
   Weston WM, 2012, VACCINE, V30, P1721, DOI 10.1016/j.vaccine.2011.12.055
   World Health Organization, 2019, WHO VACC PREV DIS MO
   Yu Y, 2007, J CLIN PATHOL, V60, P208, DOI 10.1136/jcp.2006.038893
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 24
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD JUL 28
PY 2020
VL 8
AR 393
DI 10.3389/fpubh.2020.00393
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NC6LL
UT WOS:000561328900001
PM 32850603
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Davidson, AD
   Williamson, MK
   Lewis, S
   Shoemark, D
   Carroll, MW
   Heesom, KJ
   Zambon, M
   Ellis, J
   Lewis, PA
   Hiscox, JA
   Matthews, DA
AF Davidson, Andrew D.
   Williamson, Maia Kavanagh
   Lewis, Sebastian
   Shoemark, Deborah
   Carroll, Miles W.
   Heesom, Kate J.
   Zambon, Maria
   Ellis, Joanna
   Lewis, Philip A.
   Hiscox, Julian A.
   Matthews, David A.
TI Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals
   a cell passage induced in-frame deletion of the furin-like cleavage site
   from the spike glycoprotein
SO GENOME MEDICINE
LA English
DT Article
ID SARS-CORONAVIRUS; FUSION PROTEIN; PHOSPHORYLATION; REPLICATION;
   ACTIVATION
AB Background SARS-CoV-2 is a recently emerged respiratory pathogen that has significantly impacted global human health. We wanted to rapidly characterise the transcriptomic, proteomic and phosphoproteomic landscape of this novel coronavirus to provide a fundamental description of the virus's genomic and proteomic potential. Methods We used direct RNA sequencing to determine the transcriptome of SARS-CoV-2 grown in Vero E6 cells which is widely used to propagate the novel coronavirus. The viral transcriptome was analysed using a recently developed ORF-centric pipeline. Allied to this, we used tandem mass spectrometry to investigate the proteome and phosphoproteome of the same virally infected cells. Results Our integrated analysis revealed that the viral transcripts (i.e. subgenomic mRNAs) generally fitted the expected transcription model for coronaviruses. Importantly, a 24 nt in-frame deletion was detected in over half of the subgenomic mRNAs encoding the spike (S) glycoprotein and was predicted to remove a proposed furin cleavage site from the S glycoprotein. Tandem mass spectrometry identified over 500 viral peptides and 44 phosphopeptides in virus-infected cells, covering almost all proteins predicted to be encoded by the SARS-CoV-2 genome, including peptides unique to the deleted variant of the S glycoprotein. Conclusions Detection of an apparently viable deletion in the furin cleavage site of the S glycoprotein, a leading vaccine target, shows that this and other regions of SARS-CoV-2 proteins may readily mutate. The furin site directs cleavage of the S glycoprotein into functional subunits during virus entry or exit and likely contributes strongly to the pathogenesis and zoonosis of this virus. Our data emphasises that the viral genome sequence should be carefully monitored during the growth of viral stocks for research, animal challenge models and, potentially, in clinical samples. Such variations may result in different levels of virulence, morbidity and mortality.
C1 [Davidson, Andrew D.; Williamson, Maia Kavanagh; Lewis, Sebastian; Lewis, Philip A.; Matthews, David A.] Univ Bristol, Sch Cellular & Mol Med, Fac Life Sci, Bristol BS8 1TD, Avon, England.
   [Shoemark, Deborah] Univ Bristol, Sch Biochem, Fac Life Sci, Bristol BS8 1TD, Avon, England.
   [Carroll, Miles W.] Publ Hlth, Res & Dev Inst, Natl Infect Serv, Porton Down, Wilts, England.
   [Carroll, Miles W.; Hiscox, Julian A.] Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
   [Heesom, Kate J.] Univ Bristol, Fac Life Sci, Prote Facil, Bristol BS8 1TD, Avon, England.
   [Zambon, Maria; Ellis, Joanna] Publ Hlth England Colindale, Virus Reference Dept, London, England.
   [Hiscox, Julian A.] Univ Liverpool, Inst Infect Vet & Ecol Sci, Liverpool, Merseyside, England.
   [Hiscox, Julian A.] Liverpool Hlth Partners, Liverpool, Merseyside, England.
RP Davidson, AD; Matthews, DA (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Fac Life Sci, Bristol BS8 1TD, Avon, England.
EM andrew.davidson@bristol.ac.uk; d.a.matthews@bristol.ac.uk
OI Lewis, Phil/0000-0002-2868-2459; /0000-0002-1240-8463; Matthews,
   David/0000-0003-4611-8795
FU Liverpool Malawi COVID-19 Consortium
FX The authors would also like to thank Robin Gopal and Monika Patel from
   the National Infection Service at PHE Collingdale for additional input
   on isolation, propagation and viral growth. J.A.H. would like to
   acknowledge the help and support of the Liverpool Malawi COVID-19
   Consortium. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR, the Department of Health or
   Public Health England. We would also like to thank Richard Leeves and
   Alan Baldwin for technical help with data archiving. We gratefully
   acknowledge fruitful discussions with George Taiaroa and Daniel
   Rawlinson of the University of Melbourne on direct RNAseq of SARS-CoV-2.
   We would also like to thank Prof. Stuart G. Siddell for his informed
   commentary on the manuscript.
CR Aljabr W, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100926
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Belouzard S, 2010, J BIOL CHEM, V285, P22756, DOI 10.1074/jbc.M110.103275
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   BOJKOVA D, 2020, NATURE, DOI DOI 10.21203/RS.3.RS-17218/V1
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chen HY, 2005, J VIROL, V79, P1164, DOI 10.1128/JVI.79.2.1164-1179.2005
   Chen S., 2020, BIORXIV, DOI [10.1101/2020.03.06.977876., DOI 10.1101/2020.03.06.977876]
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Davidson AD, 2020, CHARACTERISATION TRA
   Depledge DP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08734-9
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Donovan-Banfield I, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0849-9
   Evans VC, 2012, NAT METHODS, V9, P1207, DOI [10.1038/NMETH.2227, 10.1038/nmeth.2227]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Garalde DR, 2018, NAT METHODS, V15, P201, DOI [10.1038/NMETH.4577, 10.1038/nmeth.4577]
   HISCOX JA, 1995, J VIROL, V69, P6219, DOI 10.1128/JVI.69.10.6219-6227.1995
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Irigoyen N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005473
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kiyuka PK, 2018, J INFECT DIS, V217, P1728, DOI 10.1093/infdis/jiy098
   KOTIER SA, 1995, VIROLOGY, V213, P569, DOI 10.1006/viro.1995.0029
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2006, J VIROL, V80, P6794, DOI 10.1128/JVI.02744-05
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu Z, 2020, BIORXIV, DOI [10.1101/2020.03.31.015941, DOI 10.1101/2020.03.31.015941]
   MacLean OA, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa034
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Maringer K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3432-5
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Peng TY, 2008, FEBS J, V275, P4152, DOI 10.1111/j.1742-4658.2008.06564.x
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Spencer KA, 2008, VIROLOGY, V370, P373, DOI 10.1016/j.virol.2007.08.016
   Su Y. C. F., 2020, BIORXIV, DOI [10.1101/2020.03.11.987222, DOI 10.1101/2020.03.11.987222]
   Taiaroa G, 2020, BIORXIV, DOI [10.1101/2020.03.05.976167, DOI 10.1101/2020.03.05.976167]
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Viehweger A, 2019, GENOME RES, V29, P1545, DOI 10.1101/gr.247064.118
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Workman RE, 2019, NAT METHODS, V16, P1297, DOI 10.1038/s41592-019-0617-2
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CH, 2014, CELL HOST MICROBE, V16, P462, DOI 10.1016/j.chom.2014.09.009
   Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu H-Y, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.00705483726627, DOI 10.1371/JOURNAL.PONE.00705483726627]
   Wynne JW, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0532-x
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 56
TC 21
Z9 21
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD JUL 28
PY 2020
VL 12
IS 1
AR 68
DI 10.1186/s13073-020-00763-0
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA MV9EL
UT WOS:000556651700001
PM 32723359
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gao, GS
   Zhu, Z
   Fan, LY
   Ye, SY
   Huang, ZA
   Shi, QY
   Sun, YD
   Song, QF
AF Gao, Guosheng
   Zhu, Zhe
   Fan, Lingyan
   Ye, Shuyuan
   Huang, Zuoan
   Shi, Qiaoyun
   Sun, Yedan
   Song, Qifa
TI Absent immune response to SARS-CoV-2 in a 3-month recurrence of
   coronavirus disease 2019 (COVID-19) case
SO INFECTION
LA English
DT Article; Early Access
DE Novel coronavirus (SARS-CoV-2); Coronavirus disease 2019 (COVID-19);
   Immune response; Recurrence; Long-term viral shedding
ID T-CELL RESPONSES; VIRUS
AB Background The viral persistence in patients with Coronavirus Disease 2019 (COVID-19) remains to be investigated. Methods We investigated the viral loads, therapies, clinical features, and immune responses in a 70-year patient tested positive for SARS-CoV-2 for 3 months. Findings The patient exhibited the highest prevalence of abnormal indices of clinical features and immune responses at the first admission, including fever (38.3 celcius), decreased lymphocytes (0.83 x 10(9)/L) and serum potassium (3.1 mmol/L), as well as elevated serum creatinine (115 mu mol/L), urea (8.6 mmol/L), and C-reactive protein (80 mg/L). By contrast, at the second and the third admission, these indices were all normal. Through three admissions, IL-2 increased from 0.14 pg/mL, 0.69 pg/mL, to 0.91 pg/mL, while IL-6 decreased from 11.78 pg/mL, 1.52 pg/mL, to 0.69 pg/mL, so did IL-10 from 5.13 pg/mL, 1.85 pg/mL, to 1.75 pg/mL. The steady declining trend was also found in TNF-alpha (1.49, 1.15, and 0.85 pg/mL) and IFN-gamma (0.64, 0.42, and 0.27 pg/mL). The threshold cycle values of RT-PCR were 26.1, 30.5, and 23.5 forORFlabgene, and 26.2, 30.6, and 22.7 forNgene, showing the patient had higher viral loads at the first and the third admission than during the middle term of the disease. The patient also showed substantially improved acute exudative lesions on the chest CT scanning images. Conclusions The patient displayed declining immune responses in spite of the viral shedding for 3 months. We inferred the declining immune responses might result from the segregation of the virus from the immune system.
C1 [Gao, Guosheng; Ye, Shuyuan] Univ Chinese Acad Sci, HwaMei Hosp, Dept Clin Lab, Ningbo, Peoples R China.
   [Gao, Guosheng; Zhu, Zhe; Fan, Lingyan; Ye, Shuyuan; Huang, Zuoan; Shi, Qiaoyun] Univ Chinese Acad Sci, Ningbo Inst Life & Hlth Ind, Ningbo, Peoples R China.
   [Zhu, Zhe] Univ Chinese Acad Sci, HwaMei Hosp, Dept Blood Transfus, Ningbo, Peoples R China.
   [Fan, Lingyan] Univ Chinese Acad Sci, Dept Acute Infect Dis, HwaMei Hosp, Ningbo, Peoples R China.
   [Huang, Zuoan; Shi, Qiaoyun] Univ Chinese Acad Sci, HwaMei Hosp, Dept Expt Med Sci, Ningbo, Peoples R China.
   [Sun, Yedan] Cixi Ctr Dis Control & Prevent, Dept Lab, Ningbo, Peoples R China.
   [Song, Qifa] Ningbo City First Hosp, Cent Lab, Ningbo, Zhejiang, Peoples R China.
RP Song, QF (corresponding author), Ningbo City First Hosp, Cent Lab, Ningbo, Zhejiang, Peoples R China.
EM qifasong@126.com
OI song, qifa/0000-0001-9753-2924
FU COVID-19 Platform Program of Hwa Mei Hospital, University of Chinese
   Academy of Sciences [2020HMZD21, 2020HMZD27]
FX This study was supported by the COVID-19 Platform Program of Hwa Mei
   Hospital, University of Chinese Academy of Sciences (2020HMZD21,
   2020HMZD27).
CR Banchereau J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00055
   Blackburn SD, 2007, TRENDS MICROBIOL, V15, P143, DOI 10.1016/j.tim.2007.02.006
   Brooks DG, 2005, J VIROL, V79, P10514, DOI 10.1128/JVI.79.16.10514-10527.2005
   Chen D, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11122
   Fuller MJ, 2004, J IMMUNOL, V172, P4204, DOI 10.4049/jimmunol.172.7.4204
   Fuller MJ, 2003, J IMMUNOL, V170, P477, DOI 10.4049/jimmunol.170.1.477
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Loconsole D, 2020, INFECTION, DOI 10.1007/s15010-020-01444-1
   National Health Commission of the People's Republic of China, 2019, DIAGN TREATM GUID 20
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Reinberg S, 2020, SUPER SPREADER EVENT
   Sedger LM, 2013, MOL IMMUNOL, V56, P781, DOI 10.1016/j.molimm.2013.07.009
   Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y
   Tan L, 2020, SPECIAL CASE COVID 1, DOI [10.1101/2020.03.22.20040071, DOI 10.1101/2020.03.22.20040071]
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tsang TK, 2015, J INFECT DIS, V212, P1420, DOI 10.1093/infdis/jiv225
   Wortzman ME, 2013, IMMUNOL REV, V255, P125, DOI 10.1111/imr.12086
   Zhang B, 2020, J INFECTION, V81, pE49, DOI 10.1016/j.jinf.2020.04.023
   Zhou R, 2020, INT J INFECT DIS, V96, P288, DOI 10.1016/j.ijid.2020.05.030
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 21
TC 8
Z9 8
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
DI 10.1007/s15010-020-01485-6
EA JUL 2020
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA MU3BT
UT WOS:000555548600001
PM 32725596
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Escobar, LE
   Molina-Cruz, A
   Barillas-Mury, C
AF Escobar, Luis E.
   Molina-Cruz, Alvaro
   Barillas-Mury, Carolina
TI BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE BCG vaccination policy; COVID-19 coronavirus; cross-protection;
   mortality; pandemic
ID INNATE IMMUNE MEMORY; INTERFERON-GAMMA; TUBERCULOSIS; ASSOCIATION;
   INFANTS
AB A series of epidemiological explorations has suggested a negative association between national bacillus Calmette-Guerin (BCG) vac-cination policy and the prevalence and mortality of coronavirus disease 2019 (COVID-19). However, these comparisons are difficult to validate due to broad differences between countries such as socioeconomic status, demographic structure, rural vs. urban set-tings, time of arrival of the pandemic, number of diagnostic tests and criteria for testing, and national control strategies to limit the spread of COVID-19. We review evidence for a potential biological basis of BCG cross-protection from severe COVID-19, and refine the epidemiological analysis to mitigate effects of potentially con-founding factors (e.g., stage of the COVID-19 epidemic, develop-ment, rurality, population density, and age structure). A strong correlation between the BCG index, an estimation of the degree of universal BCG vaccination deployment in a country, and COVID-19 mortality in different socially similar European countries was observed (r(2) = 0.88; P = 8 x 10(-7)), indicating that every 10% in-crease in the BCG index was associated with a 10.4% reduction in COVID-19 mortality. Results fail to confirm the null hypothesis of no association between BCG vaccination and COVID-19 mortality, and suggest that BCG could have a protective effect. Nevertheless, the analyses are restricted to coarse-scale signals and should be considered with caution. BCG vaccination clinical trials are required to corroborate the patterns detected here, and to establish causal-ity between BCG vaccination and protection from severe COVID-19. Public health implications of a plausible BCG cross-protection from severe COVID-19 are discussed.
C1 [Escobar, Luis E.] Virginia Polytech Inst & State Univ, Dept Fish & Wildlife Conservat, Blacksburg, VA 24601 USA.
   [Molina-Cruz, Alvaro; Barillas-Mury, Carolina] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
RP Escobar, LE (corresponding author), Virginia Polytech Inst & State Univ, Dept Fish & Wildlife Conservat, Blacksburg, VA 24601 USA.; Barillas-Mury, C (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
EM escobar1@vt.edu; cbarillas@niaid.nih.gov
OI Molina-Cruz, Alvaro/0000-0001-5137-4836
FU Intramural Research Program of the Division of Intramural Research
   Intramural Grant, National Institute of Allergy and Infectious Diseases,
   NIH [Z01AI000947]; Virginia Polytechnic Institute and State University
   startup funds
FX We gratefully acknowledge Asher Kantor and Mark Johnson for editorial
   assistance, and Mariana Castaneda-Guzman, Huijie Qiao, and Ana Beatriz
   Barletta Ferreira for assistance on data collection and analysis. We
   thank Dr. A. Townsend Peterson for his insightful comments and
   suggestions. This work was supported by the Intramural Research Program
   of the Division of Intramural Research Intramural Grant Z01AI000947,
   National Institute of Allergy and Infectious Diseases, NIH, and Virginia
   Polytechnic Institute and State University startup funds for L.E.E.
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Abdallah Abdallah M, 2017, Adv Exp Med Biol, V1019, P155, DOI 10.1007/978-3-319-64371-7_8
   Buffen K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004485
   Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   DEFREITAS EP, 2020, TRAVEL MED INFECT DI, V35, DOI DOI 10.1017/S0269888920000338
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dye C, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0365
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Rodrigues EF, 2019, EUR J PUBLIC HEALTH, V29
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Gotelli N. J., 2013, PRIMER ECOLOGICAL ST
   Hegarty PK, 2020, EUR UROL ONCOL, V3, P259, DOI 10.1016/j.euo.2020.04.001
   Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020
   Jia J., 2020, NO EVIDENCE TEMPERAT, DOI [10.1101/2020.03.29.20046706, DOI 10.1101/2020.03.29.20046706]
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P467, DOI 10.1016/j.jmii.2020.03.026
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Luca Simona, 2013, Maedica (Bucur), V8, P53
   Lumley T., PACKAGE LEAPS REGRES
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   Mulder WJM, 2019, NAT REV DRUG DISCOV, V18, P553, DOI 10.1038/s41573-019-0025-4
   Muthamilarasan M, 2013, J BIOSCIENCES, V38, P433, DOI 10.1007/s12038-013-9302-2
   Naslund C., 1932, RAPPORTS DOCUMENTS I
   Netea MG, 2015, NAT IMMUNOL, V16, P675, DOI 10.1038/ni.3178
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Pacheco M. T., 2020, EXPONENTIAL PHASE CO, DOI [10.1101/2020.04.02.20050773, DOI 10.1101/2020.04.02.20050773]
   Rajagopalan S, 2001, CLIN INFECT DIS, V33, P1034, DOI 10.1086/322671
   Robert Koch Institute, 2020, SARS COV 2 SIT REP 1
   Rodrigues J, 2010, SCIENCE, V329, P1353, DOI 10.1126/science.1190689
   Romero-Alvarez D, 2017, REV CHIL INFECTOL, V34, P289, DOI 10.4067/S0716-10182017000300015
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   Sharquie IK, 2020, ELECT J GEN MED, V17, pem229
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   United Nations Development Program, 2020, UN DEV PROGR HUM DEV
   Wardhana, 2011, Acta Med Indones, V43, P185
   World Bank, WORLD DEV IND 2 1 PO
   World Health Organization, BCG IMM COV EST COUN
   Wu J, 2020, NY TIMES
   Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012
NR 43
TC 32
Z9 32
U1 8
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 28
PY 2020
VL 117
IS 30
BP 17720
EP 17726
DI 10.1073/pnas.2008410117
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MU7KN
UT WOS:000555848400018
PM 32647056
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Reay, RE
   Looi, JCL
   Keightley, P
AF Reay, Rebecca E.
   Looi, Jeffrey C. L.
   Keightley, Philip
TI Telehealth mental health services during COVID-19: summary of evidence
   and clinical practice
SO AUSTRALASIAN PSYCHIATRY
LA English
DT Article
DE Telehealth; telemental health; telepsychiatry; videoconferencing;
   clinician-guided
ID COGNITIVE-BEHAVIOR THERAPY; INTERNET; TELEPSYCHOLOGY; DEPRESSION;
   DISORDERS; CHILDREN; ANXIETY
AB Objective: To provide a rapid clinical update on the evidence for telehealth in mental healthcare in the context of the COVID-19 pandemic public health measures.
   Conclusions: Telehealth has been rapidly implemented in metropolitan and rural settings and the existing evidence base demonstrates that it represents an effective mode of service delivery.
C1 [Reay, Rebecca E.; Looi, Jeffrey C. L.; Keightley, Philip] Australian Natl Univ, Acad Unit Psychiat & Addict Med, Med Sch, Level 2 Blg 4,POB 11, Woden, ACT 2606, Australia.
   [Reay, Rebecca E.; Looi, Jeffrey C. L.; Keightley, Philip] ACT Hlth, Woden, ACT, Australia.
RP Reay, RE (corresponding author), Australian Natl Univ, Acad Unit Psychiat & Addict Med, Med Sch, Level 2 Blg 4,POB 11, Woden, ACT 2606, Australia.
EM Rebecca.reay@act.gov.au
OI Looi, Jeffrey/0000-0003-3351-6911; Keightley,
   Philip/0000-0001-9753-3097; Reay, Rebecca/0000-0001-9497-5842
CR Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196
   Australian Government Department of Health, AUSTR EMBR TEL SAV L
   Australian Medical Association, PAT EMBR TEL COVID 1
   Carlbring P, 2018, COGN BEHAV THERAPY, V47, P1, DOI 10.1080/16506073.2017.1401115
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Cooper SE, 2019, COUNS PSYCHOL, V47, P1074, DOI 10.1177/0011000019895276
   Cowan KE, 2019, MAYO CLIN PROC, V94, P2510, DOI 10.1016/j.mayocp.2019.04.018
   Dear BF, 2018, AUST NZ J PSYCHIAT, V52, P668, DOI 10.1177/0004867417738055
   Department of Health, HEAD HLTH WEBS
   Donker T, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2307
   Erbe D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6588
   Gloff NE, 2015, INT REV PSYCHIATR, V27, P513, DOI 10.3109/09540261.2015.1086322
   Institute for Broadband-enabled Society (IBES), 2013, UN APPR EV TEL IMPL
   Ivanova E, 2016, J ANXIETY DISORD, V44, P27, DOI 10.1016/j.janxdis.2016.09.012
   Johansson Robert, 2013, Psychodyn Psychiatry, V41, P513, DOI 10.1521/pdps.2013.41.4.513
   Looi JCL, 2020, AUSTRALAS PSYCHIATRY, V28, P508, DOI 10.1177/1039856220930675
   Myers KM, 2010, J TELEMED TELECARE, V16, P128, DOI 10.1258/jtt.2009.090712
   Nelson EL, 2011, CHILD ADOL PSYCH CL, V20, P67, DOI 10.1016/j.chc.2010.08.005
   O'Kearney R, 2019, AUST NZ J PSYCHIAT, V53, P851, DOI 10.1177/0004867419864433
   Osenbach JE, 2013, DEPRESS ANXIETY, V30, P1058, DOI 10.1002/da.22165
   Salomonsson S, 2020, COGN BEHAV THERAPY, V49, P455, DOI 10.1080/16506073.2019.1669701
   Santesteban-Echarri O, 2020, J TELEMED TELECARE, V26, P14, DOI 10.1177/1357633X18794100
   Varker T, 2019, PSYCHOL SERV, V16, P621, DOI 10.1037/ser0000239
   Vigerland S, 2016, CLIN PSYCHOL REV, V50, P1, DOI 10.1016/j.cpr.2016.09.005
NR 24
TC 5
Z9 5
U1 9
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1039-8562
EI 1440-1665
J9 AUSTRALAS PSYCHIATRY
JI Australas. Psychiatry
PD OCT
PY 2020
VL 28
IS 5
BP 514
EP 516
AR 1039856220943032
DI 10.1177/1039856220943032
EA JUL 2020
PG 3
WC Psychiatry
SC Psychiatry
GA NV8ET
UT WOS:000553827400001
PM 32722963
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zaidi, SZA
   Zaidi, FZ
   AlShehry, N
   Zaidi, ARZ
   Zaidi, SZ
   Abdullah, SM
AF Zaidi, Syed Ziauddin Ahmed
   Zaidi, Fatima Zia
   AlShehry, Nawal
   Zaidi, Abdul Rehman Zia
   Zaidi, Saleha Zia
   Abdullah, Syed Maaz
TI Aging and therapy-related hypogammaglobulinemia causing pneumonia: An
   overlooked curable entity in the chaotic COVID-19 pandemic
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter; Early Access
ID IMMUNOGLOBULIN
C1 [Zaidi, Syed Ziauddin Ahmed; AlShehry, Nawal] King Fahad Med City, Dept Adult Hematol BMT, Riyadh, Saudi Arabia.
   [Zaidi, Fatima Zia] Univ Lahore, Univ Coll Med, Lahore, Pakistan.
   [Zaidi, Abdul Rehman Zia] King Fahad Med City, Dept Med, Riyadh, Saudi Arabia.
   [Zaidi, Saleha Zia] Cleveland Clin Abu Dhabi, Oncol Inst, Abu Dhabi, U Arab Emirates.
   [Abdullah, Syed Maaz] King Edward Med Univ, Dept Med, Lahore, Pakistan.
RP Zaidi, SZA (corresponding author), King Fahad Med City, Comprehens Canc Ctr MBC 30104, Dept Adult Hematol BMT, Riyadh 11525, Saudi Arabia.
EM szaidi@kfmc.med.sa
RI Zaidi, Abdul Rehman Zia/AAC-8229-2019
OI Zaidi, Abdul Rehman Zia/0000-0003-0137-9633; Zaidi, Fatima
   Zia/0000-0002-7351-1114; Abdullah, Syed Maaz/0000-0002-3999-9195
CR Arumugam P, 2017, INT J RES MED SCI, V5, P893, DOI [10.18203/2320-6012.ijrms20170632, DOI 10.18203/2320-6012.IJRMS20170632]
   Blot M, 2014, EUR J INTERN MED, V25, P837, DOI 10.1016/j.ejim.2014.09.009
   BUCKLEY CE, 1970, J IMMUNOL, V105, P964
   Casulo C, 2013, CL LYMPH MYELOM LEUK, V13, P106, DOI 10.1016/j.clml.2012.11.011
   Cowan J, 2018, CLIN INFECT DIS, V66, P564, DOI 10.1093/cid/cix836
   Freeman JA, 2013, LEUKEMIA LYMPHOMA, V54, P99, DOI 10.3109/10428194.2012.706285
   Justiz Vaillant AA, 2020, TRANSIENT HYPOGAMMAG
   Martinot M, 2014, INT J INFECT DIS, V19, P79, DOI 10.1016/j.ijid.2013.10.020
   Na IK, 2019, EUR J HAEMATOL, V102, P447, DOI 10.1111/ejh.13223
   Patel SY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00033
   Rose ME, 2006, CLEV CLIN J MED, V73, P133, DOI 10.3949/ccjm.73.2.133
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   Saito M, 2020, CLIN INFECT DIS, V71, P893, DOI 10.1093/cid/ciaa377
   Vadamalai K, 2019, J HOSP MED, V14, P33, DOI 10.12788/jhm.3106
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26318
EA JUL 2020
PG 2
WC Virology
SC Virology
GA MS0VC
UT WOS:000554003500001
PM 32681654
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Stallard, N
   Hampson, L
   Benda, N
   Brannath, W
   Burnett, T
   Friede, T
   Kimani, PK
   Koenig, F
   Krisam, J
   Mozgunov, P
   Posch, M
   Wason, J
   Wassmer, G
   Whitehead, J
   Williamson, SF
   Zohar, S
   Jaki, T
AF Stallard, Nigel
   Hampson, Lisa
   Benda, Norbert
   Brannath, Werner
   Burnett, Thomas
   Friede, Tim
   Kimani, Peter K.
   Koenig, Franz
   Krisam, Johannes
   Mozgunov, Pavel
   Posch, Martin
   Wason, James
   Wassmer, Gernot
   Whitehead, John
   Williamson, S. Faye
   Zohar, Sarah
   Jaki, Thomas
TI Efficient Adaptive Designs for Clinical Trials of Interventions for
   COVID-19
SO STATISTICS IN BIOPHARMACEUTICAL RESEARCH
LA English
DT Article
DE Adaptive trial; Group sequential design; Multi-arm multi-stage; Pandemic
   research; Platform trial; SARS-CoV-2
ID CONDITIONALLY UNBIASED ESTIMATION; GROUP SEQUENTIAL-TESTS; PHASE-II/III
   TRIALS; SAMPLE-SIZE; CONFIDENCE-INTERVALS; MULTIARM; 2-STAGE;
   METAANALYSIS; SELECTION; TIME
AB The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this article, we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.
C1 [Stallard, Nigel; Kimani, Peter K.; Zohar, Sarah] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Stat & Epidemiol, Coventry, W Midlands, England.
   [Hampson, Lisa] Novartis Pharma AG, Adv Methodol & Data Sci, CH-4002 Basel, Switzerland.
   [Benda, Norbert] Fed Inst Drugs & Med Devices BfArM, Bonn, Germany.
   [Brannath, Werner] Univ Bremen, Inst Stat, Bremen, Germany.
   [Burnett, Thomas; Mozgunov, Pavel; Whitehead, John; Williamson, S. Faye; Jaki, Thomas] Univ Lancaster, Dept Math & Stat, Lancaster, England.
   [Friede, Tim] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany.
   [Koenig, Franz; Posch, Martin] Med Univ Vienna, CeMSIIS, Sect Med Stat, Vienna, Austria.
   [Krisam, Johannes] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany.
   [Wason, James] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Wason, James] Univ Cambridge, MRC Biostat Unit, Cambridge, England.
   [Wassmer, Gernot] RPACT GbR, Sereetz, Germany.
   Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France.
RP Stallard, N (corresponding author), Novartis Pharma AG, Adv Methodol & Data Sci, CH-4002 Basel, Switzerland.
EM lisa.hampson@novartis.com
OI Mozgunov, Pavel/0000-0001-6810-0284; Konig, Franz/0000-0002-6893-3304;
   Friede, Tim/0000-0001-5347-7441; Wason, James/0000-0002-4691-126X
FU UK Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_00002/6, MR/N028171/1, MC_UU_00002/14]; National Institute for
   Health ResearchNational Institute for Health Research (NIHR)
   [NIHR-SRF-2015-08-001]; Innovative Medicines Initiative 2 Joint
   Undertaking [853966]; European Union's Horizon 2020 Research and
   Innovation Programme; EFPIA
FX This articlewas initiated by the Adaptive Designs and Multiple Testing
   Procedures Joint Working Group of the Austro-Swiss (ROeS) and the German
   (IBS-DR) Regions of the International Biometric Society, chaired by Rene
   Schmidt and Lisa Hampson, and with support from Werner Brannath and
   Andreas Faldum. J. Wason received funding from UK Medical Research
   Council (MC_UU_00002/6 and MR/N028171/1). T. Jaki received funding from
   UK Medical Research Council (MC_UU_00002/14). This report is independent
   research arising in part from Prof Jaki's Senior Research Fellowship
   (NIHR-SRF-2015-08-001) supported by the National Institute for Health
   Research. The views expressed in this publication are those of the
   authors and not necessarily those of the NHS, the National Institute for
   Health Research or the Department of Health and Social Care (DHCS), or
   the Federal Institute for Drugs and Medical Devices (BfArM). Martin
   Posch and Franz Koenig (Medical University of Vienna) are members of the
   EU Patient-centric clinical trial platform(EU-PEARL). EU-PEARL has
   received funding from the Innovative Medicines Initiative 2 Joint
   Undertaking under grant agreement no. 853966. This Joint Undertaking
   receives support fromthe European Union's Horizon 2020 Research and
   Innovation Programme and EFPIA.
CR Anker SD, 2020, EUR HEART J, V41, P2109, DOI 10.1093/eurheartj/ehaa461
   [Anonymous], 2007, REFL PAP METH ISS CO
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115
   Bauer P, 1999, STAT MED, V18, P1833, DOI 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.3.CO;2-V
   BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441
   Bauer P, 2016, STAT MED, V35, P325, DOI 10.1002/sim.6472
   Bauer P, 2010, STAT MED, V29, P1, DOI 10.1002/sim.3716
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bennett M, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4073-1
   Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
   Bowden J, 2008, BIOMETRICAL J, V50, P515, DOI 10.1002/bimj.200810442
   Brannath W, 2009, STAT MED, V28, P1445, DOI 10.1002/sim.3559
   Bratton DJ, 2015, STATA J, V15, P350, DOI 10.1177/1536867X1501500202
   Bretz F, 2005, BIOMETRICS, V61, P738, DOI 10.1111/j.1541-0420.2005.00344.x
   Bretz F, 2009, STAT MED, V28, P1181, DOI 10.1002/sim.3538
   Bruckner M, 2017, STAT MED, V36, P3137, DOI 10.1002/sim.7367
   Carreras M, 2013, STAT MED, V32, P1677, DOI 10.1002/sim.5463
   Chiu YD, 2018, STAT MED, V37, P4335, DOI 10.1002/sim.7925
   Collignon O, 2020, CLIN PHARMACOL THER, V107, P1059, DOI 10.1002/cpt.1804
   Collignon O, 2018, TRIALS, V19, DOI 10.1186/s13063-018-3012-x
   Cooper B, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001815
   Cui L, 1999, BIOMETRICS, V55, P853, DOI 10.1111/j.0006-341X.1999.00853.x
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dimairo M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m115
   Dodd LE, 2020, CLIN TRIALS, V17, P472, DOI 10.1177/1740774520939938
   Dodd LE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw1049
   Dodd LE, 2016, J INFECT DIS, V213, P1906, DOI 10.1093/infdis/jiw061
   Elsaesser A, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-383
   European Medicines Agency, 2019, GUID INV SUBGR CONG
   European Medicines Agency, 1998, E9 ICH EUR MED AG
   Food and Drug Administration, 2019, GUID IND AD DES CLIN
   Food and Drug Administration, 2006, GUID CLIN TRIAL SPON
   Food and Drug Administration, 2020, COVID 19 DEV DRUG BI
   Friede T, 2008, BIOMETRICAL J, V50, P767, DOI 10.1002/bimj.200710453
   Friede T, 2006, BIOMETRICAL J, V48, P537, DOI 10.1002/bimj.200510238
   Friede T, 2020, BIOMETRICAL J, V62, P1264, DOI 10.1002/bimj.201900020
   Friede T, 2017, RES SYNTH METHODS, V8, P79, DOI 10.1002/jrsm.1217
   Graf AC, 2020, STAT METHODS MED RES, V29, P2945, DOI 10.1177/0962280220913071
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Griffiths G, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04473-1
   Gsponer T, 2014, PHARM STAT, V13, P71, DOI 10.1002/pst.1593
   Hampson LV, 2013, J R STAT SOC B, V75, P3, DOI 10.1111/j.1467-9868.2012.01030.x
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Herson J, 2009, CH CRC BIOSTAT SER, V30, P1
   Higgins JPT, 2011, STAT MED, V30, P903, DOI 10.1002/sim.4088
   Hommel G, 2001, BIOMETRICAL J, V43, P581, DOI 10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>3.0.CO;2-J
   ICH, 2020, ADD EST SENS AN CLIN
   Jaki T, 2019, J STAT SOFTW, V88, P1, DOI 10.18637/jss.v088.i04
   Jennison C, 1997, J AM STAT ASSOC, V92, P1330
   Jennison C., 1999, GROUP SEQUENTIAL MET
   Kieser M, 1999, BIOMETRICAL J, V41, P261, DOI 10.1002/(SICI)1521-4036(199906)41:3<261::AID-BIMJ261>3.3.CO;2-L
   KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029
   Kimani PK, 2014, BIOMETRICAL J, V56, P107, DOI 10.1002/bimj.201300036
   Kimani PK, 2013, STAT MED, V32, DOI 10.1002/sim.5757
   Koenig F, 2008, STAT MED, V27, P1612, DOI 10.1002/sim.3048
   Koopmeiners JS, 2012, STAT MED, V31, P420, DOI 10.1002/sim.4430
   Kunz C. U., 2020, ARXIV200513979
   Lehmacher W, 1999, BIOMETRICS, V55, P1286, DOI 10.1111/j.0006-341X.1999.01286.x
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   Magaret A, 2016, CONTEMP CLIN TRIALS, V46, P12, DOI 10.1016/j.cct.2015.11.003
   Magirr D, 2014, STAT MED, V33, P3269, DOI 10.1002/sim.6183
   Magirr D, 2013, BIOMETRIKA, V100, P985, DOI 10.1093/biomet/ast035
   Magirr D, 2012, BIOMETRIKA, V99, P494, DOI 10.1093/biomet/ass002
   MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.2307/2335748
   Meyer EL, 2020, CLIN THER, V42, P1330, DOI 10.1016/j.clinthera.2020.05.010
   Mielke T., 2017, HDB METHODS DESIGNIN, P247
   Mozgunov P, 2020, BIOMETRICAL J, V62, P1717, DOI 10.1002/bimj.201900332
   Mozgunov P, 2019, J BIOPHARM STAT, V29, P359, DOI 10.1080/10543406.2018.1535503
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Muller HH, 2004, STAT MED, V23, P2497, DOI 10.1002/sim.1852
   National Academies of Sciences Engineering and Medicine, 2017, INT CLIN RES EP RESP, DOI [10.17226/24739, DOI 10.17226/24739]
   Neal D, 2011, STAT MED, V30, P2804, DOI 10.1002/sim.4308
   Neuenschwander B., 2020, BAYESIAN METHODS PHA
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Ondra T, 2019, STAT METHODS MED RES, V28, P2096, DOI 10.1177/0962280217747312
   Ondra T, 2016, J BIOPHARM STAT, V26, P99, DOI 10.1080/10543406.2015.1092034
   Pallmann P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1017-7
   Parmar MKB, 2014, LANCET, V384, P283, DOI 10.1016/S0140-6736(14)61122-3
   Pinheiro J, 2014, STAT MED, V33, P1646, DOI 10.1002/sim.6052
   Proschan MA, 1995, BIOMETRICS, V51, P1315, DOI 10.2307/2533262
   Proschan Michael, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa334
   Proschan MA, 2016, CLIN TRIALS, V13, P39, DOI 10.1177/1740774515620145
   Robertson DS, 2019, BIOMETRICS, V75, P885, DOI 10.1111/biom.13042
   Robertson D. S., 2018, 80907292 ARXIV
   Robertson DS, 2019, COMMUN STAT-THEOR M, V48, P616, DOI 10.1080/03610926.2017.1417429
   Robertson DS, 2016, STAT MED, V35, P3907, DOI 10.1002/sim.6974
   Royston P, 2003, STAT MED, V22, P2239, DOI 10.1002/sim.1430
   rpact, 2020, RPACT CONF AD CLIN T
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sampson AR, 2005, BIOMETRICAL J, V47, P257, DOI 10.1002/bimj.200410119
   Schiavone F, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3216-8
   Schmidli H, 2007, STAT MED, V26, P4925, DOI 10.1002/sim.2957
   Simmonds M, 2017, J CLIN EPIDEMIOL, V91, P38, DOI 10.1016/j.jclinepi.2017.08.008
   Stallard N, 2019, ANN ONCOL, V30, P506, DOI 10.1093/annonc/mdz038
   Stallard N, 2005, J STAT PLAN INFER, V135, P402, DOI 10.1016/j.jspi.2004.05.006
   Stallard N, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-019-0892-8
   Stallard N, 2018, BIOMETRIKA, V105, P495, DOI 10.1093/biomet/asy004
   Stallard N, 2008, STAT MED, V27, P6209, DOI 10.1002/sim.3436
   Thall P, 2015, ANN ONCOL, V26, P1621, DOI 10.1093/annonc/mdv238
   Thielman NM, 2016, CLIN TRIALS, V13, P83, DOI 10.1177/1740774515619897
   Villar SS, 2018, PHARM STAT, V17, P182, DOI 10.1002/pst.1845
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wason J, 2017, STAT METHODS MED RES, V26, P508, DOI 10.1177/0962280214550759
   Wason J, 2016, STAT METHODS MED RES, V25, P716, DOI 10.1177/0962280212465498
   Wason JMS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-364
   Wason JMS, 2014, STAT MED, V33, P2206, DOI 10.1002/sim.6086
   Wason JMS, 2012, STAT MED, V31, P4269, DOI 10.1002/sim.5513
   Wassmer G, 2016, SPR SER PHARM STAT, P1, DOI 10.1007/978-3-319-32562-0
   Wassmer G, 2011, J BIOPHARM STAT, V21, P802, DOI 10.1080/10543406.2011.551336
   Whitehead A, 1997, STAT MED, V16, P2901, DOI 10.1002/(SICI)1097-0258(19971230)16:24<2901::AID-SIM700>3.0.CO;2-5
   WHITEHEAD J, 1986, BIOMETRIKA, V73, P573, DOI 10.1093/biomet/73.3.573
   Whitehead J, 1997, DESIGN ANAL SEQUENTI
   Whitehead J, 2020, STAT MED, V39, P1593, DOI 10.1002/sim.8497
   Whitehead J, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005439
   Whitehead J, 2011, STAT METHODS MED RES, V20, P635, DOI 10.1177/0962280210379036
   Williamson SF, 2020, BIOMETRICS, V76, P197, DOI 10.1111/biom.13119
   Wu SS, 2010, BIOMETRIKA, V97, P405, DOI 10.1093/biomet/asq003
   Yu ZN, 2019, J BIOPHARM STAT, V29, P306, DOI 10.1080/10543406.2019.1577682
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 120
TC 3
Z9 3
U1 7
U2 7
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1946-6315
J9 STAT BIOPHARM RES
JI Stat. Biopharm. Res.
PD OCT 1
PY 2020
VL 12
IS 4
BP 483
EP 497
DI 10.1080/19466315.2020.1790415
EA JUL 2020
PG 15
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA OK5GB
UT WOS:000553376300001
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chaudhry, ZS
   Williams, JD
   Vahia, A
   Fadel, R
   Acosta, TP
   Prashar, R
   Shrivastava, P
   Khoury, N
   Corrales, JP
   Williams, C
   Nagai, S
   Abouljoud, M
   Samaniego-Picota, M
   Abreu-Lanfranco, O
   del Busto, R
   Ramesh, MS
   Patel, A
   Alangaden, GJ
AF Chaudhry, Zohra S.
   Williams, Jonathan D.
   Vahia, Amit
   Fadel, Raef
   Acosta, Tommy Parraga
   Prashar, Rohini
   Shrivastava, Pritika
   Khoury, Nadeen
   Corrales, Julio Pinto
   Williams, Celeste
   Nagai, Shunji
   Abouljoud, Marwan
   Samaniego-Picota, Milagros
   Abreu-Lanfranco, Odaliz
   del Busto, Ramon
   Ramesh, Mayur S.
   Patel, Anita
   Alangaden, George J.
TI Clinical characteristics and outcomes of COVID-19 in solid organ
   transplant recipients: A case-control study
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; complication; infectious; infection and
   infectious agents - viral; infectious disease; kidney transplantation;
   nephrology; organ transplantation in general
AB Solid organ transplant recipients (SOTr) with coronavirus disease 2019 (COVID-19) are expected to have poorer outcomes compared to nontransplant patients because of immunosuppression and comorbidities. The clinical characteristics of 47 SOTr (38 kidneys and 9 nonkidney organs) were compared to 100 consecutive hospitalized nontransplant controls. Twelve of 47 SOTr managed as outpatients were subsequently excluded from the outcome analyses to avoid potential selection bias. Chronic kidney disease (89% vs 57%P = .0007), diabetes (66% vs 33%P = .0007), and hypertension (94% vs 72%P = .006) were more common in the 35 hospitalized SOTr compared to controls. Diarrhea (54% vs 17%,P < .0001) was more frequent in SOTr. Primary composite outcome (escalation to intensive care unit, mechanical ventilation, or in-hospital all-cause mortality) was comparable between SOTr and controls (40% vs 48%, odds ratio [OR] 0.72 confidence interval [CI] [0.33-1.58]P = .42), despite more comorbidities in SOTr. Acute kidney injury requiring renal replacement therapy occurred in 20% of SOTr compared to 4% of controls (OR 6 CI [1.64-22]P = .007). Multivariate analysis demonstrated that increasing age and clinical severity were associated with mortality. Transplant status itself was not associated with mortality.
C1 [Chaudhry, Zohra S.; Williams, Jonathan D.; Vahia, Amit; Acosta, Tommy Parraga; Abreu-Lanfranco, Odaliz; del Busto, Ramon; Ramesh, Mayur S.; Alangaden, George J.] Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA.
   [Fadel, Raef] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA.
   [Prashar, Rohini; Shrivastava, Pritika; Khoury, Nadeen; Samaniego-Picota, Milagros; Patel, Anita] Henry Ford Transplant Inst, Div Nephrol, Detroit, MI USA.
   [Corrales, Julio Pinto] Henry Ford Transplant Inst, Div Pulmonol, Detroit, MI USA.
   [Williams, Celeste] Henry Ford Transplant Inst, Div Cardiol, Detroit, MI USA.
   [Nagai, Shunji; Abouljoud, Marwan] Henry Ford Transplant Inst, Div Hepatol, Detroit, MI USA.
RP Alangaden, GJ (corresponding author), Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA.
EM galanga1@hfhs.org
OI Chaudhry, Zohra S/0000-0002-8733-2264
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F., 2020, KIDNEY INT
   [Anonymous], 2019, BMJ-BRIT MED J, V2020, pm792
   [Anonymous], 2019, J AM SOC NEPHROL, V2020, DOI [10.1681/asn.2020030375, DOI 10.1681/ASN.2020030375]
   Banerjee D, 2020, KIDNEY INT
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   CDC, COR DIS 2019 COVID 1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   D'Amico F, 2020, CLIN GASTROENTEROL H, V18, P1663, DOI 10.1016/j.cgh.2020.04.001
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fadel R, 2020, EARLY SHORT COURSE C, DOI [10.1101/2020.05.04.20074609, DOI 10.1101/2020.05.04.20074609]
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Gandhi M, 2020, ENGL J MED, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Latif F, 2020, JAMA CARDIOLOGY
   McCreary E., 2020, OPEN FORUM INFECT DI, P7
   Montagud-Marrahi E, 2020, AM J TRANSPLANT, V20, P2958, DOI 10.1111/ajt.15970
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sanders JM, 2020, JAMA
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Smith GB, 2013, RESUSCITATION, V84, P465, DOI 10.1016/j.resuscitation.2012.12.016
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, EUR UROL
NR 31
TC 6
Z9 6
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 3051
EP 3060
DI 10.1111/ajt.16188
EA JUL 2020
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000552866600001
PM 32654332
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xi, AQ
   Zhuo, M
   Dai, JT
   Ding, YH
   Ma, XZ
   Ma, XL
   Wang, XY
   Shi, LM
   Bai, HY
   Zheng, HY
   Nuermberger, E
   Xu, J
AF Xi, Aiqi
   Zhuo, Ma
   Dai, Jingtao
   Ding, Yuehe
   Ma, Xiuzhen
   Ma, Xiaoli
   Wang, Xiaoyi
   Shi, Lianmeng
   Bai, Huanying
   Zheng, Hongying
   Nuermberger, Eric
   Xu, Jian
TI Epidemiological and clinical characteristics of discharged patients
   infected with SARS-CoV-2 on the Qinghai Plateau
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE clinical characteristics; COVID-19; epidemiological; plateau; SARS-CoV-2
ID CORONAVIRUS; PNEUMONIA; OUTBREAK; WUHAN; CHINA
AB Since the outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, a series of confirmed cases of COVID-19 were found on the Qinghai-Tibet plateau. We aimed to describe the epidemiological, clinical characteristics, and outcomes of all confirmed cases in Qinghai, a province at high altitude. The region had no sustained local transmission. Of all 18 patients with confirmed SARS-CoV-2 infection, 15 patients comprising four transmission clusters were identified. Three patients were infected by direct contact without travel history to Wuhan. Of 18 patients, 10 patients showed bilateral pneumonia and two patients showed no abnormalities. Three patients with comorbidities such as hypertension, liver diseases, or diabetes developed severe illness. High C-reactive protein levels and elevations of both alanine aminotransferase and aspartate aminotransferase were observed in three severely ill patients on admission. All 18 patients were eventually discharged, including the three severe patients who recovered after treatment with noninvasive mechanical ventilation, convalescent plasma, and other therapies. Our findings confirmed human-to-human transmission of SARS-CoV-2 in clusters. Patients with comorbidities are more likely to develop severe illness.
C1 [Xi, Aiqi; Zhuo, Ma; Dai, Jingtao; Ding, Yuehe; Ma, Xiuzhen; Ma, Xiaoli; Wang, Xiaoyi; Xu, Jian] Fourth Peoples Hosp Qinghai Prov, Dept Infect Dis, Xining, Qinghai, Peoples R China.
   [Shi, Lianmeng; Bai, Huanying; Zheng, Hongying] Third Peoples Hosp Xining, Dept Med, Xining, Qinghai, Peoples R China.
   [Nuermberger, Eric] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA.
   [Nuermberger, Eric] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Xu, Jian] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Beijing Key Lab Drug Resistance TB Res, Beijing, Peoples R China.
RP Xu, J (corresponding author), Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Peoples Hosp Qinghai Prov 4, Xining 81000, Qinghai, Peoples R China.
EM xujian198303@hotmail.com
FU QingHai Department of Science and Technology [2020-SF-158]
FX QingHai Department of Science and Technology, Grant/Award Number:
   2020-SF-158
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2020, PROCEEDINGS OF THE 18TH USENIX CONFERENCE ON FILE AND STORAGE TECHNOLOGIES, P1
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang SF, 2001, INTENS CARE MED, V27, P1539, DOI 10.1007/s001340101052
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2528
EP 2535
DI 10.1002/jmv.26032
EA JUL 2020
PG 8
WC Virology
SC Virology
GA NU0EN
UT WOS:000553217900001
PM 32437017
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Battisti, V
   Wieder, O
   Garon, A
   Seidel, T
   Urban, E
   Langer, T
AF Battisti, Verena
   Wieder, Oliver
   Garon, Arthur
   Seidel, Thomas
   Urban, Ernst
   Langer, Thierry
TI A Computational Approach to Identify Potential Novel Inhibitors against
   the Coronavirus SARS-CoV-2
SO MOLECULAR INFORMATICS
LA English
DT Article
DE COVID-19; coronavirus; virtual screening; in silico; molecular docking;
   common hits approach; docking consensus approach
ID SOFTWARE NEWS; STABILITY; DOCKING
AB The current pandemic threat of COVID-19, caused by the novel coronavirus SARS-CoV-2, not only gives rise to a high number of deaths around the world but also has immense consequences for the worldwide health systems and global economy. Given the fact that this pandemic is still ongoing and there are currently no drugs or vaccines against this novel coronavirus available, this in silico study was conducted to identify a potential novel SARS-CoV-2-inhibitor. Two different approaches were pursued: 1) The Docking Consensus Approach (DCA) is a novel approach, which combines molecular dynamics simulations with molecular docking. 2) The Common Hits Approach (CHA) in contrast focuses on the combination of the feature information of pharmacophore modeling and the flexibility of molecular dynamics simulations. The application of both methods resulted in the identification of 10 compounds with high coronavirus inhibition potential.
C1 [Battisti, Verena; Wieder, Oliver; Garon, Arthur; Seidel, Thomas; Urban, Ernst; Langer, Thierry] Univ Vienna, Dept Pharmaceut Chem, Althanstr 14, A-1090 Vienna, Austria.
RP Langer, T (corresponding author), Univ Vienna, Dept Pharmaceut Chem, Althanstr 14, A-1090 Vienna, Austria.
EM thierry.langer@univie.ac.at
OI Garon, Arthur/0000-0002-0991-789X; Battisti, Verena/0000-0001-9794-366X
FU University of Vienna
FX The authors thank the University of Vienna for financial support.
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2020, ALDRICH MARKET SELEC
   [Anonymous], 2020, SCOPUS ELSEVIER CAN
   [Anonymous], 2019, SCHRODINGER RELEASE
   [Anonymous], 2020, CHEMRXIV PREPRINT SE
   [Anonymous], 2020, SCIFINDER CHEM ABSTR
   Baldwin R., 2020, EC TIME COVID 19
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Berthold M. R., 2008, DATA ANAL MACH LEARN
   Case D.A., 2016, AMBER 2016
   Colson P., 2012, DRUG DISCOVERY, V11, P505
   Espinoza-Fonseca LM, 2006, BIOORGAN MED CHEM, V14, P896, DOI 10.1016/j.bmc.2005.09.011
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Laggner Christian, 2008, P76, DOI 10.1039/9781847558879-00076
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Ledford H., 2009, NATURE, DOI [10.1038/news.2009.353, DOI 10.1038/NEWS.2009.353]
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu K, 2017, J COMPUT AID MOL DES, V31, P201, DOI 10.1007/s10822-016-0005-2
   Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004
   Ryckaert J., 1977, J COMPUT PHYS, P341
   Sakano T, 2016, BIOPHYS PHYSICOBIOL, V13, P181, DOI 10.2142/biophysico.13.0_181
   Tobinick EL, 2009, DRUG NEWS PERSPECT, V22, P119, DOI 10.1358/dnp.2009.22.2.1303818
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tubiana T, 2018, J CHEM INF MODEL, V58, P2178, DOI 10.1021/acs.jcim.8b00512
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wieder M, 2017, J CHEM INF MODEL, V57, P365, DOI 10.1021/acs.jcim.6b00674
   Wieder M, 2016, BIOCHEM BIOPH RES CO, V470, P685, DOI 10.1016/j.bbrc.2016.01.081
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 2
Z9 2
U1 7
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
PD OCT
PY 2020
VL 39
IS 10
DI 10.1002/minf.202000090
EA JUL 2020
PG 8
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA NZ5AV
UT WOS:000552791900001
PM 32721082
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Seffer, MT
   Martens-Lobenhoffer, J
   Schmidt, JJ
   Eden, G
   Bode-Boger, SM
   Kielstein, JT
AF Seffer, Malin-Theres
   Martens-Lobenhoffer, Jens
   Schmidt, Julius J.
   Eden, Gabriele
   Bode-Boeger, Stefanie M.
   Kielstein, Jan T.
TI Clearance of chloroquine and hydroxychloroquine by theSeraph (R) 100
   Microbinda Affinity Blood Filter -a device approved for the treatment
   ofCOVID-19 patients
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article; Early Access
DE blood purification; COVID-19; extracorporeal therapy
AB On April 17 2020, the United States Food and Drug Administration granted Coronavirus Disease 2019 (COVID-19) emergency use authorizations for the Seraph 100 Microbind Affinity Blood Filter. The medical device is aimed to treat critically ill COVID-19 patients with confirmed or imminent respiratory failure. The aim of this life size in vitro pharmacokinetic study was to investigate the in vitro adsorption of chloroquine and hydroxychloroquine from human plasma using equipment that is also used at the bedside. After start of the hemoperfusion, Pre (C-pre) Seraph plasma levels were obtained at 5 (C-5), 10 (C-10), 15 (C-15), 30 (C-30), 60 (C-60), and 120 (C-120) minutes into the procedure. At two timepoints (5 and 120 minutes) post (C-post) Seraph plasma levels were determined that were used to calculate the plasma clearance of the Seraph. Both drugs were determined using a validated HPLC method. Median [IQR] plasma clearance of the Seraph for chloroquine/hydroxychloroquine was 1.71 [0.51-4.38] mL/min/1.79 [0.21-3.68] mL/min respectively. The lack of elimination was also confirmed by the fact that plasma levels did not change over the 120 minutes treatment. As neither chloroquine nor hydroxychloroquine were removed by the treatment with the Seraph dose adjustments in COVID-19 patients undergoing this treatment are not necessary.
C1 [Seffer, Malin-Theres; Eden, Gabriele; Kielstein, Jan T.] Acad Teaching Hosp Braunschweig, Blood Purificat, Med Clin 5, Nephrol,Rheumatol, Braunschweig, Germany.
   [Seffer, Malin-Theres] Helmholtz Ctr Infect Res, Microbial Prote, Braunschweig, Germany.
   [Martens-Lobenhoffer, Jens; Bode-Boeger, Stefanie M.] Otto von Guericke Univ, Inst Clin Pharmacol, Magdeburg, Germany.
   [Schmidt, Julius J.] Hannover Med Sch, Deparment Nephrol & Hypertens, Hannover, Germany.
RP Kielstein, JT (corresponding author), Acad Teaching Hosp Braunschweig, Med Clin Nephrol 5, Rheumatol, Blood Purificat, Salzdahlumer Str 90, D-38126 Braunschweig, Germany.
EM j.kielstein@klinikum-braunschweig.de
FU ExThera Medical
FX MTS, JJS, GE and JTK received research funding from ExThera Medical. MTS
   and JTK received travel support from ExThera Medical. All other authors:
   none to declare.
CR BROCKS DR, 1994, J CLIN PHARMACOL, V34, P1088, DOI 10.1002/j.1552-4604.1994.tb01986.x
   COATNEY GR, 1963, AM J TROP MED HYG, V12, P121, DOI 10.4269/ajtmh.1963.12.121
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   GOTTSCHALL S, 1984, BIOMED BIOCHIM ACTA, V43, P245
   Lancet T., 2020, LANCET, V395, DOI 10.1016/S0140-6736(20)30644-9
   Matzke GR, 2011, KIDNEY INT, V80, P1122, DOI 10.1038/ki.2011.322
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Schmidt JJ, 2020, CLIN KIDNEY J, V13, P421, DOI 10.1093/ckj/sfaa063
   Seffer Malin-Theres, 2020, Blood Purif, P1, DOI 10.1159/000508647
   VANSTONE JC, 1976, J LAB CLIN MED, V88, P87
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 11
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
DI 10.1111/1744-9987.13549
EA JUL 2020
PG 5
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA MQ2EI
UT WOS:000552709600001
PM 32558210
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Alam, I
   Kamau, AA
   Kulmanov, M
   Jaremko, L
   Arold, ST
   Pain, A
   Gojobori, T
   Duarte, CM
AF Alam, Intikhab
   Kamau, Allan A.
   Kulmanov, Maxat
   Jaremko, Lukasz
   Arold, Stefan T.
   Pain, Arnab
   Gojobori, Takashi
   Duarte, Carlos M.
TI Functional Pangenome Analysis Shows Key Features of E Protein Are
   Preserved in SARS and SARS-CoV-2
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE COVID-19; envelope protein (E); therapeutic targets; ARDS (acute
   respiratory distress syndrome); SARS-CoV-2; E protein Inhibitors
ID RESPIRATORY SYNDROME CORONAVIRUS; SPIKE; INHIBITION; VIROPORINS; CHANNEL
AB The spread of the novel coronavirus (SARS-CoV-2) has triggered a global emergency, that demands urgent solutions for detection and therapy to prevent escalating health, social, and economic impacts. The spike protein (S) of this virus enables binding to the human receptor ACE2, and hence presents a prime target for vaccines preventing viral entry into host cells. The S proteins from SARS and SARS-CoV-2 are similar, but structural differences in the receptor binding domain (RBD) preclude the use of SARS-specific neutralizing antibodies to inhibit SARS-CoV-2. Here we used comparative pangenomic analysis of all sequenced referenceBetacoronaviruses, complemented with functional and structural analyses. This analysis reveals that, among all core gene clusters present in these viruses, the envelope protein E shows a variant cluster shared by SARS and SARS-CoV-2 with two completely-conserved key functional features, namely an ion-channel, and a PDZ-binding motif (PBM). These features play a key role in the activation of the inflammasome causing the acute respiratory distress syndrome, the leading cause of death in SARS and SARS-CoV-2 infections. Together with functional pangenomic analysis, mutation tracking, and previous evidence, on E protein as a determinant of pathogenicity in SARS, we suggest E protein as an alternative therapeutic target to be considered for further studies to reduce complications of SARS-CoV-2 infections in COVID-19.
C1 [Alam, Intikhab; Kamau, Allan A.; Kulmanov, Maxat; Arold, Stefan T.; Gojobori, Takashi; Duarte, Carlos M.] King Abdullah Univ Sci & Technol KAUST, Computat Biosci Res Ctr CBRC, Biol & Environm Sci & Engn BESE, Thuwal, Saudi Arabia.
   [Jaremko, Lukasz; Pain, Arnab] King Abdullah Univ Sci & Technol KAUST, Biol & Environm Sci & Engn BESE, Thuwal, Saudi Arabia.
   [Arold, Stefan T.] Univ Montpellier, INSERM, Ctr Biochim Struct, CNRS, Montpellier, France.
   [Pain, Arnab] Hokkaido Univ, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan.
RP Alam, I; Duarte, CM (corresponding author), King Abdullah Univ Sci & Technol KAUST, Computat Biosci Res Ctr CBRC, Biol & Environm Sci & Engn BESE, Thuwal, Saudi Arabia.
EM intikhab.alam@kaust.edu.sa; carlos.duarte@kaust.edu.sa
RI Duarte, Carlos M/A-7670-2013
OI Duarte, Carlos M/0000-0002-1213-1361; Jaremko,
   Lukasz/0000-0001-7684-9359; Alam, Intikhab/0000-0001-5306-847X
FU King Abdullah University of Science and Technology (KAUST)King Abdullah
   University of Science & Technology [FCC/1/1976-25-01]
FX The research reported in this publication was supported by funding from
   King Abdullah University of Science and Technology (KAUST), under award
   number FCC/1/1976-25-01.
CR Alam I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082210
   Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z
   Behmard E, 2018, BIOPHYS CHEM, V233, P47, DOI 10.1016/j.bpc.2017.11.002
   Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Chen W, 2019, BIOCHEMISTRY-US, V58, P3834, DOI 10.1021/acs.biochem.9b00636
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Ding W, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gkx977
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gutierrez-Gonzalez LH, 2019, FASEB J, V33, P10607, DOI 10.1096/fj.201900518R
   Hanel K, 2006, J BIOMED SCI, V13, P281, DOI 10.1007/s11373-005-9043-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jalily PH, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104780
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Kulmanov M, 2020, BIOINFORMATICS, V36, P422, DOI 10.1093/bioinformatics/btz595
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liao Y, 2006, ADV EXP MED BIOL, V581, P199
   Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Minakshi R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008342
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Oestringer BP, 2018, NATURE, V562, pE8, DOI 10.1038/s41586-018-0561-9
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   OuYang B, 2013, NATURE, V498, P521, DOI 10.1038/nature12283
   Park J, 2019, ELIFE, V8, DOI 10.7554/eLife.47839
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Stouffer AL, 2008, NATURE, V451, P596, DOI 10.1038/nature06528
   Surya W, 2018, BBA-BIOMEMBRANES, V1860, P1309, DOI 10.1016/j.bbamem.2018.02.017
   Torres J, 2015, VIRUSES-BASEL, V7, P2858, DOI 10.3390/v7062750
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xia B., 2020, SARS COV 2 ENVELOPE, DOI [10.1101/2020.06.27.174953, DOI 10.1101/2020.06.27.174953]
   Xu D, 2012, PROTEINS, V80, P1715, DOI 10.1002/prot.24065
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 44
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD JUL 27
PY 2020
VL 10
AR 405
DI 10.3389/fcimb.2020.00405
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NC0CW
UT WOS:000560881900001
PM 32850499
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yoshino, R
   Yasuo, N
   Sekijima, M
AF Yoshino, Ryunosuke
   Yasuo, Nobuaki
   Sekijima, Masakazu
TI Identification of key interactions between SARS-CoV-2 main protease and
   inhibitor drug candidates
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATION; CORONAVIRUS; SARS; HIV; PHASE
AB The number of cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) has reached over 114,000. SARS-CoV-2 caused a pandemic in Wuhan, China, in December 2019 and is rapidly spreading globally. It has been reported that peptide-like anti-HIV-1 drugs are effective against SARS-CoV Main protease (M-pro). Due to the close phylogenetic relationship between SARS-CoV and SARS-CoV-2, their main proteases share many structural and functional features. Thus, these drugs are also regarded as potential drug candidates targeting SARS-CoV-2 M-pro. However, the mechanism of action of SARS-CoV-2 M-pro at the atomic-level is unknown. In the present study, we revealed key interactions between SARS-CoV-2 M-pro and three drug candidates by performing pharmacophore modeling and 1 mu s molecular dynamics (MD) simulations. His41, Gly143, and Glu166 formed interactions with the functional groups that were common among peptide-like inhibitors in all MD simulations. These interactions are important targets for potential drugs against SARS-CoV-2 M-pro.
C1 [Yoshino, Ryunosuke] Univ Tsukuba, Transborder Med Res Ctr, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.
   [Yoshino, Ryunosuke] Univ Tsukuba, Ctr Computat Sci, I-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.
   [Yasuo, Nobuaki; Sekijima, Masakazu] Tokyo Inst Technol, Tokyo Tech Acad Convergence Mat & Informat TAC MI, Midori Ku, J3-23-4259 Nagatsutacho, Yokohama, Kanagawa 2268501, Japan.
   [Sekijima, Masakazu] Tokyo Inst Technol, Sch Comp, Midori Ku, J3-23-4259 Nagatsutacho, Yokohama, Kanagawa 2268501, Japan.
RP Sekijima, M (corresponding author), Tokyo Inst Technol, Tokyo Tech Acad Convergence Mat & Informat TAC MI, Midori Ku, J3-23-4259 Nagatsutacho, Yokohama, Kanagawa 2268501, Japan.; Sekijima, M (corresponding author), Tokyo Inst Technol, Sch Comp, Midori Ku, J3-23-4259 Nagatsutacho, Yokohama, Kanagawa 2268501, Japan.
EM sekijima@c.titech.ac.jp
OI Sekijima, Masakazu/0000-0002-3806-9535
FU Platform Project for Supporting Drug Discovery and Life Science Research
   (Basis for Supporting Innovative Drug Discovery and Life Science
   Research (BINDS)) from AMED [JP20am0101112]
FX This work is partially supported by the Platform Project for Supporting
   Drug Discovery and Life Science Research (Basis for Supporting
   Innovative Drug Discovery and Life Science Research (BINDS)) from AMED
   under Grant Number JP20am0101112. The authors are grateful to Professor
   Zihe Rao's group for giving opportunity to access the crystal structure
   data of Main Protease prior to publication. We would like to express the
   deepest appreciation to Schrodinger, Inc. The numerical calculations
   were carried out on the TSUBAME3.0 supercomputer at Tokyo Institute of
   Technology.
CR Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067
   [Anonymous], 2018, SCHROD REL 2018 2 DE
   [Anonymous], 2016, SCHROD REL 2016 4 MA
   Banisharif-Dehkordi F, 2019, RES PHARM SCI, V14, P20, DOI 10.4103/1735-5362.251849
   Bartova I, 2004, PROTEIN SCI, V13, P1449, DOI 10.1110/ps.03578504
   Buch I, 2011, P NATL ACAD SCI USA, V108, P10184, DOI 10.1073/pnas.1103547108
   Chiba S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10275-4
   Chiba S, 2015, SCI REP-UK, V5, DOI 10.1038/srep17209
   Dixon SL, 2006, CHEM BIOL DRUG DES, V67, P370, DOI 10.1111/j.1747-0285.2006.00384.x
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   Doruker P, 2000, PROTEINS, V40, P512, DOI 10.1002/1097-0134(20000815)40:3<512::AID-PROT180>3.0.CO;2-M
   Ghosh AK, 2008, ACCOUNTS CHEM RES, V41, P78, DOI 10.1021/ar7001232
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hayes RL, 2012, J AM CHEM SOC, V134, P12043, DOI 10.1021/ja301454u
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Ingolfsson HI, 2014, J AM CHEM SOC, V136, P14554, DOI 10.1021/ja507832e
   Jensen JH, 2005, PROTEINS, V61, P704, DOI DOI 10.1002/prot.20660
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kindt T., 1991, NAT, V352, P581, DOI DOI 10.1038/352581A0
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Ou-Yang SS, 2012, ACTA PHARMACOL SIN, V33, P1131, DOI 10.1038/aps.2012.109
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Ruigrok RWH, 2010, CURR OPIN STRUC BIOL, V20, P104, DOI 10.1016/j.sbi.2009.12.007
   Sekijima M, 2003, BIOPHYS J, V85, P1176, DOI 10.1016/S0006-3495(03)74553-6
   Shan YB, 2011, J AM CHEM SOC, V133, P9181, DOI 10.1021/ja202726y
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Takano R, 2013, J INFECT DIS, V207, P89, DOI 10.1093/infdis/jis633
   Wakui N, 2018, J MOL GRAPH MODEL, V79, P166, DOI 10.1016/j.jmgm.2017.11.011
   WHO, 2020, DIR GEN OP REM MED B
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yasuo N, 2019, J CHEM INF MODEL, V59, P1050, DOI 10.1021/acs.jcim.8b00673
   Yildirim A, 2014, J PHYS CHEM B, V118, P10874, DOI 10.1021/jp505727w
   Yoshino R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53945-1
   Yoshino R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06411-9
   Yoshino R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125829
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang XW, 2004, BIOORGAN MED CHEM, V12, P2517, DOI 10.1016/j.bmc.2004.03.035
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 42
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 27
PY 2020
VL 10
IS 1
AR 12493
DI 10.1038/s41598-020-69337-9
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MW2KN
UT WOS:000556872700026
PM 32719454
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sriram, K
   Insel, PA
AF Sriram, Krishna
   Insel, Paul A.
TI Proteinase-activated receptor 1: A target for repurposing in the
   treatment of COVID-19?
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID THROMBIN; PAR-1; CONTRIBUTES; VORAPAXAR; APOPTOSIS; VIRUS
AB In the search to rapidly identify effective therapies that will mitigate the morbidity and mortality of COVID-19, attention has been directed towards the repurposing of existing drugs. Candidates for repurposing include drugs that target COVID-19 pathobiology, including agents that alter angiotensin signalling. Recent data indicate that key findings in COVID-19 patients include thrombosis and endotheliitis. Activation of proteinase-activated receptor 1 (PAR1), in particular by the serine protease thrombin, is a critical element in platelet aggregation and coagulation. PAR1 activation also impacts on the actions of other cell types involved in COVID-19 pathobiology, including endothelial cells, fibroblasts and pulmonary alveolar epithelial cells. Vorapaxar is an approved inhibitor of PAR1, used for treatment of patients with myocardial infarction or peripheral arterial disease. We discuss evidence for a possible beneficial role for vorapaxar in the treatment of COVID-19 patients and other as-yet non-approved antagonists of PAR1 and proteinase-activated receptor 4 (PAR4).
C1 [Sriram, Krishna; Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, MC 0636,9500 Gilman Dr, La Jolla, CA 92093 USA.
   [Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
RP Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, MC 0636,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM pinsel@health.ucsd.edu
FU University of California San DiegoUniversity of California System
FX University of California San Diego
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Aerts L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072529
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS21, DOI 10.1111/bph.14748
   American Society of Hematology, 2020, COVID 19 COAG FREQ A
   Antoniak S, 2013, J CLIN INVEST, V123, P1310, DOI 10.1172/JCI66125
   Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577
   Atanelishvili I, 2014, AM J RESP CELL MOL, V50, P893, DOI 10.1165/rcmb.2013-0317OC
   Bae JS, 2009, J CELL PHYSIOL, V219, P744, DOI 10.1002/jcp.21718
   Blanc-Brude OP, 2005, EXP CELL RES, V304, P16, DOI 10.1016/j.yexcr.2004.10.021
   Bunnett N., 2019, PROTEINASE ACTIVATED
   Camprubi-Rimblas M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.08
   Frantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002
   Heuberger DM, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0194-8
   Joly BS, 2020, INTENS CARE MED, V46, P1603, DOI 10.1007/s00134-020-06088-1
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Jose RJ, 2014, THORAX, V69, P190, DOI 10.1136/thoraxjnl-2013-204367
   Khoufache K, 2013, J CLIN INVEST, V123, P206, DOI 10.1172/JCI61667
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Morrow DA, 2012, NEW ENGL J MED, V366, P1404, DOI 10.1056/NEJMoa1200933
   Motta JP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11140-w
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Posma JJ, 2019, ARTERIOSCL THROM VAS, V39, P13, DOI 10.1161/ATVBAHA.118.311655
   Song JS, 2013, EXP LUNG RES, V39, P336, DOI 10.3109/01902148.2013.820809
   Sriram K, 2020, BRIT J PHARMACOL, V177, P4825, DOI 10.1111/bph.15082
   Statkevich P, 2012, EUR J CLIN PHARMACOL, V68, P1501, DOI 10.1007/s00228-012-1269-7
   Suzuki T, 2005, AM J RESP CELL MOL, V33, P231, DOI 10.1165/rcmb.2005-0109OC
   Le VB, 2018, BRIT J PHARMACOL, V175, P388, DOI 10.1111/bph.14084
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
NR 28
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2020
VL 177
IS 21
BP 4971
EP 4974
DI 10.1111/bph.15194
EA JUL 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC7OD
UT WOS:000553574500001
PM 32639031
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mullick, JB
   Simmons, CS
   Gaire, J
AF Mullick, Jhinuk Basu
   Simmons, Chelsey S.
   Gaire, Janak
TI Animal Models to Study Emerging Technologies Against SARS-CoV-2
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE COVID-19; ACE2 receptor; Vaccine studies; Pathogenesis; Diagnostics;
   Transgenic models; Non-human primates; Domestic pets; Farm animals
ID ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS INFECTION; HUMANIZED
   MICE; SARS; PATHOGENESIS; GENERATION; MERS
AB New technologies are being developed toward the novel coronavirus SARS-CoV-2 to understand its pathogenesis and transmission, to develop therapeutics and vaccines, and to formulate preventive strategies. Animal models are indispensable to understand these processes and develop and test emerging technologies; however, the mechanism of infection for SARS-CoV-2 requires certain similarities to humans that do not exist in common laboratory rodents. Here, we review important elements of viral infection, transmission, and clinical presentation reflected by various animal models readily available or being developed and studied for SARS-CoV-2 to help bioengineers evaluate appropriate preclinical models for their emerging technologies. Importantly, applications of traditional mice and rat models are limited for studying SARS-CoV-2 and development of COVID-19. Non-human primates, Syrian hamsters, ferrets, cats, and engineered chimeras mimic the human infection more closely and hold strong potential as animal models of SARS-CoV-2 infection and progression of resulting human disease.
C1 [Mullick, Jhinuk Basu; Simmons, Chelsey S.; Gaire, Janak] Univ Florida, Herbert Wertheim Coll Engn, Dept Mech & Aerosp Engn, POB 116250, Gainesville, FL 32611 USA.
   [Simmons, Chelsey S.] Univ Florida, J Crayton Pruitt Family Dept Biomed Engn, Div Cardiovasc Med, Gainesville, FL USA.
RP Simmons, CS (corresponding author), Univ Florida, Herbert Wertheim Coll Engn, Dept Mech & Aerosp Engn, POB 116250, Gainesville, FL 32611 USA.
EM css@ufl.edu
RI Mullick, Jhinuk Basu/ABD-8318-2020
OI Simmons, Chelsey/0000-0001-6973-9813
FU National Institute of General Medical Sciences (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R35GM128831]
FX This work was supported by the National Institute of General Medical
   Sciences (NIH) through Grant R35GM128831 to CSS.
CR Banerjee A, 2016, J VIROL METHODS, V237, P166, DOI 10.1016/j.jviromet.2016.09.008
   Bao L, 2020, BIORXIV, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226]
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Baxter V.K., 2016, VIRAL PATHOGENESIS B, P125
   Bility MT, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004032
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Brehm MA, 2014, J IMMUNOL METHODS, V410, P3, DOI 10.1016/j.jim.2014.02.011
   Cavanagh D, 2005, AVIAN PATHOL, V34, P439, DOI 10.1080/03079450500367682
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Curran M, 2020, TOXICOL PATHOL, V48, P302, DOI 10.1177/0192623319886304
   Decaro N, 2020, VET MICROBIOL, V244, DOI 10.1016/j.vetmic.2020.108693
   Deng W, 2020, BIORXIV, DOI [10.1101/2020.03.13.990036, DOI 10.1101/2020.03.13.990036]
   Dyal JW, 2020, MMWR-MORBID MORTAL W, V69, P887
   Elahi S, 2007, TRENDS MICROBIOL, V15, P462, DOI 10.1016/j.tim.2007.09.003
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Golding H, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028902
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gustafson KD, 2018, EVOL APPL, V11, P694, DOI 10.1111/eva.12565
   Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400
   HAMILTON IM, 1994, CAN J ZOOL, V72, P744, DOI 10.1139/z94-100
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hosie MJ, 2020, SARS CORONAVIRUS 2 C
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kim KC, 2016, AIDS RES HUM RETROV, V32, P194, DOI [10.1089/aid.2015.0211, 10.1089/AID.2015.0211]
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kiros TG, 2012, INNOV VACCINOL, V29, P251
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Lu S, 2020, COMP SARS COV 2 INFE, DOI [10.1101/2020.04.08.031807, DOI 10.1101/2020.04.08.031807]
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Mota J, 2009, J VIROL, V83, P8638, DOI 10.1128/JVI.00581-09
   Munster Vincent J, 2020, bioRxiv, DOI 10.1101/2020.03.21.001628
   Pearson T, 2008, CURR PROTOC IMMUNOL
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Shan C., 2020, PREPRINT
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Shoenfeld Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102538
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sikes RS, 2011, J MAMMAL, V92, P235, DOI 10.1644/10-MAMM-F-355.1
   Sit T.H.C., 2020, INFECT DOGS SARS COV, P1
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Soldatov VO, 2020, RES RESULTS PHARM, V6, P1, DOI [10.3897/rrpharmacology.6.53633, DOI 10.3897/rrpharmacology.6.53633]
   Subbarao K, 2006, TRENDS MICROBIOL, V14, P299, DOI 10.1016/j.tim.2006.05.007
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Van den Brand JMA, 2008, VET PATHOL, V45, P551, DOI 10.1354/vp.45-4-551
   Wahl A, 2019, NAT BIOTECHNOL, V37, P1163, DOI 10.1038/s41587-019-0225-9
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang Q., 2020, HACE2 TRANSGENIC MOU
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Wu Xiao, 2020, medRxiv, DOI 10.1101/2020.04.05.20054502
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yong KSM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22899-1
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhang Q., 2020, MICROBIOLOGY
   Zhou P, 2016, SCI REP-UK, V6, DOI 10.1038/srep38597
NR 63
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1865-5025
EI 1865-5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD AUG
PY 2020
VL 13
IS 4
SI SI
BP 293
EP 303
DI 10.1007/s12195-020-00638-9
EA JUL 2020
PG 11
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
SC Cell Biology; Biophysics; Engineering
GA NK8WI
UT WOS:000552932400004
PM 32837584
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bevelacqua, JJ
   Mortazavi, SAR
   Mortazavi, SMJ
AF Bevelacqua, Joseph J.
   Mortazavi, S. A. R.
   Mortazavi, S. M. J.
TI Re: Low-dose radiation therapy for COVID-19 pneumonia: is there any
   supportive evidence?
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Letter
C1 [Bevelacqua, Joseph J.] Bevelacqua Resources, Washington, DC USA.
   [Mortazavi, S. A. R.] Shiraz Univ Med Sci, Sch Med, Shiraz, Iran.
   [Mortazavi, S. M. J.] Shiraz Univ Med Sci, Sch Med, Med Phys & Engn Dept, Shiraz, Iran.
RP Mortazavi, SMJ (corresponding author), Shiraz Univ Med Sci, Sch Med, Med Phys & Engn Dept, Shiraz, Iran.
EM mortazavismj@gmail.com
RI Mortazavi, SMJ/D-5830-2011
OI Mortazavi, SMJ/0000-0003-0139-2774
CR A Ghadimi-Moghadam, 2020, J Biomed Phys Eng, V10, P241, DOI 10.31661/jbpe.v0i0.2003-1085
   [Anonymous], 2020, WASHINGTON POST
   Averbeck D, 2009, HEALTH PHYS, V97, P493, DOI 10.1097/HP.0b013e3181b08a20
   Bevelacqua JJ, 2016, HLTH PHYS RAD GENERA
   Bevelacqua JJ, 2018, J NUCL MED, V59, P1777, DOI 10.2967/jnumed.118.217604
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Kirkby C, 2020, RADIOTHER ONCOL, V147, P221, DOI 10.1016/j.radonc.2020.04.004
   Lara PC, 2020, CLIN TRANSL RAD ONCO, V23, P27, DOI 10.1016/j.ctro.2020.04.006
   Salomaa S, 2020, INT J RADIAT BIOL, V96, P1224, DOI 10.1080/09553002.2020.1762020
   Tubiana M, 2009, RADIOLOGY, V251, P13, DOI 10.1148/radiol.2511080671
   Violi F, 2012, THROMB RES, V129, P378, DOI 10.1016/j.thromres.2011.12.002
NR 11
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955-3002
EI 1362-3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD OCT 2
PY 2020
VL 96
IS 10
BP 1236
EP 1237
DI 10.1080/09553002.2020.1797213
EA JUL 2020
PG 2
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA NW7JQ
UT WOS:000553370600001
PM 32673140
OA Bronze
DA 2021-01-01
ER

PT J
AU Nuismer, SL
   Bull, JJ
AF Nuismer, Scott L.
   Bull, James J.
TI Self-disseminating vaccines to suppress zoonoses
SO NATURE ECOLOGY & EVOLUTION
LA English
DT Article
ID RABBIT HEMORRHAGIC-DISEASE; MASTOMYS-NATALENSIS; RESERVOIR HOSTS;
   CURRENT STATE; LASSA FEVER; VIRUS; MYXOMATOSIS; POLIOVIRUSES;
   PREVENTION; VECTORS
AB The SARS-CoV-2 epidemic is merely the most recent demonstration that our current approach to emerging zoonotic infectious disease is ineffective. SARS, MERS, Ebola, Nipah and an array of arenavirus infections sporadically spillover into human populations and are often contained only as a result of their poor transmission in human hosts, coupled with intense public health control efforts in the early stages of an emerging epidemic. It is now more apparent than ever that we need a better and more proactive approach. One possibility is to eliminate the threat of spillover before it occurs using vaccines capable of autonomously spreading through wild animal reservoirs. We are now poised to begin developing self-disseminating vaccines targeting a wide range of human pathogens, but important decisions remain about how they can be most effectively designed and used to target pathogens with a high risk of spillover and/or emergence. In this Perspective, we first review the basic epidemiological theory establishing the feasibility and utility of self-disseminating vaccines. We then outline a road map for overcoming remaining technical challenges: identifying high-risk pathogens before they emerge, optimizing vaccine design with an eye to evolution, behaviour and epidemiology, and minimizing the risk of unintended consequences.
   Vaccines that can spread autonomously through animal populations could help to prevent zoonoses before they spillover into humans. This Perspective discusses the epidemiological theory and the practical challenges associated with transmissible and transferable vaccines.
C1 [Nuismer, Scott L.; Bull, James J.] Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA.
   [Nuismer, Scott L.] Univ Idaho, Dept Math, Moscow, ID 83843 USA.
RP Nuismer, SL (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA.; Nuismer, SL (corresponding author), Univ Idaho, Dept Math, Moscow, ID 83843 USA.
EM snuismer@uidaho.edu
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01GM122079]
FX We thank K. Riendeau for developing Figs. 1 and 3. S.L.N. and J.J.B.
   were supported by National Institutes of Health (NIH) grant no.
   R01GM122079.
CR Alizon S, 2009, J EVOLUTION BIOL, V22, P245, DOI 10.1111/j.1420-9101.2008.01658.x
   Angulo E, 2007, WILDLIFE RES, V34, P567, DOI 10.1071/WR06160
   [Anonymous], 2020, COST EB EP
   [Anonymous], 2004, FOR MICR THREATS LEA
   Anthony SJ, 2017, MBIO, V8, DOI [10.1128/mBio.00373-17, 10.1128/mbio.00373-17]
   Babayan SA, 2018, SCIENCE, V362, P577, DOI 10.1126/science.aap9072
   Bakker KM, 2019, NAT ECOL EVOL, V3, P1697, DOI 10.1038/s41559-019-1032-x
   Barcena J, 2000, J VIROL, V74, P1114, DOI 10.1128/JVI.74.3.1114-1123.2000
   Basinski AJ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007251
   Basinski AJ, 2018, VACCINE, V36, P675, DOI 10.1016/j.vaccine.2017.12.037
   Bird BH, 2018, ANNU REV ANIM BIOSCI, V6, P121, DOI 10.1146/annurev-animal-030117-014628
   Bull JJ, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev005
   Bull JJ, 2018, TRENDS MICROBIOL, V26, P6, DOI 10.1016/j.tim.2017.09.007
   Douglass RJ, 2001, AM J TROP MED HYG, V65, P33, DOI 10.4269/ajtmh.2001.65.33
   Edson D, 2015, PLOS ONE, V10
   Fenton A, 2015, AM NAT, V186, P610, DOI 10.1086/683173
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Fichet-Calvet E, 2007, VECTOR-BORNE ZOONOT, V7, P119, DOI 10.1089/vbz.2006.0520
   Garnier R, 2013, MAMM BIOL, V78, P361, DOI 10.1016/j.mambio.2012.11.004
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29
   Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2
   Grard G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002924
   Guth S, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2019.0296
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Han BA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004815
   Han BA, 2016, EMBO REP, V17, P785, DOI 10.15252/embr.201642534
   Han BA, 2015, P NATL ACAD SCI USA, V112, P7039, DOI 10.1073/pnas.1501598112
   Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09
   Kew OM, 2004, B WORLD HEALTH ORGAN, V82, P16
   Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Lecompte E, 2006, EMERG INFECT DIS, V12, P1971
   Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6
   Luby SP, 2009, CLIN INFECT DIS, V49, P1743, DOI 10.1086/647951
   Luis AD, 2010, J ANIM ECOL, V79, P462, DOI 10.1111/j.1365-2656.2009.01646.x
   Marien J, 2019, EMERG MICROBES INFEC, V8, P640, DOI 10.1080/22221751.2019.1605846
   McCormick JB, 2002, CURR TOP MICROBIOL, V262, P75
   Morse SS, 2012, LANCET, V380, P1956, DOI 10.1016/S0140-6736(12)61684-5
   Murphy AA, 2016, EXPERT REV VACCINES, V15, P31, DOI 10.1586/14760584.2016.1106942
   Nuismer SL, 2019, EVOL APPL, V12, P1595, DOI 10.1111/eva.12806
   Nuismer SL, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.1903
   Nziza J, 2020, ECOHEALTH, V17, P152, DOI 10.1007/s10393-019-01458-8
   Olayemi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep25280
   Olival KJ, 2017, NATURE, V546, P646, DOI 10.1038/nature22975
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Pepin KM, 2010, NAT REV MICROBIOL, V8, P802, DOI 10.1038/nrmicro2440
   Pernet O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6342
   Redding DW, 2016, METHODS ECOL EVOL, V7, P646, DOI 10.1111/2041-210X.12549
   Rollier CS, 2011, CURR OPIN IMMUNOL, V23, P377, DOI 10.1016/j.coi.2011.03.006
   Rupprecht CE, 2004, DEV BIOLOGICALS, V119, P173
   Schreiner CL, 2020, J APPL ECOL, V57, P307, DOI 10.1111/1365-2664.13539
   SHELLAM GR, 1994, REPROD FERT DEVELOP, V6, P401, DOI 10.1071/RD9940401
   Smithson MW, 2019, VACCINE, V37, P1153, DOI 10.1016/j.vaccine.2019.01.018
   Stading B, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005958
   Torres JM, 2001, VACCINE, V19, P4536, DOI 10.1016/S0264-410X(01)00184-0
   Towner JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000764
   TYNDALEBISCOE CH, 1994, REPROD FERT DEVELOP, V6, P281, DOI 10.1071/RD9940281
   Varrelman TJ, 2019, ONE HEALTH-AMSTERDAM, V7, DOI 10.1016/j.onehlt.2019.100084
   Viana M, 2014, TRENDS ECOL EVOL, V29, P270, DOI 10.1016/j.tree.2014.03.002
NR 60
TC 0
Z9 0
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2397-334X
J9 NAT ECOL EVOL
JI Nat. Ecol. Evol.
PD SEP
PY 2020
VL 4
IS 9
BP 1168
EP 1173
DI 10.1038/s41559-020-1254-y
EA JUL 2020
PG 6
WC Ecology; Evolutionary Biology
SC Environmental Sciences & Ecology; Evolutionary Biology
GA NF7ZD
UT WOS:000553640500003
PM 32719452
OA Bronze
DA 2021-01-01
ER

PT J
AU Bader, F
   Manla, Y
   Atallah, B
   Starling, RC
AF Bader, Feras
   Manla, Yosef
   Atallah, Bassam
   Starling, Randall C.
TI Heart failure and COVID-19
SO HEART FAILURE REVIEWS
LA English
DT Article; Early Access
DE Heart failure; COVID-19; Cardiac biomarkers; Hemodynamics
ID VENTRICULAR ASSIST DEVICE; 2019 CORONAVIRUS OUTBREAK; CONVERTING ENZYME
   ACE; CLINICAL CHARACTERISTICS; TRANSPLANT RECIPIENTS; QT INTERVAL;
   CHINA; WUHAN; ERA; INHIBITION
AB Heart failure is a common disease state that can be encountered at different stages in the course of a COVID-19 patient presentation. New or existing heart failure in the setting of COVID-19 can present a set of unique challenges that can complicate presentation, management, and prognosis. A careful understanding of the hemodynamic and diagnostic implications is essential for appropriate triage and management of these patients. Abnormal cardiac biomarkers are common in COVID-19 and can stem from a variety of mechanisms that involve the viral entry itself through the ACE2 receptors, direct cardiac injury, increased thrombotic activity, stress cardiomyopathy, and among others. The cytokine storm observed in this pandemic can be a culprit in many of the observed mechanisms and presentations. A correct understanding of the two-way interaction between heart failure medications and the infection as well as the proposed COVID-19 medications and heart failure can result in optimal management. Guideline-directed medical therapy for heart failure should not be interrupted for theoretical concerns but rather based on tolerance and clinical presentation. Initiating specific cardiac or heart failure medications to prevent the infection or mitigate the disease is also not an evidence-based practice at this time. Heart failure patients on advanced therapies including those with heart transplantation will particularly benefit from involving the advanced heart failure team members in the overall management if they contract the virus.
C1 [Bader, Feras] Cleveland Clin Abu Dhabi, Inst Heart & Vasc, POB 112412, Abu Dhabi, U Arab Emirates.
   [Bader, Feras] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Manla, Yosef] Cleveland Clin Abu Dhabi, Dept Res & Educ, POB 112412, Abu Dhabi, U Arab Emirates.
   [Atallah, Bassam] Cleveland Clin Abu Dhabi, Dept Pharm Serv, POB 112412, Abu Dhabi, U Arab Emirates.
   [Starling, Randall C.] Cleveland Clin, Kaufman Ctr Heart Failure, Dept Cardiovasc Med, Inst Heart & Vasc, Cleveland, OH 44106 USA.
RP Bader, F (corresponding author), Cleveland Clin Abu Dhabi, Inst Heart & Vasc, POB 112412, Abu Dhabi, U Arab Emirates.; Bader, F (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
EM baderf@clevelandclinicabudhabi.ae
CR Abnousi F, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0159-0
   Abraham WT, 2011, LANCET, V377, P658, DOI 10.1016/S0140-6736(11)60101-3
   Almazeedi S, 2020, CLIN CHARACTERISTICS
   Ambrosi P, 2020, J HEART LUNG TRANSPL, V39, P729, DOI 10.1016/j.healun.2020.04.002
   Andersson C, 2020, CIRC-HEART FAIL, V13, P4, DOI 10.1161/CIRCHEARTFAILURE.120.007274
   Ankersmit HJ, 1999, LANCET, V354, P550, DOI 10.1016/S0140-6736(98)10359-8
   [Anonymous], 2020, GUIDANCE CARDIOTHORA
   [Anonymous], 2020, HFSA ACC AHA STAT AD
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Badreldin Hisham A, 2021, Res Social Adm Pharm, V17, P1946, DOI 10.1016/j.sapharm.2020.05.017
   Buckner Frederick S, 2020, Clin Infect Dis, V71, P2167, DOI 10.1093/cid/ciaa632
   Chau Vinh Q, 2020, JACC Case Rep, V2, P1315, DOI 10.1016/j.jaccas.2020.04.001
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinello P, 2017, PLOS NEGLECT TROP D, V11, DOI [10.1371/journal.pntd.0006034, DOI 10.1371/JOURNAL.PNTD.0006034]
   Court O, 2002, CRIT CARE, V6, P500, DOI 10.1186/cc1822
   DeFilippis EM, 2020, JACC-HEART FAIL, V8, P681, DOI 10.1016/j.jchf.2020.05.006
   DeFilippis EM, 2020, CIRCULATION, V141, P2048, DOI 10.1161/CIRCULATIONAHA.120.047096
   Dellinger RP, 2003, CLIN INFECT DIS, V36, P1259, DOI 10.1086/374835
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fang Z., 2020, CLIN CHARACTERISTICS
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   GAO L, 2020, RESP RES, V21, DOI DOI 10.1186/S12931-019-1261-1
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorodeski EZ, 2020, J CARD FAIL, V26, P448, DOI 10.1016/j.cardfail.2020.04.008
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2008, EXP PHYSIOL, V93, P631, DOI 10.1113/expphysiol.2007.041855
   Hayeshi R, 2006, EUR J PHARM SCI, V29, P70, DOI 10.1016/j.ejps.2006.05.009
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Javanian M, 2020, ROM J INTERN MED, V58, P161, DOI 10.2478/rjim-2020-0013
   Kilic A, 2015, J THORAC DIS, V7, P2158, DOI 10.3978/j.issn.2072-1439.2015.10.64
   Kimball PM, 2008, ANN THORAC SURG, V85, P1656, DOI 10.1016/j.athoracsur.2008.01.050
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumagai Y, 2015, INT J CLIN PHARM TH, V53, P866, DOI 10.5414/CP202388
   Kytomaa S, 2019, JAMA CARDIOL, V4, P363, DOI 10.1001/jamacardio.2019.0549
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Merx MW, 2007, CIRCULATION, V116, P793, DOI 10.1161/CIRCULATIONAHA.106.678359
   Ng TMH, 2016, WORLD J CARDIOL, V8, P584, DOI 10.4330/wjc.v8.i10.584
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Patel KJ, 2020, J HEART LUNG TRANSPL, V39, P611, DOI 10.1016/j.healun.2020.04.005
   Radley G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02651
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Scally C, 2019, CIRCULATION, V139, P1581, DOI 10.1161/CIRCULATIONAHA.118.037975
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Singh R, 2020, J CARD FAIL, V26, P438, DOI 10.1016/j.cardfail.2020.04.007
   Somer M, 2000, BRIT J CLIN PHARMACO, V49, P549, DOI 10.1046/j.1365-2125.2000.00197.x
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038]
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
   Umapathi P, 2020, J CARD FAIL, V26, P637, DOI 10.1016/j.cardfail.2020.06.003
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WANG S, 2020, JAMA CARDIOL, V5, P1, DOI DOI 10.1001/JAMACARDIO.2020.1624
   WHO, 2020, WHO INT
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 72
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1382-4147
EI 1573-7322
J9 HEART FAIL REV
JI Heart Fail. Rev.
DI 10.1007/s10741-020-10008-2
EA JUL 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MR5NG
UT WOS:000553633500001
PM 32720082
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abrams, RMC
   Kim, BD
   Markantone, DM
   Reilly, K
   Paniz-Mondolfi, AE
   Gitman, MR
   Choo, SY
   Tse, W
   Robinson-Papp, J
AF Abrams, Rory M. C.
   Kim, Brian D.
   Markantone, Desiree M.
   Reilly, Kaitlin
   Paniz-Mondolfi, Alberto E.
   Gitman, Melissa R.
   Choo, S. Yoon
   Tse, Winona
   Robinson-Papp, Jessica
TI Severe rapidly progressive Guillain-Barre syndrome in the setting of
   acute COVID-19 disease
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE Coronavirus-19; SARS-CoV-2; Neuromuscular disorders; Guillain-Barre
   syndrome; Polyneuropathy
ID THERAPY
AB There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barre syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
C1 [Abrams, Rory M. C.; Robinson-Papp, Jessica] Mt Sinai Hosp, Icahn Sch Med, Dept Neurol, Div Neuromuscular Dis & Clin Neurophysiol Labs, 1468 Madison Ave, New York, NY 10029 USA.
   [Kim, Brian D.; Markantone, Desiree M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
   [Reilly, Kaitlin] Icahn Sch Med Mt Sinai, Dept Neurol, Div Neurocrit Care, New York, NY 10029 USA.
   [Paniz-Mondolfi, Alberto E.; Gitman, Melissa R.; Choo, S. Yoon] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, New York, NY 10029 USA.
   [Tse, Winona] Icahn Sch Med Mt Sinai, Dept Neurol, Div Movement Disorders, New York, NY 10029 USA.
RP Abrams, RMC (corresponding author), Mt Sinai Hosp, Icahn Sch Med, Dept Neurol, Div Neuromuscular Dis & Clin Neurophysiol Labs, 1468 Madison Ave, New York, NY 10029 USA.
EM Rory.Abrams@mssm.edu
RI Robinson-Papp, Jessica/AAX-5802-2020
OI Robinson-Papp, Jessica/0000-0001-9397-8873; Abrams,
   Rory/0000-0002-9675-4012
CR Abrams RMC, 2018, NEUROLOGIST, V23, P185, DOI 10.1097/NRL.0000000000000197
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Fehrenbacher JC, 2015, PROG MOL BIOL TRANSL, V131, P471, DOI 10.1016/bs.pmbts.2014.12.002
   Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285
   Guidon AC, 2020, NEUROLOGY, V94, P959, DOI 10.1212/WNL.0000000000009566
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   James J, 2017, J CLIN DIAGN RES, V11, pOD16, DOI 10.7860/JCDR/2017/30445.10662
   Padroni M, 2020, J NEUROL, V267, P1877, DOI 10.1007/s00415-020-09849-6
   Sauteur PMM, 2016, ANN NEUROL, V80, P566, DOI 10.1002/ana.24755
   Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
   Steinberger BA, 2003, AM J HEMATOL, V73, P97, DOI 10.1002/ajh.10325
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Wijdicks EFM, 2017, MAYO CLIN PROC, V92, P467, DOI 10.1016/j.mayocp.2016.12.002
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhao Q, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104358
NR 16
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD OCT
PY 2020
VL 26
IS 5
BP 797
EP 799
DI 10.1007/s13365-020-00884-7
EA JUL 2020
PG 3
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA NV7DY
UT WOS:000552950800002
PM 32720233
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Santos, CS
   Morales, CM
   Alvarez, ED
   Castro, CA
   Robles, AL
   Sandoval, TP
AF Santos, C. Sieiro
   Morales, C. Moriano
   alvarez, E. Diez
   Castro, C. Alvarez
   Robles, A. Lopez
   Sandoval, T. Perez
TI Determinants of COVID-19 disease severity in patients with underlying
   rheumatic disease
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Biologic; COVID-19; Disease activity; Hospitalized; Hydroxychloroquine;
   Immunosuppressive; Inflammation; Mortality; Rheumatology; Spain
AB Background Over the month of April, Spain has become the European country with more confirmed cases of COVID-19 infection, after surpassing Italy on April 2nd. The community of Castile and Leon in Spain is one of the most affected by COVID-19 infection and the province of Leon has a total of 3711 cases and 425 deaths so far. Rheumatic patients should be given special attention regarding COVID-19 infection due to their immunocompromised state resulting from their underlying immune conditions and use of targeted immune-modulating therapies. Studying epidemiological and clinical characteristics of patients with rheumatic diseases infected with SARS-CoV2 is pivotal to clarify determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Objectives To describe epidemiological characteristics of patients with rheumatic diseases hospitalized with COVID-19 and determine risk factors associated with mortality in a third level Hospital setting in Leon, Spain. Methods We performed a prospective observational study, from 1st March 2020 until the 1st of June including adults with rheumatic diseases hospitalized with COVID-19 and performed a univariate and multivariate logistic regression model to estimate ORs and 95% CIs of mortality. Age, sex, comorbidities, rheumatic disease diagnosis and treatment, disease activity prior to infection, radiographic and laboratorial results at arrival were analysed. Results During the study period, 3711 patients with COVID-19 were admitted to our hospital, of whom 38 (10%) had a rheumatic or musculoskeletal disease. Fifty-three percent were women, with a mean age at hospital admission of 75.3 (IQR 68-83) years. The median length of stay was 11 days. A total of 10 patients died (26%) during their hospital admission. Patients who died from COVID-19 were older (median age 78.4 IQR 74.5-83.5) than those who survived COVID-19 (median age 75.1 IQR 69.3-75.8) and more likely to have arterial hypertension (9 [90%] vs 14 [50%] patients; OR 9 (95% CI 1.0-80.8),p0.049), dyslipidaemia (9 (90%) vs 12 (43%); OR 12 (95% CI 1.33-108),p0.03), diabetes ((9 (90%) vs 6 (28%) patients; OR 33,p0.002), interstitial lung disease (6 (60%) vs 6 (21%); OR 5.5 (95% CI 1.16-26),p0.03), cardiovascular disease (8 (80%) vs 11 (39%); OR 6.18 (95% IC 1.10-34.7,p0.04) and a moderate/high index of rheumatic disease activity (7 (25%) vs 6(60%); OR 41.4 (4.23-405.23),p0.04). In univariate analyses, we also found that patients who died from COVID-19 had higher hyperinflammation markers than patients who survived: C-reactive protein (181 (IQR 120-220) vs 107.4 (IQR 30-150;p0.05); lactate dehydrogenase (641.8 (IQR 465.75-853.5) vs 361 (IQR 250-450),p0.03); serum ferritin (1026 (IQR 228.3-1536.3) vs 861.3 (IQR 389-1490.5),p0.04); D-dimer (12,019.8 (IQR 843.5-25,790.5) vs 1544.3 (IQR 619-1622),p0.04). No differences in sex, radiological abnormalities, rheumatological disease, background therapy or symptoms before admission between deceased patients and survivors were found. In the multivariate analysis, the following risk factors were associated with mortality: rheumatic disease activity (p = 0.003), dyslipidaemia (p = 0.01), cardiovascular disease (p = 0.02) and interstitial lung disease (p = 0.02). Age, hypertension and diabetes were significant predictors in univariate but not in multivariate analysis. Rheumatic disease activity was significantly associated with fever (p = 0.05), interstitial lung disease (p = 0.
   03), cardiovascular disease (p = 0.03) and dyslipidaemia (p = 0.01). Conclusions Our results suggest that comorbidities, rheumatic disease activity and laboratorial abnormalities such as C-reactive protein (CRP), D-Dimer, lactate dehydrogenase (LDH), serum ferritin elevation significantly associated with mortality whereas previous use of rheumatic medication did not. Inflammation is closely related to severity of COVID-19.
C1 [Santos, C. Sieiro; Morales, C. Moriano; alvarez, E. Diez; Castro, C. Alvarez; Robles, A. Lopez; Sandoval, T. Perez] Complejo Asistencial Univ Leon, Rheumatol Dept, Leon, Spain.
RP Santos, CS (corresponding author), Complejo Asistencial Univ Leon, Rheumatol Dept, Leon, Spain.
EM cristysieirosantos@gmail.com
CR Chen X., 2020, DETECTABLE SERUM SAR
   Favalli EG, 2020, AUTOIMMUN REV
   Furst DE, 2010, SEMIN ARTHRITIS RHEU, V39, P327, DOI 10.1016/j.semarthrit.2008.10.002
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Graef ER, 2020, ANN RHEUM DIS, V79, P734, DOI 10.1136/annrheumdis-2020-217480
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim AHJ, 2020, ANN INTERN MED
   Mahevas M, 2020, NO EVIDENCE CLIN EFF
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Raef Fadel DO, CLIN INFECT DIS, DOI [10.1093/cid/ciaa601, DOI 10.1093/CID/CIAA601]
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
NR 14
TC 3
Z9 3
U1 3
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD SEP
PY 2020
VL 39
IS 9
BP 2789
EP 2796
DI 10.1007/s10067-020-05301-2
EA JUL 2020
PG 8
WC Rheumatology
SC Rheumatology
GA NB8UO
UT WOS:000552918000001
PM 32720259
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ahmed, S
   Mahtarin, R
   Ahmed, SS
   Akter, S
   Islam, MS
   Al Mamun, A
   Islam, R
   Hossain, MN
   Ali, MA
   Sultana, MUC
   Parves, MR
   Ullah, MO
   Halim, MA
AF Ahmed, Sinthyia
   Mahtarin, Rumana
   Ahmed, Sayeda Samina
   Akter, Shaila
   Islam, Md. Shamiul
   Al Mamun, Abdulla
   Islam, Rajib
   Hossain, Md Nayeem
   Ali, Md Ackas
   Sultana, Mossammad U. C.
   Parves, MD. Rimon
   Ullah, M. Obayed
   Halim, Mohammad A.
TI Investigating the binding affinity, interaction, and
   structure-activity-relationship of 76 prescription antiviral drugs
   targeting RdRp and Mpro of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Antiviral drugs; SARS-CoV-2; molecular docking; molecular dynamics;
   quantitative structure-activity relationship; principal component
   analysis
ID IDENTIFICATION; INHIBITORS; ENERGIES; DOCKING; SARS
AB SARS-CoV-2 virus outbreak poses a major threat to humans worldwide due to its highly contagious nature. In this study, molecular docking, molecular dynamics, and structure-activity relationship are employed to assess the binding affinity and interaction of 76 prescription drugs against RNA dependent RNA polymerase (RdRp) and Main Protease (Mpro) of SARS-CoV-2. The RNA-dependent RNA polymerase is a vital enzyme of coronavirus replication/transcription complex whereas the main protease acts on the proteolysis of replicase polyproteins. Among 76 prescription antiviral drugs, four drugs (Raltegravir, Simeprevir, Cobicistat, and Daclatasvir) that are previously used for human immunodeficiency virus (HIV), hepatitis C virus (HCV), Ebola, and Marburg virus show higher binding energy and strong interaction with active sites of the receptor proteins. To explore the dynamic nature of the interaction, 100 ns molecular dynamics (MD) simulation is performed on the selected protein-drug complexes and apo-protein. Binding free energy of the selected drugs is performed by MM/PBSA. Besides docking and dynamics, partial least square (PLS) regression method is applied for the quantitative structure activity relationship to generate and predict the binding energy for drugs. PLS regression satisfactorily predicts the binding energy of the effective antiviral drugs compared to binding energy achieved from molecular docking with a precision of 85%. This study highly recommends researchers to screen these potential drugs in vitro and in vivo against SARS-CoV-2 for further validation of utility.
C1 [Ahmed, Sinthyia; Mahtarin, Rumana; Ahmed, Sayeda Samina; Akter, Shaila; Islam, Md. Shamiul; Islam, Rajib; Hossain, Md Nayeem; Ali, Md Ackas; Sultana, Mossammad U. C.; Parves, MD. Rimon; Ullah, M. Obayed; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Infect Dis, Dhaka, Bangladesh.
   [Ahmed, Sinthyia; Mahtarin, Rumana; Ahmed, Sayeda Samina; Akter, Shaila; Islam, Md. Shamiul; Islam, Rajib; Hossain, Md Nayeem; Ali, Md Ackas; Sultana, Mossammad U. C.; Parves, MD. Rimon; Ullah, M. Obayed; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.
   [Al Mamun, Abdulla] Nanjing Univ Sci & Technol, Sch Chem Engn, Key Lab Soft Chem & Funct Mat MOE, Nanjing, Peoples R China.
   [Halim, Mohammad A.] Univ Arkansas Ft Smith, Dept Phys Sci, Ft Smith, AR 72904 USA.
RP Halim, MA (corresponding author), BICCB, Red Green Res Ctr, Div Infect Dis, Dhaka, Bangladesh.; Halim, MA (corresponding author), BICCB, Red Green Res Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.; Halim, MA (corresponding author), Univ Arkansas Ft Smith, Dept Phys Sci, Ft Smith, AR 72904 USA.
EM mohammad.halim@uafs.edu
RI Ullah, M Obayed/AAR-7211-2020; parves/AAF-8816-2020; Ali,
   Ackas/AAP-7500-2020; Islam, Rajib/AAP-7503-2020
OI Ullah, M Obayed/0000-0002-1175-3636; parves/0000-0003-1379-7410; Ali,
   Ackas/0000-0002-8235-3517; Islam, Rajib/0000-0001-8499-5516; Ahmed,
   Sinthyia/0000-0002-9446-4724; , Sayeda Samina Ahmed/0000-0002-6838-1677
FU World Academy of Science (TWAS)
FX We are grateful to our donors (http://grc-bd.org/donate/) who supported
   to build a computational platform. The authors like to acknowledge The
   World Academy of Science (TWAS) to purchase the High-Performance
   Computers for molecular dynamics simulation.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Ahmed S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1714482
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Bertoni M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09654-8
   Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Ciliberto G, 2020, DRUG DISCOV TODAY, V25, P946, DOI 10.1016/j.drudis.2020.04.005
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Jong S., 1990, MULTIVARIATE CALIBRA, V4, P504, DOI [10.1002/CEM.1180040607, DOI 10.1002/CEM.1180040607]
   Dickson CJ, 2014, J CHEM THEORY COMPUT, V10, P865, DOI 10.1021/ct4010307
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hicks C, 2009, CLIN INFECT DIS, V48, P931, DOI 10.1086/597290
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hodos RA, 2016, WIRES SYST BIOL MED, V8, P186, DOI 10.1002/wsbm.1337
   Hosseini FS, 2020, SIMEPREVIR POTENTIAL, DOI 10.20944/preprints202002.0438.v1
   Hu F., 2020, PREDICTION POTENTIAL
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Islam MJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52308-0
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Johansen LM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5597
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Junaid M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211935
   Khan AM, 2017, J MOL GRAPH MODEL, V77, P386, DOI 10.1016/j.jmgm.2017.09.010
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Mathias AA, 2010, CLIN PHARMACOL THER, V87, P322, DOI 10.1038/clpt.2009.228
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Neves BJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01275
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   R Core Team, 2014, R LANG ENV STAT COMP
   Razzaghi-Asl N, 2018, J MOL GRAPH MODEL, V83, P138, DOI 10.1016/j.jmgm.2018.05.010
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Rstudio Team, 2019, RSTUDIO INT DEV R, DOI [10.1007/978-3-642-20966-6, DOI 10.1007/978-3-642-20966-6]
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Shahinozzaman M, 2020, J BIOMOL STRUCT DYN, V38, P3514, DOI 10.1080/07391102.2019.1659855
   Sun W, 2016, DRUG DISCOV TODAY, V21, P1189, DOI 10.1016/j.drudis.2016.05.015
   Talwani R, 2013, DRUG TODAY, V49, P769, DOI 10.1358/dot.2013.49.12.2067249
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Zhang L., 2020, BINDING MECH REMDESI, DOI [10. 20944/preprints202003.0267.v1., DOI 10.20944/PREPRINTS202003.0267.V1]
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 60
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796804
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MR1FK
UT WOS:000553337100001
PM 32720571
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ferreira, A
   Oliveira-e-Silva, A
   Bettencourt, P
AF Ferreira, Antonio
   Oliveira-e-Silva, Antonio
   Bettencourt, Paulo
TI Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE chemotherapy; disease control; economic reason; public policy; SARS
   coronavirus; social science; virus classification
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHLOROQUINE; RISK
AB Hydroxychloroquine sulfate (HCQ) is being scrutinized for repositioning in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This antimalarial drug is also chronically used to treat patients with autoimmune diseases. By analyzing the Portuguese anonymized data on private and public based medical prescriptions we have identified all cases chronically receiving HCQ for the management of diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases. Additionally, we have detected all laboratory confirmed cases of SARS-CoV-2 infection and all laboratory confirmed negative cases in the Portuguese population (mandatorily registered in a centrally managed database). Cross linking the two sets of data has allowed us to compare the proportion of HCQ chronic treatment (at least 2 grams per month) in laboratory confirmed cases of SARS-CoV-2 infection with laboratory confirmed negative cases. Out of 26 815 SARS-CoV-2 positive patients, 77 (0.29%) were chronically treated with HCQ, while 1215 (0.36%) out of 333 489 negative patients were receiving it chronically (P = .04). After adjustment for age, sex, and chronic treatment with corticosteroids and/or immunosuppressants, the odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ has been 0.51 (0.37-0.70). Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection.
C1 [Ferreira, Antonio] Univ Porto, Hosp Rainha Santa Isabel, Ctr Hosp Univ Sao Joao, Fac Med,Unidade Invest Cardiovasc UniC, P-4200319 Porto, Portugal.
   [Oliveira-e-Silva, Antonio] Hosp Braga, Braga, Portugal.
   [Bettencourt, Paulo] Univ Porto, Hosp CUF, Unidade Invest Cardiovasc UniC, Fac Med, Porto, Portugal.
RP Ferreira, A (corresponding author), Univ Porto, Hosp Rainha Santa Isabel, Ctr Hosp Univ Sao Joao, Fac Med,Unidade Invest Cardiovasc UniC, P-4200319 Porto, Portugal.
EM aloboferreira@gmail.com
OI Ferreira, Antonio/0000-0002-1974-6684
CR Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Bouza E, 2001, INFECT DIS CLIN N AM, V15, P335, DOI 10.1016/S0891-5520(05)70149-5
   Branco JC, 2011, ACTA REUMATOL PORT, V36, P203
   Chatterjee P, 2020, INDIAN J MED RES, V151, P459, DOI 10.4103/ijmr.IJMR_2234_20
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Choo HMC, 2019, ADV RHEUMATOL, V59, DOI 10.1186/s42358-019-0055-y
   Costedoat-Chalumeau N, 2015, CLIN REV ALLERG IMMU, V49, P317, DOI 10.1007/s12016-015-8469-8
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gendelman O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102566
   Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   Herrinton LJ, 2016, J RHEUMATOL, V43, P1503, DOI 10.3899/jrheum.150671
   Iliopoulos AG, 1996, SEMIN ARTHRITIS RHEU, V25, P318, DOI 10.1016/S0049-0172(96)80018-7
   Kim SC, 2018, RHEUMATOLOGY, V57, pV26, DOI 10.1093/rheumatology/kex523
   Li TH, 2019, ANN RHEUM DIS, V78, P941, DOI 10.1136/annrheumdis-2018-214844
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Liu D, 2018, DRUG DES DEV THER, V12, P1685, DOI 10.2147/DDDT.S166893
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ruil-Irastorga G, 2009, ARTHRITIS RES THER, V11, pR109, DOI [10.1186/ar2764, DOI 10.1186/AR2764]
   Tripathy S, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106028
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 24
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26286
EA JUL 2020
PG 5
WC Virology
SC Virology
GA MQ4PT
UT WOS:000552877000001
PM 32644224
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Heimer, R
   McNeil, R
   Vlahov, D
AF Heimer, Robert
   McNeil, Ryan
   Vlahov, David
TI A Community Responds to the COVID-19 Pandemic: a Case Study in
   Protecting the Health and Human Rights of People Who Use Drugs
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE People who use drugs; COVID-19; Harm reduction; Substance abuse
   disorders; Treatment for opioid use disorders; Homelessness;
   Incarceration
AB Effective responses to a global pandemic require local action. In the face of a pandemic or similar emergencies, communities of people who use drugs face risks that result from their ongoing drug use, reduced ability to secure treatment for drug use and correlated maladies, lack of access to preventive hygiene, and the realities of homelessness, street-level policing, and criminal justice involvement. Herein, we document the efforts of a coalition of people who use drugs, advocates, service providers, and academics to implement solutions to reduce these risks at a municipal and state level focusing on New Haven and the State of Connecticut. This coalition identified the communities at risk: active users needing access to harm reduction services, persons in treatment needing access to their medications, the homeless and marginally housed needing improved hygiene, people engaged in sex work, and the incarcerated needing release from custody. The section describing each of the risks demonstrates how the coalition acted preemptively at early stages of the pandemic, ahead of official initiatives, to develop ameliorative risk reduction solutions. Outcomes discussed include instances in which obstacles were overcome or still remain.
C1 [Heimer, Robert] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA.
   [Heimer, Robert] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA.
   [McNeil, Ryan] Yale Univ, Sch Med, Dept Internal Med, Yale Program Addict Med, New Haven, CT 06510 USA.
   [Vlahov, David] Yale Univ, Sch Nursing, West Haven, CT USA.
RP Heimer, R (corresponding author), Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA.; Heimer, R (corresponding author), Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA.
EM robert.heimer@yale.edu
OI Heimer, Robert/0000-0003-0589-6697
CR Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   [Anonymous], 2020, TIM COVID 19 CIV SOC
   [Anonymous], 2020, BRAINERD DRUG REHAB
   [Anonymous], 2020, FAQS PROV METH BURP
   [Anonymous], 2020, GOV LAM SIGNS EX ORD
   [Anonymous], 2020, OP TREATM PROG OTP G
   [Anonymous], 2020, COVID 19 POT IMPL IN
   Balsamo M, 2020, TIME MAGAZINE
   Becker WC, 2020, ANN INTERN MED, V173, P59, DOI 10.7326/M20-1210
   Brechlin D, 2020, HARTFORD COURANT
   Breen T, 2020, NEW HAVEN INDEPENDEN
   Centers for Disease Control and Prevention, 2020, INT GUID HOM SERV PL
   Chappell B, 2020, NPR             0420
   Cunningham A, 2020, COVID 19 RESPITE FAC
   D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474
   Fiellin DA, 2006, NEW ENGL J MED, V355, P365, DOI 10.1056/NEJMoa055255
   Joudrey P, 2020, FORMATIVE EVALUATION
   KAPLAN EH, 1995, J ACQ IMMUN DEF SYND, V10, P175, DOI 10.1097/00042560-199510020-00010
   KAPLAN EH, 1994, AIDS, V8, P567, DOI 10.1097/00002030-199405000-00001
   Lyons K, 2020, THE CT MIRROR
   Madden LM, 2018, ADDICTION, V113, P1450, DOI 10.1111/add.14198
   McGuire D, 2020, CT PRISONS JAILS WER
   Moore KE, 2018, J ADDICT MED, V12, P156, DOI 10.1097/ADM.0000000000000381
   National Alliance to End Homelessness, 2017, STAT HOM AM
   National Survey of Drug Use and Health, 2019, NAT SURV DRUG US HLT
   Navarro M, 1991, NEW YORK TIMES
   New Haven Harm Reduction Working Group, 2020, COVID 19 GUID HARM R
   Newman K, 2020, US NEWS WORLD REPORT
   Reitman J, 2020, NY TIMES MAGAZINE
   The Justice Collaborative, 2020, IMP COVID 19 OUR CRI
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Walter S, 2020, DRUG REHAB SHUTTERS
   Wirebeck T, 2020, GREENSBORO NC NEWS R
NR 33
TC 3
Z9 3
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1099-3460
EI 1468-2869
J9 J URBAN HEALTH
JI J. Urban Health
PD AUG
PY 2020
VL 97
IS 4
BP 448
EP 456
DI 10.1007/s11524-020-00465-3
EA JUL 2020
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA MT1KJ
UT WOS:000552916300001
PM 32720298
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rahman, MS
   Hogue, MN
   Islam, MR
   Akter, S
   Rubayet-Ul-Alam, A
   Siddique, MA
   Saha, O
   Rahaman, MM
   Sultana, M
   Crandall, KA
   Hossain, MA
AF Rahman, M. Shaminur
   Hogue, M. Nazmul
   Islam, M. Rafiul
   Akter, Salma
   Rubayet-Ul-Alam, Asm
   Siddique, Mohammad Anwar
   Saha, Otun
   Rahaman, Md Mizanur
   Sultana, Munawar
   Crandall, Keith A.
   Hossain, M. Anwar
TI Epitope-based chimeric peptide vaccine design against S, M and E
   proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: an
   in silico approach
SO PEERJ
LA English
DT Article
DE SARS-CoV-2; Muti-epitope; Chimeric Peptide Vaccine; B-cell Epitope;
   T-cell Epitope
ID CD4(+) T-CELLS; WEB SERVER; CORONAVIRUS; DETERMINANTS; PREDICTION;
   ANTIBODIES; PNEUMONIA; RESPONSES; OUTBREAK; AFFINITY
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19), a public health emergency of international concerns declared by the World Health Organization (WHO). An immuno-informatics approach along with comparative genomics was applied to design a multi-epitope-based peptide vaccine against SARS-CoV-2 combining the antigenic epitopes of the S, M, and E proteins. The tertiary structure was predicted, refined and validated using advanced bioinformatics tools. The candidate vaccine showed an average of >= 90.0% world population coverage for different ethnic groups. Molecular docking and dynamics simulation of the chimeric vaccine with the immune receptors (TLR3 and TLR4) predicted efficient binding. Immune simulation predicted significant primary immune response with increased IgM and secondary immune response with high levels of both IgG1 and IgG2. It also increased the proliferation of T-helper cells and cytotoxic T-cells along with the increased IFN-gamma and IL-2 cytokines. The codon optimization and mRNA secondary structure prediction revealed that the chimera is suitable for high-level expression and cloning. Overall, the constructed recombinant chimeric vaccine candidate demonstrated significant potential and can be considered for clinical validation to fight against this global threat, COVID-19.
C1 [Rahman, M. Shaminur; Hogue, M. Nazmul; Islam, M. Rafiul; Akter, Salma; Siddique, Mohammad Anwar; Saha, Otun; Rahaman, Md Mizanur; Sultana, Munawar; Hossain, M. Anwar] Univ Dhaka, Dept Microbiol, Dhaka, Bangladesh.
   [Hogue, M. Nazmul] Bangabandhu Sheikh Mujibur Rahman Agr Univ, Dept Gynecol Obstet & Reprod Hlth, Gazipur, Bangladesh.
   [Akter, Salma] Jahangirnagar Univ, Dept Microbiol, Savar, Bangladesh.
   [Rubayet-Ul-Alam, Asm] Jashore Univ Sci & Technol, Dept Microbiol, Jashore, Bangladesh.
   [Crandall, Keith A.] George Washington Univ, Milken Inst Sch Publ Hlth, Computat Biol Inst, Washington, DC USA.
   [Hossain, M. Anwar] Jashore Univ Sci & Technol, Jashore, Bangladesh.
RP Rahaman, MM; Hossain, MA (corresponding author), Univ Dhaka, Dept Microbiol, Dhaka, Bangladesh.; Hossain, MA (corresponding author), Jashore Univ Sci & Technol, Jashore, Bangladesh.
EM razu002@du.ac.bd; hossaina@du.ac.bd
OI Hossain, M Anwar/0000-0001-9777-0332; Islam, Rafiul/0000-0002-0061-3910
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adhikari UK, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6718083
   Agadjanyan MG, 2005, J IMMUNOL, V174, P1580, DOI 10.4049/jimmunol.174.3.1580
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Akhand M. R. N., 2020, GENOME BASED EVOLUTI, DOI [10.1101/2020.04.15.036285, DOI 10.1101/2020.04.15.036285]
   Almofti YA, 2018, AM J MICROBIOLOGICAL, V6, P94, DOI DOI 10.12691/AJMR-6-3-5
   Badawi MM, 2016, AM J MICROBIOLOGICAL, V4, p101~121, DOI DOI 10.12691/AJMR-4-4-2
   Biswal JK, 2015, J VIROL METHODS, V215, P45, DOI 10.1016/j.jviromet.2015.02.008
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Dawood RM, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4571-5
   De Vries SJ, 2010, NAT PROTOC, V5, P883, DOI 10.1038/nprot.2010.32
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dudek NL, 2010, CURR PHARM DESIGN, V16, P3149
   Faure G, 2019, SOURCE CODE BIOL MED, V14, DOI 10.1186/s13029-019-0075-3
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grant Oliver C, 2020, bioRxiv, DOI 10.1101/2020.04.07.030445
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hoque MN, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00860
   Hoque MN, 2020, GENOMIC DIVERSITY EV, V2020, DOI [10.20944/preprints202004.0359.v1., DOI 10.20944/PREPRINTS202004.0359.V1]
   Huang H, 2007, IMMUNOLOGY, V120, P148, DOI 10.1111/j.1365-2567.2006.02452.x
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jaimes JA, 2020, ARXIV200206196
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kallberg M, 2014, METHODS MOL BIOL, V1137, P17, DOI 10.1007/978-1-4939-0366-5_2
   Kibria KMK, 2020, MULTIEPITOPE VACCINE, DOI [10.21203/rs.3.rs-21853/v1., DOI 10.21203/RS.3.RS-21853/V1]
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Kong L, 2015, ACTA CRYSTALLOGR D, V71, P2099, DOI 10.1107/S1399004715013917
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Lane R, 2020, LANCET, V395, P1247, DOI 10.1016/S0140-6736(20)30796-0
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li HL, 2015, J BIOSCIENCES, V40, P79, DOI 10.1007/s12038-014-9495-z
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pereira MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02754
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Sakib M. Sadman, 2014, Advances in Bioinformatics, V2014, P402492, DOI 10.1155/2014/402492
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shahabinezhad F., 2020, THERAPEUTIC APPROACH, DOI [10.20944/preprints202003.0206.v2, DOI 10.20944/PREPRINTS202003.0206.V2]
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Sheridan C., 2020, NATURE BIOTECHNOLOGY
   Shey RA, 2019, SCI REPORTS, V9, p1~18, DOI [10.1038/s41598-018-37186-2., DOI 10.1038/S41598-018-37186-2]
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Shi SQ, 2006, MOL IMMUNOL, V43, P1791, DOI 10.1016/j.molimm.2005.11.005
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   VanGunsteren WF, 1996, BIOMOLECULAR SIMULAT, V86, p1~1044
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Waugh DS, 2011, PROTEIN EXPRES PURIF, V80, P283, DOI 10.1016/j.pep.2011.08.005
   Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/NCHEMBIO.1403, 10.1038/nchembio.1403]
   World Health Organization (WHO), 2020, NOV COR 2019 NCOV SI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yazdani Z., 2020, DESIGN EFFICIENT MUL, DOI [10.1101/2020.04.20.051557., DOI 10.1101/2020.04.20.051557, 10.1101/2020.04.20.051557]
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Yong SEF, 2020, LANCET INFECT DIS, V20, P809, DOI 10.1016/S1473-3099(20)30273-5
   Zander RA, 2017, CELL REP, V21, P1839, DOI 10.1016/j.celrep.2017.10.077
   Zhou HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10897-4
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 74
TC 3
Z9 3
U1 6
U2 6
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUL 27
PY 2020
VL 8
AR e9572
DI 10.7717/peerj.9572
PG 30
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MQ0GD
UT WOS:000552574200002
PM 33194329
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Graham, SP
   McLean, RK
   Spencer, AJ
   Belij-Rammerstorfer, S
   Wright, D
   Ulaszewska, M
   Edwards, JC
   Hayes, JWP
   Martini, V
   Thakur, N
   Conceicao, C
   Dietrich, I
   Shelton, H
   Waters, R
   Ludi, A
   Wilsden, G
   Browning, C
   Bialy, D
   Bhat, S
   Stevenson-Leggett, P
   Hollinghurst, P
   Gilbride, C
   Pulido, D
   Moffat, K
   Sharpe, H
   Allen, E
   Mioulet, V
   Chiu, C
   Newman, J
   Asfor, AS
   Burman, A
   Crossley, S
   Huo, JD
   Owens, RJ
   Carroll, M
   Hammond, JA
   Tchilian, E
   Bailey, D
   Charleston, B
   Gilbert, SC
   Tuthill, TJ
   Lambe, T
AF Graham, Simon P.
   McLean, Rebecca K.
   Spencer, Alexandra J.
   Belij-Rammerstorfer, Sandra
   Wright, Daniel
   Ulaszewska, Marta
   Edwards, Jane C.
   Hayes, Jack W. P.
   Martini, Veronica
   Thakur, Nazia
   Conceicao, Carina
   Dietrich, Isabelle
   Shelton, Holly
   Waters, Ryan
   Ludi, Anna
   Wilsden, Ginette
   Browning, Clare
   Bialy, Dagmara
   Bhat, Sushant
   Stevenson-Leggett, Phoebe
   Hollinghurst, Philippa
   Gilbride, Ciaran
   Pulido, David
   Moffat, Katy
   Sharpe, Hannah
   Allen, Elizabeth
   Mioulet, Valerie
   Chiu, Chris
   Newman, Joseph
   Asfor, Amin S.
   Burman, Alison
   Crossley, Sylvia
   Huo, Jiandong
   Owens, Raymond J.
   Carroll, Miles
   Hammond, John A.
   Tchilian, Elma
   Bailey, Dalan
   Charleston, Bryan
   Gilbert, Sarah C.
   Tuthill, Tobias J.
   Lambe, Teresa
TI Evaluation of the immunogenicity of prime-boost vaccination with the
   replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1
   nCoV-19
SO NPJ VACCINES
LA English
DT Article
ID MODELS
AB Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
C1 [Graham, Simon P.; McLean, Rebecca K.; Edwards, Jane C.; Hayes, Jack W. P.; Martini, Veronica; Thakur, Nazia; Conceicao, Carina; Dietrich, Isabelle; Shelton, Holly; Waters, Ryan; Ludi, Anna; Wilsden, Ginette; Browning, Clare; Bialy, Dagmara; Bhat, Sushant; Stevenson-Leggett, Phoebe; Hollinghurst, Philippa; Moffat, Katy; Mioulet, Valerie; Chiu, Chris; Newman, Joseph; Asfor, Amin S.; Burman, Alison; Crossley, Sylvia; Hammond, John A.; Tchilian, Elma; Bailey, Dalan; Charleston, Bryan; Tuthill, Tobias J.] Pirbright Inst, Ash Rd, Pirbright GU24 0NF, England.
   [Spencer, Alexandra J.; Belij-Rammerstorfer, Sandra; Wright, Daniel; Ulaszewska, Marta; Gilbride, Ciaran; Pulido, David; Sharpe, Hannah; Allen, Elizabeth; Gilbert, Sarah C.; Lambe, Teresa] Univ Oxford, Jenner Inst, Old Rd Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
   [Hollinghurst, Philippa] Univ Surrey, Fac Hlth & Med Sci, Dept Microbial Sci, Guildford GU2 7XH, Surrey, England.
   [Huo, Jiandong; Owens, Raymond J.] Protein Prod UK, Res Complex Harwell, Didcot OX11 0FA, Oxon, England.
   [Huo, Jiandong; Owens, Raymond J.] Protein Prod UK, Rosalind Franklin Inst Rutherford Appleton Lab, Didcot OX11 0FA, Oxon, England.
   [Huo, Jiandong; Owens, Raymond J.] Univ Oxford, Henry Wellcome Bldg Genom Med, Div Struct Biol, Oxford OX3 7BN, England.
   [Carroll, Miles] Publ Hlth England, Manor Farm Rd, Salisbury SP4 0JG, Wilts, England.
RP Graham, SP (corresponding author), Pirbright Inst, Ash Rd, Pirbright GU24 0NF, England.; Lambe, T (corresponding author), Univ Oxford, Jenner Inst, Old Rd Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
EM simon.graham@pirbright.ac.uk; teresa.lambe@ndm.ox.ac.uk
RI Pulido-Gomez, David/P-9297-2015; Graham, Simon/C-8337-2011
OI Pulido-Gomez, David/0000-0003-3422-0434; McLean,
   Rebecca/0000-0002-4688-3019; Wright, Daniel/0000-0002-8114-1838; Sharpe,
   Hannah/0000-0002-1194-2429; Allen, Elizabeth/0000-0002-6406-4834;
   Newman, Joseph/0000-0003-0717-8672; Graham, Simon/0000-0003-4852-405X
FU UKRI Engineering and Physical Sciences Research Council
   (EPSRC)Engineering & Physical Sciences Research Council (EPSRC)
   [EP/R013756/1]; UKRI Biotechnology and Biological Sciences Research
   Council (BBSRC)Biotechnology and Biological Sciences Research Council
   (BBSRC) [BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/00007037,
   BBS/E/I/00007039]; Bill and Melinda Gates FoundationBill & Melinda Gates
   Foundation [OPP1215550]; NIAID Centers of Excellence for Influenza
   Research and Surveillance (CEIRS) [HHSN272201400008C]; EPSRCEngineering
   & Physical Sciences Research Council (EPSRC) [EP/S025243/1]; UK
   Department for Environment Food Rural AffairsDepartment for Environment,
   Food & Rural Affairs (DEFRA)
FX This study was supported by UKRI Engineering and Physical Sciences
   Research Council (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology
   and Biological Sciences Research Council (BBSRC) Institute Strategic
   Programme and Core Capability Grants to The Pirbright Institute
   (BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/00007037 and
   BBS/E/I/00007039), and the Bill and Melinda Gates Foundation supported
   'Pirbright Livestock Antibody Hub' (Grant No. OPP1215550). Development
   of SARS-CoV-2 reagents was partially supported by the NIAID Centers of
   Excellence for Influenza Research and Surveillance (CEIRS) contract
   HHSN272201400008C and EPSRC Grant No. EP/S025243/1 to the Rosalind
   Franklin Institute. A.L., G.W., C.B., A.B., and V.M. are supported by
   the UK Department for Environment Food & Rural Affairs. We thank V.
   Clark, H. Gray, and R. Snaith for animal husbandry and the Jenner
   Institute Vector Core Facility for assistance, and The Pirbright
   Institute Animal Services Team for animal care and provision of samples.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Arunkumar GA, 2019, VACCINE, V37, P5567, DOI 10.1016/j.vaccine.2019.07.095
   Braun J., 2020, PREPRINT
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Choe PG, 2020, EMERG INFECT DIS, V26, P2484, DOI 10.3201/eid2610.202211
   Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2
   Gerdts V, 2015, ILAR J, V56, P53, DOI 10.1093/ilar/ilv009
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Holzer B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02625
   Holzer B, 2018, J IMMUNOL, V200, P4068, DOI 10.4049/jimmunol.1800142
   McLean RK, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00016
   Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002
   Morgan SB, 2016, J IMMUNOL, V196, P5014, DOI 10.4049/jimmunol.1502632
   Munster VJ, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0029-1
   Pedrera M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010115
   Rivera-Hernandez T, 2014, DISCOV MED, V18, P313
   Suleman M, 2011, VACCINE, V29, P5892, DOI 10.1016/j.vaccine.2011.06.071
   van Doremalen N, 2020, CHADOX1 NCOV 19 VACC, DOI [10.1101/2020.05.13.093195v1, DOI 10.1101/2020.05.13.093195V1]
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   van Doremalen N, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007462
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhang YL, 2018, J MOL MED, V96, P249, DOI 10.1007/s00109-017-1614-5
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 26
TC 5
Z9 4
U1 10
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD JUL 27
PY 2020
VL 5
IS 1
AR 69
DI 10.1038/s41541-020-00221-3
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MQ2KV
UT WOS:000552727000001
PM 32793398
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Silva, RQ
   Armesto, S
   Vela, CG
   Fernandez, CN
   Gonzalez-Gay, MA
AF Queiro Silva, Ruben
   Armesto, Susana
   Gonzalez Vela, Carmen
   Naharro Fernandez, Cristina
   Angel Gonzalez-Gay, Miguel
TI COVID-19 patients with psoriasis and psoriatic arthritis on biologic
   immunosuppressant therapy vs apremilast in North Spain
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE apremilast; COVID-19; cytokines; psoriasis; psoriatic arthritis
AB Immunosuppressive and immunomodulatory treatments are critical for the management of inflammatory and autoimmune conditions such as psoriasis or psoriatic arthritis. Similar to those illnesses, the lung injury and acute respiratory distress shown in coronavirus disease 2019 (COVID-19) patients are the result of a disruption in the balance of pro- and anti-inflammatory cytokines. This hyperinflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), associated with the severity of the coronavirus disease, is called the cytokine storm. There is a growing concern regarding how patients on immunosuppressant biologic therapies might be at higher risk of being infected and whether they need to discontinue their treatment preemptively. Clinical data on COVID-19-infected patients with psoriasis or psoriatic arthritis are still scarce. Here, we presented seven cases of these type of patients. The patient infected with COVID-19 on apremilast and the one on apremilast with infected spouse showed the best safety profile and mildest symptoms. One of the secukinumab patients also presented a relatively good outcome. Infliximab patients and the one with serious comorbidities showed the worst outcome. Even though more clinical data are yet needed to draw strong conclusions, apremilast could be a safer alternative for dermatology and rheumatology patients in case of clinically important active infection.
C1 [Queiro Silva, Ruben] Hosp Univ Cent Asturias, Rheumatol Div, Oviedo, Spain.
   [Armesto, Susana; Naharro Fernandez, Cristina] Hosp Univ Marques de Valdecilla, Dept Dermatol, Ave Valdecilla S-N, Santander 39008, Spain.
   [Gonzalez Vela, Carmen] Hosp Univ Marques de Valdecilla, Dept Pathol, Santander, Spain.
   [Angel Gonzalez-Gay, Miguel] Hosp Univ Marques de Valdecilla, Dept Rheumatol, Santander, Spain.
RP Armesto, S (corresponding author), Hosp Univ Marques de Valdecilla, Dept Dermatol, Ave Valdecilla S-N, Santander 39008, Spain.
EM susana.armesto@scsalud.es
RI Queiro, Ruben/D-5358-2016; Armesto, Susana/P-5544-2019
OI Queiro, Ruben/0000-0002-8418-7145; Armesto, Susana/0000-0002-8081-0606
CR Abdelmaksoud A, 2020, DERMATOL THER, VXXX
   Armesto S, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13618
   Bashiri A, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1839877, 10.1080/09546634.2020.1742438]
   Conforti C, 2020, DERMATOL THER, VXXX
   Dauden E, 2020, J AM ACAD DERMATOL, V83, P139, DOI 10.1016/j.jaad.2020.03.033
   Dommasch ED, 2019, JAMA DERMATOL, V155, P865, DOI 10.1001/jamadermatol.2019.1723
   Fougerousse AC, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16761
   Kutlu O, 2020, DERMATOL THER, VXXX
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Melis D, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13722
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Ricardo JW, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13687
   Sbidian E, 2019, BRIT J DERMATOL, DOI 10.1111/bjd.18203
   Schafer PH, 2014, CELL SIGNAL, V26, P2016, DOI 10.1016/j.cellsig.2014.05.014
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Wollina U, 2020, DERMATOL THER, VXXX
   Zheng Y, 2020, J EUR ACAD DERMATOL, V34, pE210, DOI 10.1111/jdv.16390
NR 17
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e13961
DI 10.1111/dth.13961
EA JUL 2020
PG 4
WC Dermatology
SC Dermatology
GA MQ0BU
UT WOS:000552562400001
PM 32618402
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Datta, N
   Derenne, J
   Sanders, M
   Lock, JD
AF Datta, Nandini
   Derenne, Jennifer
   Sanders, Mary
   Lock, James D.
TI Telehealth transition in a comprehensive care unit for eating disorders:
   Challenges andlong-termbenefits
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE adolescent; anorexia nervosa; COVID-19; eating disorders; inpatients;
   psychiatry; telehealth; telesupervision
ID COGNITIVE REMEDIATION THERAPY
AB The 2019 novel coronavirus disease (COVID-19) pandemic has forced many eating disorder medical stabilization units to consider adjustments that uphold both the quality of care delivered to patients while also observing social distancing public health directives for patients and staff. To date, inpatient facilities for eating disorders (both medical stabilization units and higher level of care facilities) have not needed to consider how to translate services to electronic platforms, given that most of these programs have in-person staff. We outline our transition to telehealth broadly, emphasizing some unexpected benefits of using telehealth services that we plan on integrating into our work-flow post COVID-19. These may be useful for other higher level of care eating disorder programs, including medical stabilization units, residential, partial hospitalization, and intensive outpatient programs. We also highlight aspects of transition that have been more challenging for this particular patient population, warranting the need for in-person services.
C1 [Datta, Nandini; Derenne, Jennifer; Sanders, Mary; Lock, James D.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, 401 Quarry Rd, Stanford, CA 94305 USA.
RP Datta, N (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, 401 Quarry Rd, Stanford, CA 94305 USA.
EM nandinid@stanford.edu
CR Anderson KE, 2017, INT J EAT DISORDER, V50, P1235, DOI 10.1002/eat.22759
   Cooper M., 2020, EATING DISORDERS COV, DOI [10.31234/osf.io/x7hea, DOI 10.31234/OSF.IO/X7HEA]
   Davis C, 2020, J ADOLESCENT HEALTH, V67, P131, DOI 10.1016/j.jadohealth.2020.03.037
   Dimitropoulos G, 2017, J FAM THER, V39, P537, DOI 10.1111/1467-6427.12086
   Fernandez-Aranda F, 2020, EUR EAT DISORD REV, V28, P239, DOI 10.1002/erv.2738
   Jordan SE, 2019, TRAIN EDUC PROF PSYC, V13, P323, DOI 10.1037/tep0000245
   Kazdin AE, 2017, INT J EAT DISORDER, V50, P170, DOI 10.1002/eat.22670
   Lock J, 2013, INT J EAT DISORDER, V46, P567, DOI 10.1002/eat.22134
   Lock J, 2018, CAN J SCHOLARSH TEA, V9
   Matheson BE, 2020, INT J EAT DISORDER, V53, P1142, DOI 10.1002/eat.23326
   Morris J, 2007, BMJ-BRIT MED J, V334, P894, DOI 10.1136/bmj.39171.616840.BE
   Myers K, 2017, TELEMED E-HEALTH, V23, P779, DOI 10.1089/tmj.2017.0177
   Taylor CB, 2020, INT J EAT DISORDER, V53, P1155, DOI 10.1002/eat.23300
   Tchanturia K, 2011, CURR TOP BEHAV NEURO, V6, P269, DOI 10.1007/7854_2010_90
   Touyz S, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-00295-3
   Waller G, 2020, INT J EAT DISORDER, V53, P1132, DOI 10.1002/eat.23289
   Yalom I. D., 1988, INPATIENT GROUP PSYC
   Yalom I. D., 1995, THEORY PRACTICE GROU
NR 18
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
EI 1098-108X
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD NOV
PY 2020
VL 53
IS 11
BP 1774
EP 1779
DI 10.1002/eat.23348
EA JUL 2020
PG 6
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA OQ2UO
UT WOS:000552334300001
PM 32715512
DA 2021-01-01
ER

PT J
AU Tay, EL
   Hayashida, K
   Chen, M
   Yin, WH
   Park, DW
   Seth, A
   Kao, HL
   Lin, MS
   Ho, KW
   Buddhari, W
   Chandavimol, M
   Posas, FE
   Nguyen, QN
   Kong, W
   Rosli, MA
   Hon, J
   Firman, D
   Lee, M
AF Tay, Edgar L.
   Hayashida, Kentaro
   Chen, Mao
   Yin, Wei-Hsien
   Park, Duk-Woo
   Seth, Ashok
   Kao, Hsien-Li
   Lin, Mao-Shin
   Ho, Kay-Woon
   Buddhari, Wacin
   Chandavimol, Mann
   Posas, Fabio-Enriques
   Nguyen, Quang N.
   Kong, William
   Rosli, M. A.
   Hon, Jimmy
   Firman, Doni
   Lee, Michael
TI Transcatheter aortic valve implantation during the COVID-19 pandemic:
   Clinical expert opinion and consensus statement for Asia
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Article
DE COVID 19; TAVI; TAVR; valve repair; replacement
AB Objectives The impact of the COVID-19 pandemic on the treatment of patient with aortic valve stenosis is unknown and there is uncertainty on the optimal strategies in managing these patients. Methods This study is supported and endorsed by the Asia Pacific Society of Interventional Cardiology. Due to the inability to have face to face discussions during the pandemic, an online survey was performed by inviting key opinion leaders (cardiac surgeon/interventional cardiologist/echocardiologist) in the field of transcatheter aortic valve implantation (TAVI) in Asia to participate. The answers to a series of questions pertaining to the impact of COVID-19 on TAVI were collected and analyzed. These led subsequently to an expert consensus recommendation on the conduct of TAVI during the pandemic. Results The COVID-19 pandemic had resulted in a 25% (10-80) reduction of case volume and 53% of operators required triaging to manage their patients with severe aortic stenosis. The two most important parameters used to triage were symptoms and valve area. Periprocedural changes included the introduction of teleconsultation, preprocedure COVID-19 testing, optimization of protests, and catheterization laboratory set up. In addition, length of stay was reduced from a mean of 4.4 to 4 days. Conclusion The COVID-19 pandemic has impacted on the delivery of TAVI services to patients in Asia. This expert recommendation on best practices may be a useful guide to help TAVI teams during this period until a COVID-19 vaccine becomes widely available.
C1 [Tay, Edgar L.; Kong, William; Hon, Jimmy] Natl Univ Heart Ctr, Dept Cardiol & Cardiothorac & Vasc Surg, Singapore, Singapore.
   [Hayashida, Kentaro] Keio Univ, Cardiac Dept, Tokyo, Japan.
   [Chen, Mao] Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu, Peoples R China.
   [Yin, Wei-Hsien] Cheng Hsin Gen Hosp, Cardiac Dept, Taipei, Taiwan.
   [Park, Duk-Woo] Asan Med Ctr, Dept Cardiol, Seoul, South Korea.
   [Seth, Ashok] Fortis Escorts Heart Inst, Dept Cardiol, New Delhi, India.
   [Kao, Hsien-Li; Lin, Mao-Shin] Natl Taiwan Univ Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan.
   [Ho, Kay-Woon] Natl Heart Ctr, Dept Cardiol, Singapore, Singapore.
   [Buddhari, Wacin] King Chulalongkorn Mem Hosp, Cardiac Ctr, Dept Med, Div Cardiol, Bangkok, Thailand.
   [Chandavimol, Mann] Ramathibodi Hosp, Cardiac Dept, Bangkok, Thailand.
   [Posas, Fabio-Enriques] St Lukes Med Ctr, Manila, Philippines.
   [Nguyen, Quang N.] Hanoi Med Univ, Vietnam Natl Heart Inst, Dept Cardiol, Hanoi, Vietnam.
   [Rosli, M. A.] Cardiac Vasc Sentral Kuala Lumpur, Kuala Lumpur, Malaysia.
   [Firman, Doni] Univ Indonesia, Fac Med, Dept Cardiol & Vasc Med, Jakarta, Indonesia.
   [Lee, Michael] Queen Elizabeth Hosp, Dept Cardiol, Kowloon, Hong Kong, Peoples R China.
RP Tay, EL (corresponding author), Natl Univ Heart Ctr Singapore, 1E Kent Ridge Rd, Singapore 119228, Singapore.
EM edgartay1@gmail.com
CR Elbaz-Greener G, 2018, CIRCULATION, V138, P483, DOI 10.1161/CIRCULATIONAHA.117.033432
   Shah PB, 2020, CATHETER CARDIOVASC
   Wood DA, 2020, CAN J CARDIOL, V36, P780, DOI 10.1016/j.cjca.2020.03.027
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 4
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
EI 1540-8191
J9 J CARDIAC SURG
JI J. Card. Surg.
PD SEP
PY 2020
VL 35
IS 9
BP 2142
EP 2146
DI 10.1111/jocs.14722
EA JUL 2020
PG 5
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA NC6DI
UT WOS:000552628700001
PM 32720374
OA Bronze
DA 2021-01-01
ER

PT J
AU Deng, KB
   Li, H
   Ma, X
   Yu, BB
   Yi, XL
   Chen, Y
   Tian, B
   Zhang, Q
AF Deng, Kebin
   Li, Hui
   Ma, Xin
   Yu, Bianbian
   Yi, Xinlin
   Chen, Ying
   Tian, Bo
   Zhang, Qing
TI Analysis of the positive rate of 4254 cases of COVID-19 nucleic acid
   tests in different aites in Wuhan, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; novel coronavirus pneumonia; nucleic acid test; positive rate
ID CORONAVIRUS
AB There's an outbreak of coronavirus diesase 2019 (COVID-19) since December 2019, first in Wuhan. It has caused huge medical challenges to Hubei Province with currently more than 67 thousand confirmed cases till 8th March 2020. Identification, there is no clinically effective drug. Isolation and masks are essential to limit human-to-human transmission initially. The nucleic acid test (NAT) of COVID-19 currently was the most reliable established laboratory diagnosis method in clinical. From 8th February to 7th March 2020, 4254 cases were collected for analysis at six nucleic acid collection sites in the community medical team of Hubei Provincial Hospital of Traditional Chinese Medicine, which cover almost all groups who need NAT in Wuhan. Distribution of positive rates in different sites by genders, ages, or occupations were compared. The positive rates of different sites from high to low were: hospital wards (24.71%) > fever clinics (16.57%) > nursing homes (5.51%) > isolation hotels (5.30%) > rehabilitation stations (1.36%) >close contact sites (0.17%). The confirmed patients in isolation hotels, hospital ward, and fever clinical were mainly middle-aged and elderly, and most of them were women. The positive rate in isolation hotels and fever clinics gradually decreased over time. There were no significant differences between genders among those six nucleic acid collection sites (P < .05). The hospital wards have the highest positive rate; however, close contact sites have lowest one. Patients who are discharged from hospitals may still have potential risks. Middle-aged and older people remain the focus of epidemic prevention and control.
C1 [Deng, Kebin; Li, Hui; Ma, Xin; Yu, Bianbian; Yi, Xinlin; Chen, Ying; Tian, Bo] Hubei Univ Tradit Chinese Med, Hubei Inst Tradit Chinese Med, Affiliated Hosp, Dept Otorhinolaryngol,Hubei Prov Hosp Tradit Chin, Wuhan 430074, Hubei, Peoples R China.
   [Zhang, Qing] Hubei Univ Tradit Chinese Med, Hubei Inst Tradit Chinese Med, Affiliated Hosp, COVID 19 Rehabil Clin,Hubei Prov Hosp Tradit Chin, Wuhan, Hubei, Peoples R China.
RP Li, H (corresponding author), Hubei Univ Tradit Chinese Med, Hubei Inst Tradit Chinese Med, Affiliated Hosp, Dept Otorhinolaryngol,Hubei Prov Hosp Tradit Chin, Wuhan 430074, Hubei, Peoples R China.
EM lh_sunshine@126.com
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2020YFC0845000]
FX Ministry of Science and Technology of the People's Republic of China,
   Grant/Award Number: 2020YFC0845000
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   General Office of the National Health and Health Commission, 2020, NOT GEN OFF NAT HLTH, P204
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HuiDS IAE, 2020, INT J INFECT DIS, V91, P264, DOI [10.1016/j.ijid.2020.01.009, DOI 10.1016/J.IJID.2020.01.009]
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Liu Yanbin, 2020, CHINESE RESP CRIT CA, V19, P1
   Long X, 2020, SHANGHAI PREV MED, V32, P57
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   The General Office of the National Health Commission, 2020, ISS PNEUM TREATM PRO
   The General Office of the National Health Commission, 2020, NOT ISS NEW COR INF
   The General Office of the National Health Commission, 2020, NOT ISS NEW COR PNEU
   The General Office of the National Health Commission the National Science and Technology Education Office, 2020, NOT ISS NEW COR LAB
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26323
EA JUL 2020
PG 8
WC Virology
SC Virology
GA MQ0YC
UT WOS:000552622800001
PM 32691919
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fernandez-Ruiz, M
   Lopez-Medrano, F
   Asin, MAPJ
   de la Calle, GM
   Bueno, H
   Caro-Teller, JM
   Catalan, M
   de la Calle, C
   Garcia-Garcia, R
   Gomez, C
   Laguna-Goya, R
   Lizasoain, M
   Martinez-Lopez, J
   Origuen, J
   Pablos, JL
   Ripoll, M
   San Juan, R
   Trujillo, H
   Lumbreras, C
   Aguado, JM
AF Fernandez-Ruiz, Mario
   Lopez-Medrano, Francisco
   Perez-Jacoiste Asin, Maria Asuncion
   Maestro de la Calle, Guillermo
   Bueno, Hector
   Manuel Caro-Teller, Jose
   Catalan, Mercedes
   de la Calle, Cristina
   Garcia-Garcia, Rocio
   Gomez, Carlos
   Laguna-Goya, Rocio
   Lizasoain, Manuel
   Martinez-Lopez, Joaquin
   Origuen, Julia
   Luis Pablos, Jose
   Ripoll, Mar
   San Juan, Rafael
   Trujillo, Hernando
   Lumbreras, Carlos
   Maria Aguado, Jose
TI Tocilizumab for the treatment of adult patients with severe COVID-19
   pneumonia: A single-center cohort study
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; immunomodulation; pneumonia; SARS-CoV-2; tocilizumab
ID LACTATE-DEHYDROGENASE; RESPONSES; IMMUNE
AB Coronavirus disease 2019 (COVID-19) can lead to a massive cytokine release. The use of the anti-interleukin-6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of >= 2 points on the 6-point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon-beta (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94;P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99;P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO(2)ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia.
C1 [Fernandez-Ruiz, Mario; Lopez-Medrano, Francisco; Lizasoain, Manuel; San Juan, Rafael; Maria Aguado, Jose] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Unit Infect Dis, Madrid, Spain.
   [Perez-Jacoiste Asin, Maria Asuncion; Maestro de la Calle, Guillermo; de la Calle, Cristina; Ripoll, Mar; Lumbreras, Carlos] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Internal Med, Madrid, Spain.
   [Bueno, Hector] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Cardiol, Madrid, Spain.
   [Manuel Caro-Teller, Jose] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Pharm, Madrid, Spain.
   [Catalan, Mercedes] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Intens Care Med, Madrid, Spain.
   [Garcia-Garcia, Rocio] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Pneumol, Madrid, Spain.
   [Gomez, Carlos] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Med Oncol, Madrid, Spain.
   [Laguna-Goya, Rocio] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Immunol, Madrid, Spain.
   [Martinez-Lopez, Joaquin] Univ Complutense, Ctr Nacl Invest Oncol CNIO, Dept Hematol, Hosp Univ 12 Octubre,Inst Invest Sanitaria Hosp 1, Madrid, Spain.
   [Origuen, Julia] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Emergency Med, Madrid, Spain.
   [Luis Pablos, Jose] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Rheumatol, Madrid, Spain.
   [Trujillo, Hernando] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Nephrol, Madrid, Spain.
RP Aguado, JM (corresponding author), Hosp Univ 12 Octubre, Ctr Actividades Ambulatorias, Unit Infect Dis, 2a Planta,Bloque D Avda Cordoba S-N, Madrid 28041, Spain.
EM jaguadog1@gmail.com
RI Bueno, Hector/I-3910-2015
OI Bueno, Hector/0000-0003-0277-7596; Lumbreras,
   Carlos/0000-0003-4748-8288; Fernandez-Ruiz, Mario/0000-0002-0315-8001;
   carretero, octavio/0000-0003-1839-3853; Laguna Goya,
   Rocio/0000-0003-4265-8567; Lopez-Medrano, Francisco/0000-0001-5333-7529;
   Martinez-Lopez, Joaquin/0000-0001-7908-0063
FU Instituto de Salud Carlos III, Spanish Ministry of Science and
   InnovationInstituto de Salud Carlos IIISpanish Government [COVID-19,
   COV20/00181]
FX Instituto de Salud Carlos III, Spanish Ministry of Science and
   Innovation, Grant/Award Number: COVID-19 Research Call COV20/00181
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Recasens BB, 2020, EUR J NEUROL, V27, pE40, DOI 10.1111/ene.14265
   Bhimraj A, INFECT DIS SOC AM GU
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Drent M, 1996, EUR RESPIR J, V9, P1736, DOI 10.1183/09031936.96.09081736
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gritti G, 2020, USE SILTUXIMAB PATIE, V04, P1912, DOI [10. 1101/2020.04.01.20048561., DOI 10.1101/2020.04.01.20048561, 10.1101/2020.04.01.20048561]
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1789, DOI 10.1002/jmv.25900
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Ministerio de Sanidad, 2020, DOC TECN MAN CLIN PA
   Morrison AR, 2020, J MED VIROL, V92, P1791, DOI 10.1002/jmv.25907
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   SMITH RL, 1988, CHEST, V93, P987, DOI 10.1378/chest.93.5.987
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   ZAYET S, 2020, MED MALADIES INFECT, DOI DOI 10.1016/J.MEDMAL.2020.05.001
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26308
EA JUL 2020
PG 12
WC Virology
SC Virology
GA MQ0YS
UT WOS:000552624500001
PM 32672860
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Manganotti, P
   Bellavita, G
   D'Acunto, L
   Tommasini, V
   Fabris, M
   Sartori, A
   Bonzi, L
   Stella, AB
   Pesavento, V
AF Manganotti, Paolo
   Bellavita, Giulia
   D'Acunto, Laura
   Tommasini, Valentina
   Fabris, Martina
   Sartori, Arianna
   Bonzi, Lucia
   Stella, Alex Buoite
   Pesavento, Valentina
TI Clinical neurophysiology and cerebrospinal liquor analysis to detect
   Guillain-Barre syndrome and polyneuritis cranialis in COVID-19 patients:
   A case series
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; cranial polyneuritis; immunoglobulin; interleukins;
   polyradiculonevritis
ID ZIKA VIRUS-INFECTION; MILLER-FISHER; COMPLICATIONS
AB We report a case series of five patients affected by SARS-CoV-2 who developed neurological symptoms, mainly expressing as polyradiculoneuritis and cranial polyneuritis in the 2 months of COVID-19 pandemic in a city in the northeast of Italy. A diagnosis of Guillain-Barre syndrome was made on the basis of clinical presentation, cerebrospinal fluid analysis, and electroneurography. In four of them, the therapeutic approach included the administration of intravenous immunoglobulin (0.4 g/kg for 5 days), which resulted in the improvement of neurological symptoms. Clinical neurophysiology revealed the presence of conduction block, absence of F waves, and in two cases a significant decrease in amplitude of compound motor action potential compound muscle action potential (cMAP). Four patients presented a mild facial nerve involvement limited to the muscles of the lower face, with sparing of the forehead muscles associated to ageusia. In one patient, taste assessment showed right-sided ageusia of the tongue, ipsilateral to the mild facial palsy. In three patients we observed albuminocytological dissociation in the cerebrospinal fluid, and notably, we found an increase of inflammatory mediators such as the interleukin-8. Peripheral nervous system involvement after infection with COVID-19 is possible and may include several signs that may be successfully treated with immunoglobulin therapy.
C1 [Manganotti, Paolo; Bellavita, Giulia; D'Acunto, Laura; Tommasini, Valentina; Sartori, Arianna; Stella, Alex Buoite] Univ Trieste, Cattinara Univ Hosp ASUGI, Dept Med Surg & Hlth Sci, Clin Unit Neurol, Str Fiume 447, I-34149 Trieste, Italy.
   [Fabris, Martina] Azienda Sanitaria Univ Friuli Cent, Lab Malattie Autoimmuni, SOC Ist Patol Clin, Udine, Italy.
   [Bonzi, Lucia; Pesavento, Valentina] Maggiore City Hosp, Dept Med Surg & Hlth Sci, Rehabil Unit, Trieste, Italy.
RP Manganotti, P (corresponding author), Univ Trieste, Cattinara Univ Hosp ASUGI, Dept Med Surg & Hlth Sci, Clin Unit Neurol, Str Fiume 447, I-34149 Trieste, Italy.; Manganotti, P (corresponding author), Univ Trieste, Cattinara Univ Hosp ASUGI, Dept Med Surg & Hlth Sci, Clin Unit Neurol,Neurol, Str Fiume 447, I-34149 Trieste, Italy.; Manganotti, P (corresponding author), Univ Trieste, Cattinara Univ Hosp ASUGI, Dept Med Surg & Hlth Sci, Stroke Unit,Clin Unit Neurol, Str Fiume 447, I-34149 Trieste, Italy.
EM pmanganotti@units.it
RI Stella, Alex Buoite/F-1788-2016
OI Stella, Alex Buoite/0000-0002-4871-7022
CR Ahmad I, 2020, J CLIN NEUROSCI, V77, P8, DOI 10.1016/j.jocn.2020.05.017
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Breville G, 2019, EUR CYTOKINE NETW, V30, P130, DOI 10.1684/ecn.2019.0436
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kaida K, 2006, J NEUROL NEUROSUR PS, V77, P1043, DOI 10.1136/jnnp.2006.087940
   Kassardjian CD, 2020, MUSCLE NERVE, V62, P30, DOI 10.1002/mus.26891
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Lehmann HC, 2010, LANCET INFECT DIS, V10, P643, DOI 10.1016/S1473-3099(10)70140-7
   Manganotti P, 2020, J NEUROVIROL, V26, P605, DOI 10.1007/s13365-020-00858-9
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246
   POLO A, 1992, J NEUROL NEUROSUR PS, V55, P398, DOI 10.1136/jnnp.55.5.398
   Pusch E, 2018, ALLERGO J, V27, P28, DOI [10.1007/s40629-018-0056-0, 10.1007/s15007-018-1580-4]
   Sainaghi PP, 2010, CYTOKINE, V51, P138, DOI 10.1016/j.cyto.2010.05.005
   Sekiguchi Y, 2016, EUR J NEUROL, V23, P1058, DOI 10.1111/ene.12983
   Sellers SA, 2017, INFLUENZA OTHER RESP, V11, P372, DOI 10.1111/irv.12470
   Sharma K, 2019, SAGE OPEN MED CASE R, V7, DOI 10.1177/2050313X19838750
   Uncini A, 2017, J NEUROL NEUROSUR PS, V88, P266, DOI 10.1136/jnnp-2016-314310
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Wattanasit P, 2020, CASE REP NEUROL, V12, P92, DOI 10.1159/000506191
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
NR 23
TC 6
Z9 6
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26289
EA JUL 2020
PG 9
WC Virology
SC Virology
GA MQ1EK
UT WOS:000552639500001
PM 32662899
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mohapatra, RK
   Pintilie, L
   Kandi, V
   Sarangi, AK
   Das, D
   Sahu, R
   Perekhoda, L
AF Mohapatra, Ranjan K.
   Pintilie, Lucia
   Kandi, Venkataramana
   Sarangi, Ashish K.
   Das, Debadutta
   Sahu, Raghaba
   Perekhoda, Lina
TI The recent challenges of highly contagious COVID-19, causing respiratory
   infections: Symptoms, diagnosis, transmission, possible vaccines, animal
   models, and immunotherapy
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE COVID-19 pneumonia; diagnosis; entry mechanism; possible vaccines;
   animal models and immunotherapy; symptoms; transmission
ID MERS-COV INFECTION; SYNDROME-CORONAVIRUS; DROMEDARY CAMELS;
   SARS-CORONAVIRUS; GLOBAL HEALTH; SPIKE PROTEIN; OUTBREAK; VIRUS;
   PNEUMONIA; 2019-NCOV
AB COVID-19 is highly contagious pathogenic viral infection initiated from Wuhan seafood wholesale market of China on December 2019 and spread rapidly around the whole world due to onward transmission. This recent outbreak of novel coronavirus (CoV) was believed to be originated from bats and causing respiratory infections such as common cold, dry cough, fever, headache, dyspnea, pneumonia, and finallySevere Acute Respiratory Syndrome(SARS) in humans. For this widespread zoonotic virus, human-to-human transmission has resulted in nearly 83 lakh cases in 213 countries and territories with 4,50,686 deaths as on 19 June 2020. This review presents a report on the origin, transmission, symptoms, diagnosis, possible vaccines, animal models, and immunotherapy for this novel virus and will provide ample references for the researchers toward the ongoing development of therapeutic agents and vaccines and also preventing the spread of this disease.
C1 [Mohapatra, Ranjan K.] Govt Coll Engn, Dept Chem, Keonjhar, Odisha, India.
   [Pintilie, Lucia] Natl Inst Chem & Pharmaceut Res & Dev, Dept Synth Bioact Subst & Pharmaceut Technol, Bucharest, Romania.
   [Kandi, Venkataramana] Pratima Inst Med Sci, Dept Microbiol, Hyderabad, India.
   [Sarangi, Ashish K.] Centurion Univ Technol & Management, Sch Appl Sci, Dept Chem, R Sitapur, Odisha, India.
   [Das, Debadutta] Sukanti Degree Coll, Dept Chem, Subarnapur, Odisha, India.
   [Sahu, Raghaba] Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   [Perekhoda, Lina] Natl Univ Pharm, Dept Med Chem, Kharkiv, Ukraine.
RP Mohapatra, RK (corresponding author), Govt Coll Engn, Dept Chem, Keonjhar, Odisha, India.
EM ranjank_mohapatra@yahoo.com
RI Mohapatra, Ranjan Kumar/S-6006-2019; Kandi, Venkataramana/A-6331-2010;
   Perekhoda, Lina/O-8919-2018; Pintilie, Lucia/B-3962-2017; Sarangi,
   Ashish Kumar/N-7802-2013
OI Kandi, Venkataramana/0000-0002-7197-0448; Perekhoda,
   Lina/0000-0002-8498-331X; Pintilie, Lucia/0000-0002-1036-7653; Sarangi,
   Ashish Kumar/0000-0002-5602-4736
CR AFCD, 2020, BLOOD TEST RES PET D
   AFCD, 2020, LOW LEV INF COVID 19
   AFCD, 2020, PET DOG TESTS POS CO
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Al-Tawfiq JA, 2013, J INFECT PUBLIC HEAL, V6, P319, DOI 10.1016/j.jiph.2013.06.001
   Alharbi NK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52730-4
   Almendros A, 2020, VET REC, V186, P419, DOI [10.1136/vr.m1322, 10.1136/vr.m1302, 10.1136/vr.m1194]
   American Veterinary Medical Association, 2020, SARS COV 2 AN INCL P
   AminJafari A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106455
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, XINHUANET
   ASCIA, 2020, POS STAT SPEC TREATM
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Azhar EI, 2014, MBIO, V5, DOI 10.1128/mBio.01450-14
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bardaweel SK, 2021, ACTA PHARMACEUT, V71, P175, DOI 10.2478/acph-2021-0013
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Bauerfeind R, 2016, ZOONOSES INFECT DISE
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4
   Burki TK, 2020, LANCET RESP MED, V8, pE63, DOI 10.1016/S2213-2600(20)30247-2
   Callaway E, 2020, NATURE, V579, P12, DOI DOI 10.1038/d41586-020-00551-1
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Centers for Disease Control and Prevention, 2016, MIDDL E RESP SYNDR M
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan RWY, 2014, LANCET RESP MED, V2, P813, DOI 10.1016/S2213-2600(14)70158-4
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen H, 2020, SUSCEPTIBILITY FERRE, p20200330015347, DOI [10.1101/2020.03.30.015347, DOI 10.1101/2020.03.30.015347]
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Conzade R, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080425
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dwosh HA, 2003, CAN MED ASSOC J, V168, P1415
   El-Duah P., 2019, TROP MED INFECT DIS, V4, P34
   Falzarano D, 2017, ONE HEALTH-AMSTERDAM, V3, P41, DOI 10.1016/j.onehlt.2017.03.003
   Farag E, 2019, EMERG INFECT DIS, V25, P2333, DOI 10.3201/eid2512.190882
   Finlay BB, 2004, NAT REV MICROBIOL, V2, P497, DOI 10.1038/nrmicro908
   Fisher D, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01533-w
   Franquet T, 2011, RADIOLOGY, V260, P18, DOI 10.1148/radiol.11092149
   Gallego V, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101604
   General Office of National Health Committee, 2020, NOT ISS PROGR DIAGN
   GHKSAR, 2020, PET CAT TESTS POS CO
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   GISAID: Global Initiative on Sharing All Influenza Data, 2020, PHYLO SARS BET COR I
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gross S, 2020, J MOL CELL CARDIOL, V144, P47, DOI 10.1016/j.yjmcc.2020.04.031
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Harypursat V, 2020, CHINESE MED J-PEKING, V133, P1118, DOI 10.1097/CM9.0000000000000760
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Hu D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007836
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YH, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101606
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jarvis C., 2020, MAR 16 2020 WHICH SP
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jung SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020523
   Jutel M, 2013, ALLERGOL INT, V62, P425, DOI 10.2332/allergolint.13-RAI-0608
   KANDEIL A, 2019, VIRUSES-BASEL, V11, DOI DOI 10.3390/V11080717
   Kato H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223684
   Kim H, 2020, EUR RADIOL, V30, P3266, DOI 10.1007/s00330-020-06748-2
   Kim YC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0188-3
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Klimek L, 2020, ALLERGY, V75, P1546, DOI 10.1111/all.14336
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00898-19
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee KS, 2020, KOREAN J RADIOL, V21, P257, DOI 10.3348/kjr.2020.0096
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li XD, 2020, VET REC, V186, P457, DOI 10.1136/vr.m1455
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Ling L, 2020, ANAESTH CRIT CARE PA, V39, P163, DOI 10.1016/j.accpm.2020.02.002
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu T., 2020, SSRN ELECT J, DOI [DOI 10.2139/SSRN.3548761, 10.2139/ssrn.3548761]
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Loczechin A, 2019, ACS APPL MATER INTER, V11, P42964, DOI 10.1021/acsami.9b15032
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M408
   Malainou C, 2019, INTERNIST, V60, P1127, DOI 10.1007/s00108-019-00670-6
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   McIntosh K., 2017, MIDDLE E RESP SYNDRO
   Menachery VD, 2018, P NATL ACAD SCI USA, V115, pE1012, DOI 10.1073/pnas.1706928115
   Menni C, 2020, LANCET, V395, pE107, DOI 10.1016/S0140-6736(20)31281-2
   Meyer B, 2015, EMERG INFECT DIS, V21, P181, DOI 10.3201/eid2101.141342
   Miguel E, 2017, EUROSURVEILLANCE, V22, P15, DOI 10.2807/1560-7917.ES.2017.22.13.30498
   Mobaraki K, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3987-2
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Nishiura H, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020330
   Pang BS, 2003, CHINESE MED J-PEKING, V116, P1283
   Park M, 2020, EUR J IMMUNOL, V50, P308, DOI 10.1002/eji.202070035
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Rasmussen SA, 2005, AM J PUBLIC HEALTH, V95, P1942, DOI 10.2105/AJPH.2004.054957
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reis Paulo Eduardo Ocke, 2020, J. vasc. bras., V19, pe20200057, DOI 10.1590/1677-5449.200057
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2016, EMERG INFECT DIS, V22, P1129, DOI 10.3201/eid2206.152113
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roberts A, 2008, VIRUS RES, V133, P20, DOI 10.1016/j.virusres.2007.03.025
   Rodriguez-Morales AJ, 2020, VET REC, V186, DOI 10.1136/vr.m1671
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shih HI, 2020, BIOMED J, V43, P341, DOI 10.1016/j.bj.2020.05.021
   Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479
   Sivabakya K, 2020, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-020-01293-0
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sohrab SS, 2020, J INFECT PUBLIC HEAL, V13, P709, DOI 10.1016/j.jiph.2019.11.007
   Suwannarach N, 2020, MOLECULES, V25, DOI 10.3390/molecules25081800
   Takayama K, 2020, TRENDS PHARMACOL SCI, V41, P513, DOI 10.1016/j.tips.2020.05.005
   Teengam P, 2017, ANAL CHEM, V89, P5428, DOI 10.1021/acs.analchem.7b00255
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiwari R, 2020, VET QUART, V40, P169, DOI 10.1080/01652176.2020.1766725
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   TYRRELL DA, 1966, LANCET, V1, P76
   USDA, 2020, USDA STAT CONF COVID
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LL, 2019, ANTIBODIES, V8, DOI 10.3390/antib8040053
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Wei Q., 2020, DESCRIPTION 1 STTRAI
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, 2003, SEV AC RESP SYNDR SA
   WHO, 2020, CLIN MAN SEV AC RESP
   Wise J., 2012, BMJ, V345, pe6957
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, 2018, MIDDL E RESP SYNDR C
   World Health Organization, 2020, 151 WHO
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   World Health Organization (WHO), 2020, NOV COR CHIN
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu P, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.3.2000044
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhai SL, 2020, VET REC, V186, DOI 10.1136/vr.m740
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang Q., 2020, SARS COV 2 NEUTRALIZ, DOI [10.1101/2020.04.01.021196, DOI 10.1101/2020.04.01.021196]
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
   Zhang T, 2020, PANGOLIN HOMOLOGY AS, DOI [10.1101/2020.02.19.950253, DOI 10.1101/2020.02.19.950253]
   Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu G, 2004, J INFECT DIS, V189, P1676, DOI 10.1086/382892
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu ZY, 2006, J VIROL, V80, P891, DOI 10.1128/JVI.80.2.891-899.2006
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 213
TC 1
Z9 1
U1 10
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
EI 1747-0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD NOV
PY 2020
VL 96
IS 5
BP 1187
EP 1208
DI 10.1111/cbdd.13761
EA JUL 2020
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA OY1AL
UT WOS:000552248200001
PM 32654267
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Demircan, MB
   Tohumeken, S
   Gunduz, N
   Khalily, MA
   Tekinay, T
   Guler, MO
   Tekinay, AB
AF Demircan, Muhammed Burak
   Tohumeken, Sehmus
   Gunduz, Nuray
   Khalily, Mohammad Aref
   Tekinay, Turgay
   Guler, Mustafa O.
   Tekinay, Ayse B.
TI Biotin Functionalized Self-Assembled Peptide Nanofiber as an Adjuvant
   for Immunomodulatory Response
SO BIOTECHNOLOGY JOURNAL
LA English
DT Article
DE adjuvant; peptide nanofiber; self-assembly; vaccine; virus-like
   particles
ID VACCINE ADJUVANTS; ANTIBODY-RESPONSES; CROSS-PRESENTATION; PROTEIN;
   VIRUS; IMMUNITY; NANOSTRUCTURES; MOLECULES; DELIVERY; FUTURE
AB Biotinylated peptide amphiphile (Biotin-PA) nanofibers, are designed as a noncovalent binding location for antigens, which are adjuvants to enhance, accelerate, and prolong the immune response triggered by antigens. Presenting antigens on synthetic Biotin-PA nanofibers generated a higher immune response than the free antigens delivered with a cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) (TLR9 agonist) adjuvant. Antigen attached Biotin-PA nanofibers trigger splenocytes to produce high levels of cytokines (IFN-gamma, IL-12, TNF-alpha, and IL-6) and to exhibit a superior cross-presentation of the antigen. Both Biotin-PA nanofibers and CpG ODN induce a Th-1-biased IgG subclass response; however, delivering the antigen with Biotin-PA nanofibers induce significantly greater production of total IgG and subclasses of IgG compared to delivering the antigen with CpG ODN. Contrary to CpG ODN, Biotin-PA nanofibers also enhance antigen-specific splenocyte proliferation and increase the proportion of the antigen-specific CD8(+) T cells. Given their biodegradability and biocompatibility, Biotin-PA nanofibers have a significant potential in immunoengineering applications as a biomaterial for the delivery of a diverse set of antigens derived from intracellular pathogens, emerging viral diseases such as COVID-19, or cancer cells to induce humoral and cellular immune responses against the antigens.
C1 [Demircan, Muhammed Burak; Tekinay, Ayse B.] Bilkent Univ, Neurosci Grad Program, TR-06800 Ankara, Turkey.
   [Tohumeken, Sehmus; Gunduz, Nuray; Khalily, Mohammad Aref; Tekinay, Ayse B.] Bilkent Univ, Inst Mat Sci & Nanotechnol, TR-06800 Ankara, Turkey.
   [Gunduz, Nuray] Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
   [Tekinay, Ayse B.] Ivedik OSB, Eryigit Res & Dev Ctr, TR-06100 Ankara, Turkey.
   [Demircan, Muhammed Burak] Friedrich Schiller Univ, Med Ctr, Dept Internal Med Hematol & Oncol 2, D-07743 Jena, Germany.
   [Demircan, Muhammed Burak] Leibniz Inst Aging, Fritz Lipmann Inst, D-07745 Jena, Germany.
   [Tohumeken, Sehmus] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD USA.
   [Tekinay, Turgay] Gazi Univ, TR-06100 Ankara, Turkey.
   [Guler, Mustafa O.] Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA.
RP Tekinay, AB (corresponding author), Bilkent Univ, Neurosci Grad Program, TR-06800 Ankara, Turkey.; Tekinay, AB (corresponding author), Bilkent Univ, Inst Mat Sci & Nanotechnol, TR-06800 Ankara, Turkey.; Tekinay, AB (corresponding author), Ivedik OSB, Eryigit Res & Dev Ctr, TR-06100 Ankara, Turkey.; Guler, MO (corresponding author), Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA.
EM mguler@uchicago.edu; abt@eryigit.com.tr
RI Guler, Mustafa O./C-9453-2011
OI Guler, Mustafa O./0000-0003-1168-202X
FU TUBITAK BIDEB-2210 M.Sc. fellowshipTurkiye Bilimsel ve Teknolojik
   Arastirma Kurumu (TUBITAK); TUBITAK BIDEB-2211 PhD fellowshipTurkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Scientific and
   Technological Research Council of TurkeyTurkiye Bilimsel ve Teknolojik
   Arastirma Kurumu (TUBITAK) [TUBITAK 114Z562]; Science Academy
   Outstanding Young Scientist Award (BAGEP)
FX M.B.D. and S.T. contributed equally to this work. The authors would like
   to thank TEM specialist Mr. M. Guler for technical help in TEM imaging.
   S.T. was supported by TUBITAK BIDEB-2210 M.Sc. fellowship. N.G. and A.K.
   were supported by TUBITAK BIDEB-2211 PhD fellowship. This work was
   partially supported by the Scientific and Technological Research Council
   of Turkey (TUBITAK 114Z562). A.B.T. acknowledges support from the
   Science Academy Outstanding Young Scientist Award (BAGEP).
CR Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Cao YH, 2014, ADV FUNCT MATER, V24, P6963, DOI 10.1002/adfm.201401358
   Chattopadhaya S, 2006, NAT PROTOC, V1, P2386, DOI 10.1038/nprot.2006.338
   Chesson CB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31089-y
   Chesson CB, 2014, VACCINE, V32, P1174, DOI 10.1016/j.vaccine.2013.11.047
   Chivers CE, 2011, BIOCHEM J, V435, P55, DOI 10.1042/BJ20101593
   Cui HG, 2010, BIOPOLYMERS, V94, P1, DOI 10.1002/bip.21328
   Dang YS, 2012, CLIN CANCER RES, V18, P3122, DOI 10.1158/1078-0432.CCR-12-0113
   Depelsenaire ACI, 2017, MICRO NANO TECHNOL, P47
   Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2
   Dierendonck M, 2014, ADV FUNCT MATER, V24, P4634, DOI 10.1002/adfm.201400763
   Files MA, 2019, J IMMUNOL, V202
   Foged C, 2011, THER DELIV, V2, P1057, DOI 10.4155/TDE.11.68
   Friedrich BM, 2016, VACCINE, V34, P5479, DOI 10.1016/j.vaccine.2016.09.044
   Guler MO, 2005, J MATER CHEM, V15, P4507, DOI 10.1039/b509246a
   Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604
   Hudalla GA, 2013, ADV HEALTHC MATER, V2, P1114, DOI 10.1002/adhm.201200435
   Hulseberg PD, 2010, IMMUNOL LETT, V130, P36, DOI 10.1016/j.imlet.2009.12.004
   INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717
   Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254
   Leblanc P, 2014, HUM VACC IMMUNOTHER, V10, P3022, DOI 10.4161/hv.34413
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Li DD, 2015, ADV FUNCT MATER, V25, P2993, DOI 10.1002/adfm.201500894
   Liu ZD, 2014, SCI REP-UK, V4, DOI 10.1038/srep07266
   Mammadov R, 2015, SCI REP-UK, V5, DOI 10.1038/srep16728
   Moon JJ, 2011, NAT MATER, V10, P243, DOI 10.1038/NMAT2960
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083
   Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258
   Pijlman GP, 2015, BIOTECHNOL J, V10, P659, DOI 10.1002/biot.201400427
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Rudra JS, 2012, BIOMATERIALS, V33, P6476, DOI 10.1016/j.biomaterials.2012.05.041
   Rudra JS, 2012, ACS NANO, V6, P1557, DOI 10.1021/nn204530r
   Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107
   Salem A. K., 2017, METHOD MOL BIOL, V1494, P201, DOI [10.1007/978-1-4939-6445-1_14, DOI 10.1007/978-1-4939-6445-1_14]
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Skwarczynski M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2285
   Splawn LM, 2018, DRUG TODAY, V54, P399, DOI 10.1358/dot.2018.54.7.2833984
   Tohumeken S, 2017, ADV BIOSYST, V1, DOI 10.1002/adbi.201700015
   Trent A, 2015, AAPS J, V17, P380, DOI 10.1208/s12248-014-9707-3
   Tscharke DC, 2015, NAT REV IMMUNOL, V15, P705, DOI 10.1038/nri3905
   Verdeil G, 2008, P NATL ACAD SCI USA, V105, P16683, DOI 10.1073/pnas.0805054105
   Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032
   Wang HM, 2016, ADV FUNCT MATER, V26, P1822, DOI 10.1002/adfm.201505188
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang ZY, 2020, THERANOSTICS, V10, P657, DOI 10.7150/thno.39132
   Yadav D, 2001, IMMUNOL CELL BIOL, V79, P207, DOI 10.1046/j.1440-1711.2001.00998.x
   Yang CB, 2018, ACS BIOMATER SCI ENG, V4, P2000, DOI 10.1021/acsbiomaterials.7b00488
NR 49
TC 2
Z9 2
U1 23
U2 23
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-6768
EI 1860-7314
J9 BIOTECHNOL J
JI Biotechnol. J.
PD DEC
PY 2020
VL 15
IS 12
SI SI
AR 2000100
DI 10.1002/biot.202000100
EA JUL 2020
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA PE8LR
UT WOS:000552291500001
PM 32679620
DA 2021-01-01
ER

PT J
AU Karim, SA
AF Karim, Safura Abdool
TI COVID-19 vaccine affordability and accessibility
SO LANCET
LA English
DT Letter
C1 [Karim, Safura Abdool] Univ Witwatersrand, SAMRC Ctr Hlth Econ & Decis Sci, Wits Sch Publ Hlth, ZA-2050 Johannesburg, South Africa.
RP Karim, SA (corresponding author), Univ Witwatersrand, SAMRC Ctr Hlth Econ & Decis Sci, Wits Sch Publ Hlth, ZA-2050 Johannesburg, South Africa.
EM safura.abdoolkarim@wits.ac.za
OI Abdool Karim, Safura/0000-0002-4843-9907
CR Silverman E., 2020, AZAR HAS TIN EAR IT
   Usher AD, 2020, LANCET, V395, P1822, DOI 10.1016/S0140-6736(20)31354-4
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 25
PY 2020
VL 396
IS 10246
BP 238
EP 238
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK8ZY
UT WOS:000567020100030
PM 32711799
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Warren, N
   Siskind, D
   Lie, D
AF Warren, Nicola
   Siskind, Dad
   Lie, David
TI Electroconvulsive therapy during severe acute respiratory syndrome
   coronavirus 2 pandemic
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter; Early Access
C1 [Warren, Nicola; Siskind, Dad; Lie, David] Metro South Addict & Mental Hlth, Sch Med, Brisbane, Qld, Australia.
   [Warren, Nicola; Siskind, Dad; Lie, David] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
RP Warren, N (corresponding author), Univ Queensland, 199 Ipswich Rd, Brisbane, Qld 4012, Australia.
EM n.warren@uq.edu.au
RI Warren, Nicola/O-8355-2018
OI Warren, Nicola/0000-0002-0805-1182
CR Caputo KM, 2006, CAN J ANAESTH, V53, P122, DOI 10.1007/BF03021815
   Petrides G, 2009, J ECT, V25, P232, DOI 10.1097/YCT.0b013e31819c76ff
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
AR 0004867420945777
DI 10.1177/0004867420945777
EA JUL 2020
PG 1
WC Psychiatry
SC Psychiatry
GA MQ2CF
UT WOS:000552704000001
PM 32713181
OA Bronze
DA 2021-01-01
ER

PT J
AU Vila-Corcoles, A
   Satue-Gracia, E
   Ochoa-Gondar, O
   Torrente-Fraga, C
   Gomez-Bertomeu, F
   Vila-Rovira, A
   Hospital-Guardiola, I
   de Diego-Cabanes, C
   Bejarano-Romero, F
   Rovira-Veciana, D
   Basora-Gallisa, J
AF Vila-Corcoles, Angel
   Satue-Gracia, Eva
   Ochoa-Gondar, Olga
   Torrente-Fraga, Cristina
   Gomez-Bertomeu, Frederic
   Vila-Rovira, Angel
   Hospital-Guardiola, Imma
   de Diego-Cabanes, Cinta
   Bejarano-Romero, Ferran
   Rovira-Veciana, Dolors
   Basora-Gallisa, Josep
TI Use of distinct anti-hypertensive drugs and risk for COVID-19 among
   hypertensive people: a population-based cohort study in Southern
   Catalonia, Spain
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
DE angiotensin II receptor blockers; angiotensin-converting enzyme
   inhibitors; anti-hypertensive medication; COVID-19; hypertension;
   SARS-COV-2
AB The use of some anti-hypertensive drugs in the current COVID-19 pandemic has become controversial. This study investigated possible relationships between anti-hypertensive medications use and COVID-19 infection risk in the ambulatory hypertensive population. This is a population-based retrospective cohort study involving 34 936 hypertensive adults >50 years in Tarragona (Southern Catalonia, Spain) who were retrospectively followed through pandemic period (from 01/03/2020 to 30/04/2020). Two data sets including demographic/clinical characteristics (comorbidities and cardiovascular medications use) and laboratory PCR codes for COVID-19 were linked to construct an anonymized research database. Cox regression was used to calculate multivariable hazard ratios (HRs) and estimate the risk of suffering COVID-19 infection. Across study period, 205 PCR-confirmed COVID-19 cases were observed, which means an overall incidence of 586.8 cases per 100 000 persons-period. In multivariable analyses, only age (HR: 1.03; 95% CI: 1.02-1.05;P < .001) and nursing home residence (HR: 19.60; 95% CI: 13.80-27.84;P < .001) appeared significantly associated with increased risk of COVID-19. Considering anti-hypertensive drugs, receiving diuretics (HR: 1.22; 95% CI: 0.90-1.67;P = .205), calcium channel blockers (HR: 1.29; 95%CI: 0.91-1.82;P = .148), beta-blockers (HR: 0.97; 95% CI: 0.68-1.37;P = .844), and angiotensin-converting enzyme inhibitors (HR: 0.83; 95% CI: 0.61-1.13;P = .238) did not significantly alter the risk of PCR-confirmed COVID-19, whereas receiving angiotensin II receptor blockers was associated with an almost statistically significant reduction risk (HR: 0.67; 95% CI: 0.44-1.01;P = .054). In conclusion, our data support that receiving renin-angiotensin-aldosterone system inhibitors does not predispose for suffering COVID-19 infection in ambulatory hypertensive people. Conversely, receiving angiotensin II receptor blockers could be related with a reduced risk.
C1 [Vila-Corcoles, Angel; Satue-Gracia, Eva; Ochoa-Gondar, Olga; Hospital-Guardiola, Imma; de Diego-Cabanes, Cinta] Inst Catala Salut, Primary Hlth Care Serv Camp de Tarragona, Rambla Nova 124,1A, Tarragona 43007, Spain.
   [Vila-Corcoles, Angel; Satue-Gracia, Eva; Ochoa-Gondar, Olga; Vila-Rovira, Angel] IDIAP Jordi Gol, Unitat Suport Recerca Tarragona Reus, Barcelona, Spain.
   [Torrente-Fraga, Cristina] Inst Catala Salut, DAP Camp de Tarragona, Dept Informat & Commun Technol, Tarragona, Spain.
   [Gomez-Bertomeu, Frederic] Hosp Univ Joan XXIII, Inst Catala Salut, Dept Microbiol, Tarragona, Spain.
   [Bejarano-Romero, Ferran] Inst Catala Salut, Dept Farmacol, DAP Camp de Tarragona, Tarragona, Spain.
   [Rovira-Veciana, Dolors] ACTIVA Mutua, Dept Laboral Med, Tarragona, Spain.
   [Basora-Gallisa, Josep] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain.
RP Ochoa-Gondar, O (corresponding author), Inst Catala Salut, Primary Hlth Care Serv Camp de Tarragona, Rambla Nova 124,1A, Tarragona 43007, Spain.
EM oochoa.tgn.ics@gencat.cat
OI Satue, Eva/0000-0003-1559-6778; GOMEZ, FREDERIC/0000-0002-8039-2889
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [COV20/00852]
FX Instituto de Salud Carlos III, Grant/Award Number: COV20/00852
CR American Heart Association, HFSA ACC AHA STAT AD
   Consumo. Direccion General de Salud Publica Calidad e innovacion. Centro de Coordinacion de Alertas y Emergencias Sanitarias, INF CIENT TECN ENF C
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   European Society of Cardiology, POS STAT ESC COUNC H
   Generalitat de Catalunya, SUBD GEN VIG RESP EM
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hosmer Jr DW, 1999, APPL SURVIVAL ANAL R
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Lieberman JA, 2020, J CLIN MICROBIOL
   Lopes Renato D, 2020, Am Heart J, DOI 10.1016/j.ahj.2020.05.002
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Park Sungha, 2020, Clin Hypertens, V26, P11, DOI 10.1186/s40885-020-00144-0
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Versmissen J, 2020, J HYPERTENS, V38, P1196, DOI 10.1097/HJH.0000000000002472
   Vila-Corcoles A, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-25
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   WHO Collaborating Centre for Drug Statistic Methodology, ATC DDD IND 2020
   World Health Organization, 2020, COR DIS 2019 COVID 1
   World Medical Association, WMA DECL HELS ETH PR
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 27
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD AUG
PY 2020
VL 22
IS 8
BP 1379
EP 1388
DI 10.1111/jch.13948
EA JUL 2020
PG 10
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA NE9JY
UT WOS:000552133200001
PM 32710674
OA Bronze
DA 2021-01-01
ER

PT J
AU Lee, WY
AF Lee, Wai-Yung
TI The Musings of a Family Therapist in Asia When COVID-19 Struck
SO FAMILY PROCESS
LA English
DT Article
DE COVID-19; Social Distancing; Eastern Philosophy; Buddhism; Confucianism;
   Taoism
AB In response to the COVID-19 crisis in Asia, a family therapist in Hong Kong shares her experiences and reflections, both personally and professionally from an Eastern lens. From a state of shock and immobilization to moments of contemplation, she highlights her struggle with being caught between her Eastern roots and Western training, which has become more salient in facing COVID-19. While the latter pulls her toward a more problem resolution stance, the former pulls her toward a more accepting position. As a result, her therapy is shaped in such a way that she tends to raise more questions instead of providing answers.
C1 [Lee, Wai-Yung] Tsan Yuk Hosp, 5-F,30 Hosp Rd, Hong Kong, Peoples R China.
RP Lee, WY (corresponding author), Tsan Yuk Hosp, 5-F,30 Hosp Rd, Hong Kong, Peoples R China.
EM wyleeh@hkucc.hku.hk
CR Colapinto J., 2017, ENCY COUPLE FAMILY T
   Laozi, 1988, TAO TE CHING NEW ENG
   Lau BHP, 2020, ASIA PAC J SOC WORK, DOI 10.1080/02185385.2020.1778516
   Lee W. Y., 2017, ENCY COUPLE FAMILY T
   Lee WY, 2018, J FAM THER, V40, pS128, DOI 10.1111/1467-6427.12209
   Lee WY, 2013, FAM PROCESS, V52, P499, DOI 10.1111/famp.12040
   Prasso S., 2020, CHINAS DIVORCE SPIKE
   Ryall J., 2020, CORONA DIVORCE TREND
   Teshigahara H., 1966, WOMAN DUNES
   Wilhelm R., 1950, I CHING BOOK CHANGES
NR 10
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 1018
EP 1023
DI 10.1111/famp.12577
EA JUL 2020
PG 6
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000552071000001
PM 32621312
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kato, F
   Matsuyama, S
   Kawase, M
   Hishiki, T
   Katoh, H
   Takeda, M
AF Kato, Fumihiro
   Matsuyama, Shutoku
   Kawase, Miyuki
   Hishiki, Takayuki
   Katoh, Hiroshi
   Takeda, Makoto
TI Antiviral activities of mycophenolic acid and IMD-0354 against
   SARS-CoV-2
SO MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
DE antiviral agents; IMD-0354; mycophenolic acid; SARS-CoV-2; VeroE6;
   TMPRSS2
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-COV; INHIBITORS; MICE
AB In this study, the anti-severe acute respiratory syndrome coronavirus-2 (anti-SARS-CoV-2) activity of mycophenolic acid (MPA) and IMD-0354 was analyzed. These compounds were chosen based on their antiviral activities against other coronaviruses. Because they also inhibit dengue virus (DENV) infection, other anti-DENV compounds/drugs were also assessed. On SARS-CoV-2-infected VeroE6/TMPRSS2 monolayers, both MPA and IMD-0354, but not other anti-DENV compounds/drugs, showed significant anti-SARS-CoV-2 activity. Although MPA reduced the viral RNA level by only approximately 100-fold, its half maximal effective concentration was as low as 0.87 mu m, which is easily achievable at therapeutic doses of mycophenolate mofetil. MPA targets the coronaviral papain-like protease and an in-depth study on its mechanism of action would be useful in the development of novel anti-SARS-CoV-2 drugs.
C1 [Kato, Fumihiro; Matsuyama, Shutoku; Kawase, Miyuki; Katoh, Hiroshi; Takeda, Makoto] Natl Inst Infect Dis, Dept Virol 3, 4-7-1 Gakuen, Tokyo 2080011, Japan.
   [Hishiki, Takayuki] Kanagawa Prefectural Inst Publ Hlth, Dept Microbiol, Chigasaki, Kanagawa, Japan.
RP Kato, F (corresponding author), Natl Inst Infect Dis, Dept Virol 3, 4-7-1 Gakuen, Tokyo 2080011, Japan.
EM fumihiro@nih.go.jp
RI Takeda, Makoto/J-2550-2018
OI Takeda, Makoto/0000-0002-8194-7727
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [20K16020]; Japan Agency for Medical Research
   and DevelopmentJapan Agency for Medical Research and Development (AMED)
   [JP19fk0108111j0001]
FX Japan Society for the Promotion of Science, Grant/Award Number:
   20K16020; Japan Agency for Medical Research and Development, Grant/Award
   Number: JP19fk0108111j0001
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Barnard DL, 2006, ANTIVIR RES, V71, P53, DOI 10.1016/j.antiviral.2006.03.001
   Canton J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006838
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hishiki T, 2019, ANTIVIR RES, V165, P42, DOI 10.1016/j.antiviral.2019.03.002
   Kanzawa N, 2006, FEBS LETT, V580, P6807, DOI 10.1016/j.febslet.2006.11.046
   Kato F, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104643
   Kato F, 2016, ANTIVIR RES, V131, P141, DOI 10.1016/j.antiviral.2016.04.014
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matsuyama S, 2018, J VIROL, V92, DOI 10.1128/JVI.00683-18
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Siordia JA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104357
   Tohma D, 2019, ARCH VIROL, V164, P225, DOI 10.1007/s00705-018-4079-0
   Wang YN, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1206-9
   Yang CW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04203-9
   Yang XX, 2014, J GEN VIROL, V95, P614, DOI 10.1099/vir.0.059014-0
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
NR 20
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0385-5600
EI 1348-0421
J9 MICROBIOL IMMUNOL
JI Microbiol. Immunol.
PD SEP
PY 2020
VL 64
IS 9
BP 635
EP 639
DI 10.1111/1348-0421.12828
EA JUL 2020
PG 5
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NN9RS
UT WOS:000551899900001
PM 32579258
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Azimi, SZ
   Firooz, A
   Murrell, DF
   Daneshpazhooh, M
AF Azimi, Seyyede Zeinab
   Firooz, Alireza
   Murrell, Dedee F.
   Daneshpazhooh, Maryam
TI Treatment concerns for bullous pemphigoid in theCOVID-19 pandemic era
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE autoimmune bullous disease; COVID-19; Dermatologic Therapy
AB Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day.
C1 [Azimi, Seyyede Zeinab; Firooz, Alireza] Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, 415 Taleghani Ave, Tehran 1416613675, Iran.
   [Murrell, Dedee F.] Univ New South Wales, Dept Dermatol, Sydney, NSW, Australia.
   [Daneshpazhooh, Maryam] Univ Tehran Med Sci, Autoimmune Bullous Dis Res Ctr, Dept Dermatol, Tehran, Iran.
RP Azimi, SZ (corresponding author), Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, 415 Taleghani Ave, Tehran 1416613675, Iran.
EM sz.azimi@yahoo.com
CR Abdollahimajd F, 2020, ARCH ACAD EMERG MED, V8
   American Academy of Dermatology, 2020, GUID US IMM AG
   Askanase AD, 2020, LUPUS SCI MED, V7, DOI 10.1136/lupus-2020-000396
   European Academy of Dermatology and Venereology, 2020, GUID EADV TASK FORC
   Joly P, 2002, NEW ENGL J MED, V346, P321, DOI 10.1056/NEJMoa011592
   Kasperkiewicz M, 2020, J EUR ACAD DERMATOL, V34, pE302, DOI 10.1111/jdv.16525
   Kasperkiewicz M, 2014, J AM ACAD DERMATOL, V71, P1018, DOI 10.1016/j.jaad.2014.06.014
   Pathoulas JT, 2020, J AM ACAD DERMATOL, V82, P1272, DOI 10.1016/j.jaad.2020.03.047
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7
   Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4
   Shakshouk H, 2020, J AM ACAD DERMATOL, V82, pE235, DOI 10.1016/j.jaad.2020.04.005
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e13956
DI 10.1111/dth.13956
EA JUL 2020
PG 2
WC Dermatology
SC Dermatology
GA MP4VV
UT WOS:000552202800001
PM 32621628
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Choudhary, MI
   Shaikh, M
   Atia-tul-Wahab
   Atta-ur-Rahman
AF Choudhary, M. Iqbal
   Shaikh, Muniza
   Atia-tul-Wahab
   Atta-ur-Rahman
TI In silico identification of potential inhibitors of key SARS-CoV-2 3CL
   hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy
   calculations, and molecular dynamics simulation
SO PLOS ONE
LA English
DT Article
ID DIMETHYL LITHOSPERMATE-B; LIPID-PEROXIDATION; ACCURATE DOCKING; DANSHEN;
   GLIDE
AB The incidence of 2019 novel corona virus (SARS-CoV-2) has created a medical emergency throughout the world. Various efforts have been made to develop the vaccine or effective treatments against the disease. The discovery of crystal structure of SARS-CoV-2 main protease has made the in silico identification of its inhibitors possible. Based on its critical role in viral replication, the viral protease can prove to be a promising "target" for antiviral drug therapy. We have systematically screened an in-house library of 15,754 natural and synthetic compounds, established at International Center for Chemical and Biological Sciences, University of Karachi. The in silico search for potential viral protease inhibitors resulted in nine top ranked ligands (compounds 1-9) against SARS-CoV-2 main protease (PDB ID: 6LU7) based on docking scores, and predictive binding energies. The in silico studies were updated via carrying out the docking, and predictive binding energy estimation, with a recently reported crystal structure of main protease (PDB ID: 6Y2F) at a better resolution i.e., 1.95 A. Compound 2 (molecular bank code AAA396) was found to have highest negative binding energy of -71.63 kcal/mol for 6LU7. While compound 3 (molecular bank code AAD146) exhibited highest negative binding energy of -81.92 kcal/mol for 6Y2F. The stability of the compounds- in complex with viral protease was analyzed by Molecular Dynamics simulation studies, and was found to be stable over the course of 20 ns simulation time. Compound 2, and 3 were predicted to be the significant inhibitors of SARS-CoV-2 3CL hydrolase (Mpro) among the nine short listed compounds.
C1 [Choudhary, M. Iqbal; Shaikh, Muniza; Atia-tul-Wahab; Atta-ur-Rahman] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi, Pakistan.
   [Choudhary, M. Iqbal; Atta-ur-Rahman] Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi, Pakistan.
RP Choudhary, MI; Shaikh, M; Atia-tul-Wahab (corresponding author), Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi, Pakistan.; Choudhary, MI (corresponding author), Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi, Pakistan.
EM iqbal.choudhary@iccs.edu; shaikhmuniza2016@gmail.com;
   atia.tulwahab@iccs.edu
RI Shaikh, Muniza/ABE-5751-2020; Choudhary, M. Iqbal/C-8633-2012
OI Shaikh, Muniza/0000-0002-4956-9877; Choudhary, M.
   Iqbal/0000-0001-5356-3585
FU Searle Company, Pakistan
FX The study has financial support of the Searle Company, Pakistan through
   a research project funding. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adcock SA, 2006, CHEM REV, V106, P1589, DOI 10.1021/cr040426m
   AFFANY A, 1987, FUND CLIN PHARMACOL, V1, P451, DOI 10.1111/j.1472-8206.1987.tb00578.x
   Ahmad S, 2019, INTERDISCIP SCI, V11, P508, DOI 10.1007/s12539-018-0299-y
   [Anonymous], 2020, SCHROD REL 2020 1 PR
   [Anonymous], 2020, SCHROD REL 2020 1 LI
   [Anonymous], 2020, SCHROD REL 2020 2 QI
   [Anonymous], 2020, SCHROD REL 2020 1 GL
   [Anonymous], 2020, SCHROD REL 2020 1 DE
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Choi HG, 2018, ARCH PHARM RES, V41, P64, DOI 10.1007/s12272-017-0983-1
   Fish JM, 2006, CIRCULATION, V113, P1393, DOI 10.1161/CIRCULATIONAHA.105.601690
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hashemzadeh S, 2019, INTERDISCIP SCI, V11, P115, DOI 10.1007/s12539-018-0305-4
   Hassan M, 2018, INTERDISCIP SCI, V10, P68, DOI 10.1007/s12539-016-0171-x
   Hayes JM, 2012, MOL DYNAMICS STUDIES, P171
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Khan KM, 2008, LETT DRUG DES DISCOV, V5, P152, DOI 10.2174/157018008784083974
   Lamberton J N, 1965, Bull Soc Fr Dermatol Syphiligr, V72, P808
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mbwambo ZH, 2004, PLANTA MED, V70, P706, DOI 10.1055/s-2004-827199
   Mesaik MA, 2012, CHEM BIOL DRUG DES, V79, P290, DOI 10.1111/j.1747-0285.2011.01310.x
   National Health Commission of the People's Republic of China, 2020, UPD NOV COR PNEUM OU
   Oh SH, 2006, ARCH PHARM RES, V29, P762, DOI 10.1007/BF02974077
   Richman D.D., 2016, CLIN VIROLOGY
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Tchinda AT, 2007, CHEM PHARM BULL, V55, P1402, DOI 10.1248/cpb.55.1402
   Vinothkumar R, 2014, ENVIRON TOXICOL PHAR, V37, P174, DOI 10.1016/j.etap.2013.11.022
   WACKER A, 1978, ARZNEIMITTEL-FORSCH, V28-1, P347
   World Health Organization (WHO), 2020, NOV COR CHIN
   Yoon JY, 2004, BRIT J PHARMACOL, V143, P765, DOI 10.1038/sj.bjp.0705969
   Zhang L., 2020, SCIENCE
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2020
VL 15
IS 7
AR e0235030
DI 10.1371/journal.pone.0235030
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OD5ZL
UT WOS:000579931700005
PM 32706783
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mukandavire, Z
   Nyabadza, F
   Malunguza, NJ
   Cuadros, DF
   Shiri, T
   Musuka, G
AF Mukandavire, Zindoga
   Nyabadza, Farai
   Malunguza, Noble J.
   Cuadros, Diego F.
   Shiri, Tinevimbo
   Musuka, Godfrey
TI Quantifying early COVID-19 outbreak transmission in South Africa and
   exploring vaccine efficacy scenarios
SO PLOS ONE
LA English
DT Article
ID CORONAVIRUS; CHINA
AB The emergence and fast global spread of COVID-19 has presented one of the greatest public health challenges in modern times with no proven cure or vaccine. Africa is still early in this epidemic, therefore the extent of disease severity is not yet clear. We used a mathematical model to fit to the observed cases of COVID-19 in South Africa to estimate the basic reproductive number and critical vaccination coverage to control the disease for different hypothetical vaccine efficacy scenarios. We also estimated the percentage reduction in effective contacts due to the social distancing measures implemented. Early model estimates show that COVID-19 outbreak in South Africa had a basic reproductive number of 2.95 (95% credible interval [CrI] 2.83-3.33). A vaccine with 70% efficacy had the capacity to contain COVID-19 outbreak but at very higher vaccination coverage 94.44% (95% Crl 92.44-99.92%) with a vaccine of 100% efficacy requiring 66.10% (95% Crl 64.72-69.95%) coverage. Social distancing measures put in place have so far reduced the number of social contacts by 80.31% (95% Crl 79.76-80.85%). These findings suggest that a highly efficacious vaccine would have been required to contain COVID-19 in South Africa. Therefore, the current social distancing measures to reduce contacts will remain key in controlling the infection in the absence of vaccines and other therapeutics.
C1 [Mukandavire, Zindoga] Coventry Univ, Ctr Data Sci, Coventry, W Midlands, England.
   [Mukandavire, Zindoga] Coventry Univ, Sch Comp Elect & Math, Coventry, W Midlands, England.
   [Nyabadza, Farai] Univ Johannesburg, Dept Math & Appl Math, Johannesburg, South Africa.
   [Malunguza, Noble J.] Natl Univ Sci & Technol, Dept Insurance & Actuarial Sci, Bulawayo, Zimbabwe.
   [Cuadros, Diego F.] Univ Cincinnati, Dept Geog & Geog Informat Sci, Cincinnati, OH USA.
   [Cuadros, Diego F.] Univ Cincinnati, Hlth Geog & Dis Modeling Lab, Cincinnati, OH USA.
   [Shiri, Tinevimbo] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   [Musuka, Godfrey] Columbia Univ, ICAP, Harare, Zimbabwe.
RP Musuka, G (corresponding author), Columbia Univ, ICAP, Harare, Zimbabwe.
EM gm2660@cumc.columbia.edu
OI Musuka, Godfrey/0000-0001-9077-4429; Mukandavire,
   Zindoga/0000-0002-8108-1441
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Binti Hamzah F. A., 2020, B WHO
   Cascella M, 2020, STATPEARLS
   Chen ZL, 2020, CHINESE MED J-PEKING, V133, P1044, DOI 10.1097/CM9.0000000000000782
   Chutel L., 2020, MOST CORONAVIRUS CAS
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Equils O, 2019, HUM VACC IMMUNOTHER, V15, P637, DOI 10.1080/21645515.2018.1543524
   Etbaigha F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202493
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Grant Hannah, 2020, J Public Health (Oxf), V42, pe551, DOI 10.1093/pubmed/fdz178
   Haffajee F., 2020, FREE STATE RACES CUR
   Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000424
   Hansoti Bhakti, 2019, EClinicalMedicine, V15, P14, DOI 10.1016/j.eclinm.2019.08.007
   Imai N., REPORT 3 TRANSMISSIB
   Kolifarhood G, 2020, ARCH ACAD EMERG MED, V8
   Kucharski J., 2020, LANCET INFECT DIS
   Kwon CM, 2016, INT J MODEL SIMUL SC, V7, DOI 10.1142/S1793962316430030
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leonenko N. V., 2016, RUSSIAN J NUMERICAL, V31, P1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Lin QY, 2018, STAT METHODS MED RES, V27, P1968, DOI 10.1177/0962280217746442
   Liu T., 2020, TRANSMISSION DYNAMIC
   Majumder M., 2020, SSRN
   Mukandavire Z., 2020, INT J INFECT DIS
   Mukandavire Z, 2013, SCI REP-UK, V3, DOI 10.1038/srep00997
   Mukandavire Z, 2011, P NATL ACAD SCI USA, V108, P8767, DOI 10.1073/pnas.1019712108
   Muniz-Rodriguez K., 2020, EPIDEMIC DOUBLING TI, DOI [10.1101/2020.02.05.20020750v4, DOI 10.1101/2020.02.05.20020750V4]
   National Institute for Communicable Diseases, 2020, NAT I COMM DIS COV 1
   Nicolson G., 2020, BATTLEGROUND GAUTENG
   Paton J., 2020, BLOOMBERG
   Peck M., 2019, MMWR-MORBID MORTAL W, P1010
   Plummer M., 2006, R NEWS, V6, P7, DOI DOI 10.1159/000323281
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549V2, DOI 10.1101/2020.01.23.20018549V2]
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Shen M., 2020, MODELING EPIDEMIC TR, DOI [10.1101/2020.01.23.916726v1, DOI 10.1101/2020.01.23.916726V1]
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   South African Gorvenment News Agency, 2020, NAT LOCKD EXT BY 2 W
   South African Government, 2020, COVID 19 NOV COR
   South African Government, 2020, 1 CAS COV 19 COR REP
   STATS SA, 2016, STAT S AFR
   STATS SA, 2019, MID YEAR POP EST 201
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   van den Heever Johann, 2014, OPERATIONAL CHALLENG
   WHO, 2019, GLOB TUB REP 2019
   World Health Organization, 2020, COR DIS 2019 COVID 1
   World Health Organization, 2020, 62 WHO
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yamey G., 2020, LANCET
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0
   Zhu Z. B., 2020, EPUB, V54, P3
NR 55
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2020
VL 15
IS 7
AR e0236003
DI 10.1371/journal.pone.0236003
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OD5ZL
UT WOS:000579931700015
PM 32706790
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Cappuccio, FP
   Siani, A
AF Cappuccio, Francesco P.
   Siani, Alfonso
TI Covid-19 and cardiovascular risk: Susceptibility to infection to
   SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the
   renin-angiotensin-aldosterone system. An evidence-based viewpoint
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE Covid-19; SARS-CoV-2; Hypertension; Diabetes; Cardiovascular disease;
   ACE-Inhibitors; Angiotensin-receptor-blockers; Renin-angiotensin system
ID PNEUMONIA
AB The presence of cardiovascular co-morbidities and the known effects of coronaviruses on the cardiovascular system have called attention to the potential implications for patients with cardiovascular risk factors. This evidence-based viewpoint will address two questions: (a) are individuals with underlying cardiovascular risk factors (e.g. high blood pressure or diabetes) or overt disease (e.g. coronary heart disease, heart failure, kidney disease) more likely to develop severe Covid-19 and to die than those without underlying conditions? (b) does the regular use of angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin-receptor blockers (ARB) make patients more likely to get infected and to die of Covid-19?
   With a necessary cautionary note that the evidence around the links between Covid-19 and cardiovascular disease is accruing at a fast pace, to date we can conclude that: (a) the greater susceptibility of individuals with underlying cardiovascular conditions to develop more severe Covid-19 with higher mortality rate is likely to be confounded, in part, by age and the type of co-morbidities. Patients with heart failure or chronic kidney disease might show an excess risk; (b) neither ACE-i nor ARB are associated with greater risk of SARS-Cov2 infection, or severity or risk of death in patients with Covid-19. Patients on these drugs should not stop them, unless under strict medical supervision and with the addition of a suitable replacement medicine. (C) 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
C1 [Cappuccio, Francesco P.] Univ Warwick, Warwick Med Sch, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.
   [Cappuccio, Francesco P.] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England.
   [Siani, Alfonso] CNR, Inst Food Sci, Avellino, Italy.
RP Cappuccio, FP (corresponding author), Univ Warwick, Warwick Med Sch, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.
EM f.p.cappuccio@warwick.ac.uk
RI Cappuccio, Francesco Paolo/ABF-1094-2020
OI Cappuccio, Francesco Paolo/0000-0002-7842-5493
CR [Anonymous], 2014, PHYSICAL ACTIVITY HE
   Aronson JK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1313
   Bean DM, 2020, TREATMENT ACE INHIBI, DOI [10.1101/2020.04.07.20056788v1., DOI 10.1101/2020.04.07.20056788V1, 10.1101/2020.04.07.20056788v1]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Conversano A, 2020, HYPERTENSION, V76, pe10, DOI [10.1161/HYPERTENSIONAHA.120.15312, DOI 10.1161/HYPERTENSIONAHA.120.15312]
   Cowan LT, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009683
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Dhainaut JF, 2005, CLIN INFECT DIS, V41, pS481, DOI 10.1086/432001
   Fang L, 2020, LANCET RESP MED, V4, pe1, DOI [10.1016/PII., DOI 10.1016/PII.]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, DOI [10.1001/ja-macardio.2020.1017, DOI 10.1001/JA-MACARDIO.2020.1017]
   Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li G, 2020, NUTR METAB CARDIOVAS, V30, P1057, DOI 10.1016/j.numecd.2020.04.001
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Lippi G, 2020, POL ARCH INTERN MED, DOI [10.20452/-pamw.15272, DOI 10.20452/-PAMW.15272]
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, CARDIORENAL MED, V10, P470, DOI 10.1159/000510916
NR 34
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0939-4753
EI 1590-3729
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD JUL 24
PY 2020
VL 30
IS 8
BP 1227
EP 1235
DI 10.1016/j.numecd.2020.05.013
PG 9
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA NT3NY
UT WOS:000572853200001
PM 32595085
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Riva, L
   Yuan, SF
   Yin, X
   Martin-Sancho, L
   Matsunaga, N
   Pache, L
   Burgstaller-Muehlbacher, S
   De Jesus, PD
   Teriete, P
   Hull, MV
   Chang, MW
   Chan, JFW
   Cao, JL
   Poon, VKM
   Herbert, KM
   Cheng, KY
   Nguyen, TTH
   Rubanov, A
   Pu, Y
   Nguyen, C
   Choi, A
   Rathnasinghe, R
   Schotsaert, M
   Miorin, L
   Dejosez, M
   Zwaka, TP
   Sit, KY
   Martinez-Sobrido, L
   Liu, WC
   White, KM
   Chapman, ME
   Lendy, EK
   Glynne, RJ
   Albrecht, R
   Ruppin, E
   Mesecar, AD
   Johnson, JR
   Benner, C
   Sun, R
   Schultz, PG
   Su, AI
   Garcia-Sastre, A
   Chatterjee, AK
   Yuen, KY
   Chanda, SK
AF Riva, Laura
   Yuan, Shuofeng
   Yin, Xin
   Martin-Sancho, Laura
   Matsunaga, Naoko
   Pache, Lars
   Burgstaller-Muehlbacher, Sebastian
   De Jesus, Paul D.
   Teriete, Peter
   Hull, Mitchell V.
   Chang, Max W.
   Chan, Jasper Fuk-Woo
   Cao, Jianli
   Poon, Vincent Kwok-Man
   Herbert, Kristina M.
   Cheng, Kuoyuan
   Nguyen, Tu-Trinh H.
   Rubanov, Andrey
   Pu, Yuan
   Nguyen, Courtney
   Choi, Angela
   Rathnasinghe, Raveen
   Schotsaert, Michael
   Miorin, Lisa
   Dejosez, Marion
   Zwaka, Thomas P.
   Sit, Ko-Yung
   Martinez-Sobrido, Luis
   Liu, Wen-Chun
   White, Kris M.
   Chapman, Mackenzie E.
   Lendy, Emma K.
   Glynne, Richard J.
   Albrecht, Randy
   Ruppin, Eytan
   Mesecar, Andrew D.
   Johnson, Jeffrey R.
   Benner, Christopher
   Sun, Ren
   Schultz, Peter G.
   Su, Andrew I.
   Garcia-Sastre, Adolfo
   Chatterjee, Arnab K.
   Yuen, Kwok-Yung
   Chanda, Sumit K.
TI Discovery of SARS-CoV-2 antiviral drugs through large-scale compound
   repurposing
SO NATURE
LA English
DT Article
ID EBOLA-VIRUS; CATHEPSIN-L; POSTMENOPAUSAL OSTEOPOROSIS; IL-12/IL-23
   INHIBITOR; REPLICATION; EFFICACY; APILIMOD; PIKFYVE; ONO-5334; KINASE
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19)(1). The development of a vaccine is likely to take at least 12-18 months, and the typical timeline for approval of a new antiviral therapeutic agent can exceed 10 years. Thus, repurposing of known drugs could substantially accelerate the deployment of new therapies for COVID-19. Here we profiled a library of drugs encompassing approximately 12,000 clinical-stage or Food and Drug Administration (FDA)-approved small molecules to identify candidate therapeutic drugs for COVID-19. We report the identification of 100 molecules that inhibit viral replication of SARS-CoV-2, including 21 drugs that exhibit dose-response relationships. Of these, thirteen were found to harbour effective concentrations commensurate with probable achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod(2-4)and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825 and ONO 5334. Notably, MDL-28170, ONO 5334 and apilimod were found to antagonize viral replication in human pneumocyte-like cells derived from induced pluripotent stem cells, and apilimod also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, their known pharmacological and human safety profiles will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.
   A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronavirus disease 2019 (COVID-19).
C1 [Riva, Laura; Yin, Xin; Martin-Sancho, Laura; Matsunaga, Naoko; Pache, Lars; De Jesus, Paul D.; Teriete, Peter; Herbert, Kristina M.; Rubanov, Andrey; Pu, Yuan; Nguyen, Courtney; Chanda, Sumit K.] Sanford Burnham Prebys Med Discovery Inst, Infect & Inflammatory Dis Ctr, Immun & Pathogenesis Program, La Jolla, CA 92037 USA.
   [Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Cao, Jianli; Poon, Vincent Kwok-Man; Yuen, Kwok-Yung] Univ Hong Kong Hong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
   [Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Cao, Jianli; Poon, Vincent Kwok-Man; Yuen, Kwok-Yung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China.
   [Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Cao, Jianli; Poon, Vincent Kwok-Man; Yuen, Kwok-Yung] Univ Hong Kong, Carol Yu Ctr Infect, Li Ka Shing Fac Med, Hong Kong, Peoples R China.
   [Burgstaller-Muehlbacher, Sebastian] Univ Vienna, Max Perutz Labs, Ctr Integrat Bioinformat Vienna, Vienna, Austria.
   [Burgstaller-Muehlbacher, Sebastian] Med Univ Vienna, Vienna, Austria.
   [Hull, Mitchell V.; Nguyen, Tu-Trinh H.; Schultz, Peter G.; Chatterjee, Arnab K.] Calibr Scripps Res, La Jolla, CA 92037 USA.
   [Chang, Max W.; Benner, Christopher] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Cheng, Kuoyuan; Ruppin, Eytan] NCI, Canc Data Sci Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Cheng, Kuoyuan] Univ Maryland, Biol Sci Grad Program, College Pk, MD USA.
   [Choi, Angela; Rathnasinghe, Raveen; Schotsaert, Michael; Miorin, Lisa; Liu, Wen-Chun; White, Kris M.; Albrecht, Randy; Johnson, Jeffrey R.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Choi, Angela; Rathnasinghe, Raveen; Schotsaert, Michael; Miorin, Lisa; Liu, Wen-Chun; White, Kris M.; Albrecht, Randy; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
   [Choi, Angela; Rathnasinghe, Raveen] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Dejosez, Marion; Zwaka, Thomas P.] Icahn Sch Med Mt Sinai, Ctr Cell Based Res Parkinsons Dis, Dept Cell Regenerat & Dev Biol, Black Family Stem Cell Inst,Huffington Fdn, New York, NY 10029 USA.
   [Sit, Ko-Yung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Peoples R China.
   [Martinez-Sobrido, Luis] Texas Biomed Res Inst, San Antonio, TX USA.
   [Chapman, Mackenzie E.; Mesecar, Andrew D.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.
   [Lendy, Emma K.; Mesecar, Andrew D.] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.
   [Glynne, Richard J.] Incept Therapeut, San Diego, CA USA.
   [Sun, Ren] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
   [Su, Andrew I.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
RP Chanda, SK (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Infect & Inflammatory Dis Ctr, Immun & Pathogenesis Program, La Jolla, CA 92037 USA.; Yuen, KY (corresponding author), Univ Hong Kong Hong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Carol Yu Ctr Infect, Li Ka Shing Fac Med, Hong Kong, Peoples R China.; Chatterjee, AK (corresponding author), Calibr Scripps Res, La Jolla, CA 92037 USA.
EM achatterjee@scripps.edu; kyyuen@hku.hk; schanda@sbpdiscovery.org
RI YIN, XIN/B-5862-2018
OI YIN, XIN/0000-0003-2357-6718; Cheng, Kuoyuan/0000-0001-8118-5243;
   Burgstaller-Muehlbacher, Sebastian/0000-0003-4640-3510; Hull,
   Mitchell/0000-0002-9364-1901; Pu, Yuan/0000-0002-7049-8452; Albrecht,
   Randy/0000-0003-4008-503X; Chang, Max/0000-0002-4526-489X
FU Sanford Burnham Prebys Medical Discovery Institute: DoD
   [W81XWH-20-1-0270]; DHIPC [U19 AI118610]; Fluomics/NOSI [U19 AI135972];
   Health and Medical Research Fund [COVID190121]; Food and Health Bureau,
   The Government of the Hong Kong Special Administrative Region; National
   Program on Key Research Project of China [2020YFA0707500,
   2020YFA0707504]; Theme-Based Research Scheme of the Research Grants
   Council [T11/707/15]; Hong Kong Special Administrative Region; National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human ServicesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700060C]; NIH/NIGMS T32 Training Grant for Structural Biology
   and Biophysics [GM132024]; Huffington Foundation; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation; CRIP (Center for Research for
   Influenza Pathogenesis); NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201400008C]; JPB
   Foundation; Open Philanthropy Project [2020-215611 (5384)]; NIAID
   grantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI135972, U19AI142733]; DoDUnited States
   Department of Defense [W81XWH-20-1-0270]; DARPA grantUnited States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA)
   [HR0011-19-2-0020]
FX The following reagent was deposited by the Centers for Disease Control
   and Prevention and obtained through BEI Resources, NIAID, NIH:
   SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. The authors
   thank A. Embry for guidance in securing reagents; S. Yoh for scientific
   input; H. Nymark-McMahon for manuscript editing; T. Marathe for copy
   editing; S. Blondelle and L. Adelman for facilities and biosafety
   support; M. Chacon for administrative assistance; W. Thienphrapa and H.
   Curry for literature research support; R. Eaden for shipping and
   delivery assistance; O. Harismendy for advice on data analysis; and B.
   Anson and A. Hamdani in the Mesecar laboratory for providing samples of
   SARS-CoV-2 Mpro. This work was supported by the following grants to the
   Sanford Burnham Prebys Medical Discovery Institute: DoD:
   W81XWH-20-1-0270; DHIPC: U19 AI118610; Fluomics/NOSI: U19 AI135972, as
   well as generous philanthropic donations from D. Ruch and S. Blair and
   J. Blair. The work at the University of Hong Kong was partly supported
   by the donations of R. Yu and C. Yu, the Shaw Foundation of Hong Kong,
   M. S.-K. Tong and M. T. M. M. Yin; and funding from the Health and
   Medical Research Fund (grant no. COVID190121), the Food and Health
   Bureau, The Government of the Hong Kong Special Administrative Region;
   the National Program on Key Research Project of China (grant no.
   2020YFA0707500 and 2020YFA0707504); and the Theme-Based Research Scheme
   (T11/707/15) of the Research Grants Council and Hong Kong Special
   Administrative Region. Viral protease studies have been funded in part
   with federal funds from the National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, Department of Health and Human
   Services, under Contract No. HHSN272201700060C to A.D.M. M.E.C. is
   supported by an NIH/NIGMS T32 Training Grant for Structural Biology and
   Biophysics (GM132024). The work on iPCS-derived pneumocytes was partly
   supported by the Huffington Foundation. The work at Calibr at Scripps
   Research was supported by the Bill and Melinda Gates Foundation. This
   research was also partly funded by CRIP (Center for Research for
   Influenza Pathogenesis), a NIAID supported Center of Excellence for
   Influenza Research and Surveillance (CEIRS, contract no.
   HHSN272201400008C), by DARPA grant HR0011-19-2-0020, by an
   administrative supplement to NIAID grant U19AI142733, and by the
   generous support of the JPB Foundation, the Open Philanthropy Project
   (research grant 2020-215611 (5384)) and anonymous donors to A.G.-S. and
   by supplements to NIAID grant U19AI135972 and DoD grant W81XWH-20-1-0270
   to S.K.C. and A.G.-S. The funding sources had no role in the study
   design, data collection, analysis, interpretation or writing of the
   report. Finally, we wish to thank the late Ananda Mohan Chakrabarty for
   his generous and inspiring mentorship and advice.
CR Anson B. J., 2020, BROAD SPECTRUM INHIB, DOI [10.21203/rs.3.rs-26344/v1, DOI 10.21203/RS.3.RS-26344/V1]
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Billich A, 2007, IDRUGS, V10, P53
   BJORCK L, 1990, J VIROL, V64, P941
   Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x
   Bollong MJ, 2017, P NATL ACAD SCI USA, V114, P4679, DOI 10.1073/pnas.1702750114
   Butler D. J., 2020, HOST VIRAL ENV TRANS, DOI [10.1101/2020.04.20.048066, DOI 10.1101/2020.04.20.048066]
   Cai XM, 2013, CHEM BIOL, V20, P912, DOI 10.1016/j.chembiol.2013.05.010
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen H., 2020, 1 CLIN STUDY USING H, DOI [10.1101/2020.03.22.20034041, DOI 10.1101/2020.03.22.20034041]
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Choudhary S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01664
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Cihlar T, 2016, CURR OPIN VIROL, V18, P50, DOI 10.1016/j.coviro.2016.03.004
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Deprez M, 2020, AM J RESP CRIT CARE, V34, DOI [10.1164/rccm.201911-2199OC, DOI 10.1164/RCCM.201911-21990C]
   DEWIT S, 1992, ANTIMICROB AGENTS CH, V36, P2661, DOI 10.1128/AAC.36.12.2661
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Ferenci P, 2017, LANCET INFECT DIS, V17, P1008, DOI 10.1016/S1473-3099(17)30486-3
   GARRELTS JC, 1991, DICP ANN PHARMAC, V25, P525, DOI 10.1177/106002809102500513
   Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892
   Ghaedi M, 2013, J CLIN INVEST, V123, P4950, DOI 10.1172/JCI68793
   Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P5684, DOI 10.1016/j.bmcl.2008.08.082
   Harbut MB, 2015, P NATL ACAD SCI USA, V112, P4453, DOI 10.1073/pnas.1504022112
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Jacob A, 2019, NAT PROTOC, V14, P3303, DOI 10.1038/s41596-019-0220-0
   Janes J, 2018, P NATL ACAD SCI USA, V115, P10750, DOI 10.1073/pnas.1810137115
   Kapoor Aditya, 2020, Indian Pacing Electrophysiol J, V20, P117, DOI 10.1016/j.ipej.2020.04.003
   Kim YJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104558
   Kujawski SA, 2020, 1 12 PATIENTS CORONA, DOI [10.1101/2020.03.09.20032896, DOI 10.1101/2020.03.09.20032896]
   Kwan CY, 2002, ACTA PHARMACOL SIN, V23, P1057
   Li YY, 2012, GENOME MED, V4, DOI 10.1186/gm326
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Love MS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005373
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marzi A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001923
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matthew AN, 2018, BIOCHEMISTRY-US, V57, P481, DOI 10.1021/acs.biochem.7b01160
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mori Y, 2007, J VIROL, V81, P8477, DOI 10.1128/JVI.00477-07
   Nelson EA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005540
   Park WB, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e84
   Qiu S, 2018, VIROLOGY, V513, P17, DOI 10.1016/j.virol.2017.09.028
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Rutherford AC, 2006, J CELL SCI, V119, P3944, DOI 10.1242/jcs.03153
   Sakurai Y, 2015, SCIENCE, V347, P995, DOI 10.1126/science.1258758
   Sbrissa D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204532
   Schneider M, 2012, J VIROL, V86, P10112, DOI 10.1128/JVI.01001-12
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sultana F, 2020, J CELL BIOCHEM, V121, P2927, DOI 10.1002/jcb.29534
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   US Food and Drug Administration, 2020, FDA ISS EM US AUTH P
   Wang SQ, 2007, AMINO ACIDS, V33, P129, DOI 10.1007/s00726-006-0403-1
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   WHO, 2020, COR DIS COVID 19 PAN
   Xu Z, 2020, NELFINAVIR IS ACTIVE, DOI [10.26434/chemrxiv.12039888.v1, DOI 10.26434/CHEMRXIV.12039888.V1]
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhou YC, 2012, EXPERT REV ANTI-INFE, V10, P1129, DOI [10.1586/ERI.12.104, 10.1586/eri.12.104]
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 67
TC 14
Z9 14
U1 20
U2 20
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 1
PY 2020
VL 586
IS 7827
BP 113
EP +
DI 10.1038/s41586-020-2577-1
EA JUL 2020
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NV9IH
UT WOS:000572353000001
PM 32707573
OA Bronze
DA 2021-01-01
ER

PT J
AU DePace, NL
   Soloway, S
   Roshal, D
   Soloway, AM
   Colombo, J
AF DePace, Nicholas L.
   Soloway, Stephen
   Roshal, David
   Soloway, Alyxandra Morgan
   Colombo, Joe
TI Unexpected SARS-CoV-2 cardiorespiratory arrest in a myopathy patient
   undergoing immunosuppressive treatment A case report
SO MEDICINE
LA English
DT Article
DE cardio-respiratory arrest; coronavirus (COVID-19); dysphagia;
   immunosuppressive therapy; inflammatory myopathy
AB Rationale: It is recommended that patients with Rheumatic diseases that are at high risk of developing active infections be screened for Tuberculosis, Hepatitis B, and Hepatitis C before receiving second-line immunosuppressive therapies. With the emergence 2019 novel coronavirus (SARS-CoV-2), expanded guidelines have not been proposed for screening in these patients before starting advanced therapy. Patient concerns: We present an unique circumstance whereas a patient with a 5 year history of inflammatory muscle disease, diagnosed by clinical history and muscle biopsy with elevated creatine kinase levels, suffered a hypoxemic cardiopulmonary arrest due to asymptomatic SARS-CoV-2 after receiving advanced immunosuppressive therapy. Diagnoses: The patient presented with an acute exacerbation of inflammatory muscle disease with dysphagia, muscle weakness, and elevated creatine kinase. Interventions: After no improvement with intravenous immunoglobulin the patient received mycophenolate and plasma exchange therapy. Outcomes: Subsequently the patient suffered a fatal hypoxemic cardiopulmonary arrest. Polymerase chain reaction test was positive for SARS-CoV-2 RNA. Lessons: We conclude that rheumatic patients, asymptomatic for SARS-CoV-2 infection, be screened and tested before initiating second-line immunosuppressive treatment.
C1 [DePace, Nicholas L.] Univ Penn Hlth Syst, Penn Hosp, Philadelphia, PA USA.
   [Roshal, David] Rowan Univ, New Jersey Div, Jefferson Hlth, Sch Osteopath Med, Stratford, NJ USA.
   [DePace, Nicholas L.; Colombo, Joe] Franklin Cardiovasc Associates PA, 438 Ganttown Rd, Sewell, NJ 08080 USA.
RP DePace, NL (corresponding author), Franklin Cardiovasc Associates PA, 438 Ganttown Rd, Sewell, NJ 08080 USA.
EM dovetech@erols.com
CR Basharat P, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0548-6
   Dalakas MC, 2015, NEW ENGL J MED, V373, P393, DOI 10.1056/NEJMc1506827
   European League Against Rheumatism (EULAR), EULAR GUID PAT COVID
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Marie I, 2011, SEMIN ARTHRITIS RHEU, V41, P48, DOI 10.1016/j.semarthrit.2010.08.003
   McGrath ER, 2018, NEUROTHERAPEUTICS, V15, P976, DOI 10.1007/s13311-018-00676-2
   McIntosh K., 2020, CORONAVIRUS DIS 2019
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
NR 8
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 24
PY 2020
VL 99
IS 30
AR 21377
DI 10.1097/MD.0000000000021377
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MY4WY
UT WOS:000558420900094
PM 32791748
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Krafcikova, P
   Silhan, J
   Nencka, R
   Boura, E
AF Krafcikova, Petra
   Silhan, Jan
   Nencka, Radim
   Boura, Evzen
TI Structural analysis of the SARS-CoV-2 methyltransferase complex involved
   in RNA cap creation bound to sinefungin
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CRYSTAL-STRUCTURE; CORONAVIRUS; VIRUS; DISCOVERY; METHYLATION
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic. 2-O-RNA methyltransferase (MTase) is one of the enzymes of this virus that is a potential target for antiviral therapy as it is crucial for RNA cap formation; an essential process for viral RNA stability. This MTase function is associated with the nsp16 protein, which requires a cofactor, nsp10, for its proper activity. Here we show the crystal structure of the nsp10-nsp16 complex bound to the pan-MTase inhibitor sinefungin in the active site. Our structural comparisons reveal low conservation of the MTase catalytic site between Zika and SARS-CoV-2 viruses, but high conservation of the MTase active site between SARS-CoV-2 and SARS-CoV viruses; these data suggest that the preparation of MTase inhibitors targeting several coronaviruses - but not flaviviruses - should be feasible. Together, our data add to important information for structure-based drug discovery. p id=Par SARS-CoV-2 expresses a 2 ' -O RNA methyltransferase (MTase) that is involved in the viral RNA cap formation and therefore a target for antiviral therapy. Here the authors provide the structure of nsp10-nsp16 with the panMTase inhibitor sinefungin and report that the development of MTase inhibitor therapies that target multiple coronoaviruses is feasible.
C1 [Krafcikova, Petra; Silhan, Jan; Nencka, Radim; Boura, Evzen] Inst Organ Chem & Biochem AS CR, Vvi, Flemingovo Nam 2, Prague 16610 6, Czech Republic.
RP Nencka, R; Boura, E (corresponding author), Inst Organ Chem & Biochem AS CR, Vvi, Flemingovo Nam 2, Prague 16610 6, Czech Republic.
EM nencka@uochb.cas.cz; boura@uochb.cas.cz
OI Krafcikova, Petra/0000-0002-3363-2499
FU European Regional Development Fund; OP RDEEuropean Union (EU)
   [CZ.02.1.01/0.0/0.0/16_019/0000729]; MEYS CR [LM2018127]; Academy of
   Sciences of the Czech RepublicCzech Academy of Sciences [RVO: 61388963]
FX The work was supported from European Regional Development Fund; OP RDE;
   Project: "Chemical biology for drugging undruggable targets
   (ChemBioDrug)" (No. CZ.02.1.01/0.0/0.0/16_019/0000729). We acknowledge
   CMS-Biocev ("Diffraction") supported by MEYS CR (LM2018127) and the
   Academy of Sciences of the Czech Republic (RVO: 61388963). We are
   grateful to Dr. A. Michael Downey (Max Planck Institute of Colloids and
   Interfaces) for critical reading of the manuscript.
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Baumlova A, 2014, EMBO REP, V15, P1085, DOI 10.15252/embr.201438841
   Bradrick SS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02374
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Chen YT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002152
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   De Clercq E, 2013, MED RES REV, V33, P1249, DOI 10.1002/med.21281
   Decroly E, 2008, J VIROL, V82, P8071, DOI 10.1128/JVI.00407-08
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Dong HP, 2014, J GEN VIROL, V95, P763, DOI 10.1099/vir.0.062208-0
   Dubankova A, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104536
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   HAMILL RL, 1973, J ANTIBIOT, V26, P463, DOI 10.7164/antibiotics.26.463
   Hercik K, 2017, ARCH VIROL, V162, P2091, DOI 10.1007/s00705-017-3345-x
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Joseph JS, 2006, J VIROL, V80, P7894, DOI 10.1128/JVI.00467-06
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Martinez MG, 2020, LIVER INT, V40, P27, DOI 10.1111/liv.14364
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Policarpo RL, 2019, J MED CHEM, V62, P9837, DOI 10.1021/acs.jmedchem.9b01238
   Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551
   Sawicki SG, 2005, PLOS PATHOG, V1, P310, DOI 10.1371/journal.ppat.0010039
   Smietanski M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4004
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Zhao YQ, 2015, P NATL ACAD SCI USA, V112, P14834, DOI 10.1073/pnas.1514978112
   Ziebuhr J, 2006, ADV EXP MED BIOL, V581, P3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 31
TC 6
Z9 6
U1 6
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 24
PY 2020
VL 11
IS 1
AR 3717
DI 10.1038/s41467-020-17495-9
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MV4WM
UT WOS:000556360300010
PM 32709887
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, LX
   Miao, SY
   Qin, ZH
   Wu, JP
   Chen, HY
   Sun, HB
   Xie, Y
   Du, YQ
   Shen, J
AF Zhang, Li-Xia
   Miao, Shu-Yan
   Qin, Zhong-Hua
   Wu, Jun-Pin
   Chen, Huai-Yong
   Sun, Hai-Bai
   Xie, Yi
   Du, Yan-Qing
   Shen, Jun
TI Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Article
ID SUBSETS; BLOOD
AB Background and Objective Without a specific antiviral treatment or vaccine, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, affecting over 200 countries worldwide. A better understanding of B- and T-cell immunity is critical to the diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19). Methods A cohort of 129 patients with COVID-19 and 20 suspected cases were enrolled in this study, and a lateral flow immunochromatographic assay (LFIA) and a magnetic chemiluminescence enzyme immunoassay (MCLIA) were evaluated for SARS-CoV-2 IgM/IgG detection. Additionally, 127 patients with COVID-19 were selected for the detection of IgM and IgG antibodies to SARS-CoV-2 to evaluate B-cell immunity, and peripheral blood lymphocyte subsets were quantified in 95 patients with COVID-19 to evaluate T-cell immunity. Results The sensitivity and specificity of LFIA-IgM/IgG and MCLIA-IgM/IgG assays for detecting SARS-CoV infection were > 90%, comparable with reverse transcription polymerase chain reaction detection. IgM antibody levels peaked on day 13 and began to fall on day 21, while IgG antibody levels peaked on day 17 and were maintained until tracking ended. Lymphocyte and subset enumeration suggested that lymphocytopenia occurred in patients with COVID-19. Conclusions LFIA-IgM/IgG and MCLIA-IgM/IgG assays can indicate SARS-CoV-2 infection, which elicits an antibody response. Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response.
C1 [Zhang, Li-Xia; Miao, Shu-Yan; Qin, Zhong-Hua; Wu, Jun-Pin; Chen, Huai-Yong; Sun, Hai-Bai; Xie, Yi; Du, Yan-Qing; Shen, Jun] Tianjin Haihe Hosp, Tianjin Key Lab Lung Regenerat Med, 890 Jingu Rd, Tianjin 300350, Peoples R China.
RP Shen, J (corresponding author), Tianjin Haihe Hosp, Tianjin Key Lab Lung Regenerat Med, 890 Jingu Rd, Tianjin 300350, Peoples R China.
EM shenjun@tj.gov.cn
RI Chen, Huaiyong/G-3822-2014
OI Reis, AlessanRSS/0000-0001-8486-7469
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773394]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81773394). The funders had no role in the study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript.
CR Al Kahlout RA, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1386740
   Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Blum KS, 2007, IMMUNOL LETT, V108, P45, DOI 10.1016/j.imlet.2006.10.009
   Cai YT, 2020, JPN J APPL PHYS, V59, DOI 10.35848/1347-4065/ab7863
   Chen M, 2018, J CANCER RES THER, V14, pS331, DOI 10.4103/0973-1482.235350
   Hu X, 2020, HEAT INACTIVATION SE, DOI [10.1101/2020.03.12.20034231, DOI 10.1101/2020.03.12.20]
   Jiang H.-W., 2020, GLOBAL PROFILING SAR, DOI [10.1101/2020.03.20.20039495, DOI 10.1101/2020.03.20.20039495]
   Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007
   Liu JW, 2017, INT J INFECT DIS, V58, P45, DOI 10.1016/j.ijid.2017.02.017
   Liu R, 2020, COMP SUPERIORITY IGM, DOI [10.1101/2020.03.28.20045765, DOI 10.1101/2020.03.28.20045765]
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020
   Louati Nour, 2019, Tunis Med, V97, P327
   Milioglou I, 2019, PEDIATR INT, V61, P16, DOI 10.1111/ped.13701
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Nunez J, 2011, CURR MED CHEM, V18, P3226, DOI 10.2174/092986711796391633
   Pan YB, 2020, J INFECTION, V81, pE28, DOI 10.1016/j.jinf.2020.03.051
   Qiu Feng, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P164, DOI 10.12122/j.issn.1673-4254.2020.02.04
   Retamal-Diaz A, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030147
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xue Xiongyan, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P316, DOI 10.12122/j.issn.1673-4254.2020.03.03
   Yan Y, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2106
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zhao MQ, 2020, J MICROBIOL IMMUNOL, V53, P705, DOI 10.1016/j.jmii.2019.03.001
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PD OCT
PY 2020
VL 24
IS 5
BP 601
EP 609
DI 10.1007/s40291-020-00486-3
EA JUL 2020
PG 9
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA NN5PB
UT WOS:000552167500001
PM 32710269
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU D'Angelo, G
   Palmieri, F
AF D'Angelo, Gianni
   Palmieri, Francesco
TI Discovering genomic patterns in SARS-CoV-2 variants
SO INTERNATIONAL JOURNAL OF INTELLIGENT SYSTEMS
LA English
DT Article
DE common subsequence; coronavirus; COVID-19; dynamic programming; genomic
   patterns; genomic variants; pattern recognition; SARS-CoV-2; sequence
   analysis; spike protein
AB SARS-CoV-2 is a novel severe acute respiratory syndrome-like coronavirus (SARS-CoV), which is responsible of the ongoing world pandemic of COVID-19 disease. Although many approaches are being investigated to address this issue, nowaday there are no vaccines available and there is little evidence supporting the efficiency of potential therapeutic agents. Moreover, the high mutation rate of this virus heavily affects the understanding of its evolution and diffusion mechanisms, and, in turn, the development of effective solutions. In this study, two novel algorithms are provided for finding out recurrent patterns of nucleotide subsequences of different SARS-CoV-2 genomes as a unique signature capable of identifying the most peculiar features of the pathogen. In particular, we provide several subsequence patterns related to the Spike glycoprotein, which is believed to be the main target for developing effective drugs and vaccines against the COVID-19 disease because of its role in the entrance of coronaviruses into host cells. The experimental results, obtained by analyzing 5000 genomes of SARS-CoV-2, have shown that the extracted patterns are able to recognize the Spyke protein in the 99.35% of the considered genomes. In addition, such patterns have proven to be highly discriminating with respect to other pathogenic genomes, such as SARS, Middle East respiratory syndrome, Nipah, and the streptococcus bacteria. We hope that the findings presented in this study can help specialists in speeding up the design of more accurate drugs or vaccines against SARS-CoV-2.
C1 [D'Angelo, Gianni; Palmieri, Francesco] Univ Salerno, Dept Comp Sci, Via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.
RP D'Angelo, G (corresponding author), Univ Salerno, Dept Comp Sci, Via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.
EM giadangelo@unisa.it
RI D'ANGELO, Gianni/ABF-8706-2020
CR Aditi, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819000086
   Bergroth L, 2000, SPIRE 2000: SEVENTH INTERNATIONAL SYMPOSIUM ON STRING PROCESSING AND INFORMATION RETRIEVAL - PROCEEDINGS, P39, DOI 10.1109/SPIRE.2000.878178
   Chen YC, 2011, J COMB OPTIM, V21, P383, DOI 10.1007/s10878-009-9262-5
   Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   D'Angelo G, 2019, SOFT COMPUT, V23, P11775, DOI 10.1007/s00500-018-03729-y
   D'Angelo G, 2018, SOFT COMPUT, V22, P2421, DOI 10.1007/s00500-017-2512-z
   Jia Y., 2020, ANAL MUTATION DYNAMI, DOI [10.1101/2020.04.09.034942V1, DOI 10.1101/2020.04.09.034942V1]
   Knuth D. E., 1976, SIGACT News, V8, P18
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee LYY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01568
   Lew A, 2006, STUDIES COMPUTATIONA
   Lokman SM, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104389
   MAIER D, 1978, J ACM, V25, P322, DOI 10.1145/322063.322075
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu YJ, 2014, J DISCRET ALGORITHMS, V26, P98, DOI 10.1016/j.jda.2014.01.005
NR 23
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-8173
EI 1098-111X
J9 INT J INTELL SYST
JI Int. J. Intell. Syst.
PD NOV
PY 2020
VL 35
IS 11
BP 1680
EP 1698
DI 10.1002/int.22268
EA JUL 2020
PG 19
WC Computer Science, Artificial Intelligence
SC Computer Science
GA NT6CU
UT WOS:000551845200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Basch, CH
   Hillyer, GC
   Zagnit, EA
   Basch, CE
AF Basch, Corey H.
   Hillyer, Grace C.
   Zagnit, Emily A.
   Basch, Charles E.
TI YouTube coverage of COVID-19 vaccine development: implications for
   awareness and uptake
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE YouTube; COVID-19; social media; vaccine; infectious disease
ID VIRUS DISEASE EPIDEMIC
AB This study examined 100 widely viewed YouTube videos on COVID-19 vaccination. Information such as length, format, upload source, content, and cumulative views was coded. As of April 6, 2020, the videos were viewed >33 million times. Almost 75% were uploaded by news sources (garnering >20 million views). While only 16% were uploaded by consumers, these videos garnered over 25% of cumulative views (n = 8,581,186 views). The majority of videos mentioned the vaccine manufacturing process (61.0%) and 45.0% speculated on the amount of time needed to have a vaccine ready for use, which most often was thought to be 1-2 years. Even once the biological and technical aspects of vaccine development and manufacturing are accomplished, the benefits conferred on population health will also depend on public willingness to be vaccinated. Ongoing tracking of YouTube is needed to identify what is communicated about vaccines for COVID-19. To the extent that public health officials learn how to create videos about the safety and effectiveness of a COVID-19 vaccine, which attract viewers, this could help increase awareness and interest about vaccination and help individuals make an informed decision about vaccine uptake.
C1 [Basch, Corey H.] William Paterson Univ, Dept Publ Hlth, Wayne, NJ 07470 USA.
   [Hillyer, Grace C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Zagnit, Emily A.] George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC USA.
   [Basch, Charles E.] Columbia Univ, Teachers Coll, Hlth & Behav Studies, New York, NY 10027 USA.
RP Basch, CH (corresponding author), William Paterson Univ, Dept Publ Hlth, Wayne, NJ 07470 USA.
EM baschc@wpunj.edu
CR [Anonymous], 2020, LANCET, V395, P538, DOI 10.1016/S0140-6736(20)30255-5
   Basch CH, 2017, CHILD CARE HLTH DEV, V43, P499, DOI 10.1111/cch.12442
   Basch CH, 2016, INT J ADOLESCENT MED, V30, DOI [10.1515/ijamh-2015-0122, DOI 10.1515/IJAMH-2015-0122]
   Basch Charles E, 2020, JMIR Public Health Surveill, V6, pe19145, DOI 10.2196/19145
   Basch CH, 2020, JMIR PUBLIC HLTH SUR, V6, P147, DOI 10.2196/18807
   Basch Corey H, 2017, J Prev Med Public Health, V50, P133, DOI 10.3961/jpmph.16.107
   Basch CH, 2017, AM J MENS HEALTH, V11, P154, DOI 10.1177/1557988316671459
   Basch CH, 2015, DISASTER MED PUBLIC, V9, P531, DOI 10.1017/dmp.2015.77
   Basch CH, 2015, JMIR CANCER, V1, DOI 10.2196/cancer.4204
   Basch CH, 2014, HEALTH PROMOT PERSPE, V4, P247, DOI 10.5681/hpp.2014.032
   Centers for Disease Control and Prevention, 2014, VACC IMM
   Centers for Disease Control and Prevention, 2019, FLU VACC COV US 2018
   Centers for Disease Control and Prevention, 2020, COR COVID 19
   Cohen J, 2020, SCIENCE, V368, P456, DOI 10.1126/science.368.6490.456
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Google Trends, 2020, COVID 10 MAP
   Johns Hopkins Bloomberg School of Public Health, COVID 19 SCH PUBL HL
   Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Meleo-Erwin Z, 2017, HUM VACC IMMUNOTHER, V13, P1895, DOI 10.1080/21645515.2017.1321182
   Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4
   Rubin Eric J, 2020, N Engl J Med, V382, pe58, DOI 10.1056/NEJMe2012889
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   WHO, 2020, COR DIS COVID 19 PAN
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 27
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD NOV 1
PY 2020
VL 16
IS 11
BP 2582
EP 2585
DI 10.1080/21645515.2020.1790280
EA JUL 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PC2WP
UT WOS:000551318800001
PM 32701403
OA Bronze
DA 2021-01-01
ER

PT J
AU Danilewitz, M
   Ainsworth, NJ
   Bahji, A
   Chan, P
   Rabheru, K
AF Danilewitz, Marlon
   Ainsworth, Nicholas J.
   Bahji, Anees
   Chan, Peter
   Rabheru, Kiran
TI Virtual psychiatric care for older adults in the age of COVID-19:
   Challenges and opportunities
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Letter
DE COVID-19; e-therapies; virtual psychiatric care
ID HEALTH
C1 [Danilewitz, Marlon; Ainsworth, Nicholas J.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada.
   [Bahji, Anees] Queens Univ, Dept Psychiat, Kingston, ON, Canada.
   [Chan, Peter] Univ British Columbia, Div Geriatr Psychiat, Dept Psychiat, Vancouver, BC, Canada.
   [Rabheru, Kiran] Univ Ottawa, Dept Psychiat, Ottawa, ON, Canada.
RP Danilewitz, M (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada.
EM marlondanilewitz@gmail.com
RI Bahji, Anees/AAA-4193-2020
OI Bahji, Anees/0000-0002-3490-314X; Ainsworth,
   Nicholas/0000-0002-6340-2336; Danilewitz, Marlon/0000-0002-3366-9494
CR Carlbring P, 2018, COGN BEHAV THERAPY, V47, P1, DOI 10.1080/16506073.2017.1401115
   Goldbloom D, 2017, CAN J PSYCHIAT, V62, P688, DOI 10.1177/0706743717714469
   Haralambous B, 2019, ASIA-PAC PSYCHIAT, V11, DOI 10.1111/appy.12355
   Konig Alexandra, 2015, Alzheimers Dement (Amst), V1, P112, DOI 10.1016/j.dadm.2014.11.012
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Ong AD, 2016, GERONTOLOGY, V62, P443, DOI 10.1159/000441651
   Salisbury C, 2016, LANCET PSYCHIAT, V3, P515, DOI 10.1016/S2215-0366(16)00083-3
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wildenbos GA, 2018, INT J MED INFORM, V114, P66, DOI 10.1016/j.ijmedinf.2018.03.012
   Williams KN, 2019, INNOV AGING, V3, DOI 10.1093/geroni/igz037
NR 10
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD DEC
PY 2020
VL 35
IS 12
BP 1468
EP 1469
DI 10.1002/gps.5372
EA JUL 2020
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA OW1FT
UT WOS:000551628700001
PM 32602134
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yadav, R
   Imran, M
   Dhamija, P
   Chaurasia, DK
   Handu, S
AF Yadav, Rohitash
   Imran, Mohammed
   Dhamija, Puneet
   Chaurasia, Dheeraj Kumar
   Handu, Shailendra
TI Virtual screening, ADMET prediction and dynamics simulation of potential
   compounds targeting the main protease of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Main protease; COVID-19; SARS CoV-2; docking; molecular dynamics
   simulation
ID PAPAIN-LIKE PROTEASE; CORONAVIRUS; REPLICATION; DOCKING
AB The coronavirus disease-2019 caused by a novel SARS CoV-2 virus has emerged as a global threat. Still, no drugs are available for its treatment. The main protease is the most conserved structure responsible for the posttranslational processing of non-structural polyproteins of this virus. Therefore, it can be the potential target for drug discovery against SARS CoV-2. Twenty-one thousand two hundred and seven chemical compounds used for sequential virtual screening studies including coronavirus screening compounds (Life Chemical database) and antiviral compounds (Asinex database). The Schrodinger suite 2019 employed for high throughput screening, molecular docking and MM-GBSA through the Glide module. Subsequently, 23 compounds were selected in the phase first selection criteria for re-docking with AutoDock and iDock followed by ADMET prediction. The drug-likeness predicted through Lipinski's rule of five, Veber's rule and Muegge's rule. Finally, three ligands were selected for molecular dynamics simulation studies over 150 ns against the main protease of the SARS CoV-2. They showed promising docking scores on Glide, iDock and AutoDock Vina algorithms (ligand F2679-0163: -10.75, -10.29 and -9.2; ligand F6355-0442: -9.38, -8.61 and -7.6; ligand 8250: -9.795, -7.94 and -7.5), respectively. The RMSD parameter remained stable at 2.5 angstrom for all the three ligands for 150 ns. The high RMSF fluctuations, RoG of around 22 angstrom and the binding free energy were favorable in each case. The hydrogen bond interactions of 8250, F6355-0442 and F2679-0163 were six, five and three, respectively. These compounds can be further explored forin vitroexperimental validation against SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Yadav, Rohitash; Dhamija, Puneet; Handu, Shailendra] All India Inst Med Sci, Dept Pharmacol, Rishikesh, Uttarakhand, India.
   [Imran, Mohammed] Shaqra Univ, Coll Med, Dept Pharmacol, Shaqra, Saudi Arabia.
   [Chaurasia, Dheeraj Kumar] Indian Inst Technol, Supercomp Facil Bioinformat & Computat Biol, Delhi, India.
RP Yadav, R (corresponding author), All India Inst Med Sci, Dept Pharmacol, Rishikesh, Uttarakhand, India.
EM rohitashyadav1@gmail.com
OI Yadav, Rohitash/0000-0003-0859-5603; Kumar Chaurasia,
   Dheeraj/0000-0001-9001-5238
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cascella M, 2020, STATPEARLS
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cherian Sarah S, 2020, Indian J Med Res, V151, P160, DOI 10.4103/ijmr.IJMR_585_20
   da Costa VG, 2020, ARCH VIROL, V165, P1517, DOI 10.1007/s00705-020-04628-0
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gupta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776157
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Havranek B, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1776158, 10.1080/07391102.2020.1805018]
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Hongjian Li, 2012, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), P77, DOI 10.1109/CIBCB.2012.6217214
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Kesharwani SS, 2016, J MOL RECOGNIT, V29, P370, DOI 10.1002/jmr.2537
   Krichel B, 2020, BIOCHEM J, V477, P1009, DOI 10.1042/BCJ20200029
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Muegge I, 2003, MED RES REV, V23, P302, DOI 10.1002/med.10041
   Nandekar PP, 2013, MED CHEM RES, V22, P3728, DOI 10.1007/s00044-012-0364-8
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Pal M, 2020, CUREUS, V12, DOI 10.7759/cureus.7423
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Roussel Y, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105947
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Sayad B, 2020, ARCH MED RES, V51, P577, DOI 10.1016/j.arcmed.2020.04.018
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Stobart CC, 2013, J VIROL, V87, P12611, DOI 10.1128/JVI.02050-13
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Xu LH, 2011, J BIOL CHEM, V286, P39546, DOI 10.1074/jbc.M111.242206
   Yadav R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1778536
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Zarocostas J, 2020, LANCET, V395, P401, DOI 10.1016/S0140-6736(20)30292-0
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 57
TC 0
Z9 0
U1 9
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796812
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MP9SH
UT WOS:000552537400001
PM 32715956
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alsem, MW
   Berkhout, JJ
   Buizer, AI
AF Alsem, Mattijs W.
   Berkhout, Joris J.
   Buizer, Annemieke I.
TI Therapy needs and possibilities in paediatric rehabilitation during the
   COVID-19 lockdown in the Netherlands
SO CHILD CARE HEALTH AND DEVELOPMENT
LA English
DT Letter
C1 [Alsem, Mattijs W.] Univ Amsterdam, Dept Rehabil, Amsterdam UMC, Amsterdam Movement Sci, Meibergdreef 9, Amsterdam, Netherlands.
   [Berkhout, Joris J.; Buizer, Annemieke I.] Univ Amsterdam, Vrije Univ Amsterdam, Dept Rehabil Med, Amsterdam Movement Sci, Amsterdam, Netherlands.
   [Alsem, Mattijs W.; Berkhout, Joris J.; Buizer, Annemieke I.] Amsterdam UMC, Emma Childrens Hosp, Amsterdam, Netherlands.
RP Alsem, MW (corresponding author), Univ Amsterdam, Dept Rehabil, Amsterdam UMC, Amsterdam Movement Sci, Meibergdreef 9, Amsterdam, Netherlands.; Alsem, MW (corresponding author), Amsterdam UMC, Emma Childrens Hosp, Amsterdam, Netherlands.
CR Fazzi E, 2020, DEV MED CHILD NEUROL, V62, P879, DOI 10.1111/dmcn.14557
   Novak I, 2020, DEV MED CHILD NEUROL, V62, P17, DOI 10.1111/dmcn.14345
NR 2
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1862
EI 1365-2214
J9 CHILD CARE HLTH DEV
JI Child Care Health Dev.
PD NOV
PY 2020
VL 46
IS 6
BP 749
EP 750
DI 10.1111/cch.12797
EA JUL 2020
PG 2
WC Psychology, Developmental; Pediatrics
SC Psychology; Pediatrics
GA OC3KR
UT WOS:000551485100001
PM 32692426
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Soleimani, Z
   Soleimani, A
AF Soleimani, Zahra
   Soleimani, Azam
TI ADRS due to COVID-19 in midterm pregnancy: successful management with
   plasma transfusion and corticosteroids
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article; Early Access
DE Pregnancy; convalescent plasma transfusion; acute respiratory distress
   syndrome; SARS-CoV2; corticosteroid
AB Background Management of acute respiratory distress syndrome (ARDS) in pregnant women infected with new severe acute respiratory syndrome Corona virus 2 (SARS-CoV2) is a challenging clinical task. Case A 30- year-old woman (gravid 3, parity 2) presented at her 21 and 2/7 weeks gestation (pre pregnancy BMI: 36.1 kg/m(2)), with ARDS caused by SARS-CoV(2)infection. She received lopinavir/ritonavir and azithromycin as well as early methyl prednisolone therapy. Given the persistent hypoxemia despite oxygen therapyvianon rebreather face mask (FiO(2):80%), convalescent plasma transfusion was administered that led to a mild clinical improvement as well as decrease in inflammatory markers. Growth of her fetus assessed by obstetric sonography was normal during hospital stay. Conclusion Judicious corticosteroid therapy along with convalescent plasma transfusion to suppress viremia and cytokine storm can lead to favorable outcome in the pregnant women with ARDS caused by SARS-CoV(2)infection without superimposed bacterial infection.
C1 [Soleimani, Zahra] Baqiyatallah Univ Med Sci, Nephrol & Urol Res Ctr, Tehran, Iran.
   [Soleimani, Zahra] Hope Generatin Fdn, Fetal Hlth Res Ctr, Tehran, Iran.
   [Soleimani, Azam] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Cardiac Rehabil Res Ctr, Esfahan, Iran.
RP Soleimani, A (corresponding author), Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Cardiac Rehabil Res Ctr, Esfahan, Iran.
EM asoleimanii@gmail.com
OI Soleimani, Zahra/0000-0003-3937-3800
CR Cao B, 2020, NEW ENGL J MED, V382
   Chen H, 2020, LANCET, V395
   Chen L, 2020, LANCET INFECT DIS, V20
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Cortesi M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062002
   Dashraath P, 2020, AM J OBSTET GYNECOL, V23
   Fanelli V, 2013, J THORAC DIS, V5, P326, DOI 10.3978/j.issn.2072-1439.2013.04.05
   Favre G, 2020, LANCET INFECT DIS, V20, P652, DOI 10.1016/S1473-3099(20)30157-2
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Ko JH, 2018, ANTIVIR THER LOND, V23
   LAN RC, 2020, JAMA-J AM MED ASSOC, V32, DOI DOI 10.1002/ADMA.201906319
   Leider JP, 2010, TRANSFUSION, V50, P1384, DOI 10.1111/j.1537-2995.2010.02590.x
   Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z
   Liang H, 2020, ACTA OBSTET GYN SCAN, V99, P439, DOI 10.1111/aogs.13836
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Shuai HQ, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05030-6
   Tanne JH, 2020, BMJ, V368
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Xu Z, 2020, LANCET RESP MED, V8
   Yang Z, 2020, J MATERN FETAL NEONA, V30
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zha L, 2020, MED J AUST, V8
NR 22
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
DI 10.1080/14767058.2020.1797669
EA JUL 2020
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA MP9ZC
UT WOS:000552555400001
PM 32715804
DA 2021-01-01
ER

PT J
AU Antonelli, M
   Donelli, D
AF Antonelli, Michele
   Donelli, Davide
TI Respiratory rehabilitation for post-COVID19 patients in spa centers:
   first steps from theory to practice
SO INTERNATIONAL JOURNAL OF BIOMETEOROLOGY
LA English
DT Letter
DE Medical hydrology; COVID-19; SARS-CoV-2; Spa centers; Rehabilitation;
   Public health
ID STRESS BIOMARKER; BALNEOTHERAPY; CORTISOL; THERAPY
AB With this correspondence, we would like to briefly outline a practical perspective about a possible integrative and effective management in spa settings of COVID-19 long-term sequelae, with a keen focus on post-infective lung damage and fibrosis, which is expected to become epidemiologically relevant in the general population. In order to outline a standard/baseline model of care, we think that it can be useful to refer to already existing rehabilitative plans with a long-standing tradition in Italy, such as those ones prescribed for work-related respiratory diseases like pneumoconiosis, in which long-term outcomes share some clinical characteristics with post-infective lung fibrosis. Such programs include diagnostic procedures (spirometry, ECG, blood tests) and treatments like respiratory physio-kinesiotherapy and postural drainage of the lungs; mechanical pulmonary ventilation for rehabilitative purposes, with or without drugs, along with standard medical and, when required, oxygen therapy; inhalation therapies with mineral waters; physical activity and psychological support. In conclusion, we believe that spa facilities can be a proper setting for respiratory rehabilitation and that already existing programs employed in occupational medicine can be a good starting point to plan rehabilitative strategies for post-COVID-19 patients. In particular, health spa centers can be useful not only to offer tailored programs of physical rehabilitation but also to provide patients with a psychologically supportive and health-promoting environment. Further studies on the topic are advised to properly assess and quantify with adequate outcome measurements the beneficial effect of a spa-based rehabilitative program in post-COVID-19 patients.
C1 [Antonelli, Michele] Terme Monticelli, Via Basse 5, I-43022 Parma, Italy.
   [Antonelli, Michele] Univ Parma, Inst Publ Hlth, Parma, Italy.
   [Donelli, Davide] AUSL IRCCS Reggio Emilia, USCA Med Special Units Management Patients COVID1, Reggio Emilia, Italy.
RP Antonelli, M (corresponding author), Terme Monticelli, Via Basse 5, I-43022 Parma, Italy.; Antonelli, M (corresponding author), Univ Parma, Inst Publ Hlth, Parma, Italy.
EM ricerca@termedimonticelli.it
CR [Anonymous], 2020, GUID DISCH END IS CO
   Antonelli M, 2019, INT J BIOMETEOROL, V63, P1117, DOI 10.1007/s00484-019-01717-x
   Antonelli M, 2018, RHEUMATOL INT, V38, P1807, DOI 10.1007/s00296-018-4081-6
   Antonelli M, 2018, INT J BIOMETEOROL, V62, P913, DOI 10.1007/s00484-018-1504-8
   Bello G, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.04.39
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Clementi M, 2020, PROTOCOLLI PIANI AUT
   Clini E, 2018, TXB PULMONARY REHABI
   INAIL, 1995, 48 INAIL
   Masiero S, 2020, INT J BIOMETEOROL, V64, P1807, DOI 10.1007/s00484-020-01947-4
   Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8
   Troosters T, 2019, RESPIROLOGY, V24, P830, DOI 10.1111/resp.13517
NR 12
TC 1
Z9 1
U1 9
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0020-7128
EI 1432-1254
J9 INT J BIOMETEOROL
JI Int. J. Biometeorol.
PD OCT
PY 2020
VL 64
IS 10
BP 1811
EP 1813
DI 10.1007/s00484-020-01962-5
EA JUL 2020
PG 3
WC Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences;
   Physiology
SC Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric
   Sciences; Physiology
GA NL6HA
UT WOS:000552167400001
PM 32710297
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bahmad, HF
   Abou-Kheir, W
AF Bahmad, Hisham F.
   Abou-Kheir, Wassim
TI Crosstalk between COVID-19 and prostate cancer
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
ID TMPRSS2
AB A new coronavirus, named SARS-CoV-2, emerged in Wuhan city, China, in December 2019 causing atypical pneumonia and affecting multiple body organs. The rapidly increasing numbers of infected patients and deaths due to COVID-19 disease necessitated declaring it as a global pandemic. Efforts were combined since then to rapidly develop a treatment and/or a vaccine to combat the deadly virus. Drug repurposing approach has been pursued as a temporary management tactic to treat COVID-19 patients. However, reports about the efficacy of many of the used drugs had been controversial with a dire need to keep the ongoing efforts for rapid development of new treatments. Promising data came out pointing to a possible hidden liaison between prostate cancer (PCa) and COVID-19, where androgen-deprivation therapies (ADT) used in PCa had been shown to instigate a protective role against COVID-19. Delving into the possible mechanisms underlying the crosstalk between COVID-19 and PCa alludes a potential association between SARS-CoV-2 targets on host epithelial cells and PCa genetic aberrations and molecular signatures, includingARandTMPRSS2. The question remains: Can PCa treatments serve as potential therapeutic options for COVID-19 patients?
C1 [Bahmad, Hisham F.; Abou-Kheir, Wassim] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon.
   [Bahmad, Hisham F.] Mt Sinai Med Ctr, Arkadi M Rywlin MD Dept Pathol & Lab Med, Miami Beach, FL 33140 USA.
RP Abou-Kheir, W (corresponding author), Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon.
EM wa12@aub.edu.lb
RI Bahmad, Hisham/A-5369-2019
OI Bahmad, Hisham/0000-0003-3799-2595; Abou-Kheir,
   Wassim/0000-0001-9719-9324
CR Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Montopoli M, 2020, ANN ONCOL
   Pettersson A, 2012, CANCER EPIDEM BIOMAR, V21, P1497, DOI 10.1158/1055-9965.EPI-12-0042
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Wambier CG, 2020, DRUG DEVELOP RES, V81, P771, DOI 10.1002/ddr.21688
   WHO, 2020, COR DIS COVID 19 PAN
   Wu ZS, 2020, J UROLOGY, V204, P7, DOI 10.1097/JU.0000000000001068
NR 10
TC 1
Z9 1
U1 4
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1365-7852
EI 1476-5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD DEC
PY 2020
VL 23
IS 4
BP 561
EP 563
DI 10.1038/s41391-020-0262-y
EA JUL 2020
PG 3
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA OQ3VP
UT WOS:000552166400002
PM 32709978
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Satlin, MJ
   Goyal, P
   Magleby, R
   Maldarelli, GA
   Pham, K
   Kondo, M
   Schenck, EJ
   Rennert, H
   Westblade, LF
   Choi, JJ
   Safford, MM
   Gulick, RM
AF Satlin, Michael J.
   Goyal, Parag
   Magleby, Reed
   Maldarelli, Grace A.
   Pham, Khanh
   Kondo, Maiko
   Schenck, Edward J.
   Rennert, Hanna
   Westblade, Lars F.
   Choi, Justin J.
   Safford, Monika M.
   Gulick, Roy M.
TI Safety, tolerability, and clinical outcomes of hydroxychloroquine for
   hospitalized patients with coronavirus 2019 disease
SO PLOS ONE
LA English
DT Article
ID QT-INTERVAL
AB Background
   Severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused a devastating worldwide pandemic. Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited.
   Methods
   This was a retrospective cohort study of hospitalized patients with COVID-19 who received >= 1 dose of HCQ at two New York City hospitals. We measured incident Grade 3 or 4 blood count and liver test abnormalities, ventricular arrhythmias, and vomiting and diarrhea within 10 days after HCQ initiation, and the proportion of patients who completed HCQ therapy. We also describe changes in Sequential Organ Failure Assessment hypoxia scores between baseline and day 10 after HCQ initiation and in-hospital mortality.
   Results
   None of the 153 hospitalized patients with COVID-19 who received HCQ developed a sustained ventricular tachyarrhythmia. Incident blood count and liver test abnormalities occurred in < 15% of patients and incident vomiting or diarrhea was rare. Eighty-nine percent of patients completed their HCQ course and three patients discontinued therapy because of QT prolongation. Fifty-two percent of patients had improved hypoxia scores 10 days after starting HCQ. Thirty-one percent of patients who were receiving mechanical ventilation at the time of HCQ initiation died during their hospitalization, compared to 18% of patients who were receiving supplemental oxygen but not requiring mechanical ventilation, and 8% of patients who were not requiring supplemental oxygen. Co-administration of azithromycin was not associated with improved outcomes.
   Conclusions
   HCQ appears to be reasonably safe and tolerable in most hospitalized patients with COVID-19. However, nearly one-half of patients did not improve with this treatment, highlighting the need to evaluate HCQ and alternate therapies in randomized trials.
C1 [Satlin, Michael J.; Goyal, Parag; Kondo, Maiko; Schenck, Edward J.; Westblade, Lars F.; Choi, Justin J.; Safford, Monika M.; Gulick, Roy M.] Weill Cornell Med, Dept Med, New York, NY 10065 USA.
   [Satlin, Michael J.; Goyal, Parag; Magleby, Reed; Maldarelli, Grace A.; Pham, Khanh; Schenck, Edward J.; Rennert, Hanna; Westblade, Lars F.; Choi, Justin J.; Safford, Monika M.; Gulick, Roy M.] Weill Cornell Med Ctr, NewYork Presbyterian Hosp, New York, NY 10065 USA.
   [Rennert, Hanna; Westblade, Lars F.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA.
RP Satlin, MJ; Gulick, RM (corresponding author), Weill Cornell Med, Dept Med, New York, NY 10065 USA.; Satlin, MJ; Gulick, RM (corresponding author), Weill Cornell Med Ctr, NewYork Presbyterian Hosp, New York, NY 10065 USA.
EM mjs9012@med.cornell.edu; rgulick@med.cornell.edu
FU National Center for Advancing Translational Science [UL1 TR002384];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
FX This work was partially supported by the National Center for Advancing
   Translational Science [UL1 TR002384] at the National Institutes of
   Health. No additional external funding was received for this study.
CR AHNVE S, 1985, AM HEART J, V109, P568, DOI 10.1016/0002-8703(85)90564-2
   Beigel JH, 2020, N ENGL J MED
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen Z, ME DRXIV, DOI [10.1101/2020.03.22, DOI 10.1101/2020.03.22]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Gautret P, 2020, INT J ANTIMICRO 0320
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   International Society of Antimicrobial Chemotherapy, OFF STAT IJAA PAP
   Ison MG, 2020, JAMA
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Lambden S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2663-7
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mercuro NJ, 2020, JAMA CARDIOL
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   New York City Department of Health, COVID 19 DAT
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Rosenberg ES, 2020, JAMA
   Shickel B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38491-0
   Srinivasa Amar, 2017, J Rheumatol, V44, P398, DOI 10.3899/jrheum.161063
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   US Department of Health and Human Services, 2017, COMM TERM CRIT ADV E
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, COR DIS 2019 COVID 1
   Yao X, 2010, CLIN INFECT DIS
NR 31
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2020
VL 15
IS 7
AR e0236778
DI 10.1371/journal.pone.0236778
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NX7VK
UT WOS:000575913700103
PM 32701969
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kanthi, Y
   Knight, JS
   Zuo, Y
   Pinsky, DJ
AF Kanthi, Yogendra
   Knight, Jason S.
   Zuo, Yu
   Pinsky, David J.
TI New (re)purpose for an old drug: purinergic modulation may extinguish
   the COVID-19 thromboinflammatory firestorm
SO JCI INSIGHT
LA English
DT Article
ID DIPYRIDAMOLE; THROMBOSIS
AB Severe manifestations of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as acute respiratory distress syndrome (ARDS), are characterized by hyperinflammation, exuberant cytokine release, profound and progressive hypoxia, deranged coagulation, and multiorgan failure (1). COVID-19 also presents not infrequently with a devastating thrombotic diathesis, manifesting as arterial thrombosis, pulmonary embolism, deep vein thrombosis, and thrombotic microangiopathy. Not surprisingly, dysregulation of tonic vascular homeostatic functions of endothelial and hematopoietic lineage cells has been implicated in the pathophysiology of COVID-19. Reminiscent of neutrophil and macrophage hyperactivation syndromes, the COVID-19-associated systemic inflammatory response syndrome is likely driven by the activation and/or death of infected cells and collateral damage triggered by explosive production of cytokines and chemokines. Recruited leukocytes spew a fibrin/platelet-entrapping meshwork of DNA and associated histones, which in a vicious cycle further recruits leukocytes and triggers intravascular coagulation through endothelial, platelet, and leukocyte dysfunction (2). These concepts are supported by autopsy studies that have detected clusters of activated and degenerating myeloid cells in both intravascular and extravascular spaces (3) as well as an endotheliitis that is characterized by viral inclusion bodies and SARS-CoV-2 nucleoprotein in the walls of blood vessels (4, 5).
C1 [Kanthi, Yogendra; Pinsky, David J.] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
   [Kanthi, Yogendra] NHLBI, Sect Vasc Thrombosis & Inflammat, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Knight, Jason S.; Zuo, Yu] Univ Michigan, Div Rheumatol, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Pinsky, David J.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
RP Kanthi, Y (corresponding author), NHLBI, NIH, 10 Ctr Dr,Room 5-5130, Bethesda, MD 20892 USA.; Knight, JS (corresponding author), Univ Michigan, 5560 MSRB2,1150 West Med Ctr Dr, Ann Arbor, MI 48109 USA.; Pinsky, DJ (corresponding author), Univ Michigan, 2141 Cardiovasc Ctr,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM yogen.kanthi@nih.gov; jsknight@umich.edu; dpinsky@umich.edu
OI Knight, Jason/0000-0003-0995-9771; Kanthi, MD,
   Yogendra/0000-0002-5660-5194; Zuo, Yu/0000-0001-6721-7755
FU COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan
   Medicine Frankel Cardiovascular Center; A. Alfred Taubman Medical
   Research Institute; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K08HL131993,
   R01HL150392, R01HL134846]; Falk Medical Research Trust Catalyst Award;
   JOBST-American Venous Forum Award; Intramural Research Program of the
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI); Lupus Research Alliance; Burroughs Wellcome
   FundBurroughs Wellcome Fund; Rheumatology Research Foundation; APS
   ACTION
FX The work was supported by a COVID-19 Cardiovascular Impact Research
   Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center
   as well as by the A. Alfred Taubman Medical Research Institute. YK was
   supported by the NIH (K08HL131993, R01HL150392), a Falk Medical Research
   Trust Catalyst Award, the JOBST-American Venous Forum Award, and, in
   part, by the Intramural Research Program of the NIH and National Heart,
   Lung, and Blood Institute. JSK was supported by grants from the NIH
   (R01HL134846, R01HL150392), Lupus Research Alliance, and Burroughs
   Wellcome Fund. YZ was supported by career development grants from the
   Rheumatology Research Foundation and APS ACTION. DJP was supported by
   the NIH (R01HL150392). The authors thank all members of the "NETwork to
   Target Neutrophils in COVID-19" for their helpful advice and
   encouragement.
CR Ali RA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09801-x
   [Anonymous], 2019, PERS DIP
   Anyanwu AC, 2019, ARTERIOSCL THROM VAS, V39, pE118, DOI 10.1161/ATVBAHA.119.312407
   Carta S, 2015, P NATL ACAD SCI USA, V112, P2835, DOI 10.1073/pnas.1424741112
   Chakrabarti S, 2005, J PHARMACOL EXP THER, V315, P494, DOI 10.1124/jpet.105.089987
   Colling ME, 2020, VASC MED, V25, P471, DOI 10.1177/1358863X20932640
   Cronstein BN, 2017, NAT REV RHEUMATOL, V13, P41, DOI 10.1038/nrrheum.2016.178
   Deguchi H, 1998, THROMB RES, V91, P57, DOI 10.1016/S0049-3848(98)00045-0
   FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Furlan-Freguia C, 2011, J CLIN INVEST, V121, P2932, DOI 10.1172/JCI46129
   GALABOV AS, 1984, BIOMED PHARMACOTHER, V38, P412
   Guo SZ, 2010, CEREBROVASC DIS, V30, P290, DOI 10.1159/000319072
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Karmakar M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10555
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Liu XY, 2020, ACTA PHARMACOL SIN B, V10, P1205, DOI 10.1016/j.apsb.2020.04.008
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Ramakers BP, 2011, CRIT CARE, V15, DOI 10.1186/cc10576
   Shi Hui, 2020, medRxiv, DOI 10.1101/2020.05.06.20093070
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322
   Wu CQ, 2019, IMMUNITY, V50, P1401, DOI 10.1016/j.immuni.2019.04.003
   Yadav V, 2019, J CLIN INVEST, V129, P2872, DOI 10.1172/JCI124804
   Yusuf S, 2001, NEW ENGL J MED, V345, P494
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zuo Yu, 2020, medRxiv, DOI 10.1101/2020.04.30.20086736
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 29
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JUL 23
PY 2020
VL 5
IS 14
AR e140971
DI 10.1172/jci.insight.140971
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NN5OK
UT WOS:000568837600001
PM 32530438
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alexpandi, R
   De Mesquita, JF
   Pandian, SK
   Ravi, AV
AF Alexpandi, Rajaiah
   De Mesquita, Joelma Freire
   Pandian, Shunmugiah Karutha
   Ravi, Arumugam Veera
TI Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and
   Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: Anin
   silicoAnalysis
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE drug repurposing; SARS-CoV-2; main-protease (3CLpro); RNA-dependent
   RNA-polymerase; spike-ACE2 complex; quinoline based-drugs
ID OXOLINIC ACID; SCORING FUNCTION; IN-VITRO; ACE2; ELVITEGRAVIR;
   SAQUINAVIR; RITONAVIR; LOPINAVIR; DISCOVERY; DOCKING
AB The novel coronavirus SARS-CoV-2 disease "COVID-19" emerged in China and rapidly spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a global emergency. As there is no specific treatment prescribed to treat COVID-19, the seeking of suitable therapeutics among existing drugs seems valuable. The structure availability of coronavirus macromolecules has encouraged the finding of conceivable anti-SARS-CoV-2 therapeutics throughin silicoanalysis. The results reveal that quinoline,1,2,3,4-tetrahydro-1-[(2-phenylcyclopropyl)sulfonyl]-trans-(8CI) and saquinavir strongly interact with the active site (Cys-His catalytic dyad), thereby are predicted to hinder the activity of SARS-CoV-2 3CLpro. Out of 113 quinoline-drugs, elvitegravir and oxolinic acid are able to interact with the NTP entry-channel and thus interfere with the RNA-directed 5 '-3 ' polymerase activity of SARS-CoV-2 RdRp. The bioactivity-prediction results also validate the outcome of the docking study. Moreover, as SARS-CoV-2 Spike-glycoprotein uses human ACE2-receptor for viral entry, targeting the Spike-RBD-ACE2 has been viewed as a promising strategy to control the infection. The result shows rilapladib is the only quinoline that can interrupt the Spike-RBD-ACE2 complex. In conclusion, owing to their ability to target functional macromolecules of SARS-CoV-2, along with positive ADMET properties, quinoline,1,2,3,4-tetrahydro-1-[(2-phenylcyclopropyl)sulfonyl]-trans-(8CI), saquinavir, elvitegravir, oxolinic acid, and rilapladib are suggested for the treatment of COVID-19.
C1 [Alexpandi, Rajaiah; Pandian, Shunmugiah Karutha; Ravi, Arumugam Veera] Alagappa Univ, Sch Biol Sci, Dept Biotechnol, Sci Campus, Karaikkudi, Tamil Nadu, India.
   [De Mesquita, Joelma Freire] Fed Univ Rio de Janeiro State UNIRIO, Dept Genet & Mol Biol, Lab Bioinformat & Computat Biol, Rio De Janeiro, Brazil.
RP Ravi, AV (corresponding author), Alagappa Univ, Sch Biol Sci, Dept Biotechnol, Sci Campus, Karaikkudi, Tamil Nadu, India.
EM aveeraravi@rediffmail.com
RI RAVI, ARUMUGAM VEERA/ABE-9749-2020; Alexpandi, Rajaiah/AAC-8415-2020
OI RAVI, ARUMUGAM VEERA/0000-0002-4768-8389; Alexpandi,
   Rajaiah/0000-0003-2076-5740
FU Rashtriya Uchchatar Shiksha Abhiyan (RUSA), MHRD, Government of India
   [F. 24-51/2014-U]; DBTDepartment of Biotechnology (DBT) India
   [BT/BI/25/012/2012]; DST-FISTDepartment of Science & Technology (India)
   [SR/FST/LSI-639/2015(C)]; UGC-SAPUniversity Grants Commission, India
   [F.5-1/2018/DRS-II (SAP-II)]; DST-PURSE [SR/PURSE Phase 2/38 (G)];
   RUSA-Phase 2.0, Government of India [F. 24-51/2014-U]
FX RA sincerely acknowledges Rashtriya Uchchatar Shiksha Abhiyan (RUSA),
   MHRD, Government of India [F. 24-51/2014-U, Policy (TN Multi-Gen), Dept.
   of Edn, GOI] for providing RUSA-2.0 Ph.D. Fellowship. We sincerely thank
   Prof. Hua Li, Huazhong University of Science and Technology, Wuhan,
   China for providing the modeled-structure of SARS-CoV-2 RdRp. RA thanks
   Mr. Ragupathi Thennarasu, DBT-BIF Research Assistant, ALU for assistance
   during data analysis. We also acknowledge the BIF (funded by DBT, File
   No. BT/BI/25/012/2012), DST-FIST [Grant No. SR/FST/LSI-639/2015(C)],
   UGC-SAP [Grant No. F.5-1/2018/DRS-II (SAP-II)], DST-PURSE [Grant No.
   SR/PURSE Phase 2/38 (G)], and RUSA-Phase 2.0, Government of India [F.
   24-51/2014-U, Policy (TN Multi-Gen)] for providing instrumentation
   facilities.
CR Aanismaa P, 2007, BIOCHEMISTRY-US, V46, P3394, DOI 10.1021/bi0619526
   Agarwal S, 2007, INT J PHARMACEUT, V339, P139, DOI 10.1016/j.ijpharm.2007.02.036
   Alexpandi R, 2019, J PHOTOCH PHOTOBIO B, V201, DOI 10.1016/j.jphotobiol.2019.111637
   Bakht MA, 2010, EUR J MED CHEM, V45, P5862, DOI 10.1016/j.ejmech.2010.07.069
   Balasubramaniam B, 2019, BIOCATAL AGR BIOTECH, V22, DOI 10.1016/j.bcab.2019.101385
   BARRY AL, 1984, ANTIMICROB AGENTS CH, V25, P633, DOI 10.1128/AAC.25.5.633
   Beetge E, 2000, INT J PHARMACEUT, V193, P261, DOI 10.1016/S0378-5173(99)00340-3
   Benitez-Cardoza CG, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117970
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Cada Dennis J, 2013, Hosp Pharm, V48, P48, DOI 10.1310/hpj4801-48.test
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Dey SK, 2020, J MED VIROL, V92, P632, DOI 10.1002/jmv.25743
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ganguly AK, 2011, J MED CHEM, V54, P7176, DOI 10.1021/jm200778q
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Ghosh AK, 2007, BIOORG MED CHEM LETT, V17, P5876, DOI 10.1016/j.bmcl.2007.08.031
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Guan LF, 2019, MEDCHEMCOMM, V10, P148, DOI 10.1039/c8md00472b
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Han Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00434
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S33
   Hussaini SMA, 2016, EXPERT OPIN THER PAT, V26, P1201, DOI 10.1080/13543776.2016.1216545
   Ibrahim NH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00261
   Irgi EP, 2015, RSC ADV, V5, P36353, DOI 10.1039/c5ra05308k
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   Kaur K, 2010, EUR J MED CHEM, V45, P3245, DOI 10.1016/j.ejmech.2010.04.011
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kim AE, 1998, J PHARMACOL EXP THER, V286, P1439
   Lampiris HW, 2012, EXPERT REV ANTI-INFE, V10, P13, DOI [10.1586/ERI.11.157, 10.1586/eri.11.157]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Mabkhot YN, 2016, MOLECULES, V21, DOI 10.3390/molecules21020222
   Motohashi H, 2013, AAPS J, V15, P581, DOI 10.1208/s12248-013-9465-7
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007
   O'Donnell F, 2010, INT J ANTIMICROB AG, V35, P30, DOI 10.1016/j.ijantimicag.2009.06.031
   Oudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5
   Patel VB, 2014, J MOL CELL CARDIOL, V66, P167, DOI 10.1016/j.yjmcc.2013.11.017
   Prajapati SM, 2014, RSC ADV, V4, P24463, DOI 10.1039/c4ra01814a
   Ramanathan S, 2011, CLIN PHARMACOKINET, V50, P229, DOI 10.2165/11584570-000000000-00000
   Sams C, 2004, XENOBIOTICA, V34, P861, DOI 10.1080/00498250400017273
   Samuelsen OB, 2003, J FISH DIS, V26, P339, DOI 10.1046/j.1365-2761.2003.00466.x
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   Shaddinger BC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083094
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shen MY, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-31
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Shitara Y, 2011, DRUG METAB PHARMACOK, V26, P220, DOI 10.2133/dmpk.DMPK-10-RV-094
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Taylor S, 2001, J ANTIMICROB CHEMOTH, V48, P351, DOI 10.1093/jac/48.3.351
   THOMASRUDDEL D, 2020, ANAESTHESIST 0318, DOI DOI 10.1007/S00101-020-00758-X
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velkoska E, 2016, CURR OPIN NEPHROL HY, V25, P384, DOI 10.1097/MNH.0000000000000254
   Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WRIGHT HT, 1981, SCIENCE, V213, P455, DOI 10.1126/science.7017932
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yagil Y, 2003, AM J HYPERTENS, V16, p23A, DOI 10.1016/S0895-7061(03)00135-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 74
TC 7
Z9 7
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUL 23
PY 2020
VL 11
AR 1796
DI 10.3389/fmicb.2020.01796
PG 15
WC Microbiology
SC Microbiology
GA NB1QT
UT WOS:000560290300001
PM 32793181
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Emameh, RZ
   Nosrati, H
   Eftekhari, M
   Falak, R
   Khoshmirsafa, M
AF Emameh, Reza Zolfaghari
   Nosrati, Hassan
   Eftekhari, Mahyar
   Falak, Reza
   Khoshmirsafa, Majid
TI Expansion of Single Cell Transcriptomics Data of SARS-CoV Infection in
   Human Bronchial Epithelial Cells to COVID-19
SO BIOLOGICAL PROCEDURES ONLINE
LA English
DT Article
DE Transcriptomics; Bronchial epithelial cells; Immunological regulations;
   Signaling pathways; Cytokine storm; Gene ontology; Reactome pathways;
   Severe acute respiratory syndrome; SARS-CoV-2; COVID-19
ID HEMATOPOIETIC STEM; PROTEIN; EXPRESSION; RESPONSES; PROMOTES
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19) that was emerged as a new member of coronaviruses since December 2019 in Wuhan, China and then after was spread in all continentals. Since SARS-CoV-2 has shown about 77.5% similarity to SARS-CoV, the transcriptome and immunological regulations of SARS-CoV-2 was expected to have high percentage of overlap with SARS-CoV. Results In this study, we applied the single cell transcriptomics data of human bronchial epithelial cells (2B4 cell line) infected with SARS-CoV, which was annotated in the Expression Atlas database to expand this data to COVID-19. In addition, we employed system biology methods including gene ontology (GO) and Reactome pathway analyses to define functional genes and pathways in the infected cells with SARS-CoV. The transcriptomics analysis on the Expression Atlas database revealed that most genes from infected 2B4 cell line with SARS-CoV were downregulated leading to immune system hyperactivation, induction of signaling pathways, and consequently a cytokine storm. In addition, GO:0016192 (vesicle-mediated transport), GO:0006886 (intracellular protein transport), and GO:0006888 (ER to Golgi vesicle-mediated transport) were shown as top three GOs in the ontology network of infected cells with SARS-CoV. Meanwhile, R-HAS-6807070 (phosphatase and tensin homolog or PTEN regulation) showed the highest association with other Reactome pathways in the network of infected cells with SARS-CoV. PTEN plays a critical role in the activation of dendritic cells, B- and T-cells, and secretion of proinflammatory cytokines, which cooperates with downregulated genes in the promotion of cytokine storm in the COVID-19 patients. Conclusions Based on the high similarity percentage of the transcriptome of SARS-CoV with SARS-CoV-2, the data of immunological regulations, signaling pathways, and proinflammatory cytokines in SARS-CoV infection can be expanded to COVID-19 to have a valid platform for future pharmaceutical and vaccine studies.
C1 [Emameh, Reza Zolfaghari; Eftekhari, Mahyar] Natl Inst Genet Engn & Biotechnol NIGEB, Dept Energy & Environm Biotechnol, Tehran 14965161, Iran.
   [Nosrati, Hassan] Tarbiat Modares Univ, Dept Mat Engn, Tehran, Iran.
   [Falak, Reza; Khoshmirsafa, Majid] Iran Univ Med Sci, Immunol Res Ctr, Tehran, Iran.
   [Falak, Reza; Khoshmirsafa, Majid] Iran Univ Med Sci, Sch Med, Immunol Dept, Tehran, Iran.
RP Emameh, RZ (corresponding author), Natl Inst Genet Engn & Biotechnol NIGEB, Dept Energy & Environm Biotechnol, Tehran 14965161, Iran.
EM zolfaghari@nigeb.ac.ir
RI Nosrati, Hassan/AAS-9972-2020
OI Nosrati, Hassan/0000-0003-1509-9819
FU National Institute of Genetic Engineering and Biotechnology (NIGEB) of
   the Islamic Republic of Iran
FX To perform this study, RZE received a research grant support from the
   National Institute of Genetic Engineering and Biotechnology (NIGEB) of
   the Islamic Republic of Iran.
CR Aber R, 2019, GENET RES, V101, DOI 10.1017/S0016672319000090
   Barton AJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01839
   Belew MS, 2018, STEM CELL REP, V10, P1384, DOI 10.1016/j.stemcr.2018.03.006
   Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398
   Bowie C, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1851
   Brandmaier Andrew, 2017, Front Biol (Beijing), V12, P163, DOI 10.1007/s11515-017-1443-5
   Cao Y, 2019, HEREDITAS, V156, DOI 10.1186/s41065-019-0085-9
   Chakraborty S, 2017, J BIOL CHEM, V292, P6600, DOI 10.1074/jbc.M116.742627
   Chen JN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002606
   Cheng J, 2011, CANCER LETT, V310, P35, DOI 10.1016/j.canlet.2011.06.001
   Crosetto N, 2015, NAT REV GENET, V16, P57, DOI 10.1038/nrg3832
   Cross RW, 2018, J INFECT DIS, V218, pS486, DOI 10.1093/infdis/jiy455
   Dapat C, 2016, EXPERT REV ANTI-INFE, V14, P285, DOI 10.1586/14787210.2016.1141676
   De Diego ML, 2014, VIRUS RES, V194, P124, DOI 10.1016/j.virusres.2014.07.024
   Farwell SLN, 2016, J BIOL CHEM, V291, P5342, DOI 10.1074/jbc.M115.681288
   FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X
   Fryland T, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0308-x
   Gliddon HD, 2018, IMMUNOLOGY, V153, P171, DOI 10.1111/imm.12841
   Golumbeanu M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36135-3
   Govindarajan R, 2012, J PHARM BIOALLIED SC, V4, pS310, DOI 10.4103/0975-7406.100283
   Grimble RF, 2006, J NUTR, V136, p1660S, DOI 10.1093/jn/136.6.1660S
   Haralambieva IH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160970
   Haralambieva IH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062149
   Hattermann K, 2005, ARCH VIROL, V150, P1023, DOI 10.1007/s00705-004-0461-1
   Jafari M, 2018, CELL J, V20, P604, DOI 10.22074/cellj.2019.5992
   Jiang X, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01067
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Kamp TJ, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016887
   Kopecky-Bromberg SA, 2006, J VIROL, V80, P785, DOI 10.1128/JVI.80.2.785-793.2006
   Lang R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112710
   Lee CH, 2004, J IMMUNOL, V172, P7841, DOI 10.4049/jimmunol.172.12.7841
   Liang R, 2018, VIRUSES, V10, P12
   Lim Y.X., 2016, DISEASES, V4, P26, DOI DOI 10.3390/DISEASES4030026
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lowe R, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005457
   Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108
   Maruyama SR, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0145-1
   McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   Minakshi R, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-75
   Mizutani T, 2005, BBA-MOL BASIS DIS, V1741, P4, DOI 10.1016/j.bbadis.2005.04.004
   Morales MMB, 2011, CRIT CARE, V15, DOI 10.1186/cc9401
   Murr Christian, 2014, J Amino Acids, V2014, P783730, DOI 10.1155/2014/783730
   Nadal-Ribelles M, 2019, NAT MICROBIOL, V4, P683, DOI 10.1038/s41564-018-0346-9
   O'Sullivan TE, 2015, IMMUNITY, V43, P331, DOI 10.1016/j.immuni.2015.07.012
   Ong E, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3194-6
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Papatheodorou I, 2020, NUCLEIC ACIDS RES, V48, pD77, DOI 10.1093/nar/gkz947
   Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Ruamviboonsuk P, 2020, ASIA-PAC J OPHTHALMO, V9, P85, DOI 10.1097/APO.0000000000000289
   Ruth MR, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049-1891-4-27
   Sawai CM, 2016, IMMUNITY, V45, P597, DOI 10.1016/j.immuni.2016.08.007
   Schwartz M, 2019, J VIROL, V93, DOI 10.1128/JVI.00047-19
   Sessions OM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002107
   Shahid M, 2020, ARCH VIROL, V165, P809, DOI 10.1007/s00705-020-04564-z
   Silva R, 2005, Int J Biomed Sci, V1, P46
   Spaziani A, 2006, J BIOL CHEM, V281, P10983, DOI 10.1074/jbc.M512536200
   Speranza E, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030030
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   Sztal TE, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0546-9
   Tombacz D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43751
   Tran P, 2003, IMMUNOLOGY, V109, P263, DOI 10.1046/j.1365-2567.2003.01659.x
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Waddell SJ, 2007, CURR OPIN MICROBIOL, V10, P297, DOI 10.1016/j.mib.2007.05.013
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Xu YT, 2017, INT J ONCOL, V51, P791, DOI 10.3892/ijo.2017.4066
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zhang Q, 2016, GENE, V594, P144, DOI 10.1016/j.gene.2016.09.014
   Emameh RZ, 2020, BIOL PROCED ONLINE, V22, DOI 10.1186/s12575-020-00124-6
   Emameh RZ, 2020, BIOL PROCED ONLINE, V22, DOI 10.1186/s12575-020-00121-9
NR 73
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1480-9222
J9 BIOL PROCED ONLINE
JI Biol. Proced. Online
PD JUL 23
PY 2020
VL 22
IS 1
AR 16
DI 10.1186/s12575-020-00127-3
PG 10
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA MU9AG
UT WOS:000555957600002
PM 32754004
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Feldstein, LR
   Rose, EB
   Horwitz, SM
   Collins, JP
   Newhams, MM
   Son, MBF
   Newburger, JW
   Kleinman, LC
   Heidemann, SM
   Martin, AA
   Singh, AR
   Li, S
   Tarquinio, KM
   Jaggi, P
   Oster, ME
   Zackai, SP
   Gillen, J
   Ratner, AJ
   Walsh, RF
   Fitzgerald, JC
   Keenaghan, MA
   Alharash, H
   Doymaz, S
   Clouser, KN
   Giuliano, JS
   Gupta, A
   Parker, RM
   Maddux, AB
   Havalad, V
   Ramsingh, S
   Bukulmez, H
   Bradford, TT
   Smith, LS
   Tenforde, MW
   Carroll, CL
   Riggs, BJ
   Gertz, SJ
   Daube, A
   Lansell, A
   Munoz, AC
   Hobbs, CV
   Marohn, KL
   Halasa, NB
   Patel, MM
   Randolph, AG
AF Feldstein, Leora R.
   Rose, Erica B.
   Horwitz, Steven M.
   Collins, Jennifer P.
   Newhams, Margaret M.
   Son, Mary Beth F.
   Newburger, Jane W.
   Kleinman, Lawrence C.
   Heidemann, Sabrina M.
   Martin, Amarilis A.
   Singh, Aalok R.
   Li, Simon
   Tarquinio, Keiko M.
   Jaggi, Preeti
   Oster, Matthew E.
   Zackai, Sheemon P.
   Gillen, Jennifer
   Ratner, Adam J.
   Walsh, Rowan F.
   Fitzgerald, Julie C.
   Keenaghan, Michael A.
   Alharash, Hussam
   Doymaz, Sule
   Clouser, Katharine N.
   Giuliano, John S.
   Gupta, Anjali
   Parker, Robert M.
   Maddux, Aline B.
   Havalad, Vinod
   Ramsingh, Stacy
   Bukulmez, Hulya
   Bradford, Tamara T.
   Smith, Lincoln S.
   Tenforde, Mark W.
   Carroll, Christopher L.
   Riggs, Becky J.
   Gertz, Shira J.
   Daube, Ariel
   Lansell, Amanda
   Coronado Munoz, Alvaro
   Hobbs, Charlotte V.
   Marohn, Kimberly L.
   Halasa, Natasha B.
   Patel, Manish M.
   Randolph, Adrienne G.
CA Overcoming COVID-19 Investigators
   CDC Covid-19 Response Team
TI Multisystem Inflammatory Syndrome in US Children and Adolescents
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID TOXIC-SHOCK-SYNDROME; KAWASAKI-DISEASE; INFLUENZA
AB This report describes the epidemiology and clinical course of patients younger than 21 years of age from 26 states who had multisystem inflammatory syndrome. Many were infected with SARS-CoV-2 at least 1 to 2 weeks before syndrome onset. The median age of the patients was 8.3 years, and 73% were previously healthy.
   Background Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. Methods We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. Results We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores >= 2.5) were documented in 15 patients (8%), and Kawasaki's disease-like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). Conclusions Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.)
C1 [Feldstein, Leora R.; Rose, Erica B.; Collins, Jennifer P.; Tenforde, Mark W.; Patel, Manish M.] Ctr Dis Control & Prevent, COVID 19 Response, Atlanta, GA USA.
   [Tarquinio, Keiko M.] Emory Univ, Sch Med, Dept Pediat, Div Crit Care Med, Atlanta, GA USA.
   [Jaggi, Preeti] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA USA.
   [Oster, Matthew E.] Emory Univ, Sch Med, Dept Pediat, Div Cardiol, Atlanta, GA USA.
   [Feldstein, Leora R.; Rose, Erica B.; Patel, Manish M.] Public Hlth Serv Commissioned Corps, Rockville, MD USA.
   [Riggs, Becky J.] Johns Hopkins Sch Med, Div Pediat Anesthesiol & Crit Care Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA.
   [Horwitz, Steven M.] Rutgers State Univ, Robert Wood Johnson Med Sch, Bristol Myers Squibb Childrens Hosp, Div Pediat Crit Care,Dept Pediat, New Brunswick, NJ USA.
   [Kleinman, Lawrence C.] Rutgers Robert Wood Johnson Med Sch, Div Populat Hlth Qual & Implementat Sci PopQuIS, Dept Pediat, New Brunswick, NJ USA.
   [Walsh, Rowan F.] Childrens Hosp New Jersey, Newark Beth Israel, Div Pediat Cardiol, Dept Pediat, Newark, NJ USA.
   [Clouser, Katharine N.] Hackensack Univ, Div Hosp Med, Dept Pediat, Med Ctr, Hackensack, NJ USA.
   [Gertz, Shira J.] St Barnabas Hosp, Dept Pediat, Div Pediat Crit Care, Livingston, NJ USA.
   [Newhams, Margaret M.; Randolph, Adrienne G.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA.
   [Son, Mary Beth F.] Boston Childrens Hosp, Div Immunol, Boston, MA USA.
   [Newburger, Jane W.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA.
   [Son, Mary Beth F.; Newburger, Jane W.; Randolph, Adrienne G.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
   [Randolph, Adrienne G.] Harvard Med Sch, Dept Anaesthesia, Boston, MA 02115 USA.
   [Marohn, Kimberly L.] Baystate Med Ctr, Pediat Crit Care, Dept Pediat, Springfield, MA USA.
   [Heidemann, Sabrina M.; Martin, Amarilis A.] Cent Michigan Univ, Dept Pediat, Div Pediat Crit Care Med, Detroit, MI USA.
   [Singh, Aalok R.; Li, Simon] Maria Fareri Childrens Hosp, Westchester Med Ctr, Pediat Crit Care Div, Valhalla, NY USA.
   [Singh, Aalok R.; Li, Simon] New York Med Coll, Valhalla, NY 10595 USA.
   [Zackai, Sheemon P.; Gillen, Jennifer] Icahn Sch Med Mt Sinai, Kravis Childrens Hosp, Dept Pediat, Pediat Crit Care Med, New York, NY 10029 USA.
   [Ratner, Adam J.] NYU, Grossman Sch Med, Div Pediat Infect Dis, Dept Microbiol, New York, NY USA.
   [Keenaghan, Michael A.; Alharash, Hussam] Kings Cty Hosp, New York City Hlth & Hosp, Pediat Crit Care, New York, NY USA.
   [Doymaz, Sule] SUNY Downstate Hlth Sci Univ, Dept Pediat, Div Pediat Crit Care, New York, NY USA.
   [Daube, Ariel] Maimonides Childrens Hosp, Div Pediat Crit Care, Dept Pediat, New York, NY USA.
   [Fitzgerald, Julie C.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Div Crit Care, Philadelphia, PA 19104 USA.
   [Giuliano, John S.; Gupta, Anjali] Yale Univ, Sch Med, Dept Pediat, Div Crit Care, New Haven, CT 06510 USA.
   [Parker, Robert M.; Carroll, Christopher L.] Connecticut Childrens, Div Crit Care, Hartford, CT USA.
   [Maddux, Aline B.] Univ Colorado, Sch Med, Dept Pediat, Sect Crit Care Med, Aurora, CO USA.
   [Maddux, Aline B.] Childrens Hosp Colorado, Aurora, CO USA.
   [Havalad, Vinod; Ramsingh, Stacy] Advocate Childrens Hosp, Dept Pediat, Div Pediat Crit Care Med, Chicago, IL USA.
   [Bukulmez, Hulya] Case Western Reserve Univ, Dept Pediat, Div Pediat Rheumatol, MetroHlth Med Ctr, Cleveland, OH 44106 USA.
   [Lansell, Amanda] Rainbow Babies & Childrens Hosp, Div Pediat Hosp Med, 2101 Adelbert Rd, Cleveland, OH 44106 USA.
   [Bradford, Tamara T.] Louisiana State Univ, Hlth Sci Ctr, Div Cardiol, Dept Pediat, New Orleans, LA USA.
   [Bradford, Tamara T.] Childrens Hosp New Orleans, New Orleans, LA USA.
   [Smith, Lincoln S.] Univ Washington, Dept Pediat, Div Pediat Crit Care Med, Seattle, WA 98195 USA.
   [Coronado Munoz, Alvaro] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Pediat Crit Care Div, Houston, TX 77030 USA.
   [Hobbs, Charlotte V.] Univ Mississippi, Med Ctr, Dept Microbiol, Dept Pediat,Div Infect Dis, Jackson, MS 39216 USA.
   [Halasa, Natasha B.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37232 USA.
RP Patel, MM (corresponding author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS H24-7, Atlanta, GA 30329 USA.; Randolph, AG (corresponding author), Boston Childrens Hosp, Div Crit Care Med, Bader 634, Boston, MA 02115 USA.
EM mpatel@cdc.gov; adrienne.randolph@childrens.harvard.edu
OI Ratner, Adam/0000-0003-1761-794X; Giuliano, John/0000-0003-2753-8460;
   Bukulmez, Hulya/0000-0002-2256-9068; Lansell, Amanda/0000-0002-5501-3373
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [75D30120C07725]
FX Supported by the Centers for Disease Control and Prevention under a
   contract to Boston Children's Hospital (75D30120C07725).
CR Baker AL, 2009, J PEDIATR-US, V154, P592, DOI 10.1016/j.jpeds.2008.10.006
   Belhadjer Z, 2020, CIRCULATION, DOI 10.1161/CIRCULATIONAHA.120.048360
   Benseler SM, 2005, PEDIATRICS, V116, pE760, DOI 10.1542/peds.2005-0559
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   Burns JC, 1996, J AM COLL CARDIOL, V28, P253, DOI 10.1016/0735-1097(96)00099-X
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Castagnoli R, 2020, JAMA PEDIAT
   Centers for Disease Control and Prevention, EM PREP RESP MULT IN
   Centers for Disease Control and Prevention, COR DIS 2019 CIVOD 1
   Centers for Disease Control and Prevention. National Center for Health Statistics, CLIN GROWTH CHARTS
   Data Resource Center for Child & Adolescent Health, CHILD AD HLTH MEAS I
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Esposito S, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00124
   European Centre for Disease Prevention and Control, 2020, RAP RISK ASS PAED IN
   Fliesler N, 2020, BOSTON CHILDRENS HOS
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V257, P1053, DOI 10.1001/jama.257.8.1053
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Newburger JW, 2007, NEW ENGL J MED, V356, P663, DOI 10.1056/NEJMoa061235
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Qin C, 2020, CLIN INFECT DIS
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Randolph AG, 2011, PEDIATRICS, V128, pE1450, DOI 10.1542/peds.2011-0774
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Sanders JM, 2020, JAMA
   SHACKELFORD PG, 1991, NEW ENGL J MED, V324, P1664, DOI 10.1056/NEJM199106063242311
   Shekerdemian LS, 2020, JAMA PEDIAT
   Shi S, 2020, JAMA CARDIOL
   TOFTE RW, 1981, JAMA-J AM MED ASSOC, V246, P2163
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang W, 2015, SEMIN ARTHRITIS RHEU, V44, P405, DOI 10.1016/j.semarthrit.2014.07.007
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   2019, MICROBIOME, V7, P1
NR 40
TC 161
Z9 163
U1 6
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 23
PY 2020
VL 383
IS 4
BP 334
EP 346
DI 10.1056/NEJMoa2021680
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA MU1XJ
UT WOS:000555465900018
PM 32598831
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Garrone, O
   Denaro, N
   Ruatta, F
   Vanella, P
   Granetto, C
   Vandone, AM
   Occelli, M
   Cauchi, C
   Ricci, V
   Fea, E
   Di Costanzo, G
   Colantonio, I
   Crosetto, N
   Merlano, MC
AF Garrone, Ornella
   Denaro, Nerina
   Ruatta, Fiorella
   Vanella, Paola
   Granetto, Cristina
   Vandone, Anna Maria
   Occelli, Marcella
   Cauchi, Carolina
   Ricci, Vincenzo
   Fea, Elena
   Di Costanzo, Gianna
   Colantonio, Ida
   Crosetto, Nicola
   Merlano, Marco C.
TI Treating patients with cancer amidst the COVID-19 pandemic: experience
   of a regional hospital in the Piedmont region in northern Italy
SO TUMORI J
LA English
DT Article; Early Access
DE COVID-19; cancer; pandemic; treatment; management
ID CARE
AB Background: The coronavirus disease 2019 (COVID-19) pandemic is posing an unprecedented dilemma to oncologists worldwide, forcing them to decide whether to continue or suspend treatments in order to protect their most vulnerable patients from infection. After the first report from China, the outbreak spread rapidly worldwide. To, date no clear indications on how to treat patients with cancer with COVID-19 infection are available. Methods: We report data on 21 patients with cancer referred to a single medical oncology unit of a general hospital from mid-March to April 23, 2020. Results: Nine patients were on active cancer therapy during the infection and all stopped medical treatments. Overall 8 patients developed pneumonia and 6 patients died of COVID-19. Conclusion: The management of patients with cancer during the pandemic should be carefully balanced and discussed among oncologists and other key professionals involved in the treatment of this vulnerable group of patients, in order to balance the risk of treatment and the risk of infection.
C1 [Garrone, Ornella; Denaro, Nerina; Ruatta, Fiorella; Vanella, Paola; Granetto, Cristina; Vandone, Anna Maria; Occelli, Marcella; Cauchi, Carolina; Ricci, Vincenzo; Fea, Elena; Di Costanzo, Gianna; Colantonio, Ida; Merlano, Marco C.] Azienda Osped S Croce & Carle Osped Insegnamento, Med Oncol, VM Coppino 26, I-12100 Cuneo, Italy.
   [Crosetto, Nicola] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden.
RP Garrone, O (corresponding author), Azienda Osped S Croce & Carle Osped Insegnamento, Med Oncol, VM Coppino 26, I-12100 Cuneo, Italy.
EM ornella.garrone@gmail.com
CR Agalar C, 2020, TURK J MED SCI, V50, P578, DOI 10.3906/sag-2004-132
   Comber H, 2005, Ir Med J, V98, P238
   Dai M, 2020, CANCER DISCOV, DOI [10.1158/2159-8290, DOI 10.1158/2159-8290]
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miyashita H, 2020, ANN ONCOL, DOI [10.1016/j.annonc.2020.04.006, DOI 10.1016/J.ANN0NC.2020.04.006]
   Sharma DC, 2020, LANCET ONCOL, V21, P884, DOI 10.1016/S1470-2045(20)30312-0
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang QX, 2020, INFECT CONT HOSP EP, V41, P772, DOI 10.1017/ice.2020.185
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 10
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-8916
EI 2038-2529
J9 TUMORI J
JI Tumori J.
AR 0300891620942313
DI 10.1177/0300891620942313
EA JUL 2020
PG 5
WC Oncology
SC Oncology
GA MU9IN
UT WOS:000555979100001
PM 32703089
DA 2021-01-01
ER

PT J
AU Wang, Q
   Wu, JQ
   Wang, HF
   Gao, Y
   Liu, QJ
   Mu, A
   Ji, WX
   Yan, LM
   Zhu, Y
   Zhu, C
   Fang, X
   Yang, XB
   Huang, YC
   Gao, HL
   Liu, FJ
   Ge, J
   Sun, QQ
   Yang, XN
   Xu, WQ
   Liu, ZJ
   Yang, HT
   Lou, ZY
   Jiang, B
   Guddat, LW
   Gong, P
   Rao, ZH
AF Wang, Quan
   Wu, Jiqin
   Wang, Haofeng
   Gao, Yan
   Liu, Qiaojie
   Mu, An
   Ji, Wenxin
   Yan, Liming
   Zhu, Yan
   Zhu, Chen
   Fang, Xiang
   Yang, Xiaobao
   Huang, Yucen
   Gao, Hailong
   Liu, Fengjiang
   Ge, Ji
   Sun, Qianqian
   Yang, Xiuna
   Xu, Wenqing
   Liu, Zhijie
   Yang, Haitao
   Lou, Zhiyong
   Jiang, Biao
   Guddat, Luke W.
   Gong, Peng
   Rao, Zihe
TI Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
SO CELL
LA English
DT Article
ID SARS; VISUALIZATION; INSIGHTS; GS-5734; COMPLEX; EBOLA
AB Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have shown promise in in vitro assays and some clinical studies for COVID-19 treatment, this despite an incomplete mechanistic understanding of the viral RNA-dependent RNA polymerase nsp12 drug interactions. Here, we examine the molecular basis of SARS-CoV-2 RNA replication by determining the cryo-EM structures of the stalled pre- and post- translocated polymerase complexes. Compared with the apo complex, the structures show notable structural rearrangements happening to nsp12 and its co-factors nsp7 and nsp8 to accommodate the nucleic acid, whereas there are highly conserved residues in nsp12, positioning the template and primer for an in-line attack on the incoming nucleotide. Furthermore, we investigate the inhibition mechanism of the triphosphate metabolite of remdesivir through structural and kinetic analyses. A transition model from the nsp7-nsp8 hexadecameric primase complex to the nsp12-nsp7-nsp8 polymerase complex is also proposed to provide clues for the understanding of the coronavirus transcription and replication machinery.
C1 [Wang, Quan; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Yang, Xiaobao; Liu, Fengjiang; Sun, Qianqian; Yang, Xiuna; Xu, Wenqing; Liu, Zhijie; Yang, Haitao; Jiang, Biao; Rao, Zihe] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.
   [Wang, Quan; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Yang, Xiaobao; Liu, Fengjiang; Sun, Qianqian; Yang, Xiuna; Xu, Wenqing; Liu, Zhijie; Yang, Haitao; Jiang, Biao; Rao, Zihe] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.
   [Wu, Jiqin; Liu, Qiaojie; Fang, Xiang; Gong, Peng] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Key Lab Special Pathogens & Biosafety, 44 Xiao Hong Shan, Wuhan 430071, Hubei, Peoples R China.
   [Wang, Haofeng] Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China.
   [Gao, Yan; Yan, Liming; Huang, Yucen; Ge, Ji; Lou, Zhiyong; Rao, Zihe] Tsinghua Univ, Sch Life Sci & Sch Med, Lab Struct Biol, Beijing, Peoples R China.
   [Mu, An; Ji, Wenxin; Fang, Xiang; Gao, Hailong] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Mu, An; Ji, Wenxin; Gao, Hailong; Rao, Zihe] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, CAS Ctr Excellence Biomacromol, Beijing, Peoples R China.
   [Guddat, Luke W.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
RP Wang, Q; Rao, ZH (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.; Wang, Q; Rao, ZH (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.; Gong, P (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Key Lab Special Pathogens & Biosafety, 44 Xiao Hong Shan, Wuhan 430071, Hubei, Peoples R China.; Rao, ZH (corresponding author), Tsinghua Univ, Sch Life Sci & Sch Med, Lab Struct Biol, Beijing, Peoples R China.; Rao, ZH (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, CAS Ctr Excellence Biomacromol, Beijing, Peoples R China.
EM wangq@shanghaitech.edu.cn; gongpeng@wh.iov.cn; raozh@tsinghua.edu.cn
OI Yang, Xiuna/0000-0003-3443-9815; Liu, Fengjiang/0000-0002-9400-308X
FU National Program on Key Research Project of China [2017YFC0840300,
   2020YFA0707500, 2018YFA0507200]; Strategic Priority Research Program of
   the Chinese Academy of SciencesChinese Academy of Sciences
   [XDB08020200]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81520108019, 813300237,
   32041007]; Science and Technology Commission of Shanghai Municipality,
   ChinaScience & Technology Commission of Shanghai Municipality (STCSM)
   [20431900200]
FX We would like to pay an exceptional tribute to ShanghaiTech University
   and their administrative team, as well as the Bio-Electron Microscopy
   Facility for their great care and support to our research team to enable
   us to carry out this research in a safe and healthy environment. It
   would have been impossible for us to attain this achievement without
   their tremendous efforts in the last two months during the COVID-19
   pandemic. We also must express our gratitude to the campus service team
   of ShanghaiTech University scientific research platform of Shanghai
   Institute for Advanced Immunochemical Studies (SIAIS) and National
   Center for Protein Science Shanghai (NCPSS), as well as all the manager
   and technician individuals who provided onsite or remote technical
   support. Their kind help and fearless support are pivotal to this work
   during the epidemic. We would like to thank the University of Queensland
   for their collaboration. We thank Meihua Wang for providing some of the
   RNA template samples. We are grateful to Lili Niu, Xiang Ding, and
   Fuquan Yang from the Laboratory of Proteomics, Core Facility of Protein
   Science, Institute of Biophysics, Chinese Academy of Sciences, for the
   RNA analysis with Mass spectrometry. This work was supported by the
   National Program on Key Research Project of China (2017YFC0840300 and
   2020YFA0707500 to Z.R. and 2018YFA0507200 to P.G.), the Strategic
   Priority Research Program of the Chinese Academy of Sciences
   (XDB08020200 to Z.R.), the National Natural Science Foundation of China
   (81520108019 and 813300237 to Z.R. and 32041007 to P.G.) and Science and
   Technology Commission of Shanghai Municipality, China (20431900200).
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Batey RT, 2007, RNA, V13, P1384, DOI 10.1261/rna.528007
   Chen SX, 2013, ULTRAMICROSCOPY, V135, P24, DOI 10.1016/j.ultramic.2013.06.004
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Debing Y, 2015, CURR OPIN INFECT DIS, V28, P596, DOI 10.1097/QCO.0000000000000212
   DeLano W. L., 2010, PYMOL MOL GRAPHICS S
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Hillen H.S., 2020, BIORXIV, DOI [10.1101/2020.04.27.063180., DOI 10.1101/2020.04.27.063180]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kouba T, 2019, NAT STRUCT MOL BIOL, V26, P460, DOI 10.1038/s41594-019-0232-z
   Kucukelbir A, 2014, NAT METHODS, V11, P63, DOI [10.1038/NMETH.2727, 10.1038/nmeth.2727]
   Li S, 2010, PROTEIN CELL, V1, P198, DOI 10.1007/s13238-010-0028-8
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sholders AJ, 2014, J MOL BIOL, V426, P1407, DOI 10.1016/j.jmb.2013.12.031
   Shu B, 2016, P NATL ACAD SCI USA, V113, pE4005, DOI 10.1073/pnas.1602591113
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tvarogova J, 2019, J VIROL, V93, DOI 10.1128/JVI.00291-19
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Wang MH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16234-4
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Xiao YB, 2012, J VIROL, V86, P4444, DOI 10.1128/JVI.06635-11
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 44
TC 18
Z9 18
U1 44
U2 44
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUL 23
PY 2020
VL 182
IS 2
BP 417
EP +
DI 10.1016/j.cell.2020.05.034
PG 25
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MQ2RP
UT WOS:000552745000013
PM 32526208
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Singh, S
   Sk, MF
   Sonawane, A
   Kar, P
   Sadhukhan, S
AF Singh, Satyam
   Sk, Md Fulbabu
   Sonawane, Avinash
   Kar, Parimal
   Sadhukhan, Sushabhan
TI Plant-derived natural polyphenols as potential antiviral drugs against
   SARS-CoV-2viaRNA-dependent RNA polymerase (RdRp) inhibition:
   anin-silicoanalysis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2 and RNA-dependent RNA polymerase (RdRp); molecular docking;
   molecular dynamics; MM-PBSA; natural polyphenols
ID RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR-DYNAMICS; POLAR SOLVATION;
   BINDING; BIOAVAILABILITY; DEPENDENCE; ENERGETICS; INSIGHTS; POTENCY;
   MODEL
AB The sudden outburst of Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses a massive threat to global public health. Currently, no therapeutic drug or vaccine exists to treat COVID-19. Due to the time taking process of new drug development, drug repurposing might be the only viable solution to tackle COVID-19. RNA-dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. Interestingly, several plant-derived polyphenols effectively inhibit the RdRp of other RNA viruses. More importantly, polyphenols have been used as dietary supplementations for a long time and played beneficial roles in immune homeostasis. We were curious to study the binding of polyphenols with SARS-CoV-2 RdRp and assess their potential to treat COVID-19. Herein, we made a library of polyphenols that have shown substantial therapeutic effects against various diseases. They were successfully docked in the catalytic pocket of RdRp. The investigation reveals that EGCG, theaflavin (TF1), theaflavin-3'-O-gallate (TF2a), theaflavin-3'-gallate (TF2b), theaflavin 3,3'-digallate (TF3), hesperidin, quercetagetin, and myricetin strongly bind to the active site of RdRp. Further, a 150-ns molecular dynamic simulation revealed that EGCG, TF2a, TF2b, TF3 result in highly stable bound conformations with RdRp. The binding free energy components calculated by the MM-PBSA also confirm the stability of the complexes. We also performed a detailed analysis of ADME prediction, toxicity prediction, and target analysis for their druggability. Overall, our results suggest that EGCG, TF2a, TF2b, TF3 can inhibit RdRp and represent an effective therapy for COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Singh, Satyam; Sk, Md Fulbabu; Sonawane, Avinash; Kar, Parimal] Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore, India.
   [Sadhukhan, Sushabhan] Indian Inst Technol Palakkad, Discipline Chem, Palakkad 678557, Kerala, India.
RP Sadhukhan, S (corresponding author), Indian Inst Technol Palakkad, Discipline Chem, Palakkad 678557, Kerala, India.
EM sushabhan@iitpkd.ac.in
OI Sk, Md/0000-0003-4341-8370; Singh, Satyam/0000-0003-2341-9544
FU Indian Institute of Technology Indore; Indian Institute of Technology
   Palakkad; Ministry of Human Resource Development, Govt. of India;
   Department of Science and Technology-Science & Engineering Research
   Board (DST-SERB), Govt. of IndiaDepartment of Science & Technology
   (India)Science Engineering Research Board (SERB), India
   [ECR/2017/002082]; Department of Biotechnology, Govt. of IndiaDepartment
   of Biotechnology (DBT) India [BT/RLF/Re-entry/40/2014]; DST-SERB, Govt.
   of IndiaDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India [ECR/2017/000010]; DST, Govt. of India
   under the INSPIRE Fellowship Scheme [DST/INSPIRE
   Fellowship/2017/IF170145]
FX The authors gratefully acknowledge the financial support from the Indian
   Institute of Technology Indore and Indian Institute of Technology
   Palakkad for the provision of conducting research and the scholarship
   provided by the Ministry of Human Resource Development, Govt. of India
   to S. Singh. This work was also supported by the Department of Science
   and Technology-Science & Engineering Research Board (DST-SERB), Govt. of
   India (ECR/2017/002082). PK is supported by the Department of
   Biotechnology, Govt. of India (grant number BT/RLF/Re-entry/40/2014,
   DBT-Ramalingaswami Re-entry Fellowship), and DST-SERB, Govt. of India
   (grant number ECR/2017/000010). MFS would like to thank DST, Govt. of
   India, for providing fellowship under the INSPIRE Fellowship Scheme
   (DST/INSPIRE Fellowship/2017/IF170145).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Ahmed-Belkacem A, 2014, NUCLEIC ACIDS RES, V42, P9399, DOI 10.1093/nar/gku632
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berman H. M., 2000, NUCL ACIDS RES, V7
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Borgio JF, 2020, ARCH MED SCI, V16, P508, DOI 10.5114/aoms.2020.94567
   Carneiro BM, 2016, VIROLOGY, V496, P215, DOI 10.1016/j.virol.2016.06.012
   Case D., 2018, AMBER 2018
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chow HHS, 2005, CLIN CANCER RES, V11, P4627, DOI 10.1158/1078-0432.CCR-04-2549
   Chowdhury P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198226
   Cory H, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00087
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elfiky AA, 2019, MED CHEM, V15, P130, DOI 10.2174/1573406414666181015152511
   Elfiky AA, 2017, FUTURE VIROL, V12, P720, DOI 10.2217/fvl-2017-0081
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Ho HY, 2009, J AGR FOOD CHEM, V57, P6140, DOI 10.1021/jf901128u
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Jonniya NA, 2020, J BIOMOL STRUCT DYN, V38, P1306, DOI 10.1080/07391102.2019.1602079
   Jonniya NA, 2019, ACS OMEGA, V4, P17404, DOI 10.1021/acsomega.9b02187
   Kar P, 2007, J COMPUT CHEM, V28, P2538, DOI 10.1002/jcc.20698
   Kar P, 2007, J PHYS CHEM B, V111, P8910, DOI 10.1021/jp072302u
   Kar P, 2013, J PHYS CHEM B, V117, P5793, DOI 10.1021/jp3085292
   Kar P, 2012, J PHYS CHEM B, V116, P6269, DOI 10.1021/jp300818c
   Kar P, 2012, J PHYS CHEM B, V116, P6137, DOI 10.1021/jp3022612
   Kar P, 2012, J COMPUT AID MOL DES, V26, P215, DOI 10.1007/s10822-012-9550-5
   Kar P, 2012, J PHYS CHEM B, V116, P2605, DOI 10.1021/jp211768n
   Kar P, 2011, J PHYS CHEM B, V115, P7661, DOI 10.1021/jp201538t
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Krautler V., 2001, J COMPUT CHEM, V22, DOI [10.1002/1096-987X(20010415)22:5501::AID-JCC10213.0.CO;2-V, DOI 10.1002/1096-987X(20010415)22:5501::AID-JCC10213.0.CO;2-V]
   Kuzuhara T, 2009, PLOS CURR, V1, DOI DOI 10.1371/CURRENTS.RRN1052
   Larregieu CA, 2013, AAPS J, V15, P483, DOI 10.1208/s12248-013-9456-8
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Liu SB, 2001, J TRIBOL-T ASME, V123, P17, DOI 10.1115/1.1327585
   LONCHARICH RJ, 1992, BIOPOLYMERS, V32, P523, DOI 10.1002/bip.360320508
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Moon YJ, 2007, MOL PHARM, V4, P865, DOI 10.1021/mp7000928
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Roy R., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.07392020.01724196, DOI 10.1080/07391102.07392020.01724196]
   Roy R., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.07392020.01768149, DOI 10.1080/07391102.07392020.01768149]
   Roy R, 2020, ACS OMEGA, V5, P3932, DOI 10.1021/acsomega.9b03398
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Szajdek A, 2008, PLANT FOOD HUM NUTR, V63, P147, DOI 10.1007/s11130-008-0097-5
   Trott O., 2010, J COMPUTAIONAL CHEM, V31
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JQ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10010024
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
NR 77
TC 3
Z9 3
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796810
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MR0RK
UT WOS:000553300600001
PM 32720577
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hochstatter, KR
   Akhtar, WZ
   Dietz, S
   Pe-Romashko, K
   Gustafson, DH
   Shah, DV
   Krechel, S
   Liebert, C
   Miller, R
   El-Bassel, N
   Westergaard, RP
AF Hochstatter, Karli R.
   Akhtar, Wajiha Z.
   Dietz, Sarah
   Pe-Romashko, Klaren
   Gustafson, David H.
   Shah, Dhavan V.
   Krechel, Sarah
   Liebert, Cameron
   Miller, Rebecca
   El-Bassel, Nabila
   Westergaard, Ryan P.
TI Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care
   Among People Living with HIV and Substance Use Disorders: Experience
   from a Pilot mHealth Intervention
SO AIDS AND BEHAVIOR
LA English
DT Article; Early Access
DE HIV; COVID-19; Substance use disorder; Mobile-health intervention
ID ACTIVE ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; ADHERENCE;
   MORTALITY; VISITS; RISK
AB People living with HIV (PLWH) and substance use disorder (SUD) are particularly vulnerable to harmful health consequences of the global COVID-19 pandemic. The health and social consequences of the pandemic may exacerbate substance misuse and poor management of HIV among this population. This study compares substance use and HIV care before and during the pandemic using data collected weekly through an opioid relapse prevention and HIV management mobile-health intervention. We found that during the pandemic, PLWH and SUD have increased illicit substance use and contact with other substance-using individuals and decreased their confidence to stay sober and attend recovery meetings. The proportion of people missing their HIV medications also increased, and confidence to attend HIV follow-up appointments decreased. Optimal support for PLWH and SUD is critical during pandemics like COVID-19, as drug-related and HIV antiretroviral therapy (ART) non-adherence risks such as overdose, unsafe sexual behaviors, and transmission of infectious diseases may unfold.
C1 [Hochstatter, Karli R.; El-Bassel, Nabila] Columbia Univ, Social Intervent Grp, 1255 Amsterdam Ave, New York, NY 10027 USA.
   [Hochstatter, Karli R.; Akhtar, Wajiha Z.; Dietz, Sarah; Miller, Rebecca; Westergaard, Ryan P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53726 USA.
   [Pe-Romashko, Klaren; Gustafson, David H.; Shah, Dhavan V.] Univ Wisconsin, Dept Ind & Syst Engn, Ctr Hlth Enhancement Syst Studies, Madison, WI USA.
   [Krechel, Sarah; Liebert, Cameron] Vivent Hlth, Milwaukee, WI USA.
   [Westergaard, Ryan P.] Wisconsin Dept Hlth Serv, Bur Communicable Dis, Madison, WI USA.
RP Hochstatter, KR (corresponding author), Columbia Univ, Social Intervent Grp, 1255 Amsterdam Ave, New York, NY 10027 USA.; Hochstatter, KR (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53726 USA.
EM khochsta@medicine.wisc.edu
OI Hochstatter, Karli/0000-0001-6891-953X
FU National Institutes of Health: NIDAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [T32DA037801]
FX The authors want to particularly thank the individuals who participated
   in this study. This study was funded by the National Institutes of
   Health: NIDA (Grant DP2DA042424). Dr. Hochstatter is supported by the
   National Institutes of Health: NIDA (Grant T32DA037801).
CR American Psychological Association, 2007, 407322008001 AM PSYC
   [Anonymous], 2020, COVID 19 COR DIS
   [Anonymous], 2019, EC DIS
   Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Berg CJ, 2007, INFECT DIS CLIN N AM, V21, P181, DOI 10.1016/j.idc.2007.01.005
   CDC, 2020, COR DIS 2019 COVID 1
   Cohn SE, 2011, AIDS CARE, V23, P775, DOI 10.1080/09540121.2010.525617
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Gustafson DH, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1726-1
   HAVERKOS HW, 1991, J SUBST ABUSE TREAT, V8, P269, DOI 10.1016/0740-5472(91)90050-K
   Hochstatter KR, 2019, JMIR RES PROTOC, V8, DOI 10.2196/12620
   Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012
   Horberg MA, 2013, AIDS PATIENT CARE ST, V27, P442, DOI 10.1089/apc.2013.0073
   Hosseinbor Mohsen, 2014, Int J High Risk Behav Addict, V3, pe22688, DOI 10.5812/ijhrba.22688
   LEIGH BC, 1989, PROG CLIN BIOL RES, V325, P35
   Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002
   Parienti JJ, 2004, CLIN INFECT DIS, V38, P1311, DOI 10.1086/383572
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Pellowski JA, 2013, AM PSYCHOL, V68, P197, DOI 10.1037/a0032694
   Stall R, 1987, Adv Alcohol Subst Abuse, V7, P73
   StataCorp, 2019, STAT STAT SOFTW REL
   World Health Organization (WHO), 2020, NOV COR CHIN
   Zinski A, 2015, AM J PUBLIC HEALTH, V105, P2068, DOI 10.2105/AJPH.2015.302695
NR 25
TC 1
Z9 1
U1 4
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
DI 10.1007/s10461-020-02976-1
EA JUL 2020
PG 6
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA MO8LP
UT WOS:000551770400001
PM 32705370
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tan, CW
   Chia, WN
   Qin, XJ
   Liu, P
   Chen, MIC
   Tiu, C
   Hu, ZL
   Chen, VCW
   Young, BE
   Sia, WR
   Tan, YJ
   Foo, R
   Yi, YX
   Lye, DC
   Anderson, DE
   Wang, LF
AF Tan, Chee Wah
   Chia, Wan Ni
   Qin, Xijian
   Liu, Pei
   Chen, Mark I-C
   Tiu, Charles
   Hu, Zhiliang
   Chen, Vivian Chih-Wei
   Young, Barnaby E.
   Sia, Wan Rong
   Tan, Yee-Joo
   Foo, Randy
   Yi, Yongxiang
   Lye, David C.
   Anderson, Danielle E.
   Wang, Lin-Fa
TI A SARS-CoV-2 surrogate virus neutralization test based on
   antibody-mediated blockage of ACE2-spike protein-protein interaction
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID SARS CORONAVIRUS SPIKE; BATS; RESERVOIRS; OUTBREAK; RECEPTOR; SERA
AB A blocking assay based on the recombinant receptor-binding domain of SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 receptor provides an alternative to conventional antibody neutralization assays requiring live virus.
   A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain in an isotype- and species-independent manner. Our simple and rapid test is based on antibody-mediated blockage of the interaction between the angiotensin-converting enzyme 2 (ACE2) receptor protein and the receptor-binding domain. The test, which has been validated with two cohorts of patients with COVID-19 in two different countries, achieves 99.93% specificity and 95-100% sensitivity, and differentiates antibody responses to several human coronaviruses. The surrogate virus neutralization test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.
C1 [Tan, Chee Wah; Chia, Wan Ni; Tiu, Charles; Chen, Vivian Chih-Wei; Sia, Wan Rong; Foo, Randy; Anderson, Danielle E.; Wang, Lin-Fa] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore.
   [Qin, Xijian; Liu, Pei] GenScript Biotech, Nanjing, Peoples R China.
   [Chen, Mark I-C; Young, Barnaby E.; Lye, David C.] Natl Ctr Infect Dis, Singapore, Singapore.
   [Chen, Mark I-C] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Hu, Zhiliang; Yi, Yongxiang] Nanjing Univ Chinese Med, Hosp Nanjing 2, Nanjing Infect Dis Ctr, Nanjing, Peoples R China.
   [Hu, Zhiliang] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Peoples R China.
   [Young, Barnaby E.; Lye, David C.] Tan Tock Seng Hosp, Duke NUS Med Sch, Singapore, Singapore.
   [Young, Barnaby E.; Lye, David C.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Tan, Yee-Joo] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.
   [Tan, Yee-Joo] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore, Singapore.
   [Lye, David C.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Anderson, Danielle E.; Wang, Lin-Fa] SingHlth Duke NUS Global Hlth Inst, Singapore, Singapore.
RP Anderson, DE; Wang, LF (corresponding author), Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore.; Anderson, DE; Wang, LF (corresponding author), SingHlth Duke NUS Global Hlth Inst, Singapore, Singapore.
EM Danielle.anderson@duke-nus.edu.sg; linfa.wang@duke-nus.edu.sg
RI Hu, Zhiliang/AAS-3469-2020
OI Hu, Zhiliang/0000-0001-8543-821X; Sia, Wan Rong/0000-0003-2694-4192;
   Tan, Yee-Joo/0000-0002-2278-4497; Chen, Vivian/0000-0001-8757-0644; Lye,
   David/0000-0003-0324-0205
FU Singapore National Research FoundationSingapore National Research
   Foundation [NRF2016NRF-NSFC002-013]; National Medical Research
   CouncilMedical Research Council UK (MRC) [STPRG-FY19-001, COVID19RF-003]
FX We thank S. Tang, Y. Shen, N. Mao, W. Shao and L. Zhu for technical
   assistance, advice and logistics support with assay development and
   testing; Y. Peng, A. Gamage, B. L. Lim and X. M. Ong for assistance with
   protein purification, sample management and testing; Y. Abdad and L. W.
   L. Tan for help with human CoV serum collection; V. Vijayan, B. Ng and
   V. Sivalingam of the Duke-NUS Medical School ABSL3 facility for
   logistics management and assistance. L.-F.W. and D.E.A. are supported by
   grants from the Singapore National Research Foundation
   (NRF2016NRF-NSFC002-013) and the National Medical Research Council
   (STPRG-FY19-001 and COVID19RF-003).
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Anderson DE, 2020, EMERG MICROBES INFEC, V9, P900, DOI 10.1080/22221751.2020.1761267
   [Anonymous], 2020, COVID 19 STAT REP
   [Anonymous], BBC
   Barr J, 2015, J GEN VIROL, V96, P24, DOI 10.1099/vir.0.068106-0
   BESSELAAR TG, 1992, ARCH VIROL, V125, P239, DOI 10.1007/BF01309641
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Crameri G, 2016, EMERG INFECT DIS, V22, P1071, DOI 10.3201/eid2206.160007
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Howell KA, 2017, CELL REP, V19, P413, DOI 10.1016/j.celrep.2017.03.049
   Jiang LL, 2017, SCI REP-UK, V7, DOI 10.1038/srep42963
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Klasse PJ, 2014, ADV BIOL, V2014, P1, DOI DOI 10.1155/2014/157895
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Smith I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025275
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Young PL, 1996, EMERG INFECT DIS, V2, P239, DOI 10.3201/eid0203.960315
   Yu M, 2008, J IMMUNOL METHODS, V331, P1, DOI 10.1016/j.jim.2007.11.009
   Zeng FY, 2006, FEBS LETT, V580, P5612, DOI 10.1016/j.febslet.2006.08.085
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zwick MB, 2001, J VIROL, V75, P12198, DOI 10.1128/JVI.75.24.12198-12208.2001
NR 34
TC 28
Z9 27
U1 16
U2 16
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD SEP
PY 2020
VL 38
IS 9
BP 1073
EP +
DI 10.1038/s41587-020-0631-z
EA JUL 2020
PG 17
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA NJ2ZW
UT WOS:000551779500002
PM 32704169
OA Bronze
DA 2021-01-01
ER

PT J
AU Ahmed, SA
   Abdelrheem, DA
   Abd El-Mageed, HR
   Mohamed, HS
   Rahman, AA
   Elsayed, KNM
   Ahmed, SA
AF Ahmed, Shimaa A.
   Abdelrheem, Doaa A.
   Abd El-Mageed, H. R.
   Mohamed, Hussein S.
   Rahman, Aziz A.
   Elsayed, Khaled N. M.
   Ahmed, Sayed A.
TI Destabilizing the structural integrity of COVID-19 by caulerpin and its
   derivatives along with some antiviral drugs: An in silico approaches for
   a combination therapy
SO STRUCTURAL CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; Caulerpin; Simeprevir; Molecular docking; ANCHOR and MD
   simulation
AB Presently, the SARS-CoV-2 (COVID-19) pandemic has been spreading throughout the world. Some drugs such as lopinavir, simeprevir, hydroxychloroquine, chloroquine, and amprenavir have been recommended for COVID-19 treatment by some researchers, but these drugs were not effective enough against this virus. This study based on in silico approaches was aimed to increase the anti-COVID-19 activities of these drugs by using caulerpin and its derivatives as an adjunct drug against SARS-CoV-2 receptor proteins: the SARS-CoV-2 main protease and the SARS-CoV-2 spike protein. Caulerpin exhibited antiviral activities against chikungunya virus and herpes simplex virus type 1. Caulerpin and some of its derivatives showed inhibitory activity against Alzheimer's disease. The web server ANCHOR revealed higher protein stability for the two receptors with disordered score (< 0.6). Molecular docking analysis showed that the binding energies of most of the caulerpin derivatives were higher than all the suggested drugs for the two receptors. Also, we deduced that inserting NH2, halogen, and vinyl groups can increase the binding affinity of caulerpin toward 6VYB and 6LU7, while inserting an alkyl group decreases the binding affinity of caulerpin toward 6VYB and 6LU7. So, we can modify the inhibitory effect of caulerpin against 6VYB and 6LU7 by inserting NH2, halogen, and vinyl groups. Based on the protein disordered results, the SARS-CoV-2 main protease and SARS-CoV-2 spike protein domain are highly stable proteins, so it is quite difficult to unstabilize their integrity by using individual drugs. Also, molecular dynamics (MD) simulation indicates that binding of the combination therapy of simeprevir and the candidate studied compounds to the receptors was stable and had no major effect on the flexibility of the protein throughout the simulations and provided a suitable basis for our study. So, this study suggested that caulerpin and its derivatives could be used as a combination therapy along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and amprenavir for disrupting the stability of SARS-CoV2 receptor proteins to increase the antiviral activity of these drugs.
C1 [Ahmed, Shimaa A.; Abdelrheem, Doaa A.; Ahmed, Sayed A.] Beni Suef Univ, Fac Sci, Dept Chem, Bani Suwayf 62511, Egypt.
   [Abd El-Mageed, H. R.] Beni Suef Univ, Fac Sci, Microanal & Environm Res & Community Serv Ctr, Bani Suwayf, Egypt.
   [Mohamed, Hussein S.] Beni Suef Univ, Res Inst Med & Aromat Plants RIMAP, Bani Suwayf, Egypt.
   [Rahman, Aziz A.] Univ Rajshahi, Dept Pharm, Rajshahi 6205, Bangladesh.
   [Elsayed, Khaled N. M.] Beni Suef Univ, Fac Sci, Dept Bot, Bani Suwayf 62511, Egypt.
RP Ahmed, SA (corresponding author), Beni Suef Univ, Fac Sci, Dept Chem, Bani Suwayf 62511, Egypt.
EM sayed.hassan@science.bsu.edu.eg
RI Rezk, Hamada/A-3015-2019; Elyamany, Khaled NM Elsayed/AAY-8108-2020
OI Elyamany, Khaled NM Elsayed/0000-0003-2296-8883
CR Ahmed SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1774418
   Angiolella L, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1945179
   [Anonymous], 2017, BIOVIA DISC STUD MOD
   Ayyad S. -E. N., 1994, J PHARM SCI, V8, P217
   Boxall ABA, 2004, EMBO REP, V5, P1110, DOI 10.1038/sj.embor.7400307
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XR, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00098
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   de Oliveira M.D., 2020, CEP, V11981, P7
   de Souza ET, 2009, MAR DRUGS, V7, P689, DOI 10.3390/md7040689
   Dosztanyi Z, 2005, J MOL BIOL, V347, P827, DOI 10.1016/j.jmb.2005.01.071
   Dosztanyi Z, 2018, PROTEIN SCI, V27, P331, DOI 10.1002/pro.3334
   Esteves PO, 2019, NAT PROD COMMUN, V1, p1934578X19878295
   Govenkar MB, 2000, PHYTOCHEMISTRY, V54, P979, DOI 10.1016/S0031-9422(00)00078-9
   Hughes ZE, 2016, PHYS CHEM CHEM PHYS, V18, P17525, DOI 10.1039/c6cp02323a
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Libran-Perez M, 2019, FISH SHELLFISH IMMUN, V95, P595, DOI 10.1016/j.fsi.2019.10.055
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lorenzo VP, 2015, REV BRAS FARMACOGN, V25, P690, DOI 10.1016/j.bjp.2015.08.005
   Lucena AMM, 2018, MAR DRUGS, V16, DOI 10.3390/md16090318
   Meszaros B, 2018, NUCLEIC ACIDS RES, V46, pW329, DOI 10.1093/nar/gky384
   Meszaros B, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000376
   Nagappan T, 2014, J APPL PHYCOL, V26, P1019, DOI 10.1007/s10811-013-0147-8
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Macedo NRPV, 2012, REV BRAS FARMACOGN, V22, P861, DOI 10.1590/S0102-695X2012005000072
   Raghavendra S, COMPUT BIOL CHEM, DOI [10.1016/j.compbiolchem.2015.09.008, DOI 10.1016/J.C0MPBIOLCHEM.2015.09.008]
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Srivastava AK, 2015, ARCH PHARM, V348, P548, DOI 10.1002/ardp.201400438
   Thomas PD, 1996, P NATL ACAD SCI USA, V93, P11628, DOI 10.1073/pnas.93.21.11628
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu X., 1996, ZIRAN KEXUEBAN, V35, P64
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 36
TC 1
Z9 1
U1 5
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-0400
EI 1572-9001
J9 STRUCT CHEM
JI Struct. Chem.
PD DEC
PY 2020
VL 31
IS 6
BP 2391
EP 2412
DI 10.1007/s11224-020-01586-w
EA JUL 2020
PG 22
WC Chemistry, Multidisciplinary; Chemistry, Physical; Crystallography
SC Chemistry; Crystallography
GA OE5QI
UT WOS:000551751100002
PM 32837118
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Das, P
   Majumder, R
   Mandal, M
   Basak, P
AF Das, Pratik
   Majumder, Ranabir
   Mandal, Mahitosh
   Basak, Piyali
TI In-Silico approach for identification of effective and stable inhibitors
   for COVID-19 main protease (M-pro) from flavonoid based phytochemical
   constituents ofCalendula officinalis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19 M-pro; SARS-CoV-2; calendula officinals; molecular docking;
   molecular simulation
ID CORONAVIRUS; VIRUSES; GROMACS
AB The recent outbreak of the coronavirus disease COVID-19 is putting the world towards a great threat. A recent study revealed COVID-19 main protease (M-pro) is responsible for the proteolytic mutation of this virus and is essential for its life cycle. Thus inhibition of this protease will eventually lead to the destruction of this virus. In-Silico Molecular docking was performed with the Native ligand and the 15 flavonoid based phytochemicals ofCalendula officinalsto check their binding affinity towards the COVID-19 main protease. Finally, the top 3 compounds with the highest affinity have been chosen for molecular dynamics simulation to analyses their dynamic properties and conformational flexibility or stability. In-Silico Docking showed that major phytochemicals ofCalendula officinalsi.e. rutin, isorhamnetin-3-O-beta-D, calendoflaside, narcissin, calendulaglycoside B, calenduloside, calendoflavoside have better binding energy than the native ligand (inhibitor N3). MD simulation of 100 ns revealed that all the protease-ligand docked complexes are overall stable as compare to M-pro-native ligand (inhibitor N3) complex. Overall, rutin and caledoflaside showed better stability, compactness, and flexibility. Our in silico(Virtual molecular docking and Molecular dynamics simulation) studies pointed out that flavonoid based phytochemicals of calendula (rutin, isorhamnetin-3-O-beta-D, calendoflaside) may be highly effective for inhibiting M(pro)which is the main protease for SARS-CoV-2 causing the deadly disease COVID-19. Rutin is already used as a drug and the other two compounds can be made available for future use. Thus the study points a way to combat COVID-19 by the use of major flavonoid based phytochemicals ofCalendula officinals. Communicated by Ramaswamy H. Sarma
C1 [Das, Pratik; Basak, Piyali] Jadavpur Univ, Sch Biosci & Engn, Kolkata 700032, W Bengal, India.
   [Majumder, Ranabir; Mandal, Mahitosh] Indian Inst Technol, Sch Med Sci & Technol, Kharagpur, W Bengal, India.
RP Basak, P (corresponding author), Jadavpur Univ, Sch Biosci & Engn, Kolkata 700032, W Bengal, India.
EM piyalibasak@gmail.com
OI Majumder, Ranabir/0000-0003-3585-3276; Basak, Piyali/0000-0001-9245-0014
FU "Centre of Excellence in Phase Transformation and Product
   Characterization, TEQIP-III", Jadavpur University, Kolkata; Indian
   Council of Medical ResearchIndian Council of Medical Research (ICMR); J
   C Bose Fellowship (DST, India); MHRD, Indian Institute of Technology,
   Kharagpur, India; Council of Scientific and Industrial ResearchCouncil
   of Scientific & Industrial Research (CSIR) - India
FX We would like to acknowledge the "Centre of Excellence in Phase
   Transformation and Product Characterization, TEQIP-III", Jadavpur
   University, Kolkata, MHRD, Indian Institute of Technology, Kharagpur,
   India, Indian Council of Medical Research, Council of Scientific and
   Industrial Research and J C Bose Fellowship (DST, India) for providing
   fellowship and financial support during this work. We would also like to
   acknowledge every lab member of Biomaterial, Cell Culture, and
   Microbiology lab of School of Bioscience and Engineering, Jadavpur
   University. All the authors would like to thank all the medical workers
   and emergency service providers around the globe for their incomparable
   contribution towards the society and mankind while combating COVID-19.
CR Agarwal O. P., 2006, TRADITIONAL SYSTEMS, V5, P5
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   AshwlayanVD K. A., 2018, PHARM PHARM INT J, V6, DOI DOI 10.15406/PPIJ.2018.06.00171
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Bhatnagar S. S., 1960, WEALTH INDIA RAW MAT, V10
   Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/nchem.1243, 10.1038/NCHEM.1243]
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chakraborthy G. S., 2010, International Journal of Research in Ayurveda and Pharmacy (IJRAP), V1, P131
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dahlin JL, 2015, J MED CHEM, V58, P2091, DOI 10.1021/jm5019093
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Gupta M, 2020, J THERM ANAL CALORIM, V142, P1545, DOI [10.1007/s10973-020-09453-w, 10.1080/01694243.2020.1749448]
   JIN Z, 2020, NATURE 0409, DOI DOI https://doi.org/10.1101/2020.02.26.964882
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kadam R. U., 2007, Indian Journal of Pharmaceutical Sciences, V69, P609
   KAHN JS, 2005, J PEDIAT INFECT DIS, V24, P223, DOI DOI https://doi.org/10.1097/01.inf.0000188166.17324.60
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee YS, 2005, BIOL PHARM BULL, V28, P916, DOI 10.1248/bpb.28.916
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Majumder R, 2020, NAT PROD RES, V34, P2363, DOI 10.1080/14786419.2018.1534848
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Muley BP, 2009, TROP J PHARM RES, V8, P455
   Nejadi Babadaei M. M., 2020, J BIOMOLECULAR STRUC, P1, DOI [10.1080/07391102.2020.1767211, DOI 10.1080/07391102.2020.1767211]
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Temerk YM, 2006, MICROCHIM ACTA, V153, P7, DOI 10.1007/s00604-005-0451-3
   TYRRELL DA, 1966, LANCET, V1, P76
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   Verma S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149014
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
NR 35
TC 2
Z9 2
U1 10
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796799
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO6BA
UT WOS:000551607700001
PM 32705952
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fiorucci, D
   Milletti, E
   Orofino, F
   Brizzi, A
   Mugnaini, C
   Corelli, F
AF Fiorucci, Diego
   Milletti, Eva
   Orofino, Francesco
   Brizzi, Antonella
   Mugnaini, Claudia
   Corelli, Federico
TI Computational drug repurposing for the identification of SARS-CoV-2 main
   protease inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2 Mpro; drug repurposing; molecular docking;
   molecular dynamics
AB Accepted 7 July 2020ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the known COVID-19 disease. Since currently no definitive therapies or vaccines for the SARS-CoV-2 virus are available, there is an urgent need to identify effective drugs against SARS-CoV-2 infection. One of the best-known targets available is the main protease of this virus, crucial for the processing of polyproteins codified by viral RNA. In this work, we used a computational virtual screening procedure for the repurposing of commercial drugs available in the DrugBank database as inhibitors of the SARS-CoV-2 main protease. Molecular docking calculations and molecular dynamics (MD) simulations have been applied. The computational model was validated through a self-docking procedure. The screening procedure highlighted five interesting drugs that showed a comparable or higher docking score compared to the crystallographic compound and maintained the protein binding during the MD runs. Amongst these drugs, Ritonavir has been used in clinical trials with patients affected by COVID-19 and Nelfinavir showed anti-SARS-CoV-2 activity. The five identified drugs could be evaluated experimentally as inhibitors of the SARS-CoV-2 main protease in view of a possible COVID-19 treatment. Communicated by Ramaswamy H. Sarma
C1 [Fiorucci, Diego; Orofino, Francesco; Brizzi, Antonella; Mugnaini, Claudia; Corelli, Federico] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy.
   [Milletti, Eva] Florence Careggi Hosp, AOU Careggi, Gen Lab, Florence, Italy.
   [Milletti, Eva] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy.
RP Corelli, F (corresponding author), Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy.
EM federico.corelli@unisi.it
OI Corelli, Federico/0000-0002-5750-4504; Orofino,
   Francesco/0000-0001-7029-337X
FU MIUR Progetto Dipartimenti di Eccellenza [2018-2022]
FX Partially supported by MIUR Progetto Dipartimenti di Eccellenza
   2018-2022, Grant No. L. 232/2016.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Berman H. M., 2000, NUCL ACIDS RES, V28, pD235, DOI DOI HTTPS://DOI.ORG/10.1093/NAR/28.1.235
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Case D., 2018, AMBER 2018
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Kahn J.S., 2005, PEDIAT INFECT DIS S, V24, p[S223, S226]
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   MUSARRAT F, 2020, J MED VIROL 0517, DOI DOI https://doi.org/10.1002/jmv.25985
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger, 2015, PYMOL MOL GRAPH SYST
   Schrodinger, 2018, LIGPREP REL 2018 4
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
NR 17
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796805
EA JUL 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO6DN
UT WOS:000551614200001
PM 32705942
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mahmud, S
   Uddin, MA
   Zaman, M
   Sujon, KM
   Rahman, ME
   Shehab, MN
   Islam, A
   Alom, MW
   Amin, A
   Akash, A
   Abu Saleh, M
AF Mahmud, Shafi
   Uddin, Mohammad Abu Raihan
   Zaman, Meemtaheena
   Sujon, Khaled Mahmud
   Rahman, Md Ekhtiar
   Shehab, Mobasshir Noor
   Islam, Ariful
   Alom, Md Wasim
   Amin, Al
   Akash, Al Shahriar
   Abu Saleh, Md
TI Molecular docking and dynamics study of natural compound for potential
   inhibition of main protease of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Protease inhibitors; phytochemicals; virtual screening; binding modes;
   MD simulation
ID SARS CORONAVIRUS; 3C-LIKE PROTEASE; DESIGN; VIRUS; PREDICTION;
   MUTATIONS; REVEALS; COMPLEX; BINDING; DOMAIN
AB Newly emerged SARS-CoV-2 made recent pandemic situations across the globe is accountable for countless unwanted death and insufferable panic associated with co-morbidities among mass people. The scarcity of appropriate medical treatment and no effective vaccine or medicine against SARS-CoV-2 has turned the situation worst. Therefore, in this study, we made a deep literature review to enlist plant-derived natural compounds and considered their binding mechanism with the main protease of SARS-CoV-2 through combinatorial bioinformatics approaches. Among all, a total of 14 compounds were filtered where Carinol, Albanin, Myricetin were had better binding profile than the rest of the compounds with having binding energy of -8.476, -8.036, -8.439 kcal/mol, respectively. Furthermore, MM-GBSA calculations were also considered in this selection process to support docking studies. Besides, 100 ns molecular dynamics simulation endorsed the rigid nature, less conformational variation and binding stiffness. As this study, represents a perfect model for SARS-CoV-2 main protease inhibition through bioinformatics study, these potential drug candidates may assist the researchers to find a superior and effective solution against COVID-19 after future experiments. Communicated by Ramaswamy Sarma
C1 [Mahmud, Shafi; Sujon, Khaled Mahmud; Rahman, Md Ekhtiar; Shehab, Mobasshir Noor; Islam, Ariful; Alom, Md Wasim; Abu Saleh, Md] Univ Rajshahi, Dept Genet Engn & Biotechnol, Rajshahi 6205, Bangladesh.
   [Uddin, Mohammad Abu Raihan; Zaman, Meemtaheena] Univ Sci & Technol USTC, Dept Biochem & Biotechnol, Chittagong, Bangladesh.
   [Amin, Al] Univ Rajshahi, Inst Biol Sci, Rajshahi, Bangladesh.
   [Akash, Al Shahriar] Univ Chittagong, Dept Genet Engn & Biotechnol, Chittagong, Bangladesh.
RP Mahmud, S (corresponding author), Univ Rajshahi, Dept Genet Engn & Biotechnol, Rajshahi 6205, Bangladesh.
EM shafimahmudfz@gmail.com
OI Amin, MD. Al/0000-0003-1312-3395; Mahmud, shafi/0000-0003-1604-8626;
   Uddin, Mohammad Abu Raihan/0000-0003-4369-5351; Sujon, Khaled
   Mahmud/0000-0002-1514-7342
CR Abu-Aisheh MN, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01552
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Babu TMC, 2017, RSC ADV, V7, P18277, DOI 10.1039/c6ra27872h
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Case D. A., 2006, AMBER 9 0 SOFTWARE P
   Chen F, 2016, PHYS CHEM CHEM PHYS, V18, P22129, DOI 10.1039/c6cp03670h
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Daidone F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031610
   Dasgupta J, 2003, PROTEIN ENG, V16, P489, DOI 10.1093/protein/gzg070
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Doss CGP, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/895831
   Doss CGP, 2014, MOL BIOSYST, V10, P421, DOI 10.1039/c3mb70427k
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gilis D, 1996, J MOL BIOL, V257, P1112, DOI 10.1006/jmbi.1996.0226
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Jorgensen W. L., 2016, QIKPROP
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   MAHMUD S, 2019, J BIOMOL STRUCT 1022, DOI DOI https://doi.org/10.1080/07391102.2019.1680440
   MAHMUD S, 2020, J BIOMOL STRUCT 0428, DOI DOI https://doi.org/10.1080/07391102.2020.1753579
   MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0
   Nagasundaram N, 2013, CELL BIOCHEM BIOPHYS, V66, P681, DOI 10.1007/s12013-012-9512-5
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Repasky Matthew P, 2007, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0812s18
   RIZA YM, 2019, IN SILICO PHARMACOL, V7, DOI DOI https://doi.org/10.1007/s40203-019-0050-3
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger, 2020, LIGPREP
   Schrodinger, 2019, QIKPROP
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Shi JH, 2006, FEBS J, V273, P1035, DOI 10.1111/j.1742-4658.2006.05130.x
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Talele TT, 2010, CURR TOP MED CHEM, V10, P127, DOI 10.2174/156802610790232251
   Villanueva J, 2004, PROTEIN SCI, V13, P797, DOI 10.1110/ps.03445704
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yu WB, 2017, METHODS MOL BIOL, V1520, P85, DOI 10.1007/978-1-4939-6634-9_5
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 55
TC 1
Z9 1
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796808
EA JUL 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO6AR
UT WOS:000551606800001
PM 32705962
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tscherning, C
   Sizun, J
   Kuhn, P
AF Tscherning, Charlotte
   Sizun, Jacques
   Kuhn, Pierre
TI Promoting attachment between parents and neonates despite the COVID-19
   pandemic
SO ACTA PAEDIATRICA
LA English
DT Article
DE bonding; COVID-19; guidelines; pandemic; separation
AB Social distancing is the only option available during the COVID-19 pandemic until a vaccine is developed. However, this is having a major impact on human relationships and bonding between parents and neonates is a major concern. Separation during this health emergency could have lifelong consequences for offspring, and there are even greater concerns if newborn infants are sick or vulnerable and need intensive care. We look at how bonding can be safely supported and maintained without risking infecting neonates, by comparing the international guidelines and proposing safe actions within those frameworks.
C1 [Tscherning, Charlotte] Weill Cornell Med Coll, Div Neonatol, Sidra Med, Doha, Qatar.
   [Tscherning, Charlotte] Univ Toulouse, Ctr Physiopathol Toulouse Purpan CPTP, CNRS, INSERM, Toulouse, France.
   [Sizun, Jacques] CHU Brest, Serv Neonatal & Reanimat Pediat, Brest, France.
   [Sizun, Jacques] CHU Toulouse, Serv Neonatal, Toulouse, France.
   [Kuhn, Pierre] Hop Hautepierre, Serv Med & Reanimat Nouveau Ne, Strasbourg, France.
   [Kuhn, Pierre] Inst Neurosci Cellulaires & Integrat, CNRS UPR 3212, Strasbourg, France.
RP Tscherning, C (corresponding author), Weill Cornell Med Coll, Div Neonatol, Sidra Med, Doha, Qatar.
EM charlottecasper66@gmail.com
OI Tscherning, Charlotte/0000-0001-7111-8979
CR Academy of Breastfeeding Medicine, STAT COVID 19
   American College of Obstetrics and Gynecology ( ACOG ), COVID 19 UPD
   BOWLBY J, 1958, INT J PSYCHOANAL, V39, P350
   CDC, INT INF CONTR GUID P
   CDC, PREG BREASTF
   Charpak N, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2063
   Chen DJ, 2020, INT J GYNECOL OBSTET, V149, P130, DOI 10.1002/ijgo.13146
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Alzamora MC, 2020, AM J PERINAT, V37, P861, DOI 10.1055/s-0040-1710050
   Davanzo R, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.13010
   Feldman R, 2017, TRENDS COGN SCI, V21, P80, DOI 10.1016/j.tics.2016.11.007
   Forcada-Guex M, 2011, EARLY HUM DEV, V87, P21, DOI 10.1016/j.earlhumdev.2010.09.006
   Lavallee A, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0459-x
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Lopez-Maestro M, 2017, EARLY HUM DEV, V104, P1, DOI 10.1016/j.earlhumdev.2016.11.003
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Montirosso R, 2018, EUROPEAN STANDARDS C
   Peters KL, 2009, PEDIATRICS, V124, P1009, DOI 10.1542/peds.2008-3808
   Puopolo KM, 2020, INITIAL GUIDANCE MAN
   Roue JM, 2017, ARCH DIS CHILD-FETAL, V102, pF364, DOI 10.1136/archdischild-2016-312180
   Royal Australian and New Zealand College of Obstetricians and, COR INF HUB
   Royal College of Obstetricians and Gynecologists ( RCOG ), COVID 19 INF PREGN
   Westrup B, 2018, EUROPEAN STANDARDS C
   Zaigham M, 2020, ACTA OBSTET GYN SCAN, V99, P823, DOI 10.1111/aogs.13867
NR 24
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0803-5253
EI 1651-2227
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD OCT
PY 2020
VL 109
IS 10
BP 1937
EP 1943
DI 10.1111/apa.15455
EA JUL 2020
PG 7
WC Pediatrics
SC Pediatrics
GA NR2JZ
UT WOS:000551335500001
PM 32588911
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ku, M
   Morgan, T
   Malbon, A
   Bartram, T
   Cavanagh, J
   Halvorsen, B
AF Ku, Min
   Morgan, Tanya
   Malbon, Alan
   Bartram, Timothy
   Cavanagh, Jillian
   Halvorsen, Beni
TI Provision of a consistent national approach to radiation therapy
   workforce protection measures in Australia during the COVID-19 pandemic
SO AUSTRALIAN HEALTH REVIEW
LA English
DT Article
ID BURNOUT
AB Healthcare workers are at the frontline managing COVID-19 patients with transmission of the COVID-19 virus to healthcare workers evident in many Australian states. Minimisation of this spread is vital to protecting the healthcare workforce with individual organisations detailing best practice for infection and control. However, interpretation and implementation of infection control guidelines is varied across Australian Radiation Therapy Departments, highlighting inconsistencies. Strong leadership, quality communication and clear direction is required during this crisis to ensure that radiation therapists receive all necessary support and resources required to maintain safety and well-being during the COVID-19 pandemic.
C1 [Ku, Min; Morgan, Tanya; Malbon, Alan] Australian Soc Med Imaging & Radiat Therapy, 1 Queens Rd, Melbourne, Vic 3004, Australia.
   [Ku, Min; Bartram, Timothy; Cavanagh, Jillian; Halvorsen, Beni] RMIT Univ, 124 La Trobe St, Melbourne, Vic 3000, Australia.
RP Ku, M (corresponding author), Australian Soc Med Imaging & Radiat Therapy, 1 Queens Rd, Melbourne, Vic 3004, Australia.; Ku, M (corresponding author), RMIT Univ, 124 La Trobe St, Melbourne, Vic 3000, Australia.
EM min.ku@rmit.edu.au; timothy.bartram@rmit.edu.au;
   jillian.cavanagh@rmit.edu.au; beni.halvorsen@rmit.edu.au
CR Akroyd D, 2002, INT J RADIAT ONCOL, V52, P816, DOI 10.1016/S0360-3016(01)02688-8
   Aubusson K., 2020, SYDNEY MORNING HERAL
   Australian Commission on Safety and Quality in Health Care, 2020, INF PREV CONTR COVID
   Australian Government, 2020, 3 STEP FRAM COVIDSAF
   Australian Government Department of Health, 2020, COVID 19 PRIM CAR AL
   Australian Government Department of Health, 2020, FACT SHEET COR COVID
   Australian Society of Medical Imaging and Radiation Therapy (ASMIRT), 2020, ASMIRT POS STAT PERS
   Bakker AB, 2005, J OCCUP HEALTH PSYCH, V10, P170, DOI 10.1037/1076-8998.10.2.170
   Chen YL, 2020, ADV RADIAT ONCOL, V5, P534, DOI 10.1016/j.adro.2020.03.005
   Cunningham M, 2020, SYDNEY MORNING HERAL
   Doherty B., 2020, GUARDIAN
   Gold I, 2020, OPINION WHY ARE WE C
   Hunter D, 2019, J MED RADIAT SCI, V66, P139, DOI 10.1002/jmrs.321
   International Society of Radiographers and Radiologic Technologists (ISRRT), 2020, FULL GUID PROT MEAS
   Jasperse M, 2014, EUR J CANCER CARE, V23, P82, DOI 10.1111/ecc.12098
   Krengli M, 2020, ADV RADIAT ONCOL, V5, P527, DOI 10.1016/j.adro.2020.03.003
   Medical Radiation Practice Board of Australia, 2020, TABL 1 3 AR DIV
   National Health Service (NHS) Staff Council, 2020, NHS STAFF COUNC STAT
   NSW Government Clinical Excellence Commission, 2020, INF PREV CONTR MAN C
   Rhoades L, 2002, J APPL PSYCHOL, V87, P698, DOI 10.1037//0021-9010.87.4.698
   Sarra A, 2018, J MED IMAGING RADIAT, V49, P49, DOI 10.1016/j.jmir.2017.10.008
   Simpson MR, 2009, INT J NURS STUD, V46, P1012, DOI 10.1016/j.ijnurstu.2008.05.003
   Tableau Public, 2020, COVID 19 OCC RISK AS
   Taylor T, 2020, ABC NEWS
   The Society of Radiographers, 2020, COVID 19 PERS PROT E
   Vietnam Association of Radiology Technologist (VART), 2020, HIGH IMP ROL SAF RT
   Wong JW, 1999, INT J RADIAT ONCOL, V44, P911, DOI 10.1016/S0360-3016(99)00056-5
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   Wu S, 2020, ADV RADIAT ONCOL, V5, P531, DOI 10.1016/j.adro.2020.03.004
NR 29
TC 0
Z9 0
U1 1
U2 1
PU CSIRO PUBLISHING
PI CLAYTON
PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC
   3168, AUSTRALIA
SN 0156-5788
EI 1449-8944
J9 AUST HEALTH REV
JI Aust. Health Rev.
PY 2020
VL 44
IS 4
BP 535
EP 539
DI 10.1071/AH20094
EA JUL 2020
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA MV0EZ
UT WOS:000551277300001
PM 32698942
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mitra, K
   Ghanta, P
   Acharya, S
   Chakrapani, G
   Ramaiah, B
   Doble, M
AF Mitra, Kartik
   Ghanta, Prasanth
   Acharya, Sushank
   Chakrapani, Gayathri
   Ramaiah, Basavaraju
   Doble, Mukesh
TI Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular
   dynamics based drug repositioning and phytochemical leads
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Pharmacophore; SARS-CoV-2 inhibitors; 3CL-protease; PL-protease;
   molecular dynamics; protease inhibitors; anti-HIV drugs; natural
   products
ID PAPAIN-LIKE PROTEASE; IDENTIFIES INHIBITORS; ANTIVIRAL ACTIVITY; SARS;
   CORONAVIRUS; REPLICATION; DERIVATIVES; DISCOVERY; LICORICE; DOCKING
AB SARS-related coronaviruses poses continual threat to humanity by rapidly mutating and emerging as severe pandemic outbreaks, including the current nCoV-19 pandemic. Hence a rapid drug repositioning and lead identification strategy are required to mitigate these outbreaks. We report a pharmacophore and molecular dynamics-based approach for drug repositioning and lead identification against dual targets (3CLp and PLp) of SARS-CoV-2. The pharmacophore model of 3CLp inhibitors was apolar with two aromatic and two H-bond acceptors, whereas that of PLp was relatively polar, bearing one aromatic and three H-bond acceptors. Pharmacophore-based virtual screening yielded six existing FDA-approved drugs and twelve natural products with both the pharmacophoric features. Among them are nelfinavir, tipranavir and licochalcone-D, which has shown better binding characteristics with both the proteases compared to lopinavir. The molecular dynamics revealed that the connecting loop (residues 176-199) of 3CLp is highly flexible, and hence, inhibitors should avoid high-affinity interactions with it. Lopinavir, due to its high affinity with the loop region, exhibited unstable binding. Further, the van der Waals size of the 3CLp inhibitors positively correlated with their binding affinity with 3CLp. However, the van der Waals size of a ligand should not cross a threshold of 572 angstrom(3), beyond which the ligands are likely to make high-affinity interaction with the loop and suffer unstable binding as observed in the case of lopinavir. Similarly, the total polar surface area of the ligands were found to be negatively correlated with their binding affinity with PLp.
C1 [Mitra, Kartik; Acharya, Sushank; Chakrapani, Gayathri; Doble, Mukesh] Indian Inst Technol Madras, Bhupat & Jyoti Mehta Sch Biosci, Bioengn & Drug Design Lab, Dept Biotechnol, Chennai, Tamil Nadu, India.
   [Ghanta, Prasanth; Ramaiah, Basavaraju] Sri Sathya Sai Inst Higher Learning, Dept Biosci, Puttaparthi, Andhra Pradesh, India.
RP Doble, M (corresponding author), Indian Inst Technol Madras, Bhupat & Jyoti Mehta Sch Biosci, Bioengn & Drug Design Lab, Dept Biotechnol, Chennai, Tamil Nadu, India.
EM Mukeshd@iitm.ac.in
OI Ghanta, Prasanth/0000-0001-5830-112X; Mitra, Kartik/0000-0003-4891-1463
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   [Anonymous], 2020, PROVISIONAL DEATH CO
   Arooj M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060470
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen LL, 2006, J BIOMOL SCREEN, V11, P915, DOI 10.1177/1087057106293295
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Cho JK, 2013, BIOORGAN MED CHEM, V21, P3051, DOI 10.1016/j.bmc.2013.03.027
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hassan MZ, 2016, EUR J MED CHEM, V123, P236, DOI 10.1016/j.ejmech.2016.07.056
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   IKEDA S, 1987, ANTIVIR RES, V8, P103, DOI 10.1016/0166-3542(87)90064-7
   Jana S, 2019, J BIOMOL STRUCT DYN, V37, P944, DOI 10.1080/07391102.2018.1444510
   Kim DW, 2014, J ENZYM INHIB MED CH, V29, P59, DOI 10.3109/14756366.2012.753591
   Koes DR, 2012, NUCLEIC ACIDS RES, V40, pW409, DOI 10.1093/nar/gks378
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Kuo CJ, 2009, FEBS LETT, V583, P549, DOI 10.1016/j.febslet.2008.12.059
   Lemkul J., 2019, LIVING J COMPUT MOL, V1, P5068, DOI [10.33011/livecoms.1.1.5068, DOI 10.33011/LIVECOMS.1.1.5068]
   Liu J, 2020, J BIOMOL STRUCT DYN, V38, P533, DOI 10.1080/07391102.2019.1590241
   Liu YC, 2005, BIOCHEM BIOPH RES CO, V333, P194, DOI 10.1016/j.bbrc.2005.05.095
   Mackenzie J. S., 2004, LEARNING SARS PREPAR
   Manvar D, 2012, J ETHNOPHARMACOL, V144, P545, DOI 10.1016/j.jep.2012.09.036
   Meagher KL, 2004, J AM CHEM SOC, V126, P13276, DOI 10.1021/ja0469378
   MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021
   Mitra K, 2019, EUR J PHARM SCI, V135, P103, DOI 10.1016/j.ejps.2019.04.023
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Naresh KN, 2015, J MOL GRAPH MODEL, V61, P272, DOI 10.1016/j.jmgm.2015.07.006
   Park JY, 2017, J ENZYM INHIB MED CH, V32, P504, DOI 10.1080/14756366.2016.1265519
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Park JY, 2012, BIOL PHARM BULL, V35, P2036, DOI 10.1248/bpb.b12-00623
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ramajayam R, 2010, BIOORGAN MED CHEM, V18, P7849, DOI 10.1016/j.bmc.2010.09.050
   Ramajayam R, 2010, BIOORG MED CHEM LETT, V20, P3569, DOI 10.1016/j.bmcl.2010.04.118
   Schneidman-Duhovny D, 2008, NUCLEIC ACIDS RES, V36, pW223, DOI 10.1093/nar/gkn187
   Sekiguchi JA, 1997, VIROLOGY, V235, P129, DOI 10.1006/viro.1997.8684
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Song YH, 2014, BIOL PHARM BULL, V37, P1021, DOI 10.1248/bpb.b14-00026
   Thangapandian S, 2011, J CHEM INF MODEL, V51, P33, DOI 10.1021/ci1002813
   Torbeev VY, 2009, J AM CHEM SOC, V131, P884, DOI 10.1021/ja806526z
   Vincent JL, 2020, LANCET RESP MED, V8, P430, DOI 10.1016/S2213-2600(20)30165-X
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang LQ, 2015, ACTA PHARM SIN B, V5, P310, DOI [10.1016//j.apsb.2015.05.005, 10.1016/j.apsb.2015.05.005]
   WHO, COR WWW DOC
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Xu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13684
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yuan SF, 2017, ANTIVIR RES, V145, P33, DOI 10.1016/j.antiviral.2017.07.007
NR 65
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796802
EA JUL 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO1NS
UT WOS:000551302300001
PM 32698693
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Razzaghi-Asl, N
   Ebadi, A
   Shahabipour, S
   Gholamin, D
AF Razzaghi-Asl, Nima
   Ebadi, Ahmad
   Shahabipour, Sara
   Gholamin, Danial
TI Identification of a potential SARS-CoV2 inhibitor via molecular dynamics
   simulations and amino acid decomposition analysis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; main protease; molecular dynamics; in silico hit
ID PROTEASE; EFFICIENT; DISCOVERY; COVID-19
AB Considering lack of validated therapeutic drugs or vaccines against contagious SARS-CoV2, various efforts have been focused on repurposing of existing drugs or identifying new agents. In an attempt to identify new and potential SARS-CoV2 inhibitors targeting specific enzyme of the pathogen, a few induced fit models of SARS-CoV2 main protease (Mpro) includingN-aryl amide and aryl sulfonamide based fragments were subjected to a multi-stepin silicostrategy. Sub-structure query of co-crystallographic fragments provided numerous ZINC15 driven commercially available compounds that entered molecular docking stage to find binding interactions/modes inside Mpro active site. Docking results were reevaluated through time dependent stability of top-ranked ligand-protease complexes by molecular dynamics (MD) simulations within 50 ns. Relative contribution of interacted residues in binding to the most probable binding pose was estimated through amino acid decomposition analysis in B3LYP level of theory with Def2-TZVPP split basis set. In confirmation of docking results, MD simulations revealed less perceptible torsional distortions (more stable binding mode) in binding of ZINC_252512772 (Delta G(b)-9.18 kcal/mol) into Mpro active site. H-bond interactions and hydrophobic contacts were determinant forces in binding interactions ofin silicohit. Quantum chemical calculations confirmed MD results and proved the pivotal role of a conserved residue (Glu166) in making permanent hydrogen bond (98% of MD simulations time) with ZINC_252512772. Drug-like physicochemical properties as well as desirable target binding interactions nominated ZINC_252512772 as a desirablein silicohit for further development toward SARS-CoV2 inhibitors.
C1 [Razzaghi-Asl, Nima; Shahabipour, Sara] Ardabil Univ Med Sci, Sch Pharm, Dept Med Chem, Ardebil 5618953141, Iran.
   [Ebadi, Ahmad] Hamadan Univ Med Sci, Med Plants & Nat Prod Res Ctr, Sch Pharm, Dept Med Chem, Hamadan, Hamadan, Iran.
   [Gholamin, Danial] Ardabil Univ Med Sci, Sch Pharm, Students Res Comm, Ardebil, Iran.
RP Razzaghi-Asl, N (corresponding author), Ardabil Univ Med Sci, Sch Pharm, Dept Med Chem, Ardebil 5618953141, Iran.
EM n.razzaghi@pharmacy.arums.ac.ir
RI Ebadi, Seyed Ahmad/N-5599-2017
OI Ebadi, Seyed Ahmad/0000-0002-4675-0224
FU Ardabil University of Medical Sciences [IR.ARUMS.REC.1399.002]
FX This work was supported by the Ardabil University of Medical Sciences
   under Grant no. IR.ARUMS.REC.1399.002.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   Alikhani R, 2018, J MOL STRUCT, V1164, P9, DOI 10.1016/j.molstruc.2018.03.034
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Duan YT, 2020, DRUG DISCOV TODAY, V25, P810, DOI 10.1016/j.drudis.2020.02.011
   EBADI A, 2013, DARU, V21, DOI DOI https://doi.org/10.1186/2008-2231-21-41
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elfiky AA, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117715
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   FOGARASI G, 1992, J AM CHEM SOC, V114, P8191, DOI 10.1021/ja00047a032
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jacquemard C, 2019, EXPERT OPIN DRUG DIS, V14, P413, DOI 10.1080/17460441.2019.1583643
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lin CW, 2004, FEBS LETT, V574, P131, DOI 10.1016/j.febslet.2004.08.017
   Lindorff-Larsen K., 2010, PROTEINS STRUCTURE F, V78, pNA
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Neese F, 2012, WIRES COMPUT MOL SCI, V2, P73, DOI 10.1002/wcms.81
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Qamar MTU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38450-1
   Razzaghi-Asl N, 2018, COMPUT BIOL CHEM, V77, P307, DOI 10.1016/j.compbiolchem.2018.10.015
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Rose AS, 2018, BIOINFORMATICS, V34, P3755, DOI 10.1093/bioinformatics/bty419
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Villar J, 2019, CHEST, V155, P587, DOI 10.1016/j.chest.2018.10.022
   VYAS V, 2008, SCI PHARM, V76, P333, DOI DOI 10.3797/scipharm.0803-03
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang M, 2020, CELL RES 0204, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-0]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 76
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1797536
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO6AE
UT WOS:000551605500001
PM 32705953
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Salehi, M
   Ahmadikia, K
   Mahmoudi, S
   Kalantari, S
   Jamalimoghadamsiahkali, S
   Izadi, A
   Kord, M
   Manshadi, SAD
   Seifi, A
   Ghiasvand, F
   Khajavirad, N
   Ebrahimi, S
   Koohfar, A
   Boekhout, T
   Khodavaisy, S
AF Salehi, Mohammadreza
   Ahmadikia, Kazem
   Mahmoudi, Shahram
   Kalantari, Saeed
   Jamalimoghadamsiahkali, Saeidreza
   Izadi, Alireza
   Kord, Mohammad
   Manshadi, Seyed Ali Dehghan
   Seifi, Arash
   Ghiasvand, Fereshteh
   Khajavirad, Nasim
   Ebrahimi, Saeedeh
   Koohfar, Amirhossein
   Boekhout, Teun
   Khodavaisy, Sadegh
TI Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran:
   Species identification and antifungal susceptibility pattern
SO MYCOSES
LA English
DT Article
DE coinfection; COVID-19; oral candidiasis; oropharyngeal candidiasis
ID WUHAN; SPP.; HIV
AB Background Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Apparently, the novel coronavirus (SARS-CoV-2) is armed by special abilities to spread and dysregulate the immune mechanisms. The likelihood of oropharyngeal candidiasis (OPC) development in COVID-19 patients with a list of attributable risk factors for oral infections has not yet been investigated. Objectives We here aim to investigate the prevalence, causative agents and antifungal susceptibility pattern of OPC in Iranian COVID-19 patients. Patients and Methods A total of 53 hospitalised COVID-19 patients with OPC were studied. Relevant clinical data were mined. Strain identification was performed by 21-plex PCR and sequencing of the internal transcribed spacer region (ITS1-5.8S-ITS2). Antifungal susceptibility testing to fluconazole, itraconazole, voriconazole, amphotericin B, caspofungin, micafungin and anidulafungin was performed according to the CLSI broth dilution method. Results In 53 COVID-19 patients with OPC, cardiovascular diseases (52.83%) and diabetes (37.7%) were the principal underlying conditions. The most common risk factor was lymphopaenia (71%). In total, 65Candidaisolates causing OPC were recovered.C albicans(70.7%) was the most common, followed byC glabrata(10.7%),C dubliniensis(9.2%),C parapsilosissensu stricto (4.6%),C tropicalis(3%) andPichia kudriavzevii(=C krusei, 1.5%). Majority of theCandidaisolates were susceptible to all three classes of antifungal drugs. Conclusion Our data clarified some concerns regarding the occurrence of OPC in Iranian COVID-19 patients. Further studies should be conducted to design an appropriate prophylaxis programme and improve management of OPC in critically ill COVID-19 patients.
C1 [Salehi, Mohammadreza; Manshadi, Seyed Ali Dehghan; Seifi, Arash; Ghiasvand, Fereshteh; Koohfar, Amirhossein] Univ Tehran Med Sci, Dept Infect Dis & Trop Med, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Ahmadikia, Kazem; Izadi, Alireza; Kord, Mohammad; Khodavaisy, Sadegh] Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran.
   [Mahmoudi, Shahram] Iran Univ Med Sci, Sch Med, Dept Med Parasitol & Mycol, Tehran, Iran.
   [Kalantari, Saeed; Ebrahimi, Saeedeh] Iran Univ Med Sci, Antimicrobial Resistance Res Ctr, Tehran, Iran.
   [Jamalimoghadamsiahkali, Saeidreza] Univ Tehran Med Sci, Ziaeian Hosp, Dept Infect Dis & Trop Med, Tehran, Iran.
   [Khajavirad, Nasim] Univ Tehran Med Sci, Sch Med, Dept Internal Med, Tehran, Iran.
   [Boekhout, Teun] Westerdijk Fungal Biodivers Inst, Utrecht, Netherlands.
   [Boekhout, Teun] Univ Amsterdam, Inst Biodivers & Ecosyst Dynam IBED, Amsterdam, Netherlands.
RP Khodavaisy, S (corresponding author), Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran.
EM sadegh_7392008@yahoo.com
RI Seifi, Arash/K-2336-2019; Boekhout, Teunis/ABF-2538-2020; ghiasvand,
   fereshte/AAV-4598-2020; Mahmoudi, Shahram/J-5206-2019
OI Seifi, Arash/0000-0002-6174-0315; Boekhout, Teunis/0000-0002-0476-3609;
   Mahmoudi, Shahram/0000-0003-0421-8659
FU Tehran University of Medical Sciences and Health ServicesTehran
   University of Medical Sciences [99-1-99-47198]
FX Tehran University of Medical Sciences and Health Services, Grant/Award
   Number: 99-1-99-47198
CR Aarstehfar A, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00021
   Akpan A, 2002, POSTGRAD MED J, V78, P455, DOI 10.1136/pmj.78.922.455
   Alanio A, 2020, LANCET RESP MED, V8, pE48, DOI 10.1016/S2213-2600(20)30237-X
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Arastehfar A, 2019, DIAGN MICR INFEC DIS, V93, P112, DOI 10.1016/j.diagmicrobio.2018.09.007
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chowdhary A, 2020, J GLOB ANTIMICROB RE, V22, P175, DOI 10.1016/j.jgar.2020.06.003
   CLSI, 2008, M27A3 CLSI
   CLSI, 2018, EP CUT VAL ANT SUSC
   CLSI, 2017, PERF STAND ANT SUSC
   Coronado-Castellote Laura, 2013, J Clin Exp Dent, V5, pe279, DOI 10.4317/jced.51242
   Davies AN, 2002, ORAL MICROBIOL IMMUN, V17, P79, DOI 10.1046/j.0902-0055.2001.00095.x
   Du RH, 2020, ANN AM THORAC SOC, V17, P839, DOI 10.1513/AnnalsATS.202003-225OC
   Dziedzic A, 2020, ORAL DIS, DOI 10.1111/odi.13359
   Gangneux JP, 2020, J MYCOL MED, V30, DOI 10.1016/j.mycmed.2020.100971
   Gasparoto TH, 2012, EXP GERONTOL, V47, P741, DOI 10.1016/j.exger.2012.07.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamzehee S, 2019, IRAN J MICROBIOL, V11, P114
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Kragelund C, 2016, ORAL INFECT GEN HLTH, P65
   Lahmer T, 2020, CLIN MICROBIOL INFEC, DOI [10.1016/j.cmi.2020.1005.1032, DOI 10.1016/J.CMI.2020.1005.1032]
   Laudenbach JM, 2009, EXPERT OPIN PHARMACO, V10, P1413, DOI 10.1517/14656560902952854
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Meijer EFJ, 2020, J FUNGI, V6, DOI 10.3390/jof6020079
   Nadagir Shobha D., 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P492
   Pankhurst CL, 2012, BMJ CLIN EVID, V2013, P1034
   Pfaller MA, 2012, J CLIN MICROBIOL, V50, P2846, DOI 10.1128/JCM.00937-12
   Powderly WG, 1999, AIDS RES HUM RETROV, V15, P1405, DOI 10.1089/088922299309900
   Rutsaert L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00686-4
   Sun HY, 2016, CLIN ORAL INVEST, V20, P459, DOI 10.1007/s00784-015-1524-2
   Suryana K, 2020, HIV AIDS-RES PALLIAT, V12, P33, DOI 10.2147/HIV.S236304
   Verweij Paul E, 2020, Lancet Microbe, V1, pe53, DOI 10.1016/S2666-5247(20)30027-6
   Vila T, 2020, J FUNGI, V6, DOI 10.3390/jof6010015
   White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1
   World Health Organization, 2020, CLIN MAN SEV ACT RES
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu XJ, 2020, VIRUS RES, V285, DOI 10.1016/j.virusres.2020.198005
NR 41
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
EI 1439-0507
J9 MYCOSES
JI Mycoses
PD AUG
PY 2020
VL 63
IS 8
BP 771
EP 778
DI 10.1111/myc.13137
EA JUL 2020
PG 8
WC Dermatology; Mycology
SC Dermatology; Mycology
GA MQ6YP
UT WOS:000551262800001
PM 32609906
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Martin, M
   Guerrero-Zotano, A
   Montero, A
   Jara, C
   Filipovich, E
   Rojo, F
   Moreno, F
   Garcia-Saenz, JA
   Ales, JE
   Chacon, JI
   Cruz, J
   Gimenez, J
   Cruz-Merino, L
   Algara, M
   Santisteban, M
   Tarruella, SL
AF Martin, Miguel
   Guerrero-Zotano, Angel
   Montero, Angel
   Jara, Carlos
   Filipovich, Elena
   Rojo, Federico
   Moreno, Fernando
   Angel Garcia-Saenz, Jose
   Enrique Ales, Jose
   Ignacio Chacon, Jose
   Cruz, Josefina
   Gimenez, Julia
   Cruz-Merino, Luis
   Algara, Manel
   Santisteban, Marta
   Lopez Tarruella, Sara
CA GEICAM Spanish Breast Canc Grp Ste
TI GEICAMGuidelines for the Management of Patients with Breast Cancer
   During theCOVID-19 Pandemic in Spain
SO ONCOLOGIST
LA English
DT Article
DE Breast cancer; Pandemic; COVID-19; SARS-CoV-2; Expert recommendations
ID RADIATION-THERAPY; IRRADIATION; GUIDELINES; TAMOXIFEN; WOMEN
AB Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing. Implications for Practice This work presents a set of guidelines regarding available options for breast cancer (BC) patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the suddenness of this health crisis, specialists have to make decisions with little evidence at hand. Thus, these expert guidelines may be a useful tool to facilitate medical decision making in the context of a worldwide pandemic with no resources to spare.
C1 [Martin, Miguel; Lopez Tarruella, Sara] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Dept Med, Med Oncol, Madrid, Spain.
   [Martin, Miguel; Rojo, Federico; Angel Garcia-Saenz, Jose; Lopez Tarruella, Sara] CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain.
   [Guerrero-Zotano, Angel] Inst Valenciano Oncol, Med Oncol, Valencia, Spain.
   [Montero, Angel] Hosp HM Sanchinarro, Radiat Oncol, Madrid, Spain.
   [Jara, Carlos] Univ Rey Juan Carlos, Hosp Fdn Alcorcon, Med Oncol, Madrid, Spain.
   [Filipovich, Elena; Enrique Ales, Jose] Complejo Asistencial Avila, Med Oncol, Avila, Spain.
   [Rojo, Federico] Hosp Fdn Jimenez Diaz Madrid, Pathol, Madrid, Spain.
   [Moreno, Fernando; Angel Garcia-Saenz, Jose] Hosp Univ Clin San Carlos Madrid, Med Oncol, Madrid, Spain.
   [Ignacio Chacon, Jose] Hosp Virgen Salud Toledo, Med Oncol, Toledo, Spain.
   [Cruz, Josefina] Hosp Univ Canarias, Med Oncol, Tenerife, Spain.
   [Gimenez, Julia] Inst Valenciano Oncol, Surg, Valencia, Spain.
   [Cruz-Merino, Luis] Hosp Virgen Macarena Sevilla, Med Oncol, Seville, Spain.
   [Algara, Manel] Hosp Mar Barcelona, Radiat Oncol, Barcelona, Spain.
   [Santisteban, Marta] Clin Univ Navarra, Med Oncol, Navarra, Spain.
RP Martin, M (corresponding author), CIBERONC ISCIII GEICAM Spanish Breast Canc Grp, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
EM mmartin@geicam.org
RI Santisteban, Marta/ABE-6618-2020; Garcia-Saenz, Jose
   Angel/AAW-8662-2020; Montero, Angel/ABB-7427-2020; de la Cruz-Merino,
   Luis/K-8633-2017
OI Santisteban, Marta/0000-0003-0625-686X; Garcia-Saenz, Jose
   Angel/0000-0001-6880-0301; Montero, Angel/0000-0001-5566-0493; de la
   Cruz-Merino, Luis/0000-0002-5333-0535
CR American Society for Radiation Oncology (ASTRO), 2020, COVID 19 CLIN GUID
   [Anonymous], 2020, COVID 19 GUID TRIAG
   [Anonymous], 2020, CIFR CANC ESP 2020
   Brunt AM, 2018, RADIOTHER ONCOL, V127, pS311, DOI 10.1016/S0167-8140(18)30905-8
   Brunt AM, 2016, RADIOTHER ONCOL, V120, P114, DOI 10.1016/j.radonc.2016.02.027
   Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192
   Chavez-MacGregor M, 2016, JAMA ONCOL, V2, P322, DOI 10.1001/jamaoncol.2015.3856
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Dana-Farbeer/Brigham and Women's Cancer Center, SUGG TREATM MOD MULT
   Day M., 2020, BMJ, V369, pm1549, DOI 10.1136/bmj.m1549
   de la Cruz-Merino L, 2019, CLIN TRANSL ONCOL, V21, P117, DOI 10.1007/s12094-018-1907-3
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Earl HM, 2019, LANCET, V393, P2599, DOI 10.1016/S0140-6736(19)30650-6
   Ellis MJ, 2008, J NATL CANCER I, V100, P1380, DOI 10.1093/jnci/djn309
   ESMO, 2020, ESMO MAN TREATM AD R
   European Society of Medical Oncology (ESMO), 2020, WHAT SHOULD MED ONC
   Goldvaser H, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz033
   Gradishar WJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.1004
   Hughes KS, 2013, J CLIN ONCOL, V31, P2382, DOI 10.1200/JCO.2012.45.2615
   Klijn JGM, 2001, J CLIN ONCOL, V19, P343, DOI 10.1200/JCO.2001.19.2.343
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lightowlers SV, 2017, EUR J CANCER, V82, P184, DOI 10.1016/j.ejca.2017.06.014
   Monten C, 2017, INT J RADIAT ONCOL, V98, P922, DOI 10.1016/j.ijrobp.2017.01.229
   Sanz J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8321871
   Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615
   Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X
   Van Hulle H, 2019, J GERIATR ONCOL, V10, P987, DOI 10.1016/j.jgo.2019.04.007
   von Minckwitz G, 2019, NEW ENGL J MED, V380, P617, DOI 10.1056/NEJMoa1814017
   World Health Organization, 2020, INT GUID, DOI 10.15585/mmwr.mm6942a5
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
NR 30
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP
PY 2020
VL 25
IS 9
BP E1339
EP E1345
DI 10.1634/theoncologist.2020-0363
EA JUL 2020
PG 7
WC Oncology
SC Oncology
GA NN4IS
UT WOS:000551209600001
PM 32652782
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maisonnasse, P
   Guedj, J
   Contreras, V
   Behillil, S
   Solas, C
   Marlin, R
   Naninck, T
   Pizzorno, A
   Lemaitre, J
   Goncalves, A
   Kahlaoui, N
   Terrier, O
   Fang, RHT
   Enouf, V
   Dereuddre-Bosquet, N
   Brisebarre, A
   Touret, F
   Chapon, C
   Hoen, B
   Lina, B
   Calatrava, MR
   van der Werf, S
   de Lamballerie, X
   Le Grand, R
AF Maisonnasse, Pauline
   Guedj, Jeremie
   Contreras, Vanessa
   Behillil, Sylvie
   Solas, Caroline
   Marlin, Romain
   Naninck, Thibaut
   Pizzorno, Andres
   Lemaitre, Julien
   Goncalves, Antonio
   Kahlaoui, Nidhal
   Terrier, Olivier
   Fang, Raphael Ho Tsong
   Enouf, Vincent
   Dereuddre-Bosquet, Nathalie
   Brisebarre, Angela
   Touret, Franck
   Chapon, Catherine
   Hoen, Bruno
   Lina, Bruno
   Calatrava, Manuel Rosa
   van der Werf, Sylvie
   de Lamballerie, Xavier
   Le Grand, Roger
TI Hydroxychloroquine use against SARS-CoV-2 infection in non-human
   primates
SO NATURE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; WUHAN; CHINA; CHLOROQUINE; PNEUMONIA;
   COVID-19
AB Hydroxychloroquine did not confer protection against SARS-CoV-2 infection or reduce the viral load after infection in macaques; these findings do not support the use of hydroxychloroquine as an antiviral drug treatment of COVID-19 in humans.
   Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease(1-3). Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the virus that causes COVID-19-worldwide but there is no definitive evidence that HCQ is effective for treating COVID-19(4-7). Here we evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (Vero E6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to a placebo treatment, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor the combination of HCQ and AZTH showed a significant effect on viral load in any of the analysed tissues. When the drug was used as a pre-exposure prophylaxis treatment, HCQ did not confer protection against infection with SARS-CoV-2. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral drug for the treatment of COVID-19 in humans.
C1 [Maisonnasse, Pauline; Contreras, Vanessa; Marlin, Romain; Naninck, Thibaut; Lemaitre, Julien; Kahlaoui, Nidhal; Fang, Raphael Ho Tsong; Dereuddre-Bosquet, Nathalie; Chapon, Catherine; Le Grand, Roger] Univ Paris Saclay, Ctr Immunol Viral, Autoimmune Hematol & Bacterial Dis IMVA HB IDMIT, Inserm,CEA, Fontenay Aux Roses, France.
   [Guedj, Jeremie; Goncalves, Antonio] Univ Paris, IAME, INSERM, Paris, France.
   [Behillil, Sylvie; Enouf, Vincent; Brisebarre, Angela; van der Werf, Sylvie] Univ Paris, CNRS, Inst Pasteur, Unite Genet Mol Virus ARN,GMVR,UMR 3569, Paris, France.
   [Behillil, Sylvie; Enouf, Vincent; Brisebarre, Angela; van der Werf, Sylvie] Inst Pasteur, Ctr Natl Reference Virus Infect Resp Dont Grippe, Paris, France.
   [Solas, Caroline] Aix Marseille Univ, Lab Pharmacocinet & Toxicol, Hop La Timone,APHM, Unite Virus Emergents UVE IRD 190,INSERM 1207, Marseille, France.
   [Pizzorno, Andres; Terrier, Olivier; Lina, Bruno; Calatrava, Manuel Rosa] Univ Claude Bernard Lyon 1, Univ Lyon, CNRS,INSERM,UMR3508,ENS Lyon, Ctr Int Rech Infectiol,CIRI,U1111,Team VirPath, Lyon, France.
   [Enouf, Vincent] Inst Pasteur, Plate Forme Microbiol Mutualisee P2M, Pasteur Int Bioresources Network PIBnet, Paris, France.
   [Touret, Franck; de Lamballerie, Xavier] Aix Marseille Univ, Unite Virus Emergents UVE, IRD 190, INSERM 1207,IHU Mediterranee Infect, Marseille, France.
   [Hoen, Bruno] Inst Pasteur, Emerging Dis Epidemiol Unit, Paris, France.
   [Lina, Bruno] Hosp Civils Lyon, Inst Agents Infect, Ctr Natl Reference Virus Infect Resp Dont Grippe, Lab Virol,Grop Hosp Nord, Lyon, France.
RP Le Grand, R (corresponding author), Univ Paris Saclay, Ctr Immunol Viral, Autoimmune Hematol & Bacterial Dis IMVA HB IDMIT, Inserm,CEA, Fontenay Aux Roses, France.
EM roger.le-grand@cea.fr
RI Touret, Franck/ABD-3236-2020; Terrier, Olivier/B-6301-2009; Pizzorno,
   Mario Andres/L-7810-2017; guedj, Jeremie/A-6842-2017
OI Touret, Franck/0000-0002-4734-2249; Terrier,
   Olivier/0000-0001-9393-7684; Lemaitre, Julien/0000-0001-6239-0110;
   Maisonnasse, Pauline/0000-0002-0555-207X; Goncalves,
   Antonio/0000-0002-8759-2429; Contreras, Vanessa/0000-0003-4072-9819;
   lina, bruno/0000-0002-8959-2123; Pizzorno, Mario
   Andres/0000-0002-0918-6804; guedj, Jeremie/0000-0002-5534-5482
FU Domaine d'Interet Majeur (DIM) 'One Health'; REACTing; European Union's
   Horizon 2020 (H2020) research and innovation program Fight-nCov
   [101003555]; European Union IMI2 program CARE [101005077]; European
   Infrastructure TRANSVAC2 [730964]; National Research Agency (ANR;
   AM-CoV-Path)French National Research Agency (ANR); H2020 [653316];
   'Programme Investissements d'Avenir' by the ANRFrench National Research
   Agency (ANR) [ANR-11-INBS-0008]
FX We thank B. Delache, E. Burban, J. Demilly, N. Dhooge, S. Langlois, P.
   Le Calvez, M. Potier, F. Relouzat, J. M. Robert and C. Dodan for help
   with animal studies; B. Fert and C. Mayet for help with in vivo imaging
   studies; Q. Pascal for performing the necropsies; J. Morin for help with
   the cytokine measurements and preparation of reagents; K. Barthelemy, M.
   Basso, N. Doudka and M. Giocanti for help with HCQ concentration
   measurements; B. Lacarelle and R. Guilhaumou for help with analysing
   internal drug concentration data; J. Bertrand for help with analysing
   pharmacokinetic data; D. Desjardins for help with the AZTH
   pharmacokinetic study; C. Aubenque, M. Barendji, L. Bossevot, N. Dimant,
   J. Dinh, A. S. Gallouet, M. Leonec, I. Mangeot and K. Storck for help
   with sample processing; M. Albert, M. Barbet and F. Donati for help with
   the production, titration and sequencing of the virus stocks used in
   vivo and processing of samples for RT-PCR; A. S. Gallouet, S. Keyser, E.
   Marcos-Lopez, B. Targat and B. Vaslin for help with the experimental
   studies in the context of COVID-19-induced constraints; F. Ducancel and
   Y. Gorin for help with the logistics and safety management; E. Sultan
   for providing guidance on HCQ dose selection and discussion on
   pharmacokinetics/pharmacodynamics results and commenting on the paper;
   Sanofi for providing the HCQ batch used in these experiments; the
   Fondation Bettencourt Schueller and the Region Ile-de-France for the
   contribution to the implementation of imaging facilities; and the
   Domaine d'Interet Majeur (DIM) 'One Health' for its support. This study
   received financial support from REACTing, the National Research Agency
   (ANR; AM-CoV-Path) and the European Union's Horizon 2020 (H2020)
   research and innovation program Fight-nCov (101003555), European Union
   IMI2 program CARE (101005077) and the European Infrastructure TRANSVAC2
   (730964). The virus stock was obtained through the EVAg platform
   (https://www.european-virus-archive.com/), funded by H2020 (653316). The
   Infectious Disease Models and Innovative Therapies (IDMIT) research
   infrastructure is supported by the 'Programme Investissements d'Avenir',
   managed by the ANR under reference ANR-11-INBS-0008.
CR Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chhonker YS, 2018, J CHROMATOGR B, V1072, P320, DOI 10.1016/j.jchromb.2017.11.026
   de Lamballerie CN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48013-7
   Fanouriakis A, 2020, ANN RHEUM DIS, V79, P713, DOI [10.1136/annrheumdis-2020-216924, 10.1136/annrheumdis-2020-217804]
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Monzavi SM, 2018, INFLAMMOPHARMACOLOGY, V26, P1175, DOI 10.1007/s10787-018-0512-y
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Pizzorno Andres, 2020, Cell Rep Med, V1, P100059, DOI 10.1016/j.xcrm.2020.100059
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang B, 2019, CNS NEUROSCI THER, V25, P591, DOI 10.1111/cns.13092
NR 31
TC 30
Z9 30
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD SEP 24
PY 2020
VL 585
IS 7826
BP 584
EP +
DI 10.1038/s41586-020-2558-4
EA JUL 2020
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NS9DW
UT WOS:000570130100002
PM 32698191
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hoffmann, M
   Mosbauer, K
   Hofmann-Winkler, H
   Kaul, A
   Kleine-Weber, H
   Kruger, N
   Gassen, NC
   Muller, MA
   Drosten, C
   Pohlmann, S
AF Hoffmann, Markus
   Moesbauer, Kirstin
   Hofmann-Winkler, Heike
   Kaul, Artur
   Kleine-Weber, Hannah
   Krueger, Nadine
   Gassen, Nils C.
   Mueller, Marcel A.
   Drosten, Christian
   Poehlmann, Stefan
TI Chloroquine does not inhibit infection of human lung cells with
   SARS-CoV-2
SO NATURE
LA English
DT Article
ID CORONAVIRUS
AB Expression of TMPRSS2-a protease that activates SARS-CoV-2 for entry into cells-renders SARS-CoV-2 insensitive to chloroquine.
   The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been associated with more than 780,000 deaths worldwide (as of 20 August 2020). To develop antiviral interventions quickly, drugs used for the treatment of unrelated diseases are currently being repurposed to treat COVID-19. Chloroquine is an anti-malaria drug that is used for the treatment of COVID-19 as it inhibits the spread of SARS-CoV-2 in the African green monkey kidney-derived cell line Vero(1-3). Here we show that engineered expression of TMPRSS2, a cellular protease that activates SARS-CoV-2 for entry into lung cells(4), renders SARS-CoV-2 infection of Vero cells insensitive to chloroquine. Moreover, we report that chloroquine does not block infection with SARS-CoV-2 in the TMPRSS2-expressing human lung cell line Calu-3. These results indicate that chloroquine targets a pathway for viral activation that is not active in lung cells and is unlikely to protect against the spread of SARS-CoV-2 in and between patients.
C1 [Hoffmann, Markus; Hofmann-Winkler, Heike; Kaul, Artur; Kleine-Weber, Hannah; Krueger, Nadine; Poehlmann, Stefan] Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, Gottingen, Germany.
   [Hoffmann, Markus; Kleine-Weber, Hannah; Poehlmann, Stefan] Georg August Univ Gottingen, Fac Biol & Psychol, Gottingen, Germany.
   [Moesbauer, Kirstin; Mueller, Marcel A.; Drosten, Christian] Charite Univ Med Berlin, Inst Virol, Berlin, Germany.
   [Moesbauer, Kirstin; Mueller, Marcel A.; Drosten, Christian] Free Univ Berlin, Berlin, Germany.
   [Moesbauer, Kirstin; Mueller, Marcel A.; Drosten, Christian] Humboldt Univ, Berlin, Germany.
   [Moesbauer, Kirstin; Mueller, Marcel A.; Drosten, Christian] Berlin Inst Hlth, Berlin, Germany.
   [Moesbauer, Kirstin; Mueller, Marcel A.; Drosten, Christian] Associated Partner Charite, German Ctr Infect Res, Berlin, Germany.
   [Gassen, Nils C.] Univ Bonn, Dept Psychiat & Psychotherapy, Bonn, Germany.
   [Mueller, Marcel A.] Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
RP Hoffmann, M; Pohlmann, S (corresponding author), Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, Gottingen, Germany.; Hoffmann, M; Pohlmann, S (corresponding author), Georg August Univ Gottingen, Fac Biol & Psychol, Gottingen, Germany.
EM mhoffmann@dpz.eu; spoehlmann@dpz.eu
RI ; Pohlmann, Stefan/H-2395-2011
OI Mueller, Marcel/0000-0003-2242-5117; Hoffmann,
   Markus/0000-0003-4603-7696; Pohlmann, Stefan/0000-0001-6086-9136
FU Bundesministerium fur Bildung und Forschung (RAPID Consortium)Federal
   Ministry of Education & Research (BMBF) [01KI1723A, 01KI1723D]
FX This work was supported by the Bundesministerium fur Bildung und
   Forschung (RAPID Consortium, 01KI1723A and 01KI1723D to C.D. and S.P.,
   respectively). We thank A. Maisner (Vero 76 cell line), S. Ludwig
   (Calu-3 cell line) and G. Zimmer (VSV pseudotype system) for providing
   cell lines and reagents.
CR Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Corman VM, 2019, EUROSURVEILLANCE, V2020, P25, DOI DOI 10.2807/1560-7917.ES.202025.3.2000045
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Herzog P, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-138
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kleine-Weber H, 2019, J VIROL, V93, DOI 10.1128/JVI.01381-18
   Klemm C, 2017, SCI REP-UK, V7, DOI 10.1038/srep42473
   Kupferschmidt K, 2020, SCIENCE, V368, P1166, DOI 10.1126/science.368.6496.1166
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Rentsch MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025858
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shirato K, 2017, J VIROL, V91, DOI [10.1128/JVI.01387-16, 10.1128/jvi.01387-16]
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 20
TC 19
Z9 19
U1 6
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD SEP 24
PY 2020
VL 585
IS 7826
BP 588
EP +
DI 10.1038/s41586-020-2575-3
EA JUL 2020
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NS9DW
UT WOS:000570130100001
PM 32698190
OA Bronze
DA 2021-01-01
ER

PT J
AU Merzon, E
   Manor, I
   Rotem, A
   Schneider, T
   Vinker, S
   Cohen, AG
   Lauden, A
   Weizman, A
   Green, I
AF Merzon, Eugene
   Manor, Iris
   Rotem, Ann
   Schneider, Tzipporah
   Vinker, Shlomo
   Cohen, Avivit Golan
   Lauden, Ari
   Weizman, Abraham
   Green, Ilan
TI ADHD as a Risk Factor for Infection With Covid-19
SO JOURNAL OF ATTENTION DISORDERS
LA English
DT Article; Early Access
DE ADHD; Covid-19; prevalence; stimulants
AB Background:ADHD limits the ability to comply with Covid-19 prevention recommendations. We hypothesized that ADHD constitutes a risk factor for Covid-19 infection and that pharmacotherapy may lower that risk.Methods:Study population included all subjects (N = 14,022) registered with Leumit Health Services between February 1st and April 30, 2020, who underwent at least one Covid-19 test. Data were collected from the electronic health records. Purchasing consecutively at least three ADHD-medication-prescriptions during past year was considered drug-treatment.Results:A total of 1,416 (10.1%) subjects (aged 2 months-103 years) were Covid-19-positive.They were significantly younger, and had higher rates of ADHD (adjOR 1.58 (95% CI 1.27-1.96,p < .001) than Covid-19-negative subjects. The risk for Covid-19-Positive was higher in untreated-ADHD subjects compared to non-ADHD subjects [crudeOR 1.61 (95% CI 1.36-1.89,p < .001)], while no higher risk was detected in treated ones [crudeOR 1.07 (95% CI 0.78-1.48,p = .65)].Conclusion:Untreated ADHD seems to constitute a risk factor for Covid-19 infection while drug-treatment ameliorates this effect.
C1 [Merzon, Eugene; Vinker, Shlomo; Cohen, Avivit Golan; Lauden, Ari; Green, Ilan] Leumit HMO, Tel Aviv, Israel.
   [Merzon, Eugene; Vinker, Shlomo; Cohen, Avivit Golan; Green, Ilan] Tel Aviv Univ, Sackler Fac Med, Dept Family Med, Tel Aviv, Israel.
   [Manor, Iris; Weizman, Abraham] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Manor, Iris] Geha Mental Hlth Ctr, 1 Helsinki St,POB 102, IL-4910002 Petah Tiqwa, Israel.
   [Rotem, Ann] Geha Mental Hlth Ctr, ADHD Clin, Petah Tiqwa, Israel.
   [Weizman, Abraham] Geha Mental Hlth Ctr, Res Unit, Petah Tiqwa, Israel.
   [Schneider, Tzipporah] Clalit Hlth Serv, Bnei Braq, Israel.
   [Weizman, Abraham] Felsenstein Med Res Ctr, Petah Tiqwa, Israel.
RP Manor, I (corresponding author), Geha Mental Hlth Ctr, 1 Helsinki St,POB 102, IL-4910002 Petah Tiqwa, Israel.; Manor, I (corresponding author), Geha Mental Hlth Ctr, ADHD Clin, Petah Tiqwa, Israel.; Manor, I (corresponding author), Geha Mental Hlth Ctr, Res Unit, Petah Tiqwa, Israel.
EM dr.iris.manor@gmail.com
RI Weizman, Abraham/AAK-6450-2020; Green, Ilan/ABG-9518-2020; Merzon,
   Eugene/ABB-6289-2020
OI Weizman, Abraham/0000-0002-9765-8938; Green, Ilan/0000-0002-9435-7152; 
CR American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Borjas G. J., 2020, 26952 NAT BUR EC RES
   Centers for Disease Control and Prevention, 2020, PEOPL WHO ARE HIGH R
   Centers for Disease Control and Prevention, 2020, SOC DIST
   Cheng VCC, 2020, J INFECTION, V81, P107, DOI 10.1016/j.jinf.2020.04.024
   Cortese S, 2020, LANCET CHILD ADOLESC, V4, pE15, DOI 10.1016/S2352-4642(20)30144-9
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Gang-lip K., 2020, EURONEWS
   Ginsberg Ylva, 2014, Prim Care Companion CNS Disord, V16, DOI 10.4088/PCC.13r01600
   Ginsberg Y, 2014, EXPERT REV NEUROTHER, V14, P799, DOI 10.1586/14737175.2014.926220
   Israel Ministry of Health, 2020, NEW COR GUID
   Lai SJ, 2020, NATURE, V585, P410, DOI 10.1038/s41586-020-2293-x
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Lin C, 2020, EMERG INFECT DIS, V26, P1506, DOI 10.3201/eid2607.200574
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   PRINGLE M, 1995, BRIT J GEN PRACT, V45, P537
   Shalev V, 2011, INT J CARDIOL, V152, P345, DOI 10.1016/j.ijcard.2010.08.002
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   WHO, 2020, 135 WHO
   World Health Organization?, 2020, 12 WHO
   World Health Organization, 2020, GLOB SURV HUM INF CO
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
NR 28
TC 1
Z9 1
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0547
EI 1557-1246
J9 J ATTEN DISORD
JI J. Atten. Disord.
AR 1087054720943271
DI 10.1177/1087054720943271
EA JUL 2020
PG 8
WC Psychology, Developmental; Psychiatry
SC Psychology; Psychiatry
GA MP1GN
UT WOS:000551960000001
PM 32697120
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sharma, S
AF Sharma, Sachin
TI Drawing insights from COVID-19-infected patients using CT scan images
   and machine learning techniques: a study on 200 patients
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article
DE Coronavirus; COVID-19; Machine learning; Computed tomography (CT) scan;
   Pneumonia; Polymerase chain reaction (PCR)
AB As the whole world is witnessing what novel coronavirus (COVID-19) can do to the mankind, it presents several unique features also. In the absence of specific vaccine for COVID-19, it is essential to detect the disease at an early stage and isolate an infected patient. Till today there is a global shortage of testing labs and testing kits for COVID-19. This paper discusses about the role of machine learning techniques for getting important insights like whether lung computed tomography (CT) scan should be the first screening/alternative test for real-time reverse transcriptase-polymerase chain reaction(RT-PCR), is COVID-19 pneumonia different from other viral pneumonia and if yes how to distinguish it using lung CT scan images from the carefully selected data of lung CT scan COVID-19-infected patients from the hospitals of Italy, China, Moscow and India? For training and testing the proposed system, custom vision software of Microsoft azure based on machine learning techniques is used. An overall accuracy of almost 91% is achieved for COVID-19 classification using the proposed methodology.
C1 [Sharma, Sachin] Inst Adv Res, Dept Engn & Comp, Gandhinagar, India.
RP Sharma, S (corresponding author), Inst Adv Res, Dept Engn & Comp, Gandhinagar, India.
EM sachin.sharma@iar.ac.in
CR Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041
   Shan F., 2020, ARXIV200304655
   Xu X., 2020, ARXIV200209334
NR 3
TC 0
Z9 0
U1 9
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD OCT
PY 2020
VL 27
IS 29
BP 37155
EP 37163
DI 10.1007/s11356-020-10133-3
EA JUL 2020
PG 9
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA NG0VY
UT WOS:000551389000005
PM 32700269
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pandey, P
   Rane, JS
   Chatterjee, A
   Kumar, A
   Khan, R
   Prakash, A
   Ray, S
AF Pandey, Preeti
   Rane, Jitendra Subhash
   Chatterjee, Aroni
   Kumar, Abhijeet
   Khan, Rajni
   Prakash, Amresh
   Ray, Shashikant
TI Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring
   phytochemicals: anin silicostudy for drug development
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; molecular docking; phytochemicals; flavonoids and
   non-flavonoids
ID ANTIVIRAL ACTIVITY; IN-SILICO; FLAVONOIDS; INHIBITORS; ION; INFECTION;
   LUTEOLIN; SURFACE; ENTRY
AB Spike glycoprotein, a class I fusion protein harboring the surface of SARS-CoV-2 (SARS-CoV-2S), plays a seminal role in the viral infection starting from recognition of the host cell surface receptor, attachment to the fusion of the viral envelope with the host cells. Spike glycoprotein engages host Angiotensin-converting enzyme 2 (ACE2) receptors for entry into host cells, where the receptor recognition and attachment of spike glycoprotein to the ACE2 receptors is a prerequisite step and key determinant of the host cell and tissue tropism. Binding of spike glycoprotein to the ACE2 receptor triggers a cascade of structural transitions, including transition from a metastable pre-fusion to a post-fusion form, thereby allowing membrane fusion and internalization of the virus. From ancient times people have relied on naturally occurring substances like phytochemicals to fight against diseases and infection. Among these phytochemicals, flavonoids and non-flavonoids have been the active sources of different anti-microbial agents. We performed molecular docking studies using 10 potential naturally occurring compounds (flavonoids/non-flavonoids) against the SARS-CoV-2 spike protein and compared their affinity with an FDA approved repurposed drug hydroxychloroquine (HCQ). Further, our molecular dynamics (MD) simulation and energy landscape studies with fisetin, quercetin, and kamferol revealed that these molecules bind with the hACE2-S complex with low binding free energy. The study provided an indication that these molecules might have the potential to perturb the binding of hACE2-S complex. In addition, ADME analysis also suggested that these molecules consist of drug-likeness property, which may be further explored as anti-SARS-CoV-2 agents. Communicated by Ramaswamy H. Sarma
C1 [Pandey, Preeti] Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
   [Rane, Jitendra Subhash] Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, Maharashtra, India.
   [Chatterjee, Aroni] Indian Council Med Res ICMR, NICED, Virus Res Lab, Kolkata, India.
   [Kumar, Abhijeet] Mahatma Gandhi Cent Univ, Dept Chem, Motihari, India.
   [Khan, Rajni] Motihari Coll Engn, Motihari, India.
   [Prakash, Amresh] Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.
   [Ray, Shashikant] Mahatma Gandhi Cent Univ, Dept Biotechnol, Motihari 845401, India.
RP Prakash, A (corresponding author), Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.; Ray, S (corresponding author), Mahatma Gandhi Cent Univ, Dept Biotechnol, Motihari 845401, India.
EM amreshprakash@jnu.ac.in; shashikantray@mgcub.ac.in
OI Chatterjee, Shamba/0000-0003-1415-6981; KUMAR,
   ABHIJEET/0000-0003-3617-0741; Prakash, Amresh/0000-0002-4821-1654
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abba Y, 2015, ADV VIROL, V2015, DOI 10.1155/2015/184241
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Batt SM, 2012, P NATL ACAD SCI USA, V109, P11354, DOI 10.1073/pnas.1205735109
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Campagna M, 2010, BIOCHEM SOC T, V38, P50, DOI 10.1042/BST0380050
   Chan CN, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00408-17
   Chatterjee Pranab, 2020, Indian J Med Res, V151, P147, DOI 10.4103/ijmr.IJMR_519_20
   Chen DL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501240
   Chiang LC, 2005, CLIN EXP PHARMACOL P, V32, P811, DOI 10.1111/j.1440-1681.2005.04270.x
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Docherty JJ, 2005, ANTIVIR RES, V67, P155, DOI 10.1016/j.antiviral.2005.06.008
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Fan WC, 2016, VIRUS RES, V220, P112, DOI 10.1016/j.virusres.2016.04.021
   Forni C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8748253
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   JAIN M, 2020, J BIOMOL STRUCT 0310, DOI DOI https://doi.org/10.1080/07391102.2020.1781693
   JAYARAM B, 2012, BMC BIOINFORMATI S17, V13, DOI DOI https://doi.org/10.1186/1471-2105-13-S17-S7
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Joung IS, 2008, J PHYS CHEM B, V112, P9020, DOI 10.1021/jp8001614
   KAUL TN, 1985, J MED VIROL, V15, P71, DOI 10.1002/jmv.1890150110
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kumar N, 2020, J BIOMOL STRUCT DYN, V38, P3396, DOI 10.1080/07391102.2019.1657499
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Kutzner C, 2019, J COMPUT CHEM, V40, P2418, DOI 10.1002/jcc.26011
   Li F, 2006, J VIROL, V80, P6794, DOI 10.1128/JVI.02744-05
   LIN SC, 2017, BMC INFECT DIS, V17, DOI DOI https://doi.org/10.1186/s12879-017-2253-8
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Luthra PM, 2009, NEUROSCI LETT, V463, P215, DOI 10.1016/j.neulet.2009.07.085
   Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215
   Mishra CB, 2018, EUR J MED CHEM, V151, P520, DOI 10.1016/j.ejmech.2018.04.007
   Mongre RK, 2019, CANCERS, V11, DOI 10.3390/cancers11091245
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418
   OU XY, 2020, NAT COMMUN, V11, DOI DOI https://doi.org/10.1038/s41467-020-15562-9
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Pandey P, 2018, CHEM PHYS LETT, V695, P69, DOI 10.1016/j.cplett.2018.01.059
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   PRADITYA D, 2019, FRONT MICROBIOL, V10, DOI DOI https://doi.org/10.3389/fmicb.2019.00912
   Prakash A, 2012, AMINO ACIDS, V43, P1451, DOI 10.1007/s00726-012-1218-x
   Raj S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221331
   Rajarshi Keshav, 2020, Med Drug Discov, V7, P100049, DOI 10.1016/j.medidd.2020.100049
   Rajarshi Keshav, 2020, Biotechnology Reports, V26, pe00467, DOI 10.1016/j.btre.2020.e00467
   Rocco AG, 2008, BIOPHYS J, V94, P2241, DOI 10.1529/biophysj.107.115535
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Singh R, 2020, J BIOMOL STRUCT DYN, V38, P5027, DOI 10.1080/07391102.2019.1695669
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Wang TY, 2018, ASIAN J PHARM SCI, V13, P12, DOI 10.1016/j.ajps.2017.08.004
   WU CC, 2017, J BIOMED SCI, V24, DOI DOI https://doi.org/10.1186/s12929-016-0313-9
   Wu CC, 2016, ANTIVIR RES, V132, P99, DOI 10.1016/j.antiviral.2016.05.007
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu HR, 2018, P NATL ACAD SCI USA, V115, pE12192, DOI 10.1073/pnas.1812204115
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   ZHAO XH, 2017, SCI REP UK, V7, DOI DOI https://doi.org/10.1038/s41598-017-09365-0
   Zhou YC, 2012, EXPERT REV ANTI-INFE, V10, P1129, DOI [10.1586/ERI.12.104, 10.1586/eri.12.104]
NR 78
TC 7
Z9 7
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796811
EA JUL 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MO1NZ
UT WOS:000551303000001
PM 32698689
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Henderson, R
   Edwards, RJ
   Mansouri, K
   Janowska, K
   Stalls, V
   Gobeil, SMC
   Kopp, M
   Li, DP
   Parks, R
   Hsu, AL
   Borgnia, MJ
   Haynes, BF
   Acharya, P
AF Henderson, Rory
   Edwards, Robert J.
   Mansouri, Katayoun
   Janowska, Katarzyna
   Stalls, Victoria
   Gobeil, Sophie M. C.
   Kopp, Megan
   Li, Dapeng
   Parks, Rob
   Hsu, Allen L.
   Borgnia, Mario J.
   Haynes, Barton F.
   Acharya, Priyamvada
TI Controlling the SARS-CoV-2 spike glycoprotein conformation
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article; Early Access
ID HIV-1 ENVELOPE TRIMERS; CRYO-EM STRUCTURE; IMMUNOGENICITY; CORONAVIRUS;
   VISUALIZATION; MICROSCOPY; FEATURES; DESIGN; ENV
AB The coronavirus (CoV) spike (S) protein, involved in viral-host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, to better understand S-protein mobility, we implemented a structure-based vector analysis of available beta-CoV S-protein structures. Despite an overall similarity in domain organization, we found that S-proteins from different beta-CoVs display distinct configurations. Based on this analysis, we developed two soluble ectodomain constructs for the SARS-CoV-2 S-protein, in which the highly immunogenic and mobile receptor binding domain (RBD) is either locked in the all-RBDs 'down' position or adopts 'up' state conformations more readily than the wild-type S-protein. These results demonstrate that the conformation of the S-protein can be controlled via rational design and can provide a framework for the development of engineered CoV S-proteins for vaccine applications.
   The SARS-CoV-2 spike glycoprotein is flexible, and its receptor-binding domain (RBD) fluctuates between up or down conformations. Mutations engineered into the spike ectodomain either lock the RBD in the down state or make it adopt the up conformation more readily.
C1 [Henderson, Rory; Edwards, Robert J.; Mansouri, Katayoun; Janowska, Katarzyna; Stalls, Victoria; Gobeil, Sophie M. C.; Kopp, Megan; Li, Dapeng; Parks, Rob; Haynes, Barton F.; Acharya, Priyamvada] Duke Human Vaccine Inst, Durham, NC 27710 USA.
   [Henderson, Rory; Edwards, Robert J.; Haynes, Barton F.] Duke Univ, Dept Med, Durham, NC 27708 USA.
   [Hsu, Allen L.; Borgnia, Mario J.] NIEHS, Genome Integr & Struct Biol Lab, NIH, Dept Hlth & Human Serv, Durham, NC USA.
   [Haynes, Barton F.] Duke Univ, Dept Immunol, Durham, NC USA.
   [Acharya, Priyamvada] Duke Univ, Dept Surg, Durham, NC 27708 USA.
RP Henderson, R; Acharya, P (corresponding author), Duke Human Vaccine Inst, Durham, NC 27710 USA.; Henderson, R (corresponding author), Duke Univ, Dept Med, Durham, NC 27708 USA.; Acharya, P (corresponding author), Duke Univ, Dept Surg, Durham, NC 27708 USA.
EM rory.henderson@duke.edu; priyamvada.acharya@duke.edu
OI Hsu, Allen/0000-0003-2065-3802; Henderson, Rory/0000-0002-4301-6382;
   Edwards, Robert/0000-0003-4446-1194; gobeil, sophie/0000-0002-0057-2477;
   Mansouri, Katayoun/0000-0001-6232-7330
FU NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy
   programUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U24 GM129539]; Simons Foundation
   [SF349247]; Integrated Preclinical/Clinical AIDS Vaccine Development
   Program, NIAID, NIH [U19 AI142596]; Duke University Center for AIDS
   Research (CFAR); Intramural Research Program of the NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; National Institute of Environmental Health SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS)
   [ZIC ES103326]; State of North Carolina Pandemic Recovery Office through
   the Coronavirus Aid, Relief and Economic Security (CARES) Act; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 AI145687]; Duke Research Computing at Duke
   University [NIH 1S10OD018164-01]
FX Initial cryo-EM data were collected on the Titan Krios system at the
   Shared Materials and Instrumentation Facility in Duke University. Data
   collection for high-resolution structure determination was performed at
   the National Center for Cryo-EM Access and Training (NCCAT) and the
   Simons Electron Microscopy Center located at the New York Structural
   Biology Center, supported by the NIH Common Fund Transformative High
   Resolution Cryo-Electron Microscopy program (U24 GM129539) and by grants
   from the Simons Foundation (SF349247) and NY State. We thank E. Eng, D.
   Bobe, M. Walters and H. Leddy for microscope alignments and assistance
   with cryo-EM data collection as well as J. McLellan for providing the
   plasmid for the unmutated construct and K. Manne for preparing the
   CR3022 Fab. This work was supported by U19 AI142596 (B.F.H.), Integrated
   Preclinical/Clinical AIDS Vaccine Development Program, NIAID, NIH; Duke
   University Center for AIDS Research (CFAR); an administrative supplement
   to NIH R01 AI145687 for coronavirus research and Translating Duke Health
   Initiative (P.A. and R.C.H.), the Intramural Research Program of the
   NIH; National Institute of Environmental Health Sciences (ZIC ES103326
   to M.J.B.), and a contract from the State of North Carolina Pandemic
   Recovery Office through funds from the Coronavirus Aid, Relief and
   Economic Security (CARES) Act. This study utilized the computational
   resources offered by Duke Research Computing (http://rc.duke.edu; NIH
   1S10OD018164-01) at Duke University. We thank M. DeLong, C. Kneifel, M.
   Newton, V. Orlikowski, T. Milledge and D. Lane from the Duke Office of
   Information Technology and Research Computing for providing assistance
   with setting up and maintaining the computing environment.
CR Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551
   [Anonymous], 2020, MAESTR
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cai Yongfei, 2020, bioRxiv, DOI 10.1101/2020.05.16.099317
   Chuang GY, 2017, J VIROL, V91, DOI 10.1128/JVI.02268-16
   de la Pena AT, 2017, CELL REP, V20, P1805, DOI 10.1016/j.celrep.2017.07.077
   de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Guenaga J, 2016, J VIROL, V90, P2806, DOI 10.1128/JVI.02652-15
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   He LL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau6769
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh Ching-Lin, 2020, bioRxiv, DOI 10.1101/2020.05.30.125484
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Kirchdoerfer RN, 2018, SCI REP, V8
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6
   Medina-Ramirez M, 2017, J EXP MED, V214, P2573, DOI 10.1084/jem.20161160
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   R Core Team, 2017, R LANG ENV STAT COMP
   Rey FA, 2018, CELL, V172, P1319, DOI 10.1016/j.cell.2018.02.054
   Salam NK, 2014, PROTEIN ENG DES SEL, V27, P365, DOI 10.1093/protein/gzu017
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Scheres SHW, 2016, METHOD ENZYMOL, V579, P125, DOI 10.1016/bs.mie.2016.04.012
   Schrodinger LLC, 2015, PYMOL MOL GRAPHICS S
   Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047
   Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Turoova B., 2020, BIORXIV, DOI [10.1101/2020.06.26.173476, DOI 10.1101/2020.06.26.173476]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang LS, 2018, J VIROL, V92, DOI 10.1128/JVI.02002-17
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang LF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01631
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan YC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14657
   Zhang P, 2018, CELL HOST MICROBE, V23, P832, DOI 10.1016/j.chom.2018.05.002
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 52
TC 17
Z9 16
U1 10
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
DI 10.1038/s41594-020-0479-4
EA JUL 2020
PG 24
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA MO2LA
UT WOS:000551363000001
PM 32699321
OA Bronze
DA 2021-01-01
ER

PT J
AU Koczulla, RA
   Sczepanski, B
   Koteczki, A
   Kuhnert, S
   Hecker, M
   Askevold, I
   Schneider, C
   Michel, S
   Kneidinger, N
AF Koczulla, Rembert A.
   Sczepanski, Bernd
   Koteczki, Adam
   Kuhnert, Stefan
   Hecker, Matthias
   Askevold, Ingolf
   Schneider, Christian
   Michel, Sebastian
   Kneidinger, Nikolaus
TI SARS-CoV-2 infection in two patients following recent lung
   transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; infection and infectious agents - viral;
   infectious disease; lung disease; infectious; lung transplantation;
   pulmonology
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has become a global health problem with pandemic character. Lung transplant recipients may be particularly at risk due to the high degree of immunosuppression and the lung being the organ primarily affected by COVID-19. We describe a 16-year-old male and a 64-year-old female recently lung transplanted patients with COVID-19 during inpatient rehabilitation. Both patients were receiving triple immunosuppressive therapy and had no signs of allograft dysfunction. Both patients had close contact with a person who developed COVID-19 and were tested positive for SARS-CoV-2. Subsequently, both patients underwent systematic screening and SARS-CoV-2 was ultimately detected. Although the 16-year-old boy was completely asymptomatic, the 64-year-old woman developed only mild COVID-19. Immunosuppressive therapy was unchanged and no experimental treatment was initiated. No signs of graft involvement or dysfunction were noticed. In conclusion, our report of patients with asymptomatic SARS-CoV-2 infection and mild COVID-19, respectively, may indicate that lung transplant recipients are not per se at risk for severe COVID-19. Further observations and controlled trials are urgently needed to study SARS-CoV-2 infection in lung transplant recipients.
C1 [Koczulla, Rembert A.] Schoen Klin Berchtesgadener Land, Inst Pulm Rehabil Res, Schoenau, Germany.
   [Koczulla, Rembert A.] Philipps Univ Marburg, German Ctr Lung Res DZL, Dept Pulm Rehabil, Marburg, Germany.
   [Koczulla, Rembert A.] Philipps Univ Marburg, Dept Internal Med, Div Pulm Dis, Marburg, Germany.
   [Koczulla, Rembert A.] Paracelsus Med Univ, Teaching Hosp, Salzburg, Austria.
   [Sczepanski, Bernd; Koteczki, Adam] Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, German Ctr Lung Res DZL, Dept Med Pulm & Crit Care Med, Marburg, Germany.
   [Sczepanski, Bernd; Koteczki, Adam] Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, German Ctr Lung Res DZL, Dept Med Pulm & Crit Care Med, Schonau Konigssee, Germany.
   [Kuhnert, Stefan; Hecker, Matthias] Justus Liebig Univ Giessen, Univ Hosp Giessen, Univ Giessen & Marburg Lung Ctr UGMLC, Dept Pulm Med, Giessen, Germany.
   [Askevold, Ingolf] Justus Liebig Univ Giessen, Univ Hosp Giessen, Dept Gen & Thorac Surg, Giessen, Germany.
   [Schneider, Christian] LMU, Dept Thorac Surg, Univ Munich, Munich, Germany.
   [Michel, Sebastian] Univ Munich, LMU, Clin Cardiac Surg, Munich, Germany.
   [Kneidinger, Nikolaus] LMU, Comprehens Pneumol Ctr, German Ctr Lung Res DZL, Dept Internal Med 5,CPC M,Univ Munich, Munich, Germany.
RP Koczulla, RA (corresponding author), Schoen Klin Berchtesgadener Land, Inst Pulm Rehabil Res, Schoenau, Germany.; Koczulla, RA (corresponding author), Philipps Univ Marburg, German Ctr Lung Res DZL, Dept Pulm Rehabil, Marburg, Germany.; Koczulla, RA (corresponding author), Philipps Univ Marburg, Dept Internal Med, Div Pulm Dis, Marburg, Germany.; Koczulla, RA (corresponding author), Paracelsus Med Univ, Teaching Hosp, Salzburg, Austria.
EM rkoczulla@schoen-klinik.de
OI Kneidinger, Nikolaus/0000-0001-7583-0453
CR Abadja F, 2011, TRANSPLANTATION, V92, P396, DOI 10.1097/TP.0b013e3182247b5f
   Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Bailey ES, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02861
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Romanelli A, 2020, AM J TRANSPLANT, V20, P1947, DOI 10.1111/ajt.15905
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 10
TC 7
Z9 7
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD OCT
PY 2020
VL 20
IS 10
BP 2928
EP 2932
DI 10.1111/ajt.15998
EA JUL 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA NU4CB
UT WOS:000550909100001
PM 32400084
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Morillas, JA
   Canosa, FM
   Srinivas, P
   Asadi, T
   Calabrese, C
   Rajendram, P
   Budev, M
   Poggio, ED
   Menon, KN
   Gastman, B
   Koval, C
AF Morillas, Jose A.
   Canosa, Francisco Marco
   Srinivas, Pavithra
   Asadi, Tannaz
   Calabrese, Casandra
   Rajendram, Prabalini
   Budev, Marie
   Poggio, Emilio D.
   Menon, Kv Narayanan
   Gastman, Brian
   Koval, Christine
TI Tocilizumab therapy in 5 solid and composite tissue transplant
   recipients with early ARDS due to SARS-CoV-2
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; infection and infectious agents - viral;
   infectious disease; off-label drug use
ID ANTIBODY
AB There are emerging data depicting the clinical presentation of coronavirus disease 19 (COVID-19) in solid organ transplant recipients but negligible data-driven guidance on clinical management. A biphasic course has been described in some infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), beginning with a flu-like illness followed by an intense inflammatory response characterized by elevated c-reactive protein (CRP), interleukin 6 (IL-6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL-6. Tocilizumab is an IL-6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to chimeric antigen receptor T-cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS-CoV-2-related ARDS has not been previously reported in detail. We present the clinical course of 5 SOT/CTTRs with SARS-CoV-2-related ARDS that received tocilizumab with favorable short-term outcomes in 4. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within 2 weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab's clinical utility in this population.
C1 [Morillas, Jose A.; Canosa, Francisco Marco; Koval, Christine] Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA.
   [Srinivas, Pavithra] Cleveland Clin, Dept Pharm, Cleveland, OH 44106 USA.
   [Asadi, Tannaz] Hillcrest Hosp, Dept Infect Dis, Cleveland, OH USA.
   [Calabrese, Casandra] Cleveland Clin, Dept Rheumatol & Immunol Dis, Cleveland, OH 44106 USA.
   [Rajendram, Prabalini] Cleveland Clin, Dept Crit Care Med, Cleveland, OH 44106 USA.
   [Budev, Marie] Cleveland Clin, Dept Pulm Med, Cleveland, OH 44106 USA.
   [Poggio, Emilio D.] Cleveland Clin, Dept Nephrol & Hypertens, Cleveland, OH 44106 USA.
   [Menon, Kv Narayanan] Cleveland Clin, Dept Hepatol, Cleveland, OH 44106 USA.
   [Gastman, Brian] Cleveland Clin, Dept Plast Surg, Cleveland, OH 44106 USA.
   [Budev, Marie; Poggio, Emilio D.; Menon, Kv Narayanan; Gastman, Brian; Koval, Christine] Cleveland Clin, Transplantat Ctr, Cleveland, OH 44106 USA.
RP Morillas, JA (corresponding author), Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA.
EM morillj@ccf.org
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen X, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa449
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hulbert AL, 2018, CURR OPIN ORGAN TRAN, V23, P308, DOI 10.1097/MOT.0000000000000537
   Ison M, 2010, TRANSPL INFECT DIS, V12, P95, DOI 10.1111/j.1399-3062.2010.00501.x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Tan M, 2020, IMMUNOLOGY
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 19
TC 5
Z9 5
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 3191
EP 3197
DI 10.1111/ajt.16080
EA JUL 2020
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000550908700001
PM 32476261
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Portsmore, S
   Nguyen, TNT
   Beacham, E
   Neelakantan, P
AF Portsmore, Sophie
   Tran Nguyen, Thien Ngoc
   Beacham, Emma
   Neelakantan, Pratap
TI Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH,
   potential game changer
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE secondary haemophagocytic lymphohistiocytosis; severe COVID;
   Ruxolitinib; Tocilizumab; cytokine storm
ID CYTOKINE STORM
C1 [Portsmore, Sophie; Tran Nguyen, Thien Ngoc; Beacham, Emma; Neelakantan, Pratap] Royal Berkshire Hosp NHS Fdn Trust, Reading, Berks, England.
RP Neelakantan, P (corresponding author), Royal Berkshire Hosp NHS Fdn Trust, Reading, Berks, England.
EM pratap.neelakantan@nhs.net
OI , Pratap/0000-0002-8693-6605
CR Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   [Anonymous], RAND EV COVID 19 THE
   Faguer S., 2020, ANN INTERN MED
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Geng Z, 2019, CLIN EXP RHEUMATOL, V37, P318
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Prilutskiy A, 2020, SARS COV 2 INFECT AS
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Salvi R, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110267
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
NR 15
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2020
VL 190
IS 4
BP 525
EP 528
DI 10.1111/bjh.16966
EA JUL 2020
PG 4
WC Hematology
SC Hematology
GA NA4YY
UT WOS:000550980800001
PM 32584421
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pagliusi, S
   Jarrett, S
   Hayman, B
   Kreysa, U
   Prasad, SD
   Reers, M
   Thai, PH
   Wu, K
   Zhang, YT
   Baek, YO
   Kumar, A
   Evtushenko, A
   Jadhav, S
   Meng, WN
   Dat, DT
   Huang, WD
   Desai, S
AF Pagliusi, Sonia
   Jarrett, Stephen
   Hayman, Benoit
   Kreysa, Ulrike
   Prasad, Sai D.
   Reers, Martin
   Pham Hong Thai
   Wu, Ke
   Zhang, Youn Tao
   Baek, Yeong Ok
   Kumar, Anand
   Evtushenko, Anatoly
   Jadhav, Suresh
   Meng, Weining
   Do Tuan Dat
   Huang, Weidan
   Desai, Samir
TI Emerging manufacturers engagements in the COVID-19 vaccine research,
   development and supply
SO VACCINE
LA English
DT Article
AB The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed.
   Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Pagliusi, Sonia] DCVMN Int, Route Crassier 7, CH-1262 Eysins Nyon, Switzerland.
   [Jarrett, Stephen] Gracious Int, 28 Jiafeng Rd, Shanghai 200131, Peoples R China.
   [Hayman, Benoit] DCVMN Int, Nyon, Switzerland.
   [Kreysa, Ulrike] GS1,Ave Louise 326, B-1050 Brussels, Belgium.
   [Prasad, Sai D.] Bharat Biotech, Hyderabad, India.
   [Reers, Martin] Biol E Ltd, Hyderabad, India.
   [Pham Hong Thai] BioNet Asia, Bangkok, Thailand.
   [Wu, Ke] Bravovax, Wuhan, Peoples R China.
   [Zhang, Youn Tao] China Natl Biotech Grp, Beijing, Peoples R China.
   [Baek, Yeong Ok] EuBiologics, Seoul, South Korea.
   [Kumar, Anand] Indian Immunol Ltd, Hyderabad, India.
   [Evtushenko, Anatoly] St Petersburg Res Inst Vaccines & Serums, St Petersburg, Russia.
   [Jadhav, Suresh] Serum Inst India, Pune, Maharashtra, India.
   [Meng, Weining] Sinovac Biotech, Beijing, Peoples R China.
   [Do Tuan Dat] Vabiotech, Hanoi, Vietnam.
   [Huang, Weidan] Innovax Biotech, Xiamen, Peoples R China.
   [Desai, Samir] Zydus Cadila, Ahmadabad, Gujarat, India.
RP Pagliusi, S (corresponding author), DCVMN Int, Route Crassier 7, CH-1262 Eysins Nyon, Switzerland.
EM s.pagliusi@dcvmn.net; swjarrett@graciousgroup.com; b.hayman@dcvmn.net;
   ulrike.kreysa@gs1.org; Prasadsd@bharatbiotech.com;
   martin.reers@biologicale.com; hongthai@bionet-asia.com;
   ke.wu@bravovax.com; zhangyuntao@sinopharm.com; yobaek@eubiologics.com;
   anandkumar@indimmune.com; a.e.evtushenko@spbniivs.ru;
   ssj@seruminstitute.com; mengwn@sinovac.com; dotuandat@vabiotech.com.vn;
   weidan_huang@innovax.cn; samirdesai@zyduscadila.com
RI Evtushenko, Anatoly/ABE-3910-2020
OI Evtushenko, Anatoly/0000-0002-1189-579X
FU Bill & Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1204376]
FX We would like to thank the DCVMN manufacturers members for taking time
   to complete the DCVMN progress survey: AMSON Vaccines & Pharmaceuticals
   Ltd; Arabio; BCHT; Beijing Minhai Biotechnology Co. Ltd.; PT BioFarma;
   Biological E. Ltd.; BioManguinhos/Fiocruz; BioNet-Asia Co. Ltd.;
   Liaoning Chengda Biotechnology; China National Biotech Group; CPL
   Biologicals Pvt. Ltd.; Eubiologics Co. Ltd.; The Government
   Pharmaceutical Organization; Green Cross; IMBCAMS: The Institute of
   Medical Biology, Chinese Academy of Medical Sciences; Incepta
   Pharmaceuticals Ltd.; Indian Immunologicals Ltd.; LG Chem; Nanolek LLC.;
   Panacea Biotech Ltd.; POLYVAC; Queen Saovabha Memorial Institute; Serum
   Institute of India; Sinergium Biotech; Sinovac Biotech Ltd.; SK
   bioscience; SPbSRIVS; Vabiotech; Walvax Biotechnology Co. Ltd.; Xiamen
   Innovax Biotech Co. Ltd.; Zhifei Biological Products Ltd.; Zydus Cadila;
   Biovac Institute; BravoVax Co. Ltd.; Medigen Vaccine Biologics Co.;
   Pasteur Institute of India; and VINS Bioproducts Ltd. We are to thank
   the DCVMN Executive Committee for their ongoing support and guidance.
   This work was partly supported by a grant from the Bill & Melinda Gates
   Foundation, Grant no. OPP1204376.
CR Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Hayman B, 2020, VACCINE, DOI [10.1016/j.jvacx.2020.100066., 10.1016/j.jvacx.2020.100066, DOI 10.1016/J.JVACX.2020.100066]
   Miller J, 2020, FINANCIAL TIMES
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Order-Nidovirales, 2012, VIRUS TAXONOMY, P784
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   WHO, 2020, DIR GEN OP REM MED B
   World Health Organization, 2015, VACC PRES PACK ADV G
   World Health Organization, 2020, BLUEPR DRAFT LANDSC
NR 9
TC 4
Z9 4
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 22
PY 2020
VL 38
IS 34
BP 5418
EP 5423
DI 10.1016/j.vaccine.2020.06.022
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ML2VB
UT WOS:000549329000008
PM 32600908
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garcia, LY
   Cerda, AA
AF Garcia, Leidy Y.
   Cerda, Arcadio A.
TI Contingent assessment of the COVID-19 vaccine
SO VACCINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Vaccine; Acceptance; Health economics; Contingent
   valuation
ID WILLINGNESS-TO-PAY; PREFERENCES; ADOLESCENT
AB The COVID-19 pandemic has not only had a negative impact on people's health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual's willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (p <= 0.05), knowledge of COVID-19 (p <= 0.05), being sick with COVID-19 (p <= 0.05), perception of government performance (p <= 0.01), employment status (p <= 0.01), income (p <= 0.01), health care (p <= 0.05), adaptation to quarantine with children at home (p < 0.01) and whether the person has recovered from COVID-19 (p < 0.10). According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals' WTP is US$184.72 (CI: 165.52-203.92; p < 0.01). This implies a social valuation of approximately US$2232 million, corresponding to 1.09% of the GNP per capita. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Garcia, Leidy Y.; Cerda, Arcadio A.] Univ Talca, Fac Econ & Business, 1 Poniente, Talca 1141, Chile.
RP Garcia, LY (corresponding author), Univ Talca, Fac Econ & Business, 1 Poniente, Talca 1141, Chile.
EM lgarcia@utalca.cl; acerda@utalca.cl
OI Garcia, Leidy/0000-0002-7487-5999; Cerda, Arcadio/0000-0002-3791-854X
CR Acter T, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138996
   Boyle KJ, 2017, ECON NON-MARK GOOD, V13, P83, DOI 10.1007/978-94-007-7104-8_4
   Cerda AA, 2014, SALUD PUBLICA MEXICO, V56, P48
   Cuccia T, 2020, HDB CULTURAL EC
   Jang S, 2020, TRANSPORTMETRICA A, V16, P892, DOI 10.1080/23249935.2020.1719548
   Jordan RE, 2020, COVID 19 RISK FACTOR
   Le TT, 2020, NAT REV DRUG DISCOV
   Levin A, 2019, VACCINE, V37, P3568, DOI 10.1016/j.vaccine.2019.05.023
   Lopez-Feldman A., 2012, INTRO CONTINGENT VAL
   Marshall HS, 2016, VACCINE, V34, P671, DOI 10.1016/j.vaccine.2015.11.075
   Mudatsir Mudatsir, 2019, F1000Res, V8, P1441, DOI 10.12688/f1000research.20144.2
   Muniz RL, 2019, EXPERT REV PHARM OUT, V19, P473, DOI 10.1080/14737167.2019.1552136
   Nosratnejad S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157470
   OCDE, 2018, OECD EC SURVEYS, DOI 10.1787/eco_surveys-chl-2018-en
   Rajamoorthy Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215125
   Ren X, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010007
   Sarmento TTR, 2019, EXPERT REV PHARM OUT, DOI 10.1080/14737167.2020.1703181
   Ryan M, 2004, J HEALTH ECON, V23, P237, DOI 10.1016/j.jhealeco.2003.09.003
   SUBTEL, 2020, SUBS TEL CHIL
   Wong CKH, 2018, VALUE HEALTH, V21, P622, DOI 10.1016/j.jval.2017.10.012
   WorldBank, 2020, WORLD BANK COUNTR LE
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
   Yeo HY, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0163-2
   Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
NR 24
TC 4
Z9 4
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 22
PY 2020
VL 38
IS 34
BP 5424
EP 5429
DI 10.1016/j.vaccine.2020.06.068
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ML2VB
UT WOS:000549329000009
PM 32620375
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Paguio, JA
   Yao, JS
   Dee, EC
AF Paguio, Joseph Alexander
   Yao, Jasper Seth
   Dee, Edward Christopher
TI Silver lining of COVID-19: Heightened global interest in pneumococcal
   and influenza vaccines, an infodemiology study
SO VACCINE
LA English
DT Article
DE COVID-19; Coronavirus; Pneumococcal vaccine; Influenza vaccine; Online
   health information; Health-seeking behavior; Patient education;
   Infodemiology
ID PUBLIC-HEALTH RESPONSE; UNITED-STATES; OUTBREAK; CANCER; TRENDS
AB Background: Health-seeking behaviors change during pandemics and may increase with regard to illnesses with symptoms similar to the pandemic. The global reaction to COVID-19 may drive interest in vaccines for other diseases.
   Objectives: Our study investigated the correlation between global online interest in COVID-19 and interest in CDC-recommended routine vaccines.
   Design, settings, measurements: This infodemiology study used Google Trends data to quantify worldwide interest in COVID-19 and CDC-recommended vaccines using the unit search volume index (SVI), which estimates volume of online search activity relative to highest volume of searches within a specified period. SVIs from December 30, 2019 to March 30, 2020 were collected for "coronavirus (Virus)" and compared with SVIs of search terms related to CDC-recommended adult vaccines. To account for seasonal variation, we compared SVIs from December 30, 2019 to March 30, 2020 with SVIs from the same months in 2015 to 2019. We performed country-level analyses in ten COVID-19 hotspots and ten countries with low disease burden.
   Results: There were significant positive correlations between SVIs for "coronavirus (Virus)" and search terms for pneumococcal (R = 0.89, p < 0.0001) and influenza vaccines (R = 0.93, p < 0.0001) in 2020, which were greater than SVIs for the same terms in 2015-2019 (p = 0.005, p < 0.0001, respectively). Eight in ten COVID-19 hotspots demonstrated significant positive correlations between SVIs for coronavirus and search terms for pneumococcal and influenza vaccines.
   Limitations: SVIs estimate relative changes in online interest and do not represent the interest of people with no Internet access.
   Conclusion: A peak in worldwide interest in pneumococcal and influenza vaccines coincided with the COVID-19 pandemic in February and March 2020. Trends are likely not seasonal in origin and may be driven by COVID-19 hotspots. Global events may change public perception about the importance of vaccines. Our findings may herald higher demand for pneumonia and influenza vaccines in the upcoming season. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Paguio, Joseph Alexander; Yao, Jasper Seth] Univ Philippines, Coll Med, Quezon City, Philippines.
   [Dee, Edward Christopher] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.
RP Dee, EC (corresponding author), Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.
EM Edward_Dee@hms.harvard.edu
CR Paguio JA, 2020, J CANCER EDUC, DOI 10.1007/s13187-020-01739-9
   [Anonymous], VACC INF STAT IN INF
   [Anonymous], 2020, WHO DIRECTOR GEN OPE
   [Anonymous], ADM PNEUM VACC PROV
   [Anonymous], SEAS INFL VACC SUPPL
   [Anonymous], MOD WORK POT VACC CO
   [Anonymous], BCG VACC RED IMP COV
   Bakker KM, 2016, P NATL ACAD SCI USA, V113, P6689, DOI 10.1073/pnas.1523941113
   Bernardo TM, 2013, J MED INTERNET RES, V15, P239, DOI 10.2196/jmir.2740
   Bloom R, 2015, JAMA DERMATOL, V151, P903, DOI 10.1001/jamadermatol.2015.1216
   Castleton K, 2011, SUPPORT CARE CANCER, V19, P1183, DOI 10.1007/s00520-010-0935-5
   Chang DTS, 2018, ADV UROL, DOI [10.1155/2018/, DOI 10.1155/2018/]
   Chen YY, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9370
   Choi SB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220423
   Cook S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023610
   Covolo L, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7426-5
   Dee Edward Christopher, 2019, J Cancer Educ, DOI 10.1007/s13187-019-01614-2
   Dee EC, 2020, J CANCER EDUC, V35, P988, DOI 10.1007/s13187-019-01553-y
   Dey M, 2020, RHEUMATOLOGY, V59, P245, DOI 10.1093/rheumatology/kez283
   Diaz A, 2020, AM J SURG, V219, P900, DOI 10.1016/j.amjsurg.2020.04.014
   Dreher PC, 2018, UROLOGY, V121, P74, DOI 10.1016/j.urology.2018.05.040
   Eysenbach G, 2006, AMIA ANN S P
   Eysenbach G, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1157
   Fefer M, 2020, JAMA SURG, V5, P5
   Gianfredi V, 2018, PUBLIC HEALTH, V165, P9, DOI 10.1016/j.puhe.2018.09.001
   Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634
   Hernandez-Garcia I, 2020, JMIR PUBLIC HLTH SUR, V6, P110, DOI 10.2196/18717
   Higgins Thomas S, 2020, JMIR Public Health Surveill, V6, pe19702, DOI 10.2196/19702
   Ramos MI, 2019, INT J HEALTH PLAN M, V34, pE1215, DOI 10.1002/hpm.2763
   Jella TK, 2020, J ARTHROPLASTY, V35, P2813, DOI 10.1016/j.arth.2020.05.051
   Jellison SS, 2018, RHEUMATOL INT, V38, P2133, DOI 10.1007/s00296-018-4158-2
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Klett-Tammen CJ, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2784-8
   Koh HK, 2020, JAMA-J AM MED ASSOC, V323, P914, DOI 10.1001/jama.2020.1372
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Lawrentschuk N, 2009, UROLOGY, V74, P1058, DOI 10.1016/j.urology.2009.05.091
   Liang B, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2401
   Ma W, 2018, INFECT DIS-NOR, V50, P728, DOI 10.1080/23744235.2018.1472805
   Mavragani A, 2020, JMIR PUBLIC HLTH SUR, V6, P233, DOI 10.2196/18941
   Mavragani A, 2019, JMIR PUBLIC HLTH SUR, V5, P59, DOI 10.2196/13439
   Mgbere O, 2017, EPIDEMIOL INFECT, V145, P2611, DOI 10.1017/S0950268817001467
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Polgreen PM, 2008, CLIN INFECT DIS, V47, P1443, DOI 10.1086/593098
   Reyes MSGL, 2020, VACCINE, V38, P54, DOI 10.1016/j.vaccine.2019.10.001
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ridda I, 2008, VACCINE, V26, P234, DOI 10.1016/j.vaccine.2007.10.067
   Rohde Rodney, 2019, AM SOC MICROBIOL, DOI [10.1101/2020.02.07.937862V1., DOI 10.1101/2020.02.07.937862V1]
   Roser M, 2015, OUR WORLD DATA
   Roser Max, OUR WORLD DATA
   Sakamoto A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6080-7
   Schanzer DL, 2013, ACAD EMERG MED, V20, P388, DOI 10.1111/acem.12111
   Sha Sybil T, 2020, Int J Radiat Oncol Biol Phys, V107, P33, DOI 10.1016/j.ijrobp.2019.12.043
   Smolarchuk C, 2019, SEX TRANSM INFECT, V95, P594, DOI 10.1136/sextrans-2019-053986
   Sugrue R, 2018, BREAST J, V24, P189, DOI 10.1111/tbj.12864
   THORNTON J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1401
   Varady NH, 2018, OSTEOARTHR CARTILAGE, V26, P1017, DOI 10.1016/j.joca.2018.04.017
   Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444
NR 57
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 22
PY 2020
VL 38
IS 34
BP 5430
EP 5435
DI 10.1016/j.vaccine.2020.06.069
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ML2VB
UT WOS:000549329000010
PM 32620371
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhou, XX
   Wang, GX
   Chen, LT
   Meng, FK
   Huang, L
   Huang, LF
   Wang, N
   Li, TJ
   Cao, Y
   Zhou, JF
AF Zhou, Xiaoxi
   Wang, Gaoxiang
   Chen, Liting
   Meng, Fankai
   Huang, Liang
   Huang, Lifang
   Wang, Na
   Li, Tongjuan
   Cao, Yang
   Zhou, Jianfeng
TI Clinical characteristics of hematological patients concomitant with
   COVID-19
SO CANCER SCIENCE
LA English
DT Article
DE COVID-19; hematological patient; immunocompromised state; SARS-CoV-2
AB The rapid spread of coronavirus disease 2019 (COVID-19) represented the most serious issue to public health globally. Hematological patients as immunocompromised hosts are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There is little information available regarding the clinical features of hematological patients concomitant with COVID-19. In this study, 9 concomitant patients were analyzed for their clinical manifestations, laboratory data, radiological findings, and immunologic features. The median age was 50 years (range, 17-68 years) and 6 patients were male. Seven patients were infected through hospital-associated transmission and other 2 through community-associated transmission. Onset of COVID-19 in all patients occurred during routine treatments for their hematological diseases. Eight patients were classified as moderate and 1 patient as critically ill COVID-19. Four patients died, 1 from leukemia progression, 2 from life-threatening secondary infection, and the other from respiratory failure caused by COVID-19. Abruptly elevated levels of cytokines were often correlated with progressive hematological disease or concurrent bacterial infections. Two patients had atypical computed tomography (CT) imaging findings of COVID-19. The median interval from the first CT scan imaging to improvement in survivors was 40 days (range, 14-51 days). Four of 5 survivors had negative serological tests 1 month after symptom onset. Positive viral load in 4 survivors lasted longer than 45 days. Our results indicated concomitant patients formed a distinct subgroup characterized by atypical clinical features, defective viral clearance, and lower level of SARS-CoV-2-specific Abs. Targeted therapies that impair host humoral immunity should be avoided. These findings will be helpful to tailor appropriate management for the concomitant patients.
C1 [Zhou, Xiaoxi; Wang, Gaoxiang; Chen, Liting; Meng, Fankai; Huang, Liang; Huang, Lifang; Wang, Na; Li, Tongjuan; Cao, Yang; Zhou, Jianfeng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China.
RP Cao, Y; Zhou, JF (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China.
EM yangcao@tjh.tjmu.edu.cn; jfzhou@tjh.tjmu.edu.cn
RI Huang, Liang/I-3299-2019
OI Huang, Liang/0000-0002-8370-3232
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81570197, 81670150]; Emergency Research
   Project of Tongji hospital; Emergency Research Project of Hubei province
   [2020FCA006]; Emergency Research Project of Tongji hospital of Huazhong
   University of Science and Technology [2020kfyXGYJ045]
FX National Natural Science Foundation of China, Grant/Award Number:
   81570197 and 81670150; Emergency Research Project of Tongji hospital;
   Emergency Research Project of Hubei province, Grant/Award Number:
   2020FCA006; Emergency Research Project of Tongji hospital of Huazhong
   University of Science and Technology, Grant/Award Number: 2020kfyXGYJ045
CR Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cooper L, 2020, IMMUNOL CELL BIOL, V98, P456, DOI 10.1111/imcb.12338
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin XH, 2020, LANCET HAEMATOL, V7, pE351, DOI 10.1016/S2352-3026(20)30074-0
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1036
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, COR DIS COVID 19 OUT
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 12
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD SEP
PY 2020
VL 111
IS 9
BP 3379
EP 3385
DI 10.1111/cas.14544
EA JUL 2020
PG 7
WC Oncology
SC Oncology
GA NI5TU
UT WOS:000550798000001
PM 32619034
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Prayer-Galetti, T
   Motterle, G
   Morlacco, A
   Celso, F
   Boemo, D
   Iafrate, M
   Zattoni, F
AF Prayer-Galetti, Tommaso
   Motterle, Giovanni
   Morlacco, Alessandro
   Celso, Francesco
   Boemo, Deris
   Iafrate, Massimo
   Zattoni, Filiberto
TI Urological Care and COVID-19: Looking Forward
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; management; organization; surgery; urology
ID CARBON-DIOXIDE LASER; SURGERY; PAPILLOMAVIRUS
AB The recent COVID-19 pandemic represents a worldwide emergency and it is affecting healthcare at every level, including also urological care and especially oncologic patients. Recent epidemiological models show that, without effective treatment or vaccine, there will be a long-lasting phase of cohabitation with the virus. Current experts' opinions recommend performing only non-deferrable uro-oncological surgery and postponing other activities until the end of the emergency, with particular concerns regarding the safety laparoscopy. Veneto Region and Padua Province represent one of the first site of the pandemic spread of the virus outside China, thus we present our experience as a Urological Referral Center in applying a segregated-team work model of organization during the month of March 2020, with a stratified organization of activities, adequate screening and protection for patients and staff were adopted. Compared to the same period of last year even if a 19.5% reduction was experienced in overall surgical activity while maintaining a comparable proportion of oncologic robotic and laparoscopic surgery and guaranteeing care also for high priority non-oncological patients. No cases of COVID-19 infection were reported in staff members nor in patients and the number of surgical complications was comparable to that of last year. Therefore, in our opinion the recommended significant reduction in urological care, including surgical activities, is likely unrealistic in the long period with unknown effects affecting mostly oncological patients. Our experience introducing a segregated-team work model might represent a model for future planning.
C1 [Prayer-Galetti, Tommaso; Motterle, Giovanni; Morlacco, Alessandro; Celso, Francesco; Iafrate, Massimo; Zattoni, Filiberto] Univ Padua, Dept Surg & Oncol Sci, Clin Urol, Padua, Italy.
   [Boemo, Deris] Univ Hosp Padua, Management Hlth Serv Dept, Padua, Italy.
RP Prayer-Galetti, T (corresponding author), Univ Padua, Dept Surg & Oncol Sci, Clin Urol, Padua, Italy.
EM tommaso.prayer@aopd.veneto.it
OI Motterle, Giovanni/0000-0002-3157-589X
CR [Anonymous], 2020, NUOV COR
   Besnier E, 2020, WORLD J SURG, V44, P1695, DOI 10.1007/s00268-020-05501-6
   Cohen SL, 2020, J MINIM INVAS GYN, V27, P792, DOI 10.1016/j.jmig.2020.04.003
   CONMED, AIRSEAL IFS
   Connor MJ, 2020, BJU INT, V125, pE3, DOI 10.1111/bju.15061
   Corral-Velez Vicente, 2014, Inflammation & Allergy Drug Targets, V13, P367
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Ficarra V, 2020, MINERVA UROL NEFROL, V72, P369, DOI 10.23736/S0393-2249.20.03846-1
   Gallotta V, 2018, J MINIM INVAS GYN, V25, P872, DOI 10.1016/j.jmig.2018.01.007
   GLOSTER HM, 1995, J AM ACAD DERMATOL, V32, P436, DOI 10.1016/0190-9622(95)90065-9
   Goldman HB, 2020, J UROLOGY, V204, P11, DOI 10.1097/JU.0000000000001067
   Grieco DL, 2019, ANESTHESIOLOGY, V131, P58, DOI 10.1097/ALN.0000000000002662
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1106
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584
   Morris SN, 2020, J MINIM INVAS GYN, V27, P789, DOI 10.1016/j.jmig.2020.04.002
   Mottrie A, 2020, ERUS EAU ROBOTIC URO
   Naspro R, 2020, NAT REV UROL, V17, P251, DOI 10.1038/s41585-020-0312-1
   Ngoi N, 2020, ANN ONCOL, V31, P840, DOI 10.1016/j.annonc.2020.03.306
   Ploussard G, 2018, CURR OPIN UROL, V28, P153, DOI 10.1097/MOU.0000000000000470
   Puliatti S, 2020, BJU INT, V125, pE7, DOI 10.1111/bju.15071
   Regione Veneto, 2020, COR VEN RIORG ATT SA
   Ribal MJ, 2020, EUR UROL, V78, P21, DOI 10.1016/j.eururo.2020.04.056
   SAWCHUK WS, 1989, J AM ACAD DERMATOL, V21, P41, DOI 10.1016/S0190-9622(89)70146-8
   Simonato A, 2020, MINERVA UROL NEFROL, V72, P376, DOI 10.23736/S0393-2249.20.03861-8
   Stensland KD, 2020, EUR UROL, V77, P663, DOI 10.1016/j.eururo.2020.03.027
   World Health Organization, 2020, NOV COR
   Wu ZS, 2020, J UROLOGY, V204, P7, DOI 10.1097/JU.0000000000001068
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 30
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 21
PY 2020
VL 10
AR 1313
DI 10.3389/fonc.2020.01313
PG 6
WC Oncology
SC Oncology
GA MZ7VM
UT WOS:000559334900001
PM 32793504
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jemberie, WB
   Williams, JS
   Eriksson, M
   Gronlund, AS
   Ng, N
   Nilsson, MB
   Padyab, M
   Priest, KC
   Sandlund, M
   Snellman, F
   McCarty, D
   Lundgren, LM
AF Jemberie, Wossenseged Birhane
   Stewart Williams, Jennifer
   Eriksson, Malin
   Gronlund, Ann-Sofie
   Ng, Nawi
   Blom Nilsson, Marcus
   Padyab, Mojgan
   Priest, Kelsey Caroline
   Sandlund, Mikael
   Snellman, Fredrik
   McCarty, Dennis
   Lundgren, Lena M.
TI Substance Use Disorders and COVID-19: Multi-Faceted Problems Which
   Require Multi-Pronged Solutions
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE substance use disorder (SUD); COVID-19; addiction care; integrated care;
   social capital; pandemic; evidence-based policies and practices; risk
   environment
ID ECONOMIC-CRISIS; MENTAL-HEALTH; OLDER-ADULTS; FINANCIAL CRISIS;
   HONG-KONG; DRUG-USE; JOB LOSS; IMPACT; ALCOHOL; UNEMPLOYMENT
AB COVID-19 shocked health and economic systems leaving millions of people without employment and safety nets. The pandemic disproportionately affects people with substance use disorders (SUDs) due to the collision between SUDs and COVID-19. Comorbidities and risk environments for SUDs are likely risk factors for COVID-19. The pandemic, in turn, diminishes resources that people with SUD need for their recovery and well-being. This article presents an interdisciplinary and international perspective on how COVID-19 and the related systemic shock impact on individuals with SUDs directly and indirectly. We highlight a need to understand SUDs as biopsychosocial disorders and use evidence-based policies to destigmatize SUDs. We recommend a suite of multi-sectorial actions and strategies to strengthen, modernize and complement addiction care systems which will become resilient and responsive to future systemic shocks similar to the COVID-19 pandemic.
C1 [Jemberie, Wossenseged Birhane; Eriksson, Malin; Gronlund, Ann-Sofie; Blom Nilsson, Marcus; Padyab, Mojgan; Snellman, Fredrik; Lundgren, Lena M.] Umea Univ, Dept Social Work, Umea, Sweden.
   [Jemberie, Wossenseged Birhane; Padyab, Mojgan] Umea Univ, Ctr Demog & Ageing Res CEDAR, Umea, Sweden.
   [Jemberie, Wossenseged Birhane] Lund Univ, Swedish Natl Grad Sch Competit Sci Ageing & Hlth, Dept Hlth Sci, Fac Med, Lund, Sweden.
   [Stewart Williams, Jennifer; Ng, Nawi] Umea Univ, Dept Epidemiol & Global Hlth, Fac Med, Umea, Sweden.
   [Stewart Williams, Jennifer] Univ Newcastle, Fac Hlth, Res Ctr Generat Hlth & Ageing, Callaghan, NSW, Australia.
   [Ng, Nawi] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Sch Publ Hlth & Community Med, Gothenburg, Sweden.
   [Priest, Kelsey Caroline] Oregon Hlth & Sci Univ, Sch Med, MD PhD Program, Portland, OR 97201 USA.
   [Sandlund, Mikael] Umea Univ, Dept Clin Sci, Psychiat Unit, Umea, Sweden.
   [McCarty, Dennis] Portland State Univ, Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97207 USA.
   [Lundgren, Lena M.] Univ Denver, Grad Sch Social Work, Cross Natl Behav Hlth Lab, Denver, CO USA.
RP Jemberie, WB (corresponding author), Umea Univ, Dept Social Work, Umea, Sweden.; Jemberie, WB (corresponding author), Umea Univ, Ctr Demog & Ageing Res CEDAR, Umea, Sweden.; Jemberie, WB (corresponding author), Lund Univ, Swedish Natl Grad Sch Competit Sci Ageing & Hlth, Dept Hlth Sci, Fac Med, Lund, Sweden.
EM wossenseged.jemberie@umu.se
RI Jemberie, Wossenseged/AAX-4695-2020
OI Jemberie, Wossenseged/0000-0002-4378-6803
FU Swedish Research Council for Health, Working Life and Welfare (FORTE)
   [2016-07213, 2019-01453]; National Institute on Drug AbuseUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA) [F30 DA044700]
FX Grants from The Swedish Research Council for Health, Working Life and
   Welfare (FORTE) Grant no. 2016-07213 and Grant No. 2019-01453 have
   supported this study. An award from the National Institute on Drug Abuse
   (F30 DA044700) supported KP's participation in the development of the
   manuscript. The funding organizations were not involved in the design of
   the study, data collection, data analysis, the interpretation of data,
   or writing of the manuscript.
CR Ahn WY, 2016, DRUG ALCOHOL DEPEN, V161, P247, DOI 10.1016/j.drugalcdep.2016.02.008
   Alexandrescu L, 2020, CRIME MEDIA CULT, V16, P97, DOI 10.1177/1741659019835274
   Antonakakis N, 2014, SOC SCI MED, V112, P39, DOI 10.1016/j.socscimed.2014.04.019
   Arkes J, 2007, HEALTH ECON, V16, P19, DOI 10.1002/hec.1132
   Bador K, 2020, J BEHAV HEALTH SER R, V47, P102, DOI 10.1007/s11414-019-09657-5
   Barry CL, 2014, PSYCHIAT SERV, V65, P1269, DOI 10.1176/appi.ps.201400140
   Ben Natan M, 2009, INT J NURS PRACT, V15, P566, DOI 10.1111/j.1440-172X.2009.01799.x
   Biancarelli DL, 2019, DRUG ALCOHOL DEPEN, V198, P80, DOI 10.1016/j.drugalcdep.2019.01.037
   Blazer DG, 2009, AM J GERIAT PSYCHIAT, V17, P237, DOI 10.1097/JGP.0b013e318190b8ef
   Brener L, 2010, SUBST USE MISUSE, V45, P1007, DOI 10.3109/10826081003659543
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Buckland W, 2019, WES ANDERSON'S SYMBOLIC STORYWORLD: A SEMIOTIC ANALYSIS, P1, DOI 10.5040/9781501316555
   Cantor J, 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200626.418552/full, DOI 10.1377/HBLOG20200626.418552/FULL]
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chan SSC, 2007, INT J NURS STUD, V44, P1120, DOI 10.1016/j.ijnurstu.2006.04.019
   Chen Irene Y, 2019, AMA J Ethics, V21, pE167, DOI 10.1001/amajethics.2019.167
   Claussen B, 1999, ADDICTION, V94, P133, DOI 10.1046/j.1360-0443.1999.94113310.x
   Collins AB, 2019, SOC SCI MED, V234, DOI 10.1016/j.socscimed.2019.112384
   Connor JP, 2007, SUBST USE MISUSE, V42, P2193, DOI 10.1080/10826080701658125
   Corcoran P, 2015, INT J EPIDEMIOL, V44, P969, DOI 10.1093/ije/dyv058
   Courtin E, 2017, HEALTH SOC CARE COMM, V25, P799, DOI 10.1111/hsc.12311
   DATAJOURNALISTIK, 2020, SA PAV COR MOJL ATT
   de Bruin M, 2010, HEALTH PSYCHOL, V29, P421, DOI 10.1037/a0020335
   de Goeij MCM, 2015, SOC SCI MED, V131, P131, DOI 10.1016/j.socscimed.2015.02.025
   DelliFraine JL, 2008, J TELEMED TELECARE, V14, P62, DOI 10.1258/jtt.2007.070709
   Dom G, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010122
   Economou M, 2013, J AFFECT DISORDERS, V145, P308, DOI 10.1016/j.jad.2012.08.008
   Eibl JK, 2017, DRUG ALCOHOL DEPEN, V176, P133, DOI 10.1016/j.drugalcdep.2017.01.048
   Eliason M, 2014, J STUD ALCOHOL DRUGS, V75, P35, DOI 10.15288/jsad.2014.75.35
   Eriksson M, 2009, SOC THEOR HEALTH, V7, P318, DOI 10.1057/sth.2009.6
   Esteve A, 2020, POPUL DEV REV, V46, P169, DOI 10.1111/padr.12311
   ETA, 2020, UN INS WEEKL CLAIMS
   Eurofound, 2020, LIV WORK COVID 19 1
   European Monitoring Centre for Drugs and Drug Addiction Europol, 2020, EU DRUG MARK IMP COV
   Farhoudian A, 2020, BASIC CLIN NEUROSCI, V11, P133, DOI 10.32598/bcn.11.covid19.1
   Fergusson DM, 2008, ADDICTION, V103, P969, DOI 10.1111/j.1360-0443.2008.02221.x
   Frank C, 2014, ANXIETY STRESS COPIN, V27, P422, DOI 10.1080/10615806.2013.864389
   Garcy AM, 2013, AM J PUBLIC HEALTH, V103, P1031, DOI 10.2105/AJPH.2013.301210
   Gellis ZD, 2012, GERONTOLOGIST, V52, P541, DOI 10.1093/geront/gnr134
   Ghesquiere AR, 2014, AM J GERIAT PSYCHIAT, V22, P1555, DOI 10.1016/j.jagp.2013.12.005
   Gianfrancesco MA, 2018, JAMA INTERN MED, V178, P1544, DOI 10.1001/jamainternmed.2018.3763
   Goldman-Mellor SJ, 2010, INT J MENT HEALTH, V39, P6, DOI 10.2753/IMH0020-7411390201
   Gowin JL, 2017, DRUG ALCOHOL DEPEN, V175, P255, DOI 10.1016/j.drugalcdep.2017.03.003
   Graham K, 1993, ALCOHOL TREAT Q, V9, P79, DOI [10.1300/J020v09n03_05, DOI 10.1300/J020V09N03_05]
   Green KM, 2010, ADDICTION, V105, P484, DOI 10.1111/j.1360-0443.2009.02787.x
   Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI [DOI 10.1080/14659890500114359, 10.1080/14659890500114359]
   HAMMARSTROM A, 1994, SOC SCI MED, V38, P699, DOI 10.1016/0277-9536(94)90460-X
   Hammarstrom A, 2002, J EPIDEMIOL COMMUN H, V56, P624, DOI 10.1136/jech.56.8.624
   Harris M, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00388-x
   Henkel Dieter, 2011, Curr Drug Abuse Rev, V4, P4
   Huskamp HA, 2018, HEALTH AFFAIR, V37, P1940, DOI 10.1377/hlthaff.2018.05134
   Ifanti AA, 2013, HEALTH POLICY, V113, P8, DOI 10.1016/j.healthpol.2013.05.017
   International Monetary Fund, 2020, WORLD EC OUTL APR 20
   Jemberie Wossenseged Birhane, 2020, J Addict Med, V14, pe89, DOI 10.1097/ADM.0000000000000636
   Jusot F, 2008, J EPIDEMIOL COMMUN H, V62, P332, DOI 10.1136/jech.2007.060772
   Karanikolos M, 2013, LANCET, V381, P1323, DOI 10.1016/S0140-6736(13)60102-6
   Kazemi DM, 2017, J HEALTH COMMUN, V22, P413, DOI 10.1080/10810730.2017.1303556
   Kim J, 2010, HIST SOC RES, V35, P120
   Kim S, 2018, AGING MENT HEALTH, V22, P550, DOI 10.1080/13607863.2016.1268095
   Koh HK, 2008, SOCIAL CAPITAL HLTH, P273, DOI DOI 10.1007/978-0-387-71311-3
   Kondilis E, 2013, AM J PUBLIC HEALTH, V103, P973, DOI 10.2105/AJPH.2012.301126
   Kristensen P, 2012, PSYCHIATRY, V75, P76, DOI 10.1521/psyc.2012.75.1.76
   Kuerbis A, 2018, DRUG ALCOHOL DEPEN, V183, P240, DOI 10.1016/j.drugalcdep.2017.11.012
   Kuerbis A, 2012, ADDICT BEHAV, V37, P587, DOI 10.1016/j.addbeh.2012.01.022
   Li J, 2010, 12 IEEE INT C E HLTH
   Li J, 2010, 2010 43 HAW INT C SY
   Lin CA, 2018, AM J HEALTH-SYST PH, V75, P153, DOI 10.2146/ajhp170196
   Linn AJ, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1738
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lundgren L, 2018, SCREENING ASSESSMENT
   Madianos MG, 2014, EUR J PSYCHIAT, V28, P39, DOI 10.4321/S0213-61632014000100004
   Martin-Carrasco M, 2016, EUR ARCH PSY CLIN N, V266, P89, DOI 10.1007/s00406-016-0681-x
   Masferrer L, 2015, HEROIN ADDICT REL CL, V17, P23
   McCarty D, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0160-6
   McKee-Ryan FM, 2005, J APPL PSYCHOL, V90, P53, DOI 10.1037/0021-9010.90.1.53
   McLaughlin KA, 2012, PSYCHOL MED, V42, P1441, DOI 10.1017/S0033291711002613
   McNeil R, 2014, SOC SCI MED, V105, P59, DOI 10.1016/j.socscimed.2014.01.010
   MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425
   Muvvala SB, 2020, SUBST ABUS, V41, P475, DOI 10.1080/08897077.2019.1709606
   Narasimha VL, 2020, ALCOHOL ALCOHOLISM, V55, P350, DOI 10.1093/alcalc/agaa042
   Norman S, 2006, J PSYCHIATR MENT HLT, V13, P771, DOI 10.1111/j.1365-2850.2006.01033.x
   OBHE, 2020, DOUBL JEOP COVID 19
   Paraskevis D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078941
   Peterfi A, 2014, DRUG TEST ANAL, V6, P825, DOI 10.1002/dta.1625
   Pilling J, 2012, SUBST ABUSE TREAT PR, V7, DOI 10.1186/1747-597X-7-3
   Priest KC, 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200331.557887, DOI 10.1377/HBLOG20200331.557887]
   Putnam RD, 2000, BOWLING ALONE COLLAP
   Ray PP, 2014, 2014 INTERNATIONAL CONFERENCE ON SCIENCE ENGINEERING AND MANAGEMENT RESEARCH (ICSEMR)
   Rhodes T, 1999, ADDICTION, V94, P1323, DOI 10.1046/j.1360-0443.1999.94913235.x
   Roelfs DJ, 2011, SOC SCI MED, V72, P840, DOI 10.1016/j.socscimed.2011.01.005
   Sarkar S., 2015, J GERIATRIC MENTAL H, V2, P74, DOI DOI 10.4103/2348-9995.174271
   Scalea JR, 2018, IEEE J TRANSL ENG HE, V6, DOI 10.1109/JTEHM.2018.2875704
   Simon R, 2020, SUBST ABUS, V41, P519, DOI 10.1080/08897077.2019.1671942
   Simou E, 2014, HEALTH POLICY, V115, P111, DOI 10.1016/j.healthpol.2014.02.002
   Skewes MC, 2013, PRINCIPLES OF ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 1, P61, DOI 10.1016/B978-0-12-398336-7.00006-1
   Slaunwhite AK, 2020, DRUG ALCOHOL DEPEN, V212, DOI 10.1016/j.drugalcdep.2020.108047
   Stahl ST, 2017, AGING MENT HEALTH, V21, P1065, DOI 10.1080/13607863.2016.1191060
   Stahl ST, 2014, J BEHAV MED, V37, P736, DOI 10.1007/s10865-013-9524-7
   Starace F, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796020000372
   Stuckler David, 2009, Ulster Med J, V78, P142
   Stuckler D, 2009, LANCET, V374, P315, DOI 10.1016/S0140-6736(09)61124-7
   Sypsa V, 2017, J INFECT DIS, V215, P1496, DOI 10.1093/infdis/jix100
   Tempalski B, 2007, GEOFORUM, V38, P1250, DOI 10.1016/j.geoforum.2007.03.012
   Toh XP, 2016, 2016 IEEE INTERNATIONAL CONFERENCE ON PERVASIVE COMPUTING AND COMMUNICATION WORKSHOPS (PERCOM WORKSHOPS)
   Uutela A, 2010, CURR OPIN PSYCHIATR, V23, P127, DOI 10.1097/YCO.0b013e328336657d
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Van Hal G, 2015, PSYCHOL RES BEHAV MA, V8, P17, DOI 10.2147/PRBM.S44732
   Venkatesh A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1379
   Villalonga-Olives E, 2017, SOC SCI MED, V194, P105, DOI 10.1016/j.socscimed.2017.10.020
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   von Hippel W, 2008, PSYCHOL SCI, V19, P7, DOI 10.1111/j.1467-9280.2008.02037.x
   Wahlbeck K, 2012, WORLD PSYCHIATRY, V11, P139
   Watkins J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017722
   Weinstein L, 2009, PERSPECT HLTH INF MA, V6, P1
   WHO UNODC, 2020, INT STNAD TREATM DRU
   Wilkey C, 2013, J SOC WORK PRACT ADD, V13, P192, DOI 10.1080/1533256X.2013.785872
   Winstock A. R., 2020, GLOBAL DRUG SURVEY S
   Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Yang JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199741
   Yang Y, 2020, LANCET PSYCHIAT, V7, pE19, DOI 10.1016/S2215-0366(20)30079-1
   Zuccato E, 2011, DRUG ALCOHOL DEPEN, V118, P464, DOI 10.1016/j.drugalcdep.2011.05.007
NR 122
TC 3
Z9 3
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD JUL 21
PY 2020
VL 11
AR 714
DI 10.3389/fpsyt.2020.00714
PG 9
WC Psychiatry
SC Psychiatry
GA MY6KR
UT WOS:000558524200001
PM 32848907
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Benatti, B
   Albert, U
   Maina, G
   Fiorillo, A
   Celebre, L
   Girone, N
   Fineberg, N
   Bramante, S
   Rigardetto, S
   Dell'Osso, B
AF Benatti, Beatrice
   Albert, Umberto
   Maina, Giuseppe
   Fiorillo, Andrea
   Celebre, Laura
   Girone, Nicolaja
   Fineberg, Naomi
   Bramante, Stefano
   Rigardetto, Sylvia
   Dell'Osso, Bernardo
TI What Happened to Patients With Obsessive Compulsive Disorder During the
   COVID-19 Pandemic? A Multicentre Report From Tertiary Clinics in
   Northern Italy
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE obsessive compulsive disorder; COVID-19; Internet-checking; avoidance;
   suicidal ideation
ID QUALITY-OF-LIFE; INTERNATIONAL COLLEGE
AB After the outbreak of Coronavirus disease was declared a pandemic by the World Health Organization, this resulted in extraordinary public health measures to control the infection, such as entire countries being placed under quarantine. The psychopathological consequences of the pandemic and quarantine were anticipated to be of particular relevance, especially in patients with psychiatric disorders such as Obsessive Compulsive Disorder (OCD). Aim of the present report was to describe the impact of COVID-19 pandemics within a sample of Italian patients affected by OCD. Sociodemographic and clinical variables of a sample of 123 OCD outpatients, currently attending three OCD tertiary clinics in Northern Italy, were assessed through telephone and in-person interviews. Patients showing a clinical worsening of OCD represented more than one third of the sample and reported a significant emergence of new obsessions and compulsions phenotypes along with a significant exacerbation of past ones. Moreover, they were more frequently found to experience suicidal ideation, increased Internet checking, sleep disturbances, avoidance behaviors, and work difficulties. A significantly increased need of therapy adjustment and family accommodation was also observed. Further research is warranted to clarify the potential risk and related consequences of the current COVID-19 pandemic on OCD patients.
C1 [Benatti, Beatrice; Celebre, Laura; Girone, Nicolaja; Dell'Osso, Bernardo] Univ Milan, Luigi Sacco Univ Hosp, Psychiat Unit 2, Milan, Italy.
   [Albert, Umberto] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.
   [Albert, Umberto] ASUGI Azienda Sanit Univ Giuliano Isontina, Dept Mental Hlth, Psychiat Clin, Trieste, Italy.
   [Maina, Giuseppe; Bramante, Stefano; Rigardetto, Sylvia] San Luigi Gonzaga Univ Hosp, Orbassano, Italy.
   [Maina, Giuseppe; Bramante, Stefano] Univ Turin, Rita Levi Montalcini Dept Neurosci, Turin, Italy.
   [Fiorillo, Andrea] Univ Campania L Vanvitelli, Dept Psychiat, Naples, Italy.
   [Fineberg, Naomi] Univ Hertfordshire, Hertfordshire Partnership Univ NHS Fdn Trust, Hatfield, Herts, England.
   [Fineberg, Naomi] Univ Cambridge, Sch Clin Med, Cambridge, England.
   [Dell'Osso, Bernardo] Univ Milan, Aldo Ravelli Ctr Nanotechnol & Neurostimulat, Milan, Italy.
   [Dell'Osso, Bernardo] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA USA.
   [Dell'Osso, Bernardo] Univ Milan, Ctr Studio Meccanismi Mol Base Patol Neuropsicoge, Milan, Italy.
RP Benatti, B (corresponding author), Univ Milan, Luigi Sacco Univ Hosp, Psychiat Unit 2, Milan, Italy.
EM beatricebenatti@gmail.com
RI Fineberg, Naomi/ABI-5522-2020
CR Ghebreyesus TA, 2020, WORLD PSYCHIATRY, V19, P129, DOI 10.1002/wps.20768
   Albert U, 2017, PSYCHOL RES BEHAV MA, V10, P293, DOI 10.2147/PRBM.S124359
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Banerjee D, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112966
   Benatti Beatrice, 2020, CNS Spectr, P1, DOI 10.1017/S1092852920001157
   Bobes J, 2001, EUR PSYCHIAT, V16, P239, DOI 10.1016/S0924-9338(01)00571-5
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cordeiro Trinette, 2015, Indian J Psychol Med, V37, P403, DOI 10.4103/0253-7176.168579
   Davide P, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113213
   de Girolamo G, 2020, JAMA PSYCHIAT, V77, P974, DOI 10.1001/jamapsychiatry.2020.1276
   Dell'Osso B, 2018, CNS SPECTRUMS, V23, P59, DOI 10.1017/S1092852917000177
   Fineberg NA, 2020, COMPR PSYCHIAT, V100, DOI 10.1016/j.comppsych.2020.152174
   Fiorillo A, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.35
   Fontenelle LF, 2020, DEPRESS ANXIETY, V37, P510, DOI 10.1002/da.23037
   French I, 2020, IRISH J PSYCHOL MED, V37, P291, DOI 10.1017/ipm.2020.61
   Hollander E, 2010, J CLIN PSYCHIAT, V71, P784, DOI 10.4088/JCP.09m05911blu
   Khanna Rohit C, 2020, Indian J Ophthalmol, V68, P703, DOI 10.4103/ijo.IJO_843_20
   Kumar A, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102053
   Lochner C, 2014, COMPR PSYCHIAT, V55, P1513, DOI 10.1016/j.comppsych.2014.05.020
   Morein-Zamir S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0225970
   Rubin GJ, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m313
   Vismara M, 2020, COMPR PSYCHIAT, V99, DOI 10.1016/j.comppsych.2020.152167
   WHO, 2020, DIR GEN OP REM MED B
NR 23
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD JUL 21
PY 2020
VL 11
AR 720
DI 10.3389/fpsyt.2020.00720
PG 5
WC Psychiatry
SC Psychiatry
GA MY6KO
UT WOS:000558523900001
PM 32793008
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Asghari, A
   Naseri, M
   Safari, H
   Saboory, E
   Parsamanesh, N
AF Asghari, Arghavan
   Naseri, Mohsen
   Safari, Hamidreza
   Saboory, Ehsan
   Parsamanesh, Negin
TI The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and
   Therapeutic Options
SO DNA AND CELL BIOLOGY
LA English
DT Article
DE coronaviruses; genome structure; pathogenesis; diagnosis; treatment
ID RESPIRATORY SYNDROME CORONAVIRUS; MURINE HEPATITIS-VIRUS; NUCLEIC-ACID
   DETECTION; SARS-CORONAVIRUS; BIOCHEMICAL-CHARACTERIZATION; NONSTRUCTURAL
   PROTEINS; NUCLEOCAPSID PROTEIN; CONSERVED DOMAIN; SPIKE PROTEIN;
   RNA-SYNTHESIS
AB On December 31, 2019, a novel coronavirus, being the third highly infective CoV and named as coronavirus disease 2019 (COVID-19) in the city of Wuhan, was announced by the World Health Organization. COVID-19 has a 2% mortality rate, is known as the third extremely infective CoV infection, and has a mortality rate less than MERS-CoV and SARS-CoV. The CoV family comprises a chief number of positive single-strandedss(+) RNA viruses that are recognized in mammals. The 2019-nCoV patients showed that the angiotensin-converting enzymeII(ACE2) was the same for SARS-CoV. Structural proteins have an essential role in virus released and budding to various host cells. Notably, evidence indicated human-to-human transmission, along with several exported patients of virus infection worldwide. Nowadays, no licensed antivirals drugs or vaccines for being utilized against these coronavirus infections are recognized. There is an urgent requirement for an extensive research of CoV infections to disclose the route of extension, pathogenesis, and diagnosis and then to recognize the therapeutic targets to facilitate disease control and surveillance. In this article, we present an overview of the common biological criteria of CoVs and explain pathogenesis with a focus on the therapeutic approach to suggest potential goals for treating and monitoring this emerging zoonotic disease.
C1 [Asghari, Arghavan] Birjand Univ Med Sci, Student Res Comm, Birjand, Iran.
   [Naseri, Mohsen] Birjand Univ Med Sci, Cellular & Mol Res Ctr, Birjand, Iran.
   [Safari, Hamidreza] Torbat Jam Fac Med Sci, Dept Immunol, Torbat Jam, Iran.
   [Saboory, Ehsan; Parsamanesh, Negin] Zanjan Univ Med Sci, Zanjan Metab Dis Res Ctr, Zanjan 4213956184, Iran.
RP Parsamanesh, N (corresponding author), Zanjan Univ Med Sci, Zanjan Metab Dis Res Ctr, Zanjan 4213956184, Iran.
EM neginparsa.684@gmail.com
RI Asghari, Arghavan/AAV-2655-2020; naseri, mohsen/Q-3351-2018
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ahmed-Belkacem R, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112557
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Alam I., 2020, PREPRINT, DOI [10.1101/2020.02.17.952895, DOI 10.1101/2020.02.17.952895]
   Algarroba GN, 2020, AM J OBSTET GYNECOL, V223, P275, DOI 10.1016/j.ajog.2020.05.023
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Angelini MM, 2013, MBIO, V4, DOI 10.1128/mBio.00524-13
   Arndt AL, 2010, J VIROL, V84, P11418, DOI 10.1128/JVI.01131-10
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Bauch CT, 2013, LANCET, V382, P662, DOI 10.1016/S0140-6736(13)61504-4
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Begum F., 2020, PREPRINT, DOI 10.1101/2020.05.14.095224
   Benvenuto D, 2020, J INFECTION, V81, pE24, DOI 10.1016/j.jinf.2020.03.058
   Bestle D., 2020, TMPRSS2 FURIN ARE BO
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   Braakman I, 2000, TRAFFIC, V1, P533, DOI 10.1034/j.1600-0854.2000.010702.x
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chen Q, 2010, INTERVIROLOGY, V53, P95, DOI 10.1159/000264199
   Chen Y, 2019, VET MICROBIOL, V231, P226, DOI 10.1016/j.vetmic.2019.03.018
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cornillez-Ty CT, 2009, J VIROL, V83, P10314, DOI 10.1128/JVI.00842-09
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Clercq E, 2019, CHEM-ASIAN J, V14, P3962, DOI 10.1002/asia.201900841
   De Maio F., 2020, PREPRINT, DOI [10.21203/rs.3rs-30903/v1, DOI 10.21203/RS.3RS-30903/V1]
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Durdagi S., 2020, SCREENING CLIN APPRO, DOI [10.26434/chemrxiv.12032712.v1, DOI 10.26434/CHEMRXIV.12032712.V1]
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Enosawa M, 2003, J CLIN MICROBIOL, V41, P4359, DOI 10.1128/JCM.41.9.4359-4365.2003
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Forni D, 2016, J VIROL, V90, P3627, DOI 10.1128/JVI.02988-15
   Freije CA, 2019, MOL CELL, V76, P826, DOI 10.1016/j.molcel.2019.09.013
   Fu JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020648
   Fung TS, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070184
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gadlage MJ, 2010, J VIROL, V84, P280, DOI 10.1128/JVI.01772-09
   Gadlage MJ, 2008, J VIROL, V82, P11964, DOI 10.1128/JVI.01126-07
   Gao SB, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-0182-y
   Gootenberg JS, 2018, SCIENCE, V360, P439, DOI 10.1126/science.aaq0179
   Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Grunewald ME, 2018, VIROLOGY, V517, P62, DOI 10.1016/j.virol.2017.11.020
   Hagemeijer MC, 2010, J VIROL, V84, P2134, DOI 10.1128/JVI.01716-09
   Hao W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006474
   He Q, 2015, VIRUS RES, V201, P32, DOI 10.1016/j.virusres.2015.02.014
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200
   Javier RT, 2011, J VIROL, V85, P11544, DOI 10.1128/JVI.05410-11
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Ju J., 2020, NUCLEOTIDE ANALOGUES, DOI [10.1101/2020.03.12.989186, DOI 10.1101/2020.03.12.989186]
   Kahn J.S., 2005, PEDIATR INFECT DIS J, V24, P5223
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Konkolova E, 2020, J STRUCT BIOL, V211, DOI 10.1016/j.jsb.2020.107548
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Kumar A., 2020, CHARACTERIZATION NUC, P2020050413
   Kumar V, 2016, BIOORGAN MED CHEM, V24, P3035, DOI 10.1016/j.bmc.2016.05.013
   Kuo LL, 2016, VIROLOGY, V494, P100, DOI 10.1016/j.virol.2016.04.009
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LeAo J.C., 2020, ORAL DIS, V001, P1
   Lee C, 2019, MAR DRUGS, V17, DOI 10.3390/md17100567
   Lee YG, 2016, J MICROBIOL BIOTECHN, V26, P2012, DOI 10.4014/jmb.1605.05056
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li C, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104285
   Li F, 2006, J VIROL, V80, P6794, DOI 10.1128/JVI.02744-05
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004216
   Liao Y, 2006, VIROLOGY, V349, P264, DOI 10.1016/j.virol.2006.01.028
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lin S., 2020, PREPRINT, DOI [10.1101/2020.01.31/929695, DOI 10.1101/2020.01.31/929695]
   Lopez LA, 2008, J VIROL, V82, P3000, DOI 10.1128/JVI.01914-07
   Lu XY, 2014, J CLIN MICROBIOL, V52, P67, DOI 10.1128/JCM.02533-13
   Lugari A, 2010, J BIOL CHEM, V285, P33230, DOI 10.1074/jbc.M110.120014
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Ma-Lauer Y, 2016, P NATL ACAD SCI USA, V113, pE5192, DOI 10.1073/pnas.1603435113
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   MACNAUGHTON MR, 1978, J GEN VIROL, V39, P545, DOI 10.1099/0022-1317-39-3-545
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Matsuyama S., 2020, PREPRINT, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Menachery VD, 2017, CURR OPIN VIROL, V23, P1, DOI 10.1016/j.coviro.2017.01.002
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Narayanan N, 2020, VITAMIN B12 MAY INHI
   National Health and Health Commission and the provincial health and health commission  including Hong Kong  Macao and Taiwan, 2020, DISTR NEW COR PNEUM
   Nedialkova DD, 2009, J VIROL, V83, P5671, DOI 10.1128/JVI.00261-09
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Oostra M, 2006, J VIROL, V80, P2326, DOI 10.1128/JVI.80.5.2326-2336.2006
   Ozma Mahdi Asghari, 2020, Infez Med, V28, P153
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Ray M., 2020, PREPRINT, DOI [10.26434/chemrxiv.12387290.v1, DOI 10.26434/CHEMRXIV.12387290.V1]
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rosas-Lemus Monica, 2020, bioRxiv, DOI 10.1101/2020.04.17.047498
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Setianingsih TY, 2019, INT J INFECT DIS, V86, P102, DOI 10.1016/j.ijid.2019.06.022
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shanker A., 2020, PREPRINT, DOI [10.26434/chemrxiv.11846943.v9, DOI 10.26434/CHEMRXIV.11846943.V9]
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   Shi PD, 2019, VIRUS RES, V265, P57, DOI 10.1016/j.virusres.2019.03.005
   Shu T., 2020, VIRAL SIN, V30, P1
   Singh S, 2020, LUNG INDIA, V37, P268, DOI 10.4103/lungindia.lungindia_170_20
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sparks JS, 2007, J VIROL, V81, P12554, DOI 10.1128/JVI.01257-07
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sun Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/430508
   Sun Y, 2014, ANTIVIR RES, V104, P156, DOI 10.1016/j.antiviral.2014.02.002
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Tam R., 2002, Patent application, Patent No. [WO/2000/044388, 2000044388]
   Tam RC, 2001, ANTIVIR CHEM CHEMOTH, V12, P261, DOI 10.1177/095632020101200501
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Te Helen S, 2007, Gastroenterol Hepatol (N Y), V3, P218
   Thomas S., 2020, STRUCTURE MEMBRANE P, DOI [10.20944/preprints202004.0512.v1, DOI 10.20944/PREPRINTS202004.0512.V1]
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tseng YT, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-34
   Uhlenhaut C, 2012, TRANSPL INFECT DIS, V14, P79, DOI 10.1111/j.1399-3062.2011.00657.x
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan ZZ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111880
   Wang Q, 2020, VIROL SIN, V20, P1
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Wedrowska E, 2020, ANN AGR ENV MED, V27, P175, DOI 10.26444/aaem/122079
   World Health Organization (WHO), 2020, STAT M INT HLTH REG
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wright AV, 2016, CELL, V164, P29, DOI 10.1016/j.cell.2015.12.035
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Yip CCY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072574
   Zeng Z, 2018, J VIROL, V92, DOI 10.1128/JVI.00692-18
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu XY, 2017, J VIROL, V91, DOI [10.1128/JVI.00003-17, 10.1128/jvi.00003-17]
   Zhu XY, 2017, VIROLOGY, V502, P33, DOI 10.1016/j.virol.2016.12.005
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 163
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD OCT 1
PY 2020
VL 39
IS 10
BP 1741
EP 1753
DI 10.1089/dna.2020.5703
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA NW5UM
UT WOS:000556035800001
PM 32716648
OA Bronze
DA 2021-01-01
ER

PT J
AU Silvestris, N
   Munafo, A
   Brunetti, O
   Burgaletto, C
   Scucces, L
   Bernardini, R
AF Silvestris, Nicola
   Munafo, Antonio
   Brunetti, Oronzo
   Burgaletto, Chiara
   Scucces, Luisa
   Bernardini, Renato
TI On the Management of Drug Interactions in the Course of Concomitant
   Treatments for COVID-19 and Antineoplastic Agents
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE cancer therapy; Sars-Cov2; drug-to-drug interaction; metabolism; dose
   adjustement
C1 [Silvestris, Nicola; Brunetti, Oronzo] IRCCS Ist Tumori Giovanni Paolo II, Med Oncol Unit, Bari, Italy.
   [Silvestris, Nicola] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Munafo, Antonio; Burgaletto, Chiara; Scucces, Luisa; Bernardini, Renato] Univ Catania, Sect Pharmacol, Dept Biomed & Biotechnol Sci, Sch Med, Catania, Italy.
RP Silvestris, N (corresponding author), IRCCS Ist Tumori Giovanni Paolo II, Med Oncol Unit, Bari, Italy.; Silvestris, N (corresponding author), Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.
EM n.silvestris@oncologico.bari.it
CR Ali W, 2019, J CLIN ENG, V44, P125, DOI [10.1097/jce.0000000000000347, DOI 10.1097/JCE.0000000000000347]
   Andre F, 2016, EUR J CANCER, V69, pS7, DOI 10.1016/S0959-8049(16)32619-3
   Back D, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14358
   Bossaer JB, 2017, J ONCOL PRACT, V13, pE217, DOI 10.1200/JOP.2016.016212
   Brunetti O, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00734
   Caterina P, 2013, J RES MED SCI, V18, P600
   Di Lorenzo G, 2020, CRIT REV ONCOL HEMAT, V152, DOI [10.1016/j.critrevonc.2020.102901, 10.1016/j.critrevonc.2020.102991]
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Harrach S, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00085
   Jafari A, 2020, CRIT REV ONCOL HEMAT, V151, DOI 10.1016/j.critrevonc.2020.102982
   Lynch T, 2007, AM FAM PHYSICIAN, V76, P391
   Marcath LA, 2018, J ONCOL PRACT, V14, P376, DOI [10.1200/JOP.17.00086, 10.1200/JOP.18.00086]
   Martinez-Chavez A, 2019, MOL PHARMACEUT, V16, P3842, DOI 10.1021/acs.molpharmaceut.9b00475
   Mealey KL, 2015, J VET INTERN MED, V29, P1, DOI [10.1111/jvim.12525, 10.1111/jvim.12482]
   Nacher Jose C., 2008, BMC Pharmacology, V8, P5, DOI 10.1186/1471-2210-8-5
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Thill M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918793326
   Tseng A, 2012, CURR INFECT DIS REP, V14, P67, DOI 10.1007/s11908-011-0229-1
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 21
PY 2020
VL 10
AR 1340
DI 10.3389/fonc.2020.01340
PG 3
WC Oncology
SC Oncology
GA MY5XW
UT WOS:000558490900001
PM 32850428
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bertozzi, AL
   Franco, E
   Mohler, G
   Short, MB
   Sledge, D
AF Bertozzi, Andrea L.
   Franco, Elisa
   Mohler, George
   Short, Martin B.
   Sledge, Daniel
TI The challenges of modeling and forecasting the spread of COVID-19
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE COVID-19; pandemic; branching process; compartmental models
ID EPIDEMIC; NUMBER
AB The coronavirus disease 2019 (COVID-19) pandemic has placed epidemic modeling at the forefront of worldwide public policy making. Nonetheless, modeling and forecasting the spread of COVID-19 remains a challenge. Here, we detail three regional-scale models for forecasting and assessing the course of the pandemic. This work demonstrates the utility of parsimonious models for early-time data and provides an accessible framework for generating policy-relevant insights into its course. We show how these models can be connected to each other and to time series data for a particular region. Capable of measuring and forecasting the impacts of social distancing, these models high-light the dangers of relaxing nonpharmaceutical public health interventions in the absence of a vaccine or antiviral therapies.
C1 [Bertozzi, Andrea L.] Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90095 USA.
   [Bertozzi, Andrea L.; Franco, Elisa] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA.
   [Franco, Elisa] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA.
   [Mohler, George] Indiana Univ Purdue Univ Indianapolis, Dept Comp Sci, Indianapolis, IN 46202 USA.
   [Short, Martin B.] Georgia Inst Technol, Dept Math, Atlanta, GA 30332 USA.
   [Sledge, Daniel] Univ Texas Arlington, Dept Polit Sci, Arlington, TX 76019 USA.
RP Bertozzi, AL (corresponding author), Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90095 USA.; Bertozzi, AL (corresponding author), Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA.
EM bertozzi@ucla.edu
RI Bertozzi, Andrea L/A-1831-2012; BERTOZZI, ANDREA L./W-1802-2019
OI Bertozzi, Andrea L/0000-0003-0396-7391; 
FU NSFNational Science Foundation (NSF) [DMS-2027438, DMS-1737770,
   SCC-1737585, ATD-1737996]; Simons Foundation [510776]
FX We thank Mark Lewis and Mason Porter for helpful comments on early
   drafts of the manuscript. We also thank Mark Lewis and Ron Brookmeyer
   for expert advice from the mathematical biology and epidemiology
   perspectives, respectively. This research was supported by NSF Grants
   DMS-2027438, DMS-1737770, SCC-1737585, and ATD-1737996 and Simons
   Foundation Math + X Investigator Award 510776.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Altieri N., 2020, ARXIV200507882
   Angelov AG, 2012, COMPUT MATH APPL, V64, P229, DOI 10.1016/j.camwa.2012.01.049
   Arenas A, 2020, MATH MODEL SPATIOTEM, DOI [10.1101/2020.03.21.20040022, DOI 10.1101/2020.03.21.20040022]
   Bootsma MCJ, 2007, P NATL ACAD SCI USA, V104, P7588, DOI 10.1073/pnas.0611071104
   Brauer F., 2019, MATH MODELS EPIDEMIO
   Cauchemez S, 2006, EMERG INFECT DIS, V12, P110
   Cowling BJ, 2010, EPIDEMIOLOGY, V21, P842, DOI 10.1097/EDE.0b013e3181f20977
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Evans ND, 2005, MATH BIOSCI, V194, P175, DOI 10.1016/j.mbs.2004.10.011
   Farrington CP, 2003, BIOSTATISTICS, V4, P279, DOI 10.1093/biostatistics/4.2.279
   Ferguson N, 2020, IMPACT NONPHARMACEUT, DOI [10.25561/77482, DOI 10.25561/77482]
   Fox EW, 2016, J AM STAT ASSOC, V111, P564, DOI 10.1080/01621459.2015.1135802
   Frasso G, 2016, BIOSTATISTICS, V17, P779, DOI 10.1093/biostatistics/kxw027
   Haffajee RL, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006740
   Harko T, 2014, APPL MATH COMPUT, V236, P184, DOI 10.1016/j.amc.2014.03.030
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Imai N., 2020, 3 IMP COLL LOND, DOI [10.25561/77148., DOI 10.25561/77148, 10.25561/77148]
   Kelly JD, 2019, EPIDEMICS-NETH, V28, DOI 10.1016/j.epidem.2019.100354
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Landler M, 2020, NY TIMES
   Lewis R. J., PROJECTIONS HOSP BAS
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li T., 2020, ARXIV200212280
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Meyer S, 2017, J STAT SOFTW, V77, DOI 10.18637/jss.v077.i11
   Miller Joel C, 2017, Infect Dis Model, V2, P35, DOI 10.1016/j.idm.2016.12.003
   Miller JC, 2012, B MATH BIOL, V74, P2125, DOI 10.1007/s11538-012-9749-6
   Mohler George, 2020, ARXIV200401714
   Murray C.J.L, 2020, FORECASTING COVID 19
   Obadia T, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-147
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Perkins T. A., 2020, ESTIMATING UNOBSERVE, DOI [10.1101/2020.03.15.20036582, DOI 10.1101/2020.03.15.20036582]
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   Riou J., 2020, PATTERN EARLY HUMAN, DOI [10.1101/2020.01.23.917351, DOI 10.1101/2020.01.23.917351]
   Rizoiu M. A., 2018, LINKING EPIDEMIC MOD
   Roosa K, 2019, THEOR BIOL MED MODEL, V16, DOI 10.1186/s12976-018-0097-6
   Schoenberg FP, 2019, ANN I STAT MATH, V71, P1271, DOI 10.1007/s10463-018-0690-9
   Sledge D., 2017, HLTH DIVIDED PUBLIC
   Stomakhin A, 2011, INVERSE PROBL, V27, DOI 10.1088/0266-5611/27/11/115013
   Tindale L., 2020, TRANSMISSION INTERVA, DOI [10.1101/2020.03.03.20029983, DOI 10.1101/2020.03.03.20029983]
   Tolles J, 2020, JAMA-J AM MED ASSOC, V323, P2515, DOI 10.1001/jama.2020.8420
   Verity R., 2020, ESTIMATES SEVERITY C, DOI [10.1101/2020.03.09.20033357, DOI 10.1101/2020.03.09.20033357]
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   White LF, 2008, STAT MED, V27, P2999, DOI 10.1002/sim.3136
   World Health Organization, COR DIS COVID 2019 S
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yan P, 2008, LECT NOTES MATH, V1945, P229
   You C., 2020, ESTIMATION TIME VARY
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zipkin JR, 2016, EUR J APPL MATH, V27, P502, DOI 10.1017/S0956792515000492
NR 55
TC 10
Z9 10
U1 5
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 21
PY 2020
VL 117
IS 29
BP 16732
EP 16738
DI 10.1073/pnas.2006520117
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MX8BZ
UT WOS:000557946500008
PM 32616574
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dawadi, S
   Simmons, N
   Miklossy, G
   Bohren, KM
   Faver, JC
   Ucisik, MN
   Nyshadham, P
   Yu, ZF
   Matzuk, MM
AF Dawadi, Surendra
   Simmons, Nicholas
   Miklossy, Gabriella
   Bohren, Kurt M.
   Faver, John C.
   Ucisik, Melek Nihan
   Nyshadham, Pranavanand
   Yu, Zhifeng
   Matzuk, Martin M.
TI Discovery of potent thrombin inhibitors from a protease-focused
   DNA-encoded chemical library
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE DNA-encoded chemical library; focused DECL; protease inhibitor;
   COVID-19; SARS-CoV-2
AB DNA-encoded chemical libraries are collections of compounds individually coupled to unique DNA tags serving as amplifiable identification barcodes. By bridging split-and-pool combinatorial synthesis with the ligation of unique encoding DNA oligomers, million- to billion-member libraries can be synthesized for use in hundreds of healthcare target screens. Although structural diversity and desirable molecular property ranges generally guide DNA-encoded chemical library design, recent reports have highlighted the utility of focused DNA-encoded chemical libraries that are structurally biased for a class of protein targets. Herein, a protease-focused DNA-encoded chemical library was designed that utilizes chemotypes known to engage conserved catalytic protease residues. The three-cycle library features functional moieties such as guanidine, which interacts strongly with aspartate of the protease catalytic triad, as well as mild electrophiles such as sulfonamide, urea, and carbamate. We developed a DNA-compatible method for guanidinylation of amines and reduction of nitriles. Employing these optimized reactions, we constructed a 9.8-million-membered DNA-encoded chemical library. Affinity selection of the library with thrombin, a common protease, revealed a number of enriched features which ultimately led to the discovery of a 1 nM inhibitor of thrombin. Thus, structurally focused DNA-encoded chemical libraries have tremendous potential to find clinically useful high-affinity hits for the rapid discovery of drugs for targets (e.g., proteases) with essential functions in infectious diseases (e.g., severe acute respiratory syndrome coronavirus 2) and relevant healthcare conditions (e.g., male contraception).
C1 [Dawadi, Surendra; Simmons, Nicholas; Miklossy, Gabriella; Bohren, Kurt M.; Faver, John C.; Ucisik, Melek Nihan; Nyshadham, Pranavanand; Yu, Zhifeng; Matzuk, Martin M.] Baylor Coll Med, Dept Pathol & Immunol, Ctr Drug Discovery, Houston, TX 77030 USA.
RP Dawadi, S; Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol & Immunol, Ctr Drug Discovery, Houston, TX 77030 USA.
EM dawadi@bcm.edu; mmatzuk@bcm.edu
OI Bohren, Kurt/0000-0002-3183-4118; Faver, John/0000-0002-0181-9283
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   DevelopmentUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [P01HD087157];
   Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [INV-001902]; Welch FoundationThe Welch Foundation [H-Q-0042]; Cancer
   Prevention Research Institute of Texas [RP160805]; Baylor College of
   Medicine
FX This work is supported by the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (P01HD087157), the Bill and
   Melinda Gates Foundation (INV-001902), the Welch Foundation (H-Q-0042),
   a Core Facility Support Award from the Cancer Prevention Research
   Institute of Texas (RP160805), and a COVID-19relevant exploratory grant
   from Baylor College of Medicine.
CR Acharya KR, 2003, NAT REV DRUG DISCOV, V2, P891, DOI 10.1038/nrd1227
   Agbowuro AA, 2018, MED RES REV, V38, P1295, DOI 10.1002/med.21475
   Antermite D, 2018, ORG LETT, V20, P3948, DOI 10.1021/acs.orglett.8b01521
   Bachovchin DA, 2012, NAT REV DRUG DISCOV, V11, P52, DOI 10.1038/nrd3620
   BERNATOWICZ MS, 1992, J ORG CHEM, V57, P2497, DOI 10.1021/jo00034a059
   Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145
   Deng HF, 2012, J MED CHEM, V55, P7061, DOI 10.1021/jm300449x
   Du HC, 2019, ORG LETT, V21, P2194, DOI 10.1021/acs.orglett.9b00497
   Du HC, 2017, BIOCONJUGATE CHEM, V28, P2575, DOI 10.1021/acs.bioconjchem.7b00416
   Eatemadi A, 2017, BIOMED PHARMACOTHER, V86, P221, DOI 10.1016/j.biopha.2016.12.021
   Faver JC, 2019, ACS COMB SCI, V21, P75, DOI 10.1021/acscombsci.8b00116
   Fear G, 2007, PHARMACOL THERAPEUT, V113, P354, DOI 10.1016/j.pharmthera.2006.09.001
   Franco FM, 2015, BIOORGAN MED CHEM, V23, P2328, DOI 10.1016/j.bmc.2015.03.072
   Franzini RM, 2014, ACCOUNTS CHEM RES, V47, P1247, DOI 10.1021/ar400284t
   Goodnow RA, 2017, NAT REV DRUG DISCOV, V16, P131, DOI 10.1038/nrd.2016.213
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014
   Kiyozumi D, 2020, SCIENCE, V368, P1132, DOI 10.1126/science.aay5134
   Klein T, 2018, CHEM REV, V118, P261, DOI 10.1021/acs.chemrev.7b00120
   Kobayashi K, 2020, BIOL REPROD, V103, P223, DOI 10.1093/biolre/ioaa041
   Larasati T, 2020, BIOL REPROD, V103, P254, DOI 10.1093/biolre/ioaa060
   Lerner RA, 2017, ANGEW CHEM INT EDIT, V56, P1164, DOI 10.1002/anie.201612143
   Ma PX, 2019, ANGEW CHEM INT EDIT, V58, P9254, DOI 10.1002/anie.201901485
   Mannocci L, 2010, BIOCONJUGATE CHEM, V21, P1836, DOI 10.1021/bc100198x
   Neri D, 2017, CHEMBIOCHEM, V18, P827, DOI 10.1002/cbic.201700130
   Nutescu EA, 2004, ANN PHARMACOTHER, V38, P99, DOI 10.1345/aph.1D066
   OKAMOTO S, 1981, BIOCHEM BIOPH RES CO, V101, P440, DOI 10.1016/0006-291X(81)91279-1
   Satz AL, 2015, BIOCONJUGATE CHEM, V26, P1623, DOI 10.1021/acs.bioconjchem.5b00239
   Shang X, 2018, CELL MOL LIFE SCI, V75, P4371, DOI 10.1007/s00018-018-2878-9
   Shen CL, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.107086
   Straub A, 2011, ANGEW CHEM INT EDIT, V50, P4574, DOI 10.1002/anie.201004575
   Stress CJ, 2019, ANGEW CHEM INT EDIT, V58, P9570, DOI 10.1002/anie.201902513
   Wagner J, 1998, J MED CHEM, V41, P3664, DOI 10.1021/jm981013e
   Wang SJ, 2020, ACS CHEM BIOL, V15, P112, DOI 10.1021/acschembio.9b00654
   Yuen LH, 2019, J AM CHEM SOC, V141, P5169, DOI 10.1021/jacs.8b08039
   Zambaldo C, 2016, MEDCHEMCOMM, V7, P1340, DOI 10.1039/c6md00242k
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 37
TC 3
Z9 3
U1 5
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 21
PY 2020
VL 117
IS 29
BP 16782
EP 16789
DI 10.1073/pnas.2005447117
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MX8BZ
UT WOS:000557946500016
PM 32641511
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Song, YL
   Song, J
   Wei, XY
   Huang, MJ
   Sun, M
   Zhu, L
   Lin, BQ
   Shen, HC
   Zhu, Z
   Yang, CY
AF Song, Yanling
   Song, Jia
   Wei, Xinyu
   Huang, Mengjiao
   Sun, Miao
   Zhu, Lin
   Lin, Bingqian
   Shen, Haicong
   Zhu, Zhi
   Yang, Chaoyong
TI Discovery of Aptamers Targeting the Receptor-Binding Domain of the
   SARS-CoV-2 Spike Glycoprotein
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID SELECTION
AB The World Health Organization has declared the outbreak of a novel coronavirus (SARS-CoV-2 or 2019-nCoV) as a global pandemic. However, the mechanisms behind the coronavirus infection are not yet fully understood, nor are there any targeted treatments or vaccines. In this study, we identified high-binding-affinity aptamers targeting SARS-CoV-2 RBD, using an ACE2 competition-based aptamer selection strategy and a machine learning screening algorithm. The Kd values of the optimized CoV2-RBD-1C and CoV2-RBD-4C aptamers against RBD were 5.8 nM and 19.9 nM, respectively. Simulated interaction modeling, along with competitive experiments, suggests that two aptamers may have partially identical binding sites at ACE2 on SARS-CoV-2 RBD. These aptamers present an opportunity for generating new probes for recognition of SARS-CoV-2 and could provide assistance in the diagnosis and treatment of SARS-CoV-2 while providing a new tool for in-depth study of the mechanisms behind the coronavirus infection.
C1 [Song, Yanling; Wei, Xinyu; Huang, Mengjiao; Sun, Miao; Zhu, Lin; Lin, Bingqian; Shen, Haicong; Zhu, Zhi; Yang, Chaoyong] Xiamen Univ, Coll Chem & Chem Engn, Dept Chem Biol, State Key Lab Phys Chem Solid Surfaces,MOE Key La, Xiamen 361005, Peoples R China.
   [Song, Jia; Yang, Chaoyong] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Inst Mol Med, Shanghai 200127, Peoples R China.
RP Song, YL; Yang, CY (corresponding author), Xiamen Univ, Coll Chem & Chem Engn, Dept Chem Biol, State Key Lab Phys Chem Solid Surfaces,MOE Key La, Xiamen 361005, Peoples R China.; Yang, CY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Inst Mol Med, Shanghai 200127, Peoples R China.
EM ylsong@xmu.edu.cn; cyyang@xmu.edu.cn
RI yang, chaoyong/F-9741-2010; Song, Yanling/AAT-7783-2020; Zhu,
   Zhi/D-3721-2011
OI yang, chaoyong/0000-0002-2374-5342; Zhu, Zhi/0000-0002-3287-4920; Song,
   Yanling/0000-0002-6793-6685
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21735004, 21705024, 21874089]; Fundamental
   Research Funds for the Central UniversitiesFundamental Research Funds
   for the Central Universities [20720200041]; Innovative Research Team of
   High-level Local Universities in Shanghai [SSMU-ZLCX20180701]
FX We are grateful for the National Natural Science Foundation of China
   (21735004, 21705024, 21874089), the Fundamental Research Funds for the
   Central Universities (20720200041), and Innovative Research Team of
   High-level Local Universities in Shanghai (SSMU-ZLCX20180701) for their
   financial support.
CR Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Huang MJ, 2020, ANGEW CHEM INT EDIT, V59, P4800, DOI 10.1002/anie.201916039
   Kinghorn AB, 2016, ANAL CHEM, V88, P6981, DOI 10.1021/acs.analchem.6b01635
   Li FF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01565-6
   Liu M, 2017, ACCOUNTS CHEM RES, V50, P2273, DOI 10.1021/acs.accounts.7b00262
   Liu XG, 2018, NATURE, V559, P593, DOI 10.1038/s41586-018-0332-7
   Dao P, 2016, CELL SYST, V3, P62, DOI 10.1016/j.cels.2016.07.003
   Shen QL, 2013, ADV MATER, V25, P2368, DOI 10.1002/adma.201300082
   Song J, 2020, ANAL CHEM, V92, P3307, DOI 10.1021/acs.analchem.9b05203
   Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b
   Teng IT, 2018, J AM CHEM SOC, V140, P14314, DOI 10.1021/jacs.8b08645
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang LL, 2018, J AM CHEM SOC, V140, P18066, DOI 10.1021/jacs.8b10783
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 16
TC 9
Z9 9
U1 23
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD JUL 21
PY 2020
VL 92
IS 14
BP 9895
EP 9900
DI 10.1021/acs.analchem.0c01394
PG 6
WC Chemistry, Analytical
SC Chemistry
GA MT5BG
UT WOS:000554986200057
PM 32551560
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Frick, DN
   Virdi, RS
   Vuksanovic, N
   Dahal, N
   Silvaggi, NR
AF Frick, David N.
   Virdi, Rajdeep S.
   Vuksanovic, Nemanja
   Dahal, Narayan
   Silvaggi, Nicholas R.
TI Molecular Basis for ADP-Ribose Binding to the Mac1 Domain of SARS-CoV-2
   nsp3
SO BIOCHEMISTRY
LA English
DT Article
ID NONSTRUCTURAL PROTEINS; CHIKUNGUNYA VIRUS; CRYSTAL-STRUCTURE; STRUCTURAL
   BASIS; UNIQUE DOMAIN; ADRP DOMAIN; CORONAVIRUS; REPLICATION;
   MACRODOMAINS; COV
AB The virus that causes COVID-19, SARS-CoV-2, has a large RNA genome that encodes numerous proteins that might be targets for antiviral drugs. Some of these proteins, such as the RNA-dependent RNA polymerase, helicase, and main protease, are well conserved between SARS-CoV-2 and the original SARS virus, but several others are not. This study examines one of the proteins encoded by SARS-CoV-2 that is most different, a macrodomain of nonstructural protein 3 (nsp3). Although 26% of the amino acids in this SARS-CoV-2 macrodomain differ from those observed in other coronaviruses, biochemical and structural data reveal that the protein retains the ability to bind ADP-ribose, which is an important characteristic of beta coronaviruses and a potential therapeutic target.
C1 [Frick, David N.; Virdi, Rajdeep S.; Vuksanovic, Nemanja; Silvaggi, Nicholas R.] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53217 USA.
   [Dahal, Narayan] Univ Wisconsin, Dept Phys, Milwaukee, WI 53217 USA.
RP Frick, DN (corresponding author), Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53217 USA.
EM frickd@uwm.edu
OI Frick, David/0000-0002-2434-7223; Silvaggi, Nicholas/0000-0003-0576-0714
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 AI088001];
   National Science FoundationNational Science Foundation (NSF)
   [CHE-1903899]
FX This work was supported by National Institutes of Health Grant R01
   AI088001 (to D.N.F.) and National Science Foundation Grant CHE-1903899
   (to N.R.S.).
CR Abraham R, 2020, MBIO, V11, DOI 10.1128/mBio.03253-19
   Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   Alhammad YMO, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040384
   Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Cho CC, 2016, J BIOL CHEM, V291, P4894, DOI 10.1074/jbc.M115.700542
   Clabbers MTB, 2018, ACTA CRYSTALLOGR D, V74, P506, DOI 10.1107/S2059798318007726
   Claverie JM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060646
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Eckei L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41746
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Fehr AR, 2018, TRENDS MICROBIOL, V26, P598, DOI 10.1016/j.tim.2017.11.011
   Fehr AR, 2016, MBIO, V7, DOI 10.1128/mBio.01721-16
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Johnson MA, 2010, J MOL BIOL, V400, P724, DOI 10.1016/j.jmb.2010.05.027
   Keep S, 2018, J GEN VIROL, V99, P1097, DOI 10.1099/jgv.0.001098
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Leung AKL, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006864
   Li CQ, 2016, J VIROL, V90, P8478, DOI 10.1128/JVI.00705-16
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McPherson RL, 2017, P NATL ACAD SCI USA, V114, P1666, DOI 10.1073/pnas.1621485114
   Neuman BW, 2016, ANTIVIR RES, V135, P97, DOI 10.1016/j.antiviral.2016.10.005
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Piotrowski Y, 2009, PROTEIN SCI, V18, P6, DOI 10.1002/pro.15
   Potterton L, 2018, ACTA CRYSTALLOGR D, V74, P68, DOI 10.1107/S2059798317016035
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Serrano P, 2009, J VIROL, V83, P12998, DOI 10.1128/JVI.01253-09
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235
   Wojdyla JA, 2009, ACTA CRYSTALLOGR D, V65, P1292, DOI 10.1107/S0907444909040074
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu YY, 2009, J VIROL, V83, P1083, DOI 10.1128/JVI.01862-08
NR 45
TC 8
Z9 8
U1 8
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUL 21
PY 2020
VL 59
IS 28
BP 2608
EP 2615
DI 10.1021/acs.biochem.0c00309
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MT5FU
UT WOS:000554999100004
PM 32578982
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shigdel, UK
   Lee, SJ
   Sowa, ME
   Bowman, BR
   Robison, K
   Zhou, MY
   Pua, KH
   Stiles, DT
   Blodgett, JAV
   Udwary, DW
   Rajczewski, AT
   Mann, AS
   Mostafavi, S
   Hardy, T
   Arya, S
   Weng, ZG
   Stewart, M
   Kenyon, K
   Morgenstern, JP
   Pan, ED
   Gray, DC
   Pollock, RM
   Fry, AM
   Klausner, RD
   Townson, SA
   Verdine, GL
AF Shigdel, Uddhav K.
   Lee, Seung-Joo
   Sowa, Mathew E.
   Bowman, Brian R.
   Robison, Keith
   Zhou, Minyun
   Pua, Khian Hong
   Stiles, Dylan T.
   Blodgett, Joshua A., V
   Udwary, Daniel W.
   Rajczewski, Andrew T.
   Mann, Alan S.
   Mostafavi, Siavash
   Hardy, Tara
   Arya, Sukrat
   Weng, Zhigang
   Stewart, Michelle
   Kenyon, Kyle
   Morgenstern, Jay P.
   Pan, Ende
   Gray, Daniel C.
   Pollock, Roy M.
   Fry, Andrew M.
   Klausner, Richard D.
   Townson, Sharon A.
   Verdine, Gregory L.
TI Genomic discovery of an evolutionarily programmed modality for
   small-molecule targeting of an intractable surface
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE natural products; genome mining; FK506-binding protein
ID CENTROSOMAL PROTEIN C-NAP1; FKBP12-RAPAMYCIN COMPLEX; MAXIMAL AFFINITY;
   DRUG DISCOVERY; BINDING; IMMUNOPHILIN; RAPAMYCIN; CALCINEURIN;
   SEPARATION; CHEMISTRY
AB The vast majority of intracellular protein targets are refractory toward small-molecule therapeutic engagement, and additional therapeutic modalities are needed to overcome this deficiency. Here, the identification and characterization of a natural product, WDB002, reveals a therapeutic modality that dramatically expands the currently accepted limits of druggability. WDB002, in complex with the FK506-binding protein (FKBP12), potently and selectively binds the human centrosomal protein 250 (CEP250), resulting in disruption of CEP250 function in cells. The recognition mode is unprecedented in that the targeted domain of CEP250 is a coiled coil and is topologically featureless, embodying both a structural motif and surface topology previously considered on the extreme limits of "undruggability" for an intracellular target. Structural studies reveal extensive protein-WDB002 and protein-protein contacts, with the latter being distinct from those seen in FKBP12 ternary complexes formed by FK506 and rapamycin. Outward -facing structural changes in a bound small molecule can thus repro-gram FKBP12 to engage diverse, otherwise "undruggable" targets. The flat-targeting modality demonstrated here has the potential to expand the druggable target range of small-molecule therapeutics. As CEP250 was recently found to be an interaction partner with the Nsp13 protein of the SARS-CoV-2 virus that causes COVID-19 dis-ease, it is possible that WDB002 or an analog may exert useful antiviral activity through its ability to form high-affinity ternary complexes containing CEP250 and FKBP12.
C1 [Shigdel, Uddhav K.; Lee, Seung-Joo; Sowa, Mathew E.; Bowman, Brian R.; Robison, Keith; Zhou, Minyun; Pua, Khian Hong; Stiles, Dylan T.; Blodgett, Joshua A., V; Udwary, Daniel W.; Rajczewski, Andrew T.; Mann, Alan S.; Mostafavi, Siavash; Weng, Zhigang; Stewart, Michelle; Kenyon, Kyle; Morgenstern, Jay P.; Pan, Ende; Gray, Daniel C.; Pollock, Roy M.; Townson, Sharon A.; Verdine, Gregory L.] Warp Drive Bio Inc, Redwood City, CA 94063 USA.
   [Hardy, Tara; Arya, Sukrat; Fry, Andrew M.] Univ Leicester, Dept Mol & Cell Biol, Leicester LE1 7RH, Leics, England.
   [Klausner, Richard D.] Lyell Immunopharma, San Francisco, CA 94080 USA.
   [Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
   [Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
   [Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
   [Shigdel, Uddhav K.; Verdine, Gregory L.] LifeMine Therapeut, Cambridge, MA 02140 USA.
   [Lee, Seung-Joo] Beam Therapeut, Cambridge, MA 02139 USA.
   [Sowa, Mathew E.; Pollock, Roy M.] C4 Therapeut Inc, Suite 200, Watertown, MA 02472 USA.
   [Bowman, Brian R.] Inzen Therapeut, Cambridge, MA 02143 USA.
   [Robison, Keith; Stiles, Dylan T.; Kenyon, Kyle; Morgenstern, Jay P.; Gray, Daniel C.] Ginkgo Bioworks, Boston, MA 02210 USA.
   [Zhou, Minyun] Kronos Bio, Suite H, Cambridge, MA 02139 USA.
   [Pua, Khian Hong] ASTAR, P53 Lab P53Lab, Singapore 138648, Singapore.
   [Blodgett, Joshua A., V] Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.
   [Udwary, Daniel W.] Lawrence Berkeley Labs, DOE Joint Genome Inst, Walnut Creek, CA 94598 USA.
   [Rajczewski, Andrew T.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Mann, Alan S.] Agios Pharmaceut, Cambridge, MA 02139 USA.
   [Mostafavi, Siavash] Morph Therapeut, Waltham, MA 02451 USA.
   [Arya, Sukrat] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England.
   [Weng, Zhigang] Blueprint Med, Cambridge, MA 02142 USA.
   [Stewart, Michelle] Bristol Myers Squibb, Cambridge, MA 02142 USA.
   [Pan, Ende] Amgen Inc, Cambridge, MA 02141 USA.
   [Townson, Sharon A.] Kymera Therapeut, Cambridge, MA 02139 USA.
   [Verdine, Gregory L.] FogPharma, Cambridge, MA 02140 USA.
RP Verdine, GL (corresponding author), Warp Drive Bio Inc, Redwood City, CA 94063 USA.; Klausner, RD (corresponding author), Lyell Immunopharma, San Francisco, CA 94080 USA.; Verdine, GL (corresponding author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.; Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.; Verdine, GL (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.; Verdine, GL (corresponding author), LifeMine Therapeut, Cambridge, MA 02140 USA.; Verdine, GL (corresponding author), FogPharma, Cambridge, MA 02140 USA.
EM klausner.rick@gmail.com; gregory_verdine@harvard.edu
RI Blodgett, Joshua/AAW-8242-2020
OI Blodgett, Joshua/0000-0002-7080-5870; Udwary,
   Daniel/0000-0002-3491-0198; Shigdel, Uddhav/0000-0003-2259-3719
FU DOE Office of ScienceUnited States Department of Energy (DOE)
   [DE-AC02-06CH11357]; Michigan Technology Tri-Corridor [085P1000817]
FX This research used resources of the Advanced Photon Source, a US
   Department of Energy (DOE) Office of Science User Facility operated for
   the DOE Office of Science by Argonne National Laboratory under Contract
   DE-AC02-06CH11357. Use of the Life Sciences Collaborative Access Team
   Sector 21 was supported by the Michigan Economic Development Corporation
   and the Michigan Technology Tri-Corridor (Grant 085P1000817). We thank
   Proteros BioStructures GmbH for determining the structure.
CR Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343
   CALNE RY, 1989, LANCET, V2, P227
   Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273
   Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239
   CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940
   Dixon SJ, 2009, CURR OPIN CHEM BIOL, V13, P549, DOI 10.1016/j.cbpa.2009.08.003
   Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108
   Fehr T, 1996, J ANTIBIOT, V49, P230, DOI 10.7164/antibiotics.49.230
   Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563
   Fry AM, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00102
   Gatto GJ, 2006, J AM CHEM SOC, V128, P3838, DOI 10.1021/ja0587603
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299
   GOTO T, 1987, TRANSPLANT P, V19, P4
   GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5
   Hardy T, 2014, J CELL SCI, V127, P2493, DOI 10.1242/jcs.142331
   Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892
   Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6
   Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13
   Katz L, 2016, J IND MICROBIOL BIOT, V43, P155, DOI 10.1007/s10295-015-1723-5
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997
   Lipinski CA, 2016, ADV DRUG DELIVER REV, V101, P34, DOI 10.1016/j.addr.2016.04.029
   LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H
   Marz AM, 2013, MOL CELL BIOL, V33, P1357, DOI 10.1128/MCB.00678-12
   Mardin BR, 2013, DEV CELL, V25, P229, DOI 10.1016/j.devcel.2013.03.012
   Mardin BR, 2012, J CELL BIOL, V197, P11, DOI 10.1083/jcb.201108006
   Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837
   Mayor T, 2002, J CELL SCI, V115, P3275
   Motamedi H, 1998, EUR J BIOCHEM, V256, P528, DOI 10.1046/j.1432-1327.1998.2560528.x
   Mustafi SM, 2014, BIOCHEM J, V458, P525, DOI 10.1042/BJ20131429
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Panic M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005243
   PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974
   Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359-6446(05)03666-4
   SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815
   SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904
   Silkworth WT, 2012, MOL BIOL CELL, V23, P401, DOI 10.1091/mbc.E11-02-0095
   Stumpf MPH, 2008, P NATL ACAD SCI USA, V105, P6959, DOI 10.1073/pnas.0708078105
   THOMSON AW, 1989, LANCET, V2, P443
   Visweshwaran SP, 2018, EMBO J, V37, DOI 10.15252/embj.201797706
   WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
NR 42
TC 0
Z9 0
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 21
PY 2020
VL 117
IS 29
BP 17195
EP 17203
DI 10.1073/pnas.2006560117
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MR0OZ
UT WOS:000553294300016
PM 32606248
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pruijssers, AJ
   George, AS
   Schafer, A
   Leist, SR
   Gralinksi, LE
   Dinnon, KH
   Yount, BL
   Agostini, ML
   Stevens, LJ
   Chappell, JD
   Lu, XT
   Hughes, TM
   Gully, K
   Martinez, DR
   Brown, AJ
   Graham, RL
   Perry, JK
   Du Pont, V
   Pitts, J
   Ma, B
   Babusis, D
   Murakami, E
   Feng, JY
   Bilello, JP
   Porter, DP
   Cihlar, T
   Baric, RS
   Denison, MR
   Sheahan, TP
AF Pruijssers, Andrea J.
   George, Amelia S.
   Schafer, Alexandra
   Leist, Sarah R.
   Gralinksi, Lisa E.
   Dinnon, Kenneth H., III
   Yount, Boyd L.
   Agostini, Maria L.
   Stevens, Laura J.
   Chappell, James D.
   Lu, Xiaotao
   Hughes, Tia M.
   Gully, Kendra
   Martinez, David R.
   Brown, Ariane J.
   Graham, Rachel L.
   Perry, Jason K.
   Du Pont, Venice
   Pitts, Jared
   Ma, Bin
   Babusis, Darius
   Murakami, Eisuke
   Feng, Joy Y.
   Bilello, John P.
   Porter, Danielle P.
   Cihlar, Tomas
   Baric, Ralph S.
   Denison, Mark R.
   Sheahan, Timothy P.
TI Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV
   Expressing the SARS-CoV-2 RNA Polymerase in Mice
SO CELL REPORTS
LA English
DT Article
ID LENGTH INFECTIOUS CDNA; THERAPEUTIC-EFFICACY; ANTIVIRAL ACTIVITY;
   REVERSE GENETICS; STRUCTURAL BASIS; CORONAVIRUS; NUCLEOSIDE; GS-5734;
   VIRUS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 mu M). Weaker activity is observed in Vero E6 cells (EC50 = 1.65 mu M) because of their low capacity to metabolize RDV. To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase of SARS-CoV-2. In mice infected with the chimeric virus, therapeutic RDV administration diminishes lung viral load and improves pulmonary function compared with vehicle-treated animals. These data demonstrate that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clinical testing for treatment of COVID-19.
C1 [Pruijssers, Andrea J.; George, Amelia S.; Agostini, Maria L.; Stevens, Laura J.; Chappell, James D.; Lu, Xiaotao; Hughes, Tia M.; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   [Pruijssers, Andrea J.; George, Amelia S.; Agostini, Maria L.; Stevens, Laura J.; Chappell, James D.; Lu, Xiaotao; Hughes, Tia M.; Denison, Mark R.] Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN 37232 USA.
   [Schafer, Alexandra; Leist, Sarah R.; Gralinksi, Lisa E.; Dinnon, Kenneth H., III; Yount, Boyd L.; Gully, Kendra; Martinez, David R.; Brown, Ariane J.; Graham, Rachel L.; Baric, Ralph S.; Sheahan, Timothy P.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Dinnon, Kenneth H., III; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Perry, Jason K.; Du Pont, Venice; Pitts, Jared; Ma, Bin; Babusis, Darius; Murakami, Eisuke; Feng, Joy Y.; Bilello, John P.; Porter, Danielle P.; Cihlar, Tomas] Gilead Sci Inc, Foster City, CA 94404 USA.
   [Denison, Mark R.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.
RP Pruijssers, AJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.; Pruijssers, AJ (corresponding author), Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN 37232 USA.; Sheahan, TP (corresponding author), Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.
EM ardina.pruijssers@vumc.org; sheahan@email.unc.edu
RI Denison, Mark R/O-7258-2018; Sheahan, Timothy/J-8201-2019; Pruijssers,
   Andrea/S-5725-2018
OI Denison, Mark R/0000-0003-2655-0900; Sheahan,
   Timothy/0000-0001-9181-2183; Pruijssers, Andrea/0000-0001-7910-626X;
   Gralinski, Lisa/0000-0003-1374-8002
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [1U19AI142759, R01AI132178, R01AI132178-03S1,
   R01AI108197]; Burroughs Wellcome Fund Postdoctoral Enrichment Program
   awardBurroughs Wellcome Fund; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [DK065988];
   Cystic Fibrosis Foundation grant [BOUCHE15RO]; Dolly Parton COVID-19
   Research Fund; VUMC Office of Research; Elizabeth B. Lamb Center for
   Pediatric Research at Vanderbilt University;  [T32AI007151]
FX This project was funded in part by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, Department of Health
   and Human Services awards 1U19AI142759 (Antiviral Drug Discovery and
   Development Center) (to M.R.D. and R.S.B.), R01AI132178 and
   R01AI132178-03S1 (to T.P.S. and R.S.B.), and R01AI108197 (to M.R.D. and
   R.S.B.). D.R.M. was funded by T32AI007151 and a Burroughs Wellcome Fund
   Postdoctoral Enrichment Program award. The Marsico Lung Institute Tissue
   Procurement and Cell Culture Core is supported by NIH grant DK065988 and
   Cystic Fibrosis Foundation grant BOUCHE15RO. We also are grateful for
   support from the Dolly Parton COVID-19 Research Fund, the VUMC Office of
   Research, and the Elizabeth B. Lamb Center for Pediatric Research at
   Vanderbilt University. The graphical abstract was created with
   BioRender. We thank Dr. Natalie Thornburg at the Centers for Disease
   Control and Prevention in Atlanta, Georgia for providing the stock of
   SARS-CoV-2 used in this study. We thank VUMC and UNC Environmental
   Health and Safety personnel for ensuring that our work is performed
   safely and securely. We also thank Facilities Management personnel for
   tireless commitment to excellent facility performance and our grant
   management teams for administrative support of our research operations.
CR Adachi T, 2020, EMERG INFECT DIS, V26, P2157, DOI 10.3201/eid2609.201353
   Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bojkova D., 2020, BIORXIV, DOI [10.1101/2020.04.03.024257., DOI 10.1101/2020.04.03.024257]
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Eriksson S, 2013, CURR MED CHEM, V20, P4241
   Fulcher M Leslie, 2005, Methods Mol Med, V107, P183
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Koczor CA, 2012, EXPERT OPIN DRUG MET, V8, P665, DOI 10.1517/17425255.2012.680885
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Mehellou Y, 2018, J MED CHEM, V61, P2211, DOI 10.1021/acs.jmedchem.7b00734
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Mumtaz N, 2017, ANTIVIR RES, V146, P161, DOI 10.1016/j.antiviral.2017.09.004
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Sanders J.M., 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020., DOI 10.1001/JAMA.2020]
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sims AC, 2005, J VIROL, V79, P15511, DOI 10.1128/JVI.79.24.15511-15524.2005
   Stobart CC, 2013, J VIROL, V87, P12611, DOI 10.1128/JVI.02050-13
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Williamson Brandi N, 2020, bioRxiv, DOI 10.1101/2020.04.15.043166
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 58
TC 20
Z9 19
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUL 21
PY 2020
VL 32
IS 3
AR 107940
DI 10.1016/j.celrep.2020.107940
PG 15
WC Cell Biology
SC Cell Biology
GA MP2YW
UT WOS:000552075500032
PM 32668216
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rizk, JG
   Kalantar-Zadeh, K
   Mehra, MR
   Lavie, CJ
   Rizk, Y
   Forthal, DN
AF Rizk, John G.
   Kalantar-Zadeh, Kamyar
   Mehra, Mandeep R.
   Lavie, Carl J.
   Rizk, Youssef
   Forthal, Donald N.
TI Pharmaco-Immunomodulatory Therapy in COVID-19
SO DRUGS
LA English
DT Article
ID COLONY-STIMULATING FACTOR; ACUTE RESPIRATORY SYNDROME; MACROPHAGE
   ACTIVATION SYNDROME; CONVERTING ENZYME 2; CONVALESCENT PLASMA; REDUCED
   MORTALITY; GM-CSF; SARS; INFLAMMATION; INFECTION
AB The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of COVID-19. Systemic proinflammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival. Immune modulators have the potential to inhibit cytokines and treat the cytokine storm. A literature search using PubMed, Google Scholar, and ClinicalTrials.gov was conducted through 8 July 2020 using the search terms 'coronavirus', 'immunology', 'cytokine storm', 'immunomodulators', 'pharmacology', 'severe acute respiratory syndrome 2', 'SARS-CoV-2', and 'COVID-19'. Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-alpha (e.g. adalimumab, infliximab), granulocyte-macrophage colony-stimulating factors (e.g. gimsilumab, lenzilumab, namilumab), and convalescent plasma, with promising to negative trials and other data. Non-specific immune modulators include human immunoglobulin, corticosteroids such as dexamethasone, interferons, statins, angiotensin pathway modulators, macrolides (e.g. azithromycin, clarithromycin), hydroxychloroquine and chloroquine, colchicine, and prostaglandin D2 modulators such as ramatroban. Dexamethasone 6 mg once daily (either by mouth or by intravenous injection) for 10 days may result in a reduction in mortality in COVID-19 patients by one-third for patients on ventilators, and by one-fifth for those receiving oxygen. Research efforts should focus not only on the most relevant immunomodulatory strategies but also on the optimal timing of such interventions to maximize therapeutic outcomes. In this review, we discuss the potential role and safety of these agents in the management of severe COVID-19, and their impact on survival and clinical symptoms.
C1 [Rizk, John G.] Arizona State Univ, Edson Coll, Phoenix, AZ 85004 USA.
   [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, Div Nephrol Hypertens & Kidney Transplantat, Irvine, CA 92717 USA.
   [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
   [Kalantar-Zadeh, Kamyar] Tibor Rubin VA Long Beach Healthcare Syst, Long Beach, CA USA.
   [Mehra, Mandeep R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Mehra, Mandeep R.] Harvard Med Sch, Boston, MA 02115 USA.
   [Lavie, Carl J.] Univ Queensland, Sch Med, Ochsner Clin Sch, John Ochsner Heart & Vasc Inst, New Orleans, LA USA.
   [Rizk, Youssef] Amer Univ Beirut, Dept Family Med, Med Ctr, Beirut, Lebanon.
   [Forthal, Donald N.] Univ Calif Irvine, Sch Med, Dept Med, Div Infect Dis, Irvine, CA 92717 USA.
   [Forthal, Donald N.] Univ Calif Irvine, Sch Med, Dept Mol Biol & Biochem, Irvine, CA 92717 USA.
RP Rizk, JG (corresponding author), Arizona State Univ, Edson Coll, Phoenix, AZ 85004 USA.
EM john.rizk@lau.edu
OI Rizk, John/0000-0002-5216-8695; Kalantar-Zadeh,
   Kamyar/0000-0002-8666-0725
CR Abrams EM, 2019, PEDIAT ALLER IMM PUL, V32, P78, DOI 10.1089/ped.2019.1043
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   [Anonymous], 2020, REG NARR PHAS 3 KEVZ
   [Anonymous], 2020, LOW COST DEXAMETHASO
   [Anonymous], 2019, JAK PACK INS
   [Anonymous], 2018, OL PACK INS
   [Anonymous], 2017, KEVZ PACK INS
   [Anonymous], 2019, COR DIS 2019 COVID 1
   [Anonymous], 2009, COLCR PACK INS
   [Anonymous], 2020, LETT REVOKING EUA CH
   Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bermejo-Martin JF, 2009, J INFECT DEV COUNTR, V3, P159, DOI 10.3855/jidc.18
   Bhattacharya P, 2015, J INTERF CYTOK RES, V35, P585, DOI 10.1089/jir.2014.0149
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Bonam SR, 2020, AUTOPHAGY, V16, P2260, DOI 10.1080/15548627.2020.1779467
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Centers for Disease Control, HEALTHC PROF FREQ AS
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang Y, 2015, CLIN EXP IMMUNOL, V179, P137, DOI 10.1111/cei.12467
   Chen LN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228391
   Cure MC, 2020, CLIN RHEUMATOL, V39, P2101, DOI 10.1007/s10067-020-05144-x
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Curfman G, 2020, JAMA-J AM MED ASSOC, V324, P177, DOI 10.1001/jama.2020.11401
   Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397
   De Santo C, 2008, J CLIN INVEST, V118, P4036, DOI 10.1172/JCI36264
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Elli EM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01186
   Farkas J., INTERNET BOOK CRITIC
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Franchimont D, 2002, NEUROIMMUNOMODULAT, V10, P247, DOI 10.1159/000069969
   Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039
   Gaspari V, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106023
   Gasparyan AY, 2015, EXPERT OPIN DRUG MET, V11, P1781, DOI 10.1517/17425255.2015.1076391
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gendelman O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102566
   Gerriets V, 2020, TUMOR NECROSIS FACTO
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Gupta A, 2020, PROSTAGLANDIN D2 MED
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Herold S, 2014, AM J RESP CRIT CARE, V189, P609, DOI 10.1164/rccm.201311-2041LE
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
   Hylands M, 2017, CAN J ANESTH, V64, P703, DOI 10.1007/s12630-017-0877-1
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishaqui AA, 2020, EXPERT REV RESP MED, V14, P533, DOI 10.1080/17476348.2020.1730180
   Ishizuka T, 2004, CARDIOVASC DRUG REV, V22, P71
   Jorgensen SCJ, 2020, PHARMACOTHERAPY, V40, P843, DOI 10.1002/phar.2438
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kaly L, 2012, BEST PRACT RES CL RH, V26, P157, DOI 10.1016/j.berh.2012.01.001
   Kawamura K, 2018, INT J ANTIMICROB AG, V51, P918, DOI 10.1016/j.ijantimicag.2018.02.009
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuo CH, 2019, J MICROBIOL IMMUNOL, V52, P872, DOI 10.1016/j.jmii.2019.10.001
   Kupczyk M, 2017, DRUGS, V77, P1281, DOI 10.1007/s40265-017-0777-2
   Lala A, 2020, J AM COLL CARDIOL, V76, P533, DOI 10.1016/j.jacc.2020.06.007
   Lee N, 2017, ANTIVIR RES, V144, P48, DOI 10.1016/j.antiviral.2017.05.008
   Lefebvre Ashley L, 2016, R I Med J (2013), V99, P19
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Lokugamage Kumari G, 2020, bioRxiv, DOI 10.1101/2020.03.07.982264
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1252
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Matute-Bello G, 2000, CRIT CARE MED, V28, P1, DOI 10.1097/00003246-200001000-00001
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mindt BC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00840
   Monteagudo Luke Adam, 2020, ACR Open Rheumatol, V2, P276, DOI 10.1002/acr2.11135
   Monton C, 1999, EUR RESPIR J, V14, P218, DOI 10.1034/j.1399-3003.1999.14a37.x
   National Health Commission and State Administration of Traditional Chinese Medicine, DIAGN TREATM PROT NO
   National Research Council (US) Committee on New Directions in the Study of Antimicrobial Therapeutics: New Classes of Antimicrobials; National Research Council (US) Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation, 2006, TREAT INF DIS MICR W
   Ng KHL, 2005, POSTGRAD MED J, V81, DOI 10.1136/pgmj.2004.030049
   Nguyen AA, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108459
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Overgaard CE, 2015, AM J PHYSIOL-LUNG C, V308, pL1212, DOI 10.1152/ajplung.00042.2014
   Paine R, 2012, CRIT CARE MED, V40, P90, DOI 10.1097/CCM.0b013e31822d7bf0
   Presneill JJ, 2002, AM J RESP CRIT CARE, V166, P138, DOI 10.1164/rccm.2009005
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Rodrigo C, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub2
   Rodriguez Y, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102506
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Rosler Barbara, 2016, Mol Cell Pediatr, V3, P29, DOI 10.1186/s40348-016-0055-5
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014
   Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23
   Schulert GS, 2015, ANNU REV MED, V66, P145, DOI 10.1146/annurev-med-061813-012806
   Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Swedish Orphan Biovitrum AB, 2018, KIN AN INJ SOL PRESC
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Tikellis C, 2011, CURR OPIN NEPHROL HY, V20, P62, DOI 10.1097/MNH.0b013e328341164a
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Trabanelli S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00678-2
   Troeman DPR, 2013, J INFECTION, V67, P93, DOI 10.1016/j.jinf.2013.04.015
   Umapathi T, 2004, J NEUROL, V251, P1227, DOI 10.1007/s00415-004-0519-8
   Villar Jesus, 2020, Crit Care Explor, V2, pe0111, DOI 10.1097/CCE.0000000000000111
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wang Y., 2020, EARLY LOW DOSE SHORT, DOI [10.1101/2020.03.06.20032342., DOI 10.1101/2020.03.06.20032342, 10.1101/2020.03.06. 20032342.]
   Webster NR, 2009, BRIT J ANAESTH, V103, P70, DOI 10.1093/bja/aep128
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
   Yuan X, 2014, BIOCHEM BIOPH RES CO, V446, P292, DOI 10.1016/j.bbrc.2014.02.091
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang Y, 2019, MICROBIOL IMMUNOL, V63, P343, DOI 10.1111/1348-0421.12726
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 155
TC 10
Z9 10
U1 9
U2 9
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD SEP
PY 2020
VL 80
IS 13
BP 1267
EP 1292
DI 10.1007/s40265-020-01367-z
EA JUL 2020
PG 26
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA NK8HT
UT WOS:000551013900001
PM 32696108
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Waters, L
   Rockstroh, JK
AF Waters, L.
   Rockstroh, J. K.
TI COVID-19 research: an opinion piece
SO HIV MEDICINE
LA English
DT Article
DE antiretroviral; COVID; COVID-19; HIV; hydroxychloroquine
ID HYDROXYCHLOROQUINE
AB The unprecedented global scale of COVID-19 globally has triggered a race to discover interventions to reduce associated morbidity and mortality and rapid release of research findings prior to any degree of critical review. As with previous novel infection outbreaks, antiretrovirals are just one drug class that has been held up as a potential strategy for prophylaxis and treatment with scant evidence and risk of harm. Here we summarize the evidence for antiretrovirals to treat COVID-19 and, as a drug that has also been studied in HIV, hydroxychloroquine, and flag some of the pitfalls of using therapies that have not been evaluated robustly.
C1 [Waters, L.] Cent North West London NHS Trust, Dept HIV & Sexual Hlth, Mortimer Market Ctr, London, England.
   [Rockstroh, J. K.] Univ Klinikum Bonn, Dept Med, Bonn, Germany.
RP Waters, L (corresponding author), Cent North West London NHS Trust, Dept HIV & Sexual Hlth, Mortimer Market Ctr, London, England.
EM lwaters@nhs.net
CR Baldelli S, 2020, J ANTIMICROB CHEMOTH, V75, P2704, DOI 10.1093/jac/dkaa190
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2016638, DOI 10.1056/NEJM0A2016638]
   Bruce R, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0631-5
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cattaneo D, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104898
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Cohen MS, 2020, NEW ENGL J MED, V383, P585, DOI 10.1056/NEJMe2020388
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   Del Amo J, 2020, INCIDENCE SEVERITY C, DOI [10.7326/M20-3689, DOI 10.7326/M20-3689]
   Elfiky AA, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117715
   Farha MA, 2019, NAT MICROBIOL, V4, P565, DOI 10.1038/s41564-019-0357-1
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gervasoni Cristina, 2020, Clin Infect Dis, V71, P2276, DOI 10.1093/cid/ciaa579
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Li Y, EXPLORATORY RANDOMIZ
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Melchjorsen J, 2011, JAIDS-J ACQ IMM DEF, V57, P265, DOI 10.1097/QAI.0b013e3182185276
   Million M, EARLY TREATMENT COVI, DOI [10.1016/j.tmaid.2020.101738, DOI 10.1016/J.TMAID.2020.101738]
   Nguyen LS, 2020, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.120.048238, DOI 10.1161/CIRCULATI0NAHA.120.048238]
   Owens B, 2020, LANCET RHEUMATOL, V2, pE257, DOI 10.1016/S2665-9913(20)30089-8
   Paton NI, 2012, JAMA-J AM MED ASSOC, V308, P353, DOI 10.1001/jama.2012.6936
   Ramirez D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040525
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rojek A, 2017, LANCET INFECT DIS, V17, pE280, DOI 10.1016/S1473-3099(17)30234-7
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD SEP
PY 2020
VL 21
IS 8
BP 536
EP 540
DI 10.1111/hiv.12913
EA JUL 2020
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA MX4RS
UT WOS:000550666900001
PM 32544304
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Khan, MA
   Mahmud, S
   Ul Alam, ASMR
   Rahman, ME
   Ahmed, F
   Rahmatullah, M
AF Khan, Md Arif
   Mahmud, Shafi
   Ul Alam, A. S. M. Rubayet
   Rahman, Md Ekhtiar
   Ahmed, Firoz
   Rahmatullah, Mohammed
TI Comparative molecular investigation of the potential inhibitors against
   SARS-CoV-2 main protease: a molecular docking study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; anti-viral drugs; drug discovery; epirubicin;
   vapreotida; saquinavir
ID FORCE-FIELD; LOPINAVIR/RITONAVIR; PARAMETERIZATION
AB Recent outbreak of novel coronavirus and its rapid pandemic escalation in all over the world has drawn the attention to urgent need for effective drug development. However, due to prolonged vaccine and drug development procedure against a newly emerged devastating SARS-CoV-2 virus pathogen, repurposing of existing potential pertinent drug molecules would be preferable strategy to reduce mortality immediately and further development of new drugs to combat overall global Covid-19 crisis in all over the world. Herein, we have filtered 23 prospective drug candidates through literature review. Assessing evidences from molecular docking studies, it was clearly seen that, Epirubicin, Vapreotida, and Saquinavir exhibited better binding affinity against SARS-CoV-2 Main Protease than other drug molecules among the 23 potential inhibitors. However, 50 ns molecular dynamics simulation indicated the less mobile nature of the docked complex maintaining structural integrity. Our overall prediction findings indicate that Epirubicin, Vapreotida, and Saquinavir may inhibit COVID-19 by synergistic interactions in the active cavity and those results can pave the way in drug discovery although it has to be further validated by in-vitro and in-vivo investigations. Communicated by Ramaswamy H. Sarma
C1 [Khan, Md Arif; Rahmatullah, Mohammed] Univ Dev Alternat, Dept Biotechnol & Genet Engn, Dhaka 1209, Bangladesh.
   [Mahmud, Shafi; Rahman, Md Ekhtiar] Univ Rajshahi, Dept Genet Engn & Biotechnol, Rajshahi, Bangladesh.
   [Ul Alam, A. S. M. Rubayet] Jashore Univ Sci & Technol, Dept Microbiol, Jashore, Bangladesh.
   [Ahmed, Firoz] Noakhali Sci & Technol Univ, Dept Microbiol, Noakhali, Bangladesh.
RP Rahmatullah, M (corresponding author), Univ Dev Alternat, Dept Biotechnol & Genet Engn, Dhaka 1209, Bangladesh.
EM rahamatm@hotmail.com
RI khan, Arif/ABC-4514-2020
OI khan, Arif/0000-0002-7329-0366; Mahmud, shafi/0000-0003-1604-8626
CR Accelrys Software Inc, 2012, DISC STUD MOD ENV RE
   Bappy SS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1726815
   Battegay M., 2020, SWISS MED WKLY, V150, P1
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Cherian Sarah S, 2020, Indian J Med Res, V151, P160, DOI 10.4103/ijmr.IJMR_585_20
   Chien Minchen, 2020, bioRxiv, DOI 10.1101/2020.03.18.997585
   DASH R, 2019, J MOL MODEL, V25, DOI DOI https://doi.org/10.1007/s00894-019-3979-6
   DeLano W.L., 2002, PYMOL MOL GRAPH SYST, DOI [10.1038/hr.2014.17, DOI 10.1038/HR.2014.17]
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Feng Q, 2014, BIOMATERIALS, V35, P5028, DOI 10.1016/j.biomaterials.2014.03.012
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   HASAN MA, 2015, SOURCE CODE BIOL MED, V10, DOI DOI https://doi.org/10.1186/s13029-015-0037-3
   Hossain MU, 2016, COMPUT BIOL CHEM, V65, P29, DOI 10.1016/j.compbiolchem.2016.10.002
   Hossain MU, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3187647
   Islam MJ, 2019, COMPUT BIOL CHEM, V80, P31, DOI 10.1016/j.compbiolchem.2019.03.004
   Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Kirchdoerfer RN, 2020, J BIOL CHEM, V295, P4780, DOI 10.1074/jbc.H120.013397
   Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   MAHMUD S, 2019, J BIOMOL STRUCT 1022, DOI DOI https://doi.org/10.1080/07391102.2019.1680440
   MULLARD A, 2019, NAT REV DRUG DISCOV, V18, P243
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000
   Sethi A., 2019, DRUG DISCOVERY DEV N, P1, DOI DOI 10.5772/INTECHOPEN.85991
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v3, DOI 10.26434/CHEMRXIV.11871402.V3]
   Talele TT, 2010, CURR TOP MED CHEM, V10, P127, DOI 10.2174/156802610790232251
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu L, 2014, MOL MED REP, V9, P1345, DOI 10.3892/mmr.2014.1973
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zhang G., 2020, BIORXIV, DOI [10.1101/2020.03.19.999318, DOI 10.1101/2020.03.19.999318]
NR 40
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1796813
EA JUL 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MN6LC
UT WOS:000550949400001
PM 32696718
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Grippo, A
   Assenza, G
   Scarpino, M
   Broglia, L
   Cilea, R
   Galimberti, CA
   Lanzo, G
   Michelucci, R
   Tassi, L
   Vergari, M
   Di Lazzaro, V
   Mecarelli, O
AF Grippo, Antonello
   Assenza, Giovanni
   Scarpino, Maenia
   Broglia, Lidia
   Cilea, Rosalia
   Galimberti, Carlo Andrea
   Lanzo, Giovanni
   Michelucci, Roberto
   Tassi, Laura
   Vergari, Maurizio
   Di Lazzaro, Vincenzo
   Mecarelli, Oriano
CA SINC
   LICE
   AITN
TI Electroencephalography during SARS-CoV-2 outbreak: practical
   recommendations from the task force of the Italian Society of
   Neurophysiology (SINC), the Italian League Against Epilepsy (LICE), and
   the Italian Association of Neurophysiology Technologists (AITN)
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE EEG; COVID-19; Neurophysiology; Recommendations; Italy
AB Background During COVID-19 lockdown, non-urgent medical procedures were suspended. Grade of urgency of electroencephalography (EEG) may vary according to the clinical indication, setting, and status of infection of SARS-CoV-2 virus. "Italian Society of Clinical Neurophysiology" (SINC), "Italian League Against Epilepsy" (LICE), and the "Italian Association of Neurophysiology Technologists" (AITN) aimed to provide clinical and technical recommendation for EEG indications and recording standards in this pandemic era. Methods Presidents of SINC, LICE, and AITN endorsed three members per each society to formulate recommendations: classification of the degree of urgency of EEG clinical indications, management and behavior of physicians and neurophysiology technologists, hygiene and personal protection standards, and use of technical equipment. Results Scientific societies endorsed a paper conveying the recommendation for EEG execution in accordance with clinical urgency, setting (inpatients/outpatients), status of SARS-CoV-2 virus infection (positive, negative and uncertain), and phase of governmental restrictions (phase 1 and 2). Briefly, in phase 1, EEG was recommended only for those acute/subacute neurological symptoms where EEG is necessary for diagnosis, prognosis, or therapy. Outpatient examinations should be avoided in phase 1, while they should be recommended in urgent cases in phase 2 when they could prevent an emergency room access. Reduction of staff contacts must be encouraged through rescheduling job shifts. The use of disposable electrodes and dedicated EEG devices for COVID-19-positive patients are recommended. Conclusions During the different phases of COVID-19 pandemic, the EEG should be reserved for patients really benefiting from its execution in terms of diagnosis, treatment, prognosis, and avoidance of emergency room access.
C1 [Grippo, Antonello; Scarpino, Maenia; Lanzo, Giovanni] AOU Careggi, SODc Neurophysiopathol, Florence, Italy.
   [Grippo, Antonello; Scarpino, Maenia] IRCCS Don Carlo Gnocchi Fdn, Florence, Italy.
   [Assenza, Giovanni; Di Lazzaro, Vincenzo] Univ Campus Biomed Rome, Dept Med, Unit Neurol Neurophysiol Neurobiol, Via Alvaro del Fortino 200, I-00128 Rome, Italy.
   [Broglia, Lidia] San Filippo Neri Hosp, ASL Rome 1, UOC Neurol, Rome, Italy.
   [Cilea, Rosalia; Michelucci, Roberto] IRCSS Neurol Sci, Bologna, Italy.
   [Galimberti, Carlo Andrea] IRCCS Mondino Fdn, Pavia, Italy.
   [Tassi, Laura] ASST Niguarda Hosp, Claudio Munari Epilepsy Surg Ctr, Milan, Italy.
   [Vergari, Maurizio] Osped Maggiore, IRCCS Fdn Ca Granda, Milan, Italy.
   [Mecarelli, Oriano] Sapienza Univ Rome, Dept Human Neurosciencies, Rome, Italy.
RP Assenza, G (corresponding author), Univ Campus Biomed Rome, Dept Med, Unit Neurol Neurophysiol Neurobiol, Via Alvaro del Fortino 200, I-00128 Rome, Italy.
EM g.assenza@unicampus.it
OI Assenza, Giovanni/0000-0002-6160-4348
CR [Anonymous], NON EL MED SERV TREA
   [Anonymous], PPE EQ DIS PROC PAT
   Gruppo di Lavoro ISS Prevenzione e Controllo delle Infezioni, 2020, IND AD INT UT RAZ PR
   Haines S, 2020, NEURODIAGN J, V60
   Hurley D., NEUROLOGISTS RESPOND
   Klein BC, 2020, NEUROLOGY, V94, P903, DOI 10.1212/WNL.0000000000009494
   Ministero della Salute Italiano, 7422 MIN SAL IT
   Ministero della Salute Italiano, 7865 MIN SAL IT
   Sethi NK, 2020, CLIN NEUROPHYSIOL, V131, P1462, DOI 10.1016/j.clinph.2020.04.007
   WHO Library Cataloguing-in-Publication Data, 2009, WHO GUID HAND HYG HL
   World Health Organization, 2020, RAT US PERS PROT EQ
NR 11
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD SEP
PY 2020
VL 41
IS 9
BP 2345
EP 2351
DI 10.1007/s10072-020-04585-1
EA JUL 2020
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MY3NO
UT WOS:000551060300001
PM 32696088
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Berishvili, E
   Kaiser, L
   Cohen, M
   Berney, T
   Scholz, H
   Floisand, Y
   Mattsson, J
AF Berishvili, Ekaterine
   Kaiser, Laurent
   Cohen, Marie
   Berney, Thierry
   Scholz, Hanne
   Floisand, Yngvar
   Mattsson, Jonas
TI Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell
   Therapy
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
ID MESENCHYMAL STROMAL CELLS; IMMUNOMODULATORY PROPERTIES; T-CELLS; AMNION
AB Nearly 500'000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents - antiviral and anti-inflammatory molecules - have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease.
C1 [Berishvili, Ekaterine; Berney, Thierry] Univ Geneva, Cell Isolat & Transplantat Ctr, Sch Med, Geneva, Switzerland.
   [Berishvili, Ekaterine] Ilia State Univ, Inst Med & Publ Hlth Res, Tbilisi, Georgia.
   [Berishvili, Ekaterine] Ctr Med Univ Geneva, Cell Isolat & Transplantat Ctr, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.
   [Kaiser, Laurent] Univ Geneva Hosp, Virol Lab, Div Infect Dis, Geneva, Switzerland.
   [Kaiser, Laurent] Univ Geneva Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland.
   [Cohen, Marie] Univ Geneva, Dept Pediat Gynecol & Obstet, Sch Med, Geneva, Switzerland.
   [Berney, Thierry] Univ Geneva Hosp, Div Transplantat, Geneva, Switzerland.
   [Scholz, Hanne] Univ Oslo, Dept Transplant Med, Dept Cellular Therapy, Oslo, Norway.
   [Scholz, Hanne] Univ Oslo, Ctr Excellence, Inst Basic Med Sci, Oslo, Norway.
   [Floisand, Yngvar] Oslo Univ Hosp, Dept Hematol, Oslo, Norway.
   [Floisand, Yngvar] Oslo Univ Hosp, Ctr Canc Cell Reprogramming, Inst Canc Res, Oslo, Norway.
   [Mattsson, Jonas] Univ Toronto, Gloria & Seymour Epstein Chair Cell Therapy & Tra, Toronto, ON, Canada.
RP Berishvili, E (corresponding author), Univ Geneva, Cell Isolat & Transplantat Ctr, Sch Med, Geneva, Switzerland.; Berishvili, E (corresponding author), Ilia State Univ, Inst Med & Publ Hlth Res, Tbilisi, Georgia.; Berishvili, E (corresponding author), Ctr Med Univ Geneva, Cell Isolat & Transplantat Ctr, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.
EM ekaterine.berishvili@unige.ch
OI Scholz, Hanne/0000-0003-2755-4399
FU University of Geneva
FX Open access funding provided by University of Geneva.
CR Abumaree MH, 2017, PLACENTA, V59, P87, DOI 10.1016/j.placenta.2017.04.003
   Baker EK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026265
   Baygan A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00795
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bloch E. M., 2020, J CLIN INVESTIGATION
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cargnoni A, 2020, STEM CELL TRANSL MED, V9, P1023, DOI 10.1002/sctm.20-0068
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chrzanowski W, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00554
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Erkers T, 2015, STEM CELLS DEV, V24, P253, DOI 10.1089/scd.2014.0265
   Erkers T, 2013, STEM CELLS DEV, V22, P2596, DOI 10.1089/scd.2013.0079
   Fairbairn NG, 2014, J PLAST RECONSTR AES, V67, P662, DOI 10.1016/j.bjps.2014.01.031
   Farhadihosseinabadi B, 2018, ARTIF CELL NANOMED B, V46, P431, DOI 10.1080/21691401.2018.1458730
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Hao YX, 2000, CORNEA, V19, P348, DOI 10.1097/00003226-200005000-00018
   He F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197658
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horie S, 2018, J THORAC DIS, V10, P5607, DOI 10.21037/jtd.2018.08.28
   Hosier H, 2020, SARS COV 2 INFECTION, DOI [10.11 01/2020.04.30.20083907v3, DOI 10.1101/2020.04.30.20083907V3]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jabrane-Ferrat N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01397
   Karimi-Zarchi M, 2020, FETAL PEDIATR PATHOL, V39, P246, DOI 10.1080/15513815.2020.1747120
   Khoury M, 2020, EUROPEAN RESP J
   Lebreton F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12472-3
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li HC, 2005, INVEST OPHTH VIS SCI, V46, P900, DOI 10.1167/iovs.04-0495
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liau LL, 2020, CURR RES TRANSL MED, V68, P5, DOI 10.1016/j.retram.2019.09.001
   Magatti M, 2018, CELL TRANSPLANT, V27, P31, DOI 10.1177/0963689717742819
   Magatti M, 2017, J TISSUE ENG REGEN M, V11, P2895, DOI 10.1002/term.2193
   Malhotra A, 2020, STEM CELL TRANSL MED, V9, P289, DOI 10.1002/sctm.19-0251
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miki T, 2016, STEM CELL TRANSL MED, V5, P405, DOI 10.5966/sctm.2015-0304
   Motedayyen H, 2018, PLACENTA, V71, P31, DOI 10.1016/j.placenta.2018.06.008
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Olmos-Ortiz A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153654
   Peng ZJ, 2020, J INFECT PUBLIC HEAL, V13, P818, DOI 10.1016/j.jiph.2020.04.004
   RATAJCZAK MZ, 2020, LEUKEMIA 0601, DOI DOI 10.1038/S41375-020-0887-9
   RINGDEN O, 2014, J STEM CELL RES THER, V4, P244, DOI DOI 10.4172/2157-7633.1000244
   Ringden O, 2018, STEM CELL TRANSL MED, V7, P325, DOI 10.1002/sctm.17-0167
   Sadeghi B, 2019, BIOL BLOOD MARROW TR, V25, P1965, DOI 10.1016/j.bbmt.2019.05.034
   Saito S, 2010, AM J REPROD IMMUNOL, V63, P601, DOI 10.1111/j.1600-0897.2010.00852.x
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tan JL, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt542
   Umezawa A, 2019, PLACENTA, V84, P50, DOI 10.1016/j.placenta.2019.06.381
   Vacca P, 2015, IMMUNOL LETT, V168, P170, DOI 10.1016/j.imlet.2015.05.006
   Vosdoganes P, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.054
   Wilson A, 2019, REGEN MED, V14, P595, DOI 10.2217/rme-2018-0145
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yap JKY, 2020, J IMMUNOL, V205, P307, DOI 10.4049/jimmunol.2000513
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 56
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10004-x
EA JUL 2020
PG 8
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA MN7ES
UT WOS:000551008000001
PM 32696426
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU McCarthy, C
   Savinelli, S
   Feeney, ER
   Butler, MW
   O'Broin, C
   Ryan, S
   O'Neill, L
   Murphy, DJ
   Gallagher, CG
   McKone, EF
   Waqas, S
   Cotter, A
   Doran, P
   Keane, MP
   Mallon, PW
AF McCarthy, Cormac
   Savinelli, Stefano
   Feeney, Eoin R.
   Butler, Marcus W.
   O'Broin, Cathal
   Ryan, Silke
   O'Neill, Lorraine
   Murphy, David J.
   Gallagher, Charles G.
   McKone, Edward F.
   Waqas, Sarmad
   Cotter, Aoife
   Doran, Peter
   Keane, Michael P.
   Mallon, Patrick W.
TI Tocilizumab therapy in individuals with COVID-19 infection and
   hyperinflammatory state
SO RESPIROLOGY
LA English
DT Letter
DE autoimmune disease; COVID-19; pneumonia; viral infection
C1 [McCarthy, Cormac; Butler, Marcus W.; Ryan, Silke; Gallagher, Charles G.; McKone, Edward F.; Keane, Michael P.] St Vincents Univ Hosp, Dept Resp Med, Dublin, Ireland.
   [McCarthy, Cormac; Butler, Marcus W.; Ryan, Silke; Doran, Peter; Keane, Michael P.] Univ Coll Dublin, Sch Med, Dublin, Ireland.
   [Savinelli, Stefano; Feeney, Eoin R.; O'Broin, Cathal; Waqas, Sarmad; Mallon, Patrick W.] St Vincents Univ Hosp, Dept Infect Dis, Dublin, Ireland.
   [Savinelli, Stefano; Feeney, Eoin R.; O'Broin, Cathal; Cotter, Aoife; Mallon, Patrick W.] Univ Coll Dublin, CEPHR, Dublin, Ireland.
   [O'Neill, Lorraine] St Vincents Univ Hosp, Dept Rheumatol, Dublin, Ireland.
   [Murphy, David J.] St Vincents Univ Hosp, Dept Radiol, Dublin, Ireland.
RP McCarthy, C (corresponding author), Univ Coll Dublin, St Vincents Univ Hosp, Educ & Res Ctr, Dublin 4, Ireland.
EM cormac.mccarthy@ucd.ie
RI WAQAS, SARMAD/AAR-8090-2020
OI WAQAS, SARMAD/0000-0003-3929-5259; Doran, Peter/0000-0003-2064-5335;
   McCarthy, Cormac/0000-0003-2896-5210; Feeney, Eoin/0000-0003-4118-4945
CR Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Chen HL, 2019, FRONT MED-PRC, V13, P610, DOI 10.1007/s11684-019-0714-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Watanabe E, 2016, CASE REP MED, DOI 10.1155/2016/5656320
   Xu E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14803
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-7799
EI 1440-1843
J9 RESPIROLOGY
JI Respirology
PD OCT
PY 2020
VL 25
IS 10
BP 1090
EP 1094
DI 10.1111/resp.13912
EA JUL 2020
PG 5
WC Respiratory System
SC Respiratory System
GA NO1QD
UT WOS:000550660300001
PM 32696570
OA Green Published
DA 2021-01-01
ER

PT J
AU Hu, K
   Wang, MM
   Zhao, Y
   Zhang, YT
   Wang, T
   Zheng, ZS
   Li, XC
   Zeng, SL
   Zhao, D
   Li, HL
   Xu, K
   Lan, K
AF Hu, Ke
   Wang, Mengmei
   Zhao, Yang
   Zhang, Yunting
   Wang, Tao
   Zheng, Zhishui
   Li, Xiaochen
   Zeng, Shaolin
   Zhao, Dong
   Li, Honglin
   Xu, Ke
   Lan, Ke
TI A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an
   Open-Label Blank-Controlled Clinical Trial
SO VIROLOGICA SINICA
LA English
DT Article; Early Access
DE DHODH inhibitors; Leflunomide; Coronavirus disease 2019 (COVID-19);
   Viral shedding time; Inflammation
ID GS-5734; EBOLA
AB We recently reported that inhibitors against human dihydroorotate dehydrogenase (DHODH) have broad-spectrum antiviral activities including their inhibitory efficacies on SARS-CoV-2 replication in infected cells. However, there are limited data from clinical studies to prove the application of DHODH inhibitors in Coronavirus disease 2019 (COVID-19) patients. In the present study, we evaluated Leflunomide, an approved DHODH inhibitor widely used as a modest immune regulator to treat autoimmune diseases, in treating COVID-19 disease with a small-scale of patients. Cases of 10 laboratory-confirmed COVID-19 patients of moderate type with obvious opacity in the lung were included. Five of the patients were treated with Leflunomide, and another five were treated as blank controls without a placebo. All the patients accepted standard supportive treatment for COVID-19. The patients given Leflunomide had a shorter viral shedding time (median of 5 days) than the controls (median of 11 days,P = 0.046). The patients given Leflunomide also showed a significant reduction in C-reactive protein levels, indicating that immunopathological inflammation was well controlled. No obvious adverse effects were observed in Leflunomide-treated patients, and they all discharged from the hospital faster than controls. This preliminary study on a small-scale compassionate use of Leflunomide provides clues for further understanding of Leflunomide as a potential antiviral drug against COVID-19.
C1 [Hu, Ke; Wang, Mengmei; Zhao, Yang; Zhang, Yunting; Wang, Tao; Zheng, Zhishui; Li, Xiaochen; Zeng, Shaolin; Zhao, Dong] Wuhan Univ, Dept Resp & Crit Care Med, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Li, Honglin] East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Sch Pharm, Shanghai 200237, Peoples R China.
   [Xu, Ke; Lan, Ke] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Lan, Ke] Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Wuhan 430072, Peoples R China.
RP Hu, K (corresponding author), Wuhan Univ, Dept Resp & Crit Care Med, Renmin Hosp, Wuhan 430060, Peoples R China.; Li, HL (corresponding author), East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Sch Pharm, Shanghai 200237, Peoples R China.; Xu, K; Lan, K (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.; Lan, K (corresponding author), Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Wuhan 430072, Peoples R China.
EM huke-rmhospital@163.com; hlli@ecust.edu.cn; xuke03@whu.edu.cn;
   klan@whu.edu.cn
OI Hu, Ke/0000-0001-9862-7239
FU Science and Technology Key Project on Novel Coronavirus Pneumonia, Hubei
   Province [2020FCA002]; Application & Frontier Research Program of Wuhan
   Government [2019020701011463]; Taikang Insurance Group Co., Ltd; Beijing
   Taikang Yicai Foundation; Wuhan University
FX Respectful thanks to all patients and their families enrolled in this
   study. This study was supported by the Science and Technology Key
   Project on Novel Coronavirus Pneumonia, Hubei Province (project number:
   2020FCA002 to K.H.), and the Application & Frontier Research Program of
   Wuhan Government (2019020701011463 to K.X.). We are grateful to Taikang
   Insurance Group Co., Ltd, Beijing Taikang Yicai Foundation, and Special
   Fund for COVID-19 Research of Wuhan University for their great supports
   to this work. The funding agencies had no role in the study design and
   clinical medications; collection, analysis, and interpretation of the
   data; preparation, written, review, or approval of the manuscript.
CR [Anonymous], NHC DIAGN TREATM NOV
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Breedveld FC, 2000, ANN RHEUM DIS, V59, P841, DOI 10.1136/ard.59.11.841
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chowdhury MDS, 2020, ACAD EMERG MED, V27, P493, DOI 10.1111/acem.14005
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Fragoso YD, 2015, EXPERT REV CLIN PHAR, V8, P315, DOI 10.1586/17512433.2015.1019343
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kupferschmidt K., 2020, SCI MAGAZINE
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Singh A, 2017, EUR J MED CHEM, V125, P640, DOI 10.1016/j.ejmech.2016.09.085
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Xiong R., 2020, BIORXIV, DOI [10.1101/2020.03.11.983056, DOI 10.1101/2020.03.11.983056]
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
NR 21
TC 2
Z9 2
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-0769
EI 1995-820X
J9 VIROL SIN
JI Virol. Sin.
DI 10.1007/s12250-020-00258-7
EA JUL 2020
PG 9
WC Virology
SC Virology
GA MN7VF
UT WOS:000551050900003
PM 32696396
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Millar, C
   Campbell, S
   Fisher, P
   Hutton, J
   Morgan, A
   Cherry, MG
AF Millar, Chris
   Campbell, Sophie
   Fisher, Peter
   Hutton, Jane
   Morgan, Andrew
   Cherry, Mary Gemma
TI Cancer and COVID-19: Patients' and psychologists' reflections regarding
   psycho-oncology service changes
SO PSYCHO-ONCOLOGY
LA English
DT Letter
DE cancer; COVID-19; psycho-oncology; remote working
ID THERAPY
C1 [Millar, Chris; Fisher, Peter; Morgan, Andrew; Cherry, Mary Gemma] Univ Liverpool, Liverpool, England.
   [Millar, Chris; Campbell, Sophie; Fisher, Peter; Hutton, Jane; Morgan, Andrew; Cherry, Mary Gemma] Liverpool Univ Hosp NHS Fdn Trust, Liverpool, England.
RP Cherry, MG (corresponding author), Whelan Bldg,Brownlow Hill, Liverpool L69 3GB, Merseyside, England.
EM gcherry@liv.ac.uk
OI Millar, Chris/0000-0002-9869-6215
CR Cieslak K, 2013, REP PRACT ONCOL RADI, V18, P121, DOI 10.1016/j.rpor.2012.08.002
   Cluver JS, 2005, J TELEMED TELECARE, V11, P157, DOI 10.1258/1357633053688741
   Watson M, 2017, PSYCHO-ONCOLOGY, V26, P301, DOI 10.1002/pon.4338
   Watson M, 2013, PSYCHO-ONCOLOGY, V22, P1485, DOI 10.1002/pon.3194
NR 4
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD SEP
PY 2020
VL 29
IS 9
SI SI
BP 1402
EP 1403
DI 10.1002/pon.5461
EA JUL 2020
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
   Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA NL5YW
UT WOS:000550473400001
PM 32628330
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhu, SY
   Wang, J
   Wang, Y
   Chu, JG
   Liu, Y
   Chen, XQ
   Chen, XM
AF Zhu, Suyan
   Wang, Jian
   Wang, Yong
   Chu, Jinguo
   Liu, Yao
   Chen, Xueqin
   Chen, Xiaomin
TI QTc prolongation during antiviral therapy in two COVID-19 patients
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article
DE COVID-19; drug interactions; lopinavir; ritonavir; QTc interval
   prolongation
ID INTERVAL; RISK; POPULATION
AB What is known and objective Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19). Case description We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients. What is new and conclusion Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias.
C1 [Zhu, Suyan; Liu, Yao] Ningbo First Hosp, Dept Pharm, Ningbo, Zhejiang, Peoples R China.
   [Wang, Jian; Wang, Yong; Chen, Xiaomin] Ningbo First Hosp, Dept Cardiol, 59 Liuting St, Ningbo 315010, Zhejiang, Peoples R China.
   [Chu, Jinguo] Ningbo First Hosp, Dept Infect Dis, Ningbo, Zhejiang, Peoples R China.
   [Chen, Xueqin] Ningbo First Hosp, Dept Tradit Chinese Med, 59 Liuting St, Ningbo 315010, Zhejiang, Peoples R China.
RP Chen, XM (corresponding author), Ningbo First Hosp, Dept Cardiol, 59 Liuting St, Ningbo 315010, Zhejiang, Peoples R China.; Chen, XQ (corresponding author), Ningbo First Hosp, Dept Tradit Chinese Med, 59 Liuting St, Ningbo 315010, Zhejiang, Peoples R China.
EM cxq2316@163.com; chxmin@hotmail.com
CR Ajam M, 2019, CUREUS, V11, DOI 10.7759/cureus.3821
   Anson BD, 2005, LANCET, V365, P682, DOI 10.1016/S0140-6736(05)70936-3
   Benoit SR, 2005, EUR J CARDIOV PREV R, V12, P363, DOI 10.1097/01.hjr.0000173110.21851.a9
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704
   Heemskerk C. P. M., 2017, EUROPEAN J CLIN PHAR, V74, P183
   Hoorn EJ, 2010, AM J KIDNEY DIS, V56, P112, DOI 10.1053/j.ajkd.2009.11.019
   Knudsen AD, 2019, AIDS, V33, P2205, DOI 10.1097/QAD.0000000000002327
   Nordin C, 2006, J ELECTROCARDIOL, V39, P199, DOI 10.1016/j.jelectrocard.2005.09.001
   Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426
   Singh M, 2010, AM J THER, V17, pE193, DOI 10.1097/MJT.0b013e3181ad3437
   Sohaib SMA, 2008, J ELECTROCARDIOL, V41, P704, DOI 10.1016/j.jelectrocard.2008.01.010
   Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055
   Straus SMJM, 2006, J AM COLL CARDIOL, V47, P362, DOI 10.1016/j.jacc.2005.08.067
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 17
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD OCT
PY 2020
VL 45
IS 5
BP 1190
EP 1193
DI 10.1111/jcpt.13183
EA JUL 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK6ML
UT WOS:000550502300001
PM 32779770
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Faria, KM
   Gomes-Silva, W
   Kauark-Fontes, E
   Bonfim-Alves, CG
   Kowalski, LP
   Prado-Ribeiro, AC
   Vechiato, AJ
   Lopes, MA
   Marta, GN
   de Castro, G
   Leme, AFP
   Migliorati, CA
   Santos-Silva, AR
   Brandao, TB
AF Faria, Karina Morais
   Gomes-Silva, Wagner
   Kauark-Fontes, Elisa
   Bonfim-Alves, Carolina Guimaraes
   Kowalski, Luiz Paulo
   Prado-Ribeiro, Ana Carolina
   Vechiato-Filho, Aljomar Jose
   Lopes, Marcio Ajudarte
   Marta, Gustavo Nader
   de Castro Jr, Gilberto
   Paes Leme, Adriana Franco
   Migliorati, Cesar Augusto
   Santos-Silva, Alan Roger
   Brandao, Thais Bianca
TI Impact of pandemic COVID-19 outbreak on oral mucositis preventive and
   treatment protocols: new perspectives for extraoral photobiomodulation
   therapy
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE COVID-19; Oral mucositis; Cancer; Photobiomodulation therapy; Laser
   therapy
ID LASER
AB This communication discusses the current challenges of oral mucositis (OM) management during the pandemic COVID-19 outbreak and reflects about an extraoral photobiomodulation protocol as an optimal alternative for preventing and treating OM in advanced cancer patients while minimizing the risk of infection by avoiding intraoral manipulation.
C1 [Faria, Karina Morais; Gomes-Silva, Wagner; Bonfim-Alves, Carolina Guimaraes; Prado-Ribeiro, Ana Carolina; Vechiato-Filho, Aljomar Jose; Brandao, Thais Bianca] Inst Canc Estado Sao Paulo ICESP, Dent Oncol Serv, Sao Paulo, Brazil.
   [Gomes-Silva, Wagner] Nove de Julho Univ, Med Sch, UNINOVE, Sao Paulo, Brazil.
   [Kauark-Fontes, Elisa; Bonfim-Alves, Carolina Guimaraes; Prado-Ribeiro, Ana Carolina; Lopes, Marcio Ajudarte; Santos-Silva, Alan Roger] Univ Estadual Campinas, Piracicaba Dent Sch, Oral Diag Dept, UNICAMP, Piracicaba, Brazil.
   [Kowalski, Luiz Paulo] Univ Sao Paulo, Head & Neck Surg Dept, Med Sch, Sao Paulo, Brazil.
   [Kowalski, Luiz Paulo] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otcahinolaryngol, Sao Paulo, Brazil.
   [Marta, Gustavo Nader] Inst Canc Estado Sao Paulo ICESP, Div Radiat Oncol, Sao Paulo, Brazil.
   [Marta, Gustavo Nader] Hosp Sirio Libanes, Dept Radiat Oncol, Sao Paulo, Brazil.
   [de Castro Jr, Gilberto] Inst Canc Estado Sao Paulo ICESP, Dept Med Oncol, Sao Paulo, Brazil.
   [Paes Leme, Adriana Franco] Brazilian Biosci Natl Lab, CNPEM, LNBio, Campinas, SP, Brazil.
   [Migliorati, Cesar Augusto] Univ Florida, Coll Dent, Gainesville, FL USA.
RP Santos-Silva, AR (corresponding author), Univ Estadual Campinas, Piracicaba Dent Sch, Oral Diag Dept, UNICAMP, Piracicaba, Brazil.
EM alanroger@fop.unicamp.br
RI Santos-Silva, Alan Roger/B-6121-2008; Leme, Adriana F Paes/C-9679-2012;
   Brandao, Thais Bianca/H-4151-2018
OI Santos-Silva, Alan Roger/0000-0003-2040-6617; Leme, Adriana F
   Paes/0000-0001-7959-147X; Brandao, Thais Bianca/0000-0001-9128-3138
FU SAo Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2018/02233-6, 2018/23479-3]
FX The authors would like to gratefully acknowledge the financial support
   of the SAo Paulo Research Foundation (FAPESP) processes numbers
   2018/02233-6 and 2018/23479-3.
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   [Anonymous], ONC SAF INTR EXTR PH
   Arora H, 2008, ORAL SURG ORAL MED O, V105, P180, DOI 10.1016/j.tripleo.2007.07.043
   Brandao TB, 2018, SUPPORT CARE CANCER, V26, P2417, DOI 10.1007/s00520-018-4046-z
   Hodgson BD, 2012, SUPPORT CARE CANCER, V20, P1405, DOI 10.1007/s00520-011-1223-8
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Thorp HH, 2020, SCIENCE, V367, P1282, DOI 10.1126/science.abb7518
   Treister NS, 2016, PHOTOMED LASER SURG, V34, P178, DOI 10.1089/pho.2015.4021
   World Health Organization (WHO), 2020, INF PREV CONTR HEALT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zadik Y, 2019, SUPPORT CARE CANCER, V27, P3969, DOI 10.1007/s00520-019-04890-2
   Zecha JAEM, 2016, SUPPORT CARE CANCER, V24, P2781, DOI 10.1007/s00520-016-3152-z
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 17
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT
PY 2020
VL 28
IS 10
BP 4545
EP 4548
DI 10.1007/s00520-020-05636-1
EA JUL 2020
PG 4
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NL2KY
UT WOS:000551042700001
PM 32696245
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Darabi, R
   Li, Y
AF Darabi, Radbod
   Li, Yong
TI Stem cell therapies for COVID-19: Strategy and application
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE COVID-19; MSCs; Stem Cell Therapy
AB In this perspective, the potential application of stem cells for the treatment of COVID-19 related pneumonia and their potential mechanism of action have been overviewed.
C1 [Darabi, Radbod] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis, Ctr Stem Cell & Regenerat Med, McGovern Med Sch, Houston, TX 77030 USA.
   [Li, Yong] Western Michigan Univ, Homer Stryker MD Sch Med, Dept Orthopaed Surg, Kalamazoo, MI 49008 USA.
RP Li, Y (corresponding author), Western Michigan Univ, Homer Stryker MD Sch Med, Dept Orthopaed Surg, Kalamazoo, MI 49008 USA.; Darabi, R (corresponding author), Brown Fdn Inst Mol Med Prevent Human Dis, Ctr Stem Cell & Regenerat Med, McGovern Med Sch, 1825 Pressler St SRB 630C, Houston, TX 77030 USA.
EM radbod.darabi@uth.tmc.edu; Yong.li@med.wmich.edu
CR Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Herberts CA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-29
   Horak J, 2017, STEM CELLS INT, V2017, DOI [10.1155/2017/304121, 10.1155/2017/7304121]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Melief SM, 2013, HAEMATOLOGICA, V98, P888, DOI 10.3324/haematol.2012.078055
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sun ZW, 2018, J THORAC DIS, V10, P1084, DOI 10.21037/jtd.2018.01.46
   Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 11
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2020
VL 121
IS 12
BP 4696
EP 4698
DI 10.1002/jcb.29816
EA JUL 2020
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OC9YB
UT WOS:000550518500001
PM 32692858
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Brouns, SH
   Bruggemann, R
   Linkens, AEMJH
   Magdelijns, FJ
   Joosten, H
   Heijnen, R
   ten Cate-Hoek, AJ
   Schols, JMGA
   ten Cate, H
   Spaetgens, B
AF Brouns, Steffie H.
   Bruggemann, Renee
   Linkens, Aimee E. M. J. H.
   Magdelijns, Fabienne J.
   Joosten, Hanneke
   Heijnen, Ron
   ten Cate-Hoek, Arina J.
   Schols, Jos M. G. A.
   ten Cate, Hugo
   Spaetgens, Bart
TI Mortality and the Use of Antithrombotic Therapies Among Nursing Home
   Residents withCOVID-19
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE COVID-19; nursing home; older people; thromboembolic complications;
   mortality
AB BACKGROUND/OBJECTIVES Nursing home (NH) residents are a vulnerable population, susceptible to respiratory disease outbreaks such as coronavirus disease 2019 (COVID-19). Poor outcome in COVID-19 is at least partly attributed to hypercoagulability, resulting in a high incidence of thromboembolic complications. It is unknown whether commonly used antithrombotic therapies may protect the vulnerable NH population with COVID-19 against mortality. This study aimed to investigate whether the use of oral antithrombotic therapy (OAT) was associated with a lower mortality in NH residents with COVID-19. DESIGN A retrospective case series. SETTING FourteenNHfacilities from theNHorganization Envida, Maastricht, the Netherlands PARTICIPANTS A total of 101 NH residents with COVID-19 were enrolled. MEASUREMENTS The primary outcome was all-cause mortality. The association between age, sex, comorbidity, OAT, and mortality was assessed using logistic regression analysis. RESULTS Overall mortality was 47.5% in NH residents from 14 NH facilities. Age, comorbidity, and medication use were comparable among NH residents who survived and who died. OAT was associated with a lower mortality in NH residents with COVID-19 in the univariable analysis (odds ratio (OR) = 0.89; 95% confidence interval (CI) = 0.41-1.95). However, additional adjustments for sex, age, and comorbidity attenuated this difference. Mortality in males was higher compared with female residents (OR = 3.96; 95% CI = 1.62-9.65). Male residents who died were younger compared with female residents (82.2 (standard deviation (SD) = 6.3) vs 89.1 (SD = 6.8) years;P < .001). CONCLUSION NH residents in the 14 facilities we studied were severely affected by the COVID-19 pandemic, with a mortality of 47.5%. Male NH residents with COVID-19 had worse outcomes than females. We did not find evidence for any protection against mortality by OAT, necessitating further research into strategies to mitigate poor outcome of COVID-19 in vulnerable NH populations.
C1 [Brouns, Steffie H.; Bruggemann, Renee; Linkens, Aimee E. M. J. H.; Magdelijns, Fabienne J.; Joosten, Hanneke; Spaetgens, Bart] Maastricht Univ, Dept Internal Med, Div Gen Internal Med, Sect Geriatr Med,Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [Heijnen, Ron; Schols, Jos M. G. A.] Envida Care Org, Maastricht, Netherlands.
   [ten Cate-Hoek, Arina J.; ten Cate, Hugo] Maastricht Univ, Thrombosis Expert Ctr Maastricht, Med Ctr, Maastricht, Netherlands.
   [ten Cate-Hoek, Arina J.; ten Cate, Hugo] Maastricht Univ, Dept Internal Med, Med Ctr, Sect Vasc Med, Maastricht, Netherlands.
   [ten Cate-Hoek, Arina J.; ten Cate, Hugo] Cardiovasc Res Inst CARIM, Dept Biochem, Lab Clin Thrombosis & Hemostasis, Maastricht, Netherlands.
   [Schols, Jos M. G. A.] Maastricht Univ, Dept Hlth Serv Res, Caphri, Maastricht, Netherlands.
   [Schols, Jos M. G. A.] Maastricht Univ, Dept Family Med, Maastricht, Netherlands.
RP Spaetgens, B (corresponding author), Maastricht Univ, Dept Internal Med, Div Gen Internal Med, Sect Geriatr Med,Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM bartholomeus.spaetgens@mumc.nl
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hecker L, 2018, AM J PHYSIOL-LUNG C, V314, P1642, DOI 10.1152/ajplung.00275.2017
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Lowery EM, 2013, CLIN INTERV AGING, V8, P1489, DOI 10.2147/CIA.S51152
   Makan AM, 2017, J AM MED DIR ASSOC, V18, P1037, DOI 10.1016/j.jamda.2017.06.022
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Norman RE, 2020, J AM GERIATR SOC, V68, pE36, DOI 10.1111/jgs.16526
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Sun HY, 2020, J AM GERIATR SOC, V68, pE19, DOI 10.1111/jgs.16533
NR 16
TC 5
Z9 5
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD AUG
PY 2020
VL 68
IS 8
BP 1647
EP 1652
DI 10.1111/jgs.16664
EA JUL 2020
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA MZ2CQ
UT WOS:000550533400001
PM 32633418
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sultana, J
   Cutroneo, PM
   Crisafulli, S
   Puglisi, G
   Caramori, G
   Trifiro, G
AF Sultana, Janet
   Cutroneo, Paola Maria
   Crisafulli, Salvatore
   Puglisi, Gabriele
   Caramori, Gaetano
   Trifiro, Gianluca
TI Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical
   Evidence and Prescribing Guidelines
SO DRUG SAFETY
LA English
DT Article
ID QT-INTERVAL PROLONGATION; TORSADES-DE-POINTES; CARDIOVASCULAR EVENTS;
   SECONDARY PREVENTION; CARDIAC-ARRHYTHMIA; ORAL ERYTHROMYCIN; RISK;
   ANTIBIOTICS; MACROLIDES; MORTALITY
AB The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.
C1 [Sultana, Janet; Cutroneo, Paola Maria; Crisafulli, Salvatore; Puglisi, Gabriele; Caramori, Gaetano; Trifiro, Gianluca] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
RP Trifiro, G (corresponding author), Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
EM trifirog@unime.it
CR Agence nationale de securtite du medicament et des produits de sante, 2020, HYDR INF COR SARS CO
   Almalki ZS, 2014, AM HEALTH DRUG BENEF, V7, P318
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   [Anonymous], 2020, VENTR ARRH RISK DUE
   Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041
   Arellano-Rodrigo E, 2001, MED CLIN-BARCELONA, V117, P118, DOI 10.1016/S0025-7753(01)72036-2
   Baker WL, 2007, AM J HEALTH-SYST PH, V64, P830, DOI 10.2146/ajhp060539
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Chou HW, 2015, CLIN INFECT DIS, V60, P566, DOI 10.1093/cid/ciu914
   Cipriani A, 2020, INT J CARDIOL, V316, P280, DOI 10.1016/j.ijcard.2020.05.036
   Cramer CL, 2017, POSTGRAD MED, V129, P493, DOI 10.1080/00325481.2017.1285677
   CredibleMeds, 2020, REC RE COVID 19 TREA
   De Ponti F, 2000, EUR J CLIN PHARMACOL, V56, P1, DOI 10.1007/s002280050714
   Drici MD, 1998, JAMA-J AM MED ASSOC, V280, P1774, DOI 10.1001/jama.280.20.1774
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Europan Medicines Agency, 2020, GLOB REG STRESS NEED
   European Centre for Disease Prevention and Control, 2020, SIT UPD WORLDW
   Food and Drug Administration, 2013, FDA DRUG SAF COMM AZ
   Fossa AA, 2007, AM J TROP MED HYG, V77, P929, DOI 10.4269/ajtmh.2007.77.929
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerard A, 2020, THERAPIES, VS0040-5957, P30091
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Grayston JT, 2005, NEW ENGL J MED, V352, P1637, DOI 10.1056/NEJMoa043526
   HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Italian Medicines Agency (AIFA), 2020, HYDR TREATM COVID 19
   Kakeya H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091293
   Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Kim MH, 2005, PACE, V28, P1221, DOI 10.1111/j.1540-8159.2005.50146.x
   Koh TW, 2001, PACE, V24, P1575, DOI 10.1046/j.1460-9592.2001.01575.x
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Liverpul drug interactions group, 2020, INT EXP COVID 19 THE
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7
   Matsunaga Naohisa, 2003, N Z Med J, V116, pU666
   Mercuro NJ, 2019, JAMA CARDIOL, V2020, pe201834
   Metlay JP, 2019, ANN INTERN MED, V2020, pM20
   Milberg P, 2002, J PHARMACOL EXP THER, V303, P218, DOI 10.1124/jpet.102.037911
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Mortensen EM, 2014, JAMA-J AM MED ASSOC, V311, P2199, DOI 10.1001/jama.2014.4304
   National Institute for Health and Care Excellence (NICE), 2019, PNEUM COMM ACQ ANT P
   Owens RC, 2006, CLIN INFECT DIS, V43, P1603
   Pakhale S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002109.pub4
   Parnham MJ, 2014, PHARMACOL THERAPEUT, V143, P225, DOI 10.1016/j.pharmthera.2014.03.003
   Polgreen LA, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008074
   Poluzzi E, 2010, DRUG SAFETY, V33, P303, DOI 10.2165/11531850-000000000-00000
   Rao GA, 2014, ANN FAM MED, V12, P121, DOI 10.1370/afm.1601
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V12203, P1
   Russo Vincenzo, 2006, Acta Biomed, V77, P30
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Samarendra P, 2001, PACE, V24, P1572, DOI 10.1046/j.1460-9592.2001.01572.x
   Schachtele S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155649
   Shaffer D, 2002, CLIN INFECT DIS, V35, P197, DOI 10.1086/340861
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Svanstrom H, 2013, NEW ENGL J MED, V368, P1704, DOI 10.1056/NEJMoa1300799
   The National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID AN
   Thomsen MB, 2006, BRIT J PHARMACOL, V149, P1039, DOI 10.1038/sj.bjp.0706900
   Trac MH, 2016, CAN MED ASSOC J, V188, pE120, DOI 10.1503/cmaj.150901
   Trifiro G, 2017, CAN MED ASSOC J, V189, pE560, DOI 10.1503/cmaj.160355
   Tschida SJ, 1996, PHARMACOTHERAPY, V16, P663
   Vogt AW, 1997, ANESTH ANALG, V85, P1011, DOI 10.1097/00000539-199711000-00010
   WHO, 2020, WHO CLIN MAN SEV AC
   Yang ZJ, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.115.003560
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 71
TC 2
Z9 2
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD AUG
PY 2020
VL 43
IS 8
BP 691
EP 698
DI 10.1007/s40264-020-00976-7
EA JUL 2020
PG 8
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA MU1WY
UT WOS:000551081000001
PM 32696429
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Amat-Santos, IJ
   Santos-Martinez, S
   Lopez-Otero, D
   Nombela-Franco, L
   Gutierrez-Ibanes, E
   Del Valle, R
   Munoz-Garcia, E
   Jimenez-Diaz, VA
   Regueiro, A
   Gonzalez-Ferreiro, R
   Benito, T
   Sanmartin-Pena, XC
   Catala, P
   Rodriguez-Gabella, T
   Delgado-Arana, JR
   Carrasco-Moraleja, M
   Ibanez, B
   San Roman, JA
AF Amat-Santos, Ignacio J.
   Santos-Martinez, Sandra
   Lopez-Otero, Diego
   Nombela-Franco, Luis
   Gutierrez-Ibanes, Enrique
   Del Valle, Raquel
   Munoz-Garcia, Erika
   Jimenez-Diaz, Victor A.
   Regueiro, Ander
   Gonzalez-Ferreiro, Rocio
   Benito, Tomas
   Sanmartin-Pena, Xoan Carlos
   Catala, Pablo
   Rodriguez-Gabella, Tania
   Delgado-Arana, Jose Raul
   Carrasco-Moraleja, Manuel
   Ibanez, Borja
   San Roman, J. Alberto
TI Ramipril in High-Risk Patients With COVID-19
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE COVID-19; renin-angiotensin; SARS-CoV-2; transcatheter aortic valve
   replacement
ID ANGIOTENSIN-CONVERTING ENZYME-2; FUNCTIONAL RECEPTOR; CORONAVIRUS; SARS;
   INHIBITION; PNEUMONIA; ACE2
AB BACKGROUND Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory-syndrome coronavirus-2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2. This interaction has been proposed as a potential risk factor in patients treated with RAAS inhibitors. OBJECTIVES This study analyzed whether RAAS inhibitors modify the risk for COVID-19. METHODS The RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial is an ongoing randomized clinical trial randomly allocating subjects to ramipril or control groups after successful transcatheter aortic valve replacement at 14 centers in Spain. A non-prespecified interim analysis was performed to evaluate ramipril's impact on COVID-19 risk in this vulnerable population. RESULTS As of April 1, 2020, 102 patients (50 in the ramipril group and 52 in the control group) were included in the trial. Mean age was 82.3 +/- 6.1 years, 56.9% of the participants were male. Median time of ramipril treatment was 6 months (interquartile range: 2.9 to 11.4 months). Eleven patients (10.8%) have been diagnosed with COVID-19 (6 in control group and 5 receiving ramipril; hazard ratio: 1.150; 95% confidence interval: 0.351 to 3.768). The risk of COVID-19 was increased in older patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0.084), and more comorbidities according to Society of Thoracic Surgeons score (p = 0.065). Admission and oxygen supply was required in 4.9% of patients (2 in the ramipril group and 3 in the control group), and 4 of them died (2 in each randomized group). A higher body mass index was the only factor increasing the mortality rate (p = 0.039). CONCLUSIONS In a high-risk population of older patients with cardiovascular disease, randomization to ramipril had no impact on the incidence or severity of COVID-19. This analysis supports the maintenance of RAAS inhibitor treatment during the COVID-19 crisis. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185) (c) 2020 by the American College of Cardiology Foundation.
C1 [Amat-Santos, Ignacio J.; Santos-Martinez, Sandra; Catala, Pablo; Rodriguez-Gabella, Tania; Delgado-Arana, Jose Raul; Carrasco-Moraleja, Manuel; San Roman, J. Alberto] Hosp Clin Univ, Cardiol Dept, Ctr Invest Biomed Red Enfermedades Cardiovaculare, Valladolid, Spain.
   [Lopez-Otero, Diego; Sanmartin-Pena, Xoan Carlos] Hosp Clin Univ Santiago, CIBERCV, Santiago De Compostela, Spain.
   [Nombela-Franco, Luis] Hosp Clin San Carlos, Cardiovasc Inst, Inst Invest Sanitaria San Carlos, Madrid, Spain.
   [Gutierrez-Ibanes, Enrique] Hosp Gen Gregorio Maranon, CIBERCV, Madrid, Spain.
   [Gutierrez-Ibanes, Enrique] Univ Carlos III, Madrid, Spain.
   [Del Valle, Raquel] Hosp Univ Cent Asturias, Oviedo, Spain.
   [Munoz-Garcia, Erika] Hosp Virgen de la Victoria, CIBERCV, Malaga, Spain.
   [Jimenez-Diaz, Victor A.] Hosp Univ Vigo, Vigo, Spain.
   [Regueiro, Ander] Hosp Clin Univ, Barcelona, Spain.
   [Gonzalez-Ferreiro, Rocio] Hosp Clin Univ, Salamanca, Spain.
   [Benito, Tomas] Hosp Univ Leon, Leon, Spain.
   [Ibanez, Borja] IIS Hosp Fdn Jimenez Diaz, Ctr Nacl Invest Cardiovasc, CIBERCV, Madrid, Spain.
RP Amat-Santos, IJ (corresponding author), Hosp Clin Univ Valladolid, Cardiol Dept, Inst Ciencias Corazon, Ramon & Cajal 3, Valladolid 47005, Spain.
EM ijamat@gmail.com
RI Benito-Gonzalez, Tomas/Q-1686-2016; Ibanez, Borja/J-6993-2014
OI Benito-Gonzalez, Tomas/0000-0002-8428-9248; Ibanez,
   Borja/0000-0002-5036-254X; Santos-Martinez, Sandra/0000-0003-4244-6919;
   CARRASCO, MANUEL/0000-0002-7282-2367
FU Insituto de Salud Carlos IIIInstituto de Salud Carlos III [PI17/02237]
FX This project was supported by the Insituto de Salud Carlos III (grant
   PI17/02237). Dr. Amat-Santos has served as proctor for Boston
   Scientific. Dr. Nombela-Franco has served as a proctor for Abbott; and
   has received speaker honoraria from Edwards Lifesciences. All other
   authors have reported that they have no relationships relevant to the
   contents of this paper to disclose. Florian Rader, MD, MSc, served as
   Guest Associate Editor for this paper. P.K. Shah, MD, served as Guest
   Editor-in-Chief for this paper.
CR Amat-Santos IJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020255
   Bozkurt B, 2020, ACC NEWS STORY  0317
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Corman VM, 2019, INTERNIST, V60, P1136, DOI 10.1007/s00108-019-00671-5
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Patel AB, 2020, JAMA
   Puig-Domingo M, 2020, ENDOCRINE, V68, P2, DOI 10.1007/s12020-020-02294-5
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodriguez-Gabella T, 2019, J AM COLL CARDIOL, V74, P631, DOI 10.1016/j.jacc.2019.05.055
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang L, 2020, INFLAMMATION, V43, P1772, DOI 10.1007/s10753-020-01251-8
   World Health Organization, 2020, COR DIS 2019 SIT REP
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong JC, 2010, CIRCULATION, V122, P717, DOI 10.1161/CIRCULATIONAHA.110.955369
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 15
Z9 15
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JUL 21
PY 2020
VL 76
IS 3
BP 268
EP 276
DI 10.1016/j.jacc.2020.05.040
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MK5VE
UT WOS:000548854700005
PM 32470515
OA Green Published
DA 2021-01-01
ER

PT J
AU Koulgi, S
   Jani, V
   Uppuladinne, MVN
   Sonavane, U
   Joshi, R
AF Koulgi, Shruti
   Jani, Vinod
   Uppuladinne, Mallikarjunachari V. N.
   Sonavane, Uddhavesh
   Joshi, Rajendra
TI Remdesivir-bound and ligand-free simulations reveal the probable
   mechanism of inhibiting the RNA dependent RNA polymerase of severe acute
   respiratory syndrome coronavirus 2
SO RSC ADVANCES
LA English
DT Article
ID FEATURES; MODEL
AB The efforts towards developing a potential drug against the current global pandemic, COVID-19, have increased in the past few months. Drug development strategies to target the RNA dependent RNA polymerase (RdRP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are being tried worldwide. The gene encoding this protein, is known to be conserved amongst positive strand RNA viruses. This enables an avenue to repurpose the drugs designed against earlier reported inhibitors of RdRP. One such strong inhibitor is remdesivir which has been used against EBOLA infections. The binding of remdesivir to RdRP of SARS-CoV-2 has been studied using the classical molecular dynamics and ensemble docking approach. A comparative study of the simulations of RdRP in the apo and remdesivir-bound form revealed blocking of the template entry site in the presence of remdesivir. The conformation changes leading to this event were captured through principal component analysis. The conformational and thermodynamic parameters supported the experimental information available on the involvement of crucial arginine, serine and aspartate residues belonging to the conserved motifs in RdRP functioning. The catalytic site comprising of SER 759, ASP 760, and ASP 761 (SDD) was observed to form strong contacts with remdesivir. The significantly strong interactions of these residues with remdesivir may infer the latter's binding similar to the normal nucleotides thereby remaining unidentified by the exonuclease activity of RdRP. The ensemble docking of remdesivir too, comprehended the involvement of similar residues in interaction with the inhibitor. This information on crucial interactions between conserved residues of RdRP with remdesivir throughin silicoapproaches may be useful in designing inhibitors.
C1 [Koulgi, Shruti; Jani, Vinod; Uppuladinne, Mallikarjunachari V. N.; Sonavane, Uddhavesh; Joshi, Rajendra] Ctr Dev Adv Comp C DAC, High Performance Comp Med & Bioinformat Applicat, Pune, Maharashtra, India.
RP Joshi, R (corresponding author), Ctr Dev Adv Comp C DAC, High Performance Comp Med & Bioinformat Applicat, Pune, Maharashtra, India.
EM rajendra@cdac.in
OI Koulgi, Shruti/0000-0002-0709-7461
FU National Supercomputing Mission, Ministry of Electronics and Information
   Technology (MeitY), Government of India
FX The authors would like to acknowledge the National Supercomputing
   Mission, Ministry of Electronics and Information Technology (MeitY),
   Government of India for funding this work. The authors would like to
   thank the PARAM supercomputing facility and Bioinformatics Resources and
   Applications Facility (BRAF) for providing with the required computing
   infrastructure.
CR Alanagreh L, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050331
   Allen WJ, 2015, J COMPUT CHEM, V36, P1132, DOI 10.1002/jcc.23905
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132
   Buonaguro L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02355-3
   Case D.A., 2016, AMBER 2016
   Dassault Systemes BIOVIA, 2019, DASS SYST BIOVIA BIO
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ester M., 1996, P 2 INT C KNOWL DISC, P226, DOI DOI 10.1007/S10816-016-9307-X
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gaurav A, 2019, VIRAL POLYMERASES: STRUCTURES, FUNCTIONS, AND ROLES AS ANTIVIRAL DRUG TARGETS, P271, DOI 10.1016/B978-0-12-815422-9.00010-3
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Huang JS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041131
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Juan A., 2020, BIORXIV, DOI [10.1101/2020.06.21.163592, DOI 10.1101/2020.06.21.163592]
   Kaul Dinesh, 2020, Curr Med Res Pract, V10, P54, DOI 10.1016/j.cmrp.2020.04.001
   Khan Z, 2020, ADV THER, V37, P2575, DOI 10.1007/s12325-020-01351-9
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   KOULGI S, 2020, J BIOMOL STRUCT 0716, DOI DOI 10.26434/chemrxiv.12370172.v1
   Koulgi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1792344
   Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-01295-8
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Peters MB, 2010, J CHEM THEORY COMPUT, V6, P2935, DOI 10.1021/ct1002626
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Roe DR, 2018, J COMPUT CHEM, V39, P2110, DOI 10.1002/jcc.25382
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sayad B, 2020, ARCH MED RES, VS0188-4409, P30551, DOI DOI 10.1016/J.ARCMED.2020.04.018
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Vangone A, 2019, BIOINFORMATICS, V35, P1585, DOI 10.1093/bioinformatics/bty816
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhang LL, 2020, J PHYS CHEM B, V124, P6955, DOI 10.1021/acs.jpcb.0c04198
NR 50
TC 2
Z9 2
U1 4
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD JUL 20
PY 2020
VL 10
IS 45
BP 26792
EP 26803
DI 10.1039/d0ra04743k
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA MU4AF
UT WOS:000555612200024
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Uddin, MI
   Shah, SAA
   Al-Khasawneh, MA
AF Uddin, M. Irfan
   Shah, Syed Atif Ali
   Al-Khasawneh, Mahmoud Ahmad
TI A Novel Deep Convolutional Neural Network Model to Monitor People
   following Guidelines to Avoid COVID-19
SO JOURNAL OF SENSORS
LA English
DT Article
ID CHINA
AB COVID-19, a deadly disease that originated in Wuhan, China, has resulted in a global outbreak. Patients infected with the causative virus SARS-CoV-2 are placed in quarantine, so the virus does not spread. The medical community has not discovered any vaccine that can be immediately used on patients infected with SARS-CoV-2. The only method discovered so far to protect people from this virus is keeping a distance from other people, wearing masks and gloves, as well as regularly washing and sanitizing hands. Government and law enforcement agencies are involved in banning the movement of people in different cities, to control the spread and monitor people following the guidelines of the CDC. But it is not possible for the government to monitor all places, such as shopping malls, hospitals, government offices, and banks, and guide people to follow the safety guidelines. In this paper, a novel technique is developed that can guide people to protect themselves from someone who has high exposure to the virus or has symptoms of COVID-19, such as having fever and coughing. Different deep Convolutional Neural Networks (CNN) models are implemented to test the proposed technique. The proposed intelligent monitoring system can be used as a complementary tool to be installed at different places and automatically monitor people adopting the safety guidelines. With these precautionary measurements, humans will be able to win this fight against COVID-19.
C1 [Uddin, M. Irfan] Kohat Univ Sci & Technol, Kohat, Pakistan.
   [Shah, Syed Atif Ali] Northern Univ, Nowshehra, Pakistan.
   [Shah, Syed Atif Ali; Al-Khasawneh, Mahmoud Ahmad] Al Madinah Int Univ, Kuala Lumpur, Malaysia.
RP Uddin, MI (corresponding author), Kohat Univ Sci & Technol, Kohat, Pakistan.
EM irfanuddin@kust.edu.pk; atif@northern.edu.pk; mahmoud@outlook.my
OI Uddin, Irfan/0000-0002-1355-3881; Syed, ATIF/0000-0002-4275-9731
CR Abiyev RH, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/4168538
   Shah SAA, 2020, COMPLEXITY, V2020, DOI 10.1155/2020/5843932
   Alotaiby TN, 2019, J SENSORS, V2019, DOI 10.1155/2019/6751932
   Altun O, 2019, SCI PROGRAMMING-NETH, V2019, DOI 10.1155/2019/6501264
   Antonijevic M, 2020, J SENSORS, V2020, DOI 10.1155/2020/8767865
   Bai B, 2018, NEUROCOMPUTING, V286, P109, DOI 10.1016/j.neucom.2018.01.068
   Cai LJ, 2019, J SENSORS, V2019, DOI 10.1155/2019/4896862
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chithra RS, 2020, INT J IMAG SYST TECH, V30, P994, DOI 10.1002/ima.22427
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Fatima M., 2018, INT J ADV COMPUTER S, V9, P10, DOI [10.14569/IJACSA.2018.0910642-s2.0-85057214109, DOI 10.14569/IJACSA.2018.0910642-S2.0-85057214109]
   Gozes O, 2020, RAPID AI DEV CYCLE C
   He K., 2015, CORR
   Hu JP, 2019, J SENSORS, V2019, DOI 10.1155/2019/7174602
   Kashtriya V., 2019, INT J INNOVATIVE TEC, V8, P813, DOI [10.35940/ijitee.I1131.0789S192-s2.0-85073355538, DOI 10.35940/IJITEE.I1131.0789S192-S2.0-85073355538]
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Li L, 2020, RADIOLOGY, V296, pE65, DOI 10.1148/radiol.2020200905
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin JW, 2019, IEEE INT CONF COMP V, P1681, DOI 10.1109/ICCVW.2019.00208
   Liu JE, 2020, SCI PROGRAMMING-NETH, V2020, DOI 10.1155/2020/7607612
   Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2
   Lopez-Garnier S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212094
   Meraj S. S., 2019, INT J ENG ADV TECHNO, V9, P2270, DOI DOI 10.35940/IJEAT.A2632.109119
   Nash Will, 2018, npj Materials Degradation, V2, DOI 10.1038/s41529-018-0058-x
   Ng M-Y, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200034, DOI 10.1148/RYCT.2020200034]
   Pan W. D., 2018, MACHINE LEARNING ADV, DOI [10.5772/intechopen.72426, DOI 10.5772/INTECHOPEN.72426]
   Panicker RO, 2018, BIOCYBERN BIOMED ENG, V38, P691, DOI 10.1016/j.bbe.2018.05.007
   Peng W, 2019, SCI PROGRAMMING-NETH, V2019, DOI 10.1155/2019/2753152
   Poostchi M, 2018, TRANSL RES, V194, P36, DOI 10.1016/j.trsl.2017.12.004
   Qin ZZ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51503-3
   Rajaraman S, 2019, PEERJ, V7, DOI 10.7717/peerj.6977
   Samuel RDJ, 2019, NEURAL COMPUT APPL, V31, P1533, DOI 10.1007/s00521-018-3564-4
   Simonyan K., 2015, 14091556 ARXIV, P1, DOI DOI 10.1016/J.INFSOF.2008.09.005
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Tan XJ, 2020, SCI PROGRAMMING-NETH, V2020, DOI 10.1155/2020/7380790
   Tobore I, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/11966
   Uddin I., 2015, GSTF J COMPUTING JOC, V4, P21, DOI [10.7603/s40601-014-0021-9, DOI 10.7603/S40601-014-0021-9]
   Uddin I., 2018, INT J ADV COMPUTER S, V9, P9, DOI [10.14569/ijacsa.2018.090973, DOI 10.14569/IJACSA.2018.090973, 10.14569/IJACSA.2018.090973]
   Uddin I, 2017, INT J HIGH PERFORM C, V31, P152, DOI 10.1177/1094342015584495
   Uddin MI, 2020, COMPLEXITY, V2020, DOI 10.1155/2020/1373087
   Vijayalakshmi A, 2020, MULTIMED TOOLS APPL, V79, P15297, DOI 10.1007/s11042-019-7162-y
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L., 2020, COVID NET TAILORED D
   Xiong Y, 2018, J THORAC DIS, V10, P1936, DOI 10.21037/jtd.2018.01.91
   Xu X, 2020, DEEP LEARNING SYSTEM
   Zhu FB, 2020, SCI PROGRAMMING-NETH, V2020, DOI 10.1155/2020/5629090
NR 49
TC 2
Z9 2
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-725X
EI 1687-7268
J9 J SENSORS
JI J. Sens.
PD JUL 20
PY 2020
VL 2020
AR 8856801
DI 10.1155/2020/8856801
PG 15
WC Engineering, Electrical & Electronic; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA MZ4CW
UT WOS:000559070400001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shah, SO
   Dharia, R
   Stazi, J
   DePrince, M
   Rosenwasser, RH
AF Shah, Syed Omar
   Dharia, Robin
   Stazi, Jaime
   DePrince, Maureen
   Rosenwasser, Robert H.
TI Rapid Decline in Telestroke Consults in the Setting of COVID-19
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; stroke; telestroke; telemedicine
AB Background and Purpose:As coronavirus disease 2019 (COVID-19) continues to be a global pandemic, there is a growing body of evidence suggesting that incidence of diseases that require emergent care, particularly myocardial infarction and ischemic stroke, has declined rapidly. The objective of this study is to quantify our experience of telestroke (TS) consults at a large tertiary comprehensive stroke center during the COVID-19 pandemic. Methods:We retrospectively reviewed TS consults of patients presenting to our neuroscience network. Those with a confirmed diagnosis of acute ischemic stroke or transient ischemia attack were included. Data were compared from April 1, 2019, to June 30, 2020, which include consults prepandemic and during the crisis. Results:A total of 1,982 TS consults were provided in 1 year. Prepandemic, the mean monthly consults were 148. In April 2020, only 59 patients were seen (49% decline). Mobile stroke unit consults decreased by 72% in the same month. The 30-day moving average of patients seen per day was between five and six prepandemic declined to between two and three in April, and then began to uptrend during May. The mean percentage of patients receiving intravenous tissue plasminogen activator was 16% from April 2019 to March 2020 and increased to 31% in April 2020. The mean percentage of patients receiving endovascular therapy was 10% from April 2019 to March 2020 and increased to 19% in April 2020. Conclusions:At our large tertiary comprehensive stroke center, we observed a significant and rapid decline in TS consults during the COVID-19 pandemic. We cannot be certain of the reasons for the decline, but a fear of contracting coronavirus, social distancing, and isolation likely played a major role. Further research must be done to elucidate the etiology of this decline.
C1 [Shah, Syed Omar; Stazi, Jaime; DePrince, Maureen; Rosenwasser, Robert H.] Thomas Jefferson Univ, Dept Neurol Surg, Vickie & Jack Farber Inst Neurosci, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.
   [Dharia, Robin] Thomas Jefferson Univ, Dept Neurol, Vickie & Jack Farber Inst Neurosci, Philadelphia, PA 19107 USA.
RP Shah, SO (corresponding author), Thomas Jefferson Univ, Dept Neurol Surg, Vickie & Jack Farber Inst Neurosci, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.
EM syed.o.shah@jefferson.edu
CR Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Kansagra AP, 2020, NEW ENGL J MED, V383, P400, DOI 10.1056/NEJMc2014816
   Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Rodriguez-Leor O, 2020, REC INTERV CARDIOL, V2, P82, DOI DOI 10.24875/RECIC.M20000120
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao J, 2020, STROKE, V51, P1356, DOI 10.1161/STROKEAHA.120.029701
NR 10
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
DI 10.1089/tmj.2020.0229
EA JUL 2020
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA MV1KN
UT WOS:000556121400001
PM 32706615
DA 2021-01-01
ER

PT J
AU Daval, M
   Corre, A
   Palpacuer, C
   Housset, J
   Poillon, G
   Eliezer, M
   Verillaud, B
   Slama, D
   Ayache, D
   Herman, P
   Jourdaine, C
   Herve, C
   El Bakkouri, W
   Salmon, D
   Hautefort, C
AF Daval, Mary
   Corre, Alain
   Palpacuer, Clement
   Housset, Juliette
   Poillon, Guillaume
   Eliezer, Michael
   Verillaud, Benjamin
   Slama, Dorsaf
   Ayache, Denis
   Herman, Philippe
   Jourdaine, Clement
   Herve, Camille
   El Bakkouri, Wissame
   Salmon, Dominique
   Hautefort, Charlotte
TI Efficacy of local budesonide therapy in the management of persistent
   hyposmia in COVID-19 patients without signs of severity: A structured
   summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; rotocol; hyposmia; dysgeusia;
   nasal irrigation; corticosteroid; budesonide; MRI
AB Objectives: To assess the efficacy of local intranasal treatment with budesonide (nasal irrigation), in addition to olfactory rehabilitation, in the management of loss of smell in COVID-19 patients without signs of severity and with persistent hyposmia 30 days after the onset of symptoms. To search for an association between the presence of an obstruction on MRI and the severity of olfactory loss, at inclusion and after 30 days of treatment.
   Trial design: Two center, open-label, 2-arm (1:1 ratio) parallel group randomized controlled superiority trial.
   Participants: Inclusion criteria
   - Patient over 18 years of age;
   - Patient with a suspected SARS-CoV-2 infection, whether or not confirmed by PCR, or close contact with a PCRconfirmed case, typical chest CT scan (unsystematic frosted glass patches with predominantly sub-pleural appearance, and at a later stage, alveolar condensation without excavation or nodules or masses) or positive serology;
   - Patient with isolated sudden onset hyposmia persisting 30 days after the onset of symptoms of CoV-2 SARS infection;
   - Affiliate or beneficiary of a social security scheme;
   - Written consent to participate in the study.
   Non-inclusion criteria
   - Known hypersensitivity to budesonide or any of the excipients;
   - Hemostasis disorder or epistaxis;
   - Oral-nasal and ophthalmic herpes virus infection;
   - Long-term corticosteroid treatment;
   - Treatment with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors);
   - Severe forms of SARS-CoV-2 with respiratory or other signs;
   - Hyposmia persisting for more than 90 days after the onset of symptoms
   - Other causes of hyposmia found on interrogation or MRI;
   - Patient benefiting from a legal protection measure;
   - Pregnant or breastfeeding women.
   The participants will be recruited from: Hopital Fondation Adolphe de Rothschild and Hopital Lariboisiere in Paris, France
   Intervention and comparator: Intervention:
   Experimental group: Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9 degrees/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
   Control group: Nasal irrigation with physiological saline 9 degrees/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
   Main outcomes: Percentage of patients with an improvement of more than 2 points on the ODORATEST score after 30 days of treatment.
   Randomisation: Patients will be randomized (1:1) between the experimental and control groups, using the e-CRF. The randomization list will be stratified by centre.
   Blinding (masking): Participants and caregivers are aware of the group assignment. People assessing the outcomes are blinded to the group assignment Numbers to be randomised (sample size)
   120 patients are planned to be randomized into two groups of 60 patients.
   Trial Status: MDL_2020_10. Version number 2, May 22, 2020. Recruitment started on May 22, 2020. The trial will finish recruiting by August 2020. Trial registration: EUDRACT number: 2020-001667-85; date of trial registration: 15 May 2020 Protocol registered on ClinicalTrial.gov, registration number: NCT04361474; date of trial registration: 24 April 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Daval, Mary; Corre, Alain; Palpacuer, Clement; Poillon, Guillaume; Ayache, Denis; Herve, Camille; El Bakkouri, Wissame; Salmon, Dominique] Hop Fdn Adolphe de Rothschild, Paris, France.
   [Housset, Juliette; Eliezer, Michael; Verillaud, Benjamin; Herman, Philippe; Jourdaine, Clement; Hautefort, Charlotte] Hop Lariboisiere, Paris, France.
   [Slama, Dorsaf] Hop Hotel Dieu, Paris, France.
RP Daval, M (corresponding author), Hop Fdn Adolphe de Rothschild, Paris, France.
EM mdaval@for.paris
FU French Department of Health (Innovarc)
FX The study is funded by the French Department of Health (Innovarc).
   Funding for this trial covers the run-in costs (clinical and
   paraclinicals examinations, treatments, data exploitation.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 20
PY 2020
VL 21
IS 1
AR 666
DI 10.1186/s13063-020-04585-8
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MR3HM
UT WOS:000553481200006
PM 32690074
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kudo, M
   Kurosaki, M
   Ikeda, M
   Aikata, H
   Hiraoka, A
   Torimura, T
   Sakamoto, N
AF Kudo, Masatoshi
   Kurosaki, Masayuki
   Ikeda, Masafumi
   Aikata, Hiroshi
   Hiraoka, Atsushi
   Torimura, Takuji
   Sakamoto, Naoya
TI Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The
   Working Group report of JAMTT-HCC
SO HEPATOLOGY RESEARCH
LA English
DT Article
DE COVID-19; hepatocellular carcinoma; JAMTT-HCC | liver dysfunction |
   systemic therapy | up-to-seven criteria
ID ARTERIAL INFUSION CHEMOTHERAPY; LENVATINIB; SORAFENIB;
   SUBCLASSIFICATION; PNEUMONIA; THERAPY; WUHAN; CHINA
AB This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID-19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.
C1 [Kudo, Masatoshi] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan.
   [Kurosaki, Masayuki] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan.
   [Ikeda, Masafumi] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan.
   [Aikata, Hiroshi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Metab, Higashihiroshima, Japan.
   [Hiraoka, Atsushi] Ehime Prefectural Cent Hosp, Dept Gastroenterol, Matsuyama, Ehime, Japan.
   [Torimura, Takuji] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka, Japan.
   [Sakamoto, Naoya] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan.
RP Kudo, M (corresponding author), Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan.; Sakamoto, N (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.
EM m-kudo@med.kindai.ac.jp; sakamoto@med.hokudai.ac.jp
RI Sakamoto, Naoya/G-2734-2012
OI Sakamoto, Naoya/0000-0003-0061-059X; Kudo,
   Masatoshi/0000-0002-4102-3474; Kawaoka, Tomokazu/0000-0002-1887-1096;
   Ikeda, Masafumi/0000-0002-4050-2086
CR American College of Surgeons, COVID 19 SURG
   American Society of Clinical Oncology (ASCO), COR RES
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Bolondi L, 2012, SEMIN LIVER DIS, V32, P348, DOI 10.1055/s-0032-1329906
   Cai QX, 2020, ALLERGY, V75, P1742, DOI 10.1111/all.14309
   Chai X, 2020, BIORXIV
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   EAU Guidelines Office Rapid Reaction Group, ORG WID COLL EFF AD
   ESMO, COVID 19 CANC
   Eso Y, 2019, CANCERS, V11, DOI 10.3390/cancers11030405
   Gillessen S, 2020, EUR UROL, V77, P667, DOI 10.1016/j.eururo.2020.03.026
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He MK, 2019, JAMA ONCOL, V5, P953, DOI 10.1001/jamaoncol.2019.0250
   Hiraoka A, 2019, LIVER CANCER, V8, P121, DOI 10.1159/000488778
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ikeda K, 2019, HEPATOL RES, V49, P14, DOI 10.1111/hepr.13259
   Ikeda M, 2016, ANN ONCOL, V27, P2090, DOI 10.1093/annonc/mdw323
   International Liver Cancer (ILCA), COVID 19 LIV CANC
   International Liver Cancer (ILCA), MAN HCC COVID 19 ILC
   Izumi N, 2019, J CLIN ONCOL S15, V37
   Izumoto H, 2017, ONCOLOGY-BASEL, V93, P120, DOI 10.1159/000481242
   Japan Society for Transplantation, 2020, GUID TRANSPL COVID 1
   Japanese Society of Medical Oncology (JSMO), INF NOV COR DIS
   Johnson PJ, 2015, J CLIN ONCOL, V33, P550, DOI 10.1200/JCO.2014.57.9151
   Kawamura Y, 2020, LIVER CANCER, V9, P275, DOI 10.1159/000505190
   Kawamura Y, 2020, LIVER CANCER, V9, P84, DOI 10.1159/000503577
   Kawamura Y, 2010, HEPATOL RES, V40, P1006, DOI 10.1111/j.1872-034X.2010.00703.x
   Kimura H, 2017, HEPATOL INT, V11, P105, DOI 10.1007/s12072-016-9771-0
   Kokudo N, 2019, HEPATOL RES, V49, P1109, DOI 10.1111/hepr.13411
   Kudo M, 2020, GUIDANCE TREATMENT H
   Kudo M, 2020, LIVER CANCER, V9, P245, DOI 10.1159/000507370
   Kudo M, 2019, LIVER CANCER, V8, P299, DOI 10.1159/000502905
   Kudo M, 2019, CANCERS, V11, DOI 10.3390/cancers11081084
   Kudo M, 2018, LIVER CANCER, V7, P215, DOI 10.1159/000492533
   Kudo M, 2018, LANCET GASTROENTEROL, V3, P424, DOI 10.1016/S2468-1253(18)30078-5
   Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Medicines and Healthcare products Regulatory Agency, MAN CLIN TRIALS COR
   Ogasawara S, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.323
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   The Japan Society of Hepatology, 2020, CLIN PRACT MAN HEP C
   The Ministry of Health Labour and Welfare, LAT INF COR DIS 2019
   Ueshima K, 2019, CANCERS, V11, DOI 10.3390/cancers11070952
   US Food and Drug Administration, FDA GUID COND CLIN T
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, COR DIS COVID 19 PAN
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamashita T, 2020, J GASTROENTEROL, V55, P113, DOI 10.1007/s00535-019-01642-1
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao DH, 2020, CLIN INFECT DIS, V71, P756, DOI 10.1093/cid/ciaa247
NR 56
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1386-6346
EI 1872-034X
J9 HEPATOL RES
JI Hepatol. Res.
PD SEP
PY 2020
VL 50
IS 9
BP 1004
EP 1014
DI 10.1111/hepr.13541
EA JUL 2020
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NT6IR
UT WOS:000550450600001
PM 32583525
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Bun, SS
   Taghji, P
   Courjon, J
   Squara, F
   Scarlatti, D
   Theodore, G
   Baudouy, D
   Sartre, B
   Labbaoui, M
   Dellamonica, J
   Doyen, D
   Marquette, CH
   Levraut, J
   Esnault, V
   Bun, SS
   Ferrari, E
AF Bun, Sok-Sithikun
   Taghji, Philippe
   Courjon, Johan
   Squara, Fabien
   Scarlatti, Didier
   Theodore, Guillaume
   Baudouy, Delphine
   Sartre, Benjamin
   Labbaoui, Mohamed
   Dellamonica, Jean
   Doyen, Denis
   Marquette, Charles-Hugo
   Levraut, Jacques
   Esnault, Vincent
   Bun, Sok-Siya
   Ferrari, Emile
TI QT Interval Prolongation Under Hydroxychloroquine/Azithromycin
   Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract
   Infection
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID HEALTHY-VOLUNTEERS; ANTIMALARIAL-DRUGS; COMPARING METHODS; AZITHROMYCIN;
   RHYTHM; STATEMENT; TORSADE
AB Association between Hydroxychloroquine (HCQ) and Azithromycin (AZT) is under evaluation for patients with lower respiratory tract infection (LRTI) caused by the Severe Acute Respiratory Syndrome (SARS-CoV-2). Both drugs have a known torsadogenic potential, but sparse data are available concerning QT prolongation induced by this association. Our objective was to assess for COVID-19 LRTI variations of QT interval under HCQ/AZT in patients hospitalized, and to compare manual versus automated QT measurements. Before therapy initiation, a baseline 12 lead-ECG was electronically sent to our cardiology department for automated and manual QT analysis (Bazett and Fridericia's correction), repeated 2 days after initiation. According to our institutional protocol (Pasteur University Hospital), HCQ/AZT was initiated only if baseline QTc <= 480ms and potassium level> 4.0 mmol/L. From March 24(th)to April 20(th)2020, 73 patients were included (mean age 62 +/- 14 years, male 67%). Two patients out of 73 (2.7%) were not eligible for drug initiation (QTc >= 500 ms). Baseline average automated QTc was 415 +/- 29 ms and lengthened to 438 +/- 40 ms after 48 hours of combined therapy. The treatment had to be stopped because of significant QTc prolongation in two out of 71 patients (2.8%). No drug-induced life-threatening arrhythmia, nor death was observed. Automated QTc measurements revealed accurate in comparison with manual QTc measurements. In this specific population of inpatients with COVID-19 LRTI, HCQ/AZT could not be initiated or had to be interrupted in less than 6% of the cases.
C1 [Bun, Sok-Sithikun; Squara, Fabien; Scarlatti, Didier; Theodore, Guillaume; Baudouy, Delphine; Sartre, Benjamin; Labbaoui, Mohamed; Ferrari, Emile] Pasteur Univ Hosp, Cardiol Dept, Nice, France.
   [Taghji, Philippe] Clin Casamance, Cardiol Dept, Aubagne, France.
   [Courjon, Johan] Archet Univ Hosp, Infect Dis Dept, Nice, France.
   [Dellamonica, Jean; Doyen, Denis] Archet Univ Hosp, Med Intens Care Unit, Nice, France.
   [Marquette, Charles-Hugo] Pasteur Univ Hosp, Dept Resp Med, Nice, France.
   [Levraut, Jacques] Pasteur Univ Hosp, Dept Emergency Med, Nice, France.
   [Esnault, Vincent] Pasteur Univ Hosp, Nephrol Dept, Nice, France.
   [Bun, Sok-Siya] Aix Marseille Univ, Pharm Fac, CNRS, IRD,IMBE, Marseille, France.
   [Bun, Sok-Siya] CHU Nord, AP HM, Pharm Dept, Marseille, France.
RP Bun, SS (corresponding author), Pasteur Univ Hosp, Cardiol Dept, Nice, France.
EM soksithikun@hotmail.com
RI , Sok-Sithikun/T-2761-2017
OI , Sok-Sithikun/0000-0003-3016-9192
CR Arellano-Rodrigo E, 2001, MED CLIN-BARCELONA, V117, P118, DOI 10.1016/S0025-7753(01)72036-2
   Azie NE, 2004, ANN NONINVAS ELECTRO, V9, P166, DOI 10.1111/j.1542-474X.2004.92542.x
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9
   Blinova K, 2017, TOXICOL SCI, V155, P234, DOI 10.1093/toxsci/kfw200
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Cheung Christopher C, 2020, JACC Clin Electrophysiol, V6, P878, DOI 10.1016/j.jacep.2020.04.001
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Darpo B, 2006, J CLIN PHARMACOL, V46, P598, DOI 10.1177/0091270006286900
   Etchegoyen CV, 2017, CURR CLIN PHARMACOL, V12, P210, DOI 10.2174/1574884713666180223123947
   European Centre for Disease Prevention and Control (ECDC), 2020, EUR SURV HUM INF NOV
   Fosser C, 2009, CLIN PHARMACOL THER, V86, P503, DOI 10.1038/clpt.2009.34
   Garabelli P, 2016, J CARDIOVASC ELECTR, V27, P827, DOI 10.1111/jce.12976
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Goldstein LH, 2015, PHARMACOEPIDEM DR S, V24, P1042, DOI 10.1002/pds.3842
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Hnatkova K, 2020, ANN NONINVAS ELECTRO, V25, DOI 10.1111/anec.12730
   Howard PA, 2013, ANN PHARMACOTHER, V47, P1547, DOI 10.1177/1060028013504905
   Jankelson L, 2020, HEART RHYTHM, V17, P1472, DOI 10.1016/j.hrthm.2020.05.008
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Lakkireddy DR, 2020, HEART RHYTHM, V17, pE233, DOI 10.1016/j.hrthm.2020.03.028
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Rautaharju PM, 2009, J AM COLL CARDIOL, V53, P982, DOI 10.1016/j.jacc.2008.12.014
   Sacher F, 2020, ARCH CARDIOVASC DIS, V113, P293, DOI 10.1016/j.acvd.2020.04.003
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   Vicente J, 2019, CLIN PHARMACOL THER, V105, P943, DOI 10.1002/cpt.1303
   Wu C.I., 2020, HEART RHYTHM, V31, P1547
NR 34
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD NOV
PY 2020
VL 108
IS 5
BP 1090
EP 1097
DI 10.1002/cpt.1968
EA JUL 2020
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OA1YS
UT WOS:000550525700001
PM 32588427
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rinkel, LA
   Prick, JCM
   Slot, RER
   Sombroek, NMA
   Burggraaff, J
   Groot, AE
   Emmer, BJ
   Roos, YBWEM
   Brouwer, MC
   van den Berg-Vos, RM
   Majoie, CBLM
   Beenen, LFM
   van de Beek, D
   Visser, MC
   van Schaik, SM
   Coutinho, JM
AF Rinkel, L. A.
   Prick, J. C. M.
   Slot, R. E. R.
   Sombroek, N. M. A.
   Burggraaff, J.
   Groot, A. E.
   Emmer, B. J.
   Roos, Y. B. W. E. M.
   Brouwer, M. C.
   van den Berg-Vos, R. M.
   Majoie, C. B. L. M.
   Beenen, L. F. M.
   van de Beek, D.
   Visser, M. C.
   van Schaik, S. M.
   Coutinho, J. M.
TI Impact of the COVID-19 outbreak on acute stroke care
SO JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE Stroke; Acute care; Quality; Reperfusion
AB Background and purpose There are concerns that the coronavirus disease 2019 (COVID-19) outbreak negatively affects the quality of care for acute cardiovascular conditions. We assessed the impact of the COVID-19 outbreak on trends in hospital admissions and workflow parameters of acute stroke care in Amsterdam, The Netherlands. Methods We used data from the three hospitals that provide acute stroke care for the Amsterdam region. We compared two 7-week periods: one during the peak of the COVID-19 outbreak (March 16th-May 3th 2020) and one prior to the outbreak (October 21st-December 8th 2019). We included consecutive patients who presented to the emergency departments with a suspected stroke and assessed the change in number of patients as an incidence-rate ratio (IRR) using a Poisson regression analysis. Other outcomes were the IRR for stroke subtypes, change in use of reperfusion therapy, treatment times, and in-hospital complications. Results During the COVID-19 period, 309 patients presented with a suspected stroke compared to 407 patients in the pre-COVID-19 period (IRR 0.76 95%CI 0.65-0.88). The proportion of men was higher during the COVID-19 period (59% vs. 47%,p < 0.001). There was no change in the proportion of stroke patients treated with intravenous thrombolysis (28% vs. 30%,p = 0.58) or endovascular thrombectomy (11% vs 12%,p = 0.82) or associated treatment times. Seven patients (all ischemic strokes) were diagnosed with COVID-19. Conclusion We observed a 24% decrease in suspected stroke presentations during the COVID-19 outbreak, but no evidence for a decrease in quality of acute stroke care.
C1 [Rinkel, L. A.; Groot, A. E.; Roos, Y. B. W. E. M.; Brouwer, M. C.; van den Berg-Vos, R. M.; van de Beek, D.; Coutinho, J. M.] Univ Amsterdam, Dept Neurol, Amsterdam Neurosci, Amsterdam UMC, Amsterdam, Netherlands.
   [Prick, J. C. M.; Sombroek, N. M. A.; van den Berg-Vos, R. M.; van Schaik, S. M.] OLVG, Dept Neurol, Amsterdam, Netherlands.
   [Slot, R. E. R.; Burggraaff, J.; Visser, M. C.] Vrije Univ Amsterdam, Dept Neurol, Amsterdam Neurosci, Amsterdam UMC, Amsterdam, Netherlands.
   [Emmer, B. J.; Majoie, C. B. L. M.; Beenen, L. F. M.] Univ Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC, Amsterdam, Netherlands.
RP Coutinho, JM (corresponding author), Univ Amsterdam, Dept Neurol, Amsterdam Neurosci, Amsterdam UMC, Amsterdam, Netherlands.
EM j.coutinho@amsterdamumc.nl
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Baker T, 2020, LANCET, V395, P1253, DOI 10.1016/S0140-6736(20)30793-5
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   Fransen PSS, 2016, JAMA NEUROL, V73, P190, DOI 10.1001/jamaneurol.2015.3886
   Fugate JE, 2014, LANCET INFECT DIS, V14, P869, DOI 10.1016/S1473-3099(14)70755-8
   Gumbinger C, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3429
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5
   Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Oberg AL, 2000, AM J EPIDEMIOL, V152, P558, DOI 10.1093/aje/152.6.558
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Tam C-CF, 2019, CIRCULATION, V2020, pe006631
   Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47
NR 16
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10069-1
EA JUL 2020
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA MN1PZ
UT WOS:000550621700001
PM 32691235
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, XB
   Li, Y
   Ge, YT
   Shi, YX
   Lv, P
   Zhang, JC
   Fu, G
   Zhou, YF
   Jiang, K
   Lin, NX
   Bai, T
   Jin, RM
   Wu, YJ
   Yang, XF
   Li, X
AF Zhao, Xiaobo
   Li, Yan
   Ge, Yanyan
   Shi, Yuxin
   Lv, Ping
   Zhang, Jianchu
   Fu, Gui
   Zhou, Yanfen
   Jiang, Ke
   Lin, Nengxing
   Bai, Tao
   Jin, Runming
   Wu, Yuanjue
   Yang, Xuefeng
   Li, Xin
TI Evaluation of Nutrition Risk and Its Association With Mortality Risk in
   Severely and Critically Ill COVID-19 Patients
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article; Early Access
DE clinical outcomes; COVID-19; inflammatory marker; Nutritional Risk
   Screening 2002; nutritional status
ID CORONAVIRUS OUTBREAK; GLOBAL HEALTH; PNEUMONIA; THERAPY; WUHAN
AB Background The nutrition status of coronavirus disease 2019 patients is unknown. This study evaluates clinical and nutrition characteristics of severely and critically ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and investigates the relationship between nutrition risk and clinical outcomes. Methods A retrospective, observational study was conducted at West Campus of Union Hospital in Wuhan. Patients confirmed with SARS-CoV-2 infection by a nucleic acid-positive test and identified as severely or critically ill were enrolled in this study. Clinical data and outcomes information were collected and nutrition risk was assessed using Nutritional Risk Screening 2002 (NRS). Results In total, 413 patients were enrolled in this study, including 346 severely and 67 critically ill patients. Most patients, especially critically ill patients, had significant changes in nutrition-related parameters and inflammatory markers. As for nutrition risk, the critically ill patients had significantly higher proportion of high NRS scores (P< .001), which were correlated with inflammatory and nutrition-related markers. Among 342 patients with NRS score >= 3, only 84 (of 342, 25%) received nutrition support. Critically ill patients and those with higher NRS score had a higher risk of mortality and longer stay in hospital. In logistic regression models, 1-unit increase in NRS score was associated with the risk of mortality increasing by 1.23 times (adjusted odds ratio, 2.23; 95% CI, 1.10-4.51;P= .026). Conclusions Most severely and critically ill patients infected with SARS-CoV-2 are at nutrition risk. The patients with higher nutrition risk have worse outcome and require nutrition therapy.
C1 [Zhao, Xiaobo; Li, Yan; Fu, Gui; Zhou, Yanfen; Jin, Runming; Li, Xin] Huazhong Univ Sci & Technol, Union Hosp, Dept Paediat, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Ge, Yanyan; Shi, Yuxin; Lv, Ping; Yang, Xuefeng] Huazhong Univ Sci & Technol, Hubei Key Lab Food Nutr & Safety, MOE Key Lab Environm & Hlth,Sch Publ Hlth, Dept Nutr & Food Hyg,Tongji Med Coll, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
   [Zhang, Jianchu] Huazhong Univ Sci & Technol, Union Hosp, Dept Resp & Crit Care Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Jiang, Ke] Huazhong Univ Sci & Technol, Union Hosp, Dept Thorac Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Lin, Nengxing] Huazhong Univ Sci & Technol, Union Hosp, Dept Dermatol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Bai, Tao] Huazhong Univ Sci & Technol, Union Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Wu, Yuanjue] Huazhong Univ Sci & Technol, Union Hosp, Dept Clin Nutr, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
RP Li, X (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Paediat, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.; Yang, XF (corresponding author), Huazhong Univ Sci & Technol, Hubei Key Lab Food Nutr & Safety, MOE Key Lab Environm & Hlth,Sch Publ Hlth, Dept Nutr & Food Hyg,Tongji Med Coll, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
EM xxyxf@mails.tjmu.edu.cn; doctorlixin@hotmail.com
RI Bai, Tao/ABD-7952-2020
CR Barazzoni R, 2020, CLIN NUTR, V39, P1631, DOI 10.1016/j.clnu.2020.03.022
   Berger MM, 2019, CLIN NUTR, V38, P2408, DOI 10.1016/j.clnu.2018.10.023
   Berger MM, 2019, CLIN NUTR, V38, P584, DOI 10.1016/j.clnu.2018.07.009
   Brower Roy G, 2009, Crit Care Med, V37, pS422, DOI 10.1097/CCM.0b013e3181b6e30a
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese Medical Association, 2008, CLIN PRACT GUID PAR
   Chinese Medical Association, 2020, REC MAN EXP SEV COVI
   Delliere S, 2017, CLIN NUTR, V36, P364, DOI 10.1016/j.clnu.2016.06.004
   Delliere S, 2018, CLIN NUTR, V37, P2226, DOI 10.1016/j.clnu.2018.09.021
   Heighes PT, 2010, ANAESTH INTENS CARE, V38, P167, DOI 10.1177/0310057X1003800126
   Hersberger L, 2020, CLIN NUTR, V39, P2720, DOI 10.1016/j.clnu.2019.11.041
   Hiesmayr M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122048
   Hubei Province Hospital Association, 2020, EXP CONS COVID 19 ME
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5
   Liu Yongfu, 2017, INTESTINAL ENTERAL N, V24, P98
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM PROT PN
   National Health Commission of the People's Republic of China National Administration of Traditional Chinese Medicine of the People's Republic of China, 2020, GUID COR VIR DIS 201
   Schols AM, 2014, EUR RESPIR J, V44, P1504, DOI 10.1183/09031936.00070914
   Sergi G, 2006, EUR J CLIN NUTR, V60, P203, DOI 10.1038/sj.ejcn.1602289
   Sieske L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11091986
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Stefan N, 2020, NAT REV ENDOCRINOL, V16, P341, DOI 10.1038/s41574-020-0364-6
   Tonelli AR, 2014, INTENS CARE MED, V40, P769, DOI 10.1007/s00134-014-3272-1
   Tu GW, 2014, RENAL FAILURE, V36, P202, DOI 10.3109/0886022X.2013.846771
   Uno C, 2020, NUTRITION, V71, DOI 10.1016/j.nut.2019.110613
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, COR DIS COVID 19 PAN
   Wuhan Municipal Health Commission, 2020, REP NOV COR INF PNEU
   Yang PH, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16234758
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yeo HJ, 2019, KOREAN J INTERN MED, V34, P841, DOI 10.3904/kjim.2018.037
   Zhang ZY, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080829
   Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu MW, 2017, J AM COLL NUTR, V36, P357, DOI 10.1080/07315724.2017.1304293
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 39
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
DI 10.1002/jpen.1953
EA JUL 2020
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA MM9QB
UT WOS:000550482000001
PM 32613660
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nisoli, E
   Cinti, S
   Valerio, A
AF Nisoli, Enzo
   Cinti, Saverio
   Valerio, Alessandra
TI COVID-19 and Hartnup disease: an affair of intestinal amino acid
   malabsorption
SO EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY
LA English
DT Article; Early Access
DE Amino acids; ACE2; B(0)AT1; COVID-19; Gastrointestinal disturbances;
   Hartnup disease
ID ANGIOTENSIN-CONVERTING ENZYME-2; ACE2; COLLECTRIN; MUTATIONS
AB Since the outbreak of COVID-19, clinicians have tried every effort to fight the disease, and multiple drugs have been proposed. However, no proven effective therapies currently exist, and different clinical phenotypes complicate the situation. In clinical practice, many severe or critically ill COVID-19 patients developed gastrointestinal (GI) disturbances, including vomiting, diarrhoea, or abdominal pain, even in the absence of cough and dyspnea. Understanding the mechanism of GI disturbances is warranted for exploring better clinical care for COVID-19 patients. With evidence collected from clinical studies on COVID-19 and basic research on a rare genetic disease (i.e., Hartnup disorder), we put forward a novel hypothesis to elaborate an effective nutritional therapy. We hypothesize that SARS-CoV-2 spike protein, binding to intestinal angiotensin-converting enzyme 2, negatively regulates the absorption of neutral amino acids, and this could explain not only the GI, but also systemic disturbances in COVID-19. Amino acid supplements could be recommended.
C1 [Nisoli, Enzo] Univ Milan, Dept Biomed Technol & Translat Med, Ctr Study & Res Obes, I-20129 Milan, Italy.
   [Cinti, Saverio] Marche Polytech Univ, Dept Expt & Clin Med, Ancona, Italy.
   [Valerio, Alessandra] Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy.
RP Nisoli, E (corresponding author), Univ Milan, Dept Biomed Technol & Translat Med, Ctr Study & Res Obes, I-20129 Milan, Italy.; Valerio, A (corresponding author), Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy.
EM enzo.nisoli@unimi.it; alessandra.valerio@unibs.it
RI Nisoli, Enzo/D-6526-2014
OI Nisoli, Enzo/0000-0002-6670-1630
FU Cariplo FoundationFondazione Cariplo [1006-2016]; Professional Dietetics
   (Milan, Italy)
FX The research work in the laboratories of E.N. and A.V. is partly
   supported by Cariplo Foundation (Grant 1006-2016) and Professional
   Dietetics (Milan, Italy).
CR Camargo SMR, 2009, GASTROENTEROLOGY, V136, P872, DOI 10.1053/j.gastro.2008.10.055
   D'Antona G, 2010, CELL METAB, V12, P362, DOI 10.1016/j.cmet.2010.08.016
   Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475
   Gupta R, 2020, J BIOL CHEM, V295, P11742, DOI 10.1074/jbc.RA120.014873
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jando J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184845
   Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mao R, 2020, LANCET GASTROENTEROL, V5, P667, DOI 10.1016/S2468-1253(20)30126-6
   Perlot T, 2013, MICROBES INFECT, V15, P866, DOI 10.1016/j.micinf.2013.08.003
   Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Z, 2016, AMINO ACIDS, V48, P2731, DOI 10.1007/s00726-016-2308-y
   Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
NR 23
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1124-4909
EI 1590-1262
J9 EAT WEIGHT DISORD-ST
JI Eat. Weight Disord.-Stud. Anorex.
DI 10.1007/s40519-020-00963-y
EA JUL 2020
PG 5
WC Psychiatry
SC Psychiatry
GA MN1QJ
UT WOS:000550622700002
PM 32691334
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Barcellona, D
   Marongiu, F
AF Barcellona, Doris
   Marongiu, Francesco
TI Thrombosis centres and AVKs monitoring in COVID-19 pandemic
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE Vitamin K antagonists; Direct oral anticoagulants; Thrombosis centres;
   COVID-19 pandemic
ID MANAGEMENT
AB Vitamin K-Antagonists (VKAs) are the treatment of choice in patients with indications other than atrial fibrillation and venous thromboembolism. Moreover, some patients still assume VKAs refusing to change their therapy when direct oral anticoagulants (DOACs) are properly indicated. The COVID-19 pandemic has completely changed our lives, nullifying inter-personal relationships to avoid contagion, making difficult the VKAs monitoring. We describe the re-organization of our thrombosis centre (TC) as an example on how to face the emergency due to the COVID-19 pandemic. In the first phase, to avoid overcrowding at the TC, we planned to increase the interval time between INRs checks and to encourage blood sampling at home, especially for elderly patients. Moreover, precise scheduled blood sampling was also organized while telephone and email counselling were guaranteed by two doctors of the TC. In the second phase, to reduce the number of patients who daily attended our TC a switch from VKAs to DOACs was carried out, if no contraindications were identified. In the third phase, to protect patients, healthcare staff and hospital from COVID-19 widespread, telemedicine was strengthened. We tried to extend self-testing at home by means of portable coagulometers to as more patients as possible. To avoid patients staying or coming back to the TC an ad hoc web platform for sending the therapeutic dose adjustment and the next scheduled appointment was developed. The TC re-organization allowed us to monitor anticoagulated patients respecting personal isolation and security measures to avoid possible COVID-19 contagion.
C1 [Barcellona, Doris; Marongiu, Francesco] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy.
   [Barcellona, Doris] Temple Univ, SHRO, Philadelphia, PA 19122 USA.
RP Barcellona, D (corresponding author), Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy.; Barcellona, D (corresponding author), Temple Univ, SHRO, Philadelphia, PA 19122 USA.
EM doris.barcellona@unica.it
RI Barcellona, Doris/P-7023-2018
OI Barcellona, Doris/0000-0002-0823-3357
CR Barcellona D, 1998, THROMB HAEMOSTASIS, V80, P899
   Barcellona D, 2018, PATIENT PREFER ADHER, V12, P1521, DOI 10.2147/PPA.S164680
   Barcellona D, 2017, CLIN CHEM LAB MED, V55, P800, DOI 10.1515/cclm-2016-0381
   Barcellona D, 2015, INTERN EMERG MED, V10, P157, DOI 10.1007/s11739-014-1155-7
   Barnes GD, 2018, J THROMB HAEMOST, V16, P1307, DOI 10.1111/jth.14150
   Bloomfield HE, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00005
   Kajy Marvin, 2021, Am J Ther, V28, pe87, DOI 10.1097/MJT.0000000000001083
   Palareti G, 2017, INTERN EMERG MED, V12, P1109, DOI 10.1007/s11739-017-1678-9
   Prisco D, 2017, INTERN EMERG MED, V12, P387, DOI 10.1007/s11739-017-1628-6
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sharma P, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007758
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD NOV
PY 2020
VL 15
IS 8
SI SI
BP 1365
EP 1368
DI 10.1007/s11739-020-02439-4
EA JUL 2020
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OM3BZ
UT WOS:000550099600001
PM 32686059
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Copertino, DC
   Duarte, RRR
   Powell, TR
   Rougvie, MD
   Nixon, DF
AF Copertino, Dennis C., Jr.
   Duarte, Rodrigo R. R.
   Powell, Timothy R.
   de Mulder Rougvie, Miguel
   Nixon, Douglas F.
TI Montelukast drug activity and potential against severe acute respiratory
   syndrome coronavirus 2 (SARS-CoV-2)
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter; Early Access
C1 [Copertino, Dennis C., Jr.; Duarte, Rodrigo R. R.; Powell, Timothy R.; de Mulder Rougvie, Miguel; Nixon, Douglas F.] Cornell Univ, Weill Cornell Med, Div Infect Dis, Belfer Res Bldg,Room 530,413 E 69th St, New York, NY 10021 USA.
RP Nixon, DF (corresponding author), Cornell Univ, Weill Cornell Med, Div Infect Dis, Belfer Res Bldg,Room 530,413 E 69th St, New York, NY 10021 USA.
EM dnixon@med.cornell.edu
RI de Mulder Rougvie, Miguel/AAG-6224-2020
OI de Mulder Rougvie, Miguel/0000-0002-8026-7076; Copertino Jr,
   Dennis/0000-0002-3217-4713; Nixon, Douglas/0000-0002-2801-1786; Duarte,
   Rodrigo R R/0000-0002-7666-9005
CR Aiello T, 2020, CBS
   Almerie MQ, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109883
   Cardani A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006140
   Chen YK, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03079
   Cikler E, 2009, ACTA HISTOCHEM, V111, P112, DOI 10.1016/j.acthis.2008.04.006
   Copertino D.C., 2020, ANTIRETROVIRAL DRUG, DOI [10.26434/chemrxiv.12250199.v1, DOI 10.26434/CHEMRXIV.12250199.V1]
   Coskun AK, 2011, THESCIENTIFICWORLDJO, V11, P1341, DOI 10.1100/tsw.2011.122
   Douguet D, 2005, J MED CHEM, V48, P2457, DOI 10.1021/jm0492296
   Duarte RR., 2020, REPURPOSING FDA APPR, DOI [10.26434/chemrxiv.12148764.v1, DOI 10.26434/CHEMRXIV.12148764.V1]
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   Lin YC, 2018, J MICROBIOL IMMUNOL, V51, P18, DOI 10.1016/j.jmii.2016.04.005
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 13
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26299
EA JUL 2020
PG 3
WC Virology
SC Virology
GA ML9VM
UT WOS:000549809200001
PM 32658304
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Themans, P
   Dauby, N
   Schrooyen, L
   Lebout, F
   Delforge, M
   Nasreddine, R
   Libois, A
   Payen, MC
   Konopnicki, D
   Wuillaume, F
   Lescrainier, C
   Verlinden, V
   Dogne, J
   Hamdani, J
   Musuamba, FT
AF Themans, Pauline
   Dauby, Nicolas
   Schrooyen, Loic
   Lebout, Faustine
   Delforge, Marc
   Nasreddine, Rakan
   Libois, Agnes
   Payen, Marie-Christine
   Konopnicki, Deborah
   Wuillaume, Francoise
   Lescrainier, Cecile
   Verlinden, Veerle
   Dogne, JeanMichel
   Hamdani, Jamila
   Musuamba, Flora T.
TI Model informed dosing of hydroxycholoroquine in COVID-19 patients:
   Learnings from the recent experience, remaining uncertainties and gaps
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE dosing optimization; dosing rationale; hydroxychloroquine; modelling and
   simulations; pharmacokinetics
ID POPULATION PHARMACOKINETICS; HYDROXYCHLOROQUINE
AB Aims In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID-19 disease currently vary across national guidelines and clinical study protocols. We have used a model-based approach to explore the relative impact of alternative dosing regimens proposed in different dosing protocols for hydroxychloroquine in COVID-19. Methods We compared different PK exposures using Monte Carlo simulations based on a previously published population pharmacokinetic model in patients with rheumatoid arthritis, externally validated using both independent data in lupus erythematous patients and recent data in French COVID-19 patients. Clinical efficacy and safety information from COVID-19 patients treated with HCQ were used to contextualize and assess the actual clinical value of the model predictions. Results Literature and observed clinical data confirm the variability in clinical responses in COVID-19 when treated with the same fixed doses. Confounding factors were identified that should be taken into account for dose recommendation. For 80% of patients, doses higher than 800 mg day on day 1 followed by 600 mg daily on following days might not be needed for being cured. Limited adverse drug reactions have been reported so far for this dosing regimen, most often confounded by co-medications, comorbidities or underlying COVID-19 disease effects. Conclusion Our results were clear, indicating the unmet need for characterization of target PK exposures to inform HCQ dosing optimization in COVID-19. Dosing optimization for HCQ in COVID-19 is still an unmet need. Efforts in this sense are a prerequisite for best benefit/risk balance.
C1 [Themans, Pauline] Univ Namur, Namur Inst Complex Syst NaXys, Namur, Belgium.
   [Themans, Pauline] Univ Namur, Dept Math, Namur, Belgium.
   [Dauby, Nicolas; Schrooyen, Loic; Lebout, Faustine; Delforge, Marc; Nasreddine, Rakan; Libois, Agnes; Payen, Marie-Christine; Konopnicki, Deborah] Univ Libre Bruxelles ULB, Ctr Hosp St Pierre, Dept Infect Dis, Brussels, Belgium.
   [Dauby, Nicolas] Univ Libre Bruxelles ULB, Publ Hlth Sch, Environm Hlth Res Ctr, Brussels, Belgium.
   [Wuillaume, Francoise; Lescrainier, Cecile; Verlinden, Veerle; Dogne, JeanMichel; Hamdani, Jamila; Musuamba, Flora T.] Belgian Fed Agcy Med & Hlth Prod, B-1060 Brussels, Belgium.
   [Dogne, JeanMichel] Univ Namur, Namur Thrombosis & Hemostasis Ctr, Dept Pharm, Namur, Belgium.
   [Musuamba, Flora T.] Univ Lubumbashi, Fac Pharmaceut Sci, Lubumbashi, DEM REP CONGO.
RP Musuamba, FT (corresponding author), Belgian Fed Agcy Med & Hlth Prod, B-1060 Brussels, Belgium.
EM flora.musuambashinanu@afmps.be
RI Dauby, Nicolas/F-1235-2011
OI Dauby, Nicolas/0000-0002-7697-6849
CR Abdulaziz N, 2018, CURR OPIN RHEUMATOL, V30, P249, DOI 10.1097/BOR.0000000000000500
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Blanchet B, 2019, ARTHRITIS RHEUMATOL, V71
   Carmichael SJ, 2003, THER DRUG MONIT, V25, P671, DOI 10.1097/00007691-200312000-00005
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   Salata C, 2017, EXPERT REV ANTI-INFE, V15, P483, DOI 10.1080/14787210.2017.1305888
   Singh AK, 2020, DIABETES METAB SYND, V14, P589, DOI 10.1016/j.dsx.2020.05.017
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Yao X, 2020, CLIN INFECT DIS, V2, P1, DOI DOI 10.1093/CID/CIAA237
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14436
EA JUL 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ML9SE
UT WOS:000549800300001
PM 32559820
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wilson, AJ
   Troy-Barnes, E
   Subhan, M
   Clark, F
   Gupta, R
   Fielding, AK
   Kottaridis, P
   Mansour, MR
   O'Nions, J
   Payne, E
   Chavda, N
   Baker, R
   Thomson, K
   Khwaja, A
AF Wilson, Andrew J.
   Troy-Barnes, Ethan
   Subhan, Maryam
   Clark, Fiona
   Gupta, Rajeev
   Fielding, Adele K.
   Kottaridis, Panagiotis
   Mansour, Marc R.
   O'Nions, Jenny
   Payne, Elspeth
   Chavda, Naina
   Baker, Robert
   Thomson, Kirsty
   Khwaja, Asim
TI Successful remission induction therapy with gilteritinib in a patient
   withde novo FLT3-mutated acute myeloid leukaemia and severe COVID-19
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
C1 [Wilson, Andrew J.; Troy-Barnes, Ethan; Subhan, Maryam; Clark, Fiona; Gupta, Rajeev; Fielding, Adele K.; Kottaridis, Panagiotis; Mansour, Marc R.; O'Nions, Jenny; Payne, Elspeth; Thomson, Kirsty; Khwaja, Asim] Univ Coll London Hosp UCLH, Dept Haematol, London, England.
   [Gupta, Rajeev; Fielding, Adele K.; Mansour, Marc R.; Payne, Elspeth; Khwaja, Asim] UCL, Canc Inst, Dept Haematol, London, England.
   [Wilson, Andrew J.; Gupta, Rajeev; O'Nions, Jenny; Chavda, Naina; Baker, Robert; Khwaja, Asim] Hlth Serv Labs, UCLH Specialist Integrated Haematol Malignancy Di, London, England.
RP Wilson, AJ (corresponding author), Univ Coll London Hosp UCLH, Dept Haematol, London, England.; Wilson, AJ (corresponding author), Hlth Serv Labs, UCLH Specialist Integrated Haematol Malignancy Di, London, England.
EM andrew.wilson19@nhs.net
RI Fielding, Adele/J-6949-2013
OI Fielding, Adele/0000-0002-4746-7789; Payne, Elspeth/0000-0001-5841-778X;
   Gupta, Rajeev/0000-0001-9573-0505
CR He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Levis M, 2020, BLOOD ADV, V4, P1178, DOI 10.1182/bloodadvances.2019000174
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   NCRI AML Working Party, 2020, REC MAN PAT AML COVI
   Norgaard M, 2006, CLIN MICROBIOL INFEC, V12, P217, DOI 10.1111/j.1469-0691.2005.01298.x
   Paul Shilpa, 2020, Acta Haematol, P1, DOI 10.1159/000508199
   Perl AE, 2019, NEW ENGL J MED, V381, P1728, DOI 10.1056/NEJMoa1902688
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2020
VL 190
IS 4
BP E189
EP E191
DI 10.1111/bjh.16962
EA JUL 2020
PG 3
WC Hematology
SC Hematology
GA NA4YY
UT WOS:000549827200001
PM 32584418
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yu, T
   Tian, CX
   Chu, S
   Zhou, HF
   Zhang, ZL
   Luo, SS
   Hu, DS
   Fan, H
AF Yu, Ting
   Tian, Chunxia
   Chu, Si
   Zhou, Haifeng
   Zhang, Zili
   Luo, Shanshan
   Hu, Desheng
   Fan, Heng
TI COVID-19 patients benefit from early antiviral treatment: A comparative,
   retrospective study
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE antiviral treatment; COVID-19; SARS-CoV-2 RNA; virus clearance
ID WUHAN; CHINA
AB The outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2, started in December 2019, Wuhan, China. We aimed to figure out the time-point and duration of using antiviral drugs for receiving the maximal effects in patients with COVID-19. In this study, we enrolled 129 confirmed COVID-19 mild to moderate patients who had been treated with antiviral drugs during their hospitalization in Wuhan Union Hospital China. The patients were divided into an early antiviral treatment group and late antiviral treatment group. The demographic data, laboratory tests, the virus clearance time, chest computed tomography scans, and so forth were extracted, calculated, and compared between two groups. Our data showed that the median time from illness onset to initiation of antiviral treatment was 6 days in all patients. The group with early antiviral treatment demonstrated 7 days shorter in the virus clearance time when compared to the group with late antiviral treatment. After virus clearance, the group with early antiviral treatment showed milder illness than the group with late antiviral treatment. Early antiviral treatment could effectively shorten the virus clearance time, and prevent the rapid progression of COVID-19. Therefore, the COVID-19 patients should receive combined therapies with antiviral treatment at an early stage.
C1 [Yu, Ting; Tian, Chunxia; Chu, Si; Zhou, Haifeng; Zhang, Zili; Hu, Desheng; Fan, Heng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan 430022, Peoples R China.
   [Luo, Shanshan; Hu, Desheng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan 430022, Peoples R China.
RP Hu, DS; Fan, H (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan 430022, Peoples R China.; Luo, SS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan 430022, Peoples R China.
EM shsh689@126.com; desheng.hu@hust.edu.cn; fanheng009@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81974249]; Project of Thousand Youth Talents
   [31770983]
FX National Natural Science Foundation of China, Grant/Award Number:
   81974249; Project of Thousand Youth Talents, Grant/Award Number:
   31770983
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Du QLL, 2019, INT IMMUNOPHARMACOL, V68, P58, DOI 10.1016/j.intimp.2018.09.043
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Leneva I. A., 2010, Voprosy Virusologii, V55, P19
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Teissier E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015874
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2018, J INFECT DIS, V217, P1708, DOI 10.1093/infdis/jiy115
   Xu D, 2005, EUR J CLIN MICROBIOL, V24, P165, DOI 10.1007/s10096-005-1299-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 21
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2675
EP 2683
DI 10.1002/jmv.26129
EA JUL 2020
PG 9
WC Virology
SC Virology
GA NU0EN
UT WOS:000549772100001
PM 32492205
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cheli, S
   Cavalletti, V
   Petrocchi, N
AF Cheli, Simone
   Cavalletti, Veronica
   Petrocchi, Nicola
TI An online compassion-focused crisis intervention during COVID-19
   lockdown: a cases series on patients at high risk for psychosis
SO PSYCHOSIS-PSYCHOLOGICAL SOCIAL AND INTEGRATIVE APPROACHES
LA English
DT Article; Early Access
DE Compassion; COVID-19; lockdown; psychosis; telepsychology; compassion
   focused therapy
ID HEALTH
AB Aim To pilot-test the effectiveness of a online compassion-focused crisis intervention for persons who were diagnosed with brief psychotic disorder and were still at high risk for a psychotic episode at the Italian announcement of lockdown on March 9(th), 2020. Methods Six patients who, at the moment of the lockdown, were treated through different psychotherapy approaches and antipsychotic drugs for a first brief psychotic episode accessed a 4-week online compassion-focused intervention comprising a weekly individual video-call session, and an open messenger service with audio-recorded compassion focused practices. Primary outcome (general symptomatology) was assessed one-week before and at the end of the intervention. Secondary outcomes (depression, anxiety and stress symptoms) were assessed daily during the intervention, for a total of 28 days. Results Five of six participants demonstrated a reliable change in both primary and secondary outcomes, and no one reported acute psychotic episodes during the lockdown. All participants reported a stable or increased working alliance. Conclusion These data provide the preliminary feasibility and effectiveness of a brief online compassion-focused crisis intervention for patients diagnosed with a brief psychotic disorder, in situations where the telepsychology is offered, unplanned, as the only possible treatment option.
C1 [Cheli, Simone] Univ Florence, Sch Human Hlth Sci, Florence, Italy.
   [Cheli, Simone; Cavalletti, Veronica] Tages Charity, Ctr Psychol & Hlth, Florence, Italy.
   [Petrocchi, Nicola] John Cabot Univ, Dept Econ & Social Sci, Rome, Italy.
   [Petrocchi, Nicola] Compassionate Mind Italia, Rome, Italy.
RP Cheli, S (corresponding author), Tages Onlus, Ctr Psicol Psicoterapia, Florence, Italy.
EM simone.cheli@unifi.it
RI Cheli, Simone/H-8507-2013
OI Cheli, Simone/0000-0002-0432-3769; Cavalletti,
   Veronica/0000-0002-8912-2666; Petrocchi, Nicola/0000-0002-7210-2319
CR Alvarez-Jimenez M, 2014, SCHIZOPHR RES, V156, P96, DOI 10.1016/j.schres.2014.03.021
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, P94, DOI DOI 10.1176/APPI.B00KS.9780890425596.X00DIAGN0STICCLASSIFICATI0N
   Derogatis LR, 1994, SCL 90 R SYMPTOM CHE
   Gilbert P, 2014, BRIT J CLIN PSYCHOL, V53, P6, DOI 10.1111/bjc.12043
   Gumley A., 2005, STAYING WELL PSYCHOS
   Kirby J., 2015, BEHAV THER, V48, P778
   Krieger T, 2019, BEHAV THER, V50, P430, DOI 10.1016/j.beth.2018.08.003
   Lovibond SH, 1995, MANUAL DEPRESSION AN
   Lysaker P. H., 2018, RECOVERY MEANING MAK
   Petrocchi N, 2019, PSYCHOL PSYCHOTHER-T, V92, P208, DOI 10.1111/papt.12224
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Torous J, 2020, SCHIZOPHR RES, V218, P36, DOI 10.1016/j.schres.2020.04.013
   Tracey T.J., 1989, PSYCHOL ASSESSMENT J, V1, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207]
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
NR 14
TC 0
Z9 0
U1 11
U2 11
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1752-2439
EI 1752-2447
J9 PSYCHOSIS
JI Psychosis
DI 10.1080/17522439.2020.1786148
EA JUL 2020
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MM4YI
UT WOS:000550163600001
DA 2021-01-01
ER

PT J
AU Leung, J
   Connor, J
   Hides, L
   Hall, WD
AF Leung, Janni
   Connor, Jason
   Hides, Leanne
   Hall, Wayne D.
TI Alcohol advertisers may be using social media to encourage parents to
   drink during COVID-19
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Letter; Early Access
DE Policy; drugs and alcohol; Advertising as topic; COVID-19; Stress
ID AUSTRALIA
C1 [Leung, Janni; Hides, Leanne] Univ Queensland, Brisbane, Qld, Australia.
   [Leung, Janni; Connor, Jason; Hides, Leanne; Hall, Wayne D.] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, Australia.
   [Hall, Wayne D.] Kings Coll London, Natl Addict Ctr, London, England.
RP Leung, J (corresponding author), Univ Queensland, Brisbane, Qld, Australia.; Leung, J (corresponding author), Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, Australia.
EM j.leung1@uq.edu.au
RI Leung, Janni/H-1003-2012
OI Leung, Janni/0000-0001-5816-2959
FU University of QueenslandUniversity of Queensland; National Health and
   Medical Research CouncilNational Health and Medical Research Council of
   Australia; Australian GovernmentAustralian GovernmentCGIAR
FX Janni Leung is supported by the University of Queensland Development
   Fellowship. Leanne Hides is supported by a National Health and Medical
   Research Council Senior Research Fellowship. The Centre for Youth
   Substance Abuse Research and the Lives Lived Well Group are supported by
   Commonwealth funding from the Australian Government provided under the
   Drug and Alcohol Program. The funding bodies had no role in the study
   design, collection, analysis or interpretation of the data, writing the
   manuscript, or the decision to submit it for publication. We thank Sarah
   Yeates for her assistance in preparing the manuscript for publication.
CR Alcohol and Drug Foundation, 2020, COVID 19 PAR JUGGL H
   Brennan E, 2017, AUST NZ J PUBL HEAL, V41, P352, DOI 10.1111/1753-6405.12674
   Brodmerkel S, 2013, J PUBLIC AFF, V13, P272, DOI 10.1002/pa.1466
   Cassidy T., 2020, ABC NEWS
   Connor JP, 2016, LANCET, V387, P988, DOI 10.1016/S0140-6736(15)00122-1
   Foundation for Alcohol Research and Education Cancer Council Western Australia, ALC AD EV 35 SEC SNA
   Lavarch M, 2020, ALCOHOL BEVERAGES AD
   Reeve B, 2018, QUT LAW REV, V18, P96, DOI 10.5204/qutlr.v18i1.738
NR 8
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
DI 10.5694/mja2.50707
EA JUL 2020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR6AO
UT WOS:000553672000001
PM 32683705
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rahman, MM
   Saha, T
   Islam, KJ
   Suman, RH
   Biswas, S
   Rahat, EU
   Hossen, MR
   Islam, R
   Hossain, MN
   Al Mamun, A
   Khan, M
   Ali, MA
   Halim, MA
AF Rahman, Md Mahbubur
   Saha, Titon
   Islam, Kazi Jahidul
   Suman, Rasel Hosen
   Biswas, Sourav
   Rahat, Emon Uddin
   Hossen, Md Rubel
   Islam, Rajib
   Hossain, Md Nayeem
   Al Mamun, Abdulla
   Khan, Maksud
   Ali, Md Ackas
   Halim, Mohammad A.
TI Virtual screening, molecular dynamics and structure-activity
   relationship studies to identify potent approved drugs for Covid-19
   treatment
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; FDA approved drug; structural-activity
   relationship; molecular docking; molecular dynamics; principal component
   analysis
ID SARS; DOCKING; QSAR
AB Computer-aided drug screening by molecular docking, molecular dynamics (MD) and structural-activity relationship (SAR) can offer an efficient approach to identify promising drug repurposing candidates for COVID-19 treatment. In this study, computational screening is performed by molecular docking of 1615 Food and Drug Administration (FDA) approved drugs against the main protease (Mpro) of SARS-CoV-2. Several promising approved drugs, including Simeprevir, Ergotamine, Bromocriptine and Tadalafil, stand out as the best candidates based on their binding energy, fitting score and noncovalent interactions at the binding sites of the receptor. All selected drugs interact with the key active site residues, including His41 and Cys145. Various noncovalent interactions including hydrogen bonding, hydrophobic interactions, pi-sulfur and pi-pi interactions appear to be dominant in drug-Mpro complexes. MD simulations are applied for the most promising drugs. Structural stability and compactness are observed for the drug-Mpro complexes. The protein shows low flexibility in both apo and holo form during MD simulations. The MM/PBSA binding free energies are also measured for the selected drugs. For pattern recognition, structural similarity and binding energy prediction, multiple linear regression (MLR) models are used for the quantitative structural-activity relationship. The binding energy predicted by MLR model shows an 82% accuracy with the binding energy determined by molecular docking. Our details results can facilitate rational drug design targeting the SARS-CoV-2 main protease. Communicated by Ramaswamy H. Sarma
C1 [Rahman, Md Mahbubur; Saha, Titon; Islam, Kazi Jahidul; Suman, Rasel Hosen; Biswas, Sourav; Rahat, Emon Uddin; Hossen, Md Rubel; Islam, Rajib; Hossain, Md Nayeem; Khan, Maksud; Ali, Md Ackas; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Infect Dis, Dhaka, Bangladesh.
   [Rahman, Md Mahbubur; Saha, Titon; Islam, Kazi Jahidul; Suman, Rasel Hosen; Biswas, Sourav; Rahat, Emon Uddin; Hossen, Md Rubel; Islam, Rajib; Hossain, Md Nayeem; Khan, Maksud; Ali, Md Ackas; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.
   [Al Mamun, Abdulla] Nanjing Univ Sci & Technol, Dept Chem Engn, Key Lab Soft Chem & Funct Mat MOE, Nanjing, Peoples R China.
   [Halim, Mohammad A.] Univ Arkansas Ft Smith, Dept Phys Sci, Ft Smith, AR 72904 USA.
RP Halim, MA (corresponding author), BICCB, Red Green Res Ctr, Div Infect Dis, Dhaka, Bangladesh.; Halim, MA (corresponding author), BICCB, Red Green Res Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.; Halim, MA (corresponding author), Univ Arkansas Ft Smith, Dept Phys Sci, Ft Smith, AR 72904 USA.
EM mohammad.halim@uafs.edu
RI Ali, Ackas/AAP-7500-2020; Rahman, Mahbubur/AAX-4756-2020; Islam,
   Rajib/AAP-7503-2020
OI Ali, Ackas/0000-0002-8235-3517; Rahman, Mahbubur/0000-0001-6994-2598;
   Islam, Rajib/0000-0001-8499-5516; Khan, Maksud/0000-0002-9682-9184; ,
   Emon Uddin Rahat/0000-0002-5539-9659
CR Adinsoft S, 2010, XLSTAT SOFTW VERS 10
   AHMED S, 2020, J BIOMOL STRUCT 0121, DOI DOI https://doi.org/10.1080/07391102.2020.1714482
   ALAM S, 2017, SCI REP UK, V7, DOI DOI https://doi.org/10.1038/s41598-017-06131-0
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen H, 2006, J BIOL CHEM, V281, P13894, DOI 10.1074/jbc.M510745200
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chirag N. P., 2020, IDENTIFICATION POTEN, DOI [10.26434/chemrxiv.12278588.v1, DOI 10.26434/CHEMRXIV.12278588.V1]
   Contini A, 2020, VIRTUAL SCREENING FD
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   de Sousa ACC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60221-0
   Dickson CJ, 2014, J CHEM THEORY COMPUT, V10, P865, DOI 10.1021/ct4010307
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fakayode S. O., 2009, ENCY ANAL CHEM, DOI [https://doi.org/10.1002/9780470027318.a9082, 10.1002/9780470027318.a9082, DOI 10.1002/9780470027318.A9082]
   Fakayode SO, 2014, TALANTA, V126, P151, DOI 10.1016/j.talanta.2014.03.037
   Frisch M. J., 2009, GAUSSIAN 09 A 02
   Funar-Timofei S, 2017, MOL DIVERS, V21, P437, DOI 10.1007/s11030-017-9735-x
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   ISLAM MJ, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-52308-0
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kassambara A., 2016, STHDA, V2, P1
   Krieger E., 2013, YASARA YET ANOTHER S
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mark H, 2007, CHEMOMETRICS IN SPECTROSCOPY, P1
   Martens H., 1998, DATA HANDLING SCI TE, V20, DOI [https://doi.org/10.1016/S0922-3487(98)80046-4, 10.1016/S0922-3487(98)80046-4, DOI 10.1016/S0922-3487(98)80046-4]
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Santos OA, 2009, MED CHEM, V5, P359, DOI 10.2174/157340609788681458
   Sekhar T., 2020, PREPRINTS, DOI [10.20944/ preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2, 10.20944/preprints202002.0418.v2]
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Shaghaghi N., 2020, MOL DOCKING STUDY NO, DOI [10.26434/chemrxiv.11935722.v1, DOI 10.26434/CHEMRXIV.11935722.V1]
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Studio D., 2015, DASSAULT SYSTEMES BI
   Verma J, 2010, CURR TOP MED CHEM, V10, P95, DOI 10.2174/156802610790232260
   Worldometer, 2020, COR CAS
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   ZHOU YD, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-020-0153-3
NR 46
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1794974
EA JUL 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MN2WL
UT WOS:000550706200001
PM 32692306
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharma, P
   Shanavas, A
AF Sharma, Priyanka
   Shanavas, Asifkhan
TI Natural derivatives with dual binding potential against SARS-CoV-2 main
   protease and human ACE2 possess low oral bioavailability: a brief
   computational analysis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Natural products; COVID; SARS-CoV-2; ACE2; bioavailability
ID CORONAVIRUS; AVICULARIN; ABSORPTION; DOCKING
AB The world is witnessing severe health meltdown due to COVID-19. Generic antiviral drug remdesivir has been found to reduce time to clinical recovery but with insignificant clinical benefits and the antimalarial drug, hydroxychloroquine has been red flagged by USFDA for use as a prophylactic measure due to its cardiotoxicity. There is an acute requirement for a drug candidate that has significant clinical benefit with minimal to no side effects. With restricted access to wet laboratory techniques, an alternative approach is to engage in computational screening of lead molecules that could inhibit SARS-CoV-2 at different stages of its infectious cycle. Severalin silicostudies on natural derivatives, especially that present in daily refreshments (tea and fruit juices), staple food (black rice, red onions, soy beans etc) and traditional medicines (extracts of herbs, leaves and flowers) have been identified as potential drug candidates that bind efficiently with the key viral proteins. However, oral bioavailability of these nutriments is considerably low due to either poor permeability or loss of structure and function due to digestion in the gastrointestinal tract. Here we discuss few natural secondary metabolites (Delphinidin 3,5-diglucoside, Scutellarein 7-glucoside, Avicularin and 3,5-Di-O-galloylshikimic acid) that showed encouraging binding affinity against coronavirus main protease (M-pro) and human ACE2 receptor with MM-GBSA energies up to -74.0 Kcal/mol and -79.5 Kcal/mol, respectively. However, their Abbott bioavailability score (ABS) of 0.11 or 0.17 predicts poor oral bioavailability. This study could trigger interest to engineer potential natural products in managing present or future pandemics. Communicated by Ramaswamy H. Sarma
C1 [Sharma, Priyanka; Shanavas, Asifkhan] Inst Nano Sci & Technol, Inorgan & Organ Nanomed Lab, Mohali, Punjab, India.
RP Shanavas, A (corresponding author), Inst Nano Sci & Technol, Inorgan & Organ Nanomed Lab, Mohali, Punjab, India.
EM asifkhan@inst.ac.in
OI Shanavas, Asifkhan/0000-0001-7221-7477
FU DBTDepartment of Biotechnology (DBT) India
   [BT/PR21972/NNT/28/1280/2017]; Government of India under DST-SERB core
   research grant scheme [EMR/2016/003851]; NIPER, S.A.S Nagar
FX PS is thankful for JRF fellowship received under DBT funded project
   under Nanobiotechnology scheme (BT/PR21972/NNT/28/1280/2017). AS
   acknowledge the Government of India for funding under DST-SERB core
   research grant scheme (EMR/2016/003851). The authors sincerely
   acknowledge the support received from NIPER, S.A.S Nagar in performing
   molecular docking studies. AS thank Dr.Victor Arokia Doss (Associate
   Professor, Dept of Biochemistry) and Late. Dr.N.Abitha Devi (Ex-HoD,
   Dept of Biochemistry), PSG College of Arts and Science for mentorship
   and support.
CR Arts ICW, 2004, BRIT J NUTR, V91, P841, DOI 10.1079/BJN20041123
   Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Delaney JS, 2004, J CHEM INF COMP SCI, V44, P1000, DOI 10.1021/ci034243x
   Emam AM, 1998, PHYTOCHEMISTRY, V48, P739, DOI 10.1016/S0031-9422(97)01043-1
   Farag A., 2020, IDENTIFICATION FDA A, DOI [10.26434/chemrxiv.12049647.v1, DOI 10.26434/CHEMRXIV.12049647.V1]
   Filipiak K, 2014, FOOD FUNCT, V5, P381, DOI 10.1039/c3fo60465a
   Food and Drug Administartion (FDA), 2020, HYDR FACT SHEET HLTH, P1
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Fujimori K, 2013, J AGR FOOD CHEM, V61, P5139, DOI 10.1021/jf401154c
   FUKUNAGA T, 1989, CHEM PHARM BULL, V37, P1543, DOI 10.1248/cpb.37.1543
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guimaraes CRW, 2008, J CHEM INF MODEL, V48, P958, DOI 10.1021/ci800004w
   Guo XF, 2018, BIOMED PHARMACOTHER, V103, P67, DOI 10.1016/j.biopha.2018.03.110
   HU D, 2018, EMERG MICROBES INFEC, V7, DOI DOI https://doi.org/10.1038/s41426-018-0155-5
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Lalit S., 2020, COMP DOCKING ANAL RA, DOI DOI 10.26434/CHEMRXIV.12136002.V1
   Liu HY, 2020, BRIT J NUTR, V124, P1013, DOI 10.1017/S0007114520002263
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manish M., 2020, STUDIES COMPUTATIONA, DOI DOI 10.26434/CHEMRXIV.12024789.V1
   Martin YC, 2005, J MED CHEM, V48, P3164, DOI 10.1021/jm0492002
   MAZEWSKI C, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-47903-0
   McGhie TK, 2007, MOL NUTR FOOD RES, V51, P702, DOI 10.1002/mnfr.200700092
   Mereles D, 2011, INT J MOL SCI, V12, P5592, DOI 10.3390/ijms12095592
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Okonogi S, 2016, NAT PROD COMMUN, V11, P1651
   Oliveira LD, 2020, COMP COMPUTATIONAL S, DOI [10.26434/chemrxiv.12044538.v2, DOI 10.26434/CHEMRXIV.12044538.V2]
   Pandit M., SILICO STUDIES REVEA, P1, DOI DOI 10.21203/RS.3.RS-22687/V1
   Paul A, 2018, J FOOD SCI TECH MYS, V55, P2488, DOI 10.1007/s13197-018-3166-2
   Rehecho S, 2011, LWT-FOOD SCI TECHNOL, V44, P875, DOI 10.1016/j.lwt.2010.11.035
   Rhoades A., 2020, REMDESIVIR EUA LETT, V564, P1
   Roh C, 2012, INT J NANOMED, V7, P2173, DOI 10.2147/IJN.S31379
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   STENLID G, 1976, PHYTOCHEMISTRY, V15, P911, DOI 10.1016/S0031-9422(00)84368-X
   Tallei T., 2020, POTENTIAL PLANT BIOA, P1, DOI DOI 10.20944/PREPRINTS202004.0102.V1
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Ubani A., 2020, BIORXIV, DOI 10.1101/2020.03.31.017657
   Walle T, 2004, FREE RADICAL BIO MED, V36, P829, DOI 10.1016/j.freeradbiomed.2004.01.002
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yao X, 2020, CLIN INFECT DIS, V2, P1, DOI DOI 10.1093/CID/CIAA237
   Yuan YC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14657
   Yuldashev MP, 2002, CHEM NAT COMPD+, V38, P291, DOI 10.1023/A:1020448531522
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang X.Q., 1989, CHUNG KUO I HSUEH KO, V4, P193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 52
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1794970
EA JUL 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MN2UH
UT WOS:000550700600001
PM 32691697
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Attri, B
   Goyal, A
   Gupta, Y
   Tandon, N
AF Attri, Bhawna
   Goyal, Alpesh
   Gupta, Yashdeep
   Tandon, Nikhil
TI Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and
   Diabetes Mellitus: A Practical Approach
SO DIABETES THERAPY
LA English
DT Article
DE Basal-bolus insulin; Basal insulin; Continuous glucose monitoring
   system; Correctional insulin; COVID-19; Diabetes; Hyperglycaemia;
   In-hospital hyperglycaemia; Prandial insulin
ID PERITONEAL-DIALYSIS; MANAGEMENT; HYPERGLYCEMIA; THERAPY; CARE
AB Background and Aim The coronavirus disease 2019 (COVID-19) outbreak has rapidly crossed international boundaries and placed increasing demands on healthcare facilities worldwide. Patients with diabetes and uncontrolled blood glucose levels are at increased risk for poor clinical outcomes and in-hospital mortality related to COVID-19. Therefore, achieving good glycaemic control is of paramount importance among hospitalised patients with COVID-19. Basal-bolus insulin therapy is a safe and effective intervention for the management of hyperglycaemia in hospitalised patients. The aim of this article is to provide a practical guidance for the use of the basal-bolus insulin regimen in hospitalised patients with COVID-19 and diabetes mellitus. Methods This guidance document was formulated based on the review of available literature and the combined personal experiences of the authors. We provide a comprehensive review on the use of the basal-bolus insulin regimen, including its principles, rationale, indications, prerequisites, initiation, and dose titration, and also suggest targets for blood glucose control and different levels of capillary blood glucose monitoring. Various case scenarios are used to illustrate how optimal glucose control can be achieved, such as through adjustments in doses of prandial and basal insulin, the use of correctional insulin dosing and changes in the timing and content of major and minor meals. Conclusion The practical guidance for the use of the basal-bolus insulin regimen in hospitalised patients with COVID-19 and diabetes mellitus presented here can be used for patients admitted to hospital for indications other than COVID-19 and for those in ambulatory care.
C1 [Attri, Bhawna; Goyal, Alpesh; Gupta, Yashdeep; Tandon, Nikhil] All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, India.
RP Gupta, Y; Tandon, N (corresponding author), All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, India.
EM yash_deep_gupta@yahoo.co.in; nikhil_tandon@hotmail.com
RI Goyal, Alpesh/AAF-7732-2019
OI Goyal, Alpesh/0000-0003-0922-5022; Gupta, Yashdeep/0000-0002-4345-717X
CR Ajjan R, 2019, ADV THER, V36, P579, DOI 10.1007/s12325-019-0870-x
   American Diabetes Association, 2019, CARE, V42, pS90, DOI DOI 10.2337/DC19-S005
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Chakraborty Partha Pratim, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2017-219928
   Dhatariya Ketan, 2016, Rev Diabet Stud, V13, P217, DOI 10.1900/RDS.2016.13.217
   Disse E, 2004, DIABETES CARE, V27, P2279, DOI 10.2337/diacare.27.9.2279
   Donner T, INSULIN PHARM THERAP
   Ebekozien OA, 2020, DIABETES CARE, V43, pE83, DOI 10.2337/dc20-1088
   Edelman SV, 2018, DIABETES CARE, V41, P2265, DOI 10.2337/dc18-1150
   Tamez-Perez HE, 2015, WORLD J DIABETES, V6, P1073, DOI 10.4239/wjd.v6.i8.1073
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Frias JP, 2010, DIABETES CARE, V33, P728, DOI 10.2337/dc09-1822
   Funtanilla Vienica D, 2019, P T, V44, P550
   Goyal A, 2020, DIABETES METAB SYND, V14, P753, DOI 10.1016/j.dsx.2020.05.039
   Heise T, 2017, DRUG AGING, V34, P29, DOI 10.1007/s40266-016-0418-6
   Hirsch IB, 2005, NEW ENGL J MED, V352, P174, DOI 10.1056/NEJMra040832
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018
   Iyengar R, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1044-y
   Klonoff David C, 2014, Diabetes Spectr, V27, P174, DOI 10.2337/diaspect.27.3.174
   Korytkowski M, 2020, J CLIN ENDOCR METAB, V105, P3076, DOI 10.1210/clinem/dgaa342
   Kotwal Narendra, 2012, Indian J Endocrinol Metab, V16, pS248, DOI 10.4103/2230-8210.104052
   Koufakis T, 2020, DIABETIC MED, V37, P1418, DOI 10.1111/dme.14329
   McDonnell ME, 2012, ENDOCRIN METAB CLIN, V41, P175, DOI 10.1016/j.ecl.2012.01.001
   Moghissi ES, 2009, DIABETES CARE, V32, P1119, DOI 10.2337/dc09-9029
   Nau KC, 2010, AM FAM PHYSICIAN, V81, P1130
   Porcellati F, 2007, DIABETES CARE, V30, P2447, DOI 10.2337/dc07-0002
   Potier L, 2020, Diabetes Metab, DOI 10.1016/j.diabet.2020.05.004
   Radhakutty A, 2018, EUR J ENDOCRINOL, V179, pR207, DOI 10.1530/EJE-18-0315
   Rayman G, 2020, DIABETIC MED, V37, P1214, DOI 10.1111/dme.14328
   Rhee CM, 2014, SEMIN DIALYSIS, V27, P135, DOI 10.1111/sdi.12198
   Singh AK, 2020, DIABETES METAB SYND, V14, P303, DOI 10.1016/j.dsx.2020.04.004
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Sudha M J, 2017, J Nat Sci Biol Med, V8, P64, DOI 10.4103/0976-9668.198348
   Tandon Nikhil, 2017, Indian J Endocrinol Metab, V21, P600, DOI 10.4103/ijem.IJEM_97_17
   Tonyushkina Ksenia, 2009, J Diabetes Sci Technol, V3, P971
   Tsai CY, 2010, PERITON DIALYSIS INT, V30, P329, DOI 10.3747/pdi.2008.00285
   Umpierrez GE, 2012, J CLIN ENDOCR METAB, V97, P16, DOI 10.1210/jc.2011-2098
   US Food and Drug Administration, FDA PERSP PUBL HLTH
   Viswanathan V, 2019, ADV THER, V36, P520, DOI 10.1007/s12325-019-0872-8
   Wallace MD, 2018, ANN PHARMACOTHER, V52, P86, DOI 10.1177/1060028017728297
   Wang X, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108200
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 44
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1869-6953
EI 1869-6961
J9 DIABETES THER
JI Diabetes Ther.
PD SEP
PY 2020
VL 11
IS 9
BP 2177
EP 2194
DI 10.1007/s13300-020-00873-3
EA JUL 2020
PG 18
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NE8YQ
UT WOS:000549792900001
PM 32683660
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nadan, Y
   Shachar, R
   Cramer, D
   Leshem, T
   Levenbach, D
   Rozen, R
   Salton, N
   Cramer, S
AF Nadan, Yochay
   Shachar, Razi
   Cramer, Daniella
   Leshem, Tali
   Levenbach, Darylle
   Rozen, Rinat
   Salton, Nurit
   Cramer, Saviona
TI Behind the (Virtual) Mirror: Online Live Supervision in Couple and
   Family TherapyPalabras clave(sic)(sic)(sic)
SO FAMILY PROCESS
LA English
DT Article
DE Live Supervision; Online Therapy; Technology-Assisted Counseling; Cyber
   Supervision; Outsider Witness Group
AB Online therapy and supervision, a rapidly rising practice in couple and family therapy, has been the subject of a growing body of literature. From its early days, family therapy training has included live supervision, which has typically been conducted by a supervisor and a team of trainees situated on the other side of a one-way mirror. With the outbreak of the COVID-19 global pandemic, we-the staff of supervisors at the Barcai Institute in Tel Aviv, Israel-were compelled to find solutions to continue meeting with clients and to provide supervision for family therapy trainees. To this end, we have shifted our live supervision courses ("practicums") to the virtual arena, adapting the popular application "Zoom" into what we call "PractiZoom." Based on over 100 PractiZoom sessions conducted between March and May 2020, involving 14 supervisors and 28 therapists-in-training and their clients, the article reflects on this pioneering online practicum for the online live supervision of therapists with geographically distributed participants. In this article, we outline our operational methods and adaptations for conducting live behind-the-mirror supervision online. Following a short theoretical background, we outline the process of online live supervision, discuss our reflections and those of our trainees on the challenges and possibilities it poses, and offer a number of preliminary conclusions and recommendations.
C1 [Nadan, Yochay; Shachar, Razi; Cramer, Daniella; Leshem, Tali; Levenbach, Darylle; Rozen, Rinat; Salton, Nurit; Cramer, Saviona] Barcai Inst Family Couple & Narrat Therapy, Tel Aviv, Israel.
   [Nadan, Yochay] Hebrew Univ Jerusalem, Paul Baerwald Sch Social Work & Social Welf, Jerusalem, Israel.
RP Nadan, Y (corresponding author), Barcai Inst Family, 35 Sheerit Yisrael St, IL-6816521 Tel Aviv, Israel.
EM yochay.nadan@mail.huji.ac.il
OI Nadan, Yochay/0000-0001-6797-3454
CR ANDERSEN T, 1987, FAM PROCESS, V26, P415, DOI 10.1111/j.1545-5300.1987.00415.x
   Anderson H., 1997, CONVERSATION LANGUAG
   Anderson H., 1995, J SYSTEMIC THERAPIES, V14, P1, DOI DOI 10.1177/0011000011429831
   Behan C. P., 2003, J SYSTEMIC THERAPIES, V22, P29
   Bender S, 2016, J TECHNOL HUMAN SERV, V34, P326, DOI 10.1080/15228835.2016.1250026
   Bernard J. M., 2014, FUNDAMENTALS CLIN SU
   Blumer MLC, 2014, J MARITAL FAM THER, V40, P34, DOI 10.1111/j.1752-0606.2012.00332.x
   Borcsa M., 2019, ENCY COUPLE FAMILY T, P627
   Caldwell B. E., 2017, BEST PRACTICES ONLIN
   Carey M., 2003, INT J NARRATIVE THER, V1, P12
   GERGEN KJ, 1985, AM PSYCHOL, V40, P266, DOI 10.1037/0003-066X.40.3.266
   Gershoni Y., 2002, INT J NARRATIVE THER, V2002, P39
   Hennigan J, 2016, COUNS PSYCHOTHER RES, V16, P149, DOI 10.1002/capr.12082
   Hertlein K. M., 2019, THEORY PRACTICE ONLI, P123
   Kahn S. A., 2017, J SYSTEMIC THERAPIES, V36, P7, DOI [10.1521/jyst.2017.36.1.7, DOI 10.1521/JSYT.2017.36.1.7]
   Lebensohn-Chialvo F., 2019, ENCY COUPLE FAMILY T, P1716
   Nadan Y, 2020, FAM PROCESS, V59, P509, DOI 10.1111/famp.12452
   Pennington M., 2019, THEORY PRACTICE ONLI, P79
   Rousmaniere T, 2014, WILEY INT HDB CLIN S, DOI DOI 10.1002/9781118846360
   Shachar R., 2012, J SYSTEMIC THERAPIES, V31, P34, DOI [10.1521/jsyt.2012.31.4.34, DOI 10.1521/JSYT.2012.31.4.34]
   Springer P, 2020, J MARITAL FAM THER, V46, P201, DOI 10.1111/jmft.12431
   Vaccaro N, 2007, COUNS EDUC SUPERV, V47, P46, DOI 10.1002/j.1556-6978.2007.tb00037.x
   White M., 2006, NARRATIVE THERAPY CH
   White M., 2007, MAPS NARRATIVE PRACT
   White M., 1997, NARRATIVES THERAPIST
NR 25
TC 3
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 997
EP 1006
DI 10.1111/famp.12573
EA JUL 2020
PG 10
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000549541000001
PM 32594527
OA Bronze
DA 2021-01-01
ER

PT J
AU Naidoo, D
   Roy, A
   Kar, P
   Mutanda, T
   Anandraj, A
AF Naidoo, Devashan
   Roy, Ayan
   Kar, Pallab
   Mutanda, Taurai
   Anandraj, Akash
TI Cyanobacterial metabolites as promising drug leads against the M(pro)and
   PL(pro)of SARS-CoV-2: anin silicoanalysis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; cyanobacterial metabolites; molecular docking;
   drug-likeness; molecular dynamics simulations; MM-PBSA;
   deoxycylindrospermopsin
ID PAPAIN-LIKE PROTEASE; LIGAND EFFICIENCY; OPTIMIZATION; DISCOVERY;
   TOXICITY; BIOLOGY; POTENT; SERIES; TOOL
AB A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged as the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. Treatment efforts have been severely impeded due to the lack of specific effective antiviral drugs for the treatment of COVID-associated pathologies. In the present research endeavour the inhibitory prospects of cyanobacterial metabolites were assessed at the active binding pockets of the two vital SARS-CoV-2 proteases namely, main protease (M-pro) and the papain-like protease (PLpro) that proteolytically process viral polyproteins and facilitate viral replication, employing anin silicomolecular interaction-based approach. It was evident from our analysis based on the binding energy scores that the metabolites cylindrospermopsin, deoxycylindrospermopsin, carrageenan, cryptophycin 52, eucapsitrione, tjipanazole, tolyporphin and apratoxin A exhibited promising inhibitory potential against the SARS-CoV-2 M-pro. The compounds cryptophycin 1, cryptophycin 52 and deoxycylindrospermopsin were observed to display encouraging binding energy scores with the PL(pro)of SARS-CoV-2. Subsequent estimation of physicochemical properties and potential toxicity of the metabolites followed by robust molecular dynamics simulations and analysis of MM-PBSA energy scoring function established deoxycylindrospermopsin as the most promising inhibitory candidate against both SARS-CoV-2 proteases. Present research findings bestow ample scopes to further exploit the potential of deoxycylindrospermopsin as a successful inhibitor of SARS-CoV-2in vitroandin vivoand pave the foundation for the development of novel effective therapeutics against COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Naidoo, Devashan; Mutanda, Taurai; Anandraj, Akash] Mangosuthu Univ Technol, Fac Nat Sci, Ctr Algal Biotechnol, POB 12363, ZA-4026 Durban, South Africa.
   [Roy, Ayan] Lovely Profess Univ, Dept Biotechnol, Phagwara, Punjab, India.
   [Kar, Pallab] Univ North Bengal, Dept Bot, Bioinformat Facil, Siliguri, India.
RP Naidoo, D (corresponding author), Mangosuthu Univ Technol, Fac Nat Sci, Ctr Algal Biotechnol, POB 12363, ZA-4026 Durban, South Africa.
EM naidoo.devashan@mut.ac.za
RI Roy, Ayan/ABD-5737-2020
OI Roy, Ayan/0000-0002-1578-4712; Anandraj, Akash/0000-0002-2125-9957
FU Mangosuthu University of Technology
FX The Mangosuthu University of Technology is acknowledged for financial
   support.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Bekes M, 2015, BIOCHEM J, V468, P215, DOI 10.1042/BJ20141170
   Berry JP, 2009, TOXICON, V53, P289, DOI 10.1016/j.toxicon.2008.11.016
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   BONJOUKLIAN R, 1991, TETRAHEDRON, V47, P7739, DOI 10.1016/S0040-4020(01)81932-3
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chen JH, 2003, J AM CHEM SOC, V125, P8734, DOI 10.1021/ja036050w
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Hopkins AL, 2014, NAT REV DRUG DISCOV, V13, P105, DOI 10.1038/nrd4163
   Hu HB, 2016, CELL RES, V26, P457, DOI 10.1038/cr.2016.40
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Karypidou K, 2018, BIOORG MED CHEM LETT, V28, P3472, DOI 10.1016/j.bmcl.2018.09.019
   KHAN MT, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1769733
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lagorce D, 2017, BIOINFORMATICS, V33, P3658, DOI 10.1093/bioinformatics/btx491
   Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luesch H, 2001, J AM CHEM SOC, V123, P5418, DOI 10.1021/ja010453j
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Naidoo D, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112305
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pouliot M, 2016, J MED CHEM, V59, P497, DOI 10.1021/acs.jmedchem.5b00361
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Schaeffer DJ, 2000, ECOTOX ENVIRON SAFE, V45, P208, DOI 10.1006/eesa.1999.1862
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   SCHYMAN P, 2017, FRONT PHARMACOL, V8, DOI DOI https://doi.org/10.3389/fphar.2017.00889
   Shultz MD, 2013, BIOORG MED CHEM LETT, V23, P5992, DOI 10.1016/j.bmcl.2013.08.030
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Solter P. F., 2013, HASCHEK ROUSSEAUXS H, DOI [https://doi.org/10.1016/C2010-1-67850-9, DOI 10.1016/C2010-1-67850-9]
   Sturdy M, 2010, J NAT PROD, V73, P1441, DOI 10.1021/np100299v
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   TAN LT, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25092197
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Weiss C, 2017, J PEPT SCI, V23, P514, DOI 10.1002/psc.3015
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
NR 68
TC 2
Z9 2
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1794972
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MN2YU
UT WOS:000550712300001
PM 32691680
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cao, W
   Mai, G
   Liu, Z
   Ren, HY
AF Cao, Wen
   Mai, Gang
   Liu, Zhen
   Ren, Haoyuan
TI An infant with coronavirus disease 2019 in China A case report
SO MEDICINE
LA English
DT Article
DE coronavirus disease 2019; infant; oropharyngeal swab; reverse
   transcription-polymerase chain reaction; severe acute respiratory
   syndrome coronavirus 2
ID RESPIRATORY SYNDROME; PNEUMONIA; DIAGNOSIS; OUTBREAK
AB Rationale: In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China. The initial epidemiological investigations showed that COVID-19 occurred more likely in adults, with patients younger than 10 years old accounting for less than 1% of the total number of confirmed cases, and infant infections were more rare. In our case, we present an infant who was only 35 days old when he was tested positive for COVID-19. Patient concerns: In this report, a 35 day-old male infant with atypical symptoms had close contact with 2 confirmed patients of COVID-19 who were his grandmother and mother. Diagnosis: The patient was diagnosed as COVID-19 after his oropharyngeal swab tested positive for severe acute respiratory syndrome coronavirus 2 by reverse transcription-polymerase chain reaction assay. Interventions: The therapeutic schedule included aerosol inhalation of recombinant human interferon alpha-2b and supportive therapy. Outcomes: Two consecutive (1 day apart) oropharyngeal swabs tested negative for severe acute respiratory syndrome coronavirus 2; then, the patient was discharged on February 27, 2020. Lessons: Strengthening infants' virus screening in families with infected kins is important for early diagnosis, isolation, and treatment when symptoms are atypical. The infectivity of infants with mild or asymptomatic COVID-19 should not be ignored because this may be a source of transmission in the community.
C1 [Cao, Wen; Mai, Gang; Liu, Zhen; Ren, Haoyuan] Peoples Hosp Deyang City, Taishan Rd 173, Deyang 618000, Sichuan, Peoples R China.
RP Ren, HY (corresponding author), Peoples Hosp Deyang City, Taishan Rd 173, Deyang 618000, Sichuan, Peoples R China.
EM rhy19860918@hotmail.com
CR Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Chan PKS, 2004, EMERG INFECT DIS, V10, P825, DOI 10.3201/eid1005.030682
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fang F, 2020, Zhonghua Er Ke Za Zhi, V58, P81, DOI 10.3760/cma.j.issn.0578-1310.2020.02.001
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   National Health Commission of the People's Republic of China, 2020, REP NOV COR INF PNEU
   National Health Commission of the People's Republic of China, 2020, CHIN WHO NEW COR PNE
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   She JT, 2020, J MED VIROL, V92, P747, DOI 10.1002/jmv.25807
   Stockman LJ, 2007, PEDIATR INFECT DIS J, V26, P68, DOI 10.1097/01.inf.0000247136.28950.41
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Thabet F, 2015, SAUDI MED J, V36, P484, DOI 10.15537/smj.2015.4.10243
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   XUE T, 2020, J INFECTION, P167
   Yam WC, 2005, J CLIN VIROL, V33, P19, DOI 10.1016/j.jcv.2004.09.029
NR 18
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 17
PY 2020
VL 99
IS 29
AR 21359
DI 10.1097/MD.0000000000021359
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX1UZ
UT WOS:000557513600131
PM 32702935
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xing, Y
   Li, X
   Gao, X
   Dong, QF
AF Xing, Yue
   Li, Xiao
   Gao, Xiang
   Dong, Qunfeng
TI Natural Polymorphisms Are Present in the Furin Cleavage Site of the
   SARS-CoV-2 Spike Glycoprotein
SO FRONTIERS IN GENETICS
LA English
DT Article
DE COVID-19; SARS-CoV-2; spike glycoprotein; S protein; furin; mutation;
   live-attenuated vaccine
AB The furin cleavage site in the spike glycoprotein of the SARS-CoV-2 coronavirus is considered important for the virus to enter the host cells. By analyzing 45828 SARS-CoV-2 genome sequences, we identified 103 strains of SARS-CoV-2 with various DNA mutations including 18 unique non-synonymous point mutations, one deletion, and six gains of premature stop codon that may affect the furin cleavage site. Our results revealed that the furin cleavage site might not be required for SARS-CoV-2 to enter human cellsin vivo. The identified mutants may represent a new subgroup of SARS-CoV-2 coronavirus with reduced tropism and transmissibility as potential live-attenuated vaccine candidates.
C1 [Xing, Yue] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA.
   [Li, Xiao] Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX USA.
   [Gao, Xiang; Dong, Qunfeng] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA.
   [Dong, Qunfeng] Loyola Univ Chicago, Ctr Biomed Informat, Stritch Sch Med, Maywood, IL 60153 USA.
RP Dong, QF (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA.; Dong, QF (corresponding author), Loyola Univ Chicago, Ctr Biomed Informat, Stritch Sch Med, Maywood, IL 60153 USA.
EM qdong@luc.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5R01AI116706]
FX XG and QD were partially supported by NIH grant 5R01AI116706.
CR Anand P, 2020, ELIFE, V9, DOI 10.7554/eLife.58603
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Davidson AD, 2020, BIORXIV, DOI [10.1101/2020.03.22.002204, DOI 10.1101/2020.03.22.002204]
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Toth AM, 2011, PROTEIN EXPRES PURIF, V80, P274, DOI 10.1016/j.pep.2011.08.002
   Turell MJ, 2003, AM J TROP MED HYG, V68, P218, DOI 10.4269/ajtmh.2003.68.218
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang Q, 2020, VIROL SIN, V35, P337, DOI 10.1007/s12250-020-00212-7
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xing Y, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01502
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
NR 16
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JUL 17
PY 2020
VL 11
AR 783
DI 10.3389/fgene.2020.00783
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA MW1VM
UT WOS:000556833600001
PM 32765596
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Crowley, D
   Delargy, I
AF Crowley, Des
   Delargy, Ide
TI A national model of remote care for assessing and providing opioid
   agonist treatment during the COVID-19 pandemic: a report
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE Opioid agonist therapy; OAT; COVID-19; Opioid user; Remote health;
   Telemedicine
ID INJECTING DRUG-USE; HEPATITIS-C; HIV; INTERVENTIONS; PEOPLE
AB Background Health services globally are struggling to manage the impact of COVID-19. The existing global disease burden related to opioid use is significant. Particularly challenging groups include older drug users who are more vulnerable to the effects of COVID-19. Increasing access to safe and effective opioid agonist treatment (OAT) and other harm reduction services during this pandemic is critical to reduce risk. In response to COVID-19, healthcare is increasingly being delivered by telephone and video consultation, and this report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland. Purpose and findings The purpose of this initiative is to provide easy access to OAT by developing a model of remote assessment and ongoing care and eliminate existing national waiting lists. The Irish College of General Practitioners in conjunction with the National Health Service Executive office for Social Inclusion agreed a set of protocols to enable a system of remote consultation but still delivering OAT locally to people who use drugs. This model was targeted at OAT services with existing waiting lists due to a shortage of specialist medical staff. The model involves an initial telephone assessment with COVID-risk triage, a single-patient visit to local services to provide a point of care drug screen and complete necessary documentation and remote video assessment and ongoing management by a GP addiction specialist. A secure national electronic health link system allows for the safe and timely delivery of scripts to a designated local community pharmacy. Conclusion The development of a remote model of healthcare delivery allows for the reduction in transmission risks associated with COVID-19, increases access to OAT, reduces waiting times and minimises barriers to services. An evaluation of this model is ongoing and will be reported once completed. Fast adaptation of OAT delivery is critical to ensure access to and continuity of service delivery and minimise risk to our staff, patients and community. Innovative models of remote healthcare delivery adapted during the COVID-19 crisis may inform and have important benefits to our health system into the future.
C1 [Crowley, Des; Delargy, Ide] Irish Coll Gen Practitioners, Lincoln Pl, Dublin 2, Ireland.
   [Crowley, Des] Univ Coll Dublin, Dublin 4, Ireland.
RP Crowley, D (corresponding author), Irish Coll Gen Practitioners, Lincoln Pl, Dublin 2, Ireland.; Crowley, D (corresponding author), Univ Coll Dublin, Dublin 4, Ireland.
EM des.crowley@icgp.ie
CR [Anonymous], 2020, 80 WHO
   Brooner RK, 1997, ARCH GEN PSYCHIAT, V54, P71
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cousins G, 2017, DRUG ALCOHOL DEPEN, V173, P126, DOI 10.1016/j.drugalcdep.2016.12.009
   Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9
   Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3
   Degenhardt L, 2016, LANCET INFECT DIS, V16, P1385, DOI 10.1016/S1473-3099(16)30325-5
   Delargy I, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0272-4
   Eibl JK, 2017, DRUG ALCOHOL DEPEN, V176, P133, DOI 10.1016/j.drugalcdep.2017.01.048
   Greenhalgh T, COVID 19 REMOTE ASSE, DOI [10.1136/bmj.m1182, DOI 10.1136/BMJ.M1182]
   Hay G, 2017, ESTIMATING PREVALENC
   Health Service Executive, 2017, CLIN GUID OP SUBST T
   HSE National Covid 19 Telehealth Steering Committee, 2020, CLIN GOV GUID SEC VI
   Kirby T, RHEUMATOLOGISTS RAPI, DOI [10.1016/S2665-9913(20)30094-1, DOI 10.1016/S2665-9913(20)30094-1]
   Lancet T, 2019, COVID 19 PROTECTING, DOI [10.1016/S0140-6736(20)30627-9., DOI 10.1016/S0140-6736(20)30627-9]
   Larney S, 2017, LANCET GLOB HEALTH, V5, pE1208, DOI [10.1016/S2214-109X(17)30373-X, 10.1016/s2214-109x(17)30373-x]
   Lin L, 2019, J SUBST ABUSE TREAT, V101, P38, DOI 10.1016/j.jsat.2019.03.007
   Luxembourg: Publications Office for the European Union, 2010, TREATM CAR OLD DRUG, DOI [10.2810/39905, DOI 10.2810/39905]
   Marciano S, 2017, J MED VIROL, V89, P660, DOI 10.1002/jmv.24668
   Marsch LA, 2014, J SUBST ABUSE TREAT, V46, P43, DOI 10.1016/j.jsat.2013.08.012
   McEachern J, 2019, INT J DRUG POLICY, V64, P30, DOI 10.1016/j.drugpo.2018.08.006
   New South Wales, NSW CLIN GUID TREART
   of Health D, DRUG MIS DEP UK GUID
   Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 25
TC 1
Z9 1
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD JUL 17
PY 2020
VL 17
IS 1
AR 49
DI 10.1186/s12954-020-00394-z
PG 5
WC Substance Abuse
SC Substance Abuse
GA MP6EC
UT WOS:000552294600001
PM 32680520
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fan, XY
   Cao, DF
   Kong, LF
   Zhang, XZ
AF Fan, Xiaoyi
   Cao, Duanfang
   Kong, Lingfei
   Zhang, Xinzheng
TI Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike
   glycoprotein
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; FUSION CORE; MONOCLONAL-ANTIBODIES;
   CRYSTAL-STRUCTURE; S-PROTEIN; PNEUMONIA; INFECTION; FEATURES; TARGET;
   BATS
AB Global emergencies caused by the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2 significantly endanger human health. The spike (S) glycoprotein is the key antigen and its conserved S2 subunit contributes to viral entry by mediating host-viral membrane fusion. However, structural information of the post-fusion S2 from these highly pathogenic human-infecting coronaviruses is still lacking. We used single-particle cryo-electron microscopy to show that the post-fusion SARS-CoV S2 forms a further rotated HR1-HR2 six-helix bundle and a tightly bound linker region upstream of the HR2 motif. The structures of pre- and post-fusion SARS-CoV S glycoprotein dramatically differ, resembling that of the Mouse hepatitis virus (MHV) and other class I viral fusion proteins. This structure suggests potential targets for the development of vaccines and therapies against a wide range of SARS-like coronaviruses.
C1 [Fan, Xiaoyi; Cao, Duanfang; Kong, Lingfei; Zhang, Xinzheng] Chinese Acad Sci, Natl Lab Biomacromol, CAS Ctr Excellence Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.
   [Fan, Xiaoyi; Zhang, Xinzheng] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Zhang, Xinzheng] Chinese Acad Sci, Ctr Biol Imaging, CAS Ctr Excellence Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.
RP Cao, DF; Zhang, XZ (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, CAS Ctr Excellence Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.; Zhang, XZ (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Zhang, XZ (corresponding author), Chinese Acad Sci, Ctr Biol Imaging, CAS Ctr Excellence Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.
EM caodf@ibp.ac.cn; xzzhang@ibp.ac.cn
OI Zhang, Xinzheng/0000-0002-0114-0270
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31900871, 31570874]; 'National Thousand
   (Young) Talents Program' from the Office of Global Experts Recruitment
   in China; Youth Innovation Promotion Association of the Chinese Academy
   of Sciences [2018124]
FX We thank X. Huang, B. Zhu, L. Chen and X. Li from the Center for
   Biological Imaging, Core Facilities for protein Science at the Institute
   of Biophysics (IBP), Chinese Academy of Sciences (CAS) for help with
   cryo-EM data collection. The project was funded by National Natural
   Science Foundation of China (31900871, 31570874). X.Z received
   scholarships from the 'National Thousand (Young) Talents Program' from
   the Office of Global Experts Recruitment in China. D.C is supported by
   the Youth Innovation Promotion Association of the Chinese Academy of
   Sciences (Grant No. 2018124).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Beniac DR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001082
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chu LHM, 2008, J CELL BIOCHEM, V104, P2335, DOI 10.1002/jcb.21790
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gao J, 2013, J VIROL, V87, P13134, DOI 10.1128/JVI.02433-13
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kucukelbir A, 2014, NAT METHODS, V11, P63, DOI [10.1038/NMETH.2727, 10.1038/nmeth.2727]
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lip KM, 2006, J VIROL, V80, P941, DOI 10.1128/JVI.80.2.941-950.2006
   Liu IJ, 2009, ANTIVIR RES, V81, P82, DOI 10.1016/j.antiviral.2008.10.001
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Maxmen A, 2017, NATURE, V546, P340, DOI 10.1038/nature.2017.22137
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Ng OW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102415
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   SHE JB, 2019, CLIN TRANSL MED, V9, DOI DOI 10.3390/APP9061233
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang M, 2005, EMERG INFECT DIS, V11, P1860, DOI 10.3201/eid1112.041293
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weinstein RA, 2004, NEW ENGL J MED, V350, P2332, DOI 10.1056/NEJMp048082
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CL, 2019, J STRUCT BIOL, V208, DOI 10.1016/j.jsb.2019.09.013
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yin HS, 2006, NATURE, V439, P38, DOI 10.1038/nature04322
   Yuan YC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14657
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao H, 2016, SCI REP, P6
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 62
TC 8
Z9 8
U1 5
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 17
PY 2020
VL 11
IS 1
AR 3618
DI 10.1038/s41467-020-17371-6
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MP8AS
UT WOS:000552423000037
PM 32681106
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Watanabe, Y
   Allen, JD
   Wrapp, D
   McLellan, JS
   Crispin, M
AF Watanabe, Yasunori
   Allen, Joel D.
   Wrapp, Daniel
   McLellan, Jason S.
   Crispin, Max
TI Site-specific glycan analysis of the SARS-CoV-2 spike
SO SCIENCE
LA English
DT Article
ID GLYCOSYLATION; HIV-1; GLYCOPROTEINS; CELL
AB The emergence of the betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus 2019 (COVID-19), represents a considerable threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. The SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.
C1 [Watanabe, Yasunori; Allen, Joel D.; Crispin, Max] Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, Hants, England.
   [Watanabe, Yasunori] Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, South Parks Rd, Oxford OX1 3QU, England.
   [Watanabe, Yasunori] Univ Oxford, Wellcome Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.
   [Wrapp, Daniel; McLellan, Jason S.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
RP Crispin, M (corresponding author), Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, Hants, England.
EM max.crispin@soton.ac.uk
OI Wrapp, Daniel/0000-0002-0538-9647; Watanabe,
   Yasunori/0000-0002-7952-1268; McLellan, Jason/0000-0003-3991-542X;
   Crispin, Max/0000-0002-1072-2694
FU International AIDS Vaccine Initiative; Bill and Melinda Gates Foundation
   through the Collaboration for AIDS Vaccine Discovery [OPP1084519,
   1196345]; NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01-AI127521]; Scripps
   Consortium for HIV Vaccine Development (CHAVD) [AI144462]
FX This work was funded by the International AIDS Vaccine Initiative, Bill
   and Melinda Gates Foundation through the Collaboration for AIDS Vaccine
   Discovery (OPP1084519 and 1196345 to M.C.), the NIAID (R01-AI127521 to
   J.S.M.), and the Scripps Consortium for HIV Vaccine Development (CHAVD)
   (AI144462 to M.C.). M.C. is a Supernumerary Fellow of Oriel College,
   Oxford, and professor adjunct at Scripps Research, CA.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Behrens AJ, 2017, J VIROL, V91, DOI 10.1128/JVI.01894-16
   Behrens AJ, 2016, CELL REP, V14, P2695, DOI 10.1016/j.celrep.2016.02.058
   Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009
   Cao LW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06121-4
   Cao LW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14954
   Dalziel M, 2014, SCIENCE, V343, P37, DOI 10.1126/science.1235681
   Emsley P, 2018, ACTA CRYSTALLOGR D, V74, P256, DOI 10.1107/S2059798318005119
   Grant T, 2018, ELIFE, V7, DOI 10.7554/eLife.35383
   Hargett AA, 2019, CURR OPIN VIROL, V36, P56, DOI 10.1016/j.coviro.2019.05.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Loke I, 2016, MOL ASPECTS MED, V51, P31, DOI 10.1016/j.mam.2016.04.004
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Panico M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32956
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pritchard LK, 2015, J VIROL, V89, P8932, DOI 10.1128/JVI.01190-15
   Ritchie G, 2010, VIROLOGY, V399, P257, DOI 10.1016/j.virol.2009.12.020
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Sok D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008104
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010
   Struwe WB, 2018, CELL REP, V24, P1958, DOI 10.1016/j.celrep.2018.07.080
   Tokatlian T, 2019, SCIENCE, V363, P649, DOI 10.1126/science.aat9120
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Watanabe Y, 2018, P NATL ACAD SCI USA, V115, P7320, DOI 10.1073/pnas.1803990115
   Wei CJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000799
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430
   Yang TJ, 2020, P NATL ACAD SCI USA, V117, P1438, DOI 10.1073/pnas.1908898117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
NR 38
TC 91
Z9 91
U1 37
U2 40
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUL 17
PY 2020
VL 369
IS 6501
BP 330
EP +
DI 10.1126/science.abb9983
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MO0EN
UT WOS:000551210700054
PM 32366695
OA Other Gold, Green Published, Green Accepted
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Fatoki, TH
   Ibraheem, O
   Ogunyemi, IO
   Akinmoladun, AC
   Ugboko, HU
   Adeseko, CJ
   Awofisayo, OA
   Olusegun, SJ
   Enibukun, JM
AF Fatoki, Toluwase Hezekiah
   Ibraheem, Omodele
   Ogunyemi, Ibukun Oladejo
   Akinmoladun, Afolabi Clement
   Ugboko, Harriet U.
   Adeseko, Catherine Joke
   Awofisayo, Oladoja A.
   Olusegun, Sunday Joseph
   Enibukun, Jesupemi Mercy
TI Network analysis, sequence and structure dynamics of key proteins of
   coronavirus and human host, and molecular docking of selected
   phytochemicals of nine medicinal plants
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; gene expression network; drug discovery; molecular
   docking and dynamics simulation
ID RESPIRATORY SYNDROME SARS; HERPES-SIMPLEX-VIRUS; NORMAL-MODE ANALYSIS;
   CARICA-PAPAYA L.; ANTIVIRAL ACTIVITY; IN-VITRO; ELLAGIC ACID; KINASE
   CK2; WEB SERVER; INHIBITION
AB The novel coronavirus of 2019 (nCoV-19) has become a pandemic, affecting over 205 nations with over 7,410,000 confirmed cases which has resulted to over 418,000 deaths worldwide. This study aimed to identify potential therapeutic compounds and phytochemicals of medicinal plants that have potential to modulate the expression network of genes that are involve in SARS-CoV-2 pathology in human host and to understand the dynamics key proteins involved in the virus-host interactions. The method used include gene network analysis, molecular docking, and sequence and structure dynamics simulations. The results identified DNA-dependent protein kinase (DNA-PK) and Protein kinase CK2 as key players in SARS-CoV-2 lifecycle. Among the predicted drugs compounds, clemizole, monorden, spironolactone and tanespimycin showed high binding energies; among the studied repurposing compounds, remdesivir, simeprevir and valinomycin showed high binding energies; among the predicted acidic compounds, acetylursolic acid and hardwickiic acid gave high binding energies; while among the studied anthraquinones and glycosides compounds, ellagitannin and friedelanone showed high binding energies against 3-Chymotrypsin-like protease (3CL(pro)), Papain-like protease (PLpro), helicase (nsp13), RNA-dependent RNA polymerase (nsp12), 2'-O-ribose methyltransferase (nsp16) of SARS-CoV-2 and DNA-PK and CK2alpha in human. The order of affinity for CoV proteins is 5Y3E > 6NUS > 6JYT > 2XYR > 3VB6. Finally, medicinal plants with phytochemicals such as caffeine, ellagic acid, quercetin and their derivatives could possibly remediate COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Fatoki, Toluwase Hezekiah; Ibraheem, Omodele] Fed Univ Oye Ekiti, Dept Biochem, Translat Bioinformat Unit, Oye Ekiti, Ekiti State, Nigeria.
   [Ogunyemi, Ibukun Oladejo] Tech Univ Munich, Dept Nutr & Biomed, Munich, Germany.
   [Akinmoladun, Afolabi Clement; Adeseko, Catherine Joke] Fed Univ Technol Akure, Dept Biochem, Akure, Nigeria.
   [Ugboko, Harriet U.] Covenant Univ, Dept Biol Sci, Microbiol Res Unit, Ota, Ogun State, Nigeria.
   [Awofisayo, Oladoja A.] Univ Uyo, Dept Pharmaceut & Med Chem, Uyo, Nigeria.
   [Olusegun, Sunday Joseph] Univ Fed Minas Gerias, Dept Quim, Belo Horizonte, MG, Brazil.
   [Enibukun, Jesupemi Mercy] Fed Univ Technol Akure, Dept Microbiol, Akure, Nigeria.
RP Fatoki, TH (corresponding author), Fed Univ Oye Ekiti, Dept Biochem, Translat Bioinformat Unit, Oye Ekiti, Ekiti State, Nigeria.
EM toluwase.fatoki@fuoye.edu.nghezekiahfatoki@gmail.com
OI ENIBUKUN, JESUPEMI/0000-0002-7595-5229; Fatoki,
   Toluwase/0000-0003-3202-9855
CR Abdurahman E. M., 1995, W AFRICAN J PHARM DR, V11, DOI [10.4314/wajpdr.v11i1.53381, DOI 10.4314/WAJPDR.V11I1.53381]
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   Adeseko C.J., 2019, J APPL LIFE SCI INT, V22, P1, DOI [10.9734/jalsi/2019/v22i130119, DOI 10.9734/JALSI/2019/V22I130119]
   Afolami O. I., 2019, J VIROLOGY ANTIVIRAL, V8, DOI [10.4172/2324-8955.1000186, DOI 10.4172/2324-8955.1000186]
   Anighoro A, 2014, J MED CHEM, V57, P7874, DOI 10.1021/jm5006463
   Anversa P, 1998, BASIC RES CARDIOL, V93, P8
   Asha B., 2015, J PHARMACOGNOSY PHYT, V3, P134
   Asha S., 2017, WORLD J PHARM RES, V3, P1320, DOI [https://doi.org/10.20959/wjpr201710-9320, DOI 10.20959/WJPR201710-9320]
   Aslam M.S., 2016, SYST REV PHARM, V7, P35, DOI DOI https://doi.org/10.5530/srp.2016.7.5
   ATKINSON SC, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-017-18742-8
   Azuma K, 1999, J AGR FOOD CHEM, V47, P3963, DOI 10.1021/jf990347p
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Bradwell K, 2013, GENETICS, V195, P243, DOI 10.1534/genetics.113.154963
   Burton R. M., 2003, Computational & Mathematical Organization Theory, V9, P91, DOI 10.1023/B:CMOT.0000022750.46976.3c
   Chang CH, 2013, J SCI FOOD AGR, V93, P944, DOI 10.1002/jsfa.5832
   Chen EY, 2012, BIOINFORMATICS, V28, P105, DOI 10.1093/bioinformatics/btr625
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen PC, 2014, BIOPHYS J, V107, P435, DOI 10.1016/j.bpj.2014.06.006
   Chen XJ, 2014, PROTEIN CELL, V5, P369, DOI 10.1007/s13238-014-0026-3
   Choi JG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48430-8
   Cilia E, 2014, NUCLEIC ACIDS RES, V42, pW264, DOI 10.1093/nar/gku270
   Clarke DJB, 2018, NUCLEIC ACIDS RES, V46, pW171, DOI 10.1093/nar/gky458
   CONSTANTINESCU CS, 1995, MED HYPOTHESES, V45, P455, DOI 10.1016/0306-9877(95)90220-1
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dalvi LT, 2017, SPECTROCHIM ACTA A, V173, P910, DOI 10.1016/j.saa.2016.10.034
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Diaz-de-Cerio E, 2015, J CHEM-NY, V2015, DOI 10.1155/2015/250919
   DIAZDECERIO E, 2017, INT J MOL SCI, V18, DOI DOI https://doi.org/10.3390/ijms18040897
   Donfack J. H., 2010, ASIAN J TRADIT MED, V5, P79
   Efferth T, 2018, BIOTECHNOL ADV, V36, P1730, DOI 10.1016/j.biotechadv.2018.01.001
   Einav S, 2008, NAT BIOTECHNOL, V26, P1019, DOI 10.1038/nbt.1490
   Einav S, 2010, J INFECT DIS, V202, P65, DOI 10.1086/653080
   Erinoso SM, 2012, AFR J PHARM PHARMACO, V6, P1352, DOI 10.5897/AJPP12.127
   Ewere E. G., 2019, J ASIAN SCI RES, V9, P81, DOI [https://doi.org/10.18488/journal.2.2019.98.81.94, DOI 10.18488/J0URNAL.2.2019.98.81.94]
   Fatoki TH, 2018, J ADV MED PHARM SCI, V19, P1, DOI DOI https://doi.org/10.9734/JAMPS/2018/45211
   FUNG TS, 2016, VIRUSES BASEL, V8, DOI DOI https://doi.org/10.3390/v8070184
   Glenn J. S., 2017, P1, Patent No. [WO 2017/004454 A 1, 004454A1WO]
   Goda K, 1996, BIOCHEM BIOPH RES CO, V219, P306, DOI 10.1006/bbrc.1996.0228
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Gyuris A, 2009, IN VIVO, V23, P429
   HAAS JG, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-34241-w
   Hasan H. T., 2018, IRAQI J PHARM SCI, V27, P115, DOI [https://doi.org/10.31351/vol27iss2pp115-122, DOI 10.31351/V0L27ISS2PP115-122]
   HEATON SM, 2019, CLIN TRANSL IMMUNOL, V8, DOI DOI https://doi.org/10.1002/cti2.1067
   Hevener KE, 2009, J CHEM INF MODEL, V49, P444, DOI 10.1021/ci800293n
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Hosseini FS, 2020, SIMEPREVIR POTENTIAL, DOI 10.20944/preprints202002.0438.v1
   Hou ZY, 2012, J MED CHEM, V55, P2899, DOI 10.1021/jm2015167
   Howell AB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/606212
   Igoli OJ, 2008, INT J PHYS SCI, V3, P156
   Ikeda K, 2011, INT J MOL MED, V28, P595, DOI 10.3892/ijmm.2011.739
   Islam MS, 2002, J AGR FOOD CHEM, V50, P3718, DOI 10.1021/jf020120l
   Jawaid T, 2016, INT J PHARMACOL, V12, P863, DOI 10.3923/ijp.2016.863.873
   Joseph B, 2015, FRONT LIFE SCI, V8, P18, DOI 10.1080/21553769.2014.924080
   Kamboj A., 2012, J PHARM RES, V5, P2402
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1
   Khalil H, 2019, J MED VIROL, V91, P45, DOI 10.1002/jmv.25295
   Knight CJ, 2015, NUCLEIC ACIDS RES, V43, pW225, DOI 10.1093/nar/gkv309
   Krishna K. L., 2008, Natural Product Radiance, V7, P364
   KWON HJ, 1992, CANCER RES, V52, P6926
   Lacombe B, 2016, J VIROL, V90, P10972, DOI 10.1128/JVI.01722-16
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Langland J, 2018, ANTIVIR RES, V160, P143, DOI 10.1016/j.antiviral.2018.10.021
   Lee JH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060157
   LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Li X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076007
   Lienhardt C, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002915
   Lin LT, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-187
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lin ZJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034202
   Liu JC, 2003, LIFE SCI, V73, P1543, DOI 10.1016/S0024-3205(03)00481-8
   Lo YC, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004153
   Ma'ayan A, 2007, MT SINAI J MED, V74, P27, DOI 10.1002/msj.20002
   Mizutani T, 2004, FEBS LETT, V577, P187, DOI 10.1016/j.febslet.2004.10.005
   Morchikh M, 2017, MOL CELL, V67, P387, DOI 10.1016/j.molcel.2017.06.020
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   MUANZA DN, 1995, INT J PHARMACOGN, V33, P98, DOI 10.3109/13880209509055207
   Muthukumaran S, 2017, FOOD QUAL SAF-OXFORD, V1, P227, DOI 10.1093/fqsafe/fyx023
   NACHER JC, 2008, BMC PHARMACOL, V8, DOI DOI https://doi.org/10.1186/1471-2210-8-5
   NASEER S, 2018, CLIN PHYTOSCIENCE, V4, P32, DOI DOI 10.1186/S40816-018-0093-8
   Navratil V, 2009, NUCLEIC ACIDS RES, V37, pD661, DOI 10.1093/nar/gkn794
   NAYAK TK, 2017, VIRUSES BASEL, V9, DOI DOI https://doi.org/10.3390/v9010003
   Notka F, 2004, ANTIVIR RES, V64, P93, DOI 10.1016/j.antiviral.2004.06.010
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   OGBOLE OO, 2018, VIROL J, V15, DOI DOI https://doi.org/10.1186/s12985-018-1022-7
   Ogbonnia S. O., 2010, Agriculture and Biology Journal of North America, V1, P366
   Ogbonnia S. O., 2010, Agriculture and Biology Journal of North America, V1, P139
   Ogbonnia SO, 2013, J MED MED SCI, V4, P423
   Ola SS, 2009, FOOD CHEM, V115, P1568, DOI 10.1016/j.foodchem.2009.02.013
   Paananen A, 2000, INFECT IMMUN, V68, P165, DOI 10.1128/IAI.68.1.165-169.2000
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pinto MFS, 2012, J EVID-BASED INTEGR, V17, P40, DOI 10.1177/2156587211428077
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Lopez-Blanco JR, 2011, BIOINFORMATICS, V27, P2843, DOI 10.1093/bioinformatics/btr497
   Ravindra KC, 2015, CHEM RES TOXICOL, V28, P1903, DOI 10.1021/acs.chemrestox.5b00105
   REITER RJ, 1993, EXPERIENTIA, V49, P654, DOI 10.1007/BF01923947
   Ribeiro DM, 2019, NUCLEIC ACIDS RES, V47, pD398, DOI 10.1093/nar/gky1039
   Richter JM, 2014, MOL PHARMACOL, V86, P514, DOI 10.1124/mol.114.093229
   Rios JL, 2018, PLANTA MED, V84, P1068, DOI 10.1055/a-0633-9492
   Rivera-Pastrana DM, 2010, J SCI FOOD AGR, V90, P2358, DOI 10.1002/jsfa.4092
   Roesch F, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002792
   Rotunda A, 2003, ACTA DERM-VENEREOL, V83, P1, DOI 10.1080/00015550310002611
   Saha P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156811
   Sandler Z. J., 2020, NOVEL IONOPHORES ACT, DOI [https://doi.org/10.1101/2020.01.21.914929, 10.1101/2020.01.21.914929, DOI 10.1101/2020.01.21.914929]
   Sar F. B., 2014, J POF PHYSL PATHOLOG, V5, P15, DOI [https://doi.org/10.5897/JPA2014.0094, DOI 10.5897/JPA2014.0094]
   Sasayama S, 1999, CARDIOVASC RES, V42, P557, DOI 10.1016/S0008-6363(99)00050-4
   Sathyapalan DT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228699
   Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894
   Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008
   Senthilvel P, 2013, BIOINFORMATION, V9, P889, DOI 10.6026/97320630009889
   Sepulveda L., 2012, AFRICAN J BIOTECHNOL, V43, pno, DOI [https://doi.org/10.1002/chin.201250260, DOI 10.1002/CHIN.201250260]
   Sharma N, 2019, ARCH VIROL, V164, P1095, DOI 10.1007/s00705-019-04179-z
   Shin MS, 2005, ANTIVIR RES, V67, P163, DOI 10.1016/j.antiviral.2005.06.005
   Singh IP, 2005, CURR SCI INDIA, V89, P269
   SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137
   Sriwilaijaroen N, 2012, ANTIVIR RES, V94, P139, DOI 10.1016/j.antiviral.2012.02.013
   Sun JH, 2012, J AGR FOOD CHEM, V60, P8703, DOI 10.1021/jf302703u
   TERASHIMA S, 1991, CHEM PHARM BULL, V39, P3346, DOI 10.1248/cpb.39.3346
   Titov DV, 2011, NAT CHEM BIOL, V7, P182, DOI 10.1038/NCHEMBIO.522
   Tong Tommy R., 2009, Infectious Disorders - Drug Targets, V9, P223
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   UGBOKO HU, 2019, BIOINFORM BIOL INSIG, V13, DOI DOI https://doi.org/10.1177/1177932219884297
   Utsunomiya H, 2014, INT J MOL MED, V34, P1020, DOI 10.3892/ijmm.2014.1859
   Vaishampayan UN, 2010, CLIN CANCER RES, V16, P3795, DOI 10.1158/1078-0432.CCR-10-0503
   Vemuri S., 2018, J APPL PHARM SCI, V8, P1, DOI https://doi.org/10.7324/JAPS.2018.8701
   Verbinnen T, 2015, ANTIMICROB AGENTS CH, V59, P7548, DOI 10.1128/AAC.01444-15
   Verma D, 2016, P NATL ACAD SCI USA, V113, P3609, DOI 10.1073/pnas.1523686113
   Vilhelmova-Ilieva N., 2019, INTECHOPEN, V86490, P1, DOI [https://doi.org/10.5772/intechopen.86490, DOI 10.5772/INTECH0PEN.86490]
   Wan ZT, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0088-6
   Wang HR, 2019, EXP THER MED, V18, P987, DOI 10.3892/etm.2019.7667
   Wass MN, 2010, NUCLEIC ACIDS RES, V38, pW469, DOI 10.1093/nar/gkq406
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Wu Y, 2012, CHIN J NAT MEDICINES, V10, P40, DOI [10.3724/SP.J.1009.2012.00040, 10.1016/S1875-5364(12)60009-0]
   WU ZR, 2018, FRONT PHARMACOL, V9, DOI DOI https://doi.org/10.3389/fphar.2018.01134
   Xu C., 2017, AQUAC NUTR, V2017, P1, DOI DOI 10.1007/S12583-017-0770-4
   XU JB, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12020244
   Yan YM, 2017, NUCLEIC ACIDS RES, V45, pW365, DOI 10.1093/nar/gkx407
   Yang Jing-Fang, 2020, Brief Bioinform, V21, P2206, DOI 10.1093/bib/bbz141
   Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338
   Yogeeswari P, 2005, CURR MED CHEM, V12, P657, DOI 10.2174/0929867053202214
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zandi K, 2007, AFR J BIOTECHNOL, V6, P1770
   Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   ZHOU YD, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu YF, 2019, J BIOL CHEM, V294, P28, DOI 10.1074/jbc.RA118.005392
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 152
TC 0
Z9 0
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1794971
EA JUL 2020
PG 23
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MN0RO
UT WOS:000550553500001
PM 32686993
OA Bronze
DA 2021-01-01
ER

PT J
AU Wallace, TC
AF Wallace, Taylor C.
TI Combating COVID-19 and Building Immune Resilience: A Potential Role for
   Magnesium Nutrition?
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article
DE Magnesium; COVID-19; coronavirus; COVID-19; nutrition; potassium;
   vitamin D; hypokalemia; hypomagnesemia; inflammation; cytokine
ID CYTOKINE STORM; SARS-COV; INFLAMMATION; HYPOMAGNESEMIA; RECEPTOR; SERUM;
   DEFICIENCY; PROTEIN; SUPPLEMENTATION; PRETREATMENT
AB Background In December 2019, the viral pandemic of respiratory illness caused by COVID-19 began sweeping its way across the globe. Several aspects of this infectious disease mimic metabolic events shown to occur during latent subclinical magnesium deficiency. Hypomagnesemia is a relatively common clinical occurrence that often goes unrecognized since magnesium levels are rarely monitored in the clinical setting. Magnesium is the second most abundant intracellular cation after potassium. It is involved in >600 enzymatic reactions in the body, including those contributing to the exaggerated immune and inflammatory responses exhibited by COVID-19 patients. Methods A summary of experimental findings and knowledge of the biochemical role magnesium may play in the pathogenesis of COVID-19 is presented in this perspective. The National Academy of Medicine's Standards for Systematic Reviews were independently employed to identify clinical and prospective cohort studies assessing the relationship of magnesium with interleukin-6, a prominent drug target for treating COVID-19. Results Clinical recommendations are given for prevention and treatment of COVID-19. Constant monitoring of ionized magnesium status with subsequent repletion, when appropriate, may be an effective strategy to influence disease contraction and progression. The peer-reviewed literature supports that several aspects of magnesium nutrition warrant clinical consideration. Mechanisms include its "calcium-channel blocking" effects that lead to downstream suppression of nuclear factor-K beta, interleukin-6, c-reactive protein, and other related endocrine disrupters; its role in regulating renal potassium loss; and its ability to activate and enhance the functionality of vitamin D, among others. Conclusion As the world awaits an effective vaccine, nutrition plays an important and safe role in helping mitigate patient morbidity and mortality. Our group is working with the Academy of Nutrition and Dietetics to collect patient-level data from intensive care units across the United States to better understand nutrition care practices that lead to better outcomes.
C1 [Wallace, Taylor C.] Think Hlth Grp, Washington, DC USA.
   [Wallace, Taylor C.] George Mason Univ, Dept Nutr & Food Studies, Fairfax, VA 22030 USA.
   [Wallace, Taylor C.] Ctr Magnesium Educ & Res, Pahoa, HI USA.
RP Wallace, TC (corresponding author), Think Hlth Grp Inc, 1301 20th St NW,413, Washington, DC 20036 USA.
EM taylor.wallace@me.com
OI Wallace, Taylor/0000-0002-9403-2745
CR Alipio M., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3571484, DOI 10.2139/SSRN.3571484]
   Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P304, DOI 10.1093/nar/28.1.304
   BEISEL WR, 1995, AM J CLIN NUTR, V62, P813
   Bressendorff I, 2019, NEPHROL DIAL TRANSPL, DOI 10.1002/central/CN-02005700/full
   Brune K, 2015, AM J PHYSIOL-LUNG C, V308, pL731, DOI 10.1152/ajplung.00309.2014
   Cairns CB, 1996, ACAD EMERG MED, V3, P1093, DOI 10.1111/j.1553-2712.1996.tb03366.x
   Cao S., 2019, Nutrition Today, V54, P195, DOI 10.1097/NT.0000000000000363
   Caspi R, 2012, NUCLEIC ACIDS RES, V40, pD742, DOI 10.1093/nar/gkr1014
   Castilletti C, 2005, VIROLOGY, V341, P163, DOI 10.1016/j.virol.2005.07.015
   Chacko SA, 2010, DIABETES CARE, V33, P304, DOI 10.2337/dc09-1402
   Chen D, 2020, HYPOKALEMIA CLIN IMP, DOI [10.1101/2020.02.27.20028530, 10.1101/2020.02.27, DOI 10.1101/2020.02.27.20028530]
   CHERNOW B, 1989, CHEST, V95, P391, DOI 10.1378/chest.95.2.391
   Chung HS, 2013, MAGNESIUM RES, V26, P46, DOI 10.1684/mrh.2013.0338
   Ciaglia E, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00206
   Costello RB, 2016, ADV NUTR, V7, P977, DOI 10.3945/an.116.012765
   D'Avolio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051359
   Dandona P, 2007, J HUM HYPERTENS, V21, P20, DOI 10.1038/sj.jhh.1002101
   Daneshkhah A, 2020, POSSIBLE ROLE VITAMI, DOI [10.1101/2020.04.08.20058578, DOI 10.1101/2020.04.08.20058578]
   de Baaij JHF, 2015, PHYSIOL REV, V95, P1, DOI 10.1152/physrev.00012.2014
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deng XQ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-187
   DICKERSON RN, 2001, HOSP PHARM, V36, P1201
   Dmitrasinovic G, 2016, J MED BIOCHEM, V35, P375, DOI 10.1515/jomb-2016-0021
   Ebrahimi FA, 2018, BIOL TRACE ELEM RES, V184, P300, DOI 10.1007/s12011-017-1198-5
   Eden J, 2011, FINDING WHAT WORKS IN HEALTH CARE: STANDARDS FOR SYSTEMATIC REVIEWS, P1
   Elin R J, 1991, Magnes Trace Elem, V10, P172
   ELIN RJ, 1987, CLIN CHEM, V33, P1965
   Fiser RT, 1998, CRIT CARE MED, V26, P2048, DOI 10.1097/00003246-199812000-00039
   Ford ES, 2003, J NUTR, V133, P2879
   Fryar C.D., 2018, NAT HLTH STAT REP, V122, P1
   Fryar CD, 2016, VITAL HLTH STAT, V3, P39
   Glicio EJ., 2020, SSRN
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Grimble RF, 2008, E SPEN, V3, P289, DOI DOI 10.1016/j.eclnm.2008.07.002
   Guerin C, 1996, INTENS CARE MED, V22, P724, DOI 10.1007/BF01709512
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hammond DA, 2019, J INTENSIVE CARE MED, V34, P967, DOI 10.1177/0885066617720631
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CL, 2007, J AM SOC NEPHROL, V18, P2649, DOI 10.1681/ASN.2007070792
   Huijgen HJ, 2000, AM J CLIN PATHOL, V114, P688
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, 1997, DIET REF INT CALC PH
   John Hopkins University, 2020, COVID 19 DASHB CTR S
   Kielstein JT, 2013, NEPHROL DIAL TRANSPL, V28, P785, DOI 10.1093/ndt/gfs347
   Kim DJ, 2010, DIABETES CARE, V33, P2604, DOI 10.2337/dc10-0994
   Knudsen L, 2018, HISTOCHEM CELL BIOL, V150, P661, DOI 10.1007/s00418-018-1747-9
   Laviano A, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110834
   Leiva-Juarez MM, 2018, MUCOSAL IMMUNOL, V11, P21, DOI 10.1038/mi.2017.71
   LEMAY J, 1992, ENDOCRINOLOGY, V130, P2767, DOI 10.1210/en.130.5.2767
   Li YC, 2012, CURR OPIN NEPHROL HY, V21, P72, DOI 10.1097/MNH.0b013e32834de4ee
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI0215219, 10.1172/JCI200215219]
   Mahalle N., 2014, Journal of Cardiovascular Disease Research, V5, P22
   Martindale R, 2020, CRIT CARE MED
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Mazidi M, 2018, ARCH MED SCI, V14, P707, DOI 10.5114/aoms.2018.75719
   McCoy Harriett, 1996, Magnesium Research, V9, P185
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meltzer DO, 2020, INFECT DIS HIV AIDS, DOI [10.1101/2020.05.08.20095893, DOI 10.1101/2020.05.08.20095893]
   Mojtahedzadeh M, 2016, IRAN J PHARM RES, V15, P951
   Moshfegh A, 2009, WHAT WE EAT AM NHANE
   Moslehi N, 2012, J RES MED SCI, V17, P607
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Muroi C, 2012, MAGNESIUM RES, V25, P64, DOI 10.1684/mrh.2012.0314
   National Institute of Allergy and Infectious Diseases, 2020, CORONAVIRUSES
   Navarro G, 2014, SEMIN ARTHRITIS RHEU, V43, P458, DOI 10.1016/j.semarthrit.2013.08.001
   Nielsen FH, 2018, J INFLAMM RES, V11, P25, DOI 10.2147/JIR.S136742
   Nielsen FH, 2010, NUTR REV, V68, P333, DOI 10.1111/j.1753-4887.2010.00293.x
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Raharusun P., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3585561, DOI 10.2139/SSRN.3585561]
   Rashvand S, 2019, J AM COLL NUTR, V38, P714, DOI 10.1080/07315724.2019.1599745
   Reddy P, 2019, AM J THER, V26, pE124, DOI 10.1097/MJT.0000000000000538
   REINHART RA, 1985, CRIT CARE MED, V13, P506, DOI 10.1097/00003246-198506000-00015
   Risco F, 2004, J PHYSIOL BIOCHEM, V60, P199, DOI 10.1007/BF03167029
   Rodriguez-Ortiz ME, 2014, NEPHROL DIAL TRANSPL, V29, P282, DOI 10.1093/ndt/gft400
   Ross AC, 2011, Dietary Reference Intakes for Calcium and Vitamin D, P1
   Ross AC, 2012, MODERN NUTR HLTH DIS
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   RUBEIZ GJ, 1993, CRIT CARE MED, V21, P203, DOI 10.1097/00003246-199302000-00010
   RUDE RK, 1985, J CLIN ENDOCR METAB, V61, P933, DOI 10.1210/jcem-61-5-933
   Rude RK, 1998, MINER ELECTROL METAB, V24, P314, DOI 10.1159/000057389
   RYZEN E, 1985, CRIT CARE MED, V13, P19, DOI 10.1097/00003246-198501000-00006
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Shi SQ, 2006, MOL IMMUNOL, V43, P1791, DOI 10.1016/j.molimm.2005.11.005
   Shibata M, 1999, ANGIOLOGY, V50, P573, DOI 10.1177/000331979905000707
   Silhol F, 2020, HYPERTENS RES, V43, P854, DOI 10.1038/s41440-020-0476-3
   Simental-Mendia LE, 2017, CURR PHARM DESIGN, V23, P4678, DOI 10.2174/1381612823666170525153605
   Simental-Mendia LE, 2012, MAGNESIUM RES, V25, P140, DOI 10.1684/mrh.2012.0322
   Soliman HM, 2003, CRIT CARE MED, V31, P1082, DOI 10.1097/01.CCM.0000060867.17556.A0
   Steward CJ, 2019, EUR J APPL PHYSIOL, V119, P2617, DOI 10.1007/s00421-019-04238-y
   Sugimoto J, 2012, J IMMUNOL, V188, P6338, DOI 10.4049/jimmunol.1101765
   Tan CW, 2020, COHORT STUDY EVALUAT, DOI [10.1101/2020.06.01.20112334, DOI 10.1101/2020.06.01.20112334]
   The Lancet Hiv null, 2020, LANCET HIV, V7, pe75, DOI DOI 10.1093/OFID/OFAA153
   Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977
   U.S. Department of Health and Human Services, 2014, NUTR ASS DRI REV
   Uwitonze AM, 2018, J AM OSTEOPATH ASSOC, V118, P181, DOI 10.7556/jaoa.2018.037
   Veltri Keith T, 2015, P T, V40, P185
   Vormann Juergen, 2003, Molecular Aspects of Medicine, V24, P27, DOI 10.1016/S0098-2997(02)00089-4
   WALLACH S, 1988, MAGNESIUM, V7, P262
   WHANG R, 1992, ARCH INTERN MED, V152, P40, DOI 10.1001/archinte.152.1.40
   World Health Organization, 2009, CALC MAGN DRINK WAT
   World Health Organization, 2020, COR DIS COVID 2019 R
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yokota S, 2005, ARTHRITIS RHEUM, V52, P818, DOI 10.1002/art.20944
   Zhan JD, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051245
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zittermann A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-229
   Zogovic D, 2014, J MED BIOCHEM, V33, P291, DOI 10.2478/jomb-2014-0016
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 112
TC 4
Z9 4
U1 6
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD NOV 16
PY 2020
VL 39
IS 8
BP 685
EP 693
DI 10.1080/07315724.2020.1785971
EA JUL 2020
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA OU3JV
UT WOS:000550110800001
PM 32649272
OA Bronze
DA 2021-01-01
ER

PT J
AU Spada, F
   Pellicori, S
   Zampino, G
   Funicelli, L
   Gervaso, L
   Laffi, A
   Rubino, M
   Garcia-Carbonero, R
   Fazio, N
AF Spada, F.
   Pellicori, S.
   Zampino, G.
   Funicelli, L.
   Gervaso, L.
   Laffi, A.
   Rubino, M.
   Garcia-Carbonero, R.
   Fazio, N.
TI SARS-CoV-2-related pneumonia can be successfully managed in patients
   with metastatic neuroendocrine tumors: a critical point of view
SO ENDOCRINE
LA English
DT Article
DE COVID-19; NET; Thymus; Neuroendocrine tumors
AB Primary neuroendocrine tumors of the thymus are extremely rare. In patients with advanced disease, tumor growth control, and sometimes also syndrome control are the main goals of systemic therapy. Unfortunately, no standard therapies are available in clinical practice; therefore, clinical studies are strongly recommended. Axitinib (AXI) is a tyrosine kinase inhibitor, currently under investigation in an international phase II/III trial including thymic neuroendocrine tumors. Over the past 5 months, the entire world has been facing a devastating medical emergency brought about by a pandemic due to a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China, in late 2019. Since then, health professionals have been expending all their efforts on trying to provide the best available treatments for patients involved. Patients with cancer, especially those with thoracic involvement, are at higher risk of coronavirus disease 19 (COVID-19) and its complications because of their immunosuppressive status caused by the cancer and the anticancer therapies. As it remains unclear how to optimally manage such patients, we wished to report our experience with a patient with a metastatic neuroendocrine tumor of the thymus infected with SARS-CoV-2 in the hope that it may provide some insights and reflections on the management of cancer patients during this challenging time in our history.
C1 [Spada, F.; Pellicori, S.; Zampino, G.; Gervaso, L.; Laffi, A.; Rubino, M.; Fazio, N.] European Inst Oncol IEO, Div Gastrointestinal Med Oncol & Neuroendocrine T, IRCCS, Via Ripamonti 435, I-20141 Milan, Italy.
   [Funicelli, L.] European Inst Oncol IEO, Div Radiol, IRCCS, Via Ripamonti 435, I-20141 Milan, Italy.
   [Garcia-Carbonero, R.] UCM, Hosp Univ Doce de Octubre, Dept Med Oncol, Imas12, Madrid, Spain.
RP Fazio, N (corresponding author), European Inst Oncol IEO, Div Gastrointestinal Med Oncol & Neuroendocrine T, IRCCS, Via Ripamonti 435, I-20141 Milan, Italy.
EM nicola.fazio@ieo.it
OI fazio, nicola/0000-0001-6869-0704
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bonomi L, 2020, J THORAC ONCOL, V15, pE83, DOI 10.1016/j.jtho.2020.03.021
   Fazio N, 2019, EXPERT OPIN DRUG MET, V15, P993, DOI 10.1080/17425255.2019.1700951
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hutson TE, 2013, LANCET ONCOL, V14, P1287, DOI 10.1016/S1470-2045(13)70465-0
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Sahu KK, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1292
   Strobel P, 2014, GENE CHROMOSOME CANC, V53, P738, DOI 10.1002/gcc.22183
   Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630
   World Health Organization, 2020, REP COR DIS 2019 COV
   Zhang HY, 2020, J THORAC ONCOL, V15, pE63, DOI 10.1016/j.jtho.2020.02.025
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 15
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD OCT
PY 2020
VL 70
IS 1
BP 6
EP 10
DI 10.1007/s12020-020-02419-w
EA JUL 2020
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NV3RQ
UT WOS:000549658400002
PM 32681385
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU El Morr, C
   Ritvo, P
   Ahmad, F
   Moineddin, R
AF El Morr, Christo
   Ritvo, Paul
   Ahmad, Farah
   Moineddin, Rahim
CA MVC Team
TI Effectiveness of an 8-Week Web-Based Mindfulness Virtual Community
   Intervention for University Students on Symptoms of Stress, Anxiety, and
   Depression: Randomized Controlled Trial
SO JMIR MENTAL HEALTH
LA English
DT Article
DE virtual community; virtual care; mindfulness; depression; anxiety;
   stress; students; online; randomized controlled trial; Canada
ID COGNITIVE-BEHAVIORAL THERAPY; NEGATIVE AUTOMATIC THOUGHTS; AGE-OF-ONSET;
   MULTIPLE IMPUTATION; COLLEGE-STUDENTS; CLINICAL SCIENCE; MENTAL-ILLNESS;
   HEALTH; DISORDERS; PERFECTIONISM
AB Background: A student mental health crisis is increasingly acknowledged and will only intensify with the COVID-19 crisis. Given accessibility of methods with demonstrated efficacy in reducing depression and anxiety (eg, mindfulness meditation and cognitive behavioral therapy [CBT]) and limitations imposed by geographic obstructions and localized expertise, web-based alternatives have become vehicles for scaled-up delivery of benefits at modest cost Mindfulness Virtual Community (MVC), a web-based program informed by CBT constructs and featuring online videos, discussion forums, and videoconferencing, was developed to target depression, anxiety, and experiences of excess stress among university students.
   Objective: The aim of this study was to assess the effectiveness of an 8-week web-based mindfulness and CBT program in reducing symptoms of depression, anxiety, and stress (primary outcomes) and increasing mindfulness (secondary outcome) within a randomized controlled trial (RCT) with undergraduate students at a large Canadian university.
   Methods: An RCT was designed to assess undergraduate students (n=160) who were randomly allocated to a web-based guided mindfulness-CBT condition (n=80) or to a waitlist control (WLC) condition (n=80). The 8-week intervention consisted of a web-based platform comprising (1) 12 video-based modules with psychoeducation on students' preidentified life challenges and applied mindfulness practice; (2) anonymous peer-to-peer discussion forums; and (3) anonymous, group-based, professionally guided 20-minute live videoconferences. The outcomes (depression, anxiety, stress, and mindfulness) were measured via an online survey at baseline and at 8 weeks postintervention using the Patient Health Questionnaire-9 (PHQ9), the Beck Anxiety Inventory (BAT), the Perceived Stress Scale (PSS), and the Five Facets Mindfulness Questionnaire Short Form (FFMQ-SF). Analyses employed generalized estimation equation methods with AR(1) covariance structures and were adjusted for possible covariates (gender, age, country of birth, ethnicity, English as first language, paid work, unpaid work, relationship status, physical exercise, self-rated health, and access to private mental health counseling).
   Results: Of the 159 students who provided T1 data, 32 were males and 125 were females with a mean age of 22.55 years. Participants in the MVC (n=79) and WLC (n=80) groups were similar in sociodemographic characteristics at T1 with the exception of gender and weekly hours of unpaid volunteer work. At postintervention follow-up, according to the adjusted comparisons, there were statistically significant between-group reductions in depression scores (beta=-2.21, P=.01) and anxiety scores (beta=-4.82, P=.006), and a significant increase in mindfulness scores (beta=4.84, P=.02) compared with the WLC group. There were no statistically significant differences in perceived stress for MVC (beta=.64, P=.48) compared with WLC.
   Conclusions: With the MVC intervention, there were significantly reduced depression and anxiety symptoms but no significant effect on perceived stress. Online mindfulness interventions can be effective in addressing common mental health conditions among postsecondary populations on a large scale, simultaneously reducing the current burden on traditional counseling services.
C1 [El Morr, Christo; Ahmad, Farah; MVC Team] York Univ, Sch Hlth Policy & Management, 4700 Keele St Stong 350, Toronto, ON M3J 1P3, Canada.
   [Ritvo, Paul] York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON, Canada.
   [Moineddin, Rahim] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
RP El Morr, C (corresponding author), York Univ, Sch Hlth Policy & Management, 4700 Keele St Stong 350, Toronto, ON M3J 1P3, Canada.
EM elmorr@yorku.ca
RI Morr, Christo El/F-7534-2014
OI Morr, Christo El/0000-0001-6287-3438; Ritvo, Paul/0000-0003-1141-0083;
   Moineddin, Rahim/0000-0002-5506-084X; Ahmad, Farah/0000-0001-9747-1148
FU Canadian Institutes for Health Research (CIHR) eHealth Innovations
   Partnership Program Grant (eHIPP)Canadian Institutes of Health Research
   (CIHR) [EH1-143553]
FX The authors acknowledge the contribution of all students who gave their
   valuable time to participate in the study. We thank ForaHealthyMe.com
   Inc. as an industry partner in this project who provided great support.
   The work reported in this paper was funded by the Canadian Institutes
   for Health Research (CIHR) eHealth Innovations Partnership Program Grant
   (eHIPP; Grant No. EH1-143553). The project's principal investigators are
   CE (nominated), FA, and PR.
CR Ahmad F, 2018, NOVEL APPL VIRTUAL C, P1
   Ahmad F, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/15520
   Aikens KA, 2014, J OCCUP ENVIRON MED, V56, P721, DOI 10.1097/JOM.0000000000000209
   American College Health Association. American College Health Association, 2013, CAN REF GROUP EX SUM
   American College Health Association-National College Health Assessment II, 2016, CAN REF GROUP EX SUM
   Anders S, 2012, INT J MED INFORM, V81, P842, DOI 10.1016/j.ijmedinf.2012.04.004
   Arpin-Cribbie C, 2012, PSYCHOTHER RES, V22, P194, DOI 10.1080/10503307.2011.637242
   Auerbach RP, 2018, J ABNORM PSYCHOL, V127, P623, DOI 10.1037/abn0000362
   Azam MA, 2016, INT J EDUC PSYCHOL, V5, P140, DOI 10.17583/ijep.2016.1504
   Azam MA, 2015, INT J PSYCHOPHYSIOL, V98, P27, DOI 10.1016/j.ijpsycho.2015.06.005
   Bayram N, 2008, SOC PSYCH PSYCH EPID, V43, P667, DOI 10.1007/s00127-008-0345-x
   BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893
   Bender JL, 2013, SUPPORT CARE CANCER, V21, P1253, DOI 10.1007/s00520-012-1655-9
   Benzo RP, 2013, CHRON RESP DIS, V10, P175, DOI 10.1177/1479972313497372
   Boettcher J, 2014, BEHAV THER, V45, P241, DOI 10.1016/j.beth.2013.11.003
   Bohlmeijer E, 2011, ASSESSMENT, V18, P308, DOI 10.1177/1073191111408231
   Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822
   Canadian Mental Health Association Ontario, 2008, REL MENT HLTH MENT I
   Cavanagh K, 2013, BEHAV RES THER, V51, P573, DOI 10.1016/j.brat.2013.06.003
   Chiesa A, 2009, J ALTERN COMPLEM MED, V15, P593, DOI 10.1089/acm.2008.0495
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Dahlin M, 2016, BEHAV RES THER, V77, P86, DOI 10.1016/j.brat.2015.12.007
   Depp CA, 2010, J NERV MENT DIS, V198, P715, DOI 10.1097/NMD.0b013e3181f49ea3
   Dimidjian S, 2015, AM PSYCHOL, V70, P593, DOI 10.1037/a0039589
   Drozd F, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2570
   Eberth J, 2012, MINDFULNESS, V3, P174, DOI 10.1007/s12671-012-0101-x
   Eisenberg D, 2011, J NERV MENT DIS, V199, P301, DOI 10.1097/NMD.0b013e3182175123
   El Morr Christo, 2007, International Journal of Web Based Communities, V3, P386, DOI 10.1504/IJWBC.2007.015865
   El Morr C., 2007, 3 IASTED INT C TEL
   El Morr C, 2020, HEALTH INFORM J, V26, P1560, DOI 10.1177/1460458219884840
   El Morr C, 2017, STUD HEALTH TECHNOL, V234, P104, DOI 10.3233/978-1-61499-742-9-104
   Gluck TM, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-175
   Goodyear-Smith F, 2013, J AM BOARD FAM MED, V26, P177, DOI 10.3122/jabfm.2013.02.120221
   Government of Canada, 2006, HUM FAC MENT HLTH IL
   Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7
   Gushulak BD, 2011, CAN MED ASSOC J, V183, pE952, DOI 10.1503/cmaj.090287
   Han B, 2016, J CLIN PSYCHIAT, V77, P815, DOI 10.4088/JCP.15m09929
   Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555
   Karasouli E, 2014, JMIR MENT HEALTH, V1, DOI 10.2196/mental.3708
   Kauer SD, 2012, J MED INTERNET RES, V14, P15, DOI 10.2196/jmir.1858
   Keng SL, 2011, CLIN PSYCHOL REV, V31, P1041, DOI 10.1016/j.cpr.2011.04.006
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Kessler RC, 2007, CURR OPIN PSYCHIATR, V20, P359, DOI 10.1097/YCO.0b013e32816ebc8c
   Lim KL, 2008, CHRONIC DIS CAN, V28, P92
   Ly KH, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003440
   McKenzie K., 2016, CASE DIVERSITY BUILD
   *MENT HLTH COMM CA, 2013, FAST FACTS MENT ILLN
   Meuser Jamie, 2006, J Interprof Care, V20, P436, DOI 10.1080/13561820600874726
   Morledge TJ, 2013, ANN BEHAV MED, V46, P137, DOI 10.1007/s12160-013-9490-x
   O'Driscoll M, 2017, PSYCHOL HEALTH MED, V22, P851, DOI 10.1080/13548506.2017.1280178
   O' Leary K, 2015, J ALTERN COMPLEM MED, V21, P243, DOI 10.1089/acm.2014.0119
   Onken LS, 2014, CLIN PSYCHOL SCI, V2, P22, DOI 10.1177/2167702613497932
   Pearson C, 2013, HLTH GLANCE MENTAL S
   Pfeffer A., 2016, ONTARIO CAMPUS COUNS
   Pirbaglou M, 2013, J AM COLL HEALTH, V61, P477, DOI 10.1080/07448481.2013.833932
   Radhu N, 2012, J AM COLL HEALTH, V60, P357, DOI 10.1080/07448481.2011.630703
   Radhu N, 2012, BRAIN STIMUL, V5, P44, DOI 10.1016/j.brs.2011.01.006
   Ritvo P, 2013, INT J EDUC PSYCHOL, V2, P272, DOI 10.4471/ijep.2013.28
   Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301
   Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908
   Sedlmeier P, 2012, PSYCHOL BULL, V138, P1139, DOI 10.1037/a0028168
   Smetanin P., 2011, LIFE EC IMPACT MAJOR
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Ungar T., 2015, NATL POST       0428
   van der Riet P, 2018, NURS EDUC TODAY, V65, P201, DOI 10.1016/j.nedt.2018.03.018
   Vollestad J, 2012, BRIT J CLIN PSYCHOL, V51, P239, DOI 10.1111/j.2044-8260.2011.02024.x
   Wolever RQ, 2012, J OCCUP HEALTH PSYCH, V17, P246, DOI 10.1037/a0027278
NR 67
TC 2
Z9 2
U1 24
U2 24
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2368-7959
J9 JMIR MENT HEALTH
JI JMIR Ment. Health
PD JUL 17
PY 2020
VL 7
IS 7
AR e18595
DI 10.2196/18595
PG 16
WC Psychiatry
SC Psychiatry
GA MM0PP
UT WOS:000549862500001
PM 32554380
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Davoodi, L
   Abedi, SM
   Salehifar, E
   Alizadeh-Navaei, R
   Rouhanizadeh, H
   Khorasani, G
   Hosseinimehr, SJ
AF Davoodi, Lotfollah
   Abedi, Seyed Mohammad
   Salehifar, Ebrahim
   Alizadeh-Navaei, Reza
   Rouhanizadeh, Hamed
   Khorasani, Ghasemali
   Hosseinimehr, Seyed Jalal
TI Febuxostat therapy in outpatients with suspected COVID-19: A clinical
   trial
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
ID NF-KAPPA-B; HYDROXYCHLOROQUINE; INFLAMMATION; INJURY; PROTECTS
AB Background The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection. Methods We conducted a clinical trial involving adult outpatients with the moderate respiratory illness following COVID-19 infection. Patients were randomly assigned to receive either FBX or HCQ for 5 days. The measured variables were needs to hospitalisation, clinical and laboratory data including fever, cough, breathing rate, C-Reactive Protein level, lymphocytes count at onset of admission and was well as at 5 days of treatments. In addition, CT findings were evaluated on admission and 14 days after initiation of treatment. Results Sixty subjects were enrolled in the study with a 1 to 1 ratio in FBX and HCQ groups. On admission, fever (66.7%), cough (87%), tachypnoea (44.4%), dyspnoea (35%), elevated CRP value (94.4%) and lung involvement according to chest CT (100%) were documented in enrolled patients with insignificant difference between FBX and HCQ groups. Fever, cough and tachypnoea were significantly mitigated in both groups after five days of treatments without any significant differences between groups. The mean percentages of lung involvement were significantly reduced to 7.3% and 8% after 14 days of treatment with FBX and HCQ, respectively. In adult outpatients with moderate COVID-19 infection, the effectiveness of FBX and HCQ was not different in terms of resolution of clinical manifestations, laboratory tests and lung CT findings. Conclusion This trial suggests that FBX is as an alternative treatment to HCQ for COVID-19 infection and may be considered in patients with a contraindication or precaution to HCQ.
C1 [Davoodi, Lotfollah] Mazandaran Univ Med Sci, Fac Med, Antimicrobial Resistance Res Ctr, Dept Infect Dis, Sari, Iran.
   [Abedi, Seyed Mohammad] Mazandaran Univ Med Sci, Fac Med, Dept Radiol, Sari, Iran.
   [Salehifar, Ebrahim] Mazandaran Univ Med Sci, Fac Pharm, Hemoglobinopathy Inst, Dept Clin Pharm,Pharmaceut Sci Res Ctr, Sari, Iran.
   [Alizadeh-Navaei, Reza] Mazandaran Univ Med Sci, Gastrointestinal Canc Res Ctr, Noncommunicable Dis Inst, Sari, Iran.
   [Rouhanizadeh, Hamed] Mazandaran Univ Med Sci, Fac Med, Dept Pediat, Sari, Iran.
   [Khorasani, Ghasemali] Univ Tehran Med Sci, Dept Plast & Reconstruct Surg, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Hosseinimehr, Seyed Jalal] Mazandaran Univ Med Sci, Fac Pharm, Dept Radiopharm, Sari, Iran.
RP Hosseinimehr, SJ (corresponding author), Mazandaran Univ Med Sci, Fac Pharm, Dept Radiopharm, Sari, Iran.
EM sjhosseinim@yahoo.com
RI Hosseinimehr, Seyed Jalal/E-5889-2011
OI Hosseinimehr, Seyed Jalal/0000-0001-8055-8036
FU Mazandaran University of Medical Sciences [7294]
FX Mazandaran University of Medical Sciences, Grant/Award Number: 7294
CR Ahmed MAE, 2019, LIFE SCI, V221, P56, DOI 10.1016/j.lfs.2019.02.007
   Amirshahrokhi K, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105884
   Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008
   Bauman JL, 2020, PHARMACOTHERAPY, V40, P387, DOI 10.1002/phar.2387
   Bell JS, 2020, AUST J GEN PRACT, V49, DOI 10.31128/AJGP-COVID-06
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Cascella M, 2020, FEATURES EVALUATION
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07
   Damarla M, 2017, PHYSIOL REP, V5
   Fahmi ANA, 2016, N-S ARCH PHARMACOL, V389, P269, DOI 10.1007/s00210-015-1202-6
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gbinigie K, 2020, BJGP OPEN
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hao GH, 2019, EXP THER MED, V17, P812, DOI 10.3892/etm.2018.6972
   Hu CF, 2017, CURR MED CHEM, V24, P2241, DOI 10.2174/0929867324666170316115938
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacob S, 2017, INT J BURNS TRAUMA, V7, P98
   Jiang KF, 2018, INT IMMUNOPHARMACOL, V64, P140, DOI 10.1016/j.intimp.2018.08.023
   Jin YY, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/4934592
   Kataoka H, 2015, EUR J PHARMACOL, V746, P174, DOI 10.1016/j.ejphar.2014.11.013
   Khan SI, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8095825
   Krishnamurthy B, 2015, CHEM-BIOL INTERACT, V237, P96, DOI 10.1016/j.cbi.2015.05.013
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Linard C, 2004, INT J RADIAT ONCOL, V58, P427, DOI 10.1016/j.ijrobp.2003.09.039
   Liu L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11450-3
   Muller-Calleja N, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210012
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070
   Omori H, 2012, CLIN EXP NEPHROL, V16, P549, DOI 10.1007/s10157-012-0609-3
   Pordanjani SM, 2016, CURR MED CHEM, V23, P3951, DOI 10.2174/0929867323666160824162718
   Qin C, 2020, CLIN INFECT DIS
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sun Yan, 2020, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V36, P1
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Ungheri D, 2000, INT J IMMUNOPATH PH, V13, P123
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang SL, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0578-x
   Wilkinson E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1626
   Wu Z, JAMA, V323, P1239
   Xiong Z, 2020, Zhonghua Yi Xue Za Zhi, V100, P1223, DOI 10.3760/cma.j.cn112137-20200228-00499
   Yang XY, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01132-z
   Yokozawa T, 2004, PHYTOMEDICINE, V11, P625, DOI 10.1016/j.phymed.2003.05.006
   Zeidi M, 2019, J INVEST DERMATOL, V139, P324, DOI 10.1016/j.jid.2018.07.041
NR 49
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD NOV
PY 2020
VL 74
IS 11
AR e13600
DI 10.1111/ijcp.13600
EA JUL 2020
PG 8
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA OI5GB
UT WOS:000549335400001
PM 32603531
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharma, A
   Tiwari, V
   Sowdhamini, R
AF Sharma, Abhishek
   Tiwari, Vikas
   Sowdhamini, Ramanathan
TI Computational search for potential COVID-19 drugs from FDA-approved
   drugs and small molecules of natural origin identifies several
   anti-virals and plant products
SO JOURNAL OF BIOSCIENCES
LA English
DT Article
DE Anti-virals; drug design; herbal plants; repurposing drugs; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; HOST GENE-EXPRESSION; NONSTRUCTURAL
   PROTEIN-1; ACCURATE DOCKING; DATABASE; GLIDE; RESOURCE
AB The world is currently facing the COVID-19 pandemic, for which mild symptoms include fever and dry cough. In severe cases, it could lead to pneumonia and ultimately death in some instances. Moreover, the causative pathogen is highly contagious and there are no drugs or vaccines for it yet. The pathogen, SARS-CoV-2, is one of the human coronaviruses which was identified to infect humans first in December 2019. SARS-CoV-2 shares evolutionary relationship to other highly pathogenic viruses such as Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS). We have exploited this similarity to model a target non-structural protein, NSP1, since it is implicated in the regulation of host gene expression by the virus and hijacking of host machinery. We next interrogated the capacity to repurpose around 2300 FDA-approved drugs and more than 3,00,000 small molecules of natural origin towards drug identification through virtual screening and molecular dynamics. Interestingly, we observed simple molecules like lactose, previously known anti-virals and few secondary metabolites of plants as promising hits. These herbal plants are already practiced in Ayurveda over centuries to treat respiratory problems and inflammation. Disclaimer: we would not like to recommend uptake of these small molecules for suspect COVID patients until it is approved by competent national or international authorities.
C1 [Sharma, Abhishek; Tiwari, Vikas; Sowdhamini, Ramanathan] Natl Ctr Biol Sci, GKVK Campus, Bengaluru 560065, Karnataka, India.
RP Sowdhamini, R (corresponding author), Natl Ctr Biol Sci, GKVK Campus, Bengaluru 560065, Karnataka, India.
EM mini@ncbs.res.in
FU Science and Engineering Research Board, India [SB/S2/JC-071/2015]
FX We would like to thank NCBS (TIFR) for infrastructural facilities. The
   authors thank Dr. Radhika Venkatesan for useful discussions. RS would
   like to acknowledge her JC Bose fellowship (JC Bose fellowship
   (SB/S2/JC-071/2015)) from the Science and Engineering Research Board,
   India.
CR Banerjee P, 2015, NUCLEIC ACIDS RES, V43, pD935, DOI 10.1093/nar/gku886
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Chakraborti S, 2020, REPURPOSING DRUGS MA, DOI [10.26434/chemrxiv.12057846.v2, DOI 10.26434/CHEMRXIV.12057846.V2]
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen CY, 2019, CHEM NAT COMPD+, V55, P1176, DOI 10.1007/s10600-019-02927-w
   Deftereos S, 2020, COLCHICINE POTENT AN
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Eswar N, 2006, COMP PROTEIN STRUCTU
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hatcher EL, 2017, NUCLEIC ACIDS RES, V45, pD482, DOI 10.1093/nar/gkw1065
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   HUMPHREYS DD, 1994, J PHYS CHEM-US, V98, P6885, DOI 10.1021/j100078a035
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kasibhatla SM, 2020, J MED VIROL, V92, P1932, DOI 10.1002/jmv.25909
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Law AHY, 2007, J VIROL, V81, P416, DOI 10.1128/JVI.02336-05
   Manfredonia I., 2020, BIORXIV, DOI [10.1101/2020.06.15.151647, DOI 10.1101/2020.06.15.151647]
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Martyna GJ, 1992, J CHEM PHYS
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Ming LJ, 2013, NAT PROD COMMUN, V8, P415
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Narayanan N, 2020, VITAMIN B12 MAY INHI, DOI [10.20944/preprints202003.0347.v1, DOI 10.20944/PREPRINTS202003.0347.V1]
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Pandey RP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20955-4
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Pillai MK, 2018, MINI-REV MED CHEM, V18, P1220, DOI 10.2174/1389557517666171002154123
   Piplani S., 2020, ARXIV200506199
   Quimque MTJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776639
   Rampogu S, 2018, ANN CLIN MICROB ANTI, V17, DOI 10.1186/s12941-018-0266-9
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Semwal RB, 2015, PHYTOCHEMISTRY, V117, P554, DOI 10.1016/j.phytochem.2015.07.012
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Shen Z, 2019, J BIOL CHEM, V294, P13606, DOI 10.1074/jbc.RA119.009713
   Somasundaram K, 2020, GENOMICS INDIAN SARS, DOI [10.1101/2020.04.25.20079475, DOI 10.1101/2020.04.25.20079475]
   Suk S, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700139
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Thoms M., 2020, STRUCTURAL BASIS TRA, DOI [10.1101/2020.05.18.102467, DOI 10.1101/2020.05.18.102467]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu C, 2020, ACTA PHARM SINICA B
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 57
TC 1
Z9 1
U1 2
U2 2
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-5991
EI 0973-7138
J9 J BIOSCIENCES
JI J. Biosci.
PD JUL 17
PY 2020
VL 45
IS 1
AR 100
DI 10.1007/s12038-020-00069-8
PG 18
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA ML6RX
UT WOS:000549591800001
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rodriguez-Cubillo, B
   de la Higuera, MAM
   Lucena, R
   Franci, EV
   Hurtado, M
   Romero, NC
   Moreno, AR
   Valencia, D
   Velo, M
   Fornie, IS
   Sanchez-Fructuoso, AI
AF Rodriguez-Cubillo, Beatriz
   de la Higuera, Maria Angeles Moreno
   Lucena, Rafael
   Franci, Elena V.
   Hurtado, Maria
   Romero, Natividad C.
   Moreno, Antolina R.
   Valencia, Daniela
   Velo, Mercedes
   Fornie, Inigo S.
   Sanchez-Fructuoso, Ana I.
TI Should cyclosporine be useful in renal transplant recipients affected by
   SARS-CoV-2?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; health services and outcomes research;
   kidney transplantation; nephrology; kidney disease; infectious;
   immunosuppressant
ID REPLICATION; COVID-19
AB Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.
C1 [Rodriguez-Cubillo, Beatriz; de la Higuera, Maria Angeles Moreno; Lucena, Rafael; Franci, Elena V.; Hurtado, Maria; Romero, Natividad C.; Moreno, Antolina R.; Valencia, Daniela; Velo, Mercedes] Hosp Clin San Carlos, Nephrol Dept, Madrid, Spain.
   [Fornie, Inigo S.] Hosp Clin San Carlos, Internal Med Dept, Madrid, Spain.
   [Sanchez-Fructuoso, Ana I.] Univ Med Complutense Madrid, Hosp Clin San Carlos, Nephrol Dept, Madrid, Spain.
RP Rodriguez-Cubillo, B (corresponding author), Hosp Clin San Carlos, Nephrol Dept, Madrid, Spain.
EM brcubillo@gmail.com
OI sagastagoitia, inigo/0000-0003-0905-1974; Calvo,
   Natividad/0000-0003-4031-4816
CR Akalin E, 2020, N ENGL J MED
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Bikdeli B, 2020, J AM COLL CARDIOL
   Bowman LJ, 2018, TRANSPLANTATION, V102, pS50, DOI [10.1097/TP.0000000000001777, 10.1097/tp.0000000000001777]
   British Transplant Society, GUID MAN TRANSPL REC
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CaoW LX, 2020, INFECT DIS, V7, pofaa102
   Chen XT, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182058
   Coates PT, 2020, KIDNEY INT, V97, P1074, DOI 10.1016/j.kint.2020.04.001
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Husain SA, 2020, J AM SOC NEPHROL
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li YJ, 2010, TRANSPLANTATION, V89, P299, DOI 10.1097/TP.0b013e3181c9b51c
   Lopez V, 2020, NEFROLOGIA
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morelon E, 2001, TRANSPLANTATION, V72, P787, DOI 10.1097/00007890-200109150-00008
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   Rosen MH, 2020, INFLAMM BOWEL DIS
   Sanders JM, 2020, JAMA
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Willicombe M, 2020, J AM SOC NEPHROL, V31, P1145, DOI 10.1681/ASN.2020030348
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang H, 2020, EUR UROL
NR 30
TC 6
Z9 6
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 3173
EP 3181
DI 10.1111/ajt.16141
EA JUL 2020
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000548860700001
PM 32529737
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Baig, AM
   Khaleeq, A
   Syeda, H
AF Baig, Abdul Mannan
   Khaleeq, Areeba
   Syeda, Hira
TI Elucidation of cellular targets and exploitation of the receptor-binding
   domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE 2019-nCoV; bat virus; biological agents; BSL-4; COVID-19; MERS virus;
   SARS virus; SARS-CoV-2; vaccine and antibody against SARS-CoV-2; viral
   pandemics; Wuhan coronavirus outbreak; zoonotic infections
ID NEURAL-NETWORKS
AB The pandemic caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has resulted in over 452 822 deaths in the first 20 days of June 2020 due to the coronavirus virus disease 2019 (COVID-19). The SARS-CoV-2 uses the host angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the human cells where it replicates by using the cell protein synthesis mechanisms. The knowledge of the tissue distribution of ACE2 in human organs is therefore important to predict the clinical course of the COVID-19. Also important is the understanding of the viral receptor-binding domain (RBD), a region within the spike (S) proteins, that enables the entry of the virus into the host cells to synthesize vaccine and monoclonal antibodies (mAbs). We performed an exhaustive search of human protein databases to establish the tissues that express ACE2 and performed an in-depth analysis like sequence alignments and homology modeling of the spike protein (S) of the SARS-CoV-2 to identify antigenic regions in the RBD that can be exploited to synthesize vaccine and mAbs. Our results show that ACE2 is widely expressed in human organs that may explain the pulmonary, systemic, and neurological deficits seen in COVID-19 patients. We show that though the S protein of the SARS-CoV-2 is a homolog of S protein of SARS-CoV-1, it has regions of dissimilarities in the RBD and transmembrane segments. We show peptide sequences in the RBD of SARS-CoV-2 that can bind to the major histocompatibility complex alleles and serve as effective epitopes for vaccine and mAbs synthesis.
C1 [Baig, Abdul Mannan; Khaleeq, Areeba] Aga Khan Univ, Dept Biol & Biomed Sci, Stadium Rd, Karachi 78400, Sindh, Pakistan.
   [Syeda, Hira] Mohammad Ali Jinnah Univ, Dept Biosci, Karachi, Pakistan.
RP Baig, AM (corresponding author), Aga Khan Univ, Dept Biol & Biomed Sci, Stadium Rd, Karachi 78400, Sindh, Pakistan.
EM abdul.mannan@aku.edu
OI Baig, Abdul Mannan/0000-0003-0626-216X; Khaleeq,
   Areeba/0000-0002-8514-4518
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Baig AM, DEVIL ITS DETAILS UN, DOI [10.21203/rs.3.rs-19497/v1, DOI 10.21203/RS.3.RS-19497/V1]
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bertoni M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09654-8
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m751
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   National Center for Biotechnology Information, US NAT LIB MED 8600, V8600
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Ong Edison, 2020, bioRxiv, DOI 10.1101/2020.03.20.000141
   Ou J, 2020, BIORXIV, DOI [10.1101/2020.03.15.991844, DOI 10.1101/2020.03.15.991844]
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Palasca O, 2018, DATABASE-OXFORD, DOI 10.1093/database/bay003
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tadini Eliana, 2020, Rev Med Suisse, V16, P917
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   US Centers for Disease Control and Prevention, COR DIS 2019 COV 19
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Watkins J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m810
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhao N, 2020, EUR REV MED PHARMACO, V24, P4597, DOI 10.26355/eurrev_202004_21046
NR 31
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2792
EP 2803
DI 10.1002/jmv.26212
EA JUL 2020
PG 12
WC Virology
SC Virology
GA NU0EN
UT WOS:000549046700001
PM 32573788
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Smith, SM
   Boppana, A
   Traupman, JA
   Unson, E
   Maddock, DA
   Chao, K
   Dobesh, DP
   Brufsky, A
   Connor, RI
AF Smith, Stephen M.
   Boppana, Avinash
   Traupman, Julie A.
   Unson, Enrique
   Maddock, Daniel A.
   Chao, Kathy
   Dobesh, David P.
   Brufsky, Adam
   Connor, Ruth, I
TI Impaired glucose metabolism in patients with diabetes, prediabetes, and
   obesity is associated with severe COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; diabetes mellitus; glucose metabolism disorder; hyperglycemia;
   obesity; SARS-CoV-2
AB Background Identification of risk factors of severe coronavirus disease 2019 (COVID-19) is critical for improving therapies and understanding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. We analyzed 184 patients hospitalized for COVID-19 in Livingston, New Jersey for clinical characteristics associated with severe disease. The majority of patients with COVID-19 had diabetes mellitus (DM) (62.0%), Pre-DM (23.9%) with elevated fasting blood glucose (FBG), or a body mass index >30 with normal hemoglobin A1c (HbA1C) (4.3%). SARS-CoV-2 infection was associated with new and persistent hyperglycemia in 29 patients, including several with normal HbA1C levels. Forty-four patients required intubation, which occurred significantly more often in patients with DM as compared with non-diabetics. Severe COVID-19 occurs in the presence of impaired glucose metabolism in patients, including those with DM, preDM, and obesity. COVID-19 is associated with elevated FBG and several patients presented with new onset DM or in DKA. The association of dysregulated glucose metabolism and severe COVID-19 suggests that SARS-CoV-2 pathogenesis involves a novel interplay with glucose metabolism. Exploration of pathways by which SARS-CoV-2 interacts glucose metabolism is critical for understanding disease pathogenesis and developing therapies.
C1 [Smith, Stephen M.; Boppana, Avinash; Traupman, Julie A.; Unson, Enrique; Maddock, Daniel A.; Chao, Kathy] Smith Ctr Infect Dis & Urban Hlth, 310 Cent Ave,Suite 307, E Orange, NJ 07018 USA.
   [Dobesh, David P.] RWJBarnabas Hlth, St Barnabas Med Ctr, Livingston, NJ USA.
   [Brufsky, Adam] Univ Pittsburgh, Magee Womens Hosp, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.
   [Connor, Ruth, I] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
RP Smith, SM (corresponding author), Smith Ctr Infect Dis & Urban Hlth, 310 Cent Ave,Suite 307, E Orange, NJ 07018 USA.
EM ssmith1824@gmail.com
OI Smith, Stephen/0000-0002-9158-6136; Brufsky, Adam/0000-0001-8080-7960
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI [10.2337/dc10-s062, 10.2337/dc10-S062]
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bloomgarden ZT, 2020, J DIABETES, V12, P347, DOI 10.1111/1753-0407.13027
   Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, 2020, NAT DIAB STAT REP
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Ma RCW, 2020, DIABETIC MED, V37, P723, DOI 10.1111/dme.14300
   MMWR Morbidity and Mortality Weekly Report, 2020, MMWR MORBIDITY MORTA
   Petrilli CM, 2020, FACTORS ASS HOSPITAL, DOI [10.1101/2020.04.08.20057794, DOI 10.1101/2020.04.08.20057794]
   Roca-Ho H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030563
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Selvin E, 2009, DIABETES CARE, V32, P828, DOI 10.2337/dc08-1699
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 24
TC 7
Z9 7
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26227
EA JUL 2020
PG 7
WC Virology
SC Virology
GA MK8DU
UT WOS:000549013400001
PM 32589756
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fiorentino, M
   Pentakota, R
   Mosenthal, AC
   Glass, NE
AF Fiorentino, Michele
   Pentakota, Ram
   Mosenthal, Anne C.
   Glass, Nina E.
TI The Palliative Performance Scale predicts mortality in hospitalized
   patients with COVID-19
SO PALLIATIVE MEDICINE
LA English
DT Article
DE Palliative care; coronavirus; frailty; hospital mortality; physical
   functional performance
ID CARE
AB Background: Coronavirus disease 2019 (COVID-19) has a substantial mortality risk with increased rates in the elderly. We hypothesized that age is not sufficient, and that frailty measured by preadmission Palliative Performance Scale would be a predictor of outcomes. Improved ability to identify high-risk patients will improve clinicians' ability to provide appropriate palliative care, including engaging in shared decision-making about life-sustaining therapies. Aim: To evaluate whether preadmission Palliative Performance Scale predicts mortality in hospitalized patients with COVID-19. Design: Retrospective observational cohort study of patients admitted with COVID-19. Palliative Performance Scale was calculated from the chart. Using logistic regression, Palliative Performance Scale was assessed as a predictor of mortality controlling for demographics, comorbidities, palliative care measures and socioeconomic status. Setting/participants: Patients older than 18 years of age admitted with COVID-19 to a single urban public hospital in New Jersey, USA. Results: Of 443 admitted patients, we determined the Palliative Performance Scale score for 374. Overall mortality was 31% and 81% in intubated patients. In all, 36% (134) of patients had a low Palliative Performance Scale score. Compared with patients with a high score, patients with a low score were more likely to die, have do not intubate orders and be discharged to a facility. Palliative Performance Scale independently predicts mortality (odds ratio 2.89; 95% confidence interval 1.42-5.85). Conclusions: Preadmission Palliative Performance Scale independently predicts mortality in patients hospitalized with COVID-19. Improved predictors of mortality can help clinicians caring for patients with COVID-19 to discuss prognosis and provide appropriate palliative care including decisions about life-sustaining therapy.
C1 [Fiorentino, Michele; Pentakota, Ram; Glass, Nina E.] Rutgers New Jersey Med Sch, 150 Bergen St,UH-M233, Newark, NJ 07103 USA.
   [Mosenthal, Anne C.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
RP Glass, NE (corresponding author), Rutgers New Jersey Med Sch, 150 Bergen St,UH-M233, Newark, NJ 07103 USA.
EM Ng470@njms.rutgers.edu
RI Pentakota, Sri Ram/ABB-8001-2020
OI Pentakota, Sri Ram/0000-0001-6872-1507; Glass, Nina/0000-0002-6821-4289
FU Auen Foundation [A18-63]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This work
   was supported by the Auen Foundation (grant number A18-63).
CR Anderson F, 1996, J PALLIAT CARE, V12, P5, DOI 10.1177/082585979601200102
   Baik D, 2018, J PALLIAT MED, V21, P1651, DOI 10.1089/jpm.2018.0141
   Bellelli G, 2020, INTENS CARE MED, V46, P1634, DOI 10.1007/s00134-020-06087-2
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Creber RM, 2019, ESC HEART FAIL, V6, P371, DOI 10.1002/ehf2.12398
   Ho Francis, 2008, BMC Palliat Care, V7, P10, DOI 10.1186/1472-684X-7-10
   Hubbard RE, 2020, AGE AGEING, V49, P499, DOI 10.1093/ageing/afaa095
   Hwang F, 2019, J TRAUMA ACUTE CARE, V87, P541, DOI 10.1097/TA.0000000000002382
   Lian JS, 2020, INFLUENZA OTHER RESP, V14, P564, DOI 10.1111/irv.12758
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Mosenthal AC, 2008, J TRAUMA, V64, P1587, DOI 10.1097/TA.0b013e318174f112
   Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0
   Myers J, 2015, SUPPORT CARE CANCER, V23, P913, DOI 10.1007/s00520-014-2440-8
   National Institute for Health and Care Excellence, COVID 19 RAP GUID CR
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Statista, 2020, COR COVID 19 DEATH R
   WHO, 2020, COR DIS COVID 19 PAN
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 18
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2163
EI 1477-030X
J9 PALLIATIVE MED
JI Palliat. Med.
PD OCT
PY 2020
VL 34
IS 9
BP 1228
EP 1234
AR 0269216320940566
DI 10.1177/0269216320940566
EA JUL 2020
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Medicine, General & Internal
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; General & Internal Medicine
GA NO5KE
UT WOS:000549971200001
PM 32677509
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Carannante, N
   Fiorentino, G
   Corcione, A
   Di Sarno, R
   Spatarella, M
   Maturo, N
   Fragranza, F
   Di Micco, P
AF Carannante, Novella
   Fiorentino, Giuseppe
   Corcione, Antonio
   Di Sarno, Raffaele
   Spatarella, Micaela
   Maturo, Nicola
   Fragranza, Fiorentino
   Di Micco, Pierpaolo
TI Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is
   Associated With Fast Clinical and Radiological Healing: Case Report
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE PENTAGLOBIN; immunoglobulin; SARS-CoV2; COVID 19; pneumonia; case report
AB Polyclonal preparation of IgM as an adjuvant therapy has been reported as a relevant immunomodulant therapy in several infectious diseases, exhibiting, in most cases, improvement of the clinical course. No drug has demonstrated therapeutic efficacy for COVID-19. Immunomodulatory treatment with hydroxychloroquine and biologics as tocilizumab, in fact, has not proven to show satisfactory results in several reports. We therefore treated a selected patient with interstitial multifocal pneumonia, positive to COVID-19, with polyclonal preparation of immunoglobulins as an adjuvant therapy, obtaining in few days clinical remission and improvements in radiological findings. Based on this case report, we suggest that clinical trials are conducted to test the efficacy and safety of polyclonal immunoglobulins for adjunctive therapy of COVID-19.
C1 [Carannante, Novella; Fiorentino, Giuseppe; Corcione, Antonio; Di Sarno, Raffaele; Spatarella, Micaela; Maturo, Nicola; Fragranza, Fiorentino; Di Micco, Pierpaolo] AO Colli, Emergency Infect Dis Po Cotugno Monaldi, Naples, Italy.
   [Carannante, Novella; Fiorentino, Giuseppe; Corcione, Antonio; Di Sarno, Raffaele; Spatarella, Micaela; Maturo, Nicola; Fragranza, Fiorentino; Di Micco, Pierpaolo] Osped Fatebenefratelli Naples, UOC Med, Naples, Italy.
RP Di Micco, P (corresponding author), AO Colli, Emergency Infect Dis Po Cotugno Monaldi, Naples, Italy.; Di Micco, P (corresponding author), Osped Fatebenefratelli Naples, UOC Med, Naples, Italy.
EM pdimicco@libero.it
CR Cao W, 2020, OPEN FORUM INFECT DI, P1
   Conti P, 2020, J Biol Regul Homeost Agents, V34, P339, DOI 10.23812/Editorial-Conti-3
   Domizi R, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0609-5
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mouthon L, 2003, CLIN MICROBIOL INFEC, V9, P333, DOI 10.1046/j.1469-0691.2003.00694.x
   Scaroni C, 2020, J ENDOCRINOL INVEST, V43, P1035, DOI 10.1007/s40618-020-01253-1
   Tascini C, 2018, INFECT DIS-NOR, V50, P214, DOI 10.1080/23744235.2017.1384956
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 12
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUL 16
PY 2020
VL 7
AR 388
DI 10.3389/fmed.2020.00388
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MW1RK
UT WOS:000556823000001
PM 32766266
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xiong, B
   Liu, T
   Luo, P
   Wei, YC
   Zhou, Y
   Liu, MH
   Zhang, YX
   Wang, HL
   Zhang, XC
   Wang, XH
   Zhou, FL
AF Xiong, Bei
   Liu, Tao
   Luo, Ping
   Wei, Yongchang
   Zhou, Yi
   Liu, Minghui
   Zhang, Yongxi
   Wang, Hanlun
   Zhang, Xiaochun
   Wang, Xinghuan
   Zhou, Fuling
TI Prominent Hypercoagulability Associated With Inflammatory State Among
   Cancer Patients With SARS-CoV-2 Infection
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; cancer; D-dimer; hypercoagulability
ID WUHAN
AB Abnormal coagulation parameters and potential benefits of anticoagulant therapy in general population with novel coronavirus pneumonia (COVID-19) have been reported. However, limited data are available on cancer patients. Coagulation indexes and inflammation parameters in 57 cancer patients with SARS-CoV-2 infection with different severity were retrospectively analyzed. We found that D-dimer levels were increased in 33 patients (57.9%, median: 790 ng/mL). Compared with ordinary type patients, severe and critical ill patients had decreased MPV values (P= 0.006), prolonged PT (median: 13.3 vs. 11.5 vs. 11.4 s,P< 0.001), significant higher D-dimer levels (median: 2,400 vs. 940 vs. 280 ng/mL,P< 0.001), higher PCT levels (median: 0.17 vs. 0.055 vs. 0.045 ng/mL,P= 0.002), higher IL-6 (median: 20.6 vs. 2.3 vs. 3.0 pg/mL,P= 0.040), and decreased PaO2(median: 68 vs. 84 vs. 96 mm Hg,P< 0.001). Importantly, three patients, one severe and two critical ill type, with increased D-dimer survived after anticoagulant therapy with continuous heparin infusion. Increased D-dimer levels positively correlated with increased PCT levels (r= 0.456,P= 0.002) and IL-6 levels (r= 0.501,P= 0.045). A negative correlation between D-dimer levels and PaO(2)levels (r= -0.654,P= 0.021) were also existed. Cancer patients with COVID-19 showed prominent hypercoagulability associated with severe inflammation, anticoagulation therapy might be useful to improve the prognosis and should be immediately used after the onset of hypercoagulability.
C1 [Xiong, Bei; Luo, Ping; Zhou, Yi; Liu, Minghui; Zhou, Fuling] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Liu, Tao; Wang, Xinghuan] Wuhan Univ, Ctr Evidence Based & Translat Med, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Wei, Yongchang] Wuhan Univ, Dept Radiat Oncol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Zhang, Yongxi] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan, Peoples R China.
   [Wang, Hanlun; Zhang, Xiaochun] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Peoples R China.
RP Zhou, FL (corresponding author), Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Ctr Evidence Based & Translat Med, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.
EM wangxinghuan@whu.edu.cn; zhoufuling@whu.edu.cn
OI Liu, Tao/0000-0002-4202-8218
FU National Key Research and Development Program of China [2020YFC0845500]
FX This work was supported by the National Key Research and Development
   Program of China (No. 2020YFC0845500).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   GOoNH C, 2020, DIAGN TREATM SCHEM N
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Torrealba JI, 2019, J VASC SURG, V70, P175, DOI 10.1016/j.jvs.2018.09.062
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Levi M, 2017, THROMB RES, V149, P38, DOI 10.1016/j.thromres.2016.11.007
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo W, 2020, CLIN PATHOLOGY CRITI, DOI DOI 10.1016/S1473-3099(20)30086-4
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Nasser NJ, 2020, CANCERS, V12, DOI 10.3390/cancers12030566
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Schmitt FCF, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0499-6
   Thrombosis and Hemostasis Group Hematology Society of Chinese Medical Association, 2017, Zhonghua Xue Ye Xue Za Zhi, V38, P361, DOI 10.3760/cma.j.issn.0253-2727.2017.05.001
   Van Dreden Patrick, 2017, Critical Reviews in Oncogenesis, V22, P219, DOI 10.1615/CritRevOncog.2018024859
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WANG Q, 2020, SSRN ELECT J, DOI DOI 10.2139/SSRN.354877132316065
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 16
PY 2020
VL 10
AR 1345
DI 10.3389/fonc.2020.01345
PG 9
WC Oncology
SC Oncology
GA MW0MW
UT WOS:000556742600001
PM 32766161
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Moschini, L
   Loffi, M
   Regazzoni, V
   Di Tano, G
   Gherbesi, E
   Danzi, GB
AF Moschini, Luigi
   Loffi, Marco
   Regazzoni, Valentina
   Di Tano, Giuseppe
   Gherbesi, Elisa
   Danzi, Gian Battista
TI Effects on QT interval of hydroxychloroquine associated with
   ritonavir/darunavir or azithromycin in patients with SARS-CoV-2
   infection
SO HEART AND VESSELS
LA English
DT Article; Early Access
DE COVID-19; Hydroxychloroquine; Ritonavir; Darunavir; Azithromycin
ID RISK
AB Introduction Most of the drugs associations that have been used to treat patients with SARS-CoV-2 infection increase the risk of prolongation of the corrected QT interval (QTc). Objective To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or azithromycin (AZ) on QTc intervals. Methods At the beginning of COVID-19 pandemic patients admitted to our hospital were treated with the empiric association of HY/RD; one week later the therapeutic protocol was modified with the combination of HY/AZ. Patients underwent an ECG at baseline, then 3 and 7 days after starting therapy. We prospectively enrolled 113 patients (61 in the HY/RD group-52 in the HY/AZ group). Results A significant increase in median QTc was reported after seven days of therapy in both groups: from 438 to 452 ms in HY/RD patients; from 433 to 440 ms in HY/AZ patients (p = 0.001 for both). 23 patients (21.2%) had a QTc > 500 ms at 7 days. The risk of developing a QTc > 500 ms was greater in patients with prolonged baseline QTc values (>= 440 ms for female and >= 460 ms for male patients) (OR 7.10 (95% IC 1.88-26.81);p = 0.004) and in patients with an increase in the QTc > 40 ms 3 days after onset of treatment (OR 30.15 (95% IC 6.96-130.55);p = 0.001). One patient per group suffered a malignant ventricular arrhythmia. Conclusion Hydroxychloroquine with both ritonavir/darunavir or azithromycin therapy significantly increased the QTc-interval at 7 days. The risk of developing malignant arrhythmias remained relatively low when these drugs were administered for a limited period of time.
C1 [Moschini, Luigi; Loffi, Marco; Regazzoni, Valentina; Di Tano, Giuseppe; Danzi, Gian Battista] Osped Cremona, Div Cardiol, Viale Concordia 1, I-26100 Cremona, Italy.
   [Gherbesi, Elisa] Univ Milan, Via Festa del Perdono 7, I-20122 Milan, Italy.
RP Danzi, GB (corresponding author), Osped Cremona, Div Cardiol, Viale Concordia 1, I-26100 Cremona, Italy.
EM gbdanzi@gmail.com
RI Danzi, Gian Battista/P-2244-2016; Danzi, Gian Battista/ABF-6413-2020
OI Danzi, Gian Battista/0000-0003-0897-8006; Danzi, Gian
   Battista/0000-0003-0897-8006
CR Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CHORIN E, 2020, NAT MED 0424, DOI DOI 10.1101/2020.04.02.20047050
   Chugh SS, 2009, CIRCULATION, V119, P663, DOI 10.1161/CIRCULATIONAHA.108.797035
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704
   Etchegoyen CV, 2017, CURR CLIN PHARMACOL, V12, P210, DOI 10.2174/1574884713666180223123947
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hu Ling, 2020, Clin Infect Dis, V71, P2089, DOI 10.1093/cid/ciaa539
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Simpson T., 2020, VENTRICULAR ARRHYTHM
   Simpson TF, 2020, JAMA INTERN MED, V180, P698, DOI 10.1001/jamainternmed.2020.0148
   Van Ierssel S., 2020, INTERIM CLIN GUIDANC
   World Health Organization, CARD ANT MAL POL ADV
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0910-8327
EI 1615-2573
J9 HEART VESSELS
JI Heart Vessels
DI 10.1007/s00380-020-01671-4
EA JUL 2020
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MU2NF
UT WOS:000555509800001
PM 32676695
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Spring, LM
   Specht, MC
   Jimenez, RB
   Isakoff, SJ
   Wang, GX
   Ly, A
   Shin, JA
   Bardia, A
   Moy, B
AF Spring, Laura M.
   Specht, Michelle C.
   Jimenez, Rachel B.
   Isakoff, Steven J.
   Wang, Gary X.
   Ly, Amy
   Shin, Jennifer A.
   Bardia, Aditya
   Moy, Beverly
TI Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the
   Covid-19 Pandemic
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID NEOADJUVANT ENDOCRINE THERAPY; 20-YEAR FOLLOW-UP; CONSERVING SURGERY;
   DOUBLE-BLIND; POSTMENOPAUSAL PATIENTS; RADIATION-THERAPY; PLUS
   TRASTUZUMAB; RANDOMIZED-TRIAL; RESPONSE RATE; STAGE
AB A 62-year-old woman was evaluated for a mass that had been identified in the left breast during the Covid-19 pandemic. Mammography revealed a mass with spiculated margins. Ultrasonography showed a solid mass, measuring 3.1 cm by 1.5 cm by 1.2 cm, and normal left axillary lymph nodes. A core-needle biopsy was performed, and management decisions were made.
C1 [Spring, Laura M.; Isakoff, Steven J.; Shin, Jennifer A.; Bardia, Aditya; Moy, Beverly] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Specht, Michelle C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
   [Jimenez, Rachel B.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
   [Wang, Gary X.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
   [Ly, Amy] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   [Spring, Laura M.; Isakoff, Steven J.; Shin, Jennifer A.; Bardia, Aditya; Moy, Beverly] Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
   [Specht, Michelle C.] Harvard Med Sch, Dept Surg, Boston, MA 02115 USA.
   [Jimenez, Rachel B.] Harvard Med Sch, Dept Radiat Oncol, Boston, MA 02115 USA.
   [Wang, Gary X.] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA.
   [Ly, Amy] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA.
RP Spring, LM (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Spring, LM (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
RI Isakoff, Steven/ABE-3566-2020
CR Alba E, 2012, ANN ONCOL, V23, P3069, DOI 10.1093/annonc/mds132
   Allevi G, 2013, BRIT J CANCER, V108, P1587, DOI 10.1038/bjc.2013.151
   Back AL, 2005, CA-CANCER J CLIN, V55, P164, DOI 10.3322/canjclin.55.3.164
   Back A, 2020, ANN INTERN MED, V172, P759, DOI 10.7326/M20-1376
   Baile WF, 2005, CURR OPIN ONCOL, V17, P331, DOI 10.1097/01.cco.0000167738.49325.2c
   Bartelink H, 2015, LANCET ONCOL, V16, P47, DOI 10.1016/S1470-2045(14)71156-8
   Bellon JR, 2005, J CLIN ONCOL, V23, P1934, DOI 10.1200/JCO.2005.04.032
   Blum JL, 2017, J CLIN ONCOL, V35, P2647, DOI 10.1200/JCO.2016.71.4147
   Brunt AM, 2016, RADIOTHER ONCOL, V120, P114, DOI 10.1016/j.radonc.2016.02.027
   Brunt AM, 2020, LANCET, V395, P1613, DOI 10.1016/S0140-6736(20)30932-6
   Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253
   Carey LA, 2016, J CLIN ONCOL, V34, P542, DOI 10.1200/JCO.2015.62.1268
   Cataliotti L, 2006, CANCER-AM CANCER SOC, V106, P2095, DOI 10.1002/cncr.21872
   Chiba A, 2017, ANN SURG ONCOL, V24, P418, DOI 10.1245/s10434-016-5585-5
   Coopey S, 2011, ANN SURG ONCOL, V18, P3797, DOI 10.1245/s10434-011-1802-4
   Correa C, 2017, PRACT RADIAT ONCOL, V7, P73, DOI 10.1016/j.prro.2016.09.007
   D'Orsi C, 2014, 2013 ACR BI RADS ATL
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Dixon JM, 2009, BREAST CANCER RES TR, V113, P145, DOI 10.1007/s10549-008-9915-6
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558
   Dragun AE, 2017, INT J RADIAT ONCOL, V98, P595, DOI 10.1016/j.ijrobp.2017.01.212
   Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2
   Eiermann W, 2001, ANN ONCOL, V12, P1527, DOI 10.1023/A:1013128213451
   Ellis MJ, 2017, J CLIN ONCOL, V35, P1061, DOI 10.1200/JCO.2016.69.4406
   Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808
   Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550
   Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152
   Freedman GM, 2013, RADIOTHER ONCOL, V106, P15, DOI 10.1016/j.radonc.2012.12.001
   Gianni L, 2016, LANCET ONCOL, V17, P791, DOI 10.1016/S1470-2045(16)00163-7
   Gradishar WJ, 2020, J NATL COMPR CANC NE, V18, P452, DOI 10.6004/jnccn.2020.0016
   Harper-Wynne CL, 2002, J CLIN ONCOL, V20, P1026, DOI 10.1200/JCO.20.4.1026
   Hurvitz SA, 2019, J CLIN ONCOL, V37, P2206, DOI 10.1200/JCO.19.00882
   Iwata H, 2019, BREAST CANCER RES TR, V173, P123, DOI 10.1007/s10549-018-4964-y
   Jones S, 2009, J CLIN ONCOL, V27, P1177, DOI 10.1200/JCO.2008.18.4028
   Karlsson P, 2011, INT J RADIAT ONCOL, V80, P398, DOI 10.1016/j.ijrobp.2010.02.042
   Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112
   Loibl S, 2018, LANCET ONCOL, V19, P497, DOI 10.1016/S1470-2045(18)30111-6
   Marron JM, 2020, J CLIN ONCOL
   Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645
   Masuda N, 2012, LANCET ONCOL, V13, P345, DOI 10.1016/S1470-2045(11)70373-4
   Mauri D, 2020, LANCET ONCOL, V21, P759, DOI 10.1016/S1470-2045(20)30278-3
   Mehta V, 2020, NUTR CANCER, DOI 10.1080/01635581.2020.1778746
   Nakatsukasa K, 2017, BREAST CANCER-TOKYO, V24, P63, DOI 10.1007/s12282-016-0666-7
   Olivotto IA, 2009, J CLIN ONCOL, V27, P16, DOI 10.1200/JCO.2008.18.1891
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Palmieri C, 2014, BREAST CANCER RES TR, V148, P581, DOI 10.1007/s10549-014-3183-4
   Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830
   POZO C, 1992, J CLIN ONCOL, V10, P1292, DOI 10.1200/JCO.1992.10.8.1292
   Rai A, 2018, J NATL COMPR CANC NE, V16, P975, DOI 10.6004/jnccn.2018.7034
   Schneeweiss A, 2013, ANN ONCOL, V24, P2278, DOI 10.1093/annonc/mdt182
   Semiglazov VF, 2007, CANCER-AM CANCER SOC, V110, P244, DOI 10.1002/cncr.22789
   Shah C, 2012, BREAST J, V18, P357, DOI 10.1111/j.1524-4741.2012.01252.x
   Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572
   Smith BD, 2018, PRACT RADIAT ONCOL, V8, P145, DOI 10.1016/j.prro.2018.01.012
   Smith IE, 2005, J CLIN ONCOL, V23, P5108, DOI 10.1200/JCO.2005.04.005
   Sparano JA, 2018, NEW ENGL J MED, V379, P111, DOI 10.1056/NEJMoa1804710
   Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764
   Sparano JA, 2019, NEW ENGL J MED, V380, P2395, DOI 10.1056/NEJMoa1904819
   Spring LM, 2016, JAMA ONCOL, V2, P1477, DOI 10.1001/jamaoncol.2016.1897
   Tolaney SM, 2019, J CLIN ONCOL, V37, P1868, DOI 10.1200/JCO.19.00066
   Vicini FA, 2019, LANCET, V394, P2155, DOI 10.1016/S0140-6736(19)32514-0
   von Minckwitz G, 2019, NEW ENGL J MED, V380, P617, DOI 10.1056/NEJMoa1814017
   von Minckwitz G, 2017, NEW ENGL J MED, V377, P122, DOI 10.1056/NEJMoa1703643
   Vujovic O, 2015, INT J RADIAT ONCOL, V91, P319, DOI 10.1016/j.ijrobp.2014.10.006
   WELLISCH DK, 1989, PSYCHOSOMATICS, V30, P365, DOI 10.1016/S0033-3182(89)72241-6
   Whelan TJ, 2019, LANCET, V394, P2165, DOI 10.1016/S0140-6736(19)32515-2
   Yang XD, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00097
   Yarnold JR, 2011, RADIOTHER ONCOL, V100, P93, DOI 10.1016/j.radonc.2011.06.026
NR 69
TC 0
Z9 0
U1 1
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 16
PY 2020
VL 383
IS 3
BP 262
EP 272
DI 10.1056/NEJMcpc2002422
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ8TN
UT WOS:000553165300017
PM 32610007
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Peng, HB
   Gong, TF
   Huang, XY
   Sun, X
   Luo, H
   Wang, WZ
   Luo, JB
   Luo, BW
   Chen, YH
   Wang, XX
   Long, HF
   Mei, H
   Li, C
   Dai, YN
   Li, HH
AF Peng, Hongbing
   Gong, Tiefeng
   Huang, Xiaoying
   Sun, Xun
   Luo, Hong
   Wang, Weizhong
   Luo, Junbiao
   Luo, Baowei
   Chen, Yanhui
   Wang, Xingxing
   Long, Haifeng
   Mei, Hua
   Li, Chuang
   Dai, Yanni
   Li, Honghui
TI A synergistic role of convalescent plasma and mesenchymal stem cells in
   the treatment of severely ill COVID-19 patients: a clinical case report
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Convalescent plasma; Mesenchymal stem cells; Coronavirus disease 2019;
   COVID-19; SARS-CoV-2
ID CORONAVIRUS; PNEUMONIA; THERAPY
AB Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-alpha, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.
C1 [Peng, Hongbing; Gong, Tiefeng; Huang, Xiaoying; Luo, Baowei; Chen, Yanhui; Wang, Xingxing; Long, Haifeng; Li, Honghui] Loudi Cent Hosp, Dept Resp Med, 51 Changqing Middle St, Loudi 417000, Peoples R China.
   [Li, Honghui] Loudi Cent Hosp, Med Rehabil Ctr, 51 Changqing Middle St, Loudi 417000, Peoples R China.
   [Sun, Xun] Cent South Univ, Sch Basic Med Sci, Inst Reprod & Stem Cell Engn, 172 Tongzipo Rd, Changsha 410013, Peoples R China.
   [Sun, Xun; Mei, Hua; Li, Chuang; Dai, Yanni] Natl Engn Res Ctr Human Stem Cells, Changsha 410000, Peoples R China.
   [Luo, Hong] Cent South Univ, Xiangya Hosp 2, Dept Resp & Crit Care Med, 139 Renmin Middle Rd, Changsha 410000, Peoples R China.
   [Wang, Weizhong] Nanhua Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 69 Chuanshan Rd, Hengyang City 421001, Peoples R China.
   [Luo, Junbiao] Nanhua Univ, Affiliated Hosp 2, Dept Crit Care Med, 35 Jiefang Ave, Hengyang City 421001, Peoples R China.
RP Peng, HB (corresponding author), Loudi Cent Hosp, Dept Resp Med, 51 Changqing Middle St, Loudi 417000, Peoples R China.
EM redcat8851@163.com
FU Special Topic Project for Pneumonia Epidemic Infected by New Coronavirus
   in Loudi City [2020-Respiratory medicine-02]; Special Emergency Project
   for COVID-19 from Science and Technology Department of Hunan Province
   [2020SK3016]
FX This study is supported by the Special Topic Project for Pneumonia
   Epidemic Infected by New Coronavirus in Loudi City (award number:
   2020-Respiratory medicine-02). And the study was also supported by the
   Special Emergency Project for COVID-19 from Science and Technology
   Department of Hunan Province (2020SK3016).
CR Asmussen S, 2014, THORAX, V69, P819, DOI 10.1136/thoraxjnl-2013-204980
   Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   China. NHCotPsRo, 2020, NHCOTPSRO GUIDELINE
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   Gentile P, 2020, AGING DIS, V11, P465, DOI 10.14336/AD.2020.0422
   Gentile P, 2020, EXPERT OPIN BIOL TH, V20, P711, DOI 10.1080/14712598.2020.1761322
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Kong DX, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182455
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liu S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01678-8
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Rajarshi Keshav, 2020, Biotechnology Reports, V26, pe00467, DOI 10.1016/j.btre.2020.e00467
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong HK, 2020, VOX SANG, V115, P545, DOI 10.1111/vox.12927
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang W, 2020, INTENS CARE MED, V46, P841, DOI 10.1007/s00134-020-05990-y
   Zhang YX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01725-4
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 27
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JUL 16
PY 2020
VL 11
IS 1
AR 291
DI 10.1186/s13287-020-01802-8
PG 6
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA MR9DL
UT WOS:000553889100009
PM 32678017
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Masoudi-Sobhanzadeh, Y
   Masoudi-Nejad, A
AF Masoudi-Sobhanzadeh, Yosef
   Masoudi-Nejad, Ali
TI Synthetic repurposing of drugs against hypertension: a datamining method
   based on association rules and a novel discrete algorithm
SO BMC BIOINFORMATICS
LA English
DT Article
DE Data mining; Drug repurposing; Hypertension; Optimization algorithm;
   Synthetic repurposing
ID COMBINATION THERAPY; PREDICTION; DISEASES
AB BackgroundDrug repurposing aims to detect the new therapeutic benefits of the existing drugs and reduce the spent time and cost of the drug development projects. The synthetic repurposing of drugs may prove to be more useful than the single repurposing in terms of reducing toxicity and enhancing efficacy. However, the researchers have not given it serious consideration. To address the issue, a novel datamining method is introduced and applied to repositioning of drugs for hypertension (HT) which is a serious medical condition and needs some improved treatment plans to help treat it.ResultsA novel two-step data mining method, which is based on the If-Then association rules as well as a novel discrete optimization algorithm, was introduced and applied to the synthetic repurposing of drugs for HT. The required data were also extracted from DrugBank, KEGG, and DrugR+ databases. The findings indicated that based on the different statistical criteria, the proposed method outperformed the other state-of-the-art approaches. In contrast to the previously proposed methods which had failed to discover a list on some datasets, our method could find a combination list for all of them.ConclusionSince the proposed synthetic method uses medications in small dosages, it might revive some failed drug development projects and put forward a suitable plan for treating different diseases such as COVID-19 and HT. It is also worth noting that applying efficient computational methods helps to produce better results.
C1 [Masoudi-Sobhanzadeh, Yosef; Masoudi-Nejad, Ali] Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
RP Masoudi-Nejad, A (corresponding author), Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
EM amasoudin@ut.ac.ir
OI masoudi-sobhanzadeh, yosef/0000-0002-2472-0980
FU Iranian National Science Founding (INSF)
FX The authors would like to appreciate Iranian National Science Founding
   (INSF) for their supports.
CR Abbasi K, 2020, BIOINFORMATICS
   Abbasi K, 2019, J CHEM INF MODEL, V59, P4528, DOI 10.1021/acs.jcim.9b00626
   Abdi Y, 2020, APPL SOFT COMPUT, V87, DOI 10.1016/j.asoc.2019.105991
   Alencar AK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195047
   AlQuraishi M, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2932-0
   Ambasta S, 2018, INDIAN J CLIN ANAEST, V5, P272
   Azuamah Y, 2019, INT J RES, V6, P120
   Bigazzi R, 2020, HYPERTENSION, V75, P71, DOI 10.1161/HYPERTENSIONAHA.119.13818
   Boeree MJ, 2017, LANCET INFECT DIS, V17, P39, DOI 10.1016/S1473-3099(16)30274-2
   Braschi A, 2019, AM J CARDIOVASC DRUG, V19, P133, DOI 10.1007/s40256-018-00316-2
   Carrara L, 2017, EXPERT OPIN DRUG DIS, V12, P785, DOI 10.1080/17460441.2017.1340271
   Cheng F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07323-6
   Crepinsek M, 2019, MATHEMATICS-BASEL, V7, DOI 10.3390/math7090824
   Davis J, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0890-y
   Dovrolis N, 2017, DRUG DISCOV TODAY, V22, P805, DOI 10.1016/j.drudis.2017.03.009
   dtp@adis.com AMW, 2017, DRUGS THER PERSPECT, V33, P375
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Ezugwu AES, 2017, EXPERT SYST APPL, V87, P70, DOI 10.1016/j.eswa.2017.06.007
   Ezzat Ali, 2019, Methods Mol Biol, V1903, P239, DOI 10.1007/978-1-4939-8955-3_14
   Franzese N, 2019, PLOS COMPUT BIOL, V15, DOI [10.1371/journal.pcbi.1007384, 10.1371/journal.pcbi.1007384.r001, 10.1371/journal.pcbi.1007384.r002, 10.1371/journal.pcbi.1007384.r003, 10.1371/journal.pcbi.1007384.r004]
   Frishman WH, 2016, PROG CARDIOVASC DIS, V59, P247, DOI 10.1016/j.pcad.2016.10.005
   Garcia-Alvarado F, 2019, NEUROTOXICOLOGY, V70, P99, DOI 10.1016/j.neuro.2018.11.003
   Ghaemi M, 2014, EXPERT SYST APPL, V41, P6676, DOI 10.1016/j.eswa.2014.05.009
   Gonzalez GH, 2016, BRIEF BIOINFORM, V17, P33, DOI 10.1093/bib/bbv087
   Iwata H, 2015, J CHEM INF MODEL, V55, P446, DOI 10.1021/ci500670q
   Ji Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22787-8
   Johnson RJ, 2018, AM J KIDNEY DIS, V71, P851, DOI 10.1053/j.ajkd.2017.12.009
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kaszuba AM, 2017, EUR HEART J S1, V38
   Kaur R., 2017, INT RES J ENG TECHNO, V4, P1664
   Khalvati F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41728-7
   Khouri C, 2018, CHEST, V154, P136, DOI 10.1016/j.chest.2017.12.008
   Kloxin AM, 2015, MEK INHIBITORS THEIR
   Kouhsar M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44944-3
   Kuenzi BM, 2015, OFF TARGET BASED DRU
   Masoudi-Sobhanzadeh Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45814-8
   Masoudi-Sobhanzadeh Y, 2020, GENOMICS, V112, P1087, DOI 10.1016/j.ygeno.2019.06.021
   Masoudi-Sobhanzadeh Y, 2019, COMPUT BIOL MED, V109, P254, DOI 10.1016/j.compbiomed.2019.05.006
   Masoudi-Sobhanzadeh Y, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2754-0
   Masoudi-Sobhanzadeh Yosef, 2016, Inform Med Unlocked, V3, P15, DOI 10.1016/j.imu.2016.06.002
   Motieghader H, 2017, MOL BIOSYST, V13, P2168, DOI 10.1039/c7mb00400a
   Papamichael K, 2017, AM J GASTROENTEROL, V112, P673, DOI 10.1038/ajg.2017.21
   Peng JJ, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2102-9
   Peng L, 2018, CURR BIOINFORM, V13, P352, DOI 10.2174/1574893612666170707095707
   Pogue RE, 2018, DRUG DISCOV TODAY, V23, P187, DOI 10.1016/j.drudis.2017.11.002
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Quintana-Villamandos B, 2019, PHARMACOL REP, V71, P1125, DOI 10.1016/j.pharep.2019.06.013
   Rai BB, 2020, GRAEF ARCH CLIN EXP, V258, P191, DOI 10.1007/s00417-019-04523-8
   Rajabioun R, 2011, APPL SOFT COMPUT, V11, P5508, DOI 10.1016/j.asoc.2011.05.008
   Saluja S, 2019, CIRCULATION, V140
   Sawada R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18315-9
   Seeman T, 2019, PEDIATR NEPHROL, V34, P2523, DOI 10.1007/s00467-018-4092-2
   Sfar H, 2018, ARTIF INTELL MED, V91, P57, DOI 10.1016/j.artmed.2018.06.001
   Sridhar D, 2016, BIOINFORMATICS, V32, P3175, DOI 10.1093/bioinformatics/btw342
   Sun W, 2016, DRUG DISCOV TODAY, V21, P1189, DOI 10.1016/j.drudis.2016.05.015
   Torkamanian-Afshar M, 2020, GENOMICS, V112, P2623, DOI 10.1016/j.ygeno.2020.02.013
   Ullah RS, 2019, J MATER SCI, V54, P745, DOI 10.1007/s10853-018-2843-x
   Vamathevan J, 2019, NAT REV DRUG DISCOV, V18, P463, DOI 10.1038/s41573-019-0024-5
   Vanhaelen Q, 2017, DRUG DISCOV TODAY, V22, P210, DOI 10.1016/j.drudis.2016.09.019
   Walker V, 2018, REV EPIDEMIOL SANTE, V66, pS262
   Waller JR, 2018, MEDICINE, V46, P566
   Wang P, 2019, J ETHNOPHARMACOL, V236, P277, DOI 10.1016/j.jep.2018.07.008
   Wang X, 2018, J CLIN NURS RES, V2.
   Weighill DA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004079
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu GS, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2644-5
   Yang HT, 2017, BRIEF BIOINFORM, V18, P488, DOI 10.1093/bib/bbw030
   Zack R, 2019, HYPERTENSION, V73, P990, DOI 10.1161/HYPERTENSIONAHA.118.11916
   Zhao Q, 2019, CURR PROTEIN PEPT SC, V20, P492, DOI 10.2174/1389203720666190123164310
NR 70
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD JUL 16
PY 2020
VL 21
IS 1
AR 313
DI 10.1186/s12859-020-03644-w
PG 21
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA MP7OI
UT WOS:000552390300003
PM 32677879
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

EF